<SEC-DOCUMENT>0001367644-22-000119.txt : 20220802
<SEC-HEADER>0001367644-22-000119.hdr.sgml : 20220802
<ACCEPTANCE-DATETIME>20220801180214
ACCESSION NUMBER:		0001367644-22-000119
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		108
CONFORMED PERIOD OF REPORT:	20220630
FILED AS OF DATE:		20220802
DATE AS OF CHANGE:		20220801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Emergent BioSolutions Inc.
		CENTRAL INDEX KEY:			0001367644
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				141902018
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33137
		FILM NUMBER:		221126150

	BUSINESS ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
		BUSINESS PHONE:		240-631-3200

	MAIL ADDRESS:	
		STREET 1:		400 PROFESSIONAL DR, SUITE 400
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20879
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>ebs-20220630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2022 Workiva--><!--r:76cb5594-9318-4e51-9277-4582eaf35bfa,g:cb82d48c-139c-44ae-8052-a281d9df29e8,d:4ef4253100994f989fd72d1c0fd41d25--><html xmlns:srt="http://fasb.org/srt/2022" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns="http://www.w3.org/1999/xhtml" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:ebs="http://emergentbiosolutions.com/20220630" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>ebs-20220630</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80L2ZyYWc6MDRlMzY1NTQ1MmNmNDc3Zjk2YTFkMzhiZGI3NjQ3MGQvdGFibGU6MjZiNzcyMDM3MzY1NDA5Zjk2ZjI5YzlhOTdlMjMxZTIvdGFibGVyYW5nZToyNmI3NzIwMzczNjU0MDlmOTZmMjljOWE5N2UyMzFlMl8zLTEtMS0xLTkxMjg0_73c42a08-cdfb-4a5e-ae31-a36fde012adf">0001367644</ix:nonNumeric><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:CurrentFiscalYearEndDate" format="ixt:date-month-day" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80L2ZyYWc6MDRlMzY1NTQ1MmNmNDc3Zjk2YTFkMzhiZGI3NjQ3MGQvdGFibGU6MjZiNzcyMDM3MzY1NDA5Zjk2ZjI5YzlhOTdlMjMxZTIvdGFibGVyYW5nZToyNmI3NzIwMzczNjU0MDlmOTZmMjljOWE5N2UyMzFlMl80LTEtMS0xLTkxMjg0_870c7ff1-872e-4c94-9ee1-769c0c16b841">12/31</ix:nonNumeric><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:AmendmentFlag" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80L2ZyYWc6MDRlMzY1NTQ1MmNmNDc3Zjk2YTFkMzhiZGI3NjQ3MGQvdGFibGU6MjZiNzcyMDM3MzY1NDA5Zjk2ZjI5YzlhOTdlMjMxZTIvdGFibGVyYW5nZToyNmI3NzIwMzczNjU0MDlmOTZmMjljOWE5N2UyMzFlMl8xMC0xLTEtMS05MTI4NA_9ebfc814-43d3-443a-af8c-d02e73d7646f">false</ix:nonNumeric><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80L2ZyYWc6MDRlMzY1NTQ1MmNmNDc3Zjk2YTFkMzhiZGI3NjQ3MGQvdGFibGU6MjZiNzcyMDM3MzY1NDA5Zjk2ZjI5YzlhOTdlMjMxZTIvdGFibGVyYW5nZToyNmI3NzIwMzczNjU0MDlmOTZmMjljOWE5N2UyMzFlMl8xMi0xLTEtMS05MTI4NA_9cbb9059-caa3-46fe-8e40-90ba0d0b5a5a">2022</ix:nonNumeric><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80L2ZyYWc6MDRlMzY1NTQ1MmNmNDc3Zjk2YTFkMzhiZGI3NjQ3MGQvdGFibGU6MjZiNzcyMDM3MzY1NDA5Zjk2ZjI5YzlhOTdlMjMxZTIvdGFibGVyYW5nZToyNmI3NzIwMzczNjU0MDlmOTZmMjljOWE5N2UyMzFlMl8xMy0xLTEtMS05MTI4NA_1440b707-939e-4924-9345-33e952ea4646">Q2</ix:nonNumeric><ix:nonNumeric contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_08a6d402-1277-48d2-bf99-60dd61290d59">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_1ed14031-8464-49dc-b194-cef65be5901a">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_27fc9abe-7aef-4a7b-ba2f-191204f5fc38">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_b64be59d-2273-4d6d-8743-cf67e2bb3dd4">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_a0e6f1b3-d5ea-4f24-926b-07bfa08973d9">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_b0f3a4ed-4e9d-4073-9e24-438362666e2c">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ie462a20b8c7642d6ba2baedaff5e64eb_D20200807-20200807" name="ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82MS9mcmFnOjA1NDJiYTIwNmJjMjQwYjZiODhiMzVlMzc3MDczZWI0L3RleHRyZWdpb246MDU0MmJhMjA2YmMyNDBiNmI4OGIzNWUzNzcwNzNlYjRfMzIx_47c8099f-b98d-470f-a2a7-63be2c7df602">12</ix:nonNumeric><ix:nonNumeric contextRef="ie098330be0d142e7842c556f7a93810f_I20220630" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82Ny9mcmFnOmYwYWUwMjMzYzA4MTQ1ZDliZTM4ZDgwNTAwM2NlZGU3L3RhYmxlOmEyMjU1N2VkNjRkMzQ0NGM5NzUyNDNlZWI3NjY0MTMyL3RhYmxlcmFuZ2U6YTIyNTU3ZWQ2NGQzNDQ0Yzk3NTI0M2VlYjc2NjQxMzJfMi0xLTEtMS05MTI4NA_747e848e-dd04-4b6b-b59e-5735ceeec530">P6M</ix:nonNumeric><ix:nonNumeric contextRef="i1b0d1f3a33164d8db9d0239f934f78e2_I20220630" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82Ny9mcmFnOmYwYWUwMjMzYzA4MTQ1ZDliZTM4ZDgwNTAwM2NlZGU3L3RhYmxlOmEyMjU1N2VkNjRkMzQ0NGM5NzUyNDNlZWI3NjY0MTMyL3RhYmxlcmFuZ2U6YTIyNTU3ZWQ2NGQzNDQ0Yzk3NTI0M2VlYjc2NjQxMzJfMy0xLTEtMS05MTI4NA_6f43f310-e161-4777-a866-671472e8f3a1">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="ie526f761a4724513a2cc99ec8bd346cb_I20220630" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82Ny9mcmFnOmYwYWUwMjMzYzA4MTQ1ZDliZTM4ZDgwNTAwM2NlZGU3L3RhYmxlOmEyMjU1N2VkNjRkMzQ0NGM5NzUyNDNlZWI3NjY0MTMyL3RhYmxlcmFuZ2U6YTIyNTU3ZWQ2NGQzNDQ0Yzk3NTI0M2VlYjc2NjQxMzJfNC0xLTEtMS05MTI4NA_f236acba-fa4d-4ddc-8d78-fe944fff6326">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="icd351b95704f42138af3e4b83951e506_I20220630" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82Ny9mcmFnOmYwYWUwMjMzYzA4MTQ1ZDliZTM4ZDgwNTAwM2NlZGU3L3RhYmxlOmEyMjU1N2VkNjRkMzQ0NGM5NzUyNDNlZWI3NjY0MTMyL3RhYmxlcmFuZ2U6YTIyNTU3ZWQ2NGQzNDQ0Yzk3NTI0M2VlYjc2NjQxMzJfNS0xLTEtMS05MTI4NA_7214eead-cc83-46d0-a357-dd80626c7ec8">P1Y</ix:nonNumeric><ix:nonNumeric contextRef="i5bd4b4922a534fcaa24291b742a545e6_I20220630" xsi:nil="true" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82Ny9mcmFnOmYwYWUwMjMzYzA4MTQ1ZDliZTM4ZDgwNTAwM2NlZGU3L3RhYmxlOmEyMjU1N2VkNjRkMzQ0NGM5NzUyNDNlZWI3NjY0MTMyL3RhYmxlcmFuZ2U6YTIyNTU3ZWQ2NGQzNDQ0Yzk3NTI0M2VlYjc2NjQxMzJfNi0xLTEtMS05MTI4NA_fb8da6a4-b627-43ae-991b-eee3fb083302"></ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="ic35d6a5efbec4048af7bd5ca4930dea6_D20220101-20220630" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMS0xLTEtMS05MTI4NA_ee3774d5-fbe7-4535-a72a-7a9606170289">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i7520df23b29548ddbbab5ea7b1ed4131_D20220101-20220630" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMS0yLTEtMS05MTI4NA_4927097c-d24c-46f0-9a9e-af069a6dcd43">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i274c949e1752478484975b83abb970eb_D20220101-20220630" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMi0xLTEtMS05MTI4NA_e1bba275-077c-4ed1-ab17-0274f2e0f451">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="iaee9ec75282048039fa2f0a4d9211d2c_D20220101-20220630" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMi0yLTEtMS05MTI4NA_e20d84d3-2e62-4546-9b3f-5ce637de9579">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="id64db5439834429ba7ae71901959c5cb_D20220101-20220630" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMy0xLTEtMS05MTI4NA_4e20ba92-6d43-4a63-ab12-bd09f4f3961a">33.33</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="i3fa5b647069a475dbfe6550f70c5f6b9_D20220101-20220630" decimals="4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMy0yLTEtMS05MTI4NA_c5928495-2bb3-47f9-890f-7c43c64c207e">33.33</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="ebs-20220630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a212ec24cf0433e91c08f5f7a4260f3_I20220726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="ia80f097061ac4deb804ac1a7be81e63d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i72306a994b9b4e40b4c06153d3cccd44_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i9b613598404b49b880eecce284caa409_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic14c595631e444d1b209fffe8cd22901_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11d6b9ed7cef4daf9b8dc0c61d4b8f0b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d9f1173bf46467fa504dd84e978c454_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cc2230d43ca419eb9859817a3e13e4a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4c35eb92f4e94539aef959a8629ae0e7_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i122c38cfc545444f95a68c8027e7c09e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db2e41be1c547f68cf80fdad0358d9c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib9d3fffbd0944df8a31002d86dafd0b1_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia599ba7606a14a5fa0bcefaa77322797_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifef1158a0f1b4f9c9cfe6d88fe654e3b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e3ddd561972469b83305bb2ad955b68_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibba5b2ada3cf4cb4a6b4ba683779728e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a54e7d85e014e56956c4c0661a1e4ed_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f9afc75663f4899a4fc9be307765379_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f00bb59ea1746fbb21fbadf3f414a92_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cff17dc6fc04ad7ab4b4434ef23201b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i400967d6466a4b58a011f5b045886df0_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71c6824cc4fe485ca827c9836e570401_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b115351905c4ee2931cba201308bfe2_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifcb77253dbaa4e16b55791df9ea6fddf_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib6cd72da23074b5dbf0c4367cf392a9d_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53b18d134caf4ae2bba1d299e79c0f1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53adab0b44f14127b1c4c4f2539a1807_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if87c2ef5ba4f4d7abb9178e57763e7ff_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i66eaca4aafd84de8a80ea8db300174dd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6c074f371d0a46638d50ebd9d45e0f59_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26eb6b2c35ad4617b43852b247ceea23_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic692f65706164ee49ec3a380b592e311_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7dc3abe30a64ca2932c00efd6517a60_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if12d50ad93034fe0bf993311a0d00e34_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f4f1eaec93744e09d2a5e94ada672c5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i412510cc8ecb48538d8d3800311216b7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib20d47a77df04874a03809c71af93bb8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5addde9d9dae48a8ad041d366228d429_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i461082bcdf04496582b622477c82809e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i557996cf1b9849c7acfd550d094c2417_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2336cd80ecb49729b81f005c693fca9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0ca88e5d8bf24c309e9d2a5171b224ec_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05378be1d058489c8c528d17225c53e9_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie7050e3a97a242b092682346cbd7cd4e_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3bbf3905bf542958d5e24c590031249_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide22df8c6fb348659c7397b47c73fe57_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2761304ddf59466ba7ad454fdf7d3b89_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc26b21d7d8496f9bb774f7ac399651_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f7ee7f25e24cf382b2910e45037cd5_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i780e0257b99f470bac2458708cbdb98e_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i40faa34fd48c4a798a6fe90fe21fd4e5_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idc5bcc44a9ca46599e2b25daa2a69029_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5d6dfa3b33ba4a26be19db91781e5050_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie40f227742694bbdaee04db49ed26512_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6387f180981b459b9fe20889f53d8b6c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34769cb2cad546d9a34ee9510f37cbfd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80b954c7fdb04b88b99f239e25180b5c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3a86954dc6340629ca543163504fdb4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14cd7836cc584c8fb4799a4f34d22bb3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief6c31325bb94b9094ce98e80f0a6bb3_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5589e73e44f74b778672ccad28f1df27_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cb30120c0cd4c26b09246b92a5b9300_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b789b56b81c4d9a9a529b16bb9daa53_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e62c5dc2e50467ca24d45cabc0c75e5_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie273c395662a4debaddeffc56206d4c3_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3f1aae4f21ea48c7bb113f0bb2d224ed_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84fb728efecd4d3eb00c3307db37929d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf50b30461ed4bd5aa0c129d970ef57d_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e7a561bc9634b07b67a3141075d5a76_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6b62099afb4848769e1d1bd825d654a0_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2eba64a7c8645ceb35da700cc48a11a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8db1424bf80e4508a67ed768a524f425_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id728fefbf15d4c8cabf2af784f9cb5fb_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="category"><xbrli:measure>ebs:category</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>ebs:product</xbrli:measure></xbrli:unit><xbrli:unit id="productcandidate"><xbrli:measure>ebs:productCandidate</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>ebs:segment</xbrli:measure></xbrli:unit><xbrli:context id="i280deffd19c14987aeb06f69ff2cdd96_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf95dce5cfef405cba6b0d18b94cd870_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:MilestonePaymentFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fa607b80d2746cbb317c99fbd84728f_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:MilestonePaymentThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e44623ce7f0456191e95efe535f9f33_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:MilestonePaymentTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4585a13ee1354a528f4c34f7706a0ec8_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:MilestonePaymentOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie9fd4d849f564c9fb40d3df840d093e5_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:RegulatoryMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8635afeff8644e21a1f82f113b82e3a3_D20220701-20220930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-07-01</xbrli:startDate><xbrli:endDate>2022-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="treatmentcourse"><xbrli:measure>ebs:treatmentCourse</xbrli:measure></xbrli:unit><xbrli:context id="i453d53e9bf31458986795e4f39e26923_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bd46276d3b04bd4b23ff8a4977603af_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6549082d6bea4ee292c42fcb1e41c193_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67809435803d4785af1d56017bd50fe5_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic594742899c1467ba744e0c848e9a5fc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if1a7d2d8b2634e30b07c0639a0a4ffe6_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i134070129abc4a5f994c045f64942b5a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i53d26d6afabb48b2bf9ddc2fb0a2211c_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e92b9a6f4ef4b27b44d1e0436ee4f05_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9cc08f556fb64cd7881fbaf9a720bbb2_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9546d5f25011482ea8eff2df29f3ff29_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9638e645586946feae3242935cd61d34_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec5db6327b294813891aa4350122c017_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0ae91bff48a14d479830dd7525eb8ff8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2719aab9d5794354b6d5b105d461f2f5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3702d910f4e4076ba85f38d2f42d7f4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f3ab8a51d54481e9e87b3f7cd0d98a8_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaecb377a9b7d4fc4a9340b29e791ac69_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb945e79e9d14eb897b6c2bb31d6fca4_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if7a3ff2d30f44b30ad269a86575c7d4e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i79799b3cea2d48fe835c4576542f0b52_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f5ad802356e448ab1848888d53289de_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b48ff71a5694921b7c29a1874507763_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29e74e081ffd481a81c8d31209a72a7b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84ec0dc532f44309a78a239914a64f67_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e03e34023ba4211b5ca4dafd5a90760_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if86a10b89dc447daa6d9d4bf87168919_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2ff9b0c4a1d54ae9a2bbb36bb215f296_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia002b59284bc4d199415af1950deab8e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05104b094a7244639351db2f1a5c4ae2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7aad5be81d9e42518d03593f82a64ee7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5709272ba65411cb08a6afe257ae472_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icaad2ed6a61b4a8ca6f97ee4093e90dc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f9ea93856b0488caab05e73833c90f9_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13b7d630bf0142c6885ef16b3dd8ee1b_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia00c535b28684f0fb4f18a37ffde27d1_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94171351ca92471d95422d2216ab5acb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia9e69b63b67f4da689c99626eb9b9b75_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i55840f9158e144dd8f3579713ad95750_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1827bdb5367f4f7980f91a6d166e8719_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7b0124a24a6d42f38a22a139d7a986cc_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7ec6f53ea7c40c2912590dc96df1140_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3767e06a12a4c5e98d3e3277b684a7a_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i63a027931d994feaad0cc197610c9386_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83059e6d4cbf495fac3749e03908d241_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i719981bf5f3142bcab25241944433a85_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if69c9e056c6b47ce9a39e1690508a029_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb1acd071817481e9aef10fe54fb65fb_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i64a444e1b04f441690465f4274c0ba71_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5baf28559b9c4518961b9d35563505d5_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="instrument"><xbrli:measure>ebs:instrument</xbrli:measure></xbrli:unit><xbrli:context id="i8fef5a8c0e574704b4e7fc1c219ab3d0_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec600dcf49a542e999254859b44d9453_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10a6fba32aca4cf289ec54a01e657a74_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9db202080e4f497184ae1cf6144f3e2f_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic20b9c06c3554129afcfbc3e3f02046b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic7068fe6db2b4311a9524223dac6fb00_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icee5403eeb9f41649ba99ccabe3e2da8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i05d57a1513ce46c68b959f35fdc72cec_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifa0b79c3b615467b86496c6b28174204_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc3c3a4cf51a47be9050271b2311e72e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7f1e5afa818e49f1bb83f2fde4b26d1b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i906b83ea370446e3be94c4ddaaa4083e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i95dc7a5826cb458ea6fbfdfca937dcbd_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie971a34ecfcf4b408a15bfa4996e60a7_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb778bbc0bd64de7ad6801fd66de8bbc_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1555249a53454772b48e904b14824e1d_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1485bfe38fce41ec95d481aecf94f617_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if549fa85623e479b8a4ea408bf3855e9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife82c6e169cb463d8894b9c0060a4276_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if194a1fa3b4249e29ea4d656684e16a6_I20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i854ab883416b4f61a70d7a994a7e7dc8_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7406b9184a64854a36cdc074d9b7efd_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77bd92decaae4597a010ce330d685077_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i864f4e447766464d959250dafeb367a6_I20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d27dfde1b0a4ca9bd9806ae5f1fd0e0_I20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-08-07</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd60b38179fc4f99af5a397c6f413c8c_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4154b9a491b4ef2aff17f1e88bb8277_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1e09335afe7401fabaf417e79536c26_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97df715145c94a708ee00a7a333e62fa_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9af3fed7d2eb49a0934cfdea363489d8_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98549f959da647058170049a65c7b6c1_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06495fe6675749ddb25cf196298c2fa3_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cc8672e8d254d8cbb23b229dcd959c8_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie462a20b8c7642d6ba2baedaff5e64eb_D20200807-20200807"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-07</xbrli:startDate><xbrli:endDate>2020-08-07</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i574f9adb7940424798f2d99703583daa_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7168a15913e0452ba5e8b7cc16cd596d_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37b9298740734b91b9649eca3d31f872_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb0dfd1b367d4a4bbc9a8d933e8d12c5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78916fe957f24b278cd2cf0ff71d751a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f3b32beef6f4047a8dcd6932c3b547a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3037fdadacbb4e5f923277f2e26c9563_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6995a6427d454821b7f5573c0a1da3af_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f3722b3ba404046b480130be3ff47cb_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b2c6cc57c314379aa754295fc61f0c2_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieedc7121a2874e219f1a1ca878ff2c37_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idfcb43efacdb406f820678d118bbcdd8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b31182d8bf44cb88f2e81054292fb42_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ecb5143f5f7478faa5324a51e49bd6c_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icba1568320d14f98b740134699420a7c_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i719033973c3c4e0790d3212f10dbadcd_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16ac2c2d319f4a00960710084dc7bba7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b6fd4492311495296403951539f5faf_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7a523ccb265741f5b098e936ed21f511_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia08e21eff6ed4142bc00ba76de36b98f_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib10b78dae7ed4de9bc5eb331206a3762_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i998d829e65ec4f968b9b5085e7009b74_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c33e6e45e2f4158a121a529bf2b99e5_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23b51504df3547d59b0d56b9f31e6a34_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied017d66c9a04bb4b5c3696003cdbb8e_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie51251ad5ad54f02b4a1e43a1067e7f6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i306561841c10468db12c5597d3a0468a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id856ef449e024e50a897807c5afed116_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i658c5b8c655e4fe38b0b7f174e852ede_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9e160d23cc4468b348e9ba5f68fc60_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i766a0ecaa10f4c1f94e835811699f36d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd47aaf57ffa4b1c9c70108fac1b456a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idead1f4a85bf4ee4931efc0bd2008a9a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i64e99aeb36a14462901695d8142755c7_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06918d944d12481c84ebd11d669df56b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib92f173e44b44baea23201309efbbd31_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb080faf3355468f962da743b6925f17_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7836569c48aa4398960b690e02f1638a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie645b23e92d64b44af482e9d18e83a21_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib607439c17cf47a5a315dbba5676680b_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idef67034a80d49fe8d29b21339809e4b_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i637fa78972d94585a80a29492e1528c4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f45031de4147aab74078725161519c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id805e73cf4794980a908e6c22c926058_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cf722f817414de59d8f7e7ec0bb2c95_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i265aa2e4d2d24bb5be2c124345a65d9c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic78d782fd08747beb9ebc02fbc6bca30_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i813b606241794bedb7b0678f9d44767c_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i748c972f7e3046359ad4f7b45600bbb1_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb3cc4b31c2349e6b5a80a9253019e4b_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i073a439499194e698141d7a144b95b2c_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic4a7c235f1654834a48248b64d3dc321_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:ReservationOfManufacturingCapacityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7fa5c022d91149dabba1e1fa641192ee_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:AcceleratedExpansionOfFillFinishCapacityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31dbfae47072459191568cdf89902293_I20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i078e4fd9eef24b03a26dff9571fa22d9_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie098330be0d142e7842c556f7a93810f_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1b0d1f3a33164d8db9d0239f934f78e2_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie526f761a4724513a2cc99ec8bd346cb_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icd351b95704f42138af3e4b83951e506_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5bd4b4922a534fcaa24291b742a545e6_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c1bb85380c94c46946e590854b1feb8_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icf331b5878004125a9676034ba0f2a5c_D20220101-20221231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a9aaf25fc5d48ee87baec975ac47be1_D20210101-20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46d185ce265a44359c45e086acb0e06f_I20211111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-11</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idb62694863024c3a8c06044192e2a6da_D20211111-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-11</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id438572de7754b2f9af627f967ba0ce0_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c3242ff1d6e403fa058caec92b768c4_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i444f6b6169bc431ab44cce091d529975_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68490917c6324e3abbbef73aefa2e5f9_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ba5495e2a404e7caafe9e03e3fe1861_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d37be8412c8482e947483881b8b5b51_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8109d0584c4f24a37d0e0942db1c06_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e87ee8954dc437da9f27f6e09cd767a_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i775d01162a634709894e9ca391a7f259_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i483660136dd443e5916afc6418da38ad_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3497690a3cbd40f3b831488b3657d7c6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2848bd97786b4d5ba2937b70a2f4bf70_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39ffb192289e4ce9a528e436037c0be5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83dd17fd91084cafbcc04f18320932c2_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic952574703dd49c3a143c50a76cc5bb7_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f3f3064f53498493eda16fac112d94_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i55f86755507140aaa0522c374f09ab1d_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79e636bd573c405188f12505ae586714_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i830521684abb4fd9aadb53001edc7379_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifac78b9519ad40da9ef031b1e7724460_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icb61d55a3a5f4c6eb6ebb20e951d3dd3_I20211231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec438a15507545e69f9ae19f0a3d5941_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i651fc075a09948b29a069bfed15ac793_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ae6af3ca5ff479b95eef53b77bd535e_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5904a41b0c2944d1bc9877b651a3f0fe_I20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic637379f0d8043d5af581e734aefd028_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8daff84a60ea419db78f98817926f778_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if6289d96bf3f4d3dad0b8d93584c1fb1_I20220331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43051341a0744172a54eb2e3094323d6_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c848d9c0ea44feaa1b6615d95059e2_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b18ce4c0ae74dff995c8a04ce8a3f19_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3a73d2985e143b08dff3ac4720bea90_I20201231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59961335356647079ef2934edbcfa823_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia2ba91a37c45433382623dcdb7bd5722_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id88c42efd11a49ef841182aac044455d_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31cb95adcb0a43cb82eb1863ad9f5748_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i529a638b09f04a2a8bc2cc0b002cd45c_I20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4ab0f0ae6ef4c1da3db1ce773f632c0_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i28b844ae659d4576b73d8e1361ed9d73_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1bf5df54710d4ea4b5ed41c57fe517a4_I20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45ee1c733d0e40dc98fb96a0479d1554_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35d6a5efbec4048af7bd5ca4930dea6_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7520df23b29548ddbbab5ea7b1ed4131_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i274c949e1752478484975b83abb970eb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaee9ec75282048039fa2f0a4d9211d2c_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id64db5439834429ba7ae71901959c5cb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fa5b647069a475dbfe6550f70c5f6b9_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ef607d7a3c7451f9fc91797c668e35b_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i865cea62a18543cb83411d9461069e79_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30013848203544aaab36afb676ed3c64_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b063649105148fca27b7b94d3b8e412_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46b2d87a49bb494a84bf9da22318cb73_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i05f0ccbd84a246cd8e98d3b72d6b8dd3_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i017940019b8f4dd28eddab4c25571c62_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79dd2d62f4de4d778696638252882cf2_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e1a370ad2f74ba9974ee7ae4c0046ea_D20220401-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2256cc8ca6db4b8facf112f19dc9715b_D20210401-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i47cb7eb2f6354e03ac1eaca0de11507a_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3159b0dd6390463898aef3e672bfd623_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ef70cac4db448e4864f2175f2373dfd_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4d814b28862414f8af4e0b81c135010_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bd990b6a0ad4694b2c05770255685f3_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b72f2081fbf4b8284ba76726875fc2a_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bccaec18dd645feadb40845bece9039_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10be8bddd4d942c08359df94ab97fea5_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7deb271d98c249298506cf1f896e57cb_D20220101-20220630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedc4cae43f3c454598ce8975dac330c5_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibc42e37be5a94e4f8f3591414bf596dd_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffc6765500b949268c476664a96a2cc3_D20210101-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001367644</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i4ef4253100994f989fd72d1c0fd41d25_1"></div><div style="min-height:42.75pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI5_19358248-8c0c-485a-92d7-7d4b490bf6ce">10-Q</ix:nonNumeric></span><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.985%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:DocumentQuarterlyReport" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6ZjZjODlkNzU4MTc0NGFiNThiZTg4N2QyMmFmODY4MTkvdGFibGVyYW5nZTpmNmM4OWQ3NTgxNzQ0YWI1OGJlODg3ZDIyYWY4NjgxOV8wLTAtMS0xLTkxMjg0_1afd6c91-66db-43fd-8347-71d33c3c76a9">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the quarterly period ended <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xMzI_2b9be555-ae6d-4662-a042-1e9b2974cd29">June&#160;30, 2022</ix:nonNumeric></span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OR</span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.985%"><tr><td style="width:0.1%"></td><td style="width:2.728%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:95.972%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MDU1MGYwNDk0YTFhNDNjM2FlNjgyMjJlOTY1MDlmODUvdGFibGVyYW5nZTowNTUwZjA0OTRhMWE0M2MzYWU2ODIyMmU5NjUwOWY4NV8wLTAtMS0xLTkxMjg0_82d4f8b0-dbc0-4848-906f-04c6c4db183a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the transition period from    to        </span></div><div style="margin-top:4pt;text-align:center;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODIz_95b9d553-e147-4090-9def-09e916932fba">001-33137</ix:nonNumeric></span></div><div style="margin-top:5pt;text-align:center"><img src="ebs-20220630_g1.jpg" alt="ebs-20220630_g1.jpg" style="height:20px;margin-bottom:5pt;vertical-align:text-bottom;width:150px"/></div><div style="text-align:center"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI1_b0c0404a-e413-4bb3-b028-6470ac5da3f8">EMERGENT BIOSOLUTIONS INC.</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:120%">(Exact Name of Registrant as Specified in Its Charter)</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:44.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:44.263%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF8wLTAtMS0xLTkxMjg0_a21989d8-f53c-416e-b4f8-e7027d85af67">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF8wLTItMS0xLTkxMjg0_4cbd5fe4-5df1-45e3-9b72-f418f974d0f8">14-1902018</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(State or Other Jurisdiction of<br/>Incorporation or Organization)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(I.R.S. Employer<br/>Identification No.)</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF8zLTAtMS0xLTkxMjg0_ba9f33c3-0ed2-417f-98af-e174d7fdb6f3">400 Professional Drive Suite 400</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF80LTAtMS0xLTkxMjg0_5124614f-6a27-4a57-9688-7df9c87adb25">Gaithersburg,</ix:nonNumeric>  </span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;text-indent:4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF80LTEtMS0xLTkxMjg0_55952a5e-e26e-4b97-a4b8-6699ff848ffe">Maryland</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF80LTItMS0xLTkxMjg0_01fb9ae7-fdbc-4686-8175-590e24205f69">20879</ix:nonNumeric></span></td></tr><tr><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(Address and zip code of Principal Executive Offices)</span></td></tr></table></div><div style="margin-top:1pt;text-align:center"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI2_e8d06674-4eda-4554-8308-79d30959c82e">240</ix:nonNumeric>) <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI0_7cd533cc-a061-43ad-a47c-5e43fd725f43">631-3200</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:120%">(Registrant's Telephone Number, Including Area Code)</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.855%"><tr><td style="width:1.0%"></td><td style="width:34.458%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.040%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.202%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities registered pursuant to Section 12(b) of the Act</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MzcxNjk4NjkzZDM4NDgyMTg2NTIxZGI2Njg4OTM5MWQvdGFibGVyYW5nZTozNzE2OTg2OTNkMzg0ODIxODY1MjFkYjY2ODg5MzkxZF8yLTAtMS0xLTkxMjg0_bb0a5c18-5247-4fe0-8c7a-ff3ebd9b5643">Common Stock, Par Value $0.001 per share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MzcxNjk4NjkzZDM4NDgyMTg2NTIxZGI2Njg4OTM5MWQvdGFibGVyYW5nZTozNzE2OTg2OTNkMzg0ODIxODY1MjFkYjY2ODg5MzkxZF8yLTEtMS0xLTkxMjg0_af1de316-42d2-4f2c-b908-a4450d41c0bf">EBS</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MzcxNjk4NjkzZDM4NDgyMTg2NTIxZGI2Njg4OTM5MWQvdGFibGVyYW5nZTozNzE2OTg2OTNkMzg0ODIxODY1MjFkYjY2ODg5MzkxZF8yLTItMS0xLTkxMjg0_3cf3fc94-7b72-4b0b-94dc-41d91217633b">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:9pt;margin-top:7pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746; <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODIy_b2823525-5f83-4a82-9ce9-c86ec12f11db">Yes</ix:nonNumeric> &#9744;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9746; <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI3_df487248-d2d1-42e6-8cde-65d0bebace43">Yes</ix:nonNumeric> &#9744;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:700;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">No</span></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-bottom:7pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.218%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.583%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MTU0MWFiMDU0MTE5NGEzODg2OTUyMTI1M2MyYjUxZTkvdGFibGVyYW5nZToxNTQxYWIwNTQxMTk0YTM4ODY5NTIxMjUzYzJiNTFlOV8wLTAtMS0xLTkxMjg0_966187f3-67ad-4747-8137-7a9b1cfaa1fe">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MTU0MWFiMDU0MTE5NGEzODg2OTUyMTI1M2MyYjUxZTkvdGFibGVyYW5nZToxNTQxYWIwNTQxMTk0YTM4ODY5NTIxMjUzYzJiNTFlOV8xLTMtMS0xLTkxMjg0_03c2a1bc-a651-4f5f-9eea-7c7bc407331d">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"><span style="font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><br/></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MTU0MWFiMDU0MTE5NGEzODg2OTUyMTI1M2MyYjUxZTkvdGFibGVyYW5nZToxNTQxYWIwNTQxMTk0YTM4ODY5NTIxMjUzYzJiNTFlOV8yLTMtMS0xLTkxMjg0_c3ab60d6-bb8b-4857-910a-e8e8204e8dd2">&#9744;</ix:nonNumeric></span></td></tr></table></div><div style="margin-bottom:12pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act. </span><span style="color:#2c2c2c;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes &#9744; No <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI4_b0bd934b-0d91-4abf-9076-2991484fd81e">&#9746;</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of July&#160;26, 2022 the registrant ha</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">d</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> <ix:nonFraction unitRef="shares" contextRef="i6a212ec24cf0433e91c08f5f7a4260f3_I20220726" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xNzg1_f75b1983-27d8-42bc-82a8-1bef09279b23">49,861,509</ix:nonFraction></span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> sh</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:9pt;font-weight:400;line-height:120%">ares of common stock outstanding.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_7"></div><hr style="page-break-after:always"/><div style="min-height:18pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc.</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Form 10-Q</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Fiscal Quarter Ended June&#160;30, 2022</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TABLE OF CONTENTS</span></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.856%"><tr><td style="width:1.0%"></td><td style="width:14.007%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:74.439%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.254%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_10">Part I. Financial Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_13">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_13">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_16">Condensed Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_16">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_19">Condensed Consolidated Statements of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_19">6</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_22">Condensed Consolidated Statements of Comprehensive Income</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_22">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_25">Condensed Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_25">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_28">Condensed Consolidated Statements of Changes in Stockholders' Equity</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_28">9</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_31">Notes to Condensed Consolidated Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_31">10</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_91">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_91">Management's Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_91">28</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_115">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_115">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_115">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_118">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_118">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_118">38</a></span></div></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_121">Part II. Other Information</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_124">Item 1.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_124">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_124">38</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_127">Item 1A.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_127">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_127">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_130">Item 2.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_130">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_130">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_133">Item 3.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_133">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_133">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_136">Item 4.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_136">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_136">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_139">Item 5.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_139">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_139">71</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_142">Item 6.</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_142">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_142">71</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i4ef4253100994f989fd72d1c0fd41d25_148">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><a style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i4ef4253100994f989fd72d1c0fd41d25_148">73</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PART I. FINANCIAL INFORMATION</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This quarterly report on Form 10-Q and the documents we incorporate by reference include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including statements regarding the future earnings and performance of Emergent BioSolutions Inc. or any of our businesses, our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management and the ongoing impact of the COVID-19 pandemic, are forward-looking statements. We generally identify forward-looking statements by using words like "will," "believes," "expects," "anticipates," "intends," "plans," "forecasts," "estimates" and similar expressions in conjunction with, among other things, discussions of financial performance or financial condition, growth strategy, product sales, manufacturing capabilities, product development and regulatory approvals or expenditures. These forward-looking statements are based on our current intentions, beliefs and expectations regarding future events. We cannot guarantee that any forward-looking statement will be accurate. You should realize that if underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. You are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date on which such statement is made, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events or circumstances.</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of important factors that could cause our actual results to differ materially from those indicated by such forward-looking statements, including, among others:</span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the availability of U.S. Government (USG) funding for contracts related to procurement of our medical countermeasures, including AV7909 (Anthrax vaccine adsorbed (AVA), adjuvanted), BioThrax&#174; (Anthrax Vaccine Adsorbed) and ACAM2000&#174;, (Smallpox (Vaccinia) Vaccine, Live), among others, as well as contracts related to development of medical countermeasures.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to meet our commitments to quality and manufacturing compliance at our manufacturing facilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the impact of the generic marketplace on NARCAN</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCI) Nasal Spray and future NARCAN sales;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to perform under our contracts with the USG, including the timing of and specifications relating to deliveries;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to provide contract development and manufacturing (CDMO) services for the development and/or manufacture of product and/or product candidates of our customers at required levels and on required timelines;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to obtain and maintain regulatory approvals for our product candidates and the timing of any such approvals and our ability and the ability of our contractors and suppliers to maintain compliance with current good manufacturing practices and other regulatory obligations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to negotiate additional USG procurement or follow-on contracts for our Public Health Threat (PHT) products that have expired or will be expiring;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to negotiate new CDMO contracts and the negotiation of further commitments related to the collaboration and deployment of capacity toward future commercial manufacturing under our existing CDMO contracts;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">our ability to collect reimbursement for raw materials and payment of services fees from Janssen Pharmaceuticals, Inc. or other CDMO customers</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the outcomes associated with pending shareholder litigation and government investigations and their</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">potential impact on our business;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to comply with the operating and financial covenants required by our senior secured credit facilities (Senior Secured Credit Facilities) and our 3.875% Senior Unsecured Notes due 2028;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the procurement of products by USG entities under regulatory exemptions prior to approval by the U.S. Food and Drug Administration (FDA) and corresponding procurement by government entities outside of the United States under regulatory exemptions prior to approval by the corresponding regulatory authorities in the applicable country;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the extent of any ongoing impact of COVID-19 pandemic on our supply chains and potential future impact of any variants thereof on our markets, operations and employees as well as those of our customers and suppliers;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the impact on our revenues from and duration of declines in sales of our vaccine products that target travelers due to the reduction of international travel caused by the COVID-19 pandemic;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">our ability to identify and acquire companies, businesses, products or product candidates that satisfy our selection criteria;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">our ability to commercialize, market and manufacture new product candidates successfully; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.78pt">the accuracy of our estimates regarding future revenues, expenses, capital requirements and needs for additional financing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from our expectations in any forward-looking statement. New factors emerge from time to time. and it is not possible for management to predict all such factors, nor can it assess the impact of any such factor on the business or the extent to which any factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. You should consider this cautionary statement, the risk factors identified in the sections entitled &#8220;Risk Factor Summary&#8221; and &#8220;Risk Factors&#8221; in this quarterly report on Form 10-Q and the risk factors identified in our other periodic reports filed with the Securities and Exchange Commission (SEC) when evaluating our forward-looking statements.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE REGARDING COMPANY REFERENCES</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">References in this report to &#8220;Emergent,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Emergent BioSolutions Inc. and its consolidated subsidiaries.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE REGARDING TRADE NAMES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BioThrax</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BaciThrax</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, RSDL</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, BAT</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Trobigard</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Anthrasil</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, CNJ-016</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, ACAM2000</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vivotif</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Vaxchora</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, NARCAN</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and any and all Emergent BioSolutions Inc. brands, products, services and feature names, logos and slogans are trademarks or registered trademarks of Emergent BioSolutions Inc. or its subsidiaries in the United States or other countries. All other brands, products, services and feature names or trademarks are the property of their respective owners.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. FINANCIAL STATEMEN</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">TS</span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_16"></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Balance Sheets</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(in millions, except per share amounts)</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ededed;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMy0xLTEtMS05MTI4NA_b44b9c31-2da1-43a0-b913-dbe1ce48b964">358.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMy0zLTEtMS05MTI4NA_039e860f-5788-4718-82fa-91dbf715f322">576.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNC0xLTEtMS05MTI4NA_912021b3-a8e6-4e8e-b711-aa8d7c485c9d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNC0zLTEtMS05MTI4NA_a095dbde-7816-4f70-8a5b-f4c2a66acf6c">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNS0xLTEtMS05MTI4NA_964964ce-c882-4406-bc3f-5a816ac0c18a">175.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNS0zLTEtMS05MTI4NA_cb906f86-c3df-4f01-abdf-f29a0ec7f049">274.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNi0xLTEtMS05MTI4NA_87d89b30-8391-42ed-b83a-b5543efd4aa2">425.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNi0zLTEtMS05MTI4NA_cf288b83-9185-4f63-9e47-21d65f4d9ea1">350.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNy0xLTEtMS05MTI4NA_998a14d1-4fc9-46c3-b9e3-f114c33f7371">125.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNy0zLTEtMS05MTI4NA_c20c2394-03c6-495f-994e-c7c569dd80d5">70.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfOC0xLTEtMS05MTI4NA_7be33fb1-6859-49e5-a711-6c9d1362641c">1,084.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfOC0zLTEtMS05MTI4NA_6663beb8-5d40-401a-a4a1-b841b7fb12b5">1,272.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTAtMS0xLTEtOTEyODQ_2177257e-6a8b-48d5-baeb-b254902a1c53">798.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTAtMy0xLTEtOTEyODQ_7dd1d855-dfc3-49db-9e47-258954fbf28f">800.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTEtMS0xLTEtOTEyODQ_a675c21d-3408-47f5-8463-4c4839f45d72">576.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTEtMy0xLTEtOTEyODQ_63a03743-f074-4283-8f6b-47963bf65326">604.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTItMS0xLTEtOTEyODQ_dc51dfa4-eaf0-402c-b757-05b87b01e62f">224.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTItMy0xLTEtOTEyODQ_0049ce99-6159-4cd0-b91d-a0ba221494a0">224.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTMtMS0xLTEtOTEyODQ_a5252a86-37bb-4969-8d17-b84548a3063f">51.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTMtMy0xLTEtOTEyODQ_4016b2ba-7e05-411d-ba93-f551cdefa749">57.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTQtMS0xLTEtOTEyODQ_8c39d197-2307-44fc-bbf6-b16db2d949ab">2,735.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTQtMy0xLTEtOTEyODQ_5e89c5e1-ca3a-44fc-8c06-9b1be9180677">2,959.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">LIABILITIES AND STOCKHOLDERS' EQUITY</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTgtMS0xLTEtOTEyODQ_49a0ddb1-fd57-45bc-ab1e-fd3e88caf283">106.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTgtMy0xLTEtOTEyODQ_8d4d5786-d79c-47fd-8540-c363c6ef5996">128.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses </span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTktMS0xLTEtOTEyODQ_232123f3-6da1-4547-864d-d6e2ef046f70">40.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:AccruedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTktMy0xLTEtOTEyODQ_a97ea8bb-2772-4c94-ad03-b0b3a2ba857f">51.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjAtMS0xLTEtOTEyODQ_e314b580-4f40-4d89-b2c6-a9660a1fdc5e">74.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjAtMy0xLTEtOTEyODQ_e7ecadb3-966a-446c-b811-c8edfbfe5ad7">88.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, current portion</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjEtMS0xLTEtOTEyODQ_657837a8-c54a-4d43-9761-f1d43f0d1cd8">31.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:NotesPayableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjEtMy0xLTEtOTEyODQ_28aaaff4-ca15-4829-8b38-eac66d8303f2">31.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjItMS0xLTEtOTEyODQ_656a91b5-259e-4f05-8b66-8bac3b4de0ed">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjItMy0xLTEtOTEyODQ_770c3cae-a2e6-4e9f-b681-75f3fa3cf7a3">72.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjMtMS0xLTEtOTEyODQ_44f340aa-ed5d-461b-8da2-51261cb4ba6a">276.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjMtMy0xLTEtOTEyODQ_bb5c8a00-649b-4723-8e96-3ca9a12b8dc5">373.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, net of current portion</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjYtMS0xLTEtOTEyODQ_2163dfd2-8476-4490-b9f3-f17778739438">793.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjYtMy0xLTEtOTEyODQ_e3769f1f-1035-411c-be87-abb36c8a8b25">809.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax liability</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjctMS0xLTEtOTEyODQ_554df853-c08f-4d57-9718-5083bd2fbb44">93.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjctMy0xLTEtOTEyODQ_0abc611b-50ed-4db7-91ed-c1b830634906">94.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjktMS0xLTEtOTEyODQ_b3000755-0e65-40b1-aadf-f67fa4706082">58.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:OtherLiabilitiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjktMy0xLTEtOTEyODQ_792d8010-dc68-46b1-bddc-f816769889ac">61.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzAtMS0xLTEtOTEyODQ_0588c844-edf3-4b13-b6d4-7cb89b205a60">1,222.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzAtMy0xLTEtOTEyODQ_2975b066-009f-487c-9d24-4235cbd5961d">1,340.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN18yMQ_a4bcf828-504d-4f0e-9352-ce068c72d08e"><ix:nonFraction unitRef="usdPerShare" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN18yMQ_a577647c-63ab-4d96-80fb-8f84f14c24a4">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN18zNQ_20a0f357-841a-4fcc-8d3a-da29a73fffde"><ix:nonFraction unitRef="shares" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:PreferredStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN18zNQ_82ae7f2a-d6f3-4ad4-ac6d-4a1097dd62ab">15.0</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN181Nw_31b33e30-ffaa-4868-8ead-f1308fa4515d"><ix:nonFraction unitRef="shares" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN181Nw_3c575594-cddd-4c5f-923d-90c866965e2e"><ix:nonFraction unitRef="shares" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="INF" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN181Nw_6a8661c8-8020-450c-a142-64cde27e68bc"><ix:nonFraction unitRef="shares" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN181Nw_6cb8d395-9c54-49fb-b334-97efce53db6d">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued or outstanding</span></div></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMS0xLTEtOTEyODQ_553f9da3-0da2-483d-984c-2901a74b6ea3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMy0xLTEtOTEyODQ_0db75f30-1d08-4419-a34b-dbea89f0be6d">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY18xOA_24ea57bf-f386-4fa8-af28-ac4962ed18d7"><ix:nonFraction unitRef="usdPerShare" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY18xOA_fdcf565b-22d2-4a42-852f-0a8a00594fda">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY18zMg_3bf0e4f8-aedd-4109-9875-37e4b7413581"><ix:nonFraction unitRef="shares" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:CommonStockSharesAuthorized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY18zMg_9507f12c-9d40-44b7-ae2d-336e8289516c">200.0</ix:nonFraction></ix:nonFraction> shares authorized, <ix:nonFraction unitRef="shares" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY182NTk3MDY5NzY2Nzc4_f4cf9489-a95a-4816-951f-e87d4b695769">55.5</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY182MQ_7f6382f3-e9c9-4b38-ad64-330393c63097">55.1</ix:nonFraction> shares issued; <ix:nonFraction unitRef="shares" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY182NTk3MDY5NzY2Nzg2_b672a85f-927c-4e76-ac38-f30a8aa14964">49.9</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY184Ng_8e78a166-e926-478e-a568-75b2b8457024">51.3</ix:nonFraction> shares outstanding, respectively</span></div></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMS0xLTEtOTEyODQ_98c93ab4-8775-4c77-adda-0be2d0cf3e71">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMy0xLTEtOTEyODQ_d39b935d-ef46-4c0e-9cc1-c395e01aa080">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treasury stock, at cost, <ix:nonFraction unitRef="shares" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzUtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjphNzUzZmU2YjAxODM0YWE3OTQ2ZDk4Yjk5OWRjNGU3Ml82NTk3MDY5NzY2NzI3_cba6e87f-08b3-4b6f-8f66-148dfdc25089">5.6</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:TreasuryStockShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzUtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjphNzUzZmU2YjAxODM0YWE3OTQ2ZDk4Yjk5OWRjNGU3Ml82NTk3MDY5NzY2NzMz_961d6e45-924e-4138-a203-28005e46a6a3">3.8</ix:nonFraction> common shares, respectively</span></div></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzUtMS0xLTEtOTEyODQ_88b0f74c-43cc-44da-a55f-0778abb67d35">227.7</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:TreasuryStockValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzUtMy0xLTEtOTEyODQ_a6927704-a5fc-4005-ac64-0f4400aa3418">152.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzYtMS0xLTEtOTEyODQ_501dda8f-96df-4568-9b68-80ea0f95c5fa">849.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:AdditionalPaidInCapital" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzYtMy0xLTEtOTEyODQ_f0306364-0f42-485b-93cd-3352d9634614">829.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, net</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzctMS0xLTEtOTEyODQ_72ebbb59-70c5-4380-8817-b2c60e56a92e">6.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzctMy0xLTEtOTEyODQ_39d7da36-f35b-4950-a99c-e3819a3d2057">16.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzgtMS0xLTEtOTEyODQ_d69f2166-a715-40db-a659-e1c4086e5e19">897.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzgtMy0xLTEtOTEyODQ_355fda08-aaee-41fa-8ccf-d2f08ca6fbe5">957.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzktMS0xLTEtOTEyODQ_e2c17d38-0c6a-42de-bef0-ee11da9339a5">1,513.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzktMy0xLTEtOTEyODQ_089668d4-e015-45b4-a8d0-f3b0b340c1dc">1,619.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNDAtMS0xLTEtOTEyODQ_8c931112-58ed-476e-b857-353a3936c727">2,735.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNDAtMy0xLTEtOTEyODQ_d2b6b1a0-9af3-4627-a46f-858fa7c5888e">2,959.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_19"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Operations</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except per share amounts)</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.496%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.958%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b613598404b49b880eecce284caa409_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMy0xLTEtMS05MTI4NA_c650ae41-e9fd-4bcd-99b7-b386872e2af8">237.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14c595631e444d1b209fffe8cd22901_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMy0zLTEtMS05MTI4NA_0c4f2996-8b1b-4445-9b18-0404fe6b2cd6">181.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMy01LTEtMS05MTI4NA_bef3dee7-bc7f-4d20-abfd-8c447b470f25">474.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMy03LTEtMS05MTI4NA_ef11309b-0201-4e15-b63e-44b73acd7a0b">319.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract development and manufacturing:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d6b9ed7cef4daf9b8dc0c61d4b8f0b_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNS0xLTEtMS05MTI4NA_f7709277-5360-4aa7-b1fd-05ed1804cabf">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9f1173bf46467fa504dd84e978c454_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNS0zLTEtMS05MTI4NA_5162b90a-6645-483b-ba9e-def04fb32f04">103.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc2230d43ca419eb9859817a3e13e4a_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNS01LTEtMS05MTI4NA_f3700bb8-2c47-4d84-9ac1-ee88a162e5ce">54.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c35eb92f4e94539aef959a8629ae0e7_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNS03LTEtMS05MTI4NA_914bf6cd-adc3-4e6f-9e1e-02c265791f8f">171.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i122c38cfc545444f95a68c8027e7c09e_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNi0xLTEtMS05MTI4NA_1185d7a4-2623-4a68-b463-1ab283a16bbc">4.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db2e41be1c547f68cf80fdad0358d9c_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNi0zLTEtMS05MTI4NA_160df036-2496-4b41-bac3-c1144311d812">87.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d3fffbd0944df8a31002d86dafd0b1_D20220101-20220630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNi01LTEtMS05MTI4NA_7633bb3c-7baf-4003-b5df-2b59c8f07887">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia599ba7606a14a5fa0bcefaa77322797_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNi03LTEtMS05MTI4NA_223611bd-f544-4e26-9cc6-2c6c5004560b">203.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract development and manufacturing</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifef1158a0f1b4f9c9cfe6d88fe654e3b_D20220401-20220630" decimals="-5" sign="-" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNy0xLTEtMS05MTI4NA_ed1beef0-0428-4b15-9c2d-e1e08869d6f5">1.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e3ddd561972469b83305bb2ad955b68_D20210401-20210630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNy0zLTEtMS05MTI4NA_7856c86d-594a-4d2b-814a-fa017a569438">190.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba5b2ada3cf4cb4a6b4ba683779728e_D20220101-20220630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNy01LTEtMS05MTI4NA_0a64b80a-0c08-455d-8efb-fb1dfcd78801">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a54e7d85e014e56956c4c0661a1e4ed_D20210101-20210630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNy03LTEtMS05MTI4NA_f8ce7c88-bebf-471f-b347-66cbab8090cb">374.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9afc75663f4899a4fc9be307765379_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOC0xLTEtMS05MTI4NA_096ad706-a2e1-4d07-a23b-17a18b9de0b5">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f00bb59ea1746fbb21fbadf3f414a92_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOC0zLTEtMS05MTI4NA_66cd547d-f6ac-495a-ab26-fd3b1d256676">25.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cff17dc6fc04ad7ab4b4434ef23201b_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOC01LTEtMS05MTI4NA_8a534fb2-9772-4f9d-9cf2-2246fa205bf9">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400967d6466a4b58a011f5b045886df0_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOC03LTEtMS05MTI4NA_351d17b5-8976-41e6-9afc-60d8508538a3">46.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOS0xLTEtMS05MTI4NA_05aacc0c-49bb-4ba3-9c74-959f252a3dc8">242.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOS0zLTEtMS05MTI4NA_d21a99b4-379d-4ca5-b23f-3c4e12b715b0">397.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOS01LTEtMS05MTI4NA_d8130bd9-cf70-4798-b592-1e6444c671c0">550.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOS03LTEtMS05MTI4NA_1e0786b6-3e71-4c6c-84f4-d6675269b3dc">740.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b613598404b49b880eecce284caa409_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTItMS0xLTEtOTEyODQ_ba4e6f47-0175-4440-b9b7-bb4f94854de0">91.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14c595631e444d1b209fffe8cd22901_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTItMy0xLTEtOTEyODQ_82b36723-c2e1-401d-bcfa-2fe4c9250c3d">81.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTItNS0xLTEtOTEyODQ_71e214c2-55c2-4773-8191-22aaa104e0ac">171.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTItNy0xLTEtOTEyODQ_81cc9c9b-4087-46dd-8b67-8dd4e371c13e">133.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of contract development and manufacturing</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d6b9ed7cef4daf9b8dc0c61d4b8f0b_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTMtMS0xLTEtOTEyODQ_c7742bf0-4dda-49fa-84be-a2911812fb80">78.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9f1173bf46467fa504dd84e978c454_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTMtMy0xLTEtOTEyODQ_59b98390-10a4-455a-9552-87753364407b">146.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc2230d43ca419eb9859817a3e13e4a_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTMtNS0xLTEtOTEyODQ_5883c54d-a689-45c1-a014-992242358de4">154.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c35eb92f4e94539aef959a8629ae0e7_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTMtNy0xLTEtOTEyODQ_321ef561-96a9-446e-b8e0-e9b11289f684">193.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTQtMS0xLTEtOTEyODQ_5f7a7715-e7f7-4fbf-b25e-c2ba15cf3dfb">49.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTQtMy0xLTEtOTEyODQ_270f0757-e44b-4b6d-a531-89b4f1ca1a8c">48.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTQtNS0xLTEtOTEyODQ_d84c0f67-cd13-4650-bb60-87e5bb2786a1">96.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTQtNy0xLTEtOTEyODQ_6f2deba4-7bec-48ed-9bc7-2a307bd5b689">101.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTUtMS0xLTEtOTEyODQ_9668ca24-ca5a-4936-b9e5-18e92dcfdbe7">81.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTUtMy0xLTEtOTEyODQ_df4241f9-ad9b-41f8-b30c-7552e2505347">91.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTUtNS0xLTEtOTEyODQ_b172e539-d5dd-428b-af4c-241445ea09f7">165.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTUtNy0xLTEtOTEyODQ_73479a84-046c-4819-b6e3-4bb5671e61f8">172.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTYtMS0xLTEtOTEyODQ_02bff75d-b483-4bcc-9789-859f39c3cbf8">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTYtMy0xLTEtOTEyODQ_6100e97d-9c8a-4f15-95c0-70f0e6ce8221">15.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTYtNS0xLTEtOTEyODQ_39262831-7ba8-4708-8203-d977ed4c7892">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTYtNy0xLTEtOTEyODQ_c3542337-243f-4c04-95b1-0f431301fc5b">30.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTctMS0xLTEtOTEyODQ_85c5ed90-91a6-463f-a252-68ffd9707409">314.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTctMy0xLTEtOTEyODQ_98d0d39d-023b-4e49-861b-7cdea5b69cae">383.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTctNS0xLTEtOTEyODQ_c6da47da-460a-456e-9c63-ff15a2aab08f">615.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:OperatingCostsAndExpenses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTctNy0xLTEtOTEyODQ_0c8eb9f3-a0fe-485b-afa4-b6a88bb40f1f">630.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTktMS0xLTEtOTEyODQ_98d6f79d-be1f-4f2c-b235-b4c5240d5939">72.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTktMy0xLTEtOTEyODQ_981adb4f-68e9-4ffc-942f-7b6eaa9c743f">14.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTktNS0xLTEtOTEyODQ_7ce6d80b-251b-40cc-9b3b-1a209d754eda">65.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:OperatingIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTktNy0xLTEtOTEyODQ_7f3ea9ca-34c9-43da-924b-5267953f053c">109.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjItMS0xLTEtOTEyODQ_b3dcf948-876c-4a94-9620-4e1d3c0dde1b">7.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjItMy0xLTEtOTEyODQ_eac523ee-8686-4f6d-bb5b-106fbd82e6f7">8.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjItNS0xLTEtOTEyODQ_ed11673d-4f78-4879-9614-48a2991eaa15">16.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjItNy0xLTEtOTEyODQ_c14d81cf-183d-4777-9bab-4fffd91b608c">17.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjMtMS0xLTEtOTEyODQ_423de44a-a82d-4178-9fa1-6e48a425fe1c">3.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjMtMy0xLTEtOTEyODQ_dabf9b82-32c5-4360-88fb-dd604ca5dea8">1.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjMtNS0xLTEtOTEyODQ_3bcbce68-0e5d-4da1-874a-5f6feeadd28e">5.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjMtNy0xLTEtOTEyODQ_edc05302-6fc2-4588-be5b-4636c7f4d916">0.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjQtMS0xLTEtOTEyODQ_58f8c0c7-ef6c-4255-bc09-8db7054571c8">10.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjQtMy0xLTEtOTEyODQ_5c68ab4c-7391-4f7f-8917-b63b0c4cc212">7.3</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjQtNS0xLTEtOTEyODQ_2949e0fa-2f9f-4e76-bf76-9ae399029e77">21.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjQtNy0xLTEtOTEyODQ_a52279db-89a9-4255-9696-b28432ef066f">17.5</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjYtMS0xLTEtOTEyODQ_b726c2fa-1ab9-4100-b210-d6db46e3bbd7">82.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjYtMy0xLTEtOTEyODQ_c0de5ce8-d118-47d7-9183-9afe491421b9">7.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjYtNS0xLTEtOTEyODQ_354ff8b5-e7c4-42b7-a97b-ce1b6c6ab4b9">86.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjYtNy0xLTEtOTEyODQ_b5e9ced8-8f15-4942-8f24-1a32d0b60d53">92.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjctMS0xLTEtOTEyODQ_4f388303-9310-4ba7-9691-73d84dd942bb">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjctMy0xLTEtOTEyODQ_ae30bd82-2633-44e8-91ba-bdce3cff137b">2.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjctNS0xLTEtOTEyODQ_0e36618f-b26e-40c3-89b1-219b4bcbe833">26.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjctNy0xLTEtOTEyODQ_248a9607-2a10-4345-9521-3a3f8ccd1ef4">18.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-4.5pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjgtMS0xLTEtOTEyODQ_50f2c917-1075-4dfb-97d2-c1ce38cad264">56.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjgtMy0xLTEtOTEyODQ_a464b73e-8e90-4504-acc7-0e633f37437c">4.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjgtNS0xLTEtOTEyODQ_ba7b5e54-79f6-4e0c-a0a9-2af6ef6ce1fb">60.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjgtNy0xLTEtOTEyODQ_103b998e-0455-4ffb-905b-6e26ff82128e">74.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per common share</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzEtMS0xLTEtOTEyODQ_982a85a8-8236-4082-94a3-9e42e4b4407e">1.13</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzEtMy0xLTEtOTEyODQ_e77cab18-f1be-4a13-999c-cd0081f39e41">0.09</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzEtNS0xLTEtOTEyODQ_658aba65-7fb6-4a32-a99f-6bfe4e1998df">1.19</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzEtNy0xLTEtOTEyODQ_09af742b-efe6-42d7-b2e7-157ca3a67b53">1.40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzItMS0xLTEtOTEyODQ_3c102731-de01-4536-a652-dd95da28b1a6">1.13</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzItMy0xLTEtOTEyODQ_5bf680fd-7695-41f3-bb7d-7d59e54d1e76">0.09</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzItNS0xLTEtOTEyODQ_f704e9f5-de2b-49d6-9666-d981e94f88cc">1.19</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzItNy0xLTEtOTEyODQ_509f892c-ad73-4544-9b7a-4979214b2508">1.37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares used in computing net income (loss) per common share</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzUtMS0xLTEtOTEyODQ_2c98d51b-f7e1-400b-b34c-08afc0891a64">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzUtMy0xLTEtOTEyODQ_529e6928-8044-4fb0-b203-87c507f629f9">53.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzUtNS0xLTEtOTEyODQ_22e0a6d6-5b56-420f-a3ba-0ba10a857691">50.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzUtNy0xLTEtOTEyODQ_c4599ab0-d3e7-4a99-9346-27c9fe752011">53.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzYtMS0xLTEtOTEyODQ_440b008f-764b-4f62-83e5-60a9d201643b">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzYtMy0xLTEtOTEyODQ_12f11c90-fcb8-4811-9ba1-b9f1dfc67fdb">54.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzYtNS0xLTEtOTEyODQ_fdc8d1c2-6b5b-4a17-9624-91fd0e939c17">50.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzYtNy0xLTEtOTEyODQ_e53a17c3-2564-4ca7-b588-43334f854e0d">54.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_22"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Comprehensive Income (Loss)</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:9pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:37.980%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.698%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.704%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfMi0xLTEtMS05MTI4NA_53cce15e-ae9d-4c60-ad8a-317affaf283c">56.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfMi0zLTEtMS05MTI4NA_505ba1b7-26f2-4105-aafd-59816584107f">4.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfMi01LTEtMS05MTI4NA_59d31a43-4e7e-46d6-bdcb-aba9d102e785">60.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfMi03LTEtMS05MTI4NA_53db3e92-6292-4914-87ca-123541a0f230">74.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNC0xLTEtMS05MTI4NA_60c60022-813e-42ee-a771-04f0fc353aa2">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNC0zLTEtMS05MTI4NA_0514fb88-3b5c-41fc-8e46-9ba1b08fbd54">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNC01LTEtMS05MTI4NA_61924103-00d6-42ec-a1ed-fbcee1c6bc0d">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNC03LTEtMS05MTI4NA_3d6bd1a0-61bc-4d76-b94b-918963396d2e">1.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrealized gains (losses) on hedging activities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNS0xLTEtMS05MTI4NA_869ae2d7-f30c-4f42-b65d-0614a2ea4106">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNS0zLTEtMS05MTI4NA_b614f6e0-16e2-4efa-a026-5b459b961cc3">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNS01LTEtMS05MTI4NA_987ad397-1ebe-488b-8f50-c25f57ee0238">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNS03LTEtMS05MTI4NA_182ec009-29d1-45a7-b87d-297c2445f162">4.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNi0xLTEtMS05MTI4NA_e33e3777-cd6d-4c62-991f-d9042e644c79">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNi0zLTEtMS05MTI4NA_7b516397-9554-4ca9-bfef-688096b02398">2.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNi01LTEtMS05MTI4NA_ace854af-ac70-4fe8-a192-a4bdd643761d">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNi03LTEtMS05MTI4NA_984ac430-c7c3-47c1-b132-2f73cca22493">2.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income (loss), net of tax</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNy0xLTEtMS05MTI4NA_a247933e-edd4-4374-9c8b-5b398bf4e485">53.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNy0zLTEtMS05MTI4NA_08b88061-75d0-4371-bf8f-6d58078c8ced">6.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNy01LTEtMS05MTI4NA_f23eb3e4-cbc1-426a-b964-4b23a8cfd76e">50.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNy03LTEtMS05MTI4NA_7bbea648-014d-4dd9-a874-bce3e8654b51">77.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Cash Flows</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:57.964%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.929%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.223%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in operating activities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMy0xLTEtMS05MTI4NA_588a18bd-3257-4cca-b5fe-69f0cb04acf3">60.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMy0zLTEtMS05MTI4NA_0f9c998b-17f3-4157-b306-402fd6948363">74.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 1.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income (loss) to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNS0xLTEtMS05MTI4NA_97b874ba-388e-4d2f-a7d6-806f30370553">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNS0zLTEtMS05MTI4NA_f27b9c1d-506f-405b-8d52-497efd184d4d">21.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNi0xLTEtMS05MTI4NA_951ad85e-6975-44ec-8278-ae2d010b9b2d">75.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNi0zLTEtMS05MTI4NA_10460f31-504b-4ccb-a23c-e281ccb24704">61.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value of contingent consideration, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNy0xLTEtMS05MTI4NA_2e19b6a3-64f0-48dd-ba98-02fd8f8bfa33">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNy0zLTEtMS05MTI4NA_699375bc-ca9d-40cc-b79a-6f9401eb2a3d">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of deferred financing costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfOC0xLTEtMS05MTI4NA_fdcac08a-966e-425f-974f-7e0d97294e87">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfFinancingCosts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfOC0zLTEtMS05MTI4NA_e3a621a7-1306-43aa-bf9c-25b77c129bf2">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income taxes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfOS0xLTEtMS05MTI4NA_ee3622ca-3c18-459f-88d7-6abc22ff2612">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfOS0zLTEtMS05MTI4NA_5609db26-37b2-4c1b-90bc-57aeeec31f70">3.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTAtMS0xLTEtOTEyODQ_06832e21-6db8-4664-9ce2-ce671bcfd468">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTAtMy0xLTEtOTEyODQ_4454e0df-825d-4758-9fb5-10b9472fabed">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTItMS0xLTEtOTEyODQ_077e6246-de4f-497d-a5fd-3b056926a9b6">97.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTItMy0xLTEtOTEyODQ_076b089c-2382-4cef-bb31-57beef75a1d1">34.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTMtMS0xLTEtOTEyODQ_bfb31339-bf71-476f-bbd5-57a55063731f">75.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTMtMy0xLTEtOTEyODQ_251f0e2b-ad0a-4f4e-a6ee-cd1c5d28f08d">79.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTQtMS0xLTEtOTEyODQ_be1cc175-b4a0-44da-b610-9b5f797054b1">19.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTQtMy0xLTEtOTEyODQ_70e5244d-8dc7-4311-87f1-e3aad85ff6f2">2.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTUtMS0xLTEtOTEyODQ_ca56b9d7-7587-4aca-ba54-ac934934995d">7.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTUtMy0xLTEtOTEyODQ_ed98b96e-643c-426f-b107-9b27836cd74c">8.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued expenses and other liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTYtMS0xLTEtOTEyODQ_8c3508bf-5c90-4e8c-ab77-f9dec666592f">82.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTYtMy0xLTEtOTEyODQ_0a882284-fd87-4785-b5fe-03f5c8dc2910">55.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTctMS0xLTEtOTEyODQ_44068421-2557-4985-bb41-bb4e83d11b0c">14.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTctMy0xLTEtOTEyODQ_4dc91242-d923-465d-89f5-cbb003765cf4">21.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTgtMS0xLTEtOTEyODQ_00cbb79d-fecd-4684-8957-70357ed1ed10">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTgtMy0xLTEtOTEyODQ_471fb2cb-6984-4569-9807-a4168931f5aa">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities:</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTktMS0xLTEtOTEyODQ_ded5a87d-94b0-4c89-bd58-b09ae8ab0fbd">52.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTktMy0xLTEtOTEyODQ_56b5fa72-1f09-4914-adee-a808f8eeb488">24.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in investing activities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjEtMS0xLTEtOTEyODQ_f59236cc-69fe-4cf1-ba43-8ec6f199afdb">64.3</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjEtMy0xLTEtOTEyODQ_22698dbc-4414-4862-846a-8cf8638a378d">123.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in investing activities:</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjItMS0xLTEtOTEyODQ_cac7cf47-68f5-494d-a613-40f5e1008f73">64.3</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjItMy0xLTEtOTEyODQ_1c14853b-edc1-4b67-a480-c6d728ffcfce">123.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows used in financing activities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of treasury stock</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjQtMS0xLTEtOTEyODQ_ec30d472-f801-4a3f-9cc9-bf77f7f1bb06">81.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjQtMy0xLTEtOTEyODQ_ffb33d65-cf84-4c07-8654-7babc765bb1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on term loan facility</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:RepaymentsOfMediumTermNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjUtMS0xLTEtOTEyODQ_b2af2fd1-e11b-4554-b620-b7ef71a9b5fe">16.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:RepaymentsOfMediumTermNotes" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjUtMy0xLTEtOTEyODQ_edb8bfaf-0938-4927-98c3-031d774a4250">11.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Principal payments on convertible senior notes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjYtMS0xLTEtOTEyODQ_989d814e-bd77-4d49-aed6-a7fb0ca90871">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:RepaymentsOfConvertibleDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjYtMy0xLTEtOTEyODQ_8887708a-093d-4319-9418-e294385b04cd">10.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from share-based compensation activity</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjctMS0xLTEtOTEyODQ_7f95251f-b521-49e6-a691-f1ba7c9b18b7">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjctMy0xLTEtOTEyODQ_11d4ef9d-ec09-4ca1-8767-84eeebc3f313">10.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid for share-based compensation activity</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjgtMS0xLTEtOTEyODQ_d09d1478-8b67-46b1-acb0-cdf003a60afb">5.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjgtMy0xLTEtOTEyODQ_6a279460-99e9-485b-a92b-466758cc93e7">13.0</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration payments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjktMS0xLTEtOTEyODQ_cbd79c1f-6f33-4589-aca8-f18c1df27fbc">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjktMy0xLTEtOTEyODQ_9d1e0e2d-c6f9-4cee-804a-f5f60b90bd3a">1.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in financing activities:</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzAtMS0xLTEtOTEyODQ_c816e1f6-4aa7-4673-b0b9-88ced3885486">101.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzAtMy0xLTEtOTEyODQ_67a39b8c-cc8e-4e10-9828-1a70c6708ff3">26.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzEtMS0xLTEtOTEyODQ_512e6613-a9c8-4d84-914f-07fed912060f">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzEtMy0xLTEtOTEyODQ_48d4e632-528d-433b-8fa9-c6539632c39c">0.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzItMS0xLTEtOTEyODQ_99ec4f36-374f-48ba-9de3-dce46bd739a7">218.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzItMy0xLTEtOTEyODQ_006abca9-7d03-4d0e-ab9c-57621348f486">173.8</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at beginning of period</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzMtMS0xLTEtOTEyODQ_21087853-c14d-45d3-8483-6d3a0ee60b90">576.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71c6824cc4fe485ca827c9836e570401_I20201231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzMtMy0xLTEtOTEyODQ_f1f9be4d-1c42-41fb-b143-32650cff14a6">621.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash at end of period</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzQtMS0xLTEtOTEyODQ_33436266-f473-471e-8de0-10c6794ceaae">358.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b115351905c4ee2931cba201308bfe2_I20210630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzQtMy0xLTEtOTEyODQ_1acdf8c6-f4f7-468f-bf6d-6ebc8e95b9b4">447.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during the period for interest</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzYtMS0xLTEtOTEyODQ_f62e3c78-9f3f-41ad-8835-7aec47b1daa9">14.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzYtMy0xLTEtOTEyODQ_a2988b00-1e06-4e18-a117-94a92f576eb9">15.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash paid during the period for income taxes</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzctMS0xLTEtOTEyODQ_3aa3fe0d-a879-4240-a44e-b89db776edbc">20.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:IncomeTaxesPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzctMy0xLTEtOTEyODQ_5adc9067-41eb-44fd-9743-ebacecd36472">50.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental information on non-cash investing and financing activities:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, plant and equipment unpaid at period end</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzktMS0xLTEtOTEyODQ_5786406f-f4ce-4dbc-97f8-a42ae2a6f0b8">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzktMy0xLTEtOTEyODQ_3d899b9f-5937-439d-9476-692662db75db">31.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reconciliation of cash and cash equivalents and restricted cash at June&#160;30, 2022 and December&#160;31, 2021:</span></div></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDItMS0xLTEtOTEyODQ_b44b9c31-2da1-43a0-b913-dbe1ce48b964">358.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDItMy0xLTEtOTEyODQ_4da42162-cfec-49d0-b408-ef204f4f9e35">576.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDMtMS0xLTEtOTEyODQ_912021b3-a8e6-4e8e-b711-aa8d7c485c9d">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDMtMy0xLTEtOTEyODQ_1c38ee8e-c1f5-4d22-af90-675f95257e39">0.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDQtMS0xLTEtOTEyODQ_159608b4-87ae-4428-921d-2085bc3875dd">358.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDQtMy0xLTEtOTEyODQ_b53492cd-1d04-462e-84b5-029cc1fb1e24">576.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Condensed Consolidated Statements of Changes in Stockholders' Equity</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions)</span></div><div style="margin-bottom:5pt;margin-top:2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.229%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.340%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.729%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.733%"></td><td style="width:0.1%"></td></tr><tr style="height:32pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMC0yLTEtMS05MTI4NC90ZXh0cmVnaW9uOjViYjkxNzYxZDFkYTRhNDhiOGQyZWY5MmExOGU3NDg0XzU_379b7eb9-e886-4273-956d-cba5880698c5"><ix:nonFraction unitRef="usdPerShare" contextRef="i4b115351905c4ee2931cba201308bfe2_I20210630" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMC0yLTEtMS05MTI4NC90ZXh0cmVnaW9uOjViYjkxNzYxZDFkYTRhNDhiOGQyZWY5MmExOGU3NDg0XzU_3a31a450-0fd4-43e0-adff-e96733833892">0.001</ix:nonFraction></ix:nonFraction> Par Value Common Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury Stock</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional Paid-In Capital</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Other Comprehensive Loss</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Retained Earnings</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Stockholders' Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shares</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifcb77253dbaa4e16b55791df9ea6fddf_I20211231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy0yLTEtMS05MTI4NA_c62ab42b-da2a-4b30-854e-d39c2b334dd2">55.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcb77253dbaa4e16b55791df9ea6fddf_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy00LTEtMS05MTI4NA_4e76ad79-d544-4499-9300-02e660b8b31b">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib6cd72da23074b5dbf0c4367cf392a9d_I20211231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy02LTEtMS05MTI4NA_61d63dc8-3c72-45b1-997c-6394c3bbded5">3.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6cd72da23074b5dbf0c4367cf392a9d_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy04LTEtMS05MTI4NA_d1e8d4a8-11f4-40a5-ae54-89c88a8e2754">152.2</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53b18d134caf4ae2bba1d299e79c0f1b_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy0xMC0xLTEtOTEyODQ_3a2b4e57-c421-4929-a5f7-288208502419">829.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53adab0b44f14127b1c4c4f2539a1807_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy0xMi0xLTEtOTEyODQ_1be5f205-9017-4970-bc3c-f59786901365">16.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if87c2ef5ba4f4d7abb9178e57763e7ff_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy0xNC0xLTEtOTEyODQ_d186b101-fc73-4477-aab7-1718fcd02d9b">957.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy0xNi0xLTEtOTEyODQ_8876b2ea-3a51-44c3-9b6d-664e790f63a3">1,619.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i66eaca4aafd84de8a80ea8db300174dd_D20220101-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNC0yLTEtMS05MTI4NA_8699165a-4f6d-4af9-a3f9-9e3c816bcf00">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c074f371d0a46638d50ebd9d45e0f59_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNC0xMC0xLTEtOTEyODQ_0b000e10-34ed-4361-8177-bb8d830a5610">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNC0xNi0xLTEtOTEyODQ_a1749183-a430-44f6-af5c-1afe432481db">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i26eb6b2c35ad4617b43852b247ceea23_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNS0xNC0xLTEtOTEyODQ_ab936d54-d245-4448-8255-37b67aaf79c0">60.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNS0xNi0xLTEtOTEyODQ_845b849e-963f-4203-a35f-cc3be505d0e8">60.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ic692f65706164ee49ec3a380b592e311_D20220101-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNi02LTEtMS05MTI4NA_a08e05de-1351-419e-b43a-c3f25efff3ea">1.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic692f65706164ee49ec3a380b592e311_D20220101-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNi04LTEtMS05MTI4NA_906f55dc-44a3-4c04-bee3-7b32b60bb706">75.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNi0xNi0xLTEtOTEyODQ_aeacdf5b-3c79-48b8-83bf-a3ae41c75b74">75.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7dc3abe30a64ca2932c00efd6517a60_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNy0xMi0xLTEtOTEyODQ_01ff0a47-7482-47fe-aa4e-e335eae55403">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNy0xNi0xLTEtOTEyODQ_02918060-47ea-4311-a91a-4c10a656fe11">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if12d50ad93034fe0bf993311a0d00e34_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC0yLTEtMS05MTI4NA_a8f8ba51-7327-41e8-8225-ca8abab565f7">55.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if12d50ad93034fe0bf993311a0d00e34_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC00LTEtMS05MTI4NA_3e69b2fe-b5a8-41f7-ac09-8eabd580f110">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4f4f1eaec93744e09d2a5e94ada672c5_I20220630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC02LTEtMS05MTI4NA_04db5983-7db6-4649-929c-cea7925b7869">5.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f4f1eaec93744e09d2a5e94ada672c5_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC04LTEtMS05MTI4NA_db22f94f-ea81-439c-98d8-fcb1c051c479">227.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412510cc8ecb48538d8d3800311216b7_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC0xMC0xLTEtOTEyODQ_ae1a4c1a-c8be-4057-a497-acef852f0a1e">849.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib20d47a77df04874a03809c71af93bb8_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC0xMi0xLTEtOTEyODQ_f2dd2c50-0a9c-4519-9231-ee56deeebf3a">6.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5addde9d9dae48a8ad041d366228d429_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC0xNC0xLTEtOTEyODQ_01869195-63d5-4794-8771-8b01242269c5">897.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC0xNi0xLTEtOTEyODQ_25155da9-4504-4ca9-a8e3-e1167aae17af">1,513.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i461082bcdf04496582b622477c82809e_I20220331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtMi0xLTEtOTEyODQ_2ed6be6a-2cfa-44b8-8f15-93772ea31e4b">55.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461082bcdf04496582b622477c82809e_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtNC0xLTEtOTEyODQ_1c9d40fe-d9da-49fa-adb7-60952b1ad562">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i557996cf1b9849c7acfd550d094c2417_I20220331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtNi0xLTEtOTEyODQ_a12a16ed-b526-45f7-be93-f0859065fe11">4.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i557996cf1b9849c7acfd550d094c2417_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtOC0xLTEtOTEyODQ_2227c498-2a67-413a-ba3b-0f0b3d5c9c89">204.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia2336cd80ecb49729b81f005c693fca9_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtMTAtMS0xLTkxMjg0_89d16179-6d2b-4d26-9f8f-c5fa6c246386">834.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca88e5d8bf24c309e9d2a5171b224ec_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtMTItMS0xLTkxMjg0_c2509f7e-611b-44bd-a630-3bae27c861ed">9.3</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05378be1d058489c8c528d17225c53e9_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtMTQtMS0xLTkxMjg0_c89ad52f-7b36-4f21-b4b9-de3be74ef61e">954.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7050e3a97a242b092682346cbd7cd4e_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtMTYtMS0xLTkxMjg0_cdca43ab-4eda-4432-ad97-12949a761c6f">1,575.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib3bbf3905bf542958d5e24c590031249_D20220401-20220630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTEtMi0xLTEtOTEyODQ_12d960ac-0d83-4def-8163-7201d9df525c">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide22df8c6fb348659c7397b47c73fe57_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTEtMTAtMS0xLTkxMjg0_7c687973-79bc-4b4a-a5c3-af52a7e6716c">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTEtMTYtMS0xLTkxMjg0_b9824b21-4553-4514-a5fa-95b702e97bb8">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2761304ddf59466ba7ad454fdf7d3b89_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTItMTQtMS0xLTkxMjg0_01d5f069-1619-4fdf-b564-0aec3c4f4eb0">56.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTItMTYtMS0xLTkxMjg0_f8cfd214-5579-4ae1-ade1-f455ef11ca36">56.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchases of stock</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ifcc26b21d7d8496f9bb774f7ac399651_D20220401-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTMtNi0xLTEtMTA0NTI0_3223feff-f261-49cf-82e9-79ad677bb5e1">0.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifcc26b21d7d8496f9bb774f7ac399651_D20220401-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTMtOC0xLTEtMTA0NTI0_5202a7ba-f95b-4bba-b9d6-9b6fd068add1">23.3</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTMtMTYtMS0xLTEwNDUzNA_276fa9dc-b72b-43c9-adab-c7617fd645d6">23.3</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f7ee7f25e24cf382b2910e45037cd5_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTMtMTItMS0xLTkxMjg0_a275a814-d6b0-42ec-8905-65b25d43193a">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTMtMTYtMS0xLTkxMjg0_77608e28-93be-43f2-858f-5895593bfcff">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if12d50ad93034fe0bf993311a0d00e34_I20220630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtMi0xLTEtOTEyODQ_6e29ac6a-c26b-49de-a736-73b38a2bbfd7">55.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if12d50ad93034fe0bf993311a0d00e34_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtNC0xLTEtOTEyODQ_46df22c6-f1b2-4890-992c-0ed47f051d50">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i4f4f1eaec93744e09d2a5e94ada672c5_I20220630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtNi0xLTEtOTEyODQ_74f26c56-cf89-47a7-980d-f3bad46d6f8e">5.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4f4f1eaec93744e09d2a5e94ada672c5_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtOC0xLTEtOTEyODQ_ae4a86d7-3754-40fc-be5f-638afc2f9661">227.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i412510cc8ecb48538d8d3800311216b7_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtMTAtMS0xLTkxMjg0_c2544c39-df76-4544-916d-d22f4b75802a">849.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib20d47a77df04874a03809c71af93bb8_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtMTItMS0xLTkxMjg0_6fc6eeef-ac79-4f2f-a7ea-da3f7eb7446b">6.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5addde9d9dae48a8ad041d366228d429_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtMTQtMS0xLTkxMjg0_56ba794f-c023-4d70-9fba-244c52a79d0a">897.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtMTYtMS0xLTkxMjg0_d955ab31-dc16-482c-b37e-bbee9d1b363f">1,513.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i780e0257b99f470bac2458708cbdb98e_I20201231" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctMi0xLTEtOTEyODQ_50ce0aad-7520-4233-9fcc-4c9c934a5f2f">54.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780e0257b99f470bac2458708cbdb98e_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctNC0xLTEtOTEyODQ_fe2f9c2c-e299-4470-b8ef-3409a5332199">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i40faa34fd48c4a798a6fe90fe21fd4e5_I20201231" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctNi0xLTEtOTEyODQ_03ec8b43-318e-4092-b8a6-62c9cbe08457">1.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40faa34fd48c4a798a6fe90fe21fd4e5_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctOC0xLTEtOTEyODQ_0eb001dc-f35c-47be-8994-a4158678a9de">39.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idc5bcc44a9ca46599e2b25daa2a69029_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctMTAtMS0xLTkxMjg0_6aac47c3-1c7e-44db-91f9-f8caf302943c">784.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d6dfa3b33ba4a26be19db91781e5050_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctMTItMS0xLTkxMjg0_4406577e-d697-4e33-aa23-c7c2fce845c8">25.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie40f227742694bbdaee04db49ed26512_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctMTQtMS0xLTkxMjg0_46afec67-df97-4216-81a0-339e32893916">726.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i71c6824cc4fe485ca827c9836e570401_I20201231" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctMTYtMS0xLTkxMjg0_c560b1f1-c236-4091-89e2-dfb6594074a6">1,447.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6387f180981b459b9fe20889f53d8b6c_D20210101-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTgtMi0xLTEtOTEyODQ_ae36afd0-e13f-4934-9fb3-293927ef9c48">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34769cb2cad546d9a34ee9510f37cbfd_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTgtMTAtMS0xLTkxMjg0_d3e0bd5f-a179-4d92-9a97-e6ea0ab54219">19.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTgtMTYtMS0xLTkxMjg0_1c3c9c4b-f3f7-4c42-ad4e-bd97e1047ddd">19.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80b954c7fdb04b88b99f239e25180b5c_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTktMTQtMS0xLTkxMjg0_f00e647c-4cdd-47df-8262-4a5dafefc1e2">74.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTktMTYtMS0xLTkxMjg0_b2469980-d909-4487-a1d6-3eece50e346e">74.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3a86954dc6340629ca543163504fdb4_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjAtMTItMS0xLTkxMjg0_a6fbaf79-861b-417d-8efa-8af25f71bda5">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjAtMTYtMS0xLTkxMjg0_de797d23-5cf0-4747-93c0-5515a9264b72">2.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14cd7836cc584c8fb4799a4f34d22bb3_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtMi0xLTEtOTEyODQ_da61191b-634e-49f7-a9eb-7f4ed591ea35">54.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14cd7836cc584c8fb4799a4f34d22bb3_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtNC0xLTEtOTEyODQ_9d1e6e19-8e95-4e70-b1dd-9cda1a7972b3">0.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief6c31325bb94b9094ce98e80f0a6bb3_I20210630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtNi0xLTEtOTEyODQ_d5dd53b6-0402-4ad1-8ede-abd48ed95583">1.2</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief6c31325bb94b9094ce98e80f0a6bb3_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtOC0xLTEtOTEyODQ_5f25e1c9-ac0c-408f-8cc5-49573f4f4fc2">39.6</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5589e73e44f74b778672ccad28f1df27_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtMTAtMS0xLTkxMjg0_b2ddbb0a-a264-4434-b7d2-80e242e04317">804.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cb30120c0cd4c26b09246b92a5b9300_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtMTItMS0xLTkxMjg0_ed97b61e-3c86-40cf-83cc-65a3666d4d92">22.4</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b789b56b81c4d9a9a529b16bb9daa53_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtMTQtMS0xLTkxMjg0_9e83f0af-077c-429e-bde2-60a32f035220">801.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b115351905c4ee2931cba201308bfe2_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtMTYtMS0xLTkxMjg0_524446ca-bd00-4b2e-ab87-e05b4f03875f">1,543.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0e62c5dc2e50467ca24d45cabc0c75e5_I20210331" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtMi0xLTEtOTEyODQ_e491bd4e-23dd-4bf7-b320-2ec5466679fe">54.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e62c5dc2e50467ca24d45cabc0c75e5_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtNC0xLTEtOTEyODQ_bd3eb497-54e4-4dfb-800b-4bc9ea0c5d2d">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie273c395662a4debaddeffc56206d4c3_I20210331" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtNi0xLTEtOTEyODQ_51964624-de59-4c72-8dac-14b87d39fd58">1.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie273c395662a4debaddeffc56206d4c3_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtOC0xLTEtOTEyODQ_bf323175-889f-42ec-b05e-347120e8f48c">39.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f1aae4f21ea48c7bb113f0bb2d224ed_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjItMTAtMS0xLTkyNjEz_8621ad96-5b29-4024-9021-3f7a690e74c6">790.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84fb728efecd4d3eb00c3307db37929d_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtMTItMS0xLTkxMjg0_8208859a-1f1a-4e67-b627-78bb9997c670">24.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf50b30461ed4bd5aa0c129d970ef57d_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtMTQtMS0xLTkxMjg0_b24e2298-035b-4c06-8657-ccb8b2599ccc">796.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e7a561bc9634b07b67a3141075d5a76_I20210331" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtMTYtMS0xLTkxMjg0_bdaa07b0-7e40-4e07-8541-7e0e302c1364">1,522.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6b62099afb4848769e1d1bd825d654a0_D20210401-20210630" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjQtMi0xLTEtOTEyODQ_d257dc77-3769-4c52-ae0f-cef1fb9fd692">0.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2eba64a7c8645ceb35da700cc48a11a_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtMTAtMS0xLTkyNjEz_58817825-1f35-483c-a0b1-178a5f598871">14.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjQtMTYtMS0xLTkxMjg0_c8e74a71-29a6-48f6-8925-42296294ecf1">14.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db1424bf80e4508a67ed768a524f425_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjUtMTQtMS0xLTkxMjg0_4c1164ec-6b04-4e0b-ae0f-2d78d765bb44">4.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjUtMTYtMS0xLTkxMjg0_a046bdaa-f7aa-4245-b93d-b4221029e83d">4.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income, net of tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id728fefbf15d4c8cabf2af784f9cb5fb_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjYtMTItMS0xLTkxMjg0_6c626f53-98ca-489c-b136-ce71bb4709f3">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjYtMTYtMS0xLTkxMjg0_a0dbc07d-2921-44ff-a95a-cc538c451d78">2.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i14cd7836cc584c8fb4799a4f34d22bb3_I20210630" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctMi0xLTEtOTEyODQ_d8449808-a363-4141-bd24-2251fdf0a417">54.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14cd7836cc584c8fb4799a4f34d22bb3_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctNC0xLTEtOTEyODQ_bb7d8f57-ec04-4827-a33f-cf799c2704a2">0.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ief6c31325bb94b9094ce98e80f0a6bb3_I20210630" decimals="INF" name="us-gaap:TreasuryStockCommonShares" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctNi0xLTEtOTEyODQ_a2036f03-d00c-42cc-9ecf-ef09320ca258">1.2</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief6c31325bb94b9094ce98e80f0a6bb3_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctOC0xLTEtOTEyODQ_b58f5d91-b05c-4c5e-a62e-445198b3af4a">39.6</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5589e73e44f74b778672ccad28f1df27_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjYtMTAtMS0xLTkyNjEz_d40fd832-eacb-4fe5-b64a-0e82b0351206">804.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cb30120c0cd4c26b09246b92a5b9300_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctMTItMS0xLTkxMjg0_2a8b6dfb-971b-408f-be39-76cc5301983c">22.4</ix:nonFraction>)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b789b56b81c4d9a9a529b16bb9daa53_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctMTQtMS0xLTkxMjg0_f87b4b01-c11a-451c-ad22-0939494cb1a2">801.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b115351905c4ee2931cba201308bfe2_I20210630" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctMTYtMS0xLTkxMjg0_819655d6-f968-41c9-b77d-235c0a9c04ff">1,543.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="text-align:center"><span><br/></span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_34"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNTA2OA_2cebdfac-995c-4766-b643-eeb678279cd2" continuedAt="i8e0c40138b4b455c9f23f753b72fb16f" escape="true">Business</ix:nonNumeric></span></div><ix:continuation id="i8e0c40138b4b455c9f23f753b72fb16f" continuedAt="ibcde37f2d6174acdaf4ed0d2d3b44254"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (the Company or Emergent) is a global life sciences company focused on providing</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (CDMO) services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following <ix:nonFraction unitRef="category" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="INF" name="ebs:NumberOfCategoriesOfPublicHealthThreats" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDY4_7294c2cb-74d7-4187-8a80-9e15f78a7226">five</ix:nonFraction> distinct PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; and acute/emergency care. The Company has a product portfolio of <ix:nonFraction unitRef="product" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="INF" name="ebs:NumberOfRevenueGeneratingProducts" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNTA3MA_2a3b1cf8-e79b-48eb-9f5f-b78ca9d214ca">eleven</ix:nonFraction> products (vaccines, therapeutics and drug-device combination products) that contribute a substantial portion of its revenue. The Company has <ix:nonFraction unitRef="productcandidate" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="INF" name="ebs:NumberOfProductCandidates" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNTA2Nw_11c30c5a-5ea2-414e-9249-d93d2ebdde96">one</ix:nonFraction> product candidate that is procured under special circumstances by the U.S. government (USG), although it is not approved by the U.S. Food and Drug Administration (FDA). The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include a Government - Medical Countermeasures (MCM) business line, a Commercial business line and a Services line focused on CDMO.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Government - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">AV7909</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is a procured product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has largely switched from procuring BioThrax to AV7909 for the Strategic National Stockpile (SNS) prior to its approval by the FDA;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">BioThrax</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only vaccine licensed by the FDA, for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">ACAM2000</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">BAT</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of botulism; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">CNJ-016</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also referred to as VIGIV, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Raxibacumab injection, a fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Anthrasil</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">RSDL</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Trobigard</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">atropine sulfate, obidoxime chloride AUTO-INJECTOR, is a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA, but it is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Ebanga&#8482; (ansuvimab-zykl, formerly referred to as mAb114) is a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the United States and Canada, and Ridgeback Bio will serve as the global access partner for Ebanga&#8482;.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="ibcde37f2d6174acdaf4ed0d2d3b44254" continuedAt="ibc4710f6f419445695e7da7cc857f1cd"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Commercial Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">NARCAN</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression; Recently, the Company licensed an authorized generic of naloxone nasal spray to Sandoz;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Vaxchora</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the only single-dose oral vaccine licensed by the FDA and the European Medicines Agency (EMA) for the prevention of cholera; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Vivotif</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services - Contract Development and Manufacturing </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's services line focused on CDMO offerings cover development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided across the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale.&#160;Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDg4OA_22ec5aaf-a174-4afa-8cfb-61ac42c7dd95">two</ix:nonFraction> operating segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and a services segment (Services) focused on CDMO (Note 14, Segment information).</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pending Acquisition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2022, the Company entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;), by and between the Company and Chimerix, Inc. (the &#8220;Seller&#8221;), pursuant to which the Company agreed to purchase from Seller its exclusive worldwide rights to brincidofovir, including TEMBEXA&#174; and related assets (the &#8220;Transaction&#8221;). TEMBEXA is a medical countermeasure for smallpox approved by the U.S. Food and Drug Administration in June 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Purchase Agreement, the Company will pay $<ix:nonFraction unitRef="usd" contextRef="i280deffd19c14987aeb06f69ff2cdd96_D20220701-20220930" decimals="-5" name="us-gaap:PaymentsToAcquireProductiveAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQwMw_1f264327-2011-46ec-ba66-3e3acd3ca925">225.0</ix:nonFraction>&#160;million upon closing of the Transaction, plus up to $<ix:nonFraction unitRef="usd" contextRef="i280deffd19c14987aeb06f69ff2cdd96_D20220701-20220930" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQxNw_02c2fede-ed77-4b0b-b317-ce7a6786f0c7">100.0</ix:nonFraction>&#160;million in up to four $<ix:nonFraction unitRef="usd" contextRef="ibf95dce5cfef405cba6b0d18b94cd870_D20220701-20220930" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQzMQ_6d4a8907-e709-41e2-8b0a-cf2df5759f92"><ix:nonFraction unitRef="usd" contextRef="i1fa607b80d2746cbb317c99fbd84728f_D20220701-20220930" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQzMQ_8a823e59-04cf-464b-83f2-298b7a83d364"><ix:nonFraction unitRef="usd" contextRef="i7e44623ce7f0456191e95efe535f9f33_D20220701-20220930" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQzMQ_a7e4a957-0b5e-4655-8212-3f5969dc87e6"><ix:nonFraction unitRef="usd" contextRef="i4585a13ee1354a528f4c34f7706a0ec8_D20220701-20220930" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQzMQ_e70c7d33-f617-4336-8f2c-95bf789a9fce">25.0</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;million milestone payments. The Purchase Agreement anticipates that the Seller will finalize its negotiations with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;) and enter into a procurement contract (the &#8220;BARDA Contract&#8221;) with BARDA for TEMBEXA, which the Seller is currently negotiating. Each milestone payment is associated with the exercise of future BARDA procurement options of TEMBEXA following the BARDA Contract base period. The closing payment and the milestone payments may be adjusted upward or downward based on actual procurement value. The Seller is also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="ie9fd4d849f564c9fb40d3df840d093e5_D20220701-20220930" decimals="-5" name="us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQ0NA_a9f24c3d-614f-421c-839d-d001c999efc9">12.5</ix:nonFraction>&#160;million in regulatory milestones associated with the SymBio Pharmaceuticals Ltd. brincidofovir licensing arrangements to be assumed by the Company in the Transaction.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Seller may also earn a <ix:nonFraction unitRef="number" contextRef="i8635afeff8644e21a1f82f113b82e3a3_D20220701-20220930" decimals="2" name="ebs:AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQ2OA_3ab9e2db-4e30-461c-8607-ea5df53805a6">20</ix:nonFraction>% royalty on future gross profit of TEMBEXA in the United States associated with volumes above <ix:nonFraction unitRef="treatmentcourse" contextRef="i8635afeff8644e21a1f82f113b82e3a3_D20220701-20220930" decimals="-5" name="ebs:AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfMTA5OTUxMTYyOTUyODc_95903b17-b6f6-4878-8231-664649205a7b">1.7</ix:nonFraction>&#160;million treatment courses of therapy during the exclusivity period of TEMBEXA. Outside of the United States, the Purchase Agreement also allows the Seller to earn a <ix:nonFraction unitRef="number" contextRef="i8635afeff8644e21a1f82f113b82e3a3_D20220701-20220930" decimals="2" name="ebs:AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQ3Mw_5746c873-c2ea-42d0-902b-acccc8d20784">15</ix:nonFraction>% royalty on all gross profit associated with TEMBEXA sales during the exclusivity period of TEMBEXA on a market-to-market basis.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing is subject to the execution by the Seller of the BARDA Contract, the satisfaction or waiver of the following other closing conditions: (i) the representations and warranties of the Company and the Seller contained in the Purchase Agreement being true and correct, subject to certain materiality standards; (ii) each of the Company and the Seller having performed and complied with their respective covenants in all material respects; (iii) the waiting period applicable to the consummation of the Transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, having expired; (iv) the delivery of certain ancillary documents, including a transition services agreement and pre-novation agreement; (v) the receipt of any required consent from BARDA to enter into a pre-novation agreement with the Company; (vi) no injunction or other final order preventing the consummation of the Transaction </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ibc4710f6f419445695e7da7cc857f1cd">having been issued; (vii) and there having occurred no material adverse effect on the assets being sold in the Transaction. Closing of the Transaction is currently expected to occur during the third quarter of 2022.</ix:continuation></span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_37"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNy9mcmFnOjhmMDcxZDEzZjNiYjQwNWNhODVmMmU5MmE2NjQzMmI1L3RleHRyZWdpb246OGYwNzFkMTNmM2JiNDA1Y2E4NWYyZTkyYTY2NDMyYjVfNTYzNg_6488aa00-9c94-45d9-9227-b255e49b8ed3" continuedAt="i67fde035639540bc9ffd3f8f51706dfa" escape="true">Basis of presentation and principles of consolidation</ix:nonNumeric></span></div><ix:continuation id="i67fde035639540bc9ffd3f8f51706dfa" continuedAt="i56a28cec315e4b1f92f201e61848758a"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNy9mcmFnOjhmMDcxZDEzZjNiYjQwNWNhODVmMmU5MmE2NjQzMmI1L3RleHRyZWdpb246OGYwNzFkMTNmM2JiNDA1Y2E4NWYyZTkyYTY2NDMyYjVfNTY0OA_7a26a8e9-20de-418f-94de-2797a460b008" continuedAt="i8fb97d1738d54d9eac53553a3e72e75a" escape="true">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8fb97d1738d54d9eac53553a3e72e75a">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of June&#160;30, 2022. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</ix:continuation> </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC that have materially impacted the presentation of the Company's financial statements. </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company revised the reporting that the Chief Operating Decision Maker (CODM) reviews in order to assess Company performance. The CODM manages the business with a focus on <ix:nonFraction unitRef="segment" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNy9mcmFnOjhmMDcxZDEzZjNiYjQwNWNhODVmMmU5MmE2NjQzMmI1L3RleHRyZWdpb246OGYwNzFkMTNmM2JiNDA1Y2E4NWYyZTkyYTY2NDMyYjVfNTY0Mw_f6259853-dd0d-4f31-b158-323606260f19">two</ix:nonFraction> reportable segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and 2) the services segment focused on CDMO (Services). This change is further outlined in Note 14, Segment information.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNy9mcmFnOjhmMDcxZDEzZjNiYjQwNWNhODVmMmU5MmE2NjQzMmI1L3RleHRyZWdpb246OGYwNzFkMTNmM2JiNDA1Y2E4NWYyZTkyYTY2NDMyYjVfNTY0NA_c357415f-e5fc-4bc0-b048-2e5521aa19e2" continuedAt="i133c16528d0d4b0d872f217304f623e0" escape="true">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1) and time deposits (level 2), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7, Fair value measurements and Note 8, Derivative instruments and hedging activities).</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i133c16528d0d4b0d872f217304f623e0"> On a non-recurring basis, the Company measures its long-lived assets as part of impairment evaluations using fair value measurements. Goodwill is allocated to the Company's reporting units, which are one level below its operating segments. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and earlier if an event or other circumstance indicates that the carrying value of the asset may not be recoverable. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required. Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, long-lived assets are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when there is an adverse change in the market relating to those related assets. The impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. Determining the need for a detailed impairment analysis requires the exercise of judgment about several business factors, including the timing of expected future cash flows and assumptions about the economic environment.</ix:continuation> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the Company had no other significant assets or liabilities that were measured at fair value.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i56a28cec315e4b1f92f201e61848758a" continuedAt="idad366e2e2f84882a67a085f5b902831"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting standards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) that the Company adopts as of the pronouncement's specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the consolidated financial statements or disclosures.</span></div><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNy9mcmFnOjhmMDcxZDEzZjNiYjQwNWNhODVmMmU5MmE2NjQzMmI1L3RleHRyZWdpb246OGYwNzFkMTNmM2JiNDA1Y2E4NWYyZTkyYTY2NDMyYjVfNTY0Mg_81be0689-4466-4ca5-88bd-d5763ced6257" continuedAt="i2e9d0ecd8e644921ad8517ec5ab2c38a" escape="true"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idad366e2e2f84882a67a085f5b902831"><ix:continuation id="i2e9d0ecd8e644921ad8517ec5ab2c38a">In March 2020, the FASB issued Topic 848, which was further amended in January 2021. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. Topic 848 contains optional expedients and exceptions to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes.</ix:continuation></ix:continuation> </span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_40"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RleHRyZWdpb246ZWVjY2QwYTI5YTBkNDdjZWE5YWFmYmU0YjQ3YzU1NTFfNzQ_4ee0b558-aa32-4b5a-aec3-b00fc3aee496" continuedAt="i5d595e8cf830492eafc562f1532e13d1" escape="true">Inventories, net</ix:nonNumeric></span></div><ix:continuation id="i5d595e8cf830492eafc562f1532e13d1" continuedAt="if48e2954830741e3b754320568c89118"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RleHRyZWdpb246ZWVjY2QwYTI5YTBkNDdjZWE5YWFmYmU0YjQ3YzU1NTFfNzM_48bd7b40-016f-4da3-a936-4a657e0119db" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMS0xLTEtMS05MTI4NA_64895429-1af0-40d9-b3dc-97cc563ed051">264.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMS0zLTEtMS05MTI4NA_21e59e0c-a542-4790-a9c6-307a4da6eaa4">217.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMi0xLTEtMS05MTI4NA_26b1490f-7bf8-4ddd-b181-49b4c57e03e7">108.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMi0zLTEtMS05MTI4NA_45adcd7e-0eae-4ba9-af0a-65bc4f787739">95.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMy0xLTEtMS05MTI4NA_a9956056-a8f6-41dc-b936-58a5565dcfd0">53.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMy0zLTEtMS05MTI4NA_2a43d523-904f-4452-b2df-856a160a259f">37.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfNC0xLTEtMS05MTI4NA_f3e01b77-e342-4438-91d2-48bc91bbad7e">425.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:InventoryNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfNC0zLTEtMS05MTI4NA_bedec7b4-99a3-4683-b291-4172f4fc179d">350.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="if48e2954830741e3b754320568c89118" continuedAt="i6794e688ce184f8f875d3a00d60e9226">Inventories, net is stated at the lower of cost or net realizable value. For additional information related to the termination of the manufacturing services agreement (the &#8220;Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) and associated evaluation of inventory as of June&#160;30, 2022, refer to Note 10, Revenue recognition</ix:continuation></span><span style="background-color:#ffffff;color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i6794e688ce184f8f875d3a00d60e9226">.</ix:continuation> </span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_43"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RleHRyZWdpb246NDJmZGNjNWY1YzE2NDljZWFhMDg4ZTc0N2VjODg4NThfMjU1_53e9fc83-a1cd-41a3-a441-10da4ee7fc99" continuedAt="ifbb61c1da1f14873839af2ad0669ac67" escape="true">Property, plant and equipment, net</ix:nonNumeric></span></div><ix:continuation id="ifbb61c1da1f14873839af2ad0669ac67" continuedAt="i76d49868925a4248b8dfd9c1b47fce58"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RleHRyZWdpb246NDJmZGNjNWY1YzE2NDljZWFhMDg4ZTc0N2VjODg4NThfMjU0_51c316b7-b204-4360-ba94-eb2a0f180b88" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.216%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and improvements</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i453d53e9bf31458986795e4f39e26923_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMS0xLTEtMS05MTI4NA_8d4e8105-e821-4d1f-a035-c258a92d5073">51.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bd46276d3b04bd4b23ff8a4977603af_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMS0zLTEtMS05MTI4NA_e4f586bc-5682-4302-abd6-606577c47873">52.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6549082d6bea4ee292c42fcb1e41c193_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMi0xLTEtMS05MTI4NA_9bfed634-d8ad-4496-8d12-e59a2310cd57">293.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67809435803d4785af1d56017bd50fe5_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMi0zLTEtMS05MTI4NA_9bc17d85-e79b-4277-8e28-69401a6ecdbe">269.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic594742899c1467ba744e0c848e9a5fc_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMy0xLTEtMS05MTI4NA_c62b2f4e-48d2-4227-aace-39dd3933156c">527.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a7d2d8b2634e30b07c0639a0a4ffe6_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMy0zLTEtMS05MTI4NA_fff06760-2ae8-4fa1-b165-e7e3888c5d0a">513.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i134070129abc4a5f994c045f64942b5a_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNC0xLTEtMS05MTI4NA_1f105cb8-e285-4112-8d3d-bb9d2d06063b">66.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i53d26d6afabb48b2bf9ddc2fb0a2211c_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNC0zLTEtMS05MTI4NA_b54916f2-dde5-4785-a772-1948866c725a">60.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e92b9a6f4ef4b27b44d1e0436ee4f05_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNS0xLTEtMS05MTI4NA_2792d534-e9fb-4cfb-8c6f-d7499c7073bb">218.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9cc08f556fb64cd7881fbaf9a720bbb2_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNS0zLTEtMS05MTI4NA_6e4b8413-ff46-4288-bfc0-d05aae885e86">223.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNi0xLTEtMS05MTI4NA_4afcf79e-f31b-4f16-9c4a-d7f9d0210e6d">1,156.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNi0zLTEtMS05MTI4NA_c072af1e-161a-474a-a5d7-0d62bfecdc51">1,119.2</ix:nonFraction>&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation &amp; amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNy0xLTEtMS05MTI4NA_e15d28c4-499d-422c-b90d-603573234e8b">357.7</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNy0zLTEtMS05MTI4NA_b596ffc2-bf87-4c4a-adf2-160196c6f927">319.1</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfOC0xLTEtMS05MTI4NA_bff6bb51-e1d5-49a8-803c-0ffa278a313d">798.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfOC0zLTEtMS05MTI4NA_b68f8a2a-f892-4266-bc62-ad1ee9c7d832">800.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, construction-in-progress primarily includes costs incurred related to construction to advance the Company's CDMO capabilities. </span></div></ix:continuation><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i76d49868925a4248b8dfd9c1b47fce58" continuedAt="i1792f727ab494bad89ead1d74759fa11">Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. During the three and six months ended June 30, 2022, the Company recorded accelerated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i9546d5f25011482ea8eff2df29f3ff29_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RleHRyZWdpb246NDJmZGNjNWY1YzE2NDljZWFhMDg4ZTc0N2VjODg4NThfNjU5NzA2OTc2ODc3OA_74a1bb89-8d16-425d-9e3e-87b4bc7ea915"><ix:nonFraction unitRef="usd" contextRef="i9638e645586946feae3242935cd61d34_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RleHRyZWdpb246NDJmZGNjNWY1YzE2NDljZWFhMDg4ZTc0N2VjODg4NThfNjU5NzA2OTc2ODc3OA_a74f23b8-d399-4256-86ef-ca4dbbef174a">12.7</ix:nonFraction></ix:nonFraction>&#160;million to shorten the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement with Janssen. For additional information related to the termination of the Agreement, refer to Note 10, Revenue recognition</ix:continuation></span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1792f727ab494bad89ead1d74759fa11">.</ix:continuation> </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_46"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:LesseeOperatingLeasesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RleHRyZWdpb246Mjk5OGQ5M2U3MzE5NDJiOWFjMDQxY2ZjODhiNjAyMjhfNjgw_897e909d-a2cb-43ee-bc5c-086eb1c389cd" continuedAt="i8cfc2d1a75bd43bf8fc0b955f0db1a0b" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="i8cfc2d1a75bd43bf8fc0b955f0db1a0b"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the lessee for operating leases for offices, research and development facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. For a discussion of lessor activities, see Note 10, Revenue recognition.</span></div><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:LeaseCostTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RleHRyZWdpb246Mjk5OGQ5M2U3MzE5NDJiOWFjMDQxY2ZjODhiNjAyMjhfNjc2_ed23c22b-00cd-4c28-b753-219f6901bdb0" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.808%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.991%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.997%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfMy0xLTEtMS05MTI4NA_2f9e07fc-8b68-4735-abe1-cb6d86980dec">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfMy0zLTEtMS05MTI4NA_b8b724ab-e808-4336-829b-68b237af80fd">1.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfMy01LTEtMS05MTI4NA_5721eb29-5c2e-4ef3-9972-1549bfce2a5d">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfMy03LTEtMS05MTI4NA_901e8279-29f8-4a13-8321-b9cdbf84404c">2.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNC0xLTEtMS05MTI4NA_d56e0dbc-7bee-47c4-a1ee-12f3ef2666a5">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNC0zLTEtMS05MTI4NA_233d2c4c-d069-4633-9643-33a9d0d4c458">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNC01LTEtMS05MTI4NA_43767997-bdbf-482b-9029-f925bd3268bf">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNC03LTEtMS05MTI4NA_04fe7626-c701-4d79-8127-a90f4138651b">0.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNS0xLTEtMS05MTI4NA_1615b057-9c35-4f51-b5b9-3043787fc87a">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNS0zLTEtMS05MTI4NA_bc1dcbf2-29e2-49c3-af45-2b2d688f8b1d">1.8</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNS01LTEtMS05MTI4NA_b6a35d2f-bfc5-40f5-a6ac-43e5f465434b">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:LeaseCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNS03LTEtMS05MTI4NA_8a91525d-d068-4bed-9652-bd5cd866102f">3.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are reflected as components of cost of product sales, cost of contract development and manufacturing, research and development expense and selling, general and administrative expense.</span></div><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="ebs:AssetsAndLiabilitiesLesseeTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RleHRyZWdpb246Mjk5OGQ5M2U3MzE5NDJiOWFjMDQxY2ZjODhiNjAyMjhfNjg1_a5b4e0b5-d144-44de-b897-a5fd982674a8" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.020%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.880%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except lease term and discount rate)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet location</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_08a6d402-1277-48d2-bf99-60dd61290d59"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_1ed14031-8464-49dc-b194-cef65be5901a">Other assets</span></span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0zLTEtMS05MTI4NA_dfb690e3-0046-4577-9829-f4e5261dad05">25.5</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS01LTEtMS05MTI4NA_21fa770a-34c4-4059-a620-23483335f95c">28.3</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_27fc9abe-7aef-4a7b-ba2f-191204f5fc38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_b64be59d-2273-4d6d-8743-cf67e2bb3dd4">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0zLTEtMS05MTI4NA_74888504-1ad6-4e11-a4ca-562d0a0e1f6b">5.9</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy01LTEtMS05MTI4NA_274b6e43-f9a6-40dd-9a53-8e1ca4bf2602">5.8</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_a0e6f1b3-d5ea-4f24-926b-07bfa08973d9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_b0f3a4ed-4e9d-4073-9e24-438362666e2c">Other liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0zLTEtMS05MTI4NA_9d494c46-6cef-47b7-9ec9-a9a0d00d0a33">20.9</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC01LTEtMS05MTI4NA_5e673ad5-29d5-4876-9efa-7226a51f15d5">24.2</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNS0zLTEtMS05MTI4NA_e2e0c2d7-4a86-47d9-8a19-11af88c49d89">26.8</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNS01LTEtMS05MTI4NA_96c6f9ee-abfa-4c3f-a567-1b24249bdd32">30.0</ix:nonFraction></span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfOC0zLTEtMS05MTI4NA_5528f8f0-4538-4c20-a797-8231c9ae8b36">6.7</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfOC01LTEtMS05MTI4NA_22fde7c6-ce86-4ddf-a00b-f836ff591226">7.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfOS0zLTEtMS05MTI4NA_0ec69f43-ef8c-42fd-8573-85be4cbc9b47">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfOS01LTEtMS05MTI4NA_efd4048a-b78a-4601-bd28-6fb9c117a8ca">4.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4ef4253100994f989fd72d1c0fd41d25_49"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:IntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNjE1_f58f6f6c-daa3-482b-a4b7-a449bf105d22" continuedAt="i5251e2423d3e4c8bbdbce8d17e05509c" escape="true">Intangible assets</ix:nonNumeric></span></div><ix:continuation id="i5251e2423d3e4c8bbdbce8d17e05509c" continuedAt="i9b8ad5313ffb40ad954de173999b490e"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNjE5_65f6db75-1187-4f16-bdf9-d63a6d95b5ef" continuedAt="ib1e7ac36c4e64f8fa92e7018aafffa16" escape="true">The following table summarizes the Company's Intangible assets, net:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:center"><ix:continuation id="ib1e7ac36c4e64f8fa92e7018aafffa16"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.710%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.963%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.966%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Type</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated Life</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iec5db6327b294813891aa4350122c017_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi0xLTEtMS05MTI4NC90ZXh0cmVnaW9uOmUyODM5NDMzZDQ4NzQwYmU4Y2E4Yzc5ZjNiNDExY2M1XzQ_1c33bcf5-b5c2-4009-8996-b70b062d4cf9">9</ix:nonNumeric>-<ix:nonNumeric contextRef="i0ae91bff48a14d479830dd7525eb8ff8_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi0xLTEtMS05MTI4NC90ZXh0cmVnaW9uOmUyODM5NDMzZDQ4NzQwYmU4Y2E4Yzc5ZjNiNDExY2M1Xzc_85aabdd7-7bc8-4737-a6a5-fb3830441c9f">22</ix:nonNumeric> years</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2719aab9d5794354b6d5b105d461f2f5_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi0zLTEtMS05MTI4NA_b50a3635-57f9-4883-b299-df70f4bb2f00">798.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2719aab9d5794354b6d5b105d461f2f5_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi00LTEtMS05MTI4NA_af9aa13a-123a-42fc-a724-2a82376871d1">221.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2719aab9d5794354b6d5b105d461f2f5_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi01LTEtMS05MTI4NA_40c2bdb9-f45b-4517-b903-284a6051ce5a">576.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3702d910f4e4076ba85f38d2f42d7f4_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi03LTEtMS05MTI4NA_0c4785f7-2c83-4696-9e2b-425962d39283">798.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3702d910f4e4076ba85f38d2f42d7f4_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi04LTEtMS05MTI4NA_502f81b0-460c-45cb-9673-3a818df73c51">193.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3702d910f4e4076ba85f38d2f42d7f4_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi05LTEtMS05MTI4NA_52389c7a-c29d-442e-b2c7-b384307b4a0b">604.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDMO</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1f3ab8a51d54481e9e87b3f7cd0d98a8_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC0xLTEtMS05MTI4NA_a39b8e57-2d43-466a-a0c7-03f1e0ad12bd">8</ix:nonNumeric> years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaecb377a9b7d4fc4a9340b29e791ac69_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC0zLTEtMS05MTI4NA_2bcc881a-4406-499d-8975-98af38b892bd">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaecb377a9b7d4fc4a9340b29e791ac69_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC00LTEtMS05MTI4NA_a0b5a70b-10b0-4c38-a582-c48a92212170">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaecb377a9b7d4fc4a9340b29e791ac69_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC01LTEtMS05MTI4NA_0cd481ff-1b53-4a63-9685-cc7b0d0a18a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb945e79e9d14eb897b6c2bb31d6fca4_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC03LTEtMS05MTI4NA_0ea2a38b-f104-4237-8033-f141006bb4c4">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb945e79e9d14eb897b6c2bb31d6fca4_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC04LTEtMS05MTI4NA_b59b9d35-9693-4a89-b3ba-9cb8e5e528a9">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb945e79e9d14eb897b6c2bb31d6fca4_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC05LTEtMS05MTI4NA_dde32690-a447-48c9-8bd3-7678cf5790ec">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS0zLTEtMS05MTI4NA_0ef3817e-16b3-45d7-ad08-e0149bf7503b">803.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS00LTEtMS05MTI4NA_66a087a3-bfa3-4faf-a0d7-870639f35b18">226.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS01LTEtMS05MTI4NA_ddace3eb-4dac-49ff-93bc-dbde582f0fed">576.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS03LTEtMS05MTI4NA_168c0fc7-0d5e-4976-9fbc-23e26cb2b512">803.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS04LTEtMS05MTI4NA_f6c0078c-3025-4a4d-8f27-5d0c675493f6">198.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:FiniteLivedIntangibleAssetsNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS05LTEtMS05MTI4NA_2045fdf9-27e6-435c-950e-ec61e974a5a6">604.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNjIw_05348dcf-1e58-4549-bfe6-27d5fdaf2c2c" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company's intangible assets was recorded as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.273%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization Expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmYwYTU0NjY3M2YyZTQyNGM4YTI4NWI4NmQzZjM2ZTA4L3RhYmxlcmFuZ2U6ZjBhNTQ2NjczZjJlNDI0YzhhMjg1Yjg2ZDNmMzZlMDhfMi0xLTEtMS05MTI4NA_eaf7c95b-b0c0-4afd-af98-559429733bdc">14.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmYwYTU0NjY3M2YyZTQyNGM4YTI4NWI4NmQzZjM2ZTA4L3RhYmxlcmFuZ2U6ZjBhNTQ2NjczZjJlNDI0YzhhMjg1Yjg2ZDNmMzZlMDhfMi0zLTEtMS05MTI4NA_154d9fcd-50d5-4632-ab27-5285fcba6b36">15.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmYwYTU0NjY3M2YyZTQyNGM4YTI4NWI4NmQzZjM2ZTA4L3RhYmxlcmFuZ2U6ZjBhNTQ2NjczZjJlNDI0YzhhMjg1Yjg2ZDNmMzZlMDhfMi01LTEtMS05MTI4NA_0475b6b1-5d9a-492b-8962-52a4f5656955">28.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:AmortizationOfIntangibleAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmYwYTU0NjY3M2YyZTQyNGM4YTI4NWI4NmQzZjM2ZTA4L3RhYmxlcmFuZ2U6ZjBhNTQ2NjczZjJlNDI0YzhhMjg1Yjg2ZDNmMzZlMDhfMi03LTEtMS05MTI4NA_f85999f3-bf79-4ec7-8d03-ab05410ea473">30.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the weighted average amortization period remaining for intangible assets was <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNDE3_7dc984cf-93b8-45a3-bad7-719a379c5dc3">11.4</ix:nonNumeric> years years. </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i9b8ad5313ffb40ad954de173999b490e" continuedAt="ic53eed03afef427580072bc4ae376a74"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNjE0_8aff698e-a85a-46d5-b9a1-58acdcafd89e" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of changes in our goodwill balance:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.629%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.171%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, December&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmI4ZDk4NjU2ZWZkMDQ5ZTQ4YTc1ZGE1MGVjOTQxMzhhL3RhYmxlcmFuZ2U6YjhkOTg2NTZlZmQwNDllNDhhNzVkYTUwZWM5NDEzOGFfMS0xLTEtMS05MTI4NA_0049ce99-6159-4cd0-b91d-a0ba221494a0">224.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:GoodwillForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmI4ZDk4NjU2ZWZkMDQ5ZTQ4YTc1ZGE1MGVjOTQxMzhhL3RhYmxlcmFuZ2U6YjhkOTg2NTZlZmQwNDllNDhhNzVkYTUwZWM5NDEzOGFfMi0xLTEtMS05MTI4NA_2086d3e7-9525-4176-a4bc-d0a9a98b8de8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, June&#160;30, 2022</span></div></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:Goodwill" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmI4ZDk4NjU2ZWZkMDQ5ZTQ4YTc1ZGE1MGVjOTQxMzhhL3RhYmxlcmFuZ2U6YjhkOTg2NTZlZmQwNDllNDhhNzVkYTUwZWM5NDEzOGFfMy0xLTEtMS05MTI4NA_dc51dfa4-eaf0-402c-b757-05b87b01e62f">224.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ic53eed03afef427580072bc4ae376a74">The carrying amount of goodwill included accumulated impairments of $<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNTcz_331f3d20-de65-4d67-82bb-7a9389f3a0ca"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:GoodwillImpairedAccumulatedImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNTcz_ea592e1c-e472-4625-a3a6-588606e0f07a">41.7</ix:nonFraction></ix:nonFraction> million as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</ix:continuation> </span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_52"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTk3Ng_870fb897-f217-4f7e-a893-ab9cf2e31148" continuedAt="i96c51c3787ac49a1a8e280b6ada29597" escape="true">Fair value measurements</ix:nonNumeric></span></div><ix:continuation id="i96c51c3787ac49a1a8e280b6ada29597" continuedAt="i1863ed6be8a444ada84b8f74a74876f3"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTk4MQ_6ef8ec39-3e42-48d7-874a-a615160faf0d" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques we utilized to determine fair value:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"></td><td style="width:24.441%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.135%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.135%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7a3ff2d30f44b30ad269a86575c7d4e_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy0xLTEtMS05MTI4NA_412fd647-595d-41f1-b5c2-f9393e4a56ff">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79799b3cea2d48fe835c4576542f0b52_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy0yLTEtMS05MTI4NA_f0bd643d-c776-4aef-a027-45f4f73dbe5b">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f5ad802356e448ab1848888d53289de_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy0zLTEtMS05MTI4NA_94bb3da8-ca65-4d09-9b73-4129a0c1d66a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b48ff71a5694921b7c29a1874507763_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy00LTEtMS05MTI4NA_afceea41-a74b-42da-a19e-1232b8846b1e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e74e081ffd481a81c8d31209a72a7b_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy01LTEtMS05MTI4NA_68fd2d06-5d5c-423b-a2ee-3d30b0e00950">152.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84ec0dc532f44309a78a239914a64f67_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy02LTEtMS05MTI4NA_ef41c60d-ce33-4b11-b2dd-8c01868185d3">152.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e03e34023ba4211b5ca4dafd5a90760_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy03LTEtMS05MTI4NA_b38bb379-2cb9-4218-ac84-74feb72bc0f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if86a10b89dc447daa6d9d4bf87168919_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy04LTEtMS05MTI4NA_e2974a15-8961-45b9-a7a1-b8c02ffd2f95">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2ff9b0c4a1d54ae9a2bbb36bb215f296_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC0xLTEtMS05MTI4NA_d7c77500-ac0b-4377-909e-4996cd718e31">150.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia002b59284bc4d199415af1950deab8e_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC0yLTEtMS05MTI4NA_759b797d-0eb6-422d-ab44-8988094dd834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05104b094a7244639351db2f1a5c4ae2_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC0zLTEtMS05MTI4NA_f373bdf2-3a28-42d0-8a52-18773c418792">150.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7aad5be81d9e42518d03593f82a64ee7_I20220630" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC00LTEtMS05MTI4NA_aa809095-d265-4234-8f9f-cc3de31337b2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5709272ba65411cb08a6afe257ae472_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC01LTEtMS05MTI4NA_b96b348a-5552-4cdb-9f69-48d6fa793cea">200.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icaad2ed6a61b4a8ca6f97ee4093e90dc_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC02LTEtMS05MTI4NA_98caebcf-a144-451c-ab5a-fcc96863bab3">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9ea93856b0488caab05e73833c90f9_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC03LTEtMS05MTI4NA_b4f828eb-63be-4b46-963b-c0f413005a89">200.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13b7d630bf0142c6885ef16b3dd8ee1b_I20211231" decimals="-5" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC04LTEtMS05MTI4NA_facf650d-d775-499a-a48b-a55e5d06765c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS0xLTEtMS05MTI4NA_9eaa5a2d-b771-4227-b40a-fa548b6f8145">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00c535b28684f0fb4f18a37ffde27d1_I20220630" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS0yLTEtMS05MTI4NA_6395aa9e-5bf0-4f9a-8141-415f5789a21f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94171351ca92471d95422d2216ab5acb_I20220630" decimals="-5" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS0zLTEtMS05MTI4NA_5953ed50-2a15-4cac-a9ad-811d8a880e66">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9e69b63b67f4da689c99626eb9b9b75_I20220630" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS00LTEtMS05MTI4NA_96d9d766-146a-434c-9df0-b08ae83205fe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS01LTEtMS05MTI4NA_cb63b960-2bb3-4e9d-8bc6-553002c84ab6">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55840f9158e144dd8f3579713ad95750_I20211231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS02LTEtMS05MTI4NA_43f2425b-6b76-4422-84ed-670f33d27ac0">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS03LTEtMS05MTI4NA_6b959017-9a6b-4062-b3eb-3f189fedc094">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1827bdb5367f4f7980f91a6d166e8719_I20211231" decimals="-5" name="us-gaap:DerivativeAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS04LTEtMS05MTI4NA_238327aa-b03b-41de-80d4-7ef305c45bf8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi0xLTEtMS05MTI4NA_6ddc707e-8968-4dfc-9c82-6e9063606925">181.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00c535b28684f0fb4f18a37ffde27d1_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi0yLTEtMS05MTI4NA_16a12fe6-f879-4055-84c3-456763b143cc">25.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94171351ca92471d95422d2216ab5acb_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi0zLTEtMS05MTI4NA_9a85ff91-ae9d-46b0-a469-29def408df4a">156.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9e69b63b67f4da689c99626eb9b9b75_I20220630" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi00LTEtMS05MTI4NA_7592aa7f-8062-4e7c-907d-ed1f5cb3ce1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi01LTEtMS05MTI4NA_cea7bdc4-c110-49ef-a52e-a3fd9e13eeae">352.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55840f9158e144dd8f3579713ad95750_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi02LTEtMS05MTI4NA_cf2702a9-4df2-43d2-baf5-197192f25691">152.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi03LTEtMS05MTI4NA_eec485ae-5e2c-4084-9226-911bfb92a2ef">200.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1827bdb5367f4f7980f91a6d166e8719_I20211231" decimals="-5" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi04LTEtMS05MTI4NA_9e89a285-19f5-4003-bc47-ed11f508ae64">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC0xLTEtMS05MTI4NA_2ab754bc-3ffb-41b8-80cf-db87b0e7d156">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00c535b28684f0fb4f18a37ffde27d1_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC0yLTEtMS05MTI4NA_1e7a69bd-0252-4429-b9c2-3e478f430dca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94171351ca92471d95422d2216ab5acb_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC0zLTEtMS05MTI4NA_6d6ca753-e0be-4d24-86b6-68be948b599d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9e69b63b67f4da689c99626eb9b9b75_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC00LTEtMS05MTI4NA_949f2e20-0569-4fbb-9fd7-602359f8681b">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC01LTEtMS05MTI4NA_5d3de6c1-1bd9-4164-b7fe-3fb7dd328734">37.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55840f9158e144dd8f3579713ad95750_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC02LTEtMS05MTI4NA_d3667166-2dfb-4b17-9eed-3e0cc43cb12e">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC03LTEtMS05MTI4NA_6790c9ee-723f-4894-979e-3028ddc9f4d1">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1827bdb5367f4f7980f91a6d166e8719_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC04LTEtMS05MTI4NA_c1492285-27b6-4f90-b2bc-5321555835f1">37.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS0xLTEtMS05MTI4NA_ec4525c1-9f8d-4c7e-a091-cbc0a804b6de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00c535b28684f0fb4f18a37ffde27d1_I20220630" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS0yLTEtMS05MTI4NA_5a16bbd7-d43d-4836-90f7-84af1fff95ae">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94171351ca92471d95422d2216ab5acb_I20220630" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS0zLTEtMS05MTI4NA_f8deec36-77d0-4ae3-b9d0-7e580929f99f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9e69b63b67f4da689c99626eb9b9b75_I20220630" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS00LTEtMS05MTI4NA_e2618ce5-162b-49cd-bfff-048805480c8b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS01LTEtMS05MTI4NA_9c34e3bc-9d0b-4d59-afd1-aeff49ffe166">6.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55840f9158e144dd8f3579713ad95750_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS02LTEtMS05MTI4NA_7412df7e-c533-4adb-8d4b-32e619bdf0f9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS03LTEtMS05MTI4NA_1f875e8a-ccd3-4740-bbde-37ad43b4b7d6">6.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1827bdb5367f4f7980f91a6d166e8719_I20211231" decimals="-5" name="us-gaap:DerivativeLiabilities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS04LTEtMS05MTI4NA_05c2105b-f6ae-4d8b-b8c5-a5cf7a9e54d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtMS0xLTEtOTEyODQ_ed34c8ae-9fd5-46f5-96fb-be4e07b23b36">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia00c535b28684f0fb4f18a37ffde27d1_I20220630" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtMi0xLTEtOTEyODQ_8c69dd47-c7d2-4d05-b9b9-e810d5cfc935">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94171351ca92471d95422d2216ab5acb_I20220630" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtMy0xLTEtOTEyODQ_5b8f48aa-a920-4811-95e5-905c9f354b5e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9e69b63b67f4da689c99626eb9b9b75_I20220630" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtNC0xLTEtOTEyODQ_5aa09aa1-0eaf-48a9-876e-ca6b6ede9fb3">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtNS0xLTEtOTEyODQ_18ec76eb-d238-44eb-9c3b-37345b7233dd">43.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55840f9158e144dd8f3579713ad95750_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtNi0xLTEtOTEyODQ_51d546d2-5d36-44ae-bb1f-932ea0686568">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtNy0xLTEtOTEyODQ_eb1e27a4-6bbe-4a84-a4af-b4a7fe17a083">6.1</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1827bdb5367f4f7980f91a6d166e8719_I20211231" decimals="-5" name="us-gaap:LiabilitiesFairValueDisclosure" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtOC0xLTEtOTEyODQ_51ea66f9-bdb4-4a3f-9839-a1a4a1acbd96">37.2</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#8217;s products are classified in the Company's statement of operations as cost of product sales. </span></div><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTk3Nw_21586ece-0a8c-4f3a-b2ef-3ebb8e91e2e5" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the beginning and ending balance of our contingent consideration liability: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.884%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOmRkMDk5ZmZhMjQ2NzRhNzE4NmZlY2Y3YzJhZDM2YzEyL3RhYmxlcmFuZ2U6ZGQwOTlmZmEyNDY3NGE3MTg2ZmVjZjdjMmFkMzZjMTJfMS0xLTEtMS05MTI4NA_7143f69d-0fa9-40dc-b14f-7c3bf2ddb421">37.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOmRkMDk5ZmZhMjQ2NzRhNzE4NmZlY2Y3YzJhZDM2YzEyL3RhYmxlcmFuZ2U6ZGQwOTlmZmEyNDY3NGE3MTg2ZmVjZjdjMmFkMzZjMTJfMi0xLTEtMS05MTI4NA_2e19b6a3-64f0-48dd-ba98-02fd8f8bfa33">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOmRkMDk5ZmZhMjQ2NzRhNzE4NmZlY2Y3YzJhZDM2YzEyL3RhYmxlcmFuZ2U6ZGQwOTlmZmEyNDY3NGE3MTg2ZmVjZjdjMmFkMzZjMTJfMy0xLTEtMS05MTI4NA_6b7abd73-13a3-49b4-81d9-6a0986f0ed74">30.9</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOmRkMDk5ZmZhMjQ2NzRhNzE4NmZlY2Y3YzJhZDM2YzEyL3RhYmxlcmFuZ2U6ZGQwOTlmZmEyNDY3NGE3MTg2ZmVjZjdjMmFkMzZjMTJfNC0xLTEtMS05MTI4NA_7221a530-9502-40f7-87bb-0be05be7e2b6">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the current portion of the contingent consideration liability was $<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTI1NQ_3396ea9d-47da-409f-91a9-83ee09e93024">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTI2Mg_52bdbc6f-a3e6-4acd-a075-23f2c64267db">32.7</ix:nonFraction>&#160;million, respectively, and was included in other current liabilities on the condensed consolidated balance sheets. The non-current portion of the contingent consideration liability is included in other liabilities on the condensed consolidated balance sheets.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i1863ed6be8a444ada84b8f74a74876f3"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTk4Mw_be6eb296-e251-4eaf-b695-f6074120f56c" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value as of June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average</span></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue milestone and royalty based</span></td><td colspan="3" rowspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i7b0124a24a6d42f38a22a139d7a986cc_I20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMS0xLTEtMS05MTI4NA_a89868a3-243d-4aa7-9ef4-b6aab335a9c1">8.1</ix:nonFraction> million</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounted cash flow</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7ec6f53ea7c40c2912590dc96df1140_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMS00LTEtMS05MTI4NC90ZXh0cmVnaW9uOmUxNDQ3Y2M2YmIxYTRkNDZiNjQ1YjdiMTJhYjc4ZTgwXzQ_7c06a9bb-35a3-486c-917e-72898a95f1f4">9.3</ix:nonFraction>%</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib3767e06a12a4c5e98d3e3277b684a7a_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMS01LTEtMS05MTI4NA_c948abac-76b0-471b-a01e-2a50ba23a49b">9.3</ix:nonFraction>%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i63a027931d994feaad0cc197610c9386_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMi00LTEtMS05MTI4NC90ZXh0cmVnaW9uOjFiNDI2Nzc5ODdmMTQ2MGNiNzAyODlmMjY0Mjc3NTgxXzQ_0658c4f8-9c8f-49a6-97c9-a882a5ce8d29">25</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="i83059e6d4cbf495fac3749e03908d241_I20220630" decimals="2" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMi00LTEtMS05MTI4NC90ZXh0cmVnaW9uOjFiNDI2Nzc5ODdmMTQ2MGNiNzAyODlmMjY0Mjc3NTgxXzk_6ed13189-67e0-4433-b83b-3c6dc99fd6cd">50</ix:nonFraction>%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i719981bf5f3142bcab25241944433a85_I20220630" decimals="3" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMi01LTEtMS05MTI4NA_d7f0e498-af35-45a2-bf4b-8330fa8c07b5">40.0</ix:nonFraction>%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Note 8, Derivative instruments and hedging activities</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information about our derivative instruments.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-variable rate debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022 and December&#160;31, 2021, t</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he fair value of the Company's <ix:nonFraction unitRef="number" contextRef="if69c9e056c6b47ce9a39e1690508a029_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTY5NA_0655ea8e-6d6e-4606-952e-f413f9607b99"><ix:nonFraction unitRef="number" contextRef="idb1acd071817481e9aef10fe54fb65fb_I20211231" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTY5NA_0b662871-3dd3-437b-9de2-deef382dc5e8">3.875</ix:nonFraction></ix:nonFraction>% Senior Unsecured Notes was $<ix:nonFraction unitRef="usd" contextRef="if69c9e056c6b47ce9a39e1690508a029_I20220630" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTcyNA_3f97c870-8cff-4b8f-a2da-8cb7272e4684">319.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="idb1acd071817481e9aef10fe54fb65fb_I20211231" decimals="-5" name="us-gaap:LongTermDebtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTczMQ_a2cb70e2-d68d-4775-a6e9-9122bdbafd4a">433.3</ix:nonFraction>&#160;million. The fair value was determined through market sources, which are level 2 inputs and directly observable. </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 9, Debt).</span></div></ix:continuation><div id="i4ef4253100994f989fd72d1c0fd41d25_55"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfMjk4Nw_837e4850-8c96-4aca-80e1-0a488189c8ce" continuedAt="i0869dcbe4ec5495aa0d76a55d27950e6" escape="true">Derivative instruments and hedging activities</ix:nonNumeric></span></div><ix:continuation id="i0869dcbe4ec5495aa0d76a55d27950e6" continuedAt="i4ffcda14abad4d1a8326657159cb82d0"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk management objective of using derivatives</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from the Company's senior secured credit agreement's payments of variable interest rate debt.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If current fair values of designated interest rate swaps&#160;remained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;$<ix:nonFraction unitRef="usd" contextRef="i64a444e1b04f441690465f4274c0ba71_D20220101-20220630" decimals="-5" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfOTAw_e9285e66-12c8-41b0-8da4-9c4e12df6b31">4.8</ix:nonFraction> million of net deferred gains from&#160;accumulated other comprehensive loss&#160;into the condensed consolidated statement of operations over the next&#160;twelve-month period. All outstanding cash flow hedges mature in October 2023.</span></div><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfMjk3OQ_ab34d993-c83f-4aca-abe0-e027a7378f40" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except number of instruments)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of Instruments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notional</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="instrument" contextRef="i5baf28559b9c4518961b9d35563505d5_I20220630" decimals="INF" name="us-gaap:NumberOfInterestRateDerivativesHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjdiNTE5M2U4NTA1YjQxMTZiMjhjZWFhOTZjMDFlMTRjL3RhYmxlcmFuZ2U6N2I1MTkzZTg1MDViNDExNmIyOGNlYWE5NmMwMWUxNGNfMS0xLTEtMS05MTI4NA_c12f540c-0132-406b-991b-2a2637a8a653">7</ix:nonFraction></span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i5baf28559b9c4518961b9d35563505d5_I20220630" decimals="-5" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjdiNTE5M2U4NTA1YjQxMTZiMjhjZWFhOTZjMDFlMTRjL3RhYmxlcmFuZ2U6N2I1MTkzZTg1MDViNDExNmIyOGNlYWE5NmMwMWUxNGNfMS0zLTEtMS05MTI4NA_49288a18-a929-40bf-958a-abed5e9e5cd0">350.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfMjk4MA_b3390c78-dc73-4be2-958c-4564f1b492a3" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.388%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Derivatives</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Assets</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fef5a8c0e574704b4e7fc1c219ab3d0_I20220630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfMy0yLTEtMS05MTI4NA_a8e8d689-cdee-4639-8a8e-e4e041bc2edc">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Assets</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec600dcf49a542e999254859b44d9453_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfMy00LTEtMS05MTI4NA_034949a4-c6c7-43a7-bd64-7cb9a25d89d8">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Liabilities </span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10a6fba32aca4cf289ec54a01e657a74_I20220630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfMy02LTEtMS05MTI4NA_796ebe44-51b1-4c1a-9d81-2e906d5e5840">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Liabilities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db202080e4f497184ae1cf6144f3e2f_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfMy04LTEtMS05MTI4NA_a5d853a9-86b0-49e8-9535-c5a6e2e1c080">4.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic20b9c06c3554129afcfbc3e3f02046b_I20220630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfNC0yLTEtMS05MTI4NA_48e27fda-75af-4c47-98bc-459fb3975e62">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7068fe6db2b4311a9524223dac6fb00_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfNC00LTEtMS05MTI4NA_f1b9e095-8d5f-4976-8c83-bfe3639799fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Liabilities</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icee5403eeb9f41649ba99ccabe3e2da8_I20220630" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfNC02LTEtMS05MTI4NA_0f09846c-4de7-47d6-a197-d5c29f506092">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05d57a1513ce46c68b959f35fdc72cec_I20211231" decimals="-5" name="us-gaap:DerivativeFairValueOfDerivativeLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfNC04LTEtMS05MTI4NA_e3d784a5-60ab-4764-bf48-2dae96a037fa">1.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i4ffcda14abad4d1a8326657159cb82d0"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfMjk5MQ_287dec43-6061-4dc2-9f6b-733360c1c5a4" escape="true">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</ix:nonNumeric></span></div><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfMjk4Ng_f7495479-e324-4250-9d43-8adb16f089ec" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive loss.</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"></td><td style="width:20.657%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.505%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.309%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.311%"></td><td style="width:0.1%"></td></tr><tr style="height:38pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative</span></div></td><td colspan="3" rowspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Location of Gain or (Loss) Reclassified from Accumulated OCL into Income</span></td><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount of Gain/(Loss) Reclassified from Accumulated OCL into Income</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Swaps</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64a444e1b04f441690465f4274c0ba71_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjE4YjA1ODBlODU1ZjQzYjI4MjIwMzM2MDhhMmFiZWEyL3RhYmxlcmFuZ2U6MThiMDU4MGU4NTVmNDNiMjgyMjAzMzYwOGEyYWJlYTJfMy0xLTEtMS05MTI4NA_f635cdcd-168a-430b-a498-796075638efd">6.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifa0b79c3b615467b86496c6b28174204_D20210101-20211231" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjE4YjA1ODBlODU1ZjQzYjI4MjIwMzM2MDhhMmFiZWEyL3RhYmxlcmFuZ2U6MThiMDU4MGU4NTVmNDNiMjgyMjAzMzYwOGEyYWJlYTJfMy0yLTEtMS05MTI4NA_06df2cae-59fb-4510-aa68-2fc2adad3a55">6.1</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibc3c3a4cf51a47be9050271b2311e72e_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjE4YjA1ODBlODU1ZjQzYjI4MjIwMzM2MDhhMmFiZWEyL3RhYmxlcmFuZ2U6MThiMDU4MGU4NTVmNDNiMjgyMjAzMzYwOGEyYWJlYTJfMy00LTEtMS05MTI4NA_7941c1b2-5aa0-45b7-a1cc-d1c7cab4228d">2.3</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7f1e5afa818e49f1bb83f2fde4b26d1b_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjE4YjA1ODBlODU1ZjQzYjI4MjIwMzM2MDhhMmFiZWEyL3RhYmxlcmFuZ2U6MThiMDU4MGU4NTVmNDNiMjgyMjAzMzYwOGEyYWJlYTJfMy01LTEtMS05MTI4NA_6168f327-8c37-4a57-8a5f-95711a9ad541">3.0</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4ef4253100994f989fd72d1c0fd41d25_58"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjgzMg_f35c3ff4-e937-43e6-b498-868c494dc065" continuedAt="i2142f6c4567b4f028f8049f2789a4f9e" escape="true">Debt</ix:nonNumeric></span></div><ix:continuation id="i2142f6c4567b4f028f8049f2789a4f9e" continuedAt="i1799438e26c645f58e5d5e97aac4af90"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjgyOQ_eade5df2-58b3-43cd-a1fc-3f3699c1c7fe" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of debt are as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:54.359%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured credit agreement - Term loan due 2023</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i906b83ea370446e3be94c4ddaaa4083e_I20220630" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMS0xLTEtMS05MTI4NA_099094c7-9c61-49f2-b54f-d1abe26112a9">379.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95dc7a5826cb458ea6fbfdfca937dcbd_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMS0zLTEtMS05MTI4NA_18340485-df98-4949-af61-112ab6f1aad3">396.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured credit agreement - Revolver loan due 2023</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie971a34ecfcf4b408a15bfa4996e60a7_I20220630" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMi0xLTEtMS05MTI4NA_f744ab34-a71c-4bd6-a0ab-188ae2bb556e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb778bbc0bd64de7ad6801fd66de8bbc_I20211231" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMi0zLTEtMS05MTI4NA_6cb19598-a571-4601-a9d3-cc3c2cdc2e14">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if69c9e056c6b47ce9a39e1690508a029_I20220630" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMy0wLTEtMS05MTI4NC90ZXh0cmVnaW9uOmFiMWI2MWYwZTZjZjRkNjNiZjA2M2YwNzhiNDNiNWY2XzQ_66abe4ce-57ff-4b87-a8a2-aefa7eb1e98f">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if69c9e056c6b47ce9a39e1690508a029_I20220630" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMy0xLTEtMS05MTI4NA_65e257e4-4b62-4c1f-b51f-e5555b9fba33">450.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb1acd071817481e9aef10fe54fb65fb_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMy0zLTEtMS05MTI4NA_1d468f20-b6e9-4f72-916b-938aeb0cedf8">450.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1555249a53454772b48e904b14824e1d_I20220630" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNC0xLTEtMS05MTI4NA_ec6dabf9-e25f-4ae5-9cf9-6340f1ba4d6a">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1485bfe38fce41ec95d481aecf94f617_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNC0zLTEtMS05MTI4NA_64f4f49a-61c4-43d6-be4a-296d76ce1b1b">3.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNS0xLTEtMS05MTI4NA_66c8d185-ab08-448f-8071-c14daf3e42fd">832.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNS0zLTEtMS05MTI4NA_f9722d27-cbce-4f28-baa2-f3451b780053">849.6</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, net of debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNy0xLTEtMS05MTI4NA_743ac0b0-f519-4ff1-9cc3-102998b9886e">31.6</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNy0zLTEtMS05MTI4NA_5e0541c8-dec9-4b5e-bd31-3f8b7548ac71">31.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfOC0xLTEtMS05MTI4NA_5d4f4641-3b25-4677-9bb6-0e6ac3d6863d">7.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsNoncurrentNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfOC0zLTEtMS05MTI4NA_e4e85950-f226-4608-8671-d84ecefae9fb">8.5</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfOS0xLTEtMS05MTI4NA_89061048-d11d-4566-8961-1f90d853e278">793.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfOS0zLTEtMS05MTI4NA_7f9e9420-2004-47ec-8420-04695e3220b7">809.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</span></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021 there was <ix:nonFraction unitRef="usd" contextRef="ie971a34ecfcf4b408a15bfa4996e60a7_I20220630" decimals="INF" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNzY5NjU4MTQwMjM0OA_088f798e-b38a-4c74-b5e6-637466c416b8"><ix:nonFraction unitRef="usd" contextRef="ibb778bbc0bd64de7ad6801fd66de8bbc_I20211231" decimals="INF" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNzY5NjU4MTQwMjM0OA_9f8df46e-2d8f-4e2b-bdf4-30005f068f1d">no</ix:nonFraction></ix:nonFraction> outstanding revolver balance. We classify debt issuance costs associated with the </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revolver</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loan as other current assets and other assets on the Company's consolidated balance sheets. As of June&#160;30, 2022, the Company had $<ix:nonFraction unitRef="usd" contextRef="if549fa85623e479b8a4ea408bf3855e9_I20220630" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzE4_407a496c-0180-4e0a-bcb1-a47a73f304b8">2.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ife82c6e169cb463d8894b9c0060a4276_I20220630" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzI1_a55c44cb-e8e3-4457-9fb5-a669566c621f">0.6</ix:nonFraction>&#160;million of debt issuance costs associated with the revolver loan classified as other current assets and other assets, respectively. As of December&#160;31, 2021, the Company had approximately $<ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsCurrentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDky_b1478d7d-c26d-442a-b399-08f038420d64">2.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:DeferredFinanceCostsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDk5_84edbb51-78d9-4401-a8ab-323e161f53ff">1.6</ix:nonFraction> million of debt issuance costs associated with the revolver loan that were classified as other current assets and other assets, respectively.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="if194a1fa3b4249e29ea4d656684e16a6_I20200807" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjM2_7e890c07-4707-425f-b674-cf32a761c1a4">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company completed its offering of $<ix:nonFraction unitRef="usd" contextRef="if194a1fa3b4249e29ea4d656684e16a6_I20200807" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNzI5_83ade66d-7a19-4aed-add2-8241c475eee6">450.0</ix:nonFraction>&#160;million aggregate principal amount of <ix:nonFraction unitRef="number" contextRef="if194a1fa3b4249e29ea4d656684e16a6_I20200807" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNzYy_d00a8429-7c00-45fa-92a8-f022aa180a5b">3.875</ix:nonFraction>% Senior Unsecured Notes due 2028 (the 2028 Notes) of which the majority of the net proceeds were used to pay down the Revolving Credit Facility (as defined below). Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related Indenture, plus accrued and unpaid interest. Prior to August 15, 2023 the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to <ix:nonFraction unitRef="number" contextRef="i854ab883416b4f61a70d7a994a7e7dc8_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMTQwNg_d82a90b7-bb9d-4b2e-a7fc-c47586dec50c">100</ix:nonFraction>% of the principal amount of the 2028 Notes plus a &#8220;make-whole&#8221; premium and accrued and unpaid interest. Prior to August 15, 2023, the Company may </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i1799438e26c645f58e5d5e97aac4af90"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redeem up to <ix:nonFraction unitRef="number" contextRef="ie7406b9184a64854a36cdc074d9b7efd_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMTU2Nw_c900fb38-9128-44af-b470-63a1b904b741">40</ix:nonFraction>% of the aggregate principal amount of the 2028 Notes using the net cash proceeds of certain equity offerings at the redemption price set forth in the related Indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of <ix:nonFraction unitRef="number" contextRef="i77bd92decaae4597a010ce330d685077_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentRedemptionPricePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMTg1Nw_dba42395-fd45-41fe-92cd-2b1d49fe59c3">101</ix:nonFraction>% of the principal amount of such 2028 Notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative covenants in the Indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on August 7, 2020, the Company entered into a Second Amendment (the &#8220;Credit Agreement Amendment&#8221;) to its senior secured credit agreement, dated October 15, 2018, with multiple lending institutions relating to the Company&#8217;s senior secured credit facilities (the &#8220;Credit Agreement,&#8221; and as amended, the &#8220;Amended Credit Agreement&#8221;), consisting of a senior revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and senior term loan facility (the &#8220;Term Loan Facility,&#8221; and together with the Revolving Credit Facility, the &#8220;Senior Secured Credit Facilities&#8221;).  The Credit Agreement Amendment amended, among other things, the definition of incremental facilities limit, the consolidated net leverage ratio financial covenant by increasing the maximum level, increased the permissible applicable margins based on the Company&#8217;s consolidated net leverage ratio and increased the commitment fee that the Company is required to pay in respect of the average daily unused commitments under the Revolving Credit Facility, depending on the Company&#8217;s consolidated net leverage ratio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement includes (i) a Revolving Credit Facility of $<ix:nonFraction unitRef="usd" contextRef="i864f4e447766464d959250dafeb367a6_I20200807" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzM5Mg_42b57876-71fe-4afa-851c-47b55e251acc">600.0</ix:nonFraction>&#160;million and (ii) a Term Loan Facility with a principal amount of $<ix:nonFraction unitRef="usd" contextRef="i8d27dfde1b0a4ca9bd9806ae5f1fd0e0_I20200807" decimals="-5" name="us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzQ1Mg_d1fd8b1c-6260-49f5-bb73-b820a76324e3">450.0</ix:nonFraction>&#160;million. The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as certain requirements involving our net leverage ratio will be maintained on a pro forma basis. Borrowings under the Revolving Credit Facility and the Term Loan Facility bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from <ix:nonFraction unitRef="number" contextRef="idd60b38179fc4f99af5a397c6f413c8c_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzg2Mg_33865145-4eff-49ee-aaf6-13cfe0f29c25">1.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="ia4154b9a491b4ef2aff17f1e88bb8277_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzg2OA_697d14ff-de61-4d06-a723-3b91a720e50f">2.25</ix:nonFraction>% per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus <ix:nonFraction unitRef="number" contextRef="if1e09335afe7401fabaf417e79536c26_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDAyOQ_671a36b2-9323-447e-b880-ce13c9ec75a9">0.50</ix:nonFraction>%, and a eurocurrency rate for an interest period of one month plus <ix:nonFraction unitRef="number" contextRef="i97df715145c94a708ee00a7a333e62fa_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDA5OA_96ec28da-7e4a-4930-b5f8-6f59f6593dfc">1</ix:nonFraction>% plus a margin ranging from <ix:nonFraction unitRef="number" contextRef="i9af3fed7d2eb49a0934cfdea363489d8_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDEyOA_bc68aa07-01c8-4aae-b07b-d3bbede3011d">0.25</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i98549f959da647058170049a65c7b6c1_D20200807-20200807" decimals="INF" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDEzNA_237100d0-5c79-4d35-8525-61c185038dac">1.25</ix:nonFraction>%, depending on the Company's consolidated net leverage ratio). The Company is required to make quarterly payments on the last business day of each calendar quarter under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from <ix:nonFraction unitRef="number" contextRef="i06495fe6675749ddb25cf196298c2fa3_D20200807-20200807" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDUxMw_aa94e62c-ff7d-443f-be91-e3da1415c9eb">0.15</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i3cc8672e8d254d8cbb23b229dcd959c8_D20200807-20200807" decimals="INF" name="us-gaap:LineOfCreditFacilityCommitmentFeePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDUxOQ_8770a82a-cb8b-4e19-ab44-44cad3b5ad78">0.35</ix:nonFraction>% per annum, depending on the Company's consolidated net leverage ratio, for the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments on the last business day of each calendar quarter based on an annual percentage equal to <ix:nonFraction unitRef="number" contextRef="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807" decimals="INF" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDg2OQ_f935a2aa-8c51-469a-bdc2-52af0b31f558">2.5</ix:nonFraction>% of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, <ix:nonFraction unitRef="number" contextRef="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807" decimals="INF" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDk5Mw_866f98ed-f4c5-49dc-b266-ddebeea5db8a">5</ix:nonFraction>% of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and <ix:nonFraction unitRef="number" contextRef="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807" decimals="INF" name="ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNTEwNw_304b167d-52c8-4a9f-aa3e-180d39839d07">7.5</ix:nonFraction>% of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature on October 13, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of $<ix:nonFraction unitRef="usd" contextRef="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807" decimals="-5" name="ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNTgyNQ_e0cce5cc-a4a9-45f1-abcb-51c33dceb46d">100.0</ix:nonFraction>&#160;million during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights. The financial covenants under the Amended Credit Agreement currently require the quarterly presentation of a minimum consolidated <ix:nonNumeric contextRef="ie462a20b8c7642d6ba2baedaff5e64eb_D20200807-20200807" name="ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjEyNg_043efdce-3ce2-4493-bf24-4797436e414b">12</ix:nonNumeric>-month rolling debt service coverage ratio of <ix:nonFraction unitRef="number" contextRef="i06495fe6675749ddb25cf196298c2fa3_D20200807-20200807" decimals="INF" name="ebs:DebtInstrumentCovenantDebtServiceCoverageRatio" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjE3NA_371ca1a4-f317-4e6a-aea3-d54e2226aec3">2.50</ix:nonFraction> to 1.00, and a maximum consolidated net leverage ratio of <ix:nonFraction unitRef="number" contextRef="i3cc8672e8d254d8cbb23b229dcd959c8_D20200807-20200807" decimals="INF" name="ebs:DebtInstrumentCovenantNetLeverageRatioOne" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjIzNQ_22235efb-91a6-4117-8c8e-e112bfb5f20f">4.50</ix:nonFraction> to 1.00 (subject to an increase to <ix:nonFraction unitRef="number" contextRef="i3cc8672e8d254d8cbb23b229dcd959c8_D20200807-20200807" decimals="INF" name="ebs:DebtInstrumentCovenantNetLeverageRatioTwo" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjI3Mw_46d3893c-9679-4b42-9c21-dcfd9ed39a1f">5.00</ix:nonFraction> to 1.00 for an applicable four quarter period, at the election of the Company, in connection with a permitted acquisition having an aggregate consideration in excess of $<ix:nonFraction unitRef="usd" contextRef="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807" decimals="-5" name="ebs:DebtInstrumentCovenantConsiderationThreshold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjQ0NQ_87eb3ccd-3c70-42ff-a944-43d5510a67fa">75.0</ix:nonFraction>&#160;million). Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments. As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM0Mw_fc5e37ad-e06b-4c50-b1cc-36ac2f960151" continuedAt="ib960045fb3024132925211aa01263f42" escape="true">Revenue recognition</ix:nonNumeric></span></div><ix:continuation id="ib960045fb3024132925211aa01263f42" continuedAt="i2aa6cb51eade45d1b85331ad03e77691"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as <ix:nonFraction unitRef="segment" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNTM_22ec5aaf-a174-4afa-8cfb-61ac42c7dd95">two</ix:nonFraction> operating segments (Note 14, Segment information). <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM0MA_7153a705-a896-4a65-b01d-0baf039e0fa1" continuedAt="ic51ba593a51e47e399f3ae8fab3f592a" escape="true">The Company's revenues disaggregated by the major sources were as follows:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="ic51ba593a51e47e399f3ae8fab3f592a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.750%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i574f9adb7940424798f2d99703583daa_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi0xLTEtMS05MTI4NA_dc2f0091-e18a-4467-8968-316066c6e505">118.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7168a15913e0452ba5e8b7cc16cd596d_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi0zLTEtMS05MTI4NA_7fc8427a-b4fe-4e77-8ab1-60ef68c29434">119.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b613598404b49b880eecce284caa409_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi01LTEtMS05MTI4NA_5211c697-4955-4889-9a0d-756062439e55">237.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37b9298740734b91b9649eca3d31f872_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi03LTEtMS05MTI4NA_7062e942-0216-45e9-98fa-303e688ad67d">66.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb0dfd1b367d4a4bbc9a8d933e8d12c5_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi05LTEtMS05MTI4NA_638ff5bf-c043-46d7-9582-a879fccfa119">114.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic14c595631e444d1b209fffe8cd22901_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi0xMS0xLTEtOTEyODQ_399c2457-b48b-4a41-909c-8226e8611e02">181.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract development and manufacturing:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78916fe957f24b278cd2cf0ff71d751a_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC0xLTEtMS05MTI4NA_1956c5ab-de57-442b-a9e0-c68368f13853">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f3b32beef6f4047a8dcd6932c3b547a_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC0zLTEtMS05MTI4NA_5d29e42e-550f-4445-97fb-8206c6b812c7">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d6b9ed7cef4daf9b8dc0c61d4b8f0b_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC01LTEtMS05MTI4NA_cbcd5577-0e0a-47d0-b384-bff943eda1b5">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3037fdadacbb4e5f923277f2e26c9563_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC03LTEtMS05MTI4NA_76e97324-b829-44bb-9c50-a9f6fdb7ea96">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6995a6427d454821b7f5573c0a1da3af_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC05LTEtMS05MTI4NA_5c20d587-d67d-4d58-932f-bcb2759ba3a3">103.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d9f1173bf46467fa504dd84e978c454_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC0xMS0xLTEtOTEyODQ_5b42c1ec-35b1-4cc8-872e-6fa5a243e347">103.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f3722b3ba404046b480130be3ff47cb_D20220401-20220630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS0xLTEtMS05MTI4NA_c759570d-47bb-4e74-975f-e6c947cdc42b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7b2c6cc57c314379aa754295fc61f0c2_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS0zLTEtMS05MTI4NA_eed74d72-3275-4ea6-b904-44f27452893f">4.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i122c38cfc545444f95a68c8027e7c09e_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS01LTEtMS05MTI4NA_c8460f89-883e-4ecb-862d-dc85ac87552d">4.5</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieedc7121a2874e219f1a1ca878ff2c37_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS03LTEtMS05MTI4NA_98c87572-5028-4732-b111-5bbf4afc2068">70.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfcb43efacdb406f820678d118bbcdd8_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS05LTEtMS05MTI4NA_943c5d09-5551-441c-bbeb-de844b4805eb">16.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db2e41be1c547f68cf80fdad0358d9c_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS0xMS0xLTEtOTEyODQ_13bc7950-10dd-4074-b638-62c9357399ff">87.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract development and manufacturing</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b31182d8bf44cb88f2e81054292fb42_D20220401-20220630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi0xLTEtMS05MTI4NA_f29fc072-6a22-4851-a4d7-7107da3d4470">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ecb5143f5f7478faa5324a51e49bd6c_D20220401-20220630" decimals="-5" sign="-" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi0zLTEtMS05MTI4NA_216414af-ac79-4ce9-b98d-00a835758733">1.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifef1158a0f1b4f9c9cfe6d88fe654e3b_D20220401-20220630" decimals="-5" sign="-" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi01LTEtMS05MTI4NA_fdc702ba-3d5e-46f0-ae9a-7d5d3d9093d3">1.8</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icba1568320d14f98b740134699420a7c_D20210401-20210630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi03LTEtMS05MTI4NA_3c09e37f-b3c8-4bc4-9bed-f391d34c9159">70.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i719033973c3c4e0790d3212f10dbadcd_D20210401-20210630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi05LTEtMS05MTI4NA_0426e42a-4565-44c1-ba15-c9c0ed164ed2">120.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e3ddd561972469b83305bb2ad955b68_D20210401-20210630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi0xMS0xLTEtOTEyODQ_4e001f48-ef75-4161-b689-031ad71bf330">190.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16ac2c2d319f4a00960710084dc7bba7_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy0xLTEtMS05MTI4NA_5fb7459a-2770-4bc6-b669-7bf47b721abb">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b6fd4492311495296403951539f5faf_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy0zLTEtMS05MTI4NA_6f1d21bc-a001-4b92-a0fb-20c706c7854d">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f9afc75663f4899a4fc9be307765379_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy01LTEtMS05MTI4NA_af8abfbf-3134-4a46-981f-45e4472d5fe7">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7a523ccb265741f5b098e936ed21f511_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy03LTEtMS05MTI4NA_92e0057d-18ed-4d4e-b471-937052a806ad">24.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia08e21eff6ed4142bc00ba76de36b98f_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy05LTEtMS05MTI4NA_1fc9a31b-948f-4a46-a11d-de892c6ecd3b">1.0</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f00bb59ea1746fbb21fbadf3f414a92_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy0xMS0xLTEtOTEyODQ_7542a65b-b920-4ab5-a890-9d47a2c628cf">25.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib10b78dae7ed4de9bc5eb331206a3762_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC0xLTEtMS05MTI4NA_79702fcc-d19a-4b3b-aa9a-980d3e085471">124.4</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i998d829e65ec4f968b9b5085e7009b74_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC0zLTEtMS05MTI4NA_6b86e58e-734b-43a8-8e7c-0b887425e3c1">118.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC01LTEtMS05MTI4NA_257e92ff-af22-4477-8953-68707888e9da">242.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c33e6e45e2f4158a121a529bf2b99e5_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC03LTEtMS05MTI4NA_37c787a2-615c-41f2-9907-af66e0c83f89">161.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23b51504df3547d59b0d56b9f31e6a34_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC05LTEtMS05MTI4NA_4835a2c9-a126-4df2-8b98-6dd6cb5fca5c">236.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC0xMS0xLTEtOTEyODQ_c6b5ad2d-4792-4320-9673-bc9fbd3d63f3">397.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ied017d66c9a04bb4b5c3696003cdbb8e_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItMS0xLTEtOTEyODQ_efa1125b-a56f-4875-8d65-cca452ca284e">221.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie51251ad5ad54f02b4a1e43a1067e7f6_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItMy0xLTEtOTEyODQ_d6789d71-0151-47bd-b2d9-ec4383f1d010">252.7</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItNS0xLTEtOTEyODQ_e0797e0f-f2fe-47ba-8434-2766e30e110a">474.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i306561841c10468db12c5597d3a0468a_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItNy0xLTEtOTEyODQ_b030befd-bcc5-446f-8ff7-1af0b060c5a8">122.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id856ef449e024e50a897807c5afed116_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItOS0xLTEtOTEyODQ_f9be0616-40f8-44cd-a0a3-32f14b242ffe">196.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItMTEtMS0xLTkxMjg0_310bdd45-41aa-4cbc-9747-9d31c7d4731b">319.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract development and manufacturing:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i658c5b8c655e4fe38b0b7f174e852ede_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtMS0xLTEtOTEyODQ_a56e2808-af89-425c-998d-f85dfeeddce0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9e160d23cc4468b348e9ba5f68fc60_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtMy0xLTEtOTEyODQ_fa8b9c1b-ec2c-4011-b304-10a2442f2ba1">54.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cc2230d43ca419eb9859817a3e13e4a_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtNS0xLTEtOTEyODQ_964adefd-f13f-4ae4-8402-c43832373639">54.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i766a0ecaa10f4c1f94e835811699f36d_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtNy0xLTEtOTEyODQ_e35d0d86-5ad4-4bc1-96be-df4bee6295c5">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd47aaf57ffa4b1c9c70108fac1b456a_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtOS0xLTEtOTEyODQ_494696ed-2b03-412d-846d-156d131d48d7">171.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c35eb92f4e94539aef959a8629ae0e7_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtMTEtMS0xLTkxMjg0_61329497-e56e-4c13-a933-f9ae64bbc60b">171.2</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idead1f4a85bf4ee4931efc0bd2008a9a_D20220101-20220630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtMS0xLTEtOTEyODQ_882667f7-afa7-48fc-9cb9-7850a821e3cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i64e99aeb36a14462901695d8142755c7_D20220101-20220630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtMy0xLTEtOTEyODQ_6b8661f1-7c0a-4d70-870a-6881a175a190">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9d3fffbd0944df8a31002d86dafd0b1_D20220101-20220630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtNS0xLTEtOTEyODQ_94c2921d-4629-4ad4-a792-2df8df699efe">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06918d944d12481c84ebd11d669df56b_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtNy0xLTEtOTEyODQ_01c18c59-47be-44cb-8357-07c5cc350414">167.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib92f173e44b44baea23201309efbbd31_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtOS0xLTEtOTEyODQ_47cb8255-1078-4f72-a7bc-a4acfcddbb0d">35.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia599ba7606a14a5fa0bcefaa77322797_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtMTEtMS0xLTkxMjg0_3bdc6a0f-3667-4011-972a-d8b0b02f3d41">203.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract development and manufacturing</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb080faf3355468f962da743b6925f17_D20220101-20220630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtMS0xLTEtOTEyODQ_8923826c-5d94-4531-bd8b-448579ea42ba">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7836569c48aa4398960b690e02f1638a_D20220101-20220630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtMy0xLTEtOTEyODQ_b00fbfee-7f7a-4868-b4a7-ba3463c8fe80">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba5b2ada3cf4cb4a6b4ba683779728e_D20220101-20220630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtNS0xLTEtOTEyODQ_4e06dc6e-c6da-47cf-a721-d76ed965b378">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie645b23e92d64b44af482e9d18e83a21_D20210101-20210630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtNy0xLTEtOTEyODQ_e99e4806-429f-44df-ac22-4014a1178c04">167.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib607439c17cf47a5a315dbba5676680b_D20210101-20210630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtOS0xLTEtOTEyODQ_2b96913c-e915-42ac-9f64-b3c89284a0e5">206.8</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a54e7d85e014e56956c4c0661a1e4ed_D20210101-20210630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtMTEtMS0xLTkxMjg0_c484beba-fd77-4684-8f5d-87bd938ce695">374.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idef67034a80d49fe8d29b21339809e4b_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctMS0xLTEtOTEyODQ_9ad57c17-eaa6-476f-8269-ee1d96b33416">15.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i637fa78972d94585a80a29492e1528c4_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctMy0xLTEtOTEyODQ_fff9c252-9233-4d47-a7da-0ea99969e345">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cff17dc6fc04ad7ab4b4434ef23201b_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctNS0xLTEtOTEyODQ_0b14ee04-e3b0-4ee6-aadc-c19d656ec74b">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f45031de4147aab74078725161519c_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctNy0xLTEtOTEyODQ_bccc39e9-d252-451b-b58d-4221a0a53297">44.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id805e73cf4794980a908e6c22c926058_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctOS0xLTEtOTEyODQ_d576f8b5-1916-4185-b8bb-cae983af2b64">2.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400967d6466a4b58a011f5b045886df0_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctMTEtMS0xLTkxMjg0_3ea9a153-bacb-46a4-b5a9-c4a8eb2d16b5">46.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cf722f817414de59d8f7e7ec0bb2c95_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtMS0xLTEtOTEyODQ_0733e9ec-46ba-45a6-b2db-2d8d43b99c31">236.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i265aa2e4d2d24bb5be2c124345a65d9c_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtMy0xLTEtOTEyODQ_6cf67da9-e871-4b52-8007-ce79f433e8f7">313.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtNS0xLTEtOTEyODQ_b847d4c0-c877-42e1-b11f-7e1f7caebdda">550.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic78d782fd08747beb9ebc02fbc6bca30_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtNy0xLTEtOTEyODQ_4ac2b889-4419-4dee-8b33-4d2ae4ffb316">335.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i813b606241794bedb7b0678f9d44767c_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtOS0xLTEtOTEyODQ_bbac5650-86e4-4499-9ce0-45ce4784ee8a">405.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtMTEtMS0xLTkxMjg0_49c029e2-6467-4cfd-af79-992631c31e91">740.5</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/><br/></span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2020, Emergent BioSolutions Inc., through its wholly-owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into a manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson (the "Agreement"), for large-scale drug substance manufacturing of Johnson &amp; Johnson&#8217;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#8220;Product&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, the Company provided to Janssen a notice (the &#8220;Notice&#8221;) of material breach of the Agreement for (i) failure by Janssen to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Agreement; (ii) to confirm Janssen&#8217;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Agreement; and (iii) instead, wind-down the Agreement ahead of fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#8220;Janssen Notice&#8221;) of the Agreement for asserted material breaches of the Agreement </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices (cGMP) or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> breaches were not curable and that, therefore, termination of the Agreement would be effective as of July 6, 2022. The Company disputes Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i2aa6cb51eade45d1b85331ad03e77691" continuedAt="ib0831760aee7415ab75244b0ae450c7c"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company's alleged failure to perform under the Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process including mediation and/or arbitration.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, the Company reversed $<ix:nonFraction unitRef="usd" contextRef="i748c972f7e3046359ad4f7b45600bbb1_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:Revenues" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDk0NzgwMjM0MDQxOQ_5b942410-f4d7-423d-a4db-9594efff80ab">13.3</ix:nonFraction>&#160;million of previously recognized revenue to align cumulative revenue recognized under the Agreement with cumulative cash collections. As of June&#160;30, 2022, the Company has no billed or unbilled net accounts receivable related to the Agreement. During the three months ended June 30, 2022, the Company recorded accelerated depreciation of $<ix:nonFraction unitRef="usd" contextRef="i9546d5f25011482ea8eff2df29f3ff29_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDk0NzgwMjM0MDQ2NQ_74a1bb89-8d16-425d-9e3e-87b4bc7ea915"><ix:nonFraction unitRef="usd" contextRef="i9638e645586946feae3242935cd61d34_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDk0NzgwMjM0MDQ2NQ_a74f23b8-d399-4256-86ef-ca4dbbef174a">12.7</ix:nonFraction></ix:nonFraction>&#160;million related to the conclusion of the Agreement which has been recorded in cost of contract development and manufacturing in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has $<ix:nonFraction unitRef="usd" contextRef="ibb3cc4b31c2349e6b5a80a9253019e4b_I20220630" decimals="-5" name="us-gaap:InventoryRawMaterialsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4NjQ5Mw_41f577cc-a5e6-4698-a2e8-c0e36b3df79f">126.2</ix:nonFraction>&#160;million of raw materials inventory recorded in its condensed consolidated balance sheet as of June&#160;30, 2022 representing materials purchased for the Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of this inventory as of June&#160;30, 2022, concluding that because Section 13.4 of the Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for whatever reason, the Company is entitled to payment from Janssen for these raw materials. Therefore, this inventory remains an asset on the condensed consolidated balance sheet as of June&#160;30, 2022. Additionally, the Company has approximately $<ix:nonFraction unitRef="usd" contextRef="ibb3cc4b31c2349e6b5a80a9253019e4b_I20220630" decimals="-5" name="us-gaap:AccountsPayableTradeCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4NjUxMA_1babcdaa-3b8f-4b25-8889-f2a68412ff4b">18.2</ix:nonFraction>&#160;million of non-cancelable orders as of June&#160;30, 2022 which have not been received and Janssen has not reimbursed. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BARDA COVID-19 Development Public-Private Partnership</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company announced the issuance of a task order under our existing Center for Innovation in Advanced Development and Manufacturing (CIADM) agreement with BARDA for COVID-19 vaccine development and manufacturing (the BARDA COVID-19 Development Public Private Partnership). The BARDA COVID-19 Development Public Private Partnership is considered a lease and is accounted for under ASC 842. The initial task order had a contract value of up to $<ix:nonFraction unitRef="usd" contextRef="i073a439499194e698141d7a144b95b2c_I20201231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjY5_4638acdc-6314-4665-8e11-47e14fb91f61">628.2</ix:nonFraction>&#160;million and included the reservation of manufacturing capacity and accelerated expansion of fill/finish capacity valued at $<ix:nonFraction unitRef="usd" contextRef="ic4a7c235f1654834a48248b64d3dc321_I20201231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNzg3_06070653-4482-4332-9142-c775c0fb7212">542.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i7fa5c022d91149dabba1e1fa641192ee_I20201231" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNzk0_d61134c3-267f-4e19-8c8b-6e611a382d83">85.5</ix:nonFraction>&#160;million, respectively. Subsequently, the task order was expanded to include incremental capital activities which increased the value to </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i31dbfae47072459191568cdf89902293_I20211031" decimals="-5" name="us-gaap:LessorOperatingLeasePaymentsToBeReceived" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfOTI1_fc53cbc0-f762-42e5-851c-e3f2af16829a">650.8</ix:nonFraction>&#160;million. On November 1, 2021, the Compa</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ny and BARDA mutually agreed to the completion of </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's CIADM contract and associated task orders, including the BARDA COVID-19 Development Public Private Partnership. The Company did <ix:nonFraction unitRef="usd" contextRef="idead1f4a85bf4ee4931efc0bd2008a9a_D20220101-20220630" decimals="INF" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM1Mw_6db40034-d4c9-4eae-84d0-7c8e73139814"><ix:nonFraction unitRef="usd" contextRef="i2f3722b3ba404046b480130be3ff47cb_D20220401-20220630" decimals="INF" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM1Mw_e030d324-a4a8-4b1b-8066-6c8ff940e22e">no</ix:nonFraction></ix:nonFraction>t recognize lease revenues under this arrangement during the </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> six months ended June 30, 2022. During the three and six months ended </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021 the Company recognized lease revenues of $<ix:nonFraction unitRef="usd" contextRef="ieedc7121a2874e219f1a1ca878ff2c37_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc3OTA3Mg_98c87572-5028-4732-b111-5bbf4afc2068">70.4</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i06918d944d12481c84ebd11d669df56b_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc3OTA4OQ_01c18c59-47be-44cb-8357-07c5cc350414">167.9</ix:nonFraction> million, respectively, related to this arrangement.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO operating leases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain multi-year CDMO service arrangements with commercial customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates <ix:nonNumeric contextRef="i078e4fd9eef24b03a26dff9571fa22d9_I20220630" name="us-gaap:LesseeOperatingLeaseRemainingLeaseTerm" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMTc3OA_cebcf4d7-9a83-4c4a-a0a9-8b710e4537d4">2.9</ix:nonNumeric> years. </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Excluding future amounts related to the Janssen Agreement as discussed above, we estimate future operating lease revenues to be $<ix:nonFraction unitRef="usd" contextRef="ie098330be0d142e7842c556f7a93810f_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4OTQwOQ_ddab720c-06ab-4edd-8ee1-f215eb58043e">0.4</ix:nonFraction>&#160;million in the remainder of 2022, $<ix:nonFraction unitRef="usd" contextRef="i1b0d1f3a33164d8db9d0239f934f78e2_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4OTQyOA_518d5e58-6c3d-4acf-b79b-f4d095ba1946">5.1</ix:nonFraction>&#160;million in 2023, $<ix:nonFraction unitRef="usd" contextRef="ie526f761a4724513a2cc99ec8bd346cb_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4OTQ0Mw_27b77a1a-81ed-4cdf-af78-5b8279def455">0.9</ix:nonFraction>&#160;million in 2024, $<ix:nonFraction unitRef="usd" contextRef="icd351b95704f42138af3e4b83951e506_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4OTQ1MA_5476e3d8-07e3-41dc-ba77-f3151f985058">0.9</ix:nonFraction>&#160;million million in 2025 and $<ix:nonFraction unitRef="usd" contextRef="i5bd4b4922a534fcaa24291b742a545e6_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4OTQ2NQ_487904c3-3f4a-4091-8e28-effd91eb55cb">2.7</ix:nonFraction>&#160;million in years beyond 2025.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">llocated to remaining performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company has future contract value on unsatisfied performance obligations of approximately $<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMjI2Ng_115daa13-e955-47a9-8239-3eb32ec1d085">545.1</ix:nonFraction> million associated with all arrangements entered into by the Company. The Company expects to recognize a majority of the $<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMjM4Mg_115daa13-e955-47a9-8239-3eb32ec1d085">545.1</ix:nonFraction> million of unsatisfied performance obligations within the next <ix:nonNumeric contextRef="i5c1bb85380c94c46946e590854b1feb8_I20220630" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMjQ0MA_8874c9f4-d78a-4314-a1f3-9ee2ecd537e5">24</ix:nonNumeric> months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associat</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#8217;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="ib0831760aee7415ab75244b0ae450c7c"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of June&#160;30, 2022 and December&#160;31, 2021, the Company had $<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMzM4Nw_1c1f82e3-8c9d-4012-a578-d68ea9bf9466">26.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMzM5NA_7e84d492-b753-4658-be0a-0c76a5ffeab5">21.5</ix:nonFraction> million, respectively, of contract assets</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded within accounts receivable, net on the condensed consolidated balance sheets.</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the condensed consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM0NA_db10e966-7276-47f4-85ce-268f58ba5d6d" continuedAt="i31d2ba7a1c024b3a815ea262bd523d9a" escape="true">The following table presents the roll forward of the contract liability balances:</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify"><ix:continuation id="i31d2ba7a1c024b3a815ea262bd523d9a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:76.342%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.884%"></td><td style="width:0.1%"></td></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmVlYWQxNmY1NTc5NDRhNzRhMmNlNjNjNzk1Y2ViYmJkL3RhYmxlcmFuZ2U6ZWVhZDE2ZjU1Nzk0NGE3NGEyY2U2M2M3OTVjZWJiYmRfMS0xLTEtMS05MTI4NA_6c58f45f-097c-45bc-bc0f-549960e59269">16.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferral of revenue</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="ebs:ContractWithCustomerLiabilityAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmVlYWQxNmY1NTc5NDRhNzRhMmNlNjNjNzk1Y2ViYmJkL3RhYmxlcmFuZ2U6ZWVhZDE2ZjU1Nzk0NGE3NGEyY2U2M2M3OTVjZWJiYmRfMi0xLTEtMS05MTI4NA_aaa58aba-de2e-4b55-ba97-8b82d00d4fcd">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="ebs:ContractWithCustomerLiabilityDeductions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmVlYWQxNmY1NTc5NDRhNzRhMmNlNjNjNzk1Y2ViYmJkL3RhYmxlcmFuZ2U6ZWVhZDE2ZjU1Nzk0NGE3NGEyY2U2M2M3OTVjZWJiYmRfMy0xLTEtMS05MTI4NA_2886b986-431c-42a0-8f2d-c78dd2310e9d">10.0</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmVlYWQxNmY1NTc5NDRhNzRhMmNlNjNjNzk1Y2ViYmJkL3RhYmxlcmFuZ2U6ZWVhZDE2ZjU1Nzk0NGE3NGEyY2U2M2M3OTVjZWJiYmRfNC0xLTEtMS05MTI4NA_80c3a640-56b1-4204-9c8e-79d7cf4a07de">24.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the current portion of contract liabilities was </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDAzNg_ff305e16-05e2-4901-baf5-489acbb65822">18.5</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDA0Mw_f346445a-1890-4eaa-bae5-62e5bf94f338">11.7</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and was included in other current liabilities on the balance sheet</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></div><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="ebs:ScheduleOfAccountsReceivableNetTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM0OA_6e9212bd-7c19-4cb3-8df0-7481bc20927d" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.785%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.885%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billed, net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMS0yLTEtMS05MTI4NA_55179ac3-ad87-472e-aae9-e3ac669a9746">119.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:BilledContractReceivables" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMS00LTEtMS05MTI4NA_d062d469-cb05-4484-9a21-de345b9e73dd">224.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMi0yLTEtMS05MTI4NA_10ad4760-8111-4b16-b49a-cbe206755396">55.1</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:UnbilledContractsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMi00LTEtMS05MTI4NA_1cbc9e30-421f-4315-b437-a21953fe8f19">49.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMy0yLTEtMS05MTI4NA_501ba7e1-4a7e-4574-99cb-438116def52a">175.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMy00LTEtMS05MTI4NA_706e7ea7-a84a-487f-b751-bf394f4fb4f9">274.7</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the allowances for doubtful accounts was $<ix:nonFraction unitRef="usd" contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDMxNA_bb6e85ba-a2ac-4823-a6fb-968db5ca18d4">0.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231" decimals="-5" name="us-gaap:AllowanceForDoubtfulAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDMyMg_e14de9f7-0bca-4450-a3f4-64052fdae51d">3.2</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i4ef4253100994f989fd72d1c0fd41d25_70"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfNTAy_a8744747-c29c-4594-8518-3b72000677a5" continuedAt="i8a2509ce6cff4cdbaf5d53f547da6115" escape="true">Income taxes</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i8a2509ce6cff4cdbaf5d53f547da6115">The estimated effective annual tax rate as of June 30, 2022 and 2021 for the years ended December 31, 2022 and 2021, excluding the impact of discrete adjustments, was <ix:nonFraction unitRef="number" contextRef="icf331b5878004125a9676034ba0f2a5c_D20220101-20221231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfNzY5NjU4MTM5NTU1Nw_ffa05663-dd3e-4576-a0af-786876f099f7">29</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i9a9aaf25fc5d48ee87baec975ac47be1_D20210101-20211231" decimals="2" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfMTY0_6c78c0c7-f0a9-4477-ab3b-e4b95e2d4e5d">26</ix:nonFraction>%, respectively. The Company recorded discrete tax expense (benefits) of $<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfNzY5NjU4MTM5OTk0MQ_a31c2ef7-1793-4ce9-9831-f798fa682b3d">0.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfMTY0OTI2NzQ0MjIwMDg_31fd5c33-9604-4768-98c8-d58fa4824e30">0.6</ix:nonFraction>&#160;million for the three and six months ended June&#160;30, 2022, respectively, and $<ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfNzY5NjU4MTM5OTMxMA_56f10cb8-a28c-46ed-8111-854d0b28602e">1.1</ix:nonFraction> million and $(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfNzY5NjU4MTM5OTMxOA_99bcdc5d-f503-4ead-9dd5-0d2171b02e58">5.5</ix:nonFraction>)&#160;million, for the three and six months ended June&#160;30, 2021, respectively. The discrete tax expense in 2022 was primarily due to share-based compensation activity offset by return to provision adjustments. The net discrete benefits in 2021 were primarily due to share-based compensation activity.</ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_73"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RleHRyZWdpb246YjVkYTYyODg5OGM3NDgzMTllNTI0MDkzODBiMmU4MGFfMTMxMQ_c8d7b529-2c2b-43de-af78-bf8e82515234" continuedAt="i6f828926d30a444090510e798360b21e" escape="true">Net income (loss) per share</ix:nonNumeric></span></div><ix:continuation id="i6f828926d30a444090510e798360b21e"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RleHRyZWdpb246YjVkYTYyODg5OGM3NDgzMTllNTI0MDkzODBiMmU4MGFfMTMwNw_8b27c36b-e751-4cd9-8b08-880529e9405a" escape="true"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net (loss) income per share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.160%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.226%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.373%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.943%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMy0xLTEtMS05MTI4NA_bfb745e2-2747-4cc0-a1cf-d36af84af3fa">56.4</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMy0zLTEtMS05MTI4NA_0dec8ec0-1a82-4b7f-83da-c5f06982e468">4.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMy00LTEtMS05MTI4NA_321b91a4-5612-433e-9231-673e1f91afcf">60.1</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMy02LTEtMS05MTI4NA_e9b10812-1931-4b2a-86ec-a622a157a2ab">74.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares&#8212;basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNi0xLTEtMS05MTI4NA_2db6f13f-357a-4265-9971-1e6e57051af2">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNi0zLTEtMS05MTI4NA_9f67d225-a2e3-4435-ae6e-2ce812700e11">53.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNi00LTEtMS05MTI4NA_42358c13-8c3c-4bf1-8f8b-ea1c5304b6d8">50.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNi02LTEtMS05MTI4NA_688dd207-00b1-4f7b-bdb9-1e129fa6eb3c">53.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities&#8212;equity awards</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNy0xLTEtMS05MTI4NA_96423467-baed-4a5e-a2f9-adb51e90b793">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNy0zLTEtMS05MTI4NA_1d331095-721f-4fec-918a-0535f8f34401">0.4</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNy00LTEtMS05MTI4NA_884d3243-f392-4efb-8a60-25d590bed8ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNy02LTEtMS05MTI4NA_7642ef02-d754-49a1-9eae-b56aa17af6e5">0.8</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares&#8212;diluted</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfOC0xLTEtMS05MTI4NA_3834e70b-b948-4327-b8da-a3697c9fef5c">50.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfOC0zLTEtMS05MTI4NA_196502b1-ae60-4dda-ab72-002a40d1231d">54.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfOC00LTEtMS05MTI4NA_41d3443a-4bfa-44c0-b269-eaa105565ad3">50.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfOC02LTEtMS05MTI4NA_f29bc0c7-dccf-4c49-922e-b82f4285c4a9">54.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)  per share - basic</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTAtMS0xLTEtOTEyODQ_0f5a15a4-009d-4e4c-8c1e-c0ed4fbbb4a0">1.13</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTAtMy0xLTEtOTEyODQ_4cce9eab-c2eb-43e3-b724-ee5aed7d850d">0.09</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTAtNC0xLTEtOTEyODQ_f2f72dd5-6f57-4da0-8fdf-75f06bd62333">1.19</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTAtNi0xLTEtOTEyODQ_0e6b7620-116e-4af1-8cf2-bce002e14d67">1.40</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTEtMS0xLTEtOTEyODQ_983c4f96-082a-45a8-98b5-24941990389d">1.13</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTEtMy0xLTEtOTEyODQ_2a54ea5e-57e6-4b09-bcab-f64a92c62b6a">0.09</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTEtNC0xLTEtOTEyODQ_dfcc7302-f035-4e38-8cf5-27ddd528b237">1.19</ix:nonFraction>)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTEtNi0xLTEtOTEyODQ_be388b19-71e2-4ad2-aeb7-e30ff9e9a971">1.37</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. No adjustment for the potential dilutive effect of dilutive securities is reported for the three and six months ended June&#160;30, 2022 as the effect would have been anti-dilutive due to the Company's net loss.</span></div><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RleHRyZWdpb246YjVkYTYyODg5OGM3NDgzMTllNTI0MDkzODBiMmU4MGFfMTMwNg_ef00d21c-902b-440f-a690-5c46d49ad15f" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the share-based awards that are not considered in the diluted income (loss) per share calculation generally because the exercise price of the awards was greater than the average per share closing price during the three and six months ended June&#160;30, 2022 and 2021. In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price.</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.273%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock awards</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjcyYjdhZmUwNmVkZjQ2ZThiMTA1ZWNmNWRhM2UxMDg0L3RhYmxlcmFuZ2U6NzJiN2FmZTA2ZWRmNDZlOGIxMDVlY2Y1ZGEzZTEwODRfMi0xLTEtMS05MTI4NA_13eeeb48-da21-492f-8228-efa5de06ae83">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjcyYjdhZmUwNmVkZjQ2ZThiMTA1ZWNmNWRhM2UxMDg0L3RhYmxlcmFuZ2U6NzJiN2FmZTA2ZWRmNDZlOGIxMDVlY2Y1ZGEzZTEwODRfMi0zLTEtMS05MTI4NA_bef7dcc9-2aaa-438c-bfd6-fa0a504ff80a">1.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjcyYjdhZmUwNmVkZjQ2ZThiMTA1ZWNmNWRhM2UxMDg0L3RhYmxlcmFuZ2U6NzJiN2FmZTA2ZWRmNDZlOGIxMDVlY2Y1ZGEzZTEwODRfMi00LTEtMS05MTI4NA_f624f130-d232-412a-9da2-5b5cfcfb6437">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjcyYjdhZmUwNmVkZjQ2ZThiMTA1ZWNmNWRhM2UxMDg0L3RhYmxlcmFuZ2U6NzJiN2FmZTA2ZWRmNDZlOGIxMDVlY2Y1ZGEzZTEwODRfMi02LTEtMS05MTI4NA_04c20cf0-1c5e-4884-bf21-187d69f4f8d4">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4ef4253100994f989fd72d1c0fd41d25_76"></div><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY3OQ_11afb240-0dc7-4991-9c35-df559e9c3e24" continuedAt="i96f2fbcb2da64d00a2334c4656452208" escape="true">Equity</ix:nonNumeric></span></div><ix:continuation id="i96f2fbcb2da64d00a2334c4656452208" continuedAt="ic1dc4cfd677f4a2f932771d78a65538c"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchase programs</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2021, the Company announced that its Board of Directors authorized management to repurchase up to an aggregate of $<ix:nonFraction unitRef="usd" contextRef="i46d185ce265a44359c45e086acb0e06f_I20211111" decimals="-5" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY2_8c164160-31a1-4a37-a3a2-86d49f313513">250.0</ix:nonFraction>&#160;million of Common Stock under a board-approved Share Repurchase Program, of which $<ix:nonFraction unitRef="usd" contextRef="idb62694863024c3a8c06044192e2a6da_D20211111-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMjQ0_54e9fbd7-a068-4771-bf78-d09721c41e57">187.9</ix:nonFraction>&#160;million has been utilized to purchase <ix:nonFraction unitRef="shares" contextRef="idb62694863024c3a8c06044192e2a6da_D20211111-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMjg1_1b83c718-c5c2-4bf1-862f-e1b4a423ef46">4.4</ix:nonFraction>&#160;million shares as of June&#160;30, 2022. During the three and six months ended  June&#160;30, 2022, the Company has utilized $<ix:nonFraction unitRef="usd" contextRef="ifcc26b21d7d8496f9bb774f7ac399651_D20220401-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMzI5ODUzNDg4NTI4MA_c77825f0-4acc-44db-bb39-e7eedd549a3d">23.3</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ic692f65706164ee49ec3a380b592e311_D20220101-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMzcw_e99477a5-0cfd-4635-bc78-bf2a147d59f3">75.5</ix:nonFraction>&#160;million to purchase <ix:nonFraction unitRef="shares" contextRef="ifcc26b21d7d8496f9bb774f7ac399651_D20220401-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMzI5ODUzNDg4NTI4Nw_0fcb39ca-a327-467b-a7e6-3d61e1cab637">0.7</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="shares" contextRef="ic692f65706164ee49ec3a380b592e311_D20220101-20220630" decimals="-5" name="us-gaap:StockRepurchasedDuringPeriodShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMzkz_5fd26451-0dfb-4b81-a25c-9288537fe913">1.8</ix:nonFraction>&#160;million shares, respectively. The Share Repurchase Program does not obligate the Company to acquire any specific number of shares. Repurchased shares will be available for use in connection with our stock plans and for other corporate purposes.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, the Company granted stock options to purchase <ix:nonFraction unitRef="shares" contextRef="id438572de7754b2f9af627f967ba0ce0_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfODMy_77a592a9-c8fa-4f82-b060-f8da3909a137">0.6</ix:nonFraction> million shares of common stock and <ix:nonFraction unitRef="shares" contextRef="i9c3242ff1d6e403fa058caec92b768c4_D20220101-20220630" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfODYy_bdad76a8-fc56-4cde-8fde-776a2bbc94d1">1.4</ix:nonFraction> million restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Typically, the stock option and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="ic1dc4cfd677f4a2f932771d78a65538c" continuedAt="i2bbef5082b884f2ba49577e9e883f38d"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the <ix:nonNumeric contextRef="i9c3242ff1d6e403fa058caec92b768c4_D20220101-20220630" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY4Mw_dc08edcb-2e78-42bc-ab57-2e5925052072">three-year</ix:nonNumeric> performance period based on the Company's results compared to the performance criteria. <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY4Mg_73b6d78a-24af-4d50-ac99-fecac92340f4" continuedAt="ib4947e66ec974690a49c6dff75a6f283" escape="true">Share-based compensation expense was recorded in the following financial statement line items:</ix:nonNumeric></span></div><div style="margin-bottom:9pt"><ix:continuation id="ib4947e66ec974690a49c6dff75a6f283"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.859%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.693%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.696%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i444f6b6169bc431ab44cce091d529975_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMi0xLTEtMS05MTI4NA_03b36e50-2dd6-405e-a47a-48eb735645fa">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68490917c6324e3abbbef73aefa2e5f9_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMi0zLTEtMS05MTI4NA_f1676217-f727-4b12-aab5-eafdd0114abf">1.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ba5495e2a404e7caafe9e03e3fe1861_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMi00LTEtMS05MTI4NA_99de0022-2c7b-4ecf-857e-44b6dca14b08">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d37be8412c8482e947483881b8b5b51_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMi02LTEtMS05MTI4NA_1b4a2939-0725-43f7-98b4-e5f40b349678">3.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of contract development and manufacturing</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8109d0584c4f24a37d0e0942db1c06_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMy0xLTEtMS05MTI4NA_f921bc83-f88e-4fcd-b450-3e7c895b9167">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e87ee8954dc437da9f27f6e09cd767a_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMy0zLTEtMS05MTI4NA_1600b02a-3755-484d-a4d5-a5e1d297c5d2">0.3</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i775d01162a634709894e9ca391a7f259_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMy00LTEtMS05MTI4NA_8ad76906-6b36-42a7-ac52-0fb0986e0b3a">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i483660136dd443e5916afc6418da38ad_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMy02LTEtMS05MTI4NA_381437a0-da59-440c-9f94-ffcf75211c67">0.5</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3497690a3cbd40f3b831488b3657d7c6_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNC0xLTEtMS05MTI4NA_4dfc5ef0-4484-4b81-94bb-54ea653978f5">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2848bd97786b4d5ba2937b70a2f4bf70_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNC0zLTEtMS05MTI4NA_1f8a15d8-f04f-4ae5-a8fe-6c215c5fc100">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39ffb192289e4ce9a528e436037c0be5_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNC00LTEtMS05MTI4NA_335d9650-c2ba-470c-b49f-d78eba0f0d33">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83dd17fd91084cafbcc04f18320932c2_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNC02LTEtMS05MTI4NA_465fa88b-cf2f-47c4-b2a4-ce9af90c462c">3.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic952574703dd49c3a143c50a76cc5bb7_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNS0xLTEtMS05MTI4NA_074e29f5-7f0b-48a8-8cd8-308bd51e5e43">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i05f3f3064f53498493eda16fac112d94_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNS0zLTEtMS05MTI4NA_c8f79ce8-7be7-4150-891f-f7c7d1e9bc28">7.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i55f86755507140aaa0522c374f09ab1d_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNS00LTEtMS05MTI4NA_1172d5e8-63fd-4ac0-a944-7509337b3c2d">15.0</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79e636bd573c405188f12505ae586714_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNS02LTEtMS05MTI4NA_8374e400-f4a6-4134-8c9b-264d0c5dee80">15.1</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNi0xLTEtMS05MTI4NA_34bb46fc-211c-4fba-94ec-460e6381601f">12.3</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNi0zLTEtMS05MTI4NA_bb52660c-5ed9-4e12-b540-498146c3fc65">11.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNi00LTEtMS05MTI4NA_a546e575-83c9-4be3-bff9-6767bd0e50b8">22.2</ix:nonFraction>&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNi02LTEtMS05MTI4NA_32c3f22c-4e3f-4cf9-9771-f5cc73cedcb6">21.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss, net of tax</span></div><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY3OA_2326d719-e398-4864-888d-ea6c0f1556cd" escape="true"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive loss, net of tax by component:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.049%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.250%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.825%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.254%"></td><td style="width:0.1%"></td></tr><tr style="height:30pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined Benefit Pension Plan</span></div></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, net of tax)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i830521684abb4fd9aadb53001edc7379_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMi0yLTEtMS05MTI4NA_2f5d6364-29a5-4143-a527-01c6bae2146c">4.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ifac78b9519ad40da9ef031b1e7724460_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMi00LTEtMS05MTI4NA_b61923aa-9b70-46da-88a4-76419153329e">4.5</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icb61d55a3a5f4c6eb6ebb20e951d3dd3_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMi02LTEtMS05MTI4NA_2087c97b-f423-4d0c-b11b-0bee2b6b43bf">7.6</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53adab0b44f14127b1c4c4f2539a1807_I20211231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMi04LTEtMS05MTI4NA_0fec63a2-afbb-4165-93af-1969e7775670">16.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMy00LTEtMS05MTI4NA_29af070b-6236-4330-9308-0ec30d577e63">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMy02LTEtMS05MTI4NA_0f4aef5b-0fc7-4bd9-b134-4765c5eb7164">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMy04LTEtMS05MTI4NA_51485f51-b01f-442f-ac44-dc6b7084588a">7.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNC00LTEtMS05MTI4NA_8dae3dbe-083d-4a58-ad42-d95098973a29">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNC04LTEtMS05MTI4NA_72b5cae6-48fd-4c5a-84a9-9a00e6da79ca">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec438a15507545e69f9ae19f0a3d5941_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNS0yLTEtMS05MTI4NA_6a183c4c-8705-4f99-9c35-c0e464e7961c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNS00LTEtMS05MTI4NA_43b08692-d12f-4a4c-b11b-9f39739d9ef1">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNS02LTEtMS05MTI4NA_5f6b0317-3dcc-4860-ac4d-77c03d8ebe60">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNS04LTEtMS05MTI4NA_242f6264-e6be-4743-9b59-2ae6f17cdecf">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i651fc075a09948b29a069bfed15ac793_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNi0yLTEtMS05MTI4NA_ada6aa6e-f44d-4b40-8fea-dc6f4f448086">4.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae6af3ca5ff479b95eef53b77bd535e_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNi00LTEtMS05MTI4NA_bdf5838b-95bf-479d-bed1-7760dd0245b6">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5904a41b0c2944d1bc9877b651a3f0fe_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNi02LTEtMS05MTI4NA_3e1e0c27-2eab-4c0d-96a7-1924f26d4be2">6.7</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib20d47a77df04874a03809c71af93bb8_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNi04LTEtMS05MTI4NA_26271670-868a-46e2-90b5-18f583f87308">6.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic637379f0d8043d5af581e734aefd028_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOC0yLTEtMS05MTI4NA_aff90472-cae2-4abf-b764-acb772d1e73a">4.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8daff84a60ea419db78f98817926f778_I20220331" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOC00LTEtMS05MTI4NA_9d4860b0-68ce-4d93-97c1-af7e618eff7a">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if6289d96bf3f4d3dad0b8d93584c1fb1_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOC02LTEtMS05MTI4NA_bd41bf9f-5796-4a81-845e-ff1ac24ac074">7.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0ca88e5d8bf24c309e9d2a5171b224ec_I20220331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOC04LTEtMS05MTI4NA_ec7f799d-ccd6-47d8-a2f1-c105ae1c4947">9.3</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOS00LTEtMS05MTI4NA_d9263e7e-fb0f-4d14-978d-7a3a7b78055a">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOS02LTEtMS05MTI4NA_4ee5b0ab-a8db-4627-a547-22ef48c62634">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOS04LTEtMS05MTI4NA_5bcbdf0c-278a-490e-8a2d-e443ee826396">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTAtNC0xLTEtOTEyODQ_6635df95-34c2-431e-8420-98328063e63d">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTAtOC0xLTEtOTEyODQ_64327044-cb5e-4e72-b77d-805710381c67">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43051341a0744172a54eb2e3094323d6_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtMi0xLTEtMTAxMTA1_9e878a7a-11a9-47e5-b029-b2a329d4b205">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtNC0xLTEtMTAxMTA1_7048a210-b66c-48fa-af1d-ae599971b344">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtNi0xLTEtMTAxMTA1_138d0fe6-1bf5-4076-9ba4-39597afcb833">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtOC0xLTEtMTAxMTA1_07b0b0c1-4775-4cdf-833e-9fc718a581f5">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i651fc075a09948b29a069bfed15ac793_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtMi0xLTEtOTEyODQ_950a609f-3e62-4bad-83b4-7e7211f81163">4.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ae6af3ca5ff479b95eef53b77bd535e_I20220630" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtNC0xLTEtOTEyODQ_47d4a44a-d98b-49ac-9a73-62a087245fa0">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5904a41b0c2944d1bc9877b651a3f0fe_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtNi0xLTEtOTEyODQ_7f82dc62-4b8f-4d7a-99e9-638c66af208b">6.7</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib20d47a77df04874a03809c71af93bb8_I20220630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtOC0xLTEtOTEyODQ_65cf580e-ea80-499d-8100-5771440a287b">6.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99c848d9c0ea44feaa1b6615d95059e2_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTMtMi0xLTEtOTEyODQ_dbd3553c-b42c-4aec-ba26-063863daa03d">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b18ce4c0ae74dff995c8a04ce8a3f19_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTMtNC0xLTEtOTEyODQ_9a593512-76d8-437a-ab09-2e486e41bd5e">11.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3a73d2985e143b08dff3ac4720bea90_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTMtNi0xLTEtOTEyODQ_1549e8d7-8756-449b-bc5f-8ff40ff52c29">6.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5d6dfa3b33ba4a26be19db91781e5050_I20201231" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTMtOC0xLTEtOTEyODQ_eda17e90-92a1-4b67-b969-713991390c54">25.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTQtNC0xLTEtOTEyODQ_bb66c1a8-0814-4742-b16c-fcaedb0cda22">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTQtNi0xLTEtOTEyODQ_71dd0f48-c02a-4519-abea-d3b8158f32ea">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTQtOC0xLTEtOTEyODQ_d5560524-3fb1-4dcc-9e8c-036d1bdf490a">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTUtNC0xLTEtOTEyODQ_6613e96c-f438-478e-8fc8-e7e2634b60bc">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTUtOC0xLTEtOTEyODQ_f4f5b1a6-4f2a-4b59-b94e-bcbc74bcbb1d">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2ba91a37c45433382623dcdb7bd5722_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTYtMi0xLTEtOTEyODQ_a7b6791e-ed53-4384-b2c7-e1a03c8f4b1e"><ix:nonFraction unitRef="usd" contextRef="id88c42efd11a49ef841182aac044455d_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTYtMi0xLTEtOTEyODQ_c96b824d-d67b-4fc9-b94e-c98d2fb69ef7">7.7</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTYtNC0xLTEtOTEyODQ_dd767ee0-eee4-4961-ab12-27399af58579">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTYtNi0xLTEtOTEyODQ_cd8cf2be-99b9-4e2a-858e-0a35751d418b">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTYtOC0xLTEtOTEyODQ_78b6a41f-7fa0-4392-b5f2-5ac28d7efcd4">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2ba91a37c45433382623dcdb7bd5722_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTctMi0xLTEtOTEyODQ_a7b6791e-ed53-4384-b2c7-e1a03c8f4b1e"><ix:nonFraction unitRef="usd" contextRef="id88c42efd11a49ef841182aac044455d_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTctMi0xLTEtOTEyODQ_c96b824d-d67b-4fc9-b94e-c98d2fb69ef7">7.7</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31cb95adcb0a43cb82eb1863ad9f5748_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTctNC0xLTEtOTEyODQ_f02750b3-a0bf-4c63-94f5-1755fc2a714a">6.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i529a638b09f04a2a8bc2cc0b002cd45c_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTctNi0xLTEtOTEyODQ_5882da7a-f54e-4340-acbe-596e923dcc3a">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cb30120c0cd4c26b09246b92a5b9300_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTctOC0xLTEtOTEyODQ_050c1f35-740a-4faa-8ded-f6b66d27d101">22.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia4ab0f0ae6ef4c1da3db1ce773f632c0_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTktMi0xLTEtOTEyODQ_f86367d8-1b5b-49ef-ac47-ec277846d55a">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i28b844ae659d4576b73d8e1361ed9d73_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTktNC0xLTEtOTEyODQ_4043e39a-3259-4673-a5eb-5bb6d3ef3060">7.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1bf5df54710d4ea4b5ed41c57fe517a4_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTktNi0xLTEtOTEyODQ_d6d63b83-8ff0-4941-9b90-fe46de4c4779">8.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i84fb728efecd4d3eb00c3307db37929d_I20210331" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTktOC0xLTEtOTEyODQ_9fd8afd9-e0b4-4dc0-b674-799db35d3504">24.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjAtNC0xLTEtOTEyODQ_fde88b8e-67e6-4b0e-b655-53a33f81899f">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjAtNi0xLTEtOTEyODQ_d5f06273-d46e-4364-a46f-07a75b48d6be">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjAtOC0xLTEtOTEyODQ_105799a8-d300-46bd-a4a5-124d249ba7de">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjEtNC0xLTEtOTEyODQ_f684a7ef-deb9-4790-a71a-c546486144b2">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjEtOC0xLTEtOTEyODQ_01993835-d01c-4ec1-bbde-392fe32e36c9">1.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45ee1c733d0e40dc98fb96a0479d1554_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjMtMi0xLTEtMTAxMTA5_cd708773-1c31-4f52-8947-f92f0ca020a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjMtNC0xLTEtMTAxMTA5_beab543c-1e2e-496a-a316-e24513a11f5f">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjMtNi0xLTEtMTAxMTA5_ce216b51-0998-44b1-88f5-c8bda05dff05">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjMtOC0xLTEtMTAxMTA5_8071bb8c-1104-4e1f-a3ee-4e2759abb32f">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2ba91a37c45433382623dcdb7bd5722_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjItMi0xLTEtOTEyODQ_b8b7f3f9-3e99-4418-b5a7-28250419a3b0">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i31cb95adcb0a43cb82eb1863ad9f5748_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjItNC0xLTEtOTEyODQ_32b3b700-f04c-4ffb-9c95-8e2759ed1aff">6.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i529a638b09f04a2a8bc2cc0b002cd45c_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjItNi0xLTEtOTEyODQ_d61634bb-b01c-489d-ac68-6450253384a8">8.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9cb30120c0cd4c26b09246b92a5b9300_I20210630" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjItOC0xLTEtOTEyODQ_c2685c05-fd8a-4d0e-889e-a99f27c1a5c9">22.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i2bbef5082b884f2ba49577e9e883f38d"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY4NA_2864ddc3-bcee-4d42-8e74-a3eca8a347a9" escape="true"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the tax effects related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative Instruments</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC0xLTEtMS05NjA1NA_b2f09e82-ce0d-4fd9-a842-39cdf09f9ac9">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC0zLTEtMS05NjA1Ng_8dbccd29-c51f-4d59-a9b3-132d2c491cf2">1.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC01LTEtMS05NjA2Mg_114c6c39-62e7-4419-ac6b-abd282d2d7ac">2.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC03LTEtMS05NjA3OQ_bace503b-da1b-4703-a385-ac55217bd4b5">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC05LTEtMS05NjA5NQ_a8d9e912-7d4e-4e0a-84b2-ec73143ab425">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC0xMS0xLTEtOTYxMDE_2026d1ca-2db9-41b8-a338-84aad6fdf9a3">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS0xLTEtMS05NjA1NA_3070f109-ac81-48d2-b216-d4e4d6157575">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS0zLTEtMS05NjA1Ng_a50b04bb-0e87-4a5e-83c0-7e413243fc89">0.9</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS01LTEtMS05NjA2Mg_ad692003-9a0e-4feb-97fc-178b275fd568">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS03LTEtMS05NjA4Ng_3b250744-1f32-4d1b-a282-8cfd861d816b">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS05LTEtMS05NjA5NQ_67d24b28-baa7-4a4b-bd6f-66e77ed9bd4c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS0xMS0xLTEtOTYxMDE_816822ac-8baa-458c-a0ae-e781f962fecf">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi0xLTEtMS0xMDExMjU_bbd21bb2-a722-4607-8639-37d176d7d085">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi0zLTEtMS05NjgyNQ_b5f46ee4-cd2a-40a8-9a36-a5b94df01ccf">1.9</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi01LTEtMS0xMDExMTM_c634305c-f6db-4ac4-9aa7-92c7095052a4">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi03LTEtMS0xMDExMjc_32966f1c-d577-4c75-be10-d58b69f8a962">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi05LTEtMS0xMDExMjc_3c07aedd-546c-4a60-87f0-b2bbe03f2f0b">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi0xMS0xLTEtMTAxMTE1_dc719057-2c89-4294-a770-43d72fc9f0b3">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:30.509%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.819%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.826%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative Instruments</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC0xLTEtMS05NTE3Nw_efa92a27-89d1-4906-aa94-c7b8980e2b7b">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC0zLTEtMS05NTE4Nw_73708ef4-0827-4909-8f55-e1a8ab4b30b4">3.3</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC01LTEtMS0xMDExMTc_bd84fad0-6a22-4088-b3ef-85dcd02c4974">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC03LTEtMS05NTE5NA_62a8cdbd-fb2c-4d3d-bdac-636df0aa46b7">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC05LTEtMS05NTE5MA_d503d5ab-d76f-434c-9a2f-80b98dfbe039">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC0xMS0xLTEtOTUxOTg_726e970e-1baa-4fc8-a19f-86f74ac7e7b3">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS0xLTEtMS05NTE3Nw_7c8dbb21-1f78-4301-bac0-f675fb134549">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS0zLTEtMS05NTE4Nw_bc4a5282-2f2e-4b5b-8f3c-100bf3108c8f">1.1</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS01LTEtMS0xMDExMTc_a0ee8628-e05d-4f73-85f3-8947dc5f44b6">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS03LTEtMS05NTE5NA_8c2ae8cd-eafe-4fdd-a1b6-a25fe2d1143d">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS05LTEtMS05NTE5MA_50f6808d-6cd0-47ec-815a-b93a3103d01c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS0xMS0xLTEtOTUxOTg_ee01375a-526e-4923-82a8-5392d0af090a">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi0xLTEtMS0xMDExMjk_604cc688-2f75-49a1-a0a0-4a798bf29035">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi0zLTEtMS0xMDExMjk_391b474d-ed37-46ec-b91c-9ee9b7662358">4.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi01LTEtMS0xMDExMTc_89ede9f8-5aad-46e1-b1ff-1ecb68a4f581">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi03LTEtMS0xMDExMzE_7a6be36b-7827-4925-9c4c-888bd62de00a">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" sign="-" name="us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi05LTEtMS0xMDExMzE_b1f1d4f0-5f23-4a6b-a366-647d4c2ddd5d">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi0xMS0xLTEtMTAxMTIz_9bde1c65-d539-4236-aabb-34489eefc0ba">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i4ef4253100994f989fd72d1c0fd41d25_82"></div><div style="margin-bottom:6pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RleHRyZWdpb246NjMyYmRmMjBjODkyNDVlZmEwZmRlZjQxMGYyZWMxNDVfMTkzNQ_71c0ed89-114e-4840-ba8e-9c9c70ae99cc" continuedAt="iad4915cfd8cc4e4384b8048b55cb434b" escape="true">Segment information</ix:nonNumeric></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="iad4915cfd8cc4e4384b8048b55cb434b" continuedAt="ic74c2e11ef154ba994325d554ef997cd"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RleHRyZWdpb246NjMyYmRmMjBjODkyNDVlZmEwZmRlZjQxMGYyZWMxNDVfMTkzNg_910fa5a3-c80b-42fc-b326-f60c7899785e" escape="true">The Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. During the first quarter of 2022, the Company revised the reporting that the Chief Operating Decision Maker (CODM) reviews in order to assess Company performance. The CODM manages the business with a focus on <ix:nonFraction unitRef="segment" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RleHRyZWdpb246NjMyYmRmMjBjODkyNDVlZmEwZmRlZjQxMGYyZWMxNDVfMTkzNw_76ccd230-386b-45da-846d-e7f085d1dc72">two</ix:nonFraction> reportable segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and 2) the services segment focused on CDMO (Services). The Company evaluates the performance of these reportable segments based on revenue and adjusted gross margin. Segment revenue includes external customer sales, but it does not include inter-segment services. Adjusted gross margin for each segment is segment revenue less segment cost of sales reduced for significant one-time events. We do not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. The Company has recast the related historical information for consistency.</ix:nonNumeric></ix:continuation></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="ic74c2e11ef154ba994325d554ef997cd"><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RleHRyZWdpb246NjMyYmRmMjBjODkyNDVlZmEwZmRlZjQxMGYyZWMxNDVfMTkzNA_291d1b46-f1f0-4c85-b944-02021b721689" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables include segment revenues and a reconciliation of the Company's segment adjusted gross margin to the condensed consolidated statement of operations for each of the Company's reporting segments as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:20.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.330%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi0xLTEtMS05MTI4NA_daada8c1-5f3a-44d5-9e53-899fa10abc7a">237.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ef607d7a3c7451f9fc91797c668e35b_D20220401-20220630" decimals="-5" sign="-" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi0yLTEtMS05MTI4NA_4ec6d17d-8bd4-47b5-a385-53a95a5ec6ea">1.8</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865cea62a18543cb83411d9461069e79_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi0zLTEtMS05MTI4NA_360cf0fb-a043-4fda-8784-3226f19c8bc9">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi00LTEtMS05MTI4NA_914fb836-2801-4f51-814c-eca49804bcd1">242.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi01LTEtMS05MTI4NA_d10e5133-c531-4493-9336-a763a4bfa91d">181.2</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30013848203544aaab36afb676ed3c64_D20210401-20210630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi02LTEtMS05MTI4NA_4282eeb5-7df0-4c21-a7a2-94fc1ff8d15a">190.9</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b063649105148fca27b7b94d3b8e412_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi03LTEtMS05MTI4NA_5dd4a2a7-35c6-420a-843a-31df934b2c42">25.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi04LTEtMS05MTI4NA_fba6271e-5d2b-41c0-9119-b4dcb314175c">397.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i46b2d87a49bb494a84bf9da22318cb73_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMy0zLTEtMS05MTI4NA_48249ab8-2520-4587-930b-0b38bf4dfdaa">7.3</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f9afc75663f4899a4fc9be307765379_D20220401-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMy00LTEtMS05MTI4NA_c5c4299c-bc73-4ef6-bbbc-f02d0a3d0ad6">7.3</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i05f0ccbd84a246cd8e98d3b72d6b8dd3_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMy03LTEtMS05MTI4NA_636661cc-5bca-48cf-91c4-c4761ee4cbb9">25.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6f00bb59ea1746fbb21fbadf3f414a92_D20210401-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMy04LTEtMS05MTI4NA_54298447-a187-42cf-a2a7-3efa5966248e">25.4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i017940019b8f4dd28eddab4c25571c62_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNC0xLTEtMS05MTI4NA_4012787e-e173-4ed4-bef5-2bd9caca0d63">91.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b613598404b49b880eecce284caa409_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNC00LTEtMS05MTI4NA_0eb859d8-2981-40f2-b903-946163b0ba19">91.0</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i79dd2d62f4de4d778696638252882cf2_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNC01LTEtMS05MTI4NA_df7790c5-c403-4c21-bae4-083539ce74d8">81.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic14c595631e444d1b209fffe8cd22901_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNC04LTEtMS05MTI4NA_55369a29-8b02-4e9e-bd7d-1a2aa07b6540">81.2</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of contract development and manufacturing</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2e1a370ad2f74ba9974ee7ae4c0046ea_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNS0yLTEtMS05MTI4NA_61c0b970-29a0-4de4-a259-2f2f6218216e">78.8</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i11d6b9ed7cef4daf9b8dc0c61d4b8f0b_D20220401-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNS00LTEtMS05MTI4NA_128669af-9429-4248-95c4-71dd00c868db">78.8</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2256cc8ca6db4b8facf112f19dc9715b_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNS02LTEtMS05MTI4NA_540c6636-d774-4406-874f-2e43fd441e75">146.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d9f1173bf46467fa504dd84e978c454_D20210401-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNS04LTEtMS05MTI4NA_b28ba284-7627-4c73-a3b4-a21206690fea">146.6</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS0xLTEtMS05MTI4NA_3cbeefcc-c57b-49e5-af70-7def4e31a385">146.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ef607d7a3c7451f9fc91797c668e35b_D20220401-20220630" decimals="-5" sign="-" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS0yLTEtMS05MTI4NA_2ca202eb-f13a-4487-8774-5210b405c0e8">80.6</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865cea62a18543cb83411d9461069e79_D20220401-20220630" decimals="-5" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS0zLTEtMS05MTI4NA_ce084c70-207d-462e-a66a-c77bd96fdbad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS00LTEtMS05MTI4NA_7d86a74b-24e3-4dda-a641-606a48c2da08">65.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS01LTEtMS05MTI4NA_f62d67b5-58ec-4325-a08b-54236e40908a">100.0</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30013848203544aaab36afb676ed3c64_D20210401-20210630" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS02LTEtMS05MTI4NA_485f7e76-faef-4901-b914-9af2892833e6">44.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b063649105148fca27b7b94d3b8e412_D20210401-20210630" decimals="-5" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS03LTEtMS05MTI4NA_6cbd3f22-8364-4c49-bd17-b32a1453948e">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS04LTEtMS05MTI4NA_f582e4e0-8791-4fad-8fc4-776920fd9866">144.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTAtMS0xLTEtOTEyODQ_27e8178c-c246-40b2-bbfe-18da4bc61f7e">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTAtNC0xLTEtOTEyODQ_0ee146ac-a70f-450f-a85f-8842d95f6c86">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTAtNS0xLTEtOTEyODQ_6af9331e-3d63-4540-84ce-7ea3eb555076">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTAtOC0xLTEtOTEyODQ_fad49a06-36a0-4c07-95ee-4af7ce556de6">0.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtMS0xLTEtOTEyODQ_b673cfd7-92ff-4239-96d3-9493dc9ab1e3">147.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6ef607d7a3c7451f9fc91797c668e35b_D20220401-20220630" decimals="-5" sign="-" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtMi0xLTEtOTEyODQ_d494aaba-be58-4fab-8ebc-5ba86be7a52c">80.6</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865cea62a18543cb83411d9461069e79_D20220401-20220630" decimals="-5" name="ebs:AdjustedGrossMargin" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtMy0xLTEtOTEyODQ_41cdbd14-f6b8-44f7-8733-23f3626ff122">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtNC0xLTEtOTEyODQ_61db28ec-27b8-4794-bab0-4fae1bfaca6f">66.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtNS0xLTEtOTEyODQ_3f63ffc5-027d-45f7-bc69-ad7d149efb12">100.6</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30013848203544aaab36afb676ed3c64_D20210401-20210630" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtNi0xLTEtOTEyODQ_a4219617-e772-4710-8dd3-1b13c2a16a43">44.3</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b063649105148fca27b7b94d3b8e412_D20210401-20210630" decimals="-5" name="ebs:AdjustedGrossMargin" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtNy0xLTEtOTEyODQ_6bf754f0-3a14-42a8-a73c-785a8319a847">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtOC0xLTEtOTEyODQ_98e3064c-5552-48d9-ab62-81d0dbb4098e">144.9</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Services revenue and Services adjusted gross margin for the three months ended June 30, 2021 includes the impact of $<ix:nonFraction unitRef="usd" contextRef="ieedc7121a2874e219f1a1ca878ff2c37_D20210401-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTItMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpmZjM0ZGE0NmQ0MDk0NTMzODVjNmI5M2E1NTY3N2JkNV8xMjY_98c87572-5028-4732-b111-5bbf4afc2068">70.4</ix:nonFraction> million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.042%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.371%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.471%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.189%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi0xLTEtMS05NTI3Mw_bef3dee7-bc7f-4d20-abfd-8c447b470f25">474.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibba5b2ada3cf4cb4a6b4ba683779728e_D20220101-20220630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi0yLTEtMS05NTI3Nw_0a64b80a-0c08-455d-8efb-fb1dfcd78801">59.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cff17dc6fc04ad7ab4b4434ef23201b_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi0zLTEtMS05NTI3OQ_8a534fb2-9772-4f9d-9cf2-2246fa205bf9">16.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi00LTEtMS05NTk4Nw_644e50aa-4d48-4efd-9e86-8a960baee99a">550.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi01LTEtMS05NTMwMw_ef11309b-0201-4e15-b63e-44b73acd7a0b">319.1</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a54e7d85e014e56956c4c0661a1e4ed_D20210101-20210630" decimals="-5" name="ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi02LTEtMS05NTMwNQ_f8ce7c88-bebf-471f-b347-66cbab8090cb">374.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i400967d6466a4b58a011f5b045886df0_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi03LTEtMS05NTMwNw_351d17b5-8976-41e6-9afc-60d8508538a3">46.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:Revenues" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi04LTEtMS0xMDExNDQ_3c02e92c-82a5-4591-87a0-483eeda905b8">740.5</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i47cb7eb2f6354e03ac1eaca0de11507a_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMy0zLTEtMS05NTI4MQ_9fd0efa1-f112-4380-b70d-36add426a97e">16.9</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2cff17dc6fc04ad7ab4b4434ef23201b_D20220101-20220630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMy00LTEtMS0xMDExNDA_330847c1-80f8-4784-9203-2e6e55f6ab6b">16.9</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3159b0dd6390463898aef3e672bfd623_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMy03LTEtMS05NTMwOQ_f9821675-fca4-485a-a524-67ea036c7ca7">46.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i400967d6466a4b58a011f5b045886df0_D20210101-20210630" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMy04LTEtMS0xMDExNDQ_9e3d6e2e-c959-494f-a1cd-0c342e094f7e">46.7</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5ef70cac4db448e4864f2175f2373dfd_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNC0xLTEtMS05NTI5Nw_2a0071de-ad1f-44ea-abf9-1a516c61f9b5">171.3</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNC00LTEtMS0xMDExNDA_82456558-7bed-44fd-a936-d9b65431bcd7">171.3</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id4d814b28862414f8af4e0b81c135010_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNC01LTEtMS05NTMxMw_0e412951-12a3-40ce-b62b-6b1b2d1d2f98">133.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNC04LTEtMS0xMDExNDQ_22d5a06e-1cbb-401b-8f19-92634e16d4a2">133.8</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of contract development and manufacturing</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8bd990b6a0ad4694b2c05770255685f3_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNS0yLTEtMS05NTI5MQ_38cc97a6-3f2e-4d9e-a8a3-81188aaca9b6">154.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1cc2230d43ca419eb9859817a3e13e4a_D20220101-20220630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNS00LTEtMS0xMDExNDA_3d265d76-d201-47e9-b499-e7d76bc274a5">154.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6b72f2081fbf4b8284ba76726875fc2a_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNS02LTEtMS05NTMxOQ_0f991bed-94d6-4723-94aa-b73f6e0d6707">193.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4c35eb92f4e94539aef959a8629ae0e7_D20210101-20210630" decimals="-5" name="us-gaap:CostOfGoodsAndServicesSold" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNS04LTEtMS0xMDExNDQ_21ef0c2e-0761-4a8f-81b7-453df0a94c05">193.3</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bccaec18dd645feadb40845bece9039_D20220101-20220630" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS0xLTEtMS0xMDExNDI_82a9f0fd-c22e-4378-a7d4-8691de5e0a69">303.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10be8bddd4d942c08359df94ab97fea5_D20220101-20220630" decimals="-5" sign="-" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS0yLTEtMS0xMDExNDI_09b5b384-a02c-4c29-a7f2-51256011057a">95.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7deb271d98c249298506cf1f896e57cb_D20220101-20220630" decimals="-5" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS0zLTEtMS0xMDExNDI_efd1133d-d031-45ea-8cf1-2c8396875411">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS00LTEtMS0xMDExNDA_307196ef-4cfb-41eb-bfdd-c7100a33cfcc">207.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc4cae43f3c454598ce8975dac330c5_D20210101-20210630" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS01LTEtMS0xMDExNDc_d646d8cd-0f19-490b-9483-429e0c2de12b">185.3</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc42e37be5a94e4f8f3591414bf596dd_D20210101-20210630" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS02LTEtMS0xMDExNDc_b7ceb77c-297c-4fba-b54b-53a6ec59a9c0">181.4</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc6765500b949268c476664a96a2cc3_D20210101-20210630" decimals="-5" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS03LTEtMS0xMDExNDc_db8bf146-c378-4ba6-996e-6ffe2e937425">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:GrossProfit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS04LTEtMS0xMDExNDQ_797ccf5a-8603-4d5d-95da-9ce40dab3bf8">366.7</ix:nonFraction>&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bccaec18dd645feadb40845bece9039_D20220101-20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTAtMS0xLTEtOTUyNzE_344889ba-d689-489b-83c0-d47217b38da8">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTAtNC0xLTEtMTAxMTQw_1107cf48-073c-40ee-84f2-b084e87ec2f9">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc4cae43f3c454598ce8975dac330c5_D20210101-20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTAtNS0xLTEtOTUzMjU_fa6e8e78-ee9f-4e09-a532-8385ec75e23b">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTAtOC0xLTEtMTAxMTQ0_9f89bea9-02be-49f4-9fdc-272e3a2fc088">1.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bccaec18dd645feadb40845bece9039_D20220101-20220630" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtMS0xLTEtMTAxMTQy_47d09874-3658-47b3-894c-95794e74b1c9">304.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i10be8bddd4d942c08359df94ab97fea5_D20220101-20220630" decimals="-5" sign="-" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtMi0xLTEtMTAxMTQy_836440c6-8003-45cd-8dc6-f9297c154846">95.4</ix:nonFraction>)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7deb271d98c249298506cf1f896e57cb_D20220101-20220630" decimals="-5" name="ebs:AdjustedGrossMargin" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtMy0xLTEtMTAxMTQy_11390aa1-2601-49e0-95c5-a6d0ac40c3a4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtNC0xLTEtMTAxMTQw_c1ae96bf-8b52-4ee6-b97d-ea3fa420bb73">209.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc4cae43f3c454598ce8975dac330c5_D20210101-20210630" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtNS0xLTEtMTAxMTQ3_ba322fa7-f852-47ce-9392-4baaace4ab18">187.0</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc42e37be5a94e4f8f3591414bf596dd_D20210101-20210630" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtNi0xLTEtMTAxMTQ3_9afa4bf3-f3a5-4d75-8382-97340e3cf985">181.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc6765500b949268c476664a96a2cc3_D20210101-20210630" decimals="-5" name="ebs:AdjustedGrossMargin" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtNy0xLTEtMTAxMTQ3_670be176-a7af-4a56-a88d-f2ff4454cca2">&#8212;</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="ebs:AdjustedGrossMargin" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtOC0xLTEtMTAxMTQ0_54469039-15f5-4686-a335-ceff26030f3d">368.4</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Services revenue and Services adjusted gross margin for the six months ended June 30, 2021 includes the impact of $<ix:nonFraction unitRef="usd" contextRef="i06918d944d12481c84ebd11d669df56b_D20210101-20210630" decimals="-5" name="us-gaap:OperatingLeaseLeaseIncomeLeasePayments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTItMC0xLTEtOTQ5OTIvdGV4dHJlZ2lvbjoyNjZlMTVjZDQ4ZDE0ZmJkOGU4YzEwMTQ4OWM1NjRiMl82NTk3MDY5NzY2ODgz_01c18c59-47be-44cb-8357-07c5cc350414">167.9</ix:nonFraction> million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RleHRyZWdpb246NjMyYmRmMjBjODkyNDVlZmEwZmRlZjQxMGYyZWMxNDVfMTkzOA_56992ea0-c75c-450d-a4bc-bfd5a32b34c3" escape="true"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation for each segment as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.267%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.273%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation:</span></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMy0xLTEtMS05NTQzOQ_514d6d92-94dd-4cb6-99dd-ef7650f53309">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMy0zLTEtMS05NTQzOQ_68af2d68-10ed-44c7-8595-b3955a5f62aa">8.7</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bccaec18dd645feadb40845bece9039_D20220101-20220630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMi0xLTEtMS05MTI4NA_625f8299-f4c3-4559-84ba-21164e6f16b7">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedc4cae43f3c454598ce8975dac330c5_D20210101-20210630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMi0zLTEtMS05MTI4NA_02e480ac-14eb-492b-a12d-e56676a176fb">15.9</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ef607d7a3c7451f9fc91797c668e35b_D20220401-20220630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNC0xLTEtMS05NTQzOQ_131ea74a-7197-47ba-bd1f-3ba06555ceef">20.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30013848203544aaab36afb676ed3c64_D20210401-20210630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNC0zLTEtMS05NTQzOQ_6aab75b3-34f5-4673-92c6-f23b9b3dbc83">7.6</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10be8bddd4d942c08359df94ab97fea5_D20220101-20220630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMy0xLTEtMS05MTI4NA_8e150c0e-fdf9-4838-819e-edb238b02293">28.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibc42e37be5a94e4f8f3591414bf596dd_D20210101-20210630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMy0zLTEtMS05MTI4NA_88632bb9-4fb4-4ff1-8736-28835e28267f">12.9</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i865cea62a18543cb83411d9461069e79_D20220401-20220630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNS0xLTEtMS05NTQzOQ_624d6604-9ea0-490e-9fb9-c558e14c59ee">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b063649105148fca27b7b94d3b8e412_D20210401-20210630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNS0zLTEtMS05NTQzOQ_9d506a04-6407-440c-b6c6-bd7d2434eeed">2.2</ix:nonFraction></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7deb271d98c249298506cf1f896e57cb_D20220101-20220630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNC0xLTEtMS05MTI4NA_27ac103b-efe1-4d72-a246-cf674023b77d">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc6765500b949268c476664a96a2cc3_D20210101-20210630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNC0zLTEtMS05MTI4NA_eb72502b-c3bd-4803-bf4a-99498852b272">3.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNi0xLTEtMS05NTQ0NQ_bd35f431-402d-4eaf-902e-5e18f3e7ea9c">28.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNi0zLTEtMS05NTQ0OA_a24be725-6383-4462-9514-ad4929f658d9">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNS0xLTEtMS05MTI4NA_23cbb4cc-e512-4a53-bdae-d3486f38864b">45.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630" decimals="-5" name="us-gaap:Depreciation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNS0zLTEtMS05MTI4NA_186d7722-cb4d-402f-82a8-62bc48c343ca">32.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our CODM does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_88"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84OC9mcmFnOjBmOTgzMWE5NTFkNjRlYTE4MzE5NmZhNDBlY2Q4ZjgyL3RleHRyZWdpb246MGY5ODMxYTk1MWQ2NGVhMTgzMTk2ZmE0MGVjZDhmODJfOTA2MA_cffd73e9-7dd6-4c39-a7af-6ee91aa51cbd" continuedAt="ic2dd843fcd64440c95d6b8181e2e4238" escape="true">Commitments and contingencies</ix:nonNumeric></span></div><ix:continuation id="ic2dd843fcd64440c95d6b8181e2e4238" continuedAt="i08590c2ce5d440768b31a2f372bcc5af"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities and shareholder litigation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock, seeking to pursue remedies under the Securities Exchange Act of 1934. These complaints were filed by Palm Tran, Inc. &#8211; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth; and Stephen M. Weiss, respectively. The complaints allege, among other things, that the defendants made false and misleading statements about its manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as CDMO Manufacturing Capabilities). These cases were consolidated on December 23, 2021, under the caption In re Emergent BioSolutions Inc. Securities Litigation, No. 8:21-cv-00955-PWG (the Federal Securities Class Action). The Lead Plaintiffs in the consolidated matter are Nova Scotia Health Employees&#8217; Pension Plan and The City of Fort Lauderdale Police &amp; Firefighters&#8217; Retirement System. The defendants filed a motion to dismiss on May 19, 2022 and the Lead Plaintiff filed an opposition to that motion on July 19, 2022. The defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the consolidated action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, Lincolnshire Police Pension Fund (&#8220;Lincolnshire&#8221;) and on August 16, 2021, Pooja Sayal, filed putative stockholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the Company&#8217;s CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, both cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-PWG. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022 the Court approved the parties joint stipulation to and stay of the proceedings and discovery until the close of fact  discovery in the Federal Securities Class Action. The defendants believe that the allegations in the complaints are without merit and intend to defend the matter vigorously.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, September 16, 2021, and November 12, 2021, putative stockholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp; Police Officers Pension Fund in The Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the Company&#8217;s CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption In re Emergent BioSolutions, Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#8217; filed their Motion to Dismiss the plaintiffs&#8217; complaint. However, ruling on this motion is stayed pursuant to a March 29, 2022 Order staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, December 22, 2021 and January 18, 2022, putative stockholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the laws, each allegation related to the Company&#8217;s CDMO Manufacturing Capabilities.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings and Discovery, pursuant to which the </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, in millions, except share and per share amounts)</span></div></div><ix:continuation id="i08590c2ce5d440768b31a2f372bcc5af"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties have agreed to stay all proceedings until thirty (30) calendar days after a ruling on defendants&#8217; motion to dismiss filed in the Federal Securities Class Action. The Court approved the Joint Stipulation on March 14, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> addition to the above actions, the Company has received preliminary inquiries and subpoenas to produce documents related to these matters from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis, Senator Murray of the Committee on Health, Education, Labor and Pensions, the Department of Justice, the SEC, the Maryland Attorney General&#8217;s Office, and the New York Attorney General&#8217;s Office. The Company is producing and has produced documents as required in response and will continue to cooperate with these government inquiries.</span></div><div style="text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions&#8217; Adapt Pharma subsidiaries (Emergent) are as follows: Emergent Devices Inc. (EBPA), formerly known as Adapt Pharma Inc.; Emergent Operations Ireland Limited (EIRE), formerly known as Adapt Pharma Operations Limited; and Emergent BioSolutions Ireland Limited (EIR2), formerly known as Adapt Pharma Limited.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ANDA litigation - Teva 4mg</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> BioSolutions&#8217; Adapt Pharma subsidiaries EBPA and EIRE, and Opiant Pharmaceuticals Inc. (Opiant) received notice letters from Teva Pharmaceuticals Industries Limited and Teva Pharmaceuticals USA (collectively, Teva) that Teva had filed an Abbreviated New Drug Application (ANDA) with the FDA seeking regulatory approval to market a generic version of </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCI</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Nasal Spray 4 mg/spray before the expiration of certain patents listed on the FDA&#8217;s website for Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Orange Book Listed Patents) for NARCAN. Teva&#8217;s notice letters alleged that claims of certain Orange Book Listed Patents for NARCAN were invalid and/or would not be infringed by the activities described in Teva&#8217;s ANDA. Emergent and Opian</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t filed complaints against Teva in the U.S. District Court for the District of New Jersey alleging infringement of certain Orange Book Listed Patents for NARCAN. On June 5, 2020, the U.S. District Court for the District of New Jersey ruled in favor of Teva. Emergent unsuccessfully appealed the decision to the Court of Appeals for the Federal Circuit (CAFC) and followed with a petition for rehearing that was ultimately denied on May 5, 2022.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ANDA litigation - Teva 2mg</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions&#8217; Adapt Pharma subsidiaries EBPA and EIRE, and Opiant received a notice letter from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone HCI) Nasal Spray 2 mg/spray before the expiration of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#174;. Teva&#8217;s notice letter alleged that claims of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#174; were invalid and/or would not be infringed by the activities described in Teva&#8217;s ANDA. Emergent and Opiant filed complaints against Teva in the U.S. District Court for the District of New Jersey alleging infringement of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN. This case is currently stayed and it is anticipated the matter will be dismissed.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_91"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed consolidated financial statements and accompanying notes and other financial information included elsewhere in this quarterly report on Form 10-Q and our audited consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended December&#160;31, 2021. Some of the information contained in this discussion and analysis or set forth elsewhere in this quarterly report on Form 10-Q, includes information with respect to our plans and strategy for our business and financing, as well as forward-looking statements that involve risks and uncertainties. You should carefully review the "Special Note Regarding Forward-Looking Statements" and "Risk Factors" sections of this quarterly report on Form 10-Q for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.</span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_94"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Business overview</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a global life sciences company focused on providing innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring PHTs. Our solutions include a product portfolio, a product development portfolio and a CDMO services portfolio. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently focused on the following five PHT categories: CBRNE, EID, travel health, emerging health crises and acute/emergency care. We have a product portfolio of eleven products that contribute a substantial portion of our revenue and are sold to government and commercial customers. We also have a product candidate that is procured under special circumstances by the USG, although it is not approved by the FDA. Additionally, we have a development pipeline consisting of a diversified mix of both pre-clinical and clinical stage product candidates. Finally, we have a fully-integrated portfolio of CDMO services. Our CDMO service offerings cover development services, drug substance manufacturing and drug product manufacturing and packaging. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our product revenue comes from the following products and procured product candidates:</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government - MCM products</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Anthrax vaccines, including our AV7909 (Anthrax vaccine adsorbed (AVA), adjuvanted) procured product candidate being developed as a next-generation anthrax vaccine for post-exposure prophylaxis and BioThrax</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Vaccine Adsorbed), the only vaccine licensed by the FDA for the general use prophylaxis and post-exposure prophylaxis of anthrax disease. AV7909 has not been approved by the FDA, but is procured by certain authorized government buyers for their use;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">ACAM2000</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, (Smallpox (Vaccinia) Vaccine, Live), the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">BAT</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Botulism Antitoxin Heptavalent (A,B,C,D,E,F,G)-(Equine)), the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of botulism; </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">CNJ-016</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Vaccinia Immune Globulin Intravenous (Human) (VIGIV)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Raxibacumab injection, a fully human monoclonal antibody, the first fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Anthrasil</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Anthrax Immune Globulin Intravenous (human)), the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">RSDL</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Reactive Skin Decontamination Lotion Kit), the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Trobigard</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> atropine sulfate, obidoxime chloride AUTO-INJECTOR, a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA, but is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Ebanga&#8482; (ansuvimab-zykl, formerly referred to as mAb114) is a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">collaboration with Ridgeback Biotherapeutics, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the United States and Canada, and Ridgeback Bio will serve as the global access partner for Ebanga&#8482;.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial products</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">NARCAN</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment&#160;of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Recently, the Company authorized Sandoz Inc. to distribute a generic naloxone nasal spray;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Vivotif</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever; and</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Vaxchora</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the only single-dose oral vaccine approved by the FDA and EMA for the prevention of cholera.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services - contract development and manufacturing</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our services revenue consists of distinct but interrelated CDMO services</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: drug substance manufacturing; drug product manufacturing (also referred to as "fill/finish" services) and packaging; development services including technology transfer, process and analytical development services; and, when necessary, suite reservation obligations. These services, which we refer to as "molecule-to-market" offerings, employ diverse technology platforms (mammalian, microbial, viral and plasma) across a network of nine geographically distinct development and manufacturing sites operated by us for our internal products and pipeline candidates and third party CDMO services. We service both clinical-stage and commercial-stage projects for a variety of third-party customers, including government agencies, innovative pharmaceutical companies, and non-government organizations.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pending Acquisition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On May 15, 2022, the Company entered into an Asset Purchase Agreement by and between the Company and Chimerix, Inc. (the &#8220;Seller&#8221;), pursuant to which the Company agreed to purchase from Seller its exclusive worldwide rights to brincidofovir, including TEMBEXA&#174; and related assets. TEMBEXA is a medical countermeasure for smallpox approved by the U.S. Food and Drug Administration in June 2021. </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Closing of the Transaction is currently expected to occur during the third quarter of 2022.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div id="i4ef4253100994f989fd72d1c0fd41d25_100"></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial operations overview</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Revenues</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">W</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e generate product revenues from the sale of our marketed products and procured product candidates which include vaccines, therapeutics and devices which have been described above. The USG is the largest purchaser of our MCM products and primarily purchases our products for the SNS, a national repository of medical countermeasures including critical antibiotics, vaccines, chemical antidotes, antitoxins and other critical medical supplies. The USG primarily purchases our products under long-term, firm fixed-price procurement contracts, generally with annual options. </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our opioid overdose reversal product, NARCAN&#174; Nasal Spray and our travel health products, Vivotif and Vaxchora, are sold commercially through wholesalers and distributors, physician-directed or standing order prescriptions at retail pharmacies and to state and local community healthcare agencies, practitioners and hospitals.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also generate revenue from our CDMO services provided at our established development and manufacturing infrastructure, technology platforms and expertise. Our services include a fully integrated molecule-to-market contract development and manufacturing services business offering across development </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services, drug substance and drug product for small to large pharmaceutical and biotechnology industry and government agencies/non-governmental organizations. From time to time, clients require suite reservations at our various manufacturing sites, which may be considered leases depending on the facts and circumstances. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received contracts and grants funding from the USG and other non-governmental organizations to perform research and development activities, particularly related to programs addressing certain CBRNE threats and EIDs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue, operating results and profitability vary quarterly based on the timing of production and deliveries, the timing of manufacturing services performed and the nature of providing large scale bundles of products and services as needs arise. We expect continued variability in our quarterly financial statements.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Cost of product sales and CDMO services</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Products</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The primary expenses that we incur to deliver our products consist of fixed and variable costs. We determine the cost of product sales for products sold during a reporting period based on the average manufacturing cost per unit in the period those units were manufactured. Fixed manufacturing costs include </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">facilities, utilities and amortization of intangible assets. Variable manufacturing costs primarily consist of costs for materials and personnel-related expenses for direct and indirect manufacturing support staff, contract manufacturing operations, sales-based royalties, shipping and logistics. In addition to the fixed and variable manufacturing costs described above, the cost of product sales depends on utilization of available manufacturing capacity. For our commercial sales, other associated expenses include sales-based royalties (which include fair value adjustments associated with contingent consideration), shipping and logistics.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CDMO</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The primary expenses that we incur to deliver our CDMO services consist of fixed and variable costs. We operate five facilities that perform manufacturing activities for CDMO services customers. We use the same manufacturing facilities and methods of production for our own products as well as for fulfillment of our CDMO service contracts. Our manufacturing process includes the production of bulk material and performing &#8220;fill/finish&#8221; work for containment and distribution of biological products. For &#8220;fill finish&#8221; customers, we receive work in process inventory to be prepared for distribution. When producing bulk material, we generally procure raw materials, manufacture the product and retain the risk of loss through the manufacturing and review process until delivery.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Research and development expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. Our research and development expenses consist primarily of:</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">personnel-related expenses;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">fees to professional service providers for, among other things, analytical testing, independent monitoring or other administration of our clinical trials and obtaining and evaluating data from our clinical trials and non-clinical studies;</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">costs of CDMO services for clinical trial material; and</span></div><div style="margin-bottom:8pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">costs of materials and equipment used in clinical trials and research and development.</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many cases, we plan to seek funding for development activities from external sources and third parties, such as governments and non-governmental organizations, or through collaborative partnerships. We expect our research and development spending will be dependent upon such factors as the results from our clinical trials, the availability of reimbursement of research and development spending, the number of product candidates under development, the size, </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:8pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">structure and duration of any clinical programs that we may initiate, the costs associated with manufacturing and development of our product candidates on a large-scale basis for later stage clinical trials and our ability to use or rely on data generated by government agencies.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Selling, general and administrative expenses</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel-related costs and professional fees in support of our executives, sales and marketing, business development, government affairs, finance, accounting, information technology, legal, human resource functions and other corporate functions. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Income taxes</span></div><div style="margin-bottom:8pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Uncertainty in income taxes is accounted for using a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. We recognize in our financial statements the impact of a tax position if that position is more likely than not of being sustained on audit, based on the technical merits of the position.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the assumptions and estimates related to the provision for income taxes are critical to the Company&#8217;s results of operations. </span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_103"></div><div style="margin-bottom:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New accounting standards</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of new accounting standards please see Note 2, Basis of presentation and principles of consolidation, in Part I item 1, of this Quarterly Report on Form 10-Q. </span></div><div style="margin-bottom:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical accounting policies and estimates</span></div><div style="margin-bottom:7pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the U.S., requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis we evaluate our estimates, judgments and methodologies. We base our estimates on historical experience and on various other assumptions that we believe are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and exp</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enses. Actual results may differ from these estimates. During the six months ended June 30, 2022, there have been no significant changes to our critical accounting policies and estimates contained in our Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_106"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of operations</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:21.170%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.095%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.247%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="21" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="21" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$ Change</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">% Change</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$ Change</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">% Change</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales net:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasal naloxone products</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">194.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">180.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACAM2000</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthrax vaccines</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other product sales</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total product sales, net</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract development and manufacturing:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(97)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(116.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(98)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract development and manufacturing</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192.7)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.7&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315.7)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(84)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154.8)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740.5&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(190.3)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of contract development and manufacturing</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(67.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.9)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">383.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">615.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">630.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.8)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) from operations</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65.6)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(175.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense):</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.8)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total other income (expense), net</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.0)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income (loss) before income taxes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(82.8)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(90.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(86.6)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(179.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.4)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(61.0)</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.1)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(134.4)</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM</span></td></tr><tr style="height:8pt"><td colspan="48" style="padding:0 1pt"></td></tr><tr><td colspan="48" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">NM - Not meaningful</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220630_g2.jpg" alt="ebs-20220630_g2.jpg" style="height:575px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.912%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.640%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.529%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.519%"></td><td style="width:0.1%"></td></tr><tr><td colspan="12" style="background-color:#ffffff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Legend</span></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Nasal naloxone products</span></td><td colspan="3" style="background-color:#898989;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other product sales</span></td></tr><tr><td colspan="3" style="background-color:#f7876d;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ACAM2000</span></td><td colspan="3" style="background-color:#5e838a;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDMO</span></td></tr><tr><td colspan="3" style="background-color:#ababaa;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anthrax vaccines</span></td><td colspan="3" style="background-color:#133146;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product sales, net</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Anthrax vaccines</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Anthrax vaccine sales for the three and six months ended June&#160;30, 2022 was primarily due to an increase in the number of doses sold as a result of the timing of deliveries to the USG. The price per unit of Anthrax vaccines was largely consistent period over period. Anthrax vaccine product sales are made under annual purchase options exercised by the USG. Fluctuations in revenues result from the timing of </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the exercise of annual purchase options and the USG purchases and Company delivery of orders that follow. </span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Nasal naloxone products</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Nasal naloxone product sales for the three months ended June 30, 2022 was driven by a reduction in commercial retail sales following the launch of a generic version of NARCAN Nasal Spray 4mg in December 2021. This decrease was offset by strong growth in unit sales of NARCAN Nasal Spray to U.S. public interest and Canadian customers, as well as from sales of the authorized generic product licensed to Sandoz which launched in December 2021. The increase in sales for the six months ended June 30, 2022 was driven by an increase in U.S. public interest, Canadian, and authorized generic sales offset by a reduction in commercial retail sales following the launch of a generic version of NARCAN Nasal Spray 4mg in December 2021. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ACAM2000</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no sales of ACAM2000 in the three months ended June 30, 2022 or the three and six months ended June&#160;30, 2021. The Company had sales of ACAM2000 in the first quarter 2022 to non-US customers.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Other product sales</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in Other product sales for the three months ended June 30, 2022 was due to sales of VIGIV driven by timing of deliveries to the SNS and sales of BAT driven by timing of deliveries to international customers. The increase in Other product sales for the six months ended June 30, 2022 was due to increased sales of VIGIV, BAT, and Anthrasil.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CDMO</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in CDMO services revenue for the three and six months ended June&#160;30, 2022 of $100.9 million and $116.7 million, respectively, is largely due to reduced production activities at the Company's Bayview facility as a result of a pause in manufacturing under the Janssen contract which began in the first quarter 2022 and no activities under the AstraZeneca contract in 2022. The combined services revenues from the Janssen and AstraZeneca contracts decreased $82.0&#160;million and $110.5&#160;million during the three and six months ended June&#160;30, 2022, respectively. Additionally, the Company's Camden facility had reduced production in the three and six months ended June&#160;30, 2022 compared to prior periods. These declines in revenues at the Bayview </span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Camden facilities were offset by an increase in manufacturing activities at the Company's Winnipeg facility to support drug substance and drug product manufacturing for customers products and product candidates.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Leases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in CDMO lease revenue for the three and six months ended June&#160;30, 2022 was primarily due to a reduction of $70.4 million and $167.9 million, respectively, associated with the completion of our COVID-19 development public-private partnership with BARDA in November 2021 as well as reduced lease revenues under the Janssen contract of $21.9&#160;million and $31.6&#160;million, respectively. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contracts and grants</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Contracts and grants revenue for the three and six months ended June&#160;30, 2022 was largely due to BARDA's completion of the Center of Innovation and Advanced Development and Manufacturing agreement in November 2021 as well as decreases in development activities associated with various other externally funded research and development projects.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of product sales</span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220630_g3.jpg" alt="ebs-20220630_g3.jpg" style="height:239px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales </span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit margin for Product segment</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of product sales increased for the three and six months ended June&#160;30, 2022 as compared with the three and six months ended June&#160;30, 2021, largely due to an increase in product sales. The increase in gross profit margin for the Product segment for the three and six months ended June&#160;30, 2022 was largely due to a favorable product revenue mix which was weighted more heavily to higher margin products. </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of CDMO</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Services</span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220630_g4.jpg" alt="ebs-20220630_g4.jpg" style="height:239px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of CDMO services</span></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit margin for Services segment</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#929292;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Not meaningful</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of CDMO decreased for the three and six months ended June&#160;30, 2022 as compared with the three and six months </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ended June&#160;30, 2021. The decrease is primarily due to reduced production activities across our CDMO network in Q2 2022 compared to Q2 2021 resulting in decreased raw materials consumption, as well as a $41.5&#160;million inventory write-off in Q2 2021. These decreases were partially offset by increased costs at the Company's Winnipeg facility due to an increase in manufacturing activities and Camden facility due to additional investments in quality enhancement and improvement initiatives. The decrease in gross profit margin for the Services segment was also impacted by the completion of the BARDA lease in November 2021.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and development expenses (Gross and Net)</span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220630_g5.jpg" alt="ebs-20220630_g5.jpg" style="height:238px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.764%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:93.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense, net of contracts and grants revenue</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense for the three months ended June 30, 2022 was consistent with the prior year. Research and development expense decreased for the six months ended June 30, 2022 a compared with the six months ended June 30, 2021 due to a decline in spending for the Company's COVID therapeutic product candidates partially offset by an increase in costs associated with the Company's Phase 3 study of our chikungunya virus-like particle vaccine candidate.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Selling, general and administrative expenses</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220630_g6.jpg" alt="ebs-20220630_g6.jpg" style="height:233px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SG&amp;A as a percentage of total revenue</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses for the three and six months ended June&#160;30, 2022 decreased as compared with the three and six months ended June&#160;30, 2021 due to lower professional </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">services and marketing expenses partially offset by increased compensation costs. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amortization of intangible assets</span></div><div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"><img src="ebs-20220630_g7.jpg" alt="ebs-20220630_g7.jpg" style="height:233px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization expense</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization of intangible assets and the composition of intangible assets amortized during the three and six months ended June&#160;30, 2022 were consistent with the three and six months ended June&#160;30, 2021.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Total other income (expense), net</span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220630_g8.jpg" alt="ebs-20220630_g8.jpg" style="height:233px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td></tr><tr><td colspan="3" style="background-color:#5e838a;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decrease in Other income (expense), net was primarily due to unrealized foreign currency losses recorded related to the remeasurement of certain intercompany balances. Interest expense was largely consistent between perio</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ds.</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income tax expense (benefit)</span></div><div style="margin-bottom:9pt;text-align:center"><img src="ebs-20220630_g9.jpg" alt="ebs-20220630_g9.jpg" style="height:226px;margin-bottom:5pt;vertical-align:text-bottom;width:324px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:5.072%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.728%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#b14932;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense (benefit)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:100%">l</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective tax rate</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2022 and 2021, the estimated effective annual tax rates were 29% and 26%, respectively. The actual effective tax rates include the impact of discrete tax expense recorded $0.2 million and $0.6&#160;million for the three and six months ended June&#160;30, 2022, respectively, and $1.1 million and $(5.5)&#160;million for the three and six months ended June&#160;30, 2021, respectively. Income taxes decreased during the periods largely due to the increase in the net loss before income taxes.</span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_112"></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"></div></div><div style="margin-bottom:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial condition, liquidity and capital resources</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial condition is summarized as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.882%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Change %</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financial assets:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;text-indent:4.5pt;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">358.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Borrowings:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, current portion</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt, net of current portion</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total borrowings</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">841.0&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Working capital:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,084.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,272.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 19pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 32.5pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total working capital</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">807.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">898.3&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Sources of liquidity</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have historically financed our operating and capital expenditures through cash on hand, cash from operations, debt financing and contracts and grants development funding. We also obtain financing from the sale of our common stock upon exercise of stock options. We have operated profitably for each of the last five annual fiscal years through the period ended December&#160;31, 2021. As of June&#160;30, 2022, we had unrestricted cash and cash equivalents of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$358.1 million and capacity under our revolving credit facility of $598.7&#160;million. As of June&#160;30, 2022, we believe that we have sufficient liquidity to fund our operations over the next 12 months.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash flows</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding our cash flows for the six months ended June 30, 2022 and 2021:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.147%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.417%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.418%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52.9)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(64.3)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(123.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.2)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.0)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash, cash equivalents and restricted cash</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net change in cash, cash equivalents and restricted cash</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(218.0)</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(173.8)</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Operating activities</span></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $52.9 million for the six months ended June 30, 2022 was due to a net income excluding non-cash items of $46.1&#160;million offset by negative working capital changes of $99.0&#160;million due to increases in inventory and an increase in payments for our contingent consideration and other accrued expenses, partially offset by collections on receivables.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities of $24.6 million for the six months ended June 30, 2021 was due to net loss excluding non-cash items of $160.6&#160;million offset by negative working capital changes of $185.2&#160;million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $28.3 million from cash used in operating activities of $24.6 million to cash used in operating activities of $52.9 million is due to a decline in net income excluding non-cash items of $114.5&#160;million offset by a decline in negative impacts from working capital changes of $86.2&#160;million.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investing activities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in investing activities relates to purchases of property, plant and equipment and was $64.3 million and $123.1 million for the six months ended June 30, 2022 and 2021, respectively. The cash used in investing activities decreased during the six months ended June 30, 2022 largely due to decreased infrastructure investment as projects to increase capacity and capabilities at our Rockville facility near completion. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing activities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities of $101.2 million for the six months ended June 30, 2022 was primarily due to repurchases of stock of $81.9 million and payments on debt of $16.9&#160;million.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities of $26.0 million for the six months ended June 30, 2021 was primarily due to payments on debt of $21.9&#160;million and net payments related to employee share-based compensation activity of $3.0&#160;million.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase of $75.2 million of cash used in financing activities is largely due to an increase in cash used for repurchases of stock of $81.9 million offset by a decline in debt payments of $5.0&#160;million.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Funding requirements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to fund our anticipated operating expenses, capital expenditures, debt service requirements and any future repurchase of our common stock from the following sources:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">existing cash and cash equivalents;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">net proceeds from the sale of our products and CDMO services;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">development contracts and grants funding; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">our Senior Secured Credit Facilities and any other lines of credit we may establish from time to time.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are numerous risks and uncertainties associated with product sales, delivery of CDMO services and the development and commercialization of our product candidates. We may seek additional external financing to provide additional financial flexibility. Our future capital requirements will depend on many factors, including (but not limited to):</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the level, timing and cost of product sales and cost of contract development and manufacturing services;</span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC. </span></div><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(unaudited, amounts in millions, except share and per share amounts)</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the payment obligations under our indebtedness;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the scope, progress, results and costs of our development activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">our ability to obtain funding from collaborative partners, government entities and non-governmental organizations for our development programs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the extent to which we repurchase additional shares of our common stock under our current share repurchase program; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">the costs of commercialization activities, including product marketing, sales and distribution.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans or collaboration and licensing arrangements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds by issuing equity securities, our stockholders may experience dilution. Public or bank debt financing, if available, may involve agreements that include covenants, like those contained in our Senior Unsecured Notes due 2028 and the Senior Secured Credit Facilities, which could limit or restrict our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities, buying back shares or declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions, including market volatility and adverse impacts on financial markets may make it more difficult to obtain financing on attractive terms, or at all. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Unused credit capacity</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available room under the revolving credit facility for the periods ended June&#160;30, 2022 and December&#160;31, 2021 was:</span></div><div style="margin-bottom:9pt;padding-left:9pt;padding-right:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.579%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:26.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.998%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.037%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;border-left:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total Capacity</span></div></td><td colspan="3" style="background-color:#19415e;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Outstanding Letters of Credit</span></td><td colspan="3" style="background-color:#19415e;border-bottom:1pt solid #000000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outstanding Indebtedness on Revolving Credit Facility</span></div></td><td colspan="3" style="background-color:#19415e;border-right:0.5pt solid #000;border-top:0.5pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unused Capacity</span></td></tr><tr><td colspan="3" style="background-color:#19415e;border-left:0.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;border-right:0.5pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#dbdbdb;border-left:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600.0</span></td><td colspan="3" style="background-color:#dbdbdb;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3</span></td><td colspan="3" style="background-color:#dbdbdb;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="background-color:#dbdbdb;border-right:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$598.7</span></td></tr><tr><td colspan="3" style="background-color:#19415e;border-left:0.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2021</span></div></td><td colspan="3" style="background-color:#19415e;border-right:0.5pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000;border-left:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600.0</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;</span></td><td colspan="3" style="border-bottom:0.5pt solid #000;border-right:0.5pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$597.7</span></td></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div><div style="margin-bottom:9pt;text-indent:18pt"><span><br/></span></div></div></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET&#160;RISK</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a discussion of additional risks arising from our operations, see &#8220;Item&#160;1A-Risk Factors&#8221; in this&#160;quarterly report.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have interest rate and foreign currency market risk. Because of the short-term maturities of our cash and cash equivalents, we believe that an increase in market rates would likely not have a significant impact on the realized value of our investments.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interest rate risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have debt with a mix of fixed and variable rates of interest. Floating rate debt carries interest based generally on the eurocurrency rate, as defined in our Amended Credit Agreement, plus an applicable margin. We manage the impact of interest rate changes on our variable debt through derivative interest rate swap arrangements. Increases in interest rates could result in an increase in interest payments for debt that we have not hedged through our interest rate swap arrangements. See Note 9, Debt, to the Notes of our condensed consolidated financial statements included in this 2022 Quarterly Report under the caption Item 1, "Financial Statements.&#8221;</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have assessed our exposure to changes in interest rates by analyzing the sensitivity to our operating results assuming various changes in market interest</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> rates. </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A hypothetical increase of one percentage point in the eurocurrency rate as of June&#160;30, 2022 would increase our interest expense by approximately $0.3 million annually</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Foreign currency exchange rate risk</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have exposure to foreign currency exchange rate fluctuations worldwide and primarily with respect to the Euro, Canadian dollar, Swiss franc and British pound. We manage our foreign currency exchange rate risk primarily by either entering into foreign currency hedging transactions or incurring operating expenses in the local currency in the countries in which we operate, to the extent practical. We currently do not hedge all of our foreign currency exchange exposure and the movement of foreign currency exchange rates could have an adverse or positive impact on our results of operations.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div id="i4ef4253100994f989fd72d1c0fd41d25_118"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. CONTROLS AND PROCEDURES</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our chief executive officer and chief financial officer, evaluated the effectiveness of our disclosure controls and procedures as of June&#160;30, 2022. The term "disclosure controls and procedures," as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the Exchange Act), means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of June&#160;30, 2022, our chief executive officer and chief financial officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes in internal control over financial reporting</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no changes in our internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during the three months ended June&#160;30, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_121"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATIO</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">N</span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_124"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1. LEGAL PROCEEDINGS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See "Item 1 of Part I, &#8220;Financial Statements &#8212; Notes to condensed consolidated financial statements &#8212; Note 15, Commitments and contingencies.&#8221;</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 1A. RISK FACTORS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following risk factors and other information included in this Quarterly Report on Form 10-Q should be carefully considered. The occurrence of any of the following risks or of unknown risks and uncertainties may adversely affect our business, operating results and financial condition.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISK FACTOR SUMMARY</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of government contracting risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Reduced demand for and/or funding for procurement of AV7909 and/or BioThrax or ACAM2000 and discontinuation of funding of our other USG procurement and development contracts.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Inability to receive FDA licensure of AV7909 and realize the full value of our contract for development and procurement of AV7909.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of manufacturing risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our inability to maintain quality and manufacturing compliance at our manufacturing facilities has hindered and could continue to hinder our ability to produce products and product candidates for our CDMO customers.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Disruption at, damage to or destruction of our development and/or manufacturing facilities and supply chain disruption, including lower availability of plasma, may impede our ability to manufacture our products, as well as deliver our CDMO services.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our operations, including our use of hazardous materials, chemicals, bacteria and viruses expose us to significant potential liabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of product development and commercialization risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The COVID-19 product candidates we are working on for our CDMO customers may not be safe or effective and we may be unable to manufacture sufficient quantities to meet demand.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Clinical trials of product candidates are expensive and time-consuming, and their outcome is uncertain.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">We may fail to capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to numerous factors, the COVID-19 coronavirus pandemic could have a material adverse impact on our business, results of operations and financial performance, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Changes in government priorities resulting from the pandemic and continuing supply chain shortages could impact our overall business.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">COVID-19 may impede our workers ability to work and may result in reduced production of products or services.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The evolving nature of COVID-19 and related vaccines and treatments and resulting changes in demand for such product candidates may impact sales of related services offered by our CDMO business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of regulatory and compliance risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Failure to comply with complex laws and regulations pertaining to government contracts and resources required for responding to related government inquiries.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Conditions associated with approvals and ongoing regulation of products may limit how and the extent to which we manufacture and market them.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Failure to comply with various health care laws could result in substantial penalties.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Failure to comply with obligations under USG pricing programs may require reimbursement for underpayments and the payment of substantial penalties, sanctions and fines.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The extent to which we may be able to lawfully offer to sell and sell unapproved products in many jurisdictions may be unclear or  ambiguous and such activities may subject us to regulatory enforcement actions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of competitive and political risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Development and commercialization of pharmaceutical products are subject to evolving private and public sector competition.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">NARCAN is currently subject to generic competition and may be subject to additional branded and generic competition and generic </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products rather than branded products are often distributed where a generic version is available.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Biologic Products may be affected by the approval and entry of follow-on biologics, or biosimilars in the United States and other jurisdictions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to our intellectual property that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Challenges in defense or enforcement of our intellectual property rights including against current or potential infringers.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Potential discrepancies or challenges with respect to third party licenses, including our failure to comply with obligations under such licenses.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Potential loss of proprietary information and know-how, which carries the risk of reducing the value of our technology and products.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Entry of competing generic drugs upon patent expiry or with patents no longer in force.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to reliance on third parties that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The loss of sole-source suppliers or an increase in the price of inventory.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">If third parties upon which we rely to conduct many of our clinical trials and other work do not perform as contractually required or as expected, we may not be able to obtain regulatory approval for or commercialize our product candidates or honor customer obligations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of legal and reputational risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Unfavorable results of legal proceedings and government investigations could adversely impact our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our work on PHTs has exposed us to criticism and may expose us to further criticism, from the media, government personnel and others, which could further harm our reputation, negatively affect our share price, operations, and our ability to attract and retain talent.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The potential for cyber security incidents to harm our ability to operate our business effectively in light of our heightened risk profile.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Inherent product liability exposure due to our unique business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of financial risks that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our ability to maintain sufficient cash flow from our operations to pay our substantial debt, both now and in the future.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our ability to obtain additional funding and be able to raise capital when needed.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our ability to comply with the covenants under our Senior Secured Credit Facilities and other debt agreements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks related to our strategic acquisitions and collaborations that could impact our business, financial condition, operating results and cash flows, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our strategy of generating growth through acquisitions may be unsuccessful.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our failure to successfully integrate acquired businesses and/or assets into our operations and our ability to realize the benefits of such acquisitions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of risks associated with our common stock, including, but not limited to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Our business or our share price could be negatively affected as a result of the actions of shareholders.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">The price of our common stock has been and remains subject to extreme volatility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The risk factors below contain more detailed descriptions of the risks identified above, which may materially harm our business, financial condition or results of cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GOVERNMENT CONTRACTING RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We currently derive a substantial portion of our revenue from USG procurement of AV7909 and ACAM2000 and have historically derived a substantial portion of our revenue from USG procurement of BioThrax. If the USG&#8217;s demand for and/or funding for procurement of AV7909 and/or BioThrax or ACAM2000 is substantially reduced, our business, financial condition, operating results and cash flows would be materially harmed.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We derive a substantial portion of our current and expected future revenues from USG procurement of AV7909. As AV7909 is a product development candidate, there is a higher level of risk that we may encounter challenges causing delays or an inability to deliver AV7909 than with BioThrax, which may have a material effect on our ability to generate and recognize revenue.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The success of our business and our future operating results are significantly dependent on anticipated funding for the procurement of our anthrax vaccines and the terms of such procurement by the USG, including the price per dose, the number of doses and the timing of deliveries. We have no certainty that funding will be made available for the procurement of our anthrax vaccines. If priorities for the SNS change generally, or as a result of the conclusion of the USG&#8217;s audit of the SNS, or with respect to the level of procurement of our anthrax vaccines, funding to procure future doses of AV7909 or BioThrax may be delayed, limited or not available, BARDA may never complete the anticipated full transition to stockpiling AV7909 in support of anthrax preparedness, and our future business, financial condition, operating results and cash flows could be materially harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we currently derive a substantial portion of our revenues from sales of ACAM2000 to the USG. If priorities for the SNS change with respect to ACAM2000 or the USG decides not to exercise additional options under our ACAM2000 contract, our future business, financial condition, operating results and cash flows could be materially harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not receive eventual FDA licensure of AV7909 in a timely manner or at all. Delays in our ability to achieve a favorable outcome from the FDA could prevent us from realizing the full potential value of our BARDA contract for the advanced development and procurement of AV7909.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In collaboration with us, the CDC filed with the FDA a pre-Emergency Use Authorization (EUA) submission package related to AV7909, which enables FDA review of data in anticipation of a request for an EUA. Following this submission, BARDA began procuring AV7909, exercising its first contract option in July 2019 to procure 10 million doses of AV7909, its second contract option in July 2020 and, most recently, funding another procurement commitment in October 2021 for inclusion of additional doses into the SNS in support of anthrax preparedness.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also recently completed the rolling submission of a BLA filing with the FDA related to AV7909 and the application has been accepted for review. There can be no guarantee that our submission will be approved by the FDA. The FDA may decide that our initial data are </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">insufficient and require additional pre-clinical, clinical or other studies. If we are unsuccessful in obtaining FDA licensure, in a timely manner or at all, we may not be able to realize the full potential value of the contract, which could have a material adverse effect on our future business, financial condition, operating results and cash flows. Furthermore, prior to FDA licensure, if we obtain an EUA, the EUA could be terminated if the emergency determination underlying the EUA terminates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our USG procurement and development contracts require ongoing funding decisions by the USG. Simultaneous reduction or discontinuation of funding of these contracts could cause our business, financial condition, operating results and cash flows to suffer materially.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USG is the principal customer for our MCMs and the primary source of funds for the development of most of our product candidates in our development pipeline, most notably our AV7909 procured product candidate. We anticipate that the USG will also be a principal customer for those MCMs that we successfully develop within our existing product development pipeline, as well as those we acquire in the future. Additionally, a significant portion of our revenue comes from USG development contracts and grants. Over its lifetime, a USG procurement or development program may be implemented through the award of many different individual contracts and subcontracts. The funding for such government programs is subject to Congressional appropriations, generally made on a fiscal year basis, even for programs designed to continue for several years. For example, procurement of AV7909 to be supplied under our development and procurement contract with BARDA is subject to the availability of funding, mostly from annual appropriations. These appropriations can be subject to political considerations, changes in priorities due to global pandemics, the results of elections and stringent budgetary constraints.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our government-funded development contracts typically give the USG the right, exercisable in its sole discretion, to extend these contracts for successive option periods following a base period of performance. The value of the services to be performed during these option periods may constitute the majority of the total value of the underlying contract. For example, the September 2016 contract award from BARDA for the development and delivery to the SNS of AV7909 for post-exposure prophylaxis of anthrax disease consists of a five-year base period of performance. The contract award also includes options for the delivery of additional doses of AV7909 to the SNS and options for an additional clinical study and post-marketing commitments. This contract was extended in September 2021 through 2025, and </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provides for additional procurement of AV7909 for the SNS over 18 months. If levels of government expenditures and authorizations for public health countermeasure preparedness decrease or shift to programs in areas where we do not offer products or are not developing product candidates, or if the USG otherwise declines to exercise its options under our existing contracts, our revenues would suffer, as well as our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">There can be no assurance that we will be able to secure follow-on procurement contracts with the USG upon the expiration of any of our product procurement contracts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant portion of our revenue is substantially dependent upon product procurement contracts with the USG and foreign governments for our MCMs. Upon the expiration of a procurement contract, we may not be able to negotiate a follow-on procurement contract for the particular product for a similar product volume, period of performance, pricing or other terms, or at all. The inability to secure a similar or increased procurement contract could materially affect our revenues and our business, financial condition, operating results and cash flows could be harmed. For example, in November 2019, the BARDA procurement contract for raxibacumab that we acquired in our 2017 acquisition of the product from GlaxoSmithKline LLC was completed. We intend to negotiate a follow-on procurement contract for raxibacumab and other follow-on procurement contracts for most of our MCMs upon the expiration of a related procurement contract, but there can be no assurance that we will be successful obtaining any follow-on contracts. Even if we are successful in negotiating a follow-on procurement contract, it may be for a lower product volume, over a shorter period of performance or be on less favorable pricing or other terms. An inability to secure follow-on procurement contracts for our products or procured product candidates could materially and adversely affect our revenues, and our business, financial condition, operating results and cash flows could be harmed.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The government contracting process is typically a competitive bidding process and involves unique risks and requirements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business involves government contracts and grants, which may be awarded through competitive bidding. Competitive bidding for government contracts presents many risks and requirements, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the possibility that we may be ineligible to respond to a request for proposal;</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the commitment of substantial time and attention of management and key employees to the preparation of bids and proposals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the need to accurately estimate the resources and cost structure that will be required to perform any contract that we might be awarded;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the submission by third parties of protests to our responses to requests for proposal that could result in delays or withdrawals of those requests for proposal; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">in the event our competitors protest or challenge contract or grant awards made to us through competitive bidding, the potential that we may incur expenses or delays, and that any such protest or challenge could result in the resubmission of bids based on modified specifications, or in the termination, reduction or modification of the awarded contract.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The USG may choose not to award us future contracts for either the development of our new product candidates or for the procurement of our existing MCM products and may instead award such contracts to our competitors. If we are unable to secure particular contracts, we may not be able to operate in the market for products that are provided under those contracts. Additionally, if we are unable to consistently win new contract awards over an extended period, or if we fail to anticipate all of the costs or resources that we will be required to secure and, if applicable, perform under such contract awards, our growth strategy and our business, financial condition and operating results and cash flows could be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The amount we are paid under our fixed price government procurement contracts is based on estimates we have made of the time, resources and expenses required for us to perform under those contracts. If our actual costs exceed our estimates, we may not be able to earn an adequate return or may incur a loss under these contracts, which could harm our operating results and materially reduce our net income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current procurement contracts with HHS and DoD are generally fixed price contracts. We expect that additional future procurement contracts we successfully secure with the USG would likely also be fixed price contracts. Under a fixed price contract, we are required to deliver our products at a fixed price regardless of the actual costs we incur. Estimating costs that are related to performance in accordance with contract specifications is difficult, particularly where the period of performance is over several years and when factoring in higher levels of inflation we are </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">currently experiencing. Our failure to anticipate technical problems, estimate costs accurately or control costs during performance of a fixed price contract could reduce the profitability of such a contract or cause a loss, which could harm our operating results and materially reduce our net income.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Unfavorable provisions in government contracts, some of which may be customary, may subject our business to material limitations, restrictions and uncertainties and may have a material adverse impact on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government contracts customarily contain provisions that give the USG substantial rights and remedies, many of which are not typically found in commercial contracts, including provisions that allow the USG to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">terminate existing contracts, in whole or in part, for any or no reason;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">unilaterally reduce or modify contracts or subcontracts;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">decline, in whole or in part, to exercise an option to purchase product under a procurement contract or to fund additional development under a development contract;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">decline to renew a procurement contract;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">claim certain rights to facilities or to products, including intellectual property, developed under the contract;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">require repayment of contract funds spent on construction of facilities in the event of contract default;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">take actions that result in a longer development timeline than expected;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">direct the course of a development program in a manner not chosen by the government contractor;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">suspend or debar the contractor from doing business with the government or a specific government agency;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">pursue civil or criminal remedies under acts such as the False Claims Act and False Statements Act; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">control or prohibit the export of products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, government contracts contain provisions permitting unilateral termination or modification, in whole or in part, at the USG&#8217;s convenience. Under general principles of government contracting law, if the </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">USG terminates a contract for convenience, the government contractor may recover only its incurred or committed costs, settlement expenses and profit on work completed prior to the termination. If the USG terminates a contract for default, the government contractor is entitled to recover costs incurred and associated profits on accepted items only and may be liable for excess costs incurred by the government in procuring undelivered items from another source. All of our development and procurement contracts with the USG are terminable at the USG's convenience with these potential consequences.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our USG contracts grant the USG the right to use technologies developed by us under the government contract or the right to share data related to our technologies, for or on behalf of the USG. Under our USG contracts, we may not be able to limit third parties, including our competitors, from accessing certain of these technology or data rights, including intellectual property, in providing products and services to the USG.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MANUFACTURING RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An inability to maintain manufacturing compliance at our manufacturing facilities could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA conducts periodic inspections of our manufacturing facilities for compliance with cGMP requirements relating to quality control. The failure to maintain compliance with such standards at our manufacturing facilities has hindered and could continue to hinder our ability to continue manufacturing for CDMO customers, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disruption at, damage to or destruction of our manufacturing facilities could impede our ability to manufacture anthrax vaccines, ACAM2000 or our other products, as well as impact the delivery of CDMO services, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any interruptions in our manufacturing operations could result in our inability to produce products and product candidates for delivery to satisfy the demands of our customers in a timely manner, which would reduce our revenues and materially harm our business, financial condition, operating results and cash flows. A number of factors could cause interruptions, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">equipment malfunctions or failures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">technology malfunctions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">cyber-attacks;</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">ongoing supply chain interruptions from the COVID-19 pandemic, including lower available plasma levels caused by the pandemic (which has the potential to impact our plasma-based products);</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">work stoppages or slowdowns due to the potential resurgence of new COVID-19 variants;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">civil unrest and protests, including by animal rights activists;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">injunctions;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">damage to or destruction of one or more facilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">FDA facility inspection findings/recommendations; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">product contamination or tampering.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Providers of MCMs could be subject to an increased risk of terrorist activities. The USG has designated both our Lansing, Michigan and our Bayview bulk manufacturing facility in Baltimore, Maryland as facilities requiring additional security. Although we continually evaluate and update security measures, there can be no assurance that any additional security measures would protect these facilities from terrorist efforts determined to disrupt our manufacturing activities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The factors listed above could also cause disruptions at our other facilities. We do not have any redundant manufacturing facilities for any of our products. Accordingly, any damage to, or disruption or destruction of one or more of our facilities could impede our ability to manufacture our products, our product candidates and our ability to provide manufacturing and development services for external customers, result in losses and delays, including delays in the performance of our contractual obligations or delays in our clinical trials, any of which could be costly to us and materially harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Problems may arise during the production of our products and product candidates, as well as those we produce for our CDMO customers, due to the complexity of the processes involved in their development, manufacturing and shipment. Significant delays in product manufacturing or development and our ability to ramp up production to meet the needs of our customers could cause delays in recognizing revenues, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The majority of our products and product candidates are biologics. Manufacturing biologics, especially in large quantities, is complex. The products </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">must be made consistently and in compliance with a clearly-defined manufacturing process. Problems during manufacturing may arise for a variety of reasons, including problems with raw materials, equipment malfunction and failure to follow specific protocols and procedures. Slight deviations anywhere in the manufacturing process, including obtaining materials, maintaining master seed or cell banks and preventing genetic drift, seed or cell growth, fermentation, contamination including from particulates among other things, filtration, filling, labeling, packaging, storage and shipping, potency and stability issues and other quality control testing, may result in lot failures or manufacturing shut-downs, delays in the release of lots, product recalls, spoilage or regulatory action. Such deviations may require us to revise manufacturing processes or change manufacturers. Additionally, as our equipment ages, it will need to be replaced, which has the potential to result in similar consequences. Success rates can also vary dramatically at different stages of the manufacturing process, which can reduce yields and increase costs. From time to time, we may experience deviations in the manufacturing process that may take significant time and resources to resolve and, if unresolved, may affect manufacturing output and could cause us to fail to satisfy customer orders or contractual commitments, lead to a termination of one or more of our contracts, lead to delays in our clinical trials, result in litigation or regulatory action against us, including the issuance of Forms FDA 483, warning letters and other restrictions on the marketing or manufacturing of a product, or cause the FDA to cease releasing product until the deviations are explained and corrected, any of which could be costly to us, damage our reputation and negatively impact our business. For example, in April 2021, we temporarily stopped manufacturing bulk drug substance material for Johnson &amp; Johnson&#8217;s COVID-19 vaccine at our Baltimore Bayview facility after issues were identified in a viral vaccine drug substance batch.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, if changes are made to the manufacturing process, we may be required to provide the FDA with pre-clinical and clinical data showing the comparable identity, strength, quality, purity or potency of any impacted products before and after the changes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are contractually required to ship our biologic products at a prescribed temperature range and variations from that temperature range could result in loss of product and could significantly and adversely impact our revenues, which would harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may not be able to ramp up our manufacturing processes to meet the rapidly changing demand or specifications of our customers on the desired timeframe, if at all. For example, we have not </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">previously had to ramp our organization for a commercial launch of any product or manufacture any product for our CDMO customers at the pace required to address treatments related to COVID-19 and doing so in a pandemic environment with an urgent, critical global need creates unique manufacturing challenges, challenges related to distribution channels, and the need to establish teams of people with the relevant skills.   Our inability to ramp up manufacturing to meet the demand or specifications of our customers or the inability to timely obtain regulatory authorization to produce the products or product candidates of our customers could also harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our products and product candidates procured by the USG and other customers require us to perform tests for and meet certain potency and lot release standards prescribed by the FDA and other agencies, which may not be met on a timely basis or at all.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our products and product candidates procured by the USG and other customers require us to perform tests for and meet certain potency and lot release standards prescribed by the FDA and other agencies, which may not be met on a timely basis or at all. We are unable to sell any products and product candidates that fail to satisfy such testing specifications. For example, we must provide the FDA with the results of certain tests, including potency tests, before certain lots are released for sale. Potency testing of each applicable lot is performed against qualified control lots that we maintain. We continually monitor the status of such reference lots for FDA compliance and periodically produce and qualify a new reference lot to replace the existing reference lot. If we are unable to satisfy USG requirements for the release of our products or product candidates, our ability to supply such products and product candidates to authorized buyers would be impaired until such time as we become able to meet such requirements, which could materially harm our future business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our operations, including our use of hazardous materials, chemicals, bacteria and viruses, require us to comply with regulatory requirements and expose us to significant potential liabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations involve the use of hazardous materials, including chemicals, bacteria and viruses, and may produce dangerous waste products. Accordingly, we, along with the third parties that conduct clinical trials and manufacture our products and product candidates on our behalf, are subject to federal, state, local and foreign laws and regulations that govern the use, manufacture, distribution, storage, handling, exposure, disposal and recordkeeping with respect to these materials. Under the Federal Select </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agent Program, pursuant to the Public Health Security and Bioterrorism Preparedness and Response Act, we are required to register with and be inspected by the CDC and the Animal and Plant Health Inspection Service if we have in our possession, or if we use or transfer, select biological agents or toxins that could pose a threat to public health and safety, to animal or plant health or to animal or plant products. This legislation requires stringent safeguards and security measures for these select agents and toxins, including controlled access and the screening of entities and personnel and establishes a comprehensive national database of registered entities. We are also subject to a variety of environmental and occupational health and safety laws. Compliance with current or future laws and regulations in this area can require significant costs and we could be subject to substantial fines and penalties in the event of noncompliance. In addition, the risk of contamination or injury from these materials cannot be completely eliminated. In such event, we could be held liable for substantial civil damages or costs associated with the cleanup of hazardous materials. From time to time, we have been involved in remediation activities and may be so involved in the future. Any related cost or liability might not be fully covered by insurance, could exceed our resources and could have a material adverse effect on our business, financial condition, operating results and cash flows. In addition to complying with environmental and occupational health and safety laws, we must comply with special regulations relating to biosafety administered by the CDC, HHS, U.S. Department of Agriculture and the DoD, as well as regulatory authorities in Canada.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRODUCT DEVELOPMENT AND COMMERCIALIZATION RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 product candidates we are working on for our CDMO customers may not be safe or effective and even if they are, we may be unable to manufacture sufficient quantities to meet demand.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are providing CDMO services for the development and/or manufacture of multiple therapeutic product candidates. There can be no assurance that any of these product candidates will be safe or effective. There can also be no assurance that any of these product candidates will be authorized for emergency use or approved by the FDA or any other health regulatory authority. Even if these product candidates are safe and/or effective and receive authorization or approval by a health regulatory authority, the manufacturing processes for our CDMO COVID-19 programs are under development and are complex. There can be no assurance that we will be able to produce any significant quantity of these product candidates in a timely basis or at all, or negotiate further commitments under our existing </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO contracts, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our growth depends on our success in developing and commercializing our product candidates. If we are unable to commercialize these product candidates, or experience significant delays or unanticipated costs in doing so, our business would be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have invested significant efforts and financial resources in the development of our vaccines, therapeutics and medical device product candidates and the acquisition of additional product candidates. In addition to our product sales, our ability to generate revenue is dependent on a number of factors, including the success of our development programs, the USG's interest in providing development funding for or procuring certain of our product candidates, and the commercial viability of our acquired or developed product candidates. The commercial success of our product candidates can depend on many factors, including accomplishing the following in an economical manner:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">successful development, formulation and cGMP scale-up of manufacturing that meets FDA or other foreign regulatory requirements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">successful program partnering;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">successful completion of clinical or non-clinical development;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">receipt of marketing approvals from the FDA and equivalent foreign regulatory authorities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">establishment of commercial manufacturing processes and product supply arrangements;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">training of a commercial sales force for the product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">successful registration and maintenance of relevant patent and/or other proprietary protection;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">competitive pricing and market access; and </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">acceptance of the product by potential government and other customers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical trials of product candidates are expensive and time-consuming, and their outcome is uncertain. We must invest substantial amounts of time and financial resources in these trials, which may not yield viable products. Failure to obtain regulatory approval for product candidates, particularly in the United States, could materially and adversely affect our financial </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">resources, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before obtaining regulatory approval of our product candidates, we and our collaborative partners, where applicable, must conduct pre-clinical studies and clinical trials to establish proof of concept and demonstrate the safety and efficacy of our product candidates. Pre-clinical and clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to outcome. Success in pre-clinical testing and early clinical trials does not ensure that later clinical trials will be successful, and interim results of such trials do not necessarily predict final results. An unexpected result in one or more of our clinical trials can occur at any stage of testing.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-clinical and clinical testing for certain of our MCM product candidates may face additional difficulties and uncertainties because they cannot ethically or feasibly be tested in human subjects. We therefore expect to rely on the Animal Rule to obtain regulatory approval for some of our MCM product candidates. The Animal Rule permits, for certain limited diseases and circumstances, the use of animal efficacy studies, together with human clinical safety and immunogenicity trials, to support an application for marketing approval. For a product approved under the Animal Rule, certain additional post-marketing requirements apply. For example, to the extent feasible and ethical, applicants must conduct post-marketing studies, such as field studies, to verify and describe the drug's clinical benefit and to assess its safety when used as indicated. It is possible that results from the animal efficacy studies used to support approval under the Animal Rule may not be predictive of the actual efficacy of our product candidates in humans.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to FDA approval of certain MCM product candidates, the Secretary of HHS can contract to purchase MCMs for the SNS under Project BioShield under specific circumstances. Under PAHPRA, the USG may also, at its discretion, purchase critical biodefense products for the SNS prior to FDA approval after the filing of a pre-EUA application with the FDA.  If our MCM product candidates are not procured or funded under Project BioShield, or do not qualify for EUA, they generally will have to be fully approved by the FDA through traditional regulatory mechanisms prior to sale and distribution in the United States.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience unforeseen events or issues during, or as a result of, pre-clinical testing, clinical trials or animal efficacy studies. These issues and events, which could delay or prevent our ability to receive regulatory approval for a product candidate, include, among others:</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our inability to manufacture sufficient quantities for use in trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the unavailability or variability in the number and types of subjects for each study;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">safety issues or inconclusive or incomplete testing, trial or study results;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">drug immunogenicity;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">lack of efficacy of product candidates during the trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">government or regulatory restrictions or delays; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">greater than anticipated costs of trials.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We continue to evaluate our product development strategy and, as a result, may modify our strategy in the future. In this regard, we may, from time to time, focus our product development efforts on different product candidates or may delay or halt the development of various product candidates. We may change or refocus our existing product development, commercialization and manufacturing activities based on government funding decisions. This could require changes in our facilities and our personnel. Any product development changes that we implement may not be successful. In particular, we may fail to select or capitalize on the most scientifically, clinically or commercially promising or profitable product candidates or choose candidates for which government development funds are not available. Our decisions to allocate our R&amp;D, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of viable commercial products and may divert resources from better business opportunities. Similarly, our decisions to delay or terminate product development programs may also prove to be incorrect and could cause us to miss valuable opportunities.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GLOBAL PANDEMIC RISK</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The COVID-19 coronavirus pandemic could have a material adverse impact on our business, results of operations and financial performance.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business, operations and financial condition and results have been and may continue to be impacted by the COVID-19 pandemic to varying degrees. The pandemic has presented a number of risks and challenges for our business, including, among others, prior government-mandated work-from-home or shelter-in-place orders; manufacturing </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">disruptions and delays, including at our Baltimore Bayview facility, supply chain interruptions or delays, including challenges related to reliance on third-party suppliers; disruptions to pipeline development and clinical trials and decreased product demand for our travel health vaccines due to the significant reduction in international travel. Additional travel restrictions and other governmental measures may result in further disruptions or continued delays in delivery of supplies by our third-party contractors and suppliers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also face uncertainties related to our efforts and those of our collaborative partners to develop a potential treatment or vaccine for COVID-19, including uncertainties related to pre-clinical or clinical trials, the risk that such development programs may not be successful, commercially viable, or that EUA or regulatory approval will not be received from regulatory authorities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the trading price of our common stock, and that of other biopharmaceutical companies, has been highly volatile due to the COVID-19 pandemic, especially as a result of investor concerns and uncertainty related to the impact of the pandemic on the economies of countries worldwide. These broad market and industry fluctuations, as well as general economic, political and market conditions, may negatively impact the market price of shares of our common stock.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic continues to rapidly evolve. The extent to which the pandemic and new variants of COVID-19 may further negatively impact our business, affect the supply chain, disrupt key clinical trials, divert government funding away from our primary procured products and product candidates due to changes in government priorities and potential delays in the delivery of products to our customers will depend on future developments, which are highly uncertain. The ultimate geographic spread of COVID-19 and new variants of the disease, the duration of the pandemic, further travel restrictions and social distancing in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the disease cannot be predicted with certainty.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The continually evolving nature of the COVID-19 pandemic and the resulting public health response, including the changing demand for various COVID-19 vaccines and treatments from both patients and governments around the world, may affect the demand for COVID-19 product candidates manufactured by our CDMO business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Through our CDMO business, we provide services for a variety of product candidates intended for the prevention or treatment of COVID-19 and its symptoms </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and effects. These services include product development and drug product fill and finish services.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of the COVID-19-related product candidates we develop and manufacture have yet to receive full regulatory approval from any regulatory authority, although some are being offered and sold pursuant to an EUA from the FDA or the equivalent authorization from non-U.S. regulatory authorities. Should the facilities producing these product candidates be denied an EUA or one or more of these COVID-19-related product candidates be denied an EUA (or equivalent) or be denied full regulatory approval by the FDA or other major non-U.S. regulatory authority, the demand for such product candidates could decrease significantly and therefore decrease customer orders for additional CDMO services for such product candidates. Additionally, the need for continued manufacture and supply of vaccines (including potential &#8220;booster&#8221; doses) and therapies to address the COVID-19 pandemic, including new and developing variants of COVID-19, is highly uncertain and subject to various political, economic, regulatory and other factors that are outside of our control. For example, Johnson and Johnson recently suspended its COVID-19 vaccine sales guidance due to global supply surplus and demand uncertainty. Should the United States or other major regions worldwide determine that additional manufacturing of COVID-19 vaccines, boosters, or therapies is no longer necessary, or necessary to a lesser degree, it could adversely affect our revenue and financial condition and our ability to grow our CDMO business in the near term. In addition, highly-public political and social debates relating to the need for, efficacy of, or side effects related to one or more specific COVID-19 vaccines could contribute to changes in public perception of COVID-19 vaccines manufactured by us, which could decrease demand for a COVID-19 related product candidate we develop or manufacture (in whole or in part).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The impact of working remotely may increase our cybersecurity risk profile and potentially impact productivity if there is a resurgence in COVID-19 variants.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One of the significant areas of impact of COVID-19 on our business has been a shift in company policy to hybrid work arrangements. We have recently implemented a hybrid work model through which our administrative workforce may choose a mixture of in-office and remote work, continue to work entirely on a remote basis or return to the office full time. Although we have allowed all employees to return to the office, a significant number of administrative employees have chosen to continue to work remotely either on a part-time or full-time basis. Working remotely could increase our cybersecurity risk, create data accessibility concerns, and make us more susceptible to </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">communication disruptions, any of which could adversely impact our business operations. In addition, our on-site staff conducting R&amp;D may not be able to access our laboratories if government-mandated lockdowns return, due to a resurgence in COVID-19 variants and new state and local restrictions.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REGULATORY AND COMPLIANCE RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">There are a number of complex laws and regulations that pertain to government contracts and compliance with those laws and regulations require significant time and cost, which could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a manufacturer and supplier of MCMs to the USG addressing PHTs, we must comply with numerous laws and regulations relating to the procurement, formation, administration and performance of government contracts. These laws and regulations govern how we transact business with our government clients and, in some instances, impose additional costs and related obligations on our business operations. Our status as a USG contractor means that we are subject to various statutes and regulations, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the Federal Acquisition Regulation (FAR) and agency-specific regulations supplemental to FAR, which comprehensively regulate the award, formation, administration and performance of government contracts;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the Defense Federal Acquisition Regulations (DFARs) and agency-specific regulations supplemental to DFARs, which comprehensively regulate the award, formation, administration and performance of DoD government contracts;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the Department of State Acquisition Regulation (DOSAR) which regulates the relationship between a Department of State organization and a contractor or potential contractor;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">business ethics and public integrity obligations, which govern conflicts of interest and the hiring of former government employees, restrict the granting of gratuities and funding of lobbying activities and incorporate other requirements such as the Anti-Kickback Act, the Procurement Integrity Act, the False Claims Act and the Foreign Corrupt Practices Act;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">export and import control laws and regulations, including but not limited to ITAR (International Traffic in Arms Regulations); and</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">laws, regulations and executive orders restricting the use and dissemination of information classified for national security purposes and the exportation of certain products and technical data.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be subject to government investigations of compliance with government acquisition regulations. USG agencies routinely audit and investigate government contractors for compliance with applicable laws and standards. Even though we take significant precautions to identify, prevent and deter fraud, misconduct and non-compliance, we face the risk that our personnel or outside partners may engage in misconduct, fraud or improper activities. If we are audited or investigated and such audit or investigation were to uncover improper or illegal activities, we could be subject to civil and criminal fines and penalties, administrative sanctions, including suspension or debarment from government contracting, and suffer significant reputational harm. The loss of our status as an eligible government contractor or significant fines or penalties associated with contract non-compliance or resulting from investigations could have a material adverse effect on our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our long-term success depends, in part, upon our ability to develop, receive regulatory approval for and commercialize product candidates we develop or acquire and, if we are not successful, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with them are subject to extensive FDA regulation and oversight, as well as oversight by other regulatory agencies in the United States and by comparable authorities in other countries. This includes, but is not limited to, laws and regulations governing product development, including testing, manufacturing, record keeping, storage and approval, as well as advertising and promotion. In limited circumstances, governments may procure products that have not obtained regulatory approval. In all other circumstances, failure to obtain regulatory approval for a product candidate will prevent us from selling and commercializing the product candidate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, to obtain approval from the FDA to market and sell any of our future drug, biologic, or vaccine products, we will be required to submit an NDA or BLA to the FDA. Ordinarily, the FDA requires a company to support an NDA or BLA with substantial evidence of the product candidate&#8217;s effectiveness, safety, purity and potency in treating the targeted indication based on data derived from adequate and well-controlled clinical trials, including Phase 3 trials conducted in patients with the disease or condition being targeted.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">However, many of our MCM product candidates, for example, may take advantage of a different regulatory approval pathway under the FDA&#8217;s &#8220;Animal Rule.&#8221; Under the Animal Rule, efficacy must be demonstrated, in part, by utilizing animal models rather than testing in humans. We cannot guarantee that the FDA will permit us to proceed with licensure of any of our MCM product candidates under the Animal Rule. Even if we are able to proceed under the Animal Rule, product development can take a considerable amount of time, and the FDA may decide that our data are insufficient to support approval and require additional pre-clinical, clinical or other studies, refuse to approve our products, or place restrictions on our ability to commercialize those products. Furthermore, products approved under the Animal Rule are subject to certain additional post-marketing requirements. We cannot guarantee that we will be able to meet this regulatory requirement even if one or more of our product candidates are approved under the Animal Rule.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining these regulatory approvals is expensive, often takes many years if approval is obtained at all, and can vary substantially based upon the type, complexity and novelty of the product candidate involved. Changes in the regulatory approval process may cause delays in the approval or rejection of an application. There is a high rate of failure inherent in this process, and potential products that appear promising at early stages of development may fail for a number of reasons, and positive results from pre-clinical studies may not be predictive of similar results in human clinical trials. Similarly, promising results from earlier clinical trials of a product candidate may not be replicated in later clinical trials.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are many other difficulties and uncertainties inherent in pharmaceutical R&amp;D that could significantly delay or otherwise materially delay our ability to develop future product candidates, mostly related to clinical trials.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to successfully develop future product candidates may materially adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA or BLA is submitted, the FDA has substantial discretion and may refuse to accept any application or may decide that our data are insufficient to support approval and require additional pre-clinical, clinical or other studies.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unapproved and investigational stage products are also subject to the FDA's laws and regulations governing advertising and promotion, which prohibit the promotion of both unapproved products and unapproved uses of approved products. There is some risk that the FDA could conclude that our communications relating to unapproved products or </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">unapproved uses of approved products constitute the promotion of an unapproved product or product use in violation of FDA laws and regulations.&#160;There is also a risk that a regulatory authority in another country could take a similar position under that country's laws and regulations and conclude that we have violated the laws and regulations related to product development, approval, or promotion in that country.&#160;Therefore, there is a risk that we could be subject to enforcement actions if found to be in violation of such laws or regulations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Even if we or our collaborators obtain marketing approvals for our product candidates, the conditions of approvals and ongoing regulation of our products may limit how we manufacture, market and sell our products, which could materially impair our ability to generate revenue.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once approval has been granted, an approved product and its manufacturer and marketer remain subject to ongoing review and extensive regulation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our collaborators must therefore comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Promotional communications with respect to FDA-regulated products are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved labeling. Thus, we will not be able to sell any products we develop for indications or uses for which they are not approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we and our collaborators are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for our products withdrawn by regulatory authorities and our ability to market and sell any products could be limited, which could adversely affect our ability to achieve or sustain profitability. Further, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we or our collaborators obtain marketing approval could be subject to restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with our product candidates, when and if any of them are approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate for which we or our collaborators obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to continual requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">registration and listing requirements, cGMP requirements relating to quality control and manufacturing, quality assurance and corresponding maintenance of records and documents, and requirements regarding the distribution of samples to physicians and recordkeeping. Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or to the conditions of approval, or contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the medicine.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain of our products are subject to post marketing requirements (PMRs), which we are required to conduct, and post marketing commitments (PMCs), which we have agreed to conduct. The FDA has the authority to take action against sponsors who fail to meet the obligations of a PMR, including civil monetary penalties and/or misbranding charges.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and other agencies, including the U.S. Department of Justice (DOJ) and the HHS Office of Inspector General (OIG), closely regulate and monitor the pre-approval and post-approval marketing and promotion of products to ensure that they are marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA, DOJ, and OIG impose stringent restrictions on manufacturers&#8217; communications regarding unapproved products and unapproved uses of approved products and if we market unapproved products or market our approved products for unapproved indications, we may be subject to enforcement action. Violations of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturing partners or manufacturing processes, or failure to comply with regulatory requirements, may result in various penalties and sanctions. For all FDA-regulated products, if the FDA finds that a manufacturer has failed to comply with applicable laws and regulations, or that a product is ineffective or poses an unreasonable health risk, it can institute or seek a wide variety of enforcement actions and remedies, including but not limited to:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">restrictions on such products, manufacturers or manufacturing processes;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">restrictions on the labeling or marketing of a product;</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">restrictions on distribution or use of a product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">warning letters or untitled letters;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">refusal to approve pending applications or supplements to approved applications that are submitted;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fines, restitution or disgorgement of profits or revenues; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">suspension or withdrawal of marketing approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">refusal to permit the import or export of our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">product seizure; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compliance with EU requirements regarding safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population, can also result in significant financial penalties. Similarly, failure to comply with the EU and other legal and regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions. Non-compliance with similar requirements in other foreign jurisdictions can also result in enforcement actions and significant penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the health care system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that current laws, as well as other health care reform measures that may be adopted in the future, may result in more rigorous coverage criteria and additional downward pressure on the price that we, or any collaborators, may receive for any approved products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Affordability Reconciliation Act (collectively, the ACA), passed in 2010 substantially changed the way health </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">care is financed by both governmental and private insurers, and significantly impacted the U.S. biopharmaceutical industry. However, some provisions of the ACA have yet to be fully implemented and certain provisions have been subject to legal and political challenges, as well as efforts by the last Presidential administration to repeal or replace certain aspects of the ACA. On January 28, 2021, however, the President issued an executive order to strengthen implementation of the ACA. Concurrently, Congress considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, it has enacted laws that modify certain provisions of the ACA, such as removing penalties as of January 1, 2019 for not complying with the ACA&#8217;s individual mandate to carry health insurance, delaying the implementation of certain ACA-mandated fees, and increasing the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D. On June 17, 2021, the U.S. Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court&#8217;s decision, the current Presidential administration issued an executive order initiating a special enrollment period during 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare. It is unclear how healthcare reform measures enacted by Congress or implemented by the current Presidential administration or other challenges to the ACA, if any, will impact the ACA or our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted that may negatively impact us. On August 2, 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of up to 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031 under the Coronavirus Aid, Relief and Economic Security Act, or CARES Act. These Medicare sequester reductions have been suspended through the end of March 2022. From April 2022 through June 2022 a 1% sequester cut will be in effect, with the full 2% cut resuming thereafter.</span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, there has been recent heightened federal governmental scrutiny over the manner in which manufacturers set prices for their marketed products. For example, there have been several recent Congressional inquiries and has been proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, the last Presidential administration released a &#8220;Blueprint&#8221;, or plan, to lower drug prices and reduce out of pocket costs of drugs that contains additional proposals to increase drug manufacturer competition, increase the negotiating power of certain federal healthcare programs, incentivize manufacturers to lower the list price of their products, and reduce the out-of-pocket costs of drug products paid by consumers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program, or SIP, to import certain prescription drugs from Canada into the United States. The final rule is currently the subject of ongoing litigation, but at least six states (Vermont, Colorado, Florida, Maine, New Mexico, and New Hampshire) have passed laws allowing for the importation of drugs from Canada with the intent of developing SIPs for review and approval by the FDA.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on July 9, 2021, the President signed Executive Order 14063, which focuses on, among other things, the price of pharmaceuticals. The Order directs HHS to create a plan within 45 days to combat "excessive pricing of prescription pharmaceuticals and enhance domestic pharmaceutical supply chains, to reduce the prices paid by the federal government for such pharmaceuticals, and to address the recurrent problem of price gouging." On September 9, 2021, HHS released its plan to reduce pharmaceutical prices. The key features of that plan are to: (a) make pharmaceutical prices more affordable and equitable for all consumers; (b) improve and promote competition throughout the prescription pharmaceutical industry; and (c) foster scientific innovation to promote better healthcare and improve health by supporting public and private research and making sure that market incentives promote discovery of valuable and accessible new treatments.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">countries and bulk purchasing. A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals. In addition, regional health care authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal health care reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for health care products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we fail to comply with foreign, federal, state and local health care laws, including fraud and abuse and health information privacy and security laws, and antitrust laws, we could face substantial&#160;penalties and our business, results of operations, financial condition and prospects could be adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, certain of our products are reimbursed under federal and state health care programs such as Medicaid, Medicare, TriCare, and/or state pharmaceutical assistance programs. Many foreign countries have similar laws. Federal and state laws designed to prevent fraud and abuse under these programs prohibit pharmaceutical companies from offering valuable items or services to customers or potential customers to induce them to buy, prescribe, or recommend our product (the so-called &#8220;anti-kickback&#8221; laws). Exceptions are provided for discounts and certain other arrangements if specified requirements are met. Other federal and state laws, and similar foreign laws, not only prohibit us from submitting any false information to government reimbursement programs but also prohibit us, our employees, or any third party acting on our behalf from doing anything to cause, assist, or encourage our customers to submit false claims for payment to these programs. We are also subject to various federal, state and foreign antitrust and competition laws that prohibit certain activities that may have an impact against potential competitors. Violations of the various fraud and abuse and antitrust laws may result in severe penalties against the responsible employees and us, including jail sentences, large fines, and the exclusion of our products from reimbursement under federal and state programs. Some of the laws that may affect our ability to operate include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the federal Anti-Kickback Statute makes it illegal for any person or entity, including a </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescription drug manufacturer (or a party acting on its behalf) to knowingly and willfully solicit, receive, offer or pay remuneration, directly or indirectly, overtly or covertly, to induce, or in return for, either the referral of an individual, or the purchase, lease, prescribing or recommendation of an item, good, facility or service reimbursable by a federally funded health care program, such as the Medicare or Medicaid program. The term &#8220;remuneration&#8221; has been interpreted broadly and may constrain our marketing practices, educational programs, pricing policies and relationships with health care providers or other entities, among other activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the federal False Claims Act imposes criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal health care program or making a false statement or record material to payment of a false claim or avoiding, decreasing or concealing an obligation to pay money to the federal government, with potential liability, including mandatory treble damages and significant per-claim penalties.</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the U.S. federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any health care benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statement, in connection with the delivery of, or payment for, health care benefits, items or services. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">HIPAA, as amended by HITECH, and their respective implementing regulations mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common health care transactions, as well as standards relating to the privacy, security and transmission of individually identifiable health information, </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA's security standards directly applicable to &#8220;business associates,&#8221; or independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service for or on behalf of a covered entity;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the Physician Payments Sunshine Act and its implementing regulations require certain manufacturers of drugs, biologics, medical devices and medical supplies for which payment is available under Medicare, Medicaid or the Centers for Medicare &amp; Medicaid Services (CMS) to report certain payments and transfers of value made to U.S. physicians, other healthcare providers and teaching hospitals, and ownership or investment interests held by physicians, other healthcare providers and their immediate family members; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payor, including commercial insurers; state and foreign laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts; state, local and foreign laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, obtain pharmaceutical agent licensure, and/or otherwise restrict payments that may be made to health care providers and entities; and state, local and foreign laws that require drug manufacturers to report information related to payments and other transfers of value to health care providers or entities, or marketing expenditures.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available under the federal Anti-Kickback Statute, it is possible that some of our business activities could be subject to challenges under one or more of such laws. Moreover, recent health care reform legislation has strengthened these laws. For example, the ACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal health care fraud statutes, so that a person or entity no longer needs to have actual </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">knowledge of the statute or specific intent to violate it. In addition, the ACA provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our operations are found to be in violation of any of the laws described above or otherwise, we may be subject to penalties, including civil and criminal penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from funded health care programs and the curtailment or restructuring of our operations. Any such penalties could adversely affect our financial results. We continue to improve our corporate compliance program designed to ensure that our development, marketing, and sales of existing and future products and product candidates are in compliance with all applicable laws and regulations, but we cannot guarantee that this program will protect us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of significant fines or other sanctions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws, we may be subject to significant civil, criminal and administrative penalties, damages, fines, individual imprisonment, integrity obligations, exclusion from government funded health care programs, such as Medicare and Medicaid, and the curtailment or restructuring of our operations. If a third party fails to comply with applicable laws and regulations while acting on our behalf, we may also be subject to criminal, civil, and administrative penalties, including those listed above.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to conducting the development, marketing and sale of our applicable products and product candidates and all of our activities in compliance with all applicable laws and regulations, but certain applicable laws and regulations may impose liability even in the absence of specific intent to defraud. Furthermore, should an employee or third party acting on our behalf violate these laws without our knowledge, a governmental authority may impose civil and/or criminal sanctions on us.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States government, state governments and private payors regularly investigate the pricing and competitive practices of pharmaceutical companies and biotechnology companies, and many file actions alleging that inaccurate reporting of prices has improperly inflated reimbursement rates. We may also be subject to investigations related to our pricing practices. Regardless of merit or eventual outcome, these types of investigations and related litigation can result in:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Diversion of management time and attention;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Significant legal fees and payment of damages or penalties;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Limitations on our ability to continue certain operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Decreased product demand; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">Injury to our reputation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, an adverse outcome, or the imposition of penalties or sanctions for failing to comply with the fraud and abuse and antitrust laws, could adversely affect us and may have a material adverse effect on our business, results of operations, financial condition and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If we fail to comply with our obligations under U.S. governmental pricing programs, we could&#160;be required to reimburse government programs for underpayments and could pay penalties, sanctions and fines.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of regulations and coverage expansion by various governmental agencies relating to the Medicaid rebate program will continue to increase our costs and the complexity of compliance and will be time-consuming. Changes to the definition of average manufacturer price (AMP), and the Medicaid rebate amount under the ACA and CMS and the issuance of final regulations implementing those changes has affected and could further affect our 340B &#8220;ceiling price&#8221; calculations. Because we participate in the Medicaid rebate program, we are required to report average sales price (ASP), information to CMS for certain categories of drugs that are paid for under Part B of the Medicare program. Future statutory or regulatory changes or CMS binding guidance could affect the ASP calculations for our products and the resulting Medicare payment rate and could negatively impact our results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pricing and rebate calculations vary among products and programs, involve complex calculations and are often subject to interpretation by us, governmental or regulatory agencies and the courts. The Medicaid rebate amount is computed each quarter based on our submission to CMS of our current AMP and &#8220;best price&#8221; for the quarter. If we become aware </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that our reporting for a prior quarter was incorrect, or has changed as a result of recalculation of the pricing data, we are obligated to resubmit the corrected data for a period not to exceed twelve quarters from the quarter in which the data originally were due. Any such revisions could have the impact of increasing or decreasing our rebate liability for prior quarters, depending on the direction of the revision. Such restatements and recalculations would increase our costs for complying with the laws and regulations governing the Medicaid rebate program. Price recalculations also may affect the &#8220;ceiling price&#8221; at which we are required to offer our products to certain covered entities, such as safety-net providers, under the 340B/Public Health Service (PHS) drug pricing program.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if we are found to have made a misrepresentation in the reporting of ASP, we are subject to civil monetary penalties for each such price misrepresentation and for each day in which such price misrepresentation was applied. If we are found to have knowingly submitted false AMP or &#8220;best price&#8221; information to the government, we may be liable for civil monetary penalties per item of false information. Any refusal of a request for information or knowing provision of false information in connection with an AMP survey verification would also subject us to civil monetary penalties. In addition, our failure to submit monthly/quarterly AMP or &#8220;best price&#8221; information on a timely basis could result in a civil monetary penalty per day for each day the information is late beyond the due date. Such failure could also be grounds for CMS to terminate our Medicaid drug rebate agreement, under which we participate in the Medicaid program. In the event that CMS terminates our rebate agreement, no federal payments would be available under Medicaid or Medicare Part B for our covered outpatient drugs. Governmental agencies may also make changes in program interpretations, requirements or conditions of participation, some of which may have implications for amounts previously estimated or paid. We cannot assure that our submissions will not be found by CMS to be incomplete or incorrect.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for our products to be reimbursed by the primary federal governmental programs, we must report certain pricing data to the USG. Compliance with reporting and other requirements of these federal programs is a pre-condition to: (i)&#160;the availability of federal funds to pay for our products under Medicaid and Medicare Part B; and (ii)&#160;procurement of our products by the Department of Veterans Affairs (DVA), and by covered entities under the 340B/PHS program. The pricing data reported are used as the basis for establishing Federal Supply Schedule (FSS), and 340B/PHS program contract pricing and payment and rebate rates under the Medicare Part B and Medicaid programs, respectively. Pharmaceutical companies </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have been prosecuted under federal and state false claims laws for submitting inaccurate and/or incomplete pricing information to the government that resulted in increased payments made by these programs. Although we maintain and follow strict procedures to ensure the maximum possible integrity for our federal pricing calculations, the process for making the required calculations is complex, involves some subjective judgments and the risk of errors always exists, which creates the potential for exposure under the false claims laws. If we become subject to investigations or other inquiries concerning our compliance with price reporting laws and regulations, and our methodologies for calculating federal prices are found to include flaws or to have been incorrectly applied, we could be required to pay or be subject to additional reimbursements, penalties, sanctions or fines, which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To be eligible to have our products paid for with federal funds under the Medicaid and Medicare Part B programs and purchased by certain federal agencies and grantees, we also must participate in the DVA FSS pricing program. To participate, we are required to enter into an&#160;FSS contract with the DVA, under which we must make our innovator &#8220;covered drugs&#8221; available to the &#8220;Big Four&#8221; federal agencies-the DVA, the DoD, the PHS (including the Indian Health Service), and the Coast Guard-at pricing that is capped under a statutory federal ceiling price (FCP) formula set forth in Section&#160;603 of the Veterans Health Care Act of 1992 (VHCA). The FCP is based on a weighted average wholesale price known as the Non-Federal Average Manufacturer Price (Non-FAMP), which manufacturers are required to report on a quarterly and annual basis to the DVA. Under the VHCA, knowingly providing false information in connection with a Non-FAMP filing can subject us to significant penalties for each item of false information. If we overcharge the government in connection with our FSS contract or Section&#160;703 Agreement, whether due to a misstated FCP or otherwise, we are required to disclose the error and refund the difference to the government. The failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government&#160;investigation or enforcement action, can be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">From time to time, we sell unapproved MCMs to government entities under certain circumstances. While this is permissible in some cases, the extent to which we may be able to lawfully offer to sell and sell unapproved </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">products in many jurisdictions may be unclear or ambiguous. Such sales could subject us to regulatory enforcement action, product liability and reputational risk.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under certain circumstances, MCMs may be procured by government entities prior to approval by the FDA or other regulatory authorities, a practice which we follow in connection with certain MCMs, including AV7909 and TROBIGARD in the United States. In the United States, Project BioShield permits the Secretary of HHS to contract to purchase MCMs for the SNS prior to FDA approval of the MCM in specified circumstances. Project BioShield and the Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 also allow the FDA Commissioner to authorize the emergency use of medical products that have not yet been approved by the FDA under an EUA. An EUA terminates when the emergency determination underlying the EUA terminates. An EUA is not a long-term alternative to obtaining FDA approval, licensure, or clearance for a product. Absent an applicable exception, our MCM product candidates generally will have to be approved by the FDA or other regulatory authorities in the relevant country through traditional pathways before we can sell those products to governments. Additionally, the laws in certain jurisdictions regarding the ability of government entities to purchase unapproved product candidates are ambiguous, and the permissibility of exporting unapproved products from the United States and importing them to foreign countries may be unclear. Nevertheless, government bodies, such as U.S. federal entities other than HHS, state and local governments within the United States, and foreign governments have sought and may further seek to procure our MCM product candidates that are not yet approved. If so, we would expect to assess the permissibility and liability implications of supplying our product candidates to such entities on a case-by-case basis, which presents certain challenges, both in the case of U.S. and foreign governments, and particularly under emergency conditions. In addition, agencies or branches of one country&#8217;s government may take different positions regarding the permissibility of such sales than another country&#8217;s government or even other agencies or branches of the same government. If local enforcement authorities disagree with our conclusion that such activities are permissible, they may take enforcement action against us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the sale of unapproved products also could give rise to product liability claims for which we may not be able to obtain indemnification or insurance coverage. For example, liability protections applicable to claims arising under U.S. law and resulting from the use of certain unlicensed or unauthorized products, such as a declaration issued under the PREP Act, may </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">lead plaintiffs to assert that their claims are not barred under the PREP Act.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of the permissibility and liability risks, in the event a user of one or more of our products suffers an adverse event, we may be subject to additional reputational risk if the product has not been approved by the FDA or the corresponding regulatory authority of another country, particularly because we will not have approved labeling regarding the safety or efficacy of those products. In addition, legislatures and other governmental bodies that have oversight responsibility for procuring agencies may raise concerns after the fact, even if procurement was permissible at the time, which could result in negative publicity, reputational risk and harm to our business prospects.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that our communications with governments about our unapproved products, such as in the procurement context, could be considered promotion of an unapproved product or unapproved use of an approved product. Therefore, there is a risk that we could be subject to enforcement actions if found to be in violation of such laws or regulations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Even after regulatory approval is received, if we fail to comply with regulatory requirements, or if we experience unanticipated problems with our approved products, they could be subject to restrictions, penalties or withdrawal from the market.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the requirements and uncertainties related to the pre-approval activities discussed previously, any vaccine, therapeutic product or medical device for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, advertising and promotional activities for such product, will be subject to the continual requirements of and review by the FDA and other regulatory bodies. Our approved products are subject to these requirements and ongoing review. These requirements include submissions of safety and other post-marketing information and reports, plasma donor testing, registration requirements, cGMP, requirements relating to potency and stability, quality control, quality assurance, restrictions on advertising and promotion, import and export restrictions and recordkeeping requirements. In addition, various state laws require that companies that manufacture and/or distribute drug products within the state obtain and maintain a manufacturer or distributor license, as appropriate. Because of the breadth of these laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government regulators enforce cGMP and other requirements through periodic unannounced inspections of manufacturing facilities. The FDA is authorized to inspect domestic and foreign </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing facilities without prior notice at reasonable times and in a reasonable manner. Health Canada may conduct similar inspections of our domestic and foreign facilities where products offered and sold in Canada are produced, or related formulation and filling operations are conducted. The FDA, Health Canada and other foreign regulatory agencies conduct periodic inspections of our facilities. Following several of these inspections, regulatory authorities have issued inspectional observations, some of which were significant, but all of which are being, or have been, addressed through corrective actions. If, in connection with any future inspection, regulatory authorities find that we are not in substantial compliance with all applicable requirements, or if they are not satisfied with the corrective actions we take, our regulators may undertake enforcement action against us, which may include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">warning letters and other communications;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">product seizure or withdrawal of the product from the market;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">restrictions on the marketing or manufacturing of a product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">suspension or withdrawal of regulatory approvals or refusal to approve pending applications or supplements to approved applications;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">fines or disgorgement of profits or revenue; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">injunctions or the imposition of civil or criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar action may be taken against us should we fail to comply with regulatory requirements, or later discover previously unknown problems with our products or manufacturing processes. For instance, our products are tested regularly to determine if they satisfy potency and stability requirements for their required shelf lives. Failure to meet potency, stability or other specification requirements could result in delays in distributions, recalls or other consequences. Even if regulatory approval of a product is granted, the approval may be subject to limitations on the indicated uses for which the product may be marketed or sold or to the conditions of approval. Regulatory approval may also contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the product. If we experience any of these post-approval events, our business, financial condition, operating results and cash flows could be materially and adversely affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, companies may not promote unapproved products or unapproved uses of approved </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">products (i.e. &#8220;off-label&#8221; uses or uses that are not described in the product&#8217;s approved labeling and that differ from the uses approved by the applicable regulatory agencies). A company that is found to have improperly promoted an unapproved product or unapproved use of an approved product may be subject to significant liability, including civil and administrative remedies (such as entering into corporate integrity agreements with the USG), as well as criminal sanctions. If our employees or agents engage in marketing of an unapproved product or the unapproved use of an approved product, we could be subject to civil or criminal investigations and monetary and injunctive penalties, which could adversely impact our ability to conduct business in certain markets, negatively affect our business, financial condition, operating results and cash flows, and damage our reputation.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Failure to obtain or maintain regulatory approval in international jurisdictions could prevent us from marketing our products abroad and could limit the growth of our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently sell certain of our products outside the United States and intend to expand the countries in which we sell our products and have received market authorization under the mutual recognition procedure to sell BioThrax in France, Italy, the Netherlands, Poland, and the United Kingdom. To market or sell our products in foreign jurisdictions under normal circumstances, we generally need to obtain separate regulatory approvals and comply with numerous and varying requirements or use alternative &#8220;emergency use&#8221; or other exemptions from general approval and import requirements. Approval by the FDA in the United States or the mutual recognition procedure in the European member states does not ensure approval by all foreign regulatory authorities. The approval procedures in foreign jurisdictions can vary widely and can involve additional clinical trials and data review beyond that required by the FDA or under the mutual recognition procedure. There is also a risk that a regulatory authority in another country could conclude that we have violated the rules and regulations related to product development, approval or promotion in that country. Therefore, there is a risk that we could be subject to a foreign enforcement action if found to be in violation of such laws and regulations. We and our collaborators may not be able to obtain foreign regulatory approvals on a timely basis, if at all, and we may be unable to successfully commercialize our products in desired jurisdictions internationally if no alternate procurement pathway is identified for authorized government customers in a particular jurisdiction. We have limited experience in preparing, filing and prosecuting the applications necessary to gain foreign regulatory approvals and expect to rely on third-party contract research organizations and </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">consultants to assist us in this process. Our reliance on third parties can introduce additional uncertainty into the process.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2021, the Medicines and Healthcare products Regulatory Agency (the MHRA), became responsible for supervising medicines and medical devices in Great Britain, comprising England, Scotland and Wales under domestic law, whereas Northern Ireland will continue to be subject to European Union rules under the Northern Ireland Protocol. The MHRA will rely on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended). or the HMR, as the basis for regulating medicines. The HMR has incorporated into the domestic law of the body of European Union law instruments governing medicinal products that pre-existed prior to the United Kingdom's withdrawal from the European Union. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could significantly and materially harm our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain products outside of the United States and require us to develop and implement costly compliance programs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our commercialization activities outside of the United States, we are subject to an increased risk of, and must dedicate additional resources towards avoiding inadvertently conducting activities in a manner that violates the Foreign Corrupt Practices Act (FCPA), the U.K. Bribery Act, Canada's Corruption of Foreign Public Officials Act, and other similar foreign laws, which prohibit corporations and individuals from paying, offering to pay, or authorizing the payment of anything of value to any foreign government official, government staff member, political party, or political candidate in an attempt to obtain or retain business or to otherwise influence a person working in an official capacity. The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring the Company to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including the United States, also have various lobbying laws and regulations governing the conduct of individuals and companies who interact with government officials. These laws and regulations typically include certain restrictions and disclosure obligations. We believe we are currently in compliance with such laws and regulations. If we, our employees, or third parties acting on our behalf do not comply with these laws and regulations, we may be subject to civil and criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many countries, including the United States, restrict the export or import of products to or from certain countries through, for example, bans, sanction programs, and boycotts. Such restrictions may preclude us from supplying products in certain countries, which could limit our growth potential. Furthermore, if we, or third parties acting on our behalf, do not comply with these restrictions, we may be subject to civil and criminal penalties.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations and executive orders also restrict the use and dissemination outside of the United States, or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. If we continue to expand our presence outside of the United States, it will require us to dedicate additional resources to comply with these laws, and these laws may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the United States, which could limit our growth potential and increase our development costs.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA&#8217;s accounting provisions.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPETITIVE AND POLITICAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Development and commercialization of pharmaceutical products, including for PHT preparedness, are routinely subject to evolving private and public sector competition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development and commercialization of new biopharmaceutical and medical technology products is highly competitive and subject to rapid technological advances. We may face future competition from other companies and governments, universities and other </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">non-profit research organizations in respect to our products, any products that we acquire, our current product candidates and any products we may seek to develop or commercialize in the future. The market for current products can be subject to development of safer, more effective, more convenient or less costly products. The market for current products can also depend on what resources can be devoted to marketing or selling products, or how companies are positioned to adapt more quickly to new technologies, respond to scientific advances or patient preferences and needs, initiate or withstand substantial price competition and/or procure third-party licensing and collaborative arrangements.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are a number of companies with products or product candidates addressing PHT preparedness that are competing with us for both USG procurement and development resources. Factors to consider include competitors' financial, technical, marketing and selling resources as well as potential leverage that their intellectual property estates may offer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any reduction in demand for our products or reduction or loss of development funding for our products or product candidates in favor of a competing product could lead to a loss of market share for our products and cause reduced revenues, margins and levels of profitability for us, which could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Biologic Products may face risks of competition from biosimilar manufacturers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biological products and product candidates, otherwise referred to as our &#8220;Biologic Products,&#8221; can be affected by the approval and entry of &#8220;biosimilars&#8221; in the United States and other jurisdictions. Biosimilar drugs are &#8220;highly similar,&#8221; but close enough in duplication to accomplish the same therapeutic and clinical result. Biologic Products in our current pipeline include AV7909, BioThrax, and ACAM2000. If a biosimilar version of one of our Biologic Products were approved, it could have a material adverse effect on the sales and gross profits of the affected Biologic Product and could adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">NARCAN&#174; (naloxone HCI) Nasal Spray is currently subject to generic competition and may be subject to additional branded and generic competition in the future.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN currently faces generic competition. In 2016, Teva Pharmaceuticals Industries Limited and Teva Pharmaceuticals USA (collectively, Teva) filed an Abbreviated New Drug Application (ANDA) seeking regulatory approval to market a generic version of NARCAN. In patent litigation related to Teva&#8217;s ANDA </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">filing, a trial Court decided in favor of Teva, and this decision was subsequently affirmed by the Court of Appeals for the Federal Circuit.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 22, 2021, Teva commenced the launch of their generic naloxone nasal spray. On the same date, Sandoz initiated distribution of an authorized generic naloxone nasal spray having entered into agreement with Emergent for this purpose.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN may face additional generic competition from other parties, including from Perrigo UK FINCO Limited Partnership (Perrigo), who filed their own ANDA in 2018. Emergent settled with Perrigo on February 12, 2020 providing for a license effective upon the Teva litigation decision.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of generic versions of NARCAN at prices lower than our branded product, including the generic version issued through our partnership with Sandoz, or the version provided at no cost by Teva, have the potential to erode our sales and could impact our product revenue related to NARCAN. For example, certain U.S. state laws allow for, and in some instances in the absence of specific instructions from the prescribing physician, mandate the dispensing of generic products rather than branded products where a generic version is available. In addition, in January 2019, the FDA released new proposed template Drug Facts Labels to assist sponsors of investigational naloxone nasal sprays and auto-injectors seeking approval from the FDA for over-the-counter naloxone products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN may also face branded competition.</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, on April 30, 2021, the FDA approved Kloxxado</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, a branded product developed by Hikma Pharmaceuticals, Inc. which delivers a higher dose naloxone nasal spray.</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, Orexo AB and Harm Reduction Therapeutics both have development programs for novel naloxone nasal spray formulations intended for use in opioid overdose reversal.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional branded competition may correspond to other injectable naloxone, auto-injectors and improvised nasal kits including Amphastar Pharmaceuticals, Inc.'s naloxone injection product and Kal&#233;o's EVZIO</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#8482;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCI injection) Auto-Injector.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Political or social factors may delay or impair our ability to market and sell our products and may require us to spend significant management time and financial resources to address these issues.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Products developed to counter the potential impact of PHTs are subject to changing political and social environments. The political responses and social awareness of the risks of these threats on military personnel or civilians and the level of emphasis placed on such risks by the USG may vary over time. If the </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">threat of terrorism were to decline, then the public perception of the risk on public health and safety may be reduced. This perception, as well as political or social pressures, could delay or cause resistance to bringing our products in development to market or limit pricing or purchases of our products, any of which could negatively affect our revenues and our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, substantial delays or cancellations of purchases could result from protests or challenges from third parties. Lawsuits brought against us by third parties or activists, even if not successful, could require us to spend significant management time and financial resources defending the related litigation and could potentially damage the public's perception of us and our products. Any publicity campaigns or other negative publicity may adversely affect the degree of market acceptance of our MCMs and thereby limit the demand for our products, which would adversely affect our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not be able to obtain orphan drug exclusivity for product candidates we may develop, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug or biologic intended to treat a rare disease or condition. Generally, if a product candidate with an orphan drug designation subsequently receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same product for the same therapeutic indication for that time period. The applicable period is seven years in the United States.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order for the FDA to grant orphan drug exclusivity to one of our products, the agency must find that the product is indicated for the treatment of a condition or disease with a patient population of fewer than 200,000 individuals annually in the United States. The FDA may conclude that the condition or disease for which we seek orphan drug exclusivity does not meet this standard. Even if we obtain orphan drug exclusivity for a product, that exclusivity may not effectively protect the product from competition because different products can be approved for the same condition. In addition, even after an orphan drug is approved, the FDA can subsequently approve the same product for the same condition if the FDA or such authorities conclude that the later product is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. Orphan drug exclusivity may also be lost if the FDA or EMA determines that the request for designation was </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of the patients with the rare disease or condition.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INTELLECTUAL PROPERTY RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Protection of our intellectual property rights is an important tool for sustaining our business and the failure to do so could impact our financial condition, operating results, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We actively seek to protect intellectual property rights related to our Company's assets, including patent rights, trademark rights, trade secrets and proprietary confidential information, through defense and enforcement of existing rights and pursuit of protection on new and arising innovations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining, maintaining and defending our intellectual property rights in the United States and other countries remains a critical component of the development and commercialization of our Company's assets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the risks associated with procurement, maintenance and enforcement of intellectual property rights include changes in patent laws or administrative patent office rules, evolving criteria and eligibility of obtaining patent protection on particular subject matter, the validity and enforceability of our intellectual property rights, the potential scope of coverage of our intellectual property rights, and/or the availability or strength of legal remedies in a particular country to defend and enforce intellectual property rights.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks include associated costs, such as costs of patent prosecution and maintenance and costs associated with post-grant challenges. For example, such costs include </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes review</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (IPR) proceedings in the United States and oppositions in Europe, as well as costs associated with litigating and enforcing patent and trademark rights.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional risks include limitations on our extent or ability to procure, maintain or defend intellectual property rights associated with in-licensed or acquired intellectual property, where, for example, third parties may have the first right to maintain or defend intellectual property rights in which we have an interest, or may pursue strategies that are divergent to the interest of our Company.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third party challenges for patent infringement could impact our business, financial condition, operating results, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Challenges by third parties for alleged patent infringement could delay or affect the development and commercialization of our products. Such challenges, while ongoing, could be costly, requiring and utilizing </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">company resources. Such challenges, if successful, may impact marketing or launch of products, or require ongoing license and/or royalty fees associated with potential settlement agreements. These may have the potential to materially harm our business, financial condition, operating results, and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Intellectual property licenses with third parties carry risks of challenges, which may be costly and time consuming and could impact the commercialization of our products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a party to a number of license agreements and expect to enter into additional license agreements in the future. Such license agreements or collaboration arrangements can be subject to challenges if interests or expectations under such license agreements diverge. Such challenges may be costly, risk time and resources, and could delay or impact development, commercialization or launch of our products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential loss of proprietary information and know-how generally carries the risk of reducing the value of our technology and products.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely upon unpatented proprietary technology, processes, and know-how, particularly as to our proprietary manufacturing processes. These types of confidential information and trade secrets can be difficult to protect. We seek to protect this confidential information, in part, through agreements with our employees, consultants, and third parties, as well as confidentiality policies and audits, although these may not always be successful in protecting our trade secrets and confidential information.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">One or more of our products could be subject to early competition from generic drugs and biosimilars.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One or more of our products is approved as a drug product under the provisions of the FDCA, which may render it susceptible to potential competition from generic manufacturers via the Hatch-Waxman Act and ANDA process. Other of our products may be susceptible to challenges by entry of biosimilars through the route established under the Biologics Price Competition and Innovation Action of 2009.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we intend to vigorously enforce our intellectual property rights, there can be no assurance that we will prevail in our enforcement or defense of our patent rights. Our existing patents could be invalidated, found unenforceable, or found not to cover a generic form of our product.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO RELIANCE ON THIRD PARTIES </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The loss of any of our non-exclusive, sole-source or single source suppliers, a shortage of related supplies or an increase in the price of inventory supplied to us could </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">have an adverse effect on our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We purchase certain supplies used in our manufacturing processes from non-exclusive, or single sources due to quality considerations, costs or constraints resulting from regulatory requirements. We depend on certain single-source suppliers for key materials and services necessary to manufacture the majority of our products and certain product candidates. For example, we rely on a single-source supplier to provide us with Alhydrogel in sufficient quantities to meet our needs to manufacture AV7909 and BioThrax and the specialty plasma in our hyperimmune specialty plasma products and certain ingredients for ACAM2000. We also rely on single-source suppliers for the materials necessary to produce NARCAN, such as the naloxone active pharmaceutical ingredient and other excipients, along with the vial, stopper and device.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Where a particular single-source supply relationship is terminated, we may not be able to establish additional or replacement suppliers for certain components or materials quickly. This is largely due to the FDA approval system, which mandates validation of materials prior to use in our products, and the complex nature of manufacturing processes. In addition, we may lose a sole-source supplier due to, among other things, the impact of COVID-19 on such supplier, the acquisition of a supplier by a competitor (which may cause the supplier to stop selling its products to us) or the bankruptcy of such a supplier, which may cause the supplier to cease operations. Any reduction or interruption by a sole-source supplier of the supply of materials or key components used in the manufacturing of our products or product candidates, a reduction in quality or an increase in the price of those materials or components could adversely affect us. If we are unable to locate or establish alternative suppliers, our ability to manufacture our products and product candidates could be adversely affected and could harm our revenues, cause us to fail to satisfy contractual commitments, lead to a termination of one or more of our contracts or lead to delays in our clinical trials, any of which could be costly to us and otherwise materially harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We depend on third parties to conduct many of our clinical and non-clinical trials. If these third parties do not perform as contractually required or as we expect, we may not be able to obtain regulatory approval for or commercialize our product candidates and, as a result, our business, financial condition, operating results and cash flows may suffer.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We depend on third parties, such as independent clinical investigators, contract research organizations </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and other third-party service providers to conduct the clinical and non-clinical trials of our product candidates and expect to continue to do so. We rely heavily on these third parties for successful execution of our clinical and non-clinical trials, but do not exercise day-to-day control over their activities. Our reliance on these service providers does not relieve us of our regulatory responsibilities, including ensuring that our trials are conducted in accordance with good clinical practice regulations and the plan and protocols contained in the relevant regulatory application. In addition, these organizations may not complete these activities on our anticipated or desired timeframe. We also may experience unexpected cost increases that are beyond our control. Problems with the timeliness or quality of the work of a contract research organization may lead us to seek to terminate the relationship and use an alternative service provider, which may prove difficult, costly and result in a delay of our trials. Any delay in or inability to complete our trials could delay or prevent the development, approval and commercialization of our product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain cases, government entities and NGOs conduct studies of our product candidates, and we may seek to rely on these studies in applying for marketing approval for certain of our product candidates. These government entities and NGOs have no obligation or commitment to us to conduct or complete any of these studies or clinical trials and may choose to discontinue these development efforts at any time. Furthermore, government entities depend on annual Congressional appropriations to fund their development efforts, which may not be approved.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain any necessary third-party services on acceptable terms or if these service providers do not successfully carry out their contractual duties or meet expected deadlines, our efforts to obtain regulatory approvals for our product candidates may be delayed or prevented.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">LEGAL AND REPUTATIONAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our financial condition and operating results could be adversely impacted by unfavorable results of legal proceedings or government investigations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to various claims, legal proceedings and government investigations that have not yet been fully resolved, including stockholder derivative and putative class action lawsuits, and new matters may arise in the future. In addition, agreements entered into by us sometimes include indemnification provisions which can subject us to costs and damages in the event of a claim against an indemnified third party. The number of claims, legal proceedings and government investigations involving us, and the alleged magnitude of such claims, proceedings and government investigations, has </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">generally increased over time and may continue to increase. Certain of these actions include, and future actual or threatened legal actions may include, claims for substantial and indeterminate amounts of damages, or may result in other actions adverse to us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, multiple purported class action lawsuits have been filed against us and certain of our current and former senior officers in the United States District Court for the District of Maryland seeking unspecified damages on behalf of a putative class of persons who purchased or otherwise acquired shares of our common stock during various date ranges. The complaints allege, among other things, that we made materially false and misleading statements regarding our procedures and quality controls relating to vaccine production, in violation of federal securities laws. As another example, multiple stockholder derivative lawsuits were filed in The Court of Chancery of the State of Delaware and the United States District Court for the District of Maryland on behalf of the Company against certain current and former officers and directors for breach of fiduciary duties, waste of corporate assets, unjust enrichment and insider trading, each allegation related to the Company&#8217;s capabilities to manufacture COVID-19 vaccine bulk drug substance. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we have received inquiries and subpoenas to produce documents from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis, Senator Murray of the Committee on Health, Education, Labor and Pensions, the Financial Industry Regulatory Authority, the Department of Justice), the SEC, the Maryland Attorney General&#8217;s Office, and the New York Attorney General&#8217;s Office. We are producing and have produced documents as required in response and will continue to cooperate with these government inquiries.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regardless of merit, litigation can be both time-consuming and disruptive to our operations and cause significant expense and diversion of management&#8217;s attention. The outcome of litigation or government investigations is also inherently uncertain. If one or more legal matters were resolved against us or an indemnified third party in a reporting period for amounts above management&#8217;s expectations, our financial condition and operating results for that reporting period could be materially adversely affected. Further, such an outcome could result in significant compensatory, punitive or trebled monetary damages, disgorgement of revenue or profits, remedial corporate measures or injunctive relief against us and could require us to change our business practices or limit our </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ability to offer certain products and services, all of which could materially adversely affect our financial condition and operating results. While we maintain insurance coverage for certain types of claims, such insurance coverage may be insufficient to cover all losses or all types of claims that may arise.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> rely significantly on information technology systems and any failure, inadequacy, interruption or security lapse of that technology, including any cyber security incidents, could harm our ability to operate our business effectively or result in data leakage of proprietary and confidential business and employee information.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is increasingly dependent on critical, complex and interdependent information technology systems, including Internet-based systems, to support business processes as well as internal and external communications. We also have contracted with the USG and pharmaceutical companies, such as Johnson &amp; Johnson, for the development and manufacture of a significant quantity of COVID-19 vaccines, and separately we are working on a proprietary COVID-19 therapeutic with support from the USG and other private sector entities, which has raised our security profile, and heightened potential risks that malicious actors may seek to disrupt our systems or misappropriate our information. The size and complexity of our computer systems make them potentially vulnerable to interruption, invasion, computer viruses, destruction, malicious intrusion and additional related disruptions, which may result in the impairment of production and key business processes. Our systems are also potentially vulnerable to data security breaches through employee error, phishing scams and malfeasance, which may expose sensitive data to unauthorized persons. No system of protection is adequate to protect against all such threats, even if they are deemed to be industry standard, and there can be no assurance that we will be able to repel any such attacks. Data security breaches could lead to the loss of trade secrets or other intellectual property or the public exposure of personal information, including sensitive personal information, of our employees, clinical trial patients, customers and others. Responding to any such threats may also be expensive and time-consuming.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant business disruption or a breach in security resulting in misappropriation, theft or sabotage with respect to proprietary and confidential business and employee information could result in significant financial losses, legal, business or reputational harm to us, compromise our business prospects and our commitments to the USG or other customers, any of which could materially and adversely affect our business, financial condition and operating results.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our work on PHTs has exposed us to criticism and may expose us to further criticism, from the media, government personnel, and others, that can negatively affect our share price, reputation, operations, and our ability to attract and retain talent and secure new customer contracts.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our work on PHTs, including manufacturing issues at our Baltimore Bayview facility, has exposed us to criticism and may expose us to additional potential criticism, from the media, government personnel, and others. In addition, our work on PHTs has exposed us to governmental inquiries and investigations, including by Congress and other government agencies. For example, a joint panel of the U.S. House of Representatives launched an investigation into, among other things, the cause of the previously mentioned cross-contamination issues identified in a viral vaccine drug substance batch at the Baltimore Bayview facility. Such criticism can be particularly acute during a public health emergency like the COVID-19 pandemic. The unfavorable media coverage and increased government scrutiny, including the Congressional inquiry, could further harm our reputation, distract management&#8217;s attention from our operations, and impact our ability to attract and retain talent and result in further declines to our share price. We have already incurred significant legal costs to respond to government inquiries and are likely to incur additional costs. Any adverse actions by government authorities may result in significant civil or criminal fines or penalties, all of which could adversely impact our financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face product liability exposure, which could cause us to incur substantial liabilities and negatively affect our business, financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the sale of our products, any other products that we successfully acquire or develop and the testing of our product candidates in clinical trials.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One measure of protection against such lawsuits is coverage under the PREP Act, which was signed into law in December 2005. The PREP Act creates liability protection for manufacturers of biodefense countermeasures when the Secretary of HHS issues a declaration for their manufacture, administration or use. A PREP Act declaration is meant to provide liability protection from all claims under federal or state law for loss arising out of the administration or use of a covered countermeasure under a government contract. The Secretary of HHS has issued PREP Act declarations identifying certain of our products, namely BioThrax, ACAM2000, raxibacumab, Anthrasil, BAT and VIGIV, as covered countermeasures, which expire on December 31, 2022. Manufacturers are not entitled to </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection under the PREP Act in cases of willful misconduct or for cases brought in non-U.S. tribunals or under non-U.S. law. We cannot predict whether the Secretary of HHS will renew the declarations when they expire, whether Congress will fund the relevant PREP Act compensation programs, or whether the necessary prerequisites for immunity would be triggered with respect to our products or product candidates.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, BioThrax and RSDL have been certified as anti-terrorism products under the SAFETY Act and applications for continued coverage under the SAFETY Act are currently pending. The SAFETY Act creates product liability limitations for qualifying anti-terrorism technologies for claims arising from or related to an act of terrorism. Although we have been entitled to the benefits of the SAFETY Act for BioThrax and RSDL, such benefits may not be renewed and even if they are renewed, the SAFETY Act may not provide adequate protection from claims made against us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot successfully defend ourselves against future claims that our products or product candidates caused injuries and if we are not entitled to indemnity by the USG, or the USG does not honor its obligations to us under the PREP Act or SAFETY Act, where applicable, or if the liability protections under the PREP Act and SAFETY Act, if applicable, are not adequate to cover all claims, we may incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">decreased demand or withdrawal of a product;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">injury to our reputation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">withdrawal of clinical trial participants;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">costs to defend the related litigation;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">loss of revenue; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">an inability to commercialize products that we may develop.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amount of insurance that we currently hold may not be adequate to cover all liabilities that we may incur. Further product liability insurance may be difficult and expensive to obtain. We may not be able to maintain insurance coverage at a reasonable cost and we may not be able to obtain insurance coverage that will be adequate to satisfy all potential liabilities. For example, we may not have sufficient insurance against potential liabilities associated with a possible large-scale deployment of BioThrax as a countermeasure to a bioterrorism threat. We rely on PREP Act protection for BioThrax, raxibacumab, ACAM2000, Anthrasil, BAT and VIGIV, and possible continuation of SAFETY Act </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">protection for BioThrax and RSDL in addition to our insurance coverage to help mitigate our product liability exposure for these products. Additionally, potential product liability claims related to our commercial products, including NARCAN, Vivotif and Vaxchora, may be made by patients, health care providers or others who sell or consume these products. Such claims may be made even with respect to those products that possess regulatory approval for commercial sale. Claims or losses in excess of our product liability insurance coverage could have a material adverse effect on our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">FINANCIAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We have incurred significant indebtedness in connection with our acquisitions and servicing our debt requires a significant amount of cash. We may not have sufficient cash flow from our operations to pay our substantial debt.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to make scheduled payments of the principal of, to pay interest on or to further refinance our indebtedness depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing can have significant adverse consequences for our business, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requiring us to dedicate a substantial portion of cash flows from operations to payment on our debt, which would reduce available funds for other corporate initiatives;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">increasing the amount of interest that we have to pay on debt with variable interest rates, if market rates of interest increase, to the extent we are unable to offset such risk through our hedging instruments;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">subjecting us, as under our Senior Secured Credit Facilities and the indenture governing the 3.875% Senior Unsecured Notes due 2028 (Senior Unsecured Notes), to restrictive covenants that reduce our ability to take certain corporate actions, acquire companies, products or technology, or obtain further debt financing; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">requiring us to pledge our assets as collateral, which could limit our ability to obtain additional debt financing; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limiting our flexibility in planning for, or reacting to, general adverse economic and industry conditions; and </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">placing us at a competitive disadvantage compared to our competitors that have less debt, better debt servicing options or stronger debt servicing capacity.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not have sufficient funds or be able to obtain additional financing to pay the amounts due under our indebtedness. In addition, failure to comply with the covenants under our Senior Secured Credit Facilities and other debt agreements, including the maintenance of a specified consolidated net leverage ratio and debt service coverage ratio under our Senior Secured Credit Facilities, could result in an event of default under those agreements. An event of default could result in the acceleration of amounts due under a particular debt agreement and a cross default and acceleration under other debt agreements, and we may not have sufficient funds to pay or be able to obtain additional financing to make any accelerated payments. Under these circumstances, our lenders could seek to enforce security interests in our assets securing our indebtedness.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our current indebtedness restricts and any additional debt financing may restrict the operation of our business and limit the cash available for investment in our&#160;business operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Senior Secured Credit Facilities include a </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$450 million</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Term Loan Facility which had an outstanding principal balance was $379.7 million as of </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022 </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the ability </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to borrow up to $600 million under our Revolving Credit Facility, of which we had no outstanding borrowings as of June&#160;30, 2022. On August 7, 2020, we completed an offering of </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$450 million aggregate principal amount of Senior Unsecured Notes, of which $353 million of the net proceeds were used to pay down our Revolving Credit Facility. We may also seek additional debt financing to support our ongoing activities or to provide additional financial flexibility. Debt financing can have significant adverse consequences for our business, including:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the level, timing and cost of product sales and CDMO services;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the extent to which we acquire or invest in and integrate companies, businesses, products or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the acquisition of new facilities and capital improvements to new or existing facilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the payment obligations under our indebtedness;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the scope, progress, results and costs of our development activities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">our ability to obtain funding from collaborative partners, government entities and non-</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">governmental organizations for our development programs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the extent to which we repurchase additional shares of common stock under our current share repurchase program; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the costs of commercialization activities, including product marketing, sales and distribution.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our hedging program is subject to counterparty default risk.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our interest rate risk in part by entering into interest rate swaps with a number of counterparties to swap a portion of our indebtedness that is based on variable interest rates to a fixed rate. As a result, we are subject to the risk that the counterparty to one or more of these contracts defaults on its performance under the contract. During an economic downturn, the counterparty's financial condition may deteriorate rapidly and with little notice and we may be unable to take action to protect our exposure. In the event of a counterparty default, we could incur losses, which may harm our business and financial condition. In the event that one or more of our counterparties becomes insolvent or files for bankruptcy, our ability to eventually recover any losses suffered as a result of that counterparty's default may be limited by the liquidity of the counterparty.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may require significant additional funding and be unable to raise capital when&#160;needed or on acceptable terms, which would harm our ability to grow our business, and our results of operations and financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our capital resources are insufficient to meet our future capital requirements, we will need to finance our cash needs through public or private equity or debt offerings, bank loans or collaboration and licensing arrangements. In August 2021, we filed an automatic shelf registration statement, which immediately became effective under SEC rules. For so long as we continue to satisfy the requirements to be deemed a &#8220;well-known seasoned issuer&#8221; under SEC rules (which include, among other things, the timely filing of our reports under the Exchange Act and maintenance of at least $700 million of public float or issuing an aggregate amount of $1 billion of non-convertible securities, other than common stock, in registered offerings for cash during the past three years), this shelf registration statement, effective until August 9, 2024, allows us to issue an unrestricted amount of equity, debt and certain other types of securities through one or more future primary or secondary offerings. If we do not file a new shelf registration statement prior to August 9, 2024, the existing shelf registration statement will expire, and we will not be </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">able to publicly raise capital or issue debt until a new registration statement is filed and becomes effective. There can be no assurance that we will be eligible to file an automatically effective shelf registration statement at a future date when we may need to raise funds publicly.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise funds by issuing equity securities, our stockholders may experience dilution. Debt financing, if available, may involve agreements that include covenants, like those contained in our Senior Secured Credit Facilities and the indenture governing the Senior Unsecured Notes, limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, pursuing acquisition opportunities or declaring dividends. If we raise funds through collaboration and licensing arrangements with third parties, it may be necessary to relinquish valuable rights to our technologies or product candidates or grant licenses on terms that may not be favorable to us. Our Senior Secured Credit Facilities as well as the indenture governing the Senior Unsecured Notes restrict our ability to incur additional indebtedness.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Economic conditions may make it difficult to obtain financing on attractive terms, or at all. If financing is unavailable or lost, our business, operating results, financial condition and cash flows would be adversely affected, and we could be forced to delay, reduce the scope of or eliminate many of our planned activities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We may not maintain profitability in future periods or on a consistent basis.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we have been profitable on an annual basis since becoming a public company, we have not been profitable for every quarter during that time. Our profitability has been substantially dependent on product sales, which historically have fluctuated significantly from quarter to quarter, and we expect that they will continue to fluctuate significantly based primarily on the timing of our fulfillment of orders from the USG. We may not be able to achieve consistent profitability on a quarterly basis or sustain or increase profitability on an annual basis.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The expansion of our international operations increases our risk of exposure to credit losses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we continue to expand our business activities with foreign governments in certain countries that have experienced deterioration in credit and economic conditions or otherwise, our exposure to uncollectible accounts will rise. Global economic conditions and liquidity issues in certain countries have resulted and may continue to result in delays in the collection of accounts receivable and may result in credit losses. Future governmental actions and customer specific actions may require us to re-evaluate the collectability of our accounts receivable and we may potentially incur </span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">credit losses that materially impact our operating results.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">A substantial portion of our indebtedness bears interest at variable interest rates based on LIBOR and certain of our financial contracts are also indexed to LIBOR. Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness and may otherwise adversely affect our financial condition and results of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2017, the Financial Conduct Authority, the authority that regulates the London Inter-bank Offered Rate (LIBOR) announced that it intended to stop compelling banks to submit rates for the calculation of LIBOR.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 31, 2021, the International Exchange (ICE) Benchmark Association, which administrates LIBOR, ceased (i) entering into new contracts that use LIBOR as a reference rate and (ii) publication of two LIBOR rates (one-week and two-month) and announced that the remaining LIBOR rates (overnight, one-month, three-month, six-month and 12-month) will be retired on June 30, 2023. It is unclear if LIBOR will cease to exist at that time or if new methods of calculating LIBOR will be established such that it continues to exist after 2023. We have certain financial contracts, including the amended credit agreement related to our Senior Secured Credit Facilities and our interest rate swaps, that are indexed to LIBOR. Changes in the method of determining LIBOR, or the replacement of LIBOR with an alternative reference rate, may adversely affect interest rates on our current or future indebtedness. Any transition process may involve, among other things, increased volatility or illiquidity in markets for instruments that rely on LIBOR, reductions in the value of certain instruments or the effectiveness of related transactions such as hedges, increased borrowing costs, uncertainty under applicable documentation, or difficult and costly consent processes. The transition away from LIBOR may result in increased expenses, may impair our ability to refinance our indebtedness or hedge our exposure to floating rate instruments, or may result in difficulties, complications or delays in connection with future financing efforts, any of which could adversely affect our financial condition and results of operations.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO STRATEGIC ACQUISITIONS AND COLLABORATIONS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our strategy of generating growth through acquisitions may not be successful.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business strategy includes growing our business through acquisition and in-licensing transactions. We may not be successful in identifying, </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effectively evaluating, structuring, acquiring or in-licensing, and developing and commercializing additional products on favorable terms, or at all. Competition for attractive product opportunities is intense and may require us to devote substantial resources, both managerial and financial, to an acquisition opportunity. A number of more established companies are also pursuing strategies to acquire or in-license products in the biopharmaceutical field. These companies may have a competitive advantage over us due to their size, cash resources, cost of capital, effective tax rate and greater clinical development and commercialization capabilities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Acquisition efforts can consume significant management attention and require substantial expenditures, which could detract from our other programs. In addition, we may devote significant resources to potential acquisitions that are never completed. Even if we are successful in acquiring a company or product, it may not result in a successfully developed or commercialized product or, even if an acquired product is commercialized, competing products or technologies could render a product noncompetitive, uneconomical or obsolete. Moreover, the cost of acquiring other companies or in-licensing products could be substantial, and in order to acquire companies or new products, we may need to incur substantial debt or issue dilutive securities.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unsuccessful in our efforts to acquire other companies or in-license and develop additional products, or if we acquire or in-license unproductive assets, it could have a material adverse effect on the growth of our business, and we could be compelled to record significant impairment charges to write-down the carrying value of our acquired intangible assets, which could materially harm our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our failure to successfully integrate acquired businesses and/or assets into our operations could adversely affect our ability to realize the benefits of such acquisitions and, therefore, to grow our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to integrate any acquired business successfully or operate any acquired business profitably. In addition, cost synergies, if achieved at all, may be less than we expect, or may take greater time to achieve than we anticipate.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issues that could delay or prevent successful integration or cost synergies of an acquired business or products include, among others:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">retaining existing customers and attracting new customers;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">retaining key employees;</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">diversion of management attention and resources;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">conforming internal controls, policies and procedures, business cultures and compensation programs;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidating corporate and administrative infrastructures;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">successfully executing technology transfers and obtaining required regulatory approvals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">consolidating sales and marketing operations;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">identifying and eliminating redundant and underperforming operations and assets;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">assumption of known and unknown liabilities;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">coordinating geographically dispersed organizations; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">managing tax costs or inefficiencies associated with integrating operations; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">risks associated with intellectual property rights related to an acquisition or collaboration.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to successfully integrate pending and future acquisitions with our existing businesses, or operate any acquired business profitably, we may not obtain the advantages that the acquisitions were intended to create, which may materially adversely affect the growth of our business, financial condition, operating results and cash flows.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RISKS RELATED TO OWNERSHIP OF OUR COMMON STOCK</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our business or our share price could be negatively affected as a result of the actions of shareholders.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In recent years, some shareholders have placed increasing pressure on publicly traded companies in our industry and others to effect changes to corporate governance practices, executive compensation practices, social and environmental practices and to undertake certain corporate actions. This may be true even if they only hold a minority of shares. In addition, many institutional investors are increasingly focused on ESG factors. These investors may be seeking enhanced ESG disclosures or to implement policies adverse to our business. There can be no assurances that shareholders will not publicly advocate for us to make corporate governance changes or engage in certain corporate actions. Responding to challenges from shareholders, such as proxy contests, media campaigns or other public or private means, could be costly and time consuming and could have an adverse effect on our reputation and divert the attention and </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resources of management and our board, which could have an adverse effect on our business and operational results. Any such shareholder actions or requests, or the mere public presence of shareholders with a reputation for taking such actions among our shareholder base, could also cause the market price of our common stock to experience periods of significant volatility.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and by-laws and under Delaware law may discourage acquisition proposals, delay a change in control or prevent transactions that stockholders may consider favorable.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and by-laws may discourage, delay or prevent a merger, acquisition or other changes in control that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions may also prevent or frustrate attempts by our stockholders to replace or remove our management.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions include:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the classification of our directors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations on changing the number of directors then in office;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations on the removal of directors;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">limitations on filling vacancies on the board;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">advance notice requirements for stockholder nominations of candidates for election to the Board of Directors and other proposals;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability of stockholders to act by written consent;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the inability of stockholders to call special meetings; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the ability of our Board of Directors to designate the terms of and issue a new series of preferred stock without stockholder approval.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The affirmative vote of holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal the above provisions of our certificate of incorporation. The affirmative vote of either a majority of the directors present at a meeting of our Board of Directors or holders of our capital stock representing at least 75% of the voting power of all outstanding stock entitled to vote is required to amend or repeal our by-laws.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are subject to Section 203 of the Delaware General Corporation Law (Section 203). In general and subject to certain exceptions, Section 203 prohibits a publicly-held corporation from engaging in a business combination with an interested stockholder, generally a person which, together with its affiliates, owns or within the last three years has owned 15% or more of the corporation's voting stock, for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. Accordingly, Section 203 may discourage, delay or prevent a change in control of us.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our Board of Directors may implement a new stockholder rights plan without stockholder approval, which could prevent a change in control of us in instances in which some stockholders may believe a change in control is in their best interests.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors may implement a stockholder rights plan without stockholder approval. We previously implemented a stockholder rights plan, which expired on November 14, 2016. Under our prior stockholder rights plan, we issued to each of our stockholders one preferred stock purchase right for each outstanding share of our common stock. Each right, when exercisable, would have entitled its holder to purchase from us a unit consisting of one one-thousandth of a share of series A junior participating preferred stock at a purchase price of $150 in cash, subject to adjustments. Our stockholder rights plan was intended to protect stockholders in the event of an unfair or coercive offer to acquire us and to provide our Board of Directors with adequate time to evaluate unsolicited offers.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Board of Directors may implement a new stockholder rights plan, which may have anti-takeover effects, potentially preventing a change in control of us in instances in which some stockholders may believe a change in control is in their best interests. This could cause substantial dilution to a person or group that attempts to acquire us on terms that our Board of Directors does not believe are in our best interests or those of our stockholders and may discourage, delay or prevent a merger or acquisition that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our stock price is volatile, and purchasers of our common stock could incur substantial losses.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been, and is likely to continue to be, volatile. The market price of our common stock could fluctuate significantly for many reasons, including in response to the risks described in this &#8220;Risk Factors&#8221; section, or for reasons unrelated to our operations, such as reports by industry analysts, </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investor perceptions or negative announcements by our customers, competitors or suppliers regarding their own performance, as we</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ll as industry conditions and general financial, economic and political instability. From November 15, 2006, when our common stock first began trading on the New York Stock Exchange, through July&#160;26, 2022, our common stock has traded as high as $137.61 per share and as low as $4.17 per share. Due to fears associated with current world events, current historically high levels of inflation and the possible resurgence of COVID-19, the stock market has been </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experiencing extreme volatility and the market for biopharmaceutical companies has generally experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price of our common stock may be influenced by many factors, including, among others:</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">contracts, decisions and procurement policies by the USG affecting our anthrax vaccines and our other products and product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">CDMO contracts related to COVID-19 with collaboration partners;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the success of competitive products or technologies;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">results of clinical and non-clinical trials of our product candidates;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">announcements of acquisitions, financings or other transactions by us;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">litigation or legal proceedings;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">public concern as to the safety of our products;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">termination or delay of a development program;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the recruitment or departure of key personnel;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">variations in our product revenue and profitability; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12pt">the other factors described in this &#8220;Risk Factors&#8221; section.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Because we currently do not pay dividends, investors will benefit from an investment in our common stock only if it appreciates in value.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently do not pay dividends on our common stock. Our Senior Secured Credit Facilities and the indenture governing our Senior Unsecured Notes limit and any future debt agreements that we enter into may limit our ability to pay dividends. As a result, capital appreciation, if any, of our common stock will be the sole source of gain for our stockholders based on current expectations.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Future issuances of our common stock or securities convertible into common stock could result in dilution of our stockholders and could cause our share price to decline.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to opportunistically seek access to additional capital to license or acquire additional products, product candidates or companies to expand our operations or for general corporate purposes. To the extent we raise additional capital by issuing equity securities or securities convertible or exchangeable into common stock, our stockholders may experience substantial dilution. We may sell common stock, and we may sell convertible or exchangeable securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell such common stock, convertible or exchangeable securities or other equity securities in subsequent transactions, existing stockholders may be materially diluted.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GENERAL RISKS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The accuracy of our financial reporting depends on the effectiveness of our internal control over financial reporting. A material weakness in our internal control over financial reporting could have an adverse effect on our business and financial results and our ability to meet our reporting obligations could be negatively affected, each of which could negatively affect the trading price of our common stock.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal control over financial reporting can provide only reasonable assurance with respect to the preparation and fair presentation of financial statements and may not prevent or detect misstatements. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis. Failure to maintain effective internal control over financial reporting, or lapses in disclosure controls and procedures, could impact our financial information and disclosures, require significant resources to remediate, and expose us to legal or regulatory proceedings.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review and update our internal controls and disclosure controls and procedures. In addition, we are required under the Sarbanes-Oxley Act of 2002 to report annually on our internal control over financial reporting.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our system of internal controls, however well-designed, can provide only reasonable, not absolute, assurances that the objectives of the system are met. If we, or our independent registered public accounting firm, determine that our internal controls over financial reporting, or the internal controls of other companies </span></div></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="width:100.000%"><div style="display:inline-block;vertical-align:top;width:46.551%"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may acquire, are not effective, or we discover areas that need improvement in the future, these shortcomings could have an adverse effect on our business and financial reporting, and the trading price of our common stock could be negatively affected.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our success is dependent on our continued ability to attract, motivate and retain key personnel, and any failure to attract or retain key personnel may negatively affect our business.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the specialized scientific nature of our business, our ability to develop products and to compete with our current and future competitors largely depends upon our ability to attract, retain and motivate highly qualified managerial and key scientific and technical personnel (including quality and manufacturing personnel). If we are unable to retain the services of one or more of the principal members of senior management or other key employees, our ability to implement our business strategy could be materially harmed. We face intense competition for qualified employees from biopharmaceutical companies, research organizations and academic institutions. Attracting, retaining or replacing these personnel on acceptable terms may be difficult and time-consuming given the high demand in our industry for similar personnel. We believe part of being able to attract, motivate and retain personnel is our ability to offer a competitive compensation package, including equity incentive awards. If we cannot offer a competitive compensation package to attract and retain the qualified personnel necessary for the continued development of our business, we may not be able to maintain our operations or grow our business.</span></div></div><div style="display:inline-block;max-width:6.896%;min-width:5.896%;vertical-align:top"></div><div style="display:inline-block;vertical-align:top;width:46.553%"></div></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent sales of unregistered securities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of proceeds</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Purchases of equity securities</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Share repurchase program</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information regarding shares of our common stock that we repurchased during the three months ended June&#160;30, 2022:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:22.438%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.712%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.783%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.784%"></td><td style="width:0.1%"></td></tr><tr><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Issuer Purchases of Equity Securities</span></td></tr><tr><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Periods</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Price Paid Per Share</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Approximate Dollar Value of Shares That May Yet Be Purchased Under the Plans or Programs</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">April 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$39.96&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">333,000&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72,013,726&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">May 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30.64&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">325,000&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,054,921&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 2022</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,054,921&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,000&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658,000&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2021, the Company announced that the Board of Directors had authorized management to repurchase, from time to time, up to an aggregate $250.0&#160;million of our common stock under a board-approved share repurchase program (the Share Repurchase Program). The Share Repurchase Program does not obligate the Company to acquire any specific number of shares. Repurchased shares will be available for use in connection with our stock plans and for other corporate purposes. The Share Repurchase Program expires on November 11, 2022.</span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_133"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 3. DEFAULTS UPON SENIOR SECURITIES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_136"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 4. MINE SAFETY DISCLOSURES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_139"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 5. OTHER INFORMATION</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i4ef4253100994f989fd72d1c0fd41d25_142"></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ITEM 6. EXHIBITS</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits required to be filed by Item 601 of Regulation S-K are listed in the Exhibit Index immediately preceding the exhibits hereto.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_145"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="-sec-extract:summary;margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit Index</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.275%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit</span></div><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Number</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1 &#8224;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1367644/000136764422000072/a051622-emergenttoacquir.htm">Asset Purchase Agreement, dated May 15, 2022, by and among Emergent BioSolutions Inc., the Sellers identified therein, Chimerix, Inc., (incorporated by reference to Exhibit 2 to the Company's Current Report on Form 8-K, filed on May 16, 2022).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1#&#8224;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a200-2017x92634xmod28exe.htm">Modification No. 28, effective April 14, 2022, to the CDC BioThrax Procurement Contract</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2#&#8224;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a200-2017x92634xmod29exe.htm">Modification No. 29, effective June 16, 2022, to the CDC BioThrax Procurement Contract</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1 #</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a311-kramercert63022.htm">Certification of the Chief Executive Officer, pursuant to Exchange Act Rule 13a-14(a).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.2 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a312-lindhalcert63022.htm">Certification of the Chief Financial Officer pursuant to Exchange Act Rule 13a-14(a).</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1 #</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a321-kramercert63022.htm">Certification of the Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.2 #</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a322-lindhalcert63022.htm">Certification of the Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following financial information related to the Company&#8217;s Quarterly Report on Form 10-Q for the quarter ended June&#160;30, 2022, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Cash Flows, (v) the Condensed Consolidated Statement of Changes in Stockholders' Equity; and (vi) the related Notes to the Condensed Consolidated Financial Statements.</span></div><div><span><br/></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104 #</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File, formatted in iXBRL and contained in Exhibit 101.<br/></span></td></tr></table></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">#&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;    Certain portions of this exhibit have been omitted because they are not material and they are the type of information that the registrant treats as private or confidential.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><div id="i4ef4253100994f989fd72d1c0fd41d25_148"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div style="text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:11pt;font-weight:400;line-height:120%">EMERGENT BIOSOLUTIONS INC.</span></div></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SIGNATURES</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:60.233%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EMERGENT BIOSOLUTIONS INC.</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ROBERT G. KRAMER</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Robert G. Kramer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President, Chief Executive Officer and Director</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Executive Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 1, 2022</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By: </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/RICHARD S. LINDAHL</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Richard S. Lindahl</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer and Treasurer</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial and Accounting Officer)</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: August 1, 2022</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>a200-2017x92634xmod28exe.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>a200-2017x92634xmod28exe</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- a200-2017x92634xmod28exe001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a200-2017x92634xmod28exe001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type  of information that the registrant treats as private or confidential. Double asterisks denote omissions.      AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT     1 2  2. AMENDMENT/MODIFICATION NO.     ASPR/SNS  ASPR/SNS      US DEPT OF HEALTH &amp; HUMAN SERVICES  ASPR/SNS       9A. AMENDMENT OF SOLICITATION NO.  EMERGENT BIODEFENSE OPERATIONS LANSING LLC 330303  Attn: DIANA I ORORBIA-KNAPTON             10A. MODIFICATION OF CONTRACT/ORDER NO.    FACILITY       12/08/2016        P00028    See Block 16C OS292426   6. ISSUED BY CODE ASPR/SNS  7. ADMINISTERED BY (ff other than Item 6) CODE ASPR/SNS                                11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS    D The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers Dis extended.  Dis not extended.  Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing  Items 8 and 15, and returning copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By  separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE  RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR  OFFER. If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided  each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.  12. ACCOUNTING AND APPROPRIATION DATA(lf required) Net Increase: $[**]  See Schedule  13, THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS, IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.    CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT  ORDER NO. IN ITEM 10A.    B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office,  appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).  X  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  FAR 52.212-4(c) Changes   D. OTHER (Specify type of modification and authority)      E. IMPORTANT: Contractor Dis not is required to sign this document and return  1  copies to the issuing office.  14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)  Tax ID Number: [**]  DUNS Number: [**]  This modification is to order an additional [**] doses ([**] vials) of Biothrax (AVA) for  the Department of Defense (DoD). All product is to be shipped FOB Destination.  Product to have [**] months of shelf-life remaining and is priced in accordance with CLIN  0005 pricing ($[**] per dose). Total contract value is hereby increased by $[**] from $[**]  to [**].    Period of Performance: [**] to [**]    Add Item 8 as follows:  Continued ...  Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a200-2017x92634xmod28exe002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a200-2017x92634xmod28exe002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">      15A. NAME AND TITLE OF SIGNER (Type or print)  Paul Williams SVP, Government-MCM Business  16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)    Caleb Owen  158. CONTRACTOR/OFFEROR  /s/ Paul Williams      (Signature of person authorized to sign)  15C. DATE SIGNED    Aprl4,2022  168. UNITED STATES OF AMERICA  Caleb W. Owen -S       (Signature of Contracting Officer)  16C. DATE SIGNED    04/14/2022  Previous edition unusable STANDARD FORM 30 (REV. 11/2016)  Prescribed by GSA FAR (48 CFR) 53.243    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a200-2017x92634xmod28exe003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a200-2017x92634xmod28exe003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">        CONTINUATION SHEET  REFERENCE NO. OF DOCUMENT BEING CONTINUED OF  HHSD200201792634C/P00028 2  NAME OF OFFEROR OR CONTRACTOR  EMERGENT BIODEFENSE OPERATIONS LANSING LLC 330303    ITEM NO.  (A)  SUPPLIES/SERVICES  (B)  QUANTITY  (C)  UNIT  (D)  UNIT PRICE  (E)  AMOUNT  (F)  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a200-2017x92634xmod28exe004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a200-2017x92634xmod28exe004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">          8 Biodefense Ancillary Vaccines for DoD   [**] doses ([**] vials)  Unit Price: $[**]/dose  Extended Price: $[**]    Obligated Amount: $[**]    Project Data:  132698.1.HA00OSSNS0l.26088-Strategic National  Stock. [**]  Accounting Info:  2022.1997003.26088 Appr. Yr.: 2022 CAN: 1997003  Object Class: 26088  Funded: $[**]         [**]  NSN 7540-01-152-8067 OPTIONAL FORM 336 (4-86)  Sponsored by GSA  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a200-2017x92634xmod28exe005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a200-2017x92634xmod28exe005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">      FAR (48 CFR) 53.110  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a200-2017x92634xmod29exe.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>a200-2017x92634xmod29exe</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- a200-2017x92634xmod29exe001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a200-2017x92634xmod29exe001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the  type of information that the registrant treats as private or confidential. Double asterisks denote omissions.           8. NAME AND ADDRESS OF CONTRACTOR (No.. street. county, State and ZIP Code)         LANSING Ml 489062933                 AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT  11. CONTRACT ID CODE I PAGE OF PAGES   1  I 2    P00029   See Block 16C OS296415   6. ISSUED BY CODE ASPR/SNS  7 ADMINISTERED BY (If other than Item 6) CODE IASPR/SNS  ASPR/SNS  ASPR/SNS     US DEPT OF HEALTH &amp; HUMAN  ASPR/SNS  SERVICES  2945 FLOWERS ROAD  ATLANTA, GA 30341     2945 FLOWERS ROAD  ATLANTA, GA 30341                  11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS  &#9633;The above numbered solicitation is amended as set forth in Item 14. The hour and date specified for receipt of Offers Dis extended.  Dis not extended.  Offers must acknowledge receipt of this amendment prior to the 10ur and date specified in the solicitation or as amended , by one of the following methods: (a) By completing  Items 8 and 15, and returning   copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted; or (c) By  separate letter or electronic communication which includes a reference to the solicitation and amendment numbers. FAILURE OF YOUR ACKNOWLEDGEMENT TO BE  RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR  OFFER. If by virtue of this amendment you desire to change an offer already submitted, such change may be made by letter or electronic communication, provided  each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified.  12. ACCOUNTING AND APPROPRIATION DATA/If required) Net Increase: $[**]  See Schedule    13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS. IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14.    CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT  ORDER NO. IN ITEM 10A.   B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office,  appropriation data, etc.) SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b).    X  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF:  FAR 52.212-4(c) Changes   D. OTHER (Specify type of modification and authority)  E. IMPORTANT: Contractor Dis not 0 is required to sign this document and return _________________ 1 copies to the issuing office.      14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.)  Tax ID Number: [**]  DUNS Number: [**]  This modification is to order an additional [**] doses ([**] vials) of Biothrax (AVA) for  the Department of Defense (DoD). All product is to be shipped FOB Destination. All  product to be shipped by NLT [**]in accordance with final delivery instructions Lo be  provided by SNS prior to shipment. Product to have [**] months of shelf-life remaining and  is priced in accordance with CLIN 0005 pricing ($[**] per dose). Total contract value is  hereby increased by $[**] from $[**] to $[**].    Period of Performance: [**] to [**]    Continued ...  Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect.  NER (Type or print) 16A. NAME AND TITLE OF CONTRACTING OFFICER (Type or print)  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a200-2017x92634xmod29exe002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a200-2017x92634xmod29exe002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">      Caleb Owen    16B. UNITED STATES OF AMERICA  Caleb W. Owen - S  (Signature of Contracting Officer)    16C. DATE SIGNED  06/16/222  Previous edition unusable STANDARD FORM 30 (REV. 1112016)  Prescribed by GSA FAR (48 CFR) 53.243  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a200-2017x92634xmod29exe003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a200-2017x92634xmod29exe003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">        NAME OF OFFEROR OR CONTRACTOR  EMERGENT BIODEFENSE OPERATIONS LANSING LLC 330303  ITEM NO.  (A)  SUPPLIES/SERVICES  (B)  QUANTITY  (C)  UNIT  (D)  UNIT PRICE  (E)  AMOUNT  (F)  REFERENCE NO. OF DOCUMENT BEING CONTINUED        </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- a200-2017x92634xmod29exe004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="a200-2017x92634xmod29exe004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">          9  Add Item 9 as follows:  Biodefense Ancillary Vaccine for DoD Order #2   [**] doses ([**]vials)  Unit Price: $[**]/dose  Extended Price: $[**]    Project Data:  132821.1.HA00OSSNS0l.26088-Strategic National  Stock. [**]  Accounting Info:  2022.1992211.26088 Appr. Yr.: 2022 CAN: 1992211  Object Class: 26088  Funded: $[**]    Project Data:  132698.1.HA00OSSNS0l.26088-Strategic National  Stock. [**]  Accounting Info:  2022.1997003.26088 Appr. Yr.: 2022 CAN: 1997003  Object Class: 26088  Funded: $[**]      [**]      D6      [**]      [**]  NSN 7540-01-152-8067 OPTIONAL FORM 336 (4-86)  Sponsored by GSA  FAR (48CFR) 53.110  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>a311-kramercert63022.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i3bd5ecc4b2a945688b73b0e8679682ea_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Robert G. Kramer, certify that&#58;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Emergent BioSolutions Inc.&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Date&#58; August&#160;1, 2022 </font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">&#47;s&#47;ROBERT G. KRAMER</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Robert G. Kramer</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Chief Executive Officer</font></div><div style="height:69.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>a312-lindhalcert63022.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i21fbca53cbd240c090e7b0e1b787c4f9_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 31.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Richard S. Lindahl, certify that&#58;&#160;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;I have reviewed this Quarterly Report on Form 10-Q of Emergent BioSolutions Inc.&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5)&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58; </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information, and </font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;August&#160;1, 2022</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%;text-decoration:underline">&#47;s&#47;RICHARD S. LINDAHL</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Richard S. Lindahl</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Financial Officer</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>a321-kramercert63022.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="id841872724f74d32b5c55a5e68481616_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT 32.1</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Quarterly Report on Form&#160;10-Q&#160;of Emergent BioSolutions Inc. (the &#34;Company&#34;) for the period ended&#160;June&#160;30, 2022&#160;as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned, Robert G. Kramer, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58;</font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt;text-indent:-36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-indent:-13.5pt"><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58;&#160;August&#160;1, 2022</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47;ROBERT G. KRAMER</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Robert G. Kramer</font></div><div><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Chief Executive Officer</font></div><div><font><br></font></div><div><font><br></font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>7
<FILENAME>a322-lindhalcert63022.htm
<DESCRIPTION>EX-32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2022 Workiva -->
<title>Document</title></head><body><div id="i7e92b5a0a7d2493cb1ad7ba7f299acc2_1"></div><div style="min-height:72pt;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:144%">EXHIBIT 32.2</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">In connection with the Quarterly Report on Form 10-Q of Emergent BioSolutions Inc. (the &#34;Company&#34;) for the period ended&#160;June&#160;30, 2022&#160;as filed with the Securities and Exchange Commission on the date hereof (the &#34;Report&#34;), the undersigned, Richard S. Lindahl, Chief Financial Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, that&#58; </font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(1)&#160;&#160;&#160;&#160;The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">(2)&#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Date&#58;&#160;August&#160;1, 2022</font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">&#47;s&#47;RICHARD S. LINDAHL</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Richard S. Lindahl</font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:125%">Chief Financial Officer</font></div><div style="margin-bottom:8pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:0.08pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>ebs-20220630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:76cb5594-9318-4e51-9277-4582eaf35bfa,g:cb82d48c-139c-44ae-8052-a281d9df29e8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:ebs="http://emergentbiosolutions.com/20220630" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://emergentbiosolutions.com/20220630">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20220630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20220630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20220630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="ebs-20220630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://emergentbiosolutions.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofOperations" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeLoss" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Business" roleURI="http://emergentbiosolutions.com/role/Business">
        <link:definition>2101101 - Disclosure - Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BusinessDetails" roleURI="http://emergentbiosolutions.com/role/BusinessDetails">
        <link:definition>2402401 - Disclosure - Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Basisofpresentationandprinciplesofconsolidation" roleURI="http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation">
        <link:definition>2103102 - Disclosure - Basis of presentation and principles of consolidation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandprinciplesofconsolidationPolicies" roleURI="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies">
        <link:definition>2204201 - Disclosure - Basis of presentation and principles of consolidation (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisofpresentationandprinciplesofconsolidationDetails" roleURI="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails">
        <link:definition>2405402 - Disclosure - Basis of presentation and principles of consolidation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventoriesnet" roleURI="http://emergentbiosolutions.com/role/Inventoriesnet">
        <link:definition>2106103 - Disclosure - Inventories, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetTables" roleURI="http://emergentbiosolutions.com/role/InventoriesnetTables">
        <link:definition>2307301 - Disclosure - Inventories, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesnetScheduleofInventoryDetails" roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails">
        <link:definition>2408403 - Disclosure - Inventories, net - Schedule of Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Propertyplantandequipmentnet" roleURI="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet">
        <link:definition>2109104 - Disclosure - Property, plant and equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentnetTables" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables">
        <link:definition>2310302 - Disclosure - Property, plant and equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails">
        <link:definition>2411404 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyplantandequipmentNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails">
        <link:definition>2412405 - Disclosure - Property, plant and equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://emergentbiosolutions.com/role/Leases">
        <link:definition>2113105 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://emergentbiosolutions.com/role/LeasesTables">
        <link:definition>2314303 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofLeaseExpenseDetails" roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails">
        <link:definition>2415406 - Disclosure - Leases - Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesSupplementalBalanceSheetInformationDetails" roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails">
        <link:definition>2416407 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Intangibleassets" roleURI="http://emergentbiosolutions.com/role/Intangibleassets">
        <link:definition>2117106 - Disclosure - Intangible assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsTables" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsTables">
        <link:definition>2318304 - Disclosure - Intangible assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails">
        <link:definition>2419408 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails">
        <link:definition>2420409 - Disclosure - Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails">
        <link:definition>2421410 - Disclosure - Intangible assets - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleassetsGoodwillRollForwardDetails" roleURI="http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails">
        <link:definition>2422411 - Disclosure - Intangible assets - Goodwill Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Fairvaluemeasurements" roleURI="http://emergentbiosolutions.com/role/Fairvaluemeasurements">
        <link:definition>2123107 - Disclosure - Fair value measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsTables" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables">
        <link:definition>2324305 - Disclosure - Fair value measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails">
        <link:definition>2425412 - Disclosure - Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsContingentConsiderationRollForwardDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails">
        <link:definition>2426413 - Disclosure - Fair value measurements - Contingent Consideration Roll Forward (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsAdditionalInformationDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails">
        <link:definition>2427414 - Disclosure - Fair value measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails">
        <link:definition>2428415 - Disclosure - Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Derivativeinstrumentsandhedgingactivities" roleURI="http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities">
        <link:definition>2129108 - Disclosure - Derivative instruments and hedging activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesTables" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables">
        <link:definition>2330306 - Disclosure - Derivative instruments and hedging activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails">
        <link:definition>2431416 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails">
        <link:definition>2432417 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails">
        <link:definition>2433418 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails">
        <link:definition>2434419 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Debt" roleURI="http://emergentbiosolutions.com/role/Debt">
        <link:definition>2135109 - Disclosure - Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtTables" roleURI="http://emergentbiosolutions.com/role/DebtTables">
        <link:definition>2336307 - Disclosure - Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtScheduleDetails" roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails">
        <link:definition>2437420 - Disclosure - Debt - Schedule (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DebtNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails">
        <link:definition>2438421 - Disclosure - Debt - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenuerecognition" roleURI="http://emergentbiosolutions.com/role/Revenuerecognition">
        <link:definition>2139110 - Disclosure - Revenue recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionTables" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionTables">
        <link:definition>2340308 - Disclosure - Revenue recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails">
        <link:definition>2441422 - Disclosure - Revenue recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionDisaggregationofRevenueDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails">
        <link:definition>2442423 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionPerformanceObligationsDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails">
        <link:definition>2443424 - Disclosure - Revenue recognition - Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionPerformanceObligationsDetails_1" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails_1">
        <link:definition>2443424 - Disclosure - Revenue recognition - Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionRemainingPerformanceObligationDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails">
        <link:definition>2444425 - Disclosure - Revenue recognition - Remaining Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionRemainingPerformanceObligationDetails_1" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails_1">
        <link:definition>2444425 - Disclosure - Revenue recognition - Remaining Performance Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionContractLiabilitiesDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails">
        <link:definition>2445426 - Disclosure - Revenue recognition - Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuerecognitionAccountsReceivableDetails" roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails">
        <link:definition>2446427 - Disclosure - Revenue recognition - Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Incometaxes" roleURI="http://emergentbiosolutions.com/role/Incometaxes">
        <link:definition>2147111 - Disclosure - Income taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncometaxesDetails" roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails">
        <link:definition>2448428 - Disclosure - Income taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomelosspershare" roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershare">
        <link:definition>2149112 - Disclosure - Net Income (loss) per share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomelosspershareTables" roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershareTables">
        <link:definition>2350309 - Disclosure - Net Income (loss) per share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomelosspershareDetails" roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershareDetails">
        <link:definition>2451429 - Disclosure - Net Income (loss) per share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://emergentbiosolutions.com/role/Equity">
        <link:definition>2152113 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://emergentbiosolutions.com/role/EquityTables">
        <link:definition>2353310 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/EquityNarrativeDetails">
        <link:definition>2454430 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofStockbasedCompensationExpenseDetails" roleURI="http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails">
        <link:definition>2455431 - Disclosure - Equity - Schedule of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityChangesinAccumulatedOtherComprehensiveLossDetails" roleURI="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails">
        <link:definition>2456432 - Disclosure - Equity - Changes in Accumulated Other Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" roleURI="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails">
        <link:definition>2457433 - Disclosure - Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://emergentbiosolutions.com/role/SegmentInformation">
        <link:definition>2158114 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://emergentbiosolutions.com/role/SegmentInformationTables">
        <link:definition>2359311 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails">
        <link:definition>2460434 - Disclosure - Segment Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails">
        <link:definition>2461435 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails">
        <link:definition>2462436 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Commitmentsandcontingencies" roleURI="http://emergentbiosolutions.com/role/Commitmentsandcontingencies">
        <link:definition>2163115 - Disclosure - Commitments and contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="ebs_MeasurementInputProbabilityofPaymentMember" abstract="true" name="MeasurementInputProbabilityofPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" abstract="false" name="PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_MilestonePaymentOneMember" abstract="true" name="MilestonePaymentOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantConsiderationThreshold" abstract="false" name="DebtInstrumentCovenantConsiderationThreshold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ContractsAndGrantsMember" abstract="true" name="ContractsAndGrantsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_MilestonePaymentFourMember" abstract="true" name="MilestonePaymentFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" abstract="false" name="OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ContractWithCustomerLiabilityAdditions" abstract="false" name="ContractWithCustomerLiabilityAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_ContractDevelopmentAndManufacturingLeasesMember" abstract="true" name="ContractDevelopmentAndManufacturingLeasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ChimerixAssetAcquisitionMember" abstract="true" name="ChimerixAssetAcquisitionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioOne" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioOne" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" abstract="false" name="PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_SeniorUnsecuredNotesDueAugust2028Member" abstract="true" name="SeniorUnsecuredNotesDueAugust2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AdjustedGrossMargin" abstract="false" name="AdjustedGrossMargin" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" abstract="false" name="CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_RegulatoryMilestonesMember" abstract="true" name="RegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_NumberOfProductCandidates" abstract="false" name="NumberOfProductCandidates" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_ScheduleOfAccountsReceivableNetTableTextBlock" abstract="false" name="ScheduleOfAccountsReceivableNetTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ebs_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="ebs_ProductsSegmentMember" abstract="true" name="ProductsSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ReservationOfManufacturingCapacityMember" abstract="true" name="ReservationOfManufacturingCapacityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AssetsAndLiabilitiesLesseeTableTextBlock" abstract="false" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" abstract="false" name="DebtInstrumentCovenantDebtServiceCoverageRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_NumberOfCategoriesOfPublicHealthThreats" abstract="false" name="NumberOfCategoriesOfPublicHealthThreats" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_ContractDevelopmentAndManufacturingMember" abstract="true" name="ContractDevelopmentAndManufacturingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AcceleratedExpansionOfFillFinishCapacityMember" abstract="true" name="AcceleratedExpansionOfFillFinishCapacityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AmendedCreditAgreementMember" abstract="true" name="AmendedCreditAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_MilestonePaymentThreeMember" abstract="true" name="MilestonePaymentThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioTwo" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioTwo" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="ebs_BARDAMember" abstract="true" name="BARDAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" abstract="false" name="PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" abstract="false" name="DebtInstrumentCovenantNetLeverageRatioRollingPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit" abstract="false" name="AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="ebs_JansenPharmaceuticalsIncMember" abstract="true" name="JansenPharmaceuticalsIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" abstract="false" name="AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_ContractWithCustomerLiabilityDeductions" abstract="false" name="ContractWithCustomerLiabilityDeductions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="ebs_OtherLongTermDebtFacilityMember" abstract="true" name="OtherLongTermDebtFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_ServicesSegmentMember" abstract="true" name="ServicesSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_MilestonePaymentTwoMember" abstract="true" name="MilestonePaymentTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_TermLoanFacilityMember" abstract="true" name="TermLoanFacilityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" abstract="false" name="AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="ebs_ChangeinContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeinContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="ebs_NumberOfRevenueGeneratingProducts" abstract="false" name="NumberOfRevenueGeneratingProducts" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>ebs-20220630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:76cb5594-9318-4e51-9277-4582eaf35bfa,g:cb82d48c-139c-44ae-8052-a281d9df29e8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9e944ae0-d49c-4acc-bb3f-5b857aee9c65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_b74a82e6-0b60-40c9-8866-5ac6e1157d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e944ae0-d49c-4acc-bb3f-5b857aee9c65" xlink:to="loc_us-gaap_AccountsPayableCurrent_b74a82e6-0b60-40c9-8866-5ac6e1157d58" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_44d2a98a-350d-4013-876b-f6d1ca3803cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e944ae0-d49c-4acc-bb3f-5b857aee9c65" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_44d2a98a-350d-4013-876b-f6d1ca3803cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_16a96eb9-bfe7-4252-b58f-fe973cc933e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e944ae0-d49c-4acc-bb3f-5b857aee9c65" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_16a96eb9-bfe7-4252-b58f-fe973cc933e7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_892df5c1-bf17-4f9b-aa74-ed1707c5542e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e944ae0-d49c-4acc-bb3f-5b857aee9c65" xlink:to="loc_us-gaap_NotesPayableCurrent_892df5c1-bf17-4f9b-aa74-ed1707c5542e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_2b2ad38f-1656-4e1e-a5ea-13893036b7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9e944ae0-d49c-4acc-bb3f-5b857aee9c65" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_2b2ad38f-1656-4e1e-a5ea-13893036b7cc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_1f1eb45c-a72b-483b-b226-4aca7ec6d547" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_5430be28-1ac3-4c78-a27c-51553ed65af5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1f1eb45c-a72b-483b-b226-4aca7ec6d547" xlink:to="loc_us-gaap_StockholdersEquity_5430be28-1ac3-4c78-a27c-51553ed65af5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_51a43e81-67a8-42f2-9c5c-cbb8d0779f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_1f1eb45c-a72b-483b-b226-4aca7ec6d547" xlink:to="loc_us-gaap_Liabilities_51a43e81-67a8-42f2-9c5c-cbb8d0779f06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_aadea165-16b9-431f-81c3-7b5ab411218a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8cf7c334-3f55-4694-8fcc-a0b6f78a1e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aadea165-16b9-431f-81c3-7b5ab411218a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8cf7c334-3f55-4694-8fcc-a0b6f78a1e95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_2d931121-90bb-452d-b1cf-ed57eab3f2ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aadea165-16b9-431f-81c3-7b5ab411218a" xlink:to="loc_us-gaap_RestrictedCashCurrent_2d931121-90bb-452d-b1cf-ed57eab3f2ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_eca89aa9-0f95-40cd-b5f3-18762dfa2e2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aadea165-16b9-431f-81c3-7b5ab411218a" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_eca89aa9-0f95-40cd-b5f3-18762dfa2e2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_a130d6b3-2e77-4877-a63c-ec33ca4896e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aadea165-16b9-431f-81c3-7b5ab411218a" xlink:to="loc_us-gaap_InventoryNet_a130d6b3-2e77-4877-a63c-ec33ca4896e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6a8c5e9b-8dd8-4b8a-89e2-98e68c2bca61" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_aadea165-16b9-431f-81c3-7b5ab411218a" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_6a8c5e9b-8dd8-4b8a-89e2-98e68c2bca61" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_12c6d259-42d0-490a-9f16-0a9c4e83d753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_96d50fa6-0326-4a91-aed4-11028cbcfeef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12c6d259-42d0-490a-9f16-0a9c4e83d753" xlink:to="loc_us-gaap_PreferredStockValue_96d50fa6-0326-4a91-aed4-11028cbcfeef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_470335d1-7aa4-4b4b-9dc7-6efb653a3a48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12c6d259-42d0-490a-9f16-0a9c4e83d753" xlink:to="loc_us-gaap_CommonStockValue_470335d1-7aa4-4b4b-9dc7-6efb653a3a48" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_38be7771-d006-4264-9add-f67d9442e79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12c6d259-42d0-490a-9f16-0a9c4e83d753" xlink:to="loc_us-gaap_TreasuryStockValue_38be7771-d006-4264-9add-f67d9442e79e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_bdd1376d-6abb-4a38-b15f-b1a99a18d48f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12c6d259-42d0-490a-9f16-0a9c4e83d753" xlink:to="loc_us-gaap_AdditionalPaidInCapital_bdd1376d-6abb-4a38-b15f-b1a99a18d48f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b6ba196-05f7-4efb-96f3-c8eb655a60fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12c6d259-42d0-490a-9f16-0a9c4e83d753" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b6ba196-05f7-4efb-96f3-c8eb655a60fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dbf7e4e4-f751-40ba-a21c-f8a20b7ec6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_12c6d259-42d0-490a-9f16-0a9c4e83d753" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_dbf7e4e4-f751-40ba-a21c-f8a20b7ec6bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_91cdcb46-54fe-4329-aca6-b509c8c07ae3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_aec9083a-4562-4d14-8331-e72c8b9ffa69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_91cdcb46-54fe-4329-aca6-b509c8c07ae3" xlink:to="loc_us-gaap_AssetsCurrent_aec9083a-4562-4d14-8331-e72c8b9ffa69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_29c27575-efb8-420d-ba54-c8fd02832fce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_91cdcb46-54fe-4329-aca6-b509c8c07ae3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_29c27575-efb8-420d-ba54-c8fd02832fce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69a801fa-28c7-4b03-84c3-58241ddd4920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_91cdcb46-54fe-4329-aca6-b509c8c07ae3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_69a801fa-28c7-4b03-84c3-58241ddd4920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_78d51803-e581-4b72-8e0b-c0a9f8e5db25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_91cdcb46-54fe-4329-aca6-b509c8c07ae3" xlink:to="loc_us-gaap_Goodwill_78d51803-e581-4b72-8e0b-c0a9f8e5db25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_367cbb07-abc5-4dbd-a3fc-821329a09f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_91cdcb46-54fe-4329-aca6-b509c8c07ae3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_367cbb07-abc5-4dbd-a3fc-821329a09f7c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a89f0c77-a4b5-474c-ab5c-83f3e62eefa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8760e469-6313-4b17-958a-1811c56c2bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a89f0c77-a4b5-474c-ab5c-83f3e62eefa7" xlink:to="loc_us-gaap_LiabilitiesCurrent_8760e469-6313-4b17-958a-1811c56c2bcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c6702049-452b-424c-8bf1-510455b20043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a89f0c77-a4b5-474c-ab5c-83f3e62eefa7" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c6702049-452b-424c-8bf1-510455b20043" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_e65dcdf8-194c-46da-896c-e77aaf2744b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a89f0c77-a4b5-474c-ab5c-83f3e62eefa7" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_e65dcdf8-194c-46da-896c-e77aaf2744b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_49ce66c1-5680-4761-97ac-56f13febcfee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_a89f0c77-a4b5-474c-ab5c-83f3e62eefa7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_49ce66c1-5680-4761-97ac-56f13febcfee" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_33eabb61-641f-4830-ae1c-4900f1c5c2df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bff7cbf3-1113-4862-b8a5-696a2433d1dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_33eabb61-641f-4830-ae1c-4900f1c5c2df" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bff7cbf3-1113-4862-b8a5-696a2433d1dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5b89c57f-3696-43e4-8515-5edf5637ecca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_33eabb61-641f-4830-ae1c-4900f1c5c2df" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5b89c57f-3696-43e4-8515-5edf5637ecca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84d02174-a996-4642-90ae-309b9a1d526f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_5eea3703-b7be-49ed-9820-9d1562da2306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84d02174-a996-4642-90ae-309b9a1d526f" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_5eea3703-b7be-49ed-9820-9d1562da2306" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_dad6bb5d-dddd-423e-98e9-4499d53f29e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_84d02174-a996-4642-90ae-309b9a1d526f" xlink:to="loc_us-gaap_OperatingIncomeLoss_dad6bb5d-dddd-423e-98e9-4499d53f29e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_7dceb3e5-be47-446e-82ad-106c1b3dd2fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_eea857b4-8c0b-40b3-8aee-75cb7ba9e155" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_7dceb3e5-be47-446e-82ad-106c1b3dd2fc" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_eea857b4-8c0b-40b3-8aee-75cb7ba9e155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_746c1375-6327-478a-b263-4c5630f30bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_7dceb3e5-be47-446e-82ad-106c1b3dd2fc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_746c1375-6327-478a-b263-4c5630f30bcc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bba34ed1-4d12-4497-b537-b7d1f4398c52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_7dceb3e5-be47-446e-82ad-106c1b3dd2fc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_bba34ed1-4d12-4497-b537-b7d1f4398c52" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_03a813e0-fdcd-4107-9dd9-e766c5cad169" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingCostsAndExpenses_7dceb3e5-be47-446e-82ad-106c1b3dd2fc" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_03a813e0-fdcd-4107-9dd9-e766c5cad169" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_cd217e98-8560-4d56-b544-fe1761828221" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_bf6e600d-96c5-40cb-9cc7-e7328105a13d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_cd217e98-8560-4d56-b544-fe1761828221" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_bf6e600d-96c5-40cb-9cc7-e7328105a13d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ad86084-43ef-4f72-9929-8271e0b51994" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Revenues_cd217e98-8560-4d56-b544-fe1761828221" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3ad86084-43ef-4f72-9929-8271e0b51994" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8eac87b9-7b7b-457c-b84d-9914fbc94449" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_e3269ef9-dbb0-49c7-af74-7a5f1221f691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8eac87b9-7b7b-457c-b84d-9914fbc94449" xlink:to="loc_us-gaap_Revenues_e3269ef9-dbb0-49c7-af74-7a5f1221f691" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_48d599aa-869d-42ec-b13d-2ac6860266d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_8eac87b9-7b7b-457c-b84d-9914fbc94449" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_48d599aa-869d-42ec-b13d-2ac6860266d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_b4a6e45f-f460-4d92-a425-b2a58475034c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_3cf7f825-dc23-4bc8-93cb-0b9250d52eee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b4a6e45f-f460-4d92-a425-b2a58475034c" xlink:to="loc_us-gaap_InterestExpense_3cf7f825-dc23-4bc8-93cb-0b9250d52eee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_be47f0fc-93f7-4530-97c7-e14dd34daa89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_b4a6e45f-f460-4d92-a425-b2a58475034c" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_be47f0fc-93f7-4530-97c7-e14dd34daa89" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_763398f4-9975-4b59-bc37-c0797ca3bc42" xlink:href="ebs-20220630.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_7a844a9a-0862-4be3-b469-176a840889ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_763398f4-9975-4b59-bc37-c0797ca3bc42" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_7a844a9a-0862-4be3-b469-176a840889ed" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_670d7344-9ab7-4d7d-8a73-a87455eb3691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_763398f4-9975-4b59-bc37-c0797ca3bc42" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_670d7344-9ab7-4d7d-8a73-a87455eb3691" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_656bf455-3d29-4d73-b8cf-fa5ead3b6dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0e59e2e1-767c-4cb3-b7de-04f434b5c4d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_656bf455-3d29-4d73-b8cf-fa5ead3b6dfe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0e59e2e1-767c-4cb3-b7de-04f434b5c4d9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f57a87b4-12c4-49d7-af97-e770c96629a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_656bf455-3d29-4d73-b8cf-fa5ead3b6dfe" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_f57a87b4-12c4-49d7-af97-e770c96629a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_33d34d12-6144-4ec4-a305-9dcf7b9ff55d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_fd521bea-9b14-420a-be45-dfa2b9185c4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_33d34d12-6144-4ec4-a305-9dcf7b9ff55d" xlink:to="loc_us-gaap_NetIncomeLoss_fd521bea-9b14-420a-be45-dfa2b9185c4c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e5d8b017-d7de-4f0d-9edb-b5efea550307" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_33d34d12-6144-4ec4-a305-9dcf7b9ff55d" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_e5d8b017-d7de-4f0d-9edb-b5efea550307" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_afc4db81-27b0-4bfd-8e8d-09653295b1a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4d64c3f3-72c7-4b04-bbfd-3287c44eaaf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_afc4db81-27b0-4bfd-8e8d-09653295b1a3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_4d64c3f3-72c7-4b04-bbfd-3287c44eaaf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4ba901c6-c483-435c-95e0-db2857012334" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_afc4db81-27b0-4bfd-8e8d-09653295b1a3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4ba901c6-c483-435c-95e0-db2857012334" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_25170e1f-c13a-4c3f-8da9-5e432661cd15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_afc4db81-27b0-4bfd-8e8d-09653295b1a3" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_25170e1f-c13a-4c3f-8da9-5e432661cd15" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4c59641-648a-4460-a16f-8fdca744c1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_afc4db81-27b0-4bfd-8e8d-09653295b1a3" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d4c59641-648a-4460-a16f-8fdca744c1ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_27dcd500-ecce-4025-81af-c09a1ec7396a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_ShareBasedCompensation_27dcd500-ecce-4025-81af-c09a1ec7396a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b4339b74-e601-4511-b364-2d6310424f76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b4339b74-e601-4511-b364-2d6310424f76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5ef31abd-08af-4b9e-825f-deb0678cc901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_5ef31abd-08af-4b9e-825f-deb0678cc901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fe5468ae-3b54-4acc-b7a5-c805b580f075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_fe5468ae-3b54-4acc-b7a5-c805b580f075" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_451375c7-5fd8-4558-b896-30cdf02f938e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_451375c7-5fd8-4558-b896-30cdf02f938e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_512e75d5-c15f-4608-a5e8-6db4a336ec6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_512e75d5-c15f-4608-a5e8-6db4a336ec6a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_be9c01e2-e89b-45df-9dfc-2949173bbca0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_be9c01e2-e89b-45df-9dfc-2949173bbca0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3cf50912-6494-43f0-8dbf-6fd995b45079" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_3cf50912-6494-43f0-8dbf-6fd995b45079" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_46f89080-f6cc-4a01-b61f-c24d2c62e20c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_46f89080-f6cc-4a01-b61f-c24d2c62e20c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_6751259a-2eab-4856-a0f1-296ab743d493" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_6751259a-2eab-4856-a0f1-296ab743d493" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9ae24e19-255b-420c-a58f-b866e36c301e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_9ae24e19-255b-420c-a58f-b866e36c301e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_0111fc86-95ef-45f3-9684-a0fc7d1019ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_0111fc86-95ef-45f3-9684-a0fc7d1019ab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_af7d3746-c080-4e6e-a8cf-84ab586cf399" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_NetIncomeLoss_af7d3746-c080-4e6e-a8cf-84ab586cf399" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_790fe972-07ef-4ed0-a6eb-ba912f8b635d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_bf7267d3-8cbd-4183-814e-bf5d886b13ad" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_790fe972-07ef-4ed0-a6eb-ba912f8b635d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8274f6d0-d67f-428b-8849-dab3763ff3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_427d0757-8df7-4798-81bc-a3fdfa598c55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8274f6d0-d67f-428b-8849-dab3763ff3f2" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_427d0757-8df7-4798-81bc-a3fdfa598c55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0682dfc2-a73c-4207-8cfb-6ba46fa03016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8274f6d0-d67f-428b-8849-dab3763ff3f2" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_0682dfc2-a73c-4207-8cfb-6ba46fa03016" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c63291e3-cf2a-4d12-ac0d-54a4d99cdb59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8274f6d0-d67f-428b-8849-dab3763ff3f2" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_c63291e3-cf2a-4d12-ac0d-54a4d99cdb59" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2510380d-0bf8-4b43-beaf-3f7cf31509e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8274f6d0-d67f-428b-8849-dab3763ff3f2" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_2510380d-0bf8-4b43-beaf-3f7cf31509e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_60ed799e-ae48-473a-847c-c986c93071b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8274f6d0-d67f-428b-8849-dab3763ff3f2" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_60ed799e-ae48-473a-847c-c986c93071b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_eaece194-53de-47d6-a9cb-98fe130abfb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8274f6d0-d67f-428b-8849-dab3763ff3f2" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_eaece194-53de-47d6-a9cb-98fe130abfb1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0d1796b-dae5-4cfa-8539-f80b8ffbef98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5ae85c9-ef20-4f58-9938-20084bf9ccc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0d1796b-dae5-4cfa-8539-f80b8ffbef98" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5ae85c9-ef20-4f58-9938-20084bf9ccc6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_fb352b74-3e61-4b7f-b7f5-cdf7668a953f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d0d1796b-dae5-4cfa-8539-f80b8ffbef98" xlink:to="loc_us-gaap_RestrictedCashCurrent_fb352b74-3e61-4b7f-b7f5-cdf7668a953f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16877705-ecbc-4284-a718-e490f0daa843" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e23b98b-a628-4dc2-b892-3abe903cdbe6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_16877705-ecbc-4284-a718-e490f0daa843" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_5e23b98b-a628-4dc2-b892-3abe903cdbe6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#InventoriesnetScheduleofInventoryDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_782329b9-e1da-403b-8b00-97e3c8c23a43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_edcb8898-46d5-4ba9-8d5b-1924f9898644" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_782329b9-e1da-403b-8b00-97e3c8c23a43" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_edcb8898-46d5-4ba9-8d5b-1924f9898644" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_31532e6f-c100-491d-bbd1-135afcbfa431" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_782329b9-e1da-403b-8b00-97e3c8c23a43" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_31532e6f-c100-491d-bbd1-135afcbfa431" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3994995d-2010-44f2-aba0-e95786a782ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_782329b9-e1da-403b-8b00-97e3c8c23a43" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_3994995d-2010-44f2-aba0-e95786a782ac" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0eafbc5b-f182-4255-b486-f6987c0787b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eeecb2c3-0a72-4f55-bde4-6813f9cc93de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0eafbc5b-f182-4255-b486-f6987c0787b7" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_eeecb2c3-0a72-4f55-bde4-6813f9cc93de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_54ccfb7f-bc63-4dc2-8686-6cc1bd6a2d58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_0eafbc5b-f182-4255-b486-f6987c0787b7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_54ccfb7f-bc63-4dc2-8686-6cc1bd6a2d58" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_28977dbb-c421-480c-9b06-d496bd177679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_14ef8b5d-db5f-4656-98a4-5939d5c31677" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_28977dbb-c421-480c-9b06-d496bd177679" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_14ef8b5d-db5f-4656-98a4-5939d5c31677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_6388dc5a-a3fb-4f15-978d-2da1f741ab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_28977dbb-c421-480c-9b06-d496bd177679" xlink:to="loc_us-gaap_OperatingLeaseExpense_6388dc5a-a3fb-4f15-978d-2da1f741ab7c" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_facd39a0-779a-4147-8543-e45287f68e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5d3b85cc-7c4e-464a-a89d-a34e2ba1e592" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_facd39a0-779a-4147-8543-e45287f68e1c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_5d3b85cc-7c4e-464a-a89d-a34e2ba1e592" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_88f8890b-ce56-4c0e-b4ca-fa8257adc2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_facd39a0-779a-4147-8543-e45287f68e1c" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_88f8890b-ce56-4c0e-b4ca-fa8257adc2ff" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1a49882f-e761-46ed-8958-cd2af86efe01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a1bba81a-111a-40d9-93cc-a927b4fb5d63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1a49882f-e761-46ed-8958-cd2af86efe01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_a1bba81a-111a-40d9-93cc-a927b4fb5d63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7c0e8c99-b8df-4fe1-95d5-b0e20b395a24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_1a49882f-e761-46ed-8958-cd2af86efe01" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_7c0e8c99-b8df-4fe1-95d5-b0e20b395a24" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_82ea86fe-c350-4d52-9978-85b6bd92d7aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6bec6a5d-f6e6-49bf-b3a8-851f7debed35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_82ea86fe-c350-4d52-9978-85b6bd92d7aa" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_6bec6a5d-f6e6-49bf-b3a8-851f7debed35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_3456554c-c76b-459f-b03e-df59f6954e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_82ea86fe-c350-4d52-9978-85b6bd92d7aa" xlink:to="loc_us-gaap_DerivativeAssets_3456554c-c76b-459f-b03e-df59f6954e95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_0b6f44cc-8895-4736-bb57-31f118dbfd34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a41db861-86f7-474d-98a1-20a12a031664" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_0b6f44cc-8895-4736-bb57-31f118dbfd34" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_a41db861-86f7-474d-98a1-20a12a031664" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_79cb319b-37d2-4760-b76e-d23b0ca890fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure_0b6f44cc-8895-4736-bb57-31f118dbfd34" xlink:to="loc_us-gaap_DerivativeLiabilities_79cb319b-37d2-4760-b76e-d23b0ca890fa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionAccountsReceivableDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_53320a91-d0c2-4aeb-91ed-4bf1fa33345d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_81b77d83-8a2a-407e-bfe0-312dd0b45d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_53320a91-d0c2-4aeb-91ed-4bf1fa33345d" xlink:to="loc_us-gaap_BilledContractReceivables_81b77d83-8a2a-407e-bfe0-312dd0b45d6c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_1641186a-f0e4-4741-ab1b-1245d3184016" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_53320a91-d0c2-4aeb-91ed-4bf1fa33345d" xlink:to="loc_us-gaap_UnbilledContractsReceivable_1641186a-f0e4-4741-ab1b-1245d3184016" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershareDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#NetIncomelosspershareDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/NetIncomelosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90fd2895-f988-4906-b8d5-333e32cb0ccb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04cf4a35-9bd6-4baa-a627-3cb2cfeae24e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90fd2895-f988-4906-b8d5-333e32cb0ccb" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_04cf4a35-9bd6-4baa-a627-3cb2cfeae24e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_288ea099-3982-44d7-9181-11b17a778f56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_90fd2895-f988-4906-b8d5-333e32cb0ccb" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_288ea099-3982-44d7-9181-11b17a778f56" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#EquityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1e38f585-134f-4129-986a-2cebcf45607b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_ccb46633-754d-47f4-82ba-a76d4a4ab6fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1e38f585-134f-4129-986a-2cebcf45607b" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_ccb46633-754d-47f4-82ba-a76d4a4ab6fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_d6983c7c-0de1-446d-b872-40cb3f30b890" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_1e38f585-134f-4129-986a-2cebcf45607b" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_d6983c7c-0de1-446d-b872-40cb3f30b890" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae5ea0eb-b381-401a-9bad-0e75f3bdad59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_18f5e45f-ca74-4b6d-b1a4-9b5e1bedb2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae5ea0eb-b381-401a-9bad-0e75f3bdad59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_18f5e45f-ca74-4b6d-b1a4-9b5e1bedb2bc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_4423c7d4-d64b-4336-a182-27b4a25b0444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ae5ea0eb-b381-401a-9bad-0e75f3bdad59" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_4423c7d4-d64b-4336-a182-27b4a25b0444" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:calculationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_10b16641-98be-4b1d-b36c-1491fa144358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_34b4ee9d-4818-46a4-8e20-5a7b7aedcf73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_10b16641-98be-4b1d-b36c-1491fa144358" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_34b4ee9d-4818-46a4-8e20-5a7b7aedcf73" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_db85ed77-d716-4eeb-bbe7-d0ba09868922" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_10b16641-98be-4b1d-b36c-1491fa144358" xlink:to="loc_us-gaap_Revenues_db85ed77-d716-4eeb-bbe7-d0ba09868922" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_01cd38a7-78e4-442c-b031-93553bb7ef98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_10b16641-98be-4b1d-b36c-1491fa144358" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_01cd38a7-78e4-442c-b031-93553bb7ef98" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>ebs-20220630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:76cb5594-9318-4e51-9277-4582eaf35bfa,g:cb82d48c-139c-44ae-8052-a281d9df29e8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended" id="i09ece88a708b409081f2c8aa3df926be_CondensedConsolidatedStatementsofOperations">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24cdf547-639f-4ee0-8155-4d8a19dc46e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24cdf547-639f-4ee0-8155-4d8a19dc46e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_e68065c6-81d4-4c0e-b3a4-43200a1e3068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_e68065c6-81d4-4c0e-b3a4-43200a1e3068" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_60e94351-4a51-40dd-9b06-667d2b10ebc6" xlink:href="ebs-20220630.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_60e94351-4a51-40dd-9b06-667d2b10ebc6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6c524317-8456-4063-bd55-44e05665886e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:to="loc_us-gaap_Revenues_6c524317-8456-4063-bd55-44e05665886e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6d279a5b-9ebe-4868-826b-c605e710c7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6d279a5b-9ebe-4868-826b-c605e710c7f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e62d02f2-8802-49dd-8528-e02d5377f523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e62d02f2-8802-49dd-8528-e02d5377f523" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_82e27404-7674-4806-aac4-e41fc5cf61fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_82e27404-7674-4806-aac4-e41fc5cf61fc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8ebb4f6c-e32e-467f-98f4-4efbe10f2e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8ebb4f6c-e32e-467f-98f4-4efbe10f2e3d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_d9d20c95-5566-454f-acec-21031cd50dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_d9d20c95-5566-454f-acec-21031cd50dce" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8819909b-c720-4879-95c4-d7789fc77d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_OperatingIncomeLoss_8819909b-c720-4879-95c4-d7789fc77d34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_eadb7885-848b-46c5-a6a9-a8b1de6e9a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_eadb7885-848b-46c5-a6a9-a8b1de6e9a23" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b5e008f9-8863-4f3f-a4ed-c14a0d94bbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_eadb7885-848b-46c5-a6a9-a8b1de6e9a23" xlink:to="loc_us-gaap_InterestExpense_b5e008f9-8863-4f3f-a4ed-c14a0d94bbe5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_955c0d7f-6db4-458e-b667-265acd2b9d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_eadb7885-848b-46c5-a6a9-a8b1de6e9a23" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_955c0d7f-6db4-458e-b667-265acd2b9d07" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8db1cc30-2492-468d-84d2-a25364f0ee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_eadb7885-848b-46c5-a6a9-a8b1de6e9a23" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8db1cc30-2492-468d-84d2-a25364f0ee9e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_535f665c-54c7-4573-888d-0c09210363eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_535f665c-54c7-4573-888d-0c09210363eb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_59b179de-c81f-4773-a2a2-8ae8a2075325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_59b179de-c81f-4773-a2a2-8ae8a2075325" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_130a5c84-5a84-455b-be38-aefbcb29c3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_NetIncomeLoss_130a5c84-5a84-455b-be38-aefbcb29c3a9" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_3e689e3b-266f-4926-b745-c74419bf3e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_3e689e3b-266f-4926-b745-c74419bf3e09" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d2a0c95c-396c-499e-b03a-4b53673a6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_3e689e3b-266f-4926-b745-c74419bf3e09" xlink:to="loc_us-gaap_EarningsPerShareBasic_d2a0c95c-396c-499e-b03a-4b53673a6e2c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_631c4ffa-c4ac-47f6-a86f-af712824b2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_3e689e3b-266f-4926-b745-c74419bf3e09" xlink:to="loc_us-gaap_EarningsPerShareDiluted_631c4ffa-c4ac-47f6-a86f-af712824b2b2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0e4e5859-994f-4601-ab17-2f1290d9554a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0e4e5859-994f-4601-ab17-2f1290d9554a" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1718f2db-e641-44af-8e0d-ca617d3a6bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0e4e5859-994f-4601-ab17-2f1290d9554a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1718f2db-e641-44af-8e0d-ca617d3a6bfb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f4c48283-9e0a-44da-88a9-a68dc1083a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0e4e5859-994f-4601-ab17-2f1290d9554a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f4c48283-9e0a-44da-88a9-a68dc1083a37" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_40fcba41-16e2-4bfa-aa9d-6449024194e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_StatementTable_40fcba41-16e2-4bfa-aa9d-6449024194e5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_066129dd-2523-40da-af15-4c0d27fffa6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_40fcba41-16e2-4bfa-aa9d-6449024194e5" xlink:to="loc_srt_ProductOrServiceAxis_066129dd-2523-40da-af15-4c0d27fffa6b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_066129dd-2523-40da-af15-4c0d27fffa6b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_066129dd-2523-40da-af15-4c0d27fffa6b" xlink:to="loc_srt_ProductsAndServicesDomain_066129dd-2523-40da-af15-4c0d27fffa6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4bb70af-397f-468f-aceb-b9babcfbfa2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_066129dd-2523-40da-af15-4c0d27fffa6b" xlink:to="loc_srt_ProductsAndServicesDomain_a4bb70af-397f-468f-aceb-b9babcfbfa2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_96546639-5591-456f-8dd2-1510edd32770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4bb70af-397f-468f-aceb-b9babcfbfa2b" xlink:to="loc_us-gaap_ProductMember_96546639-5591-456f-8dd2-1510edd32770" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_3ed282e7-3291-4f39-bad6-0a3c78a45397" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4bb70af-397f-468f-aceb-b9babcfbfa2b" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_3ed282e7-3291-4f39-bad6-0a3c78a45397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_6367c424-228e-4b81-bd48-2702567acbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_3ed282e7-3291-4f39-bad6-0a3c78a45397" xlink:to="loc_us-gaap_ServiceMember_6367c424-228e-4b81-bd48-2702567acbe3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_ec0b88a5-0efb-481e-959e-1e0e1133ee27" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_3ed282e7-3291-4f39-bad6-0a3c78a45397" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_ec0b88a5-0efb-481e-959e-1e0e1133ee27" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_881a137d-a824-4e88-8bae-e5f205659e4d" xlink:href="ebs-20220630.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_a4bb70af-397f-468f-aceb-b9babcfbfa2b" xlink:to="loc_ebs_ContractsAndGrantsMember_881a137d-a824-4e88-8bae-e5f205659e4d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended" id="i985411fe8d9b4a72971aff7937517d64_CondensedConsolidatedStatementsofChangesinStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2b95730c-a8af-4867-9591-dbdfc2257d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_2b95730c-a8af-4867-9591-dbdfc2257d97" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1d29cc05-c5ef-48e8-ab86-fbfa560c5e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1d29cc05-c5ef-48e8-ab86-fbfa560c5e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d7a5ea2b-be3b-4521-9ea2-9f1d74168f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_StockholdersEquity_d7a5ea2b-be3b-4521-9ea2-9f1d74168f83" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_8205432c-3b6c-42f3-990c-a6e3593cc3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_TreasuryStockCommonShares_8205432c-3b6c-42f3-990c-a6e3593cc3db" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_64b88b39-8ad6-4ee1-a6aa-96c9a5d83906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_64b88b39-8ad6-4ee1-a6aa-96c9a5d83906" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a7b244cf-2abe-417b-95ed-9d2d4e9ac511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a7b244cf-2abe-417b-95ed-9d2d4e9ac511" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2b608a3a-1748-40e6-ac91-491250265c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_NetIncomeLoss_2b608a3a-1748-40e6-ac91-491250265c44" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_18ff92c6-fb40-43bb-ae1e-8fa62b569f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_18ff92c6-fb40-43bb-ae1e-8fa62b569f87" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_ad9afe3c-8ab1-436c-841d-c317522bf142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_ad9afe3c-8ab1-436c-841d-c317522bf142" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92bcc415-9e38-45dc-82c5-dbc3b718cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92bcc415-9e38-45dc-82c5-dbc3b718cc62" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4a9d7069-e04b-4043-8506-3f8b97abd1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_43035d59-178c-4925-bbed-3ad735dd47dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fab3d2a3-c0c2-4db8-a093-add9aa68e329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_048828ee-cc39-431f-9cdd-188951da656e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_2b95730c-a8af-4867-9591-dbdfc2257d97" xlink:to="loc_us-gaap_StatementTable_048828ee-cc39-431f-9cdd-188951da656e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_83d304d9-476c-41bc-9c56-5f5a0c11b323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_048828ee-cc39-431f-9cdd-188951da656e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_83d304d9-476c-41bc-9c56-5f5a0c11b323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_83d304d9-476c-41bc-9c56-5f5a0c11b323_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83d304d9-476c-41bc-9c56-5f5a0c11b323" xlink:to="loc_us-gaap_EquityComponentDomain_83d304d9-476c-41bc-9c56-5f5a0c11b323_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83d304d9-476c-41bc-9c56-5f5a0c11b323" xlink:to="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_910c2855-8b38-4b6d-9a11-8c1060356430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:to="loc_us-gaap_CommonStockMember_910c2855-8b38-4b6d-9a11-8c1060356430" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_071e7a14-f002-4421-b866-daf3ae5d00b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:to="loc_us-gaap_TreasuryStockCommonMember_071e7a14-f002-4421-b866-daf3ae5d00b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0aaae9eb-4052-4414-b1e3-20d2140fe952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0aaae9eb-4052-4414-b1e3-20d2140fe952" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8cc9919f-5ac9-4c6e-8da3-01f2f1e14f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8cc9919f-5ac9-4c6e-8da3-01f2f1e14f25" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_25b74b38-7783-4241-8443-ba96d59c940c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:to="loc_us-gaap_RetainedEarningsMember_25b74b38-7783-4241-8443-ba96d59c940c" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#BusinessDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="extended" id="i2d018865c1604a999805d5279539b151_BusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_7ac1955c-1dc9-442f-940f-a27f9ec4c556" xlink:href="ebs-20220630.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_7ac1955c-1dc9-442f-940f-a27f9ec4c556" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts_35c513aa-6d4b-40fd-9d4a-bb98e03dcffd" xlink:href="ebs-20220630.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_NumberOfRevenueGeneratingProducts_35c513aa-6d4b-40fd-9d4a-bb98e03dcffd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductCandidates_de4f8f22-836d-4e4c-957f-af27b6ccc5a2" xlink:href="ebs-20220630.xsd#ebs_NumberOfProductCandidates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_NumberOfProductCandidates_de4f8f22-836d-4e4c-957f-af27b6ccc5a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_54eefc65-53cc-46ab-992e-6e55fb48cb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_54eefc65-53cc-46ab-992e-6e55fb48cb82" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_debf90c1-55cd-4b63-a0f5-6bf8137420f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_debf90c1-55cd-4b63-a0f5-6bf8137420f9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f7ceadac-7441-4a70-8096-bcdf19f2216e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f7ceadac-7441-4a70-8096-bcdf19f2216e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_6bc1fb9e-2885-4897-a6ec-2b25b2c9d3e7" xlink:href="ebs-20220630.xsd#ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_6bc1fb9e-2885-4897-a6ec-2b25b2c9d3e7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit_e7783a81-505a-4c48-8628-ed30ad91cab1" xlink:href="ebs-20220630.xsd#ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit_e7783a81-505a-4c48-8628-ed30ad91cab1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_3f46f3d0-2e69-4637-a64c-0a3eee501cbb" xlink:href="ebs-20220630.xsd#ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_3f46f3d0-2e69-4637-a64c-0a3eee501cbb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_6f8a87a6-1ddd-4ff8-9108-e11ae5bd994d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_us-gaap_AssetAcquisitionTable_6f8a87a6-1ddd-4ff8-9108-e11ae5bd994d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_ebb3cfc6-9502-48c8-a54c-422a005a5c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_6f8a87a6-1ddd-4ff8-9108-e11ae5bd994d" xlink:to="loc_us-gaap_AssetAcquisitionAxis_ebb3cfc6-9502-48c8-a54c-422a005a5c2f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_ebb3cfc6-9502-48c8-a54c-422a005a5c2f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_ebb3cfc6-9502-48c8-a54c-422a005a5c2f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_ebb3cfc6-9502-48c8-a54c-422a005a5c2f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_36052f40-e001-43c3-ba52-ac3e14914306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_ebb3cfc6-9502-48c8-a54c-422a005a5c2f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_36052f40-e001-43c3-ba52-ac3e14914306" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixAssetAcquisitionMember_29f19950-c1c2-47b9-b762-adf70831e624" xlink:href="ebs-20220630.xsd#ebs_ChimerixAssetAcquisitionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_36052f40-e001-43c3-ba52-ac3e14914306" xlink:to="loc_ebs_ChimerixAssetAcquisitionMember_29f19950-c1c2-47b9-b762-adf70831e624" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_e08cf155-ebe0-4cef-8172-0f6ad7ab3b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_6f8a87a6-1ddd-4ff8-9108-e11ae5bd994d" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_e08cf155-ebe0-4cef-8172-0f6ad7ab3b8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_e08cf155-ebe0-4cef-8172-0f6ad7ab3b8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_e08cf155-ebe0-4cef-8172-0f6ad7ab3b8e" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_e08cf155-ebe0-4cef-8172-0f6ad7ab3b8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_e08cf155-ebe0-4cef-8172-0f6ad7ab3b8e" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentOneMember_f93ae150-d97d-4613-b244-4726d454e457" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:to="loc_ebs_MilestonePaymentOneMember_f93ae150-d97d-4613-b244-4726d454e457" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentTwoMember_117a5cfe-6148-4ede-969d-1d4c1097d161" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:to="loc_ebs_MilestonePaymentTwoMember_117a5cfe-6148-4ede-969d-1d4c1097d161" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentThreeMember_a9be3a5e-6c61-4dfe-8628-2c9eeb8aa6e9" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:to="loc_ebs_MilestonePaymentThreeMember_a9be3a5e-6c61-4dfe-8628-2c9eeb8aa6e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentFourMember_50065b5e-cf5b-4242-9ade-a38bf653a962" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:to="loc_ebs_MilestonePaymentFourMember_50065b5e-cf5b-4242-9ade-a38bf653a962" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RegulatoryMilestonesMember_cea62cbf-2383-41c5-889f-9ead6a6ccfcb" xlink:href="ebs-20220630.xsd#ebs_RegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:to="loc_ebs_RegulatoryMilestonesMember_cea62cbf-2383-41c5-889f-9ead6a6ccfcb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_939426f0-26a2-4c05-9800-32da6153483d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_6f8a87a6-1ddd-4ff8-9108-e11ae5bd994d" xlink:to="loc_srt_StatementScenarioAxis_939426f0-26a2-4c05-9800-32da6153483d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_939426f0-26a2-4c05-9800-32da6153483d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_939426f0-26a2-4c05-9800-32da6153483d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_939426f0-26a2-4c05-9800-32da6153483d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_821391e7-c2e7-423c-b457-483213d19ee8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_939426f0-26a2-4c05-9800-32da6153483d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_821391e7-c2e7-423c-b457-483213d19ee8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5f66be19-e8b9-4ed8-ab40-28714a8e48d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_821391e7-c2e7-423c-b457-483213d19ee8" xlink:to="loc_srt_ScenarioForecastMember_5f66be19-e8b9-4ed8-ab40-28714a8e48d6" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended" id="i499bb1371cd9427da2b518cc7f3abe29_PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_69099987-2a06-4b24-a0d7-4c2013a1bd10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_c31cdf1c-4fe3-461b-8167-2ca7aa804318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_69099987-2a06-4b24-a0d7-4c2013a1bd10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_c31cdf1c-4fe3-461b-8167-2ca7aa804318" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e32f4996-1842-4de6-a822-99b9846abe26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_c31cdf1c-4fe3-461b-8167-2ca7aa804318" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e32f4996-1842-4de6-a822-99b9846abe26" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f39697eb-c40c-40ec-a3a2-b5cdf02a45d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_c31cdf1c-4fe3-461b-8167-2ca7aa804318" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f39697eb-c40c-40ec-a3a2-b5cdf02a45d5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2f54603-89d8-467c-b128-030bc654ff48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_c31cdf1c-4fe3-461b-8167-2ca7aa804318" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d2f54603-89d8-467c-b128-030bc654ff48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d9d2199-e501-43c8-a7d6-2e9cda763030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_69099987-2a06-4b24-a0d7-4c2013a1bd10" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d9d2199-e501-43c8-a7d6-2e9cda763030" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02722dc6-85ad-4fab-bc6a-001bb715fbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d9d2199-e501-43c8-a7d6-2e9cda763030" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02722dc6-85ad-4fab-bc6a-001bb715fbb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02722dc6-85ad-4fab-bc6a-001bb715fbb8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02722dc6-85ad-4fab-bc6a-001bb715fbb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_02722dc6-85ad-4fab-bc6a-001bb715fbb8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02722dc6-85ad-4fab-bc6a-001bb715fbb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_921b1c7b-68a4-4174-96e4-628e95fe7e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_921b1c7b-68a4-4174-96e4-628e95fe7e9e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_de4444bd-e069-4c44-a02e-8975a5f2678d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_de4444bd-e069-4c44-a02e-8975a5f2678d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_edcdc940-084b-4b06-8b9a-91f947a14bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_edcdc940-084b-4b06-8b9a-91f947a14bd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_09d256da-9192-40af-9524-c322e60ecd60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_09d256da-9192-40af-9524-c322e60ecd60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_17f9835c-2b15-4ef5-ac70-06b593259848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:to="loc_us-gaap_ConstructionInProgressMember_17f9835c-2b15-4ef5-ac70-06b593259848" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#PropertyplantandequipmentNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="extended" id="i33b12951c6df45bbac7f422de40f3a81_PropertyplantandequipmentNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a487581-8dc5-44fb-9740-d3882841545b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_72427ad8-8153-4cda-a616-8c897d3af780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a487581-8dc5-44fb-9740-d3882841545b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_72427ad8-8153-4cda-a616-8c897d3af780" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_75b15b00-9ba0-4dc1-8161-89e3b8eee9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a487581-8dc5-44fb-9740-d3882841545b" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_75b15b00-9ba0-4dc1-8161-89e3b8eee9d0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_557ffe49-7745-4173-aaa3-1eeba271a9ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_75b15b00-9ba0-4dc1-8161-89e3b8eee9d0" xlink:to="loc_srt_MajorCustomersAxis_557ffe49-7745-4173-aaa3-1eeba271a9ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_557ffe49-7745-4173-aaa3-1eeba271a9ca_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_557ffe49-7745-4173-aaa3-1eeba271a9ca" xlink:to="loc_srt_NameOfMajorCustomerDomain_557ffe49-7745-4173-aaa3-1eeba271a9ca_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7d8f1487-ce20-4380-8efa-db266a904d92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_557ffe49-7745-4173-aaa3-1eeba271a9ca" xlink:to="loc_srt_NameOfMajorCustomerDomain_7d8f1487-ce20-4380-8efa-db266a904d92" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_cab134e0-29da-4a59-8f9f-b5eb74d5b419" xlink:href="ebs-20220630.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_7d8f1487-ce20-4380-8efa-db266a904d92" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_cab134e0-29da-4a59-8f9f-b5eb74d5b419" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4630c05b-d4d3-4580-b7da-ccf9d86a1395" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_75b15b00-9ba0-4dc1-8161-89e3b8eee9d0" xlink:to="loc_srt_ProductOrServiceAxis_4630c05b-d4d3-4580-b7da-ccf9d86a1395" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4630c05b-d4d3-4580-b7da-ccf9d86a1395_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4630c05b-d4d3-4580-b7da-ccf9d86a1395" xlink:to="loc_srt_ProductsAndServicesDomain_4630c05b-d4d3-4580-b7da-ccf9d86a1395_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f131af7-e1c5-489d-a570-ec286bc364ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4630c05b-d4d3-4580-b7da-ccf9d86a1395" xlink:to="loc_srt_ProductsAndServicesDomain_7f131af7-e1c5-489d-a570-ec286bc364ec" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7655d5d1-7687-4248-ae4b-84df718c37c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7f131af7-e1c5-489d-a570-ec286bc364ec" xlink:to="loc_us-gaap_ServiceMember_7655d5d1-7687-4248-ae4b-84df718c37c2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended" id="ic70a5c1743bb4f138f486083f2b040ae_IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e85fade0-3b88-4eac-8713-59147367ded9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e85fade0-3b88-4eac-8713-59147367ded9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d3b67a0a-42b4-4bae-a4c7-bbbb5422ef91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d3b67a0a-42b4-4bae-a4c7-bbbb5422ef91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b963f3ec-e60a-408a-9367-699b6402cdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b963f3ec-e60a-408a-9367-699b6402cdfe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c8280a70-64e7-45b3-ba26-3757aa4e3bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c8280a70-64e7-45b3-ba26-3757aa4e3bbe" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65e7209b-e655-4e48-a965-75312b6f6756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65e7209b-e655-4e48-a965-75312b6f6756" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_754dc883-2b1e-4993-8e52-718fdb7523d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65e7209b-e655-4e48-a965-75312b6f6756" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_754dc883-2b1e-4993-8e52-718fdb7523d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_754dc883-2b1e-4993-8e52-718fdb7523d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_754dc883-2b1e-4993-8e52-718fdb7523d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_754dc883-2b1e-4993-8e52-718fdb7523d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_47392cff-f7d2-48a4-a83d-4bcb4cb5a709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_754dc883-2b1e-4993-8e52-718fdb7523d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_47392cff-f7d2-48a4-a83d-4bcb4cb5a709" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ba8c9d3e-0c28-4286-b489-a765d2049243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_47392cff-f7d2-48a4-a83d-4bcb4cb5a709" xlink:to="loc_us-gaap_ProductMember_ba8c9d3e-0c28-4286-b489-a765d2049243" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_4b3421ce-f456-4044-8985-41ae761776b4" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_47392cff-f7d2-48a4-a83d-4bcb4cb5a709" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_4b3421ce-f456-4044-8985-41ae761776b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_555d771f-543d-46ce-a158-fc78fc028e93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65e7209b-e655-4e48-a965-75312b6f6756" xlink:to="loc_srt_RangeAxis_555d771f-543d-46ce-a158-fc78fc028e93" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_555d771f-543d-46ce-a158-fc78fc028e93_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_555d771f-543d-46ce-a158-fc78fc028e93" xlink:to="loc_srt_RangeMember_555d771f-543d-46ce-a158-fc78fc028e93_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb7f1e75-d576-414b-a36b-cf0ea5ea7916" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_555d771f-543d-46ce-a158-fc78fc028e93" xlink:to="loc_srt_RangeMember_cb7f1e75-d576-414b-a36b-cf0ea5ea7916" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ab4d7c3-bb67-41ac-97be-94fea4329c0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb7f1e75-d576-414b-a36b-cf0ea5ea7916" xlink:to="loc_srt_MinimumMember_1ab4d7c3-bb67-41ac-97be-94fea4329c0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1745c582-3701-412e-8ee2-ce9cc3be140a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb7f1e75-d576-414b-a36b-cf0ea5ea7916" xlink:to="loc_srt_MaximumMember_1745c582-3701-412e-8ee2-ce9cc3be140a" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended" id="i25d285a05b744ab5a3aa947a32e2c56d_FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7884b11a-727e-4423-8049-751975faef1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7884b11a-727e-4423-8049-751975faef1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_a3a0955c-64ad-4d91-8d0d-a2b72f0dda43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_DerivativeAssets_a3a0955c-64ad-4d91-8d0d-a2b72f0dda43" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8aa51607-dde7-477e-8b71-243646553606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8aa51607-dde7-477e-8b71-243646553606" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47920442-e04a-4549-a5ad-8d9a7df3645c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47920442-e04a-4549-a5ad-8d9a7df3645c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_013c62c3-da03-4b95-9b8f-5afc5a3ee94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_DerivativeLiabilities_013c62c3-da03-4b95-9b8f-5afc5a3ee94f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e467a6ca-bbb2-4c23-a35d-c6518e7b6a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_e467a6ca-bbb2-4c23-a35d-c6518e7b6a1e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fac336e-201d-47de-acab-551c93b60281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fac336e-201d-47de-acab-551c93b60281" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_020c4055-f28e-490b-a91f-d94987e84f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fac336e-201d-47de-acab-551c93b60281" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_020c4055-f28e-490b-a91f-d94987e84f6e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020c4055-f28e-490b-a91f-d94987e84f6e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_020c4055-f28e-490b-a91f-d94987e84f6e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_020c4055-f28e-490b-a91f-d94987e84f6e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_856dbcff-4bcc-4de1-abc0-c99dcf5e3689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_020c4055-f28e-490b-a91f-d94987e84f6e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_856dbcff-4bcc-4de1-abc0-c99dcf5e3689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_eb7a04f7-76c7-438a-bd92-01136dbd62fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_856dbcff-4bcc-4de1-abc0-c99dcf5e3689" xlink:to="loc_us-gaap_MoneyMarketFundsMember_eb7a04f7-76c7-438a-bd92-01136dbd62fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_a9059725-3c63-41cc-a816-64bfd9b021d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_856dbcff-4bcc-4de1-abc0-c99dcf5e3689" xlink:to="loc_us-gaap_BankTimeDepositsMember_a9059725-3c63-41cc-a816-64bfd9b021d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4148427-8245-4359-bb8f-bb1559910ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fac336e-201d-47de-acab-551c93b60281" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4148427-8245-4359-bb8f-bb1559910ad5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4148427-8245-4359-bb8f-bb1559910ad5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4148427-8245-4359-bb8f-bb1559910ad5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a4148427-8245-4359-bb8f-bb1559910ad5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e43df4b4-7b3f-4342-8c6d-fe0d893217bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4148427-8245-4359-bb8f-bb1559910ad5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e43df4b4-7b3f-4342-8c6d-fe0d893217bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_eb1f0abe-0630-4d66-91e7-4e61d6d77c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e43df4b4-7b3f-4342-8c6d-fe0d893217bb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_eb1f0abe-0630-4d66-91e7-4e61d6d77c02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b1f059aa-c470-4600-b0fa-9b549c1acd08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e43df4b4-7b3f-4342-8c6d-fe0d893217bb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b1f059aa-c470-4600-b0fa-9b549c1acd08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_acb45952-21ea-41db-aa95-aec600952d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e43df4b4-7b3f-4342-8c6d-fe0d893217bb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_acb45952-21ea-41db-aa95-aec600952d32" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#FairvaluemeasurementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="extended" id="i7773886bf709437c965f8e5e77695bc1_FairvaluemeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_682b4723-3091-4b34-a712-57a68ba51cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2f5dea6d-3dfc-47b1-b189-6950a8d9da18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_682b4723-3091-4b34-a712-57a68ba51cb6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2f5dea6d-3dfc-47b1-b189-6950a8d9da18" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ca0dde5-b91c-46ef-ae77-377a6c6602df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_682b4723-3091-4b34-a712-57a68ba51cb6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ca0dde5-b91c-46ef-ae77-377a6c6602df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_2fe1520b-404d-413f-a04b-8f0534933de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_682b4723-3091-4b34-a712-57a68ba51cb6" xlink:to="loc_us-gaap_LongTermDebtFairValue_2fe1520b-404d-413f-a04b-8f0534933de1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0b315fa2-8961-4acb-97fc-0b2dc01f3c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_682b4723-3091-4b34-a712-57a68ba51cb6" xlink:to="loc_us-gaap_DebtInstrumentTable_0b315fa2-8961-4acb-97fc-0b2dc01f3c27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b952b1eb-7c1f-4e8d-b27f-f9452fd5d39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0b315fa2-8961-4acb-97fc-0b2dc01f3c27" xlink:to="loc_us-gaap_DebtInstrumentAxis_b952b1eb-7c1f-4e8d-b27f-f9452fd5d39b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b952b1eb-7c1f-4e8d-b27f-f9452fd5d39b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_b952b1eb-7c1f-4e8d-b27f-f9452fd5d39b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b952b1eb-7c1f-4e8d-b27f-f9452fd5d39b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a03895cf-b31e-47de-a2da-ae8b1d5480fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_b952b1eb-7c1f-4e8d-b27f-f9452fd5d39b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a03895cf-b31e-47de-a2da-ae8b1d5480fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_dd492cf4-0dcd-4f85-9121-d49793473d04" xlink:href="ebs-20220630.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a03895cf-b31e-47de-a2da-ae8b1d5480fc" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_dd492cf4-0dcd-4f85-9121-d49793473d04" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aadebde8-b014-45d1-b043-25d07667326c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_0b315fa2-8961-4acb-97fc-0b2dc01f3c27" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aadebde8-b014-45d1-b043-25d07667326c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_aadebde8-b014-45d1-b043-25d07667326c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aadebde8-b014-45d1-b043-25d07667326c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_aadebde8-b014-45d1-b043-25d07667326c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4dfd19a6-ca58-4a0a-95d4-86fdf672866f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aadebde8-b014-45d1-b043-25d07667326c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4dfd19a6-ca58-4a0a-95d4-86fdf672866f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e59f118d-9556-4ae4-84dc-b8de710b6def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4dfd19a6-ca58-4a0a-95d4-86fdf672866f" xlink:to="loc_us-gaap_SeniorNotesMember_e59f118d-9556-4ae4-84dc-b8de710b6def" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="extended" id="i89a38a5855b544408767ccdfd8bff151_FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e67192dd-0a10-4657-b7b8-fdc577a5e73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d8db8e89-4597-4794-94e7-d6c517890fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e67192dd-0a10-4657-b7b8-fdc577a5e73e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d8db8e89-4597-4794-94e7-d6c517890fa0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_1573e36b-e6cc-4e09-80d7-7eceeb73d5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e67192dd-0a10-4657-b7b8-fdc577a5e73e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_1573e36b-e6cc-4e09-80d7-7eceeb73d5b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e67192dd-0a10-4657-b7b8-fdc577a5e73e" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_a16e2dc8-5997-45ba-bad1-a327ce6989e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:to="loc_us-gaap_ValuationTechniqueAxis_a16e2dc8-5997-45ba-bad1-a327ce6989e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_a16e2dc8-5997-45ba-bad1-a327ce6989e6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a16e2dc8-5997-45ba-bad1-a327ce6989e6" xlink:to="loc_us-gaap_ValuationTechniqueDomain_a16e2dc8-5997-45ba-bad1-a327ce6989e6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f904f143-ec9d-4327-8814-c862c21b3f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a16e2dc8-5997-45ba-bad1-a327ce6989e6" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f904f143-ec9d-4327-8814-c862c21b3f72" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_bf8e1f2a-7292-4c48-a6f5-80ac9d374e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_f904f143-ec9d-4327-8814-c862c21b3f72" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_bf8e1f2a-7292-4c48-a6f5-80ac9d374e5c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e846991c-bf17-4d5e-9f3e-e95913481e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e846991c-bf17-4d5e-9f3e-e95913481e50" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e846991c-bf17-4d5e-9f3e-e95913481e50_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e846991c-bf17-4d5e-9f3e-e95913481e50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e846991c-bf17-4d5e-9f3e-e95913481e50_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5841aa58-486d-4d7d-9fe9-54ac2ebfc31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e846991c-bf17-4d5e-9f3e-e95913481e50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5841aa58-486d-4d7d-9fe9-54ac2ebfc31e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bc2ccea5-b2e8-4ee8-9b1b-224e021218c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5841aa58-486d-4d7d-9fe9-54ac2ebfc31e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bc2ccea5-b2e8-4ee8-9b1b-224e021218c6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eea7f83a-4f8c-4921-90a5-c3c8d3798cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eea7f83a-4f8c-4921-90a5-c3c8d3798cb5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_eea7f83a-4f8c-4921-90a5-c3c8d3798cb5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eea7f83a-4f8c-4921-90a5-c3c8d3798cb5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_eea7f83a-4f8c-4921-90a5-c3c8d3798cb5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_abaf97dc-aeb8-44a8-8a46-5e4bb9137f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eea7f83a-4f8c-4921-90a5-c3c8d3798cb5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_abaf97dc-aeb8-44a8-8a46-5e4bb9137f32" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f70ec90c-530b-4db9-b6c1-57a9c6527b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_abaf97dc-aeb8-44a8-8a46-5e4bb9137f32" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f70ec90c-530b-4db9-b6c1-57a9c6527b96" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7ca2d47a-b594-4706-86a0-15e516fa53db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7ca2d47a-b594-4706-86a0-15e516fa53db" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_7ca2d47a-b594-4706-86a0-15e516fa53db_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7ca2d47a-b594-4706-86a0-15e516fa53db" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_7ca2d47a-b594-4706-86a0-15e516fa53db_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_919a1255-fa27-4053-9c3f-86df07b72f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7ca2d47a-b594-4706-86a0-15e516fa53db" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_919a1255-fa27-4053-9c3f-86df07b72f06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a61713be-0b8a-43b0-be62-cea94a99644f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_919a1255-fa27-4053-9c3f-86df07b72f06" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a61713be-0b8a-43b0-be62-cea94a99644f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityofPaymentMember_f22096c2-8ccb-4703-8d92-bc8859076d10" xlink:href="ebs-20220630.xsd#ebs_MeasurementInputProbabilityofPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_919a1255-fa27-4053-9c3f-86df07b72f06" xlink:to="loc_ebs_MeasurementInputProbabilityofPaymentMember_f22096c2-8ccb-4703-8d92-bc8859076d10" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a5ff381-b994-4172-90d8-127078c44b22" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:to="loc_srt_RangeAxis_2a5ff381-b994-4172-90d8-127078c44b22" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2a5ff381-b994-4172-90d8-127078c44b22_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2a5ff381-b994-4172-90d8-127078c44b22" xlink:to="loc_srt_RangeMember_2a5ff381-b994-4172-90d8-127078c44b22_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5c102b3-0094-4074-af83-938608d30b94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2a5ff381-b994-4172-90d8-127078c44b22" xlink:to="loc_srt_RangeMember_a5c102b3-0094-4074-af83-938608d30b94" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4d8b191-ef6e-4ba1-8cd2-eceacdf911ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a5c102b3-0094-4074-af83-938608d30b94" xlink:to="loc_srt_MinimumMember_d4d8b191-ef6e-4ba1-8cd2-eceacdf911ce" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_88e21777-6c22-4d0e-ae51-c4630b233ce2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a5c102b3-0094-4074-af83-938608d30b94" xlink:to="loc_srt_MaximumMember_88e21777-6c22-4d0e-ae51-c4630b233ce2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_fc7c04ef-ac4f-4437-ba7f-12066e9203bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_a5c102b3-0094-4074-af83-938608d30b94" xlink:to="loc_srt_WeightedAverageMember_fc7c04ef-ac4f-4437-ba7f-12066e9203bc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="extended" id="i74784059d6dd400692315b5edb0bc4ac_DerivativeinstrumentsandhedgingactivitiesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_a7d19aab-7655-4ffe-9772-c73e5644e8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_39b8c639-cdff-4ffb-b8ba-07dcd814ca3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_a7d19aab-7655-4ffe-9772-c73e5644e8a9" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_39b8c639-cdff-4ffb-b8ba-07dcd814ca3b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f4258169-3d07-40e5-b866-1841cfd889bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_a7d19aab-7655-4ffe-9772-c73e5644e8a9" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f4258169-3d07-40e5-b866-1841cfd889bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ed206883-98f7-47f6-8ac4-8f67c74780b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f4258169-3d07-40e5-b866-1841cfd889bf" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ed206883-98f7-47f6-8ac4-8f67c74780b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_ed206883-98f7-47f6-8ac4-8f67c74780b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ed206883-98f7-47f6-8ac4-8f67c74780b1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_ed206883-98f7-47f6-8ac4-8f67c74780b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_30b349cc-6b1a-4846-ba3d-02f9f7b74a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ed206883-98f7-47f6-8ac4-8f67c74780b1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_30b349cc-6b1a-4846-ba3d-02f9f7b74a8b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e57bce67-bfe4-40d4-a844-331b0fc16518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_30b349cc-6b1a-4846-ba3d-02f9f7b74a8b" xlink:to="loc_us-gaap_InterestRateSwapMember_e57bce67-bfe4-40d4-a844-331b0fc16518" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="extended" id="i25fe0481b1214a7481b73783df1970ca_DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3ffbe841-37ab-4e47-ab7e-09c59469be71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_e3d2203a-47b4-46fb-9613-e5fc82123251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3ffbe841-37ab-4e47-ab7e-09c59469be71" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_e3d2203a-47b4-46fb-9613-e5fc82123251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_727e5404-3f13-4295-958b-e6ba252fa2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3ffbe841-37ab-4e47-ab7e-09c59469be71" xlink:to="loc_us-gaap_DerivativeNotionalAmount_727e5404-3f13-4295-958b-e6ba252fa2d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_4eac78d6-9719-458f-b831-bc5b3ffd222e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3ffbe841-37ab-4e47-ab7e-09c59469be71" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_4eac78d6-9719-458f-b831-bc5b3ffd222e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7bf19286-8171-491e-b9f7-8c4131c87158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_4eac78d6-9719-458f-b831-bc5b3ffd222e" xlink:to="loc_us-gaap_HedgingDesignationAxis_7bf19286-8171-491e-b9f7-8c4131c87158" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7bf19286-8171-491e-b9f7-8c4131c87158_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_7bf19286-8171-491e-b9f7-8c4131c87158" xlink:to="loc_us-gaap_HedgingDesignationDomain_7bf19286-8171-491e-b9f7-8c4131c87158_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4885e751-4174-47fc-af1f-233151095e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_7bf19286-8171-491e-b9f7-8c4131c87158" xlink:to="loc_us-gaap_HedgingDesignationDomain_4885e751-4174-47fc-af1f-233151095e73" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3ac3bdd6-0999-41d0-9c0a-d580037e3be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_4885e751-4174-47fc-af1f-233151095e73" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3ac3bdd6-0999-41d0-9c0a-d580037e3be0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fe0b7325-aa69-43d7-bd66-87d3e2cf824d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_4eac78d6-9719-458f-b831-bc5b3ffd222e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fe0b7325-aa69-43d7-bd66-87d3e2cf824d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fe0b7325-aa69-43d7-bd66-87d3e2cf824d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fe0b7325-aa69-43d7-bd66-87d3e2cf824d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fe0b7325-aa69-43d7-bd66-87d3e2cf824d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cfcf16d3-c3b2-462d-a794-2e31e1df8779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fe0b7325-aa69-43d7-bd66-87d3e2cf824d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cfcf16d3-c3b2-462d-a794-2e31e1df8779" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_580ca454-f2be-4723-a9f2-f4d5a3062f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cfcf16d3-c3b2-462d-a794-2e31e1df8779" xlink:to="loc_us-gaap_InterestRateSwapMember_580ca454-f2be-4723-a9f2-f4d5a3062f19" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="extended" id="i822d33920101462d8912350805e68640_DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_d67ce4f7-209c-4714-bc30-6cdcbd73c352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_959adb2f-4963-47b6-90b0-e8f67e803586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d67ce4f7-209c-4714-bc30-6cdcbd73c352" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_959adb2f-4963-47b6-90b0-e8f67e803586" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_454d86eb-7439-42b9-b26d-170c5570de1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d67ce4f7-209c-4714-bc30-6cdcbd73c352" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_454d86eb-7439-42b9-b26d-170c5570de1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9c6b6d86-5d09-46c9-bd06-7095bcad719d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d67ce4f7-209c-4714-bc30-6cdcbd73c352" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9c6b6d86-5d09-46c9-bd06-7095bcad719d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2a3bb1c2-12b9-46b3-9a6c-91501eadb64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9c6b6d86-5d09-46c9-bd06-7095bcad719d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2a3bb1c2-12b9-46b3-9a6c-91501eadb64e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_2a3bb1c2-12b9-46b3-9a6c-91501eadb64e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2a3bb1c2-12b9-46b3-9a6c-91501eadb64e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_2a3bb1c2-12b9-46b3-9a6c-91501eadb64e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c55c1d44-039b-4dd5-97eb-6be68afde8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2a3bb1c2-12b9-46b3-9a6c-91501eadb64e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c55c1d44-039b-4dd5-97eb-6be68afde8bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_38ced072-d5ad-4b11-870e-0fee82a9748d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c55c1d44-039b-4dd5-97eb-6be68afde8bf" xlink:to="loc_us-gaap_InterestRateSwapMember_38ced072-d5ad-4b11-870e-0fee82a9748d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5a64f54b-6a03-400e-be39-d6696ec24281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9c6b6d86-5d09-46c9-bd06-7095bcad719d" xlink:to="loc_us-gaap_HedgingDesignationAxis_5a64f54b-6a03-400e-be39-d6696ec24281" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_5a64f54b-6a03-400e-be39-d6696ec24281_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_5a64f54b-6a03-400e-be39-d6696ec24281" xlink:to="loc_us-gaap_HedgingDesignationDomain_5a64f54b-6a03-400e-be39-d6696ec24281_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_fc68bdb4-abd7-4328-9987-199225504bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_5a64f54b-6a03-400e-be39-d6696ec24281" xlink:to="loc_us-gaap_HedgingDesignationDomain_fc68bdb4-abd7-4328-9987-199225504bd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ec2129c7-33e7-4f49-85de-ac66f1befc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_fc68bdb4-abd7-4328-9987-199225504bd0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ec2129c7-33e7-4f49-85de-ac66f1befc8e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c852d831-ab05-4462-bbec-e764cf78f9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9c6b6d86-5d09-46c9-bd06-7095bcad719d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c852d831-ab05-4462-bbec-e764cf78f9dd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_c852d831-ab05-4462-bbec-e764cf78f9dd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c852d831-ab05-4462-bbec-e764cf78f9dd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_c852d831-ab05-4462-bbec-e764cf78f9dd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c852d831-ab05-4462-bbec-e764cf78f9dd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_dd191b79-4482-4c16-b826-28b144af264d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_dd191b79-4482-4c16-b826-28b144af264d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_5b9b998f-fe83-40ae-bc46-145d9d0dbea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:to="loc_us-gaap_OtherAssetsMember_5b9b998f-fe83-40ae-bc46-145d9d0dbea2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_10a69ea5-c699-4297-84d6-28282f612f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_10a69ea5-c699-4297-84d6-28282f612f1d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_465d9ae0-71f9-40cc-b255-93d128d63232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:to="loc_us-gaap_OtherLiabilitiesMember_465d9ae0-71f9-40cc-b255-93d128d63232" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="extended" id="id319f560d6fe4c739fa63dddbaba18f8_DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4238309f-4ce3-44e4-948b-01f323461efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f910c088-8248-43cd-a838-54867e8c89af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4238309f-4ce3-44e4-948b-01f323461efa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f910c088-8248-43cd-a838-54867e8c89af" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c99d1bac-ad88-48ee-8791-54ff891c5215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4238309f-4ce3-44e4-948b-01f323461efa" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c99d1bac-ad88-48ee-8791-54ff891c5215" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0a94eb37-70c8-408b-804f-a88783818e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c99d1bac-ad88-48ee-8791-54ff891c5215" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0a94eb37-70c8-408b-804f-a88783818e9e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0a94eb37-70c8-408b-804f-a88783818e9e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0a94eb37-70c8-408b-804f-a88783818e9e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0a94eb37-70c8-408b-804f-a88783818e9e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_40d27d66-5437-4e25-bfa1-0badd7abfd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0a94eb37-70c8-408b-804f-a88783818e9e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_40d27d66-5437-4e25-bfa1-0badd7abfd3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_db1e0b5f-d581-4cc3-b660-29366947b3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_40d27d66-5437-4e25-bfa1-0badd7abfd3b" xlink:to="loc_us-gaap_CashFlowHedgingMember_db1e0b5f-d581-4cc3-b660-29366947b3f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2b583241-1404-4a40-ba78-bd2c4b20ff20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c99d1bac-ad88-48ee-8791-54ff891c5215" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2b583241-1404-4a40-ba78-bd2c4b20ff20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2b583241-1404-4a40-ba78-bd2c4b20ff20_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2b583241-1404-4a40-ba78-bd2c4b20ff20" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2b583241-1404-4a40-ba78-bd2c4b20ff20_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2b17bb32-425c-435c-876f-c15b57bd6de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2b583241-1404-4a40-ba78-bd2c4b20ff20" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2b17bb32-425c-435c-876f-c15b57bd6de3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_7358c428-9007-4798-bf65-28ebd6e2ba75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b17bb32-425c-435c-876f-c15b57bd6de3" xlink:to="loc_us-gaap_InterestExpenseMember_7358c428-9007-4798-bf65-28ebd6e2ba75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6f5ae431-7da9-4618-937e-409669819f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c99d1bac-ad88-48ee-8791-54ff891c5215" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6f5ae431-7da9-4618-937e-409669819f4f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_6f5ae431-7da9-4618-937e-409669819f4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6f5ae431-7da9-4618-937e-409669819f4f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_6f5ae431-7da9-4618-937e-409669819f4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_811cb3b3-840a-42ca-8f84-86094703b5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6f5ae431-7da9-4618-937e-409669819f4f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_811cb3b3-840a-42ca-8f84-86094703b5aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_460cd3e4-53af-43ed-bd97-768a06b42c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_811cb3b3-840a-42ca-8f84-86094703b5aa" xlink:to="loc_us-gaap_InterestRateSwapMember_460cd3e4-53af-43ed-bd97-768a06b42c68" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DebtScheduleDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended" id="i705c1f9e7bfc4565b4c10a7be248d509_DebtScheduleDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_240a73a5-54a1-4cdd-a527-ad825145a140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_240a73a5-54a1-4cdd-a527-ad825145a140" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_819c75dc-4b9f-4a17-a35e-9ba2d6f74a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:to="loc_us-gaap_LongTermDebt_819c75dc-4b9f-4a17-a35e-9ba2d6f74a6c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9166a7cf-8a27-4b2c-a564-ee7970c891b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:to="loc_us-gaap_LongTermDebtCurrent_9166a7cf-8a27-4b2c-a564-ee7970c891b3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_8ccd6e27-919b-4ade-8083-1bc54c2e8112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_8ccd6e27-919b-4ade-8083-1bc54c2e8112" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_89b1c9e0-53c0-4427-bd98-875adb60b28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_89b1c9e0-53c0-4427-bd98-875adb60b28c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_773b5458-943c-4870-b3e4-f311988f0405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:to="loc_us-gaap_DebtInstrumentTable_773b5458-943c-4870-b3e4-f311988f0405" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe50b109-f62c-48bd-8037-2ed899b8728e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_773b5458-943c-4870-b3e4-f311988f0405" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe50b109-f62c-48bd-8037-2ed899b8728e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_fe50b109-f62c-48bd-8037-2ed899b8728e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe50b109-f62c-48bd-8037-2ed899b8728e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_fe50b109-f62c-48bd-8037-2ed899b8728e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b42876e9-e2b2-4103-9f03-bf040777ba6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe50b109-f62c-48bd-8037-2ed899b8728e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b42876e9-e2b2-4103-9f03-bf040777ba6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_cd16fa91-7172-490c-a5f5-66908c532cde" xlink:href="ebs-20220630.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b42876e9-e2b2-4103-9f03-bf040777ba6d" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_cd16fa91-7172-490c-a5f5-66908c532cde" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_5c1107e2-d8b0-4acc-ab78-8479c5489a77" xlink:href="ebs-20220630.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b42876e9-e2b2-4103-9f03-bf040777ba6d" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_5c1107e2-d8b0-4acc-ab78-8479c5489a77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bd883082-f996-4227-8314-a17453f19c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_773b5458-943c-4870-b3e4-f311988f0405" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bd883082-f996-4227-8314-a17453f19c04" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bd883082-f996-4227-8314-a17453f19c04_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd883082-f996-4227-8314-a17453f19c04" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bd883082-f996-4227-8314-a17453f19c04_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3a345fda-a3ab-4f67-b612-e6b16d77d09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd883082-f996-4227-8314-a17453f19c04" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3a345fda-a3ab-4f67-b612-e6b16d77d09e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_e769cfac-34ff-4543-8162-11f1efb35d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a345fda-a3ab-4f67-b612-e6b16d77d09e" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_e769cfac-34ff-4543-8162-11f1efb35d9a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1eea37db-5d26-44a2-8712-7e0d141384c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a345fda-a3ab-4f67-b612-e6b16d77d09e" xlink:to="loc_us-gaap_SeniorNotesMember_1eea37db-5d26-44a2-8712-7e0d141384c1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DebtNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended" id="iad62d122c8254aad8cdbdd4d2cbc8ca7_DebtNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5146586f-b785-4059-a282-f3f262680fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_LongTermDebt_5146586f-b785-4059-a282-f3f262680fe2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_ff056e36-b63a-42f5-8684-9fec9383e22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_ff056e36-b63a-42f5-8684-9fec9383e22a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_75836adc-45b2-4ec1-aa11-df01d3e3d742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_75836adc-45b2-4ec1-aa11-df01d3e3d742" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6844b566-6d62-4e0e-968f-10aabd3f8310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6844b566-6d62-4e0e-968f-10aabd3f8310" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9f79cb0e-076f-45a7-a13f-17628490626f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9f79cb0e-076f-45a7-a13f-17628490626f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_440d231d-4181-4032-8d02-8f77f50982d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_440d231d-4181-4032-8d02-8f77f50982d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a0cc810b-c8f3-46c3-a2ff-029e000c2ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a0cc810b-c8f3-46c3-a2ff-029e000c2ded" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c77de6a0-304a-42d7-a57f-feb1f772c0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c77de6a0-304a-42d7-a57f-feb1f772c0a9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_55dcc997-117e-46cd-b6a2-84c51b0f38ec" xlink:href="ebs-20220630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_55dcc997-117e-46cd-b6a2-84c51b0f38ec" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_84455e67-bd9c-45ca-bb4d-fb49974031fb" xlink:href="ebs-20220630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_84455e67-bd9c-45ca-bb4d-fb49974031fb" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_5de17900-12a6-4ba7-b367-fcd852305c1d" xlink:href="ebs-20220630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_5de17900-12a6-4ba7-b367-fcd852305c1d" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_f15e6690-28a0-4484-9bb1-1a3bd6879000" xlink:href="ebs-20220630.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_f15e6690-28a0-4484-9bb1-1a3bd6879000" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_a9b80ea9-d142-4881-a506-4f932790c37d" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_a9b80ea9-d142-4881-a506-4f932790c37d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_e080b774-2c53-4cae-bf95-1549ea3728df" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_e080b774-2c53-4cae-bf95-1549ea3728df" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_843bcb50-f6b8-4ff2-b6a0-0e881849b5f5" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_843bcb50-f6b8-4ff2-b6a0-0e881849b5f5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_dcaea5c4-e91c-4980-9ab3-46b9e447c72c" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_dcaea5c4-e91c-4980-9ab3-46b9e447c72c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9f93cf9d-ecba-41c2-a335-5b271a7bcfe4" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9f93cf9d-ecba-41c2-a335-5b271a7bcfe4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_b1b8cf05-00ad-4f94-bc95-cf8a4e51121a" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_b1b8cf05-00ad-4f94-bc95-cf8a4e51121a" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fe624156-f7c3-48df-a7b9-c41d064de587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_CreditFacilityAxis_fe624156-f7c3-48df-a7b9-c41d064de587" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_fe624156-f7c3-48df-a7b9-c41d064de587_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_fe624156-f7c3-48df-a7b9-c41d064de587" xlink:to="loc_us-gaap_CreditFacilityDomain_fe624156-f7c3-48df-a7b9-c41d064de587_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e12e25f9-2514-4041-904f-244744b1f808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_fe624156-f7c3-48df-a7b9-c41d064de587" xlink:to="loc_us-gaap_CreditFacilityDomain_e12e25f9-2514-4041-904f-244744b1f808" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c6273e24-a78a-40bc-8436-adf12ed8e599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_e12e25f9-2514-4041-904f-244744b1f808" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c6273e24-a78a-40bc-8436-adf12ed8e599" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember_cb245d33-8c01-48de-8701-fc8079714c6f" xlink:href="ebs-20220630.xsd#ebs_TermLoanFacilityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_e12e25f9-2514-4041-904f-244744b1f808" xlink:to="loc_ebs_TermLoanFacilityMember_cb245d33-8c01-48de-8701-fc8079714c6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c701405d-4a6f-41c8-a0fa-a8f50467a2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_DebtInstrumentAxis_c701405d-4a6f-41c8-a0fa-a8f50467a2fa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_c701405d-4a6f-41c8-a0fa-a8f50467a2fa_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_c701405d-4a6f-41c8-a0fa-a8f50467a2fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_c701405d-4a6f-41c8-a0fa-a8f50467a2fa_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14bf61d2-166c-4b99-8ce2-724720e3cc24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_c701405d-4a6f-41c8-a0fa-a8f50467a2fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14bf61d2-166c-4b99-8ce2-724720e3cc24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_fa100596-18c1-4f42-8fe5-8ba5c3abac9c" xlink:href="ebs-20220630.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14bf61d2-166c-4b99-8ce2-724720e3cc24" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_fa100596-18c1-4f42-8fe5-8ba5c3abac9c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember_51aa6618-2a3b-49a5-b5fe-f4e28c4a901c" xlink:href="ebs-20220630.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14bf61d2-166c-4b99-8ce2-724720e3cc24" xlink:to="loc_ebs_AmendedCreditAgreementMember_51aa6618-2a3b-49a5-b5fe-f4e28c4a901c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a5541115-0e31-4966-9f09-03c93aebbeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_VariableRateAxis_a5541115-0e31-4966-9f09-03c93aebbeb1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_a5541115-0e31-4966-9f09-03c93aebbeb1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_a5541115-0e31-4966-9f09-03c93aebbeb1" xlink:to="loc_us-gaap_VariableRateDomain_a5541115-0e31-4966-9f09-03c93aebbeb1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d65780b4-69fa-49c9-a59a-cc5bae3c3da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_a5541115-0e31-4966-9f09-03c93aebbeb1" xlink:to="loc_us-gaap_VariableRateDomain_d65780b4-69fa-49c9-a59a-cc5bae3c3da2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_fdfb3f15-dc11-4803-b907-61207d15084b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_d65780b4-69fa-49c9-a59a-cc5bae3c3da2" xlink:to="loc_us-gaap_EurodollarMember_fdfb3f15-dc11-4803-b907-61207d15084b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e176eb47-61ff-450e-9bc9-91fd06e54e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_d65780b4-69fa-49c9-a59a-cc5bae3c3da2" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e176eb47-61ff-450e-9bc9-91fd06e54e89" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_1139305a-3352-46e4-aa0d-a85cd9a78953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_d65780b4-69fa-49c9-a59a-cc5bae3c3da2" xlink:to="loc_us-gaap_BaseRateMember_1139305a-3352-46e4-aa0d-a85cd9a78953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6641308f-a41d-4357-a653-dd9a086e8583" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_srt_RangeAxis_6641308f-a41d-4357-a653-dd9a086e8583" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6641308f-a41d-4357-a653-dd9a086e8583_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6641308f-a41d-4357-a653-dd9a086e8583" xlink:to="loc_srt_RangeMember_6641308f-a41d-4357-a653-dd9a086e8583_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_740693fe-d18b-4d64-91c3-b8f7c0472eea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6641308f-a41d-4357-a653-dd9a086e8583" xlink:to="loc_srt_RangeMember_740693fe-d18b-4d64-91c3-b8f7c0472eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_03183747-f7d8-4fde-ab48-3c6c6405f1f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_740693fe-d18b-4d64-91c3-b8f7c0472eea" xlink:to="loc_srt_MinimumMember_03183747-f7d8-4fde-ab48-3c6c6405f1f3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d180bff3-e8fa-4402-a69e-bc8bfa2c1824" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_740693fe-d18b-4d64-91c3-b8f7c0472eea" xlink:to="loc_srt_MaximumMember_d180bff3-e8fa-4402-a69e-bc8bfa2c1824" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bc0bb47a-cf8a-47bf-af40-fa71b151ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bc0bb47a-cf8a-47bf-af40-fa71b151ee98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bc0bb47a-cf8a-47bf-af40-fa71b151ee98_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bc0bb47a-cf8a-47bf-af40-fa71b151ee98" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bc0bb47a-cf8a-47bf-af40-fa71b151ee98_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_30438991-a147-47a0-9501-5a59e5054dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bc0bb47a-cf8a-47bf-af40-fa71b151ee98" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_30438991-a147-47a0-9501-5a59e5054dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ecae050f-2a2c-491f-b58d-b560a4ebeda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_30438991-a147-47a0-9501-5a59e5054dc3" xlink:to="loc_us-gaap_LineOfCreditMember_ecae050f-2a2c-491f-b58d-b560a4ebeda3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8d21082b-9d7c-41d7-aa24-848d0fb09716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_30438991-a147-47a0-9501-5a59e5054dc3" xlink:to="loc_us-gaap_SeniorNotesMember_8d21082b-9d7c-41d7-aa24-848d0fb09716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bd738f70-827b-49b4-a048-8d437653e57e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bd738f70-827b-49b4-a048-8d437653e57e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bd738f70-827b-49b4-a048-8d437653e57e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bd738f70-827b-49b4-a048-8d437653e57e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bd738f70-827b-49b4-a048-8d437653e57e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bbb9592d-3b5a-482e-a603-ef4e4d706c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bd738f70-827b-49b4-a048-8d437653e57e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bbb9592d-3b5a-482e-a603-ef4e4d706c57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_f1a955d5-a5cf-4419-a224-5a019354ef7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bbb9592d-3b5a-482e-a603-ef4e4d706c57" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_f1a955d5-a5cf-4419-a224-5a019354ef7d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_b852066d-8171-4868-9faa-0d2d903f15db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bbb9592d-3b5a-482e-a603-ef4e4d706c57" xlink:to="loc_us-gaap_OtherAssetsMember_b852066d-8171-4868-9faa-0d2d903f15db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_349a6191-6dae-44af-9f92-44ae57a158e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_349a6191-6dae-44af-9f92-44ae57a158e5" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_349a6191-6dae-44af-9f92-44ae57a158e5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_349a6191-6dae-44af-9f92-44ae57a158e5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_349a6191-6dae-44af-9f92-44ae57a158e5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8c8213d0-fda3-4df5-b740-ad13c1668b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_349a6191-6dae-44af-9f92-44ae57a158e5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8c8213d0-fda3-4df5-b740-ad13c1668b4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_c63c9c4f-baa3-4c10-b583-85368c398616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8c8213d0-fda3-4df5-b740-ad13c1668b4a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_c63c9c4f-baa3-4c10-b583-85368c398616" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_aa179afe-4553-4372-afb1-f53e4a462a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8c8213d0-fda3-4df5-b740-ad13c1668b4a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_aa179afe-4553-4372-afb1-f53e4a462a84" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="extended" id="i28a6d3dfa6fe4834a68cd1604e948be8_RevenuerecognitionNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9cfbbafc-09f1-489c-b5e1-be77678c84d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9cfbbafc-09f1-489c-b5e1-be77678c84d1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_25f0a8e7-0635-4815-8ac9-7c6929a77109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_Revenues_25f0a8e7-0635-4815-8ac9-7c6929a77109" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e9501ba5-feb5-4869-87dc-1ed429040844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e9501ba5-feb5-4869-87dc-1ed429040844" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5dfa4e45-5004-4e49-973d-c3f6963bcb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5dfa4e45-5004-4e49-973d-c3f6963bcb84" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_31ebaac3-3060-439d-bb86-46105d2d8725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_31ebaac3-3060-439d-bb86-46105d2d8725" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e33d45d8-4497-4708-8ee3-bc9274b383c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e33d45d8-4497-4708-8ee3-bc9274b383c2" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_0c52ec40-cddc-48e1-93ec-a955b6b87f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_0c52ec40-cddc-48e1-93ec-a955b6b87f10" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_76c83232-5dee-4e66-9d21-1409b147f6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_76c83232-5dee-4e66-9d21-1409b147f6e6" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_aea368b8-98df-4a11-a138-0d4efbb14516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_aea368b8-98df-4a11-a138-0d4efbb14516" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f0c387da-7569-4678-ad91-5aa02207c68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f0c387da-7569-4678-ad91-5aa02207c68b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_09bfd7e9-138d-4ce1-acbd-3f0c1e9a324c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_09bfd7e9-138d-4ce1-acbd-3f0c1e9a324c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f03674a3-6911-4204-aa27-381209eb4f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f03674a3-6911-4204-aa27-381209eb4f24" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_fc9dd646-9512-4053-89cd-5591dd62cb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_fc9dd646-9512-4053-89cd-5591dd62cb7d" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_2635b14d-1d99-4135-8099-a7dc9ed96b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:to="loc_us-gaap_LeaseContractualTermAxis_2635b14d-1d99-4135-8099-a7dc9ed96b45" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_2635b14d-1d99-4135-8099-a7dc9ed96b45_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2635b14d-1d99-4135-8099-a7dc9ed96b45" xlink:to="loc_us-gaap_LeaseContractualTermDomain_2635b14d-1d99-4135-8099-a7dc9ed96b45_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_9ad39923-c409-41bb-ad54-f70debfdda00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2635b14d-1d99-4135-8099-a7dc9ed96b45" xlink:to="loc_us-gaap_LeaseContractualTermDomain_9ad39923-c409-41bb-ad54-f70debfdda00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ReservationOfManufacturingCapacityMember_926954d3-d7b4-4d5d-8587-a0f0b16cae1a" xlink:href="ebs-20220630.xsd#ebs_ReservationOfManufacturingCapacityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_9ad39923-c409-41bb-ad54-f70debfdda00" xlink:to="loc_ebs_ReservationOfManufacturingCapacityMember_926954d3-d7b4-4d5d-8587-a0f0b16cae1a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_928be1f6-55b6-40a9-a378-06868c6854ba" xlink:href="ebs-20220630.xsd#ebs_AcceleratedExpansionOfFillFinishCapacityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseContractualTermDomain_9ad39923-c409-41bb-ad54-f70debfdda00" xlink:to="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_928be1f6-55b6-40a9-a378-06868c6854ba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d8b591b9-883a-4032-be30-fe7f00d9755a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:to="loc_srt_StatementGeographicalAxis_d8b591b9-883a-4032-be30-fe7f00d9755a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_d8b591b9-883a-4032-be30-fe7f00d9755a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_d8b591b9-883a-4032-be30-fe7f00d9755a" xlink:to="loc_srt_SegmentGeographicalDomain_d8b591b9-883a-4032-be30-fe7f00d9755a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_247b3f73-f415-44c0-b89e-bb53a10e276e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_d8b591b9-883a-4032-be30-fe7f00d9755a" xlink:to="loc_srt_SegmentGeographicalDomain_247b3f73-f415-44c0-b89e-bb53a10e276e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9235cccf-f479-4d83-a285-d7c9a9392e77" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_247b3f73-f415-44c0-b89e-bb53a10e276e" xlink:to="loc_country_US_9235cccf-f479-4d83-a285-d7c9a9392e77" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_50bc5e1b-b4f0-41af-85dc-9a3bc2f9233a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_247b3f73-f415-44c0-b89e-bb53a10e276e" xlink:to="loc_us-gaap_NonUsMember_50bc5e1b-b4f0-41af-85dc-9a3bc2f9233a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2baeefb2-8af5-4973-af26-f329efebac18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:to="loc_srt_MajorCustomersAxis_2baeefb2-8af5-4973-af26-f329efebac18" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2baeefb2-8af5-4973-af26-f329efebac18_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2baeefb2-8af5-4973-af26-f329efebac18" xlink:to="loc_srt_NameOfMajorCustomerDomain_2baeefb2-8af5-4973-af26-f329efebac18_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_11697426-5f1b-4930-a807-bcc988985323" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2baeefb2-8af5-4973-af26-f329efebac18" xlink:to="loc_srt_NameOfMajorCustomerDomain_11697426-5f1b-4930-a807-bcc988985323" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_1e6e8190-4c6a-4db0-81e3-6388cdfbaaea" xlink:href="ebs-20220630.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_11697426-5f1b-4930-a807-bcc988985323" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_1e6e8190-4c6a-4db0-81e3-6388cdfbaaea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember_1ea046e9-e3ce-479c-b715-10533b1a1ef5" xlink:href="ebs-20220630.xsd#ebs_BARDAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_11697426-5f1b-4930-a807-bcc988985323" xlink:to="loc_ebs_BARDAMember_1ea046e9-e3ce-479c-b715-10533b1a1ef5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_34882166-5d36-4c4a-a384-2c096d7f2408" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:to="loc_srt_ProductOrServiceAxis_34882166-5d36-4c4a-a384-2c096d7f2408" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_34882166-5d36-4c4a-a384-2c096d7f2408_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_34882166-5d36-4c4a-a384-2c096d7f2408" xlink:to="loc_srt_ProductsAndServicesDomain_34882166-5d36-4c4a-a384-2c096d7f2408_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a6f8b87-e0ce-4b02-b1d7-1fafcf67db84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_34882166-5d36-4c4a-a384-2c096d7f2408" xlink:to="loc_srt_ProductsAndServicesDomain_8a6f8b87-e0ce-4b02-b1d7-1fafcf67db84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_b970750a-60eb-4ae0-b548-35e584c54e10" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a6f8b87-e0ce-4b02-b1d7-1fafcf67db84" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_b970750a-60eb-4ae0-b548-35e584c54e10" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e0154f52-9ec2-4dac-8059-ec806c06cedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_8a6f8b87-e0ce-4b02-b1d7-1fafcf67db84" xlink:to="loc_us-gaap_ServiceMember_e0154f52-9ec2-4dac-8059-ec806c06cedf" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionDisaggregationofRevenueDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="extended" id="i9fad6e678bce4f2cada71c27514ac765_RevenuerecognitionDisaggregationofRevenueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ff3a38ec-d1eb-4f72-9466-e9c7800145a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ff3a38ec-d1eb-4f72-9466-e9c7800145a6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_651a8745-76cd-4237-a90b-666bfec5151a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_651a8745-76cd-4237-a90b-666bfec5151a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_e8d02b71-d348-4569-b423-ca15cd570914" xlink:href="ebs-20220630.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_e8d02b71-d348-4569-b423-ca15cd570914" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d4d361af-bb69-405b-ad82-d479ff5a9562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:to="loc_us-gaap_Revenues_d4d361af-bb69-405b-ad82-d479ff5a9562" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_925978c9-acaa-4f21-a6a3-dfac64ac3d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_925978c9-acaa-4f21-a6a3-dfac64ac3d0b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_17096c86-4181-46b5-b8bd-2955612c3add" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_925978c9-acaa-4f21-a6a3-dfac64ac3d0b" xlink:to="loc_srt_ProductOrServiceAxis_17096c86-4181-46b5-b8bd-2955612c3add" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_17096c86-4181-46b5-b8bd-2955612c3add_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_17096c86-4181-46b5-b8bd-2955612c3add" xlink:to="loc_srt_ProductsAndServicesDomain_17096c86-4181-46b5-b8bd-2955612c3add_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6da4f575-70d9-4d49-9504-c166bd71aff3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_17096c86-4181-46b5-b8bd-2955612c3add" xlink:to="loc_srt_ProductsAndServicesDomain_6da4f575-70d9-4d49-9504-c166bd71aff3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ac8ce615-9293-4d75-a79a-7a3be1530041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6da4f575-70d9-4d49-9504-c166bd71aff3" xlink:to="loc_us-gaap_ProductMember_ac8ce615-9293-4d75-a79a-7a3be1530041" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_cf3bb2ab-6e99-4a45-9ccf-dcc077bb1b1f" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6da4f575-70d9-4d49-9504-c166bd71aff3" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_cf3bb2ab-6e99-4a45-9ccf-dcc077bb1b1f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1194dc08-7a1b-48a0-83dc-ea8ec55071eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_cf3bb2ab-6e99-4a45-9ccf-dcc077bb1b1f" xlink:to="loc_us-gaap_ServiceMember_1194dc08-7a1b-48a0-83dc-ea8ec55071eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_e6d80e87-d927-4f09-b3d4-5a496696f4db" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_cf3bb2ab-6e99-4a45-9ccf-dcc077bb1b1f" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_e6d80e87-d927-4f09-b3d4-5a496696f4db" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_4eac11a3-dadc-4173-84e6-215f36ac8d5f" xlink:href="ebs-20220630.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6da4f575-70d9-4d49-9504-c166bd71aff3" xlink:to="loc_ebs_ContractsAndGrantsMember_4eac11a3-dadc-4173-84e6-215f36ac8d5f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ef04f58b-40d2-4019-9b7d-c22c0824cd69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_925978c9-acaa-4f21-a6a3-dfac64ac3d0b" xlink:to="loc_srt_StatementGeographicalAxis_ef04f58b-40d2-4019-9b7d-c22c0824cd69" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_ef04f58b-40d2-4019-9b7d-c22c0824cd69_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_ef04f58b-40d2-4019-9b7d-c22c0824cd69" xlink:to="loc_srt_SegmentGeographicalDomain_ef04f58b-40d2-4019-9b7d-c22c0824cd69_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c94a2dfd-76ca-423d-be67-d0de6fb9293c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_ef04f58b-40d2-4019-9b7d-c22c0824cd69" xlink:to="loc_srt_SegmentGeographicalDomain_c94a2dfd-76ca-423d-be67-d0de6fb9293c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_08da6db3-23ea-4909-94e1-f361dd427e94" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c94a2dfd-76ca-423d-be67-d0de6fb9293c" xlink:to="loc_country_US_08da6db3-23ea-4909-94e1-f361dd427e94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_deb5affc-dece-4d87-89eb-9fdfead02ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c94a2dfd-76ca-423d-be67-d0de6fb9293c" xlink:to="loc_us-gaap_NonUsMember_deb5affc-dece-4d87-89eb-9fdfead02ad5" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails" xlink:type="extended" id="i7ad71d7833934518aaf06808e54738fe_RevenuerecognitionPerformanceObligationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_02fb0663-fb5c-4320-a713-4d02c3d27930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_02fb0663-fb5c-4320-a713-4d02c3d27930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_6e8b6063-f9dc-42db-afe8-658507841099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_6e8b6063-f9dc-42db-afe8-658507841099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_0b50be08-ae10-4541-b366-84f2d03d7102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_0b50be08-ae10-4541-b366-84f2d03d7102" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2215dad8-a3fa-4775-8b95-26d849bae2cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:to="loc_srt_ProductOrServiceAxis_2215dad8-a3fa-4775-8b95-26d849bae2cc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2215dad8-a3fa-4775-8b95-26d849bae2cc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2215dad8-a3fa-4775-8b95-26d849bae2cc" xlink:to="loc_srt_ProductsAndServicesDomain_2215dad8-a3fa-4775-8b95-26d849bae2cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_45219bde-90b7-4acf-9919-192c04987e64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2215dad8-a3fa-4775-8b95-26d849bae2cc" xlink:to="loc_srt_ProductsAndServicesDomain_45219bde-90b7-4acf-9919-192c04987e64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_b62ff56e-5ba7-4140-9104-3fc2e6011578" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_45219bde-90b7-4acf-9919-192c04987e64" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_b62ff56e-5ba7-4140-9104-3fc2e6011578" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails_1" xlink:type="extended" id="i2926be19a9c14a5e894142396ab7df75_RevenuerecognitionPerformanceObligationsDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_02fb0663-fb5c-4320-a713-4d02c3d27930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_02fb0663-fb5c-4320-a713-4d02c3d27930" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_6e8b6063-f9dc-42db-afe8-658507841099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_6e8b6063-f9dc-42db-afe8-658507841099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2215dad8-a3fa-4775-8b95-26d849bae2cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:to="loc_srt_ProductOrServiceAxis_2215dad8-a3fa-4775-8b95-26d849bae2cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_2215dad8-a3fa-4775-8b95-26d849bae2cc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2215dad8-a3fa-4775-8b95-26d849bae2cc" xlink:to="loc_srt_ProductsAndServicesDomain_2215dad8-a3fa-4775-8b95-26d849bae2cc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_45219bde-90b7-4acf-9919-192c04987e64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2215dad8-a3fa-4775-8b95-26d849bae2cc" xlink:to="loc_srt_ProductsAndServicesDomain_45219bde-90b7-4acf-9919-192c04987e64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_b62ff56e-5ba7-4140-9104-3fc2e6011578" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_45219bde-90b7-4acf-9919-192c04987e64" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_b62ff56e-5ba7-4140-9104-3fc2e6011578" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionRemainingPerformanceObligationDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails" xlink:type="extended" id="i0c9116f77ad5471e8865af25ca7a5e00_RevenuerecognitionRemainingPerformanceObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5c25fa68-b131-4718-aa71-3358ee2c04cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bcc583fd-5af8-4624-ba97-c271f620d182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5c25fa68-b131-4718-aa71-3358ee2c04cc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bcc583fd-5af8-4624-ba97-c271f620d182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_731d6903-23b0-4c74-8dd0-3edebebb77b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5c25fa68-b131-4718-aa71-3358ee2c04cc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_731d6903-23b0-4c74-8dd0-3edebebb77b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2767749e-4e8d-4354-a5cb-88bc211929fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_731d6903-23b0-4c74-8dd0-3edebebb77b1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2767749e-4e8d-4354-a5cb-88bc211929fc" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionRemainingPerformanceObligationDetails_1"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails_1" xlink:type="extended" id="i51564437fd1a4ce8b06b70549a56b16c_RevenuerecognitionRemainingPerformanceObligationDetails_1">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5c25fa68-b131-4718-aa71-3358ee2c04cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bcc583fd-5af8-4624-ba97-c271f620d182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5c25fa68-b131-4718-aa71-3358ee2c04cc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bcc583fd-5af8-4624-ba97-c271f620d182" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_731d6903-23b0-4c74-8dd0-3edebebb77b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5c25fa68-b131-4718-aa71-3358ee2c04cc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_731d6903-23b0-4c74-8dd0-3edebebb77b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#IncometaxesDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="extended" id="i6380fb943d7249cc91414b1f1bd6fad6_IncometaxesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesLineItems_3a0365c8-5ae7-4123-ba28-815780cb59a7" xlink:href="ebs-20220630.xsd#ebs_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_698af3ae-6173-4829-a7db-c0a915438794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_IncomeTaxesLineItems_3a0365c8-5ae7-4123-ba28-815780cb59a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_698af3ae-6173-4829-a7db-c0a915438794" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b1b806e8-556a-4562-af3a-3669ca49bf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_ebs_IncomeTaxesLineItems_3a0365c8-5ae7-4123-ba28-815780cb59a7" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b1b806e8-556a-4562-af3a-3669ca49bf6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesTable_0ca6bd2b-cbf0-4bbe-9baa-a3e06ccc6aa6" xlink:href="ebs-20220630.xsd#ebs_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_ebs_IncomeTaxesLineItems_3a0365c8-5ae7-4123-ba28-815780cb59a7" xlink:to="loc_ebs_IncomeTaxesTable_0ca6bd2b-cbf0-4bbe-9baa-a3e06ccc6aa6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2cfc816d-ab32-4d95-ab87-32a1d384f6c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_ebs_IncomeTaxesTable_0ca6bd2b-cbf0-4bbe-9baa-a3e06ccc6aa6" xlink:to="loc_srt_StatementScenarioAxis_2cfc816d-ab32-4d95-ab87-32a1d384f6c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_2cfc816d-ab32-4d95-ab87-32a1d384f6c3_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_2cfc816d-ab32-4d95-ab87-32a1d384f6c3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_2cfc816d-ab32-4d95-ab87-32a1d384f6c3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9a72db01-0bb0-46a3-98b3-d2de55f950a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_2cfc816d-ab32-4d95-ab87-32a1d384f6c3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9a72db01-0bb0-46a3-98b3-d2de55f950a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d9bd79b3-7b1b-4d5c-9ff6-097e878dead7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9a72db01-0bb0-46a3-98b3-d2de55f950a6" xlink:to="loc_srt_ScenarioForecastMember_d9bd79b3-7b1b-4d5c-9ff6-097e878dead7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#EquityNarrativeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/EquityNarrativeDetails" xlink:type="extended" id="iad25a8f72c43493d8e421ee2bd5f239b_EquityNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c038514d-68cb-408b-a725-d511f3d31953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c038514d-68cb-408b-a725-d511f3d31953" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_19dce3b4-bd6c-48ab-80c2-a51927a9c790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_19dce3b4-bd6c-48ab-80c2-a51927a9c790" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_63691db3-d0d1-4097-a3ee-87e6ffe792c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_63691db3-d0d1-4097-a3ee-87e6ffe792c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c955c7a5-d019-41cc-ae8a-ff3cea43fea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c955c7a5-d019-41cc-ae8a-ff3cea43fea6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_87de65d2-7b4c-41e1-9493-ac42f5cdaa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_87de65d2-7b4c-41e1-9493-ac42f5cdaa5d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_48be99c3-33d6-4998-9006-6fa20fdba714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_48be99c3-33d6-4998-9006-6fa20fdba714" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f6ca002a-afa7-482c-938a-ceab318e62dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f6ca002a-afa7-482c-938a-ceab318e62dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aacb0633-65ae-4da1-af5a-7b4ab3d621bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aacb0633-65ae-4da1-af5a-7b4ab3d621bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_694021f1-9674-4b4d-a3d4-4b6e0d861c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aacb0633-65ae-4da1-af5a-7b4ab3d621bf" xlink:to="loc_us-gaap_VestingAxis_694021f1-9674-4b4d-a3d4-4b6e0d861c81" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_694021f1-9674-4b4d-a3d4-4b6e0d861c81_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_694021f1-9674-4b4d-a3d4-4b6e0d861c81" xlink:to="loc_us-gaap_VestingDomain_694021f1-9674-4b4d-a3d4-4b6e0d861c81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_fe1ebd16-46bc-478a-bdf0-2964815d0fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_694021f1-9674-4b4d-a3d4-4b6e0d861c81" xlink:to="loc_us-gaap_VestingDomain_fe1ebd16-46bc-478a-bdf0-2964815d0fd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7ab989b6-034d-4cb3-a0d9-ccdad3b4635c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_fe1ebd16-46bc-478a-bdf0-2964815d0fd0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7ab989b6-034d-4cb3-a0d9-ccdad3b4635c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fb539214-ba11-476d-9dd9-9d72a7784566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_fe1ebd16-46bc-478a-bdf0-2964815d0fd0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fb539214-ba11-476d-9dd9-9d72a7784566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_030de3ff-d371-48e0-9eda-2ea5e14e802b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_fe1ebd16-46bc-478a-bdf0-2964815d0fd0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_030de3ff-d371-48e0-9eda-2ea5e14e802b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5ec23b6b-2fbc-4df9-a0d7-2a806f7e8b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aacb0633-65ae-4da1-af5a-7b4ab3d621bf" xlink:to="loc_us-gaap_AwardTypeAxis_5ec23b6b-2fbc-4df9-a0d7-2a806f7e8b6f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ec23b6b-2fbc-4df9-a0d7-2a806f7e8b6f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5ec23b6b-2fbc-4df9-a0d7-2a806f7e8b6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ec23b6b-2fbc-4df9-a0d7-2a806f7e8b6f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ed5aa99-96f6-4e48-ad7f-b2e747e5d438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5ec23b6b-2fbc-4df9-a0d7-2a806f7e8b6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ed5aa99-96f6-4e48-ad7f-b2e747e5d438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2b1a971d-fe52-4265-b192-e05b50081899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ed5aa99-96f6-4e48-ad7f-b2e747e5d438" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2b1a971d-fe52-4265-b192-e05b50081899" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bc7cb069-6d8a-4702-b7b5-3cf39608600b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ed5aa99-96f6-4e48-ad7f-b2e747e5d438" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bc7cb069-6d8a-4702-b7b5-3cf39608600b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ac6df408-a326-424f-b1f2-e235d5019d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aacb0633-65ae-4da1-af5a-7b4ab3d621bf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ac6df408-a326-424f-b1f2-e235d5019d8e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ac6df408-a326-424f-b1f2-e235d5019d8e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ac6df408-a326-424f-b1f2-e235d5019d8e" xlink:to="loc_us-gaap_EquityComponentDomain_ac6df408-a326-424f-b1f2-e235d5019d8e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6f9b995-b129-47ab-a839-6f3be87e56e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ac6df408-a326-424f-b1f2-e235d5019d8e" xlink:to="loc_us-gaap_EquityComponentDomain_a6f9b995-b129-47ab-a839-6f3be87e56e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5523b792-c1dc-4ccd-aab9-7994d70910ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6f9b995-b129-47ab-a839-6f3be87e56e6" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5523b792-c1dc-4ccd-aab9-7994d70910ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_2a98f0c5-bdfd-4c12-aa0e-8a91772cf7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_a6f9b995-b129-47ab-a839-6f3be87e56e6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_2a98f0c5-bdfd-4c12-aa0e-8a91772cf7b4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#EquityScheduleofStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended" id="i66c5eacbb97a48b08774d2af7e8882e2_EquityScheduleofStockbasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772414-50e1-4b35-8328-052a37a760ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4bc4a5e0-3899-4286-93bb-f97e3d7409df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772414-50e1-4b35-8328-052a37a760ad" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4bc4a5e0-3899-4286-93bb-f97e3d7409df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce26019e-4343-4169-bc38-6335306fde2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772414-50e1-4b35-8328-052a37a760ad" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce26019e-4343-4169-bc38-6335306fde2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7dddc9dd-9196-4f2b-b92f-7d1e2213e222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce26019e-4343-4169-bc38-6335306fde2e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7dddc9dd-9196-4f2b-b92f-7d1e2213e222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_7dddc9dd-9196-4f2b-b92f-7d1e2213e222_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7dddc9dd-9196-4f2b-b92f-7d1e2213e222" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_7dddc9dd-9196-4f2b-b92f-7d1e2213e222_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2a78ad7-a0c3-4927-a63e-810103b6a9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7dddc9dd-9196-4f2b-b92f-7d1e2213e222" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2a78ad7-a0c3-4927-a63e-810103b6a9f2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_850374dc-f1a1-469b-accf-9afd180f675f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2a78ad7-a0c3-4927-a63e-810103b6a9f2" xlink:to="loc_us-gaap_CostOfSalesMember_850374dc-f1a1-469b-accf-9afd180f675f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d815051a-e9cb-472f-b3c7-b9e838c04b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2a78ad7-a0c3-4927-a63e-810103b6a9f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d815051a-e9cb-472f-b3c7-b9e838c04b3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5cbb2bcc-31fb-4b9b-8f47-dbcfbd990991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2a78ad7-a0c3-4927-a63e-810103b6a9f2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5cbb2bcc-31fb-4b9b-8f47-dbcfbd990991" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4345273-1e4b-4fb6-9766-3a65bcff143e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce26019e-4343-4169-bc38-6335306fde2e" xlink:to="loc_srt_ProductOrServiceAxis_a4345273-1e4b-4fb6-9766-3a65bcff143e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4345273-1e4b-4fb6-9766-3a65bcff143e_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_a4345273-1e4b-4fb6-9766-3a65bcff143e" xlink:to="loc_srt_ProductsAndServicesDomain_a4345273-1e4b-4fb6-9766-3a65bcff143e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_711c411a-c674-4165-9441-03daf20f6e2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_a4345273-1e4b-4fb6-9766-3a65bcff143e" xlink:to="loc_srt_ProductsAndServicesDomain_711c411a-c674-4165-9441-03daf20f6e2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_cb661227-b00c-4c84-ac06-c03ff88ae76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_711c411a-c674-4165-9441-03daf20f6e2d" xlink:to="loc_us-gaap_ProductMember_cb661227-b00c-4c84-ac06-c03ff88ae76c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_a6db449f-f01a-4ff1-98d1-0b0eaf9da02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_711c411a-c674-4165-9441-03daf20f6e2d" xlink:to="loc_us-gaap_ServiceMember_a6db449f-f01a-4ff1-98d1-0b0eaf9da02f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#EquityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended" id="icc299c3550c34bb0885f1cc370ac9562_EquityChangesinAccumulatedOtherComprehensiveLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6f231bb0-c678-49ce-aed2-8d57b83b137d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6f231bb0-c678-49ce-aed2-8d57b83b137d" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_18985d5f-85ef-40d4-8c8c-e8774e339269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:to="loc_us-gaap_StockholdersEquity_18985d5f-85ef-40d4-8c8c-e8774e339269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f227440f-2617-4814-a24b-58f16009549f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f227440f-2617-4814-a24b-58f16009549f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_a2731732-5197-4928-aea0-81b42249c23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_a2731732-5197-4928-aea0-81b42249c23f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b72bc40-b891-4a05-bf5a-0e58917b543a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b72bc40-b891-4a05-bf5a-0e58917b543a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_19a5f108-1e6c-46ee-8f48-1d520f124648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_92e962a3-7528-4b18-a2f4-c9ffca94e129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6f231bb0-c678-49ce-aed2-8d57b83b137d" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_92e962a3-7528-4b18-a2f4-c9ffca94e129" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7fee5d7a-b5e3-4d6f-b37b-def31c19324b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_92e962a3-7528-4b18-a2f4-c9ffca94e129" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7fee5d7a-b5e3-4d6f-b37b-def31c19324b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_7fee5d7a-b5e3-4d6f-b37b-def31c19324b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7fee5d7a-b5e3-4d6f-b37b-def31c19324b" xlink:to="loc_us-gaap_EquityComponentDomain_7fee5d7a-b5e3-4d6f-b37b-def31c19324b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ef05615a-a7e8-4dad-8a3b-2c8c28e44fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7fee5d7a-b5e3-4d6f-b37b-def31c19324b" xlink:to="loc_us-gaap_EquityComponentDomain_ef05615a-a7e8-4dad-8a3b-2c8c28e44fbb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d42c24aa-1509-437e-a40c-e8da5767da6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_ef05615a-a7e8-4dad-8a3b-2c8c28e44fbb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d42c24aa-1509-437e-a40c-e8da5767da6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_c688912b-8352-4bd0-80ea-c6c23303adf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d42c24aa-1509-437e-a40c-e8da5767da6d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_c688912b-8352-4bd0-80ea-c6c23303adf5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_167a4db4-f252-490e-9a1e-67f568bee75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d42c24aa-1509-437e-a40c-e8da5767da6d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_167a4db4-f252-490e-9a1e-67f568bee75f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_37a95b77-c15c-40d0-a3a8-482bcf49aa41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d42c24aa-1509-437e-a40c-e8da5767da6d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_37a95b77-c15c-40d0-a3a8-482bcf49aa41" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended" id="i12fc17d77ad248c8bf4c72db5b5fc886_EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9e99be6b-aa63-4617-9ed9-f0d997bade6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_74152f80-cc22-4438-a478-f47ab59ead5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9e99be6b-aa63-4617-9ed9-f0d997bade6a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_74152f80-cc22-4438-a478-f47ab59ead5f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_96bc2fd5-97bd-437d-915b-64147c64cef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9e99be6b-aa63-4617-9ed9-f0d997bade6a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_96bc2fd5-97bd-437d-915b-64147c64cef1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_830c7838-a69e-47d7-9966-9e875fd688fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9e99be6b-aa63-4617-9ed9-f0d997bade6a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_830c7838-a69e-47d7-9966-9e875fd688fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192ac08f-7516-4f58-a466-88f1903d63df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9e99be6b-aa63-4617-9ed9-f0d997bade6a" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192ac08f-7516-4f58-a466-88f1903d63df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0a043bfb-e702-4bbf-bb0d-e88dcaf9ce6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192ac08f-7516-4f58-a466-88f1903d63df" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0a043bfb-e702-4bbf-bb0d-e88dcaf9ce6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0a043bfb-e702-4bbf-bb0d-e88dcaf9ce6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a043bfb-e702-4bbf-bb0d-e88dcaf9ce6d" xlink:to="loc_us-gaap_EquityComponentDomain_0a043bfb-e702-4bbf-bb0d-e88dcaf9ce6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f247f185-37af-486e-8d0c-5b7cac29c0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a043bfb-e702-4bbf-bb0d-e88dcaf9ce6d" xlink:to="loc_us-gaap_EquityComponentDomain_f247f185-37af-486e-8d0c-5b7cac29c0b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_16105f90-748a-48e3-9650-a449945e8ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f247f185-37af-486e-8d0c-5b7cac29c0b3" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_16105f90-748a-48e3-9650-a449945e8ee2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7ecfbb5a-f43d-44c5-8094-33c8aefccc96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_f247f185-37af-486e-8d0c-5b7cac29c0b3" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7ecfbb5a-f43d-44c5-8094-33c8aefccc96" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended" id="ia24c1473c2bb4bb99e77973054780fe3_SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21d9c626-3b1f-46c7-afc4-e78ea5e0ab2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21d9c626-3b1f-46c7-afc4-e78ea5e0ab2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d767e6dc-f7ab-444d-9511-79da94b653b2" xlink:href="ebs-20220630.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d767e6dc-f7ab-444d-9511-79da94b653b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b247f9ab-3323-489c-894e-e7a2a78b1378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_Revenues_b247f9ab-3323-489c-894e-e7a2a78b1378" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8ae5737f-db33-44cc-b566-042c15172403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8ae5737f-db33-44cc-b566-042c15172403" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ae9daabb-0667-4212-ab95-7193dfd1ad6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_GrossProfit_ae9daabb-0667-4212-ab95-7193dfd1ad6d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3a1ecf58-57c9-4830-8f00-1862a4d08ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3a1ecf58-57c9-4830-8f00-1862a4d08ccc" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin_b40c65ff-5013-4a43-8d4d-60d365d0284e" xlink:href="ebs-20220630.xsd#ebs_AdjustedGrossMargin"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_ebs_AdjustedGrossMargin_b40c65ff-5013-4a43-8d4d-60d365d0284e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_20935af8-38f0-46ae-90df-55f8e00225f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_20935af8-38f0-46ae-90df-55f8e00225f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4fe0679c-fc7f-4a6a-a15e-a9d44ed410d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4fe0679c-fc7f-4a6a-a15e-a9d44ed410d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_80581c87-8c97-4482-adc3-3839f6838b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4fe0679c-fc7f-4a6a-a15e-a9d44ed410d7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_80581c87-8c97-4482-adc3-3839f6838b16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_80581c87-8c97-4482-adc3-3839f6838b16_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_80581c87-8c97-4482-adc3-3839f6838b16" xlink:to="loc_us-gaap_SegmentDomain_80581c87-8c97-4482-adc3-3839f6838b16_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_31ed03e9-a15b-41aa-8504-94981363f061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_80581c87-8c97-4482-adc3-3839f6838b16" xlink:to="loc_us-gaap_SegmentDomain_31ed03e9-a15b-41aa-8504-94981363f061" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_3dddf2e2-1b08-4799-9deb-aaa5148610a9" xlink:href="ebs-20220630.xsd#ebs_ProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_31ed03e9-a15b-41aa-8504-94981363f061" xlink:to="loc_ebs_ProductsSegmentMember_3dddf2e2-1b08-4799-9deb-aaa5148610a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_ecfc6c73-a993-474b-97c0-9b72d2d53883" xlink:href="ebs-20220630.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_31ed03e9-a15b-41aa-8504-94981363f061" xlink:to="loc_ebs_ServicesSegmentMember_ecfc6c73-a993-474b-97c0-9b72d2d53883" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad153058-5977-4593-b3bb-d0606f8ff075" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4fe0679c-fc7f-4a6a-a15e-a9d44ed410d7" xlink:to="loc_srt_ProductOrServiceAxis_ad153058-5977-4593-b3bb-d0606f8ff075" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ad153058-5977-4593-b3bb-d0606f8ff075_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_ad153058-5977-4593-b3bb-d0606f8ff075" xlink:to="loc_srt_ProductsAndServicesDomain_ad153058-5977-4593-b3bb-d0606f8ff075_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ee9a06a-2b10-4978-93d6-3743df0320af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_ad153058-5977-4593-b3bb-d0606f8ff075" xlink:to="loc_srt_ProductsAndServicesDomain_6ee9a06a-2b10-4978-93d6-3743df0320af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_3b0ed43d-2aef-4692-beb7-93c08f2021fe" xlink:href="ebs-20220630.xsd#ebs_ContractsAndGrantsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6ee9a06a-2b10-4978-93d6-3743df0320af" xlink:to="loc_ebs_ContractsAndGrantsMember_3b0ed43d-2aef-4692-beb7-93c08f2021fe" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d3d82c2e-267d-4ee2-8e74-43539710ace7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6ee9a06a-2b10-4978-93d6-3743df0320af" xlink:to="loc_us-gaap_ProductMember_d3d82c2e-267d-4ee2-8e74-43539710ace7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e33784c6-cb38-4e81-bc3e-48f74c3e8912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6ee9a06a-2b10-4978-93d6-3743df0320af" xlink:to="loc_us-gaap_ServiceMember_e33784c6-cb38-4e81-bc3e-48f74c3e8912" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e758b437-a9e6-4769-ba9b-bb7fde34bb48" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4fe0679c-fc7f-4a6a-a15e-a9d44ed410d7" xlink:to="loc_srt_ConsolidationItemsAxis_e758b437-a9e6-4769-ba9b-bb7fde34bb48" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e758b437-a9e6-4769-ba9b-bb7fde34bb48_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_e758b437-a9e6-4769-ba9b-bb7fde34bb48" xlink:to="loc_srt_ConsolidationItemsDomain_e758b437-a9e6-4769-ba9b-bb7fde34bb48_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_145c67d0-a368-44e0-98b1-05e6610fa369" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_e758b437-a9e6-4769-ba9b-bb7fde34bb48" xlink:to="loc_srt_ConsolidationItemsDomain_145c67d0-a368-44e0-98b1-05e6610fa369" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_fef9ed13-bde6-4254-bffb-740b16b59393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_145c67d0-a368-44e0-98b1-05e6610fa369" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_fef9ed13-bde6-4254-bffb-740b16b59393" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:definitionLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended" id="i0683f1076c6247b5b00a5b87b6e365be_SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_15099c8d-ae19-4755-98ce-da5fa1b83033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract_2cb846af-dfb9-4d13-9adf-aa3f0041d71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_15099c8d-ae19-4755-98ce-da5fa1b83033" xlink:to="loc_us-gaap_DepreciationAbstract_2cb846af-dfb9-4d13-9adf-aa3f0041d71e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_741c22b3-df2e-4d15-a7cc-5c865ed7b9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DepreciationAbstract_2cb846af-dfb9-4d13-9adf-aa3f0041d71e" xlink:to="loc_us-gaap_Depreciation_741c22b3-df2e-4d15-a7cc-5c865ed7b9f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1410d0da-5570-411c-8bec-2416c9343100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_15099c8d-ae19-4755-98ce-da5fa1b83033" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1410d0da-5570-411c-8bec-2416c9343100" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_de3a3342-aebb-4304-b0a2-1390047947c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1410d0da-5570-411c-8bec-2416c9343100" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_de3a3342-aebb-4304-b0a2-1390047947c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_de3a3342-aebb-4304-b0a2-1390047947c4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de3a3342-aebb-4304-b0a2-1390047947c4" xlink:to="loc_us-gaap_SegmentDomain_de3a3342-aebb-4304-b0a2-1390047947c4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cf71612f-a2a4-4677-b848-db3e13c344d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de3a3342-aebb-4304-b0a2-1390047947c4" xlink:to="loc_us-gaap_SegmentDomain_cf71612f-a2a4-4677-b848-db3e13c344d8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_851a5fe0-29d6-45b8-888e-e4f7f889a971" xlink:href="ebs-20220630.xsd#ebs_ProductsSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cf71612f-a2a4-4677-b848-db3e13c344d8" xlink:to="loc_ebs_ProductsSegmentMember_851a5fe0-29d6-45b8-888e-e4f7f889a971" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_3b76792b-c68b-4b59-b18b-dacdefa6e689" xlink:href="ebs-20220630.xsd#ebs_ServicesSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_cf71612f-a2a4-4677-b848-db3e13c344d8" xlink:to="loc_ebs_ServicesSegmentMember_3b76792b-c68b-4b59-b18b-dacdefa6e689" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_847b9941-4d63-4367-b50a-693f3c91ff81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1410d0da-5570-411c-8bec-2416c9343100" xlink:to="loc_srt_ConsolidationItemsAxis_847b9941-4d63-4367-b50a-693f3c91ff81" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_847b9941-4d63-4367-b50a-693f3c91ff81_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_847b9941-4d63-4367-b50a-693f3c91ff81" xlink:to="loc_srt_ConsolidationItemsDomain_847b9941-4d63-4367-b50a-693f3c91ff81_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7f78feef-c070-4986-83d6-0cbc3d7e1f05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_847b9941-4d63-4367-b50a-693f3c91ff81" xlink:to="loc_srt_ConsolidationItemsDomain_7f78feef-c070-4986-83d6-0cbc3d7e1f05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_6bd41706-de0d-4e8e-b6a1-198b8a0845b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_7f78feef-c070-4986-83d6-0cbc3d7e1f05" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_6bd41706-de0d-4e8e-b6a1-198b8a0845b9" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>ebs-20220630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:76cb5594-9318-4e51-9277-4582eaf35bfa,g:cb82d48c-139c-44ae-8052-a281d9df29e8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_f17821c6-f290-4908-afba-c2f7a5224796_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cancelable orders</link:label>
    <link:label id="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Trade</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:to="lab_us-gaap_AccountsPayableTradeCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_e47250b0-0def-44a3-bbe4-c413825b5b4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ServicesSegmentMember_8694f4ac-4baf-4b53-be1f-6d259426ea20_terseLabel_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_ebs_ServicesSegmentMember_label_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Segment [Member]</link:label>
    <link:label id="lab_ebs_ServicesSegmentMember_documentation_en-US" xlink:label="lab_ebs_ServicesSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember" xlink:href="ebs-20220630.xsd#ebs_ServicesSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ServicesSegmentMember" xlink:to="lab_ebs_ServicesSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_7777001d-05a4-465d-a544-35a826feb262_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_259831aa-da4f-4d8d-8758-1abd8699ff1f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property Plant and Equipment Income Statement Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_4e4bfcda-9f8d-4bd0-928e-7e2e21539ad7_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_f1ba9510-b85a-45a3-aa1b-5fe3302779f9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounted cash flow</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Technique, Discounted Cash Flow [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:to="lab_us-gaap_ValuationTechniqueDiscountedCashFlowMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_a3207f8f-d23d-4002-b837-62f5120311f2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_ee5e6cc3-687f-4dcb-b6c9-2d7d6042fca7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_c90d5f42-c9b1-4fc6-9815-89c034164ce0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_56c61d8e-1508-49f8-86bb-85a838d558eb_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, consideration transferred, contingent consideration</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:to="lab_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_59f76aa6-ecc7-4b0f-a5dc-915a301be5ab_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_feb5ba7c-519e-4cf3-954c-f9a20517ea5f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, basis spread on variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_c541978d-b57e-40a0-a4ab-f6e6acdd0ce7_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_37800338-42a6-40f9-b05f-1777ddd183d1_terseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_632203ce-510b-46b2-a3c0-793458b8e119_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_ad766c39-682c-4090-ad46-b9df813f0633_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_c60a52e3-2e04-4a0f-aa92-94740e7a7a76_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis" xlink:to="lab_us-gaap_ValuationTechniqueAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_8ad4363d-2a86-449e-b914-b3e43436c73c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_e256f49d-d307-4e9a-9189-721a6c2707b9_terseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_26e054a7-ff7b-468d-ab09-1d6db7573dd1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember" xlink:to="lab_us-gaap_OtherCurrentAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_4ae09c0b-6c8c-4290-bfef-7bad4713b9b2_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_5e346b1e-4c44-4444-863f-063078c3688b_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_9dffd918-f2dd-406e-b833-d780397a81f5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_8688624c-0355-4517-8d67-ce5ad8d62cbd_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_1d4519a2-8d05-4dbb-8a23-a80c7ae41e26_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_a969288c-d108-4fb9-9d15-9c0cd84f579d_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_4f98223f-41be-4807-8e74-e515d7ae6ae1_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss)</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_dbc37773-cf19-4b47-a831-3bc0e037965f_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeDomain_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeDomain" xlink:to="lab_us-gaap_MeasurementInputTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_b564bfe7-c003-4a1d-baf6-53f19c530c75_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_30484901-1e0e-430d-b55c-622bae65bb56_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration by Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis" xlink:to="lab_us-gaap_ContingentConsiderationByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit_c5223bee-a42a-47e8-b044-067a53d83d9a_terseLabel_en-US" xlink:label="lab_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, minimum therapy treatment courses required to earn royalty on future gross profit</link:label>
    <link:label id="lab_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit_label_en-US" xlink:label="lab_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Minimum Therapy Treatment Courses Required To Earn Royalty On Future Gross Profit</link:label>
    <link:label id="lab_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit_documentation_en-US" xlink:label="lab_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Minimum Therapy Treatment Courses Required To Earn Royalty On Future Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit" xlink:href="ebs-20220630.xsd#ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit" xlink:to="lab_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_2b974c96-4948-4b15-be48-205a92002766_terseLabel_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Funds Rate</link:label>
    <link:label id="lab_us-gaap_FederalFundsEffectiveSwapRateMember_label_en-US" xlink:label="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fed Funds Effective Rate Overnight Index Swap Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:to="lab_us-gaap_FederalFundsEffectiveSwapRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_245e74c1-0eef-4ff7-8960-aea60f32c122_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_7cc59132-6ee2-43e7-a8b8-3732f404026f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseMember_ee5dd26f-4b54-4529-9821-e6d96fddfb5d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseMember_label_en-US" xlink:label="lab_us-gaap_InterestExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseMember" xlink:to="lab_us-gaap_InterestExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_d75bdda3-166f-466a-91f2-c042eee9d9c9_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_MeasurementInputDiscountRateMember_label_en-US" xlink:label="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Discount Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputDiscountRateMember" xlink:to="lab_us-gaap_MeasurementInputDiscountRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementScenarioAxis_529ee35d-8a7f-4946-8b9b-909d02319423_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_label_en-US" xlink:label="lab_srt_StatementScenarioAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis" xlink:to="lab_srt_StatementScenarioAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_dc5dcb49-d49c-4496-b3ab-cacb47e7d509_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, redemption price, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPricePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption Price, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPricePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractsAndGrantsMember_827efb7a-e900-4089-87dc-0ff477de32ad_terseLabel_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracts and grants</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_label_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contracts and Grants [Member]</link:label>
    <link:label id="lab_ebs_ContractsAndGrantsMember_documentation_en-US" xlink:label="lab_ebs_ContractsAndGrantsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember" xlink:href="ebs-20220630.xsd#ebs_ContractsAndGrantsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractsAndGrantsMember" xlink:to="lab_ebs_ContractsAndGrantsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_d63210e1-70b3-4215-8737-b05f76a4f0a5_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_468dc488-c3b4-4cbe-9b4b-ff298aa0849b_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting rights, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_a8d8d293-68b7-49ba-893a-fc25ae36ff42_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_4b0a6142-abea-446c-b99e-619514284708_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Instruments</link:label>
    <link:label id="lab_us-gaap_NumberOfInterestRateDerivativesHeld_label_en-US" xlink:label="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Interest Rate Derivatives Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:to="lab_us-gaap_NumberOfInterestRateDerivativesHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_c7055f5b-1526-4f05-8d77-62d9faa207e4_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Approach and Technique [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain" xlink:to="lab_us-gaap_ValuationTechniqueDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_606dfe2a-b1d2-458e-a523-aecbbf3c08a8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAbstract_611b770e-7627-433e-8881-9da63c0ab089_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation:</link:label>
    <link:label id="lab_us-gaap_DepreciationAbstract_label_en-US" xlink:label="lab_us-gaap_DepreciationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAbstract" xlink:to="lab_us-gaap_DepreciationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_360d0769-28db-4d15-b75a-6acbb59b0647_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_b6a579b3-b89a-44c5-97bf-7a9005564cfd_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_2e6f537e-dc3b-4cfa-8375-9dca25aacf89_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_e1d8d6ff-36f3-48e0-bd6c-4699b1e77f04_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_c092c6fa-6eca-4b9b-8cce-1d98007f3426_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_8cb417d0-c2fc-4e7b-ae4d-0ae5bce6bd25_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermDomain_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermDomain" xlink:to="lab_us-gaap_LeaseContractualTermDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_3d1133f6-577f-4223-a66d-d2081424553f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_7466afd5-53f6-4213-afab-e79f5307ac0f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_044ebd82-38bf-4963-a8a6-3785e002260c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_ac89b2c6-901f-4434-84e5-06b152692785_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_47d02b01-8a27-48fe-9572-0184fd60e325_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_7a2fb533-1545-434f-a4e5-173318d9347d_terseLabel_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ContingentConsiderationTypeDomain_label_en-US" xlink:label="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent Consideration Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain" xlink:to="lab_us-gaap_ContingentConsiderationTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ec4364a-0aac-4998-a93b-d023b1cd4f0c_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_83bb733e-e853-4571-bfe8-b58abfed8dbc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_b83947c9-51ea-4dc8-bd84-56b8016505ca_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ad5e85ac-67f3-4eb6-bf4a-e601e867268b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_43b0cd9f-954d-4ea0-9f5f-7a7f0504ac6b_negatedLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostAbstract_28570090-bb8b-425a-9464-fc856bae76b5_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease cost:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_6fc7973b-a4b3-4e54-87bc-dd2b8f8018dd_verboseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating leases:</link:label>
    <link:label id="lab_us-gaap_LeaseCostAbstract_label_en-US" xlink:label="lab_us-gaap_LeaseCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostAbstract" xlink:to="lab_us-gaap_LeaseCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_eab8e52a-912f-4954-a802-08b5436629e9_verboseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt covenant, consolidated debt service coverage ratio, minimum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Debt Service Coverage Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:to="lab_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MilestonePaymentTwoMember_983c42bf-6075-4599-9769-11ff454134be_terseLabel_en-US" xlink:label="lab_ebs_MilestonePaymentTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Two</link:label>
    <link:label id="lab_ebs_MilestonePaymentTwoMember_label_en-US" xlink:label="lab_ebs_MilestonePaymentTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Two [Member]</link:label>
    <link:label id="lab_ebs_MilestonePaymentTwoMember_documentation_en-US" xlink:label="lab_ebs_MilestonePaymentTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentTwoMember" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MilestonePaymentTwoMember" xlink:to="lab_ebs_MilestonePaymentTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_8288a757-e4f3-4dd4-847c-a41b3aa680e7_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_95e1c5dc-cf74-4715-a274-45bcc89d2bb0_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current portion of debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_c526f5e2-93f4-4124-84b4-eb343eacd50f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_cb404d3e-a07f-44d8-86cb-ba0344345738_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_87c6788b-27ee-4adb-9b8c-2c58775969d8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average remaining lease term (years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cd4564fd-63a8-4eaa-ac23-47947ead709e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_ba340970-333e-4723-b94e-a50daa3908cb_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_77b7feeb-75f0-47e5-94ee-c7adc6d86a3c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of Gain/(Loss) Reclassified from Accumulated OCL into Income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_344b48bd-19c5-4c5a-9d91-c69709051497_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_def44229-2c8f-42e5-a868-a7e028d06c7b_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_59d3a538-2350-48d2-a9bb-ecf746473b55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_BARDAMember_f77323b9-9d2b-42af-981a-5d2afd088dff_terseLabel_en-US" xlink:label="lab_ebs_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA</link:label>
    <link:label id="lab_ebs_BARDAMember_label_en-US" xlink:label="lab_ebs_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA [Member]</link:label>
    <link:label id="lab_ebs_BARDAMember_documentation_en-US" xlink:label="lab_ebs_BARDAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">BARDA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember" xlink:href="ebs-20220630.xsd#ebs_BARDAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_BARDAMember" xlink:to="lab_ebs_BARDAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_45cf3d00-6166-4f2f-93ee-4852da67168e_terseLabel_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_label_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:label id="lab_ebs_OtherLongTermDebtFacilityMember_documentation_en-US" xlink:label="lab_ebs_OtherLongTermDebtFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long Term Debt Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember" xlink:href="ebs-20220630.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OtherLongTermDebtFacilityMember" xlink:to="lab_ebs_OtherLongTermDebtFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_219ed8ff-65ea-429a-b765-9b2fa5af2b9e_verboseLabel_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility</link:label>
    <link:label id="lab_us-gaap_RevolvingCreditFacilityMember_label_en-US" xlink:label="lab_us-gaap_RevolvingCreditFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revolving Credit Facility [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevolvingCreditFacilityMember" xlink:to="lab_us-gaap_RevolvingCreditFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ac927aae-fcad-498a-a3ea-5191c02e5003_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_6f19d010-25e5-41ac-9f78-aa9a3c0ad169_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_fbc59871-1188-45fd-8b4e-ae3831695ebb_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_9da4f7cc-69e3-4ec2-a664-5d16fab169ea_terseLabel_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of revenue generating products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_label_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Revenue Generating Products</link:label>
    <link:label id="lab_ebs_NumberOfRevenueGeneratingProducts_documentation_en-US" xlink:label="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to the number of revenue generating products.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts" xlink:href="ebs-20220630.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfRevenueGeneratingProducts" xlink:to="lab_ebs_NumberOfRevenueGeneratingProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6eead649-de9a-471f-be72-ec7e2a002315_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_06d27b8a-db34-4334-82d5-39fffd325a9c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_aa55c3cd-e76e-4f34-9c2a-a060b2f97646_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_7f147ab4-48ca-41ac-9d9e-895e22bbc7a5_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_f4b6b282-6f82-4913-925f-5dc747b8d77c_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_a340789b-ba25-4841-b77e-ff8785fedd79_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_16eed496-87db-49bb-b340-b2517c4715c0_terseLabel_en-US" xlink:label="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, domestic royalty percentage</link:label>
    <link:label id="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_label_en-US" xlink:label="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Domestic Gross Profit Royalty Percentage</link:label>
    <link:label id="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_documentation_en-US" xlink:label="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Domestic Gross Profit Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:href="ebs-20220630.xsd#ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:to="lab_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_056cad33-10c2-4d7f-bfd2-cf8a183138d3_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_699688bd-cc41-4289-be37-fffa5e200d3f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_3ba47c21-ef36-467a-8d0a-68eff644be23_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, consideration threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Consideration Threshold</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantConsiderationThreshold_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Consideration Threshold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:to="lab_ebs_DebtInstrumentCovenantConsiderationThreshold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_0deb0840-60dd-47e8-8494-2d2958e40640_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_dbdc87bc-6460-465a-bc6b-0d03a17870f2_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_1a1c872f-1b8e-4c82-81a1-8636f0c0563f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rollforward of Contract Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_735dc7a1-7dd8-4319-b2c9-c53718a2df0a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_f799b91e-3f06-4680-9325-492c2bcac51e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ddb92329-971f-4a6a-a34e-a09070972d75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_cc4d151a-2be6-4ff1-8242-a7274b2b7926_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_383c1943-c93d-478a-874b-67594657b5da_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_ece220fa-93e2-4faa-9d23-f85a19a20e22_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_d09a935f-9f35-448e-a914-66225c4b536d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_b0d428c3-6a0f-4c5c-80a7-ff439daa92c7_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_7ecb0296-f701-4e51-a0c5-29ee50d6874f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_fd6ab70b-7d0d-4d91-a5e3-a01f7941f864_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ChimerixAssetAcquisitionMember_2b2e479b-b3af-4146-8b2e-b6419b1b623d_terseLabel_en-US" xlink:label="lab_ebs_ChimerixAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chimerix Asset Acquisition</link:label>
    <link:label id="lab_ebs_ChimerixAssetAcquisitionMember_label_en-US" xlink:label="lab_ebs_ChimerixAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chimerix Asset Acquisition [Member]</link:label>
    <link:label id="lab_ebs_ChimerixAssetAcquisitionMember_documentation_en-US" xlink:label="lab_ebs_ChimerixAssetAcquisitionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chimerix Asset Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixAssetAcquisitionMember" xlink:href="ebs-20220630.xsd#ebs_ChimerixAssetAcquisitionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChimerixAssetAcquisitionMember" xlink:to="lab_ebs_ChimerixAssetAcquisitionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_48bcef1c-67a9-4b5e-bdb0-e7c6c1d08819_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_fd56622b-ce06-4c61-af17-be0d2bb451be_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Benefit (Expense)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_7a443610-ab45-4fb1-8e4f-d2aec774a1ac_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long-term debt, net of debt issuance costs</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_eec09625-44da-4976-bf53-7ba5bd474647_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_5a3d40bd-90bc-48d0-a77b-99b8f3a3ab5a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_b1f76046-460a-4c63-8f4c-0e4f6715f979_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt, fair value</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue" xlink:to="lab_us-gaap_LongTermDebtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_badf85bd-b003-4c4c-9dad-dab54e5a0345_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_8df4deb0-68a9-4bde-b034-52fbb99857be_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_c716d3ac-7773-4d8d-8bd5-c804526f0e92_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_b577a620-de0c-4818-8fe5-5e449dfefab2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts reclassified from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_9645e0e5-4ace-4266-8696-7719cd023af0_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditMember_405c6d62-0815-453a-b9f2-abb94f8b0a88_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember" xlink:to="lab_us-gaap_LineOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_f71c454c-1973-4588-b999-4d12274f7e32_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_a4fe46b9-c4ed-4b2c-b5fa-84b0f9bbf072_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_f898e4b0-c589-4aa7-9ecb-aee949c961a3_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_2e0d3bdc-a8a4-4770-b1b0-73dfcdce2eef_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (loss) per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_2c876db2-c5ca-47e5-bf48-5fedd78fe852_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_ec4c7c54-ca97-4218-a47d-17c77a34a0a6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3c0500e9-ef8c-4e63-ad58-beb94d435155_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_45c83ae4-e87e-415b-9ff2-e8020be2a052_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:to="lab_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_5aee1f41-35b7-44d0-9211-cd11b37b64b5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AdjustedGrossMargin_2cef70c2-be9a-47b1-b87b-aff58feda962_terseLabel_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted gross margin</link:label>
    <link:label id="lab_ebs_AdjustedGrossMargin_label_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Gross Margin</link:label>
    <link:label id="lab_ebs_AdjustedGrossMargin_documentation_en-US" xlink:label="lab_ebs_AdjustedGrossMargin" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjusted Gross Margin</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin" xlink:href="ebs-20220630.xsd#ebs_AdjustedGrossMargin"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AdjustedGrossMargin" xlink:to="lab_ebs_AdjustedGrossMargin" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_7cb5b99a-fd41-42c9-965b-203e6077ba87_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_ed57a27e-da88-4af4-a142-e18e634c04e6_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross margin</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_c8ec4150-1f48-4a44-ad60-aba848636d83_terseLabel_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accounts Receivable, Net</link:label>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_label_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:label id="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_documentation_en-US" xlink:label="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Accounts Receivable, Net [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:href="ebs-20220630.xsd#ebs_ScheduleOfAccountsReceivableNetTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:to="lab_ebs_ScheduleOfAccountsReceivableNetTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_56d5d43d-0520-4b8c-a505-b077c945e201_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_2a9d4eda-fe27-4ad3-ae9b-f6a3e5c49649_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_GoodwillForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MeasurementInputProbabilityofPaymentMember_a43e0118-d032-461a-a500-132d904c513a_terseLabel_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityofPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of payment</link:label>
    <link:label id="lab_ebs_MeasurementInputProbabilityofPaymentMember_label_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityofPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability of Payment [Member]</link:label>
    <link:label id="lab_ebs_MeasurementInputProbabilityofPaymentMember_documentation_en-US" xlink:label="lab_ebs_MeasurementInputProbabilityofPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input, Probability of Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityofPaymentMember" xlink:href="ebs-20220630.xsd#ebs_MeasurementInputProbabilityofPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MeasurementInputProbabilityofPaymentMember" xlink:to="lab_ebs_MeasurementInputProbabilityofPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_c20d242a-badd-47bd-a636-499b1b33dd8d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation Adjustments</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_7e105197-712d-4214-add3-4147f98badb6_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_bca2b18e-4bd9-48e9-8c47-eb5730d6fbaf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_0550718f-b710-4c1c-bb5d-1c1298788954_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_655aa315-7047-48ec-8c29-d0ca60bd3900_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_93142718-c5d9-4b29-9f6c-51c09e8f6f17_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_2c26d4c0-1487-42e4-bbc7-4a538b87dd97_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ProductsSegmentMember_fb87cdc1-16f0-4400-89fc-95b97668f8d0_terseLabel_en-US" xlink:label="lab_ebs_ProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products</link:label>
    <link:label id="lab_ebs_ProductsSegmentMember_label_en-US" xlink:label="lab_ebs_ProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Segment [Member]</link:label>
    <link:label id="lab_ebs_ProductsSegmentMember_documentation_en-US" xlink:label="lab_ebs_ProductsSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember" xlink:href="ebs-20220630.xsd#ebs_ProductsSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ProductsSegmentMember" xlink:to="lab_ebs_ProductsSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_93192ca1-2cc8-4bc1-b968-d2fb9aa5180f_terseLabel_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract development and manufacturing</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_df489f94-ae6c-41f7-96e3-a34393518138_verboseLabel_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CDMO</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_label_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Development And Manufacturing [Member]</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingMember_documentation_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue earned during the period arising from manufacturing sale under the terms of a contract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember" xlink:to="lab_ebs_ContractDevelopmentAndManufacturingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b2b29de4-2af1-4a76-9390-5817834f69d8_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_aa084bee-dcfa-4372-8892-a540b9d40195_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_3557e45e-c170-459d-b9f7-ad8f595388ca_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_e1fc7e11-99b8-4ee6-84a3-a120365ef431_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, raw materials, net of reserves</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_2bdaaf85-d9ae-4351-9a4a-675f5054a9d4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_238cbb99-3ab5-4985-be5c-7a3fd457abaf_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0983a1cb-b20a-4158-ba16-45ed0332c852_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_5ee565be-4d2f-49ba-acf5-13f6abd3dfeb_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_e4f386c5-f98f-4436-96b1-de757d698445_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_0549e867-19fe-471e-a51c-7ce587f96b7c_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_562d7d49-e64e-4f01-8886-9c622734c61f_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_41e56068-8508-4280-adc8-20228f08fb57_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesMember" xlink:to="lab_us-gaap_OtherLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_bc44802e-6cc1-4753-b3a3-5907959dea19_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_IntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfProductCandidates_eba0f212-0700-4132-b31b-b72073db0ce3_terseLabel_en-US" xlink:label="lab_ebs_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of product candidates</link:label>
    <link:label id="lab_ebs_NumberOfProductCandidates_label_en-US" xlink:label="lab_ebs_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:label id="lab_ebs_NumberOfProductCandidates_documentation_en-US" xlink:label="lab_ebs_NumberOfProductCandidates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Product Candidates</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductCandidates" xlink:href="ebs-20220630.xsd#ebs_NumberOfProductCandidates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfProductCandidates" xlink:to="lab_ebs_NumberOfProductCandidates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_543eef08-e75d-45c7-a33d-55893af29809_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_484f8a47-b4d5-46d5-9bfb-ebc3cda1a431_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_c7d3e15c-36c1-4db6-b40c-1d3b508a591c_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_40f479e8-6640-4825-8650-c3e225608de5_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_44e1a793-4ee4-48e7-982d-7b545db855d7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_6bc15885-39a6-4da1-aff3-2b1f14c4c109_terseLabel_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of categories of public health threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_label_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Categories Of Public Health Threats</link:label>
    <link:label id="lab_ebs_NumberOfCategoriesOfPublicHealthThreats_documentation_en-US" xlink:label="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Refers to the number of categories of public health threats.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:href="ebs-20220630.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:to="lab_ebs_NumberOfCategoriesOfPublicHealthThreats" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_6a9a9275-805f-4cdd-8cf6-9c049644a6e6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_02b24b2e-4b09-4d87-9bb0-16ca3c1cd5fb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_0d9a377a-6267-4d53-b021-057f8dd2e549_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_eda98494-3dc2-4d7c-9227-c5d0a0fe9679_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective annual tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_962d3052-6cc3-4d23-b006-d99e53e559a7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_8de292c7-208c-4fec-988f-34eca86519e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_2f7ec462-b7a6-4060-86a7-92ca017749e9_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, beginning of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_aa4119dd-a4a3-4b32-91cb-ed8710eebaaa_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance, end of period</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_341e626f-9842-4ede-85c7-1b932462e1f7_totalLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_f5593b9d-9aff-409b-9764-456120b62751_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reversal of previously recognized revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_f4ab37c2-76be-4676-9375-f9047feab0f9_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_626fc6c7-7e42-44a9-88b7-ec09ac8f44e7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gains (losses) on hedging activities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_58ce95fc-0817-4c80-9b47-58990bf1c11f_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_61650009-1204-4d20-be90-9b53bc87942d_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityDomain_147f70bd-f9b9-46b0-a82c-7b091715f536_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain" xlink:to="lab_us-gaap_CreditFacilityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_9fa987cf-8c66-4ab1-aa99-3f1413eaa76e_terseLabel_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jansen Pharmaceuticals, Inc.</link:label>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_label_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jansen Pharmaceuticals, Inc. [Member]</link:label>
    <link:label id="lab_ebs_JansenPharmaceuticalsIncMember_documentation_en-US" xlink:label="lab_ebs_JansenPharmaceuticalsIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Jansen Pharmaceuticals, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember" xlink:href="ebs-20220630.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_JansenPharmaceuticalsIncMember" xlink:to="lab_ebs_JansenPharmaceuticalsIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_bc7a1c35-8567-4c72-9e32-6308fcfd4d3f_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_70e5f822-590a-4f8f-9fce-d96d4d1fe2be_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization Expense</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_daf17e50-2d17-42ca-9680-1053dccdc17d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_0992c997-da95-44a5-9373-e1c0ae581194_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the period for interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_99338385-e11c-43bf-be39-b07f89862efc_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingCostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingCostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingCostsAndExpenses" xlink:to="lab_us-gaap_OperatingCostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_23f96c9b-aaed-4ca5-a869-8c702dc8df6a_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_283c748c-3116-41b1-bf62-e11de4e7f71d_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_73c417e6-4d26-4369-852b-7f791dff18c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_9fec27c1-ab61-4420-9f8b-843d0e361ace_terseLabel_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and improvements</link:label>
    <link:label id="lab_us-gaap_LandAndLandImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LandAndLandImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and Land Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandAndLandImprovementsMember" xlink:to="lab_us-gaap_LandAndLandImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_d852f197-75fc-4f59-9cfe-d7882df7bc60_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on convertible senior notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfConvertibleDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Convertible Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfConvertibleDebt" xlink:to="lab_us-gaap_RepaymentsOfConvertibleDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_328ac868-9959-4a74-b920-d19b16ceb4a7_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_2c64d8a2-3b47-47a1-9402-805f52f0d0b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_5d3602a7-0f1d-4c98-a5b6-d40247cc9920_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_dd9e782e-c65a-4d3c-951b-0511bdbb01e2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments and hedging activities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_66018531-c415-4d2d-997c-74c4ac9ed32c_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_87848d22-cd58-4f0c-8119-3476ac37da93_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseContractualTermAxis_label_en-US" xlink:label="lab_us-gaap_LeaseContractualTermAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseContractualTermAxis" xlink:to="lab_us-gaap_LeaseContractualTermAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_282bf794-2da6-47e7-9cb2-b910e55c605f_terseLabel_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Contract With Customer, Liability [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:href="ebs-20220630.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:to="lab_ebs_ChangeinContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_6b197a1d-760e-4e57-98bc-4da882b4cf4d_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_164e8e0c-ac2f-4450-9573-df26d3fceee4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_c0aae6ae-37ff-4970-8c59-e53fe9ff24ac_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_5578be13-f019-4335-9d3c-ddc2df669d89_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_a7be4130-4451-4de1-a4d2-eecab80c203e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_32849873-2849-4aa3-a12b-2c86474b63e0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market accounts</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_01305e56-9004-492d-b43f-ee55b93a419b_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_4018af5d-faef-4068-acdb-b259d6895e5c_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_20802e14-85e5-47a6-8e43-23bff440d86a_terseLabel_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferral of revenue</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_label_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Additions</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityAdditions_documentation_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityAdditions" xlink:href="ebs-20220630.xsd#ebs_ContractWithCustomerLiabilityAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractWithCustomerLiabilityAdditions" xlink:to="lab_ebs_ContractWithCustomerLiabilityAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_19094ae5-450a-4fd9-aa04-36dc10d97fe1_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4b962b4f-141f-4cd1-be5b-9a1fcdc4f99a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$0.001 Par Value Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_42d06005-c263-411a-9885-b2cad7b3ee70_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_a9b9d99d-53c5-4658-933a-608623d1c740_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_9fc04da9-1081-49b5-aab5-911f9304ef71_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_e1644e00-8f8d-48ba-b501-d486818d0015_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation activity</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_5b093bd2-7d69-4f16-89c5-df95bad8ddad_terseLabel_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income before reclassifications</link:label>
    <link:label id="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, before Reclassifications, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:to="lab_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_f58c707c-1fce-4030-9132-c47ad2067c32_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_05c94774-2ffa-4fd3-a400-cdacb568784d_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_edd0b592-322e-4e7d-8e3c-39e4ee2ebb66_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of treasury stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_d6abed84-3687-4de0-90be-327401261e36_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_b5977213-26c4-4bb8-90fb-0de1ed20c8d8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of contingent purchase consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_038ba7bd-6cca-485e-ba53-47858f7040e6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_38cfbfa8-76a9-44ab-bfff-80d1b1a9dbbd_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember_6c278077-8927-4638-9bd7-b84062602ce5_terseLabel_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember_label_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Development And Manufacturing, Leases [Member]</link:label>
    <link:label id="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember_documentation_en-US" xlink:label="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract Development And Manufacturing, Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:to="lab_ebs_ContractDevelopmentAndManufacturingLeasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_072465c5-d7df-4ae4-8022-d09cd7b92658_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and equipment</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_dbda1a35-b005-4c2c-a5a4-715884305489_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_73c7db0e-f705-4ae9-88d5-5d0a3f20fa44_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_a22440f1-c3fa-46af-93b0-c08b7a615d4f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_c4fa2413-f233-492e-a6b9-68b3e59a6f8d_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_fd55bef6-799d-4e30-adaf-d4cec9079f89_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_7c5c0ad5-0d8a-45dd-802c-582e3a94823f_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration payments</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Contingent Consideration Liability, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_ed578048-b819-43bc-8fcb-2a32ac143ca9_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with customer, asset, noncurrent</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_b0ad61c4-5a33-4a31-bba0-1f3facfff469_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_0df42441-36a9-4e37-a097-ca5a2cd07969_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1842c2a4-5949-4ec3-a31f-ff28eafda656_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_c72b3a6d-2f2b-4e86-98d6-06418ad542ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_954c2636-dabf-4d13-ac65-3c66ae47e10f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_213504cf-c311-45f4-b53c-9bb1532e2fa4_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain" xlink:to="lab_srt_ScenarioUnspecifiedDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_0b81915a-85f4-4451-9bd4-310a2547ce6a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_5ecaf21f-9910-4c5e-92be-180e2a2c9c78_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_ed113dcf-33ff-4c9c-bc1c-452ed133149e_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_cd05119e-b1e4-494e-bead-14bc59192b74_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4c3c17ff-bf83-4025-8171-6337ca2f1330_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_22b778d6-7fe2-4d4e-8762-49c20c2bed98_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_275176ff-b6bb-4941-9eb4-3070de5109cc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, liability, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_610be6f4-9255-457b-99a6-ff92ac0e3864_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_1d3de8fc-6aa3-4b1b-be48-f4c734bb7fd8_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total other income (expense), net</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateDomain_75687650-4035-4e8e-af6f-5fc7eef247b8_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain" xlink:to="lab_us-gaap_VariableRateDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_a9bfca93-6741-4c29-a50d-a445f8a6639a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_23ca2408-4db3-434b-973b-80b85e4b5f8d_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_7bab9d44-82e1-4923-96df-7bbb825b5c2f_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5fda3af0-60d7-47df-a98e-739d1b1ffadc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value of contingent consideration, net</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_c5e67a34-88f8-4d56-bd73-f3c911355e01_netLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in fair value</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_26846d77-05c6-497c-b6dc-7f75163f5590_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in fair value of contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_bae570bf-845f-4d96-a4de-92c1f076f097_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_8359efb2-d87d-4038-8ffa-0ecb11a30509_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product sales, net</link:label>
    <link:label id="lab_us-gaap_ProductMember_354a2f18-af74-4ffd-92be-334f7e95e7b7_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_38040136-845c-4441-9abd-c4664e8c42c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_60988d19-2fbe-4263-bfca-1f26f4f43b4c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of stock</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_df74d1fd-7128-4369-826a-b5cf93d22a6b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_0dc0b183-9dfe-46b7-b036-afd10d351744_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember_1e0b2f2e-3c7a-4246-9897-6d9854299bdd_terseLabel_en-US" xlink:label="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Expansion Of Fill/Finish Capacity</link:label>
    <link:label id="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember_label_en-US" xlink:label="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Expansion Of Fill/Finish Capacity [Member]</link:label>
    <link:label id="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember_documentation_en-US" xlink:label="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accelerated Expansion Of Fill/Finish Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:href="ebs-20220630.xsd#ebs_AcceleratedExpansionOfFillFinishCapacityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:to="lab_ebs_AcceleratedExpansionOfFillFinishCapacityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_b73431ae-1628-44f2-89ed-4872f3fbbbd6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest on lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseExpense" xlink:to="lab_us-gaap_OperatingLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_d95edbb2-6462-4318-b9e0-48cbbb28761e_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire productive assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_524e3d78-5de1-4b3e-9d4c-eecb14333aef_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_58a13c63-bd87-4440-a031-85e3856b7778_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pretax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_d0a6c791-7fb4-4cc4-9bfa-d4991ccd2a27_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e349207e-7bc2-448d-a2c2-58b5953c7a23_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (loss) from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_9b6fc3e4-8b54-4f87-bc90-d566f9d1a7fe_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b4f13fd5-ec17-40dd-8149-bbb1b7e94eeb_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently issued accounting standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_b0bf99fa-7449-416b-b4f0-3496c1379b59_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Current Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_f97d9655-aa73-48ed-8b97-f74290f9f932_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_e9fb02a4-a864-45b6-8f42-ba126ec8b653_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_5efc7471-c27f-40c2-93a5-38a749cf0f4a_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_c76351c0-dd00-4fac-a6fc-b006fae097ef_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_641e4101-9a6e-4038-a1e7-a2e7121e948a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_4e0fb6b3-a0f7-45ae-8859-c7f816502030_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_9e2c3ee1-b40e-4c23-a45c-d34b60bf7f8b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_9dbe34e8-0deb-470f-9f31-d257e8f2a285_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, December&#160;31, 2021</link:label>
    <link:label id="lab_us-gaap_Goodwill_50dde4a5-eb14-4c7f-b921-89192c6f7487_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, June&#160;30, 2022</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_f6a48522-c429-45c6-a9d3-de9bf21af701_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_1de97eea-3ca6-4db5-b63f-e5ea8c13b697_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_4ecf4e8a-073e-4a90-a34d-6c6ef2f35b41_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosure" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_fcfde7ff-4b6f-45dd-94e4-49138de56356_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_f9549fef-0cf4-4298-9b72-d866733e9adb_negatedLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchases of stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_89d95b6f-9c03-42cd-ad49-86a4abbc8d4e_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchased during period, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodShares_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodShares" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_aca49d79-aece-4ada-a07f-93295d7a1e73_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt issuance costs, current, net</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsCurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Current, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsCurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsCurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_d00ea07c-f1f5-4922-a395-238fba3bf34a_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_2adef28e-a5b7-47d4-85dd-72a26f354554_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lease revenue</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income, Lease Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:to="lab_us-gaap_OperatingLeaseLeaseIncomeLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_dc03e82e-05f6-4d80-8063-829579ba9573_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_5f35247a-a037-4e3c-8f61-a64eecfc5ec1_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income (loss) to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_88a1a82c-dc0c-475d-8036-5422e00bf56e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_8a83de8a-281e-4776-b305-527634e21e53_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_27e6f8cd-0288-47b8-b10e-b416df15d214_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_8b28ad7c-22de-419b-8911-7b46c531b63f_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_f74fde53-5ac3-4413-ae5d-ff5a3c03d35b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_ad22f759-7998-4b67-ba34-95345fa4c74e_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_921030d7-a1f7-4d3f-9f8d-cbf37c7abb16_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-In Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_dc4e0fff-b96f-4058-9e56-1782f5dff1c8_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_b34e2369-42c2-43ba-8c75-5bdf31ebf477_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_aa83aeb5-fa5b-4244-ab49-cd43560d31fa_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods and services sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_289aff66-f771-40f3-a913-3cfd971112b6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods and services sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a7c47dda-09ad-4d8e-ac24-3e9f29d8f084_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_09315dc6-8b0e-40c6-8011-f5f437ce5ab5_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares-diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_9adc1b36-deb1-4ded-ad1d-00371f584759_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative instruments</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_569b841e-9c10-4375-8117-14d7fd744fb3_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Accumulated depreciation &amp; amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_da1f1d21-6246-4fcd-a592-ad927db048a5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityDeductions_77187a21-4e90-437a-8d5f-6a3016fe8ebf_negatedTerseLabel_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityDeductions_label_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deductions</link:label>
    <link:label id="lab_ebs_ContractWithCustomerLiabilityDeductions_documentation_en-US" xlink:label="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Deductions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityDeductions" xlink:href="ebs-20220630.xsd#ebs_ContractWithCustomerLiabilityDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ContractWithCustomerLiabilityDeductions" xlink:to="lab_ebs_ContractWithCustomerLiabilityDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BilledContractReceivables_ec468975-c49a-4809-8a20-7f166c9e813f_terseLabel_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed, net</link:label>
    <link:label id="lab_us-gaap_BilledContractReceivables_label_en-US" xlink:label="lab_us-gaap_BilledContractReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Billed Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BilledContractReceivables" xlink:to="lab_us-gaap_BilledContractReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_9f59f221-73b6-42c1-b5d2-293a275abde2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_10d7023d-0018-43fe-8532-13e6c8e0c89a_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableCurrent_77a58687-080d-42c3-a68f-66685ed4a355_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, current portion</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent" xlink:to="lab_us-gaap_NotesPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_63ef90f7-0725-47bc-98ef-45e2c47a7512_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Buildings, building improvements and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BaseRateMember_89c6c34c-ec66-4c98-ae72-dcb9b8e1745e_terseLabel_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate</link:label>
    <link:label id="lab_us-gaap_BaseRateMember_label_en-US" xlink:label="lab_us-gaap_BaseRateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Base Rate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BaseRateMember" xlink:to="lab_us-gaap_BaseRateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4252247a-9cc6-4e81-88f7-a9ab8262bd09_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 200.0 shares authorized, 55.5 and 55.1 shares issued; 49.9 and 51.3 shares outstanding, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_d5306b7b-07c3-4d67-bd8f-978ddff9fcbc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_4d4588d8-7b54-4fcb-b95c-c6c3539805b6_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_2cbe8da1-9952-4144-b899-72810ed26df9_terseLabel_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Leases Supplemental Balance Sheets</link:label>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_label_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_documentation_en-US" xlink:label="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:href="ebs-20220630.xsd#ebs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:to="lab_ebs_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_96ae1a68-3727-40e9-80fd-1d366e1d06df_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_7d60120a-e00b-4680-99b6-748674b4d508_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net deferred losses from accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_095fa794-9dcf-4658-97a8-358a789fb767_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_83177b9f-87d3-43dd-95b9-f008ff2ee4d1_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_af2e06be-11f9-43ce-a6ab-b67926a535b1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f632eed1-3a08-40ee-8e53-c394c15d10b5_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_999de748-5746-45e1-91db-33986706c712_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4144373e-56bf-4721-b515-3666c9f5c138_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_5e45581a-6116-417c-abab-685c67600672_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_254b61b7-41ae-4cd5-aef4-83e237b7d60a_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, impaired, accumulated impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Impaired, Accumulated Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_cbefa820-cf3c-49c5-aed4-69e52ca919a7_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_aa9e0cb7-cb07-4f2b-807e-00d42c51861f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1bb856c3-6aab-4837-8fac-c2b856a66df8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_f934e6e4-bfa1-42ba-984d-293caac203a5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discrete tax expense (benefits)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_976698a6-6074-4e5f-a14b-e9f68386911c_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9aeac802-aae2-41cd-a251-c3d49f784a5f_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment unpaid at period end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_579339f4-2ccf-49a6-b100-e625377a1158_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_0ce7efe7-9551-4da9-b3bd-717323dd5857_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_bacd6314-6009-49a8-871d-51a936ccfe04_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5f08b29e-9758-4711-a4e2-8726b64471cd_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_f832dcd5-410b-4e5b-b15d-3e0fc4510db5_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, operating lease, remaining lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Operating Lease, Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:to="lab_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_b0d226c5-bdc5-4690-9cf6-c466368146c0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_4409c600-f1b7-476b-b1b5-5b4dfc6d4d76_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used in investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_c057b11c-6bb9-4402-bffc-a9b127713372_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_48e88ce3-1f09-4c2b-ae9a-75888075f055_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio adjustment period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_3cb281aa-2b95-4550-9125-6f6a3b17b729_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from share-based compensation activity</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_ad6aeb99-5177-4943-82c3-9fc21bf19e9b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_706de9c1-b429-4dc5-8b41-49f85df5ecd5_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction-in-progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_827629ec-b217-4e64-afe4-0c509b3cf794_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_fe6f2d40-d30d-458c-b928-23579af4b43e_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_5521a702-532d-40fc-9c40-a0096d5f324b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_1c76ec71-da8b-4b76-997a-a98f027e7889_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_2f7c65b2-085a-4aab-83eb-06ea031c5f22_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_dc645e46-f81d-496e-a619-a4a7dbf61f8c_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original principal amount required to repay in the first two years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay in First Two Years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in the first two years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:href="ebs-20220630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_b5929b47-3389-4dd5-bad0-91aac7f96639_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MilestonePaymentOneMember_8b1ace74-32b6-4afd-8fe4-241d9cf0a7e1_terseLabel_en-US" xlink:label="lab_ebs_MilestonePaymentOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment One</link:label>
    <link:label id="lab_ebs_MilestonePaymentOneMember_label_en-US" xlink:label="lab_ebs_MilestonePaymentOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment One [Member]</link:label>
    <link:label id="lab_ebs_MilestonePaymentOneMember_documentation_en-US" xlink:label="lab_ebs_MilestonePaymentOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentOneMember" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MilestonePaymentOneMember" xlink:to="lab_ebs_MilestonePaymentOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_fca65c0a-e2f1-48e6-966f-1f474cca1144_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_e6df124e-3930-4369-801a-c2dc4872ff43_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_cd682720-e4ca-4390-8a2a-1f94ce7b7666_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAxis_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis" xlink:to="lab_us-gaap_CashAndCashEquivalentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f1a77708-353a-4dc8-8cc1-64fb4f845766_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_af2e8cc0-d932-40fb-95bc-0e46ef5fb4c2_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_f7b8687f-7b72-43b7-a1fe-2dce589cb0e1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_46b7aeb3-9170-4f67-81ef-7df31a1bf947_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_e6924068-f7c8-423f-8b15-3c28335729c8_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_f382c370-dcae-48f5-9fb3-efee0cba9d61_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, at cost, 5.6 and 3.8 common shares, respectively</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_c0d485e2-6244-4c3b-a295-1686620f2a36_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan</link:label>
    <link:label id="lab_us-gaap_NotesPayableOtherPayablesMember_label_en-US" xlink:label="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notes Payable, Other Payables [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableOtherPayablesMember" xlink:to="lab_us-gaap_NotesPayableOtherPayablesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_0d890de4-e8a7-4c22-b84e-a960e89992fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_1c87bd9b-a251-4089-a8be-4b992a9f53f3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_68742034-c51d-4bc5-b95f-2327f1b902a3_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_ea63d83c-4980-4ed1-889a-94f043fc8b46_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_feee83de-bde7-4bbf-a499-5f0a3da8e2a6_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_766eb398-8636-4e8c-a788-34b8d4b6b80e_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bd3c6b64-1eec-45a6-afa2-01096b71c2b4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_1eba8b10-5946-429a-a3ec-514a4e0b2b75_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_0439c40d-2f06-40bd-a755-c7d6f4edf586_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_56db08dd-50d6-4e82-a17d-6ca8baeacb8b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive loss, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_ReservationOfManufacturingCapacityMember_423a2db8-2b5b-467a-90d3-8c4b80778d26_terseLabel_en-US" xlink:label="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reservation Of Manufacturing Capacity</link:label>
    <link:label id="lab_ebs_ReservationOfManufacturingCapacityMember_label_en-US" xlink:label="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reservation Of Manufacturing Capacity [Member]</link:label>
    <link:label id="lab_ebs_ReservationOfManufacturingCapacityMember_documentation_en-US" xlink:label="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reservation Of Manufacturing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ReservationOfManufacturingCapacityMember" xlink:href="ebs-20220630.xsd#ebs_ReservationOfManufacturingCapacityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_ReservationOfManufacturingCapacityMember" xlink:to="lab_ebs_ReservationOfManufacturingCapacityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a409578c-493b-4771-8074-7c08ee070581_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_51295182-4e89-428a-8f06-e16463bf94cb_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_70249135-a085-4f87-a2cb-47c83ca984cb_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_bcfcae25-ac7e-4130-85e8-ce0fd7c2407d_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_RegulatoryMilestonesMember_e0808675-9be7-4758-b7a8-0b950eb87277_terseLabel_en-US" xlink:label="lab_ebs_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:label id="lab_ebs_RegulatoryMilestonesMember_label_en-US" xlink:label="lab_ebs_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones [Member]</link:label>
    <link:label id="lab_ebs_RegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_ebs_RegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RegulatoryMilestonesMember" xlink:href="ebs-20220630.xsd#ebs_RegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_RegulatoryMilestonesMember" xlink:to="lab_ebs_RegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_9aaabc58-b044-46e1-9e6a-674a275898f5_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_e45c31a7-a157-4562-a60e-ef70b21eeeda_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_09d0f8d9-42b3-45a9-9636-21686ff3ac92_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_90cdddcc-9cd9-4af8-97ac-df5755295b89_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_4a3d0d22-352d-4514-9728-80cb50ca9eea_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Amortization Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_5ebc8974-1002-4132-b09c-7e0e4100d205_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_91bd6128-6218-4b5b-8ccc-90f4309adb87_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_dd30990f-dab3-4879-a14a-6659dda1d59f_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_39d78a1a-9d56-4851-a029-966e3b67fbb3_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of presentation and principles of consolidation</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_04cb8d12-845f-4c19-958f-3f750d5a6ea7_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software</link:label>
    <link:label id="lab_us-gaap_ComputerSoftwareIntangibleAssetMember_label_en-US" xlink:label="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Computer Software, Intangible Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:to="lab_us-gaap_ComputerSoftwareIntangibleAssetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_87a70e4f-b526-4b87-b36b-6812384cafb2_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_80b00281-d4ef-46be-9646-88dca79e87d5_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_42996c96-ec6b-446a-8d9a-e76b7e0620dc_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_220e4c8c-bd38-46b4-8af0-516e33e349d8_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_5de4bc9f-308b-4caa-b234-014373ccccfb_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_23d07f2d-e536-4d28-b243-25a92e1aaab5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_7a8aecce-38ec-48a4-a5d9-3ed924528997_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_73ef06c2-ecb8-4b63-a15d-68b40b125a0d_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation activity (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_9d979468-fb43-48f2-aba8-4ba196b99b8a_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_987a98fe-c55f-47d6-8dcf-97c8b89f089e_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_f49a9185-8e7c-4bb1-92d2-4a67588ddaca_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_a7928654-d2a3-4baa-b84b-150c5f2f8665_terseLabel_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, operating lease, payments to be received</link:label>
    <link:label id="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived_label_en-US" xlink:label="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessor, Operating Lease, Payments to be Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:to="lab_us-gaap_LessorOperatingLeasePaymentsToBeReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_63072d3f-deef-465a-83b5-640a116984af_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f4adf26d-631a-4dd2-98a4-6245f19700e3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_61541676-9484-4000-accd-5914263b7719_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares used in computing net income (loss) per common share</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_c7d1da6f-6d5c-49e7-994e-5ecbbb834a38_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_48fb2311-e6a1-498a-b8ad-ea3956954047_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_6558231f-8520-48ae-94cb-75fc564b490a_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_b88c25e0-5215-407f-927e-7e3878e3f629_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_9873826b-3772-40dc-ba8f-e5986e26623c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9e1ab8d4-0e6c-4236-9d3d-b835124133f7_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cbff7d56-76ac-4d43-b2a4-b8a58c7d8a37_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_8f24589a-1a20-4878-a5a1-44652ae0695c_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average number of shares-basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_d2805ea2-d0a1-4ddb-941a-9763f7e94709_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_IncomeTaxesLineItems_8eb3d983-cce2-4972-b822-e34468e060c9_terseLabel_en-US" xlink:label="lab_ebs_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_ebs_IncomeTaxesLineItems_label_en-US" xlink:label="lab_ebs_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_ebs_IncomeTaxesLineItems_documentation_en-US" xlink:label="lab_ebs_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesLineItems" xlink:href="ebs-20220630.xsd#ebs_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_IncomeTaxesLineItems" xlink:to="lab_ebs_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_3c923bd1-7b7a-469d-b71e-574be7d172c2_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Government</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_e8864a8c-d037-49b3-801a-c760fb91771e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principal payments on term loan facility</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfMediumTermNotes_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Medium-term Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfMediumTermNotes" xlink:to="lab_us-gaap_RepaymentsOfMediumTermNotes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_024f0f0a-b61e-49e5-aacc-c6c3f89a66bf_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1d6002a5-3a93-4753-aa49-0d153ec72fcf_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_117bfbe2-ca20-47bb-a007-d781ecd7c5c3_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average amortization period</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_c4548140-32bc-450d-9911-c915bb87e1b0_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Notional</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_ca2d3e1a-4da1-4f8a-a389-03d2921242fa_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_c282d264-7f67-4504-a9d2-ac8d7ce0c574_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_5ffbcac5-0fe6-4d0c-9f7a-46ad8908be14_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_5e128c49-aa0b-4a22-8bb8-cf21c51f6405_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f4e4311d-2f8e-4480-afa6-f530f8ea297c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_cbf4909e-c347-4075-9d4d-883fb75826b5_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Services</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d7960fe-8c85-487b-8ad4-a2964dd41b6b_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_3c08af8c-c092-4762-8478-51179b1863b4_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_3972f074-2dba-4f9b-91de-63d84b1f70b9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_3b4b6d40-61c8-400b-b7e8-4273eba28474_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_4f4d70f8-654d-4045-ba8d-2056f20c5c56_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for doubtful accounts receivable</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_9dc74d16-7652-47af-a05d-7f7087988e39_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Pension Plan</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_c2b5366b-3b8c-4f0c-8762-8b5401517043_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work-in-process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_be35bb58-467e-43d5-aa87-9dc1c77db742_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_1a1b5ac2-ef57-4a5a-a280-5b8a84888945_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio, maximum</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, One</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_TermLoanFacilityMember_dcb3d458-e2b8-47bc-b1ee-e11b8367c745_verboseLabel_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_label_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term Loan Facility [Member]</link:label>
    <link:label id="lab_ebs_TermLoanFacilityMember_documentation_en-US" xlink:label="lab_ebs_TermLoanFacilityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Term loan dated December 2013.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember" xlink:href="ebs-20220630.xsd#ebs_TermLoanFacilityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_TermLoanFacilityMember" xlink:to="lab_ebs_TermLoanFacilityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_2ba9b459-895a-4f45-96cf-62b226bb7cc1_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original principal amount required to repay during the third year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay During the Third Year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in the third year.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:href="ebs-20220630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_b2f0a702-212b-4947-80ba-b7f4e2a98143_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upon the occurrence of a change in control</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScenarioForecastMember_4dd0b685-42e8-4d5e-b074-9b5d4ff24a95_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_label_en-US" xlink:label="lab_srt_ScenarioForecastMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember" xlink:to="lab_srt_ScenarioForecastMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_34f94615-54af-46c7-8f5a-2e698b5b0dae_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid for share-based compensation activity</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-Based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6bddcd70-5075-4df7-881c-8796ff923e05_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_2f3c47ab-f4eb-4083-92e2-c8c1d944e2f2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EurodollarMember_f4d350dd-4200-4f2f-8633-f3cc114e34d0_terseLabel_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurocurrency</link:label>
    <link:label id="lab_us-gaap_EurodollarMember_label_en-US" xlink:label="lab_us-gaap_EurodollarMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Eurodollar [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EurodollarMember" xlink:to="lab_us-gaap_EurodollarMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_226004a4-74ce-42a0-bc72-dce7dc525509_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of deferred financing costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCosts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCosts" xlink:to="lab_us-gaap_AmortizationOfFinancingCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_1d33990b-99ab-472d-b38f-87306ffc8497_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_2cbf6880-bae3-40d3-b798-4516fa1679d6_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_fdf1a959-971e-4fc9-a9e5-869a5c66c64e_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio, adjustment</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Two</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio, Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_d2b6a130-1476-4d92-a6bf-b86a87803d9f_terseLabel_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities-equity awards (in shares)</link:label>
    <link:label id="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_label_en-US" xlink:label="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="lab_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_b3b5f0fa-44f2-4376-8b33-c6a9600c92ec_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income (loss) per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_bc3491f8-2930-4181-9cd2-490a54e3258c_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Government</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1cd46cd3-760f-46a7-9488-6b32f28c1720_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_21c20dfe-e4ab-4dcd-8ebf-59d4c803335b_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_82512b52-5d52-41f9-bcfe-8016049464b1_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_5c800342-bb0a-4834-97fc-b05ef93ad301_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_eee4e3ec-89e8-4a85-9651-2b9564524527_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_f66df14d-b2da-4786-b8c9-0929eefd61d4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior to August 15, 2023</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_cc377980-d58d-42b4-971d-63d7bfb084cd_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_85d79e61-f4e2-464e-aab6-9d51fa781ab6_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_6c491e6e-2b33-4c58-8b32-a31ac5d82538_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_bac1aa1e-1f4b-4b5f-9df3-63271111b379_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_0e0c0562-fcf2-48f1-a6eb-4f249bc187c2_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_149abf40-9c0c-46fd-ab45-3c4f751f246e_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_b60df635-f8f1-4c46-98f0-1b43f747c0f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_85d859e0-73c1-4cc1-a094-a1ac8b07d643_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_e0359d89-6b6a-46e5-9a8d-b88e730f4fcf_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_fdaa55d3-6dee-45c8-b50c-37d70dc96ef2_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MilestonePaymentThreeMember_d36a6235-b7b5-4e16-b90b-181f440e7d59_terseLabel_en-US" xlink:label="lab_ebs_MilestonePaymentThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Three</link:label>
    <link:label id="lab_ebs_MilestonePaymentThreeMember_label_en-US" xlink:label="lab_ebs_MilestonePaymentThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Three [Member]</link:label>
    <link:label id="lab_ebs_MilestonePaymentThreeMember_documentation_en-US" xlink:label="lab_ebs_MilestonePaymentThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentThreeMember" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MilestonePaymentThreeMember" xlink:to="lab_ebs_MilestonePaymentThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_10db1358-7cdc-46fc-bb1b-1eba91c9b577_terseLabel_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.875% Senior Unsecured Notes due 2028</link:label>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_label_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due August 2028 [Member]</link:label>
    <link:label id="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member_documentation_en-US" xlink:label="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Senior Unsecured Notes Due August 2028</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:href="ebs-20220630.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:to="lab_ebs_SeniorUnsecuredNotesDueAugust2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d59bef76-30da-4876-bdea-7ba7c9715520_totalLabel_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract development and manufacturing</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_2dd1ea5f-9800-4091-bc5e-fac3f2dfd10d_terseLabel_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:label id="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_documentation_en-US" xlink:label="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="ebs-20220630.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_3b0b822c-022c-439a-b8db-eb0cdffb86e3_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, remaining performance obligation, amount</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f8f581d-2ea4-4e4e-8d5b-eb87b42cc072_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_7c458fc0-3e41-4166-ad1e-80c2d0f3a42a_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitment fee percentage</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Commitment Fee Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:to="lab_us-gaap_LineOfCreditFacilityCommitmentFeePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_80e5cd99-bd6b-45fc-b223-c297b1e37817_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_3e266ffd-32c3-46cc-a386-a6d4c78b8701_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_4fa654d9-3485-4511-aa7b-a271568dcf24_terseLabel_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of original principal amount required to repay remaining year</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_label_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of Original Principal Amount Required to Repay Remaining Years</link:label>
    <link:label id="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_documentation_en-US" xlink:label="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The rate of interest that was being paid on the original debt issue that is to repay in remaining years.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:href="ebs-20220630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:to="lab_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_66efe01d-974a-4f45-ac5e-89dce80a66fb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Derivatives</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_MilestonePaymentFourMember_873515e3-8565-4d90-a87b-7b4528c4f0f3_terseLabel_en-US" xlink:label="lab_ebs_MilestonePaymentFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Four</link:label>
    <link:label id="lab_ebs_MilestonePaymentFourMember_label_en-US" xlink:label="lab_ebs_MilestonePaymentFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Four [Member]</link:label>
    <link:label id="lab_ebs_MilestonePaymentFourMember_documentation_en-US" xlink:label="lab_ebs_MilestonePaymentFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone Payment Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentFourMember" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_MilestonePaymentFourMember" xlink:to="lab_ebs_MilestonePaymentFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_5d8e6e0a-be9a-4c93-b44c-7108e8266592_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_d089d4f8-165c-4b30-9d92-a9b1accbf245_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_f5e5b043-9540-4430-bc3e-c402e14024b2_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_75e0ca7d-ca2b-47c3-a997-c9d27a863d8a_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_27201fea-f1d2-49ad-9a67-db857a466cf3_verboseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products and Services [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_ba701ec4-5879-4b4d-a4a5-95cfce00efa1_terseLabel_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled</link:label>
    <link:label id="lab_us-gaap_UnbilledContractsReceivable_label_en-US" xlink:label="lab_us-gaap_UnbilledContractsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unbilled Contracts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnbilledContractsReceivable" xlink:to="lab_us-gaap_UnbilledContractsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_06cc3788-e27d-4b05-a003-f06559346d9e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_c29ac570-e1ee-436e-8aac-8c709dda45c4_negatedLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_5c4877b9-4563-4f0a-93d6-0981038fb1af_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CreditFacilityAxis_7f41a9be-dd77-4b7c-bb11-e51bb27c1230_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis" xlink:to="lab_us-gaap_CreditFacilityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_5475053d-8246-435d-93a1-6dabd094252c_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories, net</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_9ef305fd-4768-4533-9f92-ab7390f2a910_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of cash and cash equivalents and restricted cash at June&#160;30, 2022 and December&#160;31, 2021:</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1d33b76b-c976-47d3-a676-1e374c731bd3_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:label id="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_label_en-US" xlink:label="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="lab_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_4017c6ff-3f0d-46ba-a112-c4f3a600e664_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_63e03683-09fb-4217-a8eb-422308c245b6_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_a1279e7d-d8f6-4ccd-86c3-c92096f4f962_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_771685cd-3edd-40a2-9efc-8c4ed9805053_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_5f0e7592-0d50-4bcc-976a-2c71d76d8923_terseLabel_en-US" xlink:label="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, international royalty percentage</link:label>
    <link:label id="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_label_en-US" xlink:label="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, International Gross Profit Royalty Percentage</link:label>
    <link:label id="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_documentation_en-US" xlink:label="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, International Gross Profit Royalty Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:href="ebs-20220630.xsd#ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:to="lab_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_38332b49-2c15-479a-afc7-4d94123ba75c_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_3d591517-8820-4977-acd7-2f2cbee6343c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_e3d9b505-f4a9-4135-8ed3-8bd4ea005b55_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unobservable Input Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_7952a39c-47ea-4e6c-b237-886028f0e0c9_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_603c20f8-4800-4b08-b1b9-610ad5f87a61_terseLabel_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_label_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended Credit Agreement [Member]</link:label>
    <link:label id="lab_ebs_AmendedCreditAgreementMember_documentation_en-US" xlink:label="lab_ebs_AmendedCreditAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amended credit agreement dated October 15, 2018.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember" xlink:href="ebs-20220630.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_AmendedCreditAgreementMember" xlink:to="lab_ebs_AmendedCreditAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_c850d951-7571-4eb1-bf02-db2f9e543c0d_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business combination, contingent consideration, liability, measurement input</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Measurement Input</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_758d6f4e-1533-4f0f-96c6-82df2aaf7419_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_bd419bb0-05cd-48ad-a233-64697699f787_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_aa9a22a1-44b7-4689-86a3-f0434f2cdf35_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4dd63ec4-e624-4229-82d8-e979d457c3c9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_7ec2b3ba-43c6-4b93-9833-28515cd1f99e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_IncomeTaxesTable_20c6357c-8ac0-4a8f-bc36-3138e242170d_terseLabel_en-US" xlink:label="lab_ebs_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_ebs_IncomeTaxesTable_label_en-US" xlink:label="lab_ebs_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_ebs_IncomeTaxesTable_documentation_en-US" xlink:label="lab_ebs_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesTable" xlink:href="ebs-20220630.xsd#ebs_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_IncomeTaxesTable" xlink:to="lab_ebs_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_a33e65ce-dc7c-4bf0-9ed7-5c34f8cd9cc7_terseLabel_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:label id="lab_us-gaap_MeasurementInputTypeAxis_label_en-US" xlink:label="lab_us-gaap_MeasurementInputTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MeasurementInputTypeAxis" xlink:to="lab_us-gaap_MeasurementInputTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_0743f971-1633-496b-9296-3ac3c80aa2fc_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_3cae30e9-5fff-425e-b504-669c487b4e22_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_8f527548-4c78-49c6-8b78-8cd0fe69c87f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNoncurrentNet_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Issuance Costs, Noncurrent, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:to="lab_us-gaap_DeferredFinanceCostsNoncurrentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_1de05749-ab8a-4bde-9eb7-1746e608dd20_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_73255bbc-76a7-4343-a6c0-1ffdc4518a34_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_825bb2cf-8572-487a-9359-beac6b6f10fc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Redemption, Period [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:to="lab_us-gaap_DebtInstrumentRedemptionPeriodAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_7179dc18-b519-4d34-a041-f67b9d27aac4_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows used in financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_34f2d130-3ff1-4166-ac8a-09fea2502fe7_terseLabel_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, covenant, net leverage ratio rolling period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_label_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</link:label>
    <link:label id="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_documentation_en-US" xlink:label="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:to="lab_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_2d7cf21c-2ea3-46ff-9d70-042152761151_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental information on non-cash investing and financing activities:</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6809f2c2-d1c4-431f-b2c6-b044df023a67_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VariableRateAxis_0150a77e-40ba-4fda-8d7b-99171b77cf00_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis" xlink:to="lab_us-gaap_VariableRateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e80092bd-0207-4873-b3d9-9fd8da885573_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4b5d4977-c14e-4c2e-8d72-91180ac75d51_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_0c995f47-394f-42cb-981f-8eaabe134203_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_2d693f85-daf3-4156-b7ce-3c57b525eac4_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_ad94de95-f91d-433c-bb2f-159f2e6d0bd6_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_7222a424-544b-46c9-9fd5-0d30d670a432_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic and Diluted Net Income per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_94f02842-939b-43ad-887e-a9f9edcdcc09_terseLabel_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right</link:label>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_label_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Proceeds Excess Amount from Dispositions of Property or Casualty Events Subject to Certain Reinvestment Right</link:label>
    <link:label id="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_documentation_en-US" xlink:label="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:href="ebs-20220630.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:to="lab_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_6a843bdb-304d-47ca-b1b1-011344729b64_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of product sales</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_ca081f5c-fb4c-4746-bdac-89fbf461f5a9_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>ebs-20220630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2022 Workiva-->
<!--r:76cb5594-9318-4e51-9277-4582eaf35bfa,g:cb82d48c-139c-44ae-8052-a281d9df29e8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CoverPage" xlink:type="simple" xlink:href="ebs-20220630.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_9fb4d535-5f71-4716-a42f-7a74f80879ab" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_DocumentType_9fb4d535-5f71-4716-a42f-7a74f80879ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_43277d07-9ddb-466c-a5ef-391e164a2d96" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_DocumentQuarterlyReport_43277d07-9ddb-466c-a5ef-391e164a2d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_3d37f4b5-eb77-4bc6-b61f-34dbd4fd9549" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_DocumentPeriodEndDate_3d37f4b5-eb77-4bc6-b61f-34dbd4fd9549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_9459572a-a2d3-4744-9d4f-e4f402a260bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_DocumentTransitionReport_9459572a-a2d3-4744-9d4f-e4f402a260bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_9fad6087-fbf6-44fc-844a-40fef048cb65" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityFileNumber_9fad6087-fbf6-44fc-844a-40fef048cb65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_4ea52d44-3c31-40a8-8175-4b27c468bbe0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityRegistrantName_4ea52d44-3c31-40a8-8175-4b27c468bbe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_e69ca169-4855-4e55-9de5-d2c4cd5c4704" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityIncorporationStateCountryCode_e69ca169-4855-4e55-9de5-d2c4cd5c4704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d54d44d9-84ec-4995-816d-70f5c91bb6a3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityTaxIdentificationNumber_d54d44d9-84ec-4995-816d-70f5c91bb6a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_17e3a6c3-3276-4788-875f-5dbcd0c8a303" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityAddressAddressLine1_17e3a6c3-3276-4788-875f-5dbcd0c8a303" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_10e4057f-c582-45b8-b3b5-ebe8e3a1673e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityAddressCityOrTown_10e4057f-c582-45b8-b3b5-ebe8e3a1673e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_f2b64d4c-a1ca-48cd-85a6-e5bc44a5de2f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityAddressStateOrProvince_f2b64d4c-a1ca-48cd-85a6-e5bc44a5de2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_29069e8b-f76e-4f26-b853-e5ce4d533ecb" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityAddressPostalZipCode_29069e8b-f76e-4f26-b853-e5ce4d533ecb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_ae428a52-8f0e-462d-bac0-17bb5be705ea" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_CityAreaCode_ae428a52-8f0e-462d-bac0-17bb5be705ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_dd75ec00-5ae2-4bc8-ada0-6bbe432165f0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_LocalPhoneNumber_dd75ec00-5ae2-4bc8-ada0-6bbe432165f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_0b0e502a-c407-4f09-a47c-cbc8651be909" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_Security12bTitle_0b0e502a-c407-4f09-a47c-cbc8651be909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_0706ecad-3c6b-4892-9caa-2c5381e7ae2d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_TradingSymbol_0706ecad-3c6b-4892-9caa-2c5381e7ae2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_4c61f51e-8405-4c64-8d2a-a183d75163e5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_SecurityExchangeName_4c61f51e-8405-4c64-8d2a-a183d75163e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_7a6e66ab-455a-4e87-bd61-6dccfeac54c8" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityCurrentReportingStatus_7a6e66ab-455a-4e87-bd61-6dccfeac54c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_6dd1e9d0-c146-4908-9af0-de1529b873a7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityInteractiveDataCurrent_6dd1e9d0-c146-4908-9af0-de1529b873a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_60853236-7354-46da-9e4c-e41a29f39c12" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityFilerCategory_60853236-7354-46da-9e4c-e41a29f39c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_a5743fef-8912-4bbb-a6b1-e00b5dc9e1d4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntitySmallBusiness_a5743fef-8912-4bbb-a6b1-e00b5dc9e1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_0557136f-7ac1-4e3a-aa69-3f6b1e198b23" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityEmergingGrowthCompany_0557136f-7ac1-4e3a-aa69-3f6b1e198b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_4f2781c3-c25c-4639-925e-f3e2c84e5cb3" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityShellCompany_4f2781c3-c25c-4639-925e-f3e2c84e5cb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_357b67a1-767d-4768-9c4f-452ade6d38d7" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_357b67a1-767d-4768-9c4f-452ade6d38d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_229b2d28-d0ca-4404-966d-d0efa94a2253" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_EntityCentralIndexKey_229b2d28-d0ca-4404-966d-d0efa94a2253" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_969c7235-1b41-4058-b84e-5bc5a3fdddc4" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_CurrentFiscalYearEndDate_969c7235-1b41-4058-b84e-5bc5a3fdddc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_ec7e52e3-a312-4550-96f2-6df5a00efe06" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_AmendmentFlag_ec7e52e3-a312-4550-96f2-6df5a00efe06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_3f0fa87f-cb6c-4bbf-a53a-de7a63f4ce20" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_DocumentFiscalYearFocus_3f0fa87f-cb6c-4bbf-a53a-de7a63f4ce20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_6a94641b-7d18-499d-9cc1-041e08e30edf" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_248294eb-95f5-433c-a230-ce87efa71792" xlink:to="loc_dei_DocumentFiscalPeriodFocus_6a94641b-7d18-499d-9cc1-041e08e30edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_7732afa5-c525-490e-8468-2704048297bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_685a436f-da9f-4cb3-ac57-a791dd5b443e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7732afa5-c525-490e-8468-2704048297bf" xlink:to="loc_us-gaap_AssetsAbstract_685a436f-da9f-4cb3-ac57-a791dd5b443e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_05e35304-57f3-4e5e-b02b-1019b4621c33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_685a436f-da9f-4cb3-ac57-a791dd5b443e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_05e35304-57f3-4e5e-b02b-1019b4621c33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_732044f8-1831-4b79-abc8-dd95149a067d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05e35304-57f3-4e5e-b02b-1019b4621c33" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_732044f8-1831-4b79-abc8-dd95149a067d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_dddb3bf2-d615-4e17-9af7-bfad090abacd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05e35304-57f3-4e5e-b02b-1019b4621c33" xlink:to="loc_us-gaap_RestrictedCashCurrent_dddb3bf2-d615-4e17-9af7-bfad090abacd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_d4fce831-0dd4-4af1-aa26-7524d6fda3a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05e35304-57f3-4e5e-b02b-1019b4621c33" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_d4fce831-0dd4-4af1-aa26-7524d6fda3a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_596cc276-d127-4d3a-a00d-4b7ff8914fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05e35304-57f3-4e5e-b02b-1019b4621c33" xlink:to="loc_us-gaap_InventoryNet_596cc276-d127-4d3a-a00d-4b7ff8914fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_14d54b56-e1cd-4b43-a357-9399acfdff9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05e35304-57f3-4e5e-b02b-1019b4621c33" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_14d54b56-e1cd-4b43-a357-9399acfdff9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a5ff1539-7d70-4cc2-b55d-30c03166d8ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_05e35304-57f3-4e5e-b02b-1019b4621c33" xlink:to="loc_us-gaap_AssetsCurrent_a5ff1539-7d70-4cc2-b55d-30c03166d8ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_950c5f8d-2dc0-4ec9-9cbc-92f22481326d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_685a436f-da9f-4cb3-ac57-a791dd5b443e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_950c5f8d-2dc0-4ec9-9cbc-92f22481326d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_40af5aac-7f8b-4a83-be29-81fcd157ba7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_685a436f-da9f-4cb3-ac57-a791dd5b443e" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_40af5aac-7f8b-4a83-be29-81fcd157ba7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1ae96fb5-41c4-4245-8d42-5666fbad3691" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_685a436f-da9f-4cb3-ac57-a791dd5b443e" xlink:to="loc_us-gaap_Goodwill_1ae96fb5-41c4-4245-8d42-5666fbad3691" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_caf441d1-4c4d-4a7c-80c4-3c1b7188bc29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_685a436f-da9f-4cb3-ac57-a791dd5b443e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_caf441d1-4c4d-4a7c-80c4-3c1b7188bc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ee3f8341-5b70-475a-abf4-5095d7848dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_685a436f-da9f-4cb3-ac57-a791dd5b443e" xlink:to="loc_us-gaap_Assets_ee3f8341-5b70-475a-abf4-5095d7848dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ea5c88f-3e72-4a15-b462-51bb0441c232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_7732afa5-c525-490e-8468-2704048297bf" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ea5c88f-3e72-4a15-b462-51bb0441c232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8db51dcd-41af-43c6-a054-09a26a09742f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ea5c88f-3e72-4a15-b462-51bb0441c232" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8db51dcd-41af-43c6-a054-09a26a09742f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_fa169371-cc38-487d-83f9-c94161faa222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8db51dcd-41af-43c6-a054-09a26a09742f" xlink:to="loc_us-gaap_AccountsPayableCurrent_fa169371-cc38-487d-83f9-c94161faa222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_906c6384-585e-4a83-b423-0e00e600d60f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8db51dcd-41af-43c6-a054-09a26a09742f" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_906c6384-585e-4a83-b423-0e00e600d60f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_86fe255f-f0c7-476e-9f8a-26ecfbc21367" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8db51dcd-41af-43c6-a054-09a26a09742f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_86fe255f-f0c7-476e-9f8a-26ecfbc21367" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableCurrent_9ce15c4d-6da3-4199-815b-aa39570cc4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8db51dcd-41af-43c6-a054-09a26a09742f" xlink:to="loc_us-gaap_NotesPayableCurrent_9ce15c4d-6da3-4199-815b-aa39570cc4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_bcaa791a-e0fb-4a51-9919-41ccf1aa4184" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8db51dcd-41af-43c6-a054-09a26a09742f" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_bcaa791a-e0fb-4a51-9919-41ccf1aa4184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_b951846e-4f40-4de1-9272-c392c00413b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8db51dcd-41af-43c6-a054-09a26a09742f" xlink:to="loc_us-gaap_LiabilitiesCurrent_b951846e-4f40-4de1-9272-c392c00413b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_185fa381-b842-4a51-9ddb-018eea51ea4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ea5c88f-3e72-4a15-b462-51bb0441c232" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_185fa381-b842-4a51-9ddb-018eea51ea4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_60011a31-bb5b-4e6f-971a-0cc8f0ce8238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ea5c88f-3e72-4a15-b462-51bb0441c232" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_60011a31-bb5b-4e6f-971a-0cc8f0ce8238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c76a437b-4a14-4c0c-97ea-e664c06b95e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ea5c88f-3e72-4a15-b462-51bb0441c232" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c76a437b-4a14-4c0c-97ea-e664c06b95e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a12edf7f-9bd1-4afb-b323-04513a144651" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ea5c88f-3e72-4a15-b462-51bb0441c232" xlink:to="loc_us-gaap_Liabilities_a12edf7f-9bd1-4afb-b323-04513a144651" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3cd156a6-a84e-44f4-bd7d-47bc6859bc5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ea5c88f-3e72-4a15-b462-51bb0441c232" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3cd156a6-a84e-44f4-bd7d-47bc6859bc5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4faa8760-ee40-4adb-97d8-220889f8c26e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3cd156a6-a84e-44f4-bd7d-47bc6859bc5f" xlink:to="loc_us-gaap_PreferredStockValue_4faa8760-ee40-4adb-97d8-220889f8c26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_a5d67db2-b33b-4bb8-a614-947eba2fce97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3cd156a6-a84e-44f4-bd7d-47bc6859bc5f" xlink:to="loc_us-gaap_CommonStockValue_a5d67db2-b33b-4bb8-a614-947eba2fce97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_1a755967-7175-4e7c-9563-4430ddcb3fd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3cd156a6-a84e-44f4-bd7d-47bc6859bc5f" xlink:to="loc_us-gaap_TreasuryStockValue_1a755967-7175-4e7c-9563-4430ddcb3fd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_036fb07c-6c96-457a-968b-cd75bb82c026" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3cd156a6-a84e-44f4-bd7d-47bc6859bc5f" xlink:to="loc_us-gaap_AdditionalPaidInCapital_036fb07c-6c96-457a-968b-cd75bb82c026" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e0aed8aa-f8e5-4564-ba7b-66bab0b8c089" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3cd156a6-a84e-44f4-bd7d-47bc6859bc5f" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e0aed8aa-f8e5-4564-ba7b-66bab0b8c089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d48a2517-f3cb-47d3-8305-9b84ba24cbac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3cd156a6-a84e-44f4-bd7d-47bc6859bc5f" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_d48a2517-f3cb-47d3-8305-9b84ba24cbac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ffcdf0e6-ea3a-46f8-91fb-00f2f1d43a71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_3cd156a6-a84e-44f4-bd7d-47bc6859bc5f" xlink:to="loc_us-gaap_StockholdersEquity_ffcdf0e6-ea3a-46f8-91fb-00f2f1d43a71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_42732ecc-f867-417d-ac62-83ea4ddc0005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_2ea5c88f-3e72-4a15-b462-51bb0441c232" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_42732ecc-f867-417d-ac62-83ea4ddc0005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_ab29943e-8a26-4b20-839f-7965bdbe6f37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ae22838-8a6b-4dcd-9ad9-526a2e0382e9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_ab29943e-8a26-4b20-839f-7965bdbe6f37" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ae22838-8a6b-4dcd-9ad9-526a2e0382e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e5e61b41-7cd4-4bc1-b632-c8dd939dfc00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_4ae22838-8a6b-4dcd-9ad9-526a2e0382e9" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e5e61b41-7cd4-4bc1-b632-c8dd939dfc00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1c3c7124-e232-4b4b-9d0d-8503f49a7363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e5e61b41-7cd4-4bc1-b632-c8dd939dfc00" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_1c3c7124-e232-4b4b-9d0d-8503f49a7363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_ac864cfa-0087-4b61-a673-333942332685" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e5e61b41-7cd4-4bc1-b632-c8dd939dfc00" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_ac864cfa-0087-4b61-a673-333942332685" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7f417634-4c56-4746-9cb5-475ac1e96b47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e5e61b41-7cd4-4bc1-b632-c8dd939dfc00" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7f417634-4c56-4746-9cb5-475ac1e96b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_93a6462d-09d4-44aa-bf02-a00fa8280594" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e5e61b41-7cd4-4bc1-b632-c8dd939dfc00" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_93a6462d-09d4-44aa-bf02-a00fa8280594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_9a9ea4f7-3c28-4f32-aa47-a165914549de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e5e61b41-7cd4-4bc1-b632-c8dd939dfc00" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_9a9ea4f7-3c28-4f32-aa47-a165914549de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_6e1fd76f-96fd-4b3e-ae06-b8b7c655615c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e5e61b41-7cd4-4bc1-b632-c8dd939dfc00" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_6e1fd76f-96fd-4b3e-ae06-b8b7c655615c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_b8566d09-d34f-4653-acf1-2491446fb8d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e5e61b41-7cd4-4bc1-b632-c8dd939dfc00" xlink:to="loc_us-gaap_CommonStockSharesIssued_b8566d09-d34f-4653-acf1-2491446fb8d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2b47855d-72f9-4ef2-8cfc-da694fd6c47e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e5e61b41-7cd4-4bc1-b632-c8dd939dfc00" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2b47855d-72f9-4ef2-8cfc-da694fd6c47e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_18d0c5f7-7bfa-4785-b9fb-7bbaa9e000d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_e5e61b41-7cd4-4bc1-b632-c8dd939dfc00" xlink:to="loc_us-gaap_TreasuryStockShares_18d0c5f7-7bfa-4785-b9fb-7bbaa9e000d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedStatementsofOperations"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_adecd4fc-7e91-4f69-9331-6d1321e86e41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_40fcba41-16e2-4bfa-aa9d-6449024194e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_adecd4fc-7e91-4f69-9331-6d1321e86e41" xlink:to="loc_us-gaap_StatementTable_40fcba41-16e2-4bfa-aa9d-6449024194e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_066129dd-2523-40da-af15-4c0d27fffa6b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_40fcba41-16e2-4bfa-aa9d-6449024194e5" xlink:to="loc_srt_ProductOrServiceAxis_066129dd-2523-40da-af15-4c0d27fffa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_a4bb70af-397f-468f-aceb-b9babcfbfa2b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_066129dd-2523-40da-af15-4c0d27fffa6b" xlink:to="loc_srt_ProductsAndServicesDomain_a4bb70af-397f-468f-aceb-b9babcfbfa2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_96546639-5591-456f-8dd2-1510edd32770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4bb70af-397f-468f-aceb-b9babcfbfa2b" xlink:to="loc_us-gaap_ProductMember_96546639-5591-456f-8dd2-1510edd32770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_3ed282e7-3291-4f39-bad6-0a3c78a45397" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4bb70af-397f-468f-aceb-b9babcfbfa2b" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_3ed282e7-3291-4f39-bad6-0a3c78a45397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_6367c424-228e-4b81-bd48-2702567acbe3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_3ed282e7-3291-4f39-bad6-0a3c78a45397" xlink:to="loc_us-gaap_ServiceMember_6367c424-228e-4b81-bd48-2702567acbe3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_ec0b88a5-0efb-481e-959e-1e0e1133ee27" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_3ed282e7-3291-4f39-bad6-0a3c78a45397" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_ec0b88a5-0efb-481e-959e-1e0e1133ee27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_881a137d-a824-4e88-8bae-e5f205659e4d" xlink:href="ebs-20220630.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_a4bb70af-397f-468f-aceb-b9babcfbfa2b" xlink:to="loc_ebs_ContractsAndGrantsMember_881a137d-a824-4e88-8bae-e5f205659e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_40fcba41-16e2-4bfa-aa9d-6449024194e5" xlink:to="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24cdf547-639f-4ee0-8155-4d8a19dc46e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_24cdf547-639f-4ee0-8155-4d8a19dc46e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_e68065c6-81d4-4c0e-b3a4-43200a1e3068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_e68065c6-81d4-4c0e-b3a4-43200a1e3068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_60e94351-4a51-40dd-9b06-667d2b10ebc6" xlink:href="ebs-20220630.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_60e94351-4a51-40dd-9b06-667d2b10ebc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_6c524317-8456-4063-bd55-44e05665886e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_c3c6d770-3764-4b7a-ad31-e21d9eab23d1" xlink:to="loc_us-gaap_Revenues_6c524317-8456-4063-bd55-44e05665886e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6d279a5b-9ebe-4868-826b-c605e710c7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6d279a5b-9ebe-4868-826b-c605e710c7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e62d02f2-8802-49dd-8528-e02d5377f523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e62d02f2-8802-49dd-8528-e02d5377f523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_82e27404-7674-4806-aac4-e41fc5cf61fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_82e27404-7674-4806-aac4-e41fc5cf61fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8ebb4f6c-e32e-467f-98f4-4efbe10f2e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8ebb4f6c-e32e-467f-98f4-4efbe10f2e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingCostsAndExpenses_d9d20c95-5566-454f-acec-21031cd50dce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingCostsAndExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_fec83b80-c559-43db-b3bf-7e53574633bb" xlink:to="loc_us-gaap_OperatingCostsAndExpenses_d9d20c95-5566-454f-acec-21031cd50dce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8819909b-c720-4879-95c4-d7789fc77d34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_OperatingIncomeLoss_8819909b-c720-4879-95c4-d7789fc77d34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_eadb7885-848b-46c5-a6a9-a8b1de6e9a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_eadb7885-848b-46c5-a6a9-a8b1de6e9a23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_b5e008f9-8863-4f3f-a4ed-c14a0d94bbe5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_eadb7885-848b-46c5-a6a9-a8b1de6e9a23" xlink:to="loc_us-gaap_InterestExpense_b5e008f9-8863-4f3f-a4ed-c14a0d94bbe5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_955c0d7f-6db4-458e-b667-265acd2b9d07" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_eadb7885-848b-46c5-a6a9-a8b1de6e9a23" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_955c0d7f-6db4-458e-b667-265acd2b9d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_8db1cc30-2492-468d-84d2-a25364f0ee9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_eadb7885-848b-46c5-a6a9-a8b1de6e9a23" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_8db1cc30-2492-468d-84d2-a25364f0ee9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_535f665c-54c7-4573-888d-0c09210363eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_535f665c-54c7-4573-888d-0c09210363eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_59b179de-c81f-4773-a2a2-8ae8a2075325" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_59b179de-c81f-4773-a2a2-8ae8a2075325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_130a5c84-5a84-455b-be38-aefbcb29c3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_NetIncomeLoss_130a5c84-5a84-455b-be38-aefbcb29c3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_3e689e3b-266f-4926-b745-c74419bf3e09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDilutedAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_3e689e3b-266f-4926-b745-c74419bf3e09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d2a0c95c-396c-499e-b03a-4b53673a6e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_3e689e3b-266f-4926-b745-c74419bf3e09" xlink:to="loc_us-gaap_EarningsPerShareBasic_d2a0c95c-396c-499e-b03a-4b53673a6e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_631c4ffa-c4ac-47f6-a86f-af712824b2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_3e689e3b-266f-4926-b745-c74419bf3e09" xlink:to="loc_us-gaap_EarningsPerShareDiluted_631c4ffa-c4ac-47f6-a86f-af712824b2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0e4e5859-994f-4601-ab17-2f1290d9554a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_ba682073-7647-4e0b-91ca-43a088c6ea25" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0e4e5859-994f-4601-ab17-2f1290d9554a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1718f2db-e641-44af-8e0d-ca617d3a6bfb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0e4e5859-994f-4601-ab17-2f1290d9554a" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_1718f2db-e641-44af-8e0d-ca617d3a6bfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f4c48283-9e0a-44da-88a9-a68dc1083a37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0e4e5859-994f-4601-ab17-2f1290d9554a" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f4c48283-9e0a-44da-88a9-a68dc1083a37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dcc00b32-6c32-4e53-8764-f68218c3f338" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ac8e3252-17ea-4115-984c-fe0451a91593" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dcc00b32-6c32-4e53-8764-f68218c3f338" xlink:to="loc_us-gaap_NetIncomeLoss_ac8e3252-17ea-4115-984c-fe0451a91593" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cde3a6c9-4e61-4a01-973d-84a19506c4d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dcc00b32-6c32-4e53-8764-f68218c3f338" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cde3a6c9-4e61-4a01-973d-84a19506c4d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b37cf338-45dc-4b4d-9c80-d551cebdea5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cde3a6c9-4e61-4a01-973d-84a19506c4d3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_b37cf338-45dc-4b4d-9c80-d551cebdea5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4a824b67-6f12-4e57-b5ec-94c7cd6778cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cde3a6c9-4e61-4a01-973d-84a19506c4d3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_4a824b67-6f12-4e57-b5ec-94c7cd6778cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8d46498e-672b-4094-bc56-7d481e10b005" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_cde3a6c9-4e61-4a01-973d-84a19506c4d3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8d46498e-672b-4094-bc56-7d481e10b005" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_9dda20dc-728b-4c69-a19b-f93de33af9ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_dcc00b32-6c32-4e53-8764-f68218c3f338" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_9dda20dc-728b-4c69-a19b-f93de33af9ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_58aa4210-d082-4a02-a0da-343cd174408d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_87404101-e5b1-4e4b-b63f-8518fdbd8062" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_58aa4210-d082-4a02-a0da-343cd174408d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_87404101-e5b1-4e4b-b63f-8518fdbd8062" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_557f6fcd-358f-486c-8ce2-33b8b3d7ee04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_87404101-e5b1-4e4b-b63f-8518fdbd8062" xlink:to="loc_us-gaap_NetIncomeLoss_557f6fcd-358f-486c-8ce2-33b8b3d7ee04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_664f4a57-13e0-4fe6-b99f-f4d03ef85433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_87404101-e5b1-4e4b-b63f-8518fdbd8062" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_664f4a57-13e0-4fe6-b99f-f4d03ef85433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_bdc4bac1-547b-4a92-87d7-139a26848b7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_664f4a57-13e0-4fe6-b99f-f4d03ef85433" xlink:to="loc_us-gaap_ShareBasedCompensation_bdc4bac1-547b-4a92-87d7-139a26848b7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_b2097eed-7a4a-403d-ae69-d2aa8e314f65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_664f4a57-13e0-4fe6-b99f-f4d03ef85433" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_b2097eed-7a4a-403d-ae69-d2aa8e314f65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_66bd1631-1dfc-4c2f-89ca-a4aa8a945ea5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_664f4a57-13e0-4fe6-b99f-f4d03ef85433" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_66bd1631-1dfc-4c2f-89ca-a4aa8a945ea5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCosts_bd72212d-2189-426f-b62c-40591a477cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfFinancingCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_664f4a57-13e0-4fe6-b99f-f4d03ef85433" xlink:to="loc_us-gaap_AmortizationOfFinancingCosts_bd72212d-2189-426f-b62c-40591a477cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_255f6d9b-f7a7-451b-b67c-a772a8de8fc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_664f4a57-13e0-4fe6-b99f-f4d03ef85433" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_255f6d9b-f7a7-451b-b67c-a772a8de8fc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7cc1c9bc-3fe6-4047-883a-d715da68624b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_664f4a57-13e0-4fe6-b99f-f4d03ef85433" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_7cc1c9bc-3fe6-4047-883a-d715da68624b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bbe019c2-2e47-43c2-9f67-b97e6842e965" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_664f4a57-13e0-4fe6-b99f-f4d03ef85433" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bbe019c2-2e47-43c2-9f67-b97e6842e965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58d905d7-727f-4ab4-a012-e88f839536d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bbe019c2-2e47-43c2-9f67-b97e6842e965" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_58d905d7-727f-4ab4-a012-e88f839536d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f5fd1c01-ff7a-43cd-9d1d-888cabb3dd42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bbe019c2-2e47-43c2-9f67-b97e6842e965" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f5fd1c01-ff7a-43cd-9d1d-888cabb3dd42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_00a82ee7-e6aa-4cba-92c5-f8c5d3ad26b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bbe019c2-2e47-43c2-9f67-b97e6842e965" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_00a82ee7-e6aa-4cba-92c5-f8c5d3ad26b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_84a7d33f-69e8-47d1-8fcb-2cf44153db74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bbe019c2-2e47-43c2-9f67-b97e6842e965" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_84a7d33f-69e8-47d1-8fcb-2cf44153db74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_44e0e86f-3a1d-4504-af00-fdcb48e75a1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bbe019c2-2e47-43c2-9f67-b97e6842e965" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_44e0e86f-3a1d-4504-af00-fdcb48e75a1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e98e33c7-5dee-4cd9-b244-becb654df117" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bbe019c2-2e47-43c2-9f67-b97e6842e965" xlink:to="loc_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_e98e33c7-5dee-4cd9-b244-becb654df117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_776f21df-f9df-48e8-b211-3cf7369968ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_bbe019c2-2e47-43c2-9f67-b97e6842e965" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_776f21df-f9df-48e8-b211-3cf7369968ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4ead7a1-4565-4cfc-b10e-a3282da6f407" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_87404101-e5b1-4e4b-b63f-8518fdbd8062" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_b4ead7a1-4565-4cfc-b10e-a3282da6f407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ee65733d-d17f-47e8-9e54-759de027ec66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_58aa4210-d082-4a02-a0da-343cd174408d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ee65733d-d17f-47e8-9e54-759de027ec66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4168ae1b-d85e-4f17-a069-88e21967a58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ee65733d-d17f-47e8-9e54-759de027ec66" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_4168ae1b-d85e-4f17-a069-88e21967a58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c41a867-4303-4934-ac72-d4bda9810c12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ee65733d-d17f-47e8-9e54-759de027ec66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_7c41a867-4303-4934-ac72-d4bda9810c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7358d0b-41bb-4ef8-b7ff-7b039fb04551" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_58aa4210-d082-4a02-a0da-343cd174408d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7358d0b-41bb-4ef8-b7ff-7b039fb04551" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6110363c-7f85-485d-826d-fb0ce73c5d6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7358d0b-41bb-4ef8-b7ff-7b039fb04551" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_6110363c-7f85-485d-826d-fb0ce73c5d6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfMediumTermNotes_a33e90d1-0b4d-45da-b1bb-b13f47963b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfMediumTermNotes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7358d0b-41bb-4ef8-b7ff-7b039fb04551" xlink:to="loc_us-gaap_RepaymentsOfMediumTermNotes_a33e90d1-0b4d-45da-b1bb-b13f47963b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfConvertibleDebt_45a702fa-5e67-4d8b-af48-0ed5ddc20122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfConvertibleDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7358d0b-41bb-4ef8-b7ff-7b039fb04551" xlink:to="loc_us-gaap_RepaymentsOfConvertibleDebt_45a702fa-5e67-4d8b-af48-0ed5ddc20122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1c23c08a-3962-48b7-b604-fafaee4e6f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7358d0b-41bb-4ef8-b7ff-7b039fb04551" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1c23c08a-3962-48b7-b604-fafaee4e6f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_beb85070-5805-48fb-ad8c-ab0dbe1cb85e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7358d0b-41bb-4ef8-b7ff-7b039fb04551" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_beb85070-5805-48fb-ad8c-ab0dbe1cb85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_eab1a994-0498-4f06-8d7b-6b8b7b809dd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7358d0b-41bb-4ef8-b7ff-7b039fb04551" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities_eab1a994-0498-4f06-8d7b-6b8b7b809dd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f72cce5b-1530-4300-8724-91976946fe6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c7358d0b-41bb-4ef8-b7ff-7b039fb04551" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f72cce5b-1530-4300-8724-91976946fe6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_090c7d55-f789-4acc-a41b-266b5bd2cfba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_58aa4210-d082-4a02-a0da-343cd174408d" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_090c7d55-f789-4acc-a41b-266b5bd2cfba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bce19e8c-74d1-4f9a-b519-a59b36d78931" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_58aa4210-d082-4a02-a0da-343cd174408d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_bce19e8c-74d1-4f9a-b519-a59b36d78931" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fbb5ff90-243d-4af5-9c49-983b106c04de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_58aa4210-d082-4a02-a0da-343cd174408d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_fbb5ff90-243d-4af5-9c49-983b106c04de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a3560213-3dbc-4aa2-bada-6deb7dd958c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_58aa4210-d082-4a02-a0da-343cd174408d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a3560213-3dbc-4aa2-bada-6deb7dd958c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_dadc97b9-3593-462a-9431-81cea731d880" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_58aa4210-d082-4a02-a0da-343cd174408d" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_dadc97b9-3593-462a-9431-81cea731d880" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_cb3f061d-ddf6-4cab-a8cc-abcf2df68ffb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dadc97b9-3593-462a-9431-81cea731d880" xlink:to="loc_us-gaap_InterestPaidNet_cb3f061d-ddf6-4cab-a8cc-abcf2df68ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_a20ae7ac-8da5-4834-9444-11b20c226742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_dadc97b9-3593-462a-9431-81cea731d880" xlink:to="loc_us-gaap_IncomeTaxesPaid_a20ae7ac-8da5-4834-9444-11b20c226742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7912b307-0331-40ed-8b1c-bc080dc69c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_58aa4210-d082-4a02-a0da-343cd174408d" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7912b307-0331-40ed-8b1c-bc080dc69c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7c31b68c-71a9-4cda-8b30-363df5e9ac42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_7912b307-0331-40ed-8b1c-bc080dc69c04" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7c31b68c-71a9-4cda-8b30-363df5e9ac42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_96a364cc-407e-413b-9423-5ddd247dd170" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_58aa4210-d082-4a02-a0da-343cd174408d" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_96a364cc-407e-413b-9423-5ddd247dd170" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0902a7b9-25d4-4015-abef-408e5f7dd6cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_96a364cc-407e-413b-9423-5ddd247dd170" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0902a7b9-25d4-4015-abef-408e5f7dd6cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_fb6159e8-f5cc-4add-85d2-ee11dfeb3765" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_96a364cc-407e-413b-9423-5ddd247dd170" xlink:to="loc_us-gaap_RestrictedCashCurrent_fb6159e8-f5cc-4add-85d2-ee11dfeb3765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3934fcb2-b45c-4e70-9b36-bd5f7b905151" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_96a364cc-407e-413b-9423-5ddd247dd170" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3934fcb2-b45c-4e70-9b36-bd5f7b905151" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_784a528e-5961-471c-a64c-caf934ddc0cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_048828ee-cc39-431f-9cdd-188951da656e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_784a528e-5961-471c-a64c-caf934ddc0cb" xlink:to="loc_us-gaap_StatementTable_048828ee-cc39-431f-9cdd-188951da656e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_83d304d9-476c-41bc-9c56-5f5a0c11b323" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_048828ee-cc39-431f-9cdd-188951da656e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_83d304d9-476c-41bc-9c56-5f5a0c11b323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83d304d9-476c-41bc-9c56-5f5a0c11b323" xlink:to="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_910c2855-8b38-4b6d-9a11-8c1060356430" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:to="loc_us-gaap_CommonStockMember_910c2855-8b38-4b6d-9a11-8c1060356430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_071e7a14-f002-4421-b866-daf3ae5d00b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:to="loc_us-gaap_TreasuryStockCommonMember_071e7a14-f002-4421-b866-daf3ae5d00b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_0aaae9eb-4052-4414-b1e3-20d2140fe952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_0aaae9eb-4052-4414-b1e3-20d2140fe952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8cc9919f-5ac9-4c6e-8da3-01f2f1e14f25" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8cc9919f-5ac9-4c6e-8da3-01f2f1e14f25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_25b74b38-7783-4241-8443-ba96d59c940c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_097aaf10-fa53-4648-bedc-3591722118c8" xlink:to="loc_us-gaap_RetainedEarningsMember_25b74b38-7783-4241-8443-ba96d59c940c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_2b95730c-a8af-4867-9591-dbdfc2257d97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_048828ee-cc39-431f-9cdd-188951da656e" xlink:to="loc_us-gaap_StatementLineItems_2b95730c-a8af-4867-9591-dbdfc2257d97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_2b95730c-a8af-4867-9591-dbdfc2257d97" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1d29cc05-c5ef-48e8-ab86-fbfa560c5e77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1d29cc05-c5ef-48e8-ab86-fbfa560c5e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_d7a5ea2b-be3b-4521-9ea2-9f1d74168f83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_StockholdersEquity_d7a5ea2b-be3b-4521-9ea2-9f1d74168f83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_8205432c-3b6c-42f3-990c-a6e3593cc3db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_TreasuryStockCommonShares_8205432c-3b6c-42f3-990c-a6e3593cc3db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_64b88b39-8ad6-4ee1-a6aa-96c9a5d83906" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_64b88b39-8ad6-4ee1-a6aa-96c9a5d83906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a7b244cf-2abe-417b-95ed-9d2d4e9ac511" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_a7b244cf-2abe-417b-95ed-9d2d4e9ac511" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2b608a3a-1748-40e6-ac91-491250265c44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_NetIncomeLoss_2b608a3a-1748-40e6-ac91-491250265c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_18ff92c6-fb40-43bb-ae1e-8fa62b569f87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_18ff92c6-fb40-43bb-ae1e-8fa62b569f87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_ad9afe3c-8ab1-436c-841d-c317522bf142" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_ad9afe3c-8ab1-436c-841d-c317522bf142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92bcc415-9e38-45dc-82c5-dbc3b718cc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_92bcc415-9e38-45dc-82c5-dbc3b718cc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_4a9d7069-e04b-4043-8506-3f8b97abd1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_4a9d7069-e04b-4043-8506-3f8b97abd1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_43035d59-178c-4925-bbed-3ad735dd47dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_TreasuryStockCommonShares_43035d59-178c-4925-bbed-3ad735dd47dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_fab3d2a3-c0c2-4db8-a093-add9aa68e329" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9fa42010-9949-4ba3-8d8e-9c3f257289e5" xlink:to="loc_us-gaap_StockholdersEquity_fab3d2a3-c0c2-4db8-a093-add9aa68e329" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="simple" xlink:href="ebs-20220630.xsd#CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_adb47898-16d6-4bdb-8871-9a64dfa433ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7390693a-44f3-484e-9ae9-1d2fa379e29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_adb47898-16d6-4bdb-8871-9a64dfa433ad" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7390693a-44f3-484e-9ae9-1d2fa379e29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Business" xlink:type="simple" xlink:href="ebs-20220630.xsd#Business"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Business" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_82c1a806-5b29-4f0f-ad55-a7845d1d22e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b56303b0-d51c-4ba6-baf3-5e025203e25d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_82c1a806-5b29-4f0f-ad55-a7845d1d22e2" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_b56303b0-d51c-4ba6-baf3-5e025203e25d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#BusinessDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f90e43e-1abf-48c6-9c10-c53b7d0b522c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_6f8a87a6-1ddd-4ff8-9108-e11ae5bd994d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9f90e43e-1abf-48c6-9c10-c53b7d0b522c" xlink:to="loc_us-gaap_AssetAcquisitionTable_6f8a87a6-1ddd-4ff8-9108-e11ae5bd994d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_ebb3cfc6-9502-48c8-a54c-422a005a5c2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_6f8a87a6-1ddd-4ff8-9108-e11ae5bd994d" xlink:to="loc_us-gaap_AssetAcquisitionAxis_ebb3cfc6-9502-48c8-a54c-422a005a5c2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_36052f40-e001-43c3-ba52-ac3e14914306" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_ebb3cfc6-9502-48c8-a54c-422a005a5c2f" xlink:to="loc_us-gaap_AssetAcquisitionDomain_36052f40-e001-43c3-ba52-ac3e14914306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChimerixAssetAcquisitionMember_29f19950-c1c2-47b9-b762-adf70831e624" xlink:href="ebs-20220630.xsd#ebs_ChimerixAssetAcquisitionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_36052f40-e001-43c3-ba52-ac3e14914306" xlink:to="loc_ebs_ChimerixAssetAcquisitionMember_29f19950-c1c2-47b9-b762-adf70831e624" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationByTypeAxis_e08cf155-ebe0-4cef-8172-0f6ad7ab3b8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_6f8a87a6-1ddd-4ff8-9108-e11ae5bd994d" xlink:to="loc_us-gaap_ContingentConsiderationByTypeAxis_e08cf155-ebe0-4cef-8172-0f6ad7ab3b8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContingentConsiderationTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationByTypeAxis_e08cf155-ebe0-4cef-8172-0f6ad7ab3b8e" xlink:to="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentOneMember_f93ae150-d97d-4613-b244-4726d454e457" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:to="loc_ebs_MilestonePaymentOneMember_f93ae150-d97d-4613-b244-4726d454e457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentTwoMember_117a5cfe-6148-4ede-969d-1d4c1097d161" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:to="loc_ebs_MilestonePaymentTwoMember_117a5cfe-6148-4ede-969d-1d4c1097d161" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentThreeMember_a9be3a5e-6c61-4dfe-8628-2c9eeb8aa6e9" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:to="loc_ebs_MilestonePaymentThreeMember_a9be3a5e-6c61-4dfe-8628-2c9eeb8aa6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MilestonePaymentFourMember_50065b5e-cf5b-4242-9ade-a38bf653a962" xlink:href="ebs-20220630.xsd#ebs_MilestonePaymentFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:to="loc_ebs_MilestonePaymentFourMember_50065b5e-cf5b-4242-9ade-a38bf653a962" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_RegulatoryMilestonesMember_cea62cbf-2383-41c5-889f-9ead6a6ccfcb" xlink:href="ebs-20220630.xsd#ebs_RegulatoryMilestonesMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContingentConsiderationTypeDomain_a126388a-927c-4862-9442-85a1cc1cfcf7" xlink:to="loc_ebs_RegulatoryMilestonesMember_cea62cbf-2383-41c5-889f-9ead6a6ccfcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_939426f0-26a2-4c05-9800-32da6153483d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_6f8a87a6-1ddd-4ff8-9108-e11ae5bd994d" xlink:to="loc_srt_StatementScenarioAxis_939426f0-26a2-4c05-9800-32da6153483d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_821391e7-c2e7-423c-b457-483213d19ee8" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_939426f0-26a2-4c05-9800-32da6153483d" xlink:to="loc_srt_ScenarioUnspecifiedDomain_821391e7-c2e7-423c-b457-483213d19ee8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_5f66be19-e8b9-4ed8-ab40-28714a8e48d6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_821391e7-c2e7-423c-b457-483213d19ee8" xlink:to="loc_srt_ScenarioForecastMember_5f66be19-e8b9-4ed8-ab40-28714a8e48d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_6f8a87a6-1ddd-4ff8-9108-e11ae5bd994d" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_7ac1955c-1dc9-442f-940f-a27f9ec4c556" xlink:href="ebs-20220630.xsd#ebs_NumberOfCategoriesOfPublicHealthThreats"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_NumberOfCategoriesOfPublicHealthThreats_7ac1955c-1dc9-442f-940f-a27f9ec4c556" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfRevenueGeneratingProducts_35c513aa-6d4b-40fd-9d4a-bb98e03dcffd" xlink:href="ebs-20220630.xsd#ebs_NumberOfRevenueGeneratingProducts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_NumberOfRevenueGeneratingProducts_35c513aa-6d4b-40fd-9d4a-bb98e03dcffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_NumberOfProductCandidates_de4f8f22-836d-4e4c-957f-af27b6ccc5a2" xlink:href="ebs-20220630.xsd#ebs_NumberOfProductCandidates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_NumberOfProductCandidates_de4f8f22-836d-4e4c-957f-af27b6ccc5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_54eefc65-53cc-46ab-992e-6e55fb48cb82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_54eefc65-53cc-46ab-992e-6e55fb48cb82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_debf90c1-55cd-4b63-a0f5-6bf8137420f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_debf90c1-55cd-4b63-a0f5-6bf8137420f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f7ceadac-7441-4a70-8096-bcdf19f2216e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration_f7ceadac-7441-4a70-8096-bcdf19f2216e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_6bc1fb9e-2885-4897-a6ec-2b25b2c9d3e7" xlink:href="ebs-20220630.xsd#ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage_6bc1fb9e-2885-4897-a6ec-2b25b2c9d3e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit_e7783a81-505a-4c48-8628-ed30ad91cab1" xlink:href="ebs-20220630.xsd#ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit_e7783a81-505a-4c48-8628-ed30ad91cab1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_3f46f3d0-2e69-4637-a64c-0a3eee501cbb" xlink:href="ebs-20220630.xsd#ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_4dbf49b7-5893-4e34-899f-290756d8a12f" xlink:to="loc_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage_3f46f3d0-2e69-4637-a64c-0a3eee501cbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation" xlink:type="simple" xlink:href="ebs-20220630.xsd#Basisofpresentationandprinciplesofconsolidation"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bc834a03-cb94-4f21-ac55-5f2ab56cded6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_51e27c5f-ff00-42c9-9cbd-0ba8225cb3a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bc834a03-cb94-4f21-ac55-5f2ab56cded6" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_51e27c5f-ff00-42c9-9cbd-0ba8225cb3a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies" xlink:type="simple" xlink:href="ebs-20220630.xsd#BasisofpresentationandprinciplesofconsolidationPolicies"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_7e8874c8-dabd-4493-acdd-3115c81d6d44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_abc71898-0439-40cc-b4f8-a02d1ca67cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e8874c8-dabd-4493-acdd-3115c81d6d44" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_abc71898-0439-40cc-b4f8-a02d1ca67cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_324a33bb-e80c-4310-8fc9-5c190bf0cc5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e8874c8-dabd-4493-acdd-3115c81d6d44" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_324a33bb-e80c-4310-8fc9-5c190bf0cc5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_86385801-c2e4-4d15-9412-9ee4a7e42127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e8874c8-dabd-4493-acdd-3115c81d6d44" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_86385801-c2e4-4d15-9412-9ee4a7e42127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_13ce046f-fc1c-46e0-b47d-5280f31df0ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e8874c8-dabd-4493-acdd-3115c81d6d44" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_13ce046f-fc1c-46e0-b47d-5280f31df0ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_45a27268-a670-42a6-bb1c-a14ae9614b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_7e8874c8-dabd-4493-acdd-3115c81d6d44" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_45a27268-a670-42a6-bb1c-a14ae9614b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#BasisofpresentationandprinciplesofconsolidationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bae3e603-f252-4fa0-a4e3-1465e7d640b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_974316d5-dd83-42a8-9952-57d90485ce44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bae3e603-f252-4fa0-a4e3-1465e7d640b1" xlink:to="loc_us-gaap_NumberOfReportableSegments_974316d5-dd83-42a8-9952-57d90485ce44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Inventoriesnet" xlink:type="simple" xlink:href="ebs-20220630.xsd#Inventoriesnet"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Inventoriesnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_831631b6-9782-412b-aea4-9112826131ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_81ff3acf-1a8a-42bf-a1f3-45b027c3b4d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_831631b6-9782-412b-aea4-9112826131ac" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_81ff3acf-1a8a-42bf-a1f3-45b027c3b4d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetTables" xlink:type="simple" xlink:href="ebs-20220630.xsd#InventoriesnetTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_28ccebab-4698-4bdd-8647-7f5a2dda14d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ce84d17a-a64f-467f-b200-24ae871154d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_28ccebab-4698-4bdd-8647-7f5a2dda14d6" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_ce84d17a-a64f-467f-b200-24ae871154d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#InventoriesnetScheduleofInventoryDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_6821f012-bed3-42d9-8257-210353810bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_fa421daa-4ae7-467f-bd39-a2af7da28db4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6821f012-bed3-42d9-8257-210353810bfa" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_fa421daa-4ae7-467f-bd39-a2af7da28db4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d606f225-df3f-4a83-b481-3495b3dde659" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6821f012-bed3-42d9-8257-210353810bfa" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_d606f225-df3f-4a83-b481-3495b3dde659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_14043161-4867-4ce0-bab3-8ad2e6fbfa5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6821f012-bed3-42d9-8257-210353810bfa" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_14043161-4867-4ce0-bab3-8ad2e6fbfa5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_d990bb20-a1ea-443b-92a3-7d18ccad59c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_6821f012-bed3-42d9-8257-210353810bfa" xlink:to="loc_us-gaap_InventoryNet_d990bb20-a1ea-443b-92a3-7d18ccad59c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet" xlink:type="simple" xlink:href="ebs-20220630.xsd#Propertyplantandequipmentnet"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Propertyplantandequipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_6ffa67da-36e0-49bc-9d1b-d9e6f4578d13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1c39bb8c-b219-473d-a49f-c269937f06dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_6ffa67da-36e0-49bc-9d1b-d9e6f4578d13" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1c39bb8c-b219-473d-a49f-c269937f06dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables" xlink:type="simple" xlink:href="ebs-20220630.xsd#PropertyplantandequipmentnetTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_a7d96bc1-7a6e-4d23-b781-8587f8c5f5b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5215562d-2083-457b-92b6-4956dd3a90da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_a7d96bc1-7a6e-4d23-b781-8587f8c5f5b4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_5215562d-2083-457b-92b6-4956dd3a90da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_c12695e9-ece2-49f0-ae93-20d8b3799c19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d9d2199-e501-43c8-a7d6-2e9cda763030" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract_c12695e9-ece2-49f0-ae93-20d8b3799c19" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d9d2199-e501-43c8-a7d6-2e9cda763030" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02722dc6-85ad-4fab-bc6a-001bb715fbb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d9d2199-e501-43c8-a7d6-2e9cda763030" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02722dc6-85ad-4fab-bc6a-001bb715fbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_02722dc6-85ad-4fab-bc6a-001bb715fbb8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandAndLandImprovementsMember_921b1c7b-68a4-4174-96e4-628e95fe7e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LandAndLandImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:to="loc_us-gaap_LandAndLandImprovementsMember_921b1c7b-68a4-4174-96e4-628e95fe7e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_de4444bd-e069-4c44-a02e-8975a5f2678d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_de4444bd-e069-4c44-a02e-8975a5f2678d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_edcdc940-084b-4b06-8b9a-91f947a14bd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_edcdc940-084b-4b06-8b9a-91f947a14bd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_09d256da-9192-40af-9524-c322e60ecd60" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerSoftwareIntangibleAssetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:to="loc_us-gaap_ComputerSoftwareIntangibleAssetMember_09d256da-9192-40af-9524-c322e60ecd60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_17f9835c-2b15-4ef5-ac70-06b593259848" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_22b33fe7-229e-4d67-89ab-f0a3af7957bd" xlink:to="loc_us-gaap_ConstructionInProgressMember_17f9835c-2b15-4ef5-ac70-06b593259848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_69099987-2a06-4b24-a0d7-4c2013a1bd10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8d9d2199-e501-43c8-a7d6-2e9cda763030" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_69099987-2a06-4b24-a0d7-4c2013a1bd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_c31cdf1c-4fe3-461b-8167-2ca7aa804318" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_69099987-2a06-4b24-a0d7-4c2013a1bd10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_c31cdf1c-4fe3-461b-8167-2ca7aa804318" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_e32f4996-1842-4de6-a822-99b9846abe26" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_c31cdf1c-4fe3-461b-8167-2ca7aa804318" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_e32f4996-1842-4de6-a822-99b9846abe26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f39697eb-c40c-40ec-a3a2-b5cdf02a45d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_c31cdf1c-4fe3-461b-8167-2ca7aa804318" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f39697eb-c40c-40ec-a3a2-b5cdf02a45d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d2f54603-89d8-467c-b128-030bc654ff48" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNetAbstract_c31cdf1c-4fe3-461b-8167-2ca7aa804318" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d2f54603-89d8-467c-b128-030bc654ff48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#PropertyplantandequipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d36e8c91-160b-40a6-9135-694fa2bd59d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_75b15b00-9ba0-4dc1-8161-89e3b8eee9d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d36e8c91-160b-40a6-9135-694fa2bd59d2" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_75b15b00-9ba0-4dc1-8161-89e3b8eee9d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_557ffe49-7745-4173-aaa3-1eeba271a9ca" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_75b15b00-9ba0-4dc1-8161-89e3b8eee9d0" xlink:to="loc_srt_MajorCustomersAxis_557ffe49-7745-4173-aaa3-1eeba271a9ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_7d8f1487-ce20-4380-8efa-db266a904d92" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_557ffe49-7745-4173-aaa3-1eeba271a9ca" xlink:to="loc_srt_NameOfMajorCustomerDomain_7d8f1487-ce20-4380-8efa-db266a904d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_cab134e0-29da-4a59-8f9f-b5eb74d5b419" xlink:href="ebs-20220630.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_7d8f1487-ce20-4380-8efa-db266a904d92" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_cab134e0-29da-4a59-8f9f-b5eb74d5b419" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4630c05b-d4d3-4580-b7da-ccf9d86a1395" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_75b15b00-9ba0-4dc1-8161-89e3b8eee9d0" xlink:to="loc_srt_ProductOrServiceAxis_4630c05b-d4d3-4580-b7da-ccf9d86a1395" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7f131af7-e1c5-489d-a570-ec286bc364ec" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4630c05b-d4d3-4580-b7da-ccf9d86a1395" xlink:to="loc_srt_ProductsAndServicesDomain_7f131af7-e1c5-489d-a570-ec286bc364ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7655d5d1-7687-4248-ae4b-84df718c37c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7f131af7-e1c5-489d-a570-ec286bc364ec" xlink:to="loc_us-gaap_ServiceMember_7655d5d1-7687-4248-ae4b-84df718c37c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a487581-8dc5-44fb-9740-d3882841545b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_75b15b00-9ba0-4dc1-8161-89e3b8eee9d0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a487581-8dc5-44fb-9740-d3882841545b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_72427ad8-8153-4cda-a616-8c897d3af780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_4a487581-8dc5-44fb-9740-d3882841545b" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_72427ad8-8153-4cda-a616-8c897d3af780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Leases" xlink:type="simple" xlink:href="ebs-20220630.xsd#Leases"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d677dc5b-d145-48b4-b4f9-dc77570b894c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_417ced97-3f55-4c03-84e8-da50a33c4b11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d677dc5b-d145-48b4-b4f9-dc77570b894c" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_417ced97-3f55-4c03-84e8-da50a33c4b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="simple" xlink:href="ebs-20220630.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_060deec6-4f78-4e56-8c9f-0b66468f4c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_bff82ca7-3587-4ba9-9878-83cbefb022ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_060deec6-4f78-4e56-8c9f-0b66468f4c28" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_bff82ca7-3587-4ba9-9878-83cbefb022ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_74c9ec5b-9347-4b79-a0fd-d4f8961e4a1b" xlink:href="ebs-20220630.xsd#ebs_AssetsAndLiabilitiesLesseeTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_060deec6-4f78-4e56-8c9f-0b66468f4c28" xlink:to="loc_ebs_AssetsAndLiabilitiesLesseeTableTextBlock_74c9ec5b-9347-4b79-a0fd-d4f8961e4a1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#LeasesComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_14ba0680-448f-4067-8cde-851a7a6844f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_c6875343-f682-4cd8-81fb-242e5973febb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_14ba0680-448f-4067-8cde-851a7a6844f5" xlink:to="loc_us-gaap_LeaseCostAbstract_c6875343-f682-4cd8-81fb-242e5973febb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c7b7fcac-29cd-4625-8ad1-18b0fb1a5ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_c6875343-f682-4cd8-81fb-242e5973febb" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_c7b7fcac-29cd-4625-8ad1-18b0fb1a5ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseExpense_f9bf64f3-b6ec-4101-a708-7d881a12d864" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_c6875343-f682-4cd8-81fb-242e5973febb" xlink:to="loc_us-gaap_OperatingLeaseExpense_f9bf64f3-b6ec-4101-a708-7d881a12d864" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_5c2c5a6d-83fb-4055-9917-15f8f655d061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_c6875343-f682-4cd8-81fb-242e5973febb" xlink:to="loc_us-gaap_LeaseCost_5c2c5a6d-83fb-4055-9917-15f8f655d061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#LeasesSupplementalBalanceSheetInformationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a16283a3-b1a2-4a74-88fc-91959e0e1f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0192c3c7-1ed2-447d-a57d-a4ca79b39df7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a16283a3-b1a2-4a74-88fc-91959e0e1f8c" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0192c3c7-1ed2-447d-a57d-a4ca79b39df7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6a1a33e5-8069-42b0-bd20-f3a6a2227aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0192c3c7-1ed2-447d-a57d-a4ca79b39df7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6a1a33e5-8069-42b0-bd20-f3a6a2227aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_96431116-cf98-4319-9dc9-e8d70d9a910e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0192c3c7-1ed2-447d-a57d-a4ca79b39df7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_96431116-cf98-4319-9dc9-e8d70d9a910e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_feb06617-2aeb-4f8a-86ac-d8d004670bab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0192c3c7-1ed2-447d-a57d-a4ca79b39df7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_feb06617-2aeb-4f8a-86ac-d8d004670bab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_2d5b0639-7262-46e6-82ec-66924880a1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0192c3c7-1ed2-447d-a57d-a4ca79b39df7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_2d5b0639-7262-46e6-82ec-66924880a1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_4c963014-8709-41e9-a69d-ce25ab3a05c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0192c3c7-1ed2-447d-a57d-a4ca79b39df7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_4c963014-8709-41e9-a69d-ce25ab3a05c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8a277e84-2c79-4440-80bb-cad335b1b5a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0192c3c7-1ed2-447d-a57d-a4ca79b39df7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_8a277e84-2c79-4440-80bb-cad335b1b5a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_616c1405-baf5-403b-8cfe-77021e3d0904" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_0192c3c7-1ed2-447d-a57d-a4ca79b39df7" xlink:to="loc_us-gaap_OperatingLeaseLiability_616c1405-baf5-403b-8cfe-77021e3d0904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostAbstract_e52ef672-2a57-4aaf-8d73-b013ca79d3f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseCostAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a16283a3-b1a2-4a74-88fc-91959e0e1f8c" xlink:to="loc_us-gaap_LeaseCostAbstract_e52ef672-2a57-4aaf-8d73-b013ca79d3f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c95d0955-9c47-4ebc-a8e2-da7c8d985eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_e52ef672-2a57-4aaf-8d73-b013ca79d3f2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_c95d0955-9c47-4ebc-a8e2-da7c8d985eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a5e303b2-dedc-4e8b-92af-3e037aefe346" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseCostAbstract_e52ef672-2a57-4aaf-8d73-b013ca79d3f2" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_a5e303b2-dedc-4e8b-92af-3e037aefe346" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Intangibleassets" xlink:type="simple" xlink:href="ebs-20220630.xsd#Intangibleassets"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Intangibleassets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b4ccef2f-fa33-472a-aae0-eb4733d6e7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_07c0c6ee-586a-4d32-9f39-718709fb3527" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_b4ccef2f-fa33-472a-aae0-eb4733d6e7ff" xlink:to="loc_us-gaap_IntangibleAssetsDisclosureTextBlock_07c0c6ee-586a-4d32-9f39-718709fb3527" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsTables" xlink:type="simple" xlink:href="ebs-20220630.xsd#IntangibleassetsTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ca5cacfc-438f-4f9a-b955-64c194f40264" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c526c612-3ee4-4363-89dc-92cf2ba278e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ca5cacfc-438f-4f9a-b955-64c194f40264" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_c526c612-3ee4-4363-89dc-92cf2ba278e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_cb637b36-cb49-4beb-b34b-5d9ff9c56e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ca5cacfc-438f-4f9a-b955-64c194f40264" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_cb637b36-cb49-4beb-b34b-5d9ff9c56e2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_a62f303a-8a45-48f3-b12a-271149e39486" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ca5cacfc-438f-4f9a-b955-64c194f40264" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_a62f303a-8a45-48f3-b12a-271149e39486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a5571ad3-821c-4b99-ae4b-74ef3e3f2e30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65e7209b-e655-4e48-a965-75312b6f6756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a5571ad3-821c-4b99-ae4b-74ef3e3f2e30" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65e7209b-e655-4e48-a965-75312b6f6756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_754dc883-2b1e-4993-8e52-718fdb7523d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65e7209b-e655-4e48-a965-75312b6f6756" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_754dc883-2b1e-4993-8e52-718fdb7523d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_47392cff-f7d2-48a4-a83d-4bcb4cb5a709" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_754dc883-2b1e-4993-8e52-718fdb7523d4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_47392cff-f7d2-48a4-a83d-4bcb4cb5a709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ba8c9d3e-0c28-4286-b489-a765d2049243" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_47392cff-f7d2-48a4-a83d-4bcb4cb5a709" xlink:to="loc_us-gaap_ProductMember_ba8c9d3e-0c28-4286-b489-a765d2049243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_4b3421ce-f456-4044-8985-41ae761776b4" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_47392cff-f7d2-48a4-a83d-4bcb4cb5a709" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_4b3421ce-f456-4044-8985-41ae761776b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_555d771f-543d-46ce-a158-fc78fc028e93" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65e7209b-e655-4e48-a965-75312b6f6756" xlink:to="loc_srt_RangeAxis_555d771f-543d-46ce-a158-fc78fc028e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb7f1e75-d576-414b-a36b-cf0ea5ea7916" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_555d771f-543d-46ce-a158-fc78fc028e93" xlink:to="loc_srt_RangeMember_cb7f1e75-d576-414b-a36b-cf0ea5ea7916" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_1ab4d7c3-bb67-41ac-97be-94fea4329c0b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb7f1e75-d576-414b-a36b-cf0ea5ea7916" xlink:to="loc_srt_MinimumMember_1ab4d7c3-bb67-41ac-97be-94fea4329c0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_1745c582-3701-412e-8ee2-ce9cc3be140a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb7f1e75-d576-414b-a36b-cf0ea5ea7916" xlink:to="loc_srt_MaximumMember_1745c582-3701-412e-8ee2-ce9cc3be140a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_65e7209b-e655-4e48-a965-75312b6f6756" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e85fade0-3b88-4eac-8713-59147367ded9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_e85fade0-3b88-4eac-8713-59147367ded9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d3b67a0a-42b4-4bae-a4c7-bbbb5422ef91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_d3b67a0a-42b4-4bae-a4c7-bbbb5422ef91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b963f3ec-e60a-408a-9367-699b6402cdfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_b963f3ec-e60a-408a-9367-699b6402cdfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c8280a70-64e7-45b3-ba26-3757aa4e3bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_6791284d-a584-4cde-b5a4-829bb8687a69" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c8280a70-64e7-45b3-ba26-3757aa4e3bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_125b80d4-2501-4204-b242-3f97d6e91711" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_c9d77d90-1d98-4dd0-8640-6ce36c23c0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_125b80d4-2501-4204-b242-3f97d6e91711" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_c9d77d90-1d98-4dd0-8640-6ce36c23c0fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#IntangibleassetsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0fa48993-188b-4e99-b44b-ee106df19b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_61962551-115d-4caf-b3ad-c3a12fc8b2f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0fa48993-188b-4e99-b44b-ee106df19b0f" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_61962551-115d-4caf-b3ad-c3a12fc8b2f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c7406ef6-1379-4342-84a4-044c977a3a62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillImpairedAccumulatedImpairmentLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_0fa48993-188b-4e99-b44b-ee106df19b0f" xlink:to="loc_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss_c7406ef6-1379-4342-84a4-044c977a3a62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#IntangibleassetsGoodwillRollForwardDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41c9494d-59c5-46be-b899-77e0fc5e0d14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_62dcd860-f22f-4a13-99d9-d8b8eab3e73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_41c9494d-59c5-46be-b899-77e0fc5e0d14" xlink:to="loc_us-gaap_GoodwillRollForward_62dcd860-f22f-4a13-99d9-d8b8eab3e73c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_95d8b1f7-c4ce-43a4-b0da-cfc900c14de4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_62dcd860-f22f-4a13-99d9-d8b8eab3e73c" xlink:to="loc_us-gaap_Goodwill_95d8b1f7-c4ce-43a4-b0da-cfc900c14de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c2a84f3d-689c-4e7b-8fa8-93dc863fd258" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_62dcd860-f22f-4a13-99d9-d8b8eab3e73c" xlink:to="loc_us-gaap_GoodwillForeignCurrencyTranslationGainLoss_c2a84f3d-689c-4e7b-8fa8-93dc863fd258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f3faabab-1d43-4b95-90b9-7e458e32c3ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_62dcd860-f22f-4a13-99d9-d8b8eab3e73c" xlink:to="loc_us-gaap_Goodwill_f3faabab-1d43-4b95-90b9-7e458e32c3ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Fairvaluemeasurements" xlink:type="simple" xlink:href="ebs-20220630.xsd#Fairvaluemeasurements"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Fairvaluemeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e6aa9b61-0efd-430b-8160-80c445d2bab4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5bcdf029-2698-4758-8cdd-66020dd5621b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e6aa9b61-0efd-430b-8160-80c445d2bab4" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5bcdf029-2698-4758-8cdd-66020dd5621b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables" xlink:type="simple" xlink:href="ebs-20220630.xsd#FairvaluemeasurementsTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7950c3b2-f8f0-4d37-8fa0-449920f65bf2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_6292157e-655e-4639-ad56-f174f3998c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7950c3b2-f8f0-4d37-8fa0-449920f65bf2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_6292157e-655e-4639-ad56-f174f3998c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6cac32c5-dec2-4868-9208-87e73c1d9cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7950c3b2-f8f0-4d37-8fa0-449920f65bf2" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_6cac32c5-dec2-4868-9208-87e73c1d9cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9214ca85-1cf5-49f3-ba49-e2d7109eaf42" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7950c3b2-f8f0-4d37-8fa0-449920f65bf2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_9214ca85-1cf5-49f3-ba49-e2d7109eaf42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d75e4269-ae6d-41b3-bb0e-8f2211cbdcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fac336e-201d-47de-acab-551c93b60281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d75e4269-ae6d-41b3-bb0e-8f2211cbdcc7" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fac336e-201d-47de-acab-551c93b60281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAxis_020c4055-f28e-490b-a91f-d94987e84f6e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fac336e-201d-47de-acab-551c93b60281" xlink:to="loc_us-gaap_CashAndCashEquivalentsAxis_020c4055-f28e-490b-a91f-d94987e84f6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_856dbcff-4bcc-4de1-abc0-c99dcf5e3689" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAxis_020c4055-f28e-490b-a91f-d94987e84f6e" xlink:to="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_856dbcff-4bcc-4de1-abc0-c99dcf5e3689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_eb7a04f7-76c7-438a-bd92-01136dbd62fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_856dbcff-4bcc-4de1-abc0-c99dcf5e3689" xlink:to="loc_us-gaap_MoneyMarketFundsMember_eb7a04f7-76c7-438a-bd92-01136dbd62fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_a9059725-3c63-41cc-a816-64bfd9b021d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_856dbcff-4bcc-4de1-abc0-c99dcf5e3689" xlink:to="loc_us-gaap_BankTimeDepositsMember_a9059725-3c63-41cc-a816-64bfd9b021d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4148427-8245-4359-bb8f-bb1559910ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fac336e-201d-47de-acab-551c93b60281" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4148427-8245-4359-bb8f-bb1559910ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e43df4b4-7b3f-4342-8c6d-fe0d893217bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a4148427-8245-4359-bb8f-bb1559910ad5" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e43df4b4-7b3f-4342-8c6d-fe0d893217bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_eb1f0abe-0630-4d66-91e7-4e61d6d77c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e43df4b4-7b3f-4342-8c6d-fe0d893217bb" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_eb1f0abe-0630-4d66-91e7-4e61d6d77c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_b1f059aa-c470-4600-b0fa-9b549c1acd08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e43df4b4-7b3f-4342-8c6d-fe0d893217bb" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_b1f059aa-c470-4600-b0fa-9b549c1acd08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_acb45952-21ea-41db-aa95-aec600952d32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_e43df4b4-7b3f-4342-8c6d-fe0d893217bb" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_acb45952-21ea-41db-aa95-aec600952d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_3fac336e-201d-47de-acab-551c93b60281" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7884b11a-727e-4423-8049-751975faef1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_7884b11a-727e-4423-8049-751975faef1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_a3a0955c-64ad-4d91-8d0d-a2b72f0dda43" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_DerivativeAssets_a3a0955c-64ad-4d91-8d0d-a2b72f0dda43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_8aa51607-dde7-477e-8b71-243646553606" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_8aa51607-dde7-477e-8b71-243646553606" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47920442-e04a-4549-a5ad-8d9a7df3645c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_47920442-e04a-4549-a5ad-8d9a7df3645c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_013c62c3-da03-4b95-9b8f-5afc5a3ee94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_DerivativeLiabilities_013c62c3-da03-4b95-9b8f-5afc5a3ee94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosure_e467a6ca-bbb2-4c23-a35d-c6518e7b6a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8d0d51ae-d6be-4256-90a3-338f8fd0e9e0" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosure_e467a6ca-bbb2-4c23-a35d-c6518e7b6a1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#FairvaluemeasurementsContingentConsiderationRollForwardDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_82aa66af-287e-43ee-8328-dab3774439bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5c8e3e92-c9a7-445b-92ce-a34d85c80bca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_82aa66af-287e-43ee-8328-dab3774439bf" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5c8e3e92-c9a7-445b-92ce-a34d85c80bca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6c2a9102-4470-4edd-b16b-9a194e320559" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5c8e3e92-c9a7-445b-92ce-a34d85c80bca" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_6c2a9102-4470-4edd-b16b-9a194e320559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5cf642ec-dc17-41be-b593-3005a973f133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5c8e3e92-c9a7-445b-92ce-a34d85c80bca" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_5cf642ec-dc17-41be-b593-3005a973f133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_00325671-ac92-403a-9297-b6aa1a7e28a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5c8e3e92-c9a7-445b-92ce-a34d85c80bca" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_00325671-ac92-403a-9297-b6aa1a7e28a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_579437a7-3f66-46eb-86b0-b5d9c8c31cea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_5c8e3e92-c9a7-445b-92ce-a34d85c80bca" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_579437a7-3f66-46eb-86b0-b5d9c8c31cea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#FairvaluemeasurementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_2de129ef-99b4-47ea-8e29-097887fb4bde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_0b315fa2-8961-4acb-97fc-0b2dc01f3c27" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_2de129ef-99b4-47ea-8e29-097887fb4bde" xlink:to="loc_us-gaap_DebtInstrumentTable_0b315fa2-8961-4acb-97fc-0b2dc01f3c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_b952b1eb-7c1f-4e8d-b27f-f9452fd5d39b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b315fa2-8961-4acb-97fc-0b2dc01f3c27" xlink:to="loc_us-gaap_DebtInstrumentAxis_b952b1eb-7c1f-4e8d-b27f-f9452fd5d39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_a03895cf-b31e-47de-a2da-ae8b1d5480fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_b952b1eb-7c1f-4e8d-b27f-f9452fd5d39b" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_a03895cf-b31e-47de-a2da-ae8b1d5480fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_dd492cf4-0dcd-4f85-9121-d49793473d04" xlink:href="ebs-20220630.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_a03895cf-b31e-47de-a2da-ae8b1d5480fc" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_dd492cf4-0dcd-4f85-9121-d49793473d04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_aadebde8-b014-45d1-b043-25d07667326c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b315fa2-8961-4acb-97fc-0b2dc01f3c27" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_aadebde8-b014-45d1-b043-25d07667326c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_4dfd19a6-ca58-4a0a-95d4-86fdf672866f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_aadebde8-b014-45d1-b043-25d07667326c" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_4dfd19a6-ca58-4a0a-95d4-86fdf672866f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_e59f118d-9556-4ae4-84dc-b8de710b6def" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_4dfd19a6-ca58-4a0a-95d4-86fdf672866f" xlink:to="loc_us-gaap_SeniorNotesMember_e59f118d-9556-4ae4-84dc-b8de710b6def" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_682b4723-3091-4b34-a712-57a68ba51cb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_0b315fa2-8961-4acb-97fc-0b2dc01f3c27" xlink:to="loc_us-gaap_DebtInstrumentLineItems_682b4723-3091-4b34-a712-57a68ba51cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2f5dea6d-3dfc-47b1-b189-6950a8d9da18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_682b4723-3091-4b34-a712-57a68ba51cb6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_2f5dea6d-3dfc-47b1-b189-6950a8d9da18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ca0dde5-b91c-46ef-ae77-377a6c6602df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_682b4723-3091-4b34-a712-57a68ba51cb6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_9ca0dde5-b91c-46ef-ae77-377a6c6602df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtFairValue_2fe1520b-404d-413f-a04b-8f0534933de1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_682b4723-3091-4b34-a712-57a68ba51cb6" xlink:to="loc_us-gaap_LongTermDebtFairValue_2fe1520b-404d-413f-a04b-8f0534933de1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_89ebe0b7-e1ee-4c61-b25e-40f96506b4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_89ebe0b7-e1ee-4c61-b25e-40f96506b4d7" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueAxis_a16e2dc8-5997-45ba-bad1-a327ce6989e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:to="loc_us-gaap_ValuationTechniqueAxis_a16e2dc8-5997-45ba-bad1-a327ce6989e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDomain_f904f143-ec9d-4327-8814-c862c21b3f72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_a16e2dc8-5997-45ba-bad1-a327ce6989e6" xlink:to="loc_us-gaap_ValuationTechniqueDomain_f904f143-ec9d-4327-8814-c862c21b3f72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_bf8e1f2a-7292-4c48-a6f5-80ac9d374e5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationTechniqueDiscountedCashFlowMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_f904f143-ec9d-4327-8814-c862c21b3f72" xlink:to="loc_us-gaap_ValuationTechniqueDiscountedCashFlowMember_bf8e1f2a-7292-4c48-a6f5-80ac9d374e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e846991c-bf17-4d5e-9f3e-e95913481e50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e846991c-bf17-4d5e-9f3e-e95913481e50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5841aa58-486d-4d7d-9fe9-54ac2ebfc31e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_e846991c-bf17-4d5e-9f3e-e95913481e50" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5841aa58-486d-4d7d-9fe9-54ac2ebfc31e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_bc2ccea5-b2e8-4ee8-9b1b-224e021218c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5841aa58-486d-4d7d-9fe9-54ac2ebfc31e" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_bc2ccea5-b2e8-4ee8-9b1b-224e021218c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eea7f83a-4f8c-4921-90a5-c3c8d3798cb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eea7f83a-4f8c-4921-90a5-c3c8d3798cb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_abaf97dc-aeb8-44a8-8a46-5e4bb9137f32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_eea7f83a-4f8c-4921-90a5-c3c8d3798cb5" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_abaf97dc-aeb8-44a8-8a46-5e4bb9137f32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_f70ec90c-530b-4db9-b6c1-57a9c6527b96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_abaf97dc-aeb8-44a8-8a46-5e4bb9137f32" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_f70ec90c-530b-4db9-b6c1-57a9c6527b96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeAxis_7ca2d47a-b594-4706-86a0-15e516fa53db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:to="loc_us-gaap_MeasurementInputTypeAxis_7ca2d47a-b594-4706-86a0-15e516fa53db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputTypeDomain_919a1255-fa27-4053-9c3f-86df07b72f06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeAxis_7ca2d47a-b594-4706-86a0-15e516fa53db" xlink:to="loc_us-gaap_MeasurementInputTypeDomain_919a1255-fa27-4053-9c3f-86df07b72f06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MeasurementInputDiscountRateMember_a61713be-0b8a-43b0-be62-cea94a99644f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MeasurementInputDiscountRateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_919a1255-fa27-4053-9c3f-86df07b72f06" xlink:to="loc_us-gaap_MeasurementInputDiscountRateMember_a61713be-0b8a-43b0-be62-cea94a99644f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_MeasurementInputProbabilityofPaymentMember_f22096c2-8ccb-4703-8d92-bc8859076d10" xlink:href="ebs-20220630.xsd#ebs_MeasurementInputProbabilityofPaymentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MeasurementInputTypeDomain_919a1255-fa27-4053-9c3f-86df07b72f06" xlink:to="loc_ebs_MeasurementInputProbabilityofPaymentMember_f22096c2-8ccb-4703-8d92-bc8859076d10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2a5ff381-b994-4172-90d8-127078c44b22" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:to="loc_srt_RangeAxis_2a5ff381-b994-4172-90d8-127078c44b22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a5c102b3-0094-4074-af83-938608d30b94" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2a5ff381-b994-4172-90d8-127078c44b22" xlink:to="loc_srt_RangeMember_a5c102b3-0094-4074-af83-938608d30b94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_d4d8b191-ef6e-4ba1-8cd2-eceacdf911ce" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a5c102b3-0094-4074-af83-938608d30b94" xlink:to="loc_srt_MinimumMember_d4d8b191-ef6e-4ba1-8cd2-eceacdf911ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_88e21777-6c22-4d0e-ae51-c4630b233ce2" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a5c102b3-0094-4074-af83-938608d30b94" xlink:to="loc_srt_MaximumMember_88e21777-6c22-4d0e-ae51-c4630b233ce2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_fc7c04ef-ac4f-4437-ba7f-12066e9203bc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_a5c102b3-0094-4074-af83-938608d30b94" xlink:to="loc_srt_WeightedAverageMember_fc7c04ef-ac4f-4437-ba7f-12066e9203bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e67192dd-0a10-4657-b7b8-fdc577a5e73e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_620c9eb9-34ab-42ba-ac9e-86754e10175c" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e67192dd-0a10-4657-b7b8-fdc577a5e73e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d8db8e89-4597-4794-94e7-d6c517890fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e67192dd-0a10-4657-b7b8-fdc577a5e73e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_d8db8e89-4597-4794-94e7-d6c517890fa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_1573e36b-e6cc-4e09-80d7-7eceeb73d5b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_e67192dd-0a10-4657-b7b8-fdc577a5e73e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_1573e36b-e6cc-4e09-80d7-7eceeb73d5b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities" xlink:type="simple" xlink:href="ebs-20220630.xsd#Derivativeinstrumentsandhedgingactivities"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fb5458a2-0310-4744-aac5-5a25608e5ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_cb6fd50b-50fc-40f2-9ebd-d202c8077bdd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_fb5458a2-0310-4744-aac5-5a25608e5ffa" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock_cb6fd50b-50fc-40f2-9ebd-d202c8077bdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables" xlink:type="simple" xlink:href="ebs-20220630.xsd#DerivativeinstrumentsandhedgingactivitiesTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_83746aca-a990-414e-ae54-5baed637ec45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_08900f16-a221-496c-8290-9e617e054790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_83746aca-a990-414e-ae54-5baed637ec45" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_08900f16-a221-496c-8290-9e617e054790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_4f31c573-e8cc-4910-bd25-318a74bf5ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_83746aca-a990-414e-ae54-5baed637ec45" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_4f31c573-e8cc-4910-bd25-318a74bf5ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_134b5873-ad1c-4eac-a29b-911395e88f18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_83746aca-a990-414e-ae54-5baed637ec45" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_134b5873-ad1c-4eac-a29b-911395e88f18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_50f5cc06-43c5-4fc1-a1ff-a2078c2babeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f4258169-3d07-40e5-b866-1841cfd889bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_50f5cc06-43c5-4fc1-a1ff-a2078c2babeb" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f4258169-3d07-40e5-b866-1841cfd889bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_ed206883-98f7-47f6-8ac4-8f67c74780b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f4258169-3d07-40e5-b866-1841cfd889bf" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_ed206883-98f7-47f6-8ac4-8f67c74780b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_30b349cc-6b1a-4846-ba3d-02f9f7b74a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_ed206883-98f7-47f6-8ac4-8f67c74780b1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_30b349cc-6b1a-4846-ba3d-02f9f7b74a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_e57bce67-bfe4-40d4-a844-331b0fc16518" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_30b349cc-6b1a-4846-ba3d-02f9f7b74a8b" xlink:to="loc_us-gaap_InterestRateSwapMember_e57bce67-bfe4-40d4-a844-331b0fc16518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_a7d19aab-7655-4ffe-9772-c73e5644e8a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_f4258169-3d07-40e5-b866-1841cfd889bf" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_a7d19aab-7655-4ffe-9772-c73e5644e8a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_39b8c639-cdff-4ffb-b8ba-07dcd814ca3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_a7d19aab-7655-4ffe-9772-c73e5644e8a9" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_39b8c639-cdff-4ffb-b8ba-07dcd814ca3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ac91aa88-6e3f-4358-a82f-de9427f48148" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_4eac78d6-9719-458f-b831-bc5b3ffd222e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_ac91aa88-6e3f-4358-a82f-de9427f48148" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_4eac78d6-9719-458f-b831-bc5b3ffd222e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_7bf19286-8171-491e-b9f7-8c4131c87158" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_4eac78d6-9719-458f-b831-bc5b3ffd222e" xlink:to="loc_us-gaap_HedgingDesignationAxis_7bf19286-8171-491e-b9f7-8c4131c87158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_4885e751-4174-47fc-af1f-233151095e73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_7bf19286-8171-491e-b9f7-8c4131c87158" xlink:to="loc_us-gaap_HedgingDesignationDomain_4885e751-4174-47fc-af1f-233151095e73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3ac3bdd6-0999-41d0-9c0a-d580037e3be0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_4885e751-4174-47fc-af1f-233151095e73" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3ac3bdd6-0999-41d0-9c0a-d580037e3be0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fe0b7325-aa69-43d7-bd66-87d3e2cf824d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_4eac78d6-9719-458f-b831-bc5b3ffd222e" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fe0b7325-aa69-43d7-bd66-87d3e2cf824d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_cfcf16d3-c3b2-462d-a794-2e31e1df8779" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fe0b7325-aa69-43d7-bd66-87d3e2cf824d" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_cfcf16d3-c3b2-462d-a794-2e31e1df8779" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_580ca454-f2be-4723-a9f2-f4d5a3062f19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_cfcf16d3-c3b2-462d-a794-2e31e1df8779" xlink:to="loc_us-gaap_InterestRateSwapMember_580ca454-f2be-4723-a9f2-f4d5a3062f19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3ffbe841-37ab-4e47-ab7e-09c59469be71" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_4eac78d6-9719-458f-b831-bc5b3ffd222e" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3ffbe841-37ab-4e47-ab7e-09c59469be71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfInterestRateDerivativesHeld_e3d2203a-47b4-46fb-9613-e5fc82123251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfInterestRateDerivativesHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3ffbe841-37ab-4e47-ab7e-09c59469be71" xlink:to="loc_us-gaap_NumberOfInterestRateDerivativesHeld_e3d2203a-47b4-46fb-9613-e5fc82123251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_727e5404-3f13-4295-958b-e6ba252fa2d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_3ffbe841-37ab-4e47-ab7e-09c59469be71" xlink:to="loc_us-gaap_DerivativeNotionalAmount_727e5404-3f13-4295-958b-e6ba252fa2d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e93be88c-3062-466b-8bad-87ae149ab73c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9c6b6d86-5d09-46c9-bd06-7095bcad719d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_e93be88c-3062-466b-8bad-87ae149ab73c" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9c6b6d86-5d09-46c9-bd06-7095bcad719d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_2a3bb1c2-12b9-46b3-9a6c-91501eadb64e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9c6b6d86-5d09-46c9-bd06-7095bcad719d" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_2a3bb1c2-12b9-46b3-9a6c-91501eadb64e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c55c1d44-039b-4dd5-97eb-6be68afde8bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_2a3bb1c2-12b9-46b3-9a6c-91501eadb64e" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c55c1d44-039b-4dd5-97eb-6be68afde8bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_38ced072-d5ad-4b11-870e-0fee82a9748d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_c55c1d44-039b-4dd5-97eb-6be68afde8bf" xlink:to="loc_us-gaap_InterestRateSwapMember_38ced072-d5ad-4b11-870e-0fee82a9748d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_5a64f54b-6a03-400e-be39-d6696ec24281" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9c6b6d86-5d09-46c9-bd06-7095bcad719d" xlink:to="loc_us-gaap_HedgingDesignationAxis_5a64f54b-6a03-400e-be39-d6696ec24281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_fc68bdb4-abd7-4328-9987-199225504bd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_5a64f54b-6a03-400e-be39-d6696ec24281" xlink:to="loc_us-gaap_HedgingDesignationDomain_fc68bdb4-abd7-4328-9987-199225504bd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ec2129c7-33e7-4f49-85de-ac66f1befc8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_fc68bdb4-abd7-4328-9987-199225504bd0" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_ec2129c7-33e7-4f49-85de-ac66f1befc8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_c852d831-ab05-4462-bbec-e764cf78f9dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9c6b6d86-5d09-46c9-bd06-7095bcad719d" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_c852d831-ab05-4462-bbec-e764cf78f9dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_c852d831-ab05-4462-bbec-e764cf78f9dd" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_dd191b79-4482-4c16-b826-28b144af264d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_dd191b79-4482-4c16-b826-28b144af264d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_5b9b998f-fe83-40ae-bc46-145d9d0dbea2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:to="loc_us-gaap_OtherAssetsMember_5b9b998f-fe83-40ae-bc46-145d9d0dbea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_10a69ea5-c699-4297-84d6-28282f612f1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_10a69ea5-c699-4297-84d6-28282f612f1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesMember_465d9ae0-71f9-40cc-b255-93d128d63232" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_424b33c9-fddb-4aff-9ad1-b1084bc867e8" xlink:to="loc_us-gaap_OtherLiabilitiesMember_465d9ae0-71f9-40cc-b255-93d128d63232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_d67ce4f7-209c-4714-bc30-6cdcbd73c352" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_9c6b6d86-5d09-46c9-bd06-7095bcad719d" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_d67ce4f7-209c-4714-bc30-6cdcbd73c352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_959adb2f-4963-47b6-90b0-e8f67e803586" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d67ce4f7-209c-4714-bc30-6cdcbd73c352" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_959adb2f-4963-47b6-90b0-e8f67e803586" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_454d86eb-7439-42b9-b26d-170c5570de1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_d67ce4f7-209c-4714-bc30-6cdcbd73c352" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_454d86eb-7439-42b9-b26d-170c5570de1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_60285f10-7bd7-4764-81ab-84f5c3f84a76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c99d1bac-ad88-48ee-8791-54ff891c5215" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_60285f10-7bd7-4764-81ab-84f5c3f84a76" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c99d1bac-ad88-48ee-8791-54ff891c5215" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0a94eb37-70c8-408b-804f-a88783818e9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c99d1bac-ad88-48ee-8791-54ff891c5215" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0a94eb37-70c8-408b-804f-a88783818e9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_40d27d66-5437-4e25-bfa1-0badd7abfd3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_0a94eb37-70c8-408b-804f-a88783818e9e" xlink:to="loc_us-gaap_HedgingRelationshipDomain_40d27d66-5437-4e25-bfa1-0badd7abfd3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_db1e0b5f-d581-4cc3-b660-29366947b3f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_40d27d66-5437-4e25-bfa1-0badd7abfd3b" xlink:to="loc_us-gaap_CashFlowHedgingMember_db1e0b5f-d581-4cc3-b660-29366947b3f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2b583241-1404-4a40-ba78-bd2c4b20ff20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c99d1bac-ad88-48ee-8791-54ff891c5215" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2b583241-1404-4a40-ba78-bd2c4b20ff20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_2b17bb32-425c-435c-876f-c15b57bd6de3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2b583241-1404-4a40-ba78-bd2c4b20ff20" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_2b17bb32-425c-435c-876f-c15b57bd6de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseMember_7358c428-9007-4798-bf65-28ebd6e2ba75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_2b17bb32-425c-435c-876f-c15b57bd6de3" xlink:to="loc_us-gaap_InterestExpenseMember_7358c428-9007-4798-bf65-28ebd6e2ba75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6f5ae431-7da9-4618-937e-409669819f4f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c99d1bac-ad88-48ee-8791-54ff891c5215" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6f5ae431-7da9-4618-937e-409669819f4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_811cb3b3-840a-42ca-8f84-86094703b5aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6f5ae431-7da9-4618-937e-409669819f4f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_811cb3b3-840a-42ca-8f84-86094703b5aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_460cd3e4-53af-43ed-bd97-768a06b42c68" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_811cb3b3-840a-42ca-8f84-86094703b5aa" xlink:to="loc_us-gaap_InterestRateSwapMember_460cd3e4-53af-43ed-bd97-768a06b42c68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4238309f-4ce3-44e4-948b-01f323461efa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable_c99d1bac-ad88-48ee-8791-54ff891c5215" xlink:to="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4238309f-4ce3-44e4-948b-01f323461efa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f910c088-8248-43cd-a838-54867e8c89af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems_4238309f-4ce3-44e4-948b-01f323461efa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_f910c088-8248-43cd-a838-54867e8c89af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Debt" xlink:type="simple" xlink:href="ebs-20220630.xsd#Debt"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Debt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_89460730-217e-4b40-87c4-dc9cf03271b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_f6db2bc8-61af-4042-8d36-821c4da0609c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_89460730-217e-4b40-87c4-dc9cf03271b4" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_f6db2bc8-61af-4042-8d36-821c4da0609c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtTables" xlink:type="simple" xlink:href="ebs-20220630.xsd#DebtTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f1716417-3ce8-4550-9fa2-fde81a227059" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_ca1c2155-bcbf-4fa1-ba73-1e9f09259fb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f1716417-3ce8-4550-9fa2-fde81a227059" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_ca1c2155-bcbf-4fa1-ba73-1e9f09259fb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DebtScheduleDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtScheduleDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ffec5585-50d3-4d4b-9d57-c7ea4c08a2f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_773b5458-943c-4870-b3e4-f311988f0405" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ffec5585-50d3-4d4b-9d57-c7ea4c08a2f2" xlink:to="loc_us-gaap_DebtInstrumentTable_773b5458-943c-4870-b3e4-f311988f0405" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_fe50b109-f62c-48bd-8037-2ed899b8728e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_773b5458-943c-4870-b3e4-f311988f0405" xlink:to="loc_us-gaap_DebtInstrumentAxis_fe50b109-f62c-48bd-8037-2ed899b8728e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b42876e9-e2b2-4103-9f03-bf040777ba6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_fe50b109-f62c-48bd-8037-2ed899b8728e" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b42876e9-e2b2-4103-9f03-bf040777ba6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_cd16fa91-7172-490c-a5f5-66908c532cde" xlink:href="ebs-20220630.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b42876e9-e2b2-4103-9f03-bf040777ba6d" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_cd16fa91-7172-490c-a5f5-66908c532cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OtherLongTermDebtFacilityMember_5c1107e2-d8b0-4acc-ab78-8479c5489a77" xlink:href="ebs-20220630.xsd#ebs_OtherLongTermDebtFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b42876e9-e2b2-4103-9f03-bf040777ba6d" xlink:to="loc_ebs_OtherLongTermDebtFacilityMember_5c1107e2-d8b0-4acc-ab78-8479c5489a77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bd883082-f996-4227-8314-a17453f19c04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_773b5458-943c-4870-b3e4-f311988f0405" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bd883082-f996-4227-8314-a17453f19c04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_3a345fda-a3ab-4f67-b612-e6b16d77d09e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bd883082-f996-4227-8314-a17453f19c04" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_3a345fda-a3ab-4f67-b612-e6b16d77d09e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NotesPayableOtherPayablesMember_e769cfac-34ff-4543-8162-11f1efb35d9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NotesPayableOtherPayablesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a345fda-a3ab-4f67-b612-e6b16d77d09e" xlink:to="loc_us-gaap_NotesPayableOtherPayablesMember_e769cfac-34ff-4543-8162-11f1efb35d9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_1eea37db-5d26-44a2-8712-7e0d141384c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_3a345fda-a3ab-4f67-b612-e6b16d77d09e" xlink:to="loc_us-gaap_SeniorNotesMember_1eea37db-5d26-44a2-8712-7e0d141384c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_773b5458-943c-4870-b3e4-f311988f0405" xlink:to="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_240a73a5-54a1-4cdd-a527-ad825145a140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_240a73a5-54a1-4cdd-a527-ad825145a140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_819c75dc-4b9f-4a17-a35e-9ba2d6f74a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:to="loc_us-gaap_LongTermDebt_819c75dc-4b9f-4a17-a35e-9ba2d6f74a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_9166a7cf-8a27-4b2c-a564-ee7970c891b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:to="loc_us-gaap_LongTermDebtCurrent_9166a7cf-8a27-4b2c-a564-ee7970c891b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_8ccd6e27-919b-4ade-8083-1bc54c2e8112" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNoncurrentNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:to="loc_us-gaap_DeferredFinanceCostsNoncurrentNet_8ccd6e27-919b-4ade-8083-1bc54c2e8112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_89b1c9e0-53c0-4427-bd98-875adb60b28c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_be23ba7f-4f16-4dba-9554-ac718ff40413" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_89b1c9e0-53c0-4427-bd98-875adb60b28c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#DebtNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/DebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_dd36b3f3-2207-4959-bde2-0dcc45751d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_dd36b3f3-2207-4959-bde2-0dcc45751d50" xlink:to="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityAxis_fe624156-f7c3-48df-a7b9-c41d064de587" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_CreditFacilityAxis_fe624156-f7c3-48df-a7b9-c41d064de587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CreditFacilityDomain_e12e25f9-2514-4041-904f-244744b1f808" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CreditFacilityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_fe624156-f7c3-48df-a7b9-c41d064de587" xlink:to="loc_us-gaap_CreditFacilityDomain_e12e25f9-2514-4041-904f-244744b1f808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevolvingCreditFacilityMember_c6273e24-a78a-40bc-8436-adf12ed8e599" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevolvingCreditFacilityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_e12e25f9-2514-4041-904f-244744b1f808" xlink:to="loc_us-gaap_RevolvingCreditFacilityMember_c6273e24-a78a-40bc-8436-adf12ed8e599" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_TermLoanFacilityMember_cb245d33-8c01-48de-8701-fc8079714c6f" xlink:href="ebs-20220630.xsd#ebs_TermLoanFacilityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_e12e25f9-2514-4041-904f-244744b1f808" xlink:to="loc_ebs_TermLoanFacilityMember_cb245d33-8c01-48de-8701-fc8079714c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_c701405d-4a6f-41c8-a0fa-a8f50467a2fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_DebtInstrumentAxis_c701405d-4a6f-41c8-a0fa-a8f50467a2fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_14bf61d2-166c-4b99-8ce2-724720e3cc24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_c701405d-4a6f-41c8-a0fa-a8f50467a2fa" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_14bf61d2-166c-4b99-8ce2-724720e3cc24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_fa100596-18c1-4f42-8fe5-8ba5c3abac9c" xlink:href="ebs-20220630.xsd#ebs_SeniorUnsecuredNotesDueAugust2028Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14bf61d2-166c-4b99-8ce2-724720e3cc24" xlink:to="loc_ebs_SeniorUnsecuredNotesDueAugust2028Member_fa100596-18c1-4f42-8fe5-8ba5c3abac9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AmendedCreditAgreementMember_51aa6618-2a3b-49a5-b5fe-f4e28c4a901c" xlink:href="ebs-20220630.xsd#ebs_AmendedCreditAgreementMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_14bf61d2-166c-4b99-8ce2-724720e3cc24" xlink:to="loc_ebs_AmendedCreditAgreementMember_51aa6618-2a3b-49a5-b5fe-f4e28c4a901c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateAxis_a5541115-0e31-4966-9f09-03c93aebbeb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_VariableRateAxis_a5541115-0e31-4966-9f09-03c93aebbeb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VariableRateDomain_d65780b4-69fa-49c9-a59a-cc5bae3c3da2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_a5541115-0e31-4966-9f09-03c93aebbeb1" xlink:to="loc_us-gaap_VariableRateDomain_d65780b4-69fa-49c9-a59a-cc5bae3c3da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EurodollarMember_fdfb3f15-dc11-4803-b907-61207d15084b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EurodollarMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_d65780b4-69fa-49c9-a59a-cc5bae3c3da2" xlink:to="loc_us-gaap_EurodollarMember_fdfb3f15-dc11-4803-b907-61207d15084b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e176eb47-61ff-450e-9bc9-91fd06e54e89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FederalFundsEffectiveSwapRateMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_d65780b4-69fa-49c9-a59a-cc5bae3c3da2" xlink:to="loc_us-gaap_FederalFundsEffectiveSwapRateMember_e176eb47-61ff-450e-9bc9-91fd06e54e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BaseRateMember_1139305a-3352-46e4-aa0d-a85cd9a78953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BaseRateMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_d65780b4-69fa-49c9-a59a-cc5bae3c3da2" xlink:to="loc_us-gaap_BaseRateMember_1139305a-3352-46e4-aa0d-a85cd9a78953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6641308f-a41d-4357-a653-dd9a086e8583" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_srt_RangeAxis_6641308f-a41d-4357-a653-dd9a086e8583" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_740693fe-d18b-4d64-91c3-b8f7c0472eea" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6641308f-a41d-4357-a653-dd9a086e8583" xlink:to="loc_srt_RangeMember_740693fe-d18b-4d64-91c3-b8f7c0472eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_03183747-f7d8-4fde-ab48-3c6c6405f1f3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_740693fe-d18b-4d64-91c3-b8f7c0472eea" xlink:to="loc_srt_MinimumMember_03183747-f7d8-4fde-ab48-3c6c6405f1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_d180bff3-e8fa-4402-a69e-bc8bfa2c1824" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_740693fe-d18b-4d64-91c3-b8f7c0472eea" xlink:to="loc_srt_MaximumMember_d180bff3-e8fa-4402-a69e-bc8bfa2c1824" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_bc0bb47a-cf8a-47bf-af40-fa71b151ee98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_bc0bb47a-cf8a-47bf-af40-fa71b151ee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_30438991-a147-47a0-9501-5a59e5054dc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_bc0bb47a-cf8a-47bf-af40-fa71b151ee98" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_30438991-a147-47a0-9501-5a59e5054dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditMember_ecae050f-2a2c-491f-b58d-b560a4ebeda3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_30438991-a147-47a0-9501-5a59e5054dc3" xlink:to="loc_us-gaap_LineOfCreditMember_ecae050f-2a2c-491f-b58d-b560a4ebeda3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_8d21082b-9d7c-41d7-aa24-848d0fb09716" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_30438991-a147-47a0-9501-5a59e5054dc3" xlink:to="loc_us-gaap_SeniorNotesMember_8d21082b-9d7c-41d7-aa24-848d0fb09716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_bd738f70-827b-49b4-a048-8d437653e57e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_bd738f70-827b-49b4-a048-8d437653e57e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_bbb9592d-3b5a-482e-a603-ef4e4d706c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_bd738f70-827b-49b4-a048-8d437653e57e" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_bbb9592d-3b5a-482e-a603-ef4e4d706c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_f1a955d5-a5cf-4419-a224-5a019354ef7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bbb9592d-3b5a-482e-a603-ef4e4d706c57" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_f1a955d5-a5cf-4419-a224-5a019354ef7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_b852066d-8171-4868-9faa-0d2d903f15db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_bbb9592d-3b5a-482e-a603-ef4e4d706c57" xlink:to="loc_us-gaap_OtherAssetsMember_b852066d-8171-4868-9faa-0d2d903f15db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_349a6191-6dae-44af-9f92-44ae57a158e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_349a6191-6dae-44af-9f92-44ae57a158e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8c8213d0-fda3-4df5-b740-ad13c1668b4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodAxis_349a6191-6dae-44af-9f92-44ae57a158e5" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8c8213d0-fda3-4df5-b740-ad13c1668b4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_c63c9c4f-baa3-4c10-b583-85368c398616" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8c8213d0-fda3-4df5-b740-ad13c1668b4a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodOneMember_c63c9c4f-baa3-4c10-b583-85368c398616" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_aa179afe-4553-4372-afb1-f53e4a462a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPeriodTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentRedemptionPeriodDomain_8c8213d0-fda3-4df5-b740-ad13c1668b4a" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPeriodTwoMember_aa179afe-4553-4372-afb1-f53e4a462a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_6e1abd7c-e34c-4d62-8196-874045dc51a1" xlink:to="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_5146586f-b785-4059-a282-f3f262680fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_LongTermDebt_5146586f-b785-4059-a282-f3f262680fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsCurrentNet_ff056e36-b63a-42f5-8684-9fec9383e22a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsCurrentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_DeferredFinanceCostsCurrentNet_ff056e36-b63a-42f5-8684-9fec9383e22a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_75836adc-45b2-4ec1-aa11-df01d3e3d742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFinanceCostsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_75836adc-45b2-4ec1-aa11-df01d3e3d742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6844b566-6d62-4e0e-968f-10aabd3f8310" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6844b566-6d62-4e0e-968f-10aabd3f8310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9f79cb0e-076f-45a7-a13f-17628490626f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentRedemptionPricePercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_DebtInstrumentRedemptionPricePercentage_9f79cb0e-076f-45a7-a13f-17628490626f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_440d231d-4181-4032-8d02-8f77f50982d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity_440d231d-4181-4032-8d02-8f77f50982d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a0cc810b-c8f3-46c3-a2ff-029e000c2ded" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_a0cc810b-c8f3-46c3-a2ff-029e000c2ded" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c77de6a0-304a-42d7-a57f-feb1f772c0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityCommitmentFeePercentage"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_us-gaap_LineOfCreditFacilityCommitmentFeePercentage_c77de6a0-304a-42d7-a57f-feb1f772c0a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_55dcc997-117e-46cd-b6a2-84c51b0f38ec" xlink:href="ebs-20220630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears_55dcc997-117e-46cd-b6a2-84c51b0f38ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_84455e67-bd9c-45ca-bb4d-fb49974031fb" xlink:href="ebs-20220630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear_84455e67-bd9c-45ca-bb4d-fb49974031fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_5de17900-12a6-4ba7-b367-fcd852305c1d" xlink:href="ebs-20220630.xsd#ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears_5de17900-12a6-4ba7-b367-fcd852305c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_f15e6690-28a0-4484-9bb1-1a3bd6879000" xlink:href="ebs-20220630.xsd#ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight_f15e6690-28a0-4484-9bb1-1a3bd6879000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_a9b80ea9-d142-4881-a506-4f932790c37d" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod_a9b80ea9-d142-4881-a506-4f932790c37d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_e080b774-2c53-4cae-bf95-1549ea3728df" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantDebtServiceCoverageRatio"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio_e080b774-2c53-4cae-bf95-1549ea3728df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_843bcb50-f6b8-4ff2-b6a0-0e881849b5f5" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioOne"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioOne_843bcb50-f6b8-4ff2-b6a0-0e881849b5f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_dcaea5c4-e91c-4980-9ab3-46b9e447c72c" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioTwo"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioTwo_dcaea5c4-e91c-4980-9ab3-46b9e447c72c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9f93cf9d-ecba-41c2-a335-5b271a7bcfe4" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod_9f93cf9d-ecba-41c2-a335-5b271a7bcfe4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_b1b8cf05-00ad-4f94-bc95-cf8a4e51121a" xlink:href="ebs-20220630.xsd#ebs_DebtInstrumentCovenantConsiderationThreshold"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_a6decebb-6fb3-42ac-8804-2b661ea687ae" xlink:to="loc_ebs_DebtInstrumentCovenantConsiderationThreshold_b1b8cf05-00ad-4f94-bc95-cf8a4e51121a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Revenuerecognition" xlink:type="simple" xlink:href="ebs-20220630.xsd#Revenuerecognition"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Revenuerecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c7c6c5d3-70a7-4915-b362-c0ff3065cb8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_cb31e768-5774-4d16-a2b6-3a9e6c9978d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c7c6c5d3-70a7-4915-b362-c0ff3065cb8a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_cb31e768-5774-4d16-a2b6-3a9e6c9978d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionTables" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05129dab-4c41-465e-a21c-e25f1845549a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_407c3a20-b374-4387-809c-e1e52667cf79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05129dab-4c41-465e-a21c-e25f1845549a" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_407c3a20-b374-4387-809c-e1e52667cf79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9d0958a5-3fae-43c8-b112-96253022c75a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05129dab-4c41-465e-a21c-e25f1845549a" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9d0958a5-3fae-43c8-b112-96253022c75a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_2949789c-77b5-43d0-9944-de4a8cb6ebcb" xlink:href="ebs-20220630.xsd#ebs_ScheduleOfAccountsReceivableNetTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_05129dab-4c41-465e-a21c-e25f1845549a" xlink:to="loc_ebs_ScheduleOfAccountsReceivableNetTableTextBlock_2949789c-77b5-43d0-9944-de4a8cb6ebcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b91767a7-5eb3-49dd-a965-b69720777a05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_b91767a7-5eb3-49dd-a965-b69720777a05" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermAxis_2635b14d-1d99-4135-8099-a7dc9ed96b45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:to="loc_us-gaap_LeaseContractualTermAxis_2635b14d-1d99-4135-8099-a7dc9ed96b45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseContractualTermDomain_9ad39923-c409-41bb-ad54-f70debfdda00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseContractualTermDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermAxis_2635b14d-1d99-4135-8099-a7dc9ed96b45" xlink:to="loc_us-gaap_LeaseContractualTermDomain_9ad39923-c409-41bb-ad54-f70debfdda00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ReservationOfManufacturingCapacityMember_926954d3-d7b4-4d5d-8587-a0f0b16cae1a" xlink:href="ebs-20220630.xsd#ebs_ReservationOfManufacturingCapacityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_9ad39923-c409-41bb-ad54-f70debfdda00" xlink:to="loc_ebs_ReservationOfManufacturingCapacityMember_926954d3-d7b4-4d5d-8587-a0f0b16cae1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_928be1f6-55b6-40a9-a378-06868c6854ba" xlink:href="ebs-20220630.xsd#ebs_AcceleratedExpansionOfFillFinishCapacityMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseContractualTermDomain_9ad39923-c409-41bb-ad54-f70debfdda00" xlink:to="loc_ebs_AcceleratedExpansionOfFillFinishCapacityMember_928be1f6-55b6-40a9-a378-06868c6854ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_d8b591b9-883a-4032-be30-fe7f00d9755a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:to="loc_srt_StatementGeographicalAxis_d8b591b9-883a-4032-be30-fe7f00d9755a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_247b3f73-f415-44c0-b89e-bb53a10e276e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_d8b591b9-883a-4032-be30-fe7f00d9755a" xlink:to="loc_srt_SegmentGeographicalDomain_247b3f73-f415-44c0-b89e-bb53a10e276e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_9235cccf-f479-4d83-a285-d7c9a9392e77" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_247b3f73-f415-44c0-b89e-bb53a10e276e" xlink:to="loc_country_US_9235cccf-f479-4d83-a285-d7c9a9392e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_50bc5e1b-b4f0-41af-85dc-9a3bc2f9233a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_247b3f73-f415-44c0-b89e-bb53a10e276e" xlink:to="loc_us-gaap_NonUsMember_50bc5e1b-b4f0-41af-85dc-9a3bc2f9233a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2baeefb2-8af5-4973-af26-f329efebac18" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:to="loc_srt_MajorCustomersAxis_2baeefb2-8af5-4973-af26-f329efebac18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_11697426-5f1b-4930-a807-bcc988985323" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2baeefb2-8af5-4973-af26-f329efebac18" xlink:to="loc_srt_NameOfMajorCustomerDomain_11697426-5f1b-4930-a807-bcc988985323" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_JansenPharmaceuticalsIncMember_1e6e8190-4c6a-4db0-81e3-6388cdfbaaea" xlink:href="ebs-20220630.xsd#ebs_JansenPharmaceuticalsIncMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_11697426-5f1b-4930-a807-bcc988985323" xlink:to="loc_ebs_JansenPharmaceuticalsIncMember_1e6e8190-4c6a-4db0-81e3-6388cdfbaaea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_BARDAMember_1ea046e9-e3ce-479c-b715-10533b1a1ef5" xlink:href="ebs-20220630.xsd#ebs_BARDAMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_11697426-5f1b-4930-a807-bcc988985323" xlink:to="loc_ebs_BARDAMember_1ea046e9-e3ce-479c-b715-10533b1a1ef5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_34882166-5d36-4c4a-a384-2c096d7f2408" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:to="loc_srt_ProductOrServiceAxis_34882166-5d36-4c4a-a384-2c096d7f2408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_8a6f8b87-e0ce-4b02-b1d7-1fafcf67db84" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_34882166-5d36-4c4a-a384-2c096d7f2408" xlink:to="loc_srt_ProductsAndServicesDomain_8a6f8b87-e0ce-4b02-b1d7-1fafcf67db84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_b970750a-60eb-4ae0-b548-35e584c54e10" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a6f8b87-e0ce-4b02-b1d7-1fafcf67db84" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_b970750a-60eb-4ae0-b548-35e584c54e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e0154f52-9ec2-4dac-8059-ec806c06cedf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_8a6f8b87-e0ce-4b02-b1d7-1fafcf67db84" xlink:to="loc_us-gaap_ServiceMember_e0154f52-9ec2-4dac-8059-ec806c06cedf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_fb61a48e-0e58-4248-915c-9a148c0be299" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9cfbbafc-09f1-489c-b5e1-be77678c84d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9cfbbafc-09f1-489c-b5e1-be77678c84d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_25f0a8e7-0635-4815-8ac9-7c6929a77109" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_Revenues_25f0a8e7-0635-4815-8ac9-7c6929a77109" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e9501ba5-feb5-4869-87dc-1ed429040844" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e9501ba5-feb5-4869-87dc-1ed429040844" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5dfa4e45-5004-4e49-973d-c3f6963bcb84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsNetOfReserves"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_InventoryRawMaterialsNetOfReserves_5dfa4e45-5004-4e49-973d-c3f6963bcb84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_31ebaac3-3060-439d-bb86-46105d2d8725" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableTradeCurrentAndNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_AccountsPayableTradeCurrentAndNoncurrent_31ebaac3-3060-439d-bb86-46105d2d8725" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e33d45d8-4497-4708-8ee3-bc9274b383c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LessorOperatingLeasePaymentsToBeReceived"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_LessorOperatingLeasePaymentsToBeReceived_e33d45d8-4497-4708-8ee3-bc9274b383c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_0c52ec40-cddc-48e1-93ec-a955b6b87f10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_0c52ec40-cddc-48e1-93ec-a955b6b87f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_76c83232-5dee-4e66-9d21-1409b147f6e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRemainingLeaseTerm"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm_76c83232-5dee-4e66-9d21-1409b147f6e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_aea368b8-98df-4a11-a138-0d4efbb14516" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_aea368b8-98df-4a11-a138-0d4efbb14516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f0c387da-7569-4678-ad91-5aa02207c68b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f0c387da-7569-4678-ad91-5aa02207c68b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_09bfd7e9-138d-4ce1-acbd-3f0c1e9a324c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_09bfd7e9-138d-4ce1-acbd-3f0c1e9a324c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f03674a3-6911-4204-aa27-381209eb4f24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_f03674a3-6911-4204-aa27-381209eb4f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_fc9dd646-9512-4053-89cd-5591dd62cb7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivable"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_320f357e-a3c4-4522-8213-7b54eb137322" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivable_fc9dd646-9512-4053-89cd-5591dd62cb7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionDisaggregationofRevenueDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c23689b-4ad2-44ae-9d5a-97349c88503f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_925978c9-acaa-4f21-a6a3-dfac64ac3d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_0c23689b-4ad2-44ae-9d5a-97349c88503f" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_925978c9-acaa-4f21-a6a3-dfac64ac3d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_17096c86-4181-46b5-b8bd-2955612c3add" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_925978c9-acaa-4f21-a6a3-dfac64ac3d0b" xlink:to="loc_srt_ProductOrServiceAxis_17096c86-4181-46b5-b8bd-2955612c3add" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6da4f575-70d9-4d49-9504-c166bd71aff3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_17096c86-4181-46b5-b8bd-2955612c3add" xlink:to="loc_srt_ProductsAndServicesDomain_6da4f575-70d9-4d49-9504-c166bd71aff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_ac8ce615-9293-4d75-a79a-7a3be1530041" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6da4f575-70d9-4d49-9504-c166bd71aff3" xlink:to="loc_us-gaap_ProductMember_ac8ce615-9293-4d75-a79a-7a3be1530041" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingMember_cf3bb2ab-6e99-4a45-9ccf-dcc077bb1b1f" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6da4f575-70d9-4d49-9504-c166bd71aff3" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingMember_cf3bb2ab-6e99-4a45-9ccf-dcc077bb1b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_1194dc08-7a1b-48a0-83dc-ea8ec55071eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_cf3bb2ab-6e99-4a45-9ccf-dcc077bb1b1f" xlink:to="loc_us-gaap_ServiceMember_1194dc08-7a1b-48a0-83dc-ea8ec55071eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_e6d80e87-d927-4f09-b3d4-5a496696f4db" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ContractDevelopmentAndManufacturingMember_cf3bb2ab-6e99-4a45-9ccf-dcc077bb1b1f" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_e6d80e87-d927-4f09-b3d4-5a496696f4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_4eac11a3-dadc-4173-84e6-215f36ac8d5f" xlink:href="ebs-20220630.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6da4f575-70d9-4d49-9504-c166bd71aff3" xlink:to="loc_ebs_ContractsAndGrantsMember_4eac11a3-dadc-4173-84e6-215f36ac8d5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_ef04f58b-40d2-4019-9b7d-c22c0824cd69" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_925978c9-acaa-4f21-a6a3-dfac64ac3d0b" xlink:to="loc_srt_StatementGeographicalAxis_ef04f58b-40d2-4019-9b7d-c22c0824cd69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c94a2dfd-76ca-423d-be67-d0de6fb9293c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_ef04f58b-40d2-4019-9b7d-c22c0824cd69" xlink:to="loc_srt_SegmentGeographicalDomain_c94a2dfd-76ca-423d-be67-d0de6fb9293c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_08da6db3-23ea-4909-94e1-f361dd427e94" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c94a2dfd-76ca-423d-be67-d0de6fb9293c" xlink:to="loc_country_US_08da6db3-23ea-4909-94e1-f361dd427e94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_deb5affc-dece-4d87-89eb-9fdfead02ad5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c94a2dfd-76ca-423d-be67-d0de6fb9293c" xlink:to="loc_us-gaap_NonUsMember_deb5affc-dece-4d87-89eb-9fdfead02ad5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_925978c9-acaa-4f21-a6a3-dfac64ac3d0b" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ff3a38ec-d1eb-4f72-9466-e9c7800145a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_ff3a38ec-d1eb-4f72-9466-e9c7800145a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_651a8745-76cd-4237-a90b-666bfec5151a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_651a8745-76cd-4237-a90b-666bfec5151a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_e8d02b71-d348-4569-b423-ca15cd570914" xlink:href="ebs-20220630.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_e8d02b71-d348-4569-b423-ca15cd570914" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_d4d361af-bb69-405b-ad82-d479ff5a9562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_77838b66-66d0-44c1-8a80-1ad5259b0a30" xlink:to="loc_us-gaap_Revenues_d4d361af-bb69-405b-ad82-d479ff5a9562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19621620-1175-42b2-9f7b-1d1103c6e891" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_19621620-1175-42b2-9f7b-1d1103c6e891" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_0b50be08-ae10-4541-b366-84f2d03d7102" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_0b50be08-ae10-4541-b366-84f2d03d7102" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_2215dad8-a3fa-4775-8b95-26d849bae2cc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:to="loc_srt_ProductOrServiceAxis_2215dad8-a3fa-4775-8b95-26d849bae2cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_45219bde-90b7-4acf-9919-192c04987e64" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2215dad8-a3fa-4775-8b95-26d849bae2cc" xlink:to="loc_srt_ProductsAndServicesDomain_45219bde-90b7-4acf-9919-192c04987e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_b62ff56e-5ba7-4140-9104-3fc2e6011578" xlink:href="ebs-20220630.xsd#ebs_ContractDevelopmentAndManufacturingLeasesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_45219bde-90b7-4acf-9919-192c04987e64" xlink:to="loc_ebs_ContractDevelopmentAndManufacturingLeasesMember_b62ff56e-5ba7-4140-9104-3fc2e6011578" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_0513fab7-48e6-4244-a9fa-1e2b01ea9b59" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_02fb0663-fb5c-4320-a713-4d02c3d27930" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_02fb0663-fb5c-4320-a713-4d02c3d27930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_6e8b6063-f9dc-42db-afe8-658507841099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_70fb105f-9bb6-4e50-8e03-dfe01febcdd2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_6e8b6063-f9dc-42db-afe8-658507841099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionPerformanceObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionRemainingPerformanceObligationDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_49c0dd2b-16d5-43b2-b8e7-46793d67e948" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_731d6903-23b0-4c74-8dd0-3edebebb77b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_49c0dd2b-16d5-43b2-b8e7-46793d67e948" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_731d6903-23b0-4c74-8dd0-3edebebb77b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2767749e-4e8d-4354-a5cb-88bc211929fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_731d6903-23b0-4c74-8dd0-3edebebb77b1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_2767749e-4e8d-4354-a5cb-88bc211929fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5c25fa68-b131-4718-aa71-3358ee2c04cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_731d6903-23b0-4c74-8dd0-3edebebb77b1" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5c25fa68-b131-4718-aa71-3358ee2c04cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bcc583fd-5af8-4624-ba97-c271f620d182" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_5c25fa68-b131-4718-aa71-3358ee2c04cc" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_bcc583fd-5af8-4624-ba97-c271f620d182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails_1" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionRemainingPerformanceObligationDetails_1"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionContractLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7aa8cfd9-24f8-4e3a-8b64-f3ff7e9b6693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_be6fa495-d495-4b47-8522-1af5f12967fe" xlink:href="ebs-20220630.xsd#ebs_ChangeinContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_7aa8cfd9-24f8-4e3a-8b64-f3ff7e9b6693" xlink:to="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_be6fa495-d495-4b47-8522-1af5f12967fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_b0e2f52b-0549-42ff-a181-d1131175e858" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_be6fa495-d495-4b47-8522-1af5f12967fe" xlink:to="loc_us-gaap_ContractWithCustomerLiability_b0e2f52b-0549-42ff-a181-d1131175e858" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityAdditions_e1ce42c6-47f2-41b1-8c7f-61311dc5dd0f" xlink:href="ebs-20220630.xsd#ebs_ContractWithCustomerLiabilityAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_be6fa495-d495-4b47-8522-1af5f12967fe" xlink:to="loc_ebs_ContractWithCustomerLiabilityAdditions_e1ce42c6-47f2-41b1-8c7f-61311dc5dd0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractWithCustomerLiabilityDeductions_dddc7c8a-aa8e-4194-a3d5-86c8c5b6f94b" xlink:href="ebs-20220630.xsd#ebs_ContractWithCustomerLiabilityDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_be6fa495-d495-4b47-8522-1af5f12967fe" xlink:to="loc_ebs_ContractWithCustomerLiabilityDeductions_dddc7c8a-aa8e-4194-a3d5-86c8c5b6f94b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_2d043001-7645-48a7-8d9d-5392926365dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_ChangeinContractWithCustomerLiabilityRollForward_be6fa495-d495-4b47-8522-1af5f12967fe" xlink:to="loc_us-gaap_ContractWithCustomerLiability_2d043001-7645-48a7-8d9d-5392926365dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#RevenuerecognitionAccountsReceivableDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97bba710-62a6-4fb7-aaa1-c1d312f4cf70" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BilledContractReceivables_f6ef0cd8-fec8-4c48-b00e-56c5887962c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BilledContractReceivables"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97bba710-62a6-4fb7-aaa1-c1d312f4cf70" xlink:to="loc_us-gaap_BilledContractReceivables_f6ef0cd8-fec8-4c48-b00e-56c5887962c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnbilledContractsReceivable_ed2f69de-0997-47ff-979b-2ebd73a333bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnbilledContractsReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97bba710-62a6-4fb7-aaa1-c1d312f4cf70" xlink:to="loc_us-gaap_UnbilledContractsReceivable_ed2f69de-0997-47ff-979b-2ebd73a333bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_31d4c200-1596-4b4f-a7f8-16b96915a197" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_97bba710-62a6-4fb7-aaa1-c1d312f4cf70" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_31d4c200-1596-4b4f-a7f8-16b96915a197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Incometaxes" xlink:type="simple" xlink:href="ebs-20220630.xsd#Incometaxes"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Incometaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_fb6fe0f7-5ab9-45c2-ad4a-ddd7fc34083d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_869b8943-8122-4043-bd22-dfca110c3ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_fb6fe0f7-5ab9-45c2-ad4a-ddd7fc34083d" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_869b8943-8122-4043-bd22-dfca110c3ffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#IncometaxesDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/IncometaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_edbd8c72-845a-49ba-9e78-9a2bfcf83df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesTable_0ca6bd2b-cbf0-4bbe-9baa-a3e06ccc6aa6" xlink:href="ebs-20220630.xsd#ebs_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_edbd8c72-845a-49ba-9e78-9a2bfcf83df1" xlink:to="loc_ebs_IncomeTaxesTable_0ca6bd2b-cbf0-4bbe-9baa-a3e06ccc6aa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementScenarioAxis_2cfc816d-ab32-4d95-ab87-32a1d384f6c3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesTable_0ca6bd2b-cbf0-4bbe-9baa-a3e06ccc6aa6" xlink:to="loc_srt_StatementScenarioAxis_2cfc816d-ab32-4d95-ab87-32a1d384f6c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioUnspecifiedDomain_9a72db01-0bb0-46a3-98b3-d2de55f950a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_2cfc816d-ab32-4d95-ab87-32a1d384f6c3" xlink:to="loc_srt_ScenarioUnspecifiedDomain_9a72db01-0bb0-46a3-98b3-d2de55f950a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScenarioForecastMember_d9bd79b3-7b1b-4d5c-9ff6-097e878dead7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioForecastMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_9a72db01-0bb0-46a3-98b3-d2de55f950a6" xlink:to="loc_srt_ScenarioForecastMember_d9bd79b3-7b1b-4d5c-9ff6-097e878dead7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_IncomeTaxesLineItems_3a0365c8-5ae7-4123-ba28-815780cb59a7" xlink:href="ebs-20220630.xsd#ebs_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesTable_0ca6bd2b-cbf0-4bbe-9baa-a3e06ccc6aa6" xlink:to="loc_ebs_IncomeTaxesLineItems_3a0365c8-5ae7-4123-ba28-815780cb59a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_698af3ae-6173-4829-a7db-c0a915438794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesLineItems_3a0365c8-5ae7-4123-ba28-815780cb59a7" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_698af3ae-6173-4829-a7db-c0a915438794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b1b806e8-556a-4562-af3a-3669ca49bf6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ebs_IncomeTaxesLineItems_3a0365c8-5ae7-4123-ba28-815780cb59a7" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_b1b806e8-556a-4562-af3a-3669ca49bf6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershare" xlink:type="simple" xlink:href="ebs-20220630.xsd#NetIncomelosspershare"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NetIncomelosspershare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_e27b8887-dc07-4371-a86a-c5ead955f2d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_04ff431d-13a2-4277-ac0f-9041b1578749" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_e27b8887-dc07-4371-a86a-c5ead955f2d1" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_04ff431d-13a2-4277-ac0f-9041b1578749" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershareTables" xlink:type="simple" xlink:href="ebs-20220630.xsd#NetIncomelosspershareTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NetIncomelosspershareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c269bcae-6737-4f14-be05-de51899a9e31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a4205063-c3eb-4234-adb3-e8aab2a64c15" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c269bcae-6737-4f14-be05-de51899a9e31" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a4205063-c3eb-4234-adb3-e8aab2a64c15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_055df7d1-e9ed-4371-87f2-df4fc3077448" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c269bcae-6737-4f14-be05-de51899a9e31" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_055df7d1-e9ed-4371-87f2-df4fc3077448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/NetIncomelosspershareDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#NetIncomelosspershareDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/NetIncomelosspershareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_1af743bf-2d29-45d0-9336-8d46e01d539d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5320a62f-2161-494a-9acb-ae4e786c315e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1af743bf-2d29-45d0-9336-8d46e01d539d" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5320a62f-2161-494a-9acb-ae4e786c315e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_449e78f5-5236-4d8a-97ca-a571b486311b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract_5320a62f-2161-494a-9acb-ae4e786c315e" xlink:to="loc_us-gaap_NetIncomeLoss_449e78f5-5236-4d8a-97ca-a571b486311b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b94d626a-dd4b-4035-95fb-a6238834cf28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1af743bf-2d29-45d0-9336-8d46e01d539d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b94d626a-dd4b-4035-95fb-a6238834cf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ec4c8438-b33c-4198-9090-16a7fc80e15d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b94d626a-dd4b-4035-95fb-a6238834cf28" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_ec4c8438-b33c-4198-9090-16a7fc80e15d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a63c629f-5b25-420b-92ab-bbf7da2109e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b94d626a-dd4b-4035-95fb-a6238834cf28" xlink:to="loc_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_a63c629f-5b25-420b-92ab-bbf7da2109e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d1be4503-e603-4a82-a47a-f0d5065d7c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_b94d626a-dd4b-4035-95fb-a6238834cf28" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_d1be4503-e603-4a82-a47a-f0d5065d7c6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_3dbdc7f7-70f5-4f82-92a9-49207bc53ad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1af743bf-2d29-45d0-9336-8d46e01d539d" xlink:to="loc_us-gaap_EarningsPerShareBasic_3dbdc7f7-70f5-4f82-92a9-49207bc53ad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_9223d28f-21af-4e48-9800-674f6a5ff4ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1af743bf-2d29-45d0-9336-8d46e01d539d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_9223d28f-21af-4e48-9800-674f6a5ff4ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eed60c50-648c-438d-bef9-70f6b27b4fed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_1af743bf-2d29-45d0-9336-8d46e01d539d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_eed60c50-648c-438d-bef9-70f6b27b4fed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Equity" xlink:type="simple" xlink:href="ebs-20220630.xsd#Equity"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_4565bb79-51d2-4546-bbc6-1a8965324cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_49ba90dd-7941-4f33-8628-cbccdcb8f122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_4565bb79-51d2-4546-bbc6-1a8965324cf8" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_49ba90dd-7941-4f33-8628-cbccdcb8f122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityTables" xlink:type="simple" xlink:href="ebs-20220630.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_778007e5-7d60-45c8-9ea4-03a9835a050e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5a188a0d-5e07-4c27-9f5f-42d0fc22392c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_778007e5-7d60-45c8-9ea4-03a9835a050e" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_5a188a0d-5e07-4c27-9f5f-42d0fc22392c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_bf376b06-26ab-4b11-b735-4dd13a23f7ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_778007e5-7d60-45c8-9ea4-03a9835a050e" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_bf376b06-26ab-4b11-b735-4dd13a23f7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_dbb56c79-30c4-4759-ac4f-43073f746760" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_778007e5-7d60-45c8-9ea4-03a9835a050e" xlink:to="loc_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock_dbb56c79-30c4-4759-ac4f-43073f746760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#EquityNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_93f12c27-6d9d-4e86-bc97-232d6107dedd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aacb0633-65ae-4da1-af5a-7b4ab3d621bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_93f12c27-6d9d-4e86-bc97-232d6107dedd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aacb0633-65ae-4da1-af5a-7b4ab3d621bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_694021f1-9674-4b4d-a3d4-4b6e0d861c81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aacb0633-65ae-4da1-af5a-7b4ab3d621bf" xlink:to="loc_us-gaap_VestingAxis_694021f1-9674-4b4d-a3d4-4b6e0d861c81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_fe1ebd16-46bc-478a-bdf0-2964815d0fd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_694021f1-9674-4b4d-a3d4-4b6e0d861c81" xlink:to="loc_us-gaap_VestingDomain_fe1ebd16-46bc-478a-bdf0-2964815d0fd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7ab989b6-034d-4cb3-a0d9-ccdad3b4635c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_fe1ebd16-46bc-478a-bdf0-2964815d0fd0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_7ab989b6-034d-4cb3-a0d9-ccdad3b4635c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fb539214-ba11-476d-9dd9-9d72a7784566" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_fe1ebd16-46bc-478a-bdf0-2964815d0fd0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_fb539214-ba11-476d-9dd9-9d72a7784566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_030de3ff-d371-48e0-9eda-2ea5e14e802b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_fe1ebd16-46bc-478a-bdf0-2964815d0fd0" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_030de3ff-d371-48e0-9eda-2ea5e14e802b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5ec23b6b-2fbc-4df9-a0d7-2a806f7e8b6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aacb0633-65ae-4da1-af5a-7b4ab3d621bf" xlink:to="loc_us-gaap_AwardTypeAxis_5ec23b6b-2fbc-4df9-a0d7-2a806f7e8b6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ed5aa99-96f6-4e48-ad7f-b2e747e5d438" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5ec23b6b-2fbc-4df9-a0d7-2a806f7e8b6f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ed5aa99-96f6-4e48-ad7f-b2e747e5d438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_2b1a971d-fe52-4265-b192-e05b50081899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ed5aa99-96f6-4e48-ad7f-b2e747e5d438" xlink:to="loc_us-gaap_EmployeeStockOptionMember_2b1a971d-fe52-4265-b192-e05b50081899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_bc7cb069-6d8a-4702-b7b5-3cf39608600b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1ed5aa99-96f6-4e48-ad7f-b2e747e5d438" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_bc7cb069-6d8a-4702-b7b5-3cf39608600b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_ac6df408-a326-424f-b1f2-e235d5019d8e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aacb0633-65ae-4da1-af5a-7b4ab3d621bf" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_ac6df408-a326-424f-b1f2-e235d5019d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a6f9b995-b129-47ab-a839-6f3be87e56e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_ac6df408-a326-424f-b1f2-e235d5019d8e" xlink:to="loc_us-gaap_EquityComponentDomain_a6f9b995-b129-47ab-a839-6f3be87e56e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5523b792-c1dc-4ccd-aab9-7994d70910ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6f9b995-b129-47ab-a839-6f3be87e56e6" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_5523b792-c1dc-4ccd-aab9-7994d70910ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_2a98f0c5-bdfd-4c12-aa0e-8a91772cf7b4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_a6f9b995-b129-47ab-a839-6f3be87e56e6" xlink:to="loc_us-gaap_TreasuryStockCommonMember_2a98f0c5-bdfd-4c12-aa0e-8a91772cf7b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_aacb0633-65ae-4da1-af5a-7b4ab3d621bf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c038514d-68cb-408b-a725-d511f3d31953" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_c038514d-68cb-408b-a725-d511f3d31953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_19dce3b4-bd6c-48ab-80c2-a51927a9c790" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_19dce3b4-bd6c-48ab-80c2-a51927a9c790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodShares_63691db3-d0d1-4097-a3ee-87e6ffe792c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodShares"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodShares_63691db3-d0d1-4097-a3ee-87e6ffe792c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c955c7a5-d019-41cc-ae8a-ff3cea43fea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_c955c7a5-d019-41cc-ae8a-ff3cea43fea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_87de65d2-7b4c-41e1-9493-ac42f5cdaa5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_87de65d2-7b4c-41e1-9493-ac42f5cdaa5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_48be99c3-33d6-4998-9006-6fa20fdba714" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_48be99c3-33d6-4998-9006-6fa20fdba714" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f6ca002a-afa7-482c-938a-ceab318e62dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_a9cbc1bd-3110-47f1-9ce0-af6ec0f46a29" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_f6ca002a-afa7-482c-938a-ceab318e62dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#EquityScheduleofStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_94de1715-f5ae-489b-81c3-284567142cbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce26019e-4343-4169-bc38-6335306fde2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_94de1715-f5ae-489b-81c3-284567142cbe" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce26019e-4343-4169-bc38-6335306fde2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_7dddc9dd-9196-4f2b-b92f-7d1e2213e222" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce26019e-4343-4169-bc38-6335306fde2e" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_7dddc9dd-9196-4f2b-b92f-7d1e2213e222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d2a78ad7-a0c3-4927-a63e-810103b6a9f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_7dddc9dd-9196-4f2b-b92f-7d1e2213e222" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d2a78ad7-a0c3-4927-a63e-810103b6a9f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_850374dc-f1a1-469b-accf-9afd180f675f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2a78ad7-a0c3-4927-a63e-810103b6a9f2" xlink:to="loc_us-gaap_CostOfSalesMember_850374dc-f1a1-469b-accf-9afd180f675f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d815051a-e9cb-472f-b3c7-b9e838c04b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2a78ad7-a0c3-4927-a63e-810103b6a9f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_d815051a-e9cb-472f-b3c7-b9e838c04b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5cbb2bcc-31fb-4b9b-8f47-dbcfbd990991" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d2a78ad7-a0c3-4927-a63e-810103b6a9f2" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5cbb2bcc-31fb-4b9b-8f47-dbcfbd990991" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_a4345273-1e4b-4fb6-9766-3a65bcff143e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce26019e-4343-4169-bc38-6335306fde2e" xlink:to="loc_srt_ProductOrServiceAxis_a4345273-1e4b-4fb6-9766-3a65bcff143e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_711c411a-c674-4165-9441-03daf20f6e2d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_a4345273-1e4b-4fb6-9766-3a65bcff143e" xlink:to="loc_srt_ProductsAndServicesDomain_711c411a-c674-4165-9441-03daf20f6e2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_cb661227-b00c-4c84-ac06-c03ff88ae76c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_711c411a-c674-4165-9441-03daf20f6e2d" xlink:to="loc_us-gaap_ProductMember_cb661227-b00c-4c84-ac06-c03ff88ae76c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_a6db449f-f01a-4ff1-98d1-0b0eaf9da02f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_711c411a-c674-4165-9441-03daf20f6e2d" xlink:to="loc_us-gaap_ServiceMember_a6db449f-f01a-4ff1-98d1-0b0eaf9da02f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772414-50e1-4b35-8328-052a37a760ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_ce26019e-4343-4169-bc38-6335306fde2e" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772414-50e1-4b35-8328-052a37a760ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_4bc4a5e0-3899-4286-93bb-f97e3d7409df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_78772414-50e1-4b35-8328-052a37a760ad" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_4bc4a5e0-3899-4286-93bb-f97e3d7409df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#EquityChangesinAccumulatedOtherComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_33b8f50f-1929-4a42-b986-666ca4887706" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_92e962a3-7528-4b18-a2f4-c9ffca94e129" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_33b8f50f-1929-4a42-b986-666ca4887706" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_92e962a3-7528-4b18-a2f4-c9ffca94e129" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_7fee5d7a-b5e3-4d6f-b37b-def31c19324b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_92e962a3-7528-4b18-a2f4-c9ffca94e129" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_7fee5d7a-b5e3-4d6f-b37b-def31c19324b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_ef05615a-a7e8-4dad-8a3b-2c8c28e44fbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_7fee5d7a-b5e3-4d6f-b37b-def31c19324b" xlink:to="loc_us-gaap_EquityComponentDomain_ef05615a-a7e8-4dad-8a3b-2c8c28e44fbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d42c24aa-1509-437e-a40c-e8da5767da6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_ef05615a-a7e8-4dad-8a3b-2c8c28e44fbb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d42c24aa-1509-437e-a40c-e8da5767da6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_c688912b-8352-4bd0-80ea-c6c23303adf5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d42c24aa-1509-437e-a40c-e8da5767da6d" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_c688912b-8352-4bd0-80ea-c6c23303adf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_167a4db4-f252-490e-9a1e-67f568bee75f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d42c24aa-1509-437e-a40c-e8da5767da6d" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_167a4db4-f252-490e-9a1e-67f568bee75f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_37a95b77-c15c-40d0-a3a8-482bcf49aa41" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_d42c24aa-1509-437e-a40c-e8da5767da6d" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_37a95b77-c15c-40d0-a3a8-482bcf49aa41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6f231bb0-c678-49ce-aed2-8d57b83b137d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_92e962a3-7528-4b18-a2f4-c9ffca94e129" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6f231bb0-c678-49ce-aed2-8d57b83b137d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_6f231bb0-c678-49ce-aed2-8d57b83b137d" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_18985d5f-85ef-40d4-8c8c-e8774e339269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:to="loc_us-gaap_StockholdersEquity_18985d5f-85ef-40d4-8c8c-e8774e339269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f227440f-2617-4814-a24b-58f16009549f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:to="loc_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent_f227440f-2617-4814-a24b-58f16009549f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_a2731732-5197-4928-aea0-81b42249c23f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:to="loc_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent_a2731732-5197-4928-aea0-81b42249c23f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b72bc40-b891-4a05-bf5a-0e58917b543a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_6b72bc40-b891-4a05-bf5a-0e58917b543a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_19a5f108-1e6c-46ee-8f48-1d520f124648" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1602295b-6571-4137-850c-dfb13e91bcf0" xlink:to="loc_us-gaap_StockholdersEquity_19a5f108-1e6c-46ee-8f48-1d520f124648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_077fd169-0733-412c-a1a6-eee784adbbce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192ac08f-7516-4f58-a466-88f1903d63df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_077fd169-0733-412c-a1a6-eee784adbbce" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192ac08f-7516-4f58-a466-88f1903d63df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_0a043bfb-e702-4bbf-bb0d-e88dcaf9ce6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192ac08f-7516-4f58-a466-88f1903d63df" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_0a043bfb-e702-4bbf-bb0d-e88dcaf9ce6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_f247f185-37af-486e-8d0c-5b7cac29c0b3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_0a043bfb-e702-4bbf-bb0d-e88dcaf9ce6d" xlink:to="loc_us-gaap_EquityComponentDomain_f247f185-37af-486e-8d0c-5b7cac29c0b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_16105f90-748a-48e3-9650-a449945e8ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f247f185-37af-486e-8d0c-5b7cac29c0b3" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_16105f90-748a-48e3-9650-a449945e8ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7ecfbb5a-f43d-44c5-8094-33c8aefccc96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_f247f185-37af-486e-8d0c-5b7cac29c0b3" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_7ecfbb5a-f43d-44c5-8094-33c8aefccc96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9e99be6b-aa63-4617-9ed9-f0d997bade6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_192ac08f-7516-4f58-a466-88f1903d63df" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9e99be6b-aa63-4617-9ed9-f0d997bade6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_74152f80-cc22-4438-a478-f47ab59ead5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9e99be6b-aa63-4617-9ed9-f0d997bade6a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent_74152f80-cc22-4438-a478-f47ab59ead5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_96bc2fd5-97bd-437d-915b-64147c64cef1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9e99be6b-aa63-4617-9ed9-f0d997bade6a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1_96bc2fd5-97bd-437d-915b-64147c64cef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_830c7838-a69e-47d7-9966-9e875fd688fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_9e99be6b-aa63-4617-9ed9-f0d997bade6a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_830c7838-a69e-47d7-9966-9e875fd688fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformation" xlink:type="simple" xlink:href="ebs-20220630.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_977cf38f-2e20-403c-9410-3d8d1d65700e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_63f08918-dc17-4ad3-a13d-2b5ffacd6999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_977cf38f-2e20-403c-9410-3d8d1d65700e" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_63f08918-dc17-4ad3-a13d-2b5ffacd6999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="ebs-20220630.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_843cff96-6a1c-4f59-93ef-9d6223eef3ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_c85bcf24-b614-4502-bd4f-e7204a362fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_843cff96-6a1c-4f59-93ef-9d6223eef3ac" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_c85bcf24-b614-4502-bd4f-e7204a362fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7b1b918f-971f-4046-95a4-f2ef0a05aa20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_843cff96-6a1c-4f59-93ef-9d6223eef3ac" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_7b1b918f-971f-4046-95a4-f2ef0a05aa20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f5e0fc03-17ee-44e8-a5e3-4b8586df9743" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_4b2215cb-c12e-41c6-86e5-12f59a960c69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f5e0fc03-17ee-44e8-a5e3-4b8586df9743" xlink:to="loc_us-gaap_NumberOfReportableSegments_4b2215cb-c12e-41c6-86e5-12f59a960c69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_59617c52-e0c1-40c4-b21c-fb483694d387" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4fe0679c-fc7f-4a6a-a15e-a9d44ed410d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_59617c52-e0c1-40c4-b21c-fb483694d387" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4fe0679c-fc7f-4a6a-a15e-a9d44ed410d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_80581c87-8c97-4482-adc3-3839f6838b16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4fe0679c-fc7f-4a6a-a15e-a9d44ed410d7" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_80581c87-8c97-4482-adc3-3839f6838b16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_31ed03e9-a15b-41aa-8504-94981363f061" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_80581c87-8c97-4482-adc3-3839f6838b16" xlink:to="loc_us-gaap_SegmentDomain_31ed03e9-a15b-41aa-8504-94981363f061" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_3dddf2e2-1b08-4799-9deb-aaa5148610a9" xlink:href="ebs-20220630.xsd#ebs_ProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_31ed03e9-a15b-41aa-8504-94981363f061" xlink:to="loc_ebs_ProductsSegmentMember_3dddf2e2-1b08-4799-9deb-aaa5148610a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_ecfc6c73-a993-474b-97c0-9b72d2d53883" xlink:href="ebs-20220630.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_31ed03e9-a15b-41aa-8504-94981363f061" xlink:to="loc_ebs_ServicesSegmentMember_ecfc6c73-a993-474b-97c0-9b72d2d53883" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_ad153058-5977-4593-b3bb-d0606f8ff075" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4fe0679c-fc7f-4a6a-a15e-a9d44ed410d7" xlink:to="loc_srt_ProductOrServiceAxis_ad153058-5977-4593-b3bb-d0606f8ff075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6ee9a06a-2b10-4978-93d6-3743df0320af" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_ad153058-5977-4593-b3bb-d0606f8ff075" xlink:to="loc_srt_ProductsAndServicesDomain_6ee9a06a-2b10-4978-93d6-3743df0320af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ContractsAndGrantsMember_3b0ed43d-2aef-4692-beb7-93c08f2021fe" xlink:href="ebs-20220630.xsd#ebs_ContractsAndGrantsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6ee9a06a-2b10-4978-93d6-3743df0320af" xlink:to="loc_ebs_ContractsAndGrantsMember_3b0ed43d-2aef-4692-beb7-93c08f2021fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_d3d82c2e-267d-4ee2-8e74-43539710ace7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6ee9a06a-2b10-4978-93d6-3743df0320af" xlink:to="loc_us-gaap_ProductMember_d3d82c2e-267d-4ee2-8e74-43539710ace7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e33784c6-cb38-4e81-bc3e-48f74c3e8912" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6ee9a06a-2b10-4978-93d6-3743df0320af" xlink:to="loc_us-gaap_ServiceMember_e33784c6-cb38-4e81-bc3e-48f74c3e8912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e758b437-a9e6-4769-ba9b-bb7fde34bb48" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4fe0679c-fc7f-4a6a-a15e-a9d44ed410d7" xlink:to="loc_srt_ConsolidationItemsAxis_e758b437-a9e6-4769-ba9b-bb7fde34bb48" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_145c67d0-a368-44e0-98b1-05e6610fa369" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_e758b437-a9e6-4769-ba9b-bb7fde34bb48" xlink:to="loc_srt_ConsolidationItemsDomain_145c67d0-a368-44e0-98b1-05e6610fa369" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_fef9ed13-bde6-4254-bffb-740b16b59393" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_145c67d0-a368-44e0-98b1-05e6610fa369" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_fef9ed13-bde6-4254-bffb-740b16b59393" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable_4fe0679c-fc7f-4a6a-a15e-a9d44ed410d7" xlink:to="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21d9c626-3b1f-46c7-afc4-e78ea5e0ab2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_21d9c626-3b1f-46c7-afc4-e78ea5e0ab2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d767e6dc-f7ab-444d-9511-79da94b653b2" xlink:href="ebs-20220630.xsd#ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax_d767e6dc-f7ab-444d-9511-79da94b653b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_b247f9ab-3323-489c-894e-e7a2a78b1378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_Revenues_b247f9ab-3323-489c-894e-e7a2a78b1378" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8ae5737f-db33-44cc-b566-042c15172403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8ae5737f-db33-44cc-b566-042c15172403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_ae9daabb-0667-4212-ab95-7193dfd1ad6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_GrossProfit_ae9daabb-0667-4212-ab95-7193dfd1ad6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3a1ecf58-57c9-4830-8f00-1862a4d08ccc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3a1ecf58-57c9-4830-8f00-1862a4d08ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_AdjustedGrossMargin_b40c65ff-5013-4a43-8d4d-60d365d0284e" xlink:href="ebs-20220630.xsd#ebs_AdjustedGrossMargin"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_ebs_AdjustedGrossMargin_b40c65ff-5013-4a43-8d4d-60d365d0284e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_20935af8-38f0-46ae-90df-55f8e00225f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLeaseIncomeLeasePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems_55b92272-d290-4796-8d3f-03efa3af50de" xlink:to="loc_us-gaap_OperatingLeaseLeaseIncomeLeasePayments_20935af8-38f0-46ae-90df-55f8e00225f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="simple" xlink:href="ebs-20220630.xsd#SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_33b48392-3a3f-4b29-9fff-90899eb93161" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1410d0da-5570-411c-8bec-2416c9343100" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_33b48392-3a3f-4b29-9fff-90899eb93161" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1410d0da-5570-411c-8bec-2416c9343100" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_de3a3342-aebb-4304-b0a2-1390047947c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1410d0da-5570-411c-8bec-2416c9343100" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_de3a3342-aebb-4304-b0a2-1390047947c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_cf71612f-a2a4-4677-b848-db3e13c344d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_de3a3342-aebb-4304-b0a2-1390047947c4" xlink:to="loc_us-gaap_SegmentDomain_cf71612f-a2a4-4677-b848-db3e13c344d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ProductsSegmentMember_851a5fe0-29d6-45b8-888e-e4f7f889a971" xlink:href="ebs-20220630.xsd#ebs_ProductsSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cf71612f-a2a4-4677-b848-db3e13c344d8" xlink:to="loc_ebs_ProductsSegmentMember_851a5fe0-29d6-45b8-888e-e4f7f889a971" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ebs_ServicesSegmentMember_3b76792b-c68b-4b59-b18b-dacdefa6e689" xlink:href="ebs-20220630.xsd#ebs_ServicesSegmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_cf71612f-a2a4-4677-b848-db3e13c344d8" xlink:to="loc_ebs_ServicesSegmentMember_3b76792b-c68b-4b59-b18b-dacdefa6e689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_847b9941-4d63-4367-b50a-693f3c91ff81" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1410d0da-5570-411c-8bec-2416c9343100" xlink:to="loc_srt_ConsolidationItemsAxis_847b9941-4d63-4367-b50a-693f3c91ff81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_7f78feef-c070-4986-83d6-0cbc3d7e1f05" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_847b9941-4d63-4367-b50a-693f3c91ff81" xlink:to="loc_srt_ConsolidationItemsDomain_7f78feef-c070-4986-83d6-0cbc3d7e1f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_6bd41706-de0d-4e8e-b6a1-198b8a0845b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaterialReconcilingItemsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_7f78feef-c070-4986-83d6-0cbc3d7e1f05" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_6bd41706-de0d-4e8e-b6a1-198b8a0845b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_15099c8d-ae19-4755-98ce-da5fa1b83033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_1410d0da-5570-411c-8bec-2416c9343100" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_15099c8d-ae19-4755-98ce-da5fa1b83033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAbstract_2cb846af-dfb9-4d13-9adf-aa3f0041d71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_15099c8d-ae19-4755-98ce-da5fa1b83033" xlink:to="loc_us-gaap_DepreciationAbstract_2cb846af-dfb9-4d13-9adf-aa3f0041d71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_741c22b3-df2e-4d15-a7cc-5c865ed7b9f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DepreciationAbstract_2cb846af-dfb9-4d13-9adf-aa3f0041d71e" xlink:to="loc_us-gaap_Depreciation_741c22b3-df2e-4d15-a7cc-5c865ed7b9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://emergentbiosolutions.com/role/Commitmentsandcontingencies" xlink:type="simple" xlink:href="ebs-20220630.xsd#Commitmentsandcontingencies"/>
  <link:presentationLink xlink:role="http://emergentbiosolutions.com/role/Commitmentsandcontingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e42c5245-0aa0-473e-9359-b5b6f70364d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_02b549ce-ad4a-4422-8662-4fa5e68fd3dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_e42c5245-0aa0-473e-9359-b5b6f70364d0" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_02b549ce-ad4a-4422-8662-4fa5e68fd3dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>a200-2017x92634xmod28exe001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a200-2017x92634xmod28exe001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[FA\X16UM),Y3O(51257W-8_A?QQ;7?AW6]=U;4H/[.MM5N(+>X"X!A# 1@
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MS5KS0O NL:I82".[MK<O$Y4, <CL>#4>D>/- U>]MK""\?[3<(3 9+>2-+C
M^;RW90KX_P!DFJWQ25G^&/B!5!)-H< #W%<]JVN:9XLN/">DZ &>^M-3M[N>
M%8F4V,40.\29'R'^#!ZYH ZK4O'_ (<TJ_GL[F\E+VQ N7AMI98[?/3S'52J
M?B>.]7=7\5:-HEO:S7=WN^V?\>L=O&TTD_&<HJ EAC!R!CFO([*<>'H?$&F:
MSXMU#2+MKZYE-@EE#)]M61B5>,M&2^X$#KP>.*GGTV;PWJGA6]N-6U30]+31
M#9)>3012/;R;]^R7*LJ94@9X^[CUH ].C\;>'I-!N-;_ +0"6-M((KAGC=6A
M<L%VNA&Y3EAU'?/2F:5XZ\/ZSJJ:;9W<GVJ1#)"LMO)$)U'5HV90''T[<UY;
MJMO;WW@OQMJ=K?ZEJT=Y+8Q->W,$<<5R4E09C"*,@ [2<8.!@FO0/%<?_%?>
M!&5.$NKL9 ^Z/L[4 =7J.HV>DZ?/?ZA<1V]I NZ260X"BLG1_&FB:Y>&SM)Y
MTNO+\U8;FUD@>2/^\@=1N'TS6-\5["\O?!\;V@G*VM];W-P((Q))Y2/EBJD$
M,1PV""/EKGM,NM/UKQMH=Q#XMU+Q U@)K@RI;0QPVBE"I\UU12-V<;>N1R!0
M!W8\:^'VT2/5QJ&;22X^RKB)_,,V[;Y?EXW[L]L9[]*;K/C;0M"OC97EQ,]T
ML?FR16UM).T2?WG"*=H^M>9PLL7C,?$5M-V^%YKUH50ALQL0(_MVSH-Q&WIG
M!SUKI+#7M,\'^,_%9\0W L_[1GBNK2YD4E;B(1!=J$#DJ01MZ\\4 :[>+1+X
MTTV*UO8I=#N-&FORZ*&#%70!@<9Z$\5MR>)](B\/V^NO=XTVX$1BF\MOF\P@
M)\N,C)8=N_->?6ZG4O$^E-::(=)2X\-7HBLM@3R]TJ[<@  %L[L>]8ESXFTV
M[^$6B>'K=Y9-6MGL8;JU$+;[8QRH&,G'RC(QSU)% 'J>K^-M!T34387EU*;E
M$$LJ06\DWDH>C2%%.P>YQ6/X6\<0-\/;7Q!X@OXQYUQ-$LB1Y,I$SJBHJ#+$
MJHX R<9K.L=<T[P=XS\5IXAE-J^HW,=U:3/&Q%S%Y:J$0@'+*01MZ\\"N+M+
M:XB\%^"=762\TK3K'4;\W$L5NLCV8DDD".R,I&!R"<<;J /8]'\5Z/KBW7V2
MY=)+0 W$-S$\$D0(R"RN 0,#KTKD]>^)VGR0:<F@WTGG7.I6\"R26CK'/$T@
M63RV=0K<'JI]ZYTV'_"47'B.71M>U+7KLZ#+9+>F"*.W8N<B$,BKN?@^H&X\
MU+KGBK0M7\+^%M*L%9[^WU'3_,M!"P>RV.JMY@Q\F/N^^>.* /4/$.KIH.@7
MNIR*["WB+ +&SY;MPH)QG&3V'-<-X4^(%K9^%K/4_%'B*>XN-17?%$VFM%L8
M*K-'&%3,@_>* W.>Q/-=UXB!/AG5@!DFSF_] ->=:1!OO/A$7B)\O3)SR/NG
M[+'0!V-WX^\/V<=F6N+B26[@%S%!!:2R2^4?XV15+*/<@5--XX\-V^AVFM2:
MK$-.NY?)AG"L07PQVD 9!^5N#CD8ZUS*ZO8>$/B5XDNO$,PL[?5(K5[*[E4^
M6RQH5>/=T#!N=O?.:YF.UDN8=.U'[)+%8:EXY2\M(Y8RI,11@)-IY 9E+<_7
MO0!WR?$SPNZR@7=U]HB8 VALIA<'()!$6W<5P,YQ@=ZZ#1]8L-?TJ#4],N%N
M+28$I( 1T.""#R""",&N7MX1_P +LOYO+Y_L"%0^/^F[Y&?P%.^&*%/#E^I4
MK_Q-[W (QQYS4 5I?'S2>*/$^B1*Z'3K(26S_99.90DC.68C: -JXS@'G!-'
MA;XEZ-J&CZ%'J%^_]HWL$*/-]E=86N&4902;=F[.1@'KQ6;?WMO9?$'QG9W+
MF.XU+1HC9HRG]]Y<4V_:<8XJMJ,&SX$^&42+#*-,; 7D'S(R3]>30!W&L>-=
M#T._-C=W$SW2QB62*VMI)VB3^\^Q3M'UK8L+^TU2PAOK&XCN+6=0\<L9RK U
MY'/,WAWQSXH.K>++OP\+VX2YMY!:Q/'=1>6  K.C$LN"NT'Z"NW^&UE'9>#+
M<1"_6*::6=!?QK')AW)SM7A0<E@..#0!;U?QQH.B:A)8W=S,]S"@DG2VM9)_
M(0]&D**=@[\]JMGQ/HPGTJ+[<A_M4$V3JI,<V!G <#:#CH"<GM7EPG/AOQ5X
MICU?Q=>>'WNM0:[@ M(I$NH65=I1GC8LPQMV@\8Z=:DEL(Y?AOH'A'3[:^_M
M/4IS<637J!)K!1*9#<-L^YM!^4#!.X#U% '5^,/'$%CX>U"ZT:_03:=J%O:W
M4IC)CCW2*'7<PVDA2<X)QWQ6QH_C?0=<U,Z=974OVHQF6..>VDA\U!_$F]1N
M'TKS:Z,:?"E_#,UB+?4=)U.TM[Z  L)29T/G GEED&6S[D=J[;Q(A/Q/\#N%
M. NH D#I^Z6@#(G\=/IEMX0NY]=CO-/O[FZCN[M;,Q^<$#[%5,;@0P"\<L1[
MUTG_  F&E:KH&LSZ=J36<]A;NT[7%HZR6AV$AVB8!B.,XQSC%>9:1=V^D^'_
M (;7NH0R&VM[[4&E(C+>6,RX<@#.%)#$]@,UK:U=P>)=3\7Z[HQ,^EP^%IK%
M[I%(2><EG 4_Q;5ZD?WL4 =)%X[6/QEHF@-(US%=Z<)GNELY09)6V;",#"J0
MQ)/1> 2*T?B#KMSX;\*MJ5K.D#I=6Z/(Z@@(TJJ^<\?=)YKEK2]@TGQEX&GO
MG,$5SX?^QQ.RG#3,8<)G'!/O6U\6<#P*[-;O<(M]:,T*+N,@$Z94#OD4 ;&C
M^--"UW4#865S*+HQ^:D=Q;R0F6/^^F]1N7W&:KS_ !#\,6U]):R7[XBE\B6Y
M6WD-O')G&UI0NP'/J>*YZ^UBP\9^./#'_".7'VDZ:UQ/=W4:,%MT:(H$8D##
M,Q'R]?EY%<-IKQ:=X#F\-:OXHU6VOT66UGT"&QA>69F9N(\Q[F#9R'SWSGB@
M#V?6_%FCZ!<06U[/*UU.I>.VMH'GE91U;:@)"^YXJ&3QQX=CT2VU<:B)+2Z?
MRH/*C=Y)'YR@C W;A@Y&,CO7(65W:>"/&\ESX@FDMK.ZT:TM[2]NAD*T08/&
MS#(#DD-CH>U4]6\41;M%O+*QM/#FFWM]=L-:N;%7*\#$B@@;#-D\MU [T =Q
M:^//#UUIVI7HO)8DTQ0]['/;21RPJ1D$HRAL''85J7FMZ?8#3S<W&P:A.MO;
M?(Q\R1E+ <#CA3R<"O%Y8[C6+KQW':7U]K,ESH">1<S6ZQ_:=K/GRE55!4'@
M8!R<\FM[5/%FD^))O MMI$[W3P:M;R7!2-L08B==KDC ;)/'7@T =E>?$+PU
M87T]M<7LH%O+Y,]PMK*T$,F<;7E"[%.2,Y/'>KFM>+M'T&YAM;R>5[N9#(EO
M:V[SRE!U;:@)"^YXKRO6-1M='EU[^QM=NM.OS=3/)X:U*S6YCO)2<_NUQG;(
M>05)Z]JN7\MUI/C^\U+6==N?#$6I:=:F&9((Y(MR*1)"7=&"D,<@#&<_2@#U
M?2=7L-<TZ+4--N4N+63.UUR.0<$$'D$'J#R*Y;Q+XN/AUO$MRNH+<26&GQS1
M:?\ 9'/E.P?:S.HY5B!G^[CDC-'PSMX4TC4[VWGU&XAOM1EN!/?0I$9R0H,B
M*H&%;&1D GDXK \36\T^N?$:.*)W>3PY$J*JDECMFX'J: /0?#NKIKOA^RU%
M-_[Z)2V^)H_FQ\WRL <9SCUK*M_%-AI]KK5YJ>MI<06NIM:@+:LC0MA,0  $
MR-DYR <[O:KO@[5++5_"6F7-A.)H1;I&6 (PRJ PY[@C%><316/]C^*GU2/4
M8[=/%S2K>6/^LLV"1[9^_P JG@\'KTH ]*T3Q5I/B":X@L9IEN;<*9K>XMW@
ME0'H2C@'!]>E8_C'Q6WAGQ%X92:Y$&FWDMPMU^[WE]L64"@ MG=@ #DYQ6/X
M$UB\O?%]W:QZQ!XCTU+$-_:ZVBQ21OOX@9UX?@EO:K'C^^M=+\9>"M0OHW:T
M@N+II'6,N(LPX#D = 3DGL!GM0!T^D^+-%UJWO);6[*?8O\ CZCN8V@> 8SE
MU< @8!.>G!JEIOQ \-ZK?V]G;7LH>Z)%L\UM+%'<$=HW90K?@>>U<#XCAF\<
MWOBS4/"X>XLSH*V(GC4A;J<2F0JA_CPF5R.[8J_XA\2:/XPT;1-$\.EI=3-]
M:RK;I$P>P6-P7:3CY-H!7GUXS0!8F^)-Q>^'_&TUENANM(,OV-FM)%&Q43!8
MN,;MS'Y>#C'&.:Z/1?B!H&J7-C8+>N;NZ3]T[VTB13L!EA&Y4*W?H?I7":C>
M01Z)\5-&=BNHO-/>) 5.YH3%$H<<8(SQ72^*X0FG> %BCP(]:LP H^ZODR#\
M!0!VFL:I;Z)HU[JEV2+>TA:9\=2%&<#W/2N<M=2U.&P\,OJVKI:WNI7):6W^
MR[Q)N1G$"D#Y=HQ\QZ[3ZTGQ5@EN?AAKR0J698!(P'=5=6;_ ,=!JOXND2ZU
MKP)<6_SPOJGF*R]-I@D(/ZT :VE:O=)XNU;P_J$OF2(BWUE)M +6[DJ5..Z.
M",]P5SSDU=USQ-H_AL6QU:\%L+EF2'*,V]@NX@;0><#@=SP,DUS]P#/\:K+R
MO^7;0I3.1Z/,H0'\58_A1XRB$OC3P-N3>JZA,QXR 1 Y!_/% &SH_C#1-<2]
M-I=LC6(#74=U$\#PJ02&97 (& 3GI573OB#X;U2_M[2VO90]T2MM)-;2Q1W!
M':-V4*Q^AY[5QGC;2[[5?$_B^STZ-VN;CPS"$51S(1,Y*CU) Q^-/\0^(]'\
M7>']&T+P\6EU5KRT=;9(F#V C=2[2#'R;0".?7C- '3^&O&J:]XMU_1S&ZK8
M2JEN?LTJ;EV L69A@'<>!QD#(R.:U]<\5Z-X<FMH=4NS#-<J[01K$[M+MV@A
M0H.3\R\=3GV-<WX6OK>V^)GC+3)Y#'>7,\%S#$RD>9$($4L#C! /%3^((A)\
M5_!KE-PCMK\@X^Z=D8_QH F/Q0\)BT:X%].WELPFB2SF:2#;]XR(%W(!ZL![
M5J:CXNT33+*QNY[PR)?KNLTMXGF>X&-V41 6(P0<XXS7,Z) !K?Q(;RL&2=!
MG;]X?9E_/DG\ZY:SUF;2]"\"VTM[:Z%;OI&3K-Q:+*ZMA1Y*,W"9')SUP* .
MTUKXCZ9#X*UC6M(D::YL 8S!-;2JT<I&5$B$!E'N<#WK2/CC1K;1--O[N>96
MOQB"!;64S2L/O;8MN_ ]<8Q@]Q7E\0EOM*^*?DW-]J1GL;=XKFY@$;W"B)P6
M5551MX(&!T ZU>U348)_$WA_Q/#X@N--T2;1VLH]3@MUD2.99,LC^8A"9QC.
M!RN,XH ](C\:^'Y- N-;&H!;&UD$5PSQ.KPN6"[70C<IRPZCOGI6='XSTS6K
MS26TK66AAEOFMV22QD_TLB,MM5F VC&&W=#C'>O.M6MX+[P-XYU.UO\ 4M5C
MO'LHFO;B"..*Y*2*,Q!%&0 =I;'.!C->@>,H\>*/ X1/E34WX4< >0] %N_^
M(OAK3;JYAGNYV6U?R[F>&SEEA@8=0\BJ5!'?GCO2IKMS-\2H-)AG1],ET0WR
MA0#N?SE4,&ZXVGZ5YG?:]-J/AOQ#:S:T=+O&-W&/#6FZ<@E8_,!O)5F8-PS.
M,#!/(KIO!^6\:>&Y "5_X0N(9QW\R/CZT =]K6NZ;X?LEN]3N?)B9Q$@",[2
M.>BJJ@EB?0"L_3O&^A:G'?F*YFBDT^(SW4-S;20RQQX)W;&4$C /0&L?XCZM
M-I3Z%M:ULH);MEEU>YM1.+#"'! /"LWW=QX'-<3#<_;/%?B29-8O-9CD\*3H
ME]- L:2D.25BVJH91N'(SR3S0!Z+:?$?PO?7UI:P:@[?:W$=O,UM*L,KGH@D
M*[2WMGKQUXJ?5?'7A_2-1ET^ZO)/M$*AI_*MY)$MP1P9&52$!_VB..>E<?JT
M&SX1>"D2+!2;23@+R#E,G^=2Z1KNF>$=5\6:=XA+17=[J<MY;HT3,;V&15"+
M'@?.1@KM'2@#J?A_K%YK_@32=4U"19+NYB+2.JA03N(Z#CH*6#5[K4O'%YIU
MK+Y=AI-NOVK"@F6>495<GH%0;CCJ7'IS1^%*E/AAH*LA0B!OE(Y'SM47@P&#
MQ1XXM9?^/C^TTGY[QO"FS\/E(_"@!^C:\UVGA0GQ-%=_;UN"2+ Q_;]BDY'_
M #RV]>>N*T?#6KW4^I:SH>HR^;?:9.")=H7S8)!NB8@8&0,J<#JF>]>=^#8W
M6'X491AM34=V1T^1NM=CI@,_QBU^:+_56^E6L$Q'_/0L[C\=I_6@#<U#4#!X
MJT:R_M18!<Q7#&S-N6-SM"\A_P"#;G..^[VJC:_$/PU>7T%K#>RXN)?(@N&M
M95@FDSC:DI78QR.,'GM5#Q*K'XG^$&$32*+34<J._P D7'IS7 V.JQZ5;Z;:
M^&=:N+LB[C0>$]5M!+-;_/\ , ^ T>P9()R!CK0!Z[XKUL>'/"VI:OL+O:V[
MO&OELX9\?*"%YQG&3V')(KCI_B*(3X*OIKDV]AJ23_;PUJZEG6$%0BE=WWS@
M;<[LC&:Z[QE#)<>!]?AA1I)9--N%1%&2Q,;8 'K7!Z=?66M:G\+9[-Q<1017
M,4AVGY)$M0"#D<$&@#N]'\7:+KD%[+:793[#_P ?:7,30/ ,9RZN 0, G/3@
MU6TSQ]X=U:_@L[6\E$ESG[,\UM+%'<8Z^6[*%?\  UQ/B_2[_5=<\?V>FQNU
MS<:):;%0<R$-(2H]20"/QJA'=6&OR^'["+Q;K&JSI>02KIL5C!&]H8SG=+B-
M2BKC!YY[9H ]/\8:]_PC/A/4M75-\MM [Q*8V<%\':&"\A<XR> !W%0>'O%^
MG:U'I]N)W74+FR%UY4EO)%N4$*Y&X#HW;TP>G-.\=PR7'P_\10PQM)(^FW 5
M%&2Q\MN *XO5-4M/^$+\+>.-+D-RFA&-;GRU.3 RB*=<'N#@_P# : .UU#QM
MX>TLW@O=16%;.XCMKAVC?;'(Z[E4MC'3D^G?%/T;Q?HVNWLEE9S3+=QQB4P7
M-M) [1DX#JKJ"R^XKS;5K4Z/\-] U+5K=Y;J_P#$%MJE_$J%F9I'+;0O4D+M
M7'^SBM?4;^W\;^-M*E\+W/VA-/L+T7-[&I$:&6,)''NQ][=\V.V* .F7XB>&
M&OA:C4'VF;[.+K[/)]G,N<;/.V[,YXZUU%?/MJ]L? $/AF_\3:P+T1K:2^'(
M+"#S]^[!5<QYQGYMY;WSFO?;:,Q6L,;,S,B*I9SR2!U/O0!+1110 4444 %%
M%% !1110 4444   '048HHH **** #%%%% !115>_O8--T^YOKEMEO;1--*W
MHJ@DG\A0!8IC2QHRJ[JK,<*"<$_2N ;QUX@L]$@\4:CH%K#X=FV.P2Z9KJ&%
MR LK+MVGJ"5!R ?8UGV5C>:M\;M3GU'3M,N8K"WMVMY'G=GMXR9"CQ@IC>2!
MN&1CL30!ZCP/04M<MXQNK2VO/#"W5@MVTVLQ1PLTC)Y#E)")!CJ0 1@\<UA'
MQWXFN['6]2TWP_8O8Z-=7,,YGO&1YQ"3GRP$(SM /S'J<#I0!Z))+'$NZ1U1
M<XRQP*=7D?B<W/B_QKX+!TS3KS2+RRFO(+>\F<!@4C+%U"$;E#?+USD]*Z!?
M&/B+4X+_ %+P_H5G<Z/8RR1*9[IHYKORR0YB4*5 R"!N/..U '>48Q7GTWQ!
MU'5-2TRQ\+:1!>MJ&EC4DDNIS$L:[]I#8!YS@<=SZ"EG\:>)KB^U^VTK0K"3
M^Q&'GR7%VRB4>6'VH A^;KUP.GKP >@45YY;_$#698-"UF;0[>'0=8N8;:(F
MZ+7,9EX5V7;MVY[ YQ@^U:>K^(/$\5W?_P!FZ1IT-C9$#[1JEVT/VD[<GRP%
M( '3<3UH ["C.:\IN/%6L^(?$'P^U+28((K348[F4V\]TZ@N(R'#[5((49*G
MN2>%ZUH6GBVUT:PUM]/T4&^G\22Z?#;).?\ 2KDA?WC,V=@(!)QP-M 'HU%<
MC8^)M8M/$EKH?B33K.":_BDDLKBQG:2.1HQEXV#*"& YST(KG8/B3XAD\(0>
M,)/#UG'H?R^>OVQC<;=^QG1=FW /8G)QVH ]0HSBH+QKE;*9K)(GN0A,2S.5
M0MCC) ) ^@->(6VI:Y)\./ 5]<VZ7MT=>B:V N6+W!(F_P!8S#Y3NSS\W'/M
M0![MUZT5R&E>*-87Q+<Z#K^F6T5VMB;^!]/F:598PVTKAE4[@2/KFLJ]\<^(
MM'@L=3UC1=-M=/NIXHC:_;6-Y"LC!0Q4H%)&02H/% 'HE'?-<!H5YKLOQ<\3
M6TXMFL(H+7Y?M+DQH1(4**5QEC]X9&.Q-+\1;S7+;5O"<>DBWV3:HJLLMP\8
MD?8Y"MM4_)P3GGD#CN #OLT5Y=8W?B*/XE>-H="TVQN)-UD\LMY<-'&O^CC"
MKM4DD\^@&/>M(?$EKKP]H-S9:=&-6UF26**UN;@)'"T1(E9Y,?=4KV&3D4 =
M_17*>'/%=S?Z[=:!JUO9Q:E! MTDEE<&:&>(MMR"0"I#<$$=P:/%OBC4M$U;
M1=*TG3(KZ\U8S)$)9O+5#&H;+'!XP23WXXZT =71BN%N/&.MOJHT.RL=*35+
M6UCGU&2[O62"%WSMC0A2SD@$YP !3$^([W&BPFUTM9-=FU%M+%C]H!C6=1N9
MO, YC"_-D#H0* .]H&.H[UP8\5ZTFO7/AS7]%LT;^RI[WS[6Y9XIE4A=HRH(
M/S$'/3C'6LZQ\:M9Z-X3TK1;#3;%]0TT7,0U"\:."%%"@1JV"SM\W3T&: /3
M:*\Q\9ZUXHE\(:?*=.BTZ\_MB"WG0W;;9 )5"E&5<M&_?(! [&M6;Q9XEE\5
M3>'M/T2QFN;6VM[BZFDNV6)0^=RK\N2<CY>.0#G'2@#N:*X76O%GB>P@U/48
M-%TZ#3;!W &H7C13W2H,EHP%*@'^')Y]J)_'.I7FIZ+8:%I$-Q+JVEC48WNI
MS&D*DK]_"DD8;MSG'UH [JC%>3>+?%NN7WPV\4Q&UAL-6TJ=;:\,-TVW8P5@
M\3!<G(8#!QP3SVKTZQ:^;38FOHK>.]V?.D,C/&#VPQ4$CIVH MT5Y#HOC#7]
M \+>(]7U&R@O?*UZ2W6..Z=G+-,$9%W*/E4$!?7N!727GC#7],33].OM)TZ/
M7M2FD%O"+T_9XX44%I)'*Y&,XP <GI0!W5%<7IOC:\>75].O],CEU?3[874<
M.FS><EW&<@>62 0=PVD$<<'FJ_\ PF.OZ7K>CVNO:;I44.JSBV1+2]:2>W=E
M)7>I4 CC!(Z'\,@'>45Y/IOBS6] 7QWJ^JVT%S;6-_M6..Z=BLA6)50;DPL>
M&R6[<\'K77^'==UV_OTBU"PTV6RFA,L6H:5>&:)6!'R-N .2#D$9'% '4XQT
MHK+U_4;[3--$NFZ9)J-Y)*D4<*ML4%CC<[8.U1U)P:YRP\9ZG;^)I-#UVST\
MS&RDO(I-+N6F&$(W(RLH(;GCUH [>BN!\-^-M=\0+IVH0Z5IEQI5ZZJZV5_Y
MEQ9JW1I5*@<=" <C/>NG\4ZRWAWPMJ6L)")VLX&F$3-M#8[9[4 :^,T5PZ>,
M-=LIM(NM<T6UM=+U:=+>)H;DO-;/)_JQ*I4#GH=IX)[U!:>+M;UR[UJ*/0K3
M^QM-N;JRNIY;HAY#&#C8H7TVYY_BXZ4 =_UHK@_"7B>-8_"VE)I<=EI^IZ1Y
M]GME9]DB %H>>3A"""3DX-65\8ZI?0:E+I&A_;1#J?\ 9UJWFE4<J,22R-@[
M8U;(R,YQ0!V=%<):>+M<DUO4/#MW9Z2=433VO;:6TO':%@&"E7RFY""0>AK#
M\*^,M4TGX;>'#=P07FJ:H_DV(>[8>8,%FDF=E^7').-W;UX /5\9HKDM \67
MEUXBD\/ZS;V,=]]F^U036%P9H9HPVUAR 58$C@]0<U:\3^)+C2+K3-+TRR2]
MU;4Y'6WBDD\N-%1=SN[8)"@$< 9.: .CQ17#GQMJ6F?VW8ZYIEM%JNG:9)J<
M/V:<O!=1*#G!*@J0P (([YK4\(ZSKFO60U'4]*MK"RN8HYK,)<&21E89^<8
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ME)*B!=5GWVN'SD>0J<^G(-5_^$8\=?\ 11/_ "B0?XT?\(QXZ_Z*)_Y1(/\
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M#?VOG9\MY(SG:V.0""1GWKF]7L_B%I5B)_\ A,+.>5Y$AAA72D!DD=@JC);
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M =3#-J3:S=0S6D2:<D:&"X$N7D<_>!7L!QSWJ]7$?\(QXZ_Z*)_Y1(/\:/\
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M)" V'=F R>>C8H YK3?B-KFN:?HEIIECI_\ ;>J271+3%Q;P10R%=Q .XDX
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MQ;>%K/219Z3-]FEDU!I-UQ,!EE39PH&0,G-6OA]X&?P/%JMN;[[7!=7(D@+
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M@ HHHH **** "BBB@ KGO$O_ "%?"_\ V%C_ .DT]=#7/>)?^0KX7_["Q_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *Y[Q+_R%?"__ &%C_P"DT]=#7/>)?^0KX7_["Q_])IZ .AHHHH ****
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M1+91')/=7-Q<Q6MN&EU"U1&;<2S;YB6 52<+CD8R,YIFHZ#9Z5?1V6IP/=W
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M#K(CQMM>-U(964^H('MZY%4(/"]C#,MQ))<W%T+E;IKB:3+NZH47.   %8\
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M_P \+O\ \#[C_P"+KH:* .>_X0C0?^>%W_X'W'_Q='_"$:#_ ,\+O_P/N/\
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M* "BBB@ KGM8_P"1O\-?[US_ .BJZ&N>UC_D;_#7^]<_^BJ .AHHHH ****
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M0^URS6U_&B2!1Y4T)D5".ZX9<9[_ $%<AJ6AZJOB_0HSXKU-G>*Z*R&"URF
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MK'_0XZM_X#VG_P 9H_X1_6/^AQU;_P ![3_XS0!T-%<]_P (_K'_ $..K?\
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M]L;E DYB7S% P V.15BBB@ HHHH **** "BBB@ HHHH **** "BBB@#GI?\
MDHMK_P!@F;_T;'6OJ<-S<:5>064JPW4D+I#*W1'*D*QQZ'!K(E_Y*+:_]@F;
M_P!&QUT- %2TM/[/M[.RM(XULX(O+P2=P"@!<?KFN=NO"-U<3W.I#4'74VO5
MNX &_<J$^5%(QGF,%3C^^U=;10!R,?AW5GM'TJ>2R33GU&2\:5&=I74W!G";
M2 %Y(!.3QFJ4_@.[EM[F!;R$17,=R9$P<-*S3&)OH!.<^Z)CI7=T4 <H/"+2
MWK/=M!-:R7SW$D3 G=&UH("OUR"?I46F^$=0L;B)Y=26<Q:E)=)*PS)Y9M?(
M0'/!<<$GOC/?%=A10!RFA^&[W3]7BNWCL+1$C99A8%U6[8X^9H\!4.03QN.3
MUQG*7GA:YG\.#3@;6:0:I)?;)694=6N'E"D@$@X8#IUKK** .2'A1KI=.BNK
M*PMK:UO'N'AMI78.#"Z=2JD'+#\!5.7P3<106MK!%I]S:6=[)<11W#,A='C(
MP[!22REOO')( SS7<T4 <K'HVKVEYIUY96NEPM;6UQ;M;^?)L D>-PP.S)_U
M9R,=ZL'P[.?!NJ:0;B-KO4([HR2[2J"2;<3@<D*"V/7 KHJ* .7T#PU-INJR
MWDEO8VD4EMY#VUHS.LIW9#L6 Y R  /XCD]*TO#>C+H.A0:<!$/++DF,8!RQ
M/\B!^%:U% '$6_A>]OM MH966"4:9+9.) 0WF2NOG/\ CLR#_M>];&KZ/>W&
MH175C]D.VTDM0ESG;%O*_.H .[A<%>,\<BM^B@#D;'P?+;74"320S6<%Y'<+
MN)+NL=L(45AC&0PW]3S5$^!;QF"R7$,B7%L(;K][(@7,KR2[57&X,9#U*XP#
MSTKO** ,2UT6>ST+4+>&2)-0NVN)3. <>9(S%2>Y"@J/HM9,7@V7[.RO]F1F
M%A  F6V6]N5=HP2!U;?V'!!KL:* //O^$%U2ZRM[=6Q5K>6WEV.V)/-EC:5P
MFT*FY%<;0.K<D]1TL6C7-M!KS6TD,=S?L3;$ A8@(5C0' [%2>/6MRB@#A)/
M ]Y&BI;RP&.VN+:2W3SGBWQQ6_E!&95.W#$N",\]AUI__""2/9SP2RV[F:V2
MW)(8X#SM+<XW$GYPP Y_A[5W%% '.3>&&N-&\0632Q(VJR.P*J=J+Y:1JI''
M&U!G'J:I:7X?N8?$B3O;6]I;PN;DQ6H(B60Q>2JJ2!N.TN6.!U0<X)KL** "
MBBB@ HHHH *AN[:.]LY[67/ES1M&^#S@C!_G4U% '*OH6M7^CC0[^[M([ 6S
M6TDUN"9+@%"BDJPQ'C(8X+9( X&:CU?P_K7B*Q%KJ,MA$(8IO+: N?-E>%X@
MS CY% D8[1NYQSQSUU% '&:OX8U?7[(Q7SV$+0VLD,$<3.RL[A06=BH(&%(P
M!WSGBMC0-+FTUIP^G:?9I(!_QZ3.Y8C/7<H]:VZ* ,OQ)_R*VK_]>4W_ * :
MR;..YNO#/ARTACF$306\DL\80A J J,,?[P4]#P#6MXD_P"16U?_ *\IO_0#
M1X:_Y%71_P#KRA_] % %*.*^M$U*T-C+?PNXD4R>6JR!R!(H&<>K<@9)-6;!
M9EOP88KV.T$3>8MU(6R^1MV[B3P-V><<CKVV** .?TFPDF#_ &V*]C5;F2=(
MI601Y,K.IPIR<9!P>]12:5<7UQJK&.ZA+SB2-))<0SJ(T7:RJ3P2I!XZ8Z]*
MZ6B@#+N#)J,MG;-!)%&<3W"N!P%/RH2"1DM@\'HI]:?JH9OLZFQDN8=Q9WA?
M:\1 X9>0>Y''.#6C10!STL=ZVE72K;W4D9FC-O%*X:7:"I;))Z<'&3G]!4MM
M975OKD;I ?L(MYFCR1F)W:,F,C/3*DCMR1V%;E% '/6B7.ZT\BPO+&?<IN(F
MEW0(O\0 W$>N-H!SC.!FNAHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH 9++'#$TLKK'&HRS,< #W--MKJWO(O-
MM9XIX\D;XG##(ZC(JMK&H+IFES7!DB23&R+S6"J9#PH)],X_#-8^G7"Z->-9
MW1MXEFM1-&L=QYC.8QM9N54Y*A>G7:U &Y%J=A/<?9XKVWDFR1Y:RJ6R.O&?
M8TU-6TV6?R(]0M7FW;?+692V?3&<YK'T^>W$NE6\%U:WT"Y6 *N)H5$;#<V#
MCI\IX7EAWXIL#?VK=:I8PWEEY37)+A6WR@ )D@9X.>A[&@#:_M;3?M!M_P"T
M+3SP^PQ^<N[=Z8SG/M5MF5$9W8*JC)). !7*W3S7DFNV]K<6TL/GA;B!5WS;
M/*C#%?FQNX. 1U%:U[-%J4=K9V\BRPW8WNZG(,*XW<]]Q*K]&/I0!;;4;2.S
MANIYT@BE *&8A.HR!SWQVI5U&Q<0%+RW83DB'$JGS".H7GG'M5'5)[>+4K3=
M>QVMWY<GE-,H,;+E=P/(Y^Z1@@\'MFLNX>SNK/38II+>!)-0EVRQ,%5VV2GS
M$SWW$'OSZ]P#HUOK-WF1+J!G@YE42 F/_>].G>DMM0LKTL+6[@G*C)$4@8C\
MJY_[7%+'JPU-C 4\B"=D'"OG 89XVG*MSV//>M'3[D3:LRF:TNW\C)N+9<;!
MNX5OF/7)(Y['B@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@#-U;0-,UMH&U"W:5K?=Y3+*\97=C/*D=<"J'_  @^
M@?\ /K<?^!L__P 770T4 <]_P@^@?\^MQ_X&S_\ Q='_  @^@?\ /K<?^!L_
M_P 770T4 <]_P@^@?\^MQ_X&S_\ Q='_  @^@?\ /K<?^!L__P 770T4 <]_
MP@^@?\^MQ_X&S_\ Q='_  @^@?\ /K<?^!L__P 770T4 <]_P@^@?\^MQ_X&
MS_\ Q='_  @^@?\ /K<?^!L__P 770T4 <]_P@^@?\^MQ_X&S_\ Q='_  @^
M@?\ /K<?^!L__P 770T4 <]_P@^@?\^MQ_X&S_\ Q='_  @^@?\ /K<?^!L_
M_P 770T4 <]_P@^@?\^MQ_X&S_\ Q='_  @^@?\ /K<?^!L__P 770T4 <]_
MP@^@?\^MQ_X&S_\ Q='_  @^@?\ /K<?^!L__P 770T4 <]_P@^@?\^MQ_X&
MS_\ Q='_  @^@?\ /K<?^!L__P 770T4 <]_P@^@?\^MQ_X&S_\ Q='_  @^
M@?\ /K<?^!L__P 770T4 <]_P@^@?\^MQ_X&S_\ Q='_  @^@?\ /K<?^!L_
M_P 770T4 <?8:+8Z-\0HDL8I$$FE2EM\SR9Q+'_>)Q757%Y;6FS[3<0P[VVI
MYCA=Q]!GJ:Q)?^2BVO\ V"9O_1L=:&K.L+6-Q(P6&&Y#2.>B@HZY/MEA0!:2
M]M9)I84N86EB&9$60%D^H[4VVU&QO7*6MY;SL!DK'(&./7@]*R+JXLKC^V)Y
M)MUBUO';R31?, <ONP>AP'7UJ:QNEFU=%\^SO6%NQ$]NN#&NY?E;#$?-U'3[
MIX] #:JH-5TYKDVPO[4SAMAB$R[MWIC.<^U6ZYN2_P!-9-<M9;B&61YRH@5P
M9';RD&%4<YR/S% &Q-J^FV\S0S:A:1RK]Y'F4,/J":6;5-/MTB>:^MHTF&Z)
MGE4!QUR,GG\*PGOF@UQXWU>PMY$M[47"S$;F(=RP!W<<'T/4=*??:C:16F@R
M6D]K!$9<PBXD"J$$,@]?<#\10!MOJ5A%;QW$E[;)#(<)(TJA6/L<X/2G6NH6
M5]N^R7<%QM +>5('QGIG!]C5**T@LHWO;ZXA#F4S&0'RXT+*$XR?0#J>22>^
M*;X<^S3:/974$B2.UI#"[(^X#:N<<=P6- &O5:+4+.XN&MX;N"29,[HTD!88
MX.12:DD\FEW:6Q(N&A<1$'!W;3CGZUERW.GW-OIUOISQF5)XC#%']Z)5(WY'
M5<)N4Y]<=30!H/K6E1NZ2:G9*Z$JZM.H*D=CSQ5T$, 000>01WKGK27[7KVH
MV\5_9M!]J_?6PP9&7R$4\YZ;L=AT//:NA551%11A5& /04 1/=VT=PEO)<1+
M/("4C9P&8#J0.IJ ZOIBPI,VHV@B=BJ.9UVL1U .>2*I:C,P\1V$,%Y;0SFU
MG.V9=Y(W1] &4]C^1K*34(1I5@XU*R23^TY_WS$&/.Z4DXW#C!'?N* .ECU*
MQF@DGBO;9XH_OR+*I5?J<\4^&\M;BV-S#<PR6XR3*C@KQUY''%8+:W;6FE7#
MK?6DVH"&)'N%D41/,V57G/'()([#FG:5,FDZB^G7+6MNLMNLT2"YWGY%"L3D
M+CY0I_!C0!N6M]:7JLUI=0W"J<,8I P!]\57.N:2'*'5+(,.H-PF?YUG:9K>
MGQV>R.[MY99+Z5%C292QWW# '&>F#GZ4.-,_M=-)-Q#M:RD@,7FC?R5XZYSB
M@#7?4+*-YDDO+=&@4-*K2@&,'H6YX'UJ>.1)8UDC=71P&5E.00>A!KF=1N6^
MUZX(-0LXECME\U)4W,/E;N'&.HZCO706$B2Z?;/&ZNC1*0RG(/% $Y( R2 /
M>EKCO'S^;;V=H7MH0?-G$MVP$3%4V^6=PQN8.2,]-N><8K<\-ZA%J>@6MQ#'
M+$@!C$<S9D7:2N'_ -K !(]Z -&>XAM86FN)HX8E^\\C!5'U)J(ZC8J[H;RW
M#)'YK RKE4_O'G@>]5/$4J0Z#=,\L<7R@!Y#P#D8[BJ*R22ZO=V\E[:W$\E@
M/+6%=AP2W8LV>HYH V!J=@?(Q?6Q\_\ U.)5_>?[O//X4HU"R:R-X+RW-J,Y
MG$@V#!P?FSCKQ65#>6UV=$C@F222)O,D13\T:B%U)8?PX9@.>YK!DCC?PU>3
MK=VQTUHI99/WHYG 8*OI@_(WU4>M '9G4;$7,=L;RW\^092+S5W,,9X&<GBG
M_:K?[2;;SXO/";S%O&X+ZXZX]ZYO4;EM4O+R2P>QF6PB4+(]UM\N3(D+'"G*
M_*G.1T84Z:\MM5U/3[JPN83=&S:>V4R#+?,,H?J P/IC/:@#HK:[MKR(RVMQ
M%/&"5+1.&&1VR*E=UC1G=@JJ,EB< #UK,\/3K<Z29T#!9+FX8!A@C]\_!'8U
M+K+VR:5-]LD:*!BJ-(H^Z2P //& 2,YXQUH DBU33YTD>&^MI%C7<Y652%'J
M>>!20:MIMU*D5OJ%I-(_W4CF5BW&> #SQ5&TO8CJ,KRW%E<;+?<]U -HC4'A
M7^8CG)(Y['BL[P_J$!M-+CN=1L[IS%"MM%!@-$_EL&+#<2?E.,_H* -^'5M-
MN9A#!J%I+*20$296)(Z\ T]=0LG$Y2\MV%N<38E!\O\ WN>.AZUS45PT]H\H
MN[2738M0DDG\H9DB F+!MVXC&0">!\N2*T-0F>UNI(K9\'5%40NO.V7A6;_O
MC#?2,T :3ZOIL<,4SZC:+%+S&[3*%?MP<\U*U[:):BZ:YA%N>DID&P_CTK-U
MJ>RT[3+>W>>"W59H!&CN%^594Z9[ 4^\N+?[;I][)+&UB%DQ-N!19#M"MGH.
M-XS_ +6.] %B74=*GLI&EO+-[1AY<A>52ASD;3SCGGBG6-WITJ+;V%S:NL2
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M0E@R=3M.?ERO?I5S38XX-29#%=VTC0Y$,DWF1N 1EE^8\\@'.#R* -BBBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* .>E_Y*+:_]@F;_ -&QUT)&1@USTO\ R46U_P"P3-_Z-CJWXB9/[-6(M<!Y
MI5C0VY?>,_>(V<G"[C^% &JJA5"J  .@ H5%3.U0N3DX&*PK:>6[T*:WCGD2
M:&7R-\^^)G7<-H)(W LA W8SDY%2Z?!$E[<0-'>6[20C]Q).60@$@LA#'!Y
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M110 U45!A5"CT Q2X'H*6B@ P**** # /44A (P1QZ4M% "!550H  '0 4N
M.U%% "!%4DA0">I ZTM%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&"XN8+B02>; 28RLK*!GKD X/XUC2_\ )1;7_L$S?^C8ZV[K[1]G86OE^<2
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M!&0,\J>15N@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWS[5-;:?>F.SANY8!#:[2%B!)D91@9)Z 'G'J!SZW;2_M[[S_(8L(9#&Q*D
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M<=QSTYK<HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YZ7_ )*+:_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH YZ7_DHMK_V"9O\ T;'70USTO_)1;7_L
M$S?^C8ZZ&@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .>E
M_P"2BVO_ &"9O_1L==#7/2_\E%M?^P3-_P"C8ZZ&@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:22P>61*T<C@/\SC&]2K>V2.U1:#9:EX=\M;G2KFZ#V"1[;8QL(SYLS^7\S
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M:.D37D4$JWJW+*T^+8S!3)Y9P!NQWR&/J%(SSFL[Q')KPOP-+CNVC6$D"+8
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ML-S'&ELJPCYGA(<QDN$/$G SG;D %L4 ;/VOQW_T!] _\&,O_P 9H^U^._\
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M[;MSY77=QCKGBLR>RN?[$O\ 0_[,N&U.>]DFCNA%F/+3%TF,G0%%*\$[AMP
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M_P#@;-_\:KH:* .>\[QE_P ^&@_^!LW_ ,:H\[QE_P ^&@_^!LW_ ,:KH:*
M.>\[QE_SX:#_ .!LW_QJCSO&7_/AH/\ X&S?_&JZ&B@#GO.\9?\ /AH/_@;-
M_P#&J/.\9?\ /AH/_@;-_P#&JZ&B@#GO.\9?\^&@_P#@;-_\:H\[QE_SX:#_
M .!LW_QJNAHH J:<VHM:YU2*UBN-Q^6UD9TV]N653GKVJW110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48
MYSWHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M.>E_Y*+:_P#8)F_]&QUT-<]+_P E%M?^P3-_Z-CKH: "N>\(?\>6I_\ 86O/
M_1S5T-<]X0_X\M3_ .PM>?\ HYJ .AHHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK3K;SD$D7G72)YB_WER>1[BO&],T?Q#?>*K6R-II$^HKX7M5N5UF)I GS$=
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MIIZS6D+7UL);P$VR&5<S@#)*#/S8!SQ7D^D7?A[2_&VO/XS-G&\]G:&PDU!
M4>W$0#+&6&/O=0.2?6N3M="O]9B\(VMC--8L;C5;O16?(,:*4>'(/121^1H
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M10 4444 <]+_ ,E%M?\ L$S?^C8ZZ&N>E_Y*+:_]@F;_ -&QUT- !7/>$/\
MCRU/_L+7G_HYJZ&N>\(?\>6I_P#86O/_ $<U '0T444 %%%% !1110 4444
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M<D,P8Q.CA6*$J0<,#@CZ@T <_P#\)]X7_P"@O'_W[?\ PH_X3[PO_P!!>/\
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M [-C*%/&&!)!P2 ;G_"?>%_^@O'_ -^W_P */^$^\+_]!>/_ +]O_A7,B_\
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M\)SX;_Z":_\ ?I__ (FC_A.?#?\ T$U_[]/_ /$UT-% '/?\)SX;_P"@FO\
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M +]/_P#$UT-% '/?\)SX;_Z":_\ ?I__ (FC_A.?#?\ T$U_[]/_ /$UT-%
M'/?\)SX;_P"@FO\ WZ?_ .)H_P"$Y\-_]!-?^_3_ /Q-=#10!SW_  G/AO\
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M$+64P9I=N[:%V;CQWQB@"A)\-Y-0DU&ZUKQ%=ZE?7>G2:=',T$<0AB?DD(@
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MVK(5V$Y]#0!U-%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% '/2_P#)1;7_ +!,W_HV.NAKGI?^2BVO_8)F_P#1L==#0 5S?A6&*?3M
M4CFC21#JUYE74$']\W8UTE<]X0_X\M3_ .PM>?\ HYJ -Q[:"1XW>&-GC^XS
M*"5^GI4BJJYV@#)R<#O2T4 1):V\88)!$H888! ,CWJ0HK;<J#M.1D=#2T4
M,:&)XS&T:,A.2I4$$YST^M1_8[79L^S0[2<[?+&,^M3T4 1O!%);M;M&IA92
MA3'!4C!%1+I]K]F@@DA298%"QF50Q&!C.3WXZU9HH A>TMI'+R6\3N>K,@)-
M!M+8R>8;>+?G.[8,Y]<U-10 FU=Q;:,D8)QU%,>WAD14>&-D7[JLH('TJ2B@
M");:!%VK#&%((P$&,'K4@55)(4 DY.!UI:* &^6FUEV+M;[PQU^M116<,-U/
M<HO[Z?;O8G)PHP /0#DX]23WJ>B@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#P;PV;G2
MI]72[U?Q5I9;5KB5;:STIY8G0MPV[RFZX]>U5/%&E>(+3Q)XAUO1M-NWN+F_
MET_Y86R\,]N '''164'/0&O=[;6-,O;V:RM=1M)[J#_6PQ3*SIVY4'(IEIKV
MCW]VUI9:M87-RH):&&Y1W&.N5!SQ0!X/>>&[W2/#C6-O:ZC##9^-$=)K:U9Y
M$@2(#SD7:<@8R#@@FMGQ1]HU;X;Z_96>H^)-9N6:U94O]-:(H!,,[!Y:[O4]
M<8KV*RUC3-2,XL=1M+GR#B7R9E?RS_M8/%+I^K:=JT;R:=?VMXB-M9K>59 I
M]#@T >:0:%K5A\3;<>(+Z_U9'LIDTC4Q"J);2,N'6147 8CHQ./QZ<Z=1UC2
M/AW9^$[?3;ZTUJR#Q2V+:+]LAOCNR&#D%=I/.>>?I7MT>J6$VI3:;%>V[WT"
MAY;=9 9$4]"5Z@<C\Z6TU*QO[$7UI=P3VAW8GB<,GRD@\CC@@C\* /%[J/4K
M3X@WUW?WFO:2TVFV:M-I>GF99)!&-ZG",!@YZ58UGPO<^,?%6FRVUQJ7FP>'
MS)9:I=6[0NMU'<94N-HP3SQCH<@5ZM'XET*72)-6CUBQ?38FVR7:SJ8E.0,%
MLX!R1^8J2XUW2+32XM4N-3M(M/E"F.YDF58W#?=PQ.#GM0!YS\/H]8G\$^,Y
MM7TV:TU&\OKJ1H&C(W,85!V@]1NSC&:ZOX:6\]I\-]!M[F&2&9+4!XY%*LIR
M>"#R*W-4UO2M$MTGU34;6RAD;:DEQ*J*QQG )/7%5HO%?AV?3I]0BUW39+*#
M'G3I=(4CR<#<0>,GCF@#R/5;>Y@\>>-3/?\ B/3(+QH1$=-TYITN0(<')V'I
MG'!'4TNF:!KMS)X6M6TR33;G_A&[VURL;!('8,(RQ.=K$%6()SDFO4X?'7A.
MX<K#XETF1E5G(6[0D*H))Z]  3^%:5MK6EWMX+.UU&UFN3"MP(8Y59_+;&'P
M#G:<CGWH \>NKZ2[^$T7@*+PWJJZ^(([0V[63")75AF4R8V;>"V[/>M+3-1_
MX1'Q[XP;5=.U2[2Z@L8XGM["69;@QP;7Y"D=3W->JV5_9ZE;^?974-S#N9-\
M3AEW X(R.X/%+:WEK?1&6SN8;B,,4+PR!P&!P1D=P>U '@9T#6-#L/AVM[_:
MU@ULE^\\UA:M/+:"0@HF K<D''([GTK;URWO-;TSPU#8:EK][+%XCA9[V\T\
MQ2VZ[#\P4Q@;5ZY((R>:]8&O:0=.N-0&IVALK=RDUQYR[(V!P0S9P"":I7?C
M7PM87+6]WXATN"90"8Y+I%8 @$<$]P0?QH X;XDZ+JMMX3T>)]4U75)8]>M[
MA[I+97F@C"MEE6-,';UY!Y-9?B'SM6^'GB"QMM1\2:U/(;5EBU#36BV@3IG9
M^[7=QUZ\"O6=/U_1]6E$6G:I9W<AC\[;!,KG9G&[@],C&:@N/%?AZTM%NKG6
M]/AMVE:%97N%"EU^\N<]1W% 'EVG>'-;\-_%70])2TFN]!L%O9].G()$:2Q?
MZEFZ##+@9_O5F:6+K3]1T:UT*VUV.0:DHF\.ZI9&>WLTW'=)',R@( "2&!SS
M7L">,_#$EE+>IX@TQK6%E22872%$9L[03G )P<?2K6E^(=%ULN-*U:QOF09<
M6UPLA4>X!XH \8T'[3I=]KR76K^*M*,FLW,R6]CI;RQ2(6&'W>4W7'KT KUK
MQEIUYKG@?5]/TYBMU=6CI$"=N21]TYZ9Z?C6M/J-E:W=K:7%W#%<W186\3N
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M_A0!/_;.E_\ 02L_^_Z_XT?VSI?_ $$K/_O^O^-0?\(UH/\ T!--_P# 1/\
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M(EN[C&"ZCY7/ Y*'H/04L.FZ5JNF.+JRB\M;QKAP9"RB9'R75N.X]NX(ZBK
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MI'V RRW4LDF%;<%#LQ8+G^$'![@YK4HH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .=F /Q
M&LR1RNDSX]LRQ9_D*Z*N>E_Y*+:_]@F;_P!&QUT- !7/>$/^/+4_^PM>?^CF
MKH:Y[PA_QY:G_P!A:\_]'-0!T-%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% '/2_\ )1;7_L$S?^C8ZZ&N>E_Y*+:_]@F;_P!&QUT- !7/>$/^/+4_
M^PM>?^CFKH:\XMKK7-+T_6M1AUS1;#3(M4O"WVVQDD9?WK?Q+*N<GH N>W-
M'H]%<#<ZQXGLY8XYO$6@ R1I+E=&N65$<[59R)L("<@%L=#Z&EMM7\47>I'3
MX?$.@FXW2(,Z+<JCM&<.%<S;6*G@@$]#Z&@#O:*X;4;[QAI<D$=QK.C-)/N,
M:6^A74S$+C)PDI( R/SJ"77/$D.B'6)/$OAY+%6V,[:/<!E;=M*LGG;@0<Y!
M&1@YQB@#T"BN U/6/%FD3PPW>LZ5NG(6,P^'[N568YPH9)2,\'CK4?\ ;OBH
MW4ELFK:=)+$4$@C\-WK",LJN Q$F =K*2#TSS0!Z'17GAU_Q,MT8'U[1TQ/]
MF,S:!=B$2;MNWS/-V?>XZ]>*T[H^-;)$>?7?#R^9(L:#^RYB69C@ #S^?_UG
MH* .PHKS^VUKQ3=7BVT>NZ("\CQ1ROHERL4CIG<JN9MI(VMWYP<9Q3+?7_%%
MS:_:H]:TH6ODF?[0_AZ\2/RPN[=O,H&,<CGGM0!Z'17#6%]XSU*39!JFEK\N
M_=/X?NX5(^KR@9YZ57O=;\46$,\TVNZ,8K>4PRO%H5U($<!20=LI_O#GUXZ@
MT >@T5YZVN>*UD6+^UM.,K)YGE+X;O2ZKDC)429 )!QGKBK-K?\ BV\OI;*+
M7] %U%"D\D3Z/<(R(^=N0TPP>#D=1WQ0!W-%</9WWBN_TD:I;^)/#9L3N_?O
MI<R+A6*DY:<<9!YJF_B'Q%'8PWO_  DF@/;RQ-,LD>BW+@1J<%SB4[5_VC@4
M >B45QUD_C._21X-=\/LL<KPO_Q*I@0RG!_Y;_\ ZQ@UH?8O&'_0>T7_ ,%$
MO_R30!T-%<]]B\8?]![1?_!1+_\ )-'V+QA_T'M%_P#!1+_\DT =#17/?8O&
M'_0>T7_P42__ "31]B\8?]![1?\ P42__)- '0T5SWV+QA_T'M%_\%$O_P D
MT?8O&'_0>T7_ ,%$O_R30!T-%<]]B\8?]![1?_!1+_\ )-'V+QA_T'M%_P#!
M1+_\DT =#17/?8O&'_0>T7_P42__ "31]B\8?]![1?\ P42__)- '0T5SWV+
MQA_T'M%_\%$O_P DT?8O&'_0>T7_ ,%$O_R30!T-%<]]B\8?]![1?_!1+_\
M)-'V+QA_T'M%_P#!1+_\DT =#17/?8O&'_0>T7_P42__ "31]B\8?]![1?\
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MS-&T4E[<R71B88**QPH([':%R.QS6Q110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 455U"6]AM"^GVD5U<9&(Y9_*7'<[MK?RK(_M+Q7_ -"Y
MI_\ X-C_ /&: .AHKGO[2\5_]"YI_P#X-C_\9H_M+Q7_ -"YI_\ X-C_ /&:
M .AHKGO[2\5_]"YI_P#X-C_\9H_M+Q7_ -"YI_\ X-C_ /&: .AHKGO[2\5_
M]"YI_P#X-C_\9H_M+Q7_ -"YI_\ X-C_ /&: .AHKGO[2\5_]"YI_P#X-C_\
M9H_M+Q7_ -"YI_\ X-C_ /&: .AHKGO[2\5_]"YI_P#X-C_\9H_M+Q7_ -"Y
MI_\ X-C_ /&: .AHKGO[2\5_]"YI_P#X-C_\9H_M+Q7_ -"YI_\ X-C_ /&:
M .AHKGO[2\5_]"YI_P#X-C_\9H_M+Q7_ -"YI_\ X-C_ /&: .AHKGO[2\5_
M]"YI_P#X-C_\9H_M+Q7_ -"YI_\ X-C_ /&: .AHKGO[2\5_]"YI_P#X-C_\
M9H_M+Q7_ -"YI_\ X-C_ /&: .AHKGO[2\5_]"YI_P#X-C_\9H_M+Q7_ -"Y
MI_\ X-C_ /&: .AHKGO[2\5_]"YI_P#X-C_\9H_M+Q7_ -"YI_\ X-C_ /&:
M .AHKGO[2\5_]"YI_P#X-C_\9H_M+Q7_ -"YI_\ X-C_ /&: .AHKGO[2\5_
M]"YI_P#X-C_\9H_M+Q7_ -"YI_\ X-C_ /&: .AHKGO[2\5_]"YI_P#X-C_\
M9H_M+Q7_ -"YI_\ X-C_ /&: .AHKGO[2\5_]"YI_P#X-C_\9H_M+Q7_ -"Y
MI_\ X-C_ /&: .AHKGO[2\5_]"YI_P#X-C_\9H_M+Q7_ -"YI_\ X-C_ /&:
M #2_^1V\0_\ 7&T_E)70UQEHOBVVUS4=1.@Z<PO$A0)_:A&W8&[^3SG=^E:7
M]I>*_P#H7-/_ /!L?_C- '0T5SW]I>*_^A<T_P#\&Q_^,UDQ>-]3FU._T^/2
MM),]A$);K_B;G;"N3]YO)P",'([=Z .WHKCM&\5Z[K^G+J&FZ%I\UJSNBR?V
MHP#%6*G&8>F0:S?^%BZS_P )#_8?_")O]NW?=\Z?;MW;-^[[/C9G^+I[T >A
MT5P$?Q"U*6QTV\31+(P:B\B6Q_M%_F*!F;(\CCA&Z^E4V^*EV$@D70898I;>
M*Y:2*[F=88Y/N-(1;_)G!Z^E 'I=%</JOC77=(NXK2?PU!+<S1/-'#;7LDSL
MJLJL0%@)X+K^&3VK)B^*]]-IL-_'X8=K>XG6W@(EGS,Y#G"#[/EON-G'3% '
MIU%>>-\1]3BNM*MKGPY%:3ZK*\5K'=7<L3,R[<Y#0#;]Y<$]<T^P^(M[J.F:
MGJ4&E:<+/3)7ANIGU-U5&4 G&8.1@C&.O:@#T"BO-A\4;T6UW-/X?BM?LML;
MMX[JZFB=H<XWJK6X+#)'3UJ>?XD7EO")FTG3VB-K#>"1-2=@8I9/+0C$'=N,
M=J /0J*X[4/%FNZ7>6-K>:#81-?2-% [:HVPN!NVEO)P"0#C/7'%,L/&&MZC
MHC:S;Z%8?V>%=_/?4V4%%SEAF'[O!(/<<T =I17G@^)&H/H%IK46A6LUG=SB
MWA$5](\C29(V[!!NSE3VJ(_$Z_,4#1^'4EDFFD@6".YF:99(P"ZM']GW @$'
MD=* /2**X72_'6J:U/!#8:+82O/;&Z0?VDZ_NP^PYS!P0W&#S5:\^(VIV=P]
MNWAZ&6=;HV?E6]Y+*YE$8D( 6 D_*<YH ]#HKSRY^(NKVD5NTWA8B6>-Y5MQ
M/,9EC0X9V3[/E5!(Y/7/%2:Q\0=6T32[;4[KPW$]E<('2>WNY9553MP6*P?+
MG<,9QF@#OZ*\[N/B/J]LMLK^%BUS<1M,MHD\[3K&K;2[1BWW*N>Y SVS6A'X
MQU>7P\=>CT?3&TP0-<&<:JV-B@DG'DYR,'CKD8H TY?^2BVO_8)F_P#1L==#
M7E%SX[NX9](\7R:=8#3[Z)M.M_\ 3W),CN&^;]SE<>6P.1Q5VY^*=U;7=_:G
M1+:2>QN(K6:.&]D=O-D)"*H$'S$E2..] 'I5<]X0_P"/+4_^PM>?^CFKG3\1
MM3B-@+OP[%8M?W)M;=;V[E@+R8!QAH!@'( /0GBLG3_'6I:$)K7^PH[R:[U&
M^=$M;B:1@R2_O!M6 G"E@,]Z /6:*\[@^)=U<W^DV<&E:<\NJQO):$:DX5PN
M=V28/E(VD8.#D8JI!\6[F\M+6YL] CNUNII885M[F:1W:, MA1;YP P.: /3
MZ*X"+X@ZH^IVFFR:!:VU[=V[W,-O<W\D3LBD@\- ,'@G!YP,U1?XJZ@IL-GA
M:24:A&);0PRSN)@4W_*1;\D+R0.G>@#TVBO/K?XBZG<ZO_9L7AZ R?:&M1,;
MR40F902T?F>1MW#!XSVQ3M7^(&K:-?&RN/#L,UPD7GRQVEY+.88^1O?9 =HX
M/7TH [^BO.9/B7J0O([:V\-I?/);QW*FQN9IU\M\[&)2W(&<'KZ59UKQ[K&@
MW*6UWX<@DG:%IS';7LLS)$IPSL%@.%!/6@#O:*\YOOB9?6,K(V@P3B.%+B=[
M:[FF6"-AE6D*VYV@CGGG'-:FG^+=;U6ZN[:RT33IGM1&92NJMMQ(@="#Y.""
MI!XH [*BO-7^*=X+6WGBT&&X$\3SA+:ZFE=(E8HSLJVY*KN4C)ZXXHO?BG>6
M4-S,V@0S0VJ1RS2V]W+(L:2)O5F(@X!7N: /2J*\\O/B/J.G:59ZCJ&@6]E!
M=W MXA<WLL;ECGDJ8,A< G)&,4:I\1=9TC6(]+N?";M=2Y\H0S3R++A0QV,M
MN0V 1G'3O0!Z'17G,OQ,U",A(_#\%Q<-<36ZV]M>2RRLT3;9"%6 G:#WZ5)9
M_$F[OK[3K.WTO36GU%)'ME;4W7=L.'4Y@^5@0?E.#P: /0J*\S;XK70A@F30
M89HY+=;EFANIG$43,5#R8MSM!*GKZ5U0U/Q4RAAX<TX@C((U8_\ QF@#HJ*Y
M[^TO%?\ T+FG_P#@V/\ \9H_M+Q7_P!"YI__ (-C_P#&: .AHKGO[2\5_P#0
MN:?_ .#8_P#QFC^TO%?_ $+FG_\ @V/_ ,9H Z&BN>_M+Q7_ -"YI_\ X-C_
M /&:/[2\5_\ 0N:?_P"#8_\ QF@#H:*Y[^TO%?\ T+FG_P#@V/\ \9H_M+Q7
M_P!"YI__ (-C_P#&: .AHKGO[2\5_P#0N:?_ .#8_P#QFC^TO%?_ $+FG_\
M@V/_ ,9H Z&BN>_M+Q7_ -"YI_\ X-C_ /&:/[2\5_\ 0N:?_P"#8_\ QF@#
MH:*Y[^TO%?\ T+FG_P#@V/\ \9H_M+Q7_P!"YI__ (-C_P#&: .AHKGO[2\5
M_P#0N:?_ .#8_P#QFC^TO%?_ $+FG_\ @V/_ ,9H Z&BN>_M+Q7_ -"YI_\
MX-C_ /&:/[2\5_\ 0N:?_P"#8_\ QF@#H:*Y[^TO%?\ T+FG_P#@V/\ \9H_
MM+Q7_P!"YI__ (-C_P#&: .AHKGO[2\5_P#0N:?_ .#8_P#QFC^TO%?_ $+F
MG_\ @V/_ ,9H Z&BN>_M+Q7_ -"YI_\ X-C_ /&:/[2\5_\ 0N:?_P"#8_\
MQF@#H:*Y[^TO%?\ T+FG_P#@V/\ \9H_M+Q7_P!"YI__ (-C_P#&: .AHKGO
M[2\5_P#0N:?_ .#8_P#QFC^TO%?_ $+FG_\ @V/_ ,9H Z&BN>_M+Q7_ -"Y
MI_\ X-C_ /&:/[2\5_\ 0N:?_P"#8_\ QF@#H:*Y[^TO%?\ T+FG_P#@V/\
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MSWF>,O\ GUT'_P "9O\ XBCS/&7_ #ZZ#_X$S?\ Q% '0T5SWF>,O^?70?\
MP)F_^(H\SQE_SZZ#_P"!,W_Q% '0T5SWF>,O^?70?_ F;_XBCS/&7_/KH/\
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MJ'M[*SFN)IT2YE669Y$"[O,#;R<@9)/(XK0\SQE_SZZ#_P"!,W_Q%'F>,O\
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ME[<SI!<>8JF.1$15RF#D;*[#S/&7_/KH/_@3-_\ $4>9XR_Y]=!_\"9O_B*
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M:^$+SQ)=036YTYA'"T:_:D=9(7)XDCEC(8'_ &<X.!6EYGC+_GUT'_P)F_\
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ME%<"=I6MPFYMJJ0/F5O4U-X8O;JZMKZ&ZN#=-9WLELMR553,JX.2% &1DJ<
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MHMLCNS2$R0"1LB./+GJ?E7UX % \8:A>+]I$*P6OV4,T:28<2"Y,)P63IQW
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M$P'S!0"IYQS6GX<UZ76DN%N;9;:XAV%H?W@90P.,AT4]00",@XX-7K?1M-M
M!!8P)A77A!DA\;\^N=JYSUP*=8:58:6CK8VD5N'QN\M<9QP/P'8=J +E%%%
M!1110 4444 %%%% !1110 4444 %<G=_;[WQ'K,2:[=:?!96L$D8C6(HK,)"
MS-O0DCY1W%=969>^'-%U*[-U?:7:7,Y4*7EB#$@= <]0,F@#E+3QKJ+Z=#=?
MV<\LTT=J\L>698?,M_,8A$1GQGCHV,YX Q7::;>IJ.F6M[&4*7$*RC8^Y?F
M/!P,CWQ45UHFEWQ8W-A!(S,'+%!G<%V@YZYP2/H<5<AABMH(X((TBAC4(D:+
MA54<  #H* .:UKQ;)IFKS64&G2W(MX8YIF5)"2'9AA=J,H("D_,5!Z>I%+4_
M&%_MUNSLK6".\TP#?(\X93N<;-HP<_*26R!M.!SUKJ+O1]-O[F.YN[*"::/
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M^S[8&+R_+Q&!M\O.S'IMR<>F33;?P_I%H^ZWTVVC;<K96,#!4Y7'I@DD >M
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M:"=9UM$N(M.4Q(^W89CER 4/)QC.>![UWU[H>E:E.L][IUK<2J H>6(,< Y
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M+$W4*R1698QPE05.5V_H* .=_P"$PO+^RFN(;)(;>**V>1Q<?O-TCXVK\A!
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M;P_HS3R3MI5F99 0[F!<L"NTY..ZD@^HJU)86DQD,EK"YE14DW(#N522H/J
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M ()KK_XW1_PF5A_T#M=_\$UU_P#&Z .AHKGO^$RL/^@=KO\ X)KK_P"-T?\
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M\<@8[]%>Z98ZD(Q>V<%SY9)3S8PVW/7&?6H1H6DK-;RC3;026Z!(6$*YC4=
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M2+,.+;2[*$.ZR,(X%7+*=RG@=0>1Z&@#D#\0+Q+.ZNUTDM;I#<O!O+J2820
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MF>X*;VC?RVV@*0IVY[EN%/'/6K4GBO5GBN[BVTV%H([M;6-=S/+]P.6*#[V
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M$NJW%KY-J\;6<\<"*'A5R2K\\YS7H=9=WX9T&_N#<7FB:=<3$!3)-:H[$ 8
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M-J[V=O"]K&+5E63!4RD AM@8]<DC@'I70>)WU2WN],:QU:2UCNKN.U>-88W
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M+;7=G;W$"D%8I8E91CI@$8H Y&P\2:F+ZZN97LYM/?4+>W_=RE]GF6\+9C?
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ML2@?(05XQV(&/3%95CX2TZSU*>_8M<2S1R1$31QXVN06!VJ"^=H&7+' ]SD
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M<WK-;K%AVCB@5U0'/7D_C5N'QAK4IBMOL%JMU/);K&\FY4"RB0\KG<<>7P>
MV>V#76MI&FO<FY;3[1IS()3*85+%P-H;.,YQQGTIMKHVEV2[;33;.!=XDQ%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>O#$8KK_ +'9RI/_ *- Z70_??(")AC'S?WN..>U.EM+:=P\UO%(X &YT!.
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MT,9LI;D1W<14%0#%&1)CIPQ.?8Y/W:ZFJZV%FCS.EI KSY\YA& 9/][CG\:
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M<_Z"!_[\2?\ Q- '0T5SW_"<^'/^@@?^_$G_ ,31_P )SX<_Z"!_[\2?_$T
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M  G/AS_H('_OQ)_\31_PG/AS_H('_OQ)_P#$T =#17/?\)SX<_Z"!_[\2?\
MQ-'_  G/AS_H('_OQ)_\30!T-%<]_P )SX<_Z"!_[\2?_$T?\)SX<_Z"!_[\
M2?\ Q- '0T5SW_"<^'/^@@?^_$G_ ,31_P )SX<_Z"!_[\2?_$T =#17/?\
M"<^'/^@@?^_$G_Q-'_"<^'/^@@?^_$G_ ,30!T-%<]_PG/AS_H('_OQ)_P#$
MT?\ "<^'/^@@?^_$G_Q- '0T5SW_  G/AS_H('_OQ)_\31_PG/AS_H('_OQ)
M_P#$T =#17/?\)SX<_Z"!_[\2?\ Q-'_  G/AS_H('_OQ)_\30!T-%<]_P )
MSX<_Z"!_[\2?_$T?\)SX<_Z"!_[\2?\ Q- '0T5SW_"<^'/^@@?^_$G_ ,31
M_P )SX<_Z"!_[\2?_$T =#17/?\ "<^'/^@@?^_$G_Q-'_"<^'/^@@?^_$G_
M ,30!T-%<]_PG/AS_H('_OQ)_P#$T?\ "<^'/^@@?^_$G_Q- '0T5SW_  G/
MAS_H('_OQ)_\31_PG/AS_H('_OQ)_P#$T =#17/?\)SX<_Z"!_[\2?\ Q-'_
M  G/AS_H('_OQ)_\30!T-%<]_P )SX<_Z"!_[\2?_$T?\)SX<_Z"!_[\2?\
MQ- '0T5SW_"<^'/^@@?^_$G_ ,31_P )SX<_Z"!_[\2?_$T =#17/?\ "<^'
M/^@@?^_$G_Q-'_"<^'/^@@?^_$G_ ,30!T-%<]_PG/AS_H('_OQ)_P#$T?\
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M\*VM&\.75IKEQK>JZFM_J,MNMJC16_D1QQ*Q; 7<Q)+'))/ITKDQ\'+4/O\
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M#JC6I1&F!9]HX#E>>#][H?PJCJ'@9;_3/$UF=0*#7+A9R_DY\G:L:XQGYO\
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MHUXT,*0NT<0?82W[S!.>RD]16&?A7BWL474K-VM;JXN?*GTQ9+;]ZJJ42'>
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M^C-EL'_8-=0)%N[,26\^%FCW1RI@\$<,,\'UH P/^%>>#/\ H5](_P# 1/\
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MSSI&-5BM1]F@224(UHTI # @G< >>U &K_PKSP9_T*^D?^ B?X4?\*\\&?\
M0KZ1_P" B?X5B6VNZ_?:87MIKB6'^T'B#K' M\84C^?]TQV!EEX((SM_AS6E
MH>O7=YK&FV<EWYZ/;7K3%[<PR>9%+"JAU/W6"R'..#U'&* +/_"O/!G_ $*^
MD?\ @(G^%'_"O/!G_0KZ1_X")_A6%J?C'4+?1XQ!<0+J$NH7ZH73*F&WFD4+
M@?WML29_VB>HJX?&4W_"0P74;(_AR73K6>1]N'@:9Y0LA/\ =&P*P[9ST!H
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M=1J&C,CA2S*N!D ]!QG%4M5O]4T"( ZC_:):ZM56,Q1BXV/+M<8&U2#_  G
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M_P"A7TC_ ,!$_P */^%>>#/^A7TC_P !$_PK!L?&.JQW]M<7ICDTI;8M>L$
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M2T4 <U_PKSP9_P!"OI'_ (")_A1_PKSP9_T*^D?^ B?X5TM% '-?\*\\&?\
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MV+^7%:U% %2STVST]G:TMUB+HB';G[J#:H_ <5);VD%J9C!&$,TAEDP?O,0
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M]"<?_!G%_A1_;GBG_H3C_P"#.+_"@#IZ*YC^W/%/_0G'_P &<7^%']N>*?\
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MSB_PH Z>BN8_MSQ3_P!"<?\ P9Q?X4?VYXI_Z$X_^#.+_"@#IZ*YC^W/%/\
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M7^%']N>*?^A./_@SB_PH Z>BN8_MSQ3_ -"<?_!G%_A1_;GBG_H3C_X,XO\
M"@#IZ*YC^W/%/_0G'_P9Q?X4?VYXI_Z$X_\ @SB_PH Z>BN8_MSQ3_T)Q_\
M!G%_A1_;GBG_ *$X_P#@SB_PH Z>BN8_MSQ3_P!"<?\ P9Q?X4?VYXI_Z$X_
M^#.+_"@#IZ*YC^W/%/\ T)Q_\&<7^%']N>*?^A./_@SB_P * .GHKF/[<\4_
M]"<?_!G%_A1_;GBG_H3C_P"#.+_"@#IZ*YC^W/%/_0G'_P &<7^%']N>*?\
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MCDADU(622J^=RFS^TAQ_+Z<U2LGT*[UNVNHI[X/<7GVNVDE@9(9W%L8,(Q4
MC9EASSC(R*@\.Z;H%S)$^EKJ@MWO6U*(R6[I%EH##M5BH^3:W !XXQP,4 6M
M&\4W^KS&!(=/CN6A:0VKW#+-;,,865&4,1R0648!'<'-0OXKU:WT2YU*[M]-
MBCBOOL()G<*&^T"$NQ*\*.6HTD6+:W;H+[6M0.GR26T#36A,43#Y&S*(QNP
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MIQ3U\7:6=P;[4DBM$HB>V<.WF;MF%QGG8WN,'.*;/X2LKBS^S/<707-TVY7
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M'RY#R*!Z!<U4N_!NM7DE[+(MF))K:\0D,@\R24@*>(PVW;N^\S<A?3->BT4
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ML)K=_)N9(F\QFA(Y0@D8C;J?3BNEHH \[C\&:C93631V_P!IB@%\NU-5FMG
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M'?\ S^^'/_ 2?_XY0!T]%<QY/CO_ )_?#G_@)/\ _'*/)\=_\_OAS_P$G_\
MCE '3T5S'D^._P#G]\.?^ D__P <H\GQW_S^^'/_  $G_P#CE '3T5S'D^._
M^?WPY_X"3_\ QRCR?'?_ #^^'/\ P$G_ /CE '3T5S'D^._^?WPY_P" D_\
M\<H\GQW_ ,_OAS_P$G_^.4 =/17,>3X[_P"?WPY_X"3_ /QRCR?'?_/[X<_\
M!)__ (Y0!T]%<QY/CO\ Y_?#G_@)/_\ '*/)\=_\_OAS_P !)_\ XY0!T]%<
MQY/CO_G]\.?^ D__ ,<H\GQW_P _OAS_ ,!)_P#XY0!T]%<QY/CO_G]\.?\
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M_/[X<_\  2?_ ..4 =/17,>3X[_Y_?#G_@)/_P#'*/)\=_\ /[X<_P# 2?\
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MUK#=/-+!;N[K,K6\L1!W*.?W@_ &NNHH Y"T\(7MOH.IZ;+J"W#W-_'<132
M[A&GE!0Y[MMBP3W/-+K'ABXO?$L^J+8:7>QRVL,(6\D=&C*-(21M4Y!WC\JZ
MZB@#C+GP.)Y;O4!]G_M1M06]@9]S1\*@V.IX(^4\XR"01R*?I?A>ZT[5Y[DV
M&E2>;>SW'VKS7$P61V;&-N,@-CKVKL** .2T3P[JUO!X?MM2ELA;Z)$HB%L6
M9IG$)A#,6 VC:S' SR1SQS:USPY/JNIBZCGC11' F&SG]W<)*?S"D?6NCHH
MY6P\(RZ=>ZZ8;I#97UHEO:0D'-L 9F9?]W=*2/0<= *L-HE_:'2+NP>VDO+&
MS-G)'.66.5&V$X8 E2&C!!P>"1CH1T5% &7H>F3:=#=274L<EW>7+7,YC!"*
MQ"J%7/. JJ,]\$\9Q6'9^ +&#PB-*DYOFTUK%KHN\@0M'M9D#'Y1[#'I7844
M <=J/AG5M?$SZH]C$_V9;9$MV=E8>:DCLQ(!&?+  &<<\FG2>#GM&U./2UL#
M9WWE.UO>1>:&93\T;$@DQLO3^ZV2 0<5U]% '%VGA;5+'R+NV:SCFM[MIX;
MS2-!&C1>6R*Y&X9/S<+@'C'.:DC\'W5S+ ^H7VQ1/<7DJ6A*_OI/E4 D<JL9
M=>>I;.!TKL** .)M?!%U%;R1RWZ>=!:P0:?<@$O"8))S&S9Z_)*JL/XL,.AK
M3TSP[/8P>&8WGC8Z19?9I2,_.?+1,K[94]:Z.B@#-\0:;)K'A[4--B=8Y+F!
MXE9N@)&,FJU]IVHPZXVK:6;622:V2VGAN69 0C,R,K*#@@R/D8YR.1CG;HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !375'C9)
M%5D8$,K#(([YIU-DC2:)XI45XW!5E89# ]010!R>F6]N;^TCFB4Z1$['2-R#
M&['?Z#.SU&3R0#7755.F6!BAB-C;>7 =T2>4N(SURHQP?I5J@ HHHH BN?\
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M*=;6EM9QF.UMXH$)R5B0*"?7 H FHHHH **** "BBB@ HHHH **** "BBB@
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MM'_"2>(/^A'U/_P,M/\ X[73T4 <Q_PDGB#_ *$?4_\ P,M/_CM'_"2>(/\
MH1]3_P# RT_^.UT]% ',?\))X@_Z$?4__ RT_P#CM'_"2>(/^A'U/_P,M/\
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M\/:T)[6>^FGFNDOK=6G^T'"P10+N?;G'[R16!XSA^>E &E_PDGB#_H1]3_\
M RT_^.T?\))X@_Z$?4__  ,M/_CM4O&6G:YJ=R\6GV\OEBV"P3QR8V2,Q#-S
M(NTJ I!VL>3R.:BOM$UZ3S;VT,T>I//>RHS7'RHOEO' F,XP<QOTZCF@"Z?%
MFM"Z%K_PA>H^>4,@C^VVF=H(&?\ 6^I%2_\ "2>(/^A'U/\ \#+3_P".TSP_
MI4]GJ&IWZ:?<6P>WBAMHKNX$C,5#,S$AFQN9@#SSMSWK"M=)\2)*;A[.[5"+
M9IXTF4-*PF#RXS*V<!0N2PR'(% &Q<^,-6LU+7/@^_B 1G^>^M!\JC+'_6]
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MIZ* .8_X23Q!_P!"/J?_ (&6G_QVC_A)/$'_ $(^I_\ @9:?_':Z>B@#F/\
MA)/$'_0CZG_X&6G_ ,=H_P"$D\0?]"/J?_@9:?\ QVNGHH YC_A)/$'_ $(^
MI_\ @9:?_':/^$D\0?\ 0CZG_P"!EI_\=KIZ* .8_P"$D\0?]"/J?_@9:?\
MQVC_ (23Q!_T(^I_^!EI_P#':Z>B@#F/^$D\0?\ 0CZG_P"!EI_\=H_X23Q!
M_P!"/J?_ (&6G_QVNGHH YC_ (23Q!_T(^I_^!EI_P#':/\ A)/$'_0CZG_X
M&6G_ ,=KIZ* .8_X23Q!_P!"/J?_ (&6G_QVC_A)/$'_ $(^I_\ @9:?_':Z
M>B@#F/\ A)/$'_0CZG_X&6G_ ,=H_P"$D\0?]"/J?_@9:?\ QVNGHH YC_A)
M/$'_ $(^I_\ @9:?_':/^$D\0?\ 0CZG_P"!EI_\=KIZ* .8_P"$D\0?]"/J
M?_@9:?\ QVC_ (23Q!_T(^I_^!EI_P#':Z>B@#F/^$D\0?\ 0CZG_P"!EI_\
M=H_X23Q!_P!"/J?_ (&6G_QVNGHH YC_ (23Q!_T(^I_^!EI_P#':/\ A)/$
M'_0CZG_X&6G_ ,=KIZ* .8_X23Q!_P!"/J?_ (&6G_QVC_A)/$'_ $(^I_\
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M_P"$D\0?]"/J?_@9:?\ QVNGHH YC_A)/$'_ $(^I_\ @9:?_':/^$D\0?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#17/?VG
MXI_Z%JS_ /!I_P#:J/[3\4_]"U9_^#3_ .U4 =#17/?VGXI_Z%JS_P#!I_\
M:J/[3\4_]"U9_P#@T_\ M5 '0T5SW]I^*?\ H6K/_P &G_VJC^T_%/\ T+5G
M_P"#3_[50!T-%<]_:?BG_H6K/_P:?_:J/[3\4_\ 0M6?_@T_^U4 =#16?I=S
MJER)?[2TV&R*X\L1W7G;NN<_*N,<?G6A0 4444 %%%% !1110 4444 %%%%
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MK8R&?@<DK@'UQ]-U/5[>WL;=9KA+F-K*&#3_ "!LF@:.+S)"Q7=D;I>0P V
M$>H!Z'17!6>OZC':V-S/J-U([- VI12685+0L2'3(4$ ' P<D  YYYBGUGQ#
M=6-[=6MW<PB"WO+B!1:+^]*7#K$K!ES@H%X&">N: /0J*X'4M3\06%W-9B]E
M-K'>E#?3*D;!?(C=5+")E +LXSL_A SGJZ'4?$DL(NYKN5&A%AF".V 27S'"
MRD[T#CY3G'R[3UH [RBN0TNZNM/\$:G,9[R>[M[B\Y:(-(I\U\87 !X(;TY]
M.*S]-U/7M0O8[$ZA<) U_L^U1I'(QB^S,_#F)5(WJ!G;ZC)H [^BO,[O4M6U
M#38H=1N[F*;_ $,Q0);#%T?.'F,WRY!&.0I4+U(P:Z/7KK7(M1U!M-EE*VFE
M_:(+98E99YR9  25+'&%.U2#T_$ ZFBO.K:^U:[O=,>XU*62SAU.(>=$-V=T
M,H*NWDHN-VP<#(+G)!QAR^(M;OK/3((+F>.Z>VMDO9%M1F.9IXDD^\N P5GX
MZ#KCI0!Z'17(6MQK<6K0&6_N9X/[3>S:)X(PIA$#,')5 =V]1R"!SC%=7<3I
M;0--('*+U$<;.WX*H)/X"@"2BLO_ (2"Q_YYW_\ X+Y__B*/^$@L?^>=_P#^
M"^?_ .(H U**R_\ A(+'_GG?_P#@OG_^(H_X2"Q_YYW_ /X+Y_\ XB@#4HK+
M_P"$@L?^>=__ ."^?_XBC_A(+'_GG?\ _@OG_P#B* -2BLO_ (2"Q_YYW_\
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ML X.[YN.>/KQ52^70;&WBN?^$@UF>VD*CSH=9)5=TJQ#.7!QN8Y/0;&SS@$
M[R6-)HGBE17C=2K*PR&!Z@BJFGZ38Z6)!9P",R8W,6+,0.@R23@<X'05R;6V
M@K-$O_"2:P8)+=KC[4-8?R54.J %MW4LV!_NFK%UI.EV^A7&L1ZYKES9PPO.
M7@U61MRJ"6P=V#T/Y4 =C17.CPC;D9&L:Z0?^HI+_C2_\(A;_P#08U[_ ,&<
MO^- '0T5SW_"(6__ $&->_\ !G+_ (T?\(A;_P#08U[_ ,&<O^- '0T5SW_"
M(6__ $&->_\ !G+_ (T?\(A;_P#08U[_ ,&<O^- '0T5SW_"(6__ $&->_\
M!G+_ (T?\(A;_P#08U[_ ,&<O^- '0T5SW_"(6__ $&->_\ !G+_ (T?\(A;
M_P#08U[_ ,&<O^- '0T5SW_"(6__ $&->_\ !G+_ (T?\(A;_P#08U[_ ,&<
MO^- '0T5SW_"(6__ $&->_\ !G+_ (T?\(A;_P#08U[_ ,&<O^- '0T5SW_"
M(6__ $&->_\ !G+_ (T?\(A;_P#08U[_ ,&<O^- '0T5SW_"(6__ $&->_\
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M"%D7!R#\S9'?CD8Y2'P-"(VBN+MI1);NKRJNQQ.TYG,R]=I#MD#G&!UKKJ*
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M?3PWC73>-*@LU$0CMU7&!$N(P>V%9Y&QZ[?2J,'A74(M/T^W:[LW.F&+[-F
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M6,^643_5C);&[=C!^G%.T=I%U.!=1DE,[6_^AA7)0Q?]-,<>9ZGI_=[UTU%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7:>5! )STZD?F* *::!IJ A8'VLQ9U\Y]LA)R2XSAS_O9JQ<Z=;74HED619
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MB>YEMU;,L2JSK@\!LXY_X":EH **** "BBJ]K>P7JR- S'RWV.&1E*M@'!!
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M<L(UZE4+8_  F@":BD5E=%=3E6&0?44M !1144EQ%%/#"[8DF)"#!YP,G]*
M):**9-,D$32ONVKUVJ6/Y#F@!]%1P3Q75O'/"VZ.10RMC&14E !14<<T<KRH
MCAFB;8X'53@'!_ @_C4E !112,P12S$!0,DD\ 4 +15:UO[:]S]G=F  .2C
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MQ:-69"C$ E202#Z<4 $DD<,;22NJ1J,LS'  ]2:C@O+6ZA,UO<PS1 X+QN&
M_$56U2"69+:2.+SQ!.)6AR!Y@ (P,\9!(89[J.G6H[9)Y=2FOC:26Z>2(]C%
M=\I!R"<$@8Z#)_B/3N 16>OP:C?-#9O:2Q*[)N%TN\XZD( <C/?(K8K)T=KJ
M,2Q3Z=<0;YI90[M&1AG) ^5R<X/I6M0!0N-3>&_-I'I]S.XC$A:,Q@8)(_B<
M'M4B:E:&R%W),D,.2K&8A-K X*G/0@@BJL[W4&MO/'IUQ<1&W5 \;QCD,3_$
MX/>J$VEWZO;7@:42+),\D5L8RRF0C!'F#!V@8/0_,<>A -Y;RV>U^U+<0FWP
M3YH<;,>N>E9^E:Y'J\I-L;9H""P*7(:3&>"4 XS]:-,AEM8KN=H+UY)7#E)C
M"'<X R F%'0=3GBET07*:9#:W%E/:O%$%+.T9!/MM8_K0!=2_LY+HVJ7<#7"
MYS$) 7&/;.:;)J=A#)Y<M];))NV;6E4'=QQC/7D?G7/VFEWL5K9V,XU%Q;O&
M=RFV$65(.X';OP<9_O<GZU>DM)GFUQO[.<M<1A(V)C_? )C'WNF<_>QUH UK
MF[MK.,275Q% A. TKA03Z9- N[8VOVH7$)M\9\T.-F/7/2LFYBNBNGR?8[L2
MQP$-+!)'YD3';E2&.U@<=>>@J&33KZ72;3Y7CD@NVN#'&(A(ZDOC.08]^6#>
MF1V/( -RWNK>\C\RVN(IX\XW1.&&?3(J:LC2K:9;V>YF6]#.BH6N?)&[!.,"
M,=LGD^M:] %:[O4M9;:+:7EN)?+11]"6)]@ 3^0[U#/J;Q7[6D>GW,[K&)"T
M9C P21_$X/:H-21H];TF\()B4R6[_P"R9 NUOS0+_P "%+.]U!K<D\>G7%Q$
MUNJ!XWC'(9CT9P>XH MIJ5HUD+QYEAAR59IB$VL#@@YZ$$8IMSJ<$&ERZC%_
MI4$:%_W#*VX#K@D@>O>LY+*ZMI;:]DMOM#B2:22"-AE&<C#+NP"5 *]OO''I
M3;FUNYM-UB2.R='O(]L=L&3<6V[=['.T$\=^BCOQ0!I0:CYERMO/:SVLC@F,
M2[2'QUP58C/L?Z&I+.]2\^T*%*203-%(AZ@C!!_%2K?0U5 N;^^M9)+.2UAM
MG:7]ZR%G8JR@ *2,88DDGTIFDHSZEJUX 1%-<*D?^UY:A6;_ +Z##_@- &M1
M6??7FH6^I:?!:Z6;JVG9Q<W(G5/LP R#M/+Y/''2M"@ JGJ5_P#V=;B;[+-<
M L$VPE,Y) 'WF'4D"KE9.J075YJ%E!&MQ';(QF>XB,9PX&%4A\Y')/W3R%_
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MGDG3S$BC"AMO&22Q '4=^]5KS698M%OKR&QN/.M@X,4@4$,%W9^]@KR.A^E
M&L %    '  I:@MKB2<,9+2:VQT$I0Y^FUC4] !165-JES%K#V::;<31K")
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M#=R<-Q@C(!XXK5TZ:6XTVUGF*F62)78HN!DC/ R?YT 6:*** "BBB@ HHHH
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M*1XG#!FC4DXSP<CIS0!7GE27PE+-"TAC>Q+(9#E\&/(R?6K<5LD.F"&T7[.
MF5$"J,'KP",9^M2W=N+JRGMBVT2QM'D#ID8I;9)8[=$GD2211@LB% ?P)/\
M.@#,T"TU.TAE74I_,=I&=0FW8-Y+GMG(+$>F " .@CL;+58]=GN+BZ=K-UVH
MN$W';G&_ [[B1MQC:,]:W** ,NZAB77]/G$2"5ED5I HW$ #@GTK4JI):2RZ
MG!<M,@BA5@L8C.XDC!);/3VQ5N@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** &F1!(L9=0[ D+GD@8R<?B/SIU8.K0VBZ[9
M7%Y<RP1&WF3?]J>)=V8R!PP&2 WUQ[5)>75NT5CB]*:8^Y7N4F/) PH,F<@$
MY^;/) &>>0#:HK*TF57N+J.VN'N+%-GE2M(9/G.=ZASDL!A3U."2,\8&K0!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU0N(;B75K201J((0S,Y?DDC&,4 7Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M!6TY9$TRT66%89!"@:)>B':,J/8=*JZY(5LXX]B&.60)(\B,Z1K@G+*I!(R
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MW$<@=1D=ZW:* ,[0/(_X1[3OLPNQ!]G3RQ>;O.V[1C?NYW>N:T:** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#<FYG=XQ"+9]Z%"F[>,?*!YB')XPP/2@#9HK'NM;DMO$EII9L9!!/%)(;MF
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M;:0K&CNR*7./E^96'/3!I\GB[1XI726>5$7S?WS0.(V\K/F8;&#C!''7'&:
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MGB4M*J,1ABNUN.ORGT.)4\5:;))%&%O-SA6(-I(/+5F*HS_+\H8@XSVYZ<T
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MI7:5V@ 0QXXSE>^3EA\%0&=2=3OFMUF:X$+%&_>-"T3,6*[CPQ/)ZG\NGHH
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MENTN$FD,RICS2#@@HV5!SR,,/?/%B+P%IB78G<[PQ5Y4,,9+L$"??*[P#@'
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>a200-2017x92634xmod28exe002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a200-2017x92634xmod28exe002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M"0RLBCYP"?*4E..6*]": -W[5XZ_Z!'A[_P93?\ QBC[5XZ_Z!'A[_P93?\
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M8KF5TF74]1L8(+2W?2_M=VUE'J%LTD2P^7%T0D$#?YFWVQCC%:,WAG[5XL:
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MED41@!W)R6([G(!S5BBB@ HHHH 9%#'"I6*-(U+,Y"J "Q))/U)))]S3Z**
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MM&>,12.9V*L@Z+MZ8'TK:H \61+CP]XY\2>!;<.D'B21+NR9!@1I(<7)'IA
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MN/,E2VDCE1GD)8O&05)/4G(YSUJG:^%='LG1X+0*4N);@ L2-\B[7R#U&TX
MZ   =* ,Q/[>M=,@U2;78IC+ TDUN\"+&"8RP\D@;LAL?>+9&:YIO&VM_P#"
M!6KB:/\ MX2#[3)Y0P(@%DW[>GS))$OL9/:NQ@\&Z/ T6%NI(H%9;>":ZD>.
M ,I4[%)P/E) ] <# IQ\':&PDS:',EI'9L?,;_5(05'7KPN3U.T9Z4 1^,]2
MN],T>WDLI9HI9;R" M!$LDFUG .U6!!./:L_P[XGN9+]M,OS<32O?&WA:YA$
M$RIY'F[I$  P2K@$8R/H:Z35=)M=9M%MKOS0B2)*K12M&RNIRI#*01S6</!V
MDA00;S[1YPG^U&\D,V\(4^^6SC:Q&.G/3- &?'X\ADO=/@^Q>6MX$*O/.L>X
MM(R8CW<.1MR5R#@C ).*AL_'$C6B2?V?-/#%';O<W#2(I43.4&% Y((R1QQZ
MGBM5?!FCI'!"B7*P0A%\D7,FQPCEUW#/S88YYZ]#D5-#X5TB"TEM8[=A%*D2
M./,;D1L63OV)- &)!\1K2Y$[P6,L\8AFE@$#B21Q'V9 ,IN'(Z\#G!XHE^(4
M46G0W?V2W9)))(S*M\GD H%./-QA6.[ 5PG*MG P3L)X1TI!*H6Y\IU=%B^U
M2!(@YRVP9^4YZ$=.V*8W@[2V23+WOFRLQFF%W())0RJI#$'D;448[8XQ0!O1
MN)8DD P&4,.0>OTXKF?$?_(W>#_^OVX_])9:Z2""*VMXK>% D42!$0=%4# '
MY5S?B/\ Y&[P?_U^W'_I++0!J2Q_;M8FMY9IEA@@C=4BE:/<S%P22I!/W0 .
MG7VPDA;2+#RQ>/)))*1$9D>9L'G:%7YFP ?P&35NZL(;J1)&,B2H"%DBD*-@
M]LCJ/8U&=)M#!'$HE0QN9%D65M^XC!);.3G/?- $>E7SZC%=).N6@E\ICY+Q
M;P45L['Y'WL=^E)H\20&_AB4+&ET0JCHHV*>/SJ6VTBTM!<>3YX-P<RL;B0E
MC@#.2>#@ 9'H*6TTJVLIGEA-QN<EFWW,C@G &<,Q&>!0!D6WB&ZN8H+M+>1H
M)BI$"V4^\(V,-YF-I.#G&,>_>IK87PU;5HK+[-%&LRN3*I;<QC4D  C;ZYYZ
M]*OC1[57RC7"1[MWE).ZIG.?N@]/;I[4QM#LS<SW"FYCFG.97CN9%+\8 Z]!
MVQTYQC)H LV%U]MLH[@IL9@0R9SM8'!&>_(/-5[_ 'SZA:6/FR10R)))(8V*
MLVW: NX<C.[/'/R_6KT,,=O"D,2!(T4*JJ. !T%1W5G#>1JLP;*-N1D8JR-T
MR".1P2/H2* ,>XN+G2Y;N&UE\R*..*;_ $AFD\I6<J_).2,#<,GL>W0?Q&KR
MO) ,VUND[SAHSO(C"G*'.,'>I'J*TTTNU6VN("C2+<*5F:1RS.",8+$YZ?EV
MH@TJRMI?-AMU5O(6WZDCRUS@8/'?KU/'H* ,ZUUB]>Y@$L#NDS!61+*=/)SW
MWL,,/7A?7VH?4M21;ZX86OV>SF*E0K;Y% !)SG"D ^ASCMFK\.DVUNZ&-[G9
M&<I&;ARB_AG&/8\#M2-HUDUM=6Y68QW3;Y1]HDR3['=D=.@Q0!?HI% 50!G
M&.3FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV)$XVDC^Z6YXIL^@>'].2.35/!\-M'.CF I>-(=ZQM)LD'&UBJMT+#(QGID
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MX)+UT:%XR5= 0#N(8,.W3/>@#T^BO+;[1M T_4(-/N?#&CP7,D!G;S]7>.,
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MC% 'IE%<O_PKOPG_ - :+_OX_P#\52_\*[\)_P#0&B_[^/\ _%4 =/17,?\
M"N_"?_0&B_[^/_\ %4?\*[\)_P#0&B_[^/\ _%4 =/17,?\ "N_"?_0&B_[^
M/_\ %4?\*[\)_P#0&B_[^/\ _%4 =/17,?\ "N_"?_0&B_[^/_\ %4?\*[\)
M_P#0&B_[^/\ _%4 =/17,?\ "N_"?_0&B_[^/_\ %4?\*[\)_P#0&B_[^/\
M_%4 =/17,?\ "N_"?_0&B_[^/_\ %4?\*[\)_P#0&B_[^/\ _%4 =/17,?\
M"N_"?_0&B_[^/_\ %4?\*[\)_P#0&B_[^/\ _%4 =/17)77@7P796LMU=:7;
MPP1*6>1Y7 4#N?FK#^S?"C_GOI7_ (%-_P#%4 >DT5YM]F^%'_/?2O\ P*;_
M .*K%\4Q_#>+1XVTRXTX7'VVU!\NY8GRS.@D_BZ;-V?:@#V.BO)=7N_A7I<$
M3Q6]G>222K&$@N&^4$@%F.[  !SZGM43WOPS_M9K:*STQ[2.589+AM0VG<5W
M95"?F49 )R#G. <4 >OT5XW9:A\.[J:WDDTK38K&Y8A)3J!,J#!(:2/C:#CL
MQ(R,@<XM:O-\-+%+46-OI-Y-//Y6UK]HUC&UFW,PW8'RXZ=2* /6J*\<&I?#
M1=+O9I=.L%OK9_+%JMZ6$S$#:4?/*G<,D@8P<CBH[[4OAW%I5I?V.F:3<"98
M_,AEU%XI(F=E&",-G&>>F,'K0![/17BDNI> H[W[*--\/!U@25WEUIT3<S.-
MJG8=V @)X'WA6CJ,WPRL[6W:"#2;BXF<(5-^RQQ_*26=^<+QC..20,<T >M4
M5XVFJ_#!8XVN;"Q3]U.\GDWAE ,97 4@_-OR<=#QTIAU'X>P1R/=:3I2_P"C
MR31K#J9D;<JY"..-K'H,;AGOTR >ST5XQ/K/PP32XKR+3;1Y'M99WMVNF5XW
M0 ^6>3R22 ?;/-(^H?#^*U>4V'A^63S(HXX[?6'?)=PN6.T;0 <D\\ T >T4
M5Y+ILWPRN9I[>^MM+M)X0K96^:2.16S@JV1R,'((!''K6C]F^%'_ #WTK_P*
M;_XJ@#TFBO-OLWPH_P">^E?^!3?_ !5'V;X4?\]]*_\  IO_ (J@#TFBO-OL
MWPH_Y[Z5_P"!3?\ Q5'V;X4?\]]*_P# IO\ XJ@#TFBN<\+7'A5(YK'PU<VC
M*#YTD<$I?!.!DY)] *Z.@ HHHH **** "BBB@ HHHH **** "BBB@ K C\/W
M=GIMG:Z?J@A-NDD;&6W$BR*YSG;D$,.QSCKD&M^B@#DK3P+#8/!#;WI%C%-;
M3^6\0:;? B(@$N>%(C7(P>K#(!Q72-:?:-.DL[YEN!+&T<I"[0ZG((QGC@XJ
MQD$D9&1U%+0!S@\,W-Q:"PU+5Y;K3E@>W$*Q^4TBLI3]ZP/SD G& HSSC(%$
M_AFZU!(X]4U9KJ.!'6 + $.]D:/?(<G<P5FZ!1SG'3'1 AAD$$>HI<T <_%X
M4MH-=L-6BGD26V@\F2,#Y9R%VJY'9@,C/<8'84X^&(&LHK62;?&FI2:@0R A
MBTCR;"/3Y\9]JWJ* .:?P;:O=;//8:7]I^UC3U7:BR[2#@@Y"Y._;_>&:2+P
M@+"X^T:5?&UDCFDD@5XO,1%E"^9&1D%E9T#]00>^.*Z:B@#%?09)]-BMKK49
MIYEO(KQYF7JR2+(%5?X5^4 #L/4TEQHEVM_=W.F:G]C^VE6N%: 2?.%";TR1
MM;:JCG</E''7.W10!S$?@;2DMKFVVDQ200PQ-@>9!Y0(5U?KNS@Y]14__"-2
MM;K))J+'4TN1=+>"( >8(Q%RF<;2F01GN2,'%=!10!SC>%/M5ZE]J-X+F\\^
M*1B(0L>R,/MC5<G S(QR23D_3%^70[276+:_9(]L%M) L)C&WYV1BWL?D_6M
M2B@#G9/#EVFKWM]9WUK&MW(DC1S6(E*%8U3AMXXP@/2AO"-L(VDAF\J_%\][
M#>+&-\;,Y8J?[RD$J1W!^E=%10!S<OA61[6?3%U(KHT\CO):^2"^'8L\8DSP
MA)/&TG!P".,.'A&VCC$D$OE7Z7TM[%=K&-ZF21G9#_>4ABI&>G/! QT5% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4-
M<_Y%_4O^O67_ - -7ZH:Y_R+^I?]>LO_ * : ,C2M-75_AIINGM(8UN-+@0N
M!DKF->U6M2T&?4KL^9J)%@\T,\EL806W1,&4*^> 2JD@@GK@C-2>$O\ D3-"
M_P"P?;_^BUK8H YZQ\.7=A]GM(=8D32K:7S(K9(MLF <B,R9YC![;02  2><
MVM5T>YU32X+<WRQW,-Q'<+/Y&1N1]P!7/3@#K6O10!R\O@X7\S3:KJ#W<DTT
M+W 6/RUDCBW&., '*@.^_.221Z=)&\'6R:7K>FVUP\-IJ@SY>-WDN5"LP)/.
M< X]<^M=)10!@:KX?N+[6H]3M;RWAD6W-N4GM!,I&[=D?,,&KEWIMY<:?;11
MZB(+J AC(D/[J3Y2I5H\\J<],\$#GBM.B@#E(O UH8W2ZF$BS?://CBB$4;>
M<B(P10?D&$!ZDY).<FDN/!;ZA<QSZCJ,<\L,4D44Z6:),=T;QYD?)W8#L< *
M,\UUE% '*:GX%M=0F>5+N6!I=/EL9@J@K)NC\L2$?W@./<8!Z"I9O#5_<V+V
MTNI6B_/#+&T-AL*O'*LBD_.=P^3&..M=-10!E:;I$MK?W&HWMX;N]FC2'<(Q
M&B1J20%7)[L222<\>E:M%% !7+^(_P#D;O!__7[<?^DLM=17+^(_^1N\'_\
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M",8R>N::O@G2)6D;4HSJC/"L :^"R,JY8L0<<%F<DXQV P !6GH10Z!IYCU
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M2#\J*O89(R0/3J< TO#'@B"#X=G3?%<4.)[EM2NH%?9% Q?S-F0<;5P,]NM
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MR=+472,=/LE<D*P!X/\ $Y]2!VH ]OUG6;;0[*.YN5E<23Q6\<<0!9WD<(H
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M$ +(?49!&?J"* )**Q?[%U'_ *&C5/\ OS:__&:/[%U'_H:-4_[\VO\ \9H
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M?^AHU3_OS:__ !FFC2K\RM$/%.I[U4,5\FUX!SC_ )8^Q_*@#<HK%_L74?\
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M1JG_ 'YM?_C-:T$;PV\<<DSSNJX,L@4,Y]3M 'Y 4 24444 %%%% !5#7/\
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M\4^'9<2PS2(;M6!D19LO]P9.^1",Y.%Y:K-IKGAV0VHU'Q9H?E00QQ"-+WS
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M8R>G(KK-*\=>$++2K:VE\4:29$C <K<KC=WQ[9KL=B_W1^5&Q?[H_*@#FO\
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MAGTO_P "5_QH_P"%B>#?^AGTO_P)7_&NEV+_ '1^5&Q?[H_*@#FO^%B>#?\
MH9]+_P# E?\ &J6K_$#PA-HM_%%XDTQY'MY%55N%))*D #FNRV+_ '1^5&Q?
M[H_*@#A?#/C[PE;>%-'MY_$>FQS16,*.C7"@JP0 @CUS6K_PL3P;_P!#/I?_
M ($K_C72[%_NC\J-B_W1^5 '-?\ "Q/!O_0SZ7_X$K_C1_PL3P;_ -#/I?\
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MGBM[N=YG6=2(P;>103Z9) _&O1MB_P!T?E1L7^Z/RH YK_A8G@W_ *&?2_\
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M-=+L7^Z/RHV+_='Y4 <U_P +$\&_]#/I?_@2O^-'_"Q/!O\ T,^E_P#@2O\
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M!_SPC_[X%7XXD2-55%  Z 5UX3=F=0YW_A8G@W_H9]+_ / E?\:/^%B>#?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4UT#C!IU%)I-68$/V=?[QH^SK_ 'C4U%9^PI]BN9D2P*K
MY)Q4M%%7&$8Z(3;>X44450@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEW?D?>8D9/\ L@ "ELO"&EV=E=6?[Z>VN;=+9HYF!"QJ7VJ, 8P'('L!W&:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
?"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>a200-2017x92634xmod28exe003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a200-2017x92634xmod28exe003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P"#*/\ ^*KT^B@#S#_A+OBG_P!$ZM__  91_P#Q5'_"7?%/_HG5O_X,H_\
MXJO3Z* /,/\ A+OBG_T3JW_\&4?_ ,51_P )=\4_^B=6_P#X,H__ (JO3Z*
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M_P"5)/\ "C_A-OB5_P!$T_\ *DG^%6;+Q?K4W@S^VWN5,S6<,WE-HT\:*SE
M=KLV) -QP%Z\&KUYXBU6ST^.;[8SM+>16^Z30[B(HK!B2(R=TAX'3I0!D?\
M";?$K_HFG_E23_"C_A-OB5_T33_RI)_A5P^,-6>UA:&:-X)=4^QI>+I<Q9E$
M,CN/L^[?N5TVY^O'&:N7'BK4],N]+,P%U9217,]](UC):R111M$H98W).%,A
M)]5!(Z<@&/\ \)M\2O\ HFG_ )4D_P */^$V^)7_ $33_P J2?X5O6'B'5-;
MO_[/LIK2W*O=NURT1D!CCN&BC"KN&20,DY[=.>(;W7]<MM7@TV:Y@CD%H99)
M+/3)[P.WF,HX0Y08 .#G!)&3C- &/_PFWQ*_Z)I_Y4D_PH_X3;XE?]$T_P#*
MDG^%=EKVI7^F^$7O;,PR7X6((9XF1&9G5<LN=RCYNG45B3>-[F258K6WC2=X
MXH3#.#FWN7G$)#X/(7.>/O#&#R#0!D?\)M\2O^B:?^5)/\*/^$V^)7_1-/\
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M/%+>K-!$95MF*G?,B$B,,22 W !Y(H Y#_A-OB5_T33_ ,J2?X4?\)M\2O\
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M100&4,,]>:=0!YA_PFWQ*_Z)I_Y4D_PH_P"$V^)7_1-/_*DG^%>GT4 >8?\
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MXDF-XZ7+K)/";N3RI6"JN70'#<(H(/!QSFMZB@ HHHH **** "BBB@ HHHH
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MTA<*!ZGD=:Z.B@"EH^F1:+HECI<#N\-G D",^-S!5 !.._%>>^+/^2[^ _\
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M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F'A_\ Y.%\7?\
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M77KJ#3O[%U>\2VCMHU?[1"LC%8V+EMK'.,@*,9Z\4 4_[%^,7_0U:#_X"_\
MVNC^Q?C%_P!#5H/_ ("__:ZATSXB:[>>%=4UMWTYGM+*:X6V&FW,8#(V%S*S
M;'''(7GGV-37?CO7;7P]:WZW%A-)<ZC#: C1[N/RPR.S'RV;?(>%QMXZ]>P
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MO]@_&#_H<M&_\ A_\;H_L'XP?]#EHW_@$/\ XW7I]% 'F']@_&#_ *'+1O\
MP"'_ ,;H_L'XP?\ 0Y:-_P" 0_\ C=>GT4 >8?V#\8/^ART;_P  A_\ &Z/[
M!^,'_0Y:-_X!#_XW7I]% 'F']@_&#_H<M&_\ A_\;H_L'XP?]#EHW_@$/_C=
M>GT4 >8?V#\8/^ART;_P"'_QNC^P?C!_T.6C?^ 0_P#C=>GT4 >8?V#\8/\
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M']@_&#_H<M&_\ A_\;H_L'XP?]#EHW_@$/\ XW7I]% 'F']@_&#_ *'+1O\
MP"'_ ,;H_L'XP?\ 0Y:-_P" 0_\ C=>GT4 >8?V#\8/^ART;_P  A_\ &Z/[
M!^,'_0Y:-_X!#_XW7I]% 'F']@_&#_H<M&_\ A_\;H_L'XP?]#EHW_@$/_C=
M>GT4 >8?V#\8/^ART;_P"'_QNC^P?C!_T.6C?^ 0_P#C=>GT4 >8?V#\8/\
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M:8[90H=3NZCY!Q]?6J?_  K_ $5+6SAMY+^U:R1XK>>VNWCE2)CDQ[@<E,]
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MW&HO=/N8]I,R1(4DB/;(+$^W(!_IL4 %%9T,U\VN7%M)+;FVCB24!86#_.7
M&[?CC9Z<Y[5'K%UJ%O);II_D222;CY,D9)8*I)((88[+T/+"@#5HK'U'5;B*
M#3KNQ1)X+A_G0H2[)Y;/E.>N%/!!SG'%*-1NC/?M%Y-U#':)<VZ1(0TF[?@9
MR<_<'0=Z ->BLC3[VYN;Q5^VZ?=0^63*(%*/&W& 06/!YZX(Q3WEU(:TEL+B
MT\AHVEP;=MP 91C._&>>N/PH U**QO[2NTUJXL9/(6)E46\VP_*Y!.UQNYR
M2",=".XIMKJ%_=VUA&C6PN;B$SR2F-MB*"  %W9).?7L3[4 ;=%5;/[<#*MZ
MT#X8>6\*E=RX'4$G!SGO4\HD,3"%T23'RLZE@/J 1G\Z 'T51T>>ZN]+M[F[
M>%I)D63$490*" <<L<_6F:?-?37M]'<RV[16\HB41PLA.41\DES_ 'L=.U &
MC16:T]]=7ES%:26\,=LPC9I8C(78J&X 9< !AZY.>F.;=FURUI&;Q(TN.=ZQ
MG*CGL?I0!/11534!((=ZW4EO&F2[11!W/IC(/\C^% %NBLO3[BXU'1(YEN C
MN6VS+'DL@8@-M[,5 .#T)Z=JK6NK.NFZI<B1KI+,,4:5/+=B$W%6&!CGO@<'
MIW(!NT5F6[WEKJ4-M<W/VD3PO)N*!=CJ5R!C^$[N^2,=3FH;NZN+/4[:(WKR
M27$P5;<P!8]F3G#X^\ "?O<XZ#/ !LT5CW4]]-+?O:SB);(!5C* B5]@<[B1
MG;AE'&#UJQ=2O+8Q7274MM 4$C&*$22$'&,9!_'@_A0!H452TBZ>]TN&XD96
M+Y(=1C<N2%;'8D8..V<5=H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@"EJ=I/>VJ103QPLLT<NZ2,N#L8-C 8=
MP*IW.DZA=6US ]_;(DUO+$%BM650SD9<C?R>OI]XULT4 95SI4LVQXI+6*=I
M8Y;B06Y/FE""/XN.F.2:A.DZF([E8]0M%:9W=9/LC;HRPQP?,ZUMT4 9K:9)
M+J,TT\D$UK+ L+0/ 22%W'[V[')8]J:NF74:PO'>JT]OO2)Y(RV8FQ\C_-DG
MY5^;(/'USJ44 8'_  CSBVOUB>RMIKQ%C8PVN$4#/;<"3\QYR/I5Z*SU!;H3
M27EMM 8E(K9DWL0 "WSG.,?_ %ZT:* ,-= E-EIT,EXGG631CS(X2HDC1E;8
M06/4H#G/&/KFY?65Y<WMK-!=01);N7V/ 7+$JRGD..S>E:%% !5#4+.[N;FT
MFMKF&+[.Y?$D)?<2I7LRX^\:OT4 9]O8W,+74[7$+74X4;EA*QC;G'R[LD\G
M)SZ>E-L=.N(;6>UO9X+B&9I&*I"4^^S,P.6/'S$5I44 97]G7LD<=M<WJ2VL
M;*21$1)(%.0&.<=AG Y]J7[!J*7=W+!?6\:7#AL&V+,F%"\'?C/'I^%:E% &
M.^CW"2VXM;BW6WAMFMQ%/;F0L"5R2=XS]T=NYITVFW\UB8FOX3,;E)][0,5
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M?K5NB@"M86ALK7RFD\QR[R.P7:"S,6.!V&2?_KU9HHH **** "BBB@ HHHH
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M_@<O_P 14-W\$="@LYYEUSQ&6CC9AF^7&0,_W*]5JMJ/_(+N_P#KB_\ Z":
M/'?!WPDTCQ!X.TG5KO6_$"W%W;++(L5Z H)] 5/'XUN?\*,T#_H.^)/_  .7
M_P"(KI/AE_R3+P[_ ->,?\JZN@#S#_A1F@?]!WQ)_P"!R_\ Q%'_  HS0/\
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MF%S,\Y3YR@(SB(J' Q^\#=Z )_\ A1F@?]!WQ)_X'+_\11_PHS0/^@[XD_\
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M6S;1GIM4U)K'CG5Y;F^U_3KB=M';0H3/;(QS;23><HE7T*2(%;'8D]J -O\
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MDG7P[8O?W3S6]S!-=R%N;F.<Q-$A/<8>0?\  : .F_X49H'_ $'?$G_@<O\
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MQGWK1HH CA@BMH4A@B2*)!A4C4*JCT '2I*** "BBB@ HHHH **** "BBB@
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M@B5 3TS@#KP*K^(/^1;U3_KSE_\ 0#6C6=X@_P"1;U3_ *\Y?_0#0!F_#_\
MY)SX:_[!EO\ ^BUKHZYSX?\ _).?#7_8,M__ $6M='0 4444 %%%% !1110
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M*I[,RQ*KD?B-OU4UM4U(TB7;&BHN2<*,#DY- #J*** "JVH_\@N[_P"N+_\
MH)JS5;4?^07=_P#7%_\ T$T <[\,O^29>'?^O&/^5=77*?#+_DF7AW_KQC_E
M75T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110!B^*E;^PS)@F.&XMYIAZQ)*C/_ ..@G\*YC4='O9GU
MZ)+'5GEN[AI+8PSHMLV40*75FP1D'((.1ZUZ 0&4JP!!X(/>A55$5$4*JC
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MQC_T2[5?_ G_ .UT?\+*\8_]$NU7_P "?_M=>GT4 >8?\+*\8_\ 1+M5_P#
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M&/\ T2[5?_ G_P"UT?\ "RO&/_1+M5_\"?\ [77I]% 'F'_"RO&/_1+M5_\
M G_[71_PLKQC_P!$NU7_ ,"?_M=>GT4 >8?\+*\8_P#1+M5_\"?_ +71_P +
M*\8_]$NU7_P)_P#M=>GT4 >8?\+*\8_]$NU7_P "?_M='_"RO&/_ $2[5?\
MP)_^UUZ?10!YA_PLKQC_ -$NU7_P)_\ M='_  LKQC_T2[5?_ G_ .UUZ?10
M!YA_PLKQC_T2[5?_  )_^UT?\+*\8_\ 1+M5_P# G_[77I]% 'F'_"RO&/\
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M:K_X$_\ VNN6\1:WXSU[Q;X:UP?#O5(1HLDKF$R[O.WA1C.T;<;?0]:]XHH
M\P_X65XQ_P"B7:K_ .!/_P!KH_X65XQ_Z)=JO_@3_P#:Z]/HH \P_P"%E>,?
M^B7:K_X$_P#VNN3\%:QXS\(W&NRM\/-4NO[4OWO !)L\O<3\OW3GKUXKWNB@
M#S#_ (65XQ_Z)=JO_@3_ /:Z/^%E>,?^B7:K_P"!/_VNO3Z* /,/^%E>,?\
MHEVJ_P#@3_\ :Z/^%E>,?^B7:K_X$_\ VNO3Z* /,/\ A97C'_HEVJ_^!/\
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M  )_^UT?\+*\8_\ 1+M5_P# G_[77I]% 'F'_"RO&/\ T2[5?_ G_P"UT?\
M"RO&/_1+M5_\"?\ [77I]% 'F'_"RO&/_1+M5_\  G_[71_PLKQC_P!$NU7_
M ,"?_M=>GT4 >8?\+*\8_P#1+M5_\"?_ +71_P +*\8_]$NU7_P)_P#M=>GT
M4 <;X3\7Z_K^JR6FJ>#+W18%A,BW,\V]68,HV8VCD@D_A79444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>a200-2017x92634xmod28exe004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a200-2017x92634xmod28exe004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH \XO\ Q3\2X-1NHK/P#!<6J3.L,QU&-3(@)"M@
MMQD8.*K_ /"7?%/_ *)U;_\ @RC_ /BJ]/HH \P_X2[XI_\ 1.K?_P &4?\
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MZ-J]EI.H>"K2"^OF5;:%M04F0LVT8(..O'->T5X7\6/^2V> ?^OBV_\ 2D4
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M'^(WQ$U_2X=3TOP':W-G-N\N5=10!L,5/4@]015[_A+OBG_T3JW_ /!E'_\
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MW_\ !E'_ /%4?\)=\4_^B=6__@RC_P#BJ]/HH \P_P"$N^*?_1.K?_P91_\
MQ5'_  EWQ3_Z)U;_ /@RC_\ BJ]/HH \P_X2[XI_]$ZM_P#P91__ !5'_"7?
M%/\ Z)U;_P#@RC_^*KT^B@#S#_A+OBG_ -$ZM_\ P91__%4?\)=\4_\ HG5O
M_P"#*/\ ^*KT^B@#S#_A+OBG_P!$ZM__  91_P#Q5'_"7?%/_HG5O_X,H_\
MXJO3Z* /,/\ A+OBG_T3JW_\&4?_ ,51_P )=\4_^B=6_P#X,H__ (JO3Z*
M/,/^$N^*?_1.K?\ \&4?_P 51_PEWQ3_ .B=6_\ X,H__BJ]/HH XWPGKOC3
M4]5DA\1^$XM)LUA+I.EXDI:3<H"X!/8L<^U=E110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %97BC_ )%+6?\ KQG_ /1;5JUE>*/^12UG_KQG_P#1
M;4 <U\'/^23:#_USD_\ 1KUW5<+\'/\ DDV@_P#7.3_T:]=U0 4444 %%%%
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M **BBN(Y99HDW;H6"OE2!D@-P>_!'2F?;8!?"S)D$Q4L 8F"D#&<-C:>H[T
M6**KW-[!9M$LQD'FN$4K$S#<2  2 0N20.<58H **** "BBB@ HJNE]:R74E
MJD\;3Q#<\8/*CWI;6]MKZ-I+6=)D5BI9#D CJ* )Z*** "BBHI+B.*:&)MV^
M4D)A21P,G)[?C0!+1110 4444 %%%5;G4+>TD6.0R-(PW!(HGD;'J0H) ]Z
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M<Y/_ $:]=U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?B/_DZ/0/\
MKW7_ - DKW2O"_$?_)T>@?\ 7NO_ *!)0![I1110 4444 %%%% !7A?Q8_Y+
M9X!_Z^+;_P!*17NE>%_%C_DMG@'_ *^+;_TI% 'NE%%% !7@O[./_'_XP_ZZ
M6_\ .:O>J\%_9Q_X_P#QA_UTM_YS4 >]4444 %%%% !1110 4444 %%%% !1
M110 5QGQ9_Y)9X@_Z]A_Z$M=G7&?%G_DEGB#_KV'_H2T 4?@C_R2+1/K<?\
MH^2O0:\^^"/_ "2+1/K<?^CY*]!H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6W_I2* /=**** "O!?V<?^/_ ,8?]=+?^<U>]5X+^SC_ ,?_ (P_ZZ6_\YJ
M/>J*** "BBB@ HHHH **** "BBB@ HHHH *XSXL_\DL\0?\ 7L/_ $):[.N,
M^+/_ "2SQ!_U[#_T): */P1_Y)%HGUN/_1\E>@UY]\$?^21:)];C_P!'R5Z#
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MR<[SC/(')//<@&[<ZA963*MU=P0,PR!)(%R/7GM3[B[MK6(2W%Q%%&3@,[
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MJS:7"W=I#<*K*)$#;6&"N>Q'J* (-.OI+S2HKZ>!8A+&)52-S(=I (_A!S[
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.>]% '-V5Q_I<$%HMU_K/-DM+JV(\A6+$L'P,<[L<MGD#VU+[_D)Z7_UV?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5X7XC_P"3H] _Z]U_] DKW2O"_$?_
M "='H'_7NO\ Z!)0![I1110 4444 %%%% !7A?Q8_P"2V> ?^OBV_P#2D5[I
M7A?Q8_Y+9X!_Z^+;_P!*10![I1110 5X+^SC_P ?_C#_ *Z6_P#.:O>J\%_9
MQ_X__&'_ %TM_P"<U 'O5%%% !1110 4444 %%%% !1110 4444 %<9\6?\
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MF#4@E0RM$'!D50S+GD YP?T/Y52T;_CSF_Z^[C_T<]5;3P^MKK4FH_:)'#C
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M !1110 5X7XC_P"3H] _Z]U_] DKW2O"_$?_ "='H'_7NO\ Z!)0![I1110
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M_P G1Z!_U[K_ .@25[I7A?B/_DZ/0/\ KW7_ - DH ]THHHH **** "BBB@
MKPOXL?\ );/ /_7Q;?\ I2*]TKPOXL?\EL\ _P#7Q;?^E(H ]THHHH *\%_9
MQ_X__&'_ %TM_P"<U>]5X+^SC_Q_^,/^NEO_ #FH ]ZHHHH **** "BBB@ H
MHHH **** "BBB@ KC/BS_P DL\0?]>P_]"6NSKC/BS_R2SQ!_P!>P_\ 0EH
MH_!'_DD6B?6X_P#1\E>@UY]\$?\ DD6B?6X_]'R5Z#0 4444 %%%% !1110
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M#H#O,<CH#\NXCGH1GH>.><BHXY6L;+6KR"25XH XA6:9Y 3&IW'+$G[V5/\
MNUL6MM%9VZP0J0BY/)))).223U))))IL-G##9_90N^(@AM_._.2Q/KDDY^M
M%"&!]/U*SC%S/,L\;K+YTA?<X (8 \+_ !<# YZ<"JL;3"U@U7[1,9I+M49#
M(?+V/+L"[,X& 0<@9R/<UI6FEK:S)*US<7#1QF*+SBI\M3C(& ,]!R<GCKUR
MU-'B6X5_/G,*RF9;8E?+#DDYZ;NI)P3@'Z# !7UZ.2.UENH5OY9@F$%O,5$1
M_O%01N&>O#'V/2M:%Q)!&X=7#*#O7HW'4>U5;FPDN)'*W]W"CC#1QE,'MP2I
M(_ C\ZM11)#"D4:A8T4*JCH . * 'T444 %>%^(_^3H] _Z]U_\ 0)*]TKPO
MQ'_R='H'_7NO_H$E 'NE%%% !1110 4444 %>%_%C_DMG@'_ *^+;_TI%>Z5
MX7\6/^2V> ?^OBV_]*10![I1110 5X+^SC_Q_P#C#_KI;_SFKWJO!?V<?^/_
M ,8?]=+?^<U 'O5%%% !1110 4444 %%%% !1110 4444 %<9\6?^26>(/\
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?B/_DZ/0/\
MKW7_ - DKW2O"_$?_)T>@?\ 7NO_ *!)0![I1110 4444 %%%% !7A?Q8_Y+
M9X!_Z^+;_P!*17NE>%_%C_DMG@'_ *^+;_TI% 'NE%%% !7@O[./_'_XP_ZZ
M6_\ .:O>J\%_9Q_X_P#QA_UTM_YS4 >]4444 %%%% !1110 4444 %%%% !1
M110 5QGQ9_Y)9X@_Z]A_Z$M=G7&?%G_DEGB#_KV'_H2T 4?@C_R2+1/K<?\
MH^2O0:\^^"/_ "2+1/K<?^CY*]!H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MYVG*#C'OVKG?@Y_R2;0?^N<G_HUZ[J@#*N;74%N[I[1;9EN8U4M+(P,9&1G
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ML_\ )+/$'_7L/_0EH H_!'_DD6B?6X_]'R5Z#7GWP1_Y)%HGUN/_ $?)7H-
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %97BC_D4M9_Z\
M9_\ T6U:M97BC_D4M9_Z\9__ $6U '-?!S_DDV@_]<Y/_1KUW5<+\'/^23:#
M_P!<Y/\ T:]=U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?B/_ ).C
MT#_KW7_T"2O=*\+\1_\ )T>@?]>Z_P#H$E 'NE%%% !1110 4444 %>%_%C_
M )+9X!_Z^+;_ -*17NE>%_%C_DMG@'_KXMO_ $I% 'NE%%% !7@O[./_ !_^
M,/\ KI;_ ,YJ]ZKP7]G'_C_\8?\ 72W_ )S4 >]4444 %%%% !1110 4444
M%%%% !1110 5QGQ9_P"26>(/^O8?^A+79UQGQ9_Y)9X@_P"O8?\ H2T 4?@C
M_P DBT3ZW'_H^2O0:\^^"/\ R2+1/K<?^CY*]!H **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K*\4?\BEK/_7C/_Z+:M6LKQ1_R*6L_P#7
MC/\ ^BVH YKX.?\ ))M!_P"N<G_HUZ[JN%^#G_))M!_ZYR?^C7KNJ "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH *\+\1_\G1Z!_P!>Z_\ H$E>Z5X7XC_Y
M.CT#_KW7_P! DH ]THHHH **** "BBB@ KPOXL?\EL\ _P#7Q;?^E(KW2O"_
MBQ_R6SP#_P!?%M_Z4B@#W2BBB@ KP7]G'_C_ /&'_72W_G-7O5>"_LX_\?\
MXP_ZZ6_\YJ />J*** "BBB@ HHHH **** "BBB@ HHHH *XSXL_\DL\0?]>P
M_P#0EKLZXSXL_P#)+/$'_7L/_0EH H_!'_DD6B?6X_\ 1\E>@UY]\$?^21:)
M];C_ -'R5Z#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M65XH_P"12UG_ *\9_P#T6U:M97BC_D4M9_Z\9_\ T6U '-?!S_DDV@_]<Y/_
M $:]=U7"_!S_ ))-H/\ USD_]&O7=4 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MGWP1_P"21:)];C_T?)7H- !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %97BC_D4M9_Z\9__ $6U:M97BC_D4M9_Z\9__1;4 <U\
M'/\ DDV@_P#7.3_T:]=U7"_!S_DDV@_]<Y/_ $:]=U0 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*\4?\BEK/\
MUXS_ /HMJU:RO%'_ "*6L_\ 7C/_ .BVH YKX.?\DFT'_KG)_P"C7KNJX7X.
M?\DFT'_KG)_Z->NZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPOQ'_R
M='H'_7NO_H$E>Z5X7XC_ .3H] _Z]U_] DH ]THHHH **** "BBB@ KPOXL?
M\EL\ _\ 7Q;?^E(KW2O"_BQ_R6SP#_U\6W_I2* /=**** "O!?V<?^/_ ,8?
M]=+?^<U>]5X+^SC_ ,?_ (P_ZZ6_\YJ />J*** "BBB@ HHHH **** "BBB@
M HHHH *XSXL_\DL\0?\ 7L/_ $):[.N,^+/_ "2SQ!_U[#_T): */P1_Y)%H
MGUN/_1\E>@UY]\$?^21:)];C_P!'R5Z#0 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*RO%'_(I:S_UXS_^BVK5K*\4?\BEK/\ UXS_ /HMJ .:^#G_ "2;0?\ KG)_
MZ->NZKA?@Y_R2;0?^N<G_HUZ[J@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "O"_$?_)T>@?\ 7NO_ *!)7NE>%^(_^3H] _Z]U_\ 0)* /=**** "BBB@
M HHHH *\+^+'_);/ /\ U\6W_I2*]TKPOXL?\EL\ _\ 7Q;?^E(H ]THHHH
M*\%_9Q_X_P#QA_UTM_YS5[U7@O[./_'_ .,/^NEO_.:@#WJBBB@ HHHH ***
M* "BBB@ HHHH **** "N,^+/_)+/$'_7L/\ T):[.N,^+/\ R2SQ!_U[#_T)
M: */P1_Y)%HGUN/_ $?)7H->??!'_DD6B?6X_P#1\E>@T %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 5E>*/\ D4M9_P"O&?\ ]%M6K65X
MH_Y%+6?^O&?_ -%M0!S7P<_Y)-H/_7.3_P!&O7=5POP<_P"23:#_ -<Y/_1K
MUW5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %>%^(_P#DZ/0/^O=?_0)*
M]TKPOQ'_ ,G1Z!_U[K_Z!)0![I1110 4444 %%%% !7A?Q8_Y+9X!_Z^+;_T
MI%>Z5X7\6/\ DMG@'_KXMO\ TI% 'NE%%% !7@O[./\ Q_\ C#_KI;_SFKWJ
MO!?V<?\ C_\ &'_72W_G-0![U1110 4444 %%%% !1110 4444 %%%% !7&?
M%G_DEGB#_KV'_H2UV=<9\6?^26>(/^O8?^A+0!1^"/\ R2+1/K<?^CY*]!KS
M[X(_\DBT3ZW'_H^2O0: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *RO%'_(I:S_UXS_\ HMJU:RO%'_(I:S_UXS_^BVH YKX.?\DFT'_K
MG)_Z->NZKA?@Y_R2;0?^N<G_ *->NZH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ KPOQ'_P G1Z!_U[K_ .@25[I7A?B/_DZ/0/\ KW7_ - DH ]THHHH
M **** "BBB@ KPOXL?\ );/ /_7Q;?\ I2*]TKPOXL?\EL\ _P#7Q;?^E(H
M]THHHH *\%_9Q_X__&'_ %TM_P"<U>]5X+^SC_Q_^,/^NEO_ #FH ]ZHHHH
M**** "BBB@ HHHH **** "BBB@ KC/BS_P DL\0?]>P_]"6NSKC/BS_R2SQ!
M_P!>P_\ 0EH H_!'_DD6B?6X_P#1\E>@UY]\$?\ DD6B?6X_]'R5Z#0 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M)-H/_7.3_P!&O7=4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6NSKC/BS_P DL\0?]>P_]"6@"C\$?^21:)];C_T?)7H->??!'_DD6B?6X_\
M1\E>@T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5E>*/^
M12UG_KQG_P#1;5JUE>*/^12UG_KQG_\ 1;4 <U\'/^23:#_USD_]&O7=5POP
M<_Y)-H/_ %SD_P#1KUW5 !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>%^
M(_\ DZ/0/^O=?_0)*]TKPOQ'_P G1Z!_U[K_ .@24 >Z4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\6W_ *4BO=*\+^+'_);/ /\ U\6W_I2* /=**** "O!?V<?^/_QA_P!=+?\
MG-7O5>"_LX_\?_C#_KI;_P YJ />J*** "BBB@ HHHH **** "BBB@ HHHH
M*XSXL_\ )+/$'_7L/_0EKLZXSXL_\DL\0?\ 7L/_ $): */P1_Y)%HGUN/\
MT?)7H->??!'_ ))%HGUN/_1\E>@T %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *RO%'_ "*6L_\
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MR6SP#_U\6W_I2*]TKPOXL?\ );/ /_7Q;?\ I2* /=**** "O!?V<?\ C_\
M&'_72W_G-7O5>"_LX_\ '_XP_P"NEO\ SFH ]ZHHHH **** "BBB@ HHHH *
M*** "BBB@ KC/BS_ ,DL\0?]>P_]"6NSKC/BS_R2SQ!_U[#_ -"6@"C\$?\
MDD6B?6X_]'R5Z#7GWP1_Y)%HGUN/_1\E>@T %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 5E>*/^12UG_KQG_\ 1;5JUE>*/^12UG_KQG_]
M%M0!S7P<_P"23:#_ -<Y/_1KUW5<+\'/^23:#_USD_\ 1KUW5 !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO"_$?_)T>@?]>Z_^@25[I7A?B/\ Y.CT#_KW7_T"2@#W2BBB@ HHHH ****
M"O"_BQ_R6SP#_P!?%M_Z4BO=*\+^+'_);/ /_7Q;?^E(H ]THHHH *\%_9Q_
MX_\ QA_UTM_YS5[U7@O[./\ Q_\ C#_KI;_SFH ]ZHHHH **** "BBB@ HHH
MH **** "BBB@ KC/BS_R2SQ!_P!>P_\ 0EKLZXSXL_\ )+/$'_7L/_0EH H_
M!'_DD6B?6X_]'R5Z#7GWP1_Y)%HGUN/_ $?)7H- !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %97BC_D4M9_Z\9_\ T6U:M97BC_D4M9_Z
M\9__ $6U '-?!S_DDV@_]<Y/_1KUW5<+\'/^23:#_P!<Y/\ T:]=U0 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !7A?B/_ ).CT#_KW7_T"2O=*\+\1_\
M)T>@?]>Z_P#H$E 'NE%%% !1110 4444 %>%_%C_ )+9X!_Z^+;_ -*17NE>
M%_%C_DMG@'_KXMO_ $I% 'NE%%% !7@O[./_ !_^,/\ KI;_ ,YJ]ZKP7]G'
M_C_\8?\ 72W_ )S4 >]4444 %%%% !1110 4444 %%%% !1110 5QGQ9_P"2
M6>(/^O8?^A+79UQGQ9_Y)9X@_P"O8?\ H2T 4?@C_P DBT3ZW'_H^2O0:\^^
M"/\ R2+1/K<?^CY*]!H **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ K*\4?\BEK/_7C/_Z+:M6LKQ1_R*6L_P#7C/\ ^BVH YKX.?\ ))M!
M_P"N<G_HUZ[JN%^#G_))M!_ZYR?^C7KNJ "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6U:M97BC_D4M9_Z\9_\ T6U '-?!S_DDV@_]<Y/_ $:]=U7"_!S_ ))-H/\
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MR2;0?^N<G_HUZ[JN%^#G_))M!_ZYR?\ HUZ[J@ HHHH **** "BBB@ HHHH
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M** "BBB@ HHHH **** "LKQ1_P BEK/_ %XS_P#HMJU:RO%'_(I:S_UXS_\
MHMJ .:^#G_))M!_ZYR?^C7KNJX7X.?\ ))M!_P"N<G_HUZ[J@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "O"_$?\ R='H'_7NO_H$E>Z5X7XC_P"3H] _
MZ]U_] DH ]THHHH **** "BBB@ KPOXL?\EL\ _]?%M_Z4BO=*\+^+'_ "6S
MP#_U\6W_ *4B@#W2BBB@ KP7]G'_ (__ !A_UTM_YS5[U7@O[./_ !_^,/\
MKI;_ ,YJ />J*** "BBB@ HHHH **** "BBB@ HHHH *XSXL_P#)+/$'_7L/
M_0EKLZXSXL_\DL\0?]>P_P#0EH H_!'_ ))%HGUN/_1\E>@UY]\$?^21:)];
MC_T?)7H- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %97B
MC_D4M9_Z\9__ $6U:M97BC_D4M9_Z\9__1;4 <U\'/\ DDV@_P#7.3_T:]=U
M7"_!S_DDV@_]<Y/_ $:]=U0 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
MA?B/_DZ/0/\ KW7_ - DKW2O"_$?_)T>@?\ 7NO_ *!)0![I1110 4444 %%
M%% !7A?Q8_Y+9X!_Z^+;_P!*17NE>%_%C_DMG@'_ *^+;_TI% 'NE%%% !7@
MO[./_'_XP_ZZ6_\ .:O>J\%_9Q_X_P#QA_UTM_YS4 >]4444 %%%% !1110
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M (P_ZZ6_\YJ />J*** "BBB@ HHHH **** "BBB@ HHHH *XSXL_\DL\0?\
M7L/_ $):[.N,^+/_ "2SQ!_U[#_T): */P1_Y)%HGUN/_1\E>@UY]\$?^21:
M)];C_P!'R5Z#0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!65XH_Y%+6?^O&?_ -%M6K65XH_Y%+6?^O&?_P!%M0!S7P<_Y)-H/_7.3_T:
M]=U7"_!S_DDV@_\ 7.3_ -&O7=4 %%%% !1110 4444 %%%% !1110 4444
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M10 4444 %%%% !1110 4444 %<9\6?\ DEGB#_KV'_H2UV=<9\6?^26>(/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "O"_$?_)T>@?\ 7NO_
M *!)7NE>%^(_^3H] _Z]U_\ 0)* /=**** "BBB@ HHHH *\+^+'_);/ /\
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MP<_Y)-H/_7.3_P!&O7=5POP<_P"23:#_ -<Y/_1KUW5 !1110 4444 %%%%
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M\6?^26>(/^O8?^A+0!1^"/\ R2+1/K<?^CY*]!KS[X(_\DBT3ZW'_H^2O0:
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *RO%'_(I:S_UX
MS_\ HMJU:RO%'_(I:S_UXS_^BVH YKX.?\DFT'_KG)_Z->NZKA?@Y_R2;0?^
MN<G_ *->NZH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KPOQ'_P G1Z!_
MU[K_ .@25[I7A?B/_DZ/0/\ KW7_ - DH ]THHHH **** "BBB@ KPOXL?\
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K*\4?\
M(I:S_P!>,_\ Z+:M6LKQ1_R*6L_]>,__ *+:@#FO@Y_R2;0?^N<G_HUZ[JN%
M^#G_ "2;0?\ KG)_Z->NZH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KP
MOQ'_ ,G1Z!_U[K_Z!)7NE>%^(_\ DZ/0/^O=?_0)* /=**** "BBB@ HHHH
M*\+^+'_);/ /_7Q;?^E(KW2O"_BQ_P EL\ _]?%M_P"E(H ]THHHH *\%_9Q
M_P"/_P 8?]=+?^<U>]5X+^SC_P ?_C#_ *Z6_P#.:@#WJBBB@ HHHH ****
M"BBB@ HHHH **** "N,^+/\ R2SQ!_U[#_T):[.N,^+/_)+/$'_7L/\ T):
M*/P1_P"21:)];C_T?)7H->??!'_DD6B?6X_]'R5Z#0 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !65XH_Y%+6?^O&?_P!%M6K65XH_Y%+6
M?^O&?_T6U '-?!S_ ))-H/\ USD_]&O7=5POP<_Y)-H/_7.3_P!&O7=4 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH *\+^+'_);/ /_ %\6W_I2*]TKPOXL?\EL\ _]?%M_Z4B@#W2BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %>%^(_\ DZ/0/^O=?_0)*]TK
MPOQ'_P G1Z!_U[K_ .@24 >Z4444 %%%% !1110 5X7\6/\ DMG@'_KXMO\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %97BC_ )%+6?\
MKQG_ /1;5JUE>*/^12UG_KQG_P#1;4 <U\'/^23:#_USD_\ 1KUW5<+\'/\
MDDV@_P#7.3_T:]=U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7A?B/\
MY.CT#_KW7_T"2O=*\+\1_P#)T>@?]>Z_^@24 >Z4444 %%%% !1110 5X7\6
M/^2V> ?^OBV_]*17NE>%_%C_ )+9X!_Z^+;_ -*10![I1110 5X+^SC_ ,?_
M (P_ZZ6_\YJ]ZKP7]G'_ (__ !A_UTM_YS4 >]4444 %%%% !1110 4444 %
M%%% !1110 5QGQ9_Y)9X@_Z]A_Z$M=G7&?%G_DEGB#_KV'_H2T 4?@C_ ,DB
MT3ZW'_H^2O0:\^^"/_)(M$^MQ_Z/DKT&@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "LKQ1_R*6L_]>,__ *+:M6LKQ1_R*6L_]>,__HMJ
M .:^#G_))M!_ZYR?^C7KNJX7X.?\DFT'_KG)_P"C7KNJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7A?B/_DZ/0/^O=?_ $"2O=*\+\1_\G1Z!_U[K_Z!)0![I1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *\+\1_P#)T>@?]>Z_^@25[I7A?B/_
M ).CT#_KW7_T"2@#W2BBB@ HHHH **** "O"_BQ_R6SP#_U\6W_I2*]TKPOX
ML?\ );/ /_7Q;?\ I2* /=**** "O!?V<?\ C_\ &'_72W_G-7O5>"_LX_\
M'_XP_P"NEO\ SFH ]ZHHHH **** "BBB@ HHHH **** "BBB@ KC/BS_ ,DL
M\0?]>P_]"6NSKC/BS_R2SQ!_U[#_ -"6@"C\$?\ DD6B?6X_]'R5Z#7GWP1_
MY)%HGUN/_1\E>@T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5E>*/^12UG_KQG_\ 1;5JUE>*/^12UG_KQG_]%M0!S7P<_P"23:#_ -<Y
M/_1KUW5<+\'/^23:#_USD_\ 1KUW5 !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6::?]\/-"AHU;E4.T $@8!/KFM2@#S#_ (63XS_Z);J?_@6/_C='_"R?&?\
MT2W4_P#P+'_QNO3Z* /,/^%D^,_^B6ZG_P"!8_\ C='_  LGQG_T2W4__ L?
M_&Z]/HH \P_X63XS_P"B6ZG_ .!8_P#C='_"R?&?_1+=3_\  L?_ !NO3Z*
M/,/^%D^,_P#HENI_^!8_^-T?\+)\9_\ 1+=3_P# L?\ QNO3Z* /,/\ A9/C
M/_HENI_^!8_^-T?\+)\9_P#1+=3_ / L?_&Z]/HH \P_X63XS_Z);J?_ (%C
M_P"-T?\ "R?&?_1+=3_\"Q_\;KT^B@#S#_A9/C/_ *);J?\ X%C_ .-T?\+)
M\9_]$MU/_P "Q_\ &Z]/HH \P_X63XS_ .B6ZG_X%C_XW1_PLGQG_P!$MU/_
M ,"Q_P#&Z]/HH \P_P"%D^,_^B6ZG_X%C_XW1_PLGQG_ -$MU/\ \"Q_\;KT
M^B@#S#_A9/C/_HENI_\ @6/_ (W1_P +)\9_]$MU/_P+'_QNO3Z* /,/^%D^
M,_\ HENI_P#@6/\ XW1_PLGQG_T2W4__  +'_P ;KT^B@#S#_A9/C/\ Z);J
M?_@6/_C='_"R?&?_ $2W4_\ P+'_ ,;KT^B@#S#_ (63XS_Z);J?_@6/_C='
M_"R?&?\ T2W4_P#P+'_QNO3Z* /,/^%D^,_^B6ZG_P"!8_\ C='_  LGQG_T
M2W4__ L?_&Z]/HH \P_X63XS_P"B6ZG_ .!8_P#C='_"R?&?_1+=3_\  L?_
M !NO3Z* /,/^%D^,_P#HENI_^!8_^-T?\+)\9_\ 1+=3_P# L?\ QNO3Z* /
M,/\ A9/C/_HENI_^!8_^-T?\+)\9_P#1+=3_ / L?_&Z]/HH \P_X63XS_Z)
M;J?_ (%C_P"-T?\ "R?&?_1+=3_\"Q_\;KT^B@#S#_A9/C/_ *);J?\ X%C_
M .-T?\+)\9_]$MU/_P "Q_\ &Z]/HH \P_X63XS_ .B6ZG_X%C_XW1_PLGQG
M_P!$MU/_ ,"Q_P#&Z]/HH \P_P"%D^,_^B6ZG_X%C_XW1_PLGQG_ -$MU/\
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M3_\  L?_ !NO3Z* /,/^%D^,_P#HENI_^!8_^-T?\+)\9_\ 1+=3_P# L?\
MQNO3Z* /,/\ A9/C/_HENI_^!8_^-UPFI2>-=0^*FG^-/^$!U)%M(PGV3S,E
ML*PSOV\?>].U?15% 'F'_"R?&?\ T2W4_P#P+'_QNC_A9/C/_HENI_\ @6/_
M (W7I]% 'F'_  LGQG_T2W4__ L?_&Z/^%D^,_\ HENI_P#@6/\ XW7I]% '
MF'_"R?&?_1+=3_\  L?_ !NC_A9/C/\ Z);J?_@6/_C=>GT4 >8?\+)\9_\
M1+=3_P# L?\ QNN$\6R>-?$_CCP_XC'@'4K8:3)&Y@,F_P W9('QNVC&<8Z&
MOHJB@#S#_A9/C/\ Z);J?_@6/_C='_"R?&?_ $2W4_\ P+'_ ,;KT^B@#S#_
M (63XS_Z);J?_@6/_C=<#\-O^$U^']QK$K> M2OO[1:-@!)Y?E["_P#LG.=_
MMTKZ-HH \P_X63XS_P"B6ZG_ .!8_P#C='_"R?&?_1+=3_\  L?_ !NO3Z*
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MFSC^U+J_V)4W'!M_.,?G?^.L/]X5O:SJ=UICV\J11O;-+''(3N+#<X4G(&%
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M='_"R?&?_1+=3_\  L?_ !NO3Z* /,/^%D^,_P#HENI_^!8_^-T?\+)\9_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@  Q
MTHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
%** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>a200-2017x92634xmod28exe005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a200-2017x92634xmod28exe005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
544 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>a200-2017x92634xmod29exe001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a200-2017x92634xmod29exe001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *X>ZU;7O$OBO4M$T#4(M*LM*"+=WQ
MMQ-)),XW;$5OE  ZD@\UW%>;Q:K;> /''B ZX7MM)UF6.\M;\QLT0DV!7C<@
M':<@$9X(H W]!_X2K3];N=-UN:/4].\@36^JK&D+!LX,4B XSCD$#&.M+;?$
M/PS>7T5K#?N1-+Y$-PUO(MO+)G&U92NQCGT//:L:X\2WGCB'7=.\,P>;I/\
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M(]UJ*[!B0.RMO/\ " H)&,5S^BWD6D>"_ FH:CYUO;6.N77VIYD.Z'<9P-X
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M[92D%8YY[B>)3VC>9V7\P0?QH NQ>)['3_[?NM3UR.6VLKP0E!;,AMB57$7
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M&Q0O0X7.?[W'2J8^(GB.+2]$UJ?PU:G3M8>*WMH8[P_:/-D4F,L"NT(Q'J2
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MRQ#2X;KS@\H;)F('RKQ\H ]ZC\;3ZG;?$CP=+I-M%=7 @O\ =;RR^6)$VQ9
M;!P>XSQQ7H=5I=/M)[ZWOI;>-[JV#K#*R_-&&QN /;.!GZ4 >=:KX0\0>(=+
M\5ZC>6UO;:GJME'96=DLX<11H2?G? !9F)/' P.372^)]"O=5_X1C[*J'^SM
M6@N[C<V,1K&ZG'J<L.*ZFB@#S_4_!%]=_$:#4(GC&@SRPWU[$3\S7,"LL>!Z
M'*$_[@JMK7A34;CQQJ.IW?ARR\26=Q'$MB+NZ54LMJX92C C#-\V0":])HH
M\HMO!/B.P\%VEJEI92ZCI_B'^U$MXIO+BFC#EMJG'R?>X!'&*M:GX.ND\57V
MO/X1TK7X]5AA:6UNGC$EG,B!2%9U(9" ,XP<CI7IM% '/>#-&N=$T$PW=IIM
MG<33/.]OIL(CBBST7@#<0  6QSBL?^S_ !'X8\2:U>:/I4&K6&K2K<^6;H0/
M;S! K9W AE. >.1SQ7<T4 >;Z;X&U:RG\.W,[V\UU'J]UJFI-&V$5ID883/)
M )4?K7H[*'1D895A@BEHH \WTO2_&_A_PXGA33+6S"0,8K;6VN%(CA+$AFA*
MY+@'&.A/>KEOIWB?PGJVL_V1I=OK%CJER;U&>[6!X)F4!PX(P5)4$;>1SQ7>
M44 >=:3X%U/2[GPC)))#/+8WEY>:C*AVKOG1_N \D!F ^@S5_5/#.I77B+Q/
M>Q)&8=0T-;* EP"91YG!'8?,.:[:B@#A(/"FHBZ\!M+''Y6CZ?-;7N'Z,T"1
M@#UY4UAW/ASQI;?#^[\#6>FV4\(A>WM]3>["AX220#'C(?!V^G?->KT4 >9Z
MMX)GA\3OK:^&M,\10W=G##/:W9C62"6,8#(SJ1M(X(X/ -.3P7JIT+38QIND
M6-POB"WU&2UL(UCCA@1P=I8 >8X ZXYZ=J]*HH YJ^T6\G^(FDZTBI]CMK&X
M@D);D,[(5P/^ FN1TOPCXCB\(:#H-S8V\;:-K4%P)TN0PGA65G9P, J0& P>
MM>IT4 >5S>#-5;7=<EO/#6FZU<WMU))9:K?W 9+:)A\B&-@2-G^R.?4=:N^&
M/!VL:9+X':[BB4:/97=O=;9 <,^T)CU!V_A7H]% %'2IM2GMY6U2TBMIA,ZQ
MI%+O#1@_*Q/8D=NU<AJVG^)]/^(UQX@T;1K;4K:?38[0K+>B JRR,Q/W3GJ*
M[VB@#A].\/:YK?BF+Q!XIBL[5;2WDM['3[64R[#(,2.[D#+$#  &,5DP:'XS
MT_P9+X(MM/LI8#$]G#J[7055@;(W-%C=O"G&!QGO7IU% 'GP\/ZYX5\2V]_H
M6G0ZK9G28-->*2Z$#QF$G:^2""I!YQS66/!GBM/#1C5;$ZO_ ,)/_;'^M/D[
M=V[KC.,\8QG%>JT4 <*-)U_Q%XFM=8U?3H=,ATRUGBM;=;D3/++*H5F+  !0
MHP!UYSQ6!_PKO4+?1_"=S-H^FZO=Z59-9WFFW;*4D5L$,C,"H92.XY!/(KUF
MB@#CO!F@7.G7VH7\^@:1HD4X2.WL[&)/,51U,DB@!B3T X%4_&WAO4-6\2:9
M?G28M=TF""2.33);D1!9201+AOE?@$8/3M7>T4 >8Z-X1\2:9_PED]GI^BZ=
M+J:VS6=I& ]LH0%6B<;1U7@G&,L34GASPC>P>-K36X/#EKX8M8894NX+:[$@
MO&8 *-B *%4Y.>IXXKTJB@#R.+P#KD_@O3](O-+TZ6XT+4&N;9+B820:A&S.
M65AM^3A^,@\@5M:'X8NO[8EO1X1T/P];):211QP)$]Q+*PQGS$4!5 R,=3GF
MO0J* /.[GP?JTOP2A\++'%_:BVL,17S!MW+(K'YOH#3_ !9H&HZIJ]T+WPGI
M?B/3Y$7[([S+;SVIQ\RLY&2I/(*G(]*]!JMJ-W]@TR[O-F_R(7EV9QNV@G&?
MPH \[MOAS=S_ /"'6NOK!JEOIEE>0WK2MN&Z4+L"[N3M *@]> >*LQ:%XLL?
M#!T1K;3]7MK"Z"11WS*?M]E@X1B00DB\#)&#@5W&DWW]J:-8ZAY?E_:K>.?9
MG.W<H;&>^,U<H X'P-X5N]&\0:EJ2Z5%H6G7,*1II<-SYP,@))E./E4X(4!:
MT?$>D:M%XHTWQ/HEM%>7%M;R6=S9R2^4987(8%&(P&#*#SU'I76T4 >83^"M
M>\30>,_[:BM;!M;BM!:)'+YPB,.X@.<#/.W.!W.,XIVF>%+Z75M++>!?#6BB
MTF6:ZO8XXI6EV]!" H*Y.#N."/>O3:* ..T3P[J%CHOBRUG2,2ZEJ-[<6X#Y
M!24 +GTK'T[PQXA\--X>U:PLX+Z[MM%BTJ_L3<",D(0P>-R,$AMP(.,@UZ31
M0!YCJ/@K7M?T+QA=WJ6MMJVNQ0Q6]HLN]((X>55GQRS$G.!@<4[6/"VI:GKU
MGXIN_">F:E-+9?9+S2+J:-S$5<E)(Y&7:3@D$<<$5Z910!RO@G0[G28+^>ZT
MG2=):[F#1V>G1*!%&HP [J!O;DG/09XJMJFEZWI/C27Q'HMC#J45[:);7=HT
MXA=60DHZL1@C#$$''8UV=% 'F-QX*UZ_M+[4;M+9-5U+6;.]EMXY<I!! 5 7
M<0-S!0<D#D]*ZF;1;Q_B5::XJI]BBTJ6U9MWS>8TJ,./3"GFNEHH \VG\%ZQ
M)IVIPK'%ON/%2:K'^\'^H#1DGZ_*>*C\5^%]6UF\U*&\\*:5K/G,?[/U(3K;
M2VRE<!7.-QVG)RI.?05Z;10!YMJ/AC6A9Z=8ZGHFG>+;*&PB@8SR+%/%.HPS
MAW&2K<=P>*32_!&M66E^%+>9HW.G:M)>2Q>>7%M"RR!8U9N7V[@/SKTJB@#S
M:RT?QAX=\/7?A32],L[NU9IDLM2DNP@ACD9F_>1X+%EW'[O!XZ5I:!X-N=!\
M5:1-$RR:?8>'_P"S3*3AFE$J-G;Z$ FNWHH X%_#GB"V'BJ:RAL)7U#4H[F*
MWN\-'<PA$5XVX.TG:0#@]JK^$_"=[IWB^;6K?0;?P[8FT:&2P@NQ(+F4L"'*
MK\BA0"!CGFO1J* *6D3:A/I4$NJVL5K?,#YL,4GF*AR<8;OQBKM%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%17%S;VJ![B>*%"<!I'"@
MGTYH EHJE_;.E_\ 02L_^_Z_XT?VSI?_ $$K/_O^O^- %VBJ7]LZ7_T$K/\
M[_K_ (T?VSI?_02L_P#O^O\ C0!=HJE_;.E_]!*S_P"_Z_XT?VSI?_02L_\
MO^O^- %VBJ7]LZ7_ -!*S_[_ *_XT?VSI?\ T$K/_O\ K_C0!=HJE_;.E_\
M02L_^_Z_XT?VSI?_ $$K/_O^O^- %VBJ7]LZ7_T$K/\ [_K_ (T?VSI?_02L
M_P#O^O\ C0!=HJE_;.E_]!*S_P"_Z_XT?VSI?_02L_\ O^O^- %VBJ7]LZ7_
M -!*S_[_ *_XT?VSI?\ T$K/_O\ K_C0!=HJE_;.E_\ 02L_^_Z_XT?VSI?_
M $$K/_O^O^- %VBJ7]LZ7_T$K/\ [_K_ (T?VSI?_02L_P#O^O\ C0!=HJE_
M;.E_]!*S_P"_Z_XT?VSI?_02L_\ O^O^- %VBJ7]LZ7_ -!*S_[_ *_XT?VS
MI?\ T$K/_O\ K_C0!=HJE_;.E_\ 02L_^_Z_XT?VSI?_ $$K/_O^O^- %VBJ
M7]LZ7_T$K/\ [_K_ (T?VSI?_02L_P#O^O\ C0!=HJE_;.E_]!*S_P"_Z_XT
M?VSI?_02L_\ O^O^- %VBJ7]LZ7_ -!*S_[_ *_XT?VSI?\ T$K/_O\ K_C0
M!=HJE_;.E_\ 02L_^_Z_XT?VSI?_ $$K/_O^O^- %VBJ7]LZ7_T$K/\ [_K_
M (T?VSI?_02L_P#O^O\ C0!=HJE_;.E_]!*S_P"_Z_XT?VSI?_02L_\ O^O^
M- %VBJ7]LZ7_ -!*S_[_ *_XT?VSI?\ T$K/_O\ K_C0!=HJE_;.E_\ 02L_
M^_Z_XT?VSI?_ $$K/_O^O^- %VBJ7]LZ7_T$K/\ [_K_ (T?VSI?_02L_P#O
M^O\ C0!=HJE_;.E_]!*S_P"_Z_XT?VSI?_02L_\ O^O^- %VBJ7]LZ7_ -!*
MS_[_ *_XT?VSI?\ T$K/_O\ K_C0!=HJE_;.E_\ 02L_^_Z_XT?VSI?_ $$K
M/_O^O^- %VBJ7]LZ7_T$K/\ [_K_ (T?VSI?_02L_P#O^O\ C0!=HJE_;.E_
M]!*S_P"_Z_XT?VSI?_02L_\ O^O^- %VBJ7]LZ7_ -!*S_[_ *_XT?VSI?\
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M]><W_H!J7^V=+_Z"5G_W_7_&L[7]7TQ_#FIJNHVC,;24 "922=A]Z )O"?\
MR)VA_P#8/@_]%K6Q7-^%M6TV/PCHJ/J%HKK80!E:900?+7@\UJ2ZYI<4+R?V
MC:-M4M@3KSC\: -"BN8L?&UC.T(O/(M%FM6ND<W*.-J[<AL<AOG''U]*(/'&
MF3Z5!=(4%S/-Y*VCS(&#\GYCG &T;L^GJ>* .GHKEYO&4,(AB>*W%S).8MIO
M8_+P$+[@_IQCD YK5M==L);9'GO;**0YR@ND<#GU[T :=%8=YXGL8;I+:UFM
M;B4H9&)ND1%7..6/<]A['.*JKXSM+B2-+00.6B,C^;=)'L(8J5/7)!!Z4 =-
M16/J/B73-/TRXO!=VTS0QE_*2=<L1V'-43XULH4O5NA#'<6T22+&ERCB7>65
M55@>N5QSTR#0!TU%<W_PF>GSQ67V)X)IKJ'SMDEPD8B48R')S@Y., 'H?2HV
M\9P&>*"**W\UH?,D6:\CCV'<5QGD'IGCM@T =117-1^,[*34I+5#;LD,B13.
M+N/<I95.X+GE!N +>QXXK8_MG2_^@E9_]_U_QH NT52_MG2_^@E9_P#?]?\
M&C^V=+_Z"5G_ -_U_P : +M%4O[9TO\ Z"5G_P!_U_QH_MG2_P#H)6?_ '_7
M_&@"[15+^V=+_P"@E9_]_P!?\:!K&F$@#4K,D]O/7_&@"[1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 55OM-L-4A6'4+*VNXE;>$
MN(ED4-TS@@\\G\ZM44 >2^/)](\/:O;6NE^%]"F2UA^W:FKV,986^]4PG'WC
MEC]%IOB*XT72O'>A6=MX?T!]$N[>.:XD.GQDA9)/+5@V.!EDKLYOA_X?OM5U
M'4M5LTU*XOF4YND5O)55VA4XX'ZYK/D^%VESZ8MC<7]]-&FF_P!FJSE-PC\T
M2*?N_>4J /84 ><IKL$^@^*-27P[X?C2TGM38'^RXVQ#-*R@L,?,=H!K4NC9
M6GA'6]4MK70]0N+1(?*63PP;0*SR!<G?][@GITKMIOAGI3Z;?V,=W=PQW<5G
M$2A7,8MA\A7*]3WSFK-SX)EU#2KS3=3\2:K?6]TJ B40C85=7!&U!S\N.>QH
M XFUU+1-2NHXX?#&B021Z3=S7EL^GQEX+J$J"IXZ<_B"*;I< M+3PMJFK:-X
M:O+#7I8K=HHM(2*2W>52R$')##@@\"N\N/ >E3^)[W7T::&ZO;)[.=8R-C!@
M 7QC[V !Z<=*KZ3\/;73I=,-SJ^I:A!I>#96URR"*)@-H;"J"2!TR3B@#S*+
M7[06&O0R^&O#QU);E8]* TZ,!U,[Q'<,<[=A-2'4;.:XT2)]/T*P6[T6.^ED
M3PZ+LM*SE2 J#*C Z^WO7H:_##1A?6-VT]TTMG)<R)DKAC,23GC^$L2/US2Q
M_#J*UGL)].UW4[&:ST]=.5X?*)>)6+?-N0\Y/;TH XW4K[2M!U;0%N/#^BWV
MESV;7&H7"Z.L#(AD""38PRH4LN0<G&:6[MX[CP?K>O6&F^&XAI=Y>1[&T>.0
M31QL F#D8XSSSG->B1>$+=KZ"\U"]N=1FCL9;&0W(3$T<CACN"J!G@#C'%5;
M#X?Z9IO@J^\+07%U]BNS(6=F4N@?J <8XQW% $7AOP=IK:1%-JVE:#=SS!95
M:'28X0BE0=N.<G.>:Y)=.DUJUUO6M)T?PO:V.FW$T,%I/I*2-<^5]XN_&W)!
MQ@<5ZS:P+:VD-NA)6*-4!/4@#%<G>?#VWGGU 6FLZI86.I2-)>65LZ".5F^\
M02I*[N^#S0!Y]?:KH]UJ^FI;Z?H6D65WH\5_E] %XWF,[ K\@! XZ^WO7;ZW
MX?L=/\#RWVF>%]&U+54MT9 NEHHD)QN81XST);;G/&*W['PKI^FZ]'JEIOC,
M6G)IT< (V+$K;A[Y[=:MZYHUOK^D3:=<R311RX(D@?8Z,""&4]B"!0!Y%:ZM
MHMEH>NWTVF^'-5:Q@C>*%M'%G<)([!-LD;*1LRP^8&MHZ*?#FLZ)%KND^&;^
MUU:?[*PM])2)K>4J2NT\[UX(YP:Z6/X>V,[7\NM7][K$][:"R>2Y*+LA#;@%
M"* #NP<]<@5)I_@:.VU.ROM0UK4]5;3P?L<=XZ;821C<=JC<V.,G- &9X)TO
M1-?\,G4+WPYHGG_:)X_W>GQ@821E'&/0"N3T-XO$]IX?TZST/PY::A?6<U[=
M7;Z5&ZI&DIC4(G&23C.37>:-X'DT.1%L_$>J"S6=IC:$1&-MS%F!.S=@DGO4
M4/PYLK/3=*@T_4[^SO-+22."]B*>84=BS*X*E6&3Z<8H YZ[TAM,N/#^G:AH
M'A@7=_>S6SSP:<A5XQ&61]I'RMD#(R?KSPSP_P"'9;SQIJ^DWEKX:DMM):W,
MNS0HU,XE0M@'<=N,8[UUMIX$L+0Z6XO+V::PO)+TRS2!FGED4AB_'OT&*T;?
MP[#:ZOKFIP7,Z7.K)$LA&,1&-"BE..O.><\T >=:9?:)=_$![&7PUH(T&YGF
ML;*46,6\W$2J6)./NL=X'J14C>&[C_A8 \/"#PSY)L3?B3^P(\A?-V>7][KC
M^+]*Z-?A7X:ATJTMK6W-O>VKQR1ZE&J_:"Z,&W%L<Y(YXKHCH-N?%@\0^;+]
MI%B;+R^-FS?OSTSG/O0!Y;;SVVHBRTNT\.^'8]2U#5KRUCN)=-C*0PP<D[0!
MN;&,<XINMM'X;M?$&FW>A>'+K4K&SAO;2[CTJ-%D1Y1&0Z<X(.>AKNG^'FFF
MP6&*\O8+F*_EO[>\B=1+#)(<L!Q@J>F"#D4Q_AU8W.G:K#?ZE?WEYJBQI<7T
MK)Y@1&#*J@*%5<CIB@#EM'U#P[J>M:=!-X9T6V5;*Y?4[=K"/?!/"5#+G'3D
MGW!%946H6EGXF\.0:GX=T!=.OK**XNS_ &;$&B:9I!'SC@#" _\ UZ]!U7X>
M:5J>NWVL+-<6MU?63V4_DE=K*P +<C[VT8S3O$/P^TKQ')=-<RW$0N+**RVQ
M%0(UCD\Q67(ZYX^E 'FFE:Y;W>DZC-)X4\/&\GU"UM--5M/C5$%PNY"^!DX7
M!K=O;"/PQJ?]FZMI'AS4/MFGW5Q:7$6DQPF.6%-Y5EY!7&,'K76O\.M&DM-1
MMF>Y$=X;=E*.%:W:",)&T9 X("@\Y_*E@\!P&XN+K4]7U#4[R2TDLXYKDH/(
MC<8;8JJ!N/<G- '%:7;+9P^%=1U;1O#5[8:^\4)CBTA(I+=Y$W+@Y(8<8/ K
M)?4[-]'\,3R:7X?L3J<M\EQ<?V&MP%$+D)B-1GGH?KFO2-)^']MIT^F/<ZOJ
M6HQ:6 +*WN601PD+M#851D@="2<5-I?@/3]*DT-X;JY<Z.]T\.\K\YG)W;L#
MMGC&* .*,NCZ;=V9N=(T/4;,Z1=ZA)*FC);M)Y1^4!6!*\9'/UK2\/>%KR]7
M2M6NM'\)S6%_&)I[1-+6-K=&7<NQ^=YY&00*[/4/#-CJ>NQ:I=%W9+.6S,!Q
ML>.3&[/&>WK65IW@"'3[JQ=M;U6YM=.R;&TFD4QP'! /"@MM!P-Q.* .06^T
M0_$3["?#6@_\(\;HZ6LWV&+?]K"!O3IG*?6I+WPW<)X\AT&&#PRD-S;2WB.V
M@1DQJKA0A^;DX/7CITKHO^%4^&O[$%D(6%Z&\S^U %^U>9OW[]^.N?;I71/H
M$$GB:VUYYI3<V]HUJ$XVLK,&)/&<Y% 'F+7%G,]SIUKX;\/#4)_$,^EVLLNG
M1[(8D4,68 ?,P&>,C-&KQQ>&&UK2]0T7PY>W<&DMJ5G>1Z5'&#M?84=.1U.0
M0:[>;X?:9/:7D7VJ\CFGU-]5BN8G"R6\[8'R'&,<="#UJ,_#VTN+;5/[1U2_
MO[[4K7[))>3% \<6<[4 4*HSSTZT <EH-]HNLZQX;T^3POHEO=3BZBU2W;3X
M]R2Q(K*5XX4[LCKD'VK1O]%MM7\8WN@:'H_A[3XM.MXYKBYGTJ.9G>3)557@
M 8')KJ/^$(TM?%UEXEC,J7UK;FW(4C;*-NT%ACJ >H]O2EU?PA'J&L_VQ8ZI
M?:5J+0B"6:T*$2H#D!E92"1V/6@#S&^U2Q33+%)-#\.V%XFKSZ7?W"Z.MQ'F
M-<[T0#<0<CCZUW7A_0?#LOAIM2N]-T74%'F2">/15MOE7J/+8$YR#SWJ_:>
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MQR2>< #O6I0!B_\ "'^&/^A<TC_P!B_^)H_X0_PQ_P!"YI'_ ( Q?_$UM44
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M&SBSG.=I?;N*Y[>G!)'%*/AWX;$EC(=-M2;5G)!MX]LP8'AQC!QP1]!75T4
M<R? 7AS:X&DV(+7"S@BUCRH!!V#C[IQ@CW-1M\//#;Z@]R^EV;1,Q<P&V3;N
MVA>N,XXSMZ9YKJJ* .1/PZT% I@L;-&5I"-]G%("KG."&7G'8]0..E6(O 'A
MJ);-1I%BPM\[B]K&3-D$?/\ +SR<^U=-10!SMSX&\-7#V[#0]-B\F3S"([.,
M!_E9=K?+R/FS]0*I:=\.-!LVMS<V=I>""+RT62RA ;@#<^%R[<=2>Y[UU]%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***1RP1B@!;' )P"?K0 M%5[.>2XM]\J*CAW0A3D?*Q7K^%6* "N7\=>(
M+WP[I>GW-B(C)/J,%L_F+D;')!QSUKJ*X+XL?\@#1_\ L-6O_H1H [VBBB@
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M3T4 <Q_PL7PC_P!!RW_)O\*/^%B^$?\ H.6_Y-_A73T4 <Q_PL7PC_T'+?\
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M?L_F+YA8R"/(7.<<Y^E2Q>([26_U"U6.;-FC-N"Y$VT#>$QR2I(4^YH H?\
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M5I%EN1E(DF.U2V5=BJ;<#YB2" !DG\:?8ZI;7\DD4?FQS1@,\4T31N <X.&
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M$D MVYQUZ*B@!%SM&[&<<XI:** "BBB@ HHHH **** "BBB@#F+[_DIVB_\
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M(ZJ7;!]SG-:VF::NEP""*:21/F9C(!N>1F+,Y( Y))]O2KU% !1110 4444
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MGS3;LMS]U<D+DG)/!]N36KYD?]]?SH =13?,C_OK^='F1_WU_.@!U%-\R/\
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MB\,BQ[A""[*Y8LVXDG[H]?Y5/%<1-JLP#C)B11[D%\C]15SS(_[Z_G1YD?\
M?7\Z ,Z8QI/*T$THNFD!\KG!/ Z8^[@=?UK3IOF1_P!]?SH\R/\ OK^= #J*
M;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OY
MT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\
MR/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?
M]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .H
MIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\
MOK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?S
MH\R/^^OYT .HIOF1_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1
M_P!]?SH\R/\ OK^= #J*;YD?]]?SH\R/^^OYT .HIOF1_P!]?SH\Q/[Z_G0
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M'=,%O)IEW(\0MEVLRR0!21CJ S?F:Z!OA_X+09;PSHZCWM4']*+[_DIVB_\
M8)O?_1MM6IJ[1RFWLS&DSRN&,;$9V+R>OJ<#\30!F?\ "O?!@&?^$8TC'K]D
M3_"FKX!\$NF]?#6C%?[PMDQ_*KBSP-IC65S,D+0S+#AR' P04#<\@C /XU-#
M]G$E^'CM@WE+YLD9^5A\V 1V(_'@B@#.'@#P4P)7PUHY ZD6J<?I0OP_\%/]
MWPSH[8]+5#_2KFEP)+;VMP4M(HHX<.8FW%\KR&.!@=\<\XJOIH5(M+G9+:*
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MDA<<=R3Z 277A4W5K)"URJ-(US([JG)>7(4]>BH2ON/2@"J/!OP_:W:X71-
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M%_*MXX99D=4$28^<AD1@Q&&8@9(' Z<]<T 58?!7@&X<)#H.A2,RE@J01DD
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MA3;1@G\,5NM_I.HJG_+.V&YO=R.!^ R?^!"L^\DM=U]^\MY<L/-MI1AV8*
MIS[#'!YH IGP%X( <GPWHPV?>_T9/E^O'%-;P)X&1%=_#NBJC<*QMXP#].*O
MS-%%JMY.C(S1H@GC!!)CP<DCVX/TSZTV%X$BM!]HMXI5LTRDZY4H?3D8Z<_A
M0!6'P]\&$ CPQI!![_9$_P *7_A7G@W_ *%?2?\ P$3_  K<T_9_9UMY<0B0
M1J%C!R% ' 'M5F@#FO\ A7G@W_H5])_\!$_PH_X5YX-_Z%?2?_ 1/\*Z6B@#
MFO\ A7G@W_H5])_\!$_PH_X5YX-_Z%?2?_ 1/\*Z6B@#FO\ A7G@W_H5])_\
M!$_PI5^'W@Y'#KX8TD,IR"+5.#^5=)10 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !14#WEO'<I;O,BS/]U">3]*6>ZAMM
MHED"EN@ZDXZ\"@":BJS:A:+#'*;B/RY#A&!R&^E!U"T6$3&XC\LMLW9_B]/K
M0!9HJ*&XAN%+0R*X!P=IZ'WI?/3[3Y R7";SCH!G S]>?R- $E%5DU"TDE$2
M7"%V)"C/WL=<>N,=J/[1L_L_VC[1'Y6[9O!XW9QCZYH LT56FU"TMV*S7"(5
M&6R>%^I[?C5F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .5U^'5;7Q9I>LV&DS:E##9W-M)'#-&CJ9'B93^\901^[/?TI
M3XBUTL&/@;4RPZ'[7:?_ !VNIHH Y;_A(-<Y_P"*%U+GK_I5IS_Y%I%U_6T3
M8G@34E3^Z+JT _\ 1M=510!RP\0ZXJE1X%U, ]0+NT_^.T#Q#K@7:/ NI@>G
MVNT_^.UU-% '*IX@UR,$)X%U-026.+NTY)ZG_6T-K^MLZNW@34BR]";JTR/_
M "+7544 <M_PD6N[MW_"#:GN]?M=IG_T;2/K^MR)L?P)J3+Z&ZM"/_1M=510
M!RX\1Z\  / ^J #H!=VG_P =I?\ A)-?_P"A'U3_ ,"[3_X[73T4 <Q_PDFO
M_P#0D:I_X%VG_P =H_X237_^A'U3_P "[3_X[73T4 <Q_P ))K__ $(^J?\
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MUO/"\RLPB099Y$9!CURP'I34U&V=P@9PY!95:)E+ =< CG\* ,'_ (2K4_\
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M#@H'&[\J0WMJ(3,;F$1 [2_F#;GTS0!FW4JJUYY7FB5R0;>2'<DYV@<<9((
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MG^4%BS0LNWCW')^F:M44 8>FLT$$ <7<SE8D$4L#*L1!Y(.T#@'OZ=:D5WW
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH *YCQY_R ;/_ +"VG_\ I5%73US'CS_D V?_ &%M/_\
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M!:HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M,>//^0#9_P#86T__ -*HJZ>N8\>?\@&S_P"PMI__ *514 =/1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %<QX\_Y -G_P!A;3__ $JBKIZY
MCQY_R ;/_L+:?_Z514 =/1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPQO$TJ'_ (EK;<@@*#)_O;00_P".* -#S_'?_0.\.?\ @?/_ /&://\ '?\
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M4A<WTNHQ:4NI1[@DLCW$<:ESM* (0<J&^<$\>F ,T 5O/\=_] [PY_X'S_\
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MG_\ C-'G^._^@=X<_P# ^?\ ^,UU%% '+^?X[_Z!WAS_ ,#Y_P#XS1Y_CO\
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MW$*HGR-\P<?,I((9<?ATH 3S_'?_ $#O#G_@?/\ _&://\=_] [PY_X'S_\
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M=_\ 0.\.?^!\_P#\9H\_QW_T#O#G_@?/_P#&:ZBB@#E_/\=_] [PY_X'S_\
MQFCS_'?_ $#O#G_@?/\ _&:ZBB@#E_/\=_\ 0.\.?^!\_P#\9H\_QW_T#O#G
M_@?/_P#&:ZBB@#E_/\=_] [PY_X'S_\ QFCS_'?_ $#O#G_@?/\ _&:ZBB@#
ME_/\=_\ 0.\.?^!\_P#\9H\_QW_T#O#G_@?/_P#&:ZBB@#E_/\=_] [PY_X'
MS_\ QFCS_'?_ $#O#G_@?/\ _&:ZBB@#E_/\=_\ 0.\.?^!\_P#\9H\_QW_T
M#O#G_@?/_P#&:ZBB@#E_/\=_] [PY_X'S_\ QFCS_'?_ $#O#G_@?/\ _&:Z
MBB@#E_/\=_\ 0.\.?^!\_P#\9H\_QW_T#O#G_@?/_P#&:ZBB@#E_/\=_] [P
MY_X'S_\ QFCS_'?_ $#O#G_@?/\ _&:ZBB@#E_/\=_\ 0.\.?^!\_P#\9H\_
MQW_T#O#G_@?/_P#&:ZBB@#E_/\=_] [PY_X'S_\ QFCS_'?_ $#O#G_@?/\
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M?)\YV,K[0"V%'W>IPWY4L?B-%U.ZM+F)4CM[<2F9&+!FPI90,9X$D>.YW=*
M*O\ PG-G_P! ;Q'_ ."6X_\ B*/^$YL_^@-XC_\ !+<?_$5H6.M277AQ=6>R
M=2RLX@1U)VAB <G Z '_ !J-=<N##HQ.GN)-2V9^<;8<H7(/<D*IZ#''6@"G
M_P )S9_] ;Q'_P""6X_^(H_X3FS_ .@-XC_\$MQ_\16[I]V;VT,I3:RRR1,
M<\H[(?U6K5 ',?\ "<V?_0&\1_\ @EN/_B*/^$YL_P#H#>(__!+<?_$5T]%
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M_H#>(_\ P2W'_P 173T4 <Q_PG-G_P! ;Q'_ ."6X_\ B*/^$YL_^@-XC_\
M!+<?_$5T]% ',?\ "<V?_0&\1_\ @EN/_B*/^$YL_P#H#>(__!+<?_$5T]%
M',?\)S9_] ;Q'_X);C_XBC_A.;/_ * WB/\ \$MQ_P#$5T]% ',?\)S9_P#0
M&\1_^"6X_P#B*/\ A.;/_H#>(_\ P2W'_P 173T4 <Q_PG-G_P! ;Q'_ ."6
MX_\ B*/^$YL_^@-XC_\ !+<?_$5T]% ',?\ "<V?_0&\1_\ @EN/_B*5?&]F
M[JHT?Q$,G&3HUP!_Z!7344 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN-/M())D+RO*026*DJH&Q0.3U/2G7_A'4?$.JZE/?7LEC:M:C3[>.-(Y"\1
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M] V3_OZG^-*+N\)&=-D'OYJ?XT 7:*** "BBB@ HHHH **** "BBB@ HHHH
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M*>Z%]!:?988F821C8[-"DC,Y)X7Y\<8QM/)J9/$,DGB3[*,"P=GMDD$;<3*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %1O/%'+'$\J+))G8A8 MCDX'?%25RWB*YM[3Q?X8FN9X
MH8@;H%Y'"@?NQW- '4D@=3BC(SC/-<)XPG_X22:TT;38IM0A\I[N=K&6+*$
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MZ>N8\>?\@&S_ .PMI_\ Z514 :6L2RVIBN(Y7"#*S*#PL9ZR?5>#]":U% "
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M2<^YJ*+1]-@G:>*R@25LY8(.,]<>F>^.M7J* $    & *6BB@ HHHH ****
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M6V6Z-HUQA-JOOV D9S@M@9QWH K_ /"P?!O_ $-.C_\ @9'_ (T?\+!\&_\
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M#(_\:/\ A8/@W_H:='_\#(_\:L2:S:PWDEO+8.A4J02$Y4R+'N(!RHRP(SU
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MY$/_ #R3_OD4 <__ ,+!\&_]#3H__@9'_C1_PL'P;_T-.C_^!D?^-=!Y$/\
MSR3_ +Y%'D0_\\D_[Y% '/\ _"P?!O\ T-.C_P#@9'_C1_PL'P;_ -#3H_\
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M/_X&1_XTJ^/_  >[A5\4:068X %Y'DG\ZW_(A_YY)_WR*/(B_P">2?\ ?(H
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M_P \?#G_ ']G_P#B: .HHKE]WCO_ )X^'/\ O[/_ /$T;O'?_/'PY_W]G_\
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ML1 B[%;=MXYY8*2<_P ('K3V\.V_V._M(I7C@NW$A3KL;C)&?7:/QSZUL44
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M08%-6.-79U10S?>8#D_6@#B=8U+[#:G^R-8DN]]O(\[>>)/+  Q("/N\\8&
M<GCBC5]2DM=0CM].U-Y[5S#YY:YR(F,JJ!YG)7<I;/7[O%=JL4:A@L: ,<M@
M=3[TOEQ[=NQ=OICB@"CI#*UL^)4D.[G;=&<#C^\0,?2M"FJBH,*H7Z#%.H *
M*** "BBB@ HHHH **** "BBB@ KF/'G_ " ;/_L+:?\ ^E45=/7,>//^0#9_
M]A;3_P#TJBH Z>BBB@#E]%_Y'[Q3_P!<[+_T!ZW=2DFAT^>:!U1XXV?++NZ
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7NE76CG=]DM+F0PPH\4-P?,CS&0YX)4G!)^\,],B@#3_ .%@:!ZZI_X)[O\
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M>5"0KDG!!7L,\4R\1BFH;X[O_A)3>.;-U63A/,_=;6'RB/9MW=OO9YH U?\
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MV(MV?X<E,9XZ>U-U6*%]+G7P]%?JYTVY%[N656/[H[=V[DR[\8_BQNH W_\
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MQ>VUJ0)YTC)&0">2,A<X^K*/Q% &9_PDD?\ T"]7_P# )Z/^$DC_ .@7J_\
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M!/6U10!B_P#"21_] O5__ )Z/^$DC_Z!>K_^ 3UM44 8O_"21_\ 0+U?_P
MGH_X22/_ *!>K_\ @$];517-S#9VTES<.(X8UW.Q["@#*_X22/\ Z!>K_P#@
M$]'_  DD?_0+U?\ \ GJ[;ZO8W6\13Y9"H9"C*R[CA<J1G!/?IUJ[0!B_P#"
M21_] O5__ )Z/^$DC_Z!>K_^ 3UM44 8O_"21_\ 0+U?_P  GH_X22/_ *!>
MK_\ @$]:\4T<Z%XG5U#,A*G/*D@CZ@@C\*?0!B_\))'_ - O5_\ P">C_A)(
M_P#H%ZO_ . 3UK+/$\\D"N#+&%+KW .<?R-$\\5M$99G"(" 6/J3@?J10!D_
M\))'_P! O5__  ">C_A)(_\ H%ZO_P" 3UM44 8O_"21_P#0+U?_ , GH_X2
M2/\ Z!>K_P#@$]6H];TZ6Z^S)<CS3(T0W*P#.I(*@D8)!!X![&KL4BS1+(AR
MK#(.,4 9'_"21_\ 0+U?_P  GH_X22/_ *!>K_\ @$];5% &+_PDD?\ T"]7
M_P# )Z/^$DC_ .@7J_\ X!/6N9HQ.L)=?-92X3/) (!./3D?G3Z ,7_A)(_^
M@7J__@$]'_"21_\ 0+U?_P  GK7,T2SK 9%$KJ75,\E00"<>@+#\Q3Z ,7_A
M)(_^@7J__@$]'_"21_\ 0+U?_P  GK6DGBADA21PK3/LC!_B;:6Q^2D_A4E
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M:]M+R SVMU#/""09(I R@CKR*K_VYI/D"?\ M2R\HL5$GVA-I(QD9SUY'YT
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M"Q.=0E2=6EE9XXP TK,61@N> C,Q ]ZNV_@VVM9[9XYSY=O+!*L90'/EQ-&
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MYXH ?KFAC6=.M[/SQ$L,\4V63?NV$$ C(ZXK)/A-8D@M5,KAKYKXSH51("2
MT:KG(5E+# S[U<D\56XN;:."%YTN?(V[ 0RB3S,$@C_IF>.O7IW+'QAI]U:V
MDLJR0/.B.R,N?*WG"[C[G_$X% %_5M+;41:O'.(9K:0R1LT8D7E64@J2,\,:
MQY?!:31RQ-?-Y3B1@!"H82/$8B<C'RX.=H _+BM&#Q!#=:E';P03/$]O+.)2
MA <(R+\O'S [C^0[$59O]7M=/?9,)681F5A%&7V(.K'';]3VZ4 86J>#Q/9W
MOV:8>?)YC(I0*"6M_)"Y].].E\%I="5KF^;S)E=7,400#**@P,]@HSZ^U;<.
ML6D[7?EF0QVHS++L.S[H; /?@@\>M,AU>-_)CDBE$SHCNJ(6$6_[H8C_ #WX
M% &/_P (6I^;[<=[AA*?+)W9='XRQ(^X!R3U-)?>$2+0-:R^9<1>8R*0%#,T
MZS9)YS@KC!Z^U7K[7VM-+CN1%%YINOLKB1R%1@Q!.0"<<9''0BET_P 2VUQ;
M-)=&.$JTHWHQ9&$8!8@D C@YP1V/4<T 3>';"YT_39$N]OGRW$LS!<8&YB<<
M<5K4V*02Q)( P#J& 88(SZBG4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5K^PAU*U^SW&[
MR_,CD^4X.4<.OZJ*LU%<7,-I 9IY!'&" 6/J3@#ZDD#% &.?"EAERLMPI=Y6
M)##.)'+LH..!N)((Y&3@U=31K1)%=0^5DDE'S=W&&_2E.MZ:!$3>Q 2\KS[[
M>?3GCG'/%"ZUIK23(+V$&$.9,M@+L.'YZ<=_2@"O%X<LHKFTF#S-]D"B%&8$
M+M38"#C(X[ @$\XS4KZ+;/?&Y+S8:99VA##8TB@ -TSG '&<<9Q3O[<TP1B0
MWD8!E\D Y!WXW;<=<XY^G-13>(]+AMY)A<B18RF1&,DAFV@CU&3U'% "7GAZ
MSO=0-Y*THD+1L0I&"8VW+SC(Y'0'!]*5O#UB\$41$F(HFC0A^5RZOGZAD4@^
MU6H-3LKFY:WAN8WF7.5!]#@X]<'@XZ'K5>+7M/<8DG6%S+)$%<\_)(T>3Z L
MIP30!8L-/2P$^V665YY?-D>4@EFVA>P '"CBH?['A6'9!<7,#>?).'C<9W.2
M6X(((^8\$''%0)XFTQKHV[2-&0TRL[KM5?*QN)/8<U8_MO3?+5S>1@/)Y0!S
MDOC.W'7..?IS0!+:Z?'9PBWB9Q;+$L2QYZ8SDYZY.?TK.M/"NGV;1E&F/EB,
M+DJ !&VY1@ =^_4]S6C+J=E!=K:RW,:SM@!">YX4'T)[9Z]J:FKZ?):RW*7<
M9@B;:\F?E!Z8SW.>/KQ0!3G\,V4Z3H);B(7 D6;RW \Q7=G*GCIEFQC'4BK=
M[I%IJ#2&Y5F\R P, V/E)!_/('-1-KU@LD0\]?*DCDD,I.%7854@YY!RXXJ1
M];TU+=9VO(Q&Q903UROWLCJ,=\].] %23PQ8S6QAEEN'#,Q9MP!8,A0C   &
MT]@.>>M3V^AV\%V+MIKB:X$GF&25ADG9LZ  ?=]*;%XBTN61D^TJC"9H5#\;
MV7&<>HY'-2#7M*:(RB^B*[E7KR2P)7 ZG.#C'7'% $+>&[!K:W@(EV6\,4"?
M/SMC8,N??(%17GA]2D$EBVRY@2*.-W<C:L8<#! .#B1@2000<8JY_;=A@2?:
M(_),8D$FX8.6V@ =<YX^O'6I3J=D+);PW,?V=CM#YZG.,#WSQCKF@!FCV#:9
MI<5H\OFNI9F?GEF8L>O/4U>J@NMZ8SQ(M["6EQMPWJ<#/H200 >I&*C'B+1R
MVT:A#GZ]LXS],\$] >M &G45QY_E_P"CF,29_P"6@)&/PJE+X@TF&1XY+^%7
M0L&&>A4X8?AW].M6#J-F 3]ICP'\O.[^+;OQ_P!\\_2@"+&K?WK+_OE_\:,:
MM_>LO^^7_P :;'KFGW"JUM<QS NBG:P'W_NGGJ#@XQUP<4+KVELA=;V)@" -
MIR6SG&T=6!VM@C/0^E #L:M_>LO^^7_QHQJW]ZR_[Y?_ !J$^(+ W"PQ2>87
M2*164C:5D?8,$]\]JD&O:48WD%]#L3;EMW'S'"D>H)X!'4T .QJW]ZR_[Y?_
M !HQJW]ZR_[Y?_&IH]1LY;,7:7"& MMWYX#;MN#Z'/%5+WQ!IUE!YK7".!.(
M"$8$JWF+&V?]TN,T 2XU;^]9?]\O_C3XAJ/FKYS6OE_Q;%;/X9-1_P!MV&$<
M7$?DM'(YD+  ;&52"#SG+ ?7BH!XFTLWOV<W*CY%<.>!RQ7![@@KSG'44 :D
ML23PO#*H:-U*LI[@\$5EKX?A7RV%[>^=%@12F0%HU (V@$8Q@\Y!)XR>!BU=
M:K:6,_E7,J1 J&#,PY).  .N<TUM;TQ8XI#>Q!)02ASV!P2?0 \'/0\4 4(/
M#$$-VY$THM-L(6W#<,8R2"Q/)YP>",]\U)'X8L(KA9HC,AW!G 8?.0Q89.,C
MD]B,C@YJU;:S9W-O)*9!%Y9.]7/*CS&C!/L2C8^E1OXATU+_ .R_:$)6.622
M3("H(RH;)^K8_ T /LM%MK*_EO4>62>12FZ0@D+G.,XR>>[$FH!X:L?*:)GG
M>(1-#$C/Q"C$$JO'^R.N< 8JPVN::L F:\C";BO.<@@9.1U&!@G/8U-=:E96
M2(]Q<(BN"5[Y Y)X[#UH KZKHEKK&S[0TJ[8Y(OW; ;D< ,#Q[ _A4-YX:L;
MRZ>Z9I8[AI/,\Q"I(.Q4( 8$8(4=1U&:NW&IV-H+?S[F-/M!Q#SGS#[8Z^M9
M]YXJTRVT][N&876UXHPD1Y8R,%0_[I)^]TX.,T 6;G0[6YLK.U9I52T(:)LA
MB"%*\[@0>">OUZU%!X<L+:$1)YNT>3U?)_=2&1/_ !X\^M2_V_I0$Q>^@3R5
M+29;A0#AN>AP3@XZ'K2QZ]I<LHB2]BWD9 /'\.['UV\XZXYH K3>&+"61I T
MT;N7WLC#+!W+D9(XY8X(P1GK4TV@6%Q"894=HS)+*5W=3(K*WX88TZ/Q!I,T
M$D\=_"T<>S<0?[WW<>N[MCKVI5U[2F>%%OH2TN-F&]25&?3+ @9[@CK0 R#0
MK>*[2[>>XGG602!Y7!Y",@Z #&US_.HF\,:>UO#%B4>1#%%$VX$J(\[3R,$_
M,<Y&#GI5F[UNQL;];.ZE\IV@>XWL,($4@')]?FIL^NV$&CW6J"4RVULK&3RQ
ME@1U&#T/3@XZT 0GPW8FVG@8S,)[=K:1B_)5F+'MP<L>G Z 5:M]-6TNI989
MY0LTQFDC."I8K@X[CH#5:S\2Z7=R31_:4B>)Y%82G;PG4YZ=.?7'-7+;5+&[
M@EGAN8VCBYD8G&P8SDYZ#'/TH ISZ$EQ<M)]HEAQ<BZB>$@,DGEF-NH((*GH
M1U)J2UT:*TNK1HCB"TA=(U))8LY!9F/<\?\ CQI_]N:9Y/F_:TV[]F.=V[&<
M8Z].?IS48UVS-T8MZ^6,'SBZA"IC,FX'/(PI_G0!$?#=JUR\KW%TT3W(NS;E
MQY9E#!@>!GAE!QG'%2:+H_\ 9CWT[[//O+AIG$9.U >BC/;)9C[NU,N?$NFV
MUL]QYWF1QH[/L^\-H4XVGGD,/SJ:77M-B$V;E6:)&=E4')"C+ >I'<=10!3@
M\):= FU6GP(Q&AW % '5U(P!E@R@Y.2>^:G;P[9R2B>66XEN1@K.[_.I#;LC
MC ], 8QQBGQ^(-/:$RO,L:9 7<?F.45^@Y& W/Y]*F76=->Z6V6\A:5R JAL
MY)7<.>G(Y'K0! _AZQDABC82XB1T0A\%=SK)GZAD4CZ4A\/64FQIVEFE6Z6[
M,KL-SR* HS@ 8P!P !P*MRZG907:VLMRBS,5 4GNW"@^A/;/6H4U[2I$D=+Z
M$K&H9CN[$X&/7GCCOQUH J#PGI:V<%LJ2A(%98COR5RZOGGJ05'7C''2EE\,
M6<MLT/GW2^9&\4KHX!D1SDJ>, >F ,=JMVNM6=U93W@D"6\,K1L[G R#C^?&
M.M-?7]*CB61[Z)5.[[V01MQNR.HQD9STS0!G_P#".2OJHD><+9)++,L2,>6D
M1E/!Z'YV.<GGH!DU:?PW8FQ^RJI*AVD42'(+-$8CD#&1M8\9%6!K>F&$RB\C
M*!_+XY);&0 .IXYX[<TO]MZ89HHA?0EY0A0!LY#?=Y]^WK0!6T72KJQN+FYO
M+CSI9DCC WEMJINQR0/[Q[?F<FDD\,6#Q6\:M-'Y,/V<,C#+1^A)''U&",GF
MGMXDTM;LP?:DVK&TCRY^1<.J8S[EL>G!J6+7M*F+!+Z'Y59VRV-H7[V<]".X
MZB@"&?P[9W F222X^SRLSF!9,('/5ACG.><$XSSC-5[WPO!<:=)!'/+YS;BL
MKD#!8!3PH ' [ >O6KYUS3!$)#>1A2_E@<[MV-V-O7..?IS3K75K.]O9+6WD
M\QDACGWJ,JR/G:0>_3]10!%'H=NDT<YFG>X2?SS,S#<[;-F#QC&WC  _.G76
MBVUW=/,[S*)-GG1(V$EV'*[N,_D1GH<BECUS2Y2P2^A.W&?F]6"\>OS$#ZG%
M+<:WIEHS+/>Q1E2P()Z%0"WY!E)],T $FD6LFE76FMO\BY,I?#?-F1F9L'ZL
M<57?PW8RVOV>1IG&^9RQ89+2JRN>!Z.:67Q)ID;0 7 =993%N3G:P0OR.O('
M&/6K(U?3C+%$+R$M*%9,-D$-]WGISV]>U %:#P_:0:JFH[YGFC#+&'8$(" #
M@XW8XZ$D#L!4,WA33YYYI7:;]ZTKE0P',B,C<XR>&.,DX[8'%6AX@TE@&6^B
M*DD @\<8R<^@R!GIS6E0!G2:+9RN[.KMOD21@3P2B[1^&*@MO#5C:HB*\[*C
M1F,,PP@C;<HX SSW.2?6DFU_9K,NFQ6;2O%LW/YT:#Y^F Q!-30:Y;3ZY<:4
MJ2"6%<^80-CD!2RCW4.F?][V- $-QX9LITG02W$0N!(LWEN!YBNQ8J>.F6;&
M.>35@:+:!]WSYWS/][O+]ZH]%UV#7(O,@BDC'DPS?/CI(NX#CN!1'KT$EE:7
M0BD"7-S]F4<9#;F7)]OE- $<7AFP@F$D9F51@E PPQ"! 2<9Z <9QD9Q4C^'
M[-H1&&F3;%!$K*W*B%]Z'IU!_.LZU\9P3P6D[V,T<=Y"TT)\R-B0(S)@@-D?
M*#VQG [BM#1]:.K@,+0PQM&) QGC<\XP"%)(ZT 6;W3([V6.;SIH)HT:,20L
M =C8W+R#P=H]QCC%10:%8VRJL*,B),DZJ&X#)&L:CZ;5%02^($B2>X%G.]A;
MR-'+= KA2IPY"YR54@@G'8X!IUMKGVK4I;2*T8B*8PM(94'(&20N=V/PH DN
M-#M+C4?MI:1)"4+A" '*_=SQD?@1D<'-58?"6FP@@&8CRS$N6 V@LK9! !+!
ME!W')]2:ENO$-O:7<]G)!+]L5D6" 8W7 ;H4YZ ALY^[M)/&"8W\2HB27/V&
MX.G12F%[L%=H(;8S;<[BH8$$X[$XQS0!.V@6TJ7 GFN9GN()()'DDY*OC.,#
M Z#H *GO=+BO9(Y?.G@EC1HQ)"VUBC8W+T/7:.>HQP14#:] MA)=^5)L2]%D
M1QG<9A%GZ9.?I5.#Q7%-/"K6<J13W36J2>9&3O5F7)4-NQE3V]^E #KWPM;S
MV%Q;PSS+OCE$".^4A:0'<P[YY/4G&3C%.O\ PXEW8R6OFM(;F9'N)YF^<JN.
M%V@ <#;VZD\][EYK-O9:G:6,BN7N.KJ!MCR<+N]-QX'O4?\ ;+//(+>PN9[>
M*;R9)H]N V<'"YR0#U..QQG% %F\TZ.[,#B22"6 DQR0D KD8(Y!!!'J/2DL
M=*M=.<M;*RYACAY;/RH6(_'+MD]ZK6GB"WO[@6]M%))*'D651C]RJNR;F.>,
ME3@=3Z<'%>T\6Z?=Z;:7P$D4=P6#B08:';$TIW#TVKD8Z@@T 3Q>'+**&:(-
M,RRJB'<PX5'9U X]7-26.A6FGW1G@:4#YML9(VIN.3C R>?4G';%0'Q T:1O
M/IMU"LZ,UON*$R,$+[" ?E8A21GTZ@\4DGBBQCEF4+*R1V9O/,4#:P !V#G[
MV&4X_P!H4 3G0K4W)E+S%/,>98=WR+(P(9AQG)W-WQDDXS4;^&;!TC \U7B$
M8C<$$KL4H.""#\K$'(-6(=5CFT^ZN_*D46S2*Z'&<IG./RJBGB4'3I+UK%Q&
MD:N L\;,VX@ 8#<=>] &C9:7;V$ADA,A9H4A)=LY5"Y'XY=JI7?ABQO;F6>=
MYV>16"G>,QY(/RG&>H! )('84K^(4MS+%=V5Q!<H$*0Y1C+O;:NT@X^]P<XQ
MU/'-%SKLEE:RRW>FW$3(\2*"Z%7\QP@PV<#!/.<8H 1?#5NDC3+>7HN'=W>8
M2#<Q=45L\8Z1KT'';%6(-"L;4Q^2C(L4RS(H;@,L0B ^FT55G\2QVD%K+<VK
MHMQ=+; I(CA25+;B5/  !S3;OQ3;6MY>VHMY9)+5X$8@JJLTI(&"3VQSF@"5
M?#-C&\3QM.CQ>2$8.,CRRY7J/^FC@_6H[?PI86QB,4EP!&%7&X?,J$E03C/&
M<<$$C@YI9?$L%JEJ]Y;O$EQ.8=ZNDBI\N=S%2<#M[=3Q2W?B$VZ221Z?/.D=
MTMJS*Z#YV95'4]"7% $T&@PVLGF07%PI2%X8%+ K"KD$A1CU4=2>F*EO](@U
M"3S'EFB9HC"YB;&^,]5/'ZC!'.#4&IZS/IEG#<OI<T@D=(V5)4RC.ZHH.3SR
MPZ4PZ[.9988-)N9Y;=5-RB/'^[)&0@);YFQ@X''(YH O1:7:PV]U;HA$5R29
M%SQRH7 ]!@"H(-("^5))<2B94C24Q-M6;9]TGN/?!&>AR*9=:_;0Z79:A"K3
MPWC((<,$R&4L"2Q&.!58^*8C';E+20O-))'M:6-0"G7YMVTCGL: +1T1)K%8
M9II$E%P;HR0D B0L3QD'@9Q]!5:Z\-13Q1P[RZM=BZN99F)D<A0N!C P5&P]
MMN:V+6<W-LDS1^66&=NX-C\1P:FH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "JFIV(
MU&PDM695#%3\\8<<$'D'Z>Q]"#S5NLSQ!J4FD:-->Q*C.CQJ-X) W.JYP.3C
M=G H RV\'1OM+WCR,T7DRF5/,RF]F 7<3C&]@,[N,>E/B\.74T$J7-\T6)KI
MX!"N&C\UW(;=GGY6Z<8R>>F*+^+KQ;>Y:-()EBN((!<K;RA=SL0R^6?F+*-I
MXS]X5H1ZU?2K:6\?D/=W<KJLCV\L*1HB@DE&^9CR!U .>O% $MCX:2SNUN3<
MEG%Q]H(5,#/E&+ R2>ASR2<U6C\(E%<OJ#R2M"L0D9,DE75PS9)R<KST'H!2
M:CKNJ:?<65I-';)-.)BTB0RSJ0A3!"I\PSOYSG&.IIUSXBNK0@O%%)'%;174
M[A'C(C:0JY"MR-JC=@^AH LZ9X;BTV^%PLP=5\PHOE@,"YR<MD].@QCCKFJT
MO@^"2XDE%Q_KF;S0\0;*F5Y<+DX!S(PY!XQQ3-5\2W5M<%;:.+R#>K9B5HWE
MRWE/(Y"IR0,*O'?=Z5*NK:I/<Z?:V[6ADN8IYFDEMY8P!&T:@!&(89W]3Z4
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MD<5DP>,+V\EB6-(85>SBN3FTFF)+O*N,)]W'ECKZ^U;.LZQ-IUQ80+);1?:
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M@\*11+< W3$SQSQG:F OFB,'')Z>7QGUYJ&^\5O'<S16L)"HUNH>>WE!S(9
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M_MBKVO:YJ&G:+H=^\;132W*&YMXN25\F1S&,CU4?E0!LIX?TV)E:. KM6%0
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M:Y&& 4DY.<8!SS6QXP\3SZ9%I\>G:O;@,LGF3[E;=(JC8I 1N&.[@ 9Q@$4
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M#*W'R@)M.<C[Q;)K9U[Q1';:]9P)K*VUJT89#!&DWGR^8 4;K@;>>HZDYXH
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MB2.(# 1%  _"HTL;2-HV2U@5H@1&5C * ]AZ5YI:^+]5N%N(VUBWAD:YAB(
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MG&HPKN%*,D@\Q003M8Y"DG *X'.>U9DWB[4X8YYAK*.)$NB%V1GR!'<JBLH
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M(R@*C'3CI7E>G>/;JZMHUN?$5I"\T\'F,-F^%6W^8!N0+@87'WL=R<U;\/\
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M'\N*#96AC,9M82A !7RQ@@=./:N2\'^)VOM,N9-0U>UE96'ENS!6!V L"-J
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M +_K_C1_:^F?]!&T_P"_Z_XT 7:*I?VOIG_01M/^_P"O^-']KZ9_T$;3_O\
MK_C0!=HJE_:^F?\ 01M/^_Z_XT?VOIG_ $$;3_O^O^- %VBJ7]KZ9_T$;3_O
M^O\ C3XM2L9Y1'#>VTDC=%2523^ - %JBBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** ,#4?!'A?5[^6^U#0=/NKJ7&^:6 ,S8  R?H *J_\
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M= [@R>6)/E&X!@#@@D<=>*:;RX&G;HIBRBXV23-("$3&>'"G(S@9(XR<],T
M51\._!H&!X:TP#_K@*/^%=^#O^A;TW_OP*T]-EE:YDC-Q#)$%!"K/YK*?KM'
M!]ZAT>ZCGU76(TUAKYH9U5K<QA?LGR_<! ^;/7/- %(_#KP:1@^&M,(]X!3/
M^%;>"O\ H5]*_P# 9:ZFB@#EO^%;>"O^A7TK_P !EH_X5MX*_P"A7TK_ ,!E
MKJ:* .83X<^#8SE/#6F*>F5@ I__  K[PA_T+NG?]^17244 <W_PK[PA_P!"
M[IW_ 'Y% ^'_ (1!R/#VG@^HA KI** .;/P_\)'KX>L&/JT0)_.F-\.?!CG+
M>&=,8^IMU-=/10!RW_"MO!7_ $*^E?\ @,M'_"MO!7_0KZ5_X#+74T4 <M_P
MK;P5_P!"OI7_ (#+1_PK;P5_T*^E?^ RUU-% '+?\*V\%?\ 0KZ5_P" RT?\
M*V\%?]"OI7_@,M=310!RW_"MO!7_ $*^E?\ @,M))\._!$,;2/X;TI$499C
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M_ 9:/^%;>"O^A7TK_P !EKJ:* .6_P"%;>"O^A7TK_P&6C_A6W@K_H5]*_\
M 9:ZFB@#EO\ A6W@K_H5]*_\!EH_X5MX*_Z%?2O_  &6NIHH Y;_ (5MX*_Z
M%?2O_ 9:/^%;>"O^A7TK_P !EKJ:* .6_P"%;>"O^A7TK_P&6C_A6W@K_H5]
M*_\  9:ZFB@#EO\ A6W@K_H5]*_\!EJUIW@CPOI-_%?:?H&GVMU%GRYHH K+
MD$'!^A(K?HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR4B1^-8Y6E2Q\,+(WWF$LP)^IV5J6NJW3>('TVZAB3,3S1E-W"JP &2 &)#
MG;]WH>H)3Q%?ZCIMI#<6(M2K3PP.LZL3F25(P1@CINS^% %'?X[_ .??PY_W
M_G_^(HW^._\ GW\.?]_Y_P#XBH;_ ,82:5;ZTEU!YEWI\0=/)MY6CD;R@_+
M$*,G')Z5+>^)+Z)KE8;51'#>M;/<>3),L:B-7!9$^;DMC/08YH 7?X[_ .??
MPY_W_G_^(HW^._\ GW\.?]_Y_P#XBKCZXZ^'K'4E2WD:XGMH6$4F]/WDR1DJ
MW?&XD?3FLN[\0:W81ZW+,NGNFF1AL(DF7++N'?MF@"QO\=_\^_AS_O\ S_\
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MKP,DB2QA/0L-LHQSE.!QUSFD/B+5QI=]JAM+1;?3E/VF$LWF2,B!I=AZ+CD
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M_3;G4;.UM/(LXD::.1F#2N8EE8*>B@!P 3G)ST'- $N_QW_S[^'/^_\ /_\
M$4;_ !W_ ,^_AS_O_/\ _$5T$=Y"]@M[OV0-$)=S<87&<G\*Y:Q\8W&I:%=W
M=M:(]U#+'^ZB+2[(9,,KE5RQ(4G*CG*,!0!9W^._^??PY_W_ )__ (BC?X[_
M .??PY_W_G_^(J:+Q#*WA74]5_T::6RCF8>46"L43< RM\R'U4\C\:S-5\5:
MKHD 6]@LI)IX%GMY(0Y4#S8HW#)R3CSE(P><$8'< N[_ !W_ ,^_AS_O_/\
M_$4;_'?_ #[^'/\ O_/_ /$5%)XBU2/25NDBCF+7/E22I87 $";"=YB(WOR
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M&_QW_P ^_AS_ +_S_P#Q%&_QW_S[^'/^_P#/_P#$5T]% ',;_'?_ #[^'/\
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M#.M="TZQN99[.V2V>5E9_(&P-M& "!V]JT:** "BBB@ HHHH **** "BBB@
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M-,K13M%;D+<3JH*0D@'YN<]""< X!YQ0!E?VKXR_Z%;3?_!P?_C-']J^,O\
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M7QE_T*VF_P#@X/\ \9H_M7QE_P!"MIO_ (.#_P#&:Z>B@#F/[5\9?]"MIO\
MX.#_ /&:/[5\9?\ 0K:;_P"#@_\ QFNGHH YC^U?&7_0K:;_ .#@_P#QFC^U
M?&7_ $*VF_\ @X/_ ,9KIZ* .8_M7QE_T*VF_P#@X/\ \9H_M7QE_P!"MIO_
M (.#_P#&:Z?-% ',?VKXR_Z%;3?_  <'_P",T?VKXR_Z%;3?_!P?_C-=/10!
MS']J^,O^A6TW_P '!_\ C-']J^,O^A6TW_P<'_XS73T4 <Q_:OC+_H5M-_\
M!P?_ (S1_:OC+_H5M-_\'!_^,UT]% ',?VKXR_Z%;3?_  <'_P",T?VKXR_Z
M%;3?_!P?_C-=/10!S']J^,O^A6TW_P '!_\ C-']J^,O^A6TW_P<'_XS73T4
M <Q_:OC+_H5M-_\ !P?_ (S1_:OC+_H5M-_\'!_^,UT]&10!S']J^,O^A6TW
M_P '!_\ C-']J^,O^A6TW_P<'_XS73T9H YC^U?&7_0K:;_X.#_\9H_M7QE_
MT*VF_P#@X/\ \9KIZ* .8_M7QE_T*VF_^#@__&:/[5\9?]"MIO\ X.#_ /&:
MZ>B@#F/[5\9?]"MIO_@X/_QFC^U?&7_0K:;_ .#@_P#QFNGHH YC^U?&7_0K
M:;_X.#_\9H_M7QE_T*VF_P#@X/\ \9KIZ* .8_M7QE_T*VF_^#@__&:/[5\9
M?]"MIO\ X.#_ /&:Z?-% ',?VKXR_P"A6TW_ ,'!_P#C-']J^,O^A6TW_P '
M!_\ C-=/1F@#F/[5\9?]"MIO_@X/_P 9H_M7QE_T*VF_^#@__&:Z>B@#F/[5
M\9?]"MIO_@X/_P 9H_M7QE_T*VF_^#@__&:Z>B@#F/[5\9?]"MIO_@X/_P 9
MH_M7QE_T*VF_^#@__&:Z?-&1ZT <Q_:OC+_H5M-_\'!_^,T?VKXR_P"A6TW_
M ,'!_P#C-=/10!S']J^,O^A6TW_P<'_XS1_:OC+_ *%;3?\ P<'_ .,UT]%
M',?VKXR_Z%;3?_!P?_C-']J^,O\ H5M-_P#!P?\ XS73T9H YC^U?&7_ $*V
MF_\ @X/_ ,9H_M7QE_T*VF_^#@__ !FNGHH YC^U?&7_ $*VF_\ @X/_ ,9H
M_M7QE_T*VF_^#@__ !FNGHH YC^U?&7_ $*VF_\ @X/_ ,9H_M7QE_T*VF_^
M#@__ !FNGHH YC^U?&7_ $*VF_\ @X/_ ,9H_M7QE_T*VF_^#@__ !FNGR/6
MB@#F/[5\9?\ 0K:;_P"#@_\ QFC^U?&7_0K:;_X.#_\ &:Z>B@#F/[5\9?\
M0K:;_P"#@_\ QFC^U?&7_0K:;_X.#_\ &:Z>B@#F/[5\9?\ 0K:;_P"#@_\
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M_/\ +J_"MIK-G;7$>KVFDVV7#1+IJ%5/')8'OP*Z"B@#F/!W_'UXH_[#4O\
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M6M[C3[1MT*[U.BO; XQ]YGR&YQQ[9ID6D?9_AM-;6]@(KR;3RLD:0X=WV8Y
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MJUS#96<:A(4-QYTDC1J)>1'@A3N*G+$>RUT=% '"WFG:CK#WU_\ V9;"9[*
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M2T@>1T*.[1@EE/!!/<>U9O\ PE>C_P#/>?\ \!)?_B:/^$KT?_GO/_X"2_\
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M_P# 27_XFC_A*]'_ .>\_P#X"2__ !- &U16+_PE>C_\]Y__  $E_P#B:/\
MA*]'_P">\_\ X"2__$T ;5%8O_"5Z/\ \]Y__ 27_P")H_X2O1_^>\__ ("2
M_P#Q- &U16+_ ,)7H_\ SWG_ / 27_XFC_A*]'_Y[S_^ DO_ ,30!M45B_\
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M/_X"2_\ Q- &U16+_P )7H__ #WG_P# 27_XFC_A*]'_ .>\_P#X"2__ !-
M&U16+_PE>C_\]Y__  $E_P#B:/\ A*]'_P">\_\ X"2__$T ;5%8O_"5Z/\
M\]Y__ 27_P")H_X2O1_^>\__ ("2_P#Q- &U16+_ ,)7H_\ SWG_ / 27_XF
MC_A*]'_Y[S_^ DO_ ,30!M45B_\ "5Z/_P ]Y_\ P$E_^)H_X2O1_P#GO/\
M^ DO_P 30!M45B_\)7H__/>?_P !)?\ XFC_ (2O1_\ GO/_ . DO_Q- &U1
M6+_PE>C_ //>?_P$E_\ B:/^$KT?_GO/_P" DO\ \30!M45B_P#"5Z/_ ,]Y
M_P#P$E_^)H_X2O1_^>\__@)+_P#$T ;5%8O_  E>C_\ />?_ ,!)?_B:/^$K
MT?\ Y[S_ /@)+_\ $T ;5%8O_"5Z/_SWG_\  27_ .)H_P"$KT?_ )[S_P#@
M)+_\30!M45B_\)7H_P#SWG_\!)?_ (FC_A*]'_Y[S_\ @)+_ /$T ;5%8O\
MPE>C_P#/>?\ \!)?_B:/^$KT?_GO/_X"2_\ Q- &U16+_P )7H__ #WG_P#
M27_XFC_A*]'_ .>\_P#X"2__ !- &U16+_PE>C_\]Y__  $E_P#B:/\ A*]'
M_P">\_\ X"2__$T ;5%8O_"5Z/\ \]Y__ 27_P")H_X2O1_^>\__ ("2_P#Q
M- &U16+_ ,)7H_\ SWG_ / 27_XFC_A*]'_Y[S_^ DO_ ,30!M45B_\ "5Z/
M_P ]Y_\ P$E_^)H_X2O1_P#GO/\ ^ DO_P 30!M45B_\)7H__/>?_P !)?\
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MQD<X4&VD49^I7 H U:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** .8\'?\?7BC_L-2_P#HJ*NAN;RULHQ)=7,,
M"$[0TKA03Z9-<]X._P"/KQ1_V&I?_1453>*;.ZN9-)DM8[EA;W322&W6-G53
M#(N0)/E/+ ?C0!OQR)-&LD3JZ,,JRG((]C55=6TUY/+34+1GY^43*3QUXS5#
MPQ;75AI*6MS;R1L9IY 6V;MK2%@7"G:&.XG"\?3I4-YI<TEQKSQVRG[18I%
M1@;GQ*"/;[R_G0!N27,$2[I)HT7:7RS #:.I^G(Y]Z9;7UI>;OLMU!/MQN\J
M0-C/3.*Y/5M!U22U4)/<WA_LR>':XB&QV\K &%7.=IZYZ5NZ3Y\27!ECOF(
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M>XWJEOYY0V^S<R?ZO[W' SCG&<DZ3Z3J=[?6<T$US:&.RGC,UQ!"S;V="H9
M-N.">,=* .CGU73K;9Y]_:Q;UWIYDRKN7U&3R*4ZG8"X6W-];"9\%8_-7<<]
M,#.>:XJTTC4;.XMV%GJ-NBV"0N+<6\O[Q9)"V2XQ@[@1@#@]!C N7UC=S'7H
M/[%FN#J"(()&\L*I\E5RQW97:PSP#TXS0!UUQ<P6D1EN9HX8QU>1@H'XFF2W
M]G!;K<37<$<#XVR/( ISTP3Q69>VMQ#?Z7>-!)?1VT,D<BIC<';9B0 D9^ZP
M]?G^M5(;:>VU"#4&T9E@\J5%MXBC- S2;MQ&0,N.N"<$=^M '1B:)F11*A9U
MW* PRPXY'J.1^=5Y=5TZ!@LU_:QL1D!YE!ZX[GU!_*N8B\.W[7-I<(@M)8$N
MI;;Y@5@9Y49(S@\@KN! X&3@\ U9L]+NWTS1OM-D(YX[YYIXR5;RU/FGKW^\
M.GK0!OC4[ SK +ZV,K8Q'YJ[CGIQFK'FQ^:8MZ^8%W%,\X]<>E<E?:%J$IU2
M1=[027RRFT58P9H@D8.UB,J<J<<CIVSFI8].U==;76RD>Y[@QO!M_>"W.$ W
M;L<;5DQC/+"@#HOM]GYTD/VN#S8EW2)Y@W(/4C/ ID.J:?<%A#?6TA12[!)E
M.%'4G!Z5BZ1:S6]KIEA/HY::UR);MRFS.TAI%()+%R>F!]XYQ3TTN<6VHV_V
M8*+N^Y(Q_J#MW?F P^IH VS>V@NA:FZA%P1D1>8-Y'KCK35U&Q>Y-LEY;M."
M08A*I8$=1C.:YR73KLZ;=:6-.=KJ:Z>5+W*;!F0LLA.=P*C QC/RX''-,30]
M00Q2R;Y8%U66X>U C!"F=F1U?&>,JQ&>1D>Q .GAO[.YE:*"[@ED7[R)(&(^
MH%1QZKITQ81:A:N54LP693@#J3STKG;#3[MH-*MCIDEO-:7!EDN7V !?FR%(
M8D[@0.G0G-5++3-27PA-IKV]^;DZ6]N(Y$@$8D\O& R_,>>!D_6@#LK:^M+S
M=]ENH9]OWO*D#8^N*2:_L[>/S)KN"./>4W/( -PZC)/7VK)L-,N[3Q$;BX=[
MF,VICBFVHGE_,"R,% SG (/;!''?*&E7L#M,UK=J_P!LO'2:V,3LJR2 @%'X
M*L .1R,=LF@#KWGBC17>5%5R%4LP 8GH!]:4S1"0QF1!(%WE=PR%]<>E<U>Z
M-=:CX7TW3Y8$@E61/,6' $( ."!D@$<' )P>E4'T;5[^6>^NK0+<W,""6'>,
M$)*A,.<]&56]OG.: .N34K&6WDN([VW>"/[\BRJ57ZG.!2PW]G<0^=#=P21;
M@N]) 5W$X R.^2/SKEM:L+S5%N;BTTN6 "T\DQOL5IV\Q&48#8PH5^2?X^*2
M^TR]U&^EO+;3)+2,M9JT;E TI2Y5RQ"L1A5!ZG)R>/4 Z8:MIK3M NH6IF3.
MZ,3+N&.N1GM@YHDU;38IA#)J%HDIQA&F4,<].,]ZYVUT"^B\/ZJCRRF:?[;Y
M=J5BQ^\DD*$,!NY!!Y;O573].U*QU&9Y+?451S;D"".W=&VPQJV2_P PY4CC
MTXH Z^/4;&6Z:UCO+=[A20T2RJ7!'7(SFFW&JZ=9R^5=7]K!)C.R695./H37
M+C3;V6"2Q&E2I/\ VLUTEZQC"(GV@R;@=V[)3C&.^#QFMS5[!KO4=%E2!9%@
MO6DF8@?*GD3+GGK\S*/QH O-J%DEQ%;O>6ZS2C,<9E4,X]0,Y-+=:A96)07=
MW;V^_.WS9 F['7&3S7+WNFW0LM<T[^RGN9]0DD:&Z!0)\P 0L2=R[.!P.B@C
M)XJ[JFD:A>:U8RVUTT'DV$\37/EHX\QFB*@JWKM8\>G6@#8FU73K;9Y]_:Q>
M8NY-\RKN'J,GD4CZMIL<JQ/J%JLC@%4:906STP,]ZXRUTC4;.>U86>H0*ED(
M9/LPMY<R"5V;[XQM.[<, <'&!C V['2+I]>O;^26>WAD:!DB,<1\S$:@[OE)
M'/'!'M0!OM<P+;FX:>,0J"3(7&T >_2HH=3L+F.22"^MI4B&9&256"#W(/'0
MURIM=1D\%7>C?V9=I<A)-K'R]K$R$C:=W7!SR*FELKVXL0#;7]P(;J&=X+J.
MW0S(I.579@$@X;#=P* .A.L:8+=+@ZC:"!R563SUVL1U .<&G_VGIXMEN?MU
MM]G9MJR^:NTGT!SC/!K!U*SFU7P_KZ0:+]GFN;=DB$A023OL(R0#A>P!)SQV
MXK;U.T$^CWEO%"K,\+JB #[Q4@4 307MK=8^SW,,V<X\N0-TQGIZ9'YBF3:G
M86^WSKZVCW9QOE49P<'J?7BL<Z1=OJ.DO#++9I!8RQRR0B,D.3%A2&!'.UN0
M.W6LBUTG4[.YB9X[[ BD0O D#LQ,\C#<'X&0P/ '6@#M6GA2#SFE018!WEAM
MP>AS45SJ%E9NJ75Y;P._W5EE52WTR:RM:L+O5[>QL4C5;9OWMR;A<@[0-J%5
M(Y+$'CCY*S+:#4[:^MY-1TJ>_,5DUHSQ^6?,*R<-AF&-R@'\30!UPFB,OE"1
M#(%W[ PSM]<>E1&^M NXW4 7!;/F#& <$_@2 ?>N+M-!UK398;JWA'VJ.RBM
M1AP516:;*CU$9:(^X4XJO/X5O1 MI%8E[9;6]@"LRG(>[C= >>Z*30!Z \\,
M;;7EC5N.&8 \G _,\5']OL_/D@^UP>=&NYX_,&Y1ZD=A7'3Z%JZ7TUOY9N+6
M$6BVLY<%FC6Y5RK9.<HH//< =\U>M;"\BUB$)93+"+N6619Q$\2!M^7C<8?+
M;NAS]XC '- &['K6E2[O+U.S?:NYMLZG ]3STJ>"\M;J-I+>YAF1?O-'(& ^
MI%<Y<:+<M8:['%;A)+F_22$J%R4"PY(_%6X/I45SH^J"?4;=29WOUBA%X515
M2$%MZLJX.X9;D==XZ8- '2SZE8VT4<L][;Q1RC,;R2JH<>Q)YI8M0LIU1HKR
MWD#_ '2DH.[G''//((_"N;GT?4/^$7U;27MXYF7=]C:,!597^;: 2=NTDCKT
M JSJNAS7VIW1A18E-B@MY>,).DI=3CV.TT ;L][:6N?M%U##C&?,D"XSG'7U
MP?R-.@N;>YB\V">*6/\ OQN&'YBN2N--U*YMK?49;6>*]GU 3S11>6[PQ+&Z
M(HW?*>H)Z\NU:ES9W5[X8GM4CG,Q()2Y$:-*H8,5.SY<, 5_'F@#6AO[.XC,
MD%W!*@8(620, Q. ,@]<]JE::)2X:1 47<^6'RCGD^@X/Y5S>HVMQJD3?9=*
MELG\RU_?L8Q)A)U8X7D84 GG\ :AN]&U5[Z]@2:2XBO5MXWN;@)A8T,C.I5-
MN0?E7U^?KQ0!U0FB)C E3,@RGS#YAUX]:CFO;6WA,TUS#'$&VEWD"J#Z9/>N
M43P_J,KV5I-^[_L]YOLMW%@! 0IC(4DG Y0@]0OO2V-EJMM)%?WFG%I-UT#%
M$5<PO)(&$B@D;@0"/7!'')P =1+J-C!'')->6\:2#,;/*H#CV)/-#:C8H(2U
M[;J)O]43*H\S_=YY_"N3&G:H)M/G>TGA6,78(M(H=RAWC9=RL649VL3@FIM3
ML;R8M)#97K2RV:PY*P.LV"WR2H<!>6SE2 =Q]!0!US,J*69@JCDDG %+67=^
M:9-,BE1>7+.BGY6=4)"Y],C/_ 16+:)KD4JO)%?/$;B-I,RC<5PY(VER!AMB
MDJ0I!Z#% '74U'20$HP8 D$@YY!P1^=<W;PZNWDF\2])=!(HAG"^4[2,S!CG
MD*I0 <C@U)X?TV^L98C.9E5K7S)U:7<IGD<LP S@;>>0.=W>@#HJ*XJ&W\1.
MEP76]B\R!2P\S>5D$BD@9DY^7=RNP$=,'&-6%=4_X1^%)8YUE$^)0LF9#%O/
M())()&.-Q('?- &_O7?LW#=C.W/./6EKF$TV_>X-R!=Q.'@CC#W&XK&)"[EB
M#\W#%<'/3OUJ*.#7II78_:8?.0*_[S[C-*N[;EB/E3=@@+G/0T =917':C<W
M6F^:DTER8SY[P0I<XD+ JL?);<P.&.!G[P!'05;@M=;34HUDFF9(B@#Y^5D$
M8W9^?!+-NZJ2,YZ4 =-2*ZNNY&##)&0<UB:.NHPB\DN8[ECM#1B63EF^8E<;
MB 1P,@@'T&*KZ?8:K&;5KB6XWK.@?][\HC$7S$J#@[I ?7KVH Z2BN6>34;W
M6;I[4716&[C2)Q-MAV( 9 5SR22R\@]B.AJCYNLV-I=W=W)<1?NHFCC>3YI9
M]Y8QJ"[<X7;P%!W=* .U+J'"%@'8$A<\D#K_ #'YTZN6-AK<VHV_GS3+&Y1I
MWBEP$R7=T7O@;(DR.NXGUK+N9]1BVZ?-<W:W<BQI;K'=#?"9)6R7^;<^U"O.
M&&%)ZY- '>U!->VENY2:ZAB8+N(>0*0,XSSVSQ69K,=])-M@2Y:/R&$?D2[,
M39X+'(. /J.N0>*S9]'O7NY+QHI9)A,TPQ,0'\N':@QNQS(2U '5HZR*&1@R
MGH0<@TM<L;368K>:.(W9NXD*PRB4>45$8 ^4G#,3D\@<]\8SI:,MW;JZW1F8
M2R?NA)DE %&2<NQP3[_EF@#7HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH YCP=_Q]>*/^PU+_ .BHJZ>N8\'?\?7BC_L-2_\
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MINH7DD:W5OI-]+<VNZT!?[4S;)'N%4H)>6&Y3SR<<'O7:X&<XI%157:J@#T
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M3)] 2<?K_+TH DHHHH **** #%%%% !1110 4444 %%%% "$ D$@''2EHHH
M**** "D(!QD XY%+10 4F!G.!GUI:* "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **P]2?Q4+UQI4&C/:8&TW4TJR9QSD*I'7WJGYGCO\
MY]?#G_@3/_\ $4 =117+^9X[_P"?7PY_X$S_ /Q%'F>._P#GU\.?^!,__P 1
M0!U%%<OYGCO_ )]?#G_@3/\ _$4>9X[_ .?7PY_X$S__ !% '445R_F>._\
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MW_SZ^'/_  )G_P#B* .HHKE_,\=_\^OAS_P)G_\ B*/,\=_\^OAS_P "9_\
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MQW_SZ^'/_ F?_P"(H\SQW_SZ^'/_  )G_P#B* .HHKE_,\=_\^OAS_P)G_\
MB*/,\=_\^OAS_P "9_\ XB@#J**Y?S/'?_/KX<_\"9__ (BCS/'?_/KX<_\
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M.BM;.:'7-1NW \J>.%4P><KNS_,5HT4 9UQ9S2>(+"\4#R8()XWYYRYC(_\
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MDT$;NHPK,N2* ,Z_MXX+/R%$S&XF7"JQ)3@;MO?H"?J:C>0RZ)-$RR^9;R!
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MX811A=QRQ'4_4]Z ):*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN8\'?\?7BC_L-2_^BHJZ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **R)M 6:>27^
MU-53>Q;:EVP49[ =A4?_  C:?]!?6/\ P,:@#;HK$_X1M/\ H+ZQ_P"!C4?\
M(VG_ $%]8_\  QJ -NBL3_A&T_Z"^L?^!C4?\(VG_07UC_P,:@#;HK$_X1M/
M^@OK'_@8U'_"-I_T%]8_\#&H I^#O^/KQ1_V&I?_ $5%73USMMX.M+-IVM]1
MU6,W$IFE*WC?.Y !8^^ /RJ?_A&T_P"@OK'_ (&-0!MT5B?\(VG_ $%]8_\
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M'_@8U &W16)_PC:?]!?6/_ QJ/\ A&T_Z"^L?^!C4 ;=%8G_  C:?]!?6/\
MP,:C_A&T_P"@OK'_ (&-0!MT5B?\(VG_ $%]8_\  QJ/^$;3_H+ZQ_X&-0!M
MT5B?\(VG_07UC_P,:C_A&T_Z"^L?^!C4 ;=%8G_"-I_T%]8_\#&H_P"$;3_H
M+ZQ_X&-0!MT5B?\ "-I_T%]8_P# QJ/^$;3_ *"^L?\ @8U &W16)_PC:?\
M07UC_P #&H_X1M/^@OK'_@8U &W16)_PC:?]!?6/_ QJ/^$;3_H+ZQ_X&-0!
MMT5B?\(VG_07UC_P,:C_ (1M/^@OK'_@8U &W16)_P (VG_07UC_ ,#&H_X1
MM/\ H+ZQ_P"!C4 ;=%8G_"-I_P!!?6/_  ,:C_A&T_Z"^L?^!C4 ;=%8G_"-
MI_T%]8_\#&H_X1M/^@OK'_@8U &W16)_PC:?]!?6/_ QJ/\ A&T_Z"^L?^!C
M4 ;=%8G_  C:?]!?6/\ P,:C_A&T_P"@OK'_ (&-0!MT5B?\(VG_ $%]8_\
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MT%]8_P# QJEM]!6WN(YAJ>J2;#G9+=%E/U'>@#6HHHH **** "BBB@ HHHH
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MR&==KD'!P<\\D5)9ZA:Z@LS6LRRB&5H9-I^ZZG!% %FBJIU*P5Y4-[;!H?\
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M (JC_A$]&_Y]I/\ P)E_^*H VJ*Q?^$3T;_GVD_\"9?_ (JC_A$]&_Y]I/\
MP)E_^*H VJ*Q?^$3T;_GVD_\"9?_ (JC_A$]&_Y]I/\ P)E_^*H VJ*Q?^$3
MT;_GVD_\"9?_ (JC_A$]&_Y]I/\ P)E_^*H VJ*Q?^$3T;_GVD_\"9?_ (JC
M_A$]&_Y]I/\ P)E_^*H VJ*Q?^$3T;_GVD_\"9?_ (JC_A$]&_Y]I/\ P)E_
M^*H VJ*Q?^$3T;_GVD_\"9?_ (JC_A$]&_Y]I/\ P)E_^*H VJ*Q?^$3T;_G
MVD_\"9?_ (JC_A$]&_Y]I/\ P)E_^*H VJ*Q?^$3T;_GVD_\"9?_ (JC_A$]
M&_Y]I/\ P)E_^*H VJ*Q?^$3T;_GVD_\"9?_ (JC_A$]&_Y]I/\ P)E_^*H
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M/L<09I(8O.RT;>6(^O.&8-)R.AP>I-:6G1W6BZ?</+!*XD<ND(=25.%55 '
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MK3U544*H 4<  <"@"CK*6[Z3<BX6)E$;%?, (SM/3/>JM[%9CPZRHD APA(
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MD+,P24J-S%CC [F@"U1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4A&5(R1D=12TC,J(7=@JJ,DDX % %2#388!$-\LBP@"-7?(7
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M(SCB@ &<#/7OBEIGG1F<P[AY@4.5]LXS^E/H *@M87A63S&4L[ESM& *GHH
M***9#-'/$LL3!D;H1WH ?1110 44FX%BN1D<D4M !1110 4444 %%,>5$=$9
M@&<X4'N>M/H **** "BBB@ HHHH ***9--';PM+*X2-1EF/04 /HI&8*I8]
M,FHC=0"U%R9!Y) ;?VP: )J*0L%&6( ]32T %%,BFCF4M&P8!F0D>H."/S%/
MH **** "BHI;B*!D65PI=@JY[DG&/U%2T %%%1PSQ7 8Q.'"G:2/6@"2BFJZ
MN6"L"5.& ['&?Y$4!U,AC##> "5[@'./Y'\J '45']HB^T"#>/-*[@OJ*DH
M***9#-'/&)(G#(21D>H.#^HH ?1110 4444 %%%(2%!)( '))H 6BF--&D!G
M9P(@N\MVQC.:6-UE0.ARIZ&@!U%-1UDC5T8,C %2.A%".L@)1@P!(./4'!H
M=14<5Q%,[I&X9HSAAZ&I* "BBF2S1P('D8*I95R?4D #\R* 'T44UW6-"['"
M@9)H =13(I8YXQ)&P9&Z$4^@ HIJ2)("48-@E3@]".HIU !1137=(D+NP51R
M23@"@!U%,BFCG4M&P8 X-)-/%;Q&6>5(HQU=V"@?B: )**A@N[:Z#&WN(I@O
M4QN&Q^5.2>.262)'!>(@./3(R/TH DHHI,C=MR,]<4 +13/-3SO*W#S-N[;[
M>M/H **** "BBB@ HIKNL:[G8*,@9)[DX%1R7=M%.D$EQ$DS_=C9P&;Z#O0!
M-141N8%N%MS/&)V&1&7&XCUQU[5&=1L@DCF\M]L;;7/FKA3Z'G@T 6:*8LT3
MPB9)%:(KN#J<@CUS3@0P!!!!Y!% "T45#-=V\#A)955B,@$\X]?I0!-1110
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MT=[V0W!FB,\;/POS#.Y>B 'Z=AWJ_->6T&KQAKU%S&XD1IN 1MQP3P>M:=%
M&3JC6GV^R\^Z\HAB2//*8&UN>OKQFI-4FA@TQF^U>6XC+0GSL%B!QW^;MZUI
M44 4+NZC>"%X[@?9FEVRS1M]U<'^(=.<#/;/;K4/GP0V]U+;W4EQ& J@>:65
M"21G?SZY/7 %:M% &-IER'OI[?ST=#$K+LN&E!.3G#'\.AXXZ4[3/LL#-$;E
MOM'GRCRGG)/+L1\I/I@Y_&M>B@#,6\MDU=HQ>H0R8*--D!]V, 9X/M39Y8OM
M5P+N\DMRI'D*LA3*[1R!_&<Y&#GH./75HH R-SW%Y817-Q)%(]JSRPI(4RWR
MXZ'(ZMT]/:KFF3^?8JWFB7#.F_.<@,0/T JW10!%<-$D#&:411]"Y?;C\>U4
M;.^B?29'%T'>)'+,IWLH!.#CJ>!^-:=% &-ILN;Y4%P)OW3;C'<F52<CE@1\
MIZX /K6S110!D2"U@UBX>XN7AW1QLNZ=E#<MG SSVX]_>GW$T)NY!>736\84
M&$"4QAN.3GC)SQCZ<<UJ44 5[%Y9+*)IL[R.2PP2.Q([$C!Q3;YRB19=HXB^
M)77C:N#W[<X&??\ &K5% &?!)'FX"W!:T"KB0R$[2<Y ?/T[\9J*P=I-/$T=
MT;BZ$()3S 0#C@$#ISWZUJT4 8K2VXN+%DO'D8R_O SY_A;[P_@.>,<>E--Q
M<;W+S11W(D("M<L.,\#R]N""/Q/K6Y10!F74L7]II&][Y2&,F1!+C)RN![=3
MTP36DJ[45<DX&,GJ:6B@"AJDXB2*-F"!V.7:8Q*,#H6'.?;V-9XO=^DS9N_+
M:.Y5%D67)"EE[L.1@GJ.1ZUOT4 4+5EBU*>U69G41)(%>0N026!Y//9?\FKY
MX%%% '/P:AF^LW$R*)Y")$^TLY4%6(#*1A3G [<\<TFIRQMIVH>==R)=A952
M%7/W>0H"=P1@YQW/(QQT-% &5-<0/<R&YO&ACVJ;?9+M#@C[PQ]XYXQST''/
M-5;J)/#%N[7?ES+#E/WFQBX'((SUSU%;]% &=J1AO-*9XY=\:LK%XI.,!AGD
M'L,U+!-9_9Y1%=B2->7<SEMN?]K/%7** ,NPO$DM)X[>X2XG1I#&IEW$@$[<
M\YQTYJ.&:/S+;[->237#,!-&SD\8^8LO\&/H.>.];%% &$)E2":Z^W.3'=A!
MF;Y57> 1CH>">O/Y4W5;XQM=-'((Y8%^13<,&8@9R(P,$?7WZ5OT4 9VIW=L
MMK%NN(ANEA=<N.5\Q3D>V*OQR)-&)(W5T/1E.0?QIU% !5/30&TY 1D$L"/^
M!&KE10V\=NK+$"%)+8+$\^V>E %2PTI;&>:42O(TO)W$G:?;)X& HQ[4D>DI
M'J;7HD8[N/*YV@=L#/7)8Y_VC6C10!4F_P"0K:?]<Y/_ &6K=1?9XS<BX()D
M"[02QP!].G:I: ,Z\DC%[LN[AH+?RP4(D,89LG.6&.@V\9[GKVHV<ZFQB62Y
M=;?SYQ+*3L;.]BH8C&W(.<\=O6M^B@#(^T;;*[,=VPMPRK%<'+8S@'GN 3][
MMD\\5';SR^3??9'\Z180T86X,Z;OF[D9!/''/:MNB@#%L9W:\A"7,3!L^:GV
MMI6/!YVE1M.<>@[8Z5'!<A[R)ENC*7E/"3G?M.< Q$8 '&3QTS6]10 52U?/
M]F2_W<KYG^YN&[_QW-7:1E#*58 J1@@]Z *NJ?\ ((O/^N#_ ,C4MU!]IMGB
MW;2PX;^Z>Q%.>"-[<P,N8F785SVQC%.C01H$7=@=-S$G\S0!4LM-BLK(VH8R
M)R,R$DE>P)[X'%-TW3%TX28F>4N=V7))!/)QD\ GG'\ZOT4 5(/^0G=_[D?_
M +-5NHHK>.%Y'0'=(<L2Q.?S_E4M &3>>9;SS1*\Q:[4" [VPCYP>_ Y#?0-
M3]0DAL[>!6NRDB2)C?-@L-ZAL\\\9K3HH S;^\B,,.R6/RY22)?M!C3CMN'?
MV]CZ4FEWR&RE>>= L4K+N:3.%SQDG!/L3U]ZTZ* ,S3[RW.G2,DZ,8S([;"&
M(&YCG J#3I?],B07/GDH=YCN#(">/F92/D_ ]\5M44 9]GG^U]1V_P"K_=Y_
MZZ;>?_'=E:%,2-(@VQ0NYBQQW)[T^@#/N)(_M4BW5PT" #R@)"@;U.>YSV^G
M'-0W;J^F6YNI3&YEC.2_EEAO')''..?:M:B@"*W\LPJ89/,3LV_?G\:JZXZQ
MZ'?%G5,P. 6/&2"!5^B@#%M9C+K*2_;+:\'DLA-NN!$,@Y8[FSG''([X[U)I
M]]:-J%S!'?)*&*F-3/O).#G'-:U% &09OD9OM#_;PQ"P[SUSPNSTQWQTYS4D
MZV\>J/)<3M$'B7:3,4!()R!S]/SK3HH SI_*GU.V4SLH,#MM1]I()7'3GL?R
MJ&2[5M(23[6%<2[5DWCG#XY]>.:UZ* ,^22.&Q:2.=IE<A=YFX!S@G</NCZ5
M!;74>;N.2Y A6-7#+,SXSD$ACSV'3//Y5KT4 9-A.S742W$S!C'^X7?_ *U?
M[S<_>_SSVUJ** *5]G[38 _ZOS_F^NQMN?QQ^.*S=39]0OI;>W:V;[+$23)/
ML,<AY#X"G[H'7C[U;KQI(NUU##(.#Z@Y'ZTZ@#':_CDL[36%(*QC;.$.["M@
M,./1@I^@/K45T[P:2D#F-+S49,,LDFS[W+#//1?E!QU"UNT4 96E3>5=76GR
M^0DB-YR112[]JMR1R ?O9/3@,M6-(S_9D7]W+>7_ +FX[?\ QW%7&4.I5AD$
M8(H50BA5 "@8 ':@!:QT-G_;\^;S$A2,!?M!Y;<^5QGZ<>_O6Q10!DSS1?:K
M@7=Y);LI'DJLA7*[1R!_&<YXYZ8QZLN[AA'IIN+O[)/)CSAO"X!1B>#QU &>
MU;-% $5NJ+ OER-(AY5F??D'W[U+110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% %*UU**ZD>-4F5E
M<I\T+@<>Y&!34U.-;BYAN& :&0+E48@*54@L>@Z]_2GQ174$TBHL+122;][.
M0P!QD8QS^=12V=S);ZG&!"#=$[#O/ *!.>/;- %J:\@@?8Y<OC=M2-G('J0H
M.!4L<B2QK)&P9&&58'((K.GL)FNFN$^9I%4.GVF2, CN"O7\15VUA^SVR18
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MH NP7<-PS*A8,HR5=&1L>N" <5-5&SM)(K@S2HJD(5'^D22GD@GEL8Z>E7J
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MJPQ#_"'W$Y?KG'%7Z "J-K?R37DEO+ L>TD(Z2;@^W&[L,8W ?@?2KC[@C;
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MR L< 9&* &I<RI.L5U"D>\'8R2;E)')!R!@XR?P-+%?VT\BHCME_N$HRA_\
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M[FMWD@A\\-M*J1SP1DXZ=<_AQ4LEW<V;*;DQ2JZL0(4(8%5W=R<CC&>.<>M
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M#%%% $%Q:0W6WSE8[#E<.1@_@:5[2*2!86#E!T&]@?SSDTEO=+<0M+L:- 2
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M".]>\4'SW&&;/WAQ@?08X^I]34<KJ=8M4##<(I"5SR.5J[2;5W;MHW=,XYH
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M#DCFF&SE5G$%T\4;L6*A02I/7:3TR>><]:<]I()FE@N#$7 #@J&!QW^O^<4
M)]OW)#Y=M,TLJ;_*("L@_P!K)P.N*;)J21V;W)AF(C;;*@ W)]1GGMTSG/%/
M>S?,<D=PZS(NTNP!WC_:''Z8J.33B]H\ N'#2-NDDP"6/\AT _"@!_V[;"TL
MEM/&,@(K;<N2<   \?CCK]:BBNIGU40O'+$IA+E'"D9! !!'U.1FK#VK2VWE
M2S,SA@RR  %2#D'TJNVFO+,TL]W(Q:)H2%4*-K>GH>.M #K?5(KB[^S;2LF"
M0-Z-TQD':3@\TD>IB3#&UG2+S3"9&VX#;MO0'.,\9HCT]TN()FN2?)4JJ)&J
MK@X_P'^%*-.86OD&Y<_O_.W;1G._?CZ9H ?)>E9)%BMIIO*X<IMX.,X&2,G!
M'YU')JD:.J+$[.4$C*652H/0'<1SP>*D:TD$TCP7+1"4Y<; W. ,C/0X ]1[
M4V73@THFCD D*!&,B!PP'0GWY/2@"Q;W$=U LT1RK>O8C@C\Z;<W/V81DQ.X
M>0)\N/EST)R1Q3X8_)A6/<6QW( S^  %,O+5;RU>!G=-V"'3JI!R"/Q% $<.
MH17$_EP*TB>7Y@E4J5/)&.N<Y![=J6RF:9)BXD#+*05D"Y7H<?*2".:;;Z='
M:-.T#,GF@!1QB, 'H/J2?J:6UM)+>61VN6D$C;BI4#G ';Z4 ,L;V>Y+"2SE
MC D==Y*8 !(&<,3VJ)+^2":\66.:6&&7!EPH"J54^Q.,GMT]:LI:212L8[DK
M$SF0IL!.2<D9]"?Q]ZCDTXR0WD9N' N6W$[1\O &!^ % %ZJDTD\EW]F@=8]
MJ!W<KN/)(  _ \_X\6@"% )R<<GUJ">V+RK-%*8I0-N<9##T([_Y]30!6N)+
M^"Q=VE@$BR !A&<,I('3/!Y]:O8D\G:)%\S'WMO&?7&:K36,DUJ86NY,EMS/
MM!)YS@#& .*6.TD2665KIFD= @)0#: 2>GXT 16TMV]G/+)-&75I%7$6 -K,
M,GGGI4%OJ%U.+$,T:2NX2=-A.04+!EYX!Q[]QVJW!920V\L)N7<2%R"5 VEB
M23^9IJ:8BR6<C2NTEJ" W WC:0 P]L\?_7- %ZL^XEG/VN6.4H+8<)@$.0H8
MYR,XY XQ6A56>R\YI,2LB3#$J #YNW7L2.* $E:2:Y2&.5HE\O>S* 2<G '(
M(]?TJ,7$TT%J@?RY)&*NZ@<;0<XSGJ1^56)K<O(LL<IBD52N0 00?;\*:;-1
M!#'&[(T)RC]3G!!SZYR: (3+<?8[A%9GFB?8'51DC@YQTS@U+:2$EXW>8R+@
ME9@H(!Z?=&,<&G);&.!D69Q(S;FDP,D_R]OI2PP&.1Y9)#)(X"DXP !G  _$
MT 2R.8XV<(SE1G:N,G\ZI0:F)HX)3;3Q0SXV2/M[],@'(S5R8D0N50N=IPJX
MR?SK.TVPD6RM4N)+D"%5Q!*4(! XY')P>F30!.=1)N9;=+.X>2/&[ 7&#T.2
M<?AU]J?/.Z7MK'B54=B-P"E6.UC@\Y'3/ I([26.[DG^U,1(0638,8'047-G
M+//'(MTT8C;>JA >=I7O[$T /FNO+E$,<+S2%=Q5"!M'J22/\BH+F\?^R9KA
M8;F)@K@C:N^/&1NP3@],CDYXJ:6U=I5FBG,<NW8Q*@AQ[CVR?S--GLY)[)K<
MW<GSAE=RJY(/X8% #[NZ%I;B4Q22 LJ;8P,Y8@#J1W(I@OU5)C-%)$\0#%#@
MD@],8)SD@CZT2V<DULL3W39$BOO"#/RD$#\Q1)8K+/.\DC%9D5-HXV[22"#U
MSDF@!$OV:\CM9+.>-Y$9P6VE0HP#D@^K#BKE9EK;W!U);B4W!5(7CS.4YW%3
MP$_W>2?:M.@"O?W7V*PGN=NXQH6"_P!X]A^=17)NHK&-58M(<++*B9(&.6"C
MJ<]O?OC%37ELMY936SDJ)4*[AU'O4<UM)=6D8D<QW*#<&B8@*^TC\1R>#0 M
MA*TL#;YA*5;;G848<#A@>AI+%Y9+>21Y#(QDD"AL * Q  P/;OFI;:W6VB*Y
M+.QW.[')9L 9_05'8Q300O'*J#]X[*5;.06)YXXZT 5].O;NYN;A)[=8XU;,
M9W$Y7 ''RC(R&Y.#TXP11'>WC:O);M;*(  %DWG&1DG^'K@KQTX//!K2HH J
M3/(FHVP$K>7(&#1X&.!G/3.?QJW566*:2_@<*GE1AB6W<DD8QC']:M4 5+B]
M,%U';K;32O(C,I3;C@C.23QU%,?5(HXLO&ZR^9Y7E$J#NQNZYQC'.<_KQ4=[
M#-+J=J\:SJJ1N#+$4P"Q7@ANHP#V]*D?3(WCP9':82>;YK $EL;>1C&,<8Q^
MO- #[>_2Y64)&WFQ $QAE).<XP0<<X/?M26=_P#;4CDCMITB==P=P /IC.?Q
MQBG0VLD22?OAO?&"L:J%^@_Q)I;*U>S@2$SM*B*%7<H& ..U %FLJ]U&06K2
MP13J@< 3 *0?FQT/..V<>_3FM6LZ72VD@:W6[D2W)W!549'.<9],]OUQ0!/)
M>E99(XK:6;R\!RFT8.,XY(R<$'\:9/J<,26[*"XG7<AW!01QW8CGGIUIS6<@
MD=X;IHO-P9/E!R0 -PST. /4<=*1K%E2)+><QQQQ^6(V4.I''4'G/'K0 DFI
M)'#$SQ2+)*2%B8J&XZDDG&/?/<4Z&[%[!,L#>5,F5^;#;3C@\$@BH_[*C6WA
MC1R'A+%7*@CYCDC'3'L/05+'!+;V\NQT>9@2H*A%!QQT&<?G0 ZPNOMMA!<;
M=ID0%E_NGN/SS5BH+.V6SLH;96+"- NX]6/<_C45E936LUW)+?SW*SRF1$E"
MXA&/NK@=/K0!<IDI<0N8@#(%.T'N>U/HH RTDU+[2T9EA?R_*+*(\9#'YN=W
M8 U.VHJH>3R)3;H2&F&-HP<$XSG YYQ^E/BM'CO);@W#,)  4*@  9Q_.HVT
MXLCPBX<6LA):+:,X)R5!]#D^_/!% !+>SQZB;=;.61!'OW*4&3GW85+>7BV:
M*SID,<9+JH'_ 'T11/;.\ZSPS>4X4H<KN!&<_G3)+)VF29+@B41^679%8D>H
M]#^GMQ0 DMQ]ITIKFWE>+Y"ZL I/ /'((JU"Q>"-FZE03^55%TYH]/\ L:74
MFWY@7*J20<\=,=ZL6T3P1"-Y3+C@$J!Q^% $CNL<;.Y 5022>PJ!+MVDC5K2
M=%D. YQ@<$\X.1TJ>2-98VC<91P58>H-0QP3(R[[IW1>@V@%O]X]_P ,4 ,%
M^"%D\F00,0!+Q@Y. <9S@^N/TI)-0$;SC[-,4@/[Q_EP!@'(YYX- L2%6+SV
M-NI!$>!T!R!GT_SFE>R+QW:&9L7/7@?+QMX_ 4 $]U+%>Q0I;O(KHS$J5Z@C
MU(]:?<78M84E>&4ABJD* 2I) '&>>3VS2RV[NT<B2[98P1N*Y!!QG(_ 4V:U
MDFA1#<N"K!BVT9)!!';VH 4W++;O*]O(FW^%F0$CUSG'ZTR'489;>6;D"(X8
M AN< \8)SU%/FM6FBC#2Y>-MX8J"">1R/QJ-+# G$D[OYQ#'@#:0!@C ]A0!
M(ER[2B-[69,J6#':1QCC(/!YJ.RNYKE3YEM(GSNNXE<<,0.A)[5+%%,KAI+@
MN ,!0H4'W/O38[:2)SLG(B+E]FT9R221GTR: +-4WU!8WNE>"4?9T\PDE<,O
M/(Y]CUQTJY56ZL8[J6)V9EV<,%Z.N0<'VR!^OK0 R;4!!;Q320.GF?PR.BE?
M8Y;&?IFGB87FGB:"5X@Z[@RA21[<@BDGLVDN1<1S>6^S824#8&<\9Z'_ .MQ
MQ216+P6*VL=TXVY^<JI./3IB@ 6\,>F07,B,Y9$+;,=\<\D>M/>^CBEN%E5H
MU@C$K2'&"O/(P<\8/:F)8$:>;1YW==H56V@%<=/Y4T:<7DF>YN&F$T7E.FT*
MNWGICGN>] !!JD<L\<31M&9,[,LIR<9QP3@X!/X5>JG!8M#*K&<,J= (E!/U
M./Y8JY0!5DG<:E##B54*L<X7:YX]\C'T[TVZU!+6=(3&7=QN W*OY;B,GZ43
M6<LMRDRW;)LSM4(I SUIUQ:RRR%DN"JL@4QN@9>,\X]>?TH GAD\V&.38Z;U
M#;'&&7(Z'WI]16T"VUM' A)6-0H)Z\5+0 4444 %%%% !1110 4444 %%%%
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M,;B2%GV^>'.05QT48X)X]O:FI=R&Y23[:)(WN-B^4ZGC=@*4*@C'<@D\9Z4
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MSD@,97!&$/8GKTQC'3FK4/\ R%;K_KG'_-J +6Y0P7<-Q&0,\X_R10652H+
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !16>EQ?3P)=0
M1P&.3#+$V0VPGKNSC..<8]LU-+?Q1.Z[)76/_6.B9"<9Y]>/3- %JBJDNH1Q
MSK"L<LKNGF+Y:Y!7USTIEQJ2QPVTL44DJ3L "J] 1_.@"]140GS;^;Y4@_V"
MOS?E4,-T!I:W4K&0"/>S*F"<=>* +=%58;^.9MHCF4LAD3>F-ZC&2/S'!P>:
M5+Z)Q:D!]MS]P[?8G!]. : +-%5&U&%68[)3$C%7F"_(I'!Y]NYZ"EGO5C:2
M-%D=T&69(]P3TSZ^N!S0!:HJO83M=:=:W#[=TL2N=O3) /%6* "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY(<I9Q,@B#QR,<REY#&=GL-N>^>G'6FKXNO")9#9Q+&0^S=(H,>V18\O\Q)
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M9=[< @C'0"FIXGO'MH61+.22YC@DCV,2L/F2K'M?U(W9!XSM/ Q3_P#A,K?
M'_".>(< Y _LM^#3%\76B;MOAG7UW-N;&E.,GU/O0 ^\\375E#<S.MFQ@D:#
MR-Q60L /G] O?!Z+SGM5RUUR8Z/J5Y=1PHUD6^8,-K80-DA2Y7KC')[]ZH_\
M)?:F0R'PUX@\QEVEO[*?)'IGTH3Q?:QQ>5'X:\0+'TV+I3@?E0 MKXBU"[NQ
M8I';+.;GR3(ZG 'E&3.T,>>,8W>_'2H#XEO+ZWM'C:WM=TUB'C+$R/YKH6V_
M[."5Z<X;IBI8_%UI$ (_#.OH%Z;=*88_SF@^+;,LC'PQK^Y!A3_9394>WI0!
M:U#Q#<VNMM9Q6R-%&80Y=U4OYC8R"6&,=N#DY'%8?]K:M93"\FNOM*AKD^2,
MJN?M*PJ3EL;5#9QTP#GGFM-O&%J\B2-X:\0,Z?=8Z4Y*_0TO_"86V"/^$:\0
MX((/_$K?H>OYT 2P>(;N91&ZVEO(#-F:5QY9$80XPK':3OZ9.-I/-7M#OY[L
MWWVF>)RMTR1*@QM7 ('OUZXK*_X2VS\I8O\ A&-?\M3E4_LIL ^PIP\8VP<N
M/#?B$.3DL-+?)[4 =517,?\ ";1?]"]XC_\ !8]'_";1?]"]XC_\%CT =/17
M,?\ ";1?]"]XC_\ !8]'_";1?]"]XC_\%CT =/17,?\ ";1?]"]XC_\ !8]'
M_";1?]"]XC_\%CT =/17,?\ ";1?]"]XC_\ !8]'_";1?]"]XC_\%CT =/17
M,?\ ";1?]"]XC_\ !8]'_";1?]"]XC_\%CT =/17,?\ ";1?]"]XC_\ !8]'
M_";1?]"]XC_\%CT =/17,?\ ";1?]"]XC_\ !8]'_";1?]"]XC_\%CT =/17
M,?\ ";1?]"]XC_\ !8]6M.\41ZE?1VJZ/K5N7S^]N;%HXQ@$\L>G2@#=HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "FN-RXIU'6@#A)M#2VTS4+
M6*QO8;7^U4G461"O@+&=ZYSD;ASCG@UGWFC:[X@1;5@8H;6"5X);],N9'<^6
MWRD?,BJ/^^^>:]*P/2D*#T% &=HU[/?:7!+=6LMM<&)3+%(N-K$<C\#7F^G:
M3K6@)X=6#3YI[** W31!<M;S_9W5T/\ O,01[DUZU@#M1M'I0!Y<= UBQM+B
MSNK5+F/4[9/M)M4;'G+(&9FS_>#M_P!\BJ>H:)K5W%))-I\QDMK:ZT^ *A),
M8@D"M_P-F4#Z"O7=H]*-H]* .5\.W,\=L4F>^E>.!3LGL##C Y .!D_X5RUS
MI7B"#3KVZFLEEDU>RNDN8K=&,@D9&>/</]G)3\17J>T>E&T'M0!Y%?Z#JMG!
M>Z;!93W%C'HTXLRBEBI=HCY/U!5L>Q'I78Z:&O?%QU"WLI[:U2Q\F62:$Q&5
MRX*@ @'Y0&Y_VJZS8OH*-JCL* ..OK&=M3\3NEI(5FTR..%@G^L<++D+ZGD?
MG3K&QE36/#C/:N%ATJ2.5BG"/^ZP#Z'@_E77[%]!1M4=A0!YS)<RM\/[G3%L
MK]+Y&9BALI#_ ,M\\?+AN#G /-=/HMQ+<PSJUQ+*XQS)8O;[>..&'-;Y5?04
MQV1%+$@ =: /.K*VD:R\/:;'IMQ%J-A<A[J5H2%4!6$C;R,-O)[$YSGM6MX&
ML+W3O"VGMJ$T:*MH@\IK?RWBXZ,Q//Y"I[_QA#Y_V31K9]3NCP?)_P!6O^\_
M057/AG5==*OK^HD0=?L=K\J_0GJ:T5.VLG8R]K?2*N<C<^)=-TWQ!)]E$EXQ
MU-Y7LVA\PJ2"#+%*O&"#G:<]2.*;X7\1K)?7"7-G/&\-O)'"9[5Y5B=IG=MR
MKR-P*>F=M=YJ,ND>#=$::&TAC(&R*)% :5ST'J:K>!=#N+&SN=1U!"-1U"3S
MI0W5!_"OZU5H<C?W"4I\Z1S%O9ZD9;;78[+^S[K3M.=XD,3K$R":7*$$Y&Y-
MK8SD'%=)<>,[N+36;[-#'?0V-Q/<0L&8+)&$*D8()1@^1W[<$&NOGMHKFVEM
MYD#12H4=>F5(P15&[\.Z5?2>9<6:M)]E:S+AF4F%L97(/M]1SCK6)L8USK^H
MVNERW)F21_M$$*[M'N(=H>0*3L9MTAP>B_UK0\/ZQ/J8O6F:.2&WD"+<+ \&
MX@?,IC<EE*GN>N?:K2:'9*NUC=2@2)(!/=RR@,C!E(W,<8('UJPNGVJ7%U.D
M6V2Z4"8@G#X& <=,XXSUP!Z"@#,FU+49+.QN;5K:,7DRK''+"SG8W()(<<[0
M6(Q[=LU++KT-E%*MR'EG@+B40QXSM0.6 +'C#*.O5@*N6^GQ16UC'+^]>S4"
M-^GS!-N<?0G\ZIRZ!'<?;&GE#2W<L;2LB%?W:$80<]PN"<]_H  )-XDM;=S%
M/#+%.)-GE2-&I/RALY+;<8([YS4SZU%Y5FUO;7%Q)=Q&:.*,*&V #).X@#&Y
M1UZFGG1;$J!Y<H;<6,@F<.20 <MG)X ')[#T%27.EVEVL*R(Z^2"L;12-&R@
MC! *D'' X]AZ4 0:=K<.JSE;6"=H1$DGGL%"_.H91C.[.#Z55'BJU\I9#:7:
MK*@D@^529@9%C&T!NY=>N,@UH)ID%M;3Q62K;-)&$#*,A<+M7 SV ''M5>R\
M.Z=90P1I$SF%8PC/(S;=GW0,G@ \X''Y4 4CXJCC^U&2SNF$ =W5%3,:IA6R
M=^&.[<!CKM(QQDS0:Y/-J:P&V"6[WLEHCD@E]D98L,'^\C#\O>KBZ)IRB8"W
MXF(,GSM\V':3U_O.Q]\TEOH]O;7WVA"VU3(R1DDA7D;<[<D\D_0#GUH T:**
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "JNI7$]KIT\]M"DLR(657?:O'J>:>]Y;QWD5H\H$\RLT:'JP7&3^&1
M^=2R1K+$\;C*.I5AZ@T <U/XEN4FA54C1%M8+FX=HG90)"1U!^0#:>2&Z],
MFIH_$T3^*FTKS+?R<F%</^\\X*'/&?N[21G'52.]:,NB:?,8R\#8CC6(!9&
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MS'CI6Q'HEA&K#RG<M)'*SRRN[ED.Y,LQ)P".!G'YU:>UADNHKEDS-$K*C9/
M;&?_ $$?E0!ASZY>0WALE6%YG6V6.1HV10TIDW%E)R !'PN<YXSZ)J6J:KIH
MMHI9+1I)[H1"6*UDD(3RG?\ U2MNSE,<,>.>,5KW.E65V\SS0[FF5%=@Q!^0
MDH00>""Q((P:KGP]IS( 4GWB7SO-^TR>9NVE0=^[=]UB,9QS0!EW>O7MJUBC
M3QJLT,\LDITN<D"-D _=!MRCYSDGC@>M:=EJLDGAY-2NH@'92P6/@2#)"$ ]
M-PVG!Z;L59@TRVMY8I5$KRQ*Z(\LSR,%8J6&6)[HOY4TZ5;IIQLK8>3%O\Q
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MEY.#P!M/'2ML1[[5FE%&=).%]'S&[;7_ (UU&Q&N6,EJ\$C9BL@O)3)[GO\
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M!R.GL17%R:S:Z!J=W+H6L:;=65T=SV\DX&UCWY_SVJCI.MGPB1-::QIE];W
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M /CE'_"!:/\ \_.M_P#@ZN__ (Y73T4 <Q_P@6C_ //SK?\ X.KO_P".4?\
M"!:/_P _.M_^#J[_ /CE=/10!S'_  @6C_\ /SK?_@ZN_P#XY1_P@6C_ //S
MK?\ X.KO_P".5T]% ',?\(%H_P#S\ZW_ .#J[_\ CE'_  @6C_\ /SK?_@ZN
M_P#XY73T4 <Q_P (%H__ #\ZW_X.KO\ ^.4?\(%H_P#S\ZW_ .#J[_\ CE=/
M10!S'_"!:/\ \_.M_P#@ZN__ (Y1_P (%H__ #\ZW_X.KO\ ^.5T]% ',?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *YCQ?_P ?_A7_ +#2?^B)JZ>N8\7_ /'_
M .%?^PTG_HB:@#IZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CEF2%=TCJ
MJ^K' J/[?:=[F'_OX*=<6L-U'Y<\22H>JNH(/X&JW]B:7WTZT_[\K_A0!/\
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M(!2T44AA1110 5RT9'_"S+C@\:3'_P"C6_PKJ:Y6//\ PLF[/;^R8O\ T:]
M%#XB^)QHVD?8+9S]OO!L0#JJ]"W^%<_X.U'0/!VENEQ/]HU*;YIEMXS(R?[&
M1Z?SKDM6NX-?\<W,FJWYM+1'9=Q&2J*<!5P.O7\ZZR#Q1HNE6J67A'2Y+R]<
M!1(\9^;W)^\?Y5Z?L>6DH:W>K[?>>?[5RFY=CNM*\6Z5K&EW%]:S$);@F99%
MVO'CU'X5S7A5S>RZIXOOU(#AA;AOX(E]/0\8_ USYTS5=+TA[2[*QZIXCO 9
M$'_+- <GI[M^1KIO&MQ#X?\ !46E6_RF8+;Q\'H.3^/^-8>S47RQ^T_PZFCF
MY:OI^9C>%[^+2M)UGQCJ/SRWDI6-0>6P>%_,X^BT[P3H6I:YKG_"6ZK.ZAB3
M F[[PY'X*/2L3QS"-'T[0-&#'R8X3/)&/E#N3R?SS3%\4ZQ/I222:Q;:9;HI
M2WMK9?WC@< 8Z@>Y-=+IN47*/VM/D8*HE*TNA[7<3QVUN\TK!8XU+,3T %>4
MVGAN\\<SZCKWVV2S\Z7R[;()_=C@@\CV_6L6WO/$D?AN[%_>7,UOJ3I%;^<Q
MR3G+;<\XQ@>G-=7XJN]7\-:!INBZ1 V9(2CSHI)R.H&.YR3FL84Y4G:+5V;3
MFJBNUH<QK7A[3Q?6OAO1LW>ILV;FZ8Y"#N,#IZFNSUCQ5>Z1<6OA_1+>.ZO(
M(!YKRG"A57_ 5R.C>%_&]A&TUA"+:2<?.[E-^/J<D>M#_#OQ<^J,[7"L]PO[
MZY\WU'S ]SZ=.:VDJ;=IS3L90YTFXQM<O:?JOC'QW:K)%<PV%C'*8YY(3MS@
M!L^IX/0&L[PYH%GJGC4/:R/+I^G.))9YO^6C ]?Q/3V%=+XDTV[\+>"(-)TF
M-I%FD*7$P4[CGGMZ]/I65HGP^UJ]MHXKR<V=@[;VB#?,<C^[T[#K2A./LY24
MDELARC)S2M=]1=<UB^U?Q1=Z>WB*&TTN,,1Y+Y!4#)''4^V:@^'NAR7_ (H.
ML6HDBT^V+*K2_>D)&,<?7)_"G>//"L>AV5G!I%D6\S=YURREW)&,+GL#D^E6
M/#MKX^&FV\%BL-G:QK@&6,*3SUY!)-/W70]QI7TU)<9>TU3=CN;T_P#%P=&'
M_3A=_P#H<%=**\I:R\;MXVTU;G4;%;G[#<F)_+R-F^'<" !SDK^1KT/0X=6@
MLW75[B">??E6A3:-N!U]\YKS90Y>J/0C._0U****@L**** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ KF/%_\ Q_\ A7_L-)_Z(FKIZYCQ?_Q_^%?^PTG_ *(FH Z>
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH *@O+N&QM9+JX?9#$I9VP3@#OQ4]-;.
M.!DT <]_PGGAK_H*)_W[?_"D/CWPR#C^U8_^^'_PJW87NL33Q+>:,+:*0$[E
MN5D,9'0,,#K[9K6R?^>9H P/^$Z\-8S_ &K$/JK#^E)_PGGAC_H,0?K_ (5N
M2B3"[(E)R <G&!W-/"^L8_(4 8/_  G?AC_H,6_Z_P"%'_"=>&/^@S;?F?\
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M$ATY[%-?LE@DD>5@EPBY9H?*SQTPO/UK@[BUTO6OB#<)>:]"]CG,EY+*B[P
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M=,E$".?[Q ')Z#/L* .BHKE_^$+'_0R^(_\ P/\ _L:/^$+'_0R^(_\ P/\
M_L: .HHKE_\ A"Q_T,OB/_P/_P#L:/\ A"Q_T,OB/_P/_P#L: .HHKE_^$+'
M_0R^(_\ P/\ _L:/^$+'_0R^(_\ P/\ _L: .HHKE_\ A"Q_T,OB/_P/_P#L
M:/\ A"Q_T,OB/_P/_P#L: .HHKE_^$+'_0R^(_\ P/\ _L:/^$+'_0R^(_\
MP/\ _L: .HHKE_\ A"Q_T,OB/_P/_P#L:/\ A"Q_T,OB/_P/_P#L: .HHKE_
M^$+'_0R^(_\ P/\ _L:/^$+'_0R^(_\ P/\ _L: .HHKE_\ A"Q_T,OB/_P/
M_P#L:/\ A"Q_T,OB/_P/_P#L: .HHKE_^$+'_0R^(_\ P/\ _L:/^$+'_0R^
M(_\ P/\ _L: .HHKE_\ A"Q_T,OB/_P/_P#L:/\ A"Q_T,OB/_P/_P#L: .H
MHKE_^$+'_0R^(_\ P/\ _L:/^$+'_0R^(_\ P/\ _L: .HHKE_\ A"Q_T,OB
M/_P/_P#L:/\ A"Q_T,OB/_P/_P#L: .HHKE_^$+'_0R^(_\ P/\ _L:/^$+'
M_0R^(_\ P/\ _L: .HHKE_\ A"Q_T,OB/_P/_P#L:/\ A"Q_T,OB/_P/_P#L
M: .HHKE_^$+'_0R^(_\ P/\ _L:/^$+'_0R^(_\ P/\ _L: .HHKE_\ A"Q_
MT,OB/_P/_P#L:/\ A"Q_T,OB/_P/_P#L: .HHKE_^$+'_0R^(_\ P/\ _L:/
M^$+'_0R^(_\ P/\ _L: .HHKE_\ A"Q_T,OB/_P/_P#L:/\ A"Q_T,OB/_P/
M_P#L: .HKF/%_P#Q_P#A7_L-)_Z(FI/^$+'_ $,OB/\ \#__ +&L_4_AX][-
MISIXDUS%K=B=O.O"QP$=?DXX;YASZ9]: .XHKE_^$+'_ $,OB/\ \#__ +&C
M_A"Q_P!#+XC_ / __P"QH ZBBN7_ .$+'_0R^(__  /_ /L:/^$+'_0R^(__
M  /_ /L: .HHKE_^$+'_ $,OB/\ \#__ +&C_A"Q_P!#+XC_ / __P"QH ZB
MBN7_ .$+'_0R^(__  /_ /L:/^$+'_0R^(__  /_ /L: .HHKE_^$+'_ $,O
MB/\ \#__ +&C_A"Q_P!#+XC_ / __P"QH ZBBN7_ .$+'_0R^(__  /_ /L:
M/^$+'_0R^(__  /_ /L: .HHKE_^$+'_ $,OB/\ \#__ +&C_A"Q_P!#+XC_
M / __P"QH ZBBN7_ .$+'_0R^(__  /_ /L:/^$+'_0R^(__  /_ /L: .HH
MKE_^$+'_ $,OB/\ \#__ +&K>G>&?[.OH[K^V]:NMF?W5U=[XVR".1CGKF@#
M=HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
/ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>a200-2017x92634xmod29exe002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a200-2017x92634xmod29exe002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2P=1]U@Q W94KD^N:U:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17%^.8K
MN[U70;.UCDF,S7&85O7M0V$!!+ISQUQ5./5O$6CP7%G<7=O<?V9;6D4LAC+,
M\DG#2%F91A<$\XSGDB@#T"BN+B\3:P\^E6_DP,VI?+#(J[E!20^8QPQ',6&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M]2/F+,0,@\#GH<9 .AHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ I,#.<#/K2T4 %%%% !1110 4444 &**** "BBB
M@ HP!G ZT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>a200-2017x92634xmod29exe003.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a200-2017x92634xmod29exe003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M/^%P:)_T!O$?_@L?_&O0:* //O\ A<&B?] ;Q'_X+'_QH_X7!HG_ $!O$?\
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MO^%P:)_T!O$?_@L?_&C_ (7!HG_0&\1_^"Q_\:]!HH \^_X7!HG_ $!O$?\
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M0/J#WK-O?B1KMK\/X-2064NL6NJM9:@L0W1LJ(\A*8/=%4@^YH Z?[%\2O\
MH->&_P#P E_^.4?8OB5_T&O#?_@!+_\ '*Y.Y^)FM3OXAELI+=;."_L[>PE2
MU:9C%)-)$[; <N<QD@#KT[UVVEZ]=V_@K4=:U&>6]>TCFG^?3GL6*HF[;Y;D
MGL?F]_:@"K]B^)7_ $&O#?\ X 2__'*/L7Q*_P"@UX;_ / "7_XY6'?>+O%6
M@:7;WNHW.G77]J:7=7=ND-L4^RS1P&95R6/F)@$9.#D#UKI? FKZAK.FRW=]
MJ!N\A-H.E267EDC) WD[QR.1QQ[T 5OL7Q*_Z#7AO_P E_\ CE'V+XE?]!KP
MW_X 2_\ QRLO3/%WB*6VT+Q%=36+Z1K5\MHE@D!$ENDC,L;>9N^9L@;AM Y.
M.E8^G^/_ !#/X(U37WU&*2>WM#(ML='EB1'\P*")2VV3C/"^OM0!UGV+XE?]
M!KPW_P" $O\ \<H^Q?$K_H->&_\ P E_^.5SM]XRU^U@TE8M7:;[==3QO-_P
MCDZR($C# " MO;D_>''Y57U_Q_KFDWD=L-7BC<:5%=1B70YBUU.\DBK&5#9A
MSM4?-W- '5?8OB5_T&O#?_@!+_\ '*/L7Q*_Z#7AO_P E_\ CE4;OQ#XKO[K
M5AI[V&G'1+*&:YM[B RF>9XO,:/<&&Q0,#(R<YKG;CXG:U<:LXTZ>!6D^Q&R
MTM].DD:Y\Z&.1E,X(5"-S=>PH [#[%\2O^@UX;_\ )?_ (Y1]B^)7_0:\-_^
M $O_ ,<K5\8:U=Z+I$!T]83?7MY#96[3 F-'D<+N8#D@#)QWKBM<\9^(_#LU
MQHUY?VDEW%=6>W4(K!F!AG\P',*L264QG@'D$4 =!]B^)7_0:\-_^ $O_P <
MH^Q?$K_H->&__ "7_P".5-X(\27VM>&KW4[]X[B"&>06UW%;M +J%0#O$;$E
M>=P_X#67I_B3Q/%X8/B_4)=-GTN73);_ .PQ1M'+!A=\:A\G?D<,2!@]/2@"
M]]B^)7_0:\-_^ $O_P <H^Q?$K_H->&__ "7_P".5S^M^+_%OA?2XY[^ZTV\
MEU'3IKJV\FV,8MIHU5MIRQWIAL9X.1[T[_A.M<UBRU>739[73[C2M*2\N8)K
M;S2DZF=983\PQS$N#Z<X.: -[[%\2O\ H->&_P#P E_^.4?8OB5_T&O#?_@!
M+_\ '*YG5_&FOZ(NDKJ'B"RMUN]->_>Y71Y)@#F,+'L1R0/G/S$XZ>M7-<^(
MNK:-8^&GNK:UMKN:W2^UB"0X,<&Y$8("?O9<L!R<(: -K[%\2O\ H->&_P#P
M E_^.4?8OB5_T&O#?_@!+_\ '*:NK^)M:U[5&T6YTV&PTN]CM&M[F)B;G*H\
MC>8#\F ^%PIR1S6=+XB\2Z1JWB>2^U.SN['0;-;LP1V)C:?>DC*N[>=N"@YP
M<^U &G]B^)7_ $&O#?\ X 2__'*/L7Q*_P"@UX;_ / "7_XY6%K7BWQ7X5T[
MS-2NM.O);[2[B\MC#;&,6TT2JQ0Y8[TPW7@Y'O6OX#\4:GKVJ:E;SW<6HV-M
M''B\33Y+,I,<[HBCDDX&TY]Z )OL7Q*_Z#7AO_P E_\ CE'V+XE?]!KPW_X
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M E_^.4?8OB5_T&O#?_@!+_\ '*[6B@#BOL7Q*_Z#7AO_ , )?_CE'V+XE?\
M0:\-_P#@!+_\<KM:* .*^Q?$K_H->&__   E_P#CE'V+XE?]!KPW_P" $O\
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M@UX;_P# "7_XY1]B^)7_ $&O#?\ X 2__'*[6B@#BOL7Q*_Z#7AO_P  )?\
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MV+XE?]!KPW_X 2__ !RNUHH XK[%\2O^@UX;_P# "7_XY1]B^)7_ $&O#?\
MX 2__'*[6B@#BOL7Q*_Z#7AO_P  )?\ XY1]B^)7_0:\-_\ @!+_ /'*[6B@
M#BOL7Q*_Z#7AO_P E_\ CE'V+XE?]!KPW_X 2_\ QRNUHH XK[%\2O\ H->&
M_P#P E_^.4?8OB5_T&O#?_@!+_\ '*[6B@#BOL7Q*_Z#7AO_ , )?_CE<[XV
M\.?$O7/#4NF?:]!O(YY$$D<,+P, #NSN9R.H QCO7J]% 'DJW7QM50!IOAW
M&/O'_P"+I?M?QN_Z!OAW_OH__%UZS10!Y+]L^-V<?V;X=^NX_P#Q=;.F1_%:
MZM3)?7?ARRFW$>5]FDDR/7(?%>@T4 <5]B^)7_0:\-_^ $O_ ,<H^Q?$K_H-
M>&__   E_P#CE=K10!Q7V+XE?]!KPW_X 2__ !RC[%\2O^@UX;_\ )?_ (Y7
M:T4 <5]B^)7_ $&O#?\ X 2__'*/L7Q*_P"@UX;_ / "7_XY7:T4 <5]B^)7
M_0:\-_\ @!+_ /'*/L7Q*_Z#7AO_ , )?_CE=K10!Q7V+XE?]!KPW_X 2_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M?(/RC.><TU\+S1VMTMM+I]I/<SPRGR;,B-1&P8#:'!))'7/?I5'_ (3;6_\
MH0->_P"^X/\ XNC_ (3;6_\ H0->_P"^X/\ XN@#4NM$U2[L[RV?4K.-+BVF
MA"PV;*H:0@EV'F'<?O>G+$U831'&N6^JM=*'$3+<1)%A)7( #C).TX&#UR O
M/%8?_";:W_T(&O?]]P?_ !='_";:W_T(&O?]]P?_ != '00:??QZ_<7\EY;-
M!-$D7DK;,&"H7*_/O(S^\Y^7MVK4K@-1^)-_I%DUY?\ @C7(+=65#(SPX!9@
MJCA^Y('XU;_X3;6_^A U[_ON#_XN@#<FTW4_[8N;VVOK-(YX8X?*EM&<@(7/
M42#.2Y[>E17&A71\.'2+2]@B#HZ2226Y<?-DG8H==H&3@9.!@=JR/^$VUO\
MZ$#7O^^X/_BZ/^$VUO\ Z$#7O^^X/_BZ .AN-/O)XK:8W<*ZA;L6658"(V!R
M"I3<3@C'\74 ^U5KG1+N]L=3$]Y"+R^MOLP=828X4PW1=V2?F8DY&>/2L?\
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M<[)S\N&X;*$;3Z_>/UK&_P"$VUO_ *$#7O\ ON#_ .+H_P"$VUO_ *$#7O\
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MJEP+$3F)HS]FM]A?<5)9F)))^48],GDUB_\ ";:W_P!"!KW_ 'W!_P#%T?\
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M]EHEQ;26$4MW')9Z<2;5%B*O]PHN]MQ!VHQ' &3@\8K&_P"$VUO_ *$#7O\
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MUO\ Z$#7O^^X/_BZ/^$VUO\ Z$#7O^^X/_BZ .THKB_^$VUO_H0->_[[@_\
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M?_0@:]_WW!_\70!VE%<7_P )MK?_ $(&O?\ ?<'_ ,71_P )MK?_ $(&O?\
M?<'_ ,70!VE%<7_PFVM_]"!KW_?<'_Q='_";:W_T(&O?]]P?_%T =I17%_\
M";:W_P!"!KW_ 'W!_P#%T?\ ";:W_P!"!KW_ 'W!_P#%T =I17%_\)MK?_0@
M:]_WW!_\750_$F_75ETL^"-;%\T!N%AWPY,88*6^_P!,D"@#OZ*XO_A-M;_Z
M$#7O^^X/_BZ/^$VUO_H0->_[[@_^+H [2BN+_P"$VUO_ *$#7O\ ON#_ .+H
M_P"$VUO_ *$#7O\ ON#_ .+H [2BN+_X3;6_^A U[_ON#_XNC_A-M;_Z$#7O
M^^X/_BZ .THKB_\ A-M;_P"A U[_ +[@_P#BZ/\ A-M;_P"A U[_ +[@_P#B
MZ .THKB_^$VUO_H0->_[[@_^+H_X3;6_^A U[_ON#_XN@#M**XO_ (3;6_\
MH0->_P"^X/\ XNC_ (3;6_\ H0->_P"^X/\ XN@#M**XO_A-M;_Z$#7O^^X/
M_BZ/^$VUO_H0->_[[@_^+H [2BN+_P"$VUO_ *$#7O\ ON#_ .+H_P"$VUO_
M *$#7O\ ON#_ .+H [2BN+_X3;6_^A U[_ON#_XNC_A-M;_Z$#7O^^X/_BZ
M.THKB_\ A-M;_P"A U[_ +[@_P#BZ/\ A-M;_P"A U[_ +[@_P#BZ .THKB_
M^$VUO_H0->_[[@_^+J2W\9:S-<Q1/X%UN)7<*9'>'" GJ</T% '84444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !5:[U&QL%+7E[;VX #$S2JF 3@
M'D^O%6:PWLY)/&AN'@+6W]G>7O*Y7=YF<?7'- %G_A)-"\CSO[:T[RMVS?\
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MBC4LTA R% '<GBO$].TOQ-X?L]634M'F4>(=&N_M$D4IG+W@620.P ^3*N4
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MCKM:XKXK?\B!<_\ 7W9_^E,==K0 4444 %%%% !1110 4444 %%%% !1110
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M#Q'J5C=SVFI"UD>SN[:.::WC9%DAN#L1@I8[6#]1DC )[\ '75Q7P_\ ^/\
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MK7D?C_Q_H&N^$9[#3I+Z:Y:XMG"'3YU^5)D9CDH!P 373_\ "U_"7_/U??\
M@LN?_C= ':T5Q7_"U_"7_/U??^"RY_\ C='_  M?PE_S]7W_ (++G_XW0!VM
M%<5_PM?PE_S]7W_@LN?_ (W1_P +7\)?\_5]_P""RY_^-T =K17%?\+7\)?\
M_5]_X++G_P"-T?\ "U_"7_/U??\ @LN?_C= ':T5Q7_"U_"7_/U??^"RY_\
MC='_  M?PE_S]7W_ (++G_XW0!VM%<5_PM?PE_S]7W_@LN?_ (W1_P +7\)?
M\_5]_P""RY_^-T =K17%?\+7\)?\_5]_X++G_P"-T?\ "U_"7_/U??\ @LN?
M_C= ':T5Q7_"U_"7_/U??^"RY_\ C='_  M?PE_S]7W_ (++G_XW0!VM%<5_
MPM?PE_S]7W_@LN?_ (W1_P +7\)?\_5]_P""RY_^-T =K17%?\+7\)?\_5]_
MX++G_P"-T?\ "U_"7_/U??\ @LN?_C= ':T5Q7_"U_"7_/U??^"RY_\ C='_
M  M?PE_S]7W_ (++G_XW0!VM%<5_PM?PE_S]7W_@LN?_ (W1_P +7\)?\_5]
M_P""RY_^-T =K17%?\+7\)?\_5]_X++G_P"-T?\ "U_"7_/U??\ @LN?_C=
M':T5Q7_"U_"7_/U??^"RY_\ C='_  M?PE_S]7W_ (++G_XW0!VM%<5_PM?P
ME_S]7W_@LN?_ (W1_P +7\)?\_5]_P""RY_^-T ;&MZ$=3U&VN%)$;VUQ8W0
M#8;R90"67/\ $&1?P)^E5[;PLVG/!>?VEJ&JW%A"ZV,-X\2)&2NW_EG&O)'&
M6S@$UG_\+7\)?\_5]_X++G_XW1_PM?PE_P _5]_X++G_ .-T =)H6E_V-H=G
MIYD\QX8P)),8WN>6;'NQ)_&M&N*_X6OX2_Y^K[_P67/_ ,;H_P"%K^$O^?J^
M_P#!9<__ !N@#M:*XK_A:_A+_GZOO_!9<_\ QNC_ (6OX2_Y^K[_ ,%ES_\
M&Z .UHKBO^%K^$O^?J^_\%ES_P#&Z/\ A:_A+_GZOO\ P67/_P ;H [6BN*_
MX6OX2_Y^K[_P67/_ ,;H_P"%K^$O^?J^_P#!9<__ !N@#M:*XK_A:_A+_GZO
MO_!9<_\ QNC_ (6OX2_Y^K[_ ,%ES_\ &Z .UHKBO^%K^$O^?J^_\%ES_P#&
MZ/\ A:_A+_GZOO\ P67/_P ;H [6BN*_X6OX2_Y^K[_P67/_ ,;H_P"%K^$O
M^?J^_P#!9<__ !N@#M:*XK_A:_A+_GZOO_!9<_\ QNC_ (6OX2_Y^K[_ ,%E
MS_\ &Z .UHKBO^%K^$O^?J^_\%ES_P#&Z/\ A:_A+_GZOO\ P67/_P ;H [6
MBN*_X6OX2_Y^K[_P67/_ ,;H_P"%K^$O^?J^_P#!9<__ !N@#M:*XK_A:_A+
M_GZOO_!9<_\ QNC_ (6OX2_Y^K[_ ,%ES_\ &Z .UHKBO^%K^$O^?J^_\%ES
M_P#&Z/\ A:_A+_GZOO\ P67/_P ;H [6BN*_X6OX2_Y^K[_P67/_ ,;H_P"%
MK^$O^?J^_P#!9<__ !N@#M:IZM_R!K[_ *]Y/_037+?\+7\)?\_5]_X++G_X
MW5;4/BCX5N--NH8KB^,DD+HH_LVX&200/X* -7X;?\DU\.?]>$7_ *#74UY9
MX)^(OAS1_!&BZ=?2WT5U;6D<4J?V=<-M8#D9"8-;W_"U_"7_ #]7W_@LN?\
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M% 50H&Y$&  ,%CU/.?\ \+7\)?\ /U??^"RY_P#C='_"U_"7_/U??^"RY_\
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M7\)?\_5]_P""RY_^-T =K17%?\+7\)?\_5]_X++G_P"-T?\ "U_"7_/U??\
M@LN?_C= ':T5Q7_"U_"7_/U??^"RY_\ C='_  M?PE_S]7W_ (++G_XW0!VM
M%<5_PM?PE_S]7W_@LN?_ (W4EO\ %#PM=7,5O%<WIDE<(H.G7 &2<#DI@4 =
MC1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
I44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>a200-2017x92634xmod29exe004.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a200-2017x92634xmod29exe004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *XV35OB )7$?A;2&0$[2=5()';CRZ[*B@#B_[
M7^(?_0JZ/_X-3_\ &Z/[7^(?_0JZ/_X-3_\ &Z[2B@#B_P"U_B'_ -"KH_\
MX-3_ /&Z/[7^(?\ T*NC_P#@U/\ \;KM** .+_M?XA_]"KH__@U/_P ;H_M?
MXA_]"KH__@U/_P ;KM** .+_ +7^(?\ T*NC_P#@U/\ \;H_M?XA_P#0JZ/_
M .#4_P#QNNTHH \ZUOQCXW\/Z6^HWWA;2Q;I)'&2FILQR[A%X\OU85H_VO\
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M=']K_$/_ *%71_\ P:G_ .-UTVI7LMK]FAMXDDN+F7RHQ(VU5PK,22 3P%/
MZG'3J,ZXUJ_M!-#+:VS74#VY<B1A&8I7*!^F005;(]!UYH RO[7^(?\ T*NC
M_P#@U/\ \;H_M?XA_P#0JZ/_ .#4_P#QNMBP\1+JVH)'81+):^3([NQ*NK*P
M"_+C&'!W YZ<U'I6N7MY?0P75K%;F6-G,;>9')&1CY1O4"3J<E>F.G- &7_:
M_P 0_P#H5='_ /!J?_C=']K_ !#_ .A5T?\ \&I_^-UTJ7.HG7);9]/1=-6
M.EYYX+-)GE/+QD #G.:OT <7_:_Q#_Z%71__  :G_P"-T?VO\0_^A5T?_P &
MI_\ C==I10!Q?]K_ !#_ .A5T?\ \&I_^-T?VO\ $/\ Z%71_P#P:G_XW7:4
M4 <7_:_Q#_Z%71__  :G_P"-T?VO\0_^A5T?_P &I_\ C==I10!Q?]K_ !#_
M .A5T?\ \&I_^-T?VO\ $/\ Z%71_P#P:G_XW7:44 <7_:_Q#_Z%71__  :G
M_P"-T?VO\0_^A5T?_P &I_\ C==I10!Q?]K_ !#_ .A5T?\ \&I_^-T?VO\
M$/\ Z%71_P#P:G_XW7:44 <7_:_Q#_Z%71__  :G_P"-T?VO\0_^A5T?_P &
MI_\ C==I10!Q?]K_ !#_ .A5T?\ \&I_^-T?VO\ $/\ Z%71_P#P:G_XW7:4
M4 <7_:_Q#_Z%71__  :G_P"-T?VO\0_^A5T?_P &I_\ C==I10!Q?]K_ !#_
M .A5T?\ \&I_^-T?VO\ $/\ Z%71_P#P:G_XW7:44 <7_:_Q#_Z%71__  :G
M_P"-T?VO\0_^A5T?_P &I_\ C==I10!Q?]K_ !#_ .A5T?\ \&I_^-T?VO\
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M[%P^W<?M<NTA22!MW8P"QXQCFBYT2SNIY96,Z&;'G+%.Z++@8^8 C)P ,]2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]SQ[T :%<=\0;^XLK&T\ABHWR2-_HLDOW(I''*D ?=[_ %Z UV-5-0TVUU2
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M_P#X_P#QG_V,,W_HJ*NUKBOA_P#\?_C/_L89O_145 ':T444 %%%% !1110
M4444 %%%% !1110 5Q4W_);;/_L7IO\ THCKM:XJ;_DMMG_V+TW_ *41T =K
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 <5\5O^1 N?^ONS_P#2F.NUKBOBM_R(%S_U]V?_ *4QUVM !16?975S<ZGJ
M4;M"+:VF6%%"'>28T<DMNQ_&1C';K5&'Q)YOBB;1?L%P&CC5@YV8ZG<<[L8
M,9P/FPXR!0!O45@ZGXD_LW7+/3/L%Q*USG:R;,-QQ@E@%YX^;&<<9J[JMU=6
M?V66%H?*:XCBE1T)9@[JH*D,,8R3R#GVH T:**@O+R"Q@\ZX<JN0H"J69B>@
M"@$D^P% $]%8=IXAAGU+4XY)5CM;."*8^;"\3Q[BX(<-R?N @X'7O5ZTU:TO
M9S!&9DFV[Q'/ \3,O0D!P,@9&<=,C/6@"]169!KVGW-Q##$TY,[%87:VD6.0
M@%OE<KM/"DCGD#C-*^O:>D[1M)+A9/+:80.8E;.,&3&T<\'G@\'F@#2HK/O=
M;LK"9XIC.7CC$DGDV\DH13G!8JIQT/Y5>CD66-)$.4<!E/J#0 ZBBL_1=1;5
MM+CU#8%AG)>#'\46?D8_[PPWMG% &A16=I-W=7EO<3SF(J+B:*)(T*D*DC)R
M2QR3MSVZU2T;Q)_:^J7]D+&XB-K)M+/MP!M'4ACGYQ(N5R,H03F@#>HK!M_$
MGG^)Y]&^P7"M'&K;SLQU.XD[L8 ,9P,M\XR!FKMU=7-OK%C"&A-M<[D*E#O5
M@I;.[=C'&,8_&@#1HJF=4M1J+V!,WVA(O-*B"0C;ZAMN#] <U1NO$%N?#\FI
MV<CB,JWERS6<Q4$ G<RA=P7CKP/>@#:HJ*XN$M8&FD61E7&1'&TC>G"J"3^5
M0VM_%J$,QM699(SL99H60HV 1E6P>A!]Z +=%9^D75Q=VDINC$TT4\D):)"J
MMM8@'!)Q^9ID&O:?<7,,$;3DSL4A<VT@CD(!8[7*[3PI/7G'&: -.BL^'46;
M7+G3)4"LD*3PL/XT)*G\0P_)E]ZT* "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>K?\@:^_
MZ]Y/_035RJ>K?\@:^_Z]Y/\ T$T 87PV_P"2:^'/^O"+_P!!KJ:Y;X;?\DU\
M.?\ 7A%_Z#74T %%%% !1110 5Q7Q1_Y%6U_["ME_P"CTKM:XKXH_P#(JVO_
M &%;+_T>E ':T444 %<5\/\ _C_\9_\ 8PS?^BHJ[6N*^'__ !_^,_\ L89O
M_145 ':T444 %%%% !1110 4444 %%%% !1110 5Q4W_ "6VS_[%Z;_THCKM
M:XJ;_DMMG_V+TW_I1'0!VM%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110!Q7Q6_P"1 N?^ONS_ /2F.NUKBOBM_P B!<_]
M?=G_ .E,==K0!EZ<LT6K:NLEO(J2W"RQRG&UU\F)>.<YRI[=JT?)B#[O+3=N
MW9VC.<8S]<<4^B@!C0Q.Q9HT9CMR2H)^4Y'Y'D5G:VDTRV<$-O)(3=0R,RXV
MHJ2*Q)R?0&M(NBNJ%E#-G:I/)QUQ3J "J.I6<MTMM+;R(EQ:S>=%Y@)5CM9"
M#CGE7;GL<'G&#>HH YQ]$U*\OKVZN[BUC^T0P+&D2EO)>&1I$))QO!9N?N\#
M'O5^&SOI]1AO+]K=/LZ,D<<!+;BV,L20.P^[[]3QC4HH YS3M#OK:\M99#9P
M&(EIY+0N@NB5(.8ONKDG=G+=.V<U WA5T\^WCCM9K::1WWSR2Y4.Q8J4!PXY
M(ZKQUSU/4!T9V4,I9?O 'D?6G4 8&IZ/>7E]-,D=E)O4)%*Q>*:  ?WTY89)
M.,KC/7GC;MXWAMHHI)6F=$"M(PP7(')./6I** "LGPU93:9X?M-,G3!L4^S1
MMD'?&GRHWXJ%)]\UK44 9>A+-%:W$,]O)$RW=PP+XPZM,[*1@],$5HK#$A!2
M-%(! (4# )R?UI4D252T;JZ@E<J<C(."/P((H#H7*!EW@9*YYH 00Q!MPC0-
MDMG:,Y(P3]<5G7JS2Z[IH2WD,<)>1YN-@RC*!USG)':M3/..]&: ,O6-,GOQ
M#)9W/V6Y0/'YNW)\MQA@/?(5A[J.V:;JVFW$^A2:5IPMH8I+=K;]YG"*5VC
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M>YTNRFF;K));HS'C'4C/2IKK3[*^C2.[M(+A$.566,,%/3C/2@">/(C4%]Y
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M%% !1110 4444 %%%% !1110 4444 %%%% !5/5O^0-??]>\G_H)JY5/5O\
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M;FM2%OM-H#+;O&'!#12@$XZ8."14H15+%5 +'+$#J<8Y_ "@#$\/>(O[=>[
MLYH1!*R;WV@$9XZ,2<CG<!M/8FK=K=73:W?64[0M'%#%-$4C*D!VD&&RQSCR
MQR,=>E7DBCC^Y&JX4+\HQP.@^@R:SK1)V\1:A<O;210FW@A1W*_O"K2DD8).
M,.O7'6@#4HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH *IZM_R!K[_ *]Y/_035RJ>K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSUX:CI5]<V<<<LUJYC98IU=&8*K?*XX(PP].XJ?0[Z]U#3K>>\L_(9X4?<)
MP8D9/ Z4 :=%85AXGMKW5$L1]GWR!BGE722L-O4.%/RG\QQUZ9O-J,JZ['IH
MT^[:)[<S&]"CR5(.-A.<[N_3I0!?HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M=K7%?%'_ )%6U_["ME_Z/2@#M:*** "N*^'_ /Q_^,_^QAF_]%15VM<5\/\
M_C_\9_\ 8PS?^BHJ .UHHHH **** "BBB@ HHHH **** "BBB@ KBIO^2VV?
M_8O3?^E$==K7%3?\EML_^Q>F_P#2B.@#M:*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@#BOBM_P B!<_]?=G_ .E,==F[
M%(V8*6(!(4=3[5QGQ6_Y$"Y_Z^[/_P!*8ZZ^ZBDGLYX8IF@DDC94E49*$C 8
M?3K0!BZ3K%[J%Q;_ +[3I8Y%W7$,3%9;7Y<A6!.6YX/"D>GI8TW76O[RYMVT
M^[C$5P8@[1_+@*#DG/'7^5+'IE])?6=Q?WEO-]D+-&8;8QLQ*E?F)8\88G
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M%% !1110 4444 %%%% !1110 4444 %%%% !5/5O^0-??]>\G_H)JY5/5O\
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M15M?^PK9?^CTKM:XKXH_\BK:_P#85LO_ $>E ':T444 %<5\/_\ C_\ &?\
MV,,W_HJ*NUKBOA__ ,?_ (S_ .QAF_\ 145 ':T444 %%%% !1110 4444 %
M%%% !1110 5Q4W_);;/_ +%Z;_THCKM:XJ;_ )+;9_\ 8O3?^E$= ':T444
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MGW75Q ()/, BV$,W8L'5@<=1QP>>H%*VEK-I\UG=7=Q<B0[O-D*AU(P05VJ
M,$ CCK5^B@#-BT@1Q7FZ]NY+FZC\M[HE5D50"%V[5"C&YB..I-)INCG3!&B:
MA=2P1J56%UB"<G.?E0$GW)[FM.B@#'L-!.GN#'JM^Z&0RR))Y7[UCW9@@8]N
M_8#H*V*** ,Z?2=]U+<6U]=6;S8\T0;")"!@,0ZM@X &1C@#.<#!!I"6^HI>
M+=W3[(! L4C*ZA>N<D;LDX).[G STK1HH Q8_#HB:!AJ=\?)NGNU!$6-[A@P
M^YT.]_\ OH\]*N6&DVVFW%[-;;P;N7S74ME5;'.T=LG)/N35ZB@"AI&F?V18
M"U^W7M[\[/YUY+YDGS'.,X' S@>U7Z** ,P:0XU8ZA_:EYN(VF+;%LV9)V_<
MSCGUS[T^\TH7\Q^T7=P]J<;K3Y!&V.Q(7<1ZC=@]",<5H44 4[VP>](7[?=0
M1$;7C@*KO'^]MW#ZJ0:JW6@Q3S6;PW5Q:+9IL@C@$91.,9"NC $#@$= 2.YK
M6HH RKS1/MUE;V\VHWA\F7S3)^[)D.21N!0J0"<@8XP/2K$=C/':2PG4[MY'
M;<)V$6].G &S;CC^[W-7:* ,_3M+;3;$VB7]U*@7;&THCW1]>F$ /7OFDTW2
MFTZ69_[1N[@3,79)A'C<<<_*BGMZXK1HH **** "J>K?\@:^_P"O>3_T$U<J
MGJW_ "!K[_KWD_\ 030!A?#;_DFOAS_KPB_]!KJ:Y;X;?\DU\.?]>$7_ *#7
M4T %%%% !1110 5Q7Q1_Y%6U_P"PK9?^CTKM:XKXH_\ (JVO_85LO_1Z4 =K
M1110 5Q7P_\ ^/\ \9_]C#-_Z*BKM:XKX?\ _'_XS_[&&;_T5%0!VM%%% !1
M110 4444 %%%% !1110 4444 %<5-_R6VS_[%Z;_ -*(Z[6N*F_Y+;9_]B]-
M_P"E$= ':T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% '%?%;_D0+G_K[L_\ TICKIM:M);W1KJWA"M(Z?*C' ?'.TGT.
M,'ZUS/Q6_P"1 N?^ONS_ /2F.NUH P9[HZI=:?Y-G=Q"VF-Q,\UNR>6 C#:N
M1\[$MCY<C&>>F<+3;*,:7&D6E7L.MF<O'<2P.&4&0D,92,!-O5,YQE=N:[NB
M@#"UW3[)/(OEM(%O#>VP\\1@2',J _-UZ<?2L[7+*XDUR66[CBFLVB06_F:;
M)>!",[@ C?*V<'..1@9XQ71G2[)KX7K0![@'<K,Q;:<8R 3@''&15N@#EWMI
M%L]*&I17-]81QR+,C0,[%R5\MGC!9F 4,.=QR5)Y&0EUI-E>>%M6M[/2Y?*E
M+2107$6 6" #RT;E!Q@ @<YXP:ZFB@#-T@Z>%DCTZP>UCR&;-FUN&/T91D_A
M5G4+=[S3;JVCD\MYH7C5_P"Z2" ?UJS10!CVNHK)';6;Z7=).I57B-N1'%CN
M'("$#'&TD]./2&YOT7Q/:O\ 9[TQQ6\\+NMG*5#,\1'(7!'RMR..*WJ* .)\
M50W5W)J0CL-UU'"4LF33FFD<[,AEFR%C(8D 9!&W/.16AKJQ7SV#S6]P\8B=
MQYNGO<Q9.WAX@-P;K@\8^8=ZZ:B@#DI;8_\ ",6%O/97")]I8E([=IE"Y<JT
MD1)8HW!V<E2RC^&M+PS"8+2[ M5@C:X+1[8'@5QL49$3$E!D$8[X)QS6W10!
MA>$8K>'0]MM8ZG91^?*?)U)B9<[SD\LWRGJ.>E;M%% '-V]\=3U2*6\M;^)(
MY<6UL;20 -R/,D<KMSC.!G Z\G&(-5LYX=8U"Y+ZF?M$"?8_L8; E4,,-MX_
MND;_ )/F/O75T4 8<TDVGZK'>W4$TJS6:Q.UM"TFR16)QA03AMQYZ?+SU%4)
M=/N(=)T5;E+J)8&,DYLP6EB8J<*-N25^8@[0>W;)KJZ* .4%A<?\(<UL(KG!
MN=X8C_2/*\[=YF.OF8RP_BSCC=Q5_P /P-%<:A(GVMK:5T9);U665FVX888!
MM@P,9 Y+=L5N44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 53U;_D#7W_ %[R
M?^@FKE4]6_Y U]_U[R?^@F@#"^&W_)-?#G_7A%_Z#74URWPV_P"2:^'/^O"+
M_P!!KJ: "BBB@ HHHH *XKXH_P#(JVO_ &%;+_T>E=K7%?%'_D5;7_L*V7_H
M]* .UHHHH *XKX?_ /'_ .,_^QAF_P#145=K7%?#_P#X_P#QG_V,,W_HJ*@#
MM:*** "BBB@ HHHH **** "BBB@ HHHH *XJ;_DMMG_V+TW_ *41UVM<5-_R
M6VS_ .Q>F_\ 2B.@#M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@#BOBM_R(%S_U]V?_ *4QUVC+N0KDC(QD'D5Q?Q6_
MY$"Y_P"ONS_]*8Z[1E#H5)(!&.#@_G0!R&A+?7Z1[I]5A>,K+]HFD5HIE$IW
M* #W5<<X(W9Q6K_;5V--2Z-K#N%^+251*< &?RMRG;R>0<''UJ]INEVVE0F&
MU,_EG^&6=Y,=>FXG'6JMSX;T^ZD9I?M.QIA/Y27,B() P8, I'.0#Z9YZT 0
M7FKZG%>ZC';V=JT%C$LQ>2=@T@()V@!?E/RGG)[<>EB34;NYN_LVG0PDK D\
MCW#E1ARP50%!Y^5LGMQU[3/HUG)+>R,)RU[&(YOW[X*@8X&?EZGIBFR:):.(
M=C7,3Q1"$217#JS(.BL<Y;OR>1DX(R: ,&QUZ>QTBS@:*5[N>XNQ^^>2?RDC
MF93EE#,V,JH]?45HV_B&>:R<_8C]K^T+;Q*P>..4L,A@64$ #.>#C:0,\9LP
M^'--M[-+6WCFBCCE::)DG?=&S$EMK9R <GCISTJ?^Q[5K.2VE:XF61@[-+.[
M.&&""K9RI! (VXP: ,^QEOQXKFAO %!LU<>5.S1L=^,A#]TCOCKQSV&AIUSJ
M-Q+>K?Z>EHD5PR6S+.)//CXPY  VYY^6F6NA6=IJ'V]6N)+LQ^6TLMP[%ESD
M @G&!VXXR?4T_3M(M-*EO9+42AKVX-Q-YDK.-YQG 8G:..@XH OURS":'5OM
MUS/=E7NA"ES;3*T&PR;5B:,\@[CM) )SGY@.!U-9<7A_38=6;4([6%)2"=JQ
M@ .229/]XY.3UH ;J*F77-+B,LRQXED*QRL@8KMQG:1D<G@\56\1_P!O[[0Z
M,8BBN))E>,D[5Z@$.N2<\+T.#\PK0O+&>>_LKN"XCC-N6#*\1?>K8R!AA@\=
M>?I5^@#&\01ZU)HC0:3-#]ND7RB[(0H)&"X(;*8Z_P 7I@U;M$N+O28UU LL
M\J9D$682A/8;7)!'3(:KU1SB9H7$#HDI'RM(A90?< C/YB@"AX=D>7PSI4DL
MCR2-:1,SNQ9F)09))Y)]ZTZJ:79'3M)L[%I!*;>!(C(%V[MJ@9QDXZ=,FK=
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JGJW_(&OO^O>3_ -!-7*IZ
MM_R!K[_KWD_]!- &%\-O^2:^'/\ KPB_]!KJ:Y;X;?\ )-?#G_7A%_Z#74T
M%%%% !1110 5Q7Q1_P"15M?^PK9?^CTKM:XKXH_\BK:_]A6R_P#1Z4 =K111
M0 5Q7P__ ./_ ,9_]C#-_P"BHJ[6N*^'_P#Q_P#C/_L89O\ T5%0!VM%%% !
M1110 4444 %%%% !1110 4444 %<5-_R6VS_ .Q>F_\ 2B.NUKBIO^2VV?\
MV+TW_I1'0!VM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110!Q7Q6_Y$"Y_Z^[/_P!*8Z[6N*^*W_(@7/\ U]V?_I3'7:T
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M "N*^*/_ "*MK_V%;+_T>E=K7%?%'_D5;7_L*V7_ */2@#M:*** "N*^'_\
MQ_\ C/\ [&&;_P!%15VM<5\/_P#C_P#&?_8PS?\ HJ*@#M:*** "BBB@ HHH
MH **** "BBB@ HHHH *XJ;_DMMG_ -B]-_Z41UVM<5-_R6VS_P"Q>F_]*(Z
M.UHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXZ@* NX=3N)Y[8[Y%.YUV9-!L;UW@M#-,(;B>0%H[<_,">HR"ZA021]X$^E
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M_'-=2 !T&*,#.<<^M '(2:@1;S3_ -J2C75E98[#S>K!B%B\KNI&/GQG!W9
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MSMSAB,XSS0!9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%?%;_ )$"Y_Z^[/\
M]*8Z[.3?Y;>7MWX.W=TSVS7&?%;_ )$"Y_Z^[/\ ]*8ZZC5K6YO=*N;6TN%M
MYID*"5D+;0>"0 1SCISUH I:!K-QJ:R+=P112;1-"T3$K+"Q8*XST)VDX[ K
MZU*?$-B'3BY,,DJPI<"W<QL[,% # ="2!NZ>]5H/#HLM0T^ZL#;6P@C,4ZB-
MCYB$#*KEOE&54CKTJ:RT[4[&"WL8KNV^Q6^U$8PDR&->BGYL9P,;OTH DO/$
M%E8FX,BW+QVP)N)(;=Y%BXSR5!YQS@9QWQ4ESK%M;S>2$N)Y @D98(&D**>A
M.!QG!P.IQP*@&GZE:RW"V%U:K!/(TH$\+,T3-RV,,-P)R><8SU-.>POX+N:X
ML+F ?: OFK<1%OG V[QM([ 97VX(YR 6(]5LYIK:**1G^U1&6%E0E648S\V,
M9Y''6J\GB+3XM-6_<W @:?[/_P >\A<2;MF"H&[[W'3J1ZU%_8T]M#8&RN(S
M/:[]S3H2)-_+'@C!W<^G;W$*:'J*Z8+9M0MGE^W_ &QI/LS $>9YFT+OXYXS
MGI^= %R37(%TV]NDAN-]HI,D#0L'!QD<8R0?49'7T-3:7J::G;K*L%Q$2BL1
M+"R#D=BP&:B&ERO>ZG)+.A@O(EC5$0AD !!).2#U]!3M.M]3MXTAN9[1XHHA
M&OEQ,&8C #'+<#VY^M !IM^;VZOUW';#*JK&\#1L@V@\[OO9.2".QJ&/Q)82
MS&-1<[5G^S/(ULZHLF[:%)([G STY'K26%AJEOJ=Q<W%W9R1W#*72.W92,+@
M8)<_RJ$Z)?G3)K;[;;>:]\+M7\AL "42;2-_/(QG/X4 6;[Q#8:>;DSF<QVH
MS<2QP.Z0\;OF('H03Z @G K1@F6YMXYD#A74, ZE3CW!Y%<QXAM+N&UU*TL;
MB8#48W(B2P>5@[+M(64'8F<#[X.,D].G41(4A1#U50#0!6U.:ZMK"6>T6%I(
MU+D2YP0 3V[U4&L?8=&BU#5MJ"5HP/LT;R8WX"C !.<G'3N*MZG;W-U82V]K
M+#$\BE"TL9< $$'@$<_C5"72M2FT6WLFO+030S0OY@MVVE8V5@-N_.25ZY[]
M* +MMJL%RDY6.=)( &DA>%@X!&00N.<X.,9Y!'4&LS1=;N=3\V[F9;>S7S&V
M26<D9558@$RLVT\#)^7^6:T%L;M-6OKU+B#$\$<42-$?D*%SECNY&7/ QTJK
M9:-=KH]QI>H74$UO-')&3!"T; .3GDLW]Z@"U;:W:74\406XB,V?)::!HUEP
M,_*2.N 3@X. 3C IT6L6,VM7&CQRL;ZWB6:1/+8 *W0[L;3TZ U FGZC/<VC
MZA=6[QVK^8ODQ%3(^TJ"V6.!AB<#OCG'!GB@U)=:N)Y;V)]-:)5AMA#AT<?>
M8OGD'TQ_]< OT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]6_Y
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M PSE@/D(Y##/0@\@UD^'88[M+K6+F6WDU*3?;/<1*HV1QLR@#.< D%^<\GN
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MAMKR&VC:Z#+!+$S2*D@4MM8$*2,*QR",[2..,U]&\3VNH:=I\TV])+F- 9!
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M]0=K#H1GH?>I*** &NBR(R.H9&&"K#((J*.SM88WCBMH41^'54 #?4=ZGHH
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M7_H]* .UHHHH *XKX?\ _'_XS_[&&;_T5%7:UQ7P_P#^/_QG_P!C#-_Z*BH
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M /&?_8PS?^BHJ[6N*^'_ /Q_^,_^QAF_]%14 =K1110 4444 %%%% !1110
M4444 %%%% !7%3?\EML_^Q>F_P#2B.NUKBIO^2VV?_8O3?\ I1'0!VM%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q7Q
M6_Y$"Y_Z^[/_ -*8Z[*9HEAD:8H(@I+E\;0O?.>U<;\5O^1 N?\ K[L__2F.
MNU(R,&@#C?!UE#?:-8RR2:;<0Q6MJT!M4"R12!23O()R<;/3H>*>VMBWL;-)
MM9"W::FULR.\8:1/M!3##']S'(QU'K77!57[H ^@IHBC#LXC4.V-S8Y..F:
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MX"J!DY_B%:U5K[3[?481#<B1HPP;:DK)DCUVD9'L>* +-%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %4]6_P"0-??]>\G_ *":N53U
M;_D#7W_7O)_Z": ,+X;?\DU\.?\ 7A%_Z#74URWPV_Y)KX<_Z\(O_0:ZF@ H
MHHH **** "N*^*/_ "*MK_V%;+_T>E=K7%?%'_D5;7_L*V7_ */2@#M:***
M"N*^'_\ Q_\ C/\ [&&;_P!%15VM<5\/_P#C_P#&?_8PS?\ HJ*@#M:*** "
MBBB@ HHHH **** "BBB@ HHHH *XJ;_DMMG_ -B]-_Z41UVM<5-_R6VS_P"Q
M>F_]*(Z .UHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** .*^*W_(@7/\ U]V?_I3'7:UQ7Q6_Y$"Y_P"ONS_]*8Z[6@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH *IZM_P @:^_Z]Y/_ $$U<JGJW_(&OO\
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M %%%% !1110 4444 %%%% !5/5O^0-??]>\G_H)JY5/5O^0-??\ 7O)_Z":
M,+X;?\DU\.?]>$7_ *#74URWPV_Y)KX<_P"O"+_T&NIH **** "BBB@ KBOB
MC_R*MK_V%;+_ -'I7:UQ7Q1_Y%6U_P"PK9?^CTH [6BBB@ KBOA__P ?_C/_
M +&&;_T5%7:UQ7P__P"/_P 9_P#8PS?^BHJ .UHHHH **** "BBB@ HHHH *
M*** "BBB@ KBIO\ DMMG_P!B]-_Z41UVM<5-_P EML_^Q>F_]*(Z .UHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .*^
M*W_(@7/_ %]V?_I3'7:UQ7Q6_P"1 N?^ONS_ /2F.NUH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q7Q6_P"1 N?^
MONS_ /2F.NUKBOBM_P B!<_]?=G_ .E,==K0 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %4]6_Y U]_U[R?^@FKE4]6_P"0-??]>\G_ *": ,+X;?\ )-?#G_7A
M%_Z#74URWPV_Y)KX<_Z\(O\ T&NIH **** "BBB@ KBOBC_R*MK_ -A6R_\
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M?\DU\.?]>$7_ *#74T %%%% !1110 5Q7Q1_Y%6U_P"PK9?^CTKM:XKXH_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4]6_Y U]_P!>\G_H
M)JY5/5O^0-??]>\G_H)H POAM_R37PY_UX1?^@UU-<M\-O\ DFOAS_KPB_\
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M_I1'0!VM%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!Q7Q6_Y$"Y_Z^[/_P!*8Z[6N*^*W_(@7/\ U]V?_I3'7:T %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXJ;_ )+;9_\ 8O3?^E$==K7%3?\ );;/_L7IO_2B.@#M:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#BOBM_R(%S_P!?
M=G_Z4QUVM<5\5O\ D0+G_K[L_P#TICKM: "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JGJW_(&OO^O>3_T$U<JGJW_(&OO^O>3_ -!- &%\-O\ DFOAS_KPB_\
M0:ZFN6^&W_)-?#G_ %X1?^@UU- !1110 4444 %<5\4?^15M?^PK9?\ H]*[
M6N*^*/\ R*MK_P!A6R_]'I0!VM%%% !7%?#_ /X__&?_ &,,W_HJ*NUKBOA_
M_P ?_C/_ +&&;_T5%0!VM%%% !1110 4444 %%%% !1110 4444 %<5-_P E
MML_^Q>F_]*(Z[6N*F_Y+;9_]B]-_Z41T =K1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M )%6U_["ME_Z/2@#M:*** "N*^'_ /Q_^,_^QAF_]%15VM<5\/\ _C_\9_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !5/5O^0-??\ 7O)_Z":N53U;_D#7
MW_7O)_Z": ,+X;?\DU\.?]>$7_H-=37+?#;_ ))KX<_Z\(O_ $&NIH ****
M"BBB@ KBOBC_ ,BK:_\ 85LO_1Z5VM<5\4?^15M?^PK9?^CTH [6BBB@ KBO
MA_\ \?\ XS_[&&;_ -%15VM<5\/_ /C_ /&?_8PS?^BHJ .UHHHH **** "B
MBB@ HHHH **** "BBB@ KBIO^2VV?_8O3?\ I1'7:UQ4W_);;/\ [%Z;_P!*
M(Z .UHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** .*^*W_(@7/_7W9_\ I3'7:UQ7Q6_Y$"Y_Z^[/_P!*8Z[6@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *IZM_R!K[_KWD_P#035RJ>K?\@:^_Z]Y/_030
M!A?#;_DFOAS_ *\(O_0:ZFN6^&W_ "37PY_UX1?^@UU- !1110 4444 %<5\
M4?\ D5;7_L*V7_H]*[6N*^*/_(JVO_85LO\ T>E ':T444 %<5\/_P#C_P#&
M?_8PS?\ HJ*NUKBOA_\ \?\ XS_[&&;_ -%14 =K1110 4444 %%%% !1110
M 4444 %%%% !7%3?\EML_P#L7IO_ $HCKM:XJ;_DMMG_ -B]-_Z41T =K111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 <
M5\5O^1 N?^ONS_\ 2F.NUKBOBM_R(%S_ -?=G_Z4QUVM !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M &+TW_I1'7:UQ4W_ "6VS_[%Z;_THCH [6BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH XKXK?\B!<_\ 7W9_^E,==K7%
M?%;_ )$"Y_Z^[/\ ]*8Z[6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH **** "BBB@ HHHH **** "BBB@ HHHH *IZM_R!K[_ *]Y/_035RJ>K?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '%?%;_D0+G_K
M[L__ $ICKM:XKXK?\B!<_P#7W9_^E,==K0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %4]6_P"0-??]>\G_ *":N53U;_D#7W_7O)_Z": ,+X;?\DU\.?\ 7A%_
MZ#74URWPV_Y)KX<_Z\(O_0:ZF@ HHHH **** "N*^*/_ "*MK_V%;+_T>E=K
M7%?%'_D5;7_L*V7_ */2@#M:*** "N*^'_\ Q_\ C/\ [&&;_P!%15VM<5\/
M_P#C_P#&?_8PS?\ HJ*@#M:*** "BBB@ HHHH **** "BBB@ HHHH *XJ;_D
MMMG_ -B]-_Z41UVM<5-_R6VS_P"Q>F_]*(Z .UHHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** .*^*W_(@7/\ U]V?_I3'
M7:UQ7Q6_Y$"Y_P"ONS_]*8Z[6@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *IZM
M_P @:^_Z]Y/_ $$U<JGJW_(&OO\ KWD_]!- &%\-O^2:^'/^O"+_ -!KJ:Y;
MX;?\DU\.?]>$7_H-=30 4444 %%%% !7%?%'_D5;7_L*V7_H]*[6N*^*/_(J
MVO\ V%;+_P!'I0!VM%%% !7%?#__ (__ !G_ -C#-_Z*BKM:XKX?_P#'_P",
M_P#L89O_ $5%0!VM%%% !1110 4444 %%%% !1110 4444 %<5-_R6VS_P"Q
M>F_]*(Z[6N*F_P"2VV?_ &+TW_I1'0!VM%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110!Q7Q6_Y$"Y_P"ONS_]*8Z[6N*^
M*W_(@7/_ %]V?_I3'7:T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/5O^0-??
M]>\G_H)JY5/5O^0-??\ 7O)_Z": ,+X;?\DU\.?]>$7_ *#74URWPV_Y)KX<
M_P"O"+_T&NIH **** "BBB@ KBOBC_R*MK_V%;+_ -'I7:UQ7Q1_Y%6U_P"P
MK9?^CTH [6BBB@ KBOA__P ?_C/_ +&&;_T5%7:UQ7P__P"/_P 9_P#8PS?^
MBHJ .UHHHH **** "BBB@ HHHH **** "BBB@ KBIO\ DMMG_P!B]-_Z41UV
MM<5-_P EML_^Q>F_]*(Z .UHHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** .*^*W_(@7/_ %]V?_I3'7:UQ7Q6_P"1 N?^
MONS_ /2F.NUH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M *XKX?\ _'_XS_[&&;_T5%7:UQ7P_P#^/_QG_P!C#-_Z*BH [6BBB@ HHHH
M**** "BBB@ HHHH **** "N*F_Y+;9_]B]-_Z41UVM<5-_R6VS_[%Z;_ -*(
MZ .UHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** .*^*W_ "(%S_U]V?\ Z4QUVM<5\5O^1 N?^ONS_P#2F.NUH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "J>K?\@:^_P"O>3_T$U<JGJW_ "!K[_KWD_\
M030!A?#;_DFOAS_KPB_]!KJ:Y;X;?\DU\.?]>$7_ *#74T %%%% !1110 5Q
M7Q1_Y%6U_P"PK9?^CTKM:XKXH_\ (JVO_85LO_1Z4 =K1110 5Q7P_\ ^/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Q7Q6_Y$"Y_Z^[/_P!*8Z[6
MN*^*W_(@7/\ U]V?_I3'7:T %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/5O\
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MHH **** "BBB@ HHHH **** "BBB@#BOBM_R(%S_ -?=G_Z4QUVM<5\5O^1
MN?\ K[L__2F.NUH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>K?\ (&OO^O>3
M_P!!-7*IZM_R!K[_ *]Y/_030!A?#;_DFOAS_KPB_P#0:ZFN6^&W_)-?#G_7
MA%_Z#74T %%%% !1110 5Q7Q1_Y%6U_["ME_Z/2NUKBOBC_R*MK_ -A6R_\
M1Z4 =K1110 5Q7P__P"/_P 9_P#8PS?^BHJ[6N*^'_\ Q_\ C/\ [&&;_P!%
M14 =K1110 4444 %%%% !1110 4444 %%%% !7%3?\EML_\ L7IO_2B.NUKB
MIO\ DMMG_P!B]-_Z41T =K1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 <5\5O^1 N?\ K[L__2F.NUKBOBM_R(%S_P!?
M=G_Z4QUVM !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 53U;_D#7W_7O)_Z":N53
MU;_D#7W_ %[R?^@F@#"^&W_)-?#G_7A%_P"@UU-<M\-O^2:^'/\ KPB_]!KJ
M: "BBB@ HHHH *XKXH_\BK:_]A6R_P#1Z5VM<5\4?^15M?\ L*V7_H]* .UH
MHHH *XKX?_\ '_XS_P"QAF_]%15VM<5\/_\ C_\ &?\ V,,W_HJ*@#M:***
M"BBB@ HHHH **** "BBB@ HHHH *XJ;_ )+;9_\ 8O3?^E$==K7%3?\ );;/
M_L7IO_2B.@#M:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#BOBM_R(%S_P!?=G_Z4QUVM<5\5O\ D0+G_K[L_P#TICKM
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M^,_^QAF_]%15VM<5\/\ _C_\9_\ 8PS?^BHJ .UHHHH **** "BBB@ HHHH
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MKX<_Z\(O_0:ZFN6^&W_)-?#G_7A%_P"@UU- !1110 4444 %<5\4?^15M?\
ML*V7_H]*[6N*^*/_ "*MK_V%;+_T>E ':T444 %<5\/_ /C_ /&?_8PS?^BH
MJ[6N*^'_ /Q_^,_^QAF_]%14 =K1110 4444 %%%% !1110 4444 %%%% !7
M%3?\EML_^Q>F_P#2B.NUKBIO^2VV?_8O3?\ I1'0!VM%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Q7Q6_Y$"Y_Z^[/_
M -*8Z[6N*^*W_(@7/_7W9_\ I3'7:T %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M (,KG_XY0!VE%<7_ ,*H\(?\^-Y_X,KG_P".4?\ "J/"'_/C>?\ @RN?_CE
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MPA_SXWG_ (,KG_XY0!VE%<7_ ,*H\(?\^-Y_X,KG_P".4?\ "J/"'_/C>?\
M@RN?_CE ':45Q?\ PJCPA_SXWG_@RN?_ (Y1_P *H\(?\^-Y_P"#*Y_^.4 =
MI17%_P#"J/"'_/C>?^#*Y_\ CE'_  JCPA_SXWG_ (,KG_XY0!VE%<7_ ,*H
M\(?\^-Y_X,KG_P".4?\ "J/"'_/C>?\ @RN?_CE ':45Q?\ PJCPA_SXWG_@
MRN?_ (Y1_P *H\(?\^-Y_P"#*Y_^.4 =I17%_P#"J/"'_/C>?^#*Y_\ CE'_
M  JCPA_SXWG_ (,KG_XY0!VE%<7_ ,*H\(?\^-Y_X,KG_P".4?\ "J/"'_/C
M>?\ @RN?_CE ':53U;_D#7W_ %[R?^@FN7_X51X0_P"?&\_\&5S_ /'*0_"C
MP>1@V-V1Z'4;C_XY0!<^&W_)-?#G_7A%_P"@UU-<2GPE\&Q1K''I]TB*,!5U
M&X  _P"_E._X51X0_P"?&\_\&5S_ /'* .THKB_^%4>$/^?&\_\ !E<__'*/
M^%4>$/\ GQO/_!E<_P#QR@#M**XO_A5'A#_GQO/_  97/_QRC_A5'A#_ )\;
MS_P97/\ \<H [2N*^*/_ "*MK_V%;+_T>E+_ ,*H\(?\^-Y_X,KG_P".4R3X
M2>#)5VR:=<NN0<-J%P1D<@_?H [>BN+_ .%4>$/^?&\_\&5S_P#'*/\ A5'A
M#_GQO/\ P97/_P <H [2N*^'_P#Q_P#C/_L89O\ T5%2_P#"J/"'_/C>?^#*
MY_\ CE,7X2>#(RQ33KE2QW-MU"X&3ZGY^3Q0!V]%<7_PJCPA_P ^-Y_X,KG_
M ..4?\*H\(?\^-Y_X,KG_P".4 =I17%_\*H\(?\ /C>?^#*Y_P#CE'_"J/"'
M_/C>?^#*Y_\ CE ':45Q?_"J/"'_ #XWG_@RN?\ XY1_PJCPA_SXWG_@RN?_
M (Y0!VE%<7_PJCPA_P ^-Y_X,KG_ ..4?\*H\(?\^-Y_X,KG_P".4 =I17%_
M\*H\(?\ /C>?^#*Y_P#CE'_"J/"'_/C>?^#*Y_\ CE ':45Q?_"J/"'_ #XW
MG_@RN?\ XY1_PJCPA_SXWG_@RN?_ (Y0!VE<5-_R6VS_ .Q>F_\ 2B.E_P"%
M4>$/^?&\_P#!E<__ !RF?\*D\&>8)/[.N?, VA_[0N,X],[^E ';T5Q?_"J/
M"'_/C>?^#*Y_^.4?\*H\(?\ /C>?^#*Y_P#CE ':45Q?_"J/"'_/C>?^#*Y_
M^.4?\*H\(?\ /C>?^#*Y_P#CE ':45Q?_"J/"'_/C>?^#*Y_^.4?\*H\(?\
M/C>?^#*Y_P#CE ':45Q?_"J/"'_/C>?^#*Y_^.4?\*H\(?\ /C>?^#*Y_P#C
ME ':45Q?_"J/"'_/C>?^#*Y_^.4?\*H\(?\ /C>?^#*Y_P#CE ':45Q?_"J/
M"'_/C>?^#*Y_^.4?\*H\(?\ /C>?^#*Y_P#CE ':45Q?_"J/"'_/C>?^#*Y_
M^.4?\*H\(?\ /C>?^#*Y_P#CE ':45Q?_"J/"'_/C>?^#*Y_^.4?\*H\(?\
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ME1;_ "A$,+DXPH)ZG).>.*Z&BB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ@0\=MJ-RRQ0&)R$+[@6^8 [F /('0"H8I)OM+KK<^JQV DNQ;M#).I+BYD
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M;K.DJQ;$9UE>5F4L!DKF9N#D<#ISFK_:FJ7FJRZG;O<1Z:^I6J).;A\0PM#
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J-H(FN$G* RHK(
MK]PIP2/QVC\JDHH **** "HU@B6X><(!*ZJK/W(&<#Z#<?S-244 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
D !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>ebs-20220630_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ebs-20220630_g1.jpg
M_]C_X  02D9)1@ ! @$!+ $L  #__@ 23$5!1%1/3TQ3('8R,"XP /_; (0
M!04%" 4(# <'# P)"0D,#0P,# P-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0$%" @*!PH,!P<,#0P*# T-#0T-#0T-#0T-
M#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-#0T-_\0!H@
M 04! 0$! 0$           $" P0%!@<("0H+ 0 # 0$! 0$! 0$!
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M &22I"I>1@BCJS$ #MR3P* &PSQW"[X761<XRC!AGTR"1F@"6@ H * "@ H
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MT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_\<H
M/^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_
M\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\
M@7!_\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@">V\3Z1>RK
M!;7UG-*YPL<=Q"[L<9PJJY8G )X'2@#<H * "@ H * "@ H * "@ H * "@#
M.U#6+'2=OV^Y@M/,SL\^6.+?MQNV[V7=MW+G&<9&>HH S?\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
MA,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^
M!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\ A,="_P"@C8?^!<'_ ,<H /\
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M_A,="_Z"-A_X%P?_ !R@ _X3'0O^@C8?^!<'_P <H /^$QT+_H(V'_@7!_\
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M_BJ #^U;+_GXA_[^I_\ %4 ']JV7_/Q#_P!_4_\ BJ #^U;+_GXA_P"_J?\
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MT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_\<H
M/^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\ @7!_
M\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C8?\
M@7!_\<H /^$QT+_H(V'_ (%P?_'* #_A,="_Z"-A_P"!<'_QR@ _X3'0O^@C
M8?\ @7!_\<H /^$QT+_H(V'_ (%P?_'* 'Q^+=%E81QZA9.[D*JK=0$DDX
M#Y))X ')- '04 % !0 4 % !0 4 % $4T\=LAEF98XUY9G(50/<D@#\30!A'
MQ?H:D@ZC8@C@@W4&0?\ OY0!JV6IVFI*6LYX;E1U,,B2 ?4H2* +M !0 4 ?
ME;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 ?8G[-O_()OO^OM?_1*4T!]'4P"@ H * "@ H * "@ H *
M/,OC)_R*.H_[D/\ Z4PTF!\C_#'XB3^ K_+[I-.N2!<PCDCL)8P<#S$],@.N
M5.#M94,^^[&^@U*".[M'6:"90\<B'*LI&00?Z=0>#@U0BU0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'AWQA^)X\(VYTK3'!U2Y3EA@_9HV&-Y])6_Y9*1P/WAX
M"!T!X)\"6+^+868DL8;DDDY))C.23W)[FD,^[*H04 % !0 4 % !0 4 % !0
M 4 % !0!\9_M'_\ (=M/^O!?_1\]2QGSS0(* "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79O_14
ME S]#:H04 % !0 4 % !0 4 % !0 4 % 'RM^TS_ ,PG_M^_]LZ3 ^5J0!0
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MWQ-X=VI%=M=0KC]U=CSUPO10S$2HN.,)(HQCT& 9[QX:_:)TZ]VPZY;O8N<
MS19FASW8K@2H/91,?>G<1[WI.M6.NP"ZTV>*ZA/\<3A@#UVM@Y5O56 8=P*8
M&G0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY
M_P"1LG_ZX6__ *+%2,\;H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0![)\!O^1L@_ZX7'_HLT#/NZJ$% !0 4
M % !0 4 % !0 4 % !0!\V?&C_D*6_\ UZC_ -&RUX6,^-?X?U9]GE'\&?\
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M9^T;_P C';?]@V+_ -*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M5=3PRGD?0@FA&O0!^5M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!]B?LV_P#()OO^OM?_ $2E- ?1U, H
M * "@ H * "@ H * "@#S+XR?\BCJ/\ N0_^E,-)@?GU2 ]W^#?Q0/A6X&CZ
MF_\ Q++A_D=CQ:RL?OY_YXN?]8,@(?W@Q\^XV&?;2L' 92"",@CD$'H0>X-4
M(6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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M 4 % !0 4 % !0 4 % !0 4 % !0  XY% 'JGA/XQ>(/"I6(S&^M%X\BY)?
MZ8CE_P!:F!]T;C&/^>9H&?5/@OXOZ)XP*V^\V-ZW'V><@;SZ0R\))[+\DA[1
MX&:8CU6F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * "@ H * "@ H ]D^ W_(V0?]<+C_ -%F@9]W50@H * "@ H
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M315(SR.@04 % !0 4 % !0!]<_LU?\>6H_\ 7>#_ - >FAGTS3$% !0 4 %
M!0 4 % !0!\6?M&_\C';?]@V+_TINZE@> 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ;?AK_D+67_ %]V
M_P#Z.2@9^F]4(* "@ H * "@#Y=^/WCV2WQX8L'*%T$EZRD@[6YC@^C+B23'
M52B]"P*8S6^#/PJATRWB\0:O&)+R=1);1. 5MXSRDA4\><XPRG_EFI&,.6V@
M$&N_M"_V)J-UIO\ 9?F_8KF:W\S[9MW^3(T>_;]E;;NVYV[FQG&3UHN(RO\
MAIC_ *A/_D]_]QT7 V]$_:-TV]F$6IV<M@C''FI*+A5SW<>7$X7U*JY]C1<#
MTCQMX'TSXCZ<K IYYC#VEXF"0&&Y/F'WX7SEEY&#N7#8- 'RO\/?%-[\,/$#
MZ;J>8[9YOL][$3\J,#M6X7J#LR&W+D20DXSE"%L,^[001D<@U0C\K:D H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#[$_9M_Y!-]_P!?:_\ HE*: ^CJ8!0 4 % !0 4 % !0 4 % 'F7QD_
MY%'4?]R'_P!*8:3 _/JD 4 ?5'P1^*6/+\,ZQ)Q]VQG<\^UL['_R 2>/]5G'
MEJ&AGU53$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!ROC+Q?9>"M.?4KXYQ\L40.'FE()6-
M>#C.,LV"$4%B#@ @'YZ^)?$E[XKOY-3U!]\LIX49V1H/NQQ@D[44=!U)RS$L
M23(S!H$>R? ;_D;(/^N%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % '
MQG^T?_R';3_KP7_T?/4L9\\T""@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H ]%^$O\ R-FF_P#79O\ T5)0,_0V
MJ$% !0 4 % !0 4 % !0 4 % !0!\K?M,_\ ,)_[?O\ VSI,#Y6I % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %  #CD4 >\_
M#[XX7_API9:T7O[ 84.3NN(1_LLQ'FH/[CG(  1U VD&?8VC:U9:_:I?:=*E
MQ;R#Y70]^ZL.JL/XE8!AW%4(TZ "@ H * "@ H * "@ H * "@ H * "@ H
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M /A'X\_\C9/_ -<+?_T6*D9XW0(* "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@#V3X#?\C9!_P!<+C_T6:!GW=5"
M"@ H * "@ H * "@ H * "@ H ^;/C1_R%+?_KU'_HV6O"QGQK_#^K/L\H_@
MS_Q_^VQ/':\T^C"@#3TG5[K0[E+RR<QRQG\&'=6'1E;H0?T(!JX2=-J4'9HP
MJTH5X.G45XO\/-=F?5W@WQK:^+(/EQ%=QC][!GD=MZ9^]&2?JI.UNQ;Z&C65
M9=I+=?JO+\CX+%X.>$EKK3?PR_1]G^>Z\NTKK/-"@ H * "@ H * "@ H *
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0!EZUK-KX?LY=1OW$5O;KN=C^051W9F(55'+,0!UH _/OQ_XZN_'>HM
M>3YCMH\K;09^6*,GOS@R/@&5NY  PBJ!(SA:!!0![)\!O^1L@_ZX7'_HLT#/
MNZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/-
M@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * /1?A+_R-FF_]=F_]%24#/T-JA!0 4 % !0 4 % !0 4 % !0 4 ?
M*W[3/_,)_P"W[_VSI,#Y6I % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 =KX(\>:CX%N_M-BVZ%R//MV)\J91ZC^%P,
M[) -RYQRI96!GWIX0\8:?XTL5O\ 3FR/NR1-@20OW2103CU5@2K#E3UQ0CJ:
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H AN;F*RB:>X=8
MHHU+.[L%55'4LQP !ZF@#Y,^(WQWENR^F^&&:&'E7O<%9'['[.#S&O\ TT($
MAX*B/&6D9\T.[2,7<EF8DDDY))Y))/))/4T"&T % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0![?\.?C/?>$REAJF^^TT84 G,UN.
MG[IF/SH!_P LG( P-C)R&!GVAHVM66OVJ7VG2I<6\@^5T/?NK#JK#^)6 8=Q
M5"-.@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /A'X\_\C9/_ -<+
M?_T6*D9XW0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M3=U+ \ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M%8]2M@!<PCC/831CO&_<=8WRIX*,[ ].I@% !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % $-Q<16D33SLL44
M2EW=R%55499F)P  .23P!0!\(?%?XER>.+S[-:%DTNU8^2AX,K\@SN.N2,B-
M3]Q.P9FJ1GD5 @H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H *
M"@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!Z+\)?^1LTW_KL
MW_HJ2@9^AM4(* "@ H * "@ H * "@ H * "@#Y6_:9_YA/_ &_?^V=)@?*U
M( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H ZWP7XQO?!&H)J%D<K]V:$DA)H^Z-CN.J-@E&P<$9!!GZ#^&?$EGXK
ML(M3T]]\4HY4XWQN/O1R#^%U/4=""&4E64FA&]0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % !0 4 % !0!DZYKMEX;LWU#4I5@MXARQY))Z*JC)9V/"JH)/T
MS0!\,?$?XJ7WCJ4P1YM=,C;,=N#RY'22<CAW[J@^2/@ %LNTC/*J!!0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 =KX(\>
M:CX%N_M%BVZ%R//MV)\N91ZC^%P,[) -R]]REE(,^\?!OC/3_&UD+[3GY7"S
M0M_K(7(SM<=P>=CCY7 .#D,!0CK* "@ H * "@ H * "@ H * "@ H * "@
MH * "@#X1^//_(V3_P#7"W_]%BI&>-T""@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@
M9]W50@H * "@ H * "@ H * "@ H * /FSXT?\A2W_Z]1_Z-EKPL9\:_P_JS
M[/*/X,_\?_ML3QVO-/HPH * "@">WN)+.19X&:.6-@R.IPRL.001T---IW6C
M1$HJ:<))--6:>S1].> OB''XB5;&^(COU'!X5)P.Z]A)CED'!P63C*K[U#$*
MI[D])_@_^#Y?<?$8W /#-U:6M+\8^3\NS^3[OU*O0/#"@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /@GXY?\ (W7G^Y;?^DT52,\CH$%
M!0 4 % !0 4 ?7/[-7_'EJ/_ %W@_P#0'IH9],TQ!0 4 % !0 4 % !0 4 ?
M%G[1O_(QVW_8-B_]*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &WX:_Y"UE_P!?=O\ ^CDH&?IO
M5""@ H * "@ H ^ =!F_X5SXV5;@[(K*]D@D8CCR)-T7F8ZX\J02CC.,8J1G
MW\"",CD&J$?FSXZ_Y&+5?^PC>_\ I3)4@?6UKX13QI\/K/3L#SQ9QRVS'C;.
MBG9SD !P3&Q.0%<G&0*8SX\T35[OPEJD5_!F.YLI<E#E<[25DB?N Z[HW'H2
M*0'Z.Z#K5OXAL(-3LSN@NHPZ^HSPR-_M(P*,.S*15"/E7]HW7DNM0M-'B(/V
M*)II<'I)/MVJWH5C0./:45+&>\?#3PS#I?AK3[>ZAB:8P>:Y>-2P,[M/M8D9
MRHD"D=L8[4P/SUI""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /L3]FW_D$WW_7VO_HE*: ^CJ8!0 4 % !0
M 4 % !0 4 % 'F7QD_Y%'4?]R'_TIAI,#\^J0!0 4 % &WX=\0WGA:_BU/3W
MV30'//W74\-&X_B1QPPZ]P0P! ,_0GP5XQL_&VG)J-F=K?=GA)!>&4#YD;U'
M='P Z$' .5%".NH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MS%55F !\">/O']]X\O3<7),5K$2+>V!RD2GN>FZ5N-\A&3]U0J!5$C.#H$%
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MJ?%T??U\_P _7?XS'9>Z-ZV'5X;RCUCYKO'\O3;V*O4/G0H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /@GXY?\ (W7G^Y;?^DT52,\CH$%
M!0 4 % !0 4 ?7/[-7_'EJ/_ %W@_P#0'IH9],TQ!0 4 % !0 4 % !0 4 ?
M%G[1O_(QVW_8-B_]*;NI8'@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M@ H * "@ H * /L'X >.CJ-LWAN]?,UFN^U+'EH,_-%GN86(*CD^6V  L5-
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH ]D^ W_ "-D'_7"X_\ 19H&?=U4(* "@ H * "@ H * "@ H * "@#YL^-'
M_(4M_P#KU'_HV6O"QGQK_#^K/L\H_@S_ ,?_ +;$\=KS3Z,* "@ H * "@!0
M<<C@B@1[_P##_P")?F;-+UE\-]V*Y=OO>B3$]^RR$_-P'Y^8^QA\3M3JOTD_
MR?\ G]Y\GCLOM>OAEIO*"6WG'R[KITTT7NM>N?+!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!\$_'+_D;KS_<MO\ TFBJ1GD= @H * "@ H *
M "@#ZY_9J_X\M1_Z[P?^@/30SZ9IB"@ H * "@ H * "@ H ^+/VC?\ D8[;
M_L&Q?^E-W4L#P"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M(C<<46 ^NM"T*R\-V<>G:;&(+>(<*.I)ZL['EG8\LQY/T %4(UZ /RMJ0"@
MH * "@ H * "@#[@^&O@+P_JGANPN[RPMIYY8B7D>,%F/F.,D]S@ 4QG<_\
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M H * "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@
MH * /4_@WI%GK?B2&TU"%+F!HIR8Y!N4E8R5./4'D4#/L;_A67A?_H&6G_?H
M4Q!_PK+PO_T#+3_OT* #_A67A?\ Z!EI_P!^A0 ?\*R\+_\ 0,M/^_0H /\
MA67A?_H&6G_?H4 '_"LO"_\ T#+3_OT* #_A67A?_H&6G_?H4 '_  K+PO\
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MD\,["I&>/4""@ H * "@ H * "@ H * "@#MO#'P\UWQ<0VFVKF$G!N)/W<
M]?WC8#XSRL8=O]F@9[_X?_9OMX@)-<O'E;O%:J$0'T\V0,S#Z11GWIV$>Q:1
M\,?#.AX-KI]NS #YYE-PV1W!G,FT_P"[M]L#BBP'<11)"HCC4(B\!5   ] !
MP/PI@/H * "@!KQK*I1P&5A@@@$$>A!X(H X76/ACX9UL'[3I]NK$'YX%^SO
MD]R83'N(Z_/N'J".*5@/'/$/[-\#@R:%>-&W:*[&Y3])HE#*!Z&*0^]%@/GS
MQ-X"UOP@W_$TM7CBS@3+B2$YZ#S4RH)[*Q5_]FD,X^@04 % !0 4 % !0 4
M% !0 4 >A?#CQ[<> ]2%PNY[*<JEW"/XT!X=02!YL>2R$XSED)"N30,_06PO
MX-3MX[RT=9H)T#QNO1E89!'<>X(!!R" 015"+= !0 4 % !0 4 % !0 4 %
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M!EI_WZ% !_PK+PO_ - RT_[]"@ _X5EX7_Z!EI_WZ% !_P *R\+_ /0,M/\
MOT* #_A67A?_ *!EI_WZ% !_PK+PO_T#+3_OT* )(?AQX:MI%FBTZU22-@ZL
M(QE64Y4CW! (I@=K0 4 % !0 4 % !0 4 1RPI.ACE571N"K ,I'N#D'\: ,
M)O"&AL<MIUB2>I-K 3_Z+H U;+3;735*6<,5LIQE8HTC!QTR$ '';TH N4 %
M !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?_1DE- >B4P"@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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MV_\ (6OO^O1?_1JT(9]AU0@H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^5OVF?^83_ -OW_MG2
M8'RM2 * "@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@9]W50@H * "@ H * "@
MH * "@ H * "@ H X/QQ\.]+\=0;+Q/*ND&(KJ,#S8_0'IYD>>3&QQR2I5CN
MI ?"?B_P??\ @J^;3]17!^]%*N?+F3/#H2!]&4_,IX(Z90SE:!!0 4 % !0
M4 % !0!]@?LZ^*#=V-QH,S9>S;SX 2<^3*<2*!V5)3N^LU- ?25, H * "@
MH * "@ H * "@ H * "@ H ^7_CS\1/(0^%].?YW -\ZG[J'E;?([N,/+_L;
M4YW. F,^3:0@H * "@ H * "@ H * "@#K?"?@?5O&D_D:7"752!),^5ABS_
M 'Y,$9QR$4,Y&=JG!H&?6W@SX%Z-X>"W&I@:I>#!_>+BW0\<)#DA\'(W2E@>
M"$0\4["/;418U"( JJ   ,  <  #@ #H*8#J "@ H * "@ H * "@ H CEB2
M=&BE571P596 96!X((.00>X/!H \&\:_ 33-;#7.AE=,NCD^7@FU<^Z#+0_6
M,% !Q$2<TK ?)/B+PQJ7A2Y-GJL#6\G52>4D7^]&XRKK[J3@\, P("&8% @H
M * "@ H * "@ H * "@#Z/\ @1\0SI=P/#>H/_HMTV;5F/$4[=8L]DF/W1G
MEZ#]XQ AGV'5""@ H * "@ H * "@ H * "@ H * "@#X1^//_(V3_\ 7"W_
M /18J1GC= @H * "@ H * "@#ZP_9H_U.J?[]I_*XIH9]14Q!0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0!\V?&C_D*6_\ UZC_ -&RUX6,^-?X?U9]GE'\&?\ C_\ ;8GCM>:?
M1A0 4 % !0 4 % !0 4 >M^ /B,^A%=.U(E['HC\EX,]!ZM%ZKU7.5X&T^C0
MQ'L_<G\'XK_@>7W'S^.P"KWK4-*G5;*7^4O/KU[GTM#,DZ++$P=' 964@JRD
M9!!'!!'((KW4TU=;'Q33BW&2LUHT]TR2F(* "@ H * "@ H * "@ H * "@
MH * "@ H * /@GXY?\C=>?[EM_Z315(SR.@04 % !0 4 % !0!]<_LU?\>6H
M_P#7>#_T!Z:&?3-,04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % 'SC^TE_R";'_K[;_T2])@?'=( H * "@ H * "@#U7X)_\CCI_P#V]?\
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M@SZ\TW3;72+=+.QB2W@B&$CC4*H'T'4GJS'+,<EB22:H1=H * "@ H * "@
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M]FC_ %.J?[]I_*XIH9]14Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\Y_&FWE%_;7&UO*-OL
M#X.W>)'8KGINVD''7'->'C$^>+Z<MK^=V?8Y1)>SG"ZYN:]NMK)7]+GBU>8?
M2A0 4 % !0 4 % !0 4 % 'I?@3X@3>&7%I=[IK!SRO5H2>KQ_[/=H^AZKAL
M[NZAB'1?++6'Y>:_R/%QN!CB5[2G:-5?=+R?GV?WZ;?45I=PW\*7%LZRQ2#<
MCJ<@CV/Z$=000<$5[\6I)2B[I['PTHRIR<)IJ2T:>Z+%40% !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?!/QR_Y&Z\_W+;_ -)HJD9Y'0(* "@ H * "@ H
M ^N?V:O^/+4?^N\'_H#TT,^F:8@H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * /G']I+_ )!-C_U]M_Z)>DP/CND 4 % !0 4 % !0!ZK\$_^
M1QT__MZ_]([B@#[]J@"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#\K:D H * "@ H * "@ H _0[X2_\BGIO_7 _P#HR2F@
M/1*8!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 >9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 %
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M * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[9TF!\K4@"@ H * "@ H
M* /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H * "@ H * "@ H * "@
M H ^6_VB/!X9(?$MLN&4K;W6!U!_U,IP.QS$S$Y.8E' I,#Y1I % !0 4 %
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /RMJ0"@ H *
M"@ H * "@#]#OA+_ ,BGIO\ UP/_ *,DIH#T2F 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y
M%'4?]R'_ -*8:3 _/JD 4 % !0 4 % !0 4 % %[3-2N=&NH[ZRD:&X@8/&Z
MG!!'Z$$<,IR&4E2""10,_0#X;_$"V\>:>)AMBO8 %NH ?NMVD3/)BDP2O7:<
MH22N2Q'HE, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H CEE2W
M1I966..-2S,Q"JJJ,LS,<   $DDX Y- 'PK\6_B8_C6[^Q6+,NE6K?NQT\^0
M9'GL.#CDB)3T4EB S$+(SQN@04 % !0 4 % !0 4 % 'LGP&_P"1L@_ZX7'_
M *+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_P AVT_Z\%_]'SU+
M&?/- @H * "@ H * "@#Z/\ V;?^0M??]>B_^C5H0S[#JA!0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0!\K?M,_\PG_ +?O_;.DP/E:D 4 % !0 4 % !0![)\!O^1L@_ZX7'_H
MLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 87B?1(_$>E76ER@$7
M4+HN>BOC,;_\ D"N/=><CB@#\S9(VB8QN-K(2I!Z@@X(_ U(#* "@ H * "@
M H * /NKX":B;[PM'$?^7.XG@'T)$X_+S\?3%- >T4P"@ H * "@ H * "@
MH * "@#R/XS^,#X4T)XK=MMYJ)-O"1U1"/WT@X_A0[ 005>1&'0T@/@FD 4
M% !0 4 % !0 4 % 'V'\&?A0-(2/Q#K,?^FN-UK X_U"$<2NI_Y;,"=JG_5+
M@G]X?W;0SZ/IB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /DKXS
M_"867F>(]$3]R27O+9!_J^I:XC _Y9D\RH/]63O7]WN$:&?,5(04 % 'L?@3
MX,:MXNVW5T#IVGMR)9%_>2#K^YB)!(.1B1]J8.5WD%:!GV%X3\$:3X+@\C2X
M0C,,23/AIY>_SR8!QGD(H5 >0HJA'6T % !0 4 % !0 4 % !0 4 % !0 4
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M * "@ H * "@ H * "@ H * "@#YQ_:2_P"038_]?;?^B7I,#X[I % !0 4
M% !0 4 >J_!/_D<=/_[>O_2.XH ^_:H H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H _*VI * "@ H * "@ H * /T.^$O_(I
MZ;_UP/\ Z,DIH#T2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_TIAI,#\^J0!0
M4 % !0 4 % !0 4 % '1>%?$][X/U"/4]/;$D?#(<[)8R1NBD (RC8'N&"LN
M&4$ S]"_"7BJS\8Z='J=@?E?Y9(S]^*0 ;HW]USP>C*0PX(JA'2T % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?'_QK^*?]J._AW1Y/]%C8K=S(
M?]<ZGF%"/^62$'>>1(PP/D7,DC/FV@04 % !0 4 % !0 4 % !0![)\!O^1L
M@_ZX7'_HLT#/NZJ$% !0 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7
M_P!'SU+&?/- @H * "@ H * "@#Z/_9M_P"0M??]>B_^C5H0S[#JA!0 4 %
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MP)\9?%1\3^(9EB;=:Z?FUAP<J2A/FN,<'?)N 8?>14YXJ1GE% @H * "@ H
M* "@ H ^B/@=\-QKDX\0:FFZRM7Q;QL.)IU_C(/6*$X/H\F!DA'4B&?954(*
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * $90X*L 01@@\@@]01
MW!H ^&?C'\-O^$.O!J.GJ?[+O'.T#I;RG+&$G^XP!:$]=H9#DIN:=AGGGA?P
M;JOC&X^SZ5 TN#\\I^6&('O)(?E7CD*,NW\*L>* /L#P+\$]*\*[+O4,:C?K
M@AG7]Q$PY_=1'J0>DDFX\ JL9S3L(]JI@% !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 ?"/QY_P"1LG_ZX6__ *+%2,\;H$% !0 4 % !0 4 ?6'[
M-'^IU3_?M/Y7%-#/J*F(* "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H CFA2X1HI5#HX*LK
M%64C!!!X((X(-)I-6>PTW%J479K5-;IGS/X^^'+Z"6U#30TEB>73JT&3^;1>
MC<E>C_WCX-?#NE[\-8?E_P #S^_N_M<#CU7M1K653H]E/_*7EUZ=CR:O//H
MH * "@ H * "@ H * "@#H_#/B>[\+70N;0Y4\21,3LD7T([$?PL.5/J"0=J
M=25&7-'YKHSBQ&&ABH<E3?I);I_Y=UU/K/PYXDL_$UJ+JS;D8$D9^_$Q'W6'
MY[6'RL!D'J!]'3J1JQYH_-=4? XC#SPL_9U%Z/I)=U^JW1OUL<@4 % !0 4
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M: ]$I@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0!YE\9/\ D4=1_P!R'_TIAI,#\^J0!0 4 % !0 4
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M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!\K?M,_\PG_M^_\ ;.DP/E:D 4 % !0 4 % !0![)\!O^1L@_P"N%Q_Z
M+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\+_'VT^S>*I),$
M?:;:WEZ8SA3#D>O^JQD8Y!'4$F1GBM @H * "@ H * "@#Z8_9KN"M]J,&3A
MX(7QV^21UR?<>9QQT+=.[0'UU3 * "@ H * "@ H * "@ H XGXB^)/^$4T"
M[U!&VS"/RX/7SI?DC(]2A/F$?W4-(#\Y"23D\DT@$H * "@ H * "@ H ZOP
M3X4G\9ZM#I4&560[II ,^5"O,C^F0.%!(#.RKGF@9^C6FZ;;Z/:Q6-F@B@MT
M6.-!T"J,#ZD]68\LQ+$DDFJ$7: "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H S=7T>TUZTDT_48EGMI@ \;$@'!##!4AE(8 AE(((!!% $F
MFZ9:Z/;I9V$4=M!$,+'&H51[X'4GJS'+,>6))S0!>H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /A'X\_P#(V3_]<+?_ -%BI&>-T""@ H *
M "@ H * /K#]FC_4ZI_OVG\KBFAGU%3$% !0 4 % !0 4 % !0 4 % !0 4
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M!0 4 % !0 4 % !0 4 % !0 4 ?!/QR_Y&Z\_P!RV_\ 2:*I&>1T""@ H *
M"@ H * /KG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@#YQ_:2_Y!-C_U]M_Z)>DP/CND 4 % !0 4 % !0!Z
MK\$_^1QT_P#[>O\ TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@#]#OA+_ ,BGIO\
MUP/_ *,DIH#T2F 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_ -*8:3 _/JD 4 %
M!0 4 % !0 4 % !0 4 % 'LOPC^)K^"KO[#?,S:5=-\XZ^1(>!,@_NG $JCD
MJ P!90K S[JBE2=%EB8.C@,K*0RLK#(92,@@@@@C@CD50A] !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 >/?%GXFQ^"+3[)9%7U6Z4^4O!\A#QY[KZ_\\E88
M9@2051E* ^$YIGN)&FE8O)(Q9V8Y9F8Y+$GDDDY)/4T@(J "@ H * "@ H *
M "@ H * "@#V3X#?\C9!_P!<+C_T6:!GW=5""@ H * "@ H * "@ H * "@
MH * /C/]H_\ Y#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4 ?1_[-O\ R%K[
M_KT7_P!&K0AGV'5""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#Y6_:9_YA/_;]_P"V=)@?*U(
MH * "@ H * "@#V3X#?\C9!_UPN/_19H&?=U4(* "@ H * "@ H * "@ H *
M "@ H * "@ H * /B_\ :."CQ!:D'YCI\8(]A<7.#^))_*I8'S[0 4 % !0
M4 % !0!]'_LV_P#(6OO^O1?_ $:M"&?8=4(* "@ H * "@ H * "@ H ^4?V
MD?$!,EEH<9.%#7<HSP2Q:*'\5 F//9@:3 ^6Z0!0 4 % !0 4 % !0!]P_ O
MP6/#VCC5+A<7FI@2<CE+?K$GMYG^M;U#1@C*4T![C3 * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /A'X\_P#(V3_]<+?_ -%BI&>-T""@ H * "@
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H _*VI *
M"@ H * "@ H * /T.^$O_(IZ;_UP/_HR2F@/1*8!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?&3_
M )%'4?\ <A_]*8:3 _/JD 4 % !0 4 % !0 4 % !0 4 % !0!]*?!/XI?V8
MZ>'-8DQ:R';:3.>(7)XA<G_EFY/R$G$;?*?D;* SZ^JA!0 4 % !0 4 % !0
M 4 % !0 4 % !0!P?Q"\>6O@+3C=2XDNI<K;09P9'[DXY$:9!=N.R@[F6D!^
M?>L:O=:]=RZA?R&:XN&+NQ]3T '154855&%50%  %(9FT""@ H * "@ H *
M"@ H * "@ H ]D^ W_(V0?\ 7"X_]%F@9]W50@H * "@ H * "@ H * "@ H
M * "@#XS_:/_ .0[:?\ 7@O_ */GJ6,^>:!!0 4 % !0 4 % 'T?^S;_ ,A:
M^_Z]%_\ 1JT(9]AU0@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H ^5OVF?^83_V_?\ MG28'RM2
M * "@ H * "@ H ]D^ W_(V0?]<+C_T6:!GW=5""@ H * "@ H * "@ H *
M"@ H * "@ H * "@#X?_ &@[L7/B<1C'^C6<$1Q[M+-S[XE'3MCOFI \-H *
M "@ H * "@ H ^D_V;(B=2OY.RVT:X_WI,_IL_6A#/K^J$% !0 4 % !0 4
M% !0 4 ?G7\3]:_M[Q+?W0.Z-)C!'CIL@Q"I'LVPO]6-2,X&@04 % !0 4 %
M !0!VGP^\,'Q=KEKIC F%G\R<CC$$?SR<\X+ ;%./ONM S]'$18U"( JJ
M,  <  #@ #@ =*H0Z@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^
M$?CS_P C9/\ ]<+?_P!%BI&>-T""@ H * "@ H * /K#]FC_ %.J?[]I_*XI
MH9]14Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
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M'CA0 4 % !0 4 % !0 4 % 'P3\<O^1NO/\ <MO_ $FBJ1GD= @H * "@ H
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M % !0 4 % !0 4 % !0 4 % !0!YE\9/^11U'_<A_P#2F&DP/SZI % !0 4
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M H ^N?V<?#@@M+O79 -]PXM83SD1QX>4CMM=R@Z]8CT[M ?3-, H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * /A'X\_\C9/_ -<+?_T6*D9XW0(*
M "@ H * "@ H ^L/V:/]3JG^_:?RN*:&?45,04 % !0 4 % !0 4 % !0 4
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MWK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * /RMJ0"@ H * "@ H * "@#[0^'7Q/\-:)X=L;"^O5AN((BLB&
M*=BI+N<96)E/!!X)IC.U_P"%R>$?^@BG_?FY_P#C-%Q!_P +D\(_]!%/^_-S
M_P#&:+@'_"Y/"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3P
MC_T$4_[\W/\ \9HN ?\ "Y/"/_013_OS<_\ QFBX!_PN3PC_ -!%/^_-S_\
M&:+@'_"Y/"/_ $$4_P"_-S_\9HN ?\+D\(_]!%/^_-S_ /&:+@'_  N3PC_T
M$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\ OS<__&:+
M@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/"/\ T$4_
M[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\ \9HN ?\
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MN%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_ ,AVT_Z\%_\
M1\]2QGSS0(* "@ H * "@ H ]N^!WBK2_"FHW<^KSBUCEMPB,5D;+"16QB-'
M(X!.2 />@9]+_P#"Y/"/_013_OS<_P#QFG<0?\+D\(_]!%/^_-S_ /&:+@'_
M  N3PC_T$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\
MOS<__&:+@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/
M"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\
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M7.I$@2JAC@!_BGD!6( =]I.]A_<1CVI ?G S%B23DGDD]2:0"4 % !0 4 %
M!0 4 ?;_ .SYIQL_#1N&7!O+N:0-CJB!(1@]P'C?\=U- >YTP"@ H * "@ H
M * "@ H \F^-VH_V?X3NU'#7+0P+_P "E5F_.-''^<%,#X&I % !0 4 % !0
M 4 % 'Z2^ ]%_P"$>T"QT\C:T5NAD!XQ+)F67_R([U0'6T % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0!\(_'G_ )&R?_KA;_\ HL5(SQN@04 %
M !0 4 % !0!]$? KQIH_A**_76+E;4W#6YCRDK[@@FW?ZM'QC<O7'7C/-"&>
M^_\ "Y/"/_013_OS<_\ QFG<0?\ "Y/"/_013_OS<_\ QFBX!_PN3PC_ -!%
M/^_-S_\ &:+@'_"Y/"/_ $$4_P"_-S_\9HN ?\+D\(_]!%/^_-S_ /&:+@'_
M  N3PC_T$4_[\W/_ ,9HN ?\+D\(_P#013_OS<__ !FBX!_PN3PC_P!!%/\
MOS<__&:+@'_"Y/"/_013_OS<_P#QFBX!_P +D\(_]!%/^_-S_P#&:+@'_"Y/
M"/\ T$4_[\W/_P 9HN ?\+D\(_\ 013_ +\W/_QFBX!_PN3PC_T$4_[\W/\
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M@ H * "@ H ^<?VDO^038_\ 7VW_ *)>DP/CND 4 % !0 4 % !0!ZK\$_\
MD<=/_P"WK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * /1?A+_ ,C9IO\ UV;_ -%24#/T-JA!0 4
M% !0 4 % !0 4 % !0 4 % 'F7QD_P"11U'_ '(?_2F&DP/SZI % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!IZ-K%UH%Y%J-@YAN+=@R,/R((/#*PRK*>&4D
M'@T#/T&^'_CFU\=Z<+R#$=Q%M2Y@SS%(1U'.3&^"8V/4 @_,K ,1W-, H *
M"@ H * "@ H ;)(L2EW(5%!9F8@  #)))X  Y)/ % 'PY\8/B<WC"Y.FZ<Y&
ME6S<$<?:9%X\UAU\M3D1*>H_>, S!4D9XE0(* "@ H * "@ H * "@ H * "
M@ H * "@#V3X#?\ (V0?]<+C_P!%F@9]W50@H * "@ H * "@ H * "@ H *
M "@#XS_:/_Y#MI_UX+_Z/GJ6,^>:!!0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z,_#+_D5],_Z](OY4P.YI@% !0
M4 % !0 4 % !0 4 % !0 4 % 'RM^TS_ ,PG_M^_]LZ3 ^5J0!0 4 % !0 4
M % 'LGP&_P"1L@_ZX7'_ *+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % 'Q+\=?'*^(M272+-MUGII8,RG*R7)X=N#@K$/W:G^\92"0PJ1G@] @H
M * "@ H * "@ H _2/P!I!T+P_86+ J\=M&S@C!$D@\V08]I'8?X4P.OI@%
M!0 4 % !0 4 % !0!\Z?M(7IBT>SM!_RVNS(?I%$XQ^<H/3L.1W3 ^.*0!0
M4 % !0 4 % '1^#],&LZU8V#?<N+N!'_ -PR+O\ R3<:!GZ7U0@H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@#X1^//_(V3_\ 7"W_ /18J1GC
M= @H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@#]./#7_ "";+_KTM_\ T4E4!M4 % !0 4 % !0 4 % !0 4 % !0 4
M% 'QG^T?_P AVT_Z\%_]'SU+&?/- @H LV=Y/I\R75K(\,T3!DD1BK*PZ%2,
M$&@#[;^%GQ<@\8(NFZF4M]50 #HJ70 Y>,=%EX)>(<?Q1_+N5&![=3 * "@
MH Y?Q3X3M/%5MY%R-LJ F&8#YHV/Y;D/\2'@CD88!ASU:4:RL]^C[?\  \CN
MPV)GA)\T-8OXH]&OT?9_IH?)_B#P]>>&KIK2]7:1DHXSLD7^\C8&1ZCJIX8
MU\[4IRI/EDO\GYH^^H5X8F"J4GZKK%]FOZOT,*LCJ"@ H * "@ H * "@ H
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M % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % !0
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M 4 % !0 4 % !0!\K?M,_P#,)_[?O_;.DP/E:D 4 % !0 4 % !0![)\!O\
MD;(/^N%Q_P"BS0,^[JH04 % !0 4 % !0 4 % !0 4 % !0 4 % '@WQC^**
M>&+=M&TMP=3N$Q(ZGFUC8?>..DSJ?W8R"@/F''R;D!\3$YY-( H * "@ H *
M "@ H Z_P%H)\2Z]9:<5+1RSJTH'_/&/]Y+ST'[M6 )[D#DG% S](ZH04 %
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M !N@ _X6UXL_Z"4W_?,7_P ;H ^Y/ ]U<WV@Z?=7SF6XGM(99'.,L9$#AC@
M9(89P.M4(ZF@ H * "@ H * "@ H * "@#X1^//_ "-D_P#UPM__ $6*D9XW
M0(* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H _3CPU_R";+_ *]+?_T4E4!M4 % !0 4 % !0 4 % !0 4 % !0 4 %
M'QG^T?\ \AVT_P"O!?\ T?/4L9\\T""@ H DAF>W=98F:.2-@RLI*LK Y#*1
M@@@\@CD&@#[(^$_QB37PFC:ZXCU #;#<,0J7..BMT"SXZ?PRGIAR%9@?0U,
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M/_[>O_2.XH ^_:H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H _*VI * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H ]%^$O_ "-FF_\ 79O_ $5)0,_0VJ$% !0 4 %
M!0 4 % !0 4 % !0 4 >9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % 'I7PS^(=QX"OP[;I-/N"%N80>W02QCH)(^O^VN4
M)&0RFPS[]L+^WU2WCO+-UF@G0/&Z]&5AD'U'N" 0<@@$$50BW0 4 % !0 4
M?/?QH^*/_"/Q-H.DOC4)E_?RJ>;:-AG:I'2:13P>L:'<,,R,J ^,:0!0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0![)\!O^1L@_ZX7'_HLT#/NZJ$% !0
M 4 % !0 4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/- @H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]&?A
ME_R*^F?]>D7\J8'<TP"@ H * "@ H * "@ H * "@ H * "@#Y6_:9_YA/\
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MKD#W,I!/X[1^52QGS=0(* "@ H * "@ H ]Z_9UB63Q),S=8]/F9?J9[9/\
MT%C_ #H0'VQ5 % !0 4 % !0 4 % !0 4 ?,W[2O_'EIW_7>?_T!*3&?(U(0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Z5>!T,
M?A[2T/5=.LP?J+>,50'44 % !0 4 % !0 4 % !0 4 ?"/QY_P"1LG_ZX6__
M *+%2,\;H$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 ?IQX:_Y!-E_UZ6__HI*H#:H * "@ H * "@ H * "@ H *
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MD@(W5K?GMW:+U3JO5.ZMZ%#$.E[D]8?^D_\  \ON\_ QV 5>]6BDJG5;*?\
ME+SZ]>Z^F89H[A%EA97C<!E92"I!Z$$<$?2O>335UL?%-.+<9)IK=/1HDIDA
M0 4 % 'Q=\?/">H6FL2:^4WV%V(4$B9/END2Q[)1CY2Q3*'E6!QG<"*D9\_4
M""@ H * "@ H * /KG]FK_CRU'_KO!_Z ]-#/IFF(* "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@#YQ_:2_Y!-C_U]M_Z)>DP/CND 4 % !0
M4 % !0!ZK\$_^1QT_P#[>O\ TCN* /OVJ * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /1?A+_R-FF_]=F_]%24#
M/T-JA!0 4 % !0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_ -*8:3 _/JD
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M\D(#URSD N0 9X?0(* "@ H * "@ H ]D^ W_(V0?]<+C_T6:!GW=5""@ H
M* "@ H * "@ H * "@ H * /C/\ :/\ ^0[:?]>"_P#H^>I8SYYH$% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?HS\
M,O\ D5],_P"O2+^5,#N:8!0 4 % !0 4 % !0 4 % !0 4 % !0!\K?M,_\
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M - 2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0!^F'@\8T/3@?^?&U_P#1$=4!T5 !0 4 % !0 4 % !0 4 % 'PC\>?\
MD;)_^N%O_P"BQ4C/&Z!!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % 'Z<>&O^039?]>EO_Z*2J VJ "@ H * "@ H *
M"@ H * "@ H * "@#XS_ &C_ /D.VG_7@O\ Z/GJ6,^>:!!0 4 % !0 4 ?3
M'PF^,QTX1Z'XADS; !+>[<DM%V6*8\YB[))UCX5LQX,8,^N58. RD$$9!'((
M/0@]P:H0M !0 4 5KRSAU"%[:Y19895*NC#((/\ (CJ",$$ @@@&IE%23C)7
M3Z%PG*G)3@VI)W370^7/'7P_F\,.;JUW36#GANKQ$_PR8'3LK]#T;#8W?/U\
M.Z+YHZP[]O7_ #/N<%CHXE>SG[M5=.DO./GW7W:;>;5Q'M!0 4 % !0 4 %
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M !0 4 % !0 4 % !0 4 % !0 4 ?./[27_()L?\ K[;_ -$O28'QW2 * "@
MH * "@ H ]5^"?\ R..G_P#;U_Z1W% 'W[5 % !0 4 % !0 4 % !0 4 % !
M0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y6U(!0 4 % !0 4 % !0 4 %
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M^-<UN[\17LNHZA(9;B=MS$]!Z*H_A1!A44<*H I#,J@04 % !0 4 % !0 4
M.1&D8(@+,Q   R23P  .22>@H ^X_@_\,5\'VHU+44!U6Z3D$?\ 'M&W/E+_
M --&&#*W&#^['"L78'%?M+_ZG2_]^[_E;T,9\GTA!0 4 % !0 4 % 'LGP&_
MY&R#_KA<?^BS0,^[JH04 % !0 4 % !0 4 % !0 4 % !0!\9_M'_P#(=M/^
MO!?_ $?/4L9\\T""@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * /T9^&7_(KZ9_UZ1?RI@=S3 * "@ H * "@ H * "@
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M_P"/+3O^N\__ * E)C/D:D(* "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@#].?#BE-*LU8$$6MN"#P01$F01ZU0&S0 4 % !0 4 %
M!0 4 % !0!\(_'G_ )&R?_KA;_\ HL5(SQN@04 % !0 4 % !0 4 % !0 4
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M(X- 'QQ\6/@X^@&36="0R6!)::W4%FMNY9>I:#U[Q#KE,LLC/GB@04 % !0
M4 ?7/[-7_'EJ/_7>#_T!Z:&?3-,04 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?
M_(XZ?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0!^5M2 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!Z+\)?^1LTW_KLW_HJ2@9^AM4(* "@ H *
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M7GC;47U&\.T?=AB!.R&(?=1<]_XG;JSDG@8 D9R5 @H * "@ H * "@ H *
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M &_?^V=)@?*U( H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * /0/AQX%G\=ZHMJH9+.';)=RC^"//"*3QYDI!5!R
M1\SX*HU S]";*SATZ".TMD$4,"+'&B]%10 H'T [\^O-4(LT % !0 4 % !0
M 4 % !0 4 % 'S!^TM;EK?3+C'$<ERF>>LBPL!Z<^6??CCO28'R92 * "@ H
M * "@ H ]'^$>H#3?%>G2GI),T!_[;QO"/R9P?P[]*!GZ%U0@H * "@ H *
M"@ H * "@#YF_:5_X\M._P"N\_\ Z E)C/D:D(* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@#]0]*_P"/*W_ZXQ?^@+5 7Z "@ H
M* "@ H * "@ H * /A'X\_\ (V3_ /7"W_\ 18J1GC= @H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#]./#7_()LO\
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M0@H * "@#ZY_9J_X\M1_Z[P?^@/30SZ9IB"@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H ^<?VDO^038_]?;?^B7I,#X[I % !0 4 % !0 4
M>J_!/_D<=/\ ^WK_ -([B@#[]J@"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#\K:D H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79O_14E S]#:H04
M % !0 4 % !0 4 % !0 4 % !0!YE\9/^11U'_<A_P#2F&DP/SZI % !0 4
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M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH _1GX9?\BOIG_7I%_*F!W-, H * "@ H * "@ H * "@ H * "@ H ^5OVF
M?^83_P!OW_MG28'RM2 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * -[PUX;O?%=_'IFG)OFE/).0D:#[TDC ':BCJ
M<9)PJ@L0"#/T(\%^#[/P3IJ:;9C)'S32D8::4@;G;T'&$7G:@"Y)R36PCK*
M"@ H * "@ H * "@ H * "@ H \)_:&LOM/AI)@.;:\A<GC(5DEB(SUP6=,@
M8R0">E)@?$=( H * "@ H * "@"[IMZ^F74-Y$2)+:6.92."&C<.I!['(% S
M]/K2YCO88[F$[HYD61#ZJZAE/X@BJ$3T % !0 4 % !0 4 % !0!\S?M*_\
M'EIW_7>?_P! 2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % #D4NP5>K$ ?4\4 ?J7;PK;1)"F2L:J@SUPH &<8&<#G@50$M
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M=( H * "@ H * "@#U7X)_\ (XZ?_P!O7_I'<4 ??M4 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4
M % 'VO\ #CX<>'-8\.6-[>V,4UQ-$6DD8R L?,<9.' Z #@4QG;_ /"I?"?_
M $#8/SD_^.46$'_"I?"?_0-@_.3_ ..46 /^%2^$_P#H&P?G)_\ '*+ '_"I
M?"?_ $#8/SD_^.46 /\ A4OA/_H&P?G)_P#'*+ '_"I?"?\ T#8/SD_^.46
M/^%2^$_^@;!^<G_QRBP!_P *E\)_] V#\Y/_ (Y18 _X5+X3_P"@;!^<G_QR
MBP!_PJ7PG_T#8/SD_P#CE%@#_A4OA/\ Z!L'YR?_ !RBP!_PJ7PG_P! V#\Y
M/_CE%@#_ (5+X3_Z!L'YR?\ QRBP!_PJ7PG_ - V#\Y/_CE%@#_A4OA/_H&P
M?G)_\<HL ?\ "I?"?_0-@_.3_P".46 /^%2^$_\ H&P?G)_\<HL ?\*E\)_]
M V#\Y/\ XY18 _X5+X3_ .@;!^<G_P <HL!>TSX<>'-'N8[VRL8H;B$[HY%,
MF5)!&1ER.A(Y%%@.VI@% !0 4 % !0 4 % !0 4 % !0 4 >9?&3_D4=1_W(
M?_2F&DP/SZI % !0 4 % !0 4 3VO^NC_P!]?YBD,_4NK$% !0!X+\9_AC_P
MD]N=:TM/^)E;)^\1>MS$HZ8[S1@?N\<NN8_F(C 0'Q000<'@BD E !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0!Z3\,_A]/X\U#RSNBL+<AKJ8#H.T2'
MIYDF,#^XNYR#@*P,^_K"PM]+MX[.SC6&"!0D<:C"JHZ ?U)R2<DDDDU0BW0
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M_P#'*+ =S86$&EV\=G:((8(%"1HN<*HZ 9)/'N:8%N@ H * "@ H * "@ H
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M)[>5CRO?_4-%^.:: ]5I@% !0 4 % !0 4 % !0!\S?M*_\ 'EIW_7>?_P!
M2DQGR-2$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % &
M]X6LO[2UBQL_^>]W;Q_0/*BDG@\ ')X/':@9^FE4(* "@ H * "@ H * "@
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M?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?\ T9)30'HE, H
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M *-6A#/L.J$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % 'RM^TS_P PG_M^_P#;.DP/E:D 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'J?@
M'X3ZIXW=9R#9Z=GYKF13\X!P1 AP96R""V1&N#EMP"D&?;?A?PGIO@ZS%CI<
M7EIP7<_-)*X&-\KX&YCZ !5Z(JKQ5".DH * "@ H * "@ H * "@ H * "@
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M4 % !0 4 % !0!ZA\&M._M+Q98J?NP-).WMY43LG_D38/Q_"@9^@54(* "@
MH * "@ H * "@ H * /A'X\_\C9/_P!<+?\ ]%BI&>-T""@ H * "@ H * /
MK#]FC_4ZI_OVG\KBFAGU%3$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MO3>TOT?9_@^G9=S78>6% !0 4 >,?%'X2V_C2,W^GA+?5D'WNB7( P(Y<='
M "2XR/N/E=I1 ?#]_87&ESO:7D;03PL5>-QAE8=B/U!'!&""0<T@/J[]FK_C
MRU'_ *[P?^@/30SZ9IB"@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H ^<?VDO^038_P#7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_ .1QT_\
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M0 4 % !0 4 % !0 4 7]+TRYUFZBL;*-IKBX<)&B]23[] !U9B0JJ"S$ $T
M?H%\.? 5MX"TX6R8DO)]KW4V/ON!PB]_*CR0@/7+.0"Q >P'H-, H * "@#Y
M=_:7_P!3I?\ OW?\K>DQGR?2$% !0 4 % !0 4 >R? ;_D;(/^N%Q_Z+- S[
MNJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_R';3_KP7_T?/4L9\\T""@
MH * "@ H * /H_\ 9M_Y"U]_UZ+_ .C5H0S[#JA!0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0!\
MK?M,_P#,)_[?O_;.DP/E:D 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0!U7AKP3K'BZ3R]*MI)ESAI2-D*>N^5L(#CG:"7/\*D
M\4#/JCP3\ ].T0K=ZXRZC=+R(@"+5#_ND!IC[R!4YP8B0#3L(]^1%C4(@"JH
M   P !P  .  . !TI@.H * "@ H * "@ H * "@ H * "@ H * "@ H ^%_C
MSH7]D^)6ND&(M1B2<8& '4>5(/\ >)02-_UTJ1GBM @H * "@ H * "@"[IN
MH3:3=0WULVR:VD26-O1D8,/PR.1W'% 'Z4>&=>@\3Z9;ZK;?ZNZC#;<YV/TD
MC/NCAD)[D9'!J@-V@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H Q_$&LP^'M.N-3N/]7:1/(1G&XJ/E0>[MA%]V% 'YGWMY+J%Q+=W
M#%YKB1Y9&/5G=BS'\6)-2!5H * "@ H * "@ H ^E?V;=)\W4+[4R.+>!(%)
M_O3/O./<+#@GKAL=":$!]>U0!0 4 % !0 4 % !0 4 % !0!\(_'G_D;)_\
MKA;_ /HL5(SQN@04 % !0 4 % !0!]8?LT?ZG5/]^T_E<4T,^HJ8@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
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M % !0 4 % !0 4 % !0!\X_M)?\ ()L?^OMO_1+TF!\=T@"@ H * "@ H *
M/5?@G_R..G_]O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_
M -&24T!Z)3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?GU2 * "@ H *
M "@ H GM?]='_OK_ #%(9^I=6(* "@ H * ,[5M*MM<M)=/OD$MO<(4=#W!Y
M!'HRD!E8<JP# @@&@#\^OB%X$NO >HFTES):RY>UGQQ)'GH<<"2/(61>W# ;
M'4F=AG!T""@ H * "@ H * "@ H * "@ H <JER%4$L2  !DDGH .Y/84 ?<
M7P>^&*^#[8:GJ* ZI=(.#_R[1-SY0_Z:-QYK=O\ 5J<!B[ ]NI@% !0 4 %
M'R[^TO\ ZG2_]^[_ )6])C/D^D(* "@ H * "@ H ]D^ W_(V0?]<+C_ -%F
M@9]W50@H * "@ H * "@ H * "@ H * "@#XS_:/_P"0[:?]>"_^CYZEC/GF
M@04 % !0 4 % !0!]'_LV_\ (6OO^O1?_1JT(9]AU0@H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
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MQGO@9Q^63^9H 6@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* /G']I+_D$V/_7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_Y''3_ /MZ_P#2
M.XH ^_:H H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H _*VI * "@ H * "@ H * /T.^$O\ R*>F_P#7 _\ HR2F@/1*8!0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 >9?&3_D4=1_W(?\ TIAI,#\^J0!0 4 % !0 4 % $]K_ *Z/
M_?7^8I#/U+JQ!0 4 % !0 4 <IXS\(6?C739--O!@GYH90!NAE ^5U_DZ\;D
M)7(R" #\]/$?AZ\\*W\NF:@NR:!L9'W74_=D0\91QRIP#V8!@0)&8= @H *
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M "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@ H *
M/9/@-_R-D'_7"X_]%F@9]W50@H * "@ H * "@#,UK1[;Q!93:;?+YEO<H4=
M>A]0RGLRL R'LP![4 ?G3XR\*77@S4Y=+N^?+.Z*3&%EB;[DB_4<, 3M<,N2
M5J1G+4""@ H * "@ H * "@#V+X0?$9O!5_]DO6/]EWK 2YY$,GW5G ]!PLH
M'+)AL,T:@@S[N1UD4,A#*P!!!R"#R""."".AJA#J "@ H * "@ H * "@ H
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M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H ^,_VC_\
MD.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?0W[-__ "';O_KP;_T?!0AGV95"
M"@ H * "@ H * "@ H * "@ H Q]=T&T\16K6=\F]#RK#AT;'#HW9A^1'# J
M2*RJ4XU5RS7^:\T=-&M/#352D[/JNC79KM_2U/D[Q9X0N_"=QY4X\R!S^ZG4
M$(X]#_=<?Q(3GN,J03\[5I2HNTMNCZ/_ (/D?>X7%0Q<>:.DE\4>J_S79_J<
MG7.>@% !0 4 % !0 4 % !0 Y6*D%3@CD$<$$=Q0+?1GT3\/_B4+_9IFL.%N
M.%AG/ E[!)#T$GHW DZ'Y_O^UA\3S6IU7KT??R?GY]?7?X_'9?[.]?#KW-Y1
M_E\U_=\NGIM[57JGS04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!\X_M)?\@FQ_P"OMO\ T2])@?'=( H * "@ H * "@#U7X)
M_P#(XZ?_ -O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_T9
M)30'HE, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * /,OC)_R*.H_P"Y#_Z4PTF!^?5( H * "@ H *
M"@">U_UT?^^O\Q2&?J75B"@ H * "@ H * /+OBC\.H?'=AF$+'J5J";:0X&
M[N8)#_<<]"?]6_S#@N&0'P-=VDUA,]M<HT4T+,DB.,,C*<,K ]"",4@*] !0
M 4 % !0 4 % !0 4 >[?!OX8'Q5<#5]30_V9;/\ *C#BZE4_<YZPH?\ 6'D,
M1Y0S\Y4&?;:J%  & . !T JA"T % !0 4 % !0!\N_M+_P"ITO\ W[O^5O28
MSY/I""@ H * "@ H * /9/@-_P C9!_UPN/_ $6:!GW=5""@ H * "@ H *
M"@ H * "@ H * /C/]H__D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?1_P"S
M;_R%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[9TF!
M\K4@"@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H *
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M 009^AGA[Q!9^)[&+4]/<203+G_:1A]Z-Q_"Z'AA^()4@FA&U0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 R65($:65@B("S,Q"JJJ,EF)P  !
MDD\ <F@#X.^+GQ&;QO?BWM"1IEFS"$=/-?HT[#@\CB,'[J9. SN*D9Y#0(*
M"@ H * "@ H * /H?]GGPQ_:&JRZW,O[K3T*1'L9Y@5XXYV1;\]""\9H0S[+
MJA!0 4 % !0 4 % !0 4 % !0 4 ?"/QY_Y&R?\ ZX6__HL5(SQN@04 % !0
M 4 % !0!]8?LT?ZG5/\ ?M/Y7%-#/J*F(* "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /C/]H_\
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M>DP/CND 4 % !0 4 % !0!ZK\$_^1QT__MZ_]([B@#[]J@"@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#\K:D H * "@ H *
M "@ H _0[X2_\BGIO_7 _P#HR2F@/1*8!0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 >9?&3_D4=1_W(
M?_2F&DP/SZI % !0 4 % !0 4 3VO^NC_P!]?YBD,_4NK$% !0 4 % !0 4
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MP"@ H * "@ H * "@ H * "@ H ^$?CS_P C9/\ ]<+?_P!%BI&>-T""@ H
M* "@ H * /K#]FC_ %.J?[]I_*XIH9]14Q!0 4 % !0 4 % !0 4 % !0 4
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M0>001P01R".M>WOJCXYJVCT:'4Q!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'SC^TE_R";'_ *^V_P#1+TF!\=T@"@ H * "@ H * /5
M?@G_ ,CCI_\ V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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M5O28SY/I""@ H * "@ H * /9/@-_P C9!_UPN/_ $6:!GW=5""@ H * "@
MH * "@ H * "@ H * /C/]H__D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?1
M_P"S;_R%K[_KT7_T:M"&?8=4(* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /E;]IG_F$_\ ;]_[
M9TF!\K4@"@ H * "@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@
MH * "@""ZM8KZ%[:X1989D:.1&&59&!5E(]""0: /SW^)?@67P)JC6P#-93[
MI+24\[H\\HQZ&2+(5^F05? #BI&>>4""@ H * "@ H * "@#IO"/BF[\&ZE%
MJED?FC.V2,G"RQ-C?$_LP&0<':P5Q\RB@9^B7A[7[3Q/80ZG8-O@G7(S]Y&'
M#1N.SHV58<C(R"5()H1M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '
MS+^T#X&^U0KXFLU_>0!8KP*/O19Q',<#),9/EN3D[&3HL9I,#Y'I % !0 4
M% !0 4 % !0!Z#X!^(NH> KKS+<^=9R$>?:LQ"..,LG7RY0!A7 /HRLO% S[
MJ\*>+]-\96@O=,D#@8$D;8$L+'^&1,G:>#@\JP!*L15".GH * "@ H * "@
MH * "@ H * "@ H * "@"O=W<-A"]S<NL,,2EGD=@JJHZEF. !0!\;?%/XRR
M>) ^D:&6AT[[LLW*R7..J@<%(3_=/SR#[VU24,C/GZ@04 % !0 4 % !0 4
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MO9^_3^'JNW_ _(^SP.8*K:C7=JG26REZ]I?@_70\>KS3Z(* "@ H * "@ H
M* "@ H ]4\!?$23P\5L;\M)8$_*>KP$]U[F//+)VR63G*MWT,0Z7N3UA^7IY
M>7W>?@XW +$7JT;*KUZ*7KV?9_)]U].6]Q'=1K-"RR1R*&5E.593R"".H->^
MFFKK9GQ,HN#<9*S6C3W3):9(4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % 'SC^TE_P @FQ_Z^V_]$O28'QW2 * "@ H * "@ H ]5^"?_(XZ
M?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0!^5M2 4 % !0 4 % !0 4 ?H=\)?^13TW_K@?\ T9)30'HE
M, H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /,OC)_R*.H_[D/\ Z4PTF!^?5( H * "@ H * "@">U_
MUT?^^O\ ,4AGZEU8@H * "@ H * "@ H * (Y8DG1HI55XW4JRL RLK##*RG
M((()!!&".#0!\(_%KX:/X(O/M=FI;2KISY3<GR7.6,#DY/0$Q,3ET!!)9&-3
ML,\?H$% !0 4 7M,TVYUBZBL;*-IKB=PD:+U)/Z  9+,<!5!8D $T ?H%\./
M -MX"TX6Z[9+R?#W4X'WGQPBGKY4>2$'&3N<@%B ]@/0J8!0 4 % !0 4 %
M!0 4 ?+O[2_^ITO_ '[O^5O28SY/I""@ H * "@ H * /9/@-_R-D'_7"X_]
M%F@9]W50@H * "@ H * "@ H * "@ H * "@#XS_ &C_ /D.VG_7@O\ Z/GJ
M6,^>:!!0 4 % !0 4 % 'T?^S;_R%K[_ *]%_P#1JT(9]AU0@H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H ^5OVF?\ F$_]OW_MG28'RM2 * "@ H * "@ H ]D^ W_ "-D'_7"
MX_\ 19H&?=U4(* "@ H * "@ H * "@ H XOQ[X,M_'&E2:=-A)A^\MY2/\
M53 ':3CG8V2L@'52<?,%(0'YWZGIMQH]U+8WB&*XMW:.1#V93@\C@@]589#
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MOXF:KXZDVW#?9[)6S':1D^6,=&D/!ED _B8 #G8B9(*&>=4""@ H * "@ H
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M'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?E;4@% !0 4 % !0 4 % 'Z'?"7_D4]-_ZX'_ -&24T!Z)3 * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?GU2 * "@ H * "@ H GM?]='_OK_
M #%(9^I=6(* "@ H * "@ H * "@ H R]:T:U\064NG7Z"6WN%*NO?U#*>S*
M0&5NS 'M0!^>_CWP1=^!-2:QN,O ^7MI\866+. >,@.O21,Y4X(RK*QD9Q-
M@H <JER%4$L2  !DDGH .Y/84 ?<7P>^&*^#[8:GJ* ZI=(.#_R[1-SY0_Z:
M-QYK=O\ 5J<!B[ ]NI@% !0 4 % !0 4 % !0 4 ?+O[2_\ J=+_ -^[_E;T
MF,^3Z0@H * "@ H * "@#V3X#?\ (V0?]<+C_P!%F@9]W50@H * "@ H * "
M@ H * "@ H * "@#XS_:/_Y#MI_UX+_Z/GJ6,^>:!!0 4 % !0 4 % 'T?\
MLV_\A:^_Z]%_]&K0AGV'5""@ H * "@ H * "@ H * "@ H * "@ H * "@
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M!F[JFU?E)D6F@/?J8!0 4 % !0 4 % !0 4 % !0 4 % !0!\(_'G_D;)_\
MKA;_ /HL5(SQN@04 % !0 4 % !0!]8?LT?ZG5/]^T_E<4T,^HJ8@H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H ^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 ?0W[-__
M "';O_KP;_T?!0AGV95""@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M *"E_P#^!,O_ ,50 ?\ "P_$O_04O_\ P)E_^*H /^%A^)?^@I?_ /@3+_\
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M9?&3_D4=1_W(?_2F&DP/SZI % !0 4 % !0 4 3VO^NC_P!]?YBD,_4NK$%
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M4+R>"64AXY)Y&1AY;G#*6((R >>XH ^YJH04 % !0 4 % !0 4 % !0 4 %
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M,^@*,!TYZTK@>3Z[\1O$7B/*WU].T;<&*-A#$1Z&.((K?\"#'OG- SB:!!0
M4 % !0 4 % !0 4 % !0 4 ?0GP4^&)U^==>U6/_ $"W?,$;CBXF4_>(/WH8
MB.<_+(_R?,JR+0,^SJH04 % !0 4 % !0 4 % !0 4 % !0 4 % 'PC\>?\
MD;)_^N%O_P"BQ4C/&Z!!0 4 % !0 4 % &UI/B/4]!#C3+JXLQ+M+B"5X]^W
M.W=M(SC<<9Z9/K0,U_\ A8?B7_H*7_\ X$R__%4 '_"P_$O_ $%+_P#\"9?_
M (J@ _X6'XE_Z"E__P"!,O\ \50 ?\+#\2_]!2__ / F7_XJ@ _X6'XE_P"@
MI?\ _@3+_P#%4 '_  L/Q+_T%+__ ,"9?_BJ #_A8?B7_H*7_P#X$R__ !5
M!_PL/Q+_ -!2_P#_  )E_P#BJ #_ (6'XE_Z"E__ .!,O_Q5 !_PL/Q+_P!!
M2_\ _ F7_P"*H /^%A^)?^@I?_\ @3+_ /%4 '_"P_$O_04O_P#P)E_^*H /
M^%A^)?\ H*7_ /X$R_\ Q5 !_P +#\2_]!2__P# F7_XJ@ _X6'XE_Z"E_\
M^!,O_P 50 ?\+#\2_P#04O\ _P "9?\ XJ@ _P"%A^)?^@I?_P#@3+_\50 ?
M\+#\2_\ 04O_ /P)E_\ BJ #_A8?B7_H*7__ ($R_P#Q5 !_PL/Q+_T%+_\
M\"9?_BJ #_A8?B7_ *"E_P#^!,O_ ,50 ?\ "P_$O_04O_\ P)E_^*H ]6^#
M'B_6M8\2PVM_?75S T,Y,<LTCH2L9()5F(R#R/2@#[+JA!0 4 % !0 4 % !
M0 4 % !0 4 ?&?[1_P#R';3_ *\%_P#1\]2QGSS0(* "@ H * "@ H ^AOV;
M_P#D.W?_ %X-_P"CX*$,^S*H04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M?_V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M-&5./W<;#][D89AY7/S[4,^U54*  , < #H!5"%H * "@ H * "@ H * "@
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M@ H * "@ H * "@ H * "@ H ]D^ W_(V0?]<+C_ -%F@9]W50@H * "@ H
M* "@ H * "@ H * /C/]H_\ Y#MI_P!>"_\ H^>I8SYYH$% !0 4 % !0 4
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M H * "@ H * "@ H * "@ H ^<?VDO\ D$V/_7VW_HEZ3 ^.Z0!0 4 % !0
M4 % 'JOP3_Y''3_^WK_TCN* /OVJ * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * /RMJ0"@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /L3]FW_D$WW_7VO_HE
M*: ^CJ8!0 4 % !0 4 % !0 4 % 'F7QD_Y%'4?]R'_TIAI,#\^J0!0 4 %
M!0 4 % $]K_KH_\ ?7^8I#/U+JQ!0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0!\N_M+_ .ITO_?N_P"5O28SY/I""@ H * "
M@ H * /9/@-_R-D'_7"X_P#19H&?=U4(* "@ H * "@ H * "@ H * "@ H
M^,_VC_\ D.VG_7@O_H^>I8SYYH$% !0 4 % !0 4 % !0 4 % !0 4 % !0
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M&2QXMYCPLH[!'X27T 5\_(0QL,^Y 01D<@U0@H * "@ H * "@ H * "@ H
M* "@ H * "@ H * /GOXL?!U?$6_6=#41ZA]Z: 85+GU=>@2?U)^67OA\LR
M^-IH9+9VAF5HY$)5D8%65@<$,#@@@\$'D4@(J "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /8OA?\ "FY\;3+>W@:W
MTF-OFDZ/.5ZQPY[=GDQM7D#+\ &?<>G:=;:1;1V5E&L%O H2.-!A54?J23DL
MQ)9F)9B6)-4(NT % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY_Y&R?
M_KA;_P#HL5(SQN@04 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % 'LGP&_P"1L@_ZX7'_ *+- S[NJA!0 4 % !0
M4 % !0 4 % !0 4 ?&?[1_\ R';3_KP7_P!'SU+&?/- @H * "@ H * "@#Z
M&_9O_P"0[=_]>#?^CX*$,^S*H04 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M 4 % !0 4 % '(>+O!MIXL@V2XBN8Q^ZG RR]]K#C<A/52>"25(.<\M:C&LM
M=)+9_IZ'HX7%SPDKQU@_BCT?FNS\_O/E#6M$N_#]RUG>H8Y%Y!_A=<D!T/\
M$IQP?P(!! ^>G"5-\LU9_P!:H^]HUH8B"J4G=?BGV:Z,R*S.@* "@ H * /H
MCX*?\>MY_P!=8_\ T!J]G!;3]5^I\?F_QT_\+_-'MM>L?,A0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?./[27_ "";'_K[;_T2])@?'=(
MH * "@ H * "@#U7X)_\CCI__;U_Z1W% 'W[5 % !0 4 % !0 4 % !0 4 %
M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'Y6U(!0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % 'V)^S;_R"
M;[_K[7_T2E- ?1U, H * "@ H * "@ H * "@#S+XR?\BCJ/^Y#_ .E,-)@?
MGU2 * "@ H * "@ H GM?]='_OK_ #%(9^I=6(* "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * /EW]I?\ U.E_[]W_ "MZ3&?)
M](04 % !0 4 % !0![)\!O\ D;(/^N%Q_P"BS0,^[JH04 % !0 4 % !0 4
M% !0 4 % !0!\9_M'_\ (=M/^O!?_1\]2QGSS0(* "@ H * "@ H * "@ H
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M[."VGZK]3X_-_CI_X7^:/;:]8^9"@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H ^<?VDO^038_P#7VW_HEZ3 ^.Z0!0 4 % !0 4 % 'JOP3_
M .1QT_\ [>O_ $CN* /OVJ * "@ H * "@ H * "@ H * "@ H * "@ H *
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M@H * "@ H * "@ H * "@ H * /E;]IG_F$_]OW_ +9TF!\K4@"@ H * "@
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M?8_P[^"UAX2*7^I%;[4EPRDC]Q W_3)6^^X/25QD$ HJ$9+L(]OI@% !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?"/QY_P"1LG_ZX6__ *+%2,\;
MH$% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MKV<%M/U7ZGQ^;_'3_P +_-'MM>L?,A0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 ?./[27_()L?^OMO_ $2])@?'=( H * "@ H * "@#U7X
M)_\ (XZ?_P!O7_I'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?E;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 ?8G[-O_ "";[_K[7_T2E- ?
M1U, H * "@ H * "@ H * "@#S+XR?\ (HZC_N0_^E,-)@?GU2 * "@ H *
M"@ H GM?]='_ +Z_S%(9^I=6(* "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * /EW]I?_4Z7_OW?\K>DQGR?2$% !0 4 % !0 4
M >R? ;_D;(/^N%Q_Z+- S[NJA!0 4 % !0 4 % !0 4 % !0 4 % 'QG^T?_
M ,AVT_Z\%_\ 1\]2QGSS0(* "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@#T7X2_\C9IO_79O_14E S]#:H04 % !
M0 4 % !0 4 % !0 4 % 'RM^TS_S"?\ M^_]LZ3 ^5J0!0 4 % !0 4 % 'L
MGP&_Y&R#_KA<?^BS0,^[JH04 % !0 4 % !0 4 % !0 4 % !0 4 % &!XG\
M-VGBS3I=+OES%,O# ?-&X^Y*A[.AY'8C*ME68$ _.WQ3X9N_".HRZ7?#$D)^
M5P/EEC/W)4]5<?BIRK892!(SGJ!!0 4 % !0 4 % !0!W'P_\:W'@75$OXLO
M;O\ N[F$'B6(GG';>GWXSQAA@G:S @S]#=-U&WU:VBO;-Q+;W""2-UZ%6&1[
M@CH0<%2"" 015"+M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 (5#
M @C(/!!Z$4 >$^./@3I?B#==Z.5TR\/)11_HTAY^]&O,1/'S1?*,9,3,2:5@
M/D[Q/X*U?P?+Y.JV[PJ20DH^:&3_ ')5^4G'.TD.N?F53Q2&<K0(* "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H LVEG/?RK;6L;SS2'"1QJSNQ/95
M4$D_04 ?0_@K]GV\O]EUXC<V<!P?LT95IV'4!W^9(@>X&]^H(C;D%AGU5H?A
M^P\-6PLM+@2VA7G:@Y8_WG8Y9V/=G).,#. !5"-B@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H ^$?CS_ ,C9/_UPM_\ T6*D9XW0(* "@ H
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M'<4 ??M4 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 ?E;4@% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % !0 4 % !0 4 % !0 4 ?8G[-O_()OO^OM?_1*4T!]'4P"@ H * "@ H *
M "@ H * /,OC)_R*.H_[D/\ Z4PTF!^?5( H * "@ H * "@">U_UT?^^O\
M,4AGZEU8@H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M % !0 4 % !0 4 % 'QG^T?_ ,AVT_Z\%_\ 1\]2QGSS0(* "@ H * "@ H
M^AOV;_\ D.W?_7@W_H^"A#/LRJ$% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 07-M%>Q-;W"+)%("KHPRK ]014M*2Y9*Z?0J,
MG!J<&TUJFMT?,?CSX=R^'6:]L0TM@QR>[09/"MW*<X5^WW7YPS>#7P[I>]#6
M'Y>OEY_?Y_;X+'K$)4JME5Z=I^:[/NOFNR\MK@/=/HCX*?\ 'K>?]=8__0&K
MV<%M/U7ZGQ^;_'3_ ,+_ #1[;7K'S(4 % !0 4 % !0 4 % !0 4 % !0 4
M% !0 4 % !0 4 % 'SC^TE_R";'_ *^V_P#1+TF!\=T@"@ H * "@ H * /5
M?@G_ ,CCI_\ V]?^D=Q0!]^U0!0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0!\C_\,U7O_01A_P"_#_\ Q=*PP_X9JO?^@C#_
M -^'_P#BZ+ '_#-5[_T$8?\ OP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-
M5[_T$8?^_#__ !=%@#_AFJ]_Z",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718
M_P"&:KW_ *",/_?A_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\
MWX?_ .+HL ?\,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7
MO_01A_[\/_\ %T6 /^&:KW_H(P_]^'_^+HL ?\,U7O\ T$8?^_#_ /Q=%@#_
M (9JO?\ H(P_]^'_ /BZ+ '_  S5>_\ 01A_[\/_ /%T6 /^&:KW_H(P_P#?
MA_\ XNBP!_PS5>_]!&'_ +\/_P#%T6 /^&:KW_H(P_\ ?A__ (NBP!_PS5>_
M]!&'_OP__P 718 _X9JO?^@C#_WX?_XNBP!_PS5>_P#01A_[\/\ _%T6 /\
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M_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\ %T6
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M^"USX*UB/5I;R.X6..1/+6)E)\Q2N<ER.,YZ46 ^@:8@H * "@ H * "@ H
M* "@ H * "@ H * "@ H \)^(OP4A\97XU2PG2QGD7%P&C+K*PX60!67:^/E
M?J& 4\-N+*P'GO\ PS5>_P#01A_[\/\ _%T6&'_#-5[_ -!&'_OP_P#\718
M_P"&:KW_ *",/_?A_P#XNBP!_P ,U7O_ $$8?^_#_P#Q=%@#_AFJ]_Z",/\
MWX?_ .+HL ?\,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7
MO_01A_[\/_\ %T6 /^&:KT?\Q&'_ +\/_P#'*+ ?37AFPO\ 2].AL]4G6]N8
M%V&=5*F15X0N&+$OMP';/SD;CR33$;U !0 4 % !0 4 % !0 4 % !0 4 %
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M,U7O_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\
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M_01A_P"_#_\ Q=%@#_AFJ]_Z",/_ 'X?_P"+HL ?\,U7O_01A_[\/_\ %T6
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M>/DQC'>@1[?3 * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * &NBRJ4<!E8$,I (((P00>""."#P12WT8TVG=:-;'SEX_^&S:9
MOU/25+6O+2PCDP^K(.IB[D=8QSROW?$KX;DO.G\/5=O^!^1]C@<P52U#$.T]
MHR_F\GVE^?KOT7P4_P"/6\_ZZQ_^@-6V"VGZK]3CS?XZ?^%_FCVVO6/F0H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /,OB?X E^(%G!:0SI
M:FWF,I9T+@@H5P &7!YSFD!XI_PS5>_]!&'_ +\/_P#%T6&'_#-5[_T$8?\
MOP__ ,718 _X9JO?^@C#_P!^'_\ BZ+ '_#-5[_T$8?^_#__ !=%@#_AFJ]_
MZ",/_?A__BZ+ '_#-5[_ -!&'_OP_P#\718 _P"&:KW_ *",/_?A_P#XNBP'
M7>!/@?<^#];MM9EO8ITMO-S&L3*6\R"6(88N0,&3=TY Q181]%4P"@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H Q-)T&TT6:X>R3RA=,LCH/N
M!AN!*+CY0>I . ?N@#BL84XTW)PTYK-KIUV.JK6G6C!5'?D32?6VF[Z_GW-N
MMCE"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
+* "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>ebs-20220630_g2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ebs-20220630_g2.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M&_LZW/[2%M\+]*/Q/TS5=4UTPK+>7GV>&Y^SV5FCNB&X>X>%U))V^22$<\4
M9'[ _P"WU_P4E_:N^+=QX2_:)_X)!ZC\#/"=A8-/?>+O%'Q62\DDD.1'!;6:
M:;&T[EAEB9$1$!)8L41_LROS'_9!^*7[8?[!W_!8RQ_X)6?'?]K?Q%\=/ GQ
M#^$DOC+P;XA\:V\1US0+N">:.6&:>, S0N+:8@OD M$%VD2;_P!.* "BBB@
MHHHH **** "BBB@ HHHH _$'_@]Y_P"36?@?_P!E U'_ -(111_P>\_\FL_
M_P#[*!J/_I"** //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V
M\?\ I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH XK]I+X,6/[1W[
M.OC[]GG5-<FTNV\>>"M5\.W&IV\(DDM([VTEMFF5"0&91*6 ) )&,U^7%_\
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M:<Z>65I0=FHNS6C/?X6HT<1Q'A:56*E%SBFFKIJ^S3T9^?/_  ^+_P""CO\
MT<7_ .6CH_\ \B4?\/B_^"CO_1Q?_EHZ/_\ (E?,M%?E7]J9G_S_ )_^!2_S
M/Z>_U:X<_P"@*E_X+A_D?37_  ^+_P""CO\ T<7_ .6CH_\ \B4?\/B_^"CO
M_1Q?_EHZ/_\ (E?,M%']J9G_ ,_Y_P#@4O\ ,/\ 5KAS_H"I?^"X?Y'TU_P^
M+_X*._\ 1Q?_ ):.C_\ R)1_P^+_ ."CO_1Q?_EHZ/\ _(E?,M%']J9G_P _
MY_\ @4O\P_U:X<_Z J7_ (+A_D?37_#XO_@H[_T<7_Y:.C__ ")1_P /B_\
M@H[_ -'%_P#EHZ/_ /(E?,M%']J9G_S_ )_^!2_S#_5KAS_H"I?^"X?Y'TU_
MP^+_ ."CO_1Q?_EHZ/\ _(E'_#XO_@H[_P!'%_\ EHZ/_P#(E?,M%']J9G_S
M_G_X%+_,/]6N'/\ H"I?^"X?Y']"_P"Q3\1?&7Q;_9/\ _$OXA:Q_:&MZUX<
M@NM3O?L\<7G2L#EMD2JB_10![5ZC7BG_  3B_P"3%?A;_P!BA;?R->UU^NX*
M4IX.G*3NW%?DC^4\WA"EFV(A!62G-)+1)*3T04445TGG!1110 4444 %%%%
M'X@_\'O/_)K/P/\ ^R@:C_Z0BBC_ (/>?^36?@?_ -E U'_TA%% 'G__  :;
M?\I3/VN_^WC_ -/D]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1110
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MG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1_P>\_\ )K/P/_[*!J/_ *0BB@#S_P#X--O^4IG[7?\ V\?^GR>OW^K\ ?\
M@TV_Y2F?M=_]O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXW_P""
MZ?\ R8I-_P!C=IW_ +5K[(KXW_X+I_\ )BDW_8W:=_[5KS,Y_P"156_PL^CX
M0_Y*C!_]?(_F?B_1117X\?UJ%%%% !1110 4444 %%%% '[^_P#!.+_DQ7X6
M_P#8H6W\C7M=>*?\$XO^3%?A;_V*%M_(U[77[3@/]QI?X8_DC^.LZ_Y'.)_Z
M^3_]*84445UGF!1110 4444 %%%% 'X@_P#![S_R:S\#_P#LH&H_^D(HH_X/
M>?\ DUGX'_\ 90-1_P#2$44 >?\ _!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\
MP:;?\I3/VN_^WC_T^3U^_P!0 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?&_\
MP73_ .3%)O\ L;M._P#:M?9%?&__  73_P"3%)O^QNT[_P!JUYF<_P#(JK?X
M6?1\(?\ )48/_KY'\S\7Z**]%_99\/\ P,\3?&?0M'^/NH>(TT>XU:UA6Q\.
M:7!.]\SS*OE222W$7D1G(RZB1L9PH.#7Y#3INK44$]^Y_5^(KQPU"562;45>
MR5W\D>=45Z;^VM!!:_MC?%>VMH4CCC^)&MK'&B@*JB_F   Z"OK$>$M=/QR_
MM@>&W_X95_X0'[49?L@_L;^S?[,V^9TQ_:GVWC=_Q\^?WVUV4L"ZM64+_"[;
M>NK[15M7TNCR,5G<<+AJ55P^.#E:]ME%\JT]Z;YO=CI>SU1\ T5[1^R-X>TK
M3?#WQ,^/NJ:9;7DWP]\%BZT.*[@66./5+N\@LK:=D<%7\KSY)5# C>B'!Q5[
MX@/>?&K]C&T^/'C&X:^\6>&/B$/#VHZW,=USJ-A=V;W-O]H<\S/%);SJLC$M
MLE522$7&4<*Y4N:^K3:7DG9Z_?\ <=4\R4,4Z?+[JE&#=]I25TK6VUCK?>6V
MYX3117UK^QYX=T#X96_CGX>ZOHMK=>*M9^"GB;4M<DN8%=M'MQI<DEM9ID?)
M,^5GE(^91Y,>599E*PN'>)JJ-[+N7F6/CE^'=3EYGVVT6[\DOSLMVCY*HHHK
MF/0/W]_X)Q?\F*_"W_L4+;^1KVNO%/\ @G%_R8K\+?\ L4+;^1KVNOVG ?[C
M2_PQ_)'\=9U_R.<3_P!?)_\ I3"BBBNL\P**** "BBB@ HHHH _$'_@]Y_Y-
M9^!__90-1_\ 2$44?\'O/_)K/P/_ .R@:C_Z0BB@#S__ (--O^4IG[7?_;Q_
MZ?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ME,****ZSS HHHH **** "BBB@#\0?^#WG_DUGX'_ /90-1_](111_P 'O/\
MR:S\#_\ LH&H_P#I"** //\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\ ?^#3;_E*
M9^UW_P!O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXW_ ."Z?_)B
MDW_8W:=_[5K[(KXW_P""Z?\ R8I-_P!C=IW_ +5KS,Y_Y%5;_"SZ/A#_ )*C
M!_\ 7R/YGXOT445^/']:A1110 4444 %%%% !1110!^_O_!.+_DQ7X6_]BA;
M?R->UUXI_P $XO\ DQ7X6_\ 8H6W\C7M=?M. _W&E_AC^2/XZSK_ )'.)_Z^
M3_\ 2F%%%%=9Y@4444 %%%% !1110!^(/_![S_R:S\#_ /LH&H_^D(HH_P"#
MWG_DUGX'_P#90-1_](110!Y__P &FW_*4S]KO_MX_P#3Y/7[_5^ /_!IM_RE
M,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXW_X+I_\F*3?]C=I
MW_M6OLBOC?\ X+I_\F*3?]C=IW_M6O,SG_D55O\ "SZ/A#_DJ,'_ -?(_F?B
M_1117X\?UJ%%%% !1110 4444 %%%% '[^_\$XO^3%?A;_V*%M_(U[77BG_!
M.+_DQ7X6_P#8H6W\C7M=?M. _P!QI?X8_DC^.LZ_Y'.)_P"OD_\ TIA11176
M>8%%%% !1110 4444 ?B#_P>\_\ )K/P/_[*!J/_ *0BBC_@]Y_Y-9^!_P#V
M4#4?_2$44 >?_P#!IM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\ [>/_
M $^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5\;_\%T_^3%)O^QNT[_VK
M7V17QO\ \%T_^3%)O^QNT[_VK7F9S_R*JW^%GT?"'_)48/\ Z^1_,_%^BBBO
MQX_K4**** "BBB@ HHHH **** /W]_X)Q?\ )BOPM_[%"V_D:]KKQ3_@G%_R
M8K\+?^Q0MOY&O:Z_:<!_N-+_  Q_)'\=9U_R.<3_ -?)_P#I3"BBBNL\P***
M* "BBB@ HHHH _$'_@]Y_P"36?@?_P!E U'_ -(111_P>\_\FL_ _P#[*!J/
M_I"** //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK
M]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ KXW_X+I_\ )BDW_8W:=_[5K[(K
MXW_X+I_\F*3?]C=IW_M6O,SG_D55O\+/H^$/^2HP?_7R/YGXOT445^/']:A1
M110 4444 %%%% !1110!^_O_  3B_P"3%?A;_P!BA;?R->UUXI_P3B_Y,5^%
MO_8H6W\C7M=?M. _W&E_AC^2/XZSK_D<XG_KY/\ ]*84445UGF!1110 4444
M %%%% 'X@_\ ![S_ ,FL_ __ +*!J/\ Z0BBC_@]Y_Y-9^!__90-1_\ 2$44
M >?_ /!IM_RE,_:[_P"WC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<U\.?C%\
M,OBY<>([3X;^,K35Y?"/B6?P]XE2U+9T_4X8XI);63(&'5)HF.,C$@YKX6_X
M.>?$7[4OA7_@ESJ&M?LSP^(WL8?&>FGXJ?\ "(W3P:A_PB82<W@CEC!>)#*+
M59'4$+$TA<&/?7Y\?\$./V9?V2?VF?VI?#?[5?\ P3Z\47?AJS\ _M+:MJ&K
M?![7?&[-=0^"W\-B#3]4DLI[B5I;B*\GG@\]6<L+J4%B$% ']"M%?SP_\%+]
M4_X)M_M%?\%L_P!H#Q!_P4V\#?%W5?A]\.=#\->&/#OB/X<:-=3V.C2I9BXO
MY-0F@!,*)-<LH4!B26..F?L+_@K7_P ,H?LJ_P#!M=K/P\_X)XZ;IO\ P@GC
MK3-$T3P#)X=+3G6%U&_MVFF9L&6XN)8%N"Y;,A?(8 C: #]7**_';_@A)^S9
M_P $#=/_ &H[G4_V3_AS\0-(^.GA/P[]H7PU\<-.N;35+.V<(DFHV=K-F(%M
MP4NC-)&DN/E5\MG^"/V7]'_X+D?M'_MJ?&KX^^)?$$\OPC\7WOPY_9VCTWQ!
M=6<7@V_TV.4OJMLD,B@W$MREM*7;)(+H?E*A0#]F:*^/?^""O[8WCW]NG_@E
M7\+?CQ\6=7DU#Q;]AN]'\2ZC-]^]NK&[EM1<N>\DL444KGC+R-Q67_P4"_X)
M%P?\%1_V@(HOVNOBYKD/P/\ #?A""'PI\/O!OB&6SEOO$,L\YN]3U#,.QA%"
M+2.W0,_)F9M@)60 ^UJ*_,'_ (-<_$'QF3]G#XS?![Q-\3]6\;_#;X;?'#5O
M#'P@\6ZU<&66]TJV(5A$Y^] /W4BA?E5II%7 4*OZ?4 %%%% !1110 5\;_\
M%T_^3%)O^QNT[_VK7V17QO\ \%T_^3%)O^QNT[_VK7F9S_R*JW^%GT?"'_)4
M8/\ Z^1_,_%^BBBOQX_K4**** "BBB@ HHHH **** /W]_X)Q?\ )BOPM_[%
M"V_D:]KKQ3_@G%_R8K\+?^Q0MOY&O:Z_:<!_N-+_  Q_)'\=9U_R.<3_ -?)
M_P#I3"BBBNL\P**** "BBB@ HHHH _$'_@]Y_P"36?@?_P!E U'_ -(111_P
M>\_\FL_ _P#[*!J/_I"** //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\
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M*/\ 4K_I_P#^2_\ VP?\1B_Z@?\ RK_]S/E^BOKW[/\  O\ Z"_BW_P76O\
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MZ.+_ /+1UC_Y$K\,:*^+_P!<<S_DA]TO_DC]@_XA+PY_S]J_^!0_^5G[G?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?D[_P '"O\
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MM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?D[_P<*_\ )>/ /_8HS?\ I4]?K%7Y._\ !PK_ ,EX\ _]BC-_
MZ5/7SW%'_(FGZQ_-'WWAG_R5U+_#/_TEGY\T445^6']-!1110 4444 %%%%
M!77?L_?\EZ\$?]C?IO\ Z51UR-==^S]_R7KP1_V-^F_^E4=:4?XT?5'/B_\
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M-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\
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ML]7\606\OV^YB=!'+]Z4PQ.Z#:TD<:.06Y^9L@'G5%%% '[#?L2?\FE^ /\
ML6X/Y&O4J\M_8D_Y-+\ ?]BW!_(UZE0 4444 %%%% !1110 4444 ?B#_P '
MO/\ R:S\#_\ LH&H_P#I"**/^#WG_DUGX'_]E U'_P!(110!Y_\ \&FW_*4S
M]KO_ +>/_3Y/7[_5^ /_  :;?\I3/VN_^WC_ -/D]?O]0 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !7Y._P#!PK_R7CP#_P!BC-_Z5/7Z
MQ5^3O_!PK_R7CP#_ -BC-_Z5/7SW%'_(FGZQ_-'WWAG_ ,E=2_PS_P#26?GS
M1117Y8?TT%%%% !1110 4444 %==^S]_R7KP1_V-^F_^E4=<C77?L_?\EZ\$
M?]C?IO\ Z51UI1_C1]4<^+_W2I_A?Y']'5%%%?N!_%X4444 %?,W_!6;_DTN
M3_L9++^4E?3-?,W_  5F_P"32Y/^QDLOY24 ?F!1110 4444 %%%% !1110
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MD(HH_P"#WG_DUGX'_P#90-1_](110!Y__P &FW_*4S]KO_MX_P#3Y/7[_5^
M/_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %?D[_P<*_\ )>/ /_8HS?\ I4]?K%7Y._\ !PK_ ,EX\ _]
MBC-_Z5/7SW%'_(FGZQ_-'WWAG_R5U+_#/_TEGY\UWOP'_: UGX 7VN:CX?\
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MZBJ-:I-7\G:Z^=E]QO\ Q3^(>H_%GXA:K\1M7T+2=,N=7NC/-8:%IZVMI"<
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MH&H_^D(HH_X/>?\ DUGX'_\ 90-1_P#2$44 >?\ _!IM_P I3/VN_P#MX_\
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MTR!&G$.=@D* *7 W$ #.!12A5A&SM>_]?,56=*<KQO:VG]=OQ/IC]F#]G/\
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M_P#V4#4?_2$44 >?_P#!IM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\
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M>#O#7P[\&Z1\/_!FDQ6&CZ%IEOI^DV$ PEM;0QK'%&OLJ*JCV%?SG?M,7/\
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M4/\ ^WT?\,)_]53_ /*'_P#;Z^@J*/KV*_F_!?Y![.'8^??^&$_^JI_^4/\
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M_P#%/CGX^20O\7/B]K2:SXWM[?4'O$TB)#*UMIPN7=VN'C,\[R3%VWR3$;I
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?ZXYG_)#[I?_ "0?\0EX<_Y^U?\ P*'_ ,K/W._X?%_\$XO^CB__ "T=8_\
MD2NR^!7_  4*_8__ &EO'8^&GP3^+W]M:VUG)="R_L#4+;]U'C>V^>W1.-PX
MSDYX%?S_ -?9/_!"O_D^J+_L4-1_G%79E_%.88K&TZ,XQM)I.R=__2CR<]\,
M\ARO)J^+I5*KE3BY*[C:Z76T$_Q/V?HHHK[T_#@HHHH *_)W_@X5_P"2\> ?
M^Q1F_P#2IZ_6*OR=_P"#A7_DO'@'_L49O_2IZ^>XH_Y$T_6/YH^^\,_^2NI?
MX9_^DL_/FBBBORP_IH**** "BBB@ HHHH *Z[]G[_DO7@C_L;]-_]*HZY&NN
M_9^_Y+UX(_[&_3?_ $JCK2C_ !H^J.?%_P"Z5/\ "_R/Z.J***_<#^+PHHHH
M *^4?^"RW_)F<O\ V-%A_P"U*^KJ^4?^"RW_ "9G+_V-%A_[4K?#?QX^IQ9C
M_N-3T9^2M%%%?0GP 4444 %%%% !1110 4444 ?MU^P-_P F9_#C_L5[?^M>
MO5Y#^P-_R9G\./\ L5[?^M>O5\W5_BR]6?HN&_W:'HOR"BBBLS<**** "BBB
M@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB
M@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@
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MA_[4KZNKY1_X++?\F9R_]C18?^U*WPW\>/J<68_[C4]&?DK1117T)\ %%%%
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M -N1XG1117YV?OX4444 %%%% !1110 5]D_\$*_^3ZHO^Q0U'^<5?&U?9/\
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M?M=_]O'_ *?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8D=2>/2OGN*6EDT_6/YH^_\ #--\74K?RS_])9^:E%>@_P##+'QX_P"A$_\
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M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "OP#_X*/\
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MM#ZPZON[<O*M%V3WU>KZO1;)6*^R?^"%?_)]47_8H:C_ #BKXVK[)_X(5_\
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M]3I;/XO_ !)T^"XM;#Q9<017<0CNXX415F0,&"N N&&0#@\9 -5_^%E>-O\
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M% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U
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MN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7X!_P#!1_\
MY/K^*7_8W7/]*_?ROP#_ ."C_P#R?7\4O^QNN?Z5\?QE_N5/_%^C/UGPB_Y'
M.(_Z]_\ MR/$Z***_.S]_"BBB@ HHHH **** "OLG_@A7_R?5%_V*&H_SBKX
MVK[)_P""%?\ R?5%_P!BAJ/\XJ]+)O\ D:T?\2_,^<XO_P"27QG_ %[E^1^S
M]%%%?L1_)04444 %?GA_P68_Y*[X0_[%N3_TH:OT/K\\/^"S'_)7?"'_ &+<
MG_I0U 'QM1110 4444 %%%% !1110 5TGP<_Y*[X5_[&2Q_]*$KFZZ3X.?\
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M _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !1110 4444 %%%%
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M!^VE%%% !1110 5\H_\ !9;_ ),SE_[&BP_]J5]75\H_\%EO^3,Y?^QHL/\
MVI6^&_CQ]3BS'_<:GHS\E:***^A/@ HHHH **** "BBB@ HHHH _;K]@;_DS
M/X<?]BO;_P!:]>KR']@;_DS/X<?]BO;_ -:]>KYNK_%EZL_1<-_NT/1?D%%%
M%9FX4444 %%%% !1110!^(/_  >\_P#)K/P/_P"R@:C_ .D(HH_X/>?^36?@
M?_V4#4?_ $A%% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[
M>/\ T^3U^_U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7X0_P#!0[X9^-]6_;=^)NI:?HGF0S>*[AHW^TQ#(X[%
MLU^[U?CU^VW_ ,G:>/\ _L9)_P"8KS<SRO#YK2C3JMI)WTM^J9]#PYQ+C^&,
M3.OA8QDY+E?,FU:Z?1Q['R!_PJ/XA_\ 0O\ _DW#_P#%T?\ "H_B'_T+_P#Y
M-P__ !=>V45XO^IV6?SS^^/_ ,B?8?\ $6N(_P#GU2_\!G_\L/$_^%1_$/\
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M?_\ 8R3_ ,Q7["U^/7[;?_)VGC__ +&2?^8H \LHHHH **** "BBB@ HHHH
M*^FO^"3/_)VD?_8MWO\ ..OF6OIK_@DS_P G:1_]BW>_SCH _3ZBBB@ HHHH
M *_/#_@LQ_R5WPA_V+<G_I0U?H?7YX?\%F/^2N^$/^Q;D_\ 2AJ /C:BBB@
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MM:UAKZ#0KKS9X;>7. %D:6.S*LP\S9>.,E&7 !^S%%>4?MT_!#XD_M,?L?\
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M_L9+'_TH2N;KI/@Y_P E=\*_]C)8_P#I0E '[:4444 %%%% !7RC_P %EO\
MDS.7_L:+#_VI7U=7RC_P66_Y,SE_[&BP_P#:E;X;^/'U.+,?]QJ>C/R5HHHK
MZ$^ "BBB@ HHHH **** "BBB@#]NOV!O^3,_AQ_V*]O_ %KUZO(?V!O^3,_A
MQ_V*]O\ UKUZOFZO\67JS]%PW^[0]%^04445F;A1110 4444 %%%% 'X@_\
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M "5WPA_V+<G_ *4-0!\;4444 %%%% !1110 4444 %=)\'/^2N^%?^QDL?\
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M9^2M%%=+X#\)^!=;M[C5/B!\1QH-I%(D4,=KIAO;J=V!)*PAXPL:@?,[./O
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M'\;?]BCJ7_I+)7\XM? \:?Q:/I+]#]T\'_\ =,7_ (H?E(****^)/V0****
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M!SX*?%[6/'GQJO\ 7+:Q;P#KVE:9-X<TZ.ZO$O-0L)=/5XTEDCCRD=U+)EW
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M[]0KQ17-Q"%0-&Q6.0-(,H2K+W/_  PG_P!53_\ *'_]OH_X83_ZJG_Y0_\
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M+U9^BX;_ ':'HOR"BBBLS<**** "BBB@ HHHH _$'_@]Y_Y-9^!__90-1_\
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M_P#_ &G7RC7U=_P1I_Y/,B_[%>__ /:=8XG^!+T.S+O]^I^J/UJHHHKYT_0
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MB_(****S-PHHHH **** "BBB@#\0?^#WG_DUGX'_ /90-1_](111_P 'O/\
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MT:2EN]+^7,KI?=K^!A@LS6,Q,X6LDY*-T[RY)<LI7VLI:)=59WULN+K]8_\
M@WJ_Y(+X^_[&^+_TE2OR<K]8_P#@WJ_Y(+X^_P"QOB_])4KU>%O^1Q#TE^1\
MOXF?\DC5_P 4/_2D?H+1117ZF?S*%%%% !7XB_M\_P#)YGQ'_P"QHN/Z5^W5
M?B+^WS_R>9\1_P#L:+C^E>CEW\5^A\_Q#_NT/7]#R&BBBO7/DPHHHH ****
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MK/P/_P"R@:C_ .D(HH_X/>?^36?@?_V4#4?_ $A%% 'G_P#P:;?\I3/VN_\
MMX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !111
M0!R/[0'_ "0?QM_V*.I?^DLE?SBU_1U^T!_R0?QM_P!BCJ7_ *2R5_.+7P/&
MG\6CZ2_0_=/!_P#W3%_XH?E(6,1F11*Q5<C<RKD@=\#(S^=>N_M/_%SX3_%;
MPQ\.--^'MUXB-UX+\"6WAV_76=(@MX[@Q7%S.9XVBN92,M<;=A'1<[N<5Y#1
M7QL*LH0E!?:_34_7*N&A6KTZK;O"]OFK:_(]:\/_ !=^%'C7X1>&/A/\=[;Q
M#%'X(U*ZFT+4/#=M!-)=6-U(LT]A*)I8Q#^^#2).OF;/.D!B?C'*?'KXOZM\
M>OB[K?Q7UG38;%]5N%^S:?;L6CL[:.-88+=2>6$<,<: GD[,]ZY"BJGB*E2G
MR/;3YV5E]RT1G1P.'H5W5BM?>]%S/FE;_%))OSVL>OWGQ;^$<O[%EI^S]!>>
M(SXCM_'LWB1YWT:W%B1)8Q6IMQ)]J,G!BW;_ "^<XVC&:X?1[SX0Q_"K6K+7
M=%UV3QG)J-LV@WUM=1+80VHW>>LR$;V<_+M*G'KC&&YBBB=>4VFTM%;]/O"E
M@J=*,E&3UES;];WMIT?5=M#U^3XO_"+XI_"CP7\/_C;_ ,))IU]X#AN+'3M6
M\.6%O=_VCILMPUP+:5)IH?(DCDDE"S*9 5D ,9*Y/,_M&_&F;X_?%J_^(HT)
M=*LWMK6QT?24G,HLK&UMX[>WB+D#>PCB7<V!N8L<#.!PU%.>(J5(<K\OG967
MW+_@BHY?AZ%;VL;W]ZVNBYWS2MZM7UO;966@5^L?_!O5_P D%\??]C?%_P"D
MJ5^3E?K'_P &]7_)!?'W_8WQ?^DJ5[7"W_(XAZ2_(^.\3/\ DD:O^*'_ *4C
M]!:***_4S^90HHHH *_$7]OG_D\SXC_]C1<?TK]NJ_$7]OG_ )/,^(__ &-%
MQ_2O1R[^*_0^?XA_W:'K^AY#1117KGR84444 %%%% !1110 5]7?\$:?^3S(
MO^Q7O_\ VG7RC7U=_P $:?\ D\R+_L5[_P#]IUCB?X$O0[,N_P!^I^J/UJHH
MHKYT_0 HHHH *_/#_@LQ_P E=\(?]BW)_P"E#5^A]?GA_P %F/\ DKOA#_L6
MY/\ TH:@#XVHHHH **** "BBB@ HHHH *Z3X.?\ )7?"O_8R6/\ Z4)7-UTG
MP<_Y*[X5_P"QDL?_ $H2@#]M**** "BBB@ KY1_X++?\F9R_]C18?^U*^KJ^
M4?\ @LM_R9G+_P!C18?^U*WPW\>/J<68_P"XU/1GY*T445]"? !1110 4444
M %%%% !1110!^W7[ W_)F?PX_P"Q7M_ZUZ]7D/[ W_)F?PX_[%>W_K7KU?-U
M?XLO5GZ+AO\ =H>B_(****S-PHHHH **** "BBB@#\0?^#WG_DUGX'_]E U'
M_P!(111_P>\_\FL_ _\ [*!J/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_
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M'+OXK]#Y_B'_ ':'K^AY#1117KGR84444 %%%% !1110 5]7?\$:?^3S(O\
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M*04445\2?L@4444 %%%% !1110 5^L?_  ;U?\D%\??]C?%_Z2I7Y.5^L?\
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MR07Q]_V-\7_I*E?0\+?\CB'I+\CX'Q,_Y)&K_BA_Z4C]!:***_4S^90HHHH
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MU'V?X%_]!?Q;_P""ZU_^/5R5% '5O;_ W8?+U;Q7NQ\N[3K;&?\ O]7*444
M%%%% !7Z(?\ !&?_ ))%XO\ ^QDC_P#2=:_.^OT0_P"",_\ R2+Q?_V,D?\
MZ3K0!]D4444 %%%% !7XB_M\_P#)YGQ'_P"QHN/Z5^W5?B+^WS_R>9\1_P#L
M:+C^E>CEW\5^A\_Q#_NT/7]#R&BBBO7/DPHHHH **** "BBB@ KZN_X(T_\
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MA1110 4444 %%%% 'X@_\'O/_)K/P/\ ^R@:C_Z0BBC_ (/>?^36?@?_ -E
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M@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@
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MKYT_0 HHHH *_#;_ (.L?^3G/A?_ -B'/_Z6R5^Y-?AM_P '6/\ R<Y\+_\
ML0Y__2V2O9R'_D91]'^1XV?_ /(LEZK\S\K****^[/@ HHHH **** "BBB@
MKO/V6/\ DYWX<?\ 8^:/_P"EL-<'7>?LL?\ )SOPX_['S1__ $MAJ*G\-^A=
M+^+'U1_7!1117Y<?JH4444 %?*/_  66_P"3,Y?^QHL/_:E?5U?*/_!9;_DS
M.7_L:+#_ -J5OAOX\?4XLQ_W&IZ,_)6BBBOH3X **** "BBB@ HHHH ****
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MI'QY17V'_P ,L? ?_H1/_*I=?_':/^&6/@/_ -")_P"52Z_^.T?VE0[/\/\
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M#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH **** "BBB@ HHHH YSXQ_\DB\5?\
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MI_\ Z4QUR]=1\$/^2T^$/^QHT_\ ]*8Z4OA9=/\ B+U/WPHHHKY@_20HHHH
M*^4?^"RW_)F<O_8T6'_M2OJZOE'_ (++?\F9R_\ 8T6'_M2M\-_'CZG%F/\
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MAHHHKUSY,**** "BBB@ HHHH *^KO^"-/_)YD7_8KW__ +3KY1KZN_X(T_\
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MY6O2QU2K1YT[W>MW;=/_ ('_  ^ESV;]JW1O"_PB_9]^%WP"TGQ"=2U8+?\
MB?7W:V>'R3?"!;9!&X#IF& /APK%61BJ[L#SO]E.[T>P_:>^'5[X@*"RB\<:
M4]RTGW507<1);V'4^U<?XG\3^(O&GB"\\6>+=;N=2U/4)VFO;Z\F,DLTC'EF
M8\DUJ_$/XEZK\1]0TO4K_0M'TV32=%M=-@&AZ<MJLJ0 A99 OWYFSEGZG Z
M 52@U#E[W_$B=:,JWM$K6M9>2_X8]H^ $%_I?[:/CR7Q8&$&GZ3XS;Q+YO01
M"QO4D#_]M"H^I%?.E>B^*?VFO'GBO2]8BN-(T>TU;Q+:QVWBGQ+96LB7^L0H
MRMLF8R&-=[(C2&)(S*R@R%\G/G5$(M.[\A5IPE%1CW;^^W^05U'P0_Y+3X0_
M[&C3_P#TICKEZZCX(?\ ):?"'_8T:?\ ^E,=7+X69T_XB]3]\****^8/TD**
M** "O@3_ (.2_B%XP^&7_!-F?Q/X'U?[#?#QUI40G^SQR_(PFR-LBL.P[5]]
MU^=7_!T/_P HNY_^R@:1_*>NK!)/%P3[HY,?_N53T9^!_P#PV7^TE_T4?_RC
MV?\ \9H_X;+_ &DO^BC_ /E'L_\ XS7F%%?9^SI]D?"V1Z?_ ,-E_M)?]%'_
M /*/9_\ QFC_ (;+_:2_Z*/_ .4>S_\ C->844>SI]D%D>G_ /#9?[27_11_
M_*/9_P#QFC_ALO\ :2_Z*/\ ^4>S_P#C->844>SI]D%D>G_\-E_M)?\ 11__
M "CV?_QFC_ALO]I+_HH__E'L_P#XS7F%%'LZ?9!9'I__  V7^TE_T4?_ ,H]
MG_\ &:/^&R_VDO\ HH__ )1[/_XS7F%%'LZ?9!9']9O_  28\1ZSXO\ ^";/
MP8\3^(KS[1?7W@6TENI_+5-[D')VJ !^ %?0]?-7_!'/_E%W\#?^R?V?\C7T
MK7P]?2O+U?YGW^'_ -WAZ+\@HHHK(V"BBB@ HHHH **** /Q!_X/>?\ DUGX
M'_\ 90-1_P#2$44?\'O/_)K/P/\ ^R@:C_Z0BB@#S_\ X--O^4IG[7?_ &\?
M^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH **** "BBB@ HHHH X
M3]J7_DV/XC?]B'J__I%+7\CU?UP_M2_\FQ_$;_L0]7_](I:_D>KZ[AK^%4]5
M^I\AQ/\ Q*7H_P! HHK7\ ^!?$_Q-\9Z;X \&::;O5-6NUM[2$N$7<>K.[$+
M&BC+,[$*BJS,0 37TK:2NSY=)MV1D45ZK^V1^S%_PR1\9$^$R?$6R\5Q3>&]
M*UBVUS3K*2"&>*^LX[I-BR'=@+( "P!/4JO0=E_PP#J7]M_\*7_X6C;_ /"W
MSX0_X2/_ (5[_9#^7Y/V/[=_9_VSS/\ D(_8_P!]]G\K9_RS\[S?W=9>WI<B
ME?1Z_+OY?,U^KUN=QMJM/GV]3YXHHKTSX/?L]6?CCX;>(?CI\2O&\GA?P/X:
MU"TTVZU6WTK[==WVI7(D>&RM+<RPK-)Y<,TKEI8U2.,DMN9%;24XP5V9PA*;
MLCS.BN[_ &A?@-K_ .SYXUL_#FI:U::OIFM:'::YX7\0:>KK!JVEW2;X+A%<
M!D/#QO&PW))'(ASMR>$IQE&<;K8)1E"5GN%?N5_P:G_\FQ?%#_L?(/\ TBCK
M\-:_<K_@U/\ ^38OBA_V/D'_ *11UY&>_P#(MEZK\SU\@_Y&4?1_D?JE1117
MP9]^%%%% !7XB_M\_P#)YGQ'_P"QHN/Z5^W5?B+^WS_R>9\1_P#L:+C^E>CE
MW\5^A\_Q#_NT/7]#R&BBBO7/DPHHHH **** "BBB@ KZN_X(T_\ )YD7_8KW
M_P#[3KY1KZN_X(T_\GF1?]BO?_\ M.L<3_ EZ'9EW^_4_5'ZU4445\Z?H 44
M44 %?F7_ ,%T/^2T^"?^Q7E_]*6K]-*_,O\ X+H?\EI\$_\ 8KR_^E+5V8'_
M 'A?,\G._P#D7R]5^9\-T445[A\2%%%% !1110 4444 %=1\$/\ DM/A#_L:
M-/\ _2F.N7KJ/@A_R6GPA_V-&G_^E,=*7PLNG_$7J?OA1117S!^DA1110 5^
M=7_!T/\ \HNY_P#LH&D?RGK]%:_.K_@Z'_Y1=S_]E TC^4]=>!_WRGZHY,?_
M +E4]&?S@4445]J?#!17LO["W[&OBC]N#X]:5\&](\7V?AFPO+RWM]1\4:G;
MM+!8O<2K!;QA%(,LLLSI&D:D$Y9R52.1U\L\1>&KK0O%]]X/@9KN>SU*6S0Q
M1',SI(4&U>3DD<#GK4J<7-QOJBG"2@I-:,S:*]4^/7[,%S^S-:1>%OC#X[L[
M;X@26\,]UX"TRV-S/HJN%81:E/N6.VN-C!O(C\YTX640MP/*Z(RC-702C*#L
M]PHKZO\ #'["O[%8TWP_HOQ6_P""FNF>'?&FKZ78W&H^#M.^$VKZN^FW-U$D
MJV37%J3').HD5'5>4DW(0&4@>%_M/?![1/V?/VA?&/P,\/\ Q!A\56_A'7[C
M26\06]B;:.\E@;RY62,N^%$BNH.X[@H;OBIA5A.5E?[FBYT9PCS.WWI_DSA*
M***T,C^K_P#X(Y_\HN_@;_V3^S_D:^E:^:O^".?_ "B[^!O_ &3^S_D:^E:^
M%Q'\>?J_S/OL/_N\/1?D%%%%8FP4444 %%%% !1110!^(/\ P>\_\FL_ _\
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M/^/$WA+4)_BG#+8I;WSVCWA;1GU%44#[<;7>7+CSC$8/-^:G+&N-11Y=_/\
M2VPHX)2IN7-MY?K??]#P*BN'HK3ZSY&7U;S.XK]RO^#4_P#Y-B^*'_8^0?\
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MB_(****Q-@HHHH **** "BBB@#\0?^#WG_DUGX'_ /90-1_](111_P 'O/\
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M_&OJ:BN8[3Y9_P"'0_[,W_0__%/_ ,./>_XT?\.A_P!F;_H?_BG_ .''O?\
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MFIB!H1>Z?X[O(Y/+;&Y<ANAP/RK[BHI2Q.)DK2FVO5E1PN&A*\8)/T1\L_\
M#H?]F;_H?_BG_P"''O?\:/\ AT/^S-_T/_Q3_P##CWO^-?4U%8&Y\L_\.A_V
M9O\ H?\ XI_^''O?\:/^'0_[,W_0_P#Q3_\ #CWO^-?4U% 'RS_PZ'_9F_Z'
M_P"*?_AQ[W_&N,^)O_! #_@GK\9M1MM7^*NG>.]>NK. PVL^I>/+R1HHR=Q4
M$MP,G-?;-%5"<Z<N:+L_(F<(5(\LU=>9\ _\0SG_  2B_P"B9>*O_"UN_P#X
MJC_B&<_X)1?]$R\5?^%K=_\ Q5??U%;?6\5_S\E][,/J>$_Y]Q^Y'Q?:?\$'
M/V&]/^',GP>L/$/Q8@\)3;O-\+0_%G55TY]WWLVPE\HY[Y7FL;P3_P &Z_\
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MN_\ XJOOZBG];Q2_Y>2^]A]4PC_Y=Q^Y'P#_ ,0SG_!*+_HF7BK_ ,+6[_\
MBJFTW_@VM_X)8Z-J-OJ^E_#WQ;!=6LZ36T\?C:[#1R*0RL#NX((!K[XHH^MX
MI_\ +R7WL/JF$7_+N/W(^6?^'0_[,W_0_P#Q3_\ #CWO^-'_  Z'_9F_Z'_X
MI_\ AQ[W_&OJ:BN<Z#Y9_P"'0_[,W_0__%/_ ,./>_XT?\.A_P!F;_H?_BG_
M .''O?\ &OJ:B@#Y9_X=#_LS?]#_ /%/_P ./>_XUA?$/_@AW^Q-\6?#I\)?
M$K4OB-K>F&=9C9:A\0;R2/S%SM;!/49/YU]AT4XRE&5XNS%*,9QM)71\ _\
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M^TN5PNX\5]#_ !S^..I_";]GK6OCQX+^#'C#QY<Z9I2WMCX*\-:0R:SJ6YE
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M[Y(4>:XEVC[TMQ*QZ@+U/_" _P#!03_HO_@3_P )23_XJO=** /"_P#A ?\
M@H)_T7_P)_X2DG_Q5'_" _\ !03_ *+_ .!/_"4D_P#BJ]THH \+_P"$!_X*
M"?\ 1?\ P)_X2DG_ ,51_P (#_P4$_Z+_P"!/_"4D_\ BJ]THH \+_X0'_@H
M)_T7_P "?^$I)_\ %4?\(#_P4$_Z+_X$_P#"4D_^*KW2B@#PO_A ?^"@G_1?
M_ G_ (2DG_Q5'_" _P#!03_HO_@3_P )23_XJO=** /"_P#A ?\ @H)_T7_P
M)_X2DG_Q5'_" _\ !03_ *+_ .!/_"4D_P#BJ]THH \+_P"$!_X*"?\ 1?\
MP)_X2DG_ ,51_P (#_P4$_Z+_P"!/_"4D_\ BJ]THH \+_X0'_@H)_T7_P "
M?^$I)_\ %4?\(#_P4$_Z+_X$_P#"4D_^*KW2B@#PO_A ?^"@G_1?_ G_ (2D
MG_Q5'_" _P#!03_HO_@3_P )23_XJO=** /"_P#A ?\ @H)_T7_P)_X2DG_Q
M5'_" _\ !03_ *+_ .!/_"4D_P#BJ]THH \+_P"$!_X*"?\ 1?\ P)_X2DG_
M ,51_P (#_P4$_Z+_P"!/_"4D_\ BJ]THH \+_X0'_@H)_T7_P "?^$I)_\
M%4?\(#_P4$_Z+_X$_P#"4D_^*KW2B@#PO_A ?^"@G_1?_ G_ (2DG_Q5'_"
M_P#!03_HO_@3_P )23_XJO=** /"_P#A ?\ @H)_T7_P)_X2DG_Q5'_" _\
M!03_ *+_ .!/_"4D_P#BJ]THH \+_P"$!_X*"?\ 1?\ P)_X2DG_ ,51_P (
M#_P4$_Z+_P"!/_"4D_\ BJ]THH \+_X0'_@H)_T7_P "?^$I)_\ %4?\(#_P
M4$_Z+_X$_P#"4D_^*KW2B@#PO_A ?^"@G_1?_ G_ (2DG_Q5'_" _P#!03_H
MO_@3_P )23_XJO=** /"_P#A ?\ @H)_T7_P)_X2DG_Q5'_" _\ !03_ *+_
M .!/_"4D_P#BJ]THH \+_P"$!_X*"?\ 1?\ P)_X2DG_ ,51_P (#_P4$_Z+
M_P"!/_"4D_\ BJ]THH \+_X0'_@H)_T7_P "?^$I)_\ %4?\(#_P4$_Z+_X$
M_P#"4D_^*KW2B@#PO_A ?^"@G_1?_ G_ (2DG_Q5'_" _P#!03_HO_@3_P )
M23_XJO=** /"_P#A ?\ @H)_T7_P)_X2DG_Q5'_" _\ !03_ *+_ .!/_"4D
M_P#BJ]THH \+_P"$!_X*"?\ 1?\ P)_X2DG_ ,51_P (#_P4$_Z+_P"!/_"4
MD_\ BJ]THH \+_X0'_@H)_T7_P "?^$I)_\ %4?\(#_P4$_Z+_X$_P#"4D_^
M*KW2B@#PO_A ?^"@G_1?_ G_ (2DG_Q5'_" _P#!03_HO_@3_P )23_XJO=*
M* /"_P#A ?\ @H)_T7_P)_X2DG_Q5'_" _\ !03_ *+_ .!/_"4D_P#BJ]TH
MH \+_P"$!_X*"?\ 1?\ P)_X2DG_ ,51_P (#_P4$_Z+_P"!/_"4D_\ BJ]T
MHH \+_X0'_@H)_T7_P "?^$I)_\ %5[;I<>H1:9;1:O<1RW:P(+J6)-JO(%&
MY@.P)R0*GHH **** "BBB@ HHHH _$'_ (/>?^36?@?_ -E U'_TA%%'_![S
M_P FL_ __LH&H_\ I"** //_ /@TV_Y2F?M=_P#;Q_Z?)Z_?ZOP!_P"#3;_E
M*9^UW_V\?^GR>OW^H **** "BBB@ HHHH **** "BBOSX_X+!?&GXP?%;]K#
M]G?_ ()'_!+XBZMX.C^.6J:EJGQ/\5>'[MK;4;?POID!N+BSMIU^:![H)-&9
M%^9?+5>5D92 ??EIX@T&_P!2N-&L=;LYKRU ^U6D-RC2PYZ;U!ROXBIKZ^LM
M,LY-0U*\BM[>%"\T\\@1$4=26/ 'N:^._CS_ ,$0/V%?$_P#N_!7[,/P(\-_
M"+X@:/ISR_#WXH^ K :9KVC:JB$V]S)J$&+FZ4R!?-6:1_-4MD[B&'D/_!.N
MT\-_\%X_V$/AQ\7/^"@VD_\ "21>$%U#0?%_P]$TMKIFJ>)[2Y,+ZI>Q0.BW
M#"W2%XH<>5%)=W)"DB(Q@'Z1VEY::A:QWUA=1SP3('BFA<,CJ1D$$<$'U%25
M^='_  2!^![_ +(W_!0C]K3]D#]G_5-3/P"\'7OAB\\)^'[[49;JW\-ZYJ%@
M]U?Z?:22LS;-KPR.F24#P@_,69OT7H :DD<H)BD5@&()4YP0<$5!9:UH^I75
MS8Z=JUM<3V;A+N&"=7>!CT#@'*G@\'TKX^_8H_X)I^/OV8OV8/C5\ +7XNZA
MHUQ\5?CIXF\40Z_I-^[7VGZ-J-]"@2&8\P7;:?!\LJY,4\OF<E<5\W_MC?\
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M*H(X)K9H CN[NTL+66_O[F."""-I)IIG"I&@&2S$\  #))K\P/B7_P %E_\
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M10!^87PN_P""T7_!*GXO_%NV_;A_:0_;$\+6VHZ#97-K\'_AA;">^OO#MK<
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MA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\
M_P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (2'_XNC_B+Q_X+)?]#K\/
M_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K
M\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (2'_XNC_B+Q_X+)?]
M#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)
M?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (2'_XNC_B+Q_X
M+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_
M (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (2'_XNC_B
M+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\ BZ/^
M(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (2'_X
MNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$A_\
MBZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\ _P (
M2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__ /"$
MA_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K\/\
M_P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.OP__
M /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)?]#K
M\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@LE_T.
MOP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_ (+)
M?]#K\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O'_@L
ME_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^(O'_
M (+)?]#K\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0?^(O
M'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBOY0?^
M(O'_ (+)?]#K\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZBOY0
M?^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^KZBO
MY0?^(O'_ (+)?]#K\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@#^KZ
MBOY0?^(O'_@LE_T.OP__ /"$A_\ BZ/^(O'_ (+)?]#K\/\ _P (2'_XN@#^
MKZBOY0?^(O'_ (+)?]#K\/\ _P (2'_XNC_B+Q_X+)?]#K\/_P#PA(?_ (N@
M#] /^#WG_DUGX'_]E U'_P!(117XZ?\ !1;_ (+4?MQ?\%2/!?ASP%^U?KWA
=N\T_PKJDNH:2NA^'DLG6:2/RV+,K'<-O:B@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>ebs-20220630_g3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ebs-20220630_g3.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **YR#XM_#>Y^)=[\'K?Q=:OXETW18
M]7O]*4MOM[*21XDE=L;5!=&&"=W&<8()Z,$$9!R#T(H **C6ZM7NGLDN8S-'
M&KR0AQN56+!6(Z@$JP![[3Z&H[[5]*TLJ-3U.WMM^=GGS*F['7&3SU% %BBJ
MMEKNB:E-]GT[6;2>3;G9#<*QQZX!J>YN;>SMY+N[G2**)"\LLC!510,DDG@
M#O0 ^BD5E90RD$$9!'>EH **KZ;J^DZS$\^D:I;W:12M%(]M.L@21?O(2I.&
M'<=15B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH _$'_@]Y_P"36?@?_P!E U'_ -(111_P>\_\FL_ _P#[
M*!J/_I"** //_P#@TV_Y2F?M=_\ ;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\
MI\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\A_;
M^MOVAKW]B'XLVG[)LLZ?$J3X?ZJO@EK1PMP-1-L_E>03P)L_ZLG@2;">*]>K
MS3]LGX\ZA^R[^RSX[_:)TSPXVL3>#/#EQJPTJ.%I'O!"-[1(JD%G900H!^\1
M]* /QG_8?^&/_!+3_@J?HNO_ +-?PM^&.G?#'XR6?[.ZZ+JL&LPOI/BO3O&T
M=Q=I>WLEW\MUJ)9S&\[DR&2)@DZ*<QK^Y>LMXMT+P#<MX-T.QU77+/26_LS3
MK_4FL[:[N5C^2*2X6*5H49P 9!%(5!SL;&#^)7_!8?4O^"4/[=GC3Q=^T+\,
M_C[H5I\7-&^"]CJ'PAU+P%JIM?%EWXRCO[O[)I;V,.V[ENWVV\+12Q>= C!Q
MY87=7[#_ +'R_&Y/V3/ABG[3#%OB*/A_HX\=EMNXZQ]BB^V;MOR[O/\ ,SM^
M7.<<8H ^./\ @E3XW_:W\9_\%5_VTX?VR[;PM8^)M)T?X;6FE:'X+U:>_P!.
MTG2FM]=N;:VCN+B""29_](>21S$@,LLA557:H]Y_:M_X)1?L=_MU_'*R^,O[
M8WPYB\?V^A^%DT;PKX:U2>>*RTEFN)9KJ[40RKYDT^;9"6X1;50OWV)\7_8-
M^)GPYUK_ (+D?MQ:'H_CW1KJ\O-$^& L[6WU.)Y)S;Z1J(N BALOY9DC#XSL
MWKG&:^N?VL_V@-'_ &5OV:/''[1&MV#7D?A+PW<W]MIL8)DU"Z5"+:TC Y,D
MTYBA4=VD44 ?(?\ P2^_8%_8[^"?[>?QY^/O[)?P$T7P7X;\+0V7PQT0Z296
M%]>VX74-;N=TSNQ'VB>RL^" 'TN48))-5/\ @Y%^(?[;_@K_ ()K?%2']F_P
MQX*M/!D_@IH?'WB_6/%%RFKPV,\WV>ZL[*PCLVB=I(I$4SR7*X664"/<%>OJ
M[]A#]G_6/V8_V3/!?PC\7WRWOB:#3GU'QMJ2D'[?K]],][JESD=?,O;BX<=>
M& SQ7@/_  <7^)O#GA[_ ((R?':WU[7K.RDO_"L5O8QW5RL;7$S7UL%C0,07
M8DC@9- 'V/X)_P"1,TC_ +!=O_Z+6L[XN?"WPW\:OAYJ/PN\8W6H1Z1JZQQ:
MK%IE\]M)=6PE1Y+9I$PPBF53%(%(+1R.H*YR*W@/XA^![OX)Z9\3--\46=]H
M$?AR.^.JZ=*+F%[=( [2(8MV\!03A<DXP.:X[X+?MT_LT?'_ /97T3]M3X:>
M.9KGX;:ZKO;>([S2KBU6WBCNY+26:>.9%>"&.:-P\KJ$1%,C,(P7 !\C:7\.
MOV=_A;_P65^#?@W_ ()F>$?"N@65GX/\2)^TOHWPOLX+;1K?21:*-$_M&&T
MMTOSJ /D9 N#$)\_NP*_1>OSW^/LWP6\0_\ !4G]FG5?^"?\GANY\;IJFK3_
M !AU+X>F![7_ (0A]/ERNL/:?(P>\^S&T$Y+><':/HYK]"* "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0
M?^#WG_DUGX'_ /90-1_](111_P 'O/\ R:S\#_\ LH&H_P#I"** //\ _@TV
M_P"4IG[7?_;Q_P"GR>OW^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (*2?M(ZK^R+;6D7[/\ -I?A]&;0$5?#]QXW47 U*32_+_<$BW^RK=M!\IG
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M'J>!M(7QO(I4AM7%G$+PC;Q_K_,Z<>E '<T444 %%%% !1110 4444 %%%%
M'X@_\'O/_)K/P/\ ^R@:C_Z0BBC_ (/>?^36?@?_ -E U'_TA%% 'G__  :;
M?\I3/VN_^WC_ -/D]?O]7X _\&FW_*4S]KO_ +>/_3Y/7[_4 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M 'X@_P#![S_R:S\#_P#LH&H_^D(HH_X/>?\ DUGX'_\ 90-1_P#2$44 >?\
M_!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\ P:;?\I3/VN_^WC_T^3U^_P!0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7\UGCS_D>-9_["UQ
M_P"C6K^E.OYK/'G_ "/&L_\ 86N/_1K5\/QI\%#_ +>_]M/VCP>_BXWTI_\
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M^OE#_@BE_P H^O"__86U3_TLEKZOK]CRC_D5T/\ !'\C^1N*O^2FQG_7V?\
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M^_U !1110 4444 %%%% !1110 4444 ?DW^W+^UA_P $N/\ @I-\'_!OP?\
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M":-?ZA+=P>'M8O\ 36O-3TZTED9F,:>;;LT9)*;X\Y=G9@#]%**** "BBB@
MHHHH *_FL\>?\CQK/_86N/\ T:U?TIU_-9X\_P"1XUG_ +"UQ_Z-:OA^-/@H
M?]O?^VG[1X/?Q<;Z4_\ V\RJ***^#/W **** "BBB@ HHHH **** /VY_P""
M*7_*/KPO_P!A;5/_ $LEKZOKY0_X(I?\H^O"_P#V%M4_]+):^KZ_8\H_Y%=#
M_!'\C^1N*O\ DIL9_P!?9_\ I3"BBBO1/ "OQ'_X+6_\I!?%'_8)TO\ ](XJ
M_;BOQ'_X+6_\I!?%'_8)TO\ ](XJ^5XO_P"17'_&OR9^G>$__)2S_P"O4O\
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M!NM?#[QUX=M]0T?Q%ITMCK5E*"HNK>1#&Z,RD,/E) 8$$=000#5CPCX2\->
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MCD\>]2:%X0\)^%VE?PUX8T[3C, )C8V4<)D SC=L SC)Z^M &C1110 4444
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M5;5^6M?J5_P<1?\ (C_"[_L+:I_Z*MJ_+6ORKB?_ )'53_MW_P!)1_3WAO\
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MD?A_6?\ Z7(****\ ^Z"BBB@ HHHH **** "OH7_ ()3_P#*07X:?]A:X_\
M2.>OGJOH7_@E/_RD%^&G_86N/_2.>NS+O^1A1_QQ_-'D<0?\B'%_]>JG_I#/
MWCHHHK]H/X^"BBB@#Y[_ ."K'_*/KXE_]@FW_P#2R"OP;K]Y/^"K'_*/KXE_
M]@FW_P#2R"OP;K\XXQ_Y&$/\'ZL_H3PD_P"1!6_Z^O\ ](@%%%%?)'ZH%%%%
M !1110 4444 %%%% ']*?@/_ )$?1O\ L$V__HI:U:RO ?\ R(^C?]@FW_\
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MUW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@
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MA0HHHH **** "BBB@#\0?^#WG_DUGX'_ /90-1_](111_P 'O/\ R:S\#_\
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M:#^/@HHHH ^>_P#@JQ_RCZ^)?_8)M_\ TL@K\&Z_>3_@JQ_RCZ^)?_8)M_\
MTL@K\&Z_..,?^1A#_!^K/Z$\)/\ D05O^OK_ /2(!1117R1^J!1110 4444
M%%%% !1110!_2GX#_P"1'T;_ +!-O_Z*6M6LKP'_ ,B/HW_8)M__ $4M:M?N
M4/@1_%=7^++U844451F%?S6>//\ D>-9_P"PM<?^C6K^E.OYK/'G_(\:S_V%
MKC_T:U?#\:?!0_[>_P#;3]H\'OXN-]*?_MYE4445\&?N 4444 %%%% !1110
M 4444 ?MS_P12_Y1]>%_^PMJG_I9+7U?7RA_P12_Y1]>%_\ L+:I_P"EDM?5
M]?L>4?\ (KH?X(_D?R-Q5_R4V,_Z^S_]*84445Z)X 5^(_\ P6M_Y2"^*/\
ML$Z7_P"D<5?MQ7XC_P#!:W_E(+XH_P"P3I?_ *1Q5\KQ?_R*X_XU^3/T[PG_
M .2EG_UZE_Z5 ^3Z***_-3^B@HHHH **** "BBB@ HHHH _1_P#X-W?^1X^*
M/_8)TO\ ]&W-?J37Y;?\&[O_ "/'Q1_[!.E_^C;FOU)K]5X8_P"1+3_[>_\
M2F?S#XD?\EAB/2'_ *1$****]\^%"BBB@ HHHH **** /Q!_X/>?^36?@?\
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M_!5C_E'U\2_^P3;_ /I9!7X-U^\G_!5C_E'U\2_^P3;_ /I9!7X-U^<<8_\
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M?R['YAPIXBYYB,ZI87'R52%62C\*3BV[*W*E=7WO?3J?HI1117YZ?O04444
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M'CXH_P#8)TO_ -&W-?J37Y;?\&[O_(\?%'_L$Z7_ .C;FOU)K]5X8_Y$M/\
M[>_]*9_,/B1_R6&(](?^D1"BBBO?/A0HHHH **** "BBB@#\0?\ @]Y_Y-9^
M!_\ V4#4?_2$44?\'O/_ ":S\#_^R@:C_P"D(HH \_\ ^#3;_E*9^UW_ -O'
M_I\GK]_J_ '_ (--O^4IG[7?_;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH _.
M'_@XB_Y$?X7?]A;5/_15M7Y:U^I7_!Q%_P B/\+O^PMJG_HJVK\M:_*N)_\
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M_P#V4#4?_2$44 >?_P#!IM_RE,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\
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M$>\G(R26.?+B1<L\A&%4>I .MX.T_P :6MB;GQUXAMKR^F4&2#3K3RK6W/\
M=CW%I&ZX+.W.,A4SBDZ,XTE4>B>WGZ>7G_D5'%TIXET(7;C\5MHWV3?=[V5W
M:S=DU?8HKQS5_B;\3M4\*^.?BQX<UZVM++P9J>H6]GH,MDC1WT=AG[09I3\Z
MM(R2!-A4( A(?)KL]5\>7^ORZ)X>\#-Y=]K%M#J%U/+&&_L_3S@M(P/&]_\
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MH_\ I"**/^#WG_DUGX'_ /90-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\
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M^QG\C!1110!\]_\ !5C_ )1]?$O_ +!-O_Z605^#=?O)_P %6/\ E'U\2_\
ML$V__I9!7X-U^<<8_P#(PA_@_5G]">$G_(@K?]?7_P"D0/F?QM>?L[^-?CSX
MTD^.GB:\@CTFYL=-TH1:C?6\,*K;+)*[O;D(@,DQ7,A'W*^AO"&C>&_#OA:P
MT?P@D:Z7!:J+$Q3F16C(R&WDDOG.=Q)+9R2<U@VWQ/\ AG>V7BNQUAX=.MO#
MMY+;^((=5B2)64Q+(TVTD[XI%DX8CY\-P:Y_]D/3M8T7]FW0;?7M/N8QY5S+
M96=PA,L=F]Q*]O&0><^44P/0@5X^*E.KA4WS14>56;NG>.Z5E;:[W^+?O]9E
MD*6%S.48\DW452;G&-I*U1>[)W=U[UEM\#T[>3?!BS_97^*,EMXJ^(OB.YE\
M4>(-?O+I(KK6+^WMI&DO)7@@7YE@<^7Y8\L$YZ8/2OJA$2-!'&H55&%4#  K
MQ/X]?$'X=?$C]DC4=1TJV+C6[ 6OA_2'B5;L:CO"0PK$I)65)0,J.5V'L#7I
M>H>+],^&'PTB\5_%37XK2+3;" :OJ$@9E$IV(3\H).9& &!R33Q_M<1RRM*[
ME**BW>VVD=%WM:W3J3D?U? <]*]-I4X3=2*Y>9/FUG=O73FYF^KT5KN;X@>%
M=1\:Z&OAJUUZYTZVN;A1J<]C,8KAK8 EHXG'*%F"J6&"$+X(;!'CVF?#F'X!
M?M3>$/#7PDU+48]!\5Z9J3>(M!NM2FNHH/LT2M'<J969E9I'5,D^H'4UZUX_
M^+'@3X:>"6^('BO7X(-.*(;:0RJ#<LXRB1[B 6;MD@ 9)( )'"_#7XE_"*Z\
M6GQAK?Q6\-:KXO\ $C0V-MINBZS#>-8V^_,=I$(F)*J27DDP S;F.%50LX1X
MJ&'G[K<&FK6T;:W?^'>_2R74TS6.6UL=27/&-92A+F;2<8J5[+7:I9QLM[MZ
MV+GB_3K'QK^TA:^!/',0N=$A\&-?:7ID[D075X;HQS2,N0)&BC\G;G.WSB1@
MG-9'PM\>>*+GX<#P5X<UB2[U"\\0ZM8^&M5NW,QBTBWNGC%](S9\Q8TVHI/^
ML?R@3ABP]%^*&G_#F?PM+J_Q,\.6.I6.G_O4BO+%;AMY^0+&K DNY8(%'+%@
MO.<5Y7XN\%G3=?\  \_Q(TZVMM,\0Z\8O$&G@*+.TCCM)CIVF,!\IA63J/N2
M3'.,,JC3#SIUZ*C);;+I>*;=EU;ZKO9=5;#'4J^#QDJD'=R>KO9\LY0BN9VT
M46FHO6RO)+W6I>U>&]#T[PUH-IH6DM(UO:P*D3S2F1W']]G/+,3DECR22>]7
M:\Q^!T5IIWQ*^(/A[PBD:>&+'4;(:=!:@?9K>\:WW7<40'RJ ?*9E7@.[\ D
MUZ=7G8BFZ=5IN][/[TG]^NI]#@*\<1A5)1Y;.4;+5>[)QTVTTTTV/Z4_ ?\
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M_P SSVBO0O\ AEOXR?\ 0.T'_P +32O_ ))H_P"&6_C)_P! [0?_  M-*_\
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MT+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\
M\36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\ $UNT4 87
M_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_PJ[X9_\
M1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.]"_\%$/_
M ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$/_Q-'_"K
MOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+
M_P %$/\ \36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\
M$UNT4 87_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_
MPJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.
M]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$
M/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[
MX9_]$[T+_P %$/\ \36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0
MO_!1#_\ $UNT4 87_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q
M-;M% &%_PJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\
M*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$
M[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\
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M1]1TA9;ZXTOQ%X:UA0+S0]5MRHN+.7'#%=R.K#&Y)$8JI)5;?_!1?]MSX?\
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M@_&/X@?L>?M,_LS:E\&/CG\,H(;SQ%X%O=:CU.VO-.E*B._L[N-$6:++Q;L
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M7@F+QO9^(KR:%(V>>_GO;(^2%D:1(TA"AD^S.6+"137FO_!=KX)_M#?M1_\
M!-#XB_LN?LP_ K5/''BSQS96EK80V6M:78V]GY.HVEP[SRW]W!@&..3:(Q(2
MRX(7(-?85% '*_!/5O%&L?"K0KGQI\.-4\)ZHFF017NA:S=6<\]M(L:AE+V<
M\\+#(."LASCM75444 %%%% !1110 5\>_P#!='X3_M(_M(_\$X/B'^RY^RU^
MSOJ_CWQ5X]TVWL+,6>O:3I]K8!;RWEDDGDU"\@./+C?:(U<EL [02P^PJ* /
M O\ @F%H?QF\!?L'?"CX-_'WX&:OX"\4^ _AWHOAO5],U35]-ODGGL;**U>:
M&73[J=&C<P[QN*L X!7(-?(/[3_P%_;S\9_\%_\ X*?MY>!?V#O%6J?"WX9^
M!;_PUK6LKXT\,PW5U)=Q:E&;FWMI=45VAC-Y"2'V2,%DPF0H;].Z* /R[_;\
M^"7_  4 ^(O_  6<_9Y_;@^#G_!/7QCXF\!_!70-8MM8FC\<^%;.ZU.>]M[N
M "VBN-60[$\R)BTA0G+#;\HW='^W]H?_  5[_P""G7PKNOV)OA?^QVO[/7@/
MQHB6?Q&^)GQ%\>:-JE^-*+ SVEC8Z-=W.7D4%"TDBAU9D_=[C(OZ0T4 </\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!^(/\ P>\_\FL_ _\ [*!J/_I"**/^#WG_
M )-9^!__ &4#4?\ TA%% 'G_ /P:;?\ *4S]KO\ [>/_ $^3U^_U?@#_ ,&F
MW_*4S]KO_MX_]/D]?O\ 4 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?B#_P>\_\
M)K/P/_[*!J/_ *0BBC_@]Y_Y-9^!_P#V4#4?_2$44 >?_P#!IM_RE,_:[_[>
M/_3Y/7[_ %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M71_Q%X_\%DO^AU^'_P#X0D/_ ,70!_5]17\H/_$7C_P62_Z'7X?_ /A"0_\
MQ='_ !%X_P#!9+_H=?A__P"$)#_\70!_5]17\H/_ !%X_P#!9+_H=?A__P"$
M)#_\71_Q%X_\%DO^AU^'_P#X0D/_ ,70!_5]17\H/_$7C_P62_Z'7X?_ /A"
M0_\ Q='_ !%X_P#!9+_H=?A__P"$)#_\70!_5]17\H/_ !%X_P#!9+_H=?A_
M_P"$)#_\71_Q%X_\%DO^AU^'_P#X0D/_ ,70!_5]17\H/_$7C_P62_Z'7X?_
M /A"0_\ Q='_ !%X_P#!9+_H=?A__P"$)#_\70!_5]17\H/_ !%X_P#!9+_H
M=?A__P"$)#_\71_Q%X_\%DO^AU^'_P#X0D/_ ,70!_5]17\H/_$7C_P62_Z'
M7X?_ /A"0_\ Q='_ !%X_P#!9+_H=?A__P"$)#_\70!_5]17\H/_ !%X_P#!
M9+_H=?A__P"$)#_\71_Q%X_\%DO^AU^'_P#X0D/_ ,70!_5]17\H/_$7C_P6
M2_Z'7X?_ /A"0_\ Q='_ !%X_P#!9+_H=?A__P"$)#_\70!_5]17\H/_ !%X
M_P#!9+_H=?A__P"$)#_\71_Q%X_\%DO^AU^'_P#X0D/_ ,70!_5]17\H/_$7
MC_P62_Z'7X?_ /A"0_\ Q='_ !%X_P#!9+_H=?A__P"$)#_\70!_5]17\H/_
M !%X_P#!9+_H=?A__P"$)#_\71_Q%X_\%DO^AU^'_P#X0D/_ ,70!_5]17\H
M/_$7C_P62_Z'7X?_ /A"0_\ Q='_ !%X_P#!9+_H=?A__P"$)#_\70!_5]17
M\H/_ !%X_P#!9+_H=?A__P"$)#_\71_Q%X_\%DO^AU^'_P#X0D/_ ,70!_5]
M17\H/_$7C_P62_Z'7X?_ /A"0_\ Q='_ !%X_P#!9+_H=?A__P"$)#_\70!_
M5]17\H/_ !%X_P#!9+_H=?A__P"$)#_\71_Q%X_\%DO^AU^'_P#X0D/_ ,70
M!_5]17\H/_$7C_P62_Z'7X?_ /A"0_\ Q='_ !%X_P#!9+_H=?A__P"$)#_\
M70!_5]17\H/_ !%X_P#!9+_H=?A__P"$)#_\71_Q%X_\%DO^AU^'_P#X0D/_
M ,70!_5]17\H/_$7C_P62_Z'7X?_ /A"0_\ Q='_ !%X_P#!9+_H=?A__P"$
M)#_\70!_5]17\H/_ !%X_P#!9+_H=?A__P"$)#_\71_Q%X_\%DO^AU^'_P#X
M0D/_ ,70!_5]17\H/_$7C_P62_Z'7X?_ /A"0_\ Q='_ !%X_P#!9+_H=?A_
M_P"$)#_\70!_5]17\H/_ !%X_P#!9+_H=?A__P"$)#_\71_Q%X_\%DO^AU^'
M_P#X0D/_ ,70!_5]17\H/_$7C_P62_Z'7X?_ /A"0_\ Q='_ !%X_P#!9+_H
M=?A__P"$)#_\70!_5]17\H/_ !%X_P#!9+_H=?A__P"$)#_\71_Q%X_\%DO^
MAU^'_P#X0D/_ ,70!_5]17\H/_$7C_P62_Z'7X?_ /A"0_\ Q='_ !%X_P#!
M9+_H=?A__P"$)#_\70!_5]17\H/_ !%X_P#!9+_H=?A__P"$)#_\71_Q%X_\
M%DO^AU^'_P#X0D/_ ,70!_5]17\H/_$7C_P62_Z'7X?_ /A"0_\ Q='_ !%X
M_P#!9+_H=?A__P"$)#_\70!_5]17\H/_ !%X_P#!9+_H=?A__P"$)#_\71_Q
M%X_\%DO^AU^'_P#X0D/_ ,70!_5]17\H/_$7C_P62_Z'7X?_ /A"0_\ Q='_
M !%X_P#!9+_H=?A__P"$)#_\70!^@'_![S_R:S\#_P#LH&H_^D(HK\=/^"BW
M_!:C]N+_ (*D>"_#G@+]J_7O#=YI_A75)=0TE=#\/)9.LTD?EL696.X;>U%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>ebs-20220630_g4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ebs-20220630_g4.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MP]\&^)/&4LGE6=KX[\3W.E:=;*8W_P!(=[:TN9)MKB/]R%CWJS?O4(&?'O\
M@GG_ ,7K\??&+]NZ]_>P_$7QJWA_P-.>0/"WA]YM/M63/.RXOCJMZIX#)>QG
M'0U]+ZIJNEZ'I\VKZUJ5O9VENF^>ZNIECCC7U9F( 'N: /B?_@W?\4?$?QO_
M ,$P-!\9?&+7(]3\6ZK\1/&UWXGU&'[ESJ$GB?4GN)%X'RM*7(X'!' Z5]I^
M)8-?NO#FH6WA34+>TU22RE73;J[@,L4-P4(C=T!!=0V"5!&0",BOAC_@V^\;
M^#?%W_!,?2[;PMXKT[4I;/XB^,C=Q6-ZDK0"7Q'J$T1<*25WQ.CKGJK@C@U]
M*>#/V\OV5_'/C_XP?#?2OBE#;:A\!C;'XISZO9365IHB3VTERDK7,Z)$\8BA
ME9G1B%V') () /SS_P""Q'_!*+]F3]E#]A[5OVU?V;T\3:7^TIX,\0:-J'A7
MXMQ>(KNX\1>)_$%UJ=K:F.YW2%;IKIIV7R50(F0J*L:F,_J_X:?7I/#FGR>*
M888]3:RB.HQVQS&L^P>8%/\ =#9Q[5^86G_\%I_^"3O[4GQNT_\ :!_:$_;6
M\&Z-X'^&NLS77PL\!ZA).US?:G&'A_X2._A2-B'56D6QM<%HED:XD'G21QVO
MZ6?"[XAZ+\7/AMH'Q4\-6=];Z;XDT>VU/38M3M3!<"WGC66(R1'YHV*,I*-A
MESA@""  ;U%%% !1110 4444 %%%% !1110!^(/_  >\_P#)K/P/_P"R@:C_
M .D(HH_X/>?^36?@?_V4#4?_ $A%% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X
M _\ !IM_RE,_:[_[>/\ T^3U^_U !1110 4444 %%%% !1110 4444 %%%%
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M!_\ $5OHB1H(XT"JHPJ@8 'I2T4 %%%% !1110 4444 %%%% !1110!^(/\
MP>\_\FL_ _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\ TA%% 'G_ /P:;?\
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MO?/A0HHHH **** "BBB@#\0?^#WG_DUGX'_]E U'_P!(111_P>\_\FL_ _\
M[*!J/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?
M)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?B/_ ,%K?^4@OBC_ +!.E_\ I'%7[<5^(_\ P6M_Y2"^*/\ L$Z7_P"D<5?*
M\7_\BN/^-?DS].\)_P#DI9_]>I?^E0/D^BBBOS4_HH**** "BBB@ HHHH **
M** /T?\ ^#=W_D>/BC_V"=+_ /1MS7ZDU^6W_!N[_P CQ\4?^P3I?_HVYK]2
M:_5>&/\ D2T_^WO_ $IG\P^)'_)88CTA_P"D1"BBBO?/A0HHHH **** "BBB
M@#\0?^#WG_DUGX'_ /90-1_](111_P 'O/\ R:S\#_\ LH&H_P#I"** //\
M_@TV_P"4IG[7?_;Q_P"GR>OW^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ K\1_^"UO_*07Q1_V"=+_ /2.*OVXK\1_^"UO
M_*07Q1_V"=+_ /2.*OE>+_\ D5Q_QK\F?IWA/_R4L_\ KU+_ -*@?)]%%%?F
MI_104444 %%%% !1110 4444 ?H__P &[O\ R/'Q1_[!.E_^C;FOU)K\MO\
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MBXU'PU>37DL5O>V5P!EEV12RN%"(?+*NC,ZS+^X= 'RU_P $7OVK/B;^V_\
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M>HMJ'A+Q+H>L7.F:KHERR&-Y+6\M9(YH@Z'9(@;RY5^6177BO1:* /-_V?\
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MUGX'_P#90-1_](111_P>\_\ )K/P/_[*!J/_ *0BB@#S_P#X--O^4IG[7?\
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M44 %%%% !1110 4444 %%%% !1110 4444 %?B/_ ,%K?^4@OBC_ +!.E_\
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M(@%%%%?)'ZH%%%% !1110 4444 %%%% ']*?@/\ Y$?1O^P3;_\ HI:U:RO
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MB@ HHHH **** /GO_@JQ_P H^OB7_P!@FW_]+(*_!NOWD_X*L?\ */KXE_\
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MCS1]+AUOPSKMM8O>P317&F6MJEQ:3I%+$T4D1:)@C*Y!*T ?<E%%% !1110
M4444 %?B/_P6M_Y2"^*/^P3I?_I'%7[<5^(__!:W_E(+XH_[!.E_^D<5?*\7
M_P#(KC_C7Y,_3O"?_DI9_P#7J7_I4#Y/HHHK\U/Z*"BBB@ HHHH **** "BB
MB@#]'_\ @W=_Y'CXH_\ 8)TO_P!&W-?J37Y;?\&[O_(\?%'_ +!.E_\ HVYK
M]2:_5>&/^1+3_P"WO_2F?S#XD?\ )88CTA_Z1$****]\^%"BBB@ HHHH ***
M* /Q!_X/>?\ DUGX'_\ 90-1_P#2$44?\'O/_)K/P/\ ^R@:C_Z0BB@#S_\
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M9^G>&W#V3Y_4Q*Q]+GY%"WO25K\U_A:[+<_1_P#XB+O^K.__ #(7_P![Z/\
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M^P3I?_I'%7RO%_\ R*X_XU^3/T[PG_Y*6?\ UZE_Z5 ^3Z***_-3^B@HHHH
M**** "BBB@ HHHH _1__ (-W?^1X^*/_ &"=+_\ 1MS7ZDU^6W_!N[_R/'Q1
M_P"P3I?_ *-N:_4FOU7AC_D2T_\ M[_TIG\P^)'_ "6&(](?^D1"BBBO?/A0
MHHHH **** "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH
M&H_^D(HH \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"G
MR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP(_BNK_%EZL****HS"OYK/'G_(\:S_V%KC_T:U?TIU_-9X\_Y'C6?^PM<?\
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ML%%%% 'Z/_\ !N[_ ,CQ\4?^P3I?_HVYK]2:_+;_ (-W?^1X^*/_ &"=+_\
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M+J?_ ")Z/^K^/_GI?^#Z'_RP^\:*^#O^'Q7QD_Z,JT'_ ,/MI7_QBNA^%/\
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MOTE(XU'155;D #V%+;?LF_%>R,K6>A>'(3/*99C%XPTE?,<@ LV+GDX Y//
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M)K=HH PO^%7?#/\ Z)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)K=HH PO\
MA5WPS_Z)WH7_ (*(?_B:/^%7?#/_ *)WH7_@HA_^)K=HH PO^%7?#/\ Z)WH
M7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)K=HH PO\ A5WPS_Z)WH7_ (*(?_B:
M/^%7?#/_ *)WH7_@HA_^)K=HH PO^%7?#/\ Z)WH7_@HA_\ B:/^%7?#/_HG
M>A?^"B'_ .)K=HH PO\ A5WPS_Z)WH7_ (*(?_B:/^%7?#/_ *)WH7_@HA_^
M)K=HH PO^%7?#/\ Z)WH7_@HA_\ B:/^%7?#/_HG>A?^"B'_ .)K=HH PO\
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M_L=:A\,]!O$TGXC^%K@:_P#"GQ0DIAETS6H1NC3S5PT<4P'E.0?ERDF"T24
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M/VN_^WC_ -/D]?O]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!^(/_![S_R:S\#_
M /LH&H_^D(HH_P"#WG_DUGX'_P#90-1_](110!Y__P &FW_*4S]KO_MX_P#3
MY/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% 'X@_\ ![S_ ,FL_ __ +*!J/\ Z0BBC_@]Y_Y-9^!__90-1_\ 2$44 >?_
M /!IM_RE,_:[_P"WC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %%%%
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M'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\
M!9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$
M7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*
M#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U
M%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T
M ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__
M != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^
M$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?
M_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\
MH=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P
M62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C
M_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q
M='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__
M !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\
M_A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?
M_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_
M *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P
M62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%
MX_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@
M_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?
M45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ !=
M']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_
M /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A
M"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A
M_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z
M'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='_$7C_P %
MDO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$
M7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A"0__ !='
M_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7X?\ _A"0
M_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z'7X?_P#A
M"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\ !9+_ *'7
MX?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$7C_P62_Z
M'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*#_Q%X_\
M!9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != ']7U%?R@_P#$
M7C_P62_Z'7X?_P#A"0__ !='_$7C_P %DO\ H=?A_P#^$)#_ /%T ?U?45_*
M#_Q%X_\ !9+_ *'7X?\ _A"0_P#Q='_$7C_P62_Z'7X?_P#A"0__ != 'Z ?
M\'O/_)K/P/\ ^R@:C_Z0BBOQT_X*+?\ !:C]N+_@J1X+\.> OVK]>\-WFG^%
9=4EU#25T/P\EDZS21^6Q9E8[AM[44 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>ebs-20220630_g5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ebs-20220630_g5.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7AW6='NM,U71;ED$B1W5E=QQSP[T(=&9-DB_,C,O- 'H=%<I\9OCE\(/V=_
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ME9>'/%%SJ6HZO>VWA74HUOK]9;.WCM=MO<[8X(S+M,TVZ1_EQ[5_P67^,/Q
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M!?"?B/7OBCXCM$VM;6&J6OV+2M)ED7[TD\WVR=86Y6&*5P!YH+=S\4?VL?\
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M#=6TR[9;>XB#HX]"K @U-10!G:%X1\*>%VE;PSX8T[3C, )C8V4</F8SC=L
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M'%7[<5^(_P#P6M_Y2"^*/^P3I?\ Z1Q5\KQ?_P BN/\ C7Y,_3O"?_DI9_\
M7J7_ *5 ^3Z***_-3^B@HHHH **** "BBB@ HHHH _1__@W=_P"1X^*/_8)T
MO_T;<U^I-?EM_P &[O\ R/'Q1_[!.E_^C;FOU)K]5X8_Y$M/_M[_ -*9_,/B
M1_R6&(](?^D1"BBBO?/A0HHHH **** "BBB@#\0?^#WG_DUGX'_]E U'_P!(
M111_P>\_\FL_ _\ [*!J/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@T
MV_Y2F?M=_P#;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;FOU)K\MO^#=W_D>/BC_ -@G2_\ T;<U^I-?JO#'_(EI_P#;W_I3/YA\2/\
MDL,1Z0_](B%%%%>^?"A1110 4444 %%%% 'X@_\ ![S_ ,FL_ __ +*!J/\
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M_P!+):^KZ_8\H_Y%=#_!'\C^1N*O^2FQG_7V?_I3"BBBO1/ "OQ'_P""UO\
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MD5[116^%Q5?!UU5I.TD<.99;@\VP<\+BH<T);K\FGT:Z,_.#_AW'^U5_:_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!7\UGCS_ )'C6?\ L+7'_HUJ_I3K^:SQY_R/&L_]A:X_]&M7P_&GP4/^WO\
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M5Q_QK\F?IWA/_P E+/\ Z]2_]*@?)]%%%?FI_104444 %%%% !1110 4444
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MQ=^T?\%_'VO_  YA&CRV]M8>)M8T_P"SI]N3S6B@PK7#%T#1QR&W.WRO,VH
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M_B'XA^%_A#>>.O%>O^)_$9T[3/"^G8FCMG 2UN9+V\DDAD9+?RUCVH&DE4,
M>F_84_;)_:!^/7C[Q!\#_P!I#]F@>!?$'A/P'X:U[^VK+Q/'JFG^(XM4-\@N
M+21;>!E16L6W))&CJ[LNW:JN_P [_P#!:7_@F;XP^.&K>)/V^_V)_P!J1_AI
M\9_!/PNO]%\86@*W&G>*/#IAGG;3[^$!C&Q4RF.1D<'"?*#'')'K_P#!'/\
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M "BBB@#\0?\ @]Y_Y-9^!_\ V4#4?_2$44?\'O/_ ":S\#_^R@:C_P"D(HH
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MVD>L021/%,2F]F0.DC+C<2,]:][HH ^*5_X)L?M8)^QY_P .WD_;.T8?!_\
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M]Q!+@;AJC&>,PE*\MHQI0<G;?2R5EW;1^Q7_  ^+_P""CO\ T<7_ .6CH_\
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M_)ZG_P F?II_Q$7?]6=_^9"_^]]'_$1=_P!6=_\ F0O_ +WU^9=%'^LN=_\
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M["UQ_P"D<]=F7?\ (PH_XX_FCR.(/^1#B_\ KU4_](9^\=%%%?M!_'P4444
M?/?_  58_P"4?7Q+_P"P3;_^ED%?@W7[R?\ !5C_ )1]?$O_ +!-O_Z605^#
M=?G'&/\ R,(?X/U9_0GA)_R(*W_7U_\ I$ HHHKY(_5 HHHH **** "BBB@
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MO^!5T-%%93G*I-SEN]3JHTH8>C&E#:*27HM$?H__ ,&[O_(\?%'_ +!.E_\
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MP(_BNK_%EZL****HS"OYK/'G_(\:S_V%KC_T:U?TIU_-9X\_Y'C6?^PM<?\
MHUJ^'XT^"A_V]_[:?M'@]_%QOI3_ /;S*HHHKX,_< HHHH **** "BBB@ HH
MHH _;G_@BE_RCZ\+_P#86U3_ -+):^KZ^4/^"*7_ "CZ\+_]A;5/_2R6OJ^O
MV/*/^170_P $?R/Y&XJ_Y*;&?]?9_P#I3"BBBO1/ "OQ'_X+6_\ *07Q1_V"
M=+_](XJ_;BOQ'_X+6_\ *07Q1_V"=+_](XJ^5XO_ .17'_&OR9^G>$__ "4L
M_P#KU+_TJ!\GT445^:G]%!1110 4444 %%%% !1110!^C_\ P;N_\CQ\4?\
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M170_P1_(_D;BK_DIL9_U]G_Z4PHHHKT3P K\1_\ @M;_ ,I!?%'_ &"=+_\
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M!_\ V4#4?_2$44 >?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\
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M'&4ZDZ5DI)OWH[)KS/.SCC[A+%91B*-+$WE*$TER5-6XM):QMOW/UFHKPO\
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MT#\;/^@'X[_\(>V_^65'_#H'XV?] /QW_P"$/;?_ "RKY+_5K._^?7_DT?\
M,_5/^(B\&_\ 05_Y)4_^0/C^BOL#_AT#\;/^@'X[_P#"'MO_ )94?\.@?C9_
MT _'?_A#VW_RRH_U:SO_ )]?^31_S#_B(O!O_05_Y)4_^0/C^BOL#_AT#\;/
M^@'X[_\ "'MO_EE1_P .@?C9_P! /QW_ .$/;?\ RRH_U:SO_GU_Y-'_ ##_
M (B+P;_T%?\ DE3_ .0/C^BOL#_AT#\;/^@'X[_\(>V_^65'_#H'XV?] /QW
M_P"$/;?_ "RH_P!6L[_Y]?\ DT?\P_XB+P;_ -!7_DE3_P"0/C^BOL#_ (=
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M .*KL/(/=*_$?_@M;_RD%\4?]@G2_P#TCBK]1/\ AK#XV?\ 1C_CO_P*MO\
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M"O\ R2I_\@?']%?8'_#H'XV?] /QW_X0]M_\LJ/^'0/QL_Z ?CO_ ,(>V_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MD^!;AY/!R:KIVI?M%>);5R(].TF&6.\@\/Q2+_S$+YXX690<P6F^1P//@60
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MV4%FV--*9)2@)5-^U> *ZZBB@ HHHH **** "OF3]O3_ ()B_#O]M'QKX/\
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MU;4+_2]3M/ LFBW*->7<EW,LN;^Z20"2:3;M"8! .<9KZ:HH **** "BBB@
MHHHH **** "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH
M&H_^D(HH \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"G
MR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$4
M4?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_
M '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^
M#WG_ )-9^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*
M9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW_1ROQ _\+*^_P#CM'_#6'[4W_1ROQ _\+*^_P#CM ']WM%?PA?\-8?M3?\
M1ROQ _\ "ROO_CM'_#6'[4W_ $<K\0/_  LK[_X[0!_=[17\(7_#6'[4W_1R
MOQ _\+*^_P#CM'_#6'[4W_1ROQ _\+*^_P#CM ']WM%?PA?\-8?M3?\ 1ROQ
M _\ "ROO_CM'_#6'[4W_ $<K\0/_  LK[_X[0!_=[17\(7_#6'[4W_1ROQ _
M\+*^_P#CM'_#6'[4W_1ROQ _\+*^_P#CM ']WM%?PA?\-8?M3?\ 1ROQ _\
M"ROO_CM'_#6'[4W_ $<K\0/_  LK[_X[0!_=[17\(7_#6'[4W_1ROQ _\+*^
M_P#CM'_#6'[4W_1ROQ _\+*^_P#CM ']WM%?PA?\-8?M3?\ 1ROQ _\ "ROO
M_CM'_#6'[4W_ $<K\0/_  LK[_X[0!_=[17\(7_#6'[4W_1ROQ _\+*^_P#C
MM'_#6'[4W_1ROQ _\+*^_P#CM ']WM%?PA?\-8?M3?\ 1ROQ _\ "ROO_CM'
M_#6'[4W_ $<K\0/_  LK[_X[0!_=[17\(7_#6'[4W_1ROQ _\+*^_P#CM'_#
M6'[4W_1ROQ _\+*^_P#CM ']WM%?PA?\-8?M3?\ 1ROQ _\ "ROO_CM'_#6'
M[4W_ $<K\0/_  LK[_X[0!_=[17\(7_#6'[4W_1ROQ _\+*^_P#CM'_#6'[4
MW_1ROQ _\+*^_P#CM ']WM%?PA?\-8?M3?\ 1ROQ _\ "ROO_CM'_#6'[4W_
M $<K\0/_  LK[_X[0!_=[17\(7_#6'[4W_1ROQ _\+*^_P#CM'_#6'[4W_1R
MOQ _\+*^_P#CM ']WM%?PA?\-8?M3?\ 1ROQ _\ "ROO_CM'_#6'[4W_ $<K
M\0/_  LK[_X[0!_=[17\(7_#6'[4W_1ROQ _\+*^_P#CM'_#6'[4W_1ROQ _
M\+*^_P#CM ']WM%?PA?\-8?M3?\ 1ROQ _\ "ROO_CM'_#6'[4W_ $<K\0/_
M  LK[_X[0!_=[17\(7_#6'[4W_1ROQ _\+*^_P#CM'_#6'[4W_1ROQ _\+*^
M_P#CM ']WM%?PA?\-8?M3?\ 1ROQ _\ "ROO_CM'_#6'[4W_ $<K\0/_  LK
M[_X[0!_=[17\(7_#6'[4W_1ROQ _\+*^_P#CM'_#6'[4W_1ROQ _\+*^_P#C
MM ']WM%?PA?\-8?M3?\ 1ROQ _\ "ROO_CM'_#6'[4W_ $<K\0/_  LK[_X[
M0!_=[17\(7_#6'[4W_1ROQ _\+*^_P#CM'_#6'[4W_1ROQ _\+*^_P#CM ']
MWM%?PA?\-8?M3?\ 1ROQ _\ "ROO_CM'_#6'[4W_ $<K\0/_  LK[_X[0!_=
M[17\(7_#6'[4W_1ROQ _\+*^_P#CM'_#6'[4W_1ROQ _\+*^_P#CM ']WM%?
MPA?\-8?M3?\ 1ROQ _\ "ROO_CM'_#6'[4W_ $<K\0/_  LK[_X[0!_=[17\
M(7_#6'[4W_1ROQ _\+*^_P#CM'_#6'[4W_1ROQ _\+*^_P#CM ']WM%?PA?\
M-8?M3?\ 1ROQ _\ "ROO_CM'_#6'[4W_ $<K\0/_  LK[_X[0!^__P#P>\_\
MFL_ _P#[*!J/_I"**_GE\;_&/XN_$VU@L?B1\5/$GB&"UD,EM#KFN7%VD+D8
,+*)78*2.,BB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>ebs-20220630_g6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ebs-20220630_g6.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB
M@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%'_![
MS_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4
MIG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!
M_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V
M\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH
M \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_
M ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y
M2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
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MYI'[&_P*T?6_"G@/0XI8M-LM$\5ZA!>0I+<R74H6^6;[4I>661BRRA@'(4J
M  #X3^*VB?M?_MT_\%7O@C^RY\0OBAX&\0^$/V;M<A^(WQ;NOA]X>N[6UM=<
MBA==%@N);BYF"7<KO)*+%"3# TDC22[D"_J+7(?!+X!_!K]G#P4/AW\#OAUI
MGAO2#=RW=Q;:=#AKJZE.9;F>1B9+B=SR\TK-(YY9B:Z^@ HHHH **** "BBB
M@#\_?%__  3\_P""EOPILO"7A7]GO]K3P7XJT&S^-5YXNM['Q]\.Y)9?":7<
MFHSMY5Q!JELUY:1/>%1;LAFRR[9%C78OTE^P1^Q%X9_88^%.O>$+/QK=>*O$
M_CCQQJGC3XB>,+RQCM7US7]1D#W5RMO&2EM'\J(D*E@B(H+,=S'W"B@#Y=_:
MQ_8P_:"^.O[;GP+_ &L?A]\4/!^D6'P.O->N;+0=7T.ZN)=8;5M-_L^=9)HY
MT$ 2,NR$(_S$$Y P?J*BB@#RK]CS]G&]_9F^%-[X7\2^*XO$'B7Q%XNUCQ/X
MO\0PVA@74-2U&]EN7*QEF*1Q1O%;QKDXBMXQVKQO_@HQ^QC^W7^UI\0?!EW^
MS_\ M:^"/!'@OPG<1ZI<^$O$_P .I=9CUG5XY&:"XN\7<230P$1R0P,NU9D$
MK;V2$Q?7-% 'S;^R-\ /^"BG@?XJWOCS]M?]N+0/B)I$6AO9Z#X7\(?#U= M
M8;J26-GN[AA/*]PZI'Y:*2$42R'!8@CT'X+_  F_:&\#?'#XH^/OBM^TW)XR
M\(^+-2T^;X>^"F\,6]D/!L$,#)<0BYC8O>>=(4?,@&SR^,EVKU&B@#Y>_;&_
M8P^/_P"T-^UO\#/VD/AW\4/"&BZ?\$M>U/5;;1M9T.ZN9M8DOK V,L;RQSH(
M%6-Y"I"N=Q4D84AOJ!-^P>9C=CYMO3-+10 4444 %%%% !1110 4444 %%%%
M 'X@_P#![S_R:S\#_P#LH&H_^D(HH_X/>?\ DUGX'_\ 90-1_P#2$44 >?\
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M\_:7_@4__E9^YU%?AC_P^+_X*._]'%_^6CH__P B4?\ #XO_ (*._P#1Q?\
MY:.C_P#R)1_KCEG\D_NC_P#)!_Q"7B/_ )^TO_ I_P#RL_<ZBOPQ_P"'Q?\
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M]_\ )8_Y!_Q#K@W_ *!?_)ZG_P F?II_Q$7?]6=_^9"_^]]'_$1=_P!6=_\
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M_P#3Y/7[_5^ /_!IM_RE,_:[_P"WC_T^3U^_U !1110 4444 %%%% !1110
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M^*/_ &"=+_\ 1MS7ZDU^6W_!N[_R/'Q1_P"P3I?_ *-N:_4FOU7AC_D2T_\
MM[_TIG\P^)'_ "6&(](?^D1"BBBO?/A0HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
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M_P B6G_V]_Z4S^8?$C_DL,1Z0_\ 2(A1117OGPH4444 %%%% !1110!^(/\
MP>\_\FL_ _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\ TA%% 'G_ /P:;?\
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M7P_&GP4/^WO_ &T_:/![^+C?2G_[>95%%%?!G[@%%%% !1110 4444 %%%%
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M!YUJ8WM6=HF\Q3$Q6.7<=O#_ /!-K]CGX@^)?^"A6K?\%1]9_9XN?@]H.L_
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M6?@?_P!E U'_ -(111_P>\_\FL_ _P#[*!J/_I"** //_P#@TV_Y2F?M=_\
M;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J "BBB@ HHHH **** "BBB
M@#\X?^#B+_D1_A=_V%M4_P#15M7Y:U^I7_!Q%_R(_P +O^PMJG_HJVK\M'8(
MA=LX R<#-?E7$_\ R.JG_;O_ *2C^GO#?_DCZ'K/_P!+D+17G&M?'K6?"*6G
MB3QO\+;_ $OPQ>WL-LFM2WL;2VWFN$BDN+?AH49F4?>9EW#<JG('=>(M9/A_
M1I]773+J]:)1Y=G8Q;Y9G)"JB@D $L0,L0J]6( )'C3P]6G:ZWVU3_+KY'U]
M''86OS\K^'5W332=[.S2=G9V:T=G;8NT5PFC?&/5[?Q[IWP[^)'@"70+S7(9
MI-"N$U&.[@NFB7?)"64*8Y0GS;2"I .&)&*[NIJ4JE)I2ZZK9I_-:%X?%4,5
M%NF]G9IIIIV3LTTFM&GJMFGLPHJ.\O+33K.74+^YC@@@C:2>:5PJQHHR6)/
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MS;,<=34*]1M=M%^5K_,\;*^%\@R6NZV#H*$WUNV_ES-V^5@HHHKSCWPHHHH
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M[O,[:)G5>(?BIJ,?C.Z\ > ?![:]J>FV,=WJX-^MM%:))N\J,NRMNFD"L53
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M?7RA_P $4O\ E'UX7_["VJ?^EDM?5]?KN4?\BNA_@C^1_*7%7_)38S_K[/\
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M"K'_ "CZ^)?_ &";?_TL@K\&Z_..,?\ D80_P?JS^A/"3_D05O\ KZ__ $B
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MH_\ I"**/^#WG_DUGX'_ /90-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\
M5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !1110 4444 %%%% 'YP_P#!
MQ%_R(_PN_P"PMJG_ **MJ_+6OU*_X.(O^1'^%W_86U3_ -%6U?EK7Y5Q/_R.
MJG_;O_I*/Z>\-_\ DC\/ZS_]+D%%%%> ?=!1110 4444 %%%% !7T+_P2G_Y
M2"_#3_L+7'_I'/7SU7T+_P $I_\ E(+\-/\ L+7'_I'/79EW_(PH_P"./YH\
MCB#_ )$.+_Z]5/\ TAG[QT445^T'\?!1110!\]_\%6/^4?7Q+_[!-O\ ^ED%
M?@W7[R?\%6/^4?7Q+_[!-O\ ^ED%?@W7YQQC_P C"'^#]6?T)X2?\B"M_P!?
M7_Z1 Y'XG^*=96(?#SP#,A\2ZO;L+>0C*:; ?E:]EQT5>=B]9' 4<!F74^'?
M@CP]\-/!6F_#_P +1[++2+5;>(,P+' R6;'\3$ECZEB:X/4_V3-!U'Q/J?BZ
M'XR_$:QO-7N/.OCIGBMK='(X5=L: ;5'RJ.PX%=?X)^%>E> ?!%SX*T7Q'K4
MK7;3//K-]?\ GWSRR#;YIE<'+J H4D$ (O!Q7@5?JRPZA3G?9O3KWOY;+Y]S
M[G"K,)X^5:O12T:B^9.T;[)6WEHY._1+6R9@?%"P3XWWS_!K3FWZ+!=1/XSO
ME/R[$995L$/>20A#)C[D?7F1:]$B\KRPL&W8OR@)T&.,?ATKQ_3_ -C+PQI-
MB=+TKXW_ !/M;8N[FWM_&DB1EG8LYVJH&68DD]R23UKNO$?PA\)>)OA4?@Y>
M->PZ.;&&T#6EVT<XCB*%3Y@YR2@R?XLG.<FG7^JM0A"HW%/^7ON]]7Y=DE?J
M+!+,E*K6K4$JC6GOW3M?EA\.B5W=ZZMNW11?&/X9/\4/#5I96&KC3]4TC5[;
M5=$OWA\Q(+N!LH73(W(061AD<.:\OUVX^)OQ=_:;\)^!]=M-%AT[P.QUOQ -
M%OY;E8[DQLELKO)%&$=BS,(@"0FYBQR,>VWWA_[3H2:!9:S?64:1K&)[68><
M4 QC>ZL<D=6'S=P0>:@\&>!?"GP_TIM'\):0MK%+.T]PYD:26XE;[TLLCDO*
MY[LQ).!S10Q:H4FMWJHZ;<RLW]VR[ZZ=3'95+&XF,E[L6XN=G\7(^:,;6[[O
M2\=+/3ES?&OPYT[6]>@\>V7BJ^T#5;&QDM7U6P,)WVK$.T<BSQNC*&4."1E3
MG!P6!\ETC3;[3?$'@O2?!E[<Z79^(M1OH="U&Z19KJ*T6*2ZNK\B52IN[QP,
M,ZD)">%!9U'N/BSPMIOC/17\/:T\ILYI$-U!$^T7"*P8Q/QS&V,,O&Y25/!(
M-;QMX T+QW96EOJC7%O/IUXMWIE_8R^7/9SJ"H>-L$?=9E*D%65B""#3P^+5
M.'+-W6JVVT=O75[=KKJQ8_*GB*KJ4E9JSW:<GS1<E_=O&-KK5RL]'!,Y_P"%
MGBGQ*_CKQ;\,/$NLOJI\.RV4MEJLT,:32P7,3.(Y1&JH71HW&Y57*E,C.2>[
MK#\$_#_1? R7TUC<75W>ZI=?:=4U34)0]Q=RA0BEB % 555550JJ!P!S6Y7+
MB)4YU;P6FGEK97?S=V>C@*=>EAE&L[N\NM[)R;BF^K4;)ORW9_2GX#_Y$?1O
M^P3;_P#HI:U:RO ?_(CZ-_V";?\ ]%+6K7[9#X$?QO5_BR]6%%%%49A7\UGC
MS_D>-9_["UQ_Z-:OZ4Z_FL\>?\CQK/\ V%KC_P!&M7P_&GP4/^WO_;3]H\'O
MXN-]*?\ [>95%%%?!G[@%%%% !1110 4444 %%%% '[<_P#!%+_E'UX7_P"P
MMJG_ *62U]7U\H?\$4O^4?7A?_L+:I_Z62U]7U^QY1_R*Z'^"/Y'\C<5?\E-
MC/\ K[/_ -*84445Z)X 5^(__!:W_E(+XH_[!.E_^D<5?MQ7XC_\%K?^4@OB
MC_L$Z7_Z1Q5\KQ?_ ,BN/^-?DS].\)_^2EG_ ->I?^E0/C#XE?$SP;\)?"<_
MC+QQK$5G9PD(F^15::0_=C3<0"Q]R !DD@ D<!\-OB9\(;KQ8?&6N?%;PUJG
MB_Q&T-C:Z9HNM0WK6%OOS':1")B2 27EDP S98X55"^G>(?"7A7Q=;QVGBOP
MSI^IQ1/OBBU"R294;&,@." <=ZI:1\+OAGX?U&/6-!^'>A6-W"3Y-U9Z1#%(
MF00<,J@C()''8FO@:57"PH.,D^9]K;=%]^Y^YXK#9E6QL)PE#V<;633;OU>C
M2O;2/;7Y7=<E\,7K)X4\2):3+J<;JEE>QADN0N"RX8;6."#MZXR<8!QYA\';
M6Q\._M!^,?!?PUACB\(6>EV<EU96@Q:6&KL\GF10*/ECS%L=T7@,02 3SZKK
M.AZ)XBT]])\0:/:W]K(1YEM>6ZRQMCIE6!!I=(T;1] L$TK0=*MK*UB_U=M:
M0+'&GT50 *BG7C3HRAJ^96MTW3OZ]/UZ&V(P4\1C*571<CO=?$U9KE]&W=][
M6M?4S],^(/@S6/&>I_#W3-?AFUK1X8I=2T]0V^!)5W(3D8.00>"<9&<9%><?
M%3XU?"OQ;X@O?@M>_%O0-&L8/W?BR]O-=@MI&0_>L8=[@EW&1)(.(U)4'>WR
M>LPZ5IEO?S:K;Z= EU<JJW%RD*B24+G:&8#+ 9.,],UAW'P=^$=W.]U=?"SP
MY++*Y>2230[=F=B<DDE.23WJZ%3"TZG-)/1*VV_5[?=^-S+'8?,\10]G"4-6
M[W4M8ZVCH[WM92?76R5])OA[XM\">+_#PG^&^I6EWI-C)]CMYM/P;?\ =JOR
MQ,ORLJ@A<KD J1V-<?J_P_\  NO>.;GP3X-\&Z781,@E\:ZG8V,<4DT3G>MA
MO4 YF/SR#/$?7F96'H>C:)HOAW3H]'\/Z1:V%I%GRK6SMUBC3)).%4 #))/U
M-2VUC961E:SLXH3/*99C%&%\QR "S8ZG ')YX%1&NJ524J=]=M?Q??\ S-JF
M#EB:%.%=1NM[+[U&][)[/^[===/FFYMM)3X#:EXY:&W7XG0>,I88+D ?;X]1
M&HF."T0_>$1@V*(A\AA8G&"37TW6>WA3PL^OKXK?PUIYU18]BZD;-/M 7&-H
MDQNQCC&:T*O%XI8BUEU;]+VT7DK:>IAE>6RR]RO)/W8QT5K\O-[[_O2O[WHM
M>WZ/_P#!N[_R/'Q1_P"P3I?_ *-N:_4FORV_X-W?^1X^*/\ V"=+_P#1MS7Z
MDU^D\,?\B6G_ -O?^E,_GCQ(_P"2PQ'I#_TB(4445[Y\*%%%% !1110 4444
M ?B#_P 'O/\ R:S\#_\ LH&H_P#I"**/^#WG_DUGX'_]E U'_P!(110!Y_\
M\&FW_*4S]KO_ +>/_3Y/7[_5^ /_  :;?\I3/VN_^WC_ -/D]?O]0 4444 %
M%%% !1110 4444 ?G#_P<1?\B/\ "[_L+:I_Z*MJ_+6OU*_X.(O^1'^%W_86
MU3_T5;5^6M?E7$__ ".JG_;O_I*/Z>\-_P#DC\/ZS_\ 2Y!1117@'W04444
M%%%% !1110 5]"_\$I_^4@OPT_["UQ_Z1SU\]5]"_P#!*?\ Y2"_#3_L+7'_
M *1SUV9=_P C"C_CC^:/(X@_Y$.+_P"O53_TAG[QT445^T'\?!1110!\]_\
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MM,+5E3E:UXR<7;M=-.Q^>/\ PXVT;_GS\"?]_-;_ /DVC_AQMHW_ #Y^!/\
MOYK?_P FU^AU%<O]EY9_SXA_X#'_ "/1_P!9>(_^@VK_ .#)_P"9^>/_  XV
MT;_GS\"?]_-;_P#DVC_AQMHW_/GX$_[^:W_\FU^AU%']EY9_SXA_X#'_ "#_
M %EXC_Z#:O\ X,G_ )GYX_\ #C;1O^?/P)_W\UO_ .3:/^'&VC?\^?@3_OYK
M?_R;7Z'44?V7EG_/B'_@,?\ (/\ 67B/_H-J_P#@R?\ F?GC_P .-M&_Y\_
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MU+3TE3QKXS$;1R6*L1F33M-21Q,N=DUW+Y9#+;R!ODK]J/\ X)[_ +"7AO\
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M@D\47]O<;8&EAMW^QZ#IBOB1[2RMDE"\;Y"+BYD"F1@GT17RI^RK_P $2?\
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MMS?"RX^"/[3WA35/$'A.\93?Z#9>+]4TJWO=LL<J"<6%S!YX62*-U$A8*RY
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M*!/#UO="2XLK:8R^5-<?Q&2=XIY#(_S2.)'.22:^;/B!_P &['_!(#XJ>/\
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M .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#X%S?_ !N@#Z_HKY _X?\ '_!&W_I(3\/_ /P+F_\ C='_  _X_P""-O\
MTD)^'_\ X%S?_&Z /K^BOD#_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
F%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>ebs-20220630_g7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ebs-20220630_g7.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB
M@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%'_![
MS_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4
MIG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!
M_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V
M\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;2?#GAW2_!FF:6U]J%_=:;'?2:K?/J-I<[XLS)'! @2-EC=GWDC;Z%_P2?\
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M.C__ ")1_P /B_\ @H[_ -'%_P#EHZ/_ /(E'^N.6?R3^Z/_ ,D'_$)>(_\
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MT?\ ^1*/^'Q?_!1W_HXO_P M'1__ )$H_P!<<L_DG]T?_D@_XA+Q'_S]I?\
M@4__ )6?N=17X8_\/B_^"CO_ $<7_P"6CH__ ,B4?\/B_P#@H[_T<7_Y:.C_
M /R)1_KCEG\D_NC_ /)!_P 0EXC_ .?M+_P*?_RL_<ZBOPQ_X?%_\%'?^CB_
M_+1T?_Y$H_X?%_\ !1W_ *.+_P#+1T?_ .1*/]<<L_DG]T?_ )(/^(2\1_\
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M^?"A1110 4444 %%%% 'X@_\'O/_ ":S\#_^R@:C_P"D(HH_X/>?^36?@?\
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M!_\ V4#4?_2$44 >?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\
MMX_]/D]?O]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKWSX4**** "BBB@ HHHH _$'_@]Y_P"36?@?_P!E U'_ -(111_P>\_\FL_
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MHZSX;FUZS\,P64\A6PB/S223*ABA;C(C=U=A@A2""?4Z "BO(?CM^W-^SO\
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MT^Z641^*-44,YP,L<9)]30!]VT444 %%%% !1110 5_-9X\_Y'C6?^PM<?\
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M]/\ "=W\2/B_KOCFT^'>D:@EW:>#+*],*6NCI-'^[E,,-O&&>/Y-S$*6"AF
M/%?VJ?V>O%OP_P#^"^G[&7QH\6_M,^._&8\3:M\1K;2_#'B$Z?'I?ANVC\,7
M4HBLH;.U@.3YH5I9FEE=88PSG:*^Z_VF?CN/@'\.DUC1/#QU[Q7KNHQZ-X$\
M+)/Y;ZWK$X8P6^[!\N)0DDTTN"(;>">4@B,BOFC]O#P?\;_$7_!3[]DSXS>
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M:/![^+C?2G_[>95%%%?!G[@%%%% !1110 4444 %%%% '[<_\$4O^4?7A?\
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MCB__ "T=8_\ D2OPQHKPO]<<S_DA]TO_ )(^U_XA+PY_S]J_^!0_^5G[G?\
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MC_T^3U^_U?@#_P &FW_*4S]KO_MX_P#3Y/7[_4 %%%% !1110 4444 %%%%
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M@G2__2.*OE>+_P#D5Q_QK\F?IWA/_P E+/\ Z]2_]*@?)]%%%?FI_104444
M%%%% !1110 4444 ?H__ ,&[O_(\?%'_ +!.E_\ HVYK]2:_+;_@W=_Y'CXH
M_P#8)TO_ -&W-?J37ZKPQ_R):?\ V]_Z4S^8?$C_ )+#$>D/_2(A1117OGPH
M4444 %%%% !1110!^(/_  >\_P#)K/P/_P"R@:C_ .D(HH_X/>?^36?@?_V4
M#4?_ $A%% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\
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M_P"C6KX?C3X*'_;W_MI^T>#W\7&^E/\ ]O,JBBBO@S]P"BBB@ HHHH ****
M"BBB@#]N?^"*7_*/KPO_ -A;5/\ TLEKZOKY0_X(I?\ */KPO_V%M4_]+):^
MKZ_8\H_Y%=#_  1_(_D;BK_DIL9_U]G_ .E,****]$\ *_$?_@M;_P I!?%'
M_8)TO_TCBK]N*_$?_@M;_P I!?%'_8)TO_TCBKY7B_\ Y%<?\:_)GZ=X3_\
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M/_!Q%_R(_P +O^PMJG_HJVK\M:_4K_@XB_Y$?X7?]A;5/_15M7Y:U^5<3_\
M(ZJ?]N_^DH_I[PW_ .2/P_K/_P!+D%%%%> ?=!1110 4444 %%%% !7T+_P2
MG_Y2"_#3_L+7'_I'/7SU7T+_ ,$I_P#E(+\-/^PM<?\ I'/79EW_ ",*/^./
MYH\CB#_D0XO_ *]5/_2&?O'1117[0?Q\%%%% 'SW_P %6/\ E'U\2_\ L$V_
M_I9!7X-U^\G_  58_P"4?7Q+_P"P3;_^ED%?@W7YQQC_ ,C"'^#]6?T)X2?\
MB"M_U]?_ *1 ****^2/U0**** "BBB@ HHHH **** /Z4_ ?_(CZ-_V";?\
M]%+6K65X#_Y$?1O^P3;_ /HI:U:_<H? C^*ZO\67JPHHHJC,*_FL\>?\CQK/
M_86N/_1K5_2G7\UGCS_D>-9_["UQ_P"C6KX?C3X*'_;W_MI^T>#W\7&^E/\
M]O,JBBBO@S]P"BBB@ HHHH **** "BBB@#]N?^"*7_*/KPO_ -A;5/\ TLEK
MZOKY0_X(I?\ */KPO_V%M4_]+):^KZ_8\H_Y%=#_  1_(_D;BK_DIL9_U]G_
M .E,****]$\ *_$?_@M;_P I!?%'_8)TO_TCBK]N*_$?_@M;_P I!?%'_8)T
MO_TCBKY7B_\ Y%<?\:_)GZ=X3_\ )2S_ .O4O_2H'R?1117YJ?T4%%%% !11
M10 4444 %%%% 'Z/_P#!N[_R/'Q1_P"P3I?_ *-N:_4FORV_X-W?^1X^*/\
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M117@'W04444 %%%% !1110 5]"_\$I_^4@OPT_["UQ_Z1SU\]5]"_P#!*?\
MY2"_#3_L+7'_ *1SUV9=_P C"C_CC^:/(X@_Y$.+_P"O53_TAG[QT445^T'\
M?!1110!\]_\ !5C_ )1]?$O_ +!-O_Z605^#=?O)_P %6/\ E'U\2_\ L$V_
M_I9!7X-U^<<8_P#(PA_@_5G]">$G_(@K?]?7_P"D0"BBBODC]4"BBB@ HHHH
M **** "BBB@#^E/P'_R(^C?]@FW_ /12UJUE> _^1'T;_L$V_P#Z*6M6OW*'
MP(_BNK_%EZL****HS"OYK/'G_(\:S_V%KC_T:U?TIU_-9X\_Y'C6?^PM<?\
MHUJ^'XT^"A_V]_[:?M'@]_%QOI3_ /;S*HHHKX,_< HHHH **** "BBB@ HH
MHH _;G_@BE_RCZ\+_P#86U3_ -+):^KZ^4/^"*7_ "CZ\+_]A;5/_2R6OJ^O
MV/*/^170_P $?R/Y&XJ_Y*;&?]?9_P#I3"BBBO1/ "OQ'_X+6_\ *07Q1_V"
M=+_](XJ_;BOQ'_X+6_\ *07Q1_V"=+_](XJ^5XO_ .17'_&OR9^G>$__ "4L
M_P#KU+_TJ!\GT445^:G]%!1110 4444 %%%% !1110!^C_\ P;N_\CQ\4?\
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M_/GX$_[^:W_\FU^AU%9_V7EG_/B'_@,?\C?_ %EXC_Z#:O\ X,G_ )GYX_\
M#C;1O^?/P)_W\UO_ .3:/^'&VC?\^?@3_OYK?_R;7Z'44?V7EG_/B'_@,?\
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MHH_LO+/^?$/_  &/^0?ZR\1_]!M7_P &3_S/SQ_X<;:-_P ^?@3_ +^:W_\
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M\#?V<]=GM[R]U+3TE3QKXS$;1R6*L1F33M-21Q,N=DUW+Y9#+;R!ODK]J/\
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MV5YXT\*07>K6=MGRH+]"T%VD>23Y8N(I0N3G:!GFO*_%G[!GCW7/^"YWA/\
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M+UH ^O;Z^L=,LY-0U*\BM[>%"\T\\@1$4=26/ 'N:+&_L=4LX]0TV\BN+>9
M\,\$@='4]"&'!'N*^??VN?\ @GC\+?V]?B)IME^UK]I\3?"_P_I"/I/PXBU>
MZM+*^UIYI?.OK];=XS<B*%;=+=&8HC2W+,I)0K\A_P#!+[X!S?\ !/S_ (+3
M?'+]@']FC7-7;X O\)=,\<6WA._U.:]M_".O7-ZD"6D#S,S()H1=2X)+,J1;
MBWEAJ /U#J.VN[2]1I+.ZCE5)&C=HG#!74E64XZ$$$$=B,5YE^UG\1OVG_AQ
M\,9K_P#9*_9RL_B1XMN4ECL=/U3Q9;Z196<FS]W-<22_,\>[&4C&XXQE<[A\
MP_\ !MSXW\??$S_@E-X9^(WQ6U/[;XHU_P >^,M1\1WG'[^_G\1ZA+</QQS(
MSGCCF@#[OHHHH **** "BBB@ HHHH **** /Q!_X/>?^36?@?_V4#4?_ $A%
M%'_![S_R:S\#_P#LH&H_^D(HH \__P"#3;_E*9^UW_V\?^GR>OW^K\ ?^#3;
M_E*9^UW_ -O'_I\GK]_J "BBB@ HHHH **** "BBB@#/\7>&[+QEX4U/PAJ3
MNMMJNG3V=PT9^8)+&R,1[X8U^4G_  ;X?'CQ!^Q?^R+\3?\ @FI\3OA5XAU[
MXR_L_?$6^M1\//#,$']HZ_INH7*RVNH6QNI881;/+-(6N))$BCB,3NX$J _K
M77B7[3?_  3J_8\_:\\7Z3\2OC9\)#+XNT&$PZ+XV\-Z[?:'KEG$<GRDU#39
MH+GR\LQ\LR%,LWR_,<@'YI_\%PO^"@-M_P % ?V38?\ @E!\*/@?XS\+?M"?
M%#XGZ-X?U'X4^---BCO])LH)H]1.K-+:R3V\U@?)BQ<Q2LFSS6./*?'Z!?&/
MXD>,O!F@:!_P3T_8ZUN*X^)I\)6EI=^))X!-;> ]%6(6XUN]7.#.PC<6EH3N
MN9E).(8IY$X;Q#_P1(_9X\(>-=+^/O[('Q)\9_"KXQ:1>2R+\5+CQ#=^*;_5
M+::,1S6.HKK<]Q]MM64*1&64QNBO&R'.[FU_X-P_^"97CS5-2^)'[4?P_P#$
MWQ3^(OB/4I]2\7^/M<^(6N6%QJMW+(SDBWL+V&""*,$111(F(XHT7+;=Q /J
M+]E7X/? #]DSX:Z-^QQ\$=1A1?!VB1W%QI\]\L^HR+<2RLVH7A^\TMU<"XD:
M5@/,D\TJ/E('J5>(?L3_ /!.']B__@G7H7B#P[^QS\%T\(6WBJ^AO/$!;7M0
MU&6]FB0I&6EOKB:0!59L*&"@NQQEB3[?0 $@#)-?(?CW1],_X*L^/K+P39@7
M7[.7@7Q/%>^(M2QN@^)>N6,X>'3[?M+I%I<QK)/-REU<0I"F8XIF?Z9^+WPH
M\$?'7X8:[\'/B597MSX?\2Z;+I^LVNG:S=:?-/;2#;)&+BTEBFC#+E24=202
M,X)%?%Z_\&R7_!$9+7["G[&MX(-FSR1\5O%6S;C&W']J8QCM0!]O>%O'/@WQ
MOX>/BWPAXHL-3TM;BY@.HV5TLD'F6\SP3KO!V_)+%(C<\%&':OEF]T/3_P#@
MJ3\5/#WC*\3S?V=?AOXDCUG1'E&(OB3XAM'/D7B@_?T:RE!>-C\M[<HLBY@@
M1KCV74?V(_V9=2_9#C_8/'P\GLOA5%X:@\/IX8TCQ%J%BW]FQ!0+<W=O.ET0
MP0"1C+NF#.)"XD<-\Q-_P;)?\$1GM?L+_L:WA@V;/)/Q6\5;-N,;<?VIC&.U
M 'W#X0\8^%/'_AZ#Q;X(\16>K:7=%Q:ZCI\ZRPS['9&*.N0XW*PR"0<<$BM*
ML3X9_#?P1\'/ASH'PD^&?AZ'2/#GA?1K72=!TJW9F2SL[>)8885+$L0L:*N6
M))QDDGFMN@ HHHH **** "ORI^$^JQ?\$[O^#DOXO:=\:%?3?"'[6?@K3M4^
M''B&:-C%=ZUID,<<VEA@,&=B;EEC&6;S+90"TR@_JM7GW[2O[*?[.G[8GPWD
M^$G[3?P@T;QEX?:X6XBLM6@):VG7(6>"5"LMO* 2!+$R. Q .": /DO]KG_@
MN)\//V4OA7XSOOVE_P!F'XG_  FU*7P3J.H_"V;QYIMBUIXRNTB AL8)+"[N
M?LUVSR1L;6Y$4JQEF91L=5XO_@C1X<U7_@DU_P $8OA;X.^.7A'5+KXD^-[^
M\U#P_P##.P0#5M6U34)9)[738HW(\N1;58I)WDVI;*LSRLB1,P]<^(__  07
M_P"">GQ-\,R:3X@T3XB7.JVEKL\)>)]8^,'B'5[[PG.KK)#=:8=2O;B.UFCD
M1&5@ASMVL&4LIQ?%?_!"/X!?M2^*H/B/_P %//BQXK_:&\2Z5I,6E>&;[4-1
MN?#%KI%HCN[F.UT6XMT:XF9QYTS??$40")MY /7_ -DWX":?^S3K&M_&;]I'
MQSHMY\:OCEX@@D\47]O<;8&EAMW^QZ#IBOB1[2RMDE"\;Y"+BYD"F1@GT17R
MI^RK_P $2?\ @F)^Q/\ &JS_ &B?V:OV9SH/C/3[&XL[#6[SQKK>IM;PSILE
M"1WU[-&I925W!=P#, 0&.?JN@ KYU_:L^,WQ ^*/BN[_ &&?V2O$C6?CW5=-
M1_''C>V020_#G1YP1]L<_=;4ID#BRM3R6_TB0"&([_HJOB;X@?\ !NQ_P2 ^
M*GC_ %OXI_$/]EW5]6\0^)-4FU'7=6NOBUXJ,U[=2L6>5R-3&22?H!@   "@
M#Z3_ &:OAK^S_P#LW?#S2OV0/@"-/L-/^'6@64">'K>Z$EQ96TQE\J:X_B,D
M[Q3R&1_FD<2.<DDU\Q_\')/_ "A'^/?_ & M-_\ 3Q8U[[^Q9_P3\_9"_P""
M>/@76/AO^Q[\'X_"&D:_K)U76(3K5]J,MW=F)(O,:>^GFEP$C4! ^P'<0H+,
M3J?M:_L9_L\_MS?"RX^"/[3WA35/$'A.\93?Z#9>+]4TJWO=LL<J"<6%S!YX
M62*-U$A8*RY &3D [KX?_P#(AZ)_V"+;_P!%+6O6#\,OAMX7^$7@C3_AYX+;
M5#I>EVZP62ZSK]YJ<Z1J JJ;B\EEF<   ;G-;U !1110 4444 %?!/\ P<S?
M"OX>_$O_ ((Q_%W5?''AJVOKKPG:6.M^&[J48DT^_CO8(EGB8<JQCFEC/JLK
M ]:^]J\H_:[_ &)/V;_V[?AK)\'/VI/"6K^(?"MPZ/>:!9^--6TJUO"DBR)Y
MZ:?=0"<+(B.HDW!64$8(H Y'_@DIX=T#PQ_P2Y_9WL/#>DV]G!<?!;PU?3QV
MT842W-SIL%S<3MC[SRS2R2NQY9Y&8DDDU\<?M?.@_P"#KW]DY"PS_P *-\1<
M9_Z=M<_P-?H9^S3^R_\ !K]D+X5Z=\$O@'H^KZ9X6TBW2WTG2=4\6ZEJRV,"
M9V0POJ%Q.\4:@X"*P4   8 QY7\0/^"1G[!WQ1_:?TS]M#QS\./%=[\4=%"K
MHOC%?BWXGAN=/C7S,0P"+452&']],#$BB,B5P5(=L@'R/_P4=(_XB6OV$ER,
MCPQXMR/^X?>U]*?\%R?VO/A3^Q__ ,$QOBWXC^(GB>SM=3\5>!]4\->#M*EF
M7[1JNJ7UK);0Q0Q_>DV&7S7VCY8XW8X K:^-W_!'7]@']HSXWZ?^TE\8_AQX
MQU;QWI%H;71O$Z?&7Q5:W6FP$R$Q6S6^IQBW0^=+E8PH/F-ZFE\"_P#!&_\
MX)Q^ _B[I?QZ7]GR?Q)XPT-E;1-=^(GC?6_%,VGLIW(\ UF]NEA=6 960!E8
M @@@&@"E_P $0/V=_&_[*O\ P2?^!_P1^).DS:?KVG^#Q>ZMIUTA66SGOKB:
M_:WD4\J\?VG8R]F4CM7U5110!\Z_M6?&;X@?%'Q5=_L,_LE>)#9^/=5TY'\<
M>-[91)#\.='G!'VQS]UM2F3>+*U/);-Q(!#$=_HG[-7PU_9__9N^'FE?L@?
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M\.>&WN9;A=$N_&FK:I;0RR/OD>)-0NIQ"78EFV;=Q))R2: /7**** "BBB@
MHHHH **** "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH
M&H_^D(HH \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"G
MR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$4
M4?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_
M '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^
M#WG_ )-9^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*
M9^UW_P!O'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!
MJ/\ Z0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_FM_X-W?VW?V3_P!B/_@I
M;^U-XI_:O^.FA^!=/UR\N[72;O7)75+J9-9G=D7:IY"\U^R?_#_C_@C;_P!)
M"?A__P"!<W_QN@#Z_HKY _X?\?\ !&W_ *2$_#__ ,"YO_C='_#_ (_X(V_]
M)"?A_P#^!<W_ ,;H ^OZ*^0/^'_'_!&W_I(3\/\ _P "YO\ XW1_P_X_X(V_
M])"?A_\ ^!<W_P ;H ^OZ*^0/^'_ !_P1M_Z2$_#_P#\"YO_ (W1_P /^/\
M@C;_ -)"?A__ .!<W_QN@#Z_HKY _P"'_'_!&W_I(3\/_P#P+F_^-T?\/^/^
M"-O_ $D)^'__ (%S?_&Z /K^BOD#_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\
MC_@C;_TD)^'_ /X%S?\ QN@#Z_HKY _X?\?\$;?^DA/P_P#_  +F_P#C='_#
M_C_@C;_TD)^'_P#X%S?_ !N@#Z_HKY _X?\ '_!&W_I(3\/_ /P+F_\ C='_
M  _X_P""-O\ TD)^'_\ X%S?_&Z /K^BOD#_ (?\?\$;?^DA/P__ / N;_XW
M1_P_X_X(V_\ 20GX?_\ @7-_\;H ^OZ*^0/^'_'_  1M_P"DA/P__P# N;_X
MW1_P_P"/^"-O_20GX?\ _@7-_P#&Z /K^BOD#_A_Q_P1M_Z2$_#_ /\  N;_
M .-T?\/^/^"-O_20GX?_ /@7-_\ &Z /K^BOD#_A_P ?\$;?^DA/P_\ _ N;
M_P"-T?\ #_C_ ((V_P#20GX?_P#@7-_\;H ^OZ*^0/\ A_Q_P1M_Z2$_#_\
M\"YO_C='_#_C_@C;_P!)"?A__P"!<W_QN@#Z_HKY _X?\?\ !&W_ *2$_#__
M ,"YO_C='_#_ (_X(V_])"?A_P#^!<W_ ,;H ^OZ*^0/^'_'_!&W_I(3\/\
M_P "YO\ XW1_P_X_X(V_])"?A_\ ^!<W_P ;H ^OZ*^0/^'_ !_P1M_Z2$_#
M_P#\"YO_ (W1_P /^/\ @C;_ -)"?A__ .!<W_QN@#Z_HKY _P"'_'_!&W_I
M(3\/_P#P+F_^-T?\/^/^"-O_ $D)^'__ (%S?_&Z /K^BOD#_A_Q_P $;?\
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M /K^BOD#_A_Q_P $;?\ I(3\/_\ P+F_^-T?\/\ C_@C;_TD)^'_ /X%S?\
MQN@#Z_HKY _X?\?\$;?^DA/P_P#_  +F_P#C='_#_C_@C;_TD)^'_P#X%S?_
M !N@#Z_HKY _X?\ '_!&W_I(3\/_ /P+F_\ C='_  _X_P""-O\ TD)^'_\
MX%S?_&Z /K^BOD#_ (?\?\$;?^DA/P__ / N;_XW1_P_X_X(V_\ 20GX?_\
M@7-_\;H ^OZ*^0/^'_'_  1M_P"DA/P__P# N;_XW1_P_P"/^"-O_20GX?\
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M])"?A_\ ^!<W_P ;H ^OZ*^0/^'_ !_P1M_Z2$_#_P#\"YO_ (W1_P /^/\
M@C;_ -)"?A__ .!<W_QN@#X _P"#WG_DUGX'_P#90-1_](117B?_  =I?\%'
M/V'?VW/V>/A)X6_90_:5\-^.M0T/QI?76K6FAS.[VL+V@17;<HX+<44 ?C9^
MUA_R=-\2_P#LH&L_^ETU<!110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>ebs-20220630_g8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ebs-20220630_g8.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
MRH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&
MN?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /Y/?^"PO_  2[_P""@?\ P1[^
M&W@[XD?$C_@HIKGC&#QCKD^FVUMH>OZK ]N\4(E+L99L$$'&!17Z"?\ ![S_
M ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y
M2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH _$'_@]Y_Y-9^!_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB
M@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9^!__ &4#4?\ TA%%'_![
MS_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O'_I\GK]_J_ '_@TV_P"4
MIG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!
M_P#V4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V
M\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'Y1?MW^*O^"6G_  6(^%?@SPW\<_$?@JP\3>'?CC>^#?&=U'K=
MI8^(?"T%JVJ0RLL\O[V&W=[>&X4L&A;*Y#$$#V?_ (-V/$W[06L_L1>)O#/Q
MF^+.I?$+PWX2^+WB#P]\'_B-J[,\WBCPG9R116E^LCDF:%Y1<B-RS?(H4$JB
MD_4/QI_8B_91_:$N/#=S\7?@)X4UIO"FL)J.CB]\/6LH211(/+8/&=T1,K,T
M?W2P5CR*]/T_3[#2;"'2]+LH;:UMHEBM[:WC"1Q1J,*BJ.%4   #@ 4 ?#__
M  5.U+3K+]OC]A.&\OX8GE^-^K^6DDH4O_Q(+M. >OS.B_5U'<5]9?M#_M$?
M!;]D_P"#>M_M!?M#^/K7POX.\.112:UKE['(\=L)9HX(\K$K.Q:66- %4DEP
M,5%\0_V8OV:_B[XD@\8_%?\ 9Z\#>)]7M55;75?$/A.SO;F$*<J%EFC9E (!
M&#QBNF\2^"O!OC/PO/X'\8>$M,U;1;J$0W6CZG81SVLT8((1HG4HR@@8!&.!
MZ4 4-7^+?PUT#PAIGQ!UOQG8VN@ZN]JMAK4\FVU?[2!]G+2GY(UD+(JLY4,\
MB(#N=0?A_P")'PV^%?[,_P#P6$^ '@S]@_P1HGA/5/&NE>(Y_CWX1\#V$5GI
MUWX<AL=UCJFI6MN%BCG34&CBM[EE$DAEEBW,F0/OF^T;1]4TB;P_J6E6UQ87
M%NUO/8SP*\,D3+M,;(1M*E3@J1@CBN?^%WP,^"?P.L;K3/@K\'O"W@^VOI1+
M>V_A;P];:?'<2 8#NL"*'8 ]3DT =31110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M ":-\,_^Q%TO_P!)8Z],KS)+EDT?1TY\]-2[JX4444BPHHHH **** "BBB@
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M$=\*_P#A/6W_ ,17N4L?[*FH\NWG_P  ^)Q61_6<1*K[2U_+_@GX(45^]_\
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M^(H_X>D?\$^?^CK/"O\ X$2?_$5^,=%']F_W_P /^"'^L7_3K_R;_@'[.?\
M#TC_ ()\_P#1UGA7_P ")/\ XBC_ (>D?\$^?^CK/"O_ ($2?_$5\I?\$1/
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M?JE^9[A_P](_X)\_]'6>%?\ P(D_^(H_X>D?\$^?^CK/"O\ X$2?_$5\W_\
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MO?\ D_OX8_\ 8?;_ -$2U^]M?HO!W^X5/\7Z(_G[Q<_Y'E#_ *]_^W2/ _\
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M(H/%?AK3K;Q!H5S&NU-=\.W<DD4-VJ]%E@N(IK6=!P&2&4!%N4C0 ]9HHHH
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M%?D]_P '"O\ R7?P#_V*,W_I4]?K#7Y/?\'"O_)=_ /_ &*,W_I4]?/<4?\
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M0BB@#S__ (--O^4IG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H
M**** "BBB@#\4?\ @MY_R?WK7_8OZ9_Z(%?(M?77_!;S_D_O6O\ L7],_P#1
M KY%K\<SC_D:U_\ $_S/ZXX3_P"29P?_ %[A^2"BBBO./H HHHH _I)^%/\
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M\ _]BC-_Z5/7ZPU^3W_!PK_R7?P#_P!BC-_Z5/7SW%'_ ")I^L?S1]]X9_\
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M_K7U_!O^_5/\/ZH_)O%W_D38?_KY_P"VL]LHHHK]%/P **** "BBB@ HHHH
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MT^&V\[9M\SRT";L9.,XSC)QZU?HHKW$DE9'Q4I.4G)[L****8@HHHH ****
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M_2IZ_6&OR>_X.%?^2[^ ?^Q1F_\ 2IZ^>XH_Y$T_6/YH^^\,_P#DKJ7^&?\
MZ2S\^****_+#^F@HHHH *_?S_@G!_P F*?"W_L4;;^M?@'7[^?\ !.#_ ),4
M^%O_ &*-M_6OK^#?]^J?X?U1^3>+O_(FP_\ U\_]M9[91117Z*?@ 4444 %%
M%% !1110 4444 %%%% 'X@_\'O/_ ":S\#_^R@:C_P"D(HH_X/>?^36?@?\
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MOGN*/^1-/UC^:/OO#/\ Y*ZE_AG_ .DL_/BBBBORP_IH**** "OW\_X)P?\
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M20 ?;GQJ^$_A/X\?![Q5\$?'EFMQHGC#PY>Z+JT+*"'MKJ!X9!@]]KFO O\
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M>_\ VZ04445]>?E 4444 %%%% !1110 4444 %?D]_P<*_\ )=_ /_8HS?\
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M^1-A_P#KY_[:SVRBBBOT4_  HHHH **** "BBB@ HHHH **** /Q!_X/>?\
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M;_E*9^UW_P!O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#S']M#6OCGX<_94\>:_\ LR^'9M8^(5EX<GF\&Z3 RJU[J*@&&#+$*H=P
M%+,0 "22 ":_-/\ X*,ZKJ'_  4.U_Q_^SGXO_X)??%&]^)/BCX!6ND^%O#W
MB'P_9&#POX@.H7I@U0ZPEPUI':P2N&-Q%*3*D;Q[#N:.OUZJ :9IHU)M9&G0
M"\: 0M=B%?-,08L$+8SM!).,XR2: /@#_@HU^RW\3_A=_P $*O#_ ,-Y-5F\
M7>+_ ( ^'/!6OWUY;;G;57\-SV,]]*F[YFW6]M=.N?F)VYY)K[WT#Q/H/BGP
MO9>,_#>I)?:7J-A'>V%Y:@R+<6\B"1)$P,L&4@C'7(JY=6MM?6TEE>V\<T,T
M926*5 RNI&"I!X((X(-<;\ ?@MI7[//PYMO@[X1U&27PSHDC0^$[&<$OI6G9
MS%IX;/SQ0 F*$\%85BC;<8S(X!\F_P#!,D^,=._;Q_:Z\2>*_@YX_P##VD_$
M'XDZ7J_@K5_$O@/4M/M-6L[?1X+.61)9X%5")86PDA1F#*5!&<=%^T'\,_B=
M\ /^"IGAO_@HGH?PPU[QGX(USX+2_#?QS:^$].:_U/P\\.JG4[+4DLX\SW<#
MM+/!*ENKRH3$^QE#$?8M% 'R!^RC\*?BI\7O^"D7Q._X*+^-_AIK7@KPO>_#
M;1_A[\.M'\2VOV74]7L[6\N;^ZU2YM"=]HK3W BACFVS%(V9XX\J#[;\&_CO
M\5/B3\>/BC\*/&G[,?B+P?H'@2^TV#PMXXU6]ADL_&27%NTLTMJB#=&(&54;
M<6R77E6#(OJ5% 'PG\%8OCA_P3-U#XX?!'P[^S+XS^(&F^+?B)K'CCX&W/A#
M23<V5U-JY6>;1+V8'9I7V>_,S?:+EHX6MYE97+H\=>Z_\$S/V2]8_8>_8<\
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M+BXL/"7AR]U>[M;1-TUPEO \IBC49+2/LVJH!)9@ "37P%_P<0?LF?L^:U\
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MX<\$Z'+J.H"  RW!&%BMX@2 9996CB0$@%Y%!('- 'HM%?GW^QIX+_X*9_\
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M/XK^-Z>!+!M8\<_"OXM^'-$\K7M,A&^[:PNM+L+2>RGCB$DB(3*K;<%6("L
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M[;'P>_;#U#]H'P'X)C6^^)'PN^*7A31[2^ETI6 N+RPU'2+*U,<D2$N4EC=
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M%QL\4ZY!X)_MFZU&PVX:RC/VVV^SI(>)&&YG3*?*K-N /-8?!%I_P4I_;?\
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M=(^'/AE?%'Q-\8S2:7\,?!"2[7U?4MA;S)2/]396Z_OKFX/RQ1*>KM&CY?\
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M$;?^DA/P_P#_  +F_P#C= 'U_17R!_P_X_X(V_\ 20GX?_\ @7-_\;H_X?\
M'_!&W_I(3\/_ /P+F_\ C= 'U_17R!_P_P"/^"-O_20GX?\ _@7-_P#&Z/\
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M !NC_A_Q_P $;?\ I(3\/_\ P+F_^-T ?7]%?('_  _X_P""-O\ TD)^'_\
MX%S?_&Z/^'_'_!&W_I(3\/\ _P "YO\ XW0!]?T5\@?\/^/^"-O_ $D)^'__
M (%S?_&Z/^'_ !_P1M_Z2$_#_P#\"YO_ (W0!]?T5\@?\/\ C_@C;_TD)^'_
M /X%S?\ QNC_ (?\?\$;?^DA/P__ / N;_XW0!]?T5\@?\/^/^"-O_20GX?_
M /@7-_\ &Z/^'_'_  1M_P"DA/P__P# N;_XW0!]?T5\@?\ #_C_ ((V_P#2
M0GX?_P#@7-_\;H_X?\?\$;?^DA/P_P#_  +F_P#C= 'U_17R!_P_X_X(V_\
M20GX?_\ @7-_\;H_X?\ '_!&W_I(3\/_ /P+F_\ C= 'U_17R!_P_P"/^"-O
M_20GX?\ _@7-_P#&Z/\ A_Q_P1M_Z2$_#_\ \"YO_C= 'U_17R!_P_X_X(V_
M])"?A_\ ^!<W_P ;H_X?\?\ !&W_ *2$_#__ ,"YO_C= 'U_17R!_P /^/\
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M= 'U_17R!_P_X_X(V_\ 20GX?_\ @7-_\;H_X?\ '_!&W_I(3\/_ /P+F_\
MC= 'U_17R!_P_P"/^"-O_20GX?\ _@7-_P#&Z/\ A_Q_P1M_Z2$_#_\ \"YO
M_C= 'U_17R!_P_X_X(V_])"?A_\ ^!<W_P ;H_X?\?\ !&W_ *2$_#__ ,"Y
MO_C= 'U_17R!_P /^/\ @C;_ -)"?A__ .!<W_QNC_A_Q_P1M_Z2$_#_ /\
M N;_ .-T ?7]%?('_#_C_@C;_P!)"?A__P"!<W_QNC_A_P ?\$;?^DA/P_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
JHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>ebs-20220630_g9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ebs-20220630_g9.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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M_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\
M27;_ ,J&N?\ QZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV
M_P#*AKG_ ,>H_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_ )-9
M^!__ &4#4?\ TA%%'_![S_R:S\#_ /LH&H_^D(HH \__ .#3;_E*9^UW_P!O
M'_I\GK]_J_ '_@TV_P"4IG[7?_;Q_P"GR>OW^H **** "BBB@ HHHH ****
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MZOJ=C(/&_C)[FZ%WJ5W:+,UW#%?W]O=K!<2!MQ\E2L:-&3]'^#_V0/&^N_\
M!03Q%^V_\?/$VE:K%H?AQ/#/P2\.Z>973PWI\P634[V8R(H-]=S*B%HQA+>!
M(]S;FKP_X7_\$O\ ]IKPK9?#+]E3Q3\0O LGP(^#OQ?_ .$[\*:E8F]/B?4T
MM[ZYU#3-*NH7C%K"EO<W";[E)7:9+6,>5&7=J /O6BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _$'_@]Y_Y-9^!_P#V
M4#4?_2$44?\ ![S_ ,FL_ __ +*!J/\ Z0BB@#S_ /X--O\ E*9^UW_V\?\
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M%/BZ]N;C6_B%XOO)&:77O$%X_G7UX=W*H96*1I@;(HXU_AH ]EHHHH ****
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M<V!YDTCG)(554!515554>B4 %%%% !1110 4444 %%%% !1110!^3G_!?/\
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MH3Z<?$8ENKK3))6@MY]Z,/+<2G?LPW'RL*]B^*O[%?[5O_!07]D/X@?LM?\
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MFPO0@+B(2%G25 S1,\AV.'*U^%__ !"9_P#!:S_A._\ A$?^%#^%_P"S_/\
M+_X2G_A86F_8-N?]9L\W[5M[_P"HW>U !_P::?\ "=?\/K? 7_"(^?\ V?\
M\(QXA_X2CRL[?L']F3;-^/X?M?V3K_%M]J_K6K\^?^"$/_!"'P#_ ,$@O .K
M>,?&/BVS\7_%SQ?9I;>)/$=C R6>GV:L'%A9!P',1D"N\KA6E9(SL0(%K]!J
M "BBB@ HHHH **** "BBB@ HHHH _,__ (.+/^/3X0?]=->_EIU?F/7Z<?\
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M_A! [5Z;110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M ,M'6/\ Y$H_X?%_\$XO^CB__+1UC_Y$KX\_XAZ/C;_T<'X5_P#!=<_X4?\
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MJ4:D,-=22:]^GL]5]L_;"BOQ/_X??_\ !0;_ *'+PK_X2<?_ ,71_P /O_\
M@H-_T.7A7_PDX_\ XNI_UER3_G[_ .2R_P C3_B'7&7_ $"_^3T__DS]L**_
M$_\ X??_ /!0;_H<O"O_ (2<?_Q='_#[_P#X*#?]#EX5_P#"3C_^+H_UER3_
M )^_^2R_R#_B'7&7_0+_ .3T_P#Y,_;"BOQ/_P"'W_\ P4&_Z'+PK_X2<?\
M\71_P^__ ."@W_0Y>%?_  DX_P#XNC_67)/^?O\ Y++_ "#_ (AUQE_T"_\
MD]/_ .3/VPHK\3_^'W__  4&_P"AR\*_^$G'_P#%T?\ #[__ (*#?]#EX5_\
M)./_ .+H_P!9<D_Y^_\ DLO\@_XAUQE_T"_^3T__ ),_;"BOQ/\ ^'W_ /P4
M&_Z'+PK_ .$G'_\ %U]2?L/_ !T_X*D_MP_"S4OBGX1_:"^'FAV^F^()-*DM
M=1\$M([ND$$Q<%'QC$X'KE373A,ZRS'5O94*EY=K27YI'G9IP?Q'DV$>)QE#
MD@FE?F@]7MI&3?X'Z&45\L_\*G_X*Y?]':?"S_P@Y?\ XNC_ (5/_P %<O\
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M6?@?_P!E U'_ -(111_P>\_\FL_ _P#[*!J/_I"** //_P#@TV_Y2F?M=_\
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ME7#_  3_ "/A2BBBOR\_I4**** "BBB@ HHHH **** /N/\ X( _\GG>(/\
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M_P 'O/\ R:S\#_\ LH&H_P#I"** //\ _@TV_P"4IG[7?_;Q_P"GR>OW^K\
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MBBB@ HHHH **** "BBB@#\0?^#WG_DUGX'_]E U'_P!(111_P>\_\FL_ _\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '\]'[;_\ R>=\6O\
MLI.N?^E\U>75ZC^V_P#\GG?%K_LI.N?^E\U>75^)8K_>JG^)_F?V5E?_ "+*
M'^"/_I*"BBBL#N"BBB@ HHHH **** "OU]_X-^?^30/%/_92;K_TWV%?D%7Z
M^_\ !OS_ ,F@>*?^RDW7_IOL*^DX4_Y&Z]&?GOB?_P DI/\ QP_,^ZZ***_4
M#^:0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /Q!_X/>?\ DUGX'_\ 90-1_P#2$44?\'O/_)K/P/\ ^R@:C_Z0BB@#S_\
MX--O^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH *
M*** "O(/V@OV"_V3_P!J;QA:^/?CQ\*?[=U:RTU-/MKO^W;^UV6ZR22*FVWG
MC4X>60Y()^;&<  >OT5E5HT:\.2K%279JZ_$Z,+C,7@:OM<-4E"7>+<7]ZLS
MYE_X<Z?\$XO^C=/_ "[M8_\ DNC_ (<Z?\$XO^C=/_+NUC_Y+KZ:HKE_LO+/
M^?$/_ 8_Y'I_ZR\1_P#0;5_\&3_S/F7_ (<Z?\$XO^C=/_+NUC_Y+H_X<Z?\
M$XO^C=/_ "[M8_\ DNOIJBC^R\L_Y\0_\!C_ )!_K+Q'_P!!M7_P9/\ S/F7
M_ASI_P $XO\ HW3_ ,N[6/\ Y+H_X<Z?\$XO^C=/_+NUC_Y+KZ:HH_LO+/\
MGQ#_ ,!C_D'^LO$?_0;5_P#!D_\ ,^9?^'.G_!.+_HW3_P N[6/_ )+H_P"'
M.G_!.+_HW3_R[M8_^2Z^FJ*/[+RS_GQ#_P !C_D'^LO$?_0;5_\ !D_\SYE_
MX<Z?\$XO^C=/_+NUC_Y+H_X<Z?\ !.+_ *-T_P#+NUC_ .2Z^FJ*/[+RS_GQ
M#_P&/^0?ZR\1_P#0;5_\&3_S/'O@!^P-^R7^RYXSN/B%\"?A/_86L76FOI\]
MY_;M_=;K=Y(Y&39<3R*,M%&<@9^7&<$Y]AHHKJI4:-"')2BHKLDDOP/-Q6,Q
M>.J^UQ-24Y=Y-R?WN["BBBM3F"BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH ^>?''_!*C]@CXD>,]6^(7C3X#_;=8UW4I]0U
M6\_X2C5(_/N)I&DD?9'=*JY9B<* !G  %9?_  YT_P""<7_1NG_EW:Q_\EU]
M-45PO+,MD[NC"_\ A7^1[,.(^(:<5&.,JI+1)5)Z?B?,O_#G3_@G%_T;I_Y=
MVL?_ "71_P .=/\ @G%_T;I_Y=VL?_)=?35%+^R\L_Y\0_\  8_Y%?ZR\1_]
M!M7_ ,&3_P SYE_X<Z?\$XO^C=/_ "[M8_\ DNC_ (<Z?\$XO^C=/_+NUC_Y
M+KZ:HH_LO+/^?$/_  &/^0?ZR\1_]!M7_P &3_S/F7_ASI_P3B_Z-T_\N[6/
M_DNC_ASI_P $XO\ HW3_ ,N[6/\ Y+KZ:HH_LO+/^?$/_ 8_Y!_K+Q'_ -!M
M7_P9/_,^9?\ ASI_P3B_Z-T_\N[6/_DNC_ASI_P3B_Z-T_\ +NUC_P"2Z^FJ
M*/[+RS_GQ#_P&/\ D'^LO$?_ $&U?_!D_P#,^9?^'.G_  3B_P"C=/\ R[M8
M_P#DNO7_ -GW]FCX)?LL^#[KP%\!_!7]A:3>ZD^H7-I_:5S=;[AHXXV?=<22
M,,I%&, @?+G&22>[HK6E@<%0GSTJ48ONHI/\$<^*SK.,=2]EB<34G'M*<I+[
MFV@HHHKJ/,"BBB@ HHHH **** "BBOAGQS_P27OOVX_VL_B+\7_^"H&LCQQ\
M/;2^M[#X'_"O1?%FH6^BZ7IJP*9M0O8(3 9M0FE+;MQD5 N%9P(]@!]S45^9
M?[!^MV?[!'_!37]H[]B+X5?$;Q%K?[/WPZ^$.F^.3HFN:W/JG_" :I(6:32K
M:XN'>58IK56N5AD<XV@CG>S8W_!._P#X)U_ O_@K=^RO9?\ !1K_ (*3>'=7
M\<_$#XO7NH:OX>BE\5ZA;6_@32/M4T-A8:2EM-&MOLAC24S!?,>20EF;DD _
M4VBOQJLOVBOCK8_L2_%[]A+]HKXOZ_X@TS]GO]J/POX,^)WQ"NM2DCU*_P#A
M;>:K:R&ZOKF,JX;[&9(;F92#]G#EF/SL>[\%_M:_"7]@SXA_M(:/_P $]],T
MCQ5X#OW\%^'_ ()>!O"FIK<Z)>_$S4XKY+C3M/:-S$D8@73KN\6-@L2I(YVN
MS9 /U:HKQK]@G]E6Z_8]_9KTCX5^)_&MSXI\77MS<:W\0O%]Y(S2Z]X@O'\Z
M^O#NY5#*Q2-,#9%'&O\ #7LM !1110 4444 %%%% !1110!^(/\ P>\_\FL_
M _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\ TA%% 'G_ /P:;?\ *4S]KO\
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M )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\4=,^-OQS^).K?&;Q#H=TESHEEK&C1:=HUO.AW),]DLDS3NI *B25H\C)0D
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH _$'_ (/>?^36?@?_ -E U'_TA%%'_![S_P FL_ __LH&H_\ I"** //_
M /@TV_Y2F?M=_P#;Q_Z?)Z_?ZOP!_P"#3;_E*9^UW_V\?^GR>OW^H *S_%?B
MOPYX&\.7?BWQ;J\-AIMA"9;R\G.$B3IN..W-:%17UA8ZI:2:?J=E%<6\J[98
M)XPZ./0J>"* /+?^&Y_V1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\
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M?#/_ *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?]D?_ *+UH/\
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MFNZ_X5=\,_\ HG>A?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@#A?^&Y_V1_\
MHO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\ ^)KNO^%7?#/_ *)WH7_@HA_^
M)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?]D?_ *+UH/\ W^?_ .)H_P"&Y_V1
M_P#HO6@_]_G_ /B:[K_A5WPS_P"B=Z%_X*(?_B:/^%7?#/\ Z)WH7_@HA_\
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MX*(?_B:/^%7?#/\ Z)WH7_@HA_\ B: .%_X;G_9'_P"B]:#_ -_G_P#B:/\
MAN?]D?\ Z+UH/_?Y_P#XFNZ_X5=\,_\ HG>A?^"B'_XFC_A5WPS_ .B=Z%_X
M*(?_ (F@#A?^&Y_V1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\ ^)KN
MO^%7?#/_ *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?]D?_ *+U
MH/\ W^?_ .)H_P"&Y_V1_P#HO6@_]_G_ /B:[K_A5WPS_P"B=Z%_X*(?_B:/
M^%7?#/\ Z)WH7_@HA_\ B: .%_X;G_9'_P"B]:#_ -_G_P#B:/\ AN?]D?\
MZ+UH/_?Y_P#XFNZ_X5=\,_\ HG>A?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@
M#A?^&Y_V1_\ HO6@_P#?Y_\ XFC_ (;G_9'_ .B]:#_W^?\ ^)KNO^%7?#/_
M *)WH7_@HA_^)H_X5=\,_P#HG>A?^"B'_P")H X7_AN?]D?_ *+UH/\ W^?_
M .)H_P"&Y_V1_P#HO6@_]_G_ /B:[K_A5WPS_P"B=Z%_X*(?_B:/^%7?#/\
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M%_X;G_9'_P"B]:#_ -_G_P#B:/\ AN?]D?\ Z+UH/_?Y_P#XFNZ_X5=\,_\
MHG>A?^"B'_XFC_A5WPS_ .B=Z%_X*(?_ (F@#A?^&Y_V1_\ HO6@_P#?Y_\
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M2?\ !0W5] _X*R^'O^"8J? .]GM==^$$WCEOB"NL@1VXCO)K;[.;7RCN7=$
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MT*J8SGWJ@ HHHH **** "BBB@#\0?^#WG_DUGX'_ /90-1_](111_P 'O/\
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M%?$.CV&C6/C+PQ+;ZI+>W%]/;RI<_P!JA(HQ]IC23?AU(8JKB@#0_P"#5/\
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ME,_:[_[>/_3Y/7[_ %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'X@_P#![S_R:S\#_P#LH&H_^D(HH_X/>?\ DUGX'_\
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M** #_AK#]J;_ *.5^('_ (65]_\ ':/^&L/VIO\ HY7X@?\ A97W_P =HHH
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M #_AK#]J;_HY7X@?^%E??_':/^&L/VIO^CE?B!_X65]_\=HHH /^&L/VIO\
MHY7X@?\ A97W_P =H_X:P_:F_P"CE?B!_P"%E??_ !VBB@ _X:P_:F_Z.5^(
M'_A97W_QVC_AK#]J;_HY7X@?^%E??_':** #_AK#]J;_ *.5^('_ (65]_\
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MK#]J;_HY7X@?^%E??_':** #_AK#]J;_ *.5^('_ (65]_\ ':/^&L/VIO\
MHY7X@?\ A97W_P =HHH /^&L/VIO^CE?B!_X65]_\=H_X:P_:F_Z.5^('_A9
M7W_QVBB@ _X:P_:F_P"CE?B!_P"%E??_ !VC_AK#]J;_ *.5^('_ (65]_\
M':** #_AK#]J;_HY7X@?^%E??_':/^&L/VIO^CE?B!_X65]_\=HHH Q/&_QC
H^+OQ-M8+'XD?%3Q)XA@M9#);0ZYKEQ=I"Y&"RB5V"DCC(HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018607200592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jul. 26, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-33137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EMERGENT BIOSOLUTIONS INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">14-1902018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">400 Professional Drive Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Gaithersburg,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">631-3200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EBS<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,861,509<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001367644<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018608472960">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 358.1<span></span>
</td>
<td class="nump">$ 576.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">175.0<span></span>
</td>
<td class="nump">274.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">425.5<span></span>
</td>
<td class="nump">350.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">125.4<span></span>
</td>
<td class="nump">70.3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,084.2<span></span>
</td>
<td class="nump">1,272.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">798.4<span></span>
</td>
<td class="nump">800.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">576.6<span></span>
</td>
<td class="nump">604.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">224.9<span></span>
</td>
<td class="nump">224.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">51.3<span></span>
</td>
<td class="nump">57.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,735.4<span></span>
</td>
<td class="nump">2,959.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">106.2<span></span>
</td>
<td class="nump">128.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">40.3<span></span>
</td>
<td class="nump">51.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">74.4<span></span>
</td>
<td class="nump">88.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Debt, current portion</a></td>
<td class="nump">31.6<span></span>
</td>
<td class="nump">31.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">24.2<span></span>
</td>
<td class="nump">72.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">276.7<span></span>
</td>
<td class="nump">373.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt, net of current portion</a></td>
<td class="nump">793.6<span></span>
</td>
<td class="nump">809.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">93.4<span></span>
</td>
<td class="nump">94.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">58.5<span></span>
</td>
<td class="nump">61.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">1,222.2<span></span>
</td>
<td class="nump">1,340.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 200.0 shares authorized, 55.5 and 55.1 shares issued; 49.9 and 51.3 shares outstanding, respectively</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, at cost, 5.6 and 3.8 common shares, respectively</a></td>
<td class="num">(227.7)<span></span>
</td>
<td class="num">(152.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">849.2<span></span>
</td>
<td class="nump">829.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss, net</a></td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">897.7<span></span>
</td>
<td class="nump">957.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">1,513.2<span></span>
</td>
<td class="nump">1,619.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 2,735.4<span></span>
</td>
<td class="nump">$ 2,959.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018608240288">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000.0<span></span>
</td>
<td class="nump">200,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">55,500,000<span></span>
</td>
<td class="nump">55,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">49,900,000<span></span>
</td>
<td class="nump">51,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock (in shares)</a></td>
<td class="nump">5,600,000<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018603133488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 242.7<span></span>
</td>
<td class="nump">$ 397.5<span></span>
</td>
<td class="nump">$ 550.2<span></span>
</td>
<td class="nump">$ 740.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">49.8<span></span>
</td>
<td class="nump">48.9<span></span>
</td>
<td class="nump">96.2<span></span>
</td>
<td class="nump">101.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">81.1<span></span>
</td>
<td class="nump">91.2<span></span>
</td>
<td class="nump">165.9<span></span>
</td>
<td class="nump">172.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">14.0<span></span>
</td>
<td class="nump">15.1<span></span>
</td>
<td class="nump">28.0<span></span>
</td>
<td class="nump">30.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">314.7<span></span>
</td>
<td class="nump">383.0<span></span>
</td>
<td class="nump">615.8<span></span>
</td>
<td class="nump">630.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="num">(72.0)<span></span>
</td>
<td class="nump">14.5<span></span>
</td>
<td class="num">(65.6)<span></span>
</td>
<td class="nump">109.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(7.8)<span></span>
</td>
<td class="num">(8.6)<span></span>
</td>
<td class="num">(16.0)<span></span>
</td>
<td class="num">(17.1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other, net</a></td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
<td class="num">(5.0)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="num">(10.8)<span></span>
</td>
<td class="num">(7.3)<span></span>
</td>
<td class="num">(21.0)<span></span>
</td>
<td class="num">(17.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before income taxes</a></td>
<td class="num">(82.8)<span></span>
</td>
<td class="nump">7.2<span></span>
</td>
<td class="num">(86.6)<span></span>
</td>
<td class="nump">92.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income taxes</a></td>
<td class="nump">26.4<span></span>
</td>
<td class="num">(2.6)<span></span>
</td>
<td class="nump">26.5<span></span>
</td>
<td class="num">(18.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (56.4)<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="num">$ (60.1)<span></span>
</td>
<td class="nump">$ 74.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Net income (loss) per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (1.13)<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (1.13)<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Shares used in computing net income (loss) per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">53.6<span></span>
</td>
<td class="nump">50.3<span></span>
</td>
<td class="nump">53.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">54.0<span></span>
</td>
<td class="nump">50.3<span></span>
</td>
<td class="nump">54.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Services</a></td>
<td class="nump">$ 237.2<span></span>
</td>
<td class="nump">$ 181.2<span></span>
</td>
<td class="nump">$ 474.3<span></span>
</td>
<td class="nump">$ 319.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">91.0<span></span>
</td>
<td class="nump">81.2<span></span>
</td>
<td class="nump">171.3<span></span>
</td>
<td class="nump">133.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">Total contract development and manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total contract development and manufacturing</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="nump">190.9<span></span>
</td>
<td class="nump">59.0<span></span>
</td>
<td class="nump">374.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Services</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">103.6<span></span>
</td>
<td class="nump">54.5<span></span>
</td>
<td class="nump">171.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">78.8<span></span>
</td>
<td class="nump">146.6<span></span>
</td>
<td class="nump">154.4<span></span>
</td>
<td class="nump">193.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="num">(4.5)<span></span>
</td>
<td class="nump">87.3<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="nump">203.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Services</a></td>
<td class="nump">$ 7.3<span></span>
</td>
<td class="nump">$ 25.4<span></span>
</td>
<td class="nump">$ 16.9<span></span>
</td>
<td class="nump">$ 46.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018604865264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (56.4)<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="num">$ (60.1)<span></span>
</td>
<td class="nump">$ 74.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Foreign currency translation</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Unrealized gains (losses) on hedging activities</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income (loss), net of tax</a></td>
<td class="num">$ (53.2)<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="num">$ (50.1)<span></span>
</td>
<td class="nump">$ 77.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018607343280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (60.1)<span></span>
</td>
<td class="nump">$ 74.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income (loss) to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">22.2<span></span>
</td>
<td class="nump">21.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">75.4<span></span>
</td>
<td class="nump">61.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration, net</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCosts', window );">Amortization of deferred financing costs</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="num">(3.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">97.7<span></span>
</td>
<td class="num">(34.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(75.5)<span></span>
</td>
<td class="num">(79.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(19.4)<span></span>
</td>
<td class="num">(2.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(7.6)<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses and other liabilities</a></td>
<td class="num">(82.8)<span></span>
</td>
<td class="num">(55.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation</a></td>
<td class="num">(14.1)<span></span>
</td>
<td class="num">(21.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities:</a></td>
<td class="num">(52.9)<span></span>
</td>
<td class="num">(24.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows used in investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(64.3)<span></span>
</td>
<td class="num">(123.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities:</a></td>
<td class="num">(64.3)<span></span>
</td>
<td class="num">(123.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows used in financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of treasury stock</a></td>
<td class="num">(81.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfMediumTermNotes', window );">Principal payments on term loan facility</a></td>
<td class="num">(16.9)<span></span>
</td>
<td class="num">(11.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfConvertibleDebt', window );">Principal payments on convertible senior notes</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(10.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from share-based compensation activity</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid for share-based compensation activity</a></td>
<td class="num">(5.4)<span></span>
</td>
<td class="num">(13.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities', window );">Contingent consideration payments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities:</a></td>
<td class="num">(101.2)<span></span>
</td>
<td class="num">(26.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash, cash equivalents and restricted cash</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="num">(218.0)<span></span>
</td>
<td class="num">(173.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at beginning of period</a></td>
<td class="nump">576.3<span></span>
</td>
<td class="nump">621.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash at end of period</a></td>
<td class="nump">358.3<span></span>
</td>
<td class="nump">447.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">14.8<span></span>
</td>
<td class="nump">15.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid during the period for income taxes</a></td>
<td class="nump">20.0<span></span>
</td>
<td class="nump">50.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental information on non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, plant and equipment unpaid at period end</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">31.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash and cash equivalents and restricted cash at June&#160;30, 2022 and December&#160;31, 2021:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">358.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="nump">$ 358.3<span></span>
</td>
<td class="nump">$ 447.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfConvertibleDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfConvertibleDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfMediumTermNotes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfMediumTermNotes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018599791904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>$0.001 Par Value Common Stock</div></th>
<th class="th"><div>Treasury Stock</div></th>
<th class="th"><div>Additional Paid-In Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Retained Earnings</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 1,447.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="nump">$ 784.9<span></span>
</td>
<td class="num">$ (25.3)<span></span>
</td>
<td class="nump">$ 726.9<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">19.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">74.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">74.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">1,543.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="nump">804.4<span></span>
</td>
<td class="num">(22.4)<span></span>
</td>
<td class="nump">801.2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">1,522.8<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="nump">790.1<span></span>
</td>
<td class="num">(24.4)<span></span>
</td>
<td class="nump">796.6<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">14.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,200,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 1,543.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (39.6)<span></span>
</td>
<td class="nump">804.4<span></span>
</td>
<td class="num">(22.4)<span></span>
</td>
<td class="nump">801.2<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">51,300,000<span></span>
</td>
<td class="nump">55,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 1,619.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (152.2)<span></span>
</td>
<td class="nump">829.4<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
<td class="nump">957.8<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(60.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,800,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of stock</a></td>
<td class="num">(75.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (75.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">49,900,000<span></span>
</td>
<td class="nump">55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 1,513.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">849.2<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="nump">897.7<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2022</a></td>
<td class="nump">1,575.3<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (204.4)<span></span>
</td>
<td class="nump">834.8<span></span>
</td>
<td class="num">(9.3)<span></span>
</td>
<td class="nump">954.1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Beginning balance (in shares) at Mar. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,900,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based compensation activity (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based compensation activity</a></td>
<td class="nump">14.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(56.4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Repurchases of stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(700,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of stock</a></td>
<td class="num">(23.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (23.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income, net of tax</a></td>
<td class="nump">$ 3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="nump">49,900,000<span></span>
</td>
<td class="nump">55,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Jun. 30, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,600,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2022</a></td>
<td class="nump">$ 1,513.2<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (227.7)<span></span>
</td>
<td class="nump">$ 849.2<span></span>
</td>
<td class="num">$ (6.1)<span></span>
</td>
<td class="nump">$ 897.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018609483008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605787968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Business</a></td>
<td class="text">Business<div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions Inc. (the Company or Emergent) is a global life sciences company focused on providing</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (CDMO) services portfolio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is focused on the following five distinct PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; and acute/emergency care. The Company has a product portfolio of eleven products (vaccines, therapeutics and drug-device combination products) that contribute a substantial portion of its revenue. The Company has one product candidate that is procured under special circumstances by the U.S. government (USG), although it is not approved by the U.S. Food and Drug Administration (FDA). The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include a Government - Medical Countermeasures (MCM) business line, a Commercial business line and a Services line focused on CDMO.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The Company's products and services include:</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Government - MCM Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">AV7909</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, is a procured product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has largely switched from procuring BioThrax to AV7909 for the Strategic National Stockpile (SNS) prior to its approval by the FDA;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">BioThrax</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only vaccine licensed by the FDA, for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">ACAM2000</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">BAT</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of botulism; </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">CNJ-016</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, also referred to as VIGIV, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Raxibacumab injection, a fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Anthrasil</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">RSDL</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Trobigard</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174; </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">atropine sulfate, obidoxime chloride AUTO-INJECTOR, is a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA, but it is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure. </span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Ebanga&#8482; (ansuvimab-zykl, formerly referred to as mAb114) is a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#8482; in the United States and Canada, and Ridgeback Bio will serve as the global access partner for Ebanga&#8482;.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Commercial Products</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">NARCAN</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression; Recently, the Company licensed an authorized generic of naloxone nasal spray to Sandoz;</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Vaxchora</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Cholera Vaccine, Live, Oral), the only single-dose oral vaccine licensed by the FDA and the European Medicines Agency (EMA) for the prevention of cholera; and</span></div><div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt">Vivotif</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Services - Contract Development and Manufacturing </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's services line focused on CDMO offerings cover development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided across the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale.&#160;Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as two operating segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and a services segment (Services) focused on CDMO (Note 14, Segment information).</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pending Acquisition</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 15, 2022, the Company entered into an Asset Purchase Agreement (the &#8220;Purchase Agreement&#8221;), by and between the Company and Chimerix, Inc. (the &#8220;Seller&#8221;), pursuant to which the Company agreed to purchase from Seller its exclusive worldwide rights to brincidofovir, including TEMBEXA&#174; and related assets (the &#8220;Transaction&#8221;). TEMBEXA is a medical countermeasure for smallpox approved by the U.S. Food and Drug Administration in June 2021.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Purchase Agreement, the Company will pay $225.0&#160;million upon closing of the Transaction, plus up to $100.0&#160;million in up to four $25.0&#160;million milestone payments. The Purchase Agreement anticipates that the Seller will finalize its negotiations with the Biomedical Advanced Research and Development Authority (&#8220;BARDA&#8221;) and enter into a procurement contract (the &#8220;BARDA Contract&#8221;) with BARDA for TEMBEXA, which the Seller is currently negotiating. Each milestone payment is associated with the exercise of future BARDA procurement options of TEMBEXA following the BARDA Contract base period. The closing payment and the milestone payments may be adjusted upward or downward based on actual procurement value. The Seller is also eligible to receive up to $12.5&#160;million in regulatory milestones associated with the SymBio Pharmaceuticals Ltd. brincidofovir licensing arrangements to be assumed by the Company in the Transaction.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Seller may also earn a 20% royalty on future gross profit of TEMBEXA in the United States associated with volumes above 1.7&#160;million treatment courses of therapy during the exclusivity period of TEMBEXA. Outside of the United States, the Purchase Agreement also allows the Seller to earn a 15% royalty on all gross profit associated with TEMBEXA sales during the exclusivity period of TEMBEXA on a market-to-market basis.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The closing is subject to the execution by the Seller of the BARDA Contract, the satisfaction or waiver of the following other closing conditions: (i) the representations and warranties of the Company and the Seller contained in the Purchase Agreement being true and correct, subject to certain materiality standards; (ii) each of the Company and the Seller having performed and complied with their respective covenants in all material respects; (iii) the waiting period applicable to the consummation of the Transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, having expired; (iv) the delivery of certain ancillary documents, including a transition services agreement and pre-novation agreement; (v) the receipt of any required consent from BARDA to enter into a pre-novation agreement with the Company; (vi) no injunction or other final order preventing the consummation of the Transaction </span></div>having been issued; (vii) and there having occurred no material adverse effect on the assets being sold in the Transaction. Closing of the Transaction is currently expected to occur during the third quarter of 2022.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018690206160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and principles of consolidation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Basis of presentation and principles of consolidation</a></td>
<td class="text">Basis of presentation and principles of consolidation<div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of presentation</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of June&#160;30, 2022. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant accounting policies</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2022, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC that have materially impacted the presentation of the Company's financial statements. </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">six months ended June 30, 2022</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company revised the reporting that the Chief Operating Decision Maker (CODM) reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and 2) the services segment focused on CDMO (Services). This change is further outlined in Note 14, Segment information.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair value measurements</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1) and time deposits (level 2), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7, Fair value measurements and Note 8, Derivative instruments and hedging activities).</span></div><div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> On a non-recurring basis, the Company measures its long-lived assets as part of impairment evaluations using fair value measurements. Goodwill is allocated to the Company's reporting units, which are one level below its operating segments. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and earlier if an event or other circumstance indicates that the carrying value of the asset may not be recoverable. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required. Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, long-lived assets are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when there is an adverse change in the market relating to those related assets. The impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. Determining the need for a detailed impairment analysis requires the exercise of judgment about several business factors, including the timing of expected future cash flows and assumptions about the economic environment. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the Company had no other significant assets or liabilities that were measured at fair value.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently issued accounting standards</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) that the Company adopts as of the pronouncement's specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the consolidated financial statements or disclosures.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div>In March 2020, the FASB issued Topic 848, which was further amended in January 2021. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. Topic 848 contains optional expedients and exceptions to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018690206160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories, net</a></td>
<td class="text">Inventories, net<div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.5&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>Inventories, net is stated at the lower of cost or net realizable value. For additional information related to the termination of the manufacturing services agreement (the &#8220;Agreement&#8221;) with Janssen Pharmaceuticals, Inc. (&#8220;Janssen&#8221;) and associated evaluation of inventory as of June&#160;30, 2022, refer to Note 10, Revenue recognition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018609479888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, plant and equipment, net</a></td>
<td class="text">Property, plant and equipment, net<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and improvements</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156.1&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119.2&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation &amp; amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357.7)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.4&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, construction-in-progress primarily includes costs incurred related to construction to advance the Company's CDMO capabilities. </span></div>Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. During the three and six months ended June 30, 2022, the Company recorded accelerated depreciation of $12.7&#160;million to shorten the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement with Janssen. For additional information related to the termination of the Agreement, refer to Note 10, Revenue recognition.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605636272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is the lessee for operating leases for offices, research and development facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. For a discussion of lessor activities, see Note 10, Revenue recognition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease costs are reflected as components of cost of product sales, cost of contract development and manufacturing, research and development expense and selling, general and administrative expense.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.880%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except lease term and discount rate)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet location</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_08a6d402-1277-48d2-bf99-60dd61290d59"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_1ed14031-8464-49dc-b194-cef65be5901a">Other assets</span></span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_27fc9abe-7aef-4a7b-ba2f-191204f5fc38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_b64be59d-2273-4d6d-8743-cf67e2bb3dd4">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_a0e6f1b3-d5ea-4f24-926b-07bfa08973d9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_b0f3a4ed-4e9d-4073-9e24-438362666e2c">Other liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605682752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsDisclosureTextBlock', window );">Intangible Assets</a></td>
<td class="text">Intangible assets<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the Company's Intangible assets, net:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Type</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated Life</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9-22 years</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDMO</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.6&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company's intangible assets was recorded as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization Expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the weighted average amortization period remaining for intangible assets was 11.4 years years. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of changes in our goodwill balance:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.171%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, December&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, June&#160;30, 2022</span></div></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div>The carrying amount of goodwill included accumulated impairments of $41.7 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all or part of the information related to intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2144471<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605618384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair value measurements</a></td>
<td class="text">Fair value measurements<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques we utilized to determine fair value:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:24.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.6&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#8217;s products are classified in the Company's statement of operations as cost of product sales. </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the beginning and ending balance of our contingent consideration liability: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the current portion of the contingent consideration liability was $3.6 million and $32.7&#160;million, respectively, and was included in other current liabilities on the condensed consolidated balance sheets. The non-current portion of the contingent consideration liability is included in other liabilities on the condensed consolidated balance sheets.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value as of June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average</span></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue milestone and royalty based</span></td><td colspan="3" rowspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.1 million</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounted cash flow</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3%</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25% - 50%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Derivative instruments</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Note 8, Derivative instruments and hedging activities</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for more information about our derivative instruments.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-variable rate debt</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2022 and December&#160;31, 2021, t</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he fair value of the Company's 3.875% Senior Unsecured Notes was $319.0&#160;million and $433.3&#160;million. The fair value was determined through market sources, which are level 2 inputs and directly observable. </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amounts of the Company&#8217;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 9, Debt).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605636272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock', window );">Derivative instruments and hedging activities</a></td>
<td class="text">Derivative instruments and hedging activities<div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk management objective of using derivatives</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from the Company's senior secured credit agreement's payments of variable interest rate debt.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If current fair values of designated interest rate swaps&#160;remained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;$4.8 million of net deferred gains from&#160;accumulated other comprehensive loss&#160;into the condensed consolidated statement of operations over the next&#160;twelve-month period. All outstanding cash flow hedges mature in October 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except number of instruments)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of Instruments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notional</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$350.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Derivatives</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Assets</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Assets</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Liabilities </span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Liabilities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Liabilities</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive loss.</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.505%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.311%"/><td style="width:0.1%"/></tr><tr style="height:38pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative</span></div></td><td colspan="3" rowspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Location of Gain or (Loss) Reclassified from Accumulated OCL into Income</span></td><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount of Gain/(Loss) Reclassified from Accumulated OCL into Income</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Swaps</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -URI https://asc.fasb.org/topic&amp;trid=2229140<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=d3e90205-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605508144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt</a></td>
<td class="text">Debt<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of debt are as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured credit agreement - Term loan due 2023</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured credit agreement - Revolver loan due 2023</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.875% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, net of debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793.6&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</span></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021 there was no outstanding revolver balance. We classify debt issuance costs associated with the </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">revolver</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> loan as other current assets and other assets on the Company's consolidated balance sheets. As of June&#160;30, 2022, the Company had $2.0&#160;million and $0.6&#160;million of debt issuance costs associated with the revolver loan classified as other current assets and other assets, respectively. As of December&#160;31, 2021, the Company had approximately $2.0 million and $1.6 million of debt issuance costs associated with the revolver loan that were classified as other current assets and other assets, respectively.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.875% Senior Unsecured Notes due 2028</span><span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 7, 2020, the Company completed its offering of $450.0&#160;million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the 2028 Notes) of which the majority of the net proceeds were used to pay down the Revolving Credit Facility (as defined below). Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On or after August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related Indenture, plus accrued and unpaid interest. Prior to August 15, 2023 the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to 100% of the principal amount of the 2028 Notes plus a &#8220;make-whole&#8221; premium and accrued and unpaid interest. Prior to August 15, 2023, the Company may </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">redeem up to 40% of the aggregate principal amount of the 2028 Notes using the net cash proceeds of certain equity offerings at the redemption price set forth in the related Indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of 101% of the principal amount of such 2028 Notes plus accrued and unpaid interest.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Negative covenants in the Indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Senior secured credit agreement</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also on August 7, 2020, the Company entered into a Second Amendment (the &#8220;Credit Agreement Amendment&#8221;) to its senior secured credit agreement, dated October 15, 2018, with multiple lending institutions relating to the Company&#8217;s senior secured credit facilities (the &#8220;Credit Agreement,&#8221; and as amended, the &#8220;Amended Credit Agreement&#8221;), consisting of a senior revolving credit facility (the &#8220;Revolving Credit Facility&#8221;) and senior term loan facility (the &#8220;Term Loan Facility,&#8221; and together with the Revolving Credit Facility, the &#8220;Senior Secured Credit Facilities&#8221;).  The Credit Agreement Amendment amended, among other things, the definition of incremental facilities limit, the consolidated net leverage ratio financial covenant by increasing the maximum level, increased the permissible applicable margins based on the Company&#8217;s consolidated net leverage ratio and increased the commitment fee that the Company is required to pay in respect of the average daily unused commitments under the Revolving Credit Facility, depending on the Company&#8217;s consolidated net leverage ratio.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement includes (i) a Revolving Credit Facility of $600.0&#160;million and (ii) a Term Loan Facility with a principal amount of $450.0&#160;million. The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as certain requirements involving our net leverage ratio will be maintained on a pro forma basis. Borrowings under the Revolving Credit Facility and the Term Loan Facility bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from 1.25% to 2.25% per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus 0.50%, and a eurocurrency rate for an interest period of one month plus 1% plus a margin ranging from 0.25% to 1.25%, depending on the Company's consolidated net leverage ratio). The Company is required to make quarterly payments on the last business day of each calendar quarter under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from 0.15% to 0.35% per annum, depending on the Company's consolidated net leverage ratio, for the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments on the last business day of each calendar quarter based on an annual percentage equal to 2.5% of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, 5% of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and 7.5% of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature on October 13, 2023.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of $100.0&#160;million during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights. The financial covenants under the Amended Credit Agreement currently require the quarterly presentation of a minimum consolidated 12-month rolling debt service coverage ratio of 2.50 to 1.00, and a maximum consolidated net leverage ratio of 4.50 to 1.00 (subject to an increase to 5.00 to 1.00 for an applicable four quarter period, at the election of the Company, in connection with a permitted acquisition having an aggregate consideration in excess of $75.0&#160;million). Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments. As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605643472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue recognition</a></td>
<td class="text">Revenue recognition<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates as two operating segments (Note 14, Segment information). The Company's revenues disaggregated by the major sources were as follows:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract development and manufacturing:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract development and manufacturing</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.6&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract development and manufacturing:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract development and manufacturing</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.9&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550.2&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><br/><br/></span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 2, 2020, Emergent BioSolutions Inc., through its wholly-owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into a manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson (the "Agreement"), for large-scale drug substance manufacturing of Johnson &amp; Johnson&#8217;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#8220;Product&#8221;).</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2022, the Company provided to Janssen a notice (the &#8220;Notice&#8221;) of material breach of the Agreement for (i) failure by Janssen to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Agreement; (ii) to confirm Janssen&#8217;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Agreement; and (iii) instead, wind-down the Agreement ahead of fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#8220;Janssen Notice&#8221;) of the Agreement for asserted material breaches of the Agreement </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices (cGMP) or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8217;s</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> breaches were not curable and that, therefore, termination of the Agreement would be effective as of July 6, 2022. The Company disputes Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the Company's alleged failure to perform under the Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process including mediation and/or arbitration.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three months ended June 30, 2022, the Company reversed $13.3&#160;million of previously recognized revenue to align cumulative revenue recognized under the Agreement with cumulative cash collections. As of June&#160;30, 2022, the Company has no billed or unbilled net accounts receivable related to the Agreement. During the three months ended June 30, 2022, the Company recorded accelerated depreciation of $12.7&#160;million related to the conclusion of the Agreement which has been recorded in cost of contract development and manufacturing in the condensed consolidated statements of operations.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has $126.2&#160;million of raw materials inventory recorded in its condensed consolidated balance sheet as of June&#160;30, 2022 representing materials purchased for the Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of this inventory as of June&#160;30, 2022, concluding that because Section 13.4 of the Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for whatever reason, the Company is entitled to payment from Janssen for these raw materials. Therefore, this inventory remains an asset on the condensed consolidated balance sheet as of June&#160;30, 2022. Additionally, the Company has approximately $18.2&#160;million of non-cancelable orders as of June&#160;30, 2022 which have not been received and Janssen has not reimbursed. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">BARDA COVID-19 Development Public-Private Partnership</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the Company announced the issuance of a task order under our existing Center for Innovation in Advanced Development and Manufacturing (CIADM) agreement with BARDA for COVID-19 vaccine development and manufacturing (the BARDA COVID-19 Development Public Private Partnership). The BARDA COVID-19 Development Public Private Partnership is considered a lease and is accounted for under ASC 842. The initial task order had a contract value of up to $628.2&#160;million and included the reservation of manufacturing capacity and accelerated expansion of fill/finish capacity valued at $542.7&#160;million and $85.5&#160;million, respectively. Subsequently, the task order was expanded to include incremental capital activities which increased the value to </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$650.8&#160;million. On November 1, 2021, the Compa</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ny and BARDA mutually agreed to the completion of </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the Company's CIADM contract and associated task orders, including the BARDA COVID-19 Development Public Private Partnership. The Company did not recognize lease revenues under this arrangement during the </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three and</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> six months ended June 30, 2022. During the three and six months ended </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021 the Company recognized lease revenues of $70.4 million and $167.9 million, respectively, related to this arrangement.</span></div><div style="margin-bottom:9pt"><span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMO operating leases</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain multi-year CDMO service arrangements with commercial customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates 2.9 years. </span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Excluding future amounts related to the Janssen Agreement as discussed above, we estimate future operating lease revenues to be $0.4&#160;million in the remainder of 2022, $5.1&#160;million in 2023, $0.9&#160;million in 2024, $0.9&#160;million million in 2025 and $2.7&#160;million in years beyond 2025.</span></div><div><span><br/></span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transaction price </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%">a</span><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">llocated to remaining performance obligations</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company has future contract value on unsatisfied performance obligations of approximately $545.1 million associated with all arrangements entered into by the Company. The Company expects to recognize a majority of the $545.1 million of unsatisfied performance obligations within the next 24 months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associat</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#8217;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of June&#160;30, 2022 and December&#160;31, 2021, the Company had $26.3 million and $21.5 million, respectively, of contract assets</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> recorded within accounts receivable, net on the condensed consolidated balance sheets.</span><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract liabilities</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the condensed consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the roll forward of the contract liability balances:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferral of revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the current portion of contract liabilities was </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$18.5&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$11.7&#160;million</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, respectively</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and was included in other current liabilities on the balance sheet</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billed, net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022 and December&#160;31, 2021, the allowances for doubtful accounts was $0.9 million and $3.2 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI https://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605628976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income taxes</a></td>
<td class="text">Income taxesThe estimated effective annual tax rate as of June 30, 2022 and 2021 for the years ended December 31, 2022 and 2021, excluding the impact of discrete adjustments, was 29% and 26%, respectively. The Company recorded discrete tax expense (benefits) of $0.2&#160;million and $0.6&#160;million for the three and six months ended June&#160;30, 2022, respectively, and $1.1 million and $(5.5)&#160;million, for the three and six months ended June&#160;30, 2021, respectively. The discrete tax expense in 2022 was primarily due to share-based compensation activity offset by return to provision adjustments. The net discrete benefits in 2021 were primarily due to share-based compensation activity.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605485120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (loss) per share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (loss) per share</a></td>
<td class="text">Net income (loss) per share<div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net (loss) income per share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.943%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.4)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.1)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares&#8212;basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities&#8212;equity awards</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares&#8212;diluted</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)  per share - basic</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.13)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.19)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.13)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.19)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. No adjustment for the potential dilutive effect of dilutive securities is reported for the three and six months ended June&#160;30, 2022 as the effect would have been anti-dilutive due to the Company's net loss.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the share-based awards that are not considered in the diluted income (loss) per share calculation generally because the exercise price of the awards was greater than the average per share closing price during the three and six months ended June&#160;30, 2022 and 2021. In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price.</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock awards</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605622864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text">Equity<div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Repurchase programs</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 11, 2021, the Company announced that its Board of Directors authorized management to repurchase up to an aggregate of $250.0&#160;million of Common Stock under a board-approved Share Repurchase Program, of which $187.9&#160;million has been utilized to purchase 4.4&#160;million shares as of June&#160;30, 2022. During the three and six months ended  June&#160;30, 2022, the Company has utilized $23.3&#160;million and $75.5&#160;million to purchase 0.7&#160;million and 1.8&#160;million shares, respectively. The Share Repurchase Program does not obligate the Company to acquire any specific number of shares. Repurchased shares will be available for use in connection with our stock plans and for other corporate purposes.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Share-based compensation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2022, the Company granted stock options to purchase 0.6 million shares of common stock and 1.4 million restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Typically, the stock option and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of the three-year performance period based on the Company's results compared to the performance criteria. Share-based compensation expense was recorded in the following financial statement line items:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of contract development and manufacturing</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated other comprehensive loss, net of tax</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive loss, net of tax by component:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.049%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.254%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined Benefit Pension Plan</span></div></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, net of tax)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the tax effects related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative Instruments</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative Instruments</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126731327&amp;loc=SL126733271-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605636272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment informationThe Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. During the first quarter of 2022, the Company revised the reporting that the Chief Operating Decision Maker (CODM) reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and 2) the services segment focused on CDMO (Services). The Company evaluates the performance of these reportable segments based on revenue and adjusted gross margin. Segment revenue includes external customer sales, but it does not include inter-segment services. Adjusted gross margin for each segment is segment revenue less segment cost of sales reduced for significant one-time events. We do not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. The Company has recast the related historical information for consistency.<div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables include segment revenues and a reconciliation of the Company's segment adjusted gross margin to the condensed consolidated statement of operations for each of the Company's reporting segments as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.330%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of contract development and manufacturing</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.8)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.8)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.6)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.6)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Services revenue and Services adjusted gross margin for the three months ended June 30, 2021 includes the impact of $70.4 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of contract development and manufacturing</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.4)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.8&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.4)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.4&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Services revenue and Services adjusted gross margin for the six months ended June 30, 2021 includes the impact of $167.9 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation for each segment as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation:</span></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our CODM does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605599984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Commitments and contingencies</a></td>
<td class="text">Commitments and contingencies<div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Securities and shareholder litigation</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#8217;s common stock, seeking to pursue remedies under the Securities Exchange Act of 1934. These complaints were filed by Palm Tran, Inc. &#8211; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth; and Stephen M. Weiss, respectively. The complaints allege, among other things, that the defendants made false and misleading statements about its manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as CDMO Manufacturing Capabilities). These cases were consolidated on December 23, 2021, under the caption In re Emergent BioSolutions Inc. Securities Litigation, No. 8:21-cv-00955-PWG (the Federal Securities Class Action). The Lead Plaintiffs in the consolidated matter are Nova Scotia Health Employees&#8217; Pension Plan and The City of Fort Lauderdale Police &amp; Firefighters&#8217; Retirement System. The defendants filed a motion to dismiss on May 19, 2022 and the Lead Plaintiff filed an opposition to that motion on July 19, 2022. The defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the consolidated action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2021, Lincolnshire Police Pension Fund (&#8220;Lincolnshire&#8221;) and on August 16, 2021, Pooja Sayal, filed putative stockholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the Company&#8217;s CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, both cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-PWG. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022 the Court approved the parties joint stipulation to and stay of the proceedings and discovery until the close of fact  discovery in the Federal Securities Class Action. The defendants believe that the allegations in the complaints are without merit and intend to defend the matter vigorously.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 15, 2021, September 16, 2021, and November 12, 2021, putative stockholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp; Police Officers Pension Fund in The Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the Company&#8217;s CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption In re Emergent BioSolutions, Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#8217; filed their Motion to Dismiss the plaintiffs&#8217; complaint. However, ruling on this motion is stayed pursuant to a March 29, 2022 Order staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 3, 2021, December 22, 2021 and January 18, 2022, putative stockholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the laws, each allegation related to the Company&#8217;s CDMO Manufacturing Capabilities.</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings and Discovery, pursuant to which the </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">parties have agreed to stay all proceedings until thirty (30) calendar days after a ruling on defendants&#8217; motion to dismiss filed in the Federal Securities Class Action. The Court approved the Joint Stipulation on March 14, 2022.</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> addition to the above actions, the Company has received preliminary inquiries and subpoenas to produce documents related to these matters from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis, Senator Murray of the Committee on Health, Education, Labor and Pensions, the Department of Justice, the SEC, the Maryland Attorney General&#8217;s Office, and the New York Attorney General&#8217;s Office. The Company is producing and has produced documents as required in response and will continue to cooperate with these government inquiries.</span></div><div style="text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual property</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions&#8217; Adapt Pharma subsidiaries (Emergent) are as follows: Emergent Devices Inc. (EBPA), formerly known as Adapt Pharma Inc.; Emergent Operations Ireland Limited (EIRE), formerly known as Adapt Pharma Operations Limited; and Emergent BioSolutions Ireland Limited (EIR2), formerly known as Adapt Pharma Limited.</span></div><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ANDA litigation - Teva 4mg</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> BioSolutions&#8217; Adapt Pharma subsidiaries EBPA and EIRE, and Opiant Pharmaceuticals Inc. (Opiant) received notice letters from Teva Pharmaceuticals Industries Limited and Teva Pharmaceuticals USA (collectively, Teva) that Teva had filed an Abbreviated New Drug Application (ANDA) with the FDA seeking regulatory approval to market a generic version of </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NARCAN&#174;</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (naloxone </span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HCI</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">) Nasal Spray 4 mg/spray before the expiration of certain patents listed on the FDA&#8217;s website for Approved Drug Products with Therapeutic Equivalence Evaluations</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Orange Book Listed Patents) for NARCAN. Teva&#8217;s notice letters alleged that claims of certain Orange Book Listed Patents for NARCAN were invalid and/or would not be infringed by the activities described in Teva&#8217;s ANDA. Emergent and Opian</span><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t filed complaints against Teva in the U.S. District Court for the District of New Jersey alleging infringement of certain Orange Book Listed Patents for NARCAN. On June 5, 2020, the U.S. District Court for the District of New Jersey ruled in favor of Teva. Emergent unsuccessfully appealed the decision to the Court of Appeals for the Federal Circuit (CAFC) and followed with a petition for rehearing that was ultimately denied on May 5, 2022.</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">ANDA litigation - Teva 2mg</span></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Emergent BioSolutions&#8217; Adapt Pharma subsidiaries EBPA and EIRE, and Opiant received a notice letter from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#174; (naloxone HCI) Nasal Spray 2 mg/spray before the expiration of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#174;. Teva&#8217;s notice letter alleged that claims of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#174; were invalid and/or would not be infringed by the activities described in Teva&#8217;s ANDA. Emergent and Opiant filed complaints against Teva in the U.S. District Court for the District of New Jersey alleging infringement of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN. This case is currently stayed and it is anticipated the matter will be dismissed.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018608134464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and principles of consolidation (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of presentation</a></td>
<td class="text">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of June&#160;30, 2022. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair value measurements</a></td>
<td class="text">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1) and time deposits (level 2), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7, Fair value measurements and Note 8, Derivative instruments and hedging activities). On a non-recurring basis, the Company measures its long-lived assets as part of impairment evaluations using fair value measurements. Goodwill is allocated to the Company's reporting units, which are one level below its operating segments. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and earlier if an event or other circumstance indicates that the carrying value of the asset may not be recoverable. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required. Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, long-lived assets are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when there is an adverse change in the market relating to those related assets. The impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. Determining the need for a detailed impairment analysis requires the exercise of judgment about several business factors, including the timing of expected future cash flows and assumptions about the economic environment.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently issued accounting standards</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-left:18pt"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Not Yet Adopted</span></div><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting</span></div>In March 2020, the FASB issued Topic 848, which was further amended in January 2021. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. Topic 848 contains optional expedients and exceptions to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivatives</a></td>
<td class="text">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#8217;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text">The Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. During the first quarter of 2022, the Company revised the reporting that the Chief Operating Decision Maker (CODM) reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and 2) the services segment focused on CDMO (Services). The Company evaluates the performance of these reportable segments based on revenue and adjusted gross margin. Segment revenue includes external customer sales, but it does not include inter-segment services. Adjusted gross margin for each segment is segment revenue less segment cost of sales reduced for significant one-time events. We do not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. The Company has recast the related historical information for consistency.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605566640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">264.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">217.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work-in-process</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425.5&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">350.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605602416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract', window );"><strong>Property Plant and Equipment Income Statement Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, plant and equipment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment, net consisted of the following:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.216%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and improvements</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings, building improvements and leasehold improvements</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">293.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">269.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Furniture and equipment</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">527.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">513.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction-in-progress</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">223.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, gross</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,156.1&#160;</span></td><td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119.2&#160;</span></td><td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Accumulated depreciation &amp; amortization</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(357.7)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(319.1)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.4&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">800.1&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605704944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.808%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.991%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.997%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease cost:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of right-of-use assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest on lease liabilities</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease cost</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_AssetsAndLiabilitiesLesseeTableTextBlock', window );">Schedule of Leases Supplemental Balance Sheets</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental balance sheet information related to lessee activities is as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.020%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.880%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(In millions, except lease term and discount rate)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet location</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_08a6d402-1277-48d2-bf99-60dd61290d59"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_1ed14031-8464-49dc-b194-cef65be5901a">Other assets</span></span></span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.3</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, current portion</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_27fc9abe-7aef-4a7b-ba2f-191204f5fc38"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_b64be59d-2273-4d6d-8743-cf67e2bb3dd4">Other current liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_a0e6f1b3-d5ea-4f24-926b-07bfa08973d9"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_b0f3a4ed-4e9d-4073-9e24-438362666e2c">Other liabilities</span></span></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.9</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.2</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating lease liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.8</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating leases:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average remaining lease term (years)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted average discount rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018609498832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text">The following table summarizes the Company's Intangible assets, net:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.710%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.963%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.262%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.966%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Type</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Estimated Life</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accumulated Amortization</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9-22 years</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">798.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CDMO</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8 years</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Total intangible assets</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">226.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576.6&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">803.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">604.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Finite-lived Intangible Assets Amortization Expense</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense associated with the Company's intangible assets was recorded as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization Expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a roll forward of changes in our goodwill balance:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.629%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.171%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, December&#160;31, 2021</span></div></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign currency translation</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, June&#160;30, 2022</span></div></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018609345488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques we utilized to determine fair value:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"><tr><td style="width:1.0%"/><td style="width:24.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.135%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December&#160;31, 2021</span></div></td></tr><tr><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 1</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 3</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market accounts</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.6&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.1&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">156.5&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative instruments</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a reconciliation of the beginning and ending balance of our contingent consideration liability: </span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 31, 2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change in fair value</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.9)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June 30, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Fair Value Measurement Inputs and Valuation Techniques</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: </span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration Liability</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value as of June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Valuation Technique</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unobservable Input</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Range</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted Average</span></td></tr><tr style="height:18pt"><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue milestone and royalty based</span></td><td colspan="3" rowspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$8.1 million</span></td><td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discounted cash flow</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3%</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Probability of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25% - 50%</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.0%</span></td></tr><tr style="height:24pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected year of payment</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 - 2028</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018609362528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Instruments</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2022, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, except number of instruments)</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Number of Instruments</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Notional</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$350.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the fair value of the Company&#8217;s derivative financial instruments designated as hedges as well as their classification on the balance sheets:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.388%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.394%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Asset Derivatives</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Liability Derivatives</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance Sheet Location</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair Value</span></td></tr><tr style="height:33pt"><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Swaps</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Assets</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Assets</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Liabilities </span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Current Liabilities</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:23pt"><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Assets</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Liabilities</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other Liabilities</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Derivative Instruments, Gain (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive loss.</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"><tr><td style="width:1.0%"/><td style="width:20.657%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.505%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.309%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.311%"/><td style="width:0.1%"/></tr><tr style="height:38pt"><td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative</span></div></td><td colspan="3" rowspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Location of Gain or (Loss) Reclassified from Accumulated OCL into Income</span></td><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amount of Gain/(Loss) Reclassified from Accumulated OCL into Income</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31,</span></td><td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest Rate Swaps</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.0)</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605599984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Schedule of Debt</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of debt are as follows:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured credit agreement - Term loan due 2023</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">379.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior secured credit agreement - Revolver loan due 2023</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.875% Senior Unsecured Notes due 2028</span></div></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">450.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">832.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">849.6&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion of long-term debt, net of debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unamortized debt issuance costs</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current portion of debt</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793.6&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">809.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018604853232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue</a></td>
<td class="text">The Company's revenues disaggregated by the major sources were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:22.750%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.120%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S. Government</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.2&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract development and manufacturing:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract development and manufacturing</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124.4&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></div></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-U.S.<br/>Government</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Total</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product sales, net</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221.6&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">252.7&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">196.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract development and manufacturing:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">171.2&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leases</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">203.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract development and manufacturing</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">167.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">206.8&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236.9&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550.2&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">335.0&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">405.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740.5&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Rollforward of Contract Liabilities</a></td>
<td class="text">The following table presents the roll forward of the contract liability balances:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:76.342%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.884%"/><td style="width:0.1%"/></tr><tr style="height:20pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferral of revenue</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue recognized</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.0)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ScheduleOfAccountsReceivableNetTableTextBlock', window );">Schedule of Accounts Receivable, Net</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.785%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Billed, net</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unbilled</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.1&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total accounts receivable, net</span></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">175.0&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">274.7&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ScheduleOfAccountsReceivableNetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Accounts Receivable, Net [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ScheduleOfAccountsReceivableNetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018603092336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (loss) per share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Basic and Diluted Net Income per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the calculation of basic and diluted net (loss) income per share:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.160%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.226%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.373%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.943%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(56.4)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(60.1)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares&#8212;basic</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities&#8212;equity awards</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average number of shares&#8212;diluted</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.0&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50.3&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54.3&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss)  per share - basic</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.13)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.19)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.40&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income (loss) per share - diluted</span></td><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.13)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.09&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.19)</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.37&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the share-based awards that are not considered in the diluted income (loss) per share calculation generally because the exercise price of the awards was greater than the average per share closing price during the three and six months ended June&#160;30, 2022 and 2021. In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price.</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.704%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive stock awards</span></td><td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605774288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount</a></td>
<td class="text">Share-based compensation expense was recorded in the following financial statement line items:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.859%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.693%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.696%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of contract development and manufacturing</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</span></td><td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.1&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.3&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.2&#160;</span></td><td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.9&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes changes in accumulated other comprehensive loss, net of tax by component:</span></div><div style="margin-bottom:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:50.049%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.250%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.825%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.254%"/><td style="width:0.1%"/></tr><tr style="height:30pt"><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Defined Benefit Pension Plan</span></div></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative Instruments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td></tr><tr style="height:23pt"><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(in millions, net of tax)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2021</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income before reclassifications</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.1)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, December&#160;31, 2020</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:11pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, March&#160;31, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss) before reclassifications</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amounts reclassified from accumulated other comprehensive loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net current period other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance, June&#160;30, 2021</span></div></td><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents the tax effects related to each component of other comprehensive income (loss):</span></div><div style="margin-bottom:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative Instruments</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.8&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:30.509%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.819%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.826%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended</span></td><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pretax</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax Benefit (Expense)</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net of tax</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Derivative Instruments</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.4&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.3)</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Foreign Currency Translation Adjustments</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total adjustments</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e526-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018608131616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables include segment revenues and a reconciliation of the Company's segment adjusted gross margin to the condensed consolidated statement of operations for each of the Company's reporting segments as follows:</span></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:20.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.330%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Three Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">237.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.8)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242.7&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.2&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190.9&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">397.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(91.0)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.2)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of contract development and manufacturing</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.8)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(78.8)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(146.6)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.6)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.0&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">147.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.6)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66.9&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.6&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.3&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144.9&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Services revenue and Services adjusted gross margin for the three months ended June 30, 2021 includes the impact of $70.4 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.042%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.371%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.471%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.189%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Six Months Ended June 30, 2021</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Products</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Services </span><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consolidated</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">474.3&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.9&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">550.2&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319.1&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">374.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">740.5&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less:</span></td><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contracts and grants revenue</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46.7)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of product sales</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(171.3)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(133.8)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of contract development and manufacturing</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(154.4)</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(193.3)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">303.0&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.4)</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">207.6&#160;</span></td><td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185.3&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">366.7&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in fair value of contingent consideration</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted gross margin</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">304.8&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.4)</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">209.4&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">187.0&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">368.4&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> Services revenue and Services adjusted gross margin for the six months ended June 30, 2021 includes the impact of $167.9 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.</span></div></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, by Segment</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table includes depreciation for each segment as follows:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.560%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.374%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.267%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.518%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.273%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span></td><td colspan="3" style="background-color:#19415e;padding:0 1pt"/><td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2021</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation:</span></td><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Products</span></td><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.9&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Services</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.8&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.6&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total </span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28.5&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</span></td><td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018606957024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business (Details)<br> treatmentCourse in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2022 </div>
<div>USD ($) </div>
<div>treatmentCourse</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>segment </div>
<div>category </div>
<div>productCandidate </div>
<div>product</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_NumberOfCategoriesOfPublicHealthThreats', window );">Number of categories of public health threats | category</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_NumberOfRevenueGeneratingProducts', window );">Number of revenue generating products | product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_NumberOfProductCandidates', window );">Number of product candidates | productCandidate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage', window );">Asset acquisition, domestic royalty percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit', window );">Asset acquisition, minimum therapy treatment courses required to earn royalty on future gross profit | treatmentCourse</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage', window );">Asset acquisition, international royalty percentage</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember', window );">Chimerix Asset Acquisition | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire productive assets</a></td>
<td class="nump">$ 225.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Asset acquisition, consideration transferred, contingent consideration</a></td>
<td class="nump">100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember', window );">Chimerix Asset Acquisition | Milestone Payment One | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Asset acquisition, consideration transferred, contingent consideration</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember', window );">Chimerix Asset Acquisition | Milestone Payment Two | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Asset acquisition, consideration transferred, contingent consideration</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember', window );">Chimerix Asset Acquisition | Milestone Payment Three | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Asset acquisition, consideration transferred, contingent consideration</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember', window );">Chimerix Asset Acquisition | Milestone Payment Four | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Asset acquisition, consideration transferred, contingent consideration</a></td>
<td class="nump">25.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember', window );">Chimerix Asset Acquisition | Regulatory Milestones | Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration', window );">Asset acquisition, consideration transferred, contingent consideration</a></td>
<td class="nump">$ 12.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Domestic Gross Profit Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, International Gross Profit Royalty Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Minimum Therapy Treatment Courses Required To Earn Royalty On Future Gross Profit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfCategoriesOfPublicHealthThreats">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of categories of public health threats.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfCategoriesOfPublicHealthThreats</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfProductCandidates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Product Candidates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfProductCandidates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_NumberOfRevenueGeneratingProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Refers to the number of revenue generating products.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_NumberOfRevenueGeneratingProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126928898&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=127000608&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=ebs_ChimerixAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ebs_MilestonePaymentOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ebs_MilestonePaymentOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ebs_MilestonePaymentTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ebs_MilestonePaymentTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ebs_MilestonePaymentThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ebs_MilestonePaymentThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ebs_MilestonePaymentFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ebs_MilestonePaymentFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=ebs_RegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=ebs_RegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605740080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of presentation and principles of consolidation (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018604767536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories, net - Schedule of Inventory (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 264.0<span></span>
</td>
<td class="nump">$ 217.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">108.4<span></span>
</td>
<td class="nump">95.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">53.1<span></span>
</td>
<td class="nump">37.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories, net</a></td>
<td class="nump">$ 425.5<span></span>
</td>
<td class="nump">$ 350.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018603465872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,156.1<span></span>
</td>
<td class="nump">$ 1,119.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation &amp; amortization</a></td>
<td class="num">(357.7)<span></span>
</td>
<td class="num">(319.1)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">798.4<span></span>
</td>
<td class="nump">800.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember', window );">Land and improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">51.2<span></span>
</td>
<td class="nump">52.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Buildings, building improvements and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">293.0<span></span>
</td>
<td class="nump">269.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">527.3<span></span>
</td>
<td class="nump">513.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">66.2<span></span>
</td>
<td class="nump">60.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction-in-progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 218.4<span></span>
</td>
<td class="nump">$ 223.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandAndLandImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerSoftwareIntangibleAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018599607424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, plant and equipment - Narrative (Details) - Services - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">$ 78.8<span></span>
</td>
<td class="nump">$ 146.6<span></span>
</td>
<td class="nump">$ 154.4<span></span>
</td>
<td class="nump">$ 193.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember', window );">Jansen Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018604767088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating lease cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
<td class="nump">$ 2.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Interest on lease liabilities</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total operating lease cost</a></td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 1.8<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018608508816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Supplemental Balance Sheet Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other assets<span></span>
</td>
<td class="text">Other assets<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">$ 25.5<span></span>
</td>
<td class="nump">$ 28.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other current liabilities<span></span>
</td>
<td class="text">Other current liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 5.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]</a></td>
<td class="text">Other liabilities<span></span>
</td>
<td class="text">Other liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities</a></td>
<td class="nump">$ 20.9<span></span>
</td>
<td class="nump">$ 24.2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="nump">$ 26.8<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Operating leases:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted average remaining lease term (years)</a></td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate</a></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018607323952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Schedule of Finite-lived Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 803.5<span></span>
</td>
<td class="nump">$ 803.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">226.9<span></span>
</td>
<td class="nump">198.9<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">576.6<span></span>
</td>
<td class="nump">604.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">798.0<span></span>
</td>
<td class="nump">798.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">221.4<span></span>
</td>
<td class="nump">193.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 576.6<span></span>
</td>
<td class="nump">604.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember', window );">Products | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember', window );">Products | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life</a></td>
<td class="text">22 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">CDMO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Estimated Life</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Cost</a></td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Accumulated Amortization</a></td>
<td class="nump">5.5<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Net</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractDevelopmentAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=ebs_ContractDevelopmentAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018603107168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization Expense</a></td>
<td class="nump">$ 14.0<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="nump">$ 30.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018604801920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Weighted average amortization period</a></td>
<td class="text">11 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss', window );">Goodwill, impaired, accumulated impairment loss</a></td>
<td class="nump">$ 41.7<span></span>
</td>
<td class="nump">$ 41.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairedAccumulatedImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairedAccumulatedImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018609449856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible assets - Goodwill Roll Forward (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, December&#160;31, 2021</a></td>
<td class="nump">$ 224.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss', window );">Foreign currency translation</a></td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill, June&#160;30, 2022</a></td>
<td class="nump">$ 224.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018604583376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">181.6<span></span>
</td>
<td class="nump">352.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">43.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">25.1<span></span>
</td>
<td class="nump">152.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">6.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">156.5<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">6.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative instruments</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">37.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">25.1<span></span>
</td>
<td class="nump">152.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">25.1<span></span>
</td>
<td class="nump">152.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market accounts | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">150.2<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Fair Value, Inputs, Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Fair Value, Inputs, Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">150.2<span></span>
</td>
<td class="nump">200.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits | Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash equivalents</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018604766592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair value measurements - Contingent Consideration Roll Forward (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Unobservable Input Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, beginning of period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value</a></td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance, end of period</a></td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018606929648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Business combination, contingent consideration, liability, current</a></td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 32.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, fair value</a></td>
<td class="nump">$ 319.0<span></span>
</td>
<td class="nump">$ 433.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018599824112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent purchase consideration</a></td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="nump">$ 37.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent purchase consideration</a></td>
<td class="nump">8.1<span></span>
</td>
<td class="nump">$ 37.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 | Fair Value, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent purchase consideration</a></td>
<td class="nump">$ 8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Discount rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Discount rate | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.093<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Probability of payment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Probability of payment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember', window );">Discounted cash flow | Fair Value, Inputs, Level 3 | Fair Value, Recurring | Probability of payment | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Business combination, contingent consideration, liability, measurement input</a></td>
<td class="nump">0.400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_ValuationTechniqueDiscountedCashFlowMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=ebs_MeasurementInputProbabilityofPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=ebs_MeasurementInputProbabilityofPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018604862208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Net deferred losses from accumulated other comprehensive loss</a></td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605576992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details) - Designated as Hedging Instrument - Interest rate swaps<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>instrument</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfInterestRateDerivativesHeld', window );">Number of Instruments | instrument</a></td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Notional | $</a></td>
<td class="nump">$ 350.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfInterestRateDerivativesHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of interest rate derivative instruments held by the entity at the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfInterestRateDerivativesHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018607248256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details) - Interest rate swaps - Designated as Hedging Instrument - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset Derivatives</a></td>
<td class="nump">$ 4.8<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Asset Derivatives</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability Derivatives</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesFairValueLineItems', window );"><strong>Derivatives, Fair Value [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Liability Derivatives</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 1.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesFairValueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesFairValueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018599814304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details) - Interest rate swaps - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gain/(Loss) Reclassified from Accumulated OCL into Income</a></td>
<td class="nump">$ 6.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6.1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember', window );">Cash Flow Hedging | Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems', window );"><strong>Derivative Instruments and Hedging Activities Disclosures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gain/(Loss) Reclassified from Accumulated OCL into Income</a></td>
<td class="num">$ (2.3)<span></span>
</td>
<td class="num">$ (3.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018599582016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Schedule (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 832.7<span></span>
</td>
<td class="nump">$ 849.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, net of debt issuance costs</a></td>
<td class="num">(31.6)<span></span>
</td>
<td class="num">(31.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNoncurrentNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(7.5)<span></span>
</td>
<td class="num">(8.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Non-current portion of debt</a></td>
<td class="nump">793.6<span></span>
</td>
<td class="nump">809.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember', window );">Term Loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 379.7<span></span>
</td>
<td class="nump">$ 396.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
<td class="nump">$ 450.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total debt</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNoncurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNoncurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableOtherPayablesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_OtherLongTermDebtFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018603684256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Debt - Narrative (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Aug. 07, 2020</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 832,700,000<span></span>
</td>
<td class="nump">$ 849,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance costs, current, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod', window );">Debt instrument, covenant, net leverage ratio rolling period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod', window );">Debt instrument, covenant, net leverage ratio adjustment period</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsCurrentNet', window );">Debt issuance costs, current, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember', window );">Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Debt issuance costs, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Prior to August 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Senior Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
<td class="nump">$ 450,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated percentage</a></td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
<td class="nump">3.875%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Maximum | Prior to August 15, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member', window );">3.875% Senior Unsecured Notes due 2028 | Maximum | Upon the occurrence of a change in control</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRedemptionPricePercentage', window );">Debt instrument, redemption price, percentage</a></td>
<td class="nump">101.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio', window );">Debt covenant, consolidated debt service coverage ratio, minimum</a></td>
<td class="nump">2.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage', window );">Commitment fee percentage</a></td>
<td class="nump">0.35%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioOne', window );">Debt instrument, covenant, net leverage ratio, maximum</a></td>
<td class="nump">4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantNetLeverageRatioTwo', window );">Debt instrument, covenant, net leverage ratio, adjustment</a></td>
<td class="nump">5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Eurocurrency | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Federal Funds Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Base Rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember', window );">Amended Credit Agreement | Base Rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt instrument, basis spread on variable rate</a></td>
<td class="nump">1.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Line of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember', window );">Revolving Credit Facility | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="nump">$ 600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember', window );">Term Loan Facility | Amended Credit Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity', window );">Current borrowing capacity</a></td>
<td class="nump">$ 450,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears', window );">Percentage of original principal amount required to repay in the first two years</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear', window );">Percentage of original principal amount required to repay during the third year</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears', window );">Percentage of original principal amount required to repay remaining year</a></td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight', window );">Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right</a></td>
<td class="nump">$ 100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_DebtInstrumentCovenantConsiderationThreshold', window );">Debt instrument, covenant, consideration threshold</a></td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantConsiderationThreshold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Consideration Threshold</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantConsiderationThreshold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantDebtServiceCoverageRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Debt Service Coverage Ratio</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantDebtServiceCoverageRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, One</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio Rolling Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_DebtInstrumentCovenantNetLeverageRatioTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Covenant, Net Leverage Ratio, Two</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_DebtInstrumentCovenantNetLeverageRatioTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in the third year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in the first two years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The rate of interest that was being paid on the original debt issue that is to repay in remaining years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPricePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph e<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPricePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsCurrentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsCurrentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCommitmentFeePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCommitmentFeePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_SeniorUnsecuredNotesDueAugust2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRedemptionPeriodAxis=us-gaap_DebtInstrumentRedemptionPeriodTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=ebs_AmendedCreditAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_EurodollarMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_EurodollarMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_FederalFundsEffectiveSwapRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_BaseRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_BaseRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=ebs_TermLoanFacilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018603769632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Reversal of previously recognized revenue</a></td>
<td class="num">$ (242,700,000)<span></span>
</td>
<td class="num">$ (397,500,000)<span></span>
</td>
<td class="num">$ (550,200,000)<span></span>
</td>
<td class="num">$ (740,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">545,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">545,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Contract with customer, asset, noncurrent</a></td>
<td class="nump">26,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion of contract liabilities</a></td>
<td class="nump">18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivable', window );">Allowance for doubtful accounts receivable</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Lease revenue</a></td>
<td class="num">(4,500,000)<span></span>
</td>
<td class="nump">87,300,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">203,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">78,800,000<span></span>
</td>
<td class="nump">146,600,000<span></span>
</td>
<td class="nump">154,400,000<span></span>
</td>
<td class="nump">193,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember', window );">Jansen Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Reversal of previously recognized revenue</a></td>
<td class="nump">13,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Inventory, raw materials, net of reserves</a></td>
<td class="nump">126,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">126,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent', window );">Non-cancelable orders</a></td>
<td class="nump">18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember', window );">Jansen Pharmaceuticals, Inc. | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=ebs_BARDAMember', window );">BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, operating lease, payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650,800,000<span></span>
</td>
<td class="nump">$ 628,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Reversal of previously recognized revenue</a></td>
<td class="num">(124,400,000)<span></span>
</td>
<td class="num">(161,100,000)<span></span>
</td>
<td class="num">(236,900,000)<span></span>
</td>
<td class="num">(335,000,000.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. Government | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Lease revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">167,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Reversal of previously recognized revenue</a></td>
<td class="num">$ (118,300,000)<span></span>
</td>
<td class="num">(236,400,000)<span></span>
</td>
<td class="num">$ (313,300,000)<span></span>
</td>
<td class="num">(405,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm', window );">Lessee, operating lease, remaining lease term</a></td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-U.S. Government | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Lease revenue</a></td>
<td class="num">$ (4,500,000)<span></span>
</td>
<td class="nump">$ 16,900,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="nump">$ 35,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ebs_ReservationOfManufacturingCapacityMember', window );">Reservation Of Manufacturing Capacity | BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, operating lease, payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">542,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=ebs_AcceleratedExpansionOfFillFinishCapacityMember', window );">Accelerated Expansion Of Fill/Finish Capacity | BARDA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived', window );">Lessor, operating lease, payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,500,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableTradeCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableTradeCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRemainingLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRemainingLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LessorOperatingLeasePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease payments to be received by lessor for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919396-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LessorOperatingLeasePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_JansenPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=ebs_BARDAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=ebs_BARDAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ebs_ReservationOfManufacturingCapacityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ebs_ReservationOfManufacturingCapacityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=ebs_AcceleratedExpansionOfFillFinishCapacityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=ebs_AcceleratedExpansionOfFillFinishCapacityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018604665424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Disaggregation of Revenue (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 242,700,000<span></span>
</td>
<td class="nump">$ 397,500,000<span></span>
</td>
<td class="nump">$ 550,200,000<span></span>
</td>
<td class="nump">$ 740,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">124,400,000<span></span>
</td>
<td class="nump">161,100,000<span></span>
</td>
<td class="nump">236,900,000<span></span>
</td>
<td class="nump">335,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">118,300,000<span></span>
</td>
<td class="nump">236,400,000<span></span>
</td>
<td class="nump">313,300,000<span></span>
</td>
<td class="nump">405,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">237,200,000<span></span>
</td>
<td class="nump">181,200,000<span></span>
</td>
<td class="nump">474,300,000<span></span>
</td>
<td class="nump">319,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">118,200,000<span></span>
</td>
<td class="nump">66,300,000<span></span>
</td>
<td class="nump">221,600,000<span></span>
</td>
<td class="nump">122,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">119,000,000.0<span></span>
</td>
<td class="nump">114,900,000<span></span>
</td>
<td class="nump">252,700,000<span></span>
</td>
<td class="nump">196,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">Total contract development and manufacturing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total contract development and manufacturing</a></td>
<td class="num">(1,800,000)<span></span>
</td>
<td class="nump">190,900,000<span></span>
</td>
<td class="nump">59,000,000.0<span></span>
</td>
<td class="nump">374,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">Total contract development and manufacturing | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total contract development and manufacturing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">167,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember', window );">Total contract development and manufacturing | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Total contract development and manufacturing</a></td>
<td class="num">(1,800,000)<span></span>
</td>
<td class="nump">120,500,000<span></span>
</td>
<td class="nump">59,000,000.0<span></span>
</td>
<td class="nump">206,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">103,600,000<span></span>
</td>
<td class="nump">54,500,000<span></span>
</td>
<td class="nump">171,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">103,600,000<span></span>
</td>
<td class="nump">54,500,000<span></span>
</td>
<td class="nump">171,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="num">(4,500,000)<span></span>
</td>
<td class="nump">87,300,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">203,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">70,400,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">167,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember', window );">Leases | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments', window );">Leases</a></td>
<td class="num">(4,500,000)<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="nump">4,500,000<span></span>
</td>
<td class="nump">35,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,300,000<span></span>
</td>
<td class="nump">25,400,000<span></span>
</td>
<td class="nump">16,900,000<span></span>
</td>
<td class="nump">46,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,200,000<span></span>
</td>
<td class="nump">24,400,000<span></span>
</td>
<td class="nump">15,300,000<span></span>
</td>
<td class="nump">44,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | Non-U.S. Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLeaseIncomeLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6A<br> -URI https://asc.fasb.org/extlink&amp;oid=126900988&amp;loc=SL77927221-108306<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124258985&amp;loc=SL77919372-209981<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLeaseIncomeLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018607322080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 545.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01 | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 0.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01 | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 5.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01 | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01 | Leases</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation, amount</a></td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractDevelopmentAndManufacturingLeasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2023-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2025-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018694877200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Remaining Performance Obligation (Details)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-07-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">24 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2022-07-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605864800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue recognition - Contract Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ChangeinContractWithCustomerLiabilityRollForward', window );"><strong>Change in Contract With Customer, Liability [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning of period</a></td>
<td class="nump">$ 16.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ContractWithCustomerLiabilityAdditions', window );">Deferral of revenue</a></td>
<td class="nump">17.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_ContractWithCustomerLiabilityDeductions', window );">Revenue recognized</a></td>
<td class="num">(10.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">End of period</a></td>
<td class="nump">$ 24.3<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ChangeinContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in Contract With Customer, Liability [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ChangeinContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_ContractWithCustomerLiabilityDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Deductions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_ContractWithCustomerLiabilityDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126919976&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018609139680">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Revenue recognition - Accounts Receivable (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BilledContractReceivables', window );">Billed, net</a></td>
<td class="nump">$ 119.9<span></span>
</td>
<td class="nump">$ 224.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnbilledContractsReceivable', window );">Unbilled</a></td>
<td class="nump">55.1<span></span>
</td>
<td class="nump">49.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Total accounts receivable, net</a></td>
<td class="nump">$ 175.0<span></span>
</td>
<td class="nump">$ 274.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BilledContractReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BilledContractReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnbilledContractsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126938201&amp;loc=d3e55302-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnbilledContractsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018603130304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective annual tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Discrete tax expense (benefits)</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="num">$ (5.5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective annual tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018604839088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (loss) per share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">$ (56.4)<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="num">$ (60.1)<span></span>
</td>
<td class="nump">$ 74.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of shares-basic (in shares)</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">53.6<span></span>
</td>
<td class="nump">50.3<span></span>
</td>
<td class="nump">53.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Dilutive securities-equity awards (in shares)</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of shares-diluted (in shares)</a></td>
<td class="nump">50.0<span></span>
</td>
<td class="nump">54.0<span></span>
</td>
<td class="nump">50.3<span></span>
</td>
<td class="nump">54.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="num">$ (1.13)<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="nump">$ 1.40<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.13)<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="num">$ (1.19)<span></span>
</td>
<td class="nump">$ 1.37<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive stock awards (in shares)</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126962052&amp;loc=d3e4991-113900<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1707-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1500-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018599875632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Narrative (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Nov. 11, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of stock</a></td>
<td class="nump">$ 23.3<span></span>
</td>
<td class="nump">$ 75.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Repurchases of stock</a></td>
<td class="nump">$ 23.3<span></span>
</td>
<td class="nump">$ 75.5<span></span>
</td>
<td class="nump">$ 187.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodShares', window );">Stock repurchased during period, shares (in shares)</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Stock options granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember', window );">Tranche One | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Tranche Two | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Stock Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Tranche Three | Restricted Stock Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Award vesting rights, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockCommonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018602958832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 12.3<span></span>
</td>
<td class="nump">$ 11.4<span></span>
</td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="nump">$ 21.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product sales | Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of product sales | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">3.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 8.3<span></span>
</td>
<td class="nump">$ 7.7<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="nump">$ 15.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018599555776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Changes in Accumulated Other Comprehensive Loss (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 1,575.3<span></span>
</td>
<td class="nump">$ 1,522.8<span></span>
</td>
<td class="nump">$ 1,619.0<span></span>
</td>
<td class="nump">$ 1,447.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">7.7<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">1,513.2<span></span>
</td>
<td class="nump">1,543.7<span></span>
</td>
<td class="nump">1,513.2<span></span>
</td>
<td class="nump">1,543.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(9.3)<span></span>
</td>
<td class="num">(24.4)<span></span>
</td>
<td class="num">(16.1)<span></span>
</td>
<td class="num">(25.3)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(22.4)<span></span>
</td>
<td class="num">(6.1)<span></span>
</td>
<td class="num">(22.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember', window );">Defined Benefit Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
<td class="num">(4.0)<span></span>
</td>
<td class="num">(7.7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">1.8<span></span>
</td>
<td class="num">(7.9)<span></span>
</td>
<td class="num">(4.5)<span></span>
</td>
<td class="num">(11.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">1.9<span></span>
</td>
<td class="num">(0.1)<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent', window );">Amounts reclassified from accumulated other comprehensive loss</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">4.6<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="num">(6.4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>AOCI Attributable to Parent, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(7.1)<span></span>
</td>
<td class="num">(8.8)<span></span>
</td>
<td class="num">(7.6)<span></span>
</td>
<td class="num">(6.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent', window );">Other comprehensive income before reclassifications</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">$ (6.7)<span></span>
</td>
<td class="num">$ (8.3)<span></span>
</td>
<td class="num">$ (6.7)<span></span>
</td>
<td class="num">$ (8.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018599825040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="nump">$ 5.1<span></span>
</td>
<td class="nump">$ 1.7<span></span>
</td>
<td class="nump">$ 14.4<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Benefit (Expense)</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(4.4)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">3.2<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
<td class="nump">3.6<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Benefit (Expense)</a></td>
<td class="num">(1.0)<span></span>
</td>
<td class="nump">0.3<span></span>
</td>
<td class="num">(3.3)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">2.8<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent', window );">Pretax</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="num">(1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1', window );">Tax Benefit (Expense)</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(1.1)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive income (loss), net of tax</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="num">$ (1.7)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018605783824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018603485136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">$ 242.7<span></span>
</td>
<td class="nump">$ 397.5<span></span>
</td>
<td class="nump">$ 550.2<span></span>
</td>
<td class="nump">$ 740.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">65.6<span></span>
</td>
<td class="nump">144.3<span></span>
</td>
<td class="nump">207.6<span></span>
</td>
<td class="nump">366.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Adjusted gross margin</a></td>
<td class="nump">66.9<span></span>
</td>
<td class="nump">144.9<span></span>
</td>
<td class="nump">209.4<span></span>
</td>
<td class="nump">368.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Adjusted gross margin</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember', window );">Contracts and grants | Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7.3<span></span>
</td>
<td class="nump">25.4<span></span>
</td>
<td class="nump">16.9<span></span>
</td>
<td class="nump">46.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">237.2<span></span>
</td>
<td class="nump">181.2<span></span>
</td>
<td class="nump">474.3<span></span>
</td>
<td class="nump">319.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="num">(91.0)<span></span>
</td>
<td class="num">(81.2)<span></span>
</td>
<td class="num">(171.3)<span></span>
</td>
<td class="num">(133.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">103.6<span></span>
</td>
<td class="nump">54.5<span></span>
</td>
<td class="nump">171.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="num">(78.8)<span></span>
</td>
<td class="num">(146.6)<span></span>
</td>
<td class="num">(154.4)<span></span>
</td>
<td class="num">(193.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">237.2<span></span>
</td>
<td class="nump">181.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="nump">146.2<span></span>
</td>
<td class="nump">100.0<span></span>
</td>
<td class="nump">303.0<span></span>
</td>
<td class="nump">185.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Changes in fair value of contingent consideration</a></td>
<td class="nump">1.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Adjusted gross margin</a></td>
<td class="nump">147.5<span></span>
</td>
<td class="nump">100.6<span></span>
</td>
<td class="nump">304.8<span></span>
</td>
<td class="nump">187.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember', window );">Products | Product sales, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="num">(91.0)<span></span>
</td>
<td class="num">(81.2)<span></span>
</td>
<td class="num">(171.3)<span></span>
</td>
<td class="num">(133.8)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="num">(1.8)<span></span>
</td>
<td class="nump">190.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross margin</a></td>
<td class="num">(80.6)<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
<td class="num">(95.4)<span></span>
</td>
<td class="nump">181.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_ebs_AdjustedGrossMargin', window );">Adjusted gross margin</a></td>
<td class="num">(80.6)<span></span>
</td>
<td class="nump">44.3<span></span>
</td>
<td class="num">(95.4)<span></span>
</td>
<td class="nump">181.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services | Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems', window );"><strong>Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods and services sold</a></td>
<td class="num">$ (78.8)<span></span>
</td>
<td class="num">$ (146.6)<span></span>
</td>
<td class="num">$ (154.4)<span></span>
</td>
<td class="num">$ (193.3)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_AdjustedGrossMargin">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjusted Gross Margin</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_AdjustedGrossMargin</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ebs_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=ebs_ContractsAndGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.2</span><table class="report" border="0" cellspacing="2" id="idm140018607244816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Segment Reporting Information, by Segment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">$ 28.5<span></span>
</td>
<td class="nump">$ 18.5<span></span>
</td>
<td class="nump">$ 45.1<span></span>
</td>
<td class="nump">$ 32.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">2.4<span></span>
</td>
<td class="nump">3.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember', window );">Products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">6.7<span></span>
</td>
<td class="nump">8.7<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
<td class="nump">15.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember', window );">Services</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAbstract', window );"><strong>Depreciation:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Total</a></td>
<td class="nump">$ 20.8<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 28.6<span></span>
</td>
<td class="nump">$ 12.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ProductsSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=ebs_ServicesSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>ebs-20220630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:ebs="http://emergentbiosolutions.com/20220630"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="ebs-20220630.xsd" xlink:type="simple"/>
    <context id="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6a212ec24cf0433e91c08f5f7a4260f3_I20220726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2022-07-26</instant>
        </period>
    </context>
    <context id="ia80f097061ac4deb804ac1a7be81e63d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i72306a994b9b4e40b4c06153d3cccd44_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9b613598404b49b880eecce284caa409_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic14c595631e444d1b209fffe8cd22901_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i11d6b9ed7cef4daf9b8dc0c61d4b8f0b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7d9f1173bf46467fa504dd84e978c454_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i1cc2230d43ca419eb9859817a3e13e4a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i4c35eb92f4e94539aef959a8629ae0e7_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i122c38cfc545444f95a68c8027e7c09e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5db2e41be1c547f68cf80fdad0358d9c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib9d3fffbd0944df8a31002d86dafd0b1_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia599ba7606a14a5fa0bcefaa77322797_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ifef1158a0f1b4f9c9cfe6d88fe654e3b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2e3ddd561972469b83305bb2ad955b68_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibba5b2ada3cf4cb4a6b4ba683779728e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3a54e7d85e014e56956c4c0661a1e4ed_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2f9afc75663f4899a4fc9be307765379_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6f00bb59ea1746fbb21fbadf3f414a92_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2cff17dc6fc04ad7ab4b4434ef23201b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i400967d6466a4b58a011f5b045886df0_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id735715fbe6545b19ac836411202a5f0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i71c6824cc4fe485ca827c9836e570401_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i4b115351905c4ee2931cba201308bfe2_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ifcb77253dbaa4e16b55791df9ea6fddf_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ib6cd72da23074b5dbf0c4367cf392a9d_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53b18d134caf4ae2bba1d299e79c0f1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i53adab0b44f14127b1c4c4f2539a1807_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if87c2ef5ba4f4d7abb9178e57763e7ff_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i66eaca4aafd84de8a80ea8db300174dd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6c074f371d0a46638d50ebd9d45e0f59_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i26eb6b2c35ad4617b43852b247ceea23_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic692f65706164ee49ec3a380b592e311_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie7dc3abe30a64ca2932c00efd6517a60_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="if12d50ad93034fe0bf993311a0d00e34_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i4f4f1eaec93744e09d2a5e94ada672c5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i412510cc8ecb48538d8d3800311216b7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib20d47a77df04874a03809c71af93bb8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5addde9d9dae48a8ad041d366228d429_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i461082bcdf04496582b622477c82809e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i557996cf1b9849c7acfd550d094c2417_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ia2336cd80ecb49729b81f005c693fca9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i0ca88e5d8bf24c309e9d2a5171b224ec_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i05378be1d058489c8c528d17225c53e9_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ie7050e3a97a242b092682346cbd7cd4e_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="ib3bbf3905bf542958d5e24c590031249_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ide22df8c6fb348659c7397b47c73fe57_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2761304ddf59466ba7ad454fdf7d3b89_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ifcc26b21d7d8496f9bb774f7ac399651_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i12f7ee7f25e24cf382b2910e45037cd5_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i780e0257b99f470bac2458708cbdb98e_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i40faa34fd48c4a798a6fe90fe21fd4e5_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="idc5bcc44a9ca46599e2b25daa2a69029_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5d6dfa3b33ba4a26be19db91781e5050_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ie40f227742694bbdaee04db49ed26512_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i6387f180981b459b9fe20889f53d8b6c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i34769cb2cad546d9a34ee9510f37cbfd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i80b954c7fdb04b88b99f239e25180b5c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id3a86954dc6340629ca543163504fdb4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i14cd7836cc584c8fb4799a4f34d22bb3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ief6c31325bb94b9094ce98e80f0a6bb3_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i5589e73e44f74b778672ccad28f1df27_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i9cb30120c0cd4c26b09246b92a5b9300_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i6b789b56b81c4d9a9a529b16bb9daa53_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i0e62c5dc2e50467ca24d45cabc0c75e5_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie273c395662a4debaddeffc56206d4c3_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i3f1aae4f21ea48c7bb113f0bb2d224ed_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i84fb728efecd4d3eb00c3307db37929d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="idf50b30461ed4bd5aa0c129d970ef57d_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i7e7a561bc9634b07b67a3141075d5a76_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i6b62099afb4848769e1d1bd825d654a0_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id2eba64a7c8645ceb35da700cc48a11a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8db1424bf80e4508a67ed768a524f425_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id728fefbf15d4c8cabf2af784f9cb5fb_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i280deffd19c14987aeb06f69ff2cdd96_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ibf95dce5cfef405cba6b0d18b94cd870_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:MilestonePaymentFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i1fa607b80d2746cbb317c99fbd84728f_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:MilestonePaymentThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i7e44623ce7f0456191e95efe535f9f33_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:MilestonePaymentTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i4585a13ee1354a528f4c34f7706a0ec8_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:MilestonePaymentOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="ie9fd4d849f564c9fb40d3df840d093e5_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">ebs:ChimerixAssetAcquisitionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">ebs:RegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i8635afeff8644e21a1f82f113b82e3a3_D20220701-20220930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-01</startDate>
            <endDate>2022-09-30</endDate>
        </period>
    </context>
    <context id="i453d53e9bf31458986795e4f39e26923_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1bd46276d3b04bd4b23ff8a4977603af_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandAndLandImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i6549082d6bea4ee292c42fcb1e41c193_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i67809435803d4785af1d56017bd50fe5_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic594742899c1467ba744e0c848e9a5fc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if1a7d2d8b2634e30b07c0639a0a4ffe6_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i134070129abc4a5f994c045f64942b5a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i53d26d6afabb48b2bf9ddc2fb0a2211c_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerSoftwareIntangibleAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e92b9a6f4ef4b27b44d1e0436ee4f05_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9cc08f556fb64cd7881fbaf9a720bbb2_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i9546d5f25011482ea8eff2df29f3ff29_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9638e645586946feae3242935cd61d34_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iec5db6327b294813891aa4350122c017_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0ae91bff48a14d479830dd7525eb8ff8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2719aab9d5794354b6d5b105d461f2f5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia3702d910f4e4076ba85f38d2f42d7f4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1f3ab8a51d54481e9e87b3f7cd0d98a8_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaecb377a9b7d4fc4a9340b29e791ac69_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibb945e79e9d14eb897b6c2bb31d6fca4_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if7a3ff2d30f44b30ad269a86575c7d4e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i79799b3cea2d48fe835c4576542f0b52_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7f5ad802356e448ab1848888d53289de_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5b48ff71a5694921b7c29a1874507763_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i29e74e081ffd481a81c8d31209a72a7b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i84ec0dc532f44309a78a239914a64f67_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i8e03e34023ba4211b5ca4dafd5a90760_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if86a10b89dc447daa6d9d4bf87168919_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i2ff9b0c4a1d54ae9a2bbb36bb215f296_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia002b59284bc4d199415af1950deab8e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i05104b094a7244639351db2f1a5c4ae2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i7aad5be81d9e42518d03593f82a64ee7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="id5709272ba65411cb08a6afe257ae472_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icaad2ed6a61b4a8ca6f97ee4093e90dc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i0f9ea93856b0488caab05e73833c90f9_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i13b7d630bf0142c6885ef16b3dd8ee1b_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ia00c535b28684f0fb4f18a37ffde27d1_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i94171351ca92471d95422d2216ab5acb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia9e69b63b67f4da689c99626eb9b9b75_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i55840f9158e144dd8f3579713ad95750_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1827bdb5367f4f7980f91a6d166e8719_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i7b0124a24a6d42f38a22a139d7a986cc_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ia7ec6f53ea7c40c2912590dc96df1140_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ib3767e06a12a4c5e98d3e3277b684a7a_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i63a027931d994feaad0cc197610c9386_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i83059e6d4cbf495fac3749e03908d241_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i719981bf5f3142bcab25241944433a85_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">ebs:MeasurementInputProbabilityofPaymentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:ValuationTechniqueDiscountedCashFlowMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if69c9e056c6b47ce9a39e1690508a029_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="idb1acd071817481e9aef10fe54fb65fb_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i64a444e1b04f441690465f4274c0ba71_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5baf28559b9c4518961b9d35563505d5_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i8fef5a8c0e574704b4e7fc1c219ab3d0_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="iec600dcf49a542e999254859b44d9453_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i10a6fba32aca4cf289ec54a01e657a74_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i9db202080e4f497184ae1cf6144f3e2f_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ic20b9c06c3554129afcfbc3e3f02046b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic7068fe6db2b4311a9524223dac6fb00_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icee5403eeb9f41649ba99ccabe3e2da8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i05d57a1513ce46c68b959f35fdc72cec_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifa0b79c3b615467b86496c6b28174204_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="ibc3c3a4cf51a47be9050271b2311e72e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7f1e5afa818e49f1bb83f2fde4b26d1b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i906b83ea370446e3be94c4ddaaa4083e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i95dc7a5826cb458ea6fbfdfca937dcbd_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableOtherPayablesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ie971a34ecfcf4b408a15bfa4996e60a7_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ibb778bbc0bd64de7ad6801fd66de8bbc_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i1555249a53454772b48e904b14824e1d_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1485bfe38fce41ec95d481aecf94f617_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:OtherLongTermDebtFacilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="if549fa85623e479b8a4ea408bf3855e9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ife82c6e169cb463d8894b9c0060a4276_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="if194a1fa3b4249e29ea4d656684e16a6_I20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="i854ab883416b4f61a70d7a994a7e7dc8_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="ie7406b9184a64854a36cdc074d9b7efd_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i77bd92decaae4597a010ce330d685077_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:SeniorUnsecuredNotesDueAugust2028Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentRedemptionPeriodAxis">us-gaap:DebtInstrumentRedemptionPeriodTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i864f4e447766464d959250dafeb367a6_I20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:RevolvingCreditFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="i8d27dfde1b0a4ca9bd9806ae5f1fd0e0_I20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-08-07</instant>
        </period>
    </context>
    <context id="idd60b38179fc4f99af5a397c6f413c8c_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="ia4154b9a491b4ef2aff17f1e88bb8277_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="if1e09335afe7401fabaf417e79536c26_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:FederalFundsEffectiveSwapRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i97df715145c94a708ee00a7a333e62fa_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:EurodollarMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i9af3fed7d2eb49a0934cfdea363489d8_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i98549f959da647058170049a65c7b6c1_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:BaseRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i06495fe6675749ddb25cf196298c2fa3_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i3cc8672e8d254d8cbb23b229dcd959c8_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">ebs:TermLoanFacilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">ebs:AmendedCreditAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="ie462a20b8c7642d6ba2baedaff5e64eb_D20200807-20200807">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2020-08-07</startDate>
            <endDate>2020-08-07</endDate>
        </period>
    </context>
    <context id="i574f9adb7940424798f2d99703583daa_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7168a15913e0452ba5e8b7cc16cd596d_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i37b9298740734b91b9649eca3d31f872_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="icb0dfd1b367d4a4bbc9a8d933e8d12c5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i78916fe957f24b278cd2cf0ff71d751a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6f3b32beef6f4047a8dcd6932c3b547a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3037fdadacbb4e5f923277f2e26c9563_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6995a6427d454821b7f5573c0a1da3af_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2f3722b3ba404046b480130be3ff47cb_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7b2c6cc57c314379aa754295fc61f0c2_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ieedc7121a2874e219f1a1ca878ff2c37_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idfcb43efacdb406f820678d118bbcdd8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i7b31182d8bf44cb88f2e81054292fb42_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6ecb5143f5f7478faa5324a51e49bd6c_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="icba1568320d14f98b740134699420a7c_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i719033973c3c4e0790d3212f10dbadcd_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i16ac2c2d319f4a00960710084dc7bba7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7b6fd4492311495296403951539f5faf_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7a523ccb265741f5b098e936ed21f511_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia08e21eff6ed4142bc00ba76de36b98f_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib10b78dae7ed4de9bc5eb331206a3762_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i998d829e65ec4f968b9b5085e7009b74_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5c33e6e45e2f4158a121a529bf2b99e5_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i23b51504df3547d59b0d56b9f31e6a34_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ied017d66c9a04bb4b5c3696003cdbb8e_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie51251ad5ad54f02b4a1e43a1067e7f6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i306561841c10468db12c5597d3a0468a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id856ef449e024e50a897807c5afed116_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i658c5b8c655e4fe38b0b7f174e852ede_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3b9e160d23cc4468b348e9ba5f68fc60_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i766a0ecaa10f4c1f94e835811699f36d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idd47aaf57ffa4b1c9c70108fac1b456a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idead1f4a85bf4ee4931efc0bd2008a9a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i64e99aeb36a14462901695d8142755c7_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i06918d944d12481c84ebd11d669df56b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib92f173e44b44baea23201309efbbd31_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idb080faf3355468f962da743b6925f17_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7836569c48aa4398960b690e02f1638a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ie645b23e92d64b44af482e9d18e83a21_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib607439c17cf47a5a315dbba5676680b_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="idef67034a80d49fe8d29b21339809e4b_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i637fa78972d94585a80a29492e1528c4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia7f45031de4147aab74078725161519c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="id805e73cf4794980a908e6c22c926058_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4cf722f817414de59d8f7e7ec0bb2c95_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i265aa2e4d2d24bb5be2c124345a65d9c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ic78d782fd08747beb9ebc02fbc6bca30_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i813b606241794bedb7b0678f9d44767c_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i748c972f7e3046359ad4f7b45600bbb1_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ibb3cc4b31c2349e6b5a80a9253019e4b_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:JansenPharmaceuticalsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i073a439499194e698141d7a144b95b2c_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ic4a7c235f1654834a48248b64d3dc321_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:ReservationOfManufacturingCapacityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i7fa5c022d91149dabba1e1fa641192ee_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">ebs:AcceleratedExpansionOfFillFinishCapacityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i31dbfae47072459191568cdf89902293_I20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">ebs:BARDAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-31</instant>
        </period>
    </context>
    <context id="i078e4fd9eef24b03a26dff9571fa22d9_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie098330be0d142e7842c556f7a93810f_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i1b0d1f3a33164d8db9d0239f934f78e2_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2023-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ie526f761a4724513a2cc99ec8bd346cb_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2024-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icd351b95704f42138af3e4b83951e506_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2025-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5bd4b4922a534fcaa24291b742a545e6_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractDevelopmentAndManufacturingLeasesMember</xbrldi:explicitMember>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5c1bb85380c94c46946e590854b1feb8_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2022-07-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="icf331b5878004125a9676034ba0f2a5c_D20220101-20221231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="i9a9aaf25fc5d48ee87baec975ac47be1_D20210101-20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i46d185ce265a44359c45e086acb0e06f_I20211111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
        </entity>
        <period>
            <instant>2021-11-11</instant>
        </period>
    </context>
    <context id="idb62694863024c3a8c06044192e2a6da_D20211111-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-11</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id438572de7754b2f9af627f967ba0ce0_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i9c3242ff1d6e403fa058caec92b768c4_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i444f6b6169bc431ab44cce091d529975_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i68490917c6324e3abbbef73aefa2e5f9_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i4ba5495e2a404e7caafe9e03e3fe1861_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i5d37be8412c8482e947483881b8b5b51_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3d8109d0584c4f24a37d0e0942db1c06_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6e87ee8954dc437da9f27f6e09cd767a_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i775d01162a634709894e9ca391a7f259_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i483660136dd443e5916afc6418da38ad_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3497690a3cbd40f3b831488b3657d7c6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2848bd97786b4d5ba2937b70a2f4bf70_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i39ffb192289e4ce9a528e436037c0be5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i83dd17fd91084cafbcc04f18320932c2_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic952574703dd49c3a143c50a76cc5bb7_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i05f3f3064f53498493eda16fac112d94_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i55f86755507140aaa0522c374f09ab1d_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i79e636bd573c405188f12505ae586714_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i830521684abb4fd9aadb53001edc7379_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="ifac78b9519ad40da9ef031b1e7724460_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="icb61d55a3a5f4c6eb6ebb20e951d3dd3_I20211231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iec438a15507545e69f9ae19f0a3d5941_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i651fc075a09948b29a069bfed15ac793_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i6ae6af3ca5ff479b95eef53b77bd535e_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="i5904a41b0c2944d1bc9877b651a3f0fe_I20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="ic637379f0d8043d5af581e734aefd028_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8daff84a60ea419db78f98817926f778_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="if6289d96bf3f4d3dad0b8d93584c1fb1_I20220331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i43051341a0744172a54eb2e3094323d6_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i99c848d9c0ea44feaa1b6615d95059e2_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i5b18ce4c0ae74dff995c8a04ce8a3f19_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="ib3a73d2985e143b08dff3ac4720bea90_I20201231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i59961335356647079ef2934edbcfa823_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ia2ba91a37c45433382623dcdb7bd5722_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="id88c42efd11a49ef841182aac044455d_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i31cb95adcb0a43cb82eb1863ad9f5748_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i529a638b09f04a2a8bc2cc0b002cd45c_I20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="ia4ab0f0ae6ef4c1da3db1ce773f632c0_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i28b844ae659d4576b73d8e1361ed9d73_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="i1bf5df54710d4ea4b5ed41c57fe517a4_I20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i45ee1c733d0e40dc98fb96a0479d1554_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ic35d6a5efbec4048af7bd5ca4930dea6_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7520df23b29548ddbbab5ea7b1ed4131_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i274c949e1752478484975b83abb970eb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iaee9ec75282048039fa2f0a4d9211d2c_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id64db5439834429ba7ae71901959c5cb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3fa5b647069a475dbfe6550f70c5f6b9_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6ef607d7a3c7451f9fc91797c668e35b_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i865cea62a18543cb83411d9461069e79_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i30013848203544aaab36afb676ed3c64_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i3b063649105148fca27b7b94d3b8e412_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i46b2d87a49bb494a84bf9da22318cb73_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i05f0ccbd84a246cd8e98d3b72d6b8dd3_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i017940019b8f4dd28eddab4c25571c62_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i79dd2d62f4de4d778696638252882cf2_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2e1a370ad2f74ba9974ee7ae4c0046ea_D20220401-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i2256cc8ca6db4b8facf112f19dc9715b_D20210401-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i47cb7eb2f6354e03ac1eaca0de11507a_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i3159b0dd6390463898aef3e672bfd623_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">ebs:ContractsAndGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i5ef70cac4db448e4864f2175f2373dfd_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="id4d814b28862414f8af4e0b81c135010_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i8bd990b6a0ad4694b2c05770255685f3_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i6b72f2081fbf4b8284ba76726875fc2a_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i6bccaec18dd645feadb40845bece9039_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i10be8bddd4d942c08359df94ab97fea5_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="i7deb271d98c249298506cf1f896e57cb_D20220101-20220630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-06-30</endDate>
        </period>
    </context>
    <context id="iedc4cae43f3c454598ce8975dac330c5_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ProductsSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="ibc42e37be5a94e4f8f3591414bf596dd_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">ebs:ServicesSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="iffc6765500b949268c476664a96a2cc3_D20210101-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001367644</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="category">
        <measure>ebs:category</measure>
    </unit>
    <unit id="product">
        <measure>ebs:product</measure>
    </unit>
    <unit id="productcandidate">
        <measure>ebs:productCandidate</measure>
    </unit>
    <unit id="segment">
        <measure>ebs:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="treatmentcourse">
        <measure>ebs:treatmentCourse</measure>
    </unit>
    <unit id="instrument">
        <measure>ebs:instrument</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80L2ZyYWc6MDRlMzY1NTQ1MmNmNDc3Zjk2YTFkMzhiZGI3NjQ3MGQvdGFibGU6MjZiNzcyMDM3MzY1NDA5Zjk2ZjI5YzlhOTdlMjMxZTIvdGFibGVyYW5nZToyNmI3NzIwMzczNjU0MDlmOTZmMjljOWE5N2UyMzFlMl8zLTEtMS0xLTkxMjg0_73c42a08-cdfb-4a5e-ae31-a36fde012adf">0001367644</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80L2ZyYWc6MDRlMzY1NTQ1MmNmNDc3Zjk2YTFkMzhiZGI3NjQ3MGQvdGFibGU6MjZiNzcyMDM3MzY1NDA5Zjk2ZjI5YzlhOTdlMjMxZTIvdGFibGVyYW5nZToyNmI3NzIwMzczNjU0MDlmOTZmMjljOWE5N2UyMzFlMl80LTEtMS0xLTkxMjg0_870c7ff1-872e-4c94-9ee1-769c0c16b841">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:AmendmentFlag
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80L2ZyYWc6MDRlMzY1NTQ1MmNmNDc3Zjk2YTFkMzhiZGI3NjQ3MGQvdGFibGU6MjZiNzcyMDM3MzY1NDA5Zjk2ZjI5YzlhOTdlMjMxZTIvdGFibGVyYW5nZToyNmI3NzIwMzczNjU0MDlmOTZmMjljOWE5N2UyMzFlMl8xMC0xLTEtMS05MTI4NA_9ebfc814-43d3-443a-af8c-d02e73d7646f">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80L2ZyYWc6MDRlMzY1NTQ1MmNmNDc3Zjk2YTFkMzhiZGI3NjQ3MGQvdGFibGU6MjZiNzcyMDM3MzY1NDA5Zjk2ZjI5YzlhOTdlMjMxZTIvdGFibGVyYW5nZToyNmI3NzIwMzczNjU0MDlmOTZmMjljOWE5N2UyMzFlMl8xMi0xLTEtMS05MTI4NA_9cbb9059-caa3-46fe-8e40-90ba0d0b5a5a">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80L2ZyYWc6MDRlMzY1NTQ1MmNmNDc3Zjk2YTFkMzhiZGI3NjQ3MGQvdGFibGU6MjZiNzcyMDM3MzY1NDA5Zjk2ZjI5YzlhOTdlMjMxZTIvdGFibGVyYW5nZToyNmI3NzIwMzczNjU0MDlmOTZmMjljOWE5N2UyMzFlMl8xMy0xLTEtMS05MTI4NA_1440b707-939e-4924-9345-33e952ea4646">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_08a6d402-1277-48d2-bf99-60dd61290d59">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_1ed14031-8464-49dc-b194-cef65be5901a">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_27fc9abe-7aef-4a7b-ba2f-191204f5fc38">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_b64be59d-2273-4d6d-8743-cf67e2bb3dd4">http://fasb.org/us-gaap/2022#OtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_a0e6f1b3-d5ea-4f24-926b-07bfa08973d9">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_b0f3a4ed-4e9d-4073-9e24-438362666e2c">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod
      contextRef="ie462a20b8c7642d6ba2baedaff5e64eb_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82MS9mcmFnOjA1NDJiYTIwNmJjMjQwYjZiODhiMzVlMzc3MDczZWI0L3RleHRyZWdpb246MDU0MmJhMjA2YmMyNDBiNmI4OGIzNWUzNzcwNzNlYjRfMzIx_47c8099f-b98d-470f-a2a7-63be2c7df602">P12M</ebs:DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ie098330be0d142e7842c556f7a93810f_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82Ny9mcmFnOmYwYWUwMjMzYzA4MTQ1ZDliZTM4ZDgwNTAwM2NlZGU3L3RhYmxlOmEyMjU1N2VkNjRkMzQ0NGM5NzUyNDNlZWI3NjY0MTMyL3RhYmxlcmFuZ2U6YTIyNTU3ZWQ2NGQzNDQ0Yzk3NTI0M2VlYjc2NjQxMzJfMi0xLTEtMS05MTI4NA_747e848e-dd04-4b6b-b59e-5735ceeec530">P6M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i1b0d1f3a33164d8db9d0239f934f78e2_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82Ny9mcmFnOmYwYWUwMjMzYzA4MTQ1ZDliZTM4ZDgwNTAwM2NlZGU3L3RhYmxlOmEyMjU1N2VkNjRkMzQ0NGM5NzUyNDNlZWI3NjY0MTMyL3RhYmxlcmFuZ2U6YTIyNTU3ZWQ2NGQzNDQ0Yzk3NTI0M2VlYjc2NjQxMzJfMy0xLTEtMS05MTI4NA_6f43f310-e161-4777-a866-671472e8f3a1">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="ie526f761a4724513a2cc99ec8bd346cb_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82Ny9mcmFnOmYwYWUwMjMzYzA4MTQ1ZDliZTM4ZDgwNTAwM2NlZGU3L3RhYmxlOmEyMjU1N2VkNjRkMzQ0NGM5NzUyNDNlZWI3NjY0MTMyL3RhYmxlcmFuZ2U6YTIyNTU3ZWQ2NGQzNDQ0Yzk3NTI0M2VlYjc2NjQxMzJfNC0xLTEtMS05MTI4NA_f236acba-fa4d-4ddc-8d78-fe944fff6326">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="icd351b95704f42138af3e4b83951e506_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82Ny9mcmFnOmYwYWUwMjMzYzA4MTQ1ZDliZTM4ZDgwNTAwM2NlZGU3L3RhYmxlOmEyMjU1N2VkNjRkMzQ0NGM5NzUyNDNlZWI3NjY0MTMyL3RhYmxlcmFuZ2U6YTIyNTU3ZWQ2NGQzNDQ0Yzk3NTI0M2VlYjc2NjQxMzJfNS0xLTEtMS05MTI4NA_7214eead-cc83-46d0-a357-dd80626c7ec8">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i5bd4b4922a534fcaa24291b742a545e6_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82Ny9mcmFnOmYwYWUwMjMzYzA4MTQ1ZDliZTM4ZDgwNTAwM2NlZGU3L3RhYmxlOmEyMjU1N2VkNjRkMzQ0NGM5NzUyNDNlZWI3NjY0MTMyL3RhYmxlcmFuZ2U6YTIyNTU3ZWQ2NGQzNDQ0Yzk3NTI0M2VlYjc2NjQxMzJfNi0xLTEtMS05MTI4NA_fb8da6a4-b627-43ae-991b-eee3fb083302"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ic35d6a5efbec4048af7bd5ca4930dea6_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMS0xLTEtMS05MTI4NA_ee3774d5-fbe7-4535-a72a-7a9606170289"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i7520df23b29548ddbbab5ea7b1ed4131_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMS0yLTEtMS05MTI4NA_4927097c-d24c-46f0-9a9e-af069a6dcd43"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i274c949e1752478484975b83abb970eb_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMi0xLTEtMS05MTI4NA_e1bba275-077c-4ed1-ab17-0274f2e0f451"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="iaee9ec75282048039fa2f0a4d9211d2c_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMi0yLTEtMS05MTI4NA_e20d84d3-2e62-4546-9b3f-5ce637de9579"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="id64db5439834429ba7ae71901959c5cb_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMy0xLTEtMS05MTI4NA_4e20ba92-6d43-4a63-ab12-bd09f4f3961a"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i3fa5b647069a475dbfe6550f70c5f6b9_D20220101-20220630"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83OS9mcmFnOjIyYjQ2YjBmMTA0MzRlMmY4OWJiY2RjZDQzZWMwYzVjL3RhYmxlOjEwMDhkNWIzNTg1YTRmY2U5MmI0ODg2ODFjMWY2NTQ2L3RhYmxlcmFuZ2U6MTAwOGQ1YjM1ODVhNGZjZTkyYjQ4ODY4MWMxZjY1NDZfMy0yLTEtMS05MTI4NA_c5928495-2bb3-47f9-890f-7c43c64c207e"
      unitRef="number">0.3333</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI5_19358248-8c0c-485a-92d7-7d4b490bf6ce">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6ZjZjODlkNzU4MTc0NGFiNThiZTg4N2QyMmFmODY4MTkvdGFibGVyYW5nZTpmNmM4OWQ3NTgxNzQ0YWI1OGJlODg3ZDIyYWY4NjgxOV8wLTAtMS0xLTkxMjg0_1afd6c91-66db-43fd-8347-71d33c3c76a9">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xMzI_2b9be555-ae6d-4662-a042-1e9b2974cd29">2022-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MDU1MGYwNDk0YTFhNDNjM2FlNjgyMjJlOTY1MDlmODUvdGFibGVyYW5nZTowNTUwZjA0OTRhMWE0M2MzYWU2ODIyMmU5NjUwOWY4NV8wLTAtMS0xLTkxMjg0_82d4f8b0-dbc0-4848-906f-04c6c4db183a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODIz_95b9d553-e147-4090-9def-09e916932fba">001-33137</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI1_b0c0404a-e413-4bb3-b028-6470ac5da3f8">EMERGENT BIOSOLUTIONS INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF8wLTAtMS0xLTkxMjg0_a21989d8-f53c-416e-b4f8-e7027d85af67">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF8wLTItMS0xLTkxMjg0_4cbd5fe4-5df1-45e3-9b72-f418f974d0f8">14-1902018</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF8zLTAtMS0xLTkxMjg0_ba9f33c3-0ed2-417f-98af-e174d7fdb6f3">400 Professional Drive Suite 400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF80LTAtMS0xLTkxMjg0_5124614f-6a27-4a57-9688-7df9c87adb25">Gaithersburg,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF80LTEtMS0xLTkxMjg0_55952a5e-e26e-4b97-a4b8-6699ff848ffe">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MmYzNzhjNWE0YTJhNDMyMjhmMDk5Y2U3MjZhNjAxOWQvdGFibGVyYW5nZToyZjM3OGM1YTRhMmE0MzIyOGYwOTljZTcyNmE2MDE5ZF80LTItMS0xLTkxMjg0_01fb9ae7-fdbc-4686-8175-590e24205f69">20879</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI2_e8d06674-4eda-4554-8308-79d30959c82e">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI0_7cd533cc-a061-43ad-a47c-5e43fd725f43">631-3200</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MzcxNjk4NjkzZDM4NDgyMTg2NTIxZGI2Njg4OTM5MWQvdGFibGVyYW5nZTozNzE2OTg2OTNkMzg0ODIxODY1MjFkYjY2ODg5MzkxZF8yLTAtMS0xLTkxMjg0_bb0a5c18-5247-4fe0-8c7a-ff3ebd9b5643">Common Stock, Par Value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MzcxNjk4NjkzZDM4NDgyMTg2NTIxZGI2Njg4OTM5MWQvdGFibGVyYW5nZTozNzE2OTg2OTNkMzg0ODIxODY1MjFkYjY2ODg5MzkxZF8yLTEtMS0xLTkxMjg0_af1de316-42d2-4f2c-b908-a4450d41c0bf">EBS</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MzcxNjk4NjkzZDM4NDgyMTg2NTIxZGI2Njg4OTM5MWQvdGFibGVyYW5nZTozNzE2OTg2OTNkMzg0ODIxODY1MjFkYjY2ODg5MzkxZF8yLTItMS0xLTkxMjg0_3cf3fc94-7b72-4b0b-94dc-41d91217633b">NYSE</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODIy_b2823525-5f83-4a82-9ce9-c86ec12f11db">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI3_df487248-d2d1-42e6-8cde-65d0bebace43">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MTU0MWFiMDU0MTE5NGEzODg2OTUyMTI1M2MyYjUxZTkvdGFibGVyYW5nZToxNTQxYWIwNTQxMTk0YTM4ODY5NTIxMjUzYzJiNTFlOV8wLTAtMS0xLTkxMjg0_966187f3-67ad-4747-8137-7a9b1cfaa1fe">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MTU0MWFiMDU0MTE5NGEzODg2OTUyMTI1M2MyYjUxZTkvdGFibGVyYW5nZToxNTQxYWIwNTQxMTk0YTM4ODY5NTIxMjUzYzJiNTFlOV8xLTMtMS0xLTkxMjg0_03c2a1bc-a651-4f5f-9eea-7c7bc407331d">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGFibGU6MTU0MWFiMDU0MTE5NGEzODg2OTUyMTI1M2MyYjUxZTkvdGFibGVyYW5nZToxNTQxYWIwNTQxMTk0YTM4ODY5NTIxMjUzYzJiNTFlOV8yLTMtMS0xLTkxMjg0_c3ab60d6-bb8b-4857-910a-e8e8204e8dd2">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xODI4_b0bd934b-0d91-4abf-9076-2991484fd81e">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i6a212ec24cf0433e91c08f5f7a4260f3_I20220726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xL2ZyYWc6NjBjMmIzYTViZTM4NDNkMDgwNjExZWYwOGY4NzU2MmYvdGV4dHJlZ2lvbjo2MGMyYjNhNWJlMzg0M2QwODA2MTFlZjA4Zjg3NTYyZl8xNzg1_f75b1983-27d8-42bc-82a8-1bef09279b23"
      unitRef="shares">49861509</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMy0xLTEtMS05MTI4NA_b44b9c31-2da1-43a0-b913-dbe1ce48b964"
      unitRef="usd">358100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMy0zLTEtMS05MTI4NA_039e860f-5788-4718-82fa-91dbf715f322"
      unitRef="usd">576100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNC0xLTEtMS05MTI4NA_912021b3-a8e6-4e8e-b711-aa8d7c485c9d"
      unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNC0zLTEtMS05MTI4NA_a095dbde-7816-4f70-8a5b-f4c2a66acf6c"
      unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNS0xLTEtMS05MTI4NA_964964ce-c882-4406-bc3f-5a816ac0c18a"
      unitRef="usd">175000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNS0zLTEtMS05MTI4NA_cb906f86-c3df-4f01-abdf-f29a0ec7f049"
      unitRef="usd">274700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNi0xLTEtMS05MTI4NA_87d89b30-8391-42ed-b83a-b5543efd4aa2"
      unitRef="usd">425500000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNi0zLTEtMS05MTI4NA_cf288b83-9185-4f63-9e47-21d65f4d9ea1"
      unitRef="usd">350800000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNy0xLTEtMS05MTI4NA_998a14d1-4fc9-46c3-b9e3-f114c33f7371"
      unitRef="usd">125400000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNy0zLTEtMS05MTI4NA_c20c2394-03c6-495f-994e-c7c569dd80d5"
      unitRef="usd">70300000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfOC0xLTEtMS05MTI4NA_7be33fb1-6859-49e5-a711-6c9d1362641c"
      unitRef="usd">1084200000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfOC0zLTEtMS05MTI4NA_6663beb8-5d40-401a-a4a1-b841b7fb12b5"
      unitRef="usd">1272100000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTAtMS0xLTEtOTEyODQ_2177257e-6a8b-48d5-baeb-b254902a1c53"
      unitRef="usd">798400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTAtMy0xLTEtOTEyODQ_7dd1d855-dfc3-49db-9e47-258954fbf28f"
      unitRef="usd">800100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTEtMS0xLTEtOTEyODQ_a675c21d-3408-47f5-8463-4c4839f45d72"
      unitRef="usd">576600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTEtMy0xLTEtOTEyODQ_63a03743-f074-4283-8f6b-47963bf65326"
      unitRef="usd">604600000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTItMS0xLTEtOTEyODQ_dc51dfa4-eaf0-402c-b757-05b87b01e62f"
      unitRef="usd">224900000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTItMy0xLTEtOTEyODQ_0049ce99-6159-4cd0-b91d-a0ba221494a0"
      unitRef="usd">224900000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTMtMS0xLTEtOTEyODQ_a5252a86-37bb-4969-8d17-b84548a3063f"
      unitRef="usd">51300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTMtMy0xLTEtOTEyODQ_4016b2ba-7e05-411d-ba93-f551cdefa749"
      unitRef="usd">57300000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTQtMS0xLTEtOTEyODQ_8c39d197-2307-44fc-bbf6-b16db2d949ab"
      unitRef="usd">2735400000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTQtMy0xLTEtOTEyODQ_5e89c5e1-ca3a-44fc-8c06-9b1be9180677"
      unitRef="usd">2959000000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTgtMS0xLTEtOTEyODQ_49a0ddb1-fd57-45bc-ab1e-fd3e88caf283"
      unitRef="usd">106200000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTgtMy0xLTEtOTEyODQ_8d4d5786-d79c-47fd-8540-c363c6ef5996"
      unitRef="usd">128900000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTktMS0xLTEtOTEyODQ_232123f3-6da1-4547-864d-d6e2ef046f70"
      unitRef="usd">40300000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMTktMy0xLTEtOTEyODQ_a97ea8bb-2772-4c94-ad03-b0b3a2ba857f"
      unitRef="usd">51700000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjAtMS0xLTEtOTEyODQ_e314b580-4f40-4d89-b2c6-a9660a1fdc5e"
      unitRef="usd">74400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjAtMy0xLTEtOTEyODQ_e7ecadb3-966a-446c-b811-c8edfbfe5ad7"
      unitRef="usd">88700000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjEtMS0xLTEtOTEyODQ_657837a8-c54a-4d43-9761-f1d43f0d1cd8"
      unitRef="usd">31600000</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjEtMy0xLTEtOTEyODQ_28aaaff4-ca15-4829-8b38-eac66d8303f2"
      unitRef="usd">31600000</us-gaap:NotesPayableCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjItMS0xLTEtOTEyODQ_656a91b5-259e-4f05-8b66-8bac3b4de0ed"
      unitRef="usd">24200000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjItMy0xLTEtOTEyODQ_770c3cae-a2e6-4e9f-b681-75f3fa3cf7a3"
      unitRef="usd">72900000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjMtMS0xLTEtOTEyODQ_44f340aa-ed5d-461b-8da2-51261cb4ba6a"
      unitRef="usd">276700000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjMtMy0xLTEtOTEyODQ_bb5c8a00-649b-4723-8e96-3ca9a12b8dc5"
      unitRef="usd">373800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjYtMS0xLTEtOTEyODQ_2163dfd2-8476-4490-b9f3-f17778739438"
      unitRef="usd">793600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjYtMy0xLTEtOTEyODQ_e3769f1f-1035-411c-be87-abb36c8a8b25"
      unitRef="usd">809400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjctMS0xLTEtOTEyODQ_554df853-c08f-4d57-9718-5083bd2fbb44"
      unitRef="usd">93400000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjctMy0xLTEtOTEyODQ_0abc611b-50ed-4db7-91ed-c1b830634906"
      unitRef="usd">94900000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjktMS0xLTEtOTEyODQ_b3000755-0e65-40b1-aadf-f67fa4706082"
      unitRef="usd">58500000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMjktMy0xLTEtOTEyODQ_792d8010-dc68-46b1-bddc-f816769889ac"
      unitRef="usd">61900000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzAtMS0xLTEtOTEyODQ_0588c844-edf3-4b13-b6d4-7cb89b205a60"
      unitRef="usd">1222200000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzAtMy0xLTEtOTEyODQ_2975b066-009f-487c-9d24-4235cbd5961d"
      unitRef="usd">1340000000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN18yMQ_a4bcf828-504d-4f0e-9352-ce068c72d08e"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN18yMQ_a577647c-63ab-4d96-80fb-8f84f14c24a4"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN18zNQ_20a0f357-841a-4fcc-8d3a-da29a73fffde"
      unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN18zNQ_82ae7f2a-d6f3-4ad4-ac6d-4a1097dd62ab"
      unitRef="shares">15000000.0</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN181Nw_31b33e30-ffaa-4868-8ead-f1308fa4515d"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN181Nw_3c575594-cddd-4c5f-923d-90c866965e2e"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN181Nw_6a8661c8-8020-450c-a142-64cde27e68bc"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpjYjQ1OGNkMGQzMDc0NGEzYWQyMGQzNDUwM2I2M2UwN181Nw_6cb8d395-9c54-49fb-b334-97efce53db6d"
      unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMS0xLTEtOTEyODQ_553f9da3-0da2-483d-984c-2901a74b6ea3"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzMtMy0xLTEtOTEyODQ_0db75f30-1d08-4419-a34b-dbea89f0be6d"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY18xOA_24ea57bf-f386-4fa8-af28-ac4962ed18d7"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY18xOA_fdcf565b-22d2-4a42-852f-0a8a00594fda"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY18zMg_3bf0e4f8-aedd-4109-9875-37e4b7413581"
      unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY18zMg_9507f12c-9d40-44b7-ae2d-336e8289516c"
      unitRef="shares">200000000.0</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY182NTk3MDY5NzY2Nzc4_f4cf9489-a95a-4816-951f-e87d4b695769"
      unitRef="shares">55500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY182MQ_7f6382f3-e9c9-4b38-ad64-330393c63097"
      unitRef="shares">55100000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY182NTk3MDY5NzY2Nzg2_b672a85f-927c-4e76-ac38-f30a8aa14964"
      unitRef="shares">49900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjo4MDNmYjBjY2M4NTU0ZTg0OTgxOTNiMTI3YjNhYWQyY184Ng_8e78a166-e926-478e-a568-75b2b8457024"
      unitRef="shares">51300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMS0xLTEtOTEyODQ_98c93ab4-8775-4c77-adda-0be2d0cf3e71"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzQtMy0xLTEtOTEyODQ_d39b935d-ef46-4c0e-9cc1-c395e01aa080"
      unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:TreasuryStockShares
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzUtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjphNzUzZmU2YjAxODM0YWE3OTQ2ZDk4Yjk5OWRjNGU3Ml82NTk3MDY5NzY2NzI3_cba6e87f-08b3-4b6f-8f66-148dfdc25089"
      unitRef="shares">5600000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzUtMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjphNzUzZmU2YjAxODM0YWE3OTQ2ZDk4Yjk5OWRjNGU3Ml82NTk3MDY5NzY2NzMz_961d6e45-924e-4138-a203-28005e46a6a3"
      unitRef="shares">3800000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzUtMS0xLTEtOTEyODQ_88b0f74c-43cc-44da-a55f-0778abb67d35"
      unitRef="usd">227700000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzUtMy0xLTEtOTEyODQ_a6927704-a5fc-4005-ac64-0f4400aa3418"
      unitRef="usd">152200000</us-gaap:TreasuryStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzYtMS0xLTEtOTEyODQ_501dda8f-96df-4568-9b68-80ea0f95c5fa"
      unitRef="usd">849200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzYtMy0xLTEtOTEyODQ_f0306364-0f42-485b-93cd-3352d9634614"
      unitRef="usd">829400000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzctMS0xLTEtOTEyODQ_72ebbb59-70c5-4380-8817-b2c60e56a92e"
      unitRef="usd">-6100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzctMy0xLTEtOTEyODQ_39d7da36-f35b-4950-a99c-e3819a3d2057"
      unitRef="usd">-16100000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzgtMS0xLTEtOTEyODQ_d69f2166-a715-40db-a659-e1c4086e5e19"
      unitRef="usd">897700000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzgtMy0xLTEtOTEyODQ_355fda08-aaee-41fa-8ccf-d2f08ca6fbe5"
      unitRef="usd">957800000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzktMS0xLTEtOTEyODQ_e2c17d38-0c6a-42de-bef0-ee11da9339a5"
      unitRef="usd">1513200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfMzktMy0xLTEtOTEyODQ_089668d4-e015-45b4-a8d0-f3b0b340c1dc"
      unitRef="usd">1619000000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNDAtMS0xLTEtOTEyODQ_8c931112-58ed-476e-b857-353a3936c727"
      unitRef="usd">2735400000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xNi9mcmFnOjU0ODkwMjVlZmI2MDRhZjQ4MmYxNWQwZTE2NDg5ODUzL3RhYmxlOjkzOGU3YmY3NjRiMjRjN2I4YzViYTkxODFkMjVmOGUxL3RhYmxlcmFuZ2U6OTM4ZTdiZjc2NGIyNGM3YjhjNWJhOTE4MWQyNWY4ZTFfNDAtMy0xLTEtOTEyODQ_d2b6b1a0-9af3-4627-a46f-858fa7c5888e"
      unitRef="usd">2959000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b613598404b49b880eecce284caa409_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMy0xLTEtMS05MTI4NA_c650ae41-e9fd-4bcd-99b7-b386872e2af8"
      unitRef="usd">237200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic14c595631e444d1b209fffe8cd22901_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMy0zLTEtMS05MTI4NA_0c4f2996-8b1b-4445-9b18-0404fe6b2cd6"
      unitRef="usd">181200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMy01LTEtMS05MTI4NA_bef3dee7-bc7f-4d20-abfd-8c447b470f25"
      unitRef="usd">474300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMy03LTEtMS05MTI4NA_ef11309b-0201-4e15-b63e-44b73acd7a0b"
      unitRef="usd">319100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11d6b9ed7cef4daf9b8dc0c61d4b8f0b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNS0xLTEtMS05MTI4NA_f7709277-5360-4aa7-b1fd-05ed1804cabf"
      unitRef="usd">2700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d9f1173bf46467fa504dd84e978c454_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNS0zLTEtMS05MTI4NA_5162b90a-6645-483b-ba9e-def04fb32f04"
      unitRef="usd">103600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cc2230d43ca419eb9859817a3e13e4a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNS01LTEtMS05MTI4NA_f3700bb8-2c47-4d84-9ac1-ee88a162e5ce"
      unitRef="usd">54500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c35eb92f4e94539aef959a8629ae0e7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNS03LTEtMS05MTI4NA_914bf6cd-adc3-4e6f-9e1e-02c265791f8f"
      unitRef="usd">171200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i122c38cfc545444f95a68c8027e7c09e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNi0xLTEtMS05MTI4NA_1185d7a4-2623-4a68-b463-1ab283a16bbc"
      unitRef="usd">-4500000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i5db2e41be1c547f68cf80fdad0358d9c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNi0zLTEtMS05MTI4NA_160df036-2496-4b41-bac3-c1144311d812"
      unitRef="usd">87300000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ib9d3fffbd0944df8a31002d86dafd0b1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNi01LTEtMS05MTI4NA_7633bb3c-7baf-4003-b5df-2b59c8f07887"
      unitRef="usd">4500000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ia599ba7606a14a5fa0bcefaa77322797_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNi03LTEtMS05MTI4NA_223611bd-f544-4e26-9cc6-2c6c5004560b"
      unitRef="usd">203500000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifef1158a0f1b4f9c9cfe6d88fe654e3b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNy0xLTEtMS05MTI4NA_ed1beef0-0428-4b15-9c2d-e1e08869d6f5"
      unitRef="usd">-1800000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e3ddd561972469b83305bb2ad955b68_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNy0zLTEtMS05MTI4NA_7856c86d-594a-4d2b-814a-fa017a569438"
      unitRef="usd">190900000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibba5b2ada3cf4cb4a6b4ba683779728e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNy01LTEtMS05MTI4NA_0a64b80a-0c08-455d-8efb-fb1dfcd78801"
      unitRef="usd">59000000.0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a54e7d85e014e56956c4c0661a1e4ed_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfNy03LTEtMS05MTI4NA_f8ce7c88-bebf-471f-b347-66cbab8090cb"
      unitRef="usd">374700000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f9afc75663f4899a4fc9be307765379_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOC0xLTEtMS05MTI4NA_096ad706-a2e1-4d07-a23b-17a18b9de0b5"
      unitRef="usd">7300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f00bb59ea1746fbb21fbadf3f414a92_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOC0zLTEtMS05MTI4NA_66cd547d-f6ac-495a-ab26-fd3b1d256676"
      unitRef="usd">25400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cff17dc6fc04ad7ab4b4434ef23201b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOC01LTEtMS05MTI4NA_8a534fb2-9772-4f9d-9cf2-2246fa205bf9"
      unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i400967d6466a4b58a011f5b045886df0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOC03LTEtMS05MTI4NA_351d17b5-8976-41e6-9afc-60d8508538a3"
      unitRef="usd">46700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOS0xLTEtMS05MTI4NA_05aacc0c-49bb-4ba3-9c74-959f252a3dc8"
      unitRef="usd">242700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOS0zLTEtMS05MTI4NA_d21a99b4-379d-4ca5-b23f-3c4e12b715b0"
      unitRef="usd">397500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOS01LTEtMS05MTI4NA_d8130bd9-cf70-4798-b592-1e6444c671c0"
      unitRef="usd">550200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfOS03LTEtMS05MTI4NA_1e0786b6-3e71-4c6c-84f4-d6675269b3dc"
      unitRef="usd">740500000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9b613598404b49b880eecce284caa409_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTItMS0xLTEtOTEyODQ_ba4e6f47-0175-4440-b9b7-bb4f94854de0"
      unitRef="usd">91000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic14c595631e444d1b209fffe8cd22901_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTItMy0xLTEtOTEyODQ_82b36723-c2e1-401d-bcfa-2fe4c9250c3d"
      unitRef="usd">81200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTItNS0xLTEtOTEyODQ_71e214c2-55c2-4773-8191-22aaa104e0ac"
      unitRef="usd">171300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTItNy0xLTEtOTEyODQ_81cc9c9b-4087-46dd-8b67-8dd4e371c13e"
      unitRef="usd">133800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i11d6b9ed7cef4daf9b8dc0c61d4b8f0b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTMtMS0xLTEtOTEyODQ_c7742bf0-4dda-49fa-84be-a2911812fb80"
      unitRef="usd">78800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7d9f1173bf46467fa504dd84e978c454_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTMtMy0xLTEtOTEyODQ_59b98390-10a4-455a-9552-87753364407b"
      unitRef="usd">146600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1cc2230d43ca419eb9859817a3e13e4a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTMtNS0xLTEtOTEyODQ_5883c54d-a689-45c1-a014-992242358de4"
      unitRef="usd">154400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4c35eb92f4e94539aef959a8629ae0e7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTMtNy0xLTEtOTEyODQ_321ef561-96a9-446e-b8e0-e9b11289f684"
      unitRef="usd">193300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTQtMS0xLTEtOTEyODQ_5f7a7715-e7f7-4fbf-b25e-c2ba15cf3dfb"
      unitRef="usd">49800000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTQtMy0xLTEtOTEyODQ_270f0757-e44b-4b6d-a531-89b4f1ca1a8c"
      unitRef="usd">48900000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTQtNS0xLTEtOTEyODQ_d84c0f67-cd13-4650-bb60-87e5bb2786a1"
      unitRef="usd">96200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTQtNy0xLTEtOTEyODQ_6f2deba4-7bec-48ed-9bc7-2a307bd5b689"
      unitRef="usd">101400000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTUtMS0xLTEtOTEyODQ_9668ca24-ca5a-4936-b9e5-18e92dcfdbe7"
      unitRef="usd">81100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTUtMy0xLTEtOTEyODQ_df4241f9-ad9b-41f8-b30c-7552e2505347"
      unitRef="usd">91200000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTUtNS0xLTEtOTEyODQ_b172e539-d5dd-428b-af4c-241445ea09f7"
      unitRef="usd">165900000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTUtNy0xLTEtOTEyODQ_73479a84-046c-4819-b6e3-4bb5671e61f8"
      unitRef="usd">172100000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTYtMS0xLTEtOTEyODQ_02bff75d-b483-4bcc-9789-859f39c3cbf8"
      unitRef="usd">14000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTYtMy0xLTEtOTEyODQ_6100e97d-9c8a-4f15-95c0-70f0e6ce8221"
      unitRef="usd">15100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTYtNS0xLTEtOTEyODQ_39262831-7ba8-4708-8203-d977ed4c7892"
      unitRef="usd">28000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTYtNy0xLTEtOTEyODQ_c3542337-243f-4c04-95b1-0f431301fc5b"
      unitRef="usd">30000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTctMS0xLTEtOTEyODQ_85c5ed90-91a6-463f-a252-68ffd9707409"
      unitRef="usd">314700000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTctMy0xLTEtOTEyODQ_98d0d39d-023b-4e49-861b-7cdea5b69cae"
      unitRef="usd">383000000.0</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTctNS0xLTEtOTEyODQ_c6da47da-460a-456e-9c63-ff15a2aab08f"
      unitRef="usd">615800000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingCostsAndExpenses
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTctNy0xLTEtOTEyODQ_0c8eb9f3-a0fe-485b-afa4-b6a88bb40f1f"
      unitRef="usd">630600000</us-gaap:OperatingCostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTktMS0xLTEtOTEyODQ_98d6f79d-be1f-4f2c-b235-b4c5240d5939"
      unitRef="usd">-72000000.0</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTktMy0xLTEtOTEyODQ_981adb4f-68e9-4ffc-942f-7b6eaa9c743f"
      unitRef="usd">14500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTktNS0xLTEtOTEyODQ_7ce6d80b-251b-40cc-9b3b-1a209d754eda"
      unitRef="usd">-65600000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMTktNy0xLTEtOTEyODQ_7f3ea9ca-34c9-43da-924b-5267953f053c"
      unitRef="usd">109900000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjItMS0xLTEtOTEyODQ_b3dcf948-876c-4a94-9620-4e1d3c0dde1b"
      unitRef="usd">7800000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjItMy0xLTEtOTEyODQ_eac523ee-8686-4f6d-bb5b-106fbd82e6f7"
      unitRef="usd">8600000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjItNS0xLTEtOTEyODQ_ed11673d-4f78-4879-9614-48a2991eaa15"
      unitRef="usd">16000000.0</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjItNy0xLTEtOTEyODQ_c14d81cf-183d-4777-9bab-4fffd91b608c"
      unitRef="usd">17100000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjMtMS0xLTEtOTEyODQ_423de44a-a82d-4178-9fa1-6e48a425fe1c"
      unitRef="usd">-3000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjMtMy0xLTEtOTEyODQ_dabf9b82-32c5-4360-88fb-dd604ca5dea8"
      unitRef="usd">1300000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjMtNS0xLTEtOTEyODQ_3bcbce68-0e5d-4da1-874a-5f6feeadd28e"
      unitRef="usd">-5000000.0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjMtNy0xLTEtOTEyODQ_edc05302-6fc2-4588-be5b-4636c7f4d916"
      unitRef="usd">-400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjQtMS0xLTEtOTEyODQ_58f8c0c7-ef6c-4255-bc09-8db7054571c8"
      unitRef="usd">-10800000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjQtMy0xLTEtOTEyODQ_5c68ab4c-7391-4f7f-8917-b63b0c4cc212"
      unitRef="usd">-7300000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjQtNS0xLTEtOTEyODQ_2949e0fa-2f9f-4e76-bf76-9ae399029e77"
      unitRef="usd">-21000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjQtNy0xLTEtOTEyODQ_a52279db-89a9-4255-9696-b28432ef066f"
      unitRef="usd">-17500000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjYtMS0xLTEtOTEyODQ_b726c2fa-1ab9-4100-b210-d6db46e3bbd7"
      unitRef="usd">-82800000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjYtMy0xLTEtOTEyODQ_c0de5ce8-d118-47d7-9183-9afe491421b9"
      unitRef="usd">7200000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjYtNS0xLTEtOTEyODQ_354ff8b5-e7c4-42b7-a97b-ce1b6c6ab4b9"
      unitRef="usd">-86600000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjYtNy0xLTEtOTEyODQ_b5e9ced8-8f15-4942-8f24-1a32d0b60d53"
      unitRef="usd">92400000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjctMS0xLTEtOTEyODQ_4f388303-9310-4ba7-9691-73d84dd942bb"
      unitRef="usd">-26400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjctMy0xLTEtOTEyODQ_ae30bd82-2633-44e8-91ba-bdce3cff137b"
      unitRef="usd">2600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjctNS0xLTEtOTEyODQ_0e36618f-b26e-40c3-89b1-219b4bcbe833"
      unitRef="usd">-26500000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjctNy0xLTEtOTEyODQ_248a9607-2a10-4345-9521-3a3f8ccd1ef4"
      unitRef="usd">18100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjgtMS0xLTEtOTEyODQ_50f2c917-1075-4dfb-97d2-c1ce38cad264"
      unitRef="usd">-56400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjgtMy0xLTEtOTEyODQ_a464b73e-8e90-4504-acc7-0e633f37437c"
      unitRef="usd">4600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjgtNS0xLTEtOTEyODQ_ba7b5e54-79f6-4e0c-a0a9-2af6ef6ce1fb"
      unitRef="usd">-60100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMjgtNy0xLTEtOTEyODQ_103b998e-0455-4ffb-905b-6e26ff82128e"
      unitRef="usd">74300000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzEtMS0xLTEtOTEyODQ_982a85a8-8236-4082-94a3-9e42e4b4407e"
      unitRef="usdPerShare">-1.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzEtMy0xLTEtOTEyODQ_e77cab18-f1be-4a13-999c-cd0081f39e41"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzEtNS0xLTEtOTEyODQ_658aba65-7fb6-4a32-a99f-6bfe4e1998df"
      unitRef="usdPerShare">-1.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzEtNy0xLTEtOTEyODQ_09af742b-efe6-42d7-b2e7-157ca3a67b53"
      unitRef="usdPerShare">1.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzItMS0xLTEtOTEyODQ_3c102731-de01-4536-a652-dd95da28b1a6"
      unitRef="usdPerShare">-1.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzItMy0xLTEtOTEyODQ_5bf680fd-7695-41f3-bb7d-7d59e54d1e76"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzItNS0xLTEtOTEyODQ_f704e9f5-de2b-49d6-9666-d981e94f88cc"
      unitRef="usdPerShare">-1.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzItNy0xLTEtOTEyODQ_509f892c-ad73-4544-9b7a-4979214b2508"
      unitRef="usdPerShare">1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzUtMS0xLTEtOTEyODQ_2c98d51b-f7e1-400b-b34c-08afc0891a64"
      unitRef="shares">50000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzUtMy0xLTEtOTEyODQ_529e6928-8044-4fb0-b203-87c507f629f9"
      unitRef="shares">53600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzUtNS0xLTEtOTEyODQ_22e0a6d6-5b56-420f-a3ba-0ba10a857691"
      unitRef="shares">50300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzUtNy0xLTEtOTEyODQ_c4599ab0-d3e7-4a99-9346-27c9fe752011"
      unitRef="shares">53500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzYtMS0xLTEtOTEyODQ_440b008f-764b-4f62-83e5-60a9d201643b"
      unitRef="shares">50000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzYtMy0xLTEtOTEyODQ_12f11c90-fcb8-4811-9ba1-b9f1dfc67fdb"
      unitRef="shares">54000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzYtNS0xLTEtOTEyODQ_fdc8d1c2-6b5b-4a17-9624-91fd0e939c17"
      unitRef="shares">50300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8xOS9mcmFnOmZjYzY5M2I3MTU0MzRkNDQ4ZjlkOWM2NWE4MmUyYWNkL3RhYmxlOjJmZmYwOGE5ODlhMDQxYTdhOWNiNzViYzM5NTQzOWM5L3RhYmxlcmFuZ2U6MmZmZjA4YTk4OWEwNDFhN2E5Y2I3NWJjMzk1NDM5YzlfMzYtNy0xLTEtOTEyODQ_e53a17c3-2564-4ca7-b588-43334f854e0d"
      unitRef="shares">54300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfMi0xLTEtMS05MTI4NA_53cce15e-ae9d-4c60-ad8a-317affaf283c"
      unitRef="usd">-56400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfMi0zLTEtMS05MTI4NA_505ba1b7-26f2-4105-aafd-59816584107f"
      unitRef="usd">4600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfMi01LTEtMS05MTI4NA_59d31a43-4e7e-46d6-bdcb-aba9d102e785"
      unitRef="usd">-60100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfMi03LTEtMS05MTI4NA_53db3e92-6292-4914-87ca-123541a0f230"
      unitRef="usd">74300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNC0xLTEtMS05MTI4NA_60c60022-813e-42ee-a771-04f0fc353aa2"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNC0zLTEtMS05MTI4NA_0514fb88-3b5c-41fc-8e46-9ba1b08fbd54"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNC01LTEtMS05MTI4NA_61924103-00d6-42ec-a1ed-fbcee1c6bc0d"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNC03LTEtMS05MTI4NA_3d6bd1a0-61bc-4d76-b94b-918963396d2e"
      unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNS0xLTEtMS05MTI4NA_869ae2d7-f30c-4f42-b65d-0614a2ea4106"
      unitRef="usd">2800000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNS0zLTEtMS05MTI4NA_b614f6e0-16e2-4efa-a026-5b459b961cc3"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNS01LTEtMS05MTI4NA_987ad397-1ebe-488b-8f50-c25f57ee0238"
      unitRef="usd">9100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNS03LTEtMS05MTI4NA_182ec009-29d1-45a7-b87d-297c2445f162"
      unitRef="usd">4600000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNi0xLTEtMS05MTI4NA_e33e3777-cd6d-4c62-991f-d9042e644c79"
      unitRef="usd">3200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNi0zLTEtMS05MTI4NA_7b516397-9554-4ca9-bfef-688096b02398"
      unitRef="usd">2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNi01LTEtMS05MTI4NA_ace854af-ac70-4fe8-a192-a4bdd643761d"
      unitRef="usd">10000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNi03LTEtMS05MTI4NA_984ac430-c7c3-47c1-b132-2f73cca22493"
      unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNy0xLTEtMS05MTI4NA_a247933e-edd4-4374-9c8b-5b398bf4e485"
      unitRef="usd">-53200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNy0zLTEtMS05MTI4NA_08b88061-75d0-4371-bf8f-6d58078c8ced"
      unitRef="usd">6600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNy01LTEtMS05MTI4NA_f23eb3e4-cbc1-426a-b964-4b23a8cfd76e"
      unitRef="usd">-50100000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yMi9mcmFnOmRhNGM4YzM2N2E5NTRmOTM5ZGE4Yjk3OTVmNGZhMmQ2L3RhYmxlOjQwYWFmMDc1ZmU3MzQwNzc5NjAxMjIxNTc0ZjM5NjJjL3RhYmxlcmFuZ2U6NDBhYWYwNzVmZTczNDA3Nzk2MDEyMjE1NzRmMzk2MmNfNy03LTEtMS05MTI4NA_7bbea648-014d-4dd9-a874-bce3e8654b51"
      unitRef="usd">77200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:NetIncomeLoss
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMy0xLTEtMS05MTI4NA_588a18bd-3257-4cca-b5fe-69f0cb04acf3"
      unitRef="usd">-60100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMy0zLTEtMS05MTI4NA_0f9c998b-17f3-4157-b306-402fd6948363"
      unitRef="usd">74300000</us-gaap:NetIncomeLoss>
    <us-gaap:ShareBasedCompensation
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNS0xLTEtMS05MTI4NA_97b874ba-388e-4d2f-a7d6-806f30370553"
      unitRef="usd">22200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNS0zLTEtMS05MTI4NA_f27b9c1d-506f-405b-8d52-497efd184d4d"
      unitRef="usd">21900000</us-gaap:ShareBasedCompensation>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNi0xLTEtMS05MTI4NA_951ad85e-6975-44ec-8278-ae2d010b9b2d"
      unitRef="usd">75400000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNi0zLTEtMS05MTI4NA_10460f31-504b-4ccb-a23c-e281ccb24704"
      unitRef="usd">61900000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNy0xLTEtMS05MTI4NA_2e19b6a3-64f0-48dd-ba98-02fd8f8bfa33"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNy0zLTEtMS05MTI4NA_699375bc-ca9d-40cc-b79a-6f9401eb2a3d"
      unitRef="usd">1700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfOC0xLTEtMS05MTI4NA_fdcac08a-966e-425f-974f-7e0d97294e87"
      unitRef="usd">2000000.0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfOC0zLTEtMS05MTI4NA_e3a621a7-1306-43aa-bf9c-25b77c129bf2"
      unitRef="usd">2000000.0</us-gaap:AmortizationOfFinancingCosts>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfOS0xLTEtMS05MTI4NA_ee3622ca-3c18-459f-88d7-6abc22ff2612"
      unitRef="usd">2600000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfOS0zLTEtMS05MTI4NA_5609db26-37b2-4c1b-90bc-57aeeec31f70"
      unitRef="usd">-3200000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTAtMS0xLTEtOTEyODQ_06832e21-6db8-4664-9ce2-ce671bcfd468"
      unitRef="usd">-2200000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTAtMy0xLTEtOTEyODQ_4454e0df-825d-4758-9fb5-10b9472fabed"
      unitRef="usd">-2000000.0</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTItMS0xLTEtOTEyODQ_077e6246-de4f-497d-a5fd-3b056926a9b6"
      unitRef="usd">-97700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTItMy0xLTEtOTEyODQ_076b089c-2382-4cef-bb31-57beef75a1d1"
      unitRef="usd">34700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTMtMS0xLTEtOTEyODQ_bfb31339-bf71-476f-bbd5-57a55063731f"
      unitRef="usd">75500000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTMtMy0xLTEtOTEyODQ_251f0e2b-ad0a-4f4e-a6ee-cd1c5d28f08d"
      unitRef="usd">79700000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTQtMS0xLTEtOTEyODQ_be1cc175-b4a0-44da-b610-9b5f797054b1"
      unitRef="usd">19400000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTQtMy0xLTEtOTEyODQ_70e5244d-8dc7-4311-87f1-e3aad85ff6f2"
      unitRef="usd">2400000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTUtMS0xLTEtOTEyODQ_ca56b9d7-7587-4aca-ba54-ac934934995d"
      unitRef="usd">-7600000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTUtMy0xLTEtOTEyODQ_ed98b96e-643c-426f-b107-9b27836cd74c"
      unitRef="usd">8000000.0</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTYtMS0xLTEtOTEyODQ_8c3508bf-5c90-4e8c-ab77-f9dec666592f"
      unitRef="usd">-82800000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTYtMy0xLTEtOTEyODQ_0a882284-fd87-4785-b5fe-03f5c8dc2910"
      unitRef="usd">-55400000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTctMS0xLTEtOTEyODQ_44068421-2557-4985-bb41-bb4e83d11b0c"
      unitRef="usd">-14100000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTctMy0xLTEtOTEyODQ_4dc91242-d923-465d-89f5-cbb003765cf4"
      unitRef="usd">-21400000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTgtMS0xLTEtOTEyODQ_00cbb79d-fecd-4684-8957-70357ed1ed10"
      unitRef="usd">2700000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTgtMy0xLTEtOTEyODQ_471fb2cb-6984-4569-9807-a4168931f5aa"
      unitRef="usd">400000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTktMS0xLTEtOTEyODQ_ded5a87d-94b0-4c89-bd58-b09ae8ab0fbd"
      unitRef="usd">-52900000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMTktMy0xLTEtOTEyODQ_56b5fa72-1f09-4914-adee-a808f8eeb488"
      unitRef="usd">-24600000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjEtMS0xLTEtOTEyODQ_f59236cc-69fe-4cf1-ba43-8ec6f199afdb"
      unitRef="usd">64300000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjEtMy0xLTEtOTEyODQ_22698dbc-4414-4862-846a-8cf8638a378d"
      unitRef="usd">123100000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjItMS0xLTEtOTEyODQ_cac7cf47-68f5-494d-a613-40f5e1008f73"
      unitRef="usd">-64300000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjItMy0xLTEtOTEyODQ_1c14853b-edc1-4b67-a480-c6d728ffcfce"
      unitRef="usd">-123100000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjQtMS0xLTEtOTEyODQ_ec30d472-f801-4a3f-9cc9-bf77f7f1bb06"
      unitRef="usd">81900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjQtMy0xLTEtOTEyODQ_ffb33d65-cf84-4c07-8654-7babc765bb1f"
      unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjUtMS0xLTEtOTEyODQ_b2af2fd1-e11b-4554-b620-b7ef71a9b5fe"
      unitRef="usd">16900000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfMediumTermNotes
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjUtMy0xLTEtOTEyODQ_edb8bfaf-0938-4927-98c3-031d774a4250"
      unitRef="usd">11300000</us-gaap:RepaymentsOfMediumTermNotes>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjYtMS0xLTEtOTEyODQ_989d814e-bd77-4d49-aed6-a7fb0ca90871"
      unitRef="usd">0</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:RepaymentsOfConvertibleDebt
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjYtMy0xLTEtOTEyODQ_8887708a-093d-4319-9418-e294385b04cd"
      unitRef="usd">10600000</us-gaap:RepaymentsOfConvertibleDebt>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjctMS0xLTEtOTEyODQ_7f95251f-b521-49e6-a691-f1ba7c9b18b7"
      unitRef="usd">3000000.0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjctMy0xLTEtOTEyODQ_11d4ef9d-ec09-4ca1-8767-84eeebc3f313"
      unitRef="usd">10000000.0</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjgtMS0xLTEtOTEyODQ_d09d1478-8b67-46b1-acb0-cdf003a60afb"
      unitRef="usd">5400000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjgtMy0xLTEtOTEyODQ_6a279460-99e9-485b-a92b-466758cc93e7"
      unitRef="usd">13000000.0</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjktMS0xLTEtOTEyODQ_cbd79c1f-6f33-4589-aca8-f18c1df27fbc"
      unitRef="usd">0</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMjktMy0xLTEtOTEyODQ_9d1e0e2d-c6f9-4cee-804a-f5f60b90bd3a"
      unitRef="usd">1100000</us-gaap:PaymentForContingentConsiderationLiabilityFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzAtMS0xLTEtOTEyODQ_c816e1f6-4aa7-4673-b0b9-88ced3885486"
      unitRef="usd">-101200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzAtMy0xLTEtOTEyODQ_67a39b8c-cc8e-4e10-9828-1a70c6708ff3"
      unitRef="usd">-26000000.0</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzEtMS0xLTEtOTEyODQ_512e6613-a9c8-4d84-914f-07fed912060f"
      unitRef="usd">400000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzEtMy0xLTEtOTEyODQ_48d4e632-528d-433b-8fa9-c6539632c39c"
      unitRef="usd">-100000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzItMS0xLTEtOTEyODQ_99ec4f36-374f-48ba-9de3-dce46bd739a7"
      unitRef="usd">-218000000.0</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzItMy0xLTEtOTEyODQ_006abca9-7d03-4d0e-ab9c-57621348f486"
      unitRef="usd">-173800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzMtMS0xLTEtOTEyODQ_21087853-c14d-45d3-8483-6d3a0ee60b90"
      unitRef="usd">576300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i71c6824cc4fe485ca827c9836e570401_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzMtMy0xLTEtOTEyODQ_f1f9be4d-1c42-41fb-b143-32650cff14a6"
      unitRef="usd">621500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzQtMS0xLTEtOTEyODQ_33436266-f473-471e-8de0-10c6794ceaae"
      unitRef="usd">358300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i4b115351905c4ee2931cba201308bfe2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzQtMy0xLTEtOTEyODQ_1acdf8c6-f4f7-468f-bf6d-6ebc8e95b9b4"
      unitRef="usd">447700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzYtMS0xLTEtOTEyODQ_f62e3c78-9f3f-41ad-8835-7aec47b1daa9"
      unitRef="usd">14800000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzYtMy0xLTEtOTEyODQ_a2988b00-1e06-4e18-a117-94a92f576eb9"
      unitRef="usd">15500000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzctMS0xLTEtOTEyODQ_3aa3fe0d-a879-4240-a44e-b89db776edbc"
      unitRef="usd">20000000.0</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzctMy0xLTEtOTEyODQ_5adc9067-41eb-44fd-9743-ebacecd36472"
      unitRef="usd">50300000</us-gaap:IncomeTaxesPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzktMS0xLTEtOTEyODQ_5786406f-f4ce-4dbc-97f8-a42ae2a6f0b8"
      unitRef="usd">7300000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfMzktMy0xLTEtOTEyODQ_3d899b9f-5937-439d-9476-692662db75db"
      unitRef="usd">31700000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDItMS0xLTEtOTEyODQ_b44b9c31-2da1-43a0-b913-dbe1ce48b964"
      unitRef="usd">358100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDItMy0xLTEtOTEyODQ_4da42162-cfec-49d0-b408-ef204f4f9e35"
      unitRef="usd">576100000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDMtMS0xLTEtOTEyODQ_912021b3-a8e6-4e8e-b711-aa8d7c485c9d"
      unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDMtMy0xLTEtOTEyODQ_1c38ee8e-c1f5-4d22-af90-675f95257e39"
      unitRef="usd">200000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDQtMS0xLTEtOTEyODQ_159608b4-87ae-4428-921d-2085bc3875dd"
      unitRef="usd">358300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yNS9mcmFnOjk5OWNiYjgyM2E0NjQ0ZWRhZTA3N2UzY2M0YTJiNzdkL3RhYmxlOjIwZmRlYjVkMjdhZDRmMTBhNTg2NjBlNDYxMzQyZjA3L3RhYmxlcmFuZ2U6MjBmZGViNWQyN2FkNGYxMGE1ODY2MGU0NjEzNDJmMDdfNDQtMy0xLTEtOTEyODQ_b53492cd-1d04-462e-84b5-029cc1fb1e24"
      unitRef="usd">576300000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMC0yLTEtMS05MTI4NC90ZXh0cmVnaW9uOjViYjkxNzYxZDFkYTRhNDhiOGQyZWY5MmExOGU3NDg0XzU_379b7eb9-e886-4273-956d-cba5880698c5"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i4b115351905c4ee2931cba201308bfe2_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMC0yLTEtMS05MTI4NC90ZXh0cmVnaW9uOjViYjkxNzYxZDFkYTRhNDhiOGQyZWY5MmExOGU3NDg0XzU_3a31a450-0fd4-43e0-adff-e96733833892"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ifcb77253dbaa4e16b55791df9ea6fddf_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy0yLTEtMS05MTI4NA_c62ab42b-da2a-4b30-854e-d39c2b334dd2"
      unitRef="shares">55100000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ifcb77253dbaa4e16b55791df9ea6fddf_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy00LTEtMS05MTI4NA_4e76ad79-d544-4499-9300-02e660b8b31b"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ib6cd72da23074b5dbf0c4367cf392a9d_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy02LTEtMS05MTI4NA_61d63dc8-3c72-45b1-997c-6394c3bbded5"
      unitRef="shares">3800000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="ib6cd72da23074b5dbf0c4367cf392a9d_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy04LTEtMS05MTI4NA_d1e8d4a8-11f4-40a5-ae54-89c88a8e2754"
      unitRef="usd">-152200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53b18d134caf4ae2bba1d299e79c0f1b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy0xMC0xLTEtOTEyODQ_3a2b4e57-c421-4929-a5f7-288208502419"
      unitRef="usd">829400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53adab0b44f14127b1c4c4f2539a1807_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy0xMi0xLTEtOTEyODQ_1be5f205-9017-4970-bc3c-f59786901365"
      unitRef="usd">-16100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if87c2ef5ba4f4d7abb9178e57763e7ff_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy0xNC0xLTEtOTEyODQ_d186b101-fc73-4477-aab7-1718fcd02d9b"
      unitRef="usd">957800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMy0xNi0xLTEtOTEyODQ_8876b2ea-3a51-44c3-9b6d-664e790f63a3"
      unitRef="usd">1619000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i66eaca4aafd84de8a80ea8db300174dd_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNC0yLTEtMS05MTI4NA_8699165a-4f6d-4af9-a3f9-9e3c816bcf00"
      unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i6c074f371d0a46638d50ebd9d45e0f59_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNC0xMC0xLTEtOTEyODQ_0b000e10-34ed-4361-8177-bb8d830a5610"
      unitRef="usd">19800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNC0xNi0xLTEtOTEyODQ_a1749183-a430-44f6-af5c-1afe432481db"
      unitRef="usd">19800000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i26eb6b2c35ad4617b43852b247ceea23_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNS0xNC0xLTEtOTEyODQ_ab936d54-d245-4448-8255-37b67aaf79c0"
      unitRef="usd">-60100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNS0xNi0xLTEtOTEyODQ_845b849e-963f-4203-a35f-cc3be505d0e8"
      unitRef="usd">-60100000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ic692f65706164ee49ec3a380b592e311_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNi02LTEtMS05MTI4NA_a08e05de-1351-419e-b43a-c3f25efff3ea"
      unitRef="shares">1800000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic692f65706164ee49ec3a380b592e311_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNi04LTEtMS05MTI4NA_906f55dc-44a3-4c04-bee3-7b32b60bb706"
      unitRef="usd">75500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNi0xNi0xLTEtOTEyODQ_aeacdf5b-3c79-48b8-83bf-a3ae41c75b74"
      unitRef="usd">75500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie7dc3abe30a64ca2932c00efd6517a60_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNy0xMi0xLTEtOTEyODQ_01ff0a47-7482-47fe-aa4e-e335eae55403"
      unitRef="usd">10000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfNy0xNi0xLTEtOTEyODQ_02918060-47ea-4311-a91a-4c10a656fe11"
      unitRef="usd">10000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if12d50ad93034fe0bf993311a0d00e34_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC0yLTEtMS05MTI4NA_a8f8ba51-7327-41e8-8225-ca8abab565f7"
      unitRef="shares">55500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if12d50ad93034fe0bf993311a0d00e34_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC00LTEtMS05MTI4NA_3e69b2fe-b5a8-41f7-ac09-8eabd580f110"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i4f4f1eaec93744e09d2a5e94ada672c5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC02LTEtMS05MTI4NA_04db5983-7db6-4649-929c-cea7925b7869"
      unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i4f4f1eaec93744e09d2a5e94ada672c5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC04LTEtMS05MTI4NA_db22f94f-ea81-439c-98d8-fcb1c051c479"
      unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i412510cc8ecb48538d8d3800311216b7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC0xMC0xLTEtOTEyODQ_ae1a4c1a-c8be-4057-a497-acef852f0a1e"
      unitRef="usd">849200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib20d47a77df04874a03809c71af93bb8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC0xMi0xLTEtOTEyODQ_f2dd2c50-0a9c-4519-9231-ee56deeebf3a"
      unitRef="usd">-6100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5addde9d9dae48a8ad041d366228d429_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC0xNC0xLTEtOTEyODQ_01869195-63d5-4794-8771-8b01242269c5"
      unitRef="usd">897700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfOC0xNi0xLTEtOTEyODQ_25155da9-4504-4ca9-a8e3-e1167aae17af"
      unitRef="usd">1513200000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i461082bcdf04496582b622477c82809e_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtMi0xLTEtOTEyODQ_2ed6be6a-2cfa-44b8-8f15-93772ea31e4b"
      unitRef="shares">55300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i461082bcdf04496582b622477c82809e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtNC0xLTEtOTEyODQ_1c9d40fe-d9da-49fa-adb7-60952b1ad562"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i557996cf1b9849c7acfd550d094c2417_I20220331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtNi0xLTEtOTEyODQ_a12a16ed-b526-45f7-be93-f0859065fe11"
      unitRef="shares">4900000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i557996cf1b9849c7acfd550d094c2417_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtOC0xLTEtOTEyODQ_2227c498-2a67-413a-ba3b-0f0b3d5c9c89"
      unitRef="usd">-204400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia2336cd80ecb49729b81f005c693fca9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtMTAtMS0xLTkxMjg0_89d16179-6d2b-4d26-9f8f-c5fa6c246386"
      unitRef="usd">834800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0ca88e5d8bf24c309e9d2a5171b224ec_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtMTItMS0xLTkxMjg0_c2509f7e-611b-44bd-a630-3bae27c861ed"
      unitRef="usd">-9300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i05378be1d058489c8c528d17225c53e9_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtMTQtMS0xLTkxMjg0_c89ad52f-7b36-4f21-b4b9-de3be74ef61e"
      unitRef="usd">954100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie7050e3a97a242b092682346cbd7cd4e_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTAtMTYtMS0xLTkxMjg0_cdca43ab-4eda-4432-ad97-12949a761c6f"
      unitRef="usd">1575300000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib3bbf3905bf542958d5e24c590031249_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTEtMi0xLTEtOTEyODQ_12d960ac-0d83-4def-8163-7201d9df525c"
      unitRef="shares">200000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ide22df8c6fb348659c7397b47c73fe57_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTEtMTAtMS0xLTkxMjg0_7c687973-79bc-4b4a-a5c3-af52a7e6716c"
      unitRef="usd">14400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTEtMTYtMS0xLTkxMjg0_b9824b21-4553-4514-a5fa-95b702e97bb8"
      unitRef="usd">14400000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i2761304ddf59466ba7ad454fdf7d3b89_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTItMTQtMS0xLTkxMjg0_01d5f069-1619-4fdf-b564-0aec3c4f4eb0"
      unitRef="usd">-56400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTItMTYtMS0xLTkxMjg0_f8cfd214-5579-4ae1-ade1-f455ef11ca36"
      unitRef="usd">-56400000</us-gaap:NetIncomeLoss>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ifcc26b21d7d8496f9bb774f7ac399651_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTMtNi0xLTEtMTA0NTI0_3223feff-f261-49cf-82e9-79ad677bb5e1"
      unitRef="shares">700000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ifcc26b21d7d8496f9bb774f7ac399651_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTMtOC0xLTEtMTA0NTI0_5202a7ba-f95b-4bba-b9d6-9b6fd068add1"
      unitRef="usd">23300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTMtMTYtMS0xLTEwNDUzNA_276fa9dc-b72b-43c9-adab-c7617fd645d6"
      unitRef="usd">23300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i12f7ee7f25e24cf382b2910e45037cd5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTMtMTItMS0xLTkxMjg0_a275a814-d6b0-42ec-8905-65b25d43193a"
      unitRef="usd">3200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTMtMTYtMS0xLTkxMjg0_77608e28-93be-43f2-858f-5895593bfcff"
      unitRef="usd">3200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="if12d50ad93034fe0bf993311a0d00e34_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtMi0xLTEtOTEyODQ_6e29ac6a-c26b-49de-a736-73b38a2bbfd7"
      unitRef="shares">55500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="if12d50ad93034fe0bf993311a0d00e34_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtNC0xLTEtOTEyODQ_46df22c6-f1b2-4890-992c-0ed47f051d50"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i4f4f1eaec93744e09d2a5e94ada672c5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtNi0xLTEtOTEyODQ_74f26c56-cf89-47a7-980d-f3bad46d6f8e"
      unitRef="shares">5600000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i4f4f1eaec93744e09d2a5e94ada672c5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtOC0xLTEtOTEyODQ_ae4a86d7-3754-40fc-be5f-638afc2f9661"
      unitRef="usd">-227700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i412510cc8ecb48538d8d3800311216b7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtMTAtMS0xLTkxMjg0_c2544c39-df76-4544-916d-d22f4b75802a"
      unitRef="usd">849200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib20d47a77df04874a03809c71af93bb8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtMTItMS0xLTkxMjg0_6fc6eeef-ac79-4f2f-a7ea-da3f7eb7446b"
      unitRef="usd">-6100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5addde9d9dae48a8ad041d366228d429_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtMTQtMS0xLTkxMjg0_56ba794f-c023-4d70-9fba-244c52a79d0a"
      unitRef="usd">897700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTQtMTYtMS0xLTkxMjg0_d955ab31-dc16-482c-b37e-bbee9d1b363f"
      unitRef="usd">1513200000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i780e0257b99f470bac2458708cbdb98e_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctMi0xLTEtOTEyODQ_50ce0aad-7520-4233-9fcc-4c9c934a5f2f"
      unitRef="shares">54300000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i780e0257b99f470bac2458708cbdb98e_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctNC0xLTEtOTEyODQ_fe2f9c2c-e299-4470-b8ef-3409a5332199"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="i40faa34fd48c4a798a6fe90fe21fd4e5_I20201231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctNi0xLTEtOTEyODQ_03ec8b43-318e-4092-b8a6-62c9cbe08457"
      unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="i40faa34fd48c4a798a6fe90fe21fd4e5_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctOC0xLTEtOTEyODQ_0eb001dc-f35c-47be-8994-a4158678a9de"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idc5bcc44a9ca46599e2b25daa2a69029_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctMTAtMS0xLTkxMjg0_6aac47c3-1c7e-44db-91f9-f8caf302943c"
      unitRef="usd">784900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d6dfa3b33ba4a26be19db91781e5050_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctMTItMS0xLTkxMjg0_4406577e-d697-4e33-aa23-c7c2fce845c8"
      unitRef="usd">-25300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ie40f227742694bbdaee04db49ed26512_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctMTQtMS0xLTkxMjg0_46afec67-df97-4216-81a0-339e32893916"
      unitRef="usd">726900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i71c6824cc4fe485ca827c9836e570401_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTctMTYtMS0xLTkxMjg0_c560b1f1-c236-4091-89e2-dfb6594074a6"
      unitRef="usd">1447000000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6387f180981b459b9fe20889f53d8b6c_D20210101-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTgtMi0xLTEtOTEyODQ_ae36afd0-e13f-4934-9fb3-293927ef9c48"
      unitRef="shares">600000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i34769cb2cad546d9a34ee9510f37cbfd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTgtMTAtMS0xLTkxMjg0_d3e0bd5f-a179-4d92-9a97-e6ea0ab54219"
      unitRef="usd">19500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTgtMTYtMS0xLTkxMjg0_1c3c9c4b-f3f7-4c42-ad4e-bd97e1047ddd"
      unitRef="usd">19500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i80b954c7fdb04b88b99f239e25180b5c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTktMTQtMS0xLTkxMjg0_f00e647c-4cdd-47df-8262-4a5dafefc1e2"
      unitRef="usd">74300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMTktMTYtMS0xLTkxMjg0_b2469980-d909-4487-a1d6-3eece50e346e"
      unitRef="usd">74300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id3a86954dc6340629ca543163504fdb4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjAtMTItMS0xLTkxMjg0_a6fbaf79-861b-417d-8efa-8af25f71bda5"
      unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjAtMTYtMS0xLTkxMjg0_de797d23-5cf0-4747-93c0-5515a9264b72"
      unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i14cd7836cc584c8fb4799a4f34d22bb3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtMi0xLTEtOTEyODQ_da61191b-634e-49f7-a9eb-7f4ed591ea35"
      unitRef="shares">54900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i14cd7836cc584c8fb4799a4f34d22bb3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtNC0xLTEtOTEyODQ_9d1e6e19-8e95-4e70-b1dd-9cda1a7972b3"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ief6c31325bb94b9094ce98e80f0a6bb3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtNi0xLTEtOTEyODQ_d5dd53b6-0402-4ad1-8ede-abd48ed95583"
      unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="ief6c31325bb94b9094ce98e80f0a6bb3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtOC0xLTEtOTEyODQ_5f25e1c9-ac0c-408f-8cc5-49573f4f4fc2"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5589e73e44f74b778672ccad28f1df27_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtMTAtMS0xLTkxMjg0_b2ddbb0a-a264-4434-b7d2-80e242e04317"
      unitRef="usd">804400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cb30120c0cd4c26b09246b92a5b9300_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtMTItMS0xLTkxMjg0_ed97b61e-3c86-40cf-83cc-65a3666d4d92"
      unitRef="usd">-22400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b789b56b81c4d9a9a529b16bb9daa53_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtMTQtMS0xLTkxMjg0_9e83f0af-077c-429e-bde2-60a32f035220"
      unitRef="usd">801200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b115351905c4ee2931cba201308bfe2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjEtMTYtMS0xLTkxMjg0_524446ca-bd00-4b2e-ab87-e05b4f03875f"
      unitRef="usd">1543700000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i0e62c5dc2e50467ca24d45cabc0c75e5_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtMi0xLTEtOTEyODQ_e491bd4e-23dd-4bf7-b320-2ec5466679fe"
      unitRef="shares">54800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i0e62c5dc2e50467ca24d45cabc0c75e5_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtNC0xLTEtOTEyODQ_bd3eb497-54e4-4dfb-800b-4bc9ea0c5d2d"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ie273c395662a4debaddeffc56206d4c3_I20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtNi0xLTEtOTEyODQ_51964624-de59-4c72-8dac-14b87d39fd58"
      unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="ie273c395662a4debaddeffc56206d4c3_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtOC0xLTEtOTEyODQ_bf323175-889f-42ec-b05e-347120e8f48c"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3f1aae4f21ea48c7bb113f0bb2d224ed_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjItMTAtMS0xLTkyNjEz_8621ad96-5b29-4024-9021-3f7a690e74c6"
      unitRef="usd">790100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84fb728efecd4d3eb00c3307db37929d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtMTItMS0xLTkxMjg0_8208859a-1f1a-4e67-b627-78bb9997c670"
      unitRef="usd">-24400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="idf50b30461ed4bd5aa0c129d970ef57d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtMTQtMS0xLTkxMjg0_b24e2298-035b-4c06-8657-ccb8b2599ccc"
      unitRef="usd">796600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7e7a561bc9634b07b67a3141075d5a76_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtMTYtMS0xLTkxMjg0_bdaa07b0-7e40-4e07-8541-7e0e302c1364"
      unitRef="usd">1522800000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i6b62099afb4848769e1d1bd825d654a0_D20210401-20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjQtMi0xLTEtOTEyODQ_d257dc77-3769-4c52-ae0f-cef1fb9fd692"
      unitRef="shares">100000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id2eba64a7c8645ceb35da700cc48a11a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjMtMTAtMS0xLTkyNjEz_58817825-1f35-483c-a0b1-178a5f598871"
      unitRef="usd">14300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjQtMTYtMS0xLTkxMjg0_c8e74a71-29a6-48f6-8925-42296294ecf1"
      unitRef="usd">14300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:NetIncomeLoss
      contextRef="i8db1424bf80e4508a67ed768a524f425_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjUtMTQtMS0xLTkxMjg0_4c1164ec-6b04-4e0b-ae0f-2d78d765bb44"
      unitRef="usd">4600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjUtMTYtMS0xLTkxMjg0_a046bdaa-f7aa-4245-b93d-b4221029e83d"
      unitRef="usd">4600000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id728fefbf15d4c8cabf2af784f9cb5fb_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjYtMTItMS0xLTkxMjg0_6c626f53-98ca-489c-b136-ce71bb4709f3"
      unitRef="usd">2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjYtMTYtMS0xLTkxMjg0_a0dbc07d-2921-44ff-a95a-cc538c451d78"
      unitRef="usd">2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i14cd7836cc584c8fb4799a4f34d22bb3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctMi0xLTEtOTEyODQ_d8449808-a363-4141-bd24-2251fdf0a417"
      unitRef="shares">54900000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i14cd7836cc584c8fb4799a4f34d22bb3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctNC0xLTEtOTEyODQ_bb7d8f57-ec04-4827-a33f-cf799c2704a2"
      unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares
      contextRef="ief6c31325bb94b9094ce98e80f0a6bb3_I20210630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctNi0xLTEtOTEyODQ_a2036f03-d00c-42cc-9ecf-ef09320ca258"
      unitRef="shares">1200000</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity
      contextRef="ief6c31325bb94b9094ce98e80f0a6bb3_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctOC0xLTEtOTEyODQ_b58f5d91-b05c-4c5e-a62e-445198b3af4a"
      unitRef="usd">-39600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5589e73e44f74b778672ccad28f1df27_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjYtMTAtMS0xLTkyNjEz_d40fd832-eacb-4fe5-b64a-0e82b0351206"
      unitRef="usd">804400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cb30120c0cd4c26b09246b92a5b9300_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctMTItMS0xLTkxMjg0_2a8b6dfb-971b-408f-be39-76cc5301983c"
      unitRef="usd">-22400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6b789b56b81c4d9a9a529b16bb9daa53_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctMTQtMS0xLTkxMjg0_f87b4b01-c11a-451c-ad22-0939494cb1a2"
      unitRef="usd">801200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i4b115351905c4ee2931cba201308bfe2_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8yOC9mcmFnOjVmNGRhMDk5MDlkMTQxOTZhZGU5N2ZjNmFkOTYxYWEzL3RhYmxlOmZhODEyNzUxZDM2YjQ1ZmNhNmY1Mjk0N2NhOGQzMGI4L3RhYmxlcmFuZ2U6ZmE4MTI3NTFkMzZiNDVmY2E2ZjUyOTQ3Y2E4ZDMwYjhfMjctMTYtMS0xLTkxMjg0_819655d6-f968-41c9-b77d-235c0a9c04ff"
      unitRef="usd">1543700000</us-gaap:StockholdersEquity>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNTA2OA_2cebdfac-995c-4766-b643-eeb678279cd2">Business&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Overview&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Emergent BioSolutions Inc. (the Company or Emergent) is a global life sciences company focused on providing&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;innovative preparedness and response solutions addressing accidental, deliberate, and naturally occurring Public Health Threats (PHTs). The Company's solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing (CDMO) services portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is focused on the following five distinct PHT categories: chemical, biological, radiological, nuclear and explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; and acute/emergency care. The Company has a product portfolio of eleven products (vaccines, therapeutics and drug-device combination products) that contribute a substantial portion of its revenue. The Company has one product candidate that is procured under special circumstances by the U.S. government (USG), although it is not approved by the U.S. Food and Drug Administration (FDA). The Company structures the business with a focus on markets and customers. As such, the key components of the business structure include a Government - Medical Countermeasures (MCM) business line, a Commercial business line and a Services line focused on CDMO.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;The Company's products and services include:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Government - MCM Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;AV7909&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, is a procured product candidate being developed as a next generation anthrax vaccine for post-exposure prophylaxis of disease resulting from suspected or confirmed Bacillus anthracis exposure. The USG has largely switched from procuring BioThrax to AV7909 for the Strategic National Stockpile (SNS) prior to its approval by the FDA;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;BioThrax&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the only vaccine licensed by the FDA, for the general use prophylaxis and post-exposure prophylaxis of anthrax disease;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;ACAM2000&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the only single-dose smallpox vaccine licensed by the FDA for active immunization against smallpox disease for persons determined to be at high risk for smallpox infection;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;BAT&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the only heptavalent antitoxin licensed by the FDA and Health Canada for the treatment of botulism; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;CNJ-016&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, also referred to as VIGIV, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada to address certain complications from smallpox vaccination;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Raxibacumab injection, a fully human monoclonal antibody therapeutic licensed by the FDA for the treatment and prophylaxis of inhalational anthrax;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Anthrasil&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the only polyclonal antibody therapeutic licensed by the FDA and Health Canada for the treatment of inhalational anthrax;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;RSDL&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the only medical device cleared by the FDA to remove or neutralize the following chemical warfare agents from the skin: tabun, sarin, soman, cyclohexyl sarin, VR, VX, mustard gas and T-2 toxin; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Trobigard&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae; &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;atropine sulfate, obidoxime chloride AUTO-INJECTOR, is a combination drug-device auto-injector procured product candidate that contains atropine sulfate and obidoxime chloride. It has not been approved by the FDA, but it is procured by certain authorized government buyers under special circumstances for potential use as a nerve agent countermeasure. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Ebanga&#x2122; (ansuvimab-zykl, formerly referred to as mAb114) is a monoclonal antibody with antiviral activity provided through a single IV infusion for the treatment of Ebola. Under the terms of a collaboration with Ridgeback Biotherapeutics, Emergent will be responsible for the manufacturing, sale, and distribution of Ebanga&#x2122; in the United States and Canada, and Ridgeback Bio will serve as the global access partner for Ebanga&#x2122;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Commercial Products&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;NARCAN&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (naloxone HCl) Nasal Spray, the first needle-free formulation of naloxone approved by the FDA and Health Canada, for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression; Recently, the Company licensed an authorized generic of naloxone nasal spray to Sandoz;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Vaxchora&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Cholera Vaccine, Live, Oral), the only single-dose oral vaccine licensed by the FDA and the European Medicines Agency (EMA) for the prevention of cholera; and&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x25aa;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:15.08pt"&gt;Vivotif&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Typhoid Vaccine Live Oral Ty21a), the only oral vaccine licensed by the FDA for the prevention of typhoid fever.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Services - Contract Development and Manufacturing &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's services line focused on CDMO offerings cover development services, drug substance manufacturing, drug product manufacturing, and when necessary, suite reservations, which depending on facts and circumstances could be considered a lease. These services are provided across the pharmaceutical and biotechnology industries as well as the USG and non-governmental organizations. The Company's technology platforms include mammalian, microbial, viral, plasma and advanced therapies utilizing the Company's core capabilities for manufacturing to third parties on a clinical and commercial (small and large) scale.&#160;Additional services include fill/finish formulation and analytical development services for injectable and other sterile products, inclusive of process design, technical transfer, manufacturing validations, aseptic filling, lyophilization, final packaging and stability studies, as well as manufacturing of vial and pre-filled syringe formats on multiple platforms. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as two operating segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and a services segment (Services) focused on CDMO (Note 14, Segment information).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pending Acquisition&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 15, 2022, the Company entered into an Asset Purchase Agreement (the &#x201c;Purchase Agreement&#x201d;), by and between the Company and Chimerix, Inc. (the &#x201c;Seller&#x201d;), pursuant to which the Company agreed to purchase from Seller its exclusive worldwide rights to brincidofovir, including TEMBEXA&#xae; and related assets (the &#x201c;Transaction&#x201d;). TEMBEXA is a medical countermeasure for smallpox approved by the U.S. Food and Drug Administration in June 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Purchase Agreement, the Company will pay $225.0&#160;million upon closing of the Transaction, plus up to $100.0&#160;million in up to four $25.0&#160;million milestone payments. The Purchase Agreement anticipates that the Seller will finalize its negotiations with the Biomedical Advanced Research and Development Authority (&#x201c;BARDA&#x201d;) and enter into a procurement contract (the &#x201c;BARDA Contract&#x201d;) with BARDA for TEMBEXA, which the Seller is currently negotiating. Each milestone payment is associated with the exercise of future BARDA procurement options of TEMBEXA following the BARDA Contract base period. The closing payment and the milestone payments may be adjusted upward or downward based on actual procurement value. The Seller is also eligible to receive up to $12.5&#160;million in regulatory milestones associated with the SymBio Pharmaceuticals Ltd. brincidofovir licensing arrangements to be assumed by the Company in the Transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Seller may also earn a 20% royalty on future gross profit of TEMBEXA in the United States associated with volumes above 1.7&#160;million treatment courses of therapy during the exclusivity period of TEMBEXA. Outside of the United States, the Purchase Agreement also allows the Seller to earn a 15% royalty on all gross profit associated with TEMBEXA sales during the exclusivity period of TEMBEXA on a market-to-market basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The closing is subject to the execution by the Seller of the BARDA Contract, the satisfaction or waiver of the following other closing conditions: (i) the representations and warranties of the Company and the Seller contained in the Purchase Agreement being true and correct, subject to certain materiality standards; (ii) each of the Company and the Seller having performed and complied with their respective covenants in all material respects; (iii) the waiting period applicable to the consummation of the Transaction under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, having expired; (iv) the delivery of certain ancillary documents, including a transition services agreement and pre-novation agreement; (v) the receipt of any required consent from BARDA to enter into a pre-novation agreement with the Company; (vi) no injunction or other final order preventing the consummation of the Transaction &lt;/span&gt;&lt;/div&gt;having been issued; (vii) and there having occurred no material adverse effect on the assets being sold in the Transaction. Closing of the Transaction is currently expected to occur during the third quarter of 2022.</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <ebs:NumberOfCategoriesOfPublicHealthThreats
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDY4_7294c2cb-74d7-4187-8a80-9e15f78a7226"
      unitRef="category">5</ebs:NumberOfCategoriesOfPublicHealthThreats>
    <ebs:NumberOfRevenueGeneratingProducts
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNTA3MA_2a3b1cf8-e79b-48eb-9f5f-b78ca9d214ca"
      unitRef="product">11</ebs:NumberOfRevenueGeneratingProducts>
    <ebs:NumberOfProductCandidates
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNTA2Nw_11c30c5a-5ea2-414e-9249-d93d2ebdde96"
      unitRef="productcandidate">1</ebs:NumberOfProductCandidates>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDg4OA_22ec5aaf-a174-4afa-8cfb-61ac42c7dd95"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="i280deffd19c14987aeb06f69ff2cdd96_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQwMw_1f264327-2011-46ec-ba66-3e3acd3ca925"
      unitRef="usd">225000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="i280deffd19c14987aeb06f69ff2cdd96_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQxNw_02c2fede-ed77-4b0b-b317-ce7a6786f0c7"
      unitRef="usd">100000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="ibf95dce5cfef405cba6b0d18b94cd870_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQzMQ_6d4a8907-e709-41e2-8b0a-cf2df5759f92"
      unitRef="usd">25000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="i1fa607b80d2746cbb317c99fbd84728f_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQzMQ_8a823e59-04cf-464b-83f2-298b7a83d364"
      unitRef="usd">25000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="i7e44623ce7f0456191e95efe535f9f33_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQzMQ_a7e4a957-0b5e-4655-8212-3f5969dc87e6"
      unitRef="usd">25000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="i4585a13ee1354a528f4c34f7706a0ec8_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQzMQ_e70c7d33-f617-4336-8f2c-95bf789a9fce"
      unitRef="usd">25000000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration
      contextRef="ie9fd4d849f564c9fb40d3df840d093e5_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQ0NA_a9f24c3d-614f-421c-839d-d001c999efc9"
      unitRef="usd">12500000</us-gaap:AssetAcquisitionConsiderationTransferredContingentConsideration>
    <ebs:AssetAcquisitionDomesticGrossProfitRoyaltyPercentage
      contextRef="i8635afeff8644e21a1f82f113b82e3a3_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQ2OA_3ab9e2db-4e30-461c-8607-ea5df53805a6"
      unitRef="number">0.20</ebs:AssetAcquisitionDomesticGrossProfitRoyaltyPercentage>
    <ebs:AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit
      contextRef="i8635afeff8644e21a1f82f113b82e3a3_D20220701-20220930"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfMTA5OTUxMTYyOTUyODc_95903b17-b6f6-4878-8231-664649205a7b"
      unitRef="treatmentcourse">1700000</ebs:AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit>
    <ebs:AssetAcquisitionInternationalGrossProfitRoyaltyPercentage
      contextRef="i8635afeff8644e21a1f82f113b82e3a3_D20220701-20220930"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNC9mcmFnOmNhYTM0OTJiNjgxNDQzZDA5YTMwNjZmMTRhMmJiNjRiL3RleHRyZWdpb246Y2FhMzQ5MmI2ODE0NDNkMDlhMzA2NmYxNGEyYmI2NGJfNDk0NzgwMjM0MjQ3Mw_5746c873-c2ea-42d0-902b-acccc8d20784"
      unitRef="number">0.15</ebs:AssetAcquisitionInternationalGrossProfitRoyaltyPercentage>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNy9mcmFnOjhmMDcxZDEzZjNiYjQwNWNhODVmMmU5MmE2NjQzMmI1L3RleHRyZWdpb246OGYwNzFkMTNmM2JiNDA1Y2E4NWYyZTkyYTY2NDMyYjVfNTYzNg_6488aa00-9c94-45d9-9227-b255e49b8ed3">Basis of presentation and principles of consolidation&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of presentation&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of June&#160;30, 2022. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant accounting policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2022, there have been no significant changes to the Company's summary of significant accounting policies contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC that have materially impacted the presentation of the Company's financial statements. &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;six months ended June 30, 2022&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company revised the reporting that the Chief Operating Decision Maker (CODM) reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and 2) the services segment focused on CDMO (Services). This change is further outlined in Note 14, Segment information.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair value measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1) and time deposits (level 2), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7, Fair value measurements and Note 8, Derivative instruments and hedging activities).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; On a non-recurring basis, the Company measures its long-lived assets as part of impairment evaluations using fair value measurements. Goodwill is allocated to the Company's reporting units, which are one level below its operating segments. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and earlier if an event or other circumstance indicates that the carrying value of the asset may not be recoverable. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required. Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, long-lived assets are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when there is an adverse change in the market relating to those related assets. The impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. Determining the need for a detailed impairment analysis requires the exercise of judgment about several business factors, including the timing of expected future cash flows and assumptions about the economic environment. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, the Company had no other significant assets or liabilities that were measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently issued accounting standards&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (FASB) that the Company adopts as of the pronouncement's specified effective date. Unless otherwise discussed below, the Company does not believe that the adoption of recently issued standards have or may have a material impact on the consolidated financial statements or disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;/div&gt;In March 2020, the FASB issued Topic 848, which was further amended in January 2021. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. Topic 848 contains optional expedients and exceptions to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNy9mcmFnOjhmMDcxZDEzZjNiYjQwNWNhODVmMmU5MmE2NjQzMmI1L3RleHRyZWdpb246OGYwNzFkMTNmM2JiNDA1Y2E4NWYyZTkyYTY2NDMyYjVfNTY0OA_7a26a8e9-20de-418f-94de-2797a460b008">The accompanying unaudited condensed consolidated financial statements include the accounts of Emergent and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. generally accepted accounting principles (GAAP) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X issued by the SEC. Certain information and footnote disclosures normally included in consolidated financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto contained in the Company's Annual Report on Form 10-K for the year ended December&#160;31, 2021, as filed with the SEC.All adjustments contained in the accompanying unaudited condensed consolidated financial statements are of a normal recurring nature and are necessary to present fairly the financial position of the Company as of June&#160;30, 2022. Interim results are not necessarily indicative of results that may be expected for any other interim period or for an entire year.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNy9mcmFnOjhmMDcxZDEzZjNiYjQwNWNhODVmMmU5MmE2NjQzMmI1L3RleHRyZWdpb246OGYwNzFkMTNmM2JiNDA1Y2E4NWYyZTkyYTY2NDMyYjVfNTY0Mw_f6259853-dd0d-4f31-b158-323606260f19"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNy9mcmFnOjhmMDcxZDEzZjNiYjQwNWNhODVmMmU5MmE2NjQzMmI1L3RleHRyZWdpb246OGYwNzFkMTNmM2JiNDA1Y2E4NWYyZTkyYTY2NDMyYjVfNTY0NA_c357415f-e5fc-4bc0-b048-2e5521aa19e2">Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis from those measured at fair value on a non-recurring basis. The Company has cash held in money market accounts (level 1) and time deposits (level 2), contingent purchase consideration (level 3) and interest rate swaps arrangements (level 2) that are measured at fair value on a recurring basis (Note 7, Fair value measurements and Note 8, Derivative instruments and hedging activities). On a non-recurring basis, the Company measures its long-lived assets as part of impairment evaluations using fair value measurements. Goodwill is allocated to the Company's reporting units, which are one level below its operating segments. The Company evaluates goodwill and other indefinite-lived intangible assets for impairment annually as of October&#160;1 and earlier if an event or other circumstance indicates that the carrying value of the asset may not be recoverable. If the Company believes that as a result of its qualitative assessment it is more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, the quantitative impairment test is not required. If however it is determined that it is not more likely than not that the fair value of a reporting unit or other indefinite-lived intangible asset is greater than its carrying amount, a quantitative test is required. Long-lived assets such as intangible assets and property, plant and equipment are not required to be tested for impairment annually. Instead, long-lived assets are tested for impairment whenever circumstances indicate that the carrying amount of the asset may not be recoverable, such as when there is an adverse change in the market relating to those related assets. The impairment test first requires a comparison of undiscounted future cash flows to the carrying value of the asset. Determining the need for a detailed impairment analysis requires the exercise of judgment about several business factors, including the timing of expected future cash flows and assumptions about the economic environment.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV8zNy9mcmFnOjhmMDcxZDEzZjNiYjQwNWNhODVmMmU5MmE2NjQzMmI1L3RleHRyZWdpb246OGYwNzFkMTNmM2JiNDA1Y2E4NWYyZTkyYTY2NDMyYjVfNTY0Mg_81be0689-4466-4ca5-88bd-d5763ced6257">&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#00497f;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting&lt;/span&gt;&lt;/div&gt;In March 2020, the FASB issued Topic 848, which was further amended in January 2021. Topic 848 provides relief for impacted areas as it relates to impending reference rate reform. Topic 848 contains optional expedients and exceptions to debt arrangements, contracts, hedging relationships, and other areas or transactions that are impacted by reference rate reform. This guidance is effective upon issuance for all entities and elections of certain optional expedients are required to apply the provisions of the guidance. The Company continues to assess all potential impacts of the standard and will disclose the nature and reason for any elections that the Company makes.</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RleHRyZWdpb246ZWVjY2QwYTI5YTBkNDdjZWE5YWFmYmU0YjQ3YzU1NTFfNzQ_4ee0b558-aa32-4b5a-aec3-b00fc3aee496">Inventories, net&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Inventories, net is stated at the lower of cost or net realizable value. For additional information related to the termination of the manufacturing services agreement (the &#x201c;Agreement&#x201d;) with Janssen Pharmaceuticals, Inc. (&#x201c;Janssen&#x201d;) and associated evaluation of inventory as of June&#160;30, 2022, refer to Note 10, Revenue recognition.</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RleHRyZWdpb246ZWVjY2QwYTI5YTBkNDdjZWE5YWFmYmU0YjQ3YzU1NTFfNzM_48bd7b40-016f-4da3-a936-4a657e0119db">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;264.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;217.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work-in-process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;108.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;95.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;350.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMS0xLTEtMS05MTI4NA_64895429-1af0-40d9-b3dc-97cc563ed051"
      unitRef="usd">264000000.0</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMS0zLTEtMS05MTI4NA_21e59e0c-a542-4790-a9c6-307a4da6eaa4"
      unitRef="usd">217500000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMi0xLTEtMS05MTI4NA_26b1490f-7bf8-4ddd-b181-49b4c57e03e7"
      unitRef="usd">108400000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMi0zLTEtMS05MTI4NA_45adcd7e-0eae-4ba9-af0a-65bc4f787739"
      unitRef="usd">95800000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMy0xLTEtMS05MTI4NA_a9956056-a8f6-41dc-b936-58a5565dcfd0"
      unitRef="usd">53100000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfMy0zLTEtMS05MTI4NA_2a43d523-904f-4452-b2df-856a160a259f"
      unitRef="usd">37500000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfNC0xLTEtMS05MTI4NA_f3e01b77-e342-4438-91d2-48bc91bbad7e"
      unitRef="usd">425500000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80MC9mcmFnOmVlY2NkMGEyOWEwZDQ3Y2VhOWFhZmJlNGI0N2M1NTUxL3RhYmxlOmI3OTU0YmY2MWZmYTQ3YTRhYTE5YjhhMTY1ZTA0YjUwL3RhYmxlcmFuZ2U6Yjc5NTRiZjYxZmZhNDdhNGFhMTliOGExNjVlMDRiNTBfNC0zLTEtMS05MTI4NA_bedec7b4-99a3-4683-b291-4172f4fc179d"
      unitRef="usd">350800000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RleHRyZWdpb246NDJmZGNjNWY1YzE2NDljZWFhMDg4ZTc0N2VjODg4NThfMjU1_53e9fc83-a1cd-41a3-a441-10da4ee7fc99">Property, plant and equipment, net&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation &amp;amp; amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(319.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, construction-in-progress primarily includes costs incurred related to construction to advance the Company's CDMO capabilities. &lt;/span&gt;&lt;/div&gt;Property, plant and equipment, net is stated at cost, less accumulated depreciation and amortization. During the three and six months ended June 30, 2022, the Company recorded accelerated depreciation of $12.7&#160;million to shorten the useful life of certain property, plant and equipment which were to be used in the manufacturing process to fulfill the manufacturing services agreement with Janssen. For additional information related to the termination of the Agreement, refer to Note 10, Revenue recognition.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RleHRyZWdpb246NDJmZGNjNWY1YzE2NDljZWFhMDg4ZTc0N2VjODg4NThfMjU0_51c316b7-b204-4360-ba94-eb2a0f180b88">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment, net consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.216%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and improvements&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings, building improvements and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;293.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;269.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Furniture and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;527.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;513.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction-in-progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;223.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,156.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Accumulated depreciation &amp;amp; amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(357.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(319.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;800.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i453d53e9bf31458986795e4f39e26923_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMS0xLTEtMS05MTI4NA_8d4e8105-e821-4d1f-a035-c258a92d5073"
      unitRef="usd">51200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i1bd46276d3b04bd4b23ff8a4977603af_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMS0zLTEtMS05MTI4NA_e4f586bc-5682-4302-abd6-606577c47873"
      unitRef="usd">52100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i6549082d6bea4ee292c42fcb1e41c193_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMi0xLTEtMS05MTI4NA_9bfed634-d8ad-4496-8d12-e59a2310cd57"
      unitRef="usd">293000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i67809435803d4785af1d56017bd50fe5_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMi0zLTEtMS05MTI4NA_9bc17d85-e79b-4277-8e28-69401a6ecdbe"
      unitRef="usd">269700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ic594742899c1467ba744e0c848e9a5fc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMy0xLTEtMS05MTI4NA_c62b2f4e-48d2-4227-aace-39dd3933156c"
      unitRef="usd">527300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if1a7d2d8b2634e30b07c0639a0a4ffe6_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfMy0zLTEtMS05MTI4NA_fff06760-2ae8-4fa1-b165-e7e3888c5d0a"
      unitRef="usd">513500000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i134070129abc4a5f994c045f64942b5a_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNC0xLTEtMS05MTI4NA_1f105cb8-e285-4112-8d3d-bb9d2d06063b"
      unitRef="usd">66200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i53d26d6afabb48b2bf9ddc2fb0a2211c_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNC0zLTEtMS05MTI4NA_b54916f2-dde5-4785-a772-1948866c725a"
      unitRef="usd">60700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8e92b9a6f4ef4b27b44d1e0436ee4f05_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNS0xLTEtMS05MTI4NA_2792d534-e9fb-4cfb-8c6f-d7499c7073bb"
      unitRef="usd">218400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i9cc08f556fb64cd7881fbaf9a720bbb2_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNS0zLTEtMS05MTI4NA_6e4b8413-ff46-4288-bfc0-d05aae885e86"
      unitRef="usd">223200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNi0xLTEtMS05MTI4NA_4afcf79e-f31b-4f16-9c4a-d7f9d0210e6d"
      unitRef="usd">1156100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNi0zLTEtMS05MTI4NA_c072af1e-161a-474a-a5d7-0d62bfecdc51"
      unitRef="usd">1119200000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNy0xLTEtMS05MTI4NA_e15d28c4-499d-422c-b90d-603573234e8b"
      unitRef="usd">357700000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfNy0zLTEtMS05MTI4NA_b596ffc2-bf87-4c4a-adf2-160196c6f927"
      unitRef="usd">319100000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfOC0xLTEtMS05MTI4NA_bff6bb51-e1d5-49a8-803c-0ffa278a313d"
      unitRef="usd">798400000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RhYmxlOmE2OGViOWE0MGJkZjQzMDBhYjk0MWQ0N2VhNjkxZDM3L3RhYmxlcmFuZ2U6YTY4ZWI5YTQwYmRmNDMwMGFiOTQxZDQ3ZWE2OTFkMzdfOC0zLTEtMS05MTI4NA_b68f8a2a-f892-4266-bc62-ad1ee9c7d832"
      unitRef="usd">800100000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9546d5f25011482ea8eff2df29f3ff29_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RleHRyZWdpb246NDJmZGNjNWY1YzE2NDljZWFhMDg4ZTc0N2VjODg4NThfNjU5NzA2OTc2ODc3OA_74a1bb89-8d16-425d-9e3e-87b4bc7ea915"
      unitRef="usd">12700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9638e645586946feae3242935cd61d34_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80My9mcmFnOjQyZmRjYzVmNWMxNjQ5Y2VhYTA4OGU3NDdlYzg4ODU4L3RleHRyZWdpb246NDJmZGNjNWY1YzE2NDljZWFhMDg4ZTc0N2VjODg4NThfNjU5NzA2OTc2ODc3OA_a74f23b8-d399-4256-86ef-ca4dbbef174a"
      unitRef="usd">12700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RleHRyZWdpb246Mjk5OGQ5M2U3MzE5NDJiOWFjMDQxY2ZjODhiNjAyMjhfNjgw_897e909d-a2cb-43ee-bc5c-086eb1c389cd">Leases&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is the lessee for operating leases for offices, research and development facilities and manufacturing facilities. The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (ROU) assets and liabilities. For a discussion of lessor activities, see Note 10, Revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease costs are reflected as components of cost of product sales, cost of contract development and manufacturing, research and development expense and selling, general and administrative expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to lessee activities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions, except lease term and discount rate)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance Sheet location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_08a6d402-1277-48d2-bf99-60dd61290d59"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_1ed14031-8464-49dc-b194-cef65be5901a"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_27fc9abe-7aef-4a7b-ba2f-191204f5fc38"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_b64be59d-2273-4d6d-8743-cf67e2bb3dd4"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_a0e6f1b3-d5ea-4f24-926b-07bfa08973d9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_b0f3a4ed-4e9d-4073-9e24-438362666e2c"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RleHRyZWdpb246Mjk5OGQ5M2U3MzE5NDJiOWFjMDQxY2ZjODhiNjAyMjhfNjc2_ed23c22b-00cd-4c28-b753-219f6901bdb0">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:32.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.991%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.997%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest on lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:0.5pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfMy0xLTEtMS05MTI4NA_2f9e07fc-8b68-4735-abe1-cb6d86980dec"
      unitRef="usd">1400000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfMy0zLTEtMS05MTI4NA_b8b724ab-e808-4336-829b-68b237af80fd"
      unitRef="usd">1500000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfMy01LTEtMS05MTI4NA_5721eb29-5c2e-4ef3-9972-1549bfce2a5d"
      unitRef="usd">2800000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfMy03LTEtMS05MTI4NA_901e8279-29f8-4a13-8321-b9cdbf84404c"
      unitRef="usd">2800000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNC0xLTEtMS05MTI4NA_d56e0dbc-7bee-47c4-a1ee-12f3ef2666a5"
      unitRef="usd">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNC0zLTEtMS05MTI4NA_233d2c4c-d069-4633-9643-33a9d0d4c458"
      unitRef="usd">300000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNC01LTEtMS05MTI4NA_43767997-bdbf-482b-9029-f925bd3268bf"
      unitRef="usd">600000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNC03LTEtMS05MTI4NA_04fe7626-c701-4d79-8127-a90f4138651b"
      unitRef="usd">700000</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCost
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNS0xLTEtMS05MTI4NA_1615b057-9c35-4f51-b5b9-3043787fc87a"
      unitRef="usd">1700000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNS0zLTEtMS05MTI4NA_bc1dcbf2-29e2-49c3-af45-2b2d688f8b1d"
      unitRef="usd">1800000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNS01LTEtMS05MTI4NA_b6a35d2f-bfc5-40f5-a6ac-43e5f465434b"
      unitRef="usd">3400000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmNjYzE1ZTBlYjU1MDQ4YmM5MzVjZjY4MDM5ZTgwMTkyL3RhYmxlcmFuZ2U6Y2NjMTVlMGViNTUwNDhiYzkzNWNmNjgwMzllODAxOTJfNS03LTEtMS05MTI4NA_8a91525d-d068-4bed-9652-bd5cd866102f"
      unitRef="usd">3500000</us-gaap:LeaseCost>
    <ebs:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RleHRyZWdpb246Mjk5OGQ5M2U3MzE5NDJiOWFjMDQxY2ZjODhiNjAyMjhfNjg1_a5b4e0b5-d144-44de-b897-a5fd982674a8">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental balance sheet information related to lessee activities is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.020%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.880%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(In millions, except lease term and discount rate)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance Sheet location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease right-of-use assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_08a6d402-1277-48d2-bf99-60dd61290d59"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0xLTEtMS05MTI4NA_1ed14031-8464-49dc-b194-cef65be5901a"&gt;Other assets&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities, current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_27fc9abe-7aef-4a7b-ba2f-191204f5fc38"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0xLTEtMS05MTI4NA_b64be59d-2273-4d6d-8743-cf67e2bb3dd4"&gt;Other current liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_a0e6f1b3-d5ea-4f24-926b-07bfa08973d9"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0xLTEtMS05MTI4NA_b0f3a4ed-4e9d-4073-9e24-438362666e2c"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.9&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.2&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Operating leases:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average remaining lease term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted average discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ebs:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS0zLTEtMS05MTI4NA_dfb690e3-0046-4577-9829-f4e5261dad05"
      unitRef="usd">25500000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMS01LTEtMS05MTI4NA_21fa770a-34c4-4059-a620-23483335f95c"
      unitRef="usd">28300000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy0zLTEtMS05MTI4NA_74888504-1ad6-4e11-a4ca-562d0a0e1f6b"
      unitRef="usd">5900000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfMy01LTEtMS05MTI4NA_274b6e43-f9a6-40dd-9a53-8e1ca4bf2602"
      unitRef="usd">5800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC0zLTEtMS05MTI4NA_9d494c46-6cef-47b7-9ec9-a9a0d00d0a33"
      unitRef="usd">20900000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNC01LTEtMS05MTI4NA_5e673ad5-29d5-4876-9efa-7226a51f15d5"
      unitRef="usd">24200000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNS0zLTEtMS05MTI4NA_e2e0c2d7-4a86-47d9-8a19-11af88c49d89"
      unitRef="usd">26800000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfNS01LTEtMS05MTI4NA_96c6f9ee-abfa-4c3f-a567-1b24249bdd32"
      unitRef="usd">30000000.0</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfOC0zLTEtMS05MTI4NA_5528f8f0-4538-4c20-a797-8231c9ae8b36">P6Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfOC01LTEtMS05MTI4NA_22fde7c6-ce86-4ddf-a00b-f836ff591226">P7Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfOS0zLTEtMS05MTI4NA_0ec69f43-ef8c-42fd-8573-85be4cbc9b47"
      unitRef="number">0.041</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80Ni9mcmFnOjI5OThkOTNlNzMxOTQyYjlhYzA0MWNmYzg4YjYwMjI4L3RhYmxlOmYwZWQ3NjJjNmY5MjQxMTdhZjYwYzk5OTZhY2ZlYzgyL3RhYmxlcmFuZ2U6ZjBlZDc2MmM2ZjkyNDExN2FmNjBjOTk5NmFjZmVjODJfOS01LTEtMS05MTI4NA_efd4048a-b78a-4601-bd28-6fb9c117a8ca"
      unitRef="number">0.041</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:IntangibleAssetsDisclosureTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNjE1_f58f6f6c-daa3-482b-a4b7-a449bf105d22">Intangible assets&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's intangible assets consist of products acquired via business combinations or asset acquisitions. The following table summarizes the Company's Intangible assets, net:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9-22 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense associated with the Company's intangible assets was recorded as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the weighted average amortization period remaining for intangible assets was 11.4 years years. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;The carrying amount of goodwill included accumulated impairments of $41.7 million as of June&#160;30, 2022 and December&#160;31, 2021, respectively.</us-gaap:IntangibleAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNjE5_65f6db75-1187-4f16-bdf9-d63a6d95b5ef">The following table summarizes the Company's Intangible assets, net:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.710%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.963%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.262%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.966%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset Type&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Estimated Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9-22 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;798.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CDMO&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8 years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt 2px 7pt;text-align:left;text-indent:-9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Total intangible assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;226.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;803.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;604.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="iec5db6327b294813891aa4350122c017_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi0xLTEtMS05MTI4NC90ZXh0cmVnaW9uOmUyODM5NDMzZDQ4NzQwYmU4Y2E4Yzc5ZjNiNDExY2M1XzQ_1c33bcf5-b5c2-4009-8996-b70b062d4cf9">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i0ae91bff48a14d479830dd7525eb8ff8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi0xLTEtMS05MTI4NC90ZXh0cmVnaW9uOmUyODM5NDMzZDQ4NzQwYmU4Y2E4Yzc5ZjNiNDExY2M1Xzc_85aabdd7-7bc8-4737-a6a5-fb3830441c9f">P22Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i2719aab9d5794354b6d5b105d461f2f5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi0zLTEtMS05MTI4NA_b50a3635-57f9-4883-b299-df70f4bb2f00"
      unitRef="usd">798000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i2719aab9d5794354b6d5b105d461f2f5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi00LTEtMS05MTI4NA_af9aa13a-123a-42fc-a724-2a82376871d1"
      unitRef="usd">221400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i2719aab9d5794354b6d5b105d461f2f5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi01LTEtMS05MTI4NA_40c2bdb9-f45b-4517-b903-284a6051ce5a"
      unitRef="usd">576600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia3702d910f4e4076ba85f38d2f42d7f4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi03LTEtMS05MTI4NA_0c4785f7-2c83-4696-9e2b-425962d39283"
      unitRef="usd">798000000.0</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia3702d910f4e4076ba85f38d2f42d7f4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi04LTEtMS05MTI4NA_502f81b0-460c-45cb-9673-3a818df73c51"
      unitRef="usd">193500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia3702d910f4e4076ba85f38d2f42d7f4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfMi05LTEtMS05MTI4NA_52389c7a-c29d-442e-b2c7-b384307b4a0b"
      unitRef="usd">604500000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1f3ab8a51d54481e9e87b3f7cd0d98a8_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC0xLTEtMS05MTI4NA_a39b8e57-2d43-466a-a0c7-03f1e0ad12bd">P8Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="iaecb377a9b7d4fc4a9340b29e791ac69_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC0zLTEtMS05MTI4NA_2bcc881a-4406-499d-8975-98af38b892bd"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="iaecb377a9b7d4fc4a9340b29e791ac69_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC00LTEtMS05MTI4NA_a0b5a70b-10b0-4c38-a582-c48a92212170"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="iaecb377a9b7d4fc4a9340b29e791ac69_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC01LTEtMS05MTI4NA_0cd481ff-1b53-4a63-9685-cc7b0d0a18a6"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ibb945e79e9d14eb897b6c2bb31d6fca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC03LTEtMS05MTI4NA_0ea2a38b-f104-4237-8033-f141006bb4c4"
      unitRef="usd">5500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ibb945e79e9d14eb897b6c2bb31d6fca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC04LTEtMS05MTI4NA_b59b9d35-9693-4a89-b3ba-9cb8e5e528a9"
      unitRef="usd">5400000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ibb945e79e9d14eb897b6c2bb31d6fca4_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNC05LTEtMS05MTI4NA_dde32690-a447-48c9-8bd3-7678cf5790ec"
      unitRef="usd">100000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS0zLTEtMS05MTI4NA_0ef3817e-16b3-45d7-ad08-e0149bf7503b"
      unitRef="usd">803500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS00LTEtMS05MTI4NA_66a087a3-bfa3-4faf-a0d7-870639f35b18"
      unitRef="usd">226900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS01LTEtMS05MTI4NA_ddace3eb-4dac-49ff-93bc-dbde582f0fed"
      unitRef="usd">576600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS03LTEtMS05MTI4NA_168c0fc7-0d5e-4976-9fbc-23e26cb2b512"
      unitRef="usd">803500000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS04LTEtMS05MTI4NA_f6c0078c-3025-4a4d-8f27-5d0c675493f6"
      unitRef="usd">198900000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmFiOWM4MzA4NWQyYjQ0ZDk5MjE3NDNkODE0MzgyZTY3L3RhYmxlcmFuZ2U6YWI5YzgzMDg1ZDJiNDRkOTkyMTc0M2Q4MTQzODJlNjdfNS05LTEtMS05MTI4NA_2045fdf9-27e6-435c-950e-ec61e974a5a6"
      unitRef="usd">604600000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNjIw_05348dcf-1e58-4549-bfe6-27d5fdaf2c2c">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense associated with the Company's intangible assets was recorded as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmYwYTU0NjY3M2YyZTQyNGM4YTI4NWI4NmQzZjM2ZTA4L3RhYmxlcmFuZ2U6ZjBhNTQ2NjczZjJlNDI0YzhhMjg1Yjg2ZDNmMzZlMDhfMi0xLTEtMS05MTI4NA_eaf7c95b-b0c0-4afd-af98-559429733bdc"
      unitRef="usd">14000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmYwYTU0NjY3M2YyZTQyNGM4YTI4NWI4NmQzZjM2ZTA4L3RhYmxlcmFuZ2U6ZjBhNTQ2NjczZjJlNDI0YzhhMjg1Yjg2ZDNmMzZlMDhfMi0zLTEtMS05MTI4NA_154d9fcd-50d5-4632-ab27-5285fcba6b36"
      unitRef="usd">15100000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmYwYTU0NjY3M2YyZTQyNGM4YTI4NWI4NmQzZjM2ZTA4L3RhYmxlcmFuZ2U6ZjBhNTQ2NjczZjJlNDI0YzhhMjg1Yjg2ZDNmMzZlMDhfMi01LTEtMS05MTI4NA_0475b6b1-5d9a-492b-8962-52a4f5656955"
      unitRef="usd">28000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmYwYTU0NjY3M2YyZTQyNGM4YTI4NWI4NmQzZjM2ZTA4L3RhYmxlcmFuZ2U6ZjBhNTQ2NjczZjJlNDI0YzhhMjg1Yjg2ZDNmMzZlMDhfMi03LTEtMS05MTI4NA_f85999f3-bf79-4ec7-8d03-ab05410ea473"
      unitRef="usd">30000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNDE3_7dc984cf-93b8-45a3-bad7-719a379c5dc3">P11Y4M24D</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNjE0_8aff698e-a85a-46d5-b9a1-58acdcafd89e">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a roll forward of changes in our goodwill balance:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.629%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.171%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign currency translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmI4ZDk4NjU2ZWZkMDQ5ZTQ4YTc1ZGE1MGVjOTQxMzhhL3RhYmxlcmFuZ2U6YjhkOTg2NTZlZmQwNDllNDhhNzVkYTUwZWM5NDEzOGFfMS0xLTEtMS05MTI4NA_0049ce99-6159-4cd0-b91d-a0ba221494a0"
      unitRef="usd">224900000</us-gaap:Goodwill>
    <us-gaap:GoodwillForeignCurrencyTranslationGainLoss
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmI4ZDk4NjU2ZWZkMDQ5ZTQ4YTc1ZGE1MGVjOTQxMzhhL3RhYmxlcmFuZ2U6YjhkOTg2NTZlZmQwNDllNDhhNzVkYTUwZWM5NDEzOGFfMi0xLTEtMS05MTI4NA_2086d3e7-9525-4176-a4bc-d0a9a98b8de8"
      unitRef="usd">0</us-gaap:GoodwillForeignCurrencyTranslationGainLoss>
    <us-gaap:Goodwill
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RhYmxlOmI4ZDk4NjU2ZWZkMDQ5ZTQ4YTc1ZGE1MGVjOTQxMzhhL3RhYmxlcmFuZ2U6YjhkOTg2NTZlZmQwNDllNDhhNzVkYTUwZWM5NDEzOGFfMy0xLTEtMS05MTI4NA_dc51dfa4-eaf0-402c-b757-05b87b01e62f"
      unitRef="usd">224900000</us-gaap:Goodwill>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNTcz_331f3d20-de65-4d67-82bb-7a9389f3a0ca"
      unitRef="usd">41700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:GoodwillImpairedAccumulatedImpairmentLoss
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV80OS9mcmFnOjZjM2JhMTkxYmEyMzQ3NDg4OGYyOTRjNTM2YTBlMjE4L3RleHRyZWdpb246NmMzYmExOTFiYTIzNDc0ODg4ZjI5NGM1MzZhMGUyMThfNTcz_ea592e1c-e472-4625-a3a6-588606e0f07a"
      unitRef="usd">41700000</us-gaap:GoodwillImpairedAccumulatedImpairmentLoss>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTk3Ng_870fb897-f217-4f7e-a893-ab9cf2e31148">Fair value measurements&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques we utilized to determine fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contingent consideration liabilities associated with business combinations are measured at fair value. These liabilities represent an obligation of the Company to transfer additional assets to the selling shareholders and owners if future events occur or conditions are met. These liabilities associated with business combinations are measured at fair value at inception and at each subsequent reporting date. The changes in the fair value are primarily due to the expected amount and timing of future net sales, which are inputs that have no observable market. Any changes in fair value for the contingent consideration liabilities related to the Company&#x2019;s products are classified in the Company's statement of operations as cost of product sales. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a reconciliation of the beginning and ending balance of our contingent consideration liability: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, the current portion of the contingent consideration liability was $3.6 million and $32.7&#160;million, respectively, and was included in other current liabilities on the condensed consolidated balance sheets. The non-current portion of the contingent consideration liability is included in other liabilities on the condensed consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value as of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue milestone and royalty based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.1 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25% - 50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Derivative instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Refer to&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Note 8, Derivative instruments and hedging activities&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;for more information about our derivative instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-variable rate debt&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2022 and December&#160;31, 2021, t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he fair value of the Company's 3.875% Senior Unsecured Notes was $319.0&#160;million and $433.3&#160;million. The fair value was determined through market sources, which are level 2 inputs and directly observable. &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amounts of the Company&#x2019;s other long-term variable interest rate debt arrangements approximate their fair values (see Note 9, Debt).&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTk4MQ_6ef8ec39-3e42-48d7-874a-a615160faf0d">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents information about the Company's assets and liabilities that are regularly measured and carried at fair value and indicates the level within the fair value hierarchy of the valuation techniques we utilized to determine fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.568%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:24.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.135%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market accounts&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;156.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;152.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if7a3ff2d30f44b30ad269a86575c7d4e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy0xLTEtMS05MTI4NA_412fd647-595d-41f1-b5c2-f9393e4a56ff"
      unitRef="usd">25100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i79799b3cea2d48fe835c4576542f0b52_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy0yLTEtMS05MTI4NA_f0bd643d-c776-4aef-a027-45f4f73dbe5b"
      unitRef="usd">25100000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7f5ad802356e448ab1848888d53289de_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy0zLTEtMS05MTI4NA_94bb3da8-ca65-4d09-9b73-4129a0c1d66a"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5b48ff71a5694921b7c29a1874507763_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy00LTEtMS05MTI4NA_afceea41-a74b-42da-a19e-1232b8846b1e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i29e74e081ffd481a81c8d31209a72a7b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy01LTEtMS05MTI4NA_68fd2d06-5d5c-423b-a2ee-3d30b0e00950"
      unitRef="usd">152400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i84ec0dc532f44309a78a239914a64f67_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy02LTEtMS05MTI4NA_ef41c60d-ce33-4b11-b2dd-8c01868185d3"
      unitRef="usd">152400000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i8e03e34023ba4211b5ca4dafd5a90760_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy03LTEtMS05MTI4NA_b38bb379-2cb9-4218-ac84-74feb72bc0f7"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="if86a10b89dc447daa6d9d4bf87168919_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMy04LTEtMS05MTI4NA_e2974a15-8961-45b9-a7a1-b8c02ffd2f95"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2ff9b0c4a1d54ae9a2bbb36bb215f296_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC0xLTEtMS05MTI4NA_d7c77500-ac0b-4377-909e-4996cd718e31"
      unitRef="usd">150200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ia002b59284bc4d199415af1950deab8e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC0yLTEtMS05MTI4NA_759b797d-0eb6-422d-ab44-8988094dd834"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i05104b094a7244639351db2f1a5c4ae2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC0zLTEtMS05MTI4NA_f373bdf2-3a28-42d0-8a52-18773c418792"
      unitRef="usd">150200000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i7aad5be81d9e42518d03593f82a64ee7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC00LTEtMS05MTI4NA_aa809095-d265-4234-8f9f-cc3de31337b2"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="id5709272ba65411cb08a6afe257ae472_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC01LTEtMS05MTI4NA_b96b348a-5552-4cdb-9f69-48d6fa793cea"
      unitRef="usd">200000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="icaad2ed6a61b4a8ca6f97ee4093e90dc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC02LTEtMS05MTI4NA_98caebcf-a144-451c-ab5a-fcc96863bab3"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i0f9ea93856b0488caab05e73833c90f9_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC03LTEtMS05MTI4NA_b4f828eb-63be-4b46-963b-c0f413005a89"
      unitRef="usd">200000000.0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i13b7d630bf0142c6885ef16b3dd8ee1b_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNC04LTEtMS05MTI4NA_facf650d-d775-499a-a48b-a55e5d06765c"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DerivativeAssets
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS0xLTEtMS05MTI4NA_9eaa5a2d-b771-4227-b40a-fa548b6f8145"
      unitRef="usd">6300000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia00c535b28684f0fb4f18a37ffde27d1_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS0yLTEtMS05MTI4NA_6395aa9e-5bf0-4f9a-8141-415f5789a21f"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i94171351ca92471d95422d2216ab5acb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS0zLTEtMS05MTI4NA_5953ed50-2a15-4cac-a9ad-811d8a880e66"
      unitRef="usd">6300000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ia9e69b63b67f4da689c99626eb9b9b75_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS00LTEtMS05MTI4NA_96d9d766-146a-434c-9df0-b08ae83205fe"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS01LTEtMS05MTI4NA_cb63b960-2bb3-4e9d-8bc6-553002c84ab6"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i55840f9158e144dd8f3579713ad95750_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS02LTEtMS05MTI4NA_43f2425b-6b76-4422-84ed-670f33d27ac0"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS03LTEtMS05MTI4NA_6b959017-9a6b-4062-b3eb-3f189fedc094"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="i1827bdb5367f4f7980f91a6d166e8719_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNS04LTEtMS05MTI4NA_238327aa-b03b-41de-80d4-7ef305c45bf8"
      unitRef="usd">0</us-gaap:DerivativeAssets>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi0xLTEtMS05MTI4NA_6ddc707e-8968-4dfc-9c82-6e9063606925"
      unitRef="usd">181600000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia00c535b28684f0fb4f18a37ffde27d1_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi0yLTEtMS05MTI4NA_16a12fe6-f879-4055-84c3-456763b143cc"
      unitRef="usd">25100000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i94171351ca92471d95422d2216ab5acb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi0zLTEtMS05MTI4NA_9a85ff91-ae9d-46b0-a469-29def408df4a"
      unitRef="usd">156500000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ia9e69b63b67f4da689c99626eb9b9b75_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi00LTEtMS05MTI4NA_7592aa7f-8062-4e7c-907d-ed1f5cb3ce1d"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi01LTEtMS05MTI4NA_cea7bdc4-c110-49ef-a52e-a3fd9e13eeae"
      unitRef="usd">352400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i55840f9158e144dd8f3579713ad95750_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi02LTEtMS05MTI4NA_cf2702a9-4df2-43d2-baf5-197192f25691"
      unitRef="usd">152400000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi03LTEtMS05MTI4NA_eec485ae-5e2c-4084-9226-911bfb92a2ef"
      unitRef="usd">200000000.0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i1827bdb5367f4f7980f91a6d166e8719_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfNi04LTEtMS05MTI4NA_9e89a285-19f5-4003-bc47-ed11f508ae64"
      unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC0xLTEtMS05MTI4NA_2ab754bc-3ffb-41b8-80cf-db87b0e7d156"
      unitRef="usd">8100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia00c535b28684f0fb4f18a37ffde27d1_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC0yLTEtMS05MTI4NA_1e7a69bd-0252-4429-b9c2-3e478f430dca"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i94171351ca92471d95422d2216ab5acb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC0zLTEtMS05MTI4NA_6d6ca753-e0be-4d24-86b6-68be948b599d"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ia9e69b63b67f4da689c99626eb9b9b75_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC00LTEtMS05MTI4NA_949f2e20-0569-4fbb-9fd7-602359f8681b"
      unitRef="usd">8100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC01LTEtMS05MTI4NA_5d3de6c1-1bd9-4164-b7fe-3fb7dd328734"
      unitRef="usd">37200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i55840f9158e144dd8f3579713ad95750_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC02LTEtMS05MTI4NA_d3667166-2dfb-4b17-9eed-3e0cc43cb12e"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC03LTEtMS05MTI4NA_6790c9ee-723f-4894-979e-3028ddc9f4d1"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1827bdb5367f4f7980f91a6d166e8719_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOC04LTEtMS05MTI4NA_c1492285-27b6-4f90-b2bc-5321555835f1"
      unitRef="usd">37200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeLiabilities
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS0xLTEtMS05MTI4NA_ec4525c1-9f8d-4c7e-a091-cbc0a804b6de"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia00c535b28684f0fb4f18a37ffde27d1_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS0yLTEtMS05MTI4NA_5a16bbd7-d43d-4836-90f7-84af1fff95ae"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i94171351ca92471d95422d2216ab5acb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS0zLTEtMS05MTI4NA_f8deec36-77d0-4ae3-b9d0-7e580929f99f"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ia9e69b63b67f4da689c99626eb9b9b75_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS00LTEtMS05MTI4NA_e2618ce5-162b-49cd-bfff-048805480c8b"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS01LTEtMS05MTI4NA_9c34e3bc-9d0b-4d59-afd1-aeff49ffe166"
      unitRef="usd">6100000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i55840f9158e144dd8f3579713ad95750_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS02LTEtMS05MTI4NA_7412df7e-c533-4adb-8d4b-32e619bdf0f9"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS03LTEtMS05MTI4NA_1f875e8a-ccd3-4740-bbde-37ad43b4b7d6"
      unitRef="usd">6100000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="i1827bdb5367f4f7980f91a6d166e8719_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfOS04LTEtMS05MTI4NA_05c2105b-f6ae-4d8b-b8c5-a5cf7a9e54d8"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtMS0xLTEtOTEyODQ_ed34c8ae-9fd5-46f5-96fb-be4e07b23b36"
      unitRef="usd">8100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia00c535b28684f0fb4f18a37ffde27d1_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtMi0xLTEtOTEyODQ_8c69dd47-c7d2-4d05-b9b9-e810d5cfc935"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i94171351ca92471d95422d2216ab5acb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtMy0xLTEtOTEyODQ_5b8f48aa-a920-4811-95e5-905c9f354b5e"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="ia9e69b63b67f4da689c99626eb9b9b75_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtNC0xLTEtOTEyODQ_5aa09aa1-0eaf-48a9-876e-ca6b6ede9fb3"
      unitRef="usd">8100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtNS0xLTEtOTEyODQ_18ec76eb-d238-44eb-9c3b-37345b7233dd"
      unitRef="usd">43300000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i55840f9158e144dd8f3579713ad95750_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtNi0xLTEtOTEyODQ_51d546d2-5d36-44ae-bb1f-932ea0686568"
      unitRef="usd">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i7ed0b0fbb33d47d1b6084875e0566d42_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtNy0xLTEtOTEyODQ_eb1e27a4-6bbe-4a84-a4af-b4a7fe17a083"
      unitRef="usd">6100000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i1827bdb5367f4f7980f91a6d166e8719_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjk4YmI2YjkzYWYzMjQ1NWE4MDBmZmFiMjY2NmEyMzA4L3RhYmxlcmFuZ2U6OThiYjZiOTNhZjMyNDU1YTgwMGZmYWIyNjY2YTIzMDhfMTAtOC0xLTEtOTEyODQ_51ea66f9-bdb4-4a3f-9839-a1a4a1acbd96"
      unitRef="usd">37200000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTk3Nw_21586ece-0a8c-4f3a-b2ef-3ebb8e91e2e5">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a reconciliation of the beginning and ending balance of our contingent consideration liability: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;37.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Change in fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOmRkMDk5ZmZhMjQ2NzRhNzE4NmZlY2Y3YzJhZDM2YzEyL3RhYmxlcmFuZ2U6ZGQwOTlmZmEyNDY3NGE3MTg2ZmVjZjdjMmFkMzZjMTJfMS0xLTEtMS05MTI4NA_7143f69d-0fa9-40dc-b14f-7c3bf2ddb421"
      unitRef="usd">37200000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOmRkMDk5ZmZhMjQ2NzRhNzE4NmZlY2Y3YzJhZDM2YzEyL3RhYmxlcmFuZ2U6ZGQwOTlmZmEyNDY3NGE3MTg2ZmVjZjdjMmFkMzZjMTJfMi0xLTEtMS05MTI4NA_2e19b6a3-64f0-48dd-ba98-02fd8f8bfa33"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOmRkMDk5ZmZhMjQ2NzRhNzE4NmZlY2Y3YzJhZDM2YzEyL3RhYmxlcmFuZ2U6ZGQwOTlmZmEyNDY3NGE3MTg2ZmVjZjdjMmFkMzZjMTJfMy0xLTEtMS05MTI4NA_6b7abd73-13a3-49b4-81d9-6a0986f0ed74"
      unitRef="usd">30900000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOmRkMDk5ZmZhMjQ2NzRhNzE4NmZlY2Y3YzJhZDM2YzEyL3RhYmxlcmFuZ2U6ZGQwOTlmZmEyNDY3NGE3MTg2ZmVjZjdjMmFkMzZjMTJfNC0xLTEtMS05MTI4NA_7221a530-9502-40f7-87bb-0be05be7e2b6"
      unitRef="usd">8100000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTI1NQ_3396ea9d-47da-409f-91a9-83ee09e93024"
      unitRef="usd">3600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTI2Mg_52bdbc6f-a3e6-4acd-a075-23f2c64267db"
      unitRef="usd">32700000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTk4Mw_be6eb296-e251-4eaf-b695-f6074120f56c">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The recurring Level 3 fair value measurements for the Company's contingent consideration liability include the following significant unobservable inputs: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent Consideration Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value as of June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Valuation Technique&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unobservable Input&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted Average&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:18pt"&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue milestone and royalty based&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$8.1 million&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Discounted cash flow&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Probability of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25% - 50%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.0%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:24pt"&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected year of payment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022 - 2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i7b0124a24a6d42f38a22a139d7a986cc_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMS0xLTEtMS05MTI4NA_a89868a3-243d-4aa7-9ef4-b6aab335a9c1"
      unitRef="usd">8100000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ia7ec6f53ea7c40c2912590dc96df1140_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMS00LTEtMS05MTI4NC90ZXh0cmVnaW9uOmUxNDQ3Y2M2YmIxYTRkNDZiNjQ1YjdiMTJhYjc4ZTgwXzQ_7c06a9bb-35a3-486c-917e-72898a95f1f4"
      unitRef="number">0.093</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="ib3767e06a12a4c5e98d3e3277b684a7a_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMS01LTEtMS05MTI4NA_c948abac-76b0-471b-a01e-2a50ba23a49b"
      unitRef="number">0.093</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i63a027931d994feaad0cc197610c9386_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMi00LTEtMS05MTI4NC90ZXh0cmVnaW9uOjFiNDI2Nzc5ODdmMTQ2MGNiNzAyODlmMjY0Mjc3NTgxXzQ_0658c4f8-9c8f-49a6-97c9-a882a5ce8d29"
      unitRef="number">0.25</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i83059e6d4cbf495fac3749e03908d241_I20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMi00LTEtMS05MTI4NC90ZXh0cmVnaW9uOjFiNDI2Nzc5ODdmMTQ2MGNiNzAyODlmMjY0Mjc3NTgxXzk_6ed13189-67e0-4433-b83b-3c6dc99fd6cd"
      unitRef="number">0.50</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="i719981bf5f3142bcab25241944433a85_I20220630"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RhYmxlOjU4ZTMyMzMyNDdmMTRjYWNhYmZjMjUwNThkZGFkYWU4L3RhYmxlcmFuZ2U6NThlMzIzMzI0N2YxNGNhY2FiZmMyNTA1OGRkYWRhZThfMi01LTEtMS05MTI4NA_d7f0e498-af35-45a2-bf4b-8330fa8c07b5"
      unitRef="number">0.400</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if69c9e056c6b47ce9a39e1690508a029_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTY5NA_0655ea8e-6d6e-4606-952e-f413f9607b99"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idb1acd071817481e9aef10fe54fb65fb_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTY5NA_0b662871-3dd3-437b-9de2-deef382dc5e8"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebtFairValue
      contextRef="if69c9e056c6b47ce9a39e1690508a029_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTcyNA_3f97c870-8cff-4b8f-a2da-8cb7272e4684"
      unitRef="usd">319000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="idb1acd071817481e9aef10fe54fb65fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81Mi9mcmFnOjMyNTkxN2E3ZTNmMjQwYWNiZTRjZGU2NjU4M2YzOTA2L3RleHRyZWdpb246MzI1OTE3YTdlM2YyNDBhY2JlNGNkZTY2NTgzZjM5MDZfMTczMQ_a2cb70e2-d68d-4775-a6e9-9122bdbafd4a"
      unitRef="usd">433300000</us-gaap:LongTermDebtFairValue>
    <us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfMjk4Nw_837e4850-8c96-4aca-80e1-0a488189c8ce">Derivative instruments and hedging activities&lt;div style="margin-bottom:9pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Risk management objective of using derivatives&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is exposed to certain risks arising from both its business operations and economic conditions. The Company principally manages its exposures to a wide variety of business and operational risks through management of its core business activities. The Company manages economic risks, including interest rate, liquidity and credit risk primarily by managing the amount, sources and duration of its assets and liabilities and the use of derivative financial instruments. Specifically, the Company has entered into interest rate swaps to manage exposures that arise from the Company's senior secured credit agreement's payments of variable interest rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;If current fair values of designated interest rate swaps&#160;remained static over the next&#160;twelve&#160;months, the Company would reclassify&#160;$4.8 million of net deferred gains from&#160;accumulated other comprehensive loss&#160;into the condensed consolidated statement of operations over the next&#160;twelve-month period. All outstanding cash flow hedges mature in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except number of instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Number of Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$350.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Current Liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:38pt"&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Location of Gain or (Loss) Reclassified from Accumulated OCL into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount of Gain/(Loss) Reclassified from Accumulated OCL into Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="i64a444e1b04f441690465f4274c0ba71_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfOTAw_e9285e66-12c8-41b0-8da4-9c4e12df6b31"
      unitRef="usd">4800000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfMjk3OQ_ab34d993-c83f-4aca-abe0-e027a7378f40">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company had the following outstanding interest rate derivatives that were designated as cash flow hedges of interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, except number of instruments)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Number of Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Notional&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$350.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:NumberOfInterestRateDerivativesHeld
      contextRef="i5baf28559b9c4518961b9d35563505d5_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjdiNTE5M2U4NTA1YjQxMTZiMjhjZWFhOTZjMDFlMTRjL3RhYmxlcmFuZ2U6N2I1MTkzZTg1MDViNDExNmIyOGNlYWE5NmMwMWUxNGNfMS0xLTEtMS05MTI4NA_c12f540c-0132-406b-991b-2a2637a8a653"
      unitRef="instrument">7</us-gaap:NumberOfInterestRateDerivativesHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5baf28559b9c4518961b9d35563505d5_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjdiNTE5M2U4NTA1YjQxMTZiMjhjZWFhOTZjMDFlMTRjL3RhYmxlcmFuZ2U6N2I1MTkzZTg1MDViNDExNmIyOGNlYWE5NmMwMWUxNGNfMS0zLTEtMS05MTI4NA_49288a18-a929-40bf-958a-abed5e9e5cd0"
      unitRef="usd">350000000.0</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfMjk4MA_b3390c78-dc73-4be2-958c-4564f1b492a3">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the fair value of the Company&#x2019;s derivative financial instruments designated as hedges as well as their classification on the balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.388%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.394%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Asset Derivatives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Liability Derivatives&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Balance Sheet Location&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:33pt"&gt;&lt;td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Current Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Current Liabilities &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Current Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i8fef5a8c0e574704b4e7fc1c219ab3d0_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfMy0yLTEtMS05MTI4NA_a8e8d689-cdee-4639-8a8e-e4e041bc2edc"
      unitRef="usd">4800000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="iec600dcf49a542e999254859b44d9453_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfMy00LTEtMS05MTI4NA_034949a4-c6c7-43a7-bd64-7cb9a25d89d8"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i10a6fba32aca4cf289ec54a01e657a74_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfMy02LTEtMS05MTI4NA_796ebe44-51b1-4c1a-9d81-2e906d5e5840"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i9db202080e4f497184ae1cf6144f3e2f_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfMy04LTEtMS05MTI4NA_a5d853a9-86b0-49e8-9535-c5a6e2e1c080"
      unitRef="usd">4500000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic20b9c06c3554129afcfbc3e3f02046b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfNC0yLTEtMS05MTI4NA_48e27fda-75af-4c47-98bc-459fb3975e62"
      unitRef="usd">1500000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ic7068fe6db2b4311a9524223dac6fb00_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfNC00LTEtMS05MTI4NA_f1b9e095-8d5f-4976-8c83-bfe3639799fd"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="icee5403eeb9f41649ba99ccabe3e2da8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfNC02LTEtMS05MTI4NA_0f09846c-4de7-47d6-a197-d5c29f506092"
      unitRef="usd">0</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i05d57a1513ce46c68b959f35fdc72cec_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOmVjYjFiM2NlMTFhODRjNDNiZDI0YzY0ZTU5OTg1OWNhL3RhYmxlcmFuZ2U6ZWNiMWIzY2UxMWE4NGM0M2JkMjRjNjRlNTk5ODU5Y2FfNC04LTEtMS05MTI4NA_e3d784a5-60ab-4764-bf48-2dae96a037fa"
      unitRef="usd">1600000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfMjk5MQ_287dec43-6061-4dc2-9f6b-733360c1c5a4">The valuation of the interest rate swaps is determined using widely accepted valuation techniques, including discounted cash flow analysis on the expected cash flows of each interest rate swap. This analysis reflects the contractual terms of the interest rate swaps, including the period to maturity, and uses observable market-based inputs, including interest rate curves and implied volatilities. The fair values of interest rate swaps are determined using the market standard methodology of netting the discounted future fixed cash payments (or receipts) and the discounted expected variable cash receipts (or payments). The variable cash payments (or receipts) are based on an expectation of future interest rates (forward curves) derived from observable market interest rate curves. We incorporate credit valuation adjustments in the fair value measurements to appropriately reflect both our own nonperformance risk and the respective counterparty&#x2019;s nonperformance risk. These credit valuation adjustments were not significant inputs for the fair value calculations for the periods presented. In adjusting the fair value of our derivative contracts for the effect of nonperformance risk, we have considered the impact of netting and any applicable credit enhancements, such as the posting of collateral, thresholds, mutual puts and guarantees. The valuation of interest rate swaps fall into Level 2 in the fair value hierarchy.</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RleHRyZWdpb246NzcyYmU2YjdlNjlhNDdmNjg2YjU3NjJkYjg5YThjZDJfMjk4Ng_f7495479-e324-4250-9d43-8adb16f089ec">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The table below presents the effect of cash flow hedge accounting on accumulated other comprehensive loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.712%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.657%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.309%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.311%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:38pt"&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cumulative Amount of Gain/(Loss) Recognized in OCI on Derivative&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Location of Gain or (Loss) Reclassified from Accumulated OCL into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amount of Gain/(Loss) Reclassified from Accumulated OCL into Income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest Rate Swaps&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i64a444e1b04f441690465f4274c0ba71_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjE4YjA1ODBlODU1ZjQzYjI4MjIwMzM2MDhhMmFiZWEyL3RhYmxlcmFuZ2U6MThiMDU4MGU4NTVmNDNiMjgyMjAzMzYwOGEyYWJlYTJfMy0xLTEtMS05MTI4NA_f635cdcd-168a-430b-a498-796075638efd"
      unitRef="usd">6300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ifa0b79c3b615467b86496c6b28174204_D20210101-20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjE4YjA1ODBlODU1ZjQzYjI4MjIwMzM2MDhhMmFiZWEyL3RhYmxlcmFuZ2U6MThiMDU4MGU4NTVmNDNiMjgyMjAzMzYwOGEyYWJlYTJfMy0yLTEtMS05MTI4NA_06df2cae-59fb-4510-aa68-2fc2adad3a55"
      unitRef="usd">-6100000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="ibc3c3a4cf51a47be9050271b2311e72e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjE4YjA1ODBlODU1ZjQzYjI4MjIwMzM2MDhhMmFiZWEyL3RhYmxlcmFuZ2U6MThiMDU4MGU4NTVmNDNiMjgyMjAzMzYwOGEyYWJlYTJfMy00LTEtMS05MTI4NA_7941c1b2-5aa0-45b7-a1cc-d1c7cab4228d"
      unitRef="usd">-2300000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="i7f1e5afa818e49f1bb83f2fde4b26d1b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81NS9mcmFnOjc3MmJlNmI3ZTY5YTQ3ZjY4NmI1NzYyZGI4OWE4Y2QyL3RhYmxlOjE4YjA1ODBlODU1ZjQzYjI4MjIwMzM2MDhhMmFiZWEyL3RhYmxlcmFuZ2U6MThiMDU4MGU4NTVmNDNiMjgyMjAzMzYwOGEyYWJlYTJfMy01LTEtMS05MTI4NA_6168f327-8c37-4a57-8a5f-95711a9ad541"
      unitRef="usd">-3000000.0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjgzMg_f35c3ff4-e937-43e6-b498-868c494dc065">Debt&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior secured credit agreement - Term loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior secured credit agreement - Revolver loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, net of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021 there was no outstanding revolver balance. We classify debt issuance costs associated with the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;revolver&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; loan as other current assets and other assets on the Company's consolidated balance sheets. As of June&#160;30, 2022, the Company had $2.0&#160;million and $0.6&#160;million of debt issuance costs associated with the revolver loan classified as other current assets and other assets, respectively. As of December&#160;31, 2021, the Company had approximately $2.0 million and $1.6 million of debt issuance costs associated with the revolver loan that were classified as other current assets and other assets, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Medium',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 7, 2020, the Company completed its offering of $450.0&#160;million aggregate principal amount of 3.875% Senior Unsecured Notes due 2028 (the 2028 Notes) of which the majority of the net proceeds were used to pay down the Revolving Credit Facility (as defined below). Interest on the 2028 Notes is payable on February 15th and August 15th of each year until maturity, beginning on February 15, 2021. The 2028 Notes will mature on August 15, 2028.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On or after August 15, 2023, the Company may redeem the 2028 Notes, in whole or in part, at the redemption prices set forth in the related Indenture, plus accrued and unpaid interest. Prior to August 15, 2023 the Company may redeem all or a portion of the 2028 Notes at a redemption price equal to 100% of the principal amount of the 2028 Notes plus a &#x201c;make-whole&#x201d; premium and accrued and unpaid interest. Prior to August 15, 2023, the Company may &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;redeem up to 40% of the aggregate principal amount of the 2028 Notes using the net cash proceeds of certain equity offerings at the redemption price set forth in the related Indenture. Upon the occurrence of a change of control, the Company must offer to repurchase the 2028 Notes at a purchase price of 101% of the principal amount of such 2028 Notes plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Negative covenants in the Indenture governing the 2028 Notes, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Senior secured credit agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also on August 7, 2020, the Company entered into a Second Amendment (the &#x201c;Credit Agreement Amendment&#x201d;) to its senior secured credit agreement, dated October 15, 2018, with multiple lending institutions relating to the Company&#x2019;s senior secured credit facilities (the &#x201c;Credit Agreement,&#x201d; and as amended, the &#x201c;Amended Credit Agreement&#x201d;), consisting of a senior revolving credit facility (the &#x201c;Revolving Credit Facility&#x201d;) and senior term loan facility (the &#x201c;Term Loan Facility,&#x201d; and together with the Revolving Credit Facility, the &#x201c;Senior Secured Credit Facilities&#x201d;).  The Credit Agreement Amendment amended, among other things, the definition of incremental facilities limit, the consolidated net leverage ratio financial covenant by increasing the maximum level, increased the permissible applicable margins based on the Company&#x2019;s consolidated net leverage ratio and increased the commitment fee that the Company is required to pay in respect of the average daily unused commitments under the Revolving Credit Facility, depending on the Company&#x2019;s consolidated net leverage ratio.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement includes (i) a Revolving Credit Facility of $600.0&#160;million and (ii) a Term Loan Facility with a principal amount of $450.0&#160;million. The Company may request incremental term loan facilities or increases in the Revolving Credit Facility (each an "Incremental Loan") as long as certain requirements involving our net leverage ratio will be maintained on a pro forma basis. Borrowings under the Revolving Credit Facility and the Term Loan Facility bear interest at a rate per annum equal to (a) a eurocurrency rate plus a margin ranging from 1.25% to 2.25% per annum, depending on the Company's consolidated net leverage ratio or (b) a base rate (which is the highest of the prime rate, the federal funds rate plus 0.50%, and a eurocurrency rate for an interest period of one month plus 1% plus a margin ranging from 0.25% to 1.25%, depending on the Company's consolidated net leverage ratio). The Company is required to make quarterly payments on the last business day of each calendar quarter under the Amended Credit Agreement for accrued and unpaid interest on the outstanding principal balance, based on the above interest rates. In addition, the Company is required to pay commitment fees ranging from 0.15% to 0.35% per annum, depending on the Company's consolidated net leverage ratio, for the average daily unused commitments under the Revolving Credit Facility. The Company is to repay the outstanding principal amount of the Term Loan Facility in quarterly installments on the last business day of each calendar quarter based on an annual percentage equal to 2.5% of the original principal amount of the Term Loan Facility during each of the first two years of the Term Loan Facility, 5% of the original principal amount of the Term Loan Facility during the third year of the Term Loan Facility and 7.5% of the original principal amount of the Term Loan Facility during each year of the remainder of the term of the Term Loan Facility until the maturity date of the Term Loan Facility, at which time the entire unpaid principal balance of the Term Loan Facility will be due and payable. The Company has the right to prepay the Term Loan Facility without premium or penalty. The Revolving Credit Facility and the Term Loan Facility mature on October 13, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Amended Credit Agreement also requires mandatory prepayments of the Term Loan Facility in the event the Company or its Subsidiaries (a) incur indebtedness not otherwise permitted under the Amended Credit Agreement or (b) receive cash proceeds in excess of $100.0&#160;million during the term of the Credit Agreement from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights. The financial covenants under the Amended Credit Agreement currently require the quarterly presentation of a minimum consolidated 12-month rolling debt service coverage ratio of 2.50 to 1.00, and a maximum consolidated net leverage ratio of 4.50 to 1.00 (subject to an increase to 5.00 to 1.00 for an applicable four quarter period, at the election of the Company, in connection with a permitted acquisition having an aggregate consideration in excess of $75.0&#160;million). Negative covenants in the Amended Credit Agreement, among other things, limit the ability of the Company to incur indebtedness and liens, dispose of assets, make investments, enter into certain merger or consolidation transactions and make restricted payments. As of the date of these financial statements, the Company is in compliance with all affirmative and negative covenants.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjgyOQ_eade5df2-58b3-43cd-a1fc-3f3699c1c7fe">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of debt are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:54.359%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior secured credit agreement - Term loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;379.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Senior secured credit agreement - Revolver loan due 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.875% Senior Unsecured Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;450.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;832.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;849.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion of long-term debt, net of debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unamortized debt issuance costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current portion of debt&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;809.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
    <us-gaap:LongTermDebt
      contextRef="i906b83ea370446e3be94c4ddaaa4083e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMS0xLTEtMS05MTI4NA_099094c7-9c61-49f2-b54f-d1abe26112a9"
      unitRef="usd">379700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i95dc7a5826cb458ea6fbfdfca937dcbd_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMS0zLTEtMS05MTI4NA_18340485-df98-4949-af61-112ab6f1aad3"
      unitRef="usd">396600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ie971a34ecfcf4b408a15bfa4996e60a7_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMi0xLTEtMS05MTI4NA_f744ab34-a71c-4bd6-a0ab-188ae2bb556e"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibb778bbc0bd64de7ad6801fd66de8bbc_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMi0zLTEtMS05MTI4NA_6cb19598-a571-4601-a9d3-cc3c2cdc2e14"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if69c9e056c6b47ce9a39e1690508a029_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMy0wLTEtMS05MTI4NC90ZXh0cmVnaW9uOmFiMWI2MWYwZTZjZjRkNjNiZjA2M2YwNzhiNDNiNWY2XzQ_66abe4ce-57ff-4b87-a8a2-aefa7eb1e98f"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if69c9e056c6b47ce9a39e1690508a029_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMy0xLTEtMS05MTI4NA_65e257e4-4b62-4c1f-b51f-e5555b9fba33"
      unitRef="usd">450000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="idb1acd071817481e9aef10fe54fb65fb_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfMy0zLTEtMS05MTI4NA_1d468f20-b6e9-4f72-916b-938aeb0cedf8"
      unitRef="usd">450000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1555249a53454772b48e904b14824e1d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNC0xLTEtMS05MTI4NA_ec6dabf9-e25f-4ae5-9cf9-6340f1ba4d6a"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i1485bfe38fce41ec95d481aecf94f617_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNC0zLTEtMS05MTI4NA_64f4f49a-61c4-43d6-be4a-296d76ce1b1b"
      unitRef="usd">3000000.0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNS0xLTEtMS05MTI4NA_66c8d185-ab08-448f-8071-c14daf3e42fd"
      unitRef="usd">832700000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNS0zLTEtMS05MTI4NA_f9722d27-cbce-4f28-baa2-f3451b780053"
      unitRef="usd">849600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNy0xLTEtMS05MTI4NA_743ac0b0-f519-4ff1-9cc3-102998b9886e"
      unitRef="usd">31600000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfNy0zLTEtMS05MTI4NA_5e0541c8-dec9-4b5e-bd31-3f8b7548ac71"
      unitRef="usd">31600000</us-gaap:LongTermDebtCurrent>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfOC0xLTEtMS05MTI4NA_5d4f4641-3b25-4677-9bb6-0e6ac3d6863d"
      unitRef="usd">7500000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:DeferredFinanceCostsNoncurrentNet
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfOC0zLTEtMS05MTI4NA_e4e85950-f226-4608-8671-d84ecefae9fb"
      unitRef="usd">8500000</us-gaap:DeferredFinanceCostsNoncurrentNet>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfOS0xLTEtMS05MTI4NA_89061048-d11d-4566-8961-1f90d853e278"
      unitRef="usd">793600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RhYmxlOmNjM2EyNTVlODBkZjRlMGU5ZWM3M2RhNmQ3NWIxNDQ3L3RhYmxlcmFuZ2U6Y2MzYTI1NWU4MGRmNGUwZTllYzczZGE2ZDc1YjE0NDdfOS0zLTEtMS05MTI4NA_7f9e9420-2004-47ec-8420-04695e3220b7"
      unitRef="usd">809400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebt
      contextRef="ie971a34ecfcf4b408a15bfa4996e60a7_I20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNzY5NjU4MTQwMjM0OA_088f798e-b38a-4c74-b5e6-637466c416b8"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="ibb778bbc0bd64de7ad6801fd66de8bbc_I20211231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNzY5NjU4MTQwMjM0OA_9f8df46e-2d8f-4e2b-bdf4-30005f068f1d"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="if549fa85623e479b8a4ea408bf3855e9_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzE4_407a496c-0180-4e0a-bcb1-a47a73f304b8"
      unitRef="usd">2000000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="ife82c6e169cb463d8894b9c0060a4276_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzI1_a55c44cb-e8e3-4457-9fb5-a669566c621f"
      unitRef="usd">600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DeferredFinanceCostsCurrentNet
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDky_b1478d7d-c26d-442a-b399-08f038420d64"
      unitRef="usd">2000000</us-gaap:DeferredFinanceCostsCurrentNet>
    <us-gaap:DeferredFinanceCostsNet
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDk5_84edbb51-78d9-4401-a8ab-323e161f53ff"
      unitRef="usd">1600000</us-gaap:DeferredFinanceCostsNet>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if194a1fa3b4249e29ea4d656684e16a6_I20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjM2_7e890c07-4707-425f-b674-cf32a761c1a4"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if194a1fa3b4249e29ea4d656684e16a6_I20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNzI5_83ade66d-7a19-4aed-add2-8241c475eee6"
      unitRef="usd">450000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if194a1fa3b4249e29ea4d656684e16a6_I20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNzYy_d00a8429-7c00-45fa-92a8-f022aa180a5b"
      unitRef="number">0.03875</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i854ab883416b4f61a70d7a994a7e7dc8_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMTQwNg_d82a90b7-bb9d-4b2e-a7fc-c47586dec50c"
      unitRef="number">1</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="ie7406b9184a64854a36cdc074d9b7efd_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMTU2Nw_c900fb38-9128-44af-b470-63a1b904b741"
      unitRef="number">0.40</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:DebtInstrumentRedemptionPricePercentage
      contextRef="i77bd92decaae4597a010ce330d685077_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMTg1Nw_dba42395-fd45-41fe-92cd-2b1d49fe59c3"
      unitRef="number">1.01</us-gaap:DebtInstrumentRedemptionPricePercentage>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="i864f4e447766464d959250dafeb367a6_I20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzM5Mg_42b57876-71fe-4afa-851c-47b55e251acc"
      unitRef="usd">600000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity
      contextRef="i8d27dfde1b0a4ca9bd9806ae5f1fd0e0_I20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzQ1Mg_d1fd8b1c-6260-49f5-bb73-b820a76324e3"
      unitRef="usd">450000000</us-gaap:LineOfCreditFacilityCurrentBorrowingCapacity>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="idd60b38179fc4f99af5a397c6f413c8c_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzg2Mg_33865145-4eff-49ee-aaf6-13cfe0f29c25"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="ia4154b9a491b4ef2aff17f1e88bb8277_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfMzg2OA_697d14ff-de61-4d06-a723-3b91a720e50f"
      unitRef="number">0.0225</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="if1e09335afe7401fabaf417e79536c26_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDAyOQ_671a36b2-9323-447e-b880-ce13c9ec75a9"
      unitRef="number">0.0050</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i97df715145c94a708ee00a7a333e62fa_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDA5OA_96ec28da-7e4a-4930-b5f8-6f59f6593dfc"
      unitRef="number">0.01</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i9af3fed7d2eb49a0934cfdea363489d8_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDEyOA_bc68aa07-01c8-4aae-b07b-d3bbede3011d"
      unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="i98549f959da647058170049a65c7b6c1_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDEzNA_237100d0-5c79-4d35-8525-61c185038dac"
      unitRef="number">0.0125</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i06495fe6675749ddb25cf196298c2fa3_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDUxMw_aa94e62c-ff7d-443f-be91-e3da1415c9eb"
      unitRef="number">0.0015</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <us-gaap:LineOfCreditFacilityCommitmentFeePercentage
      contextRef="i3cc8672e8d254d8cbb23b229dcd959c8_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDUxOQ_8770a82a-cb8b-4e19-ab44-44cad3b5ad78"
      unitRef="number">0.0035</us-gaap:LineOfCreditFacilityCommitmentFeePercentage>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears
      contextRef="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDg2OQ_f935a2aa-8c51-469a-bdc2-52af0b31f558"
      unitRef="number">0.025</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear
      contextRef="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNDk5Mw_866f98ed-f4c5-49dc-b266-ddebeea5db8a"
      unitRef="number">0.05</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear>
    <ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears
      contextRef="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNTEwNw_304b167d-52c8-4a9f-aa3e-180d39839d07"
      unitRef="number">0.075</ebs:PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears>
    <ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight
      contextRef="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNTgyNQ_e0cce5cc-a4a9-45f1-abcb-51c33dceb46d"
      unitRef="usd">100000000</ebs:CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight>
    <ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod
      contextRef="ie462a20b8c7642d6ba2baedaff5e64eb_D20200807-20200807"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjEyNg_043efdce-3ce2-4493-bf24-4797436e414b">P12M</ebs:DebtInstrumentCovenantNetLeverageRatioRollingPeriod>
    <ebs:DebtInstrumentCovenantDebtServiceCoverageRatio
      contextRef="i06495fe6675749ddb25cf196298c2fa3_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjE3NA_371ca1a4-f317-4e6a-aea3-d54e2226aec3"
      unitRef="number">2.50</ebs:DebtInstrumentCovenantDebtServiceCoverageRatio>
    <ebs:DebtInstrumentCovenantNetLeverageRatioOne
      contextRef="i3cc8672e8d254d8cbb23b229dcd959c8_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjIzNQ_22235efb-91a6-4117-8c8e-e112bfb5f20f"
      unitRef="number">4.50</ebs:DebtInstrumentCovenantNetLeverageRatioOne>
    <ebs:DebtInstrumentCovenantNetLeverageRatioTwo
      contextRef="i3cc8672e8d254d8cbb23b229dcd959c8_D20200807-20200807"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjI3Mw_46d3893c-9679-4b42-9c21-dcfd9ed39a1f"
      unitRef="number">5.00</ebs:DebtInstrumentCovenantNetLeverageRatioTwo>
    <ebs:DebtInstrumentCovenantConsiderationThreshold
      contextRef="id6c23a69f3d44e72bbf53e0f529e8cee_D20200807-20200807"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV81OC9mcmFnOmQxNGJlNTVlZjYyMjRjMThiMDMxZmJiZDQ4ZTkyYzliL3RleHRyZWdpb246ZDE0YmU1NWVmNjIyNGMxOGIwMzFmYmJkNDhlOTJjOWJfNjQ0NQ_87eb3ccd-3c70-42ff-a944-43d5510a67fa"
      unitRef="usd">75000000</ebs:DebtInstrumentCovenantConsiderationThreshold>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM0Mw_fc5e37ad-e06b-4c50-b1cc-36ac2f960151">Revenue recognition&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company operates as two operating segments (Note 14, Segment information). The Company's revenues disaggregated by the major sources were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract development and manufacturing:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract development and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract development and manufacturing:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract development and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;&lt;br/&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Termination of manufacturing services agreement with Janssen Pharmaceuticals, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 2, 2020, Emergent BioSolutions Inc., through its wholly-owned subsidiary, Emergent Manufacturing Operations Baltimore, LLC, entered into a manufacturing services agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson &amp;amp; Johnson (the "Agreement"), for large-scale drug substance manufacturing of Johnson &amp;amp; Johnson&#x2019;s investigational SARS-CoV-2 vaccine, Ad26.COV2-S, recombinant based on the AdVac technology (the &#x201c;Product&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 6, 2022, the Company provided to Janssen a notice (the &#x201c;Notice&#x201d;) of material breach of the Agreement for (i) failure by Janssen to provide the Company the requisite forecasts of the required quantity of Product to be purchased by Janssen under the Agreement; (ii) to confirm Janssen&#x2019;s intent to not purchase the requisite minimum quantity of the Product pursuant to the Agreement; and (iii) instead, wind-down the Agreement ahead of fulfilling these minimum requirements. Later on June 6, 2022, the Company received from Janssen a purported written notice of termination (the &#x201c;Janssen Notice&#x201d;) of the Agreement for asserted material breaches of the Agreement &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;by the Company, including alleged failure by the Company to perform its obligations in compliance with current good manufacturing practices (cGMP) or other applicable laws and regulations and alleged failure by the Company to supply Janssen with the Product. Janssen alleged that the &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2019;s&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; breaches were not curable and that, therefore, termination of the Agreement would be effective as of July 6, 2022. The Company disputes Janssen's assertions and allegations, including Janssen's ability to effect termination pursuant to the Janssen Notice. The Company and Janssen disagree on the monetary amounts that are due to the Company as a result of termination by any means. The Company believes the amounts due to the Company include, but are not limited to, compensation for services provided, reimbursement for raw materials purchased and non-cancelable orders, and fees for early termination. Janssen has alleged that no additional amount is due to the Company and that the Company should pay Janssen an unspecified amount as a result &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the Company's alleged failure to perform under the Agreement. The Company has not recorded any contingent liabilities related to Janssen's allegations as the Company believes they are without merit and intends to vigorously defend the Company's position during the dispute resolution process including mediation and/or arbitration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three months ended June 30, 2022, the Company reversed $13.3&#160;million of previously recognized revenue to align cumulative revenue recognized under the Agreement with cumulative cash collections. As of June&#160;30, 2022, the Company has no billed or unbilled net accounts receivable related to the Agreement. During the three months ended June 30, 2022, the Company recorded accelerated depreciation of $12.7&#160;million related to the conclusion of the Agreement which has been recorded in cost of contract development and manufacturing in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has $126.2&#160;million of raw materials inventory recorded in its condensed consolidated balance sheet as of June&#160;30, 2022 representing materials purchased for the Agreement which Janssen has not reimbursed. The Company evaluated the net realizable value of this inventory as of June&#160;30, 2022, concluding that because Section 13.4 of the Agreement specifies the Company is entitled to, among other things, reimbursement of raw materials and non-cancelable orders in the event of a contract termination for whatever reason, the Company is entitled to payment from Janssen for these raw materials. Therefore, this inventory remains an asset on the condensed consolidated balance sheet as of June&#160;30, 2022. Additionally, the Company has approximately $18.2&#160;million of non-cancelable orders as of June&#160;30, 2022 which have not been received and Janssen has not reimbursed. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;BARDA COVID-19 Development Public-Private Partnership&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2020, the Company announced the issuance of a task order under our existing Center for Innovation in Advanced Development and Manufacturing (CIADM) agreement with BARDA for COVID-19 vaccine development and manufacturing (the BARDA COVID-19 Development Public Private Partnership). The BARDA COVID-19 Development Public Private Partnership is considered a lease and is accounted for under ASC 842. The initial task order had a contract value of up to $628.2&#160;million and included the reservation of manufacturing capacity and accelerated expansion of fill/finish capacity valued at $542.7&#160;million and $85.5&#160;million, respectively. Subsequently, the task order was expanded to include incremental capital activities which increased the value to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$650.8&#160;million. On November 1, 2021, the Compa&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ny and BARDA mutually agreed to the completion of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the Company's CIADM contract and associated task orders, including the BARDA COVID-19 Development Public Private Partnership. The Company did not recognize lease revenues under this arrangement during the &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;three and&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; six months ended June 30, 2022. During the three and six months ended &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2021 the Company recognized lease revenues of $70.4 million and $167.9 million, respectively, related to this arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="background-color:#ffffff;color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;CDMO operating leases&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain multi-year CDMO service arrangements with commercial customers include operating leases whereby the customer has the right to direct the use of and obtain substantially all of the economic benefits of specific manufacturing suites operated by the Company. The associated revenue is recognized on a straight-line basis over the term of the lease. The remaining term on the Company's operating lease components approximates 2.9 years. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company utilizes a cost-plus model to determine the stand-alone selling price of the lease component to allocate contract consideration between the lease and non-lease components&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Excluding future amounts related to the Janssen Agreement as discussed above, we estimate future operating lease revenues to be $0.4&#160;million in the remainder of 2022, $5.1&#160;million in 2023, $0.9&#160;million in 2024, $0.9&#160;million million in 2025 and $2.7&#160;million in years beyond 2025.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Transaction price &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;a&lt;/span&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;llocated to remaining performance obligations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022, the Company has future contract value on unsatisfied performance obligations of approximately $545.1 million associated with all arrangements entered into by the Company. The Company expects to recognize a majority of the $545.1 million of unsatisfied performance obligations within the next 24 months. The amount and timing of revenue recognition for unsatisfied performance obligations can change. The future revenues associat&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ed with unsatisfied performance obligations exclude the value of unexercised option periods in the Company&#x2019;s revenue arrangements. Often the timing of manufacturing activities changes based on customer needs and resource availability. Government funding appropriations can impact the timing of product deliveries. The success of the Company's development activities that receive development funding support from the USG under development contracts can also impact the timing of revenue recognition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company considers accounts receivable and deferred costs associated with revenue generating contracts, which are not included in inventory or property, plant and equipment and the Company does not currently have a contractual right to bill, to be contract assets. As of June&#160;30, 2022 and December&#160;31, 2021, the Company had $26.3 million and $21.5 million, respectively, of contract assets&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; recorded within accounts receivable, net on the condensed consolidated balance sheets.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When performance obligations are not transferred to a customer at the end of a reporting period, cash received associated with amounts allocated to those performance obligations is reflected as contract liabilities on the condensed consolidated balance sheets and is deferred until control of these performance obligations is transferred to the customer. The following table presents the roll forward of the contract liability balances:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, the current portion of contract liabilities was &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$18.5&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$11.7&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, respectively&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and was included in other current liabilities on the balance sheet&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Billed, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2022 and December&#160;31, 2021, the allowances for doubtful accounts was $0.9 million and $3.2 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNTM_22ec5aaf-a174-4afa-8cfb-61ac42c7dd95"
      unitRef="segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM0MA_7153a705-a896-4a65-b01d-0baf039e0fa1">The Company's revenues disaggregated by the major sources were as follows:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.112%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S. Government&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract development and manufacturing:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;103.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;87.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract development and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-U.S.&lt;br/&gt;Government&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product sales, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;221.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;252.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;122.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;196.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract development and manufacturing:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;171.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;203.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract development and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;167.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;206.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts and grants&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;335.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;405.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i574f9adb7940424798f2d99703583daa_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi0xLTEtMS05MTI4NA_dc2f0091-e18a-4467-8968-316066c6e505"
      unitRef="usd">118200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7168a15913e0452ba5e8b7cc16cd596d_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi0zLTEtMS05MTI4NA_7fc8427a-b4fe-4e77-8ab1-60ef68c29434"
      unitRef="usd">119000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b613598404b49b880eecce284caa409_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi01LTEtMS05MTI4NA_5211c697-4955-4889-9a0d-756062439e55"
      unitRef="usd">237200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37b9298740734b91b9649eca3d31f872_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi03LTEtMS05MTI4NA_7062e942-0216-45e9-98fa-303e688ad67d"
      unitRef="usd">66300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb0dfd1b367d4a4bbc9a8d933e8d12c5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi05LTEtMS05MTI4NA_638ff5bf-c043-46d7-9582-a879fccfa119"
      unitRef="usd">114900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic14c595631e444d1b209fffe8cd22901_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMi0xMS0xLTEtOTEyODQ_399c2457-b48b-4a41-909c-8226e8611e02"
      unitRef="usd">181200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78916fe957f24b278cd2cf0ff71d751a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC0xLTEtMS05MTI4NA_1956c5ab-de57-442b-a9e0-c68368f13853"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f3b32beef6f4047a8dcd6932c3b547a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC0zLTEtMS05MTI4NA_5d29e42e-550f-4445-97fb-8206c6b812c7"
      unitRef="usd">2700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11d6b9ed7cef4daf9b8dc0c61d4b8f0b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC01LTEtMS05MTI4NA_cbcd5577-0e0a-47d0-b384-bff943eda1b5"
      unitRef="usd">2700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3037fdadacbb4e5f923277f2e26c9563_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC03LTEtMS05MTI4NA_76e97324-b829-44bb-9c50-a9f6fdb7ea96"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6995a6427d454821b7f5573c0a1da3af_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC05LTEtMS05MTI4NA_5c20d587-d67d-4d58-932f-bcb2759ba3a3"
      unitRef="usd">103600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d9f1173bf46467fa504dd84e978c454_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNC0xMS0xLTEtOTEyODQ_5b42c1ec-35b1-4cc8-872e-6fa5a243e347"
      unitRef="usd">103600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i2f3722b3ba404046b480130be3ff47cb_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS0xLTEtMS05MTI4NA_c759570d-47bb-4e74-975f-e6c947cdc42b"
      unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i7b2c6cc57c314379aa754295fc61f0c2_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS0zLTEtMS05MTI4NA_eed74d72-3275-4ea6-b904-44f27452893f"
      unitRef="usd">-4500000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i122c38cfc545444f95a68c8027e7c09e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS01LTEtMS05MTI4NA_c8460f89-883e-4ecb-862d-dc85ac87552d"
      unitRef="usd">-4500000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ieedc7121a2874e219f1a1ca878ff2c37_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS03LTEtMS05MTI4NA_98c87572-5028-4732-b111-5bbf4afc2068"
      unitRef="usd">70400000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="idfcb43efacdb406f820678d118bbcdd8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS05LTEtMS05MTI4NA_943c5d09-5551-441c-bbeb-de844b4805eb"
      unitRef="usd">16900000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i5db2e41be1c547f68cf80fdad0358d9c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNS0xMS0xLTEtOTEyODQ_13bc7950-10dd-4074-b638-62c9357399ff"
      unitRef="usd">87300000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b31182d8bf44cb88f2e81054292fb42_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi0xLTEtMS05MTI4NA_f29fc072-6a22-4851-a4d7-7107da3d4470"
      unitRef="usd">0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ecb5143f5f7478faa5324a51e49bd6c_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi0zLTEtMS05MTI4NA_216414af-ac79-4ce9-b98d-00a835758733"
      unitRef="usd">-1800000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifef1158a0f1b4f9c9cfe6d88fe654e3b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi01LTEtMS05MTI4NA_fdc702ba-3d5e-46f0-ae9a-7d5d3d9093d3"
      unitRef="usd">-1800000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icba1568320d14f98b740134699420a7c_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi03LTEtMS05MTI4NA_3c09e37f-b3c8-4bc4-9bed-f391d34c9159"
      unitRef="usd">70400000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i719033973c3c4e0790d3212f10dbadcd_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi05LTEtMS05MTI4NA_0426e42a-4565-44c1-ba15-c9c0ed164ed2"
      unitRef="usd">120500000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2e3ddd561972469b83305bb2ad955b68_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNi0xMS0xLTEtOTEyODQ_4e001f48-ef75-4161-b689-031ad71bf330"
      unitRef="usd">190900000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16ac2c2d319f4a00960710084dc7bba7_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy0xLTEtMS05MTI4NA_5fb7459a-2770-4bc6-b669-7bf47b721abb"
      unitRef="usd">6200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b6fd4492311495296403951539f5faf_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy0zLTEtMS05MTI4NA_6f1d21bc-a001-4b92-a0fb-20c706c7854d"
      unitRef="usd">1100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f9afc75663f4899a4fc9be307765379_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy01LTEtMS05MTI4NA_af8abfbf-3134-4a46-981f-45e4472d5fe7"
      unitRef="usd">7300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7a523ccb265741f5b098e936ed21f511_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy03LTEtMS05MTI4NA_92e0057d-18ed-4d4e-b471-937052a806ad"
      unitRef="usd">24400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia08e21eff6ed4142bc00ba76de36b98f_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy05LTEtMS05MTI4NA_1fc9a31b-948f-4a46-a11d-de892c6ecd3b"
      unitRef="usd">1000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f00bb59ea1746fbb21fbadf3f414a92_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfNy0xMS0xLTEtOTEyODQ_7542a65b-b920-4ab5-a890-9d47a2c628cf"
      unitRef="usd">25400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ib10b78dae7ed4de9bc5eb331206a3762_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC0xLTEtMS05MTI4NA_79702fcc-d19a-4b3b-aa9a-980d3e085471"
      unitRef="usd">124400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i998d829e65ec4f968b9b5085e7009b74_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC0zLTEtMS05MTI4NA_6b86e58e-734b-43a8-8e7c-0b887425e3c1"
      unitRef="usd">118300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC01LTEtMS05MTI4NA_257e92ff-af22-4477-8953-68707888e9da"
      unitRef="usd">242700000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i5c33e6e45e2f4158a121a529bf2b99e5_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC03LTEtMS05MTI4NA_37c787a2-615c-41f2-9907-af66e0c83f89"
      unitRef="usd">161100000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i23b51504df3547d59b0d56b9f31e6a34_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC05LTEtMS05MTI4NA_4835a2c9-a126-4df2-8b98-6dd6cb5fca5c"
      unitRef="usd">236400000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfOC0xMS0xLTEtOTEyODQ_c6b5ad2d-4792-4320-9673-bc9fbd3d63f3"
      unitRef="usd">397500000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ied017d66c9a04bb4b5c3696003cdbb8e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItMS0xLTEtOTEyODQ_efa1125b-a56f-4875-8d65-cca452ca284e"
      unitRef="usd">221600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie51251ad5ad54f02b4a1e43a1067e7f6_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItMy0xLTEtOTEyODQ_d6789d71-0151-47bd-b2d9-ec4383f1d010"
      unitRef="usd">252700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItNS0xLTEtOTEyODQ_e0797e0f-f2fe-47ba-8434-2766e30e110a"
      unitRef="usd">474300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i306561841c10468db12c5597d3a0468a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItNy0xLTEtOTEyODQ_b030befd-bcc5-446f-8ff7-1af0b060c5a8"
      unitRef="usd">122700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id856ef449e024e50a897807c5afed116_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItOS0xLTEtOTEyODQ_f9be0616-40f8-44cd-a0a3-32f14b242ffe"
      unitRef="usd">196400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTItMTEtMS0xLTkxMjg0_310bdd45-41aa-4cbc-9747-9d31c7d4731b"
      unitRef="usd">319100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i658c5b8c655e4fe38b0b7f174e852ede_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtMS0xLTEtOTEyODQ_a56e2808-af89-425c-998d-f85dfeeddce0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b9e160d23cc4468b348e9ba5f68fc60_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtMy0xLTEtOTEyODQ_fa8b9c1b-ec2c-4011-b304-10a2442f2ba1"
      unitRef="usd">54500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cc2230d43ca419eb9859817a3e13e4a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtNS0xLTEtOTEyODQ_964adefd-f13f-4ae4-8402-c43832373639"
      unitRef="usd">54500000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i766a0ecaa10f4c1f94e835811699f36d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtNy0xLTEtOTEyODQ_e35d0d86-5ad4-4bc1-96be-df4bee6295c5"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idd47aaf57ffa4b1c9c70108fac1b456a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtOS0xLTEtOTEyODQ_494696ed-2b03-412d-846d-156d131d48d7"
      unitRef="usd">171200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4c35eb92f4e94539aef959a8629ae0e7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTQtMTEtMS0xLTkxMjg0_61329497-e56e-4c13-a933-f9ae64bbc60b"
      unitRef="usd">171200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="idead1f4a85bf4ee4931efc0bd2008a9a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtMS0xLTEtOTEyODQ_882667f7-afa7-48fc-9cb9-7850a821e3cf"
      unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i64e99aeb36a14462901695d8142755c7_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtMy0xLTEtOTEyODQ_6b8661f1-7c0a-4d70-870a-6881a175a190"
      unitRef="usd">4500000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ib9d3fffbd0944df8a31002d86dafd0b1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtNS0xLTEtOTEyODQ_94c2921d-4629-4ad4-a792-2df8df699efe"
      unitRef="usd">4500000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i06918d944d12481c84ebd11d669df56b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtNy0xLTEtOTEyODQ_01c18c59-47be-44cb-8357-07c5cc350414"
      unitRef="usd">167900000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ib92f173e44b44baea23201309efbbd31_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtOS0xLTEtOTEyODQ_47cb8255-1078-4f72-a7bc-a4acfcddbb0d"
      unitRef="usd">35600000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ia599ba7606a14a5fa0bcefaa77322797_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTUtMTEtMS0xLTkxMjg0_3bdc6a0f-3667-4011-972a-d8b0b02f3d41"
      unitRef="usd">203500000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idb080faf3355468f962da743b6925f17_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtMS0xLTEtOTEyODQ_8923826c-5d94-4531-bd8b-448579ea42ba"
      unitRef="usd">0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7836569c48aa4398960b690e02f1638a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtMy0xLTEtOTEyODQ_b00fbfee-7f7a-4868-b4a7-ba3463c8fe80"
      unitRef="usd">59000000.0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibba5b2ada3cf4cb4a6b4ba683779728e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtNS0xLTEtOTEyODQ_4e06dc6e-c6da-47cf-a721-d76ed965b378"
      unitRef="usd">59000000.0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie645b23e92d64b44af482e9d18e83a21_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtNy0xLTEtOTEyODQ_e99e4806-429f-44df-ac22-4014a1178c04"
      unitRef="usd">167900000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib607439c17cf47a5a315dbba5676680b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtOS0xLTEtOTEyODQ_2b96913c-e915-42ac-9f64-b3c89284a0e5"
      unitRef="usd">206800000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a54e7d85e014e56956c4c0661a1e4ed_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTYtMTEtMS0xLTkxMjg0_c484beba-fd77-4684-8f5d-87bd938ce695"
      unitRef="usd">374700000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idef67034a80d49fe8d29b21339809e4b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctMS0xLTEtOTEyODQ_9ad57c17-eaa6-476f-8269-ee1d96b33416"
      unitRef="usd">15300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i637fa78972d94585a80a29492e1528c4_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctMy0xLTEtOTEyODQ_fff9c252-9233-4d47-a7da-0ea99969e345"
      unitRef="usd">1600000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cff17dc6fc04ad7ab4b4434ef23201b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctNS0xLTEtOTEyODQ_0b14ee04-e3b0-4ee6-aadc-c19d656ec74b"
      unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7f45031de4147aab74078725161519c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctNy0xLTEtOTEyODQ_bccc39e9-d252-451b-b58d-4221a0a53297"
      unitRef="usd">44400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id805e73cf4794980a908e6c22c926058_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctOS0xLTEtOTEyODQ_d576f8b5-1916-4185-b8bb-cae983af2b64"
      unitRef="usd">2300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i400967d6466a4b58a011f5b045886df0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTctMTEtMS0xLTkxMjg0_3ea9a153-bacb-46a4-b5a9-c4a8eb2d16b5"
      unitRef="usd">46700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="i4cf722f817414de59d8f7e7ec0bb2c95_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtMS0xLTEtOTEyODQ_0733e9ec-46ba-45a6-b2db-2d8d43b99c31"
      unitRef="usd">236900000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i265aa2e4d2d24bb5be2c124345a65d9c_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtMy0xLTEtOTEyODQ_6cf67da9-e871-4b52-8007-ce79f433e8f7"
      unitRef="usd">313300000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtNS0xLTEtOTEyODQ_b847d4c0-c877-42e1-b11f-7e1f7caebdda"
      unitRef="usd">550200000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ic78d782fd08747beb9ebc02fbc6bca30_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtNy0xLTEtOTEyODQ_4ac2b889-4419-4dee-8b33-4d2ae4ffb316"
      unitRef="usd">335000000.0</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i813b606241794bedb7b0678f9d44767c_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtOS0xLTEtOTEyODQ_bbac5650-86e4-4499-9ce0-45ce4784ee8a"
      unitRef="usd">405500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOjNiZjU3ZjkxNDIwZjQ5ZjZiYjMxMTY0MjQxMDAxMGRmL3RhYmxlcmFuZ2U6M2JmNTdmOTE0MjBmNDlmNmJiMzExNjQyNDEwMDEwZGZfMTgtMTEtMS0xLTkxMjg0_49c029e2-6467-4cfd-af79-992631c31e91"
      unitRef="usd">740500000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="i748c972f7e3046359ad4f7b45600bbb1_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDk0NzgwMjM0MDQxOQ_5b942410-f4d7-423d-a4db-9594efff80ab"
      unitRef="usd">-13300000</us-gaap:Revenues>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9546d5f25011482ea8eff2df29f3ff29_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDk0NzgwMjM0MDQ2NQ_74a1bb89-8d16-425d-9e3e-87b4bc7ea915"
      unitRef="usd">12700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9638e645586946feae3242935cd61d34_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDk0NzgwMjM0MDQ2NQ_a74f23b8-d399-4256-86ef-ca4dbbef174a"
      unitRef="usd">12700000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="ibb3cc4b31c2349e6b5a80a9253019e4b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4NjQ5Mw_41f577cc-a5e6-4698-a2e8-c0e36b3df79f"
      unitRef="usd">126200000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:AccountsPayableTradeCurrentAndNoncurrent
      contextRef="ibb3cc4b31c2349e6b5a80a9253019e4b_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4NjUxMA_1babcdaa-3b8f-4b25-8889-f2a68412ff4b"
      unitRef="usd">18200000</us-gaap:AccountsPayableTradeCurrentAndNoncurrent>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i073a439499194e698141d7a144b95b2c_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjY5_4638acdc-6314-4665-8e11-47e14fb91f61"
      unitRef="usd">628200000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="ic4a7c235f1654834a48248b64d3dc321_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNzg3_06070653-4482-4332-9142-c775c0fb7212"
      unitRef="usd">542700000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i7fa5c022d91149dabba1e1fa641192ee_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNzk0_d61134c3-267f-4e19-8c8b-6e611a382d83"
      unitRef="usd">85500000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:LessorOperatingLeasePaymentsToBeReceived
      contextRef="i31dbfae47072459191568cdf89902293_I20211031"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfOTI1_fc53cbc0-f762-42e5-851c-e3f2af16829a"
      unitRef="usd">650800000</us-gaap:LessorOperatingLeasePaymentsToBeReceived>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="idead1f4a85bf4ee4931efc0bd2008a9a_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM1Mw_6db40034-d4c9-4eae-84d0-7c8e73139814"
      unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i2f3722b3ba404046b480130be3ff47cb_D20220401-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM1Mw_e030d324-a4a8-4b1b-8066-6c8ff940e22e"
      unitRef="usd">0</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ieedc7121a2874e219f1a1ca878ff2c37_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc3OTA3Mg_98c87572-5028-4732-b111-5bbf4afc2068"
      unitRef="usd">70400000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i06918d944d12481c84ebd11d669df56b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc3OTA4OQ_01c18c59-47be-44cb-8357-07c5cc350414"
      unitRef="usd">167900000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm
      contextRef="i078e4fd9eef24b03a26dff9571fa22d9_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMTc3OA_cebcf4d7-9a83-4c4a-a0a9-8b710e4537d4">P2Y10M24D</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ie098330be0d142e7842c556f7a93810f_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4OTQwOQ_ddab720c-06ab-4edd-8ee1-f215eb58043e"
      unitRef="usd">400000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i1b0d1f3a33164d8db9d0239f934f78e2_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4OTQyOA_518d5e58-6c3d-4acf-b79b-f4d095ba1946"
      unitRef="usd">5100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ie526f761a4724513a2cc99ec8bd346cb_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4OTQ0Mw_27b77a1a-81ed-4cdf-af78-5b8279def455"
      unitRef="usd">900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="icd351b95704f42138af3e4b83951e506_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4OTQ1MA_5476e3d8-07e3-41dc-ba77-f3151f985058"
      unitRef="usd">900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i5bd4b4922a534fcaa24291b742a545e6_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNjU5NzA2OTc4OTQ2NQ_487904c3-3f4a-4091-8e28-effd91eb55cb"
      unitRef="usd">2700000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMjI2Ng_115daa13-e955-47a9-8239-3eb32ec1d085"
      unitRef="usd">545100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMjM4Mg_115daa13-e955-47a9-8239-3eb32ec1d085"
      unitRef="usd">545100000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
      contextRef="i5c1bb85380c94c46946e590854b1feb8_I20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMjQ0MA_8874c9f4-d78a-4314-a1f3-9ee2ecd537e5">P24M</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMzM4Nw_1c1f82e3-8c9d-4012-a578-d68ea9bf9466"
      unitRef="usd">26300000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfMzM5NA_7e84d492-b753-4658-be0a-0c76a5ffeab5"
      unitRef="usd">21500000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM0NA_db10e966-7276-47f4-85ce-268f58ba5d6d">The following table presents the roll forward of the contract liability balances:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:76.342%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.884%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:20pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferral of revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenue recognized&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmVlYWQxNmY1NTc5NDRhNzRhMmNlNjNjNzk1Y2ViYmJkL3RhYmxlcmFuZ2U6ZWVhZDE2ZjU1Nzk0NGE3NGEyY2U2M2M3OTVjZWJiYmRfMS0xLTEtMS05MTI4NA_6c58f45f-097c-45bc-bc0f-549960e59269"
      unitRef="usd">16400000</us-gaap:ContractWithCustomerLiability>
    <ebs:ContractWithCustomerLiabilityAdditions
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmVlYWQxNmY1NTc5NDRhNzRhMmNlNjNjNzk1Y2ViYmJkL3RhYmxlcmFuZ2U6ZWVhZDE2ZjU1Nzk0NGE3NGEyY2U2M2M3OTVjZWJiYmRfMi0xLTEtMS05MTI4NA_aaa58aba-de2e-4b55-ba97-8b82d00d4fcd"
      unitRef="usd">17900000</ebs:ContractWithCustomerLiabilityAdditions>
    <ebs:ContractWithCustomerLiabilityDeductions
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmVlYWQxNmY1NTc5NDRhNzRhMmNlNjNjNzk1Y2ViYmJkL3RhYmxlcmFuZ2U6ZWVhZDE2ZjU1Nzk0NGE3NGEyY2U2M2M3OTVjZWJiYmRfMy0xLTEtMS05MTI4NA_2886b986-431c-42a0-8f2d-c78dd2310e9d"
      unitRef="usd">10000000.0</ebs:ContractWithCustomerLiabilityDeductions>
    <us-gaap:ContractWithCustomerLiability
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmVlYWQxNmY1NTc5NDRhNzRhMmNlNjNjNzk1Y2ViYmJkL3RhYmxlcmFuZ2U6ZWVhZDE2ZjU1Nzk0NGE3NGEyY2U2M2M3OTVjZWJiYmRfNC0xLTEtMS05MTI4NA_80c3a640-56b1-4204-9c8e-79d7cf4a07de"
      unitRef="usd">24300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDAzNg_ff305e16-05e2-4901-baf5-489acbb65822"
      unitRef="usd">18500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDA0Mw_f346445a-1890-4eaa-bae5-62e5bf94f338"
      unitRef="usd">11700000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <ebs:ScheduleOfAccountsReceivableNetTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDM0OA_6e9212bd-7c19-4cb3-8df0-7481bc20927d">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts receivable, including unbilled accounts receivable contract assets, consist of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.785%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Billed, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unbilled&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total accounts receivable, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;175.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;274.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ebs:ScheduleOfAccountsReceivableNetTableTextBlock>
    <us-gaap:BilledContractReceivables
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMS0yLTEtMS05MTI4NA_55179ac3-ad87-472e-aae9-e3ac669a9746"
      unitRef="usd">119900000</us-gaap:BilledContractReceivables>
    <us-gaap:BilledContractReceivables
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMS00LTEtMS05MTI4NA_d062d469-cb05-4484-9a21-de345b9e73dd"
      unitRef="usd">224900000</us-gaap:BilledContractReceivables>
    <us-gaap:UnbilledContractsReceivable
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMi0yLTEtMS05MTI4NA_10ad4760-8111-4b16-b49a-cbe206755396"
      unitRef="usd">55100000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:UnbilledContractsReceivable
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMi00LTEtMS05MTI4NA_1cbc9e30-421f-4315-b437-a21953fe8f19"
      unitRef="usd">49800000</us-gaap:UnbilledContractsReceivable>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMy0yLTEtMS05MTI4NA_501ba7e1-4a7e-4574-99cb-438116def52a"
      unitRef="usd">175000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RhYmxlOmY4YWMxYjdlYjM0ZTQzNzk5YzI5Mzg4YjEwZTA3NmY0L3RhYmxlcmFuZ2U6ZjhhYzFiN2ViMzRlNDM3OTljMjkzODhiMTBlMDc2ZjRfMy00LTEtMS05MTI4NA_706e7ea7-a84a-487f-b751-bf394f4fb4f9"
      unitRef="usd">274700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="ia80f097061ac4deb804ac1a7be81e63d_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDMxNA_bb6e85ba-a2ac-4823-a6fb-968db5ca18d4"
      unitRef="usd">900000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:AllowanceForDoubtfulAccountsReceivable
      contextRef="i72306a994b9b4e40b4c06153d3cccd44_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV82NC9mcmFnOjRmMzQzYWQ3MGZlMDRjM2VhOWI2ZTI5NGI3OTU4YWRmL3RleHRyZWdpb246NGYzNDNhZDcwZmUwNGMzZWE5YjZlMjk0Yjc5NThhZGZfNDMyMg_e14de9f7-0bca-4450-a3f4-64052fdae51d"
      unitRef="usd">3200000</us-gaap:AllowanceForDoubtfulAccountsReceivable>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfNTAy_a8744747-c29c-4594-8518-3b72000677a5">Income taxesThe estimated effective annual tax rate as of June 30, 2022 and 2021 for the years ended December 31, 2022 and 2021, excluding the impact of discrete adjustments, was 29% and 26%, respectively. The Company recorded discrete tax expense (benefits) of $0.2&#160;million and $0.6&#160;million for the three and six months ended June&#160;30, 2022, respectively, and $1.1 million and $(5.5)&#160;million, for the three and six months ended June&#160;30, 2021, respectively. The discrete tax expense in 2022 was primarily due to share-based compensation activity offset by return to provision adjustments. The net discrete benefits in 2021 were primarily due to share-based compensation activity.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="icf331b5878004125a9676034ba0f2a5c_D20220101-20221231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfNzY5NjU4MTM5NTU1Nw_ffa05663-dd3e-4576-a0af-786876f099f7"
      unitRef="number">0.29</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i9a9aaf25fc5d48ee87baec975ac47be1_D20210101-20211231"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfMTY0_6c78c0c7-f0a9-4477-ab3b-e4b95e2d4e5d"
      unitRef="number">0.26</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfNzY5NjU4MTM5OTk0MQ_a31c2ef7-1793-4ce9-9831-f798fa682b3d"
      unitRef="usd">200000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfMTY0OTI2NzQ0MjIwMDg_31fd5c33-9604-4768-98c8-d58fa4824e30"
      unitRef="usd">600000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfNzY5NjU4MTM5OTMxMA_56f10cb8-a28c-46ed-8111-854d0b28602e"
      unitRef="usd">1100000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83MC9mcmFnOjQ2NWI2NzRiYTlmMjRlNzdhYjdhZmE1ZTgwNjBlMWJiL3RleHRyZWdpb246NDY1YjY3NGJhOWYyNGU3N2FiN2FmYTVlODA2MGUxYmJfNzY5NjU4MTM5OTMxOA_99bcdc5d-f503-4ead-9dd5-0d2171b02e58"
      unitRef="usd">-5500000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RleHRyZWdpb246YjVkYTYyODg5OGM3NDgzMTllNTI0MDkzODBiMmU4MGFfMTMxMQ_c8d7b529-2c2b-43de-af78-bf8e82515234">Net income (loss) per share&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted net (loss) income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&#x2014;equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)  per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period. Diluted net income (loss) per share is computed using the treasury method by dividing net income (loss) by the weighted average number of shares of common stock outstanding during the period, adjusted for the potential dilutive effect of other securities if such securities were converted or exercised and are not anti-dilutive. No adjustment for the potential dilutive effect of dilutive securities is reported for the three and six months ended June&#160;30, 2022 as the effect would have been anti-dilutive due to the Company's net loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the share-based awards that are not considered in the diluted income (loss) per share calculation generally because the exercise price of the awards was greater than the average per share closing price during the three and six months ended June&#160;30, 2022 and 2021. In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RleHRyZWdpb246YjVkYTYyODg5OGM3NDgzMTllNTI0MDkzODBiMmU4MGFfMTMwNw_8b27c36b-e751-4cd9-8b08-880529e9405a">&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the calculation of basic and diluted net (loss) income per share:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.160%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.226%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.373%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#1b51bf;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(56.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(60.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares&#x2014;basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&#x2014;equity awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average number of shares&#x2014;diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;50.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;54.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#e5e5e5;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss)  per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.40&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income (loss) per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.19)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMy0xLTEtMS05MTI4NA_bfb745e2-2747-4cc0-a1cf-d36af84af3fa"
      unitRef="usd">-56400000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMy0zLTEtMS05MTI4NA_0dec8ec0-1a82-4b7f-83da-c5f06982e468"
      unitRef="usd">4600000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMy00LTEtMS05MTI4NA_321b91a4-5612-433e-9231-673e1f91afcf"
      unitRef="usd">-60100000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMy02LTEtMS05MTI4NA_e9b10812-1931-4b2a-86ec-a622a157a2ab"
      unitRef="usd">74300000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNi0xLTEtMS05MTI4NA_2db6f13f-357a-4265-9971-1e6e57051af2"
      unitRef="shares">50000000.0</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNi0zLTEtMS05MTI4NA_9f67d225-a2e3-4435-ae6e-2ce812700e11"
      unitRef="shares">53600000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNi00LTEtMS05MTI4NA_42358c13-8c3c-4bf1-8f8b-ea1c5304b6d8"
      unitRef="shares">50300000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNi02LTEtMS05MTI4NA_688dd207-00b1-4f7b-bdb9-1e129fa6eb3c"
      unitRef="shares">53500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNy0xLTEtMS05MTI4NA_96423467-baed-4a5e-a2f9-adb51e90b793"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNy0zLTEtMS05MTI4NA_1d331095-721f-4fec-918a-0535f8f34401"
      unitRef="shares">400000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNy00LTEtMS05MTI4NA_884d3243-f392-4efb-8a60-25d590bed8ee"
      unitRef="shares">0</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfNy02LTEtMS05MTI4NA_7642ef02-d754-49a1-9eae-b56aa17af6e5"
      unitRef="shares">800000</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfOC0xLTEtMS05MTI4NA_3834e70b-b948-4327-b8da-a3697c9fef5c"
      unitRef="shares">50000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfOC0zLTEtMS05MTI4NA_196502b1-ae60-4dda-ab72-002a40d1231d"
      unitRef="shares">54000000.0</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfOC00LTEtMS05MTI4NA_41d3443a-4bfa-44c0-b269-eaa105565ad3"
      unitRef="shares">50300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfOC02LTEtMS05MTI4NA_f29bc0c7-dccf-4c49-922e-b82f4285c4a9"
      unitRef="shares">54300000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTAtMS0xLTEtOTEyODQ_0f5a15a4-009d-4e4c-8c1e-c0ed4fbbb4a0"
      unitRef="usdPerShare">-1.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTAtMy0xLTEtOTEyODQ_4cce9eab-c2eb-43e3-b724-ee5aed7d850d"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTAtNC0xLTEtOTEyODQ_f2f72dd5-6f57-4da0-8fdf-75f06bd62333"
      unitRef="usdPerShare">-1.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTAtNi0xLTEtOTEyODQ_0e6b7620-116e-4af1-8cf2-bce002e14d67"
      unitRef="usdPerShare">1.40</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTEtMS0xLTEtOTEyODQ_983c4f96-082a-45a8-98b5-24941990389d"
      unitRef="usdPerShare">-1.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTEtMy0xLTEtOTEyODQ_2a54ea5e-57e6-4b09-bcab-f64a92c62b6a"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTEtNC0xLTEtOTEyODQ_dfcc7302-f035-4e38-8cf5-27ddd528b237"
      unitRef="usdPerShare">-1.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjkzZWM3YWVlMDhmMzQyYTNhYmQwODZiMDIwNmFiOTExL3RhYmxlcmFuZ2U6OTNlYzdhZWUwOGYzNDJhM2FiZDA4NmIwMjA2YWI5MTFfMTEtNi0xLTEtOTEyODQ_be388b19-71e2-4ad2-aeb7-e30ff9e9a971"
      unitRef="usdPerShare">1.37</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RleHRyZWdpb246YjVkYTYyODg5OGM3NDgzMTllNTI0MDkzODBiMmU4MGFfMTMwNg_ef00d21c-902b-440f-a690-5c46d49ad15f">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the share-based awards that are not considered in the diluted income (loss) per share calculation generally because the exercise price of the awards was greater than the average per share closing price during the three and six months ended June&#160;30, 2022 and 2021. In certain instances, awards may be anti-dilutive even if the average market price exceeds the exercise price when the sum of the assumed proceeds exceeds the difference between the market price and the exercise price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.704%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive stock awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjcyYjdhZmUwNmVkZjQ2ZThiMTA1ZWNmNWRhM2UxMDg0L3RhYmxlcmFuZ2U6NzJiN2FmZTA2ZWRmNDZlOGIxMDVlY2Y1ZGEzZTEwODRfMi0xLTEtMS05MTI4NA_13eeeb48-da21-492f-8228-efa5de06ae83"
      unitRef="shares">1800000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjcyYjdhZmUwNmVkZjQ2ZThiMTA1ZWNmNWRhM2UxMDg0L3RhYmxlcmFuZ2U6NzJiN2FmZTA2ZWRmNDZlOGIxMDVlY2Y1ZGEzZTEwODRfMi0zLTEtMS05MTI4NA_bef7dcc9-2aaa-438c-bfd6-fa0a504ff80a"
      unitRef="shares">1400000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjcyYjdhZmUwNmVkZjQ2ZThiMTA1ZWNmNWRhM2UxMDg0L3RhYmxlcmFuZ2U6NzJiN2FmZTA2ZWRmNDZlOGIxMDVlY2Y1ZGEzZTEwODRfMi00LTEtMS05MTI4NA_f624f130-d232-412a-9da2-5b5cfcfb6437"
      unitRef="shares">3000000.0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83My9mcmFnOmI1ZGE2Mjg4OThjNzQ4MzE5ZTUyNDA5MzgwYjJlODBhL3RhYmxlOjcyYjdhZmUwNmVkZjQ2ZThiMTA1ZWNmNWRhM2UxMDg0L3RhYmxlcmFuZ2U6NzJiN2FmZTA2ZWRmNDZlOGIxMDVlY2Y1ZGEzZTEwODRfMi02LTEtMS05MTI4NA_04c20cf0-1c5e-4884-bf21-187d69f4f8d4"
      unitRef="shares">500000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY3OQ_11afb240-0dc7-4991-9c35-df559e9c3e24">Equity&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Repurchase programs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 11, 2021, the Company announced that its Board of Directors authorized management to repurchase up to an aggregate of $250.0&#160;million of Common Stock under a board-approved Share Repurchase Program, of which $187.9&#160;million has been utilized to purchase 4.4&#160;million shares as of June&#160;30, 2022. During the three and six months ended  June&#160;30, 2022, the Company has utilized $23.3&#160;million and $75.5&#160;million to purchase 0.7&#160;million and 1.8&#160;million shares, respectively. The Share Repurchase Program does not obligate the Company to acquire any specific number of shares. Repurchased shares will be available for use in connection with our stock plans and for other corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Share-based compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2022, the Company granted stock options to purchase 0.6 million shares of common stock and 1.4 million restricted and performance stock units under the Emergent BioSolutions Inc. Stock Incentive Plan. Typically, the stock option and restricted stock unit grants vest over three equal annual installments beginning on the day prior to the anniversary of the grant date. The performance stock units settle in stock at the end &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of the three-year performance period based on the Company's results compared to the performance criteria. Share-based compensation expense was recorded in the following financial statement line items:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of contract development and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accumulated other comprehensive loss, net of tax&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes changes in accumulated other comprehensive loss, net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined Benefit Pension Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, net of tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the tax effects related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i46d185ce265a44359c45e086acb0e06f_I20211111"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY2_8c164160-31a1-4a37-a3a2-86d49f313513"
      unitRef="usd">250000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="idb62694863024c3a8c06044192e2a6da_D20211111-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMjQ0_54e9fbd7-a068-4771-bf78-d09721c41e57"
      unitRef="usd">187900000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="idb62694863024c3a8c06044192e2a6da_D20211111-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMjg1_1b83c718-c5c2-4bf1-862f-e1b4a423ef46"
      unitRef="shares">4400000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ifcc26b21d7d8496f9bb774f7ac399651_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMzI5ODUzNDg4NTI4MA_c77825f0-4acc-44db-bb39-e7eedd549a3d"
      unitRef="usd">23300000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ic692f65706164ee49ec3a380b592e311_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMzcw_e99477a5-0cfd-4635-bc78-bf2a147d59f3"
      unitRef="usd">75500000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ifcc26b21d7d8496f9bb774f7ac399651_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMzI5ODUzNDg4NTI4Nw_0fcb39ca-a327-467b-a7e6-3d61e1cab637"
      unitRef="shares">700000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:StockRepurchasedDuringPeriodShares
      contextRef="ic692f65706164ee49ec3a380b592e311_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMzkz_5fd26451-0dfb-4b81-a25c-9288537fe913"
      unitRef="shares">1800000</us-gaap:StockRepurchasedDuringPeriodShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="id438572de7754b2f9af627f967ba0ce0_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfODMy_77a592a9-c8fa-4f82-b060-f8da3909a137"
      unitRef="shares">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="i9c3242ff1d6e403fa058caec92b768c4_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfODYy_bdad76a8-fc56-4cde-8fde-776a2bbc94d1"
      unitRef="shares">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i9c3242ff1d6e403fa058caec92b768c4_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY4Mw_dc08edcb-2e78-42bc-ab57-2e5925052072">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY4Mg_73b6d78a-24af-4d50-ac99-fecac92340f4">Share-based compensation expense was recorded in the following financial statement line items:&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.859%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.693%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.696%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 7.75pt 2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of contract development and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#e5e5e5;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#e5e5e5;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i444f6b6169bc431ab44cce091d529975_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMi0xLTEtMS05MTI4NA_03b36e50-2dd6-405e-a47a-48eb735645fa"
      unitRef="usd">1900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i68490917c6324e3abbbef73aefa2e5f9_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMi0zLTEtMS05MTI4NA_f1676217-f727-4b12-aab5-eafdd0114abf"
      unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4ba5495e2a404e7caafe9e03e3fe1861_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMi00LTEtMS05MTI4NA_99de0022-2c7b-4ecf-857e-44b6dca14b08"
      unitRef="usd">3600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d37be8412c8482e947483881b8b5b51_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMi02LTEtMS05MTI4NA_1b4a2939-0725-43f7-98b4-e5f40b349678"
      unitRef="usd">3200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3d8109d0584c4f24a37d0e0942db1c06_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMy0xLTEtMS05MTI4NA_f921bc83-f88e-4fcd-b450-3e7c895b9167"
      unitRef="usd">600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6e87ee8954dc437da9f27f6e09cd767a_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMy0zLTEtMS05MTI4NA_1600b02a-3755-484d-a4d5-a5e1d297c5d2"
      unitRef="usd">300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i775d01162a634709894e9ca391a7f259_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMy00LTEtMS05MTI4NA_8ad76906-6b36-42a7-ac52-0fb0986e0b3a"
      unitRef="usd">1000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i483660136dd443e5916afc6418da38ad_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfMy02LTEtMS05MTI4NA_381437a0-da59-440c-9f94-ffcf75211c67"
      unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3497690a3cbd40f3b831488b3657d7c6_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNC0xLTEtMS05MTI4NA_4dfc5ef0-4484-4b81-94bb-54ea653978f5"
      unitRef="usd">1500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2848bd97786b4d5ba2937b70a2f4bf70_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNC0zLTEtMS05MTI4NA_1f8a15d8-f04f-4ae5-a8fe-6c215c5fc100"
      unitRef="usd">1700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i39ffb192289e4ce9a528e436037c0be5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNC00LTEtMS05MTI4NA_335d9650-c2ba-470c-b49f-d78eba0f0d33"
      unitRef="usd">2600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i83dd17fd91084cafbcc04f18320932c2_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNC02LTEtMS05MTI4NA_465fa88b-cf2f-47c4-b2a4-ce9af90c462c"
      unitRef="usd">3100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ic952574703dd49c3a143c50a76cc5bb7_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNS0xLTEtMS05MTI4NA_074e29f5-7f0b-48a8-8cd8-308bd51e5e43"
      unitRef="usd">8300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i05f3f3064f53498493eda16fac112d94_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNS0zLTEtMS05MTI4NA_c8f79ce8-7be7-4150-891f-f7c7d1e9bc28"
      unitRef="usd">7700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i55f86755507140aaa0522c374f09ab1d_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNS00LTEtMS05MTI4NA_1172d5e8-63fd-4ac0-a944-7509337b3c2d"
      unitRef="usd">15000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i79e636bd573c405188f12505ae586714_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNS02LTEtMS05MTI4NA_8374e400-f4a6-4134-8c9b-264d0c5dee80"
      unitRef="usd">15100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNi0xLTEtMS05MTI4NA_34bb46fc-211c-4fba-94ec-460e6381601f"
      unitRef="usd">12300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNi0zLTEtMS05MTI4NA_bb52660c-5ed9-4e12-b540-498146c3fc65"
      unitRef="usd">11400000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNi00LTEtMS05MTI4NA_a546e575-83c9-4be3-bff9-6767bd0e50b8"
      unitRef="usd">22200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjUwZGQyMjE1OTYyZDQ4M2Q5ZjY3YzJkYzQ2MDU0M2Y1L3RhYmxlcmFuZ2U6NTBkZDIyMTU5NjJkNDgzZDlmNjdjMmRjNDYwNTQzZjVfNi02LTEtMS05MTI4NA_32c3f22c-4e3f-4cf9-9771-f5cc73cedcb6"
      unitRef="usd">21900000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY3OA_2326d719-e398-4864-888d-ea6c0f1556cd">&lt;div style="margin-bottom:9pt;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes changes in accumulated other comprehensive loss, net of tax by component:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.049%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.250%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.825%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.254%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:30pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Defined Benefit Pension Plan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" rowspan="2" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:23pt"&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;(in millions, net of tax)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March&#160;31, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, June&#160;30, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:11pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, March&#160;31, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other comprehensive income (loss) before reclassifications&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amounts reclassified from accumulated other comprehensive loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 7.75pt 2px 1pt;text-align:justify;text-indent:9pt;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net current period other comprehensive income (loss)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt;text-align:justify;text-indent:9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance, June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="i830521684abb4fd9aadb53001edc7379_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMi0yLTEtMS05MTI4NA_2f5d6364-29a5-4143-a527-01c6bae2146c"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ifac78b9519ad40da9ef031b1e7724460_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMi00LTEtMS05MTI4NA_b61923aa-9b70-46da-88a4-76419153329e"
      unitRef="usd">-4500000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="icb61d55a3a5f4c6eb6ebb20e951d3dd3_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMi02LTEtMS05MTI4NA_2087c97b-f423-4d0c-b11b-0bee2b6b43bf"
      unitRef="usd">-7600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i53adab0b44f14127b1c4c4f2539a1807_I20211231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMi04LTEtMS05MTI4NA_0fec63a2-afbb-4165-93af-1969e7775670"
      unitRef="usd">-16100000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMy00LTEtMS05MTI4NA_29af070b-6236-4330-9308-0ec30d577e63"
      unitRef="usd">6800000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMy02LTEtMS05MTI4NA_0f4aef5b-0fc7-4bd9-b134-4765c5eb7164"
      unitRef="usd">900000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMy04LTEtMS05MTI4NA_51485f51-b01f-442f-ac44-dc6b7084588a"
      unitRef="usd">7700000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNC00LTEtMS05MTI4NA_8dae3dbe-083d-4a58-ad42-d95098973a29"
      unitRef="usd">-2300000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNC04LTEtMS05MTI4NA_72b5cae6-48fd-4c5a-84a9-9a00e6da79ca"
      unitRef="usd">-2300000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="iec438a15507545e69f9ae19f0a3d5941_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNS0yLTEtMS05MTI4NA_6a183c4c-8705-4f99-9c35-c0e464e7961c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNS00LTEtMS05MTI4NA_43b08692-d12f-4a4c-b11b-9f39739d9ef1"
      unitRef="usd">9100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNS02LTEtMS05MTI4NA_5f6b0317-3dcc-4860-ac4d-77c03d8ebe60"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNS04LTEtMS05MTI4NA_242f6264-e6be-4743-9b59-2ae6f17cdecf"
      unitRef="usd">10000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i651fc075a09948b29a069bfed15ac793_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNi0yLTEtMS05MTI4NA_ada6aa6e-f44d-4b40-8fea-dc6f4f448086"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ae6af3ca5ff479b95eef53b77bd535e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNi00LTEtMS05MTI4NA_bdf5838b-95bf-479d-bed1-7760dd0245b6"
      unitRef="usd">4600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5904a41b0c2944d1bc9877b651a3f0fe_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNi02LTEtMS05MTI4NA_3e1e0c27-2eab-4c0d-96a7-1924f26d4be2"
      unitRef="usd">-6700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib20d47a77df04874a03809c71af93bb8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfNi04LTEtMS05MTI4NA_26271670-868a-46e2-90b5-18f583f87308"
      unitRef="usd">-6100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic637379f0d8043d5af581e734aefd028_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOC0yLTEtMS05MTI4NA_aff90472-cae2-4abf-b764-acb772d1e73a"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8daff84a60ea419db78f98817926f778_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOC00LTEtMS05MTI4NA_9d4860b0-68ce-4d93-97c1-af7e618eff7a"
      unitRef="usd">1800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if6289d96bf3f4d3dad0b8d93584c1fb1_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOC02LTEtMS05MTI4NA_bd41bf9f-5796-4a81-845e-ff1ac24ac074"
      unitRef="usd">-7100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0ca88e5d8bf24c309e9d2a5171b224ec_I20220331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOC04LTEtMS05MTI4NA_ec7f799d-ccd6-47d8-a2f1-c105ae1c4947"
      unitRef="usd">-9300000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOS00LTEtMS05MTI4NA_d9263e7e-fb0f-4d14-978d-7a3a7b78055a"
      unitRef="usd">1900000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOS02LTEtMS05MTI4NA_4ee5b0ab-a8db-4627-a547-22ef48c62634"
      unitRef="usd">400000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfOS04LTEtMS05MTI4NA_5bcbdf0c-278a-490e-8a2d-e443ee826396"
      unitRef="usd">2300000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTAtNC0xLTEtOTEyODQ_6635df95-34c2-431e-8420-98328063e63d"
      unitRef="usd">-900000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTAtOC0xLTEtOTEyODQ_64327044-cb5e-4e72-b77d-805710381c67"
      unitRef="usd">-900000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i43051341a0744172a54eb2e3094323d6_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtMi0xLTEtMTAxMTA1_9e878a7a-11a9-47e5-b029-b2a329d4b205"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtNC0xLTEtMTAxMTA1_7048a210-b66c-48fa-af1d-ae599971b344"
      unitRef="usd">2800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtNi0xLTEtMTAxMTA1_138d0fe6-1bf5-4076-9ba4-39597afcb833"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtOC0xLTEtMTAxMTA1_07b0b0c1-4775-4cdf-833e-9fc718a581f5"
      unitRef="usd">3200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i651fc075a09948b29a069bfed15ac793_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtMi0xLTEtOTEyODQ_950a609f-3e62-4bad-83b4-7e7211f81163"
      unitRef="usd">-4000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i6ae6af3ca5ff479b95eef53b77bd535e_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtNC0xLTEtOTEyODQ_47d4a44a-d98b-49ac-9a73-62a087245fa0"
      unitRef="usd">4600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5904a41b0c2944d1bc9877b651a3f0fe_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtNi0xLTEtOTEyODQ_7f82dc62-4b8f-4d7a-99e9-638c66af208b"
      unitRef="usd">-6700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib20d47a77df04874a03809c71af93bb8_I20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTEtOC0xLTEtOTEyODQ_65cf580e-ea80-499d-8100-5771440a287b"
      unitRef="usd">-6100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i99c848d9c0ea44feaa1b6615d95059e2_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTMtMi0xLTEtOTEyODQ_dbd3553c-b42c-4aec-ba26-063863daa03d"
      unitRef="usd">-7700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5b18ce4c0ae74dff995c8a04ce8a3f19_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTMtNC0xLTEtOTEyODQ_9a593512-76d8-437a-ab09-2e486e41bd5e"
      unitRef="usd">-11000000.0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ib3a73d2985e143b08dff3ac4720bea90_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTMtNi0xLTEtOTEyODQ_1549e8d7-8756-449b-bc5f-8ff40ff52c29"
      unitRef="usd">-6600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5d6dfa3b33ba4a26be19db91781e5050_I20201231"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTMtOC0xLTEtOTEyODQ_eda17e90-92a1-4b67-b969-713991390c54"
      unitRef="usd">-25300000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTQtNC0xLTEtOTEyODQ_bb66c1a8-0814-4742-b16c-fcaedb0cda22"
      unitRef="usd">1600000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTQtNi0xLTEtOTEyODQ_71dd0f48-c02a-4519-abea-d3b8158f32ea"
      unitRef="usd">-1700000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTQtOC0xLTEtOTEyODQ_d5560524-3fb1-4dcc-9e8c-036d1bdf490a"
      unitRef="usd">-100000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTUtNC0xLTEtOTEyODQ_6613e96c-f438-478e-8fc8-e7e2634b60bc"
      unitRef="usd">-3000000.0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTUtOC0xLTEtOTEyODQ_f4f5b1a6-4f2a-4b59-b94e-bcbc74bcbb1d"
      unitRef="usd">-3000000.0</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="ia2ba91a37c45433382623dcdb7bd5722_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTYtMi0xLTEtOTEyODQ_a7b6791e-ed53-4384-b2c7-e1a03c8f4b1e"
      unitRef="usd">-7700000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id88c42efd11a49ef841182aac044455d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTYtMi0xLTEtOTEyODQ_c96b824d-d67b-4fc9-b94e-c98d2fb69ef7"
      unitRef="usd">-7700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTYtNC0xLTEtOTEyODQ_dd767ee0-eee4-4961-ab12-27399af58579"
      unitRef="usd">4600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTYtNi0xLTEtOTEyODQ_cd8cf2be-99b9-4e2a-858e-0a35751d418b"
      unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTYtOC0xLTEtOTEyODQ_78b6a41f-7fa0-4392-b5f2-5ac28d7efcd4"
      unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="ia2ba91a37c45433382623dcdb7bd5722_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTctMi0xLTEtOTEyODQ_a7b6791e-ed53-4384-b2c7-e1a03c8f4b1e"
      unitRef="usd">-7700000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id88c42efd11a49ef841182aac044455d_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTctMi0xLTEtOTEyODQ_c96b824d-d67b-4fc9-b94e-c98d2fb69ef7"
      unitRef="usd">-7700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="i31cb95adcb0a43cb82eb1863ad9f5748_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTctNC0xLTEtOTEyODQ_f02750b3-a0bf-4c63-94f5-1755fc2a714a"
      unitRef="usd">-6400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i529a638b09f04a2a8bc2cc0b002cd45c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTctNi0xLTEtOTEyODQ_5882da7a-f54e-4340-acbe-596e923dcc3a"
      unitRef="usd">-8300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cb30120c0cd4c26b09246b92a5b9300_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTctOC0xLTEtOTEyODQ_050c1f35-740a-4faa-8ded-f6b66d27d101"
      unitRef="usd">-22400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia4ab0f0ae6ef4c1da3db1ce773f632c0_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTktMi0xLTEtOTEyODQ_f86367d8-1b5b-49ef-ac47-ec277846d55a"
      unitRef="usd">-7700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i28b844ae659d4576b73d8e1361ed9d73_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTktNC0xLTEtOTEyODQ_4043e39a-3259-4673-a5eb-5bb6d3ef3060"
      unitRef="usd">-7900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i1bf5df54710d4ea4b5ed41c57fe517a4_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTktNi0xLTEtOTEyODQ_d6d63b83-8ff0-4941-9b90-fe46de4c4779"
      unitRef="usd">-8800000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84fb728efecd4d3eb00c3307db37929d_I20210331"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMTktOC0xLTEtOTEyODQ_9fd8afd9-e0b4-4dc0-b674-799db35d3504"
      unitRef="usd">-24400000</us-gaap:StockholdersEquity>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjAtNC0xLTEtOTEyODQ_fde88b8e-67e6-4b0e-b655-53a33f81899f"
      unitRef="usd">-100000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjAtNi0xLTEtOTEyODQ_d5f06273-d46e-4364-a46f-07a75b48d6be"
      unitRef="usd">500000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjAtOC0xLTEtOTEyODQ_105799a8-d300-46bd-a4a5-124d249ba7de"
      unitRef="usd">400000</us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjEtNC0xLTEtOTEyODQ_f684a7ef-deb9-4790-a71a-c546486144b2"
      unitRef="usd">-1600000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjEtOC0xLTEtOTEyODQ_01993835-d01c-4ec1-bbde-392fe32e36c9"
      unitRef="usd">-1600000</us-gaap:ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i45ee1c733d0e40dc98fb96a0479d1554_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjMtMi0xLTEtMTAxMTA5_cd708773-1c31-4f52-8947-f92f0ca020a9"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjMtNC0xLTEtMTAxMTA5_beab543c-1e2e-496a-a316-e24513a11f5f"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjMtNi0xLTEtMTAxMTA5_ce216b51-0998-44b1-88f5-c8bda05dff05"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjMtOC0xLTEtMTAxMTA5_8071bb8c-1104-4e1f-a3ee-4e2759abb32f"
      unitRef="usd">2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="ia2ba91a37c45433382623dcdb7bd5722_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjItMi0xLTEtOTEyODQ_b8b7f3f9-3e99-4418-b5a7-28250419a3b0"
      unitRef="usd">-7700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i31cb95adcb0a43cb82eb1863ad9f5748_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjItNC0xLTEtOTEyODQ_32b3b700-f04c-4ffb-9c95-8e2759ed1aff"
      unitRef="usd">-6400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i529a638b09f04a2a8bc2cc0b002cd45c_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjItNi0xLTEtOTEyODQ_d61634bb-b01c-489d-ac68-6450253384a8"
      unitRef="usd">-8300000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9cb30120c0cd4c26b09246b92a5b9300_I20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRkMjA0Mjg4ZjliYTRhZDNhNmE5ODA2YzcwNzBhNzRiL3RhYmxlcmFuZ2U6NGQyMDQyODhmOWJhNGFkM2E2YTk4MDZjNzA3MGE3NGJfMjItOC0xLTEtOTEyODQ_c2685c05-fd8a-4d0e-889e-a99f27c1a5c9"
      unitRef="usd">-22400000</us-gaap:StockholdersEquity>
    <us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RleHRyZWdpb246NzAyYzZkYWE1MDVlNGFlOTg5ZjRlZDdmNmYzNmYyNTJfMTY4NA_2864ddc3-bcee-4d42-8e74-a3eca8a347a9">&lt;div style="margin-bottom:9pt;margin-top:9pt;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table presents the tax effects related to each component of other comprehensive income (loss):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.509%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.826%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="15" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pretax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax Benefit (Expense)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net of tax&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Derivative Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Foreign Currency Translation Adjustments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total adjustments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC0xLTEtMS05NjA1NA_b2f09e82-ce0d-4fd9-a842-39cdf09f9ac9"
      unitRef="usd">3800000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC0zLTEtMS05NjA1Ng_8dbccd29-c51f-4d59-a9b3-132d2c491cf2"
      unitRef="usd">1000000.0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i8d173b2389384c47b1fbe9763c9db25a_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC01LTEtMS05NjA2Mg_114c6c39-62e7-4419-ac6b-abd282d2d7ac"
      unitRef="usd">2800000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC03LTEtMS05NjA3OQ_bace503b-da1b-4703-a385-ac55217bd4b5"
      unitRef="usd">1200000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC05LTEtMS05NjA5NQ_a8d9e912-7d4e-4e0a-84b2-ec73143ab425"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ie6d9ecd59ed34586a04b5eff883fa509_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNC0xMS0xLTEtOTYxMDE_2026d1ca-2db9-41b8-a338-84aad6fdf9a3"
      unitRef="usd">1500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS0xLTEtMS05NjA1NA_3070f109-ac81-48d2-b216-d4e4d6157575"
      unitRef="usd">1300000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS0zLTEtMS05NjA1Ng_a50b04bb-0e87-4a5e-83c0-7e413243fc89"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia5c81281b3d048ff811d16bd409cf74e_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS01LTEtMS05NjA2Mg_ad692003-9a0e-4feb-97fc-178b275fd568"
      unitRef="usd">400000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS03LTEtMS05NjA4Ng_3b250744-1f32-4d1b-a282-8cfd861d816b"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS05LTEtMS05NjA5NQ_67d24b28-baa7-4a4b-bd6f-66e77ed9bd4c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i91472ff101dd44659fd240d7422be7c8_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNS0xMS0xLTEtOTYxMDE_816822ac-8baa-458c-a0ae-e781f962fecf"
      unitRef="usd">500000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi0xLTEtMS0xMDExMjU_bbd21bb2-a722-4607-8639-37d176d7d085"
      unitRef="usd">5100000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi0zLTEtMS05NjgyNQ_b5f46ee4-cd2a-40a8-9a36-a5b94df01ccf"
      unitRef="usd">1900000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi01LTEtMS0xMDExMTM_c634305c-f6db-4ac4-9aa7-92c7095052a4"
      unitRef="usd">3200000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi03LTEtMS0xMDExMjc_32966f1c-d577-4c75-be10-d58b69f8a962"
      unitRef="usd">1700000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi05LTEtMS0xMDExMjc_3c07aedd-546c-4a60-87f0-b2bbe03f2f0b"
      unitRef="usd">-300000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOjRlNzkxZDRmMzM0YjQxYWI4YzEwY2EwMTRiNTc0YzYxL3RhYmxlcmFuZ2U6NGU3OTFkNGYzMzRiNDFhYjhjMTBjYTAxNGI1NzRjNjFfNi0xMS0xLTEtMTAxMTE1_dc719057-2c89-4294-a770-43d72fc9f0b3"
      unitRef="usd">2000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC0xLTEtMS05NTE3Nw_efa92a27-89d1-4906-aa94-c7b8980e2b7b"
      unitRef="usd">12400000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC0zLTEtMS05NTE4Nw_73708ef4-0827-4909-8f55-e1a8ab4b30b4"
      unitRef="usd">3300000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i54fec86523ba46b099635d2bef8715ab_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC01LTEtMS0xMDExMTc_bd84fad0-6a22-4088-b3ef-85dcd02c4974"
      unitRef="usd">9100000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC03LTEtMS05NTE5NA_62a8cdbd-fb2c-4d3d-bdac-636df0aa46b7"
      unitRef="usd">3600000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC05LTEtMS05NTE5MA_d503d5ab-d76f-434c-9a2f-80b98dfbe039"
      unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i59961335356647079ef2934edbcfa823_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNC0xMS0xLTEtOTUxOTg_726e970e-1baa-4fc8-a19f-86f74ac7e7b3"
      unitRef="usd">4600000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS0xLTEtMS05NTE3Nw_7c8dbb21-1f78-4301-bac0-f675fb134549"
      unitRef="usd">2000000.0</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS0zLTEtMS05NTE4Nw_bc4a5282-2f2e-4b5b-8f3c-100bf3108c8f"
      unitRef="usd">1100000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i40a27c4612a64adb91a095733a9e0098_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS01LTEtMS0xMDExMTc_a0ee8628-e05d-4f73-85f3-8947dc5f44b6"
      unitRef="usd">900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS03LTEtMS05NTE5NA_8c2ae8cd-eafe-4fdd-a1b6-a25fe2d1143d"
      unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS05LTEtMS05NTE5MA_50f6808d-6cd0-47ec-815a-b93a3103d01c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib65aac0a5ecd48299a7a7abb6d8dc6e4_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNS0xMS0xLTEtOTUxOTg_ee01375a-526e-4923-82a8-5392d0af090a"
      unitRef="usd">-1700000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi0xLTEtMS0xMDExMjk_604cc688-2f75-49a1-a0a0-4a798bf29035"
      unitRef="usd">14400000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi0zLTEtMS0xMDExMjk_391b474d-ed37-46ec-b91c-9ee9b7662358"
      unitRef="usd">4400000</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi01LTEtMS0xMDExMTc_89ede9f8-5aad-46e1-b1ff-1ecb68a4f581"
      unitRef="usd">10000000.0</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi03LTEtMS0xMDExMzE_7a6be36b-7827-4925-9c4c-888bd62de00a"
      unitRef="usd">1900000</us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi05LTEtMS0xMDExMzE_b1f1d4f0-5f23-4a6b-a366-647d4c2ddd5d"
      unitRef="usd">-1000000.0</us-gaap:OtherComprehensiveIncomeLossTaxPortionAttributableToParent1>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV83Ni9mcmFnOjcwMmM2ZGFhNTA1ZTRhZTk4OWY0ZWQ3ZjZmMzZmMjUyL3RhYmxlOmQ4ZjM0N2QxNWIxOTRhYmFhODM4MDc1MjJiZjJlODZmL3RhYmxlcmFuZ2U6ZDhmMzQ3ZDE1YjE5NGFiYWE4MzgwNzUyMmJmMmU4NmZfNi0xMS0xLTEtMTAxMTIz_9bde1c65-d539-4236-aabb-34489eefc0ba"
      unitRef="usd">2900000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RleHRyZWdpb246NjMyYmRmMjBjODkyNDVlZmEwZmRlZjQxMGYyZWMxNDVfMTkzNQ_71c0ed89-114e-4840-ba8e-9c9c70ae99cc">Segment informationThe Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. During the first quarter of 2022, the Company revised the reporting that the Chief Operating Decision Maker (CODM) reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and 2) the services segment focused on CDMO (Services). The Company evaluates the performance of these reportable segments based on revenue and adjusted gross margin. Segment revenue includes external customer sales, but it does not include inter-segment services. Adjusted gross margin for each segment is segment revenue less segment cost of sales reduced for significant one-time events. We do not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. The Company has recast the related historical information for consistency.&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables include segment revenues and a reconciliation of the Company's segment adjusted gross margin to the condensed consolidated statement of operations for each of the Company's reporting segments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of contract development and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; Services revenue and Services adjusted gross margin for the three months ended June 30, 2021 includes the impact of $70.4 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of contract development and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; Services revenue and Services adjusted gross margin for the six months ended June 30, 2021 includes the impact of $167.9 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes depreciation for each segment as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage our assets on a total company basis, not by operating segment, as our operating assets are shared or commingled. Therefore, our CODM does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RleHRyZWdpb246NjMyYmRmMjBjODkyNDVlZmEwZmRlZjQxMGYyZWMxNDVfMTkzNg_910fa5a3-c80b-42fc-b326-f60c7899785e">The Company reports segment information based on the internal reporting used by management for making decisions and assessing performance. During the first quarter of 2022, the Company revised the reporting that the Chief Operating Decision Maker (CODM) reviews in order to assess Company performance. The CODM manages the business with a focus on two reportable segments: 1) a products segment (Products) consisting of the Government - MCM and Commercial business lines and 2) the services segment focused on CDMO (Services). The Company evaluates the performance of these reportable segments based on revenue and adjusted gross margin. Segment revenue includes external customer sales, but it does not include inter-segment services. Adjusted gross margin for each segment is segment revenue less segment cost of sales reduced for significant one-time events. We do not allocate research and development, selling, general and administrative costs, amortization of intangibles assets, interest and other income (expense) or taxes to operating segments in the management reporting reviewed by the CODM. The accounting policies for segment reporting are the same as for the Company as a whole. The Company has recast the related historical information for consistency.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RleHRyZWdpb246NjMyYmRmMjBjODkyNDVlZmEwZmRlZjQxMGYyZWMxNDVfMTkzNw_76ccd230-386b-45da-846d-e7f085d1dc72"
      unitRef="segment">2</us-gaap:NumberOfReportableSegments>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RleHRyZWdpb246NjMyYmRmMjBjODkyNDVlZmEwZmRlZjQxMGYyZWMxNDVfMTkzNA_291d1b46-f1f0-4c85-b944-02021b721689">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables include segment revenues and a reconciliation of the Company's segment adjusted gross margin to the condensed consolidated statement of operations for each of the Company's reporting segments as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.330%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Three Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;237.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;397.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(91.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of contract development and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(78.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(146.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;147.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; Services revenue and Services adjusted gross margin for the three months ended June 30, 2021 includes the impact of $70.4 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.042%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.900%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.371%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.471%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.189%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="12" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Six Months Ended June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Services &lt;/span&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Consolidated&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;474.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;550.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;374.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;740.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contracts and grants revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of product sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(171.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(133.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of contract development and manufacturing&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(154.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(193.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross margin&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;303.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;207.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;185.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;366.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in fair value of contingent consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted gross margin&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;304.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;209.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;187.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;368.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="30" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt; Services revenue and Services adjusted gross margin for the six months ended June 30, 2021 includes the impact of $167.9 million of CDMO leases revenues related to the BARDA COVID-19 Development Public Private Partnership which ended in November 2021.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi0xLTEtMS05MTI4NA_daada8c1-5f3a-44d5-9e53-899fa10abc7a"
      unitRef="usd">237200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ef607d7a3c7451f9fc91797c668e35b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi0yLTEtMS05MTI4NA_4ec6d17d-8bd4-47b5-a385-53a95a5ec6ea"
      unitRef="usd">-1800000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i865cea62a18543cb83411d9461069e79_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi0zLTEtMS05MTI4NA_360cf0fb-a043-4fda-8784-3226f19c8bc9"
      unitRef="usd">7300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi00LTEtMS05MTI4NA_914fb836-2801-4f51-814c-eca49804bcd1"
      unitRef="usd">242700000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi01LTEtMS05MTI4NA_d10e5133-c531-4493-9336-a763a4bfa91d"
      unitRef="usd">181200000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30013848203544aaab36afb676ed3c64_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi02LTEtMS05MTI4NA_4282eeb5-7df0-4c21-a7a2-94fc1ff8d15a"
      unitRef="usd">190900000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b063649105148fca27b7b94d3b8e412_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi03LTEtMS05MTI4NA_5dd4a2a7-35c6-420a-843a-31df934b2c42"
      unitRef="usd">25400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMi04LTEtMS05MTI4NA_fba6271e-5d2b-41c0-9119-b4dcb314175c"
      unitRef="usd">397500000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46b2d87a49bb494a84bf9da22318cb73_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMy0zLTEtMS05MTI4NA_48249ab8-2520-4587-930b-0b38bf4dfdaa"
      unitRef="usd">7300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f9afc75663f4899a4fc9be307765379_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMy00LTEtMS05MTI4NA_c5c4299c-bc73-4ef6-bbbc-f02d0a3d0ad6"
      unitRef="usd">7300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i05f0ccbd84a246cd8e98d3b72d6b8dd3_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMy03LTEtMS05MTI4NA_636661cc-5bca-48cf-91c4-c4761ee4cbb9"
      unitRef="usd">25400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f00bb59ea1746fbb21fbadf3f414a92_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMy04LTEtMS05MTI4NA_54298447-a187-42cf-a2a7-3efa5966248e"
      unitRef="usd">25400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i017940019b8f4dd28eddab4c25571c62_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNC0xLTEtMS05MTI4NA_4012787e-e173-4ed4-bef5-2bd9caca0d63"
      unitRef="usd">91000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i9b613598404b49b880eecce284caa409_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNC00LTEtMS05MTI4NA_0eb859d8-2981-40f2-b903-946163b0ba19"
      unitRef="usd">91000000.0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i79dd2d62f4de4d778696638252882cf2_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNC01LTEtMS05MTI4NA_df7790c5-c403-4c21-bae4-083539ce74d8"
      unitRef="usd">81200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic14c595631e444d1b209fffe8cd22901_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNC04LTEtMS05MTI4NA_55369a29-8b02-4e9e-bd7d-1a2aa07b6540"
      unitRef="usd">81200000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2e1a370ad2f74ba9974ee7ae4c0046ea_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNS0yLTEtMS05MTI4NA_61c0b970-29a0-4de4-a259-2f2f6218216e"
      unitRef="usd">78800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i11d6b9ed7cef4daf9b8dc0c61d4b8f0b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNS00LTEtMS05MTI4NA_128669af-9429-4248-95c4-71dd00c868db"
      unitRef="usd">78800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i2256cc8ca6db4b8facf112f19dc9715b_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNS02LTEtMS05MTI4NA_540c6636-d774-4406-874f-2e43fd441e75"
      unitRef="usd">146600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7d9f1173bf46467fa504dd84e978c454_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfNS04LTEtMS05MTI4NA_b28ba284-7627-4c73-a3b4-a21206690fea"
      unitRef="usd">146600000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS0xLTEtMS05MTI4NA_3cbeefcc-c57b-49e5-af70-7def4e31a385"
      unitRef="usd">146200000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i6ef607d7a3c7451f9fc91797c668e35b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS0yLTEtMS05MTI4NA_2ca202eb-f13a-4487-8774-5210b405c0e8"
      unitRef="usd">-80600000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i865cea62a18543cb83411d9461069e79_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS0zLTEtMS05MTI4NA_ce084c70-207d-462e-a66a-c77bd96fdbad"
      unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS00LTEtMS05MTI4NA_7d86a74b-24e3-4dda-a641-606a48c2da08"
      unitRef="usd">65600000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS01LTEtMS05MTI4NA_f62d67b5-58ec-4325-a08b-54236e40908a"
      unitRef="usd">100000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i30013848203544aaab36afb676ed3c64_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS02LTEtMS05MTI4NA_485f7e76-faef-4901-b914-9af2892833e6"
      unitRef="usd">44300000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i3b063649105148fca27b7b94d3b8e412_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS03LTEtMS05MTI4NA_6cbd3f22-8364-4c49-bd17-b32a1453948e"
      unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfOS04LTEtMS05MTI4NA_f582e4e0-8791-4fad-8fc4-776920fd9866"
      unitRef="usd">144300000</us-gaap:GrossProfit>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTAtMS0xLTEtOTEyODQ_27e8178c-c246-40b2-bbfe-18da4bc61f7e"
      unitRef="usd">1300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTAtNC0xLTEtOTEyODQ_0ee146ac-a70f-450f-a85f-8842d95f6c86"
      unitRef="usd">1300000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTAtNS0xLTEtOTEyODQ_6af9331e-3d63-4540-84ce-7ea3eb555076"
      unitRef="usd">600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTAtOC0xLTEtOTEyODQ_fad49a06-36a0-4c07-95ee-4af7ce556de6"
      unitRef="usd">600000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <ebs:AdjustedGrossMargin
      contextRef="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtMS0xLTEtOTEyODQ_b673cfd7-92ff-4239-96d3-9493dc9ab1e3"
      unitRef="usd">147500000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i6ef607d7a3c7451f9fc91797c668e35b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtMi0xLTEtOTEyODQ_d494aaba-be58-4fab-8ebc-5ba86be7a52c"
      unitRef="usd">-80600000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i865cea62a18543cb83411d9461069e79_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtMy0xLTEtOTEyODQ_41cdbd14-f6b8-44f7-8733-23f3626ff122"
      unitRef="usd">0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtNC0xLTEtOTEyODQ_61db28ec-27b8-4794-bab0-4fae1bfaca6f"
      unitRef="usd">66900000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtNS0xLTEtOTEyODQ_3f63ffc5-027d-45f7-bc69-ad7d149efb12"
      unitRef="usd">100600000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i30013848203544aaab36afb676ed3c64_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtNi0xLTEtOTEyODQ_a4219617-e772-4710-8dd3-1b13c2a16a43"
      unitRef="usd">44300000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i3b063649105148fca27b7b94d3b8e412_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtNy0xLTEtOTEyODQ_6bf754f0-3a14-42a8-a73c-785a8319a847"
      unitRef="usd">0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTEtOC0xLTEtOTEyODQ_98e3064c-5552-48d9-ab62-81d0dbb4098e"
      unitRef="usd">144900000</ebs:AdjustedGrossMargin>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="ieedc7121a2874e219f1a1ca878ff2c37_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOmFhZThmYWVlOWY3NDRjZDM5OGUxODU3NDk1NjA4MGRlL3RhYmxlcmFuZ2U6YWFlOGZhZWU5Zjc0NGNkMzk4ZTE4NTc0OTU2MDgwZGVfMTItMC0xLTEtOTEyODQvdGV4dHJlZ2lvbjpmZjM0ZGE0NmQ0MDk0NTMzODVjNmI5M2E1NTY3N2JkNV8xMjY_98c87572-5028-4732-b111-5bbf4afc2068"
      unitRef="usd">70400000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi0xLTEtMS05NTI3Mw_bef3dee7-bc7f-4d20-abfd-8c447b470f25"
      unitRef="usd">474300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibba5b2ada3cf4cb4a6b4ba683779728e_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi0yLTEtMS05NTI3Nw_0a64b80a-0c08-455d-8efb-fb1dfcd78801"
      unitRef="usd">59000000.0</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cff17dc6fc04ad7ab4b4434ef23201b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi0zLTEtMS05NTI3OQ_8a534fb2-9772-4f9d-9cf2-2246fa205bf9"
      unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi00LTEtMS05NTk4Nw_644e50aa-4d48-4efd-9e86-8a960baee99a"
      unitRef="usd">550200000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi01LTEtMS05NTMwMw_ef11309b-0201-4e15-b63e-44b73acd7a0b"
      unitRef="usd">319100000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a54e7d85e014e56956c4c0661a1e4ed_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi02LTEtMS05NTMwNQ_f8ce7c88-bebf-471f-b347-66cbab8090cb"
      unitRef="usd">374700000</ebs:OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i400967d6466a4b58a011f5b045886df0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi03LTEtMS05NTMwNw_351d17b5-8976-41e6-9afc-60d8508538a3"
      unitRef="usd">46700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMi04LTEtMS0xMDExNDQ_3c02e92c-82a5-4591-87a0-483eeda905b8"
      unitRef="usd">740500000</us-gaap:Revenues>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i47cb7eb2f6354e03ac1eaca0de11507a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMy0zLTEtMS05NTI4MQ_9fd0efa1-f112-4380-b70d-36add426a97e"
      unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cff17dc6fc04ad7ab4b4434ef23201b_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMy00LTEtMS0xMDExNDA_330847c1-80f8-4784-9203-2e6e55f6ab6b"
      unitRef="usd">16900000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3159b0dd6390463898aef3e672bfd623_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMy03LTEtMS05NTMwOQ_f9821675-fca4-485a-a524-67ea036c7ca7"
      unitRef="usd">46700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i400967d6466a4b58a011f5b045886df0_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMy04LTEtMS0xMDExNDQ_9e3d6e2e-c959-494f-a1cd-0c342e094f7e"
      unitRef="usd">46700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i5ef70cac4db448e4864f2175f2373dfd_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNC0xLTEtMS05NTI5Nw_2a0071de-ad1f-44ea-abf9-1a516c61f9b5"
      unitRef="usd">171300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i3782ad4a20bc4ae1a6544d4021387ed5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNC00LTEtMS0xMDExNDA_82456558-7bed-44fd-a936-d9b65431bcd7"
      unitRef="usd">171300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="id4d814b28862414f8af4e0b81c135010_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNC01LTEtMS05NTMxMw_0e412951-12a3-40ce-b62b-6b1b2d1d2f98"
      unitRef="usd">133800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i13a8a1d9795b41d88baf9f42c725ef84_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNC04LTEtMS0xMDExNDQ_22d5a06e-1cbb-401b-8f19-92634e16d4a2"
      unitRef="usd">133800000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i8bd990b6a0ad4694b2c05770255685f3_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNS0yLTEtMS05NTI5MQ_38cc97a6-3f2e-4d9e-a8a3-81188aaca9b6"
      unitRef="usd">154400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i1cc2230d43ca419eb9859817a3e13e4a_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNS00LTEtMS0xMDExNDA_3d265d76-d201-47e9-b499-e7d76bc274a5"
      unitRef="usd">154400000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6b72f2081fbf4b8284ba76726875fc2a_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNS02LTEtMS05NTMxOQ_0f991bed-94d6-4723-94aa-b73f6e0d6707"
      unitRef="usd">193300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i4c35eb92f4e94539aef959a8629ae0e7_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfNS04LTEtMS0xMDExNDQ_21ef0c2e-0761-4a8f-81b7-453df0a94c05"
      unitRef="usd">193300000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i6bccaec18dd645feadb40845bece9039_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS0xLTEtMS0xMDExNDI_82a9f0fd-c22e-4378-a7d4-8691de5e0a69"
      unitRef="usd">303000000.0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i10be8bddd4d942c08359df94ab97fea5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS0yLTEtMS0xMDExNDI_09b5b384-a02c-4c29-a7f2-51256011057a"
      unitRef="usd">-95400000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i7deb271d98c249298506cf1f896e57cb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS0zLTEtMS0xMDExNDI_efd1133d-d031-45ea-8cf1-2c8396875411"
      unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS00LTEtMS0xMDExNDA_307196ef-4cfb-41eb-bfdd-c7100a33cfcc"
      unitRef="usd">207600000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="iedc4cae43f3c454598ce8975dac330c5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS01LTEtMS0xMDExNDc_d646d8cd-0f19-490b-9483-429e0c2de12b"
      unitRef="usd">185300000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ibc42e37be5a94e4f8f3591414bf596dd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS02LTEtMS0xMDExNDc_b7ceb77c-297c-4fba-b54b-53a6ec59a9c0"
      unitRef="usd">181400000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="iffc6765500b949268c476664a96a2cc3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS03LTEtMS0xMDExNDc_db8bf146-c378-4ba6-996e-6ffe2e937425"
      unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfOS04LTEtMS0xMDExNDQ_797ccf5a-8603-4d5d-95da-9ce40dab3bf8"
      unitRef="usd">366700000</us-gaap:GrossProfit>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6bccaec18dd645feadb40845bece9039_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTAtMS0xLTEtOTUyNzE_344889ba-d689-489b-83c0-d47217b38da8"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTAtNC0xLTEtMTAxMTQw_1107cf48-073c-40ee-84f2-b084e87ec2f9"
      unitRef="usd">1800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="iedc4cae43f3c454598ce8975dac330c5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTAtNS0xLTEtOTUzMjU_fa6e8e78-ee9f-4e09-a532-8385ec75e23b"
      unitRef="usd">1700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTAtOC0xLTEtMTAxMTQ0_9f89bea9-02be-49f4-9fdc-272e3a2fc088"
      unitRef="usd">1700000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <ebs:AdjustedGrossMargin
      contextRef="i6bccaec18dd645feadb40845bece9039_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtMS0xLTEtMTAxMTQy_47d09874-3658-47b3-894c-95794e74b1c9"
      unitRef="usd">304800000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i10be8bddd4d942c08359df94ab97fea5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtMi0xLTEtMTAxMTQy_836440c6-8003-45cd-8dc6-f9297c154846"
      unitRef="usd">-95400000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="i7deb271d98c249298506cf1f896e57cb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtMy0xLTEtMTAxMTQy_11390aa1-2601-49e0-95c5-a6d0ac40c3a4"
      unitRef="usd">0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtNC0xLTEtMTAxMTQw_c1ae96bf-8b52-4ee6-b97d-ea3fa420bb73"
      unitRef="usd">209400000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="iedc4cae43f3c454598ce8975dac330c5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtNS0xLTEtMTAxMTQ3_ba322fa7-f852-47ce-9392-4baaace4ab18"
      unitRef="usd">187000000.0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="ibc42e37be5a94e4f8f3591414bf596dd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtNi0xLTEtMTAxMTQ3_9afa4bf3-f3a5-4d75-8382-97340e3cf985"
      unitRef="usd">181400000</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="iffc6765500b949268c476664a96a2cc3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtNy0xLTEtMTAxMTQ3_670be176-a7af-4a56-a88d-f2ff4454cca2"
      unitRef="usd">0</ebs:AdjustedGrossMargin>
    <ebs:AdjustedGrossMargin
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTEtOC0xLTEtMTAxMTQ0_54469039-15f5-4686-a335-ceff26030f3d"
      unitRef="usd">368400000</ebs:AdjustedGrossMargin>
    <us-gaap:OperatingLeaseLeaseIncomeLeasePayments
      contextRef="i06918d944d12481c84ebd11d669df56b_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjg5NGQ5MDdjMzI4OTQ3MWE5NTEyYjQ0NDU1ZTU1MWRmL3RhYmxlcmFuZ2U6ODk0ZDkwN2MzMjg5NDcxYTk1MTJiNDQ0NTVlNTUxZGZfMTItMC0xLTEtOTQ5OTIvdGV4dHJlZ2lvbjoyNjZlMTVjZDQ4ZDE0ZmJkOGU4YzEwMTQ4OWM1NjRiMl82NTk3MDY5NzY2ODgz_01c18c59-47be-44cb-8357-07c5cc350414"
      unitRef="usd">167900000</us-gaap:OperatingLeaseLeaseIncomeLeasePayments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RleHRyZWdpb246NjMyYmRmMjBjODkyNDVlZmEwZmRlZjQxMGYyZWMxNDVfMTkzOA_56992ea0-c75c-450d-a4bc-bfd5a32b34c3">&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table includes depreciation for each segment as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.560%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.267%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.518%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.273%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#19415e;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#19415e;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#ffffff;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ededed;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Products&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Services&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.9&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ededed;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ededed;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Depreciation
      contextRef="i8c6da9c84b3f4aa6a4c84b9fc13b0798_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMy0xLTEtMS05NTQzOQ_514d6d92-94dd-4cb6-99dd-ef7650f53309"
      unitRef="usd">6700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i0475e384415c4b6a9890a1211cafd54d_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMy0zLTEtMS05NTQzOQ_68af2d68-10ed-44c7-8595-b3955a5f62aa"
      unitRef="usd">8700000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6bccaec18dd645feadb40845bece9039_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMi0xLTEtMS05MTI4NA_625f8299-f4c3-4559-84ba-21164e6f16b7"
      unitRef="usd">14100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iedc4cae43f3c454598ce8975dac330c5_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMi0zLTEtMS05MTI4NA_02e480ac-14eb-492b-a12d-e56676a176fb"
      unitRef="usd">15900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i6ef607d7a3c7451f9fc91797c668e35b_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNC0xLTEtMS05NTQzOQ_131ea74a-7197-47ba-bd1f-3ba06555ceef"
      unitRef="usd">20800000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i30013848203544aaab36afb676ed3c64_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNC0zLTEtMS05NTQzOQ_6aab75b3-34f5-4673-92c6-f23b9b3dbc83"
      unitRef="usd">7600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i10be8bddd4d942c08359df94ab97fea5_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMy0xLTEtMS05MTI4NA_8e150c0e-fdf9-4838-819e-edb238b02293"
      unitRef="usd">28600000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ibc42e37be5a94e4f8f3591414bf596dd_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfMy0zLTEtMS05MTI4NA_88632bb9-4fb4-4ff1-8736-28835e28267f"
      unitRef="usd">12900000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i865cea62a18543cb83411d9461069e79_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNS0xLTEtMS05NTQzOQ_624d6604-9ea0-490e-9fb9-c558e14c59ee"
      unitRef="usd">1000000.0</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i3b063649105148fca27b7b94d3b8e412_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNS0zLTEtMS05NTQzOQ_9d506a04-6407-440c-b6c6-bd7d2434eeed"
      unitRef="usd">2200000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="i7deb271d98c249298506cf1f896e57cb_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNC0xLTEtMS05MTI4NA_27ac103b-efe1-4d72-a246-cf674023b77d"
      unitRef="usd">2400000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="iffc6765500b949268c476664a96a2cc3_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNC0zLTEtMS05MTI4NA_eb72502b-c3bd-4803-bf4a-99498852b272"
      unitRef="usd">3300000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNi0xLTEtMS05NTQ0NQ_bd35f431-402d-4eaf-902e-5e18f3e7ea9c"
      unitRef="usd">28500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="id735715fbe6545b19ac836411202a5f0_D20210401-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNi0zLTEtMS05NTQ0OA_a24be725-6383-4462-9514-ad4929f658d9"
      unitRef="usd">18500000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNS0xLTEtMS05MTI4NA_23cbb4cc-e512-4a53-bdae-d3486f38864b"
      unitRef="usd">45100000</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="ia7a8aca92a774c7aa84a62b8e3e43611_D20210101-20210630"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84Mi9mcmFnOjYzMmJkZjIwYzg5MjQ1ZWZhMGZkZWY0MTBmMmVjMTQ1L3RhYmxlOjZiZTA2NDA3YzJmZDQxNGViYjE3ZDM0ZmY2OTBmM2VjL3RhYmxlcmFuZ2U6NmJlMDY0MDdjMmZkNDE0ZWJiMTdkMzRmZjY5MGYzZWNfNS0zLTEtMS05MTI4NA_186d7722-cb4d-402f-82a8-62bc48c343ca"
      unitRef="usd">32100000</us-gaap:Depreciation>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630"
      id="id3VybDovL2RvY3MudjEvZG9jOjRlZjQyNTMxMDA5OTRmOTg5ZmQ3MmQxYzBmZDQxZDI1L3NlYzo0ZWY0MjUzMTAwOTk0Zjk4OWZkNzJkMWMwZmQ0MWQyNV84OC9mcmFnOjBmOTgzMWE5NTFkNjRlYTE4MzE5NmZhNDBlY2Q4ZjgyL3RleHRyZWdpb246MGY5ODMxYTk1MWQ2NGVhMTgzMTk2ZmE0MGVjZDhmODJfOTA2MA_cffd73e9-7dd6-4c39-a7af-6ee91aa51cbd">Commitments and contingencies&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;Securities and shareholder litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 20, 2021, May 14, 2021, and June 2, 2021, putative class action lawsuits were filed against the Company and certain of its current and former senior officers in the United States District Court for the District of Maryland on behalf of purchasers of the Company&#x2019;s common stock, seeking to pursue remedies under the Securities Exchange Act of 1934. These complaints were filed by Palm Tran, Inc. &#x2013; Amalgamated Transit Union Local 1577 Pension Plan; Alan I. Roth; and Stephen M. Weiss, respectively. The complaints allege, among other things, that the defendants made false and misleading statements about its manufacturing capabilities with respect to COVID-19 vaccine bulk drug substance (referred to herein as CDMO Manufacturing Capabilities). These cases were consolidated on December 23, 2021, under the caption In re Emergent BioSolutions Inc. Securities Litigation, No. 8:21-cv-00955-PWG (the Federal Securities Class Action). The Lead Plaintiffs in the consolidated matter are Nova Scotia Health Employees&#x2019; Pension Plan and The City of Fort Lauderdale Police &amp;amp; Firefighters&#x2019; Retirement System. The defendants filed a motion to dismiss on May 19, 2022 and the Lead Plaintiff filed an opposition to that motion on July 19, 2022. The defendants believe that the allegations in the complaints are without merit and intend to defend the matters vigorously. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot reasonably estimate the possible loss or range of loss, if any, that may result from the consolidated action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;With respect to the specific legal proceedings and claims described below, unless otherwise noted, the amount or range of possible losses is not reasonably estimable. There can be no assurance that the settlement, resolution, or other outcome of one or more matters, including the matters set forth below, during any subsequent reporting period will not have a material adverse effect on the Company's results of operations or cash flows for that period or on the Company's financial condition.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 29, 2021, Lincolnshire Police Pension Fund (&#x201c;Lincolnshire&#x201d;) and on August 16, 2021, Pooja Sayal, filed putative stockholder derivative lawsuits in the United States District Court for the District of Maryland on behalf of the Company against certain of the Company's current and former officers and directors for breach of fiduciary duties, waste of corporate assets, and unjust enrichment, each allegation related to the Company&#x2019;s CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On November 16, 2021, both cases were consolidated under the caption In re Emergent BioSolutions Inc. Stockholder Derivative Litigation, Master Case No. 8:21-cv-01595-PWG. On January 3, 2022, the Lincolnshire complaint was designated as the operative complaint in the consolidated action. On April 13, 2022 the Court approved the parties joint stipulation to and stay of the proceedings and discovery until the close of fact  discovery in the Federal Securities Class Action. The defendants believe that the allegations in the complaints are without merit and intend to defend the matter vigorously.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 15, 2021, September 16, 2021, and November 12, 2021, putative stockholder derivative lawsuits were filed by Chang Kyum Kim, Mark Nevins and Employees Retirement System of the State of Rhode Island, North Collier Fire Control and Rescue District Firefighters Pension Plan, and Pembroke Pines Firefighters &amp;amp; Police Officers Pension Fund in The Court of Chancery of the State of Delaware on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duties, unjust enrichment and insider trading, each allegation related to the Company&#x2019;s CDMO Manufacturing Capabilities. In addition to monetary damages, the complaints seek the implementation of multiple corporate governance and internal policy changes. On February 2, 2022, the cases were consolidated under the caption In re Emergent BioSolutions, Inc. Derivative Litigation, C.A. No. 2021-0974-MTZ with the institutional investors as co-lead plaintiffs. On March 4, 2022, the defendants&#x2019; filed their Motion to Dismiss the plaintiffs&#x2019; complaint. However, ruling on this motion is stayed pursuant to a March 29, 2022 Order staying all proceedings pending a final, non-appealable judgment in the Federal Securities Class Action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 3, 2021, December 22, 2021 and January 18, 2022, putative stockholder derivative lawsuits were filed by Zachary Elton, Eric White and Jeffrey Reynolds in the Circuit Court for Montgomery County, Maryland on behalf of the Company against certain of its current and former officers and directors for breach of fiduciary duty, unjust enrichment, waste of corporate assets, failing to maintain internal controls, making or causing to be made false and/or misleading statements and material omissions, insider trading and otherwise violating the laws, each allegation related to the Company&#x2019;s CDMO Manufacturing Capabilities.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The complaints seek monetary and punitive damages. On February 22, 2022, the Court entered an order consolidating these actions under case number C-15-21-CV-000496. On March 9, 2022, the parties filed a Joint Stipulation of Stay of Proceedings and Discovery, pursuant to which the &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;parties have agreed to stay all proceedings until thirty (30) calendar days after a ruling on defendants&#x2019; motion to dismiss filed in the Federal Securities Class Action. The Court approved the Joint Stipulation on March 14, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; addition to the above actions, the Company has received preliminary inquiries and subpoenas to produce documents related to these matters from Representative Carolyn Maloney and Representative Jim Clyburn, members of the House Committee on Oversight and Reform and the Select Subcommittee on the Coronavirus Crisis, Senator Murray of the Committee on Health, Education, Labor and Pensions, the Department of Justice, the SEC, the Maryland Attorney General&#x2019;s Office, and the New York Attorney General&#x2019;s Office. The Company is producing and has produced documents as required in response and will continue to cooperate with these government inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Demi',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intellectual property&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Emergent BioSolutions&#x2019; Adapt Pharma subsidiaries (Emergent) are as follows: Emergent Devices Inc. (EBPA), formerly known as Adapt Pharma Inc.; Emergent Operations Ireland Limited (EIRE), formerly known as Adapt Pharma Operations Limited; and Emergent BioSolutions Ireland Limited (EIR2), formerly known as Adapt Pharma Limited.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;ANDA litigation - Teva 4mg&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Emergent&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; BioSolutions&#x2019; Adapt Pharma subsidiaries EBPA and EIRE, and Opiant Pharmaceuticals Inc. (Opiant) received notice letters from Teva Pharmaceuticals Industries Limited and Teva Pharmaceuticals USA (collectively, Teva) that Teva had filed an Abbreviated New Drug Application (ANDA) with the FDA seeking regulatory approval to market a generic version of &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;NARCAN&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (naloxone &lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;HCI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;) Nasal Spray 4 mg/spray before the expiration of certain patents listed on the FDA&#x2019;s website for Approved Drug Products with Therapeutic Equivalence Evaluations&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(Orange Book Listed Patents) for NARCAN. Teva&#x2019;s notice letters alleged that claims of certain Orange Book Listed Patents for NARCAN were invalid and/or would not be infringed by the activities described in Teva&#x2019;s ANDA. Emergent and Opian&lt;/span&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;t filed complaints against Teva in the U.S. District Court for the District of New Jersey alleging infringement of certain Orange Book Listed Patents for NARCAN. On June 5, 2020, the U.S. District Court for the District of New Jersey ruled in favor of Teva. Emergent unsuccessfully appealed the decision to the Court of Appeals for the Federal Circuit (CAFC) and followed with a petition for rehearing that was ultimately denied on May 5, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"&gt;&lt;span style="color:#19415e;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline"&gt;ANDA litigation - Teva 2mg&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#2c2c2c;font-family:'Franklin Gothic Book',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Emergent BioSolutions&#x2019; Adapt Pharma subsidiaries EBPA and EIRE, and Opiant received a notice letter from Teva that Teva had filed an ANDA with the FDA seeking regulatory approval to market a generic version of NARCAN&#xae; (naloxone HCI) Nasal Spray 2 mg/spray before the expiration of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#xae;. Teva&#x2019;s notice letter alleged that claims of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN&#xae; were invalid and/or would not be infringed by the activities described in Teva&#x2019;s ANDA. Emergent and Opiant filed complaints against Teva in the U.S. District Court for the District of New Jersey alleging infringement of certain Orange Book Listed Patents for the 2 mg/spray dose of NARCAN. This case is currently stayed and it is anticipated the matter will be dismissed.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>103
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M,@JBM0%\_\"YVMWH7Q3VOR!M_@=02P,$%     @ (9 !5:)'_90* P  _0H
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M1V3@^GTF&O>[VVOBNRKN1,$?2AL'D=U]D%$G\7Z@/^D"MANUB2X,OV&^(9E
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M2HLJ46YEJ7Y-E9Y<K7FQ56%G6Z0^"9ZEVT2JBUNI_JA\D +Q'?KMR,JDBJM
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MA#VS.P?$ N.@-8; PB[MZ%NI>R3JY"$=ZK1;<HH6.46+7:'UXZ&[)6KOEEY
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M6@"^;SE7SQ-MH'UZ)5\!4$L#!!0    ( "&0 56O-O= W@<  #PE   8
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MC='O#Y_0]]_]@+Y#O$*?>5' ;*B;J08P1N4T:U_\L7DQ'GCQ#'T6E=XH]",
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M:[LS4\XTZC-S^S @G$X];J@<A%E_-MAGV;=_Q@0TV\Q\?O)&MI&C/+L<!9B
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MDT+ATH!MJHJ;^TN4>C=C8_8P<24VI?,343:M^0:OT7VOEX:\J&<I1(7*"JW
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MB*[2<PB%2WT#") F$#+0Q0DN-*YR='.S0U1K5"=LAHL)=U0\&X[#&X0C/-<
M.E$A:\6PDVF7-17=17Z?;]BKG\<W8[&T2$K# ;/_^>:7 X043&B;90$QZ$1C
M$4HUY1-.[>]\;VW.FK^#YF*6HX1H C368O_]N]DPZ 7>-12)$(#.F+>HL-9P
MF8PA1P&'"GZG0C1J+%/*^;&8(6F:K&#+BSNUX:R',0A*8;/!D=U5O>SZ9:OH
MH;A4.44C9&M,4*Y"=+%@^Y=GEP?;<PC>* FA H1@2P[>I?2[:1.*G_5RA_+M
M8>9WP41[NU1,<KY\(.;9)6I)6O_#=S\_/YF^$K,O+WX^_AD?)R].7HE1Q,7.
M[X]#8ZXH-1(R8 6'NU'W02 CE&NK5BB<O!<IP*&$0T3Z<(@4M60;.K@N-J6\
MUVSOE)($H6 I# W.5G 1A5P@]1W%^D+#N+DXE9DNR\:G>S*<T1X<[8/0X^@N
M)?(4J.H1%4"3/)X:M:-+4#!N6=!@6T.0J.3]&XH]!901'UDGKK8VNZMUJ<3^
MS<>; YRC:;'E#(M!32Z-08V(?=49N;NG,S,ML0:BM28"UH-!;I,"^T>=,-&T
MI4 D#"Q'3G_2KJTCDGVW$LW.9I?@P\<[)*)J5:K#W%(EJU"5:GO_E)@L922M
M0E=5TU(9(9?@VCYL#VF]S.& -*2"E2O*&!R=DR7G2((@"C!4 =2]XY7=]A;"
M3<^PL]L=&A2J#A*^B'4KZ&#OM=DI.ADP5=@S:60N.Y,'JK><.##CW(:FU+[:
M7GSV\=?#X\GS[>6R]);(OW(NJH+P^W+QR\67GERU+3=9R;%$8LUMONDC_U^4
MD,Z.M$)DR@78F,$+FV7D #%UAIZ30[M=(T#F*&:5G,.L_XUF)6Q:-,1""KP
M=%IC_ZZXC\W',3J,2FT*6;99E4*T%YK\P.MRAV?_/Q;<Z>.GA;J^>??;#GFJ
MA/QMI28N,KP]4%14@&&", ,ID<?ZJWI A%JJ(];2+7 $<H=+$;N2EOH[;5Z*
M(.<-W.0ET O_6'AI)#*R2*'N-V7[XLLU_OM])"K4.^ERL901*FX/IX)S(9*9
M5K=;9^=Z20N3@C+ 7Y3M .,%DU0LR+&Q@HI%"7J&&CC[?/OI\.+CK^=GMY^N
M4]WH,Y4^@Y%-L(<QSBCUOUU=.E)#R/%(#I;ZL2AC<1$8[HE<S!4HUD.&P6 *
MEI1(2"< 7K<I!!$+G/853WLD9MYL@%-/TI]8VX**O(L0.I5$="O1C5"HSPO&
MG>'/Y](LY0_?_73R$S[M2^.;E49*'G[=W)6,_N )B+('L%+-YI/)26IA=B5I
MY$#XM-)4-1B;==BD-H;.*1QS,IG 7EQ\(71M>(*Q,SO.Y[:48_&9#<%OH4\L
M,5"O+.7<IMK/EU_K?*D ,'=4^OKD=K3MUM:HX03XJ6W2\U)U=P\Z#0KX,G5*
MU"PPX4WD=FA"'1N,ST839^#N.$9^3/QXQ$"V*(6/SHI4,C6%@$V"6+1X ;YD
MR0:7C?L\[A&M^CB[/IM];!-J'^ZQ]\2U/YR5!V 4GNA$[>0F8@EX#>JD42I'
MX5TXQ8:HFK)K^;O].R+[,<!MB<.V4QEX\\[8M2% ZA&L6EN-?Q#Z7/DISJ1!
M8^Q#O(W<A'!" F_HQB-B9(H:Q9)CG1HKO\'B"F!8<]-+!>=:T:(RZ=F2]PZF
MY3#QB.8 Q?L*&[:5)UM1^-_@:OMUB\M?Y'V&[;*S]%EA2X0;7C!A&8G?P$M&
MXA/D//@&R;&DPU,$APQ,?Y\WP",%F9GP$W$7LVC=_?/+V4%G]9K;K=9W691H
MB+E?],H&O>C$OMW4!=D_B<U2L]#B=C.=R+[H?RKN;C%"NF&!AVZ\[3(.:>(4
M^_UW#_K]RT&__V#D\%27@ON 6-A$TQ1<-Y@DM#M'7"+:KC5[E/3\MBT1#]Z1
M=.L"2&\49:ET"##?(.M%G!-%)C3"&IT5%)#*\/B&X$VV[=(0QP'294YXE!$8
M >8H/$5)A)6;"F+#K<XR,NT(IC)SUD?HJ OI*IDQU#$@YS2Z""HK#(TL-@"H
MO"$ HS/0JRI@3T(=:EEX%&3-X;8 X1#;FP[ZA^U?[^@::$&HL9T!5;(""=3$
M$4 NJ,C3Q(1KPHB6@R+&EC-?D0GRQ*1(."@ ED(6"X/[,@O-,UG+.=X'G<K?
M<"Z$+ V%!IL@Z*0EU J &J&A;XV2;9%SGXDJ/^5N[4!XK(+)9WFN$QM[V-<"
M+\OR:$$3@F* E*P-=FQ"R\H>11T+'*F(I(K#E((41YN/D"V[<0BBAZ^C@1+E
M#Y$&*@BY\GH)D[+I^1HDC_&(]]$#0Z #26-<G(4PJHFADN@<PN4&G)BLG.:^
M4(?F-JA+DJ=/W-"':&@:=S2Y5GQ.%S;#VR#B2B?[(O,/Z2+XU&_H;2PH-$"D
MD0BUV#5IVH;,<+0"C'.Q<B+ UC9]ICN\6O*T^:68'&RG7+Y]+O:ONO$49Y$/
M23**HD>S""[,WYB%^#0,Z=S67=$"U\$CT-G_B%03DY,1P"TN!J=AM6'@@[&X
M2B PR_YHM.?@$I\ YJ@LDV=QFC\L4XI8&R[0AHB7$3/O51!7C<L*:F-G2U3J
M*!3M B^83H]?/7[-+R:O@.'S3<0$%=9$4_MWL3$*T%JG[T>]X74Z]08^5VY[
M4MTXWX#B4;9%D!L<1E<S7:Q;:;B3B*?PO$+=M[&]MJ[,UT3I'7TSY+D/1]!D
MX-D+8)Q+B<"VNSV_/#W_?=8V"CSU1A3Q(,C3G*TO]"TEAN3>LI5\W)Z0V&OJ
MGX8,>=CV__UQ(6C@KPVJ$CPZV<E9Z<-C/PV=S\2P1FQ\/YT^&Q\#0I&X.+P!
M606:6=\+[9ZBA*R@0DU-9OQ^<GS<VZI->KZPC<.Y_6/Q+Z@6CV/EAI,L)N6.
M:"-FG^F:4Y0;)IY71=>RU PEU&22HXU:@FFDT0"3<UH.ZMO:?M;"_S5JG,1M
MT:X][)Q%B@88VD^>/9U=OYNU/HW#=_)?RI2VP:IB\Y/813\R>']'/+J#6+SX
MCD(@A<JH%^%M!*,4-6B)B%IN-33+L3B76/G(F!QMWEL #<5J9P9U3^#C&> 7
M#<]XX_5]#6P=C8<U;?!N.W<VYD ;_O*5YEO:YM&';;2TPK1\\K'/@>D;'H+E
M_VV8>#?UFAIS&",'9>>_Z7@&/8)^*AD]45%RVBG_UE(\FE*E7G*+Q0.)3%'F
MMT$Z'3_KQZA32RJH1/0["7>;[V9340]U-: ]7OP6H/@ 0A)/Y;KFD"S+]*UE
M&OEYWU3;!.^^.3(/DVN@&9DJJB8=,8SI\3^$LQOT01OF>=&=2R9GL-%"A[X'
M=[>*#W1<V1*"X?F<!CB3\8O.3-MV"M#EZ,ND" 7@3QN1)R+$ 19AEMMO#HF>
M$&/QJ0G$-5L<&4@S^@9,1:4E!:#OYT3H+#%Y-K $\:N!&1ZJV=J$VFS_EZ6/
MO"Y^OW(8[&'\B\)3^V'<:_JR94Z4*Y)#SKLL]O#)YTF'9(=A0D5#>"2X7\0X
MH'Q82[W:[M@F9"1S[=5 GT@CP5GV]0&O==R?MM^H1Z:QYK",='7QJ##W)$S#
M*68%WW)0_(XDN$8EM@ND(C5Z1FC'3B GL*M,' ^KD>$>_:"&K(J@[&EI"KEB
M8%&.AT5YRZ[K4O?R%/E'W;N*,WKJR(RD[-,Q-EH9VD7Q_F0LF#FD*\C]*,8T
M:$Y 0@N(Z-$/9;H^<YBR:79&3S^@'SB\R6P(A]<6;,+2J%?#3#Z(BXJ+?$2%
M6<:I.OGYQ7,FO!*/T6F-6G75?:W!RTC,5922OE!'-&RXWVXG>H:^)4)K".A$
MGT<G]YF,C+P]TL!M9]>KLI%'Q^_[^>N,] KWKMI( I#6(7[30B,2$$LBC&03
M.H-)5PQFRLYAB=QU]!9:D\/I+G@"MD+/TI@N^F.4QY[!.K)PV^VGU/TSM^SZ
M8<=1[^<Y/#BB'R'Y2,[B+W6ZI]WOG&;QYSW;Y?%'4I>2OD,'EU<+;#T>OWBV
M%^EE^R'8FG_L,T<XV(K_+)2$(K0 [Q<69#Y]H NZ7W^]_1]02P,$%     @
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MD"M>?Q95',$QF0-OQK%8>FU@[  BLT*:C>)N'U90(G/DGO^*-?_S.HR!9I^
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MC_=']->>.W%9,X-+)3[QTNZFP74 )6Y8(^P'M7^#!SX#AU<H8?P_[%O=?!1
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MKBC+DR0NY>;'FSJ<Y7/C<3,(GRM<Q<CR /0O#/:W]H<GV%[N9O\!4$L#!!0
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M@=,45UBNN,JEGDZ=$LT&E0B9@M4M4%19:=&GU$XCRS%841^B*M3G)&J]V03
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M&SP==/LI1T+7P!2F@MN.2Q=FN_V,-![TKRY!MY"J*,@\%*M?*G8,J3$=),*
MXD,C$><S.F1+U48XF8]F"5C?0#>.MF0.94L"9"M@(&Y05E)/%)@VF18PN'#3
M9.6EH=$$ZI7.Y#A>-5Q,V$K$8M5(#\.I+G=W2NFAS"TP%:>I[$X]*B/F!R*H
MU&#LLW(S?GE4V-IJ;\*ABDRQPLK8WS4ICM&!^ PM7/%M@8#_AGES\OH.!X[$
M/6XH")7_<)T3'V]N"7MP3^S;:4LGX-(M:3MM=+EX-9#IX\U=,LDMLJYZ@?T?
MP.CGC9U1XT$_[7RJV!M+>!+9/AV:!5Z)T_$"OZ]/Q[.C[0FJ3IBN:6,^7AS1
M_V(\/3ITSY\,/N-4RJ_X8U5(R9V^Z/2K_?>PJ_09:'L\?4S[4?H5W0>,*D Z
M';]],T*>\ >J]!)=S1^%4&VBJ_BQ5!)Y0P>P7S@7NQ=BT'\EO/PO4$L#!!0
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M#<%6?+E4$G%#"_!\;FUH?M &[;]P7/T74$L#!!0    ( "&0 55])C]V:@\
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MMURW.?EX3,U55&N/"[@HS.L.I^^5!APC0>=*5;O#N/8Y#J O[(YT%0\KD(A
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MK_0\7UE:@/L+8^KX@PYHWT]^]U]02P,$%     @ (9 !58@\%, . P  10<
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M+W-H965T,C N>&ULQ5=M;]LV$/XK![7H.B"1Y=>DJ6T@+QW6 @V"9EL_#/M
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MM3A&"7J+YL'!?[^U+YK@(9V50F <)>P.8Q04'#&P5QC/(G ^QX BJ;=ZQIY
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MBC;@^4)KM_E!!W1O-B__ U!+ P04    "  AD %5;!WK1G<'  ")%   &0
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M/NN$NW\7) .6(532..#8/"WRLWI R)W>.W9[?>L""8Q;H3.)3#0@*.<^S.G
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M;&X8?BVV7AY^<P>V/*,IKE%3;.UU'Q_M"!=^QQ8^E+;@WXY-+,AQQG\"1H!
MM #OI]:6]0<ZH/DQX8L_ 5!+ P04    "  AD %5DM9H@98+  #5'P  &0
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MS BIGJ,K)K.Y_P[V2L;AND>9#T6P&6=/63+*O-8D>\'%OZ)=U*#XP$*[HFN
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M><$LFTVT:D&[:&)S$Y^J1Y,X+MU/N;>:3CGA[.Q:/J.T2G,TQR"I"3X\L(5
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M?EK1QP:U,Z#SC5+VL' .^L_7XC=02P,$%     @ (9 !5>)L$%YY P  A @
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M])N VBV@^;U2]OSA-FA^/-;_ E!+ P04    "  AD %5<"D5'J4#  ! "0
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M'-3N IUOE+*'A5/0?C0M_P502P,$%     @ (9 !5:WUTR#%!   MPP  !D
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M4+$ >H&;)V1@GB2Z(/^>L&@8A+OA]:MQ%$8?]V;A, H&C?%GF0>D3S1MJ:U
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M5=N)OV%G")^T<KF%GU2*Z:Y^1)Q;XO&:^%7<"?A+I4(8](XA[L5Q!]Z@=<3
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M*<FB%"MTE-$OB2CQ'O)<WGMY)'JVY>*K7%.JT&.:9/+"6RNU.?=]&:UI2N2
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M_;&Q3PQHYV#M>Z7P*+@$TZ.5_P502P,$%     @ (9 !5;9[RSFF @  ]P8
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M-9HP+ILPOLHB,3[1H ]K<_]86$N0>TZGDY+PI)/P?4YH3-*M&(!U<=B0K*F
M8N4:=HP^K^;.AUTZD#V!-?H"G<HE.%?3<P'=4Q_Z0FLVHF:7X%4T7<#Z-;VZ
M$^^)IHN@NJC=8%+[;VF2KAP+[/0"\X\Y3XG,.6[2;>79JT7I"ZU9=V52H'<]
MU78:H(L;T1-:LQ&5\8'=SN?%JCVU,;X;#D]TVQ(&O:%_1K>5VX'==F?%-O*
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MB3@!YS2UVZ+>R_;:7NR2+.Z2+.F(;*<D85.2\#]>%F&7!>J2+.Z2+.F(;*=
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M[[WSNW-L]S=2/>HE@"%/.1=Z$"R-*7IAJ*=+R*ENR ($?IE+E5.#7;4(=:&
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M2V--S ]7]C>#R@78_8649C=Q"9H?5_X+4$L#!!0    ( "&0 55[SW$5;0(
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M5PPMT-D2*3E.YQAH$A3-D Q!NW8/PQX8FXF)ZL,5::<%]N-'?504*^I*"AC
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M ->7C,G]0+W"*U[9SOX%4$L#!!0    ( "&0 55YJKB/?P(  +\%   9
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MV.0&;/(7K\E8\7UZ=NXO(/AD*"C]0*G9YAKZR6'79W)0T %5PU!JMI4&=/+
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M!J-8IRO<P'(;Q6L[)+9<Z=:VRU+/>!#&0+_?<:Z.&P/H_C72/U!+ P04
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M;9/EYQMY0]"E_KQ^I$)^K.O+!> I,!4@[\\H%;N&2E >,OE_ 5!+ P04
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M@=3B'O8'BW,-2'S->X.H2(<*G&$O9#0H*:S (X,WU/42R-Q+6)I (K6^A\K
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M?K]ZC]@Z(AS$>"556?VA#!K+KRSS@:#;[$[NF0I!D^QQ@]$2,P60[U>4BN-
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M5PPMT-@2*;]EB8'&TK8.+5HDZ_9AV ?5IFVMLNA)=-(!_?&C9,44Q3,=MU?
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M;E#OYB?U+N/7(9=KS_<:K_^35(_G<_/U\I?E]\[)3;C@7-]6E*>_4$L#!!0
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M96>;_BV?C?^:/'\!4$L! A0#%     @ (9 !50=!36*!    L0   !
M         ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  AD %5
M8%-E>>X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX
M;6Q02P$"% ,4    "  AD %5F5R<(Q &  "<)P  $P              @ ',
M 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "&0 57E I@8ZP4
M .X>   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX
M;6Q02P$"% ,4    "  AD %5_9G2$4$&  !-&@  &               @($N
M#@  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ (9 !5:)'
M_90* P  _0H  !@              ("!I10  'AL+W=O<FMS:&5E=',O<VAE
M970S+GAM;%!+ 0(4 Q0    ( "&0 55S<WV-*P@  .<U   8
M  " @>47  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  A
MD %5Y/'-5IP#  "&#0  &               @(%&(   >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&UL4$L! A0#%     @ (9 !5:\V]T#>!P  /"4  !@
M         ("!&"0  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0
M   ( "&0 57F:7%$^ D  -EA   8              " @2PL  !X;"]W;W)K
M<VAE971S+W-H965T-RYX;6Q02P$"% ,4    "  AD %5&^3)I&("   W!@
M&               @(%:-@  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L!
M A0#%     @ (9 !53$3Q@<Z#P  "28  !@              ("!\C@  'AL
M+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( "&0 57:B _@00D
M /L8   9              " @6)(  !X;"]W;W)K<VAE971S+W-H965T,3 N
M>&UL4$L! A0#%     @ (9 !56[0.9][ @  A 4  !D              ("!
MVE$  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    "  AD %5
M$V]XDT\#  "3!P  &0              @(&,5   >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+ 0(4 Q0    ( "&0 552)@6N)P0  .@)   9
M      " @1)8  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%
M  @ (9 !5>N&I$RY P  MP@  !D              ("!<%P  'AL+W=O<FMS
M:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4    "  AD %5I:2F-:T&  #$$0
M&0              @(%@8   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+
M 0(4 Q0    ( "&0 5629\=OEP<  #$4   9              " @41G  !X
M;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ (9 !50= =B?-
M"@  SB$  !D              ("!$F\  'AL+W=O<FMS:&5E=',O<VAE970Q
M-RYX;6Q02P$"% ,4    "  AD %5?28_=FH/  "K+   &0
M@($6>@  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "&0
M 56(/!3 #@,  $4'   9              " @;>)  !X;"]W;W)K<VAE971S
M+W-H965T,3DN>&UL4$L! A0#%     @ (9 !54"E2PJ2!   10P  !D
M         ("!_(P  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
M    "  AD %5$\LCL5P'  #E%   &0              @('%D0  >&PO=V]R
M:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "&0 55L'>M&=P<  (D4
M   9              " @5B9  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL
M4$L! A0#%     @ (9 !572ZTF(4#@  6"@  !D              ("!!J$
M 'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  AD %5DM9H
M@98+  #5'P  &0              @(%1KP  >&PO=V]R:W-H965T<R]S:&5E
M=#(T+GAM;%!+ 0(4 Q0    ( "&0 55K?WZS@P(  '<%   9
M  " @1Z[  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @
M(9 !53_(N@,' P  R@8  !D              ("!V+T  'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6Q02P$"% ,4    "  AD %5XFP07GD#  "$"   &0
M            @($6P0  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4
M Q0    ( "&0 55P*14>I0,  $ )   9              " @<;$  !X;"]W
M;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ (9 !5:WUTR#%!
MMPP  !D              ("!HL@  'AL+W=O<FMS:&5E=',O<VAE970R.2YX
M;6Q02P$"% ,4    "  AD %5FZHFZ$8$  "]"P  &0              @(&>
MS0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( "&0 554
M:#85[ (  &\&   9              " @1O2  !X;"]W;W)K<VAE971S+W-H
M965T,S$N>&UL4$L! A0#%     @ (9 !57$Z!4BA!   %@P  !D
M     ("!/M4  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "&0 54(\\,G- (  , $   9              "
M@5SO  !X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ (9 !
M5;9[RSFF @  ]P8  !D              ("!Q_$  'AL+W=O<FMS:&5E=',O
M<VAE970S."YX;6Q02P$"% ,4    "  AD %5PLG6Y@D$  !H%   &0
M        @(&D]   >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0
M   ( "&0 57FD&A@% ,  ',,   9              " @>3X  !X;"]W;W)K
M<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ (9 !56E19]'Q @  K@D
M !D              ("!+_P  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q0
M2P$"% ,4    "  AD %5H\B)39(#   I#0  &0              @(%7_P
M>&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( "&0 55BZ?F'
M&00  /84   9              " @2 # 0!X;"]W;W)K<VAE971S+W-H965T
M-#,N>&UL4$L! A0#%     @ (9 !58R;5RZK @   @@  !D
M ("!< <! 'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  A
MD %5+YGROZX"  #$!@  &0              @(%2"@$ >&PO=V]R:W-H965T
M<R]S:&5E=#0U+GAM;%!+ 0(4 Q0    ( "&0 55[SW$5;0(  ,@%   9
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M970U,"YX;6Q02P$"% ,4    "  AD %5>:JXCW\"  "_!0  &0
M    @(&2(0$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (
M "&0 55R%M$:9@(  $H%   9              " @4@D 0!X;"]W;W)K<VAE
M971S+W-H965T-3(N>&UL4$L! A0#%     @ (9 !587#('H_ P  'PX  !D
M             ("!Y28! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"
M% ,4    "  AD %5[)@LY"T#  !H"P  &0              @(%;*@$ >&PO
M=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( "&0 55O45!0ZP,
M  84   9              " @;\M 0!X;"]W;W)K<VAE971S+W-H965T-34N
M>&UL4$L! A0#%     @ (9 !53\*Z!"3"0  Z58  !D              ("!
MX3$! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4    "  AD %5
M=,ZKL D*  !4;   &0              @(&K.P$ >&PO=V]R:W-H965T<R]S
M:&5E=#4W+GAM;%!+ 0(4 Q0    ( "&0 577;HK''0@  ()/   9
M      " @>M% 0!X;"]W;W)K<VAE971S+W-H965T-3@N>&UL4$L! A0#%
M  @ (9 !52?O:XRY P  !Q@  !D              ("!/TX! 'AL+W=O<FMS
M:&5E=',O<VAE970U.2YX;6Q02P$"% ,4    "  AD %5L7'%74$"  "M!0
M&0              @($O4@$ >&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+
M 0(4 Q0    ( "&0 55%:[V-E (  $$&   9              " @:=4 0!X
M;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ (9 !5=OCIOR"
M @  708  !D              ("!<E<! 'AL+W=O<FMS:&5E=',O<VAE970V
M,BYX;6Q02P$"% ,4    "  AD %5]SDT3&0#  !P$@  &0
M@($K6@$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( "&0
M 57 =E["TP,  (T/   9              " @<9= 0!X;"]W;W)K<VAE971S
M+W-H965T-C0N>&UL4$L! A0#%     @ (9 !5>AH^ALK!@  S#<  !D
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M=#8Y+GAM;%!+ 0(4 Q0    ( "&0 54@^X2ZG@<  $ \   9
M  " @6%Z 0!X;"]W;W)K<VAE971S+W-H965T-S N>&UL4$L! A0#%     @
M(9 !52B*L(JB P  CA,  !D              ("!-H(! 'AL+W=O<FMS:&5E
M=',O<VAE970W,2YX;6Q02P$"% ,4    "  AD %53A40R%D#  "0%@  #0
M            @ $/A@$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( "&0 567
MBKL<P    !,"   +              "  9.) 0!?<F5L<R\N<F5L<U!+ 0(4
M Q0    ( "&0 57FXZ,I;04  * N   /              "  7R* 0!X;"]W
M;W)K8F]O:RYX;6Q02P$"% ,4    "  AD %5L 4 O38"   <*@  &@
M        @ $6D $ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4
M    "  AD %5X<M&R/T!   ]*0  $P              @ &$D@$ 6T-O;G1E
C;G1?5'EP97-=+GAM;%!+!08     3P!/ * 5  "RE $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>315</ContextCount>
  <ElementCount>271</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>78</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>10</UnitCount>
  <MyReports>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Business</Role>
      <ShortName>Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2103102 - Disclosure - Basis of presentation and principles of consolidation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation</Role>
      <ShortName>Basis of presentation and principles of consolidation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2106103 - Disclosure - Inventories, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Inventoriesnet</Role>
      <ShortName>Inventories, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2109104 - Disclosure - Property, plant and equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Propertyplantandequipmentnet</Role>
      <ShortName>Property, plant and equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2113105 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2117106 - Disclosure - Intangible assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Intangibleassets</Role>
      <ShortName>Intangible assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2123107 - Disclosure - Fair value measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Fairvaluemeasurements</Role>
      <ShortName>Fair value measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2129108 - Disclosure - Derivative instruments and hedging activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities</Role>
      <ShortName>Derivative instruments and hedging activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2135109 - Disclosure - Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Debt</Role>
      <ShortName>Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2139110 - Disclosure - Revenue recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Revenuerecognition</Role>
      <ShortName>Revenue recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2147111 - Disclosure - Income taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Incometaxes</Role>
      <ShortName>Income taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2149112 - Disclosure - Net Income (loss) per share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NetIncomelosspershare</Role>
      <ShortName>Net Income (loss) per share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2152113 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2158114 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2163115 - Disclosure - Commitments and contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/Commitmentsandcontingencies</Role>
      <ShortName>Commitments and contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2204201 - Disclosure - Basis of presentation and principles of consolidation (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies</Role>
      <ShortName>Basis of presentation and principles of consolidation (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Inventories, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesnetTables</Role>
      <ShortName>Inventories, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Inventoriesnet</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2310302 - Disclosure - Property, plant and equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables</Role>
      <ShortName>Property, plant and equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Propertyplantandequipmentnet</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2314303 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Leases</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2318304 - Disclosure - Intangible assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsTables</Role>
      <ShortName>Intangible assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Intangibleassets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2324305 - Disclosure - Fair value measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsTables</Role>
      <ShortName>Fair value measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Fairvaluemeasurements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2330306 - Disclosure - Derivative instruments and hedging activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables</Role>
      <ShortName>Derivative instruments and hedging activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2336307 - Disclosure - Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtTables</Role>
      <ShortName>Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Debt</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2340308 - Disclosure - Revenue recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionTables</Role>
      <ShortName>Revenue recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Revenuerecognition</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2350309 - Disclosure - Net Income (loss) per share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NetIncomelosspershareTables</Role>
      <ShortName>Net Income (loss) per share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/NetIncomelosspershare</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2353310 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Equity</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2359311 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/SegmentInformation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2402401 - Disclosure - Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BusinessDetails</Role>
      <ShortName>Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Business</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Basis of presentation and principles of consolidation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails</Role>
      <ShortName>Basis of presentation and principles of consolidation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Inventories, net - Schedule of Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails</Role>
      <ShortName>Inventories, net - Schedule of Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails</Role>
      <ShortName>Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2412405 - Disclosure - Property, plant and equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails</Role>
      <ShortName>Property, plant and equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2415406 - Disclosure - Leases - Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails</Role>
      <ShortName>Leases - Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2416407 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails</Role>
      <ShortName>Leases - Supplemental Balance Sheet Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2419408 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails</Role>
      <ShortName>Intangible assets - Schedule of Finite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2420409 - Disclosure - Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails</Role>
      <ShortName>Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2421410 - Disclosure - Intangible assets - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails</Role>
      <ShortName>Intangible assets - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2422411 - Disclosure - Intangible assets - Goodwill Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails</Role>
      <ShortName>Intangible assets - Goodwill Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2425412 - Disclosure - Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails</Role>
      <ShortName>Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2426413 - Disclosure - Fair value measurements - Contingent Consideration Roll Forward (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails</Role>
      <ShortName>Fair value measurements - Contingent Consideration Roll Forward (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2427414 - Disclosure - Fair value measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair value measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2428415 - Disclosure - Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2431416 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2432417 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2433418 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2434419 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails</Role>
      <ShortName>Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2437420 - Disclosure - Debt - Schedule (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtScheduleDetails</Role>
      <ShortName>Debt - Schedule (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2438421 - Disclosure - Debt - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/DebtNarrativeDetails</Role>
      <ShortName>Debt - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2441422 - Disclosure - Revenue recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails</Role>
      <ShortName>Revenue recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2442423 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails</Role>
      <ShortName>Revenue recognition - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2443424 - Disclosure - Revenue recognition - Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails</Role>
      <ShortName>Revenue recognition - Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2444425 - Disclosure - Revenue recognition - Remaining Performance Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails</Role>
      <ShortName>Revenue recognition - Remaining Performance Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2445426 - Disclosure - Revenue recognition - Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails</Role>
      <ShortName>Revenue recognition - Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2446427 - Disclosure - Revenue recognition - Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails</Role>
      <ShortName>Revenue recognition - Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2448428 - Disclosure - Income taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/IncometaxesDetails</Role>
      <ShortName>Income taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/Incometaxes</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2451429 - Disclosure - Net Income (loss) per share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/NetIncomelosspershareDetails</Role>
      <ShortName>Net Income (loss) per share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://emergentbiosolutions.com/role/NetIncomelosspershareTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2454430 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2455431 - Disclosure - Equity - Schedule of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails</Role>
      <ShortName>Equity - Schedule of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2456432 - Disclosure - Equity - Changes in Accumulated Other Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails</Role>
      <ShortName>Equity - Changes in Accumulated Other Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2457433 - Disclosure - Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails</Role>
      <ShortName>Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2460434 - Disclosure - Segment Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2461435 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails</Role>
      <ShortName>Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="ebs-20220630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2462436 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails</Role>
      <ShortName>Segment Information - Schedule of Segment Reporting Information, by Segment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="ebs-20220630.htm">ebs-20220630.htm</File>
    <File>a200-2017x92634xmod28exe.htm</File>
    <File>a200-2017x92634xmod29exe.htm</File>
    <File>a311-kramercert63022.htm</File>
    <File>a312-lindhalcert63022.htm</File>
    <File>a321-kramercert63022.htm</File>
    <File>a322-lindhalcert63022.htm</File>
    <File>ebs-20220630.xsd</File>
    <File>ebs-20220630_cal.xml</File>
    <File>ebs-20220630_def.xml</File>
    <File>ebs-20220630_lab.xml</File>
    <File>ebs-20220630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>ebs-20220630_g1.jpg</File>
    <File>ebs-20220630_g2.jpg</File>
    <File>ebs-20220630_g3.jpg</File>
    <File>ebs-20220630_g4.jpg</File>
    <File>ebs-20220630_g5.jpg</File>
    <File>ebs-20220630_g6.jpg</File>
    <File>ebs-20220630_g7.jpg</File>
    <File>ebs-20220630_g8.jpg</File>
    <File>ebs-20220630_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="973">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="29">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>109
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "ebs-20220630.htm": {
   "axisCustom": 0,
   "axisStandard": 31,
   "contextCount": 315,
   "dts": {
    "calculationLink": {
     "local": [
      "ebs-20220630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "ebs-20220630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "ebs-20220630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "ebs-20220630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "ebs-20220630_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "ebs-20220630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 494,
   "entityCount": 1,
   "hidden": {
    "http://emergentbiosolutions.com/20220630": 1,
    "http://fasb.org/us-gaap/2022": 17,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 23
   },
   "keyCustom": 22,
   "keyStandard": 249,
   "memberCustom": 20,
   "memberStandard": 56,
   "nsprefix": "ebs",
   "nsuri": "http://emergentbiosolutions.com/20220630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://emergentbiosolutions.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103102 - Disclosure - Basis of presentation and principles of consolidation",
     "role": "http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation",
     "shortName": "Basis of presentation and principles of consolidation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106103 - Disclosure - Inventories, net",
     "role": "http://emergentbiosolutions.com/role/Inventoriesnet",
     "shortName": "Inventories, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109104 - Disclosure - Property, plant and equipment, net",
     "role": "http://emergentbiosolutions.com/role/Propertyplantandequipmentnet",
     "shortName": "Property, plant and equipment, net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113105 - Disclosure - Leases",
     "role": "http://emergentbiosolutions.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117106 - Disclosure - Intangible assets",
     "role": "http://emergentbiosolutions.com/role/Intangibleassets",
     "shortName": "Intangible assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2123107 - Disclosure - Fair value measurements",
     "role": "http://emergentbiosolutions.com/role/Fairvaluemeasurements",
     "shortName": "Fair value measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2129108 - Disclosure - Derivative instruments and hedging activities",
     "role": "http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities",
     "shortName": "Derivative instruments and hedging activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135109 - Disclosure - Debt",
     "role": "http://emergentbiosolutions.com/role/Debt",
     "shortName": "Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2139110 - Disclosure - Revenue recognition",
     "role": "http://emergentbiosolutions.com/role/Revenuerecognition",
     "shortName": "Revenue recognition",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147111 - Disclosure - Income taxes",
     "role": "http://emergentbiosolutions.com/role/Incometaxes",
     "shortName": "Income taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2149112 - Disclosure - Net Income (loss) per share",
     "role": "http://emergentbiosolutions.com/role/NetIncomelosspershare",
     "shortName": "Net Income (loss) per share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2152113 - Disclosure - Equity",
     "role": "http://emergentbiosolutions.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2158114 - Disclosure - Segment Information",
     "role": "http://emergentbiosolutions.com/role/SegmentInformation",
     "shortName": "Segment Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2163115 - Disclosure - Commitments and contingencies",
     "role": "http://emergentbiosolutions.com/role/Commitmentsandcontingencies",
     "shortName": "Commitments and contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2204201 - Disclosure - Basis of presentation and principles of consolidation (Policies)",
     "role": "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies",
     "shortName": "Basis of presentation and principles of consolidation (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Inventories, net (Tables)",
     "role": "http://emergentbiosolutions.com/role/InventoriesnetTables",
     "shortName": "Inventories, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310302 - Disclosure - Property, plant and equipment, net (Tables)",
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables",
     "shortName": "Property, plant and equipment, net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314303 - Disclosure - Leases (Tables)",
     "role": "http://emergentbiosolutions.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318304 - Disclosure - Intangible assets (Tables)",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsTables",
     "shortName": "Intangible assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2324305 - Disclosure - Fair value measurements (Tables)",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables",
     "shortName": "Fair value measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2330306 - Disclosure - Derivative instruments and hedging activities (Tables)",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables",
     "shortName": "Derivative instruments and hedging activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336307 - Disclosure - Debt (Tables)",
     "role": "http://emergentbiosolutions.com/role/DebtTables",
     "shortName": "Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2340308 - Disclosure - Revenue recognition (Tables)",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionTables",
     "shortName": "Revenue recognition (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2350309 - Disclosure - Net Income (loss) per share (Tables)",
     "role": "http://emergentbiosolutions.com/role/NetIncomelosspershareTables",
     "shortName": "Net Income (loss) per share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2353310 - Disclosure - Equity (Tables)",
     "role": "http://emergentbiosolutions.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2359311 - Disclosure - Segment Information (Tables)",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationTables",
     "shortName": "Segment Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "reportCount": 1,
      "unique": true,
      "unitRef": "category",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402401 - Disclosure - Business (Details)",
     "role": "http://emergentbiosolutions.com/role/BusinessDetails",
     "shortName": "Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "ebs:NumberOfCategoriesOfPublicHealthThreats",
      "reportCount": 1,
      "unique": true,
      "unitRef": "category",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Basis of presentation and principles of consolidation (Details)",
     "role": "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
     "shortName": "Basis of presentation and principles of consolidation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408403 - Disclosure - Inventories, net - Schedule of Inventory (Details)",
     "role": "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails",
     "shortName": "Inventories, net - Schedule of Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)",
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails",
     "shortName": "Property, plant and equipment, net - Schedule of Property, Plant, and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Operations",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
     "shortName": "Condensed Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i11d6b9ed7cef4daf9b8dc0c61d4b8f0b_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412405 - Disclosure - Property, plant and equipment - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
     "shortName": "Property, plant and equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415406 - Disclosure - Leases - Components of Lease Expense (Details)",
     "role": "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails",
     "shortName": "Leases - Components of Lease Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416407 - Disclosure - Leases - Supplemental Balance Sheet Information (Details)",
     "role": "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails",
     "shortName": "Leases - Supplemental Balance Sheet Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419408 - Disclosure - Intangible assets - Schedule of Finite-lived Intangible Assets (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails",
     "shortName": "Intangible assets - Schedule of Finite-lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420409 - Disclosure - Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails",
     "shortName": "Intangible assets - Finite-lived Intangible Assets Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2421410 - Disclosure - Intangible assets - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails",
     "shortName": "Intangible assets - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i72306a994b9b4e40b4c06153d3cccd44_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2422411 - Disclosure - Intangible assets - Goodwill Roll Forward (Details)",
     "role": "http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails",
     "shortName": "Intangible assets - Goodwill Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425412 - Disclosure - Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
     "shortName": "Fair value measurements - Fair Value Hierarchy of Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i72306a994b9b4e40b4c06153d3cccd44_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426413 - Disclosure - Fair value measurements - Contingent Consideration Roll Forward (Details)",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails",
     "shortName": "Fair value measurements - Contingent Consideration Roll Forward (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i72306a994b9b4e40b4c06153d3cccd44_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427414 - Disclosure - Fair value measurements - Additional Information (Details)",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails",
     "shortName": "Fair value measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2428415 - Disclosure - Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)",
     "role": "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails",
     "shortName": "Fair value measurements - Fair Value Level 3 of Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i7b0124a24a6d42f38a22a139d7a986cc_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i64a444e1b04f441690465f4274c0ba71_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431416 - Disclosure - Derivative instruments and hedging activities - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails",
     "shortName": "Derivative instruments and hedging activities - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i64a444e1b04f441690465f4274c0ba71_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i5baf28559b9c4518961b9d35563505d5_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "instrument",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2432417 - Disclosure - Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
     "shortName": "Derivative instruments and hedging activities - Derivative Designated as Cash Flow Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i5baf28559b9c4518961b9d35563505d5_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfInterestRateDerivativesHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "instrument",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i8fef5a8c0e574704b4e7fc1c219ab3d0_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2433418 - Disclosure - Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
     "shortName": "Derivative instruments and hedging activities - Fair Value by Balance Sheet Location (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i8fef5a8c0e574704b4e7fc1c219ab3d0_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeAsset",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i64a444e1b04f441690465f4274c0ba71_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434419 - Disclosure - Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)",
     "role": "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
     "shortName": "Derivative instruments and hedging activities - Cash Flow Hedging on AOCI (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i64a444e1b04f441690465f4274c0ba71_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437420 - Disclosure - Debt - Schedule (Details)",
     "role": "http://emergentbiosolutions.com/role/DebtScheduleDetails",
     "shortName": "Debt - Schedule (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438421 - Disclosure - Debt - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
     "shortName": "Debt - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i72306a994b9b4e40b4c06153d3cccd44_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:DeferredFinanceCostsCurrentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2441422 - Disclosure - Revenue recognition - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
     "shortName": "Revenue recognition - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i72306a994b9b4e40b4c06153d3cccd44_I20211231",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442423 - Disclosure - Revenue recognition - Disaggregation of Revenue (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
     "shortName": "Revenue recognition - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i574f9adb7940424798f2d99703583daa_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2443424 - Disclosure - Revenue recognition - Performance Obligations (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails",
     "shortName": "Revenue recognition - Performance Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ie098330be0d142e7842c556f7a93810f_I20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i5c1bb85380c94c46946e590854b1feb8_I20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2444425 - Disclosure - Revenue recognition - Remaining Performance Obligation (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails",
     "shortName": "Revenue recognition - Remaining Performance Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i72306a994b9b4e40b4c06153d3cccd44_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445426 - Disclosure - Revenue recognition - Contract Liabilities (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails",
     "shortName": "Revenue recognition - Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i72306a994b9b4e40b4c06153d3cccd44_I20211231",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:ScheduleOfAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446427 - Disclosure - Revenue recognition - Accounts Receivable (Details)",
     "role": "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails",
     "shortName": "Revenue recognition - Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ebs:ScheduleOfAccountsReceivableNetTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BilledContractReceivables",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i9a9aaf25fc5d48ee87baec975ac47be1_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2448428 - Disclosure - Income taxes (Details)",
     "role": "http://emergentbiosolutions.com/role/IncometaxesDetails",
     "shortName": "Income taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i9a9aaf25fc5d48ee87baec975ac47be1_D20210101-20211231",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2451429 - Disclosure - Net Income (loss) per share (Details)",
     "role": "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails",
     "shortName": "Net Income (loss) per share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i46d185ce265a44359c45e086acb0e06f_I20211111",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2454430 - Disclosure - Equity - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/EquityNarrativeDetails",
     "shortName": "Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i46d185ce265a44359c45e086acb0e06f_I20211111",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2455431 - Disclosure - Equity - Schedule of Stock-based Compensation Expense (Details)",
     "role": "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails",
     "shortName": "Equity - Schedule of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ie7050e3a97a242b092682346cbd7cd4e_I20220331",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2456432 - Disclosure - Equity - Changes in Accumulated Other Comprehensive Loss (Details)",
     "role": "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
     "shortName": "Equity - Changes in Accumulated Other Comprehensive Loss (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2457433 - Disclosure - Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)",
     "role": "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails",
     "shortName": "Equity - Tax Effects Related to Each Component of Accumulated Other Comprehensive (Loss) Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfReportableSegments",
      "reportCount": 1,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2460434 - Disclosure - Segment Information - Narrative (Details)",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails",
     "shortName": "Segment Information - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i780e0257b99f470bac2458708cbdb98e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i780e0257b99f470bac2458708cbdb98e_I20201231",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2461435 - Disclosure - Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
     "shortName": "Segment Information - Reconciliation of Operating Profit (Loss) from Segments to Consolidated (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2462436 - Disclosure - Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "role": "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails",
     "shortName": "Segment Information - Schedule of Segment Reporting Information, by Segment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ief2e92fc8ea548a696f5854cb8903cb5_D20220401-20220630",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ia80f097061ac4deb804ac1a7be81e63d_I20220630",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "role": "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockParOrStatedValuePerShare",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "i4b115351905c4ee2931cba201308bfe2_I20210630",
      "decimals": "INF",
      "lang": "en-US",
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Business",
     "role": "http://emergentbiosolutions.com/role/Business",
     "shortName": "Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "ebs-20220630.htm",
      "contextRef": "ib61d9e52f3494f4dae404396d10909a1_D20220101-20220630",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 78,
   "tag": {
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S. Government"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r584"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r585"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r586"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r582"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r583"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "ebs_AcceleratedExpansionOfFillFinishCapacityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accelerated Expansion Of Fill/Finish Capacity",
        "label": "Accelerated Expansion Of Fill/Finish Capacity [Member]",
        "terseLabel": "Accelerated Expansion Of Fill/Finish Capacity"
       }
      }
     },
     "localname": "AcceleratedExpansionOfFillFinishCapacityMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_AdjustedGrossMargin": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted Gross Margin",
        "label": "Adjusted Gross Margin",
        "terseLabel": "Adjusted gross margin"
       }
      }
     },
     "localname": "AdjustedGrossMargin",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_AmendedCreditAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended credit agreement dated October 15, 2018.",
        "label": "Amended Credit Agreement [Member]",
        "terseLabel": "Amended Credit Agreement"
       }
      }
     },
     "localname": "AmendedCreditAgreementMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_AssetAcquisitionDomesticGrossProfitRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Domestic Gross Profit Royalty Percentage",
        "label": "Asset Acquisition, Domestic Gross Profit Royalty Percentage",
        "terseLabel": "Asset acquisition, domestic royalty percentage"
       }
      }
     },
     "localname": "AssetAcquisitionDomesticGrossProfitRoyaltyPercentage",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_AssetAcquisitionInternationalGrossProfitRoyaltyPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, International Gross Profit Royalty Percentage",
        "label": "Asset Acquisition, International Gross Profit Royalty Percentage",
        "terseLabel": "Asset acquisition, international royalty percentage"
       }
      }
     },
     "localname": "AssetAcquisitionInternationalGrossProfitRoyaltyPercentage",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Minimum Therapy Treatment Courses Required To Earn Royalty On Future Gross Profit",
        "label": "Asset Acquisition, Minimum Therapy Treatment Courses Required To Earn Royalty On Future Gross Profit",
        "terseLabel": "Asset acquisition, minimum therapy treatment courses required to earn royalty on future gross profit"
       }
      }
     },
     "localname": "AssetAcquisitionMinimumTherapyTreatmentCoursesRequiredToEarnRoyaltyOnFutureGrossProfit",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "Schedule of Leases Supplemental Balance Sheets"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ebs_BARDAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "BARDA",
        "label": "BARDA [Member]",
        "terseLabel": "BARDA"
       }
      }
     },
     "localname": "BARDAMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash proceeds in excess during the term of the Senior Secured Credit Facility from certain dispositions of property or from casualty events involving their property, subject to certain reinvestment rights.",
        "label": "Cash Proceeds Excess Amount from Dispositions of Property or Casualty Events Subject to Certain Reinvestment Right",
        "terseLabel": "Cash proceeds excess amount from dispositions of property or casualty events subject to certain reinvestment right"
       }
      }
     },
     "localname": "CashProceedsExcessAmountFromDispositionsOfPropertyOrCasualtyEventsSubjectToCertainReinvestmentRight",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ChangeinContractWithCustomerLiabilityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in Contract With Customer, Liability [Roll Forward]",
        "label": "Change in Contract With Customer, Liability [Roll Forward]",
        "terseLabel": "Change in Contract With Customer, Liability [Roll Forward]"
       }
      }
     },
     "localname": "ChangeinContractWithCustomerLiabilityRollForward",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_ChimerixAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chimerix Asset Acquisition",
        "label": "Chimerix Asset Acquisition [Member]",
        "terseLabel": "Chimerix Asset Acquisition"
       }
      }
     },
     "localname": "ChimerixAssetAcquisitionMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ContractDevelopmentAndManufacturingLeasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Development And Manufacturing, Leases",
        "label": "Contract Development And Manufacturing, Leases [Member]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "ContractDevelopmentAndManufacturingLeasesMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ContractDevelopmentAndManufacturingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue earned during the period arising from manufacturing sale under the terms of a contract.",
        "label": "Contract Development And Manufacturing [Member]",
        "terseLabel": "Total contract development and manufacturing",
        "verboseLabel": "CDMO"
       }
      }
     },
     "localname": "ContractDevelopmentAndManufacturingMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable recorded during the current reporting period.",
        "label": "Contract with Customer, Liability, Additions",
        "terseLabel": "Deferral of revenue"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ContractWithCustomerLiabilityDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract with Customer, Liability, Deductions",
        "label": "Contract with Customer, Liability, Deductions",
        "negatedTerseLabel": "Revenue recognized"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityDeductions",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_ContractsAndGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and grants.",
        "label": "Contracts and Grants [Member]",
        "terseLabel": "Contracts and grants"
       }
      }
     },
     "localname": "ContractsAndGrantsMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_DebtInstrumentCovenantConsiderationThreshold": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Consideration Threshold",
        "label": "Debt Instrument, Covenant, Consideration Threshold",
        "terseLabel": "Debt instrument, covenant, consideration threshold"
       }
      }
     },
     "localname": "DebtInstrumentCovenantConsiderationThreshold",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_DebtInstrumentCovenantDebtServiceCoverageRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Debt Service Coverage Ratio",
        "label": "Debt Instrument, Covenant, Debt Service Coverage Ratio",
        "verboseLabel": "Debt covenant, consolidated debt service coverage ratio, minimum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantDebtServiceCoverageRatio",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio Adjustment Period",
        "terseLabel": "Debt instrument, covenant, net leverage ratio adjustment period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioAdjustmentPeriod",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioOne": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, One",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, One",
        "terseLabel": "Debt instrument, covenant, net leverage ratio, maximum"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioOne",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioRollingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio Rolling Period",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio Rolling Period",
        "terseLabel": "Debt instrument, covenant, net leverage ratio rolling period"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioRollingPeriod",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "ebs_DebtInstrumentCovenantNetLeverageRatioTwo": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Covenant, Net Leverage Ratio, Two",
        "label": "Debt Instrument, Covenant, Net Leverage Ratio, Two",
        "terseLabel": "Debt instrument, covenant, net leverage ratio, adjustment"
       }
      }
     },
     "localname": "DebtInstrumentCovenantNetLeverageRatioTwo",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "ebs_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income Taxes",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "ebs_JansenPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Jansen Pharmaceuticals, Inc.",
        "label": "Jansen Pharmaceuticals, Inc. [Member]",
        "terseLabel": "Jansen Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "JansenPharmaceuticalsIncMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_MeasurementInputProbabilityofPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement Input, Probability of Payment [Member]",
        "label": "Measurement Input, Probability of Payment [Member]",
        "terseLabel": "Probability of payment"
       }
      }
     },
     "localname": "MeasurementInputProbabilityofPaymentMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_MilestonePaymentFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Four",
        "label": "Milestone Payment Four [Member]",
        "terseLabel": "Milestone Payment Four"
       }
      }
     },
     "localname": "MilestonePaymentFourMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_MilestonePaymentOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment One",
        "label": "Milestone Payment One [Member]",
        "terseLabel": "Milestone Payment One"
       }
      }
     },
     "localname": "MilestonePaymentOneMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_MilestonePaymentThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Three",
        "label": "Milestone Payment Three [Member]",
        "terseLabel": "Milestone Payment Three"
       }
      }
     },
     "localname": "MilestonePaymentThreeMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_MilestonePaymentTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone Payment Two",
        "label": "Milestone Payment Two [Member]",
        "terseLabel": "Milestone Payment Two"
       }
      }
     },
     "localname": "MilestonePaymentTwoMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_NumberOfCategoriesOfPublicHealthThreats": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the number of categories of public health threats.",
        "label": "Number Of Categories Of Public Health Threats",
        "terseLabel": "Number of categories of public health threats"
       }
      }
     },
     "localname": "NumberOfCategoriesOfPublicHealthThreats",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_NumberOfProductCandidates": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Product Candidates",
        "label": "Number Of Product Candidates",
        "terseLabel": "Number of product candidates"
       }
      }
     },
     "localname": "NumberOfProductCandidates",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_NumberOfRevenueGeneratingProducts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Refers to the number of revenue generating products.",
        "label": "Number Of Revenue Generating Products",
        "terseLabel": "Number of revenue generating products"
       }
      }
     },
     "localname": "NumberOfRevenueGeneratingProducts",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax",
        "label": "Operating Lease, Lease Income And Revenue From Contract With Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues",
        "totalLabel": "Total contract development and manufacturing"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ebs_OtherLongTermDebtFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long Term Debt Facility [Member]",
        "label": "Other Long Term Debt Facility [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherLongTermDebtFacilityMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in the third year.",
        "label": "Percentage of Original Principal Amount Required to Repay During the Third Year",
        "terseLabel": "Percentage of original principal amount required to repay during the third year"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayDuringTheThirdYear",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in the first two years.",
        "label": "Percentage of Original Principal Amount Required to Repay in First Two Years",
        "terseLabel": "Percentage of original principal amount required to repay in the first two years"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayInFirstTwoYears",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The rate of interest that was being paid on the original debt issue that is to repay in remaining years.",
        "label": "Percentage of Original Principal Amount Required to Repay Remaining Years",
        "terseLabel": "Percentage of original principal amount required to repay remaining year"
       }
      }
     },
     "localname": "PercentageOfOriginalPrincipalAmountRequiredToRepayRemainingYears",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "ebs_ProductsSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Segment",
        "label": "Products Segment [Member]",
        "terseLabel": "Products"
       }
      }
     },
     "localname": "ProductsSegmentMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_RegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory Milestones",
        "label": "Regulatory Milestones [Member]",
        "terseLabel": "Regulatory Milestones"
       }
      }
     },
     "localname": "RegulatoryMilestonesMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ReservationOfManufacturingCapacityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reservation Of Manufacturing Capacity",
        "label": "Reservation Of Manufacturing Capacity [Member]",
        "terseLabel": "Reservation Of Manufacturing Capacity"
       }
      }
     },
     "localname": "ReservationOfManufacturingCapacityMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ScheduleOfAccountsReceivableNetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Accounts Receivable, Net [Table Text Block]",
        "label": "Schedule Of Accounts Receivable, Net [Table Text Block]",
        "terseLabel": "Schedule of Accounts Receivable, Net"
       }
      }
     },
     "localname": "ScheduleOfAccountsReceivableNetTableTextBlock",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ebs_SeniorUnsecuredNotesDueAugust2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Senior Unsecured Notes Due August 2028",
        "label": "Senior Unsecured Notes Due August 2028 [Member]",
        "terseLabel": "3.875% Senior Unsecured Notes due 2028"
       }
      }
     },
     "localname": "SeniorUnsecuredNotesDueAugust2028Member",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_ServicesSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Services Segment",
        "label": "Services Segment [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServicesSegmentMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "ebs_TermLoanFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan dated December 2013.",
        "label": "Term Loan Facility [Member]",
        "verboseLabel": "Term Loan Facility"
       }
      }
     },
     "localname": "TermLoanFacilityMember",
     "nsuri": "http://emergentbiosolutions.com/20220630",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r113",
      "r152",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r178",
      "r182",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r113",
      "r152",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r178",
      "r182",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r250",
      "r251",
      "r253",
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r188",
      "r329",
      "r334",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r261",
      "r294",
      "r349",
      "r351",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r554",
      "r558",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r237",
      "r238",
      "r239",
      "r240",
      "r261",
      "r294",
      "r349",
      "r351",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r554",
      "r558",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r188",
      "r329",
      "r334",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r184",
      "r238",
      "r239",
      "r329",
      "r332",
      "r520",
      "r553",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]",
        "verboseLabel": "Products and Services [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r184",
      "r238",
      "r239",
      "r329",
      "r332",
      "r520",
      "r553",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r232",
      "r237",
      "r238",
      "r239",
      "r240",
      "r261",
      "r294",
      "r340",
      "r349",
      "r351",
      "r377",
      "r378",
      "r379",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r554",
      "r558",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r232",
      "r237",
      "r238",
      "r239",
      "r240",
      "r261",
      "r294",
      "r340",
      "r349",
      "r351",
      "r377",
      "r378",
      "r379",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r516",
      "r554",
      "r558",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r123",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails",
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r123",
      "r128",
      "r236",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails",
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r185",
      "r186",
      "r329",
      "r333",
      "r556",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r185",
      "r186",
      "r329",
      "r333",
      "r556",
      "r565",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r123",
      "r128",
      "r236",
      "r350",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails",
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r509",
      "r511",
      "r514",
      "r578",
      "r579"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r504"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsPayableTradeCurrentAndNoncurrent": {
     "auth_ref": [
      "r529",
      "r547"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Accounts Payable, Trade",
        "terseLabel": "Non-cancelable orders"
       }
      }
     },
     "localname": "AccountsPayableTradeCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r190",
      "r191"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "totalLabel": "Total accounts receivable, net",
        "verboseLabel": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "terseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": {
     "auth_ref": [
      "r56",
      "r60",
      "r68",
      "r69",
      "r70",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]",
        "terseLabel": "Defined Benefit Pension Plan"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r11",
      "r227"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation &amp; amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r60",
      "r68",
      "r69",
      "r70",
      "r71",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivative Instruments"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r58",
      "r59",
      "r60",
      "r543",
      "r563",
      "r564"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss, net"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r68",
      "r69",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r57",
      "r60",
      "r68",
      "r69",
      "r70",
      "r115",
      "r116",
      "r117",
      "r425",
      "r501",
      "r559",
      "r560"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Loss",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r54",
      "r60",
      "r68",
      "r69",
      "r70",
      "r425",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Weighted average amortization period"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r504"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r384",
      "r385",
      "r386",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-In Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income (loss) to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r382"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Total share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivable": {
     "auth_ref": [
      "r27",
      "r192",
      "r196",
      "r197",
      "r198"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable.",
        "label": "Accounts Receivable, Allowance for Credit Loss",
        "terseLabel": "Allowance for doubtful accounts receivable"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfFinancingCosts": {
     "auth_ref": [
      "r78",
      "r95",
      "r281",
      "r485"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense attributable to debt issuance costs.",
        "label": "Amortization of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred financing costs"
       }
      }
     },
     "localname": "AmortizationOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r95",
      "r215",
      "r222"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "verboseLabel": "Amortization Expense"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/IntangibleassetsFinitelivedIntangibleAssetsAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive stock awards (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionConsiderationTransferredContingentConsideration": {
     "auth_ref": [
      "r416",
      "r417",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contingent consideration recognized as part of consideration transferred in asset acquisition.",
        "label": "Asset Acquisition, Consideration Transferred, Contingent Consideration",
        "terseLabel": "Asset acquisition, consideration transferred, contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredContingentConsideration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r15",
      "r108",
      "r160",
      "r173",
      "r180",
      "r194",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r421",
      "r426",
      "r473",
      "r502",
      "r504",
      "r525",
      "r541"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r35",
      "r108",
      "r194",
      "r243",
      "r244",
      "r245",
      "r247",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r421",
      "r426",
      "r473",
      "r502",
      "r504"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r436",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r535"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BaseRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum rate investor will accept.",
        "label": "Base Rate [Member]",
        "terseLabel": "Base Rate"
       }
      }
     },
     "localname": "BaseRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BilledContractReceivables": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts due for billed services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the Company and, at a minimum, one other party. An example would be amounts billed to customers under contracts or programs but not paid as of the balance sheet date.",
        "label": "Billed Contracts Receivable",
        "terseLabel": "Billed, net"
       }
      }
     },
     "localname": "BilledContractReceivables",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Buildings, building improvements and leasehold improvements"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r94",
      "r414"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "netLabel": "Change in fair value",
        "terseLabel": "Change in fair value of contingent consideration, net",
        "verboseLabel": "Changes in fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r410",
      "r411",
      "r413"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Fair value of contingent purchase consideration",
        "verboseLabel": "Contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r410",
      "r412"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Business combination, contingent consideration, liability, current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination, Contingent Consideration, Liability, Measurement Input",
        "terseLabel": "Business combination, contingent consideration, liability, measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r99",
      "r100",
      "r101"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchases of property, plant and equipment unpaid at period end"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r9",
      "r97"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r90",
      "r97",
      "r102"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash and cash equivalents and restricted cash at June\u00a030, 2022 and December\u00a031, 2021:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r90",
      "r474"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r453"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within 12 Months",
        "terseLabel": "Net deferred losses from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental information on non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r115",
      "r116",
      "r456"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "$0.001 Par Value Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r20"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r20",
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r20",
      "r504"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 200.0 shares authorized, 55.5 and 55.1 shares issued; 49.9 and 51.3 shares outstanding, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r64",
      "r66",
      "r67",
      "r76",
      "r532",
      "r549"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerSoftwareIntangibleAssetMember": {
     "auth_ref": [
      "r216",
      "r220",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks.",
        "label": "Computer Software, Intangible Asset [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "ComputerSoftwareIntangibleAssetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r104",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of presentation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction-in-progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration by Type [Axis]",
        "terseLabel": "Contingent Consideration by Type [Axis]"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type [Domain]"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r318"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Rollforward of Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r315",
      "r317",
      "r330"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Contract with customer, asset, noncurrent"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r315",
      "r316",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "periodEndLabel": "End of period",
        "periodStartLabel": "Beginning of period"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r315",
      "r316",
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion of contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r80",
      "r520"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "negatedTerseLabel": "Cost of goods and services sold",
        "terseLabel": "Cost of goods and services sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of product sales"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r105",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r275",
      "r282",
      "r283",
      "r285",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Debt"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Debt"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r17",
      "r18",
      "r107",
      "r113",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r287",
      "r288",
      "r289",
      "r290",
      "r486",
      "r526",
      "r527",
      "r540"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "Debt Instrument, Basis Spread on Variable Rate",
        "terseLabel": "Debt instrument, basis spread on variable rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r42",
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r43",
      "r107",
      "r113",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r287",
      "r288",
      "r289",
      "r290",
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodAxis": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about timing of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period [Axis]",
        "terseLabel": "Debt Instrument, Redemption, Period [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodDomain": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period as defined under terms of the debt agreement for debt redemption features.",
        "label": "Debt Instrument, Redemption, Period [Domain]",
        "terseLabel": "Debt Instrument, Redemption, Period [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodOneMember": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period one representing most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period One [Member]",
        "terseLabel": "Prior to August 15, 2023"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPeriodTwoMember": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period two representing second most current period of debt redemption features under terms of the debt agreement.",
        "label": "Debt Instrument, Redemption, Period Two [Member]",
        "terseLabel": "Upon the occurrence of a change in control"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPeriodTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRedemptionPricePercentage": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage price of original principal amount of debt at which debt can be redeemed by the issuer.",
        "label": "Debt Instrument, Redemption Price, Percentage",
        "terseLabel": "Debt instrument, redemption price, percentage"
       }
      }
     },
     "localname": "DebtInstrumentRedemptionPricePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r43",
      "r107",
      "r113",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r265",
      "r271",
      "r272",
      "r273",
      "r274",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r284",
      "r287",
      "r288",
      "r289",
      "r290",
      "r307",
      "r308",
      "r309",
      "r310",
      "r483",
      "r484",
      "r486",
      "r487",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsCurrentNet": {
     "auth_ref": [
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as current. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Current, Net",
        "terseLabel": "Debt issuance costs, current, net"
       }
      }
     },
     "localname": "DeferredFinanceCostsCurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNet": {
     "auth_ref": [
      "r271",
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Net",
        "terseLabel": "Debt issuance costs, net"
       }
      }
     },
     "localname": "DeferredFinanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFinanceCostsNoncurrentNet": {
     "auth_ref": [
      "r485"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt issuance costs classified as noncurrent. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Noncurrent, Net",
        "negatedTerseLabel": "Unamortized debt issuance costs"
       }
      }
     },
     "localname": "DeferredFinanceCostsNoncurrentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r95",
      "r109",
      "r396",
      "r401",
      "r402",
      "r403"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r389",
      "r390"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r95",
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "Depreciation",
        "terseLabel": "Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation [Abstract]",
        "terseLabel": "Depreciation:"
       }
      }
     },
     "localname": "DepreciationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r95",
      "r155"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r472"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "terseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r438",
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Asset Derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r47",
      "r50",
      "r51",
      "r438",
      "r515"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Liability Derivatives"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r50",
      "r437",
      "r439",
      "r443",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instruments and Hedging Activities Disclosure [Abstract]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosure [Abstract]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r454",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for derivative instruments and hedging activities including, but not limited to, risk management strategies, non-hedging derivative instruments, assets, liabilities, revenue and expenses, and methodologies and assumptions used in determining the amounts.",
        "label": "Derivative Instruments and Hedging Activities Disclosure [Text Block]",
        "terseLabel": "Derivative instruments and hedging activities"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Derivativeinstrumentsandhedgingactivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Line Items]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about derivatives and hedging activities.",
        "label": "Derivative Instruments and Hedging Activities Disclosures [Table]",
        "terseLabel": "Derivative Instruments and Hedging Activities Disclosures [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsAndHedgingActivitiesDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r434",
      "r437",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r48",
      "r49",
      "r50",
      "r472"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "terseLabel": "Derivative instruments"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r430",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Notional"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r112",
      "r429",
      "r431",
      "r434",
      "r435",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivatives"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r329",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r77",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r129",
      "r131",
      "r136",
      "r137",
      "r138",
      "r142",
      "r143",
      "r457",
      "r458",
      "r533",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income per share - basic (in dollars per share)",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r77",
      "r120",
      "r121",
      "r122",
      "r123",
      "r124",
      "r131",
      "r136",
      "r137",
      "r138",
      "r142",
      "r143",
      "r457",
      "r458",
      "r533",
      "r550"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income per share - diluted (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Net income (loss) per common share"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r139",
      "r140",
      "r141",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (loss) per share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r474"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "terseLabel": "Effect of exchange rate changes on cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective annual tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock Options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r68",
      "r69",
      "r70",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r146",
      "r195",
      "r306",
      "r311",
      "r384",
      "r385",
      "r386",
      "r397",
      "r398",
      "r456",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r501",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EurodollarMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate based on U.S. dollar denominated deposits at foreign banks or foreign branches of U.S. banks.",
        "label": "Eurodollar [Member]",
        "terseLabel": "Eurocurrency"
       }
      }
     },
     "localname": "EurodollarMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r460",
      "r461",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r460",
      "r461",
      "r462",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]",
        "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r273",
      "r287",
      "r288",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r461",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r460",
      "r461",
      "r464",
      "r465",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Fairvaluemeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r273",
      "r341",
      "r342",
      "r347",
      "r348",
      "r461",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r273",
      "r287",
      "r288",
      "r341",
      "r342",
      "r347",
      "r348",
      "r461",
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r273",
      "r287",
      "r288",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r461",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value, Inputs, Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]",
        "terseLabel": "Unobservable Input Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r466",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r466",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]",
        "terseLabel": "Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair value measurements"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r466"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Balance, end of period",
        "periodStartLabel": "Balance, beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsContingentConsiderationRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r273",
      "r287",
      "r288",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r506",
      "r507",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r468",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r436",
      "r441",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FederalFundsEffectiveSwapRateMember": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap having its variable-rate leg referenced to Federal Funds effective rate with no additional spread over Federal Funds effective rate on that variable-rate leg.",
        "label": "Fed Funds Effective Rate Overnight Index Swap Rate [Member]",
        "terseLabel": "Federal Funds Rate"
       }
      }
     },
     "localname": "FederalFundsEffectiveSwapRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Estimated Life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r13",
      "r221"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "terseLabel": "Accumulated Amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Finite-lived Intangible Assets Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r216",
      "r218",
      "r221",
      "r223",
      "r521",
      "r522"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r221",
      "r522"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Cost"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r216",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r221",
      "r521"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and equipment"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r12",
      "r201",
      "r202",
      "r209",
      "r213",
      "r504",
      "r524"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, June\u00a030, 2022",
        "periodStartLabel": "Goodwill, December\u00a031, 2021",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) an asset representing future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "GoodwillForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillImpairedAccumulatedImpairmentLoss": {
     "auth_ref": [
      "r202",
      "r209",
      "r213"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated impairment loss for an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impaired, Accumulated Impairment Loss",
        "terseLabel": "Goodwill, impaired, accumulated impairment loss"
       }
      }
     },
     "localname": "GoodwillImpairedAccumulatedImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsGoodwillRollForwardDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r79",
      "r108",
      "r160",
      "r172",
      "r176",
      "r179",
      "r182",
      "r194",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r473"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross margin"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r434",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r74",
      "r160",
      "r172",
      "r176",
      "r179",
      "r182",
      "r523",
      "r530",
      "r536",
      "r551"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income (loss) before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r110",
      "r393",
      "r394",
      "r395",
      "r399",
      "r404",
      "r406",
      "r407",
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Incometaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r111",
      "r126",
      "r127",
      "r158",
      "r391",
      "r400",
      "r405",
      "r552"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r392"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Amount",
        "terseLabel": "Discrete tax expense (benefits)"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IncometaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r92",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid during the period for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "terseLabel": "Accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r94",
      "r517"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Increase (Decrease) in Employee Related Liabilities",
        "terseLabel": "Accrued compensation"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r132",
      "r133",
      "r134",
      "r138",
      "r354"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements",
        "terseLabel": "Dilutive securities-equity awards (in shares)"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all or part of the information related to intangible assets.",
        "label": "Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "IntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Intangibleassets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r214",
      "r219"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "terseLabel": "Intangible assets, net"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r72",
      "r154",
      "r482",
      "r485",
      "r534"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseMember": {
     "auth_ref": [
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing interest expense.",
        "label": "Interest Expense [Member]",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r89",
      "r91",
      "r98"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid during the period for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest rate swaps"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r200"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Inventoriesnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r199"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r34",
      "r504"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories, net",
        "verboseLabel": "Inventories, net"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r34",
      "r199"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Inventory, Raw Materials, Net of Reserves",
        "terseLabel": "Inventory, raw materials, net of reserves"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r29",
      "r199"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetScheduleofInventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LandAndLandImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Real estate held and assets that are an addition or improvement to real estate held.",
        "label": "Land and Land Improvements [Member]",
        "terseLabel": "Land and improvements"
       }
      }
     },
     "localname": "LandAndLandImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r496",
      "r497"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total operating lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Operating lease cost:",
        "verboseLabel": "Operating leases:"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails",
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r496"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Lease, Cost"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases [Abstract]",
        "terseLabel": "Leases [Abstract]"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Commitmentsandcontingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Remaining Lease Term",
        "terseLabel": "Lessee, operating lease, remaining lease term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRemainingLeaseTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LessorOperatingLeasePaymentsToBeReceived": {
     "auth_ref": [
      "r499"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease payments to be received by lessor for operating lease.",
        "label": "Lessor, Operating Lease, Payments to be Received",
        "terseLabel": "Lessor, operating lease, payments to be received"
       }
      }
     },
     "localname": "LessorOperatingLeasePaymentsToBeReceived",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r39",
      "r108",
      "r174",
      "r194",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r422",
      "r426",
      "r427",
      "r473",
      "r502",
      "r503"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r108",
      "r194",
      "r473",
      "r504",
      "r528",
      "r545"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r41",
      "r108",
      "r194",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r422",
      "r426",
      "r427",
      "r473",
      "r502",
      "r503",
      "r504"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r460"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used.",
        "label": "Line of Credit Facility, Commitment Fee Percentage",
        "terseLabel": "Commitment fee percentage"
       }
      }
     },
     "localname": "LineOfCreditFacilityCommitmentFeePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Current Borrowing Capacity",
        "terseLabel": "Current borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityCurrentBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r18",
      "r272",
      "r286",
      "r287",
      "r288",
      "r527",
      "r542"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Total debt",
        "verboseLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r38"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "negatedTerseLabel": "Current portion of long-term debt, net of debt issuance costs"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-Term Debt, Fair Value",
        "terseLabel": "Long-term debt, fair value"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Non-current portion of debt",
        "verboseLabel": "Debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r43",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input, Discount Rate [Member]",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market accounts"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows used in financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r90"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows used in investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r90",
      "r93",
      "r96"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows used in operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r62",
      "r65",
      "r70",
      "r75",
      "r96",
      "r108",
      "r118",
      "r120",
      "r121",
      "r122",
      "r123",
      "r126",
      "r127",
      "r135",
      "r160",
      "r172",
      "r176",
      "r179",
      "r182",
      "r194",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r458",
      "r473",
      "r531",
      "r548"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income (loss)",
        "terseLabel": "Net income (loss)",
        "totalLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently issued accounting standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-U.S. Government"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income (Expense)",
        "totalLabel": "Total other income (expense), net"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income (Expense) [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NotesPayableCurrent": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.",
        "label": "Notes Payable, Current",
        "terseLabel": "Debt, current portion"
       }
      }
     },
     "localname": "NotesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NotesPayableOtherPayablesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A written promise to pay a note to a third party.",
        "label": "Notes Payable, Other Payables [Member]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "NotesPayableOtherPayablesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtScheduleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfInterestRateDerivativesHeld": {
     "auth_ref": [
      "r430",
      "r432"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of interest rate derivative instruments held by the entity at the reporting date.",
        "label": "Number of Interest Rate Derivatives Held",
        "terseLabel": "Number of Instruments"
       }
      }
     },
     "localname": "NumberOfInterestRateDerivativesHeld",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesDerivativeDesignatedasCashFlowHedgesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of reportable segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OciBeforeReclassificationsNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r60",
      "r71"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax, before reclassification adjustments, of other comprehensive income (loss), attributable to parent.",
        "label": "OCI, before Reclassifications, Net of Tax, Attributable to Parent",
        "terseLabel": "Other comprehensive income before reclassifications"
       }
      }
     },
     "localname": "OciBeforeReclassificationsNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingCostsAndExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.",
        "label": "Operating Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingCostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r160",
      "r172",
      "r176",
      "r179",
      "r182"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r491"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Interest on lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": {
     "auth_ref": [
      "r145",
      "r500"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable.",
        "label": "Operating Lease, Lease Income, Lease Payments",
        "terseLabel": "Leases",
        "verboseLabel": "Lease revenue"
       }
      }
     },
     "localname": "OperatingLeaseLeaseIncomeLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r489"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r489"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r489"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for right-of-use asset from operating lease.",
        "label": "Operating Lease, Right-of-Use Asset, Amortization Expense",
        "terseLabel": "Amortization of right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesComponentsofLeaseExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r495",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r494",
      "r497"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted average remaining lease term (years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/LeasesSupplementalBalanceSheetInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r3",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Business"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r436",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent": {
     "auth_ref": [
      "r419",
      "r420",
      "r424"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), before Tax, Portion Attributable to Parent",
        "terseLabel": "Pretax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r55",
      "r58"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "terseLabel": "Unrealized gains (losses) on hedging activities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r58",
      "r61",
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Amount of Gain/(Loss) Reclassified from Accumulated OCL into Income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesCashFlowHedgingonAOCIDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "verboseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r63",
      "r66",
      "r419",
      "r420",
      "r424"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "terseLabel": "Other comprehensive income, net of tax",
        "totalLabel": "Total other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeLoss",
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxPortionAttributableToParent1": {
     "auth_ref": [
      "r419",
      "r420",
      "r424"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Tax, Portion Attributable to Parent",
        "negatedTerseLabel": "Tax Benefit (Expense)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxPortionAttributableToParent1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r436",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r40",
      "r504"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesMember": {
     "auth_ref": [
      "r436",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other liabilities.",
        "label": "Other Liabilities [Member]",
        "terseLabel": "Other Liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesFairValuebyBalanceSheetLocationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityFinancingActivities": {
     "auth_ref": [
      "r88"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow, not made soon after acquisition date of business combination, to settle contingent consideration liability up to amount recognized at acquisition date, including, but not limited to, measurement period adjustment and less amount paid soon after acquisition date.",
        "label": "Payment for Contingent Consideration Liability, Financing Activities",
        "negatedLabel": "Contingent consideration payments"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedTerseLabel": "Purchases of treasury stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-Based Payment Arrangement",
        "negatedLabel": "Taxes paid for share-based compensation activity"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r84",
      "r416",
      "r417",
      "r418"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire productive assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BusinessDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r19",
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r19",
      "r504"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value; 15.0 shares authorized, no shares issued or outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r85",
      "r383"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from share-based compensation activity"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product sales, net",
        "verboseLabel": "Products"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails",
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r231",
      "r566",
      "r567",
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Propertyplantandequipmentnet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r10",
      "r226"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property Plant and Equipment Income Statement Disclosures [Abstract]",
        "terseLabel": "Property Plant and Equipment Income Statement Disclosures [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentIncomeStatementDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r228",
      "r504",
      "r537",
      "r546"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, net",
        "totalLabel": "Total property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "verboseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent": {
     "auth_ref": [
      "r60",
      "r71"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustments of other comprehensive income (loss) attributable to parent.",
        "label": "Reclassification from AOCI, Current Period, Net of Tax, Attributable to Parent",
        "negatedTerseLabel": "Amounts reclassified from accumulated other comprehensive loss"
       }
      }
     },
     "localname": "ReclassificationFromAociCurrentPeriodNetOfTaxAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable": {
     "auth_ref": [
      "r172",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table]"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r172",
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfConvertibleDebt": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.",
        "label": "Repayments of Convertible Debt",
        "negatedTerseLabel": "Principal payments on convertible senior notes"
       }
      }
     },
     "localname": "RepaymentsOfConvertibleDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfMediumTermNotes": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to pay off borrowing used to receive debt funding on a regular basis with maturities ranging from 5-10 years.",
        "label": "Repayments of Medium-term Notes",
        "negatedTerseLabel": "Principal payments on term loan facility"
       }
      }
     },
     "localname": "RepaymentsOfMediumTermNotes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r388",
      "r519",
      "r580"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueHierarchyofAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashCurrent": {
     "auth_ref": [
      "r9",
      "r102"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Current",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r311",
      "r504",
      "r544",
      "r562",
      "r564"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r195",
      "r384",
      "r385",
      "r386",
      "r397",
      "r398",
      "r456",
      "r559",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r151",
      "r152",
      "r171",
      "r177",
      "r178",
      "r184",
      "r185",
      "r188",
      "r328",
      "r329",
      "r520"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 2.0,
       "parentTag": "ebs_OperatingLeaseLeaseIncomeAndRevenueFromContractWithCustomerExcludingAssessedTax",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Services",
        "verboseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r326",
      "r327",
      "r331",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "Revenue recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Revenuerecognition"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Revenue, remaining performance obligation, amount"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation.",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionPerformanceObligationsDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionRemainingPerformanceObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r73",
      "r108",
      "r151",
      "r152",
      "r171",
      "r177",
      "r178",
      "r184",
      "r185",
      "r188",
      "r194",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r250",
      "r252",
      "r254",
      "r256",
      "r257",
      "r473",
      "r536"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      },
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "negatedTerseLabel": "Reversal of previously recognized revenue",
        "totalLabel": "Total revenues",
        "verboseLabel": "Total revenues"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevolvingCreditFacilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount.",
        "label": "Revolving Credit Facility [Member]",
        "verboseLabel": "Revolving Credit Facility"
       }
      }
     },
     "localname": "RevolvingCreditFacilityMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r60",
      "r480",
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r52"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of components of comprehensive income (loss). Includes, but is not limited to, foreign currency translation adjustments, foreign currency transactions designated as economic hedges of a net investment in foreign entity, gain (loss) and prior service cost (credit) for pension plans and other postretirement benefit plans.",
        "label": "Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.",
        "label": "Schedule of Debt [Table Text Block]",
        "terseLabel": "Schedule of Debt"
       }
      }
     },
     "localname": "ScheduleOfDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r437",
      "r443",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Derivative Instruments, Gain (Loss)"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r441"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r429",
      "r431",
      "r432",
      "r434",
      "r435",
      "r441",
      "r443",
      "r448",
      "r450"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivative Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DerivativeinstrumentsandhedgingactivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r138"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Basic and Diluted Net Income per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r381",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r381"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r216",
      "r220",
      "r521"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsScheduleofFinitelivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r216",
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/IntangibleassetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r8",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/InventoriesnetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentnetScheduleofPropertyPlantandEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r160",
      "r163",
      "r175",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r160",
      "r163",
      "r175",
      "r210"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r352",
      "r353",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r147",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r188",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r234",
      "r235",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r147",
      "r149",
      "r150",
      "r160",
      "r164",
      "r176",
      "r180",
      "r181",
      "r182",
      "r183",
      "r184",
      "r187",
      "r188",
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r170",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/BasisofpresentationandprinciplesofconsolidationPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]",
        "terseLabel": "Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingReconcilingItemForOperatingProfitLossFromSegmentToConsolidatedLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingCostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails",
      "http://emergentbiosolutions.com/role/DebtScheduleDetails",
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "terseLabel": "Services"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/EquityScheduleofStockbasedCompensationExpenseDetails",
      "http://emergentbiosolutions.com/role/PropertyplantandequipmentNarrativeDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionDisaggregationofRevenueDetails",
      "http://emergentbiosolutions.com/role/RevenuerecognitionNarrativeDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r94"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Restricted stock units granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Stock options granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Award vesting rights, percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r103",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of presentation and principles of consolidation"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Basisofpresentationandprinciplesofconsolidation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r1",
      "r147",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r162",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r180",
      "r182",
      "r188",
      "r202",
      "r203",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r230",
      "r234",
      "r235",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/SegmentInformationReconciliationofOperatingProfitLossfromSegmentstoConsolidatedDetails",
      "http://emergentbiosolutions.com/role/SegmentInformationScheduleofSegmentReportingInformationbySegmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r46",
      "r68",
      "r69",
      "r70",
      "r115",
      "r116",
      "r117",
      "r119",
      "r125",
      "r127",
      "r146",
      "r195",
      "r306",
      "r311",
      "r384",
      "r385",
      "r386",
      "r397",
      "r398",
      "r456",
      "r475",
      "r476",
      "r477",
      "r478",
      "r479",
      "r481",
      "r501",
      "r559",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails",
      "http://emergentbiosolutions.com/role/EquityTaxEffectsRelatedtoEachComponentofAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r115",
      "r116",
      "r117",
      "r146",
      "r520"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r306",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation activity (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r19",
      "r20",
      "r311",
      "r372"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based compensation activity"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodShares": {
     "auth_ref": [
      "r19",
      "r20",
      "r306",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and have not been retired and are not held in treasury. Some state laws may govern the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Shares",
        "negatedLabel": "Repurchases of stock (in shares)",
        "terseLabel": "Stock repurchased during period, shares (in shares)"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r19",
      "r20",
      "r306",
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "negatedTerseLabel": "Repurchases of stock",
        "terseLabel": "Repurchases of stock"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r20",
      "r24",
      "r25",
      "r108",
      "r193",
      "r194",
      "r473",
      "r504"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityChangesinAccumulatedOtherComprehensiveLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Stockholders' equity:"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets",
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]",
        "terseLabel": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r106",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r311",
      "r314",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TreasuryStockCommonMember": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common [Member]",
        "terseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockCommonMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity",
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockCommonShares": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury.",
        "label": "Treasury Stock, Common, Shares",
        "negatedPeriodEndLabel": "Ending balance (in shares)",
        "negatedPeriodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "TreasuryStockCommonShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r45",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock (in shares)"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r45",
      "r312",
      "r313"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, at cost, 5.6 and 3.8 common shares, respectively"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnbilledContractsReceivable": {
     "auth_ref": [
      "r518"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccountsReceivableNetCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unbilled amounts due for services rendered or to be rendered, actions taken or to be taken, or a promise to refrain from taking certain actions in accordance with the terms of a legally binding agreement between the entity and, at a minimum, one other party. An example would be amounts associated with contracts or programs where the recognized revenue for performance thereunder exceeds the amounts billed under the terms thereof as of the date of the balance sheet.",
        "label": "Unbilled Contracts Receivable",
        "terseLabel": "Unbilled"
       }
      }
     },
     "localname": "UnbilledContractsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/RevenuerecognitionAccountsReceivableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationTechniqueAxis": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation approach and technique.",
        "label": "Valuation Approach and Technique [Axis]",
        "terseLabel": "Valuation Approach and Technique [Axis]"
       }
      }
     },
     "localname": "ValuationTechniqueAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ValuationTechniqueDiscountedCashFlowMember": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation technique calculating present value of future cash flows.",
        "label": "Valuation Technique, Discounted Cash Flow [Member]",
        "terseLabel": "Discounted cash flow"
       }
      }
     },
     "localname": "ValuationTechniqueDiscountedCashFlowMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationTechniqueDomain": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation approach and technique.",
        "label": "Valuation Approach and Technique [Domain]",
        "terseLabel": "Valuation Approach and Technique [Domain]"
       }
      }
     },
     "localname": "ValuationTechniqueDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/FairvaluemeasurementsFairValueLevel3ofSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/DebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r130",
      "r138"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average number of shares-diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "Shares used in computing net income (loss) per common share"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r129",
      "r138"
     ],
     "calculation": {
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of shares-basic (in shares)",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/CondensedConsolidatedStatementsofOperations",
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://emergentbiosolutions.com/role/NetIncomelosspershareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 10
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1707-109256"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1757-109256"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1500-109256"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900988&loc=SL77927221-108306"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/subtopic&trid=2144471"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130531-203044"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130532-203044"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126919976&loc=SL49130533-203044"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130551-203045"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130554-203045"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130558-203045"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130549-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130550-203045"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126962052&loc=d3e4991-113900"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5504-128473"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=127000608&loc=d3e9135-128495"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9212-128498"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126928898&loc=d3e9215-128498"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=124256753&loc=SL5864739-113975"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "815",
   "URI": "https://asc.fasb.org/topic&trid=2229140"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL7498348-110258"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919396-209981"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=124258985&loc=SL77919372-209981"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55302-109406"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e526-108580"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "e",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r581": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r582": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r583": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r584": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r585": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r586": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(8))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>110
<FILENAME>0001367644-22-000119-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001367644-22-000119-xbrl.zip
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M3,8>MIX&^Q!%;V,$RW[^Z;3?[9Y-D9[QO+@7E&_7<U&B(*HB2Y-4ZAQ&?L=
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MV_R>L>/;-K/('[69:'_E]-\^T5=^Y-/[XUZGU3%:QK'9.NGTWP,=&!HPCVA
M[_:!U:T31O)H RI2E'L@WR'Y#L@-H_.#R_7-%_^A0/W=@/\P\7]02P,$%
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MD<Q7E^$5><]"WO[3D4<B5R5\RS!9^K(!V$$<S7:E794YB$,R0>!WJJL,8\*
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M(Z<K64QTK$\>_'<G_GL3LLSU8>%IDY=\*VROU3=-^74U^ =02P,$%     @
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MR8[!N39Z:]O627"*/$,JF0QRYX<\@U'L!EAV\BG 2(TJI1 H^9@UV!179%@
M,GQ!,12E+::([8+ 42+GU/;9^7:A %!*L5K9'R9#RMK(&(SCM!F4U!Z+)HA>
M!R/)"+LBPR*0X?/6,Z<D$&%NI^1K/TL6;=3&<=3P@N5C<FS//TP&$S-$"$JA
MX<"0$!6H(*,#_@%8#7Y*AN-Q]_Z@V_O7'59^M.+&_+CQN80HT6>T".UHE>.$
M JD=&,8VJP==HJBRD.7D5XCQ='2&0.MHT#VCQ>"H'VETYXK?T"9;-%0B)1#
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M&DF4685 +J3:\KXT$#W,>3H)(/9>8#>O#Q[C87>"O<; A!FCX)2P2)#*19F
M@YZJ]232"[<\,*5TU#_JU96TIO,$UOU&M%_/]H[6!VG8OX8BDVN!K'B7%''R
MAW44F*LC^*7S+$R<U>3*\L2E+9I@=T#Y"8[JI#G7D!!>"S[6$DMN0"QU[#1Y
M](+0YZCY73K(N0$M+HLD(.;?]F(3JXRBG<P"P5KMLQ$4<\A@2!3SQ;'$S0;T
MQF+:_,%5EJ*-*FF#&:QT$;0W*BIPB8@%YO*!>_UN=?ZH)AM4L:8.4;6<O4*@
MI%%[$4U0I&43ZK,6,5.8/[#D,B-9>Q/1<FJA@E9)""K9&NG0BN4#=B["=?Y
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M]HDFSX?I"[>Q.=FGT6/.!&H8G,X&M6+]=WA&2E:(G H$-* HA* ,>':4 #F
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M/*B=;4J[S2U4$B'X[%4@:ZC.*5(7H(I&>$..]2?GO\U';NDCNTEU-#J!(55
M&H^U+X<U82PJAD!+4!2YK)%6Z<B:74 NVH#+)D21#<?8HB6QXX3F([?TD8^R
MD"Y;FP(*B!$B6Z/EQ%WHE&/T35A-ZQ85K<]E(2HR4AF)V?!?*$)%0$F@D>W9
MD2NV(129?]/@C8^!N7FN:&&-E1YD8K=O?8YU5(,)+FNLW[$!BY;=(G<RE_6^
MLC>6"D @H8",0!^<%R[5":^RE+8A%+EM[F0N7+'&)Q-]LL80U-52(N?I13H@
M;Q3EY5 G2U.T/I^($P-)*W)M' 8.,5'7-8XBFF)]258TA"*+XTYN; S,')94
MM19%G5Y=B@))EL!^1!O/02=PSFIS0T+/+7$G\U$G&1QB,:X4A"A32([YX LF
M&<'8I@C8V^9.YL,5PBP+8%W)#8@@:$FEKKQ8YUC!@ T)/:O"\WG%(PL4 M9E
M$5"R=E%!<"0RV4M0SICD&D*@^3N;12H\GPN3A W2YP"0I0(ODP>*G$QG:T,N
MQC9AL?B5*YIG+(M!<5ZM"2#R7R146M4!G8%*C%G+AA!HY8KFSJ0<A1<%B];&
M<#Y>@E49'>AH@S+,L88$M5M>A#Z?_-QK:VQ(X!%!!Q^L8-8($NR;K/9-$=2-
M<4++J(3(@HE*4U#9UEB&!;RBD*4GKU$U)9#=<O<S'PUD!<>ID*1+!1P:U-+D
M&-$PLM:+IHCHE?N9:YM0L4YH0"\RA%+G_0Y12<W1C+4TQ(:$L 4J/EY6L6.U
M*^A\<(KS=N,-,P95@*!(&N43K)BRR,5Z<Z$,N@)&:)D)9.VFJ.-[G7?*2"N-
M#*DA 6J!*+.L4B9[8<CIJF/8I;!G"<*334JEH*PP?L64178N<Z$,I.*4*EXZ
M=BZ93,B^.'*41(Q,&].0>'0+E82R!E$19)45Q&@BJ205:#!H30ZI^<@M?61/
MSF?G5<G".W"18J"8A"HQV9A0BX;XZUL8:;W4T0JK0'*DC92CBW7VL!(R@+.N
M*9IL08QO+A Z\(G3,(YV6H#5)F"&XFJYC^#8%V5#QA!V\& X>GPTG@S[-!I_
ME$J_XV!,@Q?[..ICHJ-)17:\/DC+.)8PQEH&&K5,2D,@&Z=I=5!&"SEM?EE?
M(?A7"'8'C!/O^SDH%UM^ A3A=.W.@1!D ++!2Y#9U9*7& QKRRDH0BHMFP3*
MHX=;:P^O%0'1EJJMY0P02(".+<(4:0UX#0A>@8\6LLY)*[F\"'SS A?1;=HA
M?Y%5'F&O+E?W\5);-.8,%"=\R&:YU(C]& \Q?7LYNT5A@BMH6%BJ'.K,.QEC
M1$FRH 4I@R):7"9\'U /4Z(>C3A\Y"?'AS@]=K,\[?9Z3[N#[GC_.^&Z-9Y!
MRQP+$CCA%!AVT'4"P92+#X%9$O24#U**Q>/#?!&0;2EF@X!PGJ#D0%37^1$:
ME<VE!./8*JN=+K9DF5_><"U2A43PNBYC4&?05.0\U/&KMC@,VDM1Y@W&Y.20
M\M=]XQ:]H\$1;5$?V=L-]E[0J Q9- X2;<9>=V\:P-@O4F+_N-WM\RZ;Y17_
M.J[QC+>]NE#I9Q#^=CTGOIN']3SGT+EIEG"]5_I O$]>X,S:H.=0YG<MY)>1
M65\T:BU9&?H<0Q9*AQ(TI\.>U(K\,R:_OFCM6)%_[N0GH]C-6XE0A9#D,)Q2
M")1\S!ILFGO+P=*1'U;D7QCRIZR-C*PY!1104GLLFB#Z.B<K&6%7Y)\Q^<V*
M_ M#?A,S1 A*H6&ADQ 5J""C _X!#*W(/VORVQ7Y%X?\2<;HC?8B!4A@ U@R
M07@#41:*?D7^94IX%X5UJ7".&8UW7@B0RF!@6@@-$45AKWNU8F41FZ,O-7Z]
M2C1 ?OHS$DTWG?_R=#BBA..%FNSM4MOQK\R]BP&Q*%.2R>")O(M(*3B#J=:P
M7!UJ<Q,H7FN]P:S>&]@LO4E4Z[8 M F)98;P%E,4)&PY;W/G/POPNBZW>=>_
M,[#_'*WB4.,YK"A(&GT25@#4'BB%-I_/LE+_+&S%Q8?Y32Y\P)/_'/%]/1[V
M#X<#_CJ^W B^/6)5<#0Z>349IK>\4W\XN/92FDMHW4S]10;MC5.9G&,%H4K
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M<[IZO.H3ZU6Z<OO4-5J71QNC;S^UY\,5O&T:;SZ* '<(3(1?+^*59'CX6';
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M] *Y(YL>3FE?#S)(@2+-%?A6W.0>7BD/]E-*:<4,9SJWKV?E9&+%@#<W$Z8
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M]:I+MM!,I#)9"8Z%M=[C;(D[A[BS##2^XL@(DZB@E@6?.S_R^=6"KVJ _CG
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MU,M,ZF5R[(135'H*MB&Q#M0+;!O0+ 2C((/C,C+G0L[XI27/_AEG+10 +Q&
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M(+Q)RAL:IF5"7K&:RH2\E:<N,DY=)C!B.4,\JHAX+C%QP3MDG34@*AJ5%F5
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ML=L(54RFW:IJQHLY\+#FP!_]+MQ/MPM^AFNT*CF\NI#/JZOBV>ITLCRKV-M
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M 4Z59M('$.3:IEZ1I(M54O2=?IP: +B2;U'4_U*I_RRQORZE4[AG)NXYG+
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M+5,YZ910ML+1;W4MK>):6HWD5=?2NKF67DW7KQJC5T2EY5I3WGKE$U=(ZB3
M&.4!64D8XCB)"'M")\6NBR94U](:2_.MNY:J-%^#-"]P#.()UX(Y%(,GB#N9
M#Z\T1EX&175*/OFX*L>HOJ6?]"V=-0*KOJ4+"*6Z)^%*<ZZE<3Z4GPQ/8"0#
M_ZGZDN[(E_1R,'P3C]N%R7TFCXX&_;=Y2:HZ64F=+-<JB9[AP!5%2<.R<,L2
M,MZ7TF4JJ42<PW)C2Y_7YKKZD!Y+E-)EY# -AD=V#$__.GZ6NE]C0-_B<%#E
M<U7Y7*![*3G&@A3(IQRPY+%"6@J.E+/.*RF<R[4$_^L_-"7TUWL1M'1OB,"P
M"Y3NV/9RW9*R_3L@=N,X/.KT!C:WI_<E)J^R@EMF!0!![8+LI]T8NI.C UB4
MO<&X6I<KPLUR_1)';:(I$!0)<8@+0!HG*49.Q:2(S17,LG4I*QVX1Q)X[7R@
M2N U2N!2[1*G7;()8<,TXH8J9+1G"#,28/DLIP*#!)(5O+55T5]!T8,$E9&Z
M7NR,8K\[&';Z>8,_1G6_+MK^^=F:O(AN7(V.:\&@Y1HF1IN@"8_( >0@'KA!
M-@:)K$H.@R+!6I$K&AV5#3QH-K DH5425Y/$!3:@M58*:YO90,C52@TRG&@4
MJ>%,"X>YSQ$E>(5 XLH&?L &!C[&,.JDX>"H,SJT0X!!.UHH93(]YWF4UO^=
M'@FTR_,25N?5:#2Q?1_WT]N\3*,_^R$.7\$O^K VN6YR^?5O>?&>SZQ=CGL;
MP66]29[]XK[</\X?5.-E-;A:+GVBDA&Y\P)R@A(P7B)P!FD(2L19Y8TCVJG<
MPWK%PHN5-#RX$X4JQNLDQHLQ)B3PF$Q T>?T)6]SC72ID.8Q1N=98H05UG$_
M"JC>%^IQ8+_&7"6]&[)A6[G'VIT\3,]!V\),!P-8L5RGX7#0RY/Y<C \'ZHJ
M(*T$2,OU5 (V@7"ED<[Q;EPZ@JQW&/F0,&968IO<QM8J]1LKI;AKZ;RQ*(4J
MG3<MG0MT05JJ#)<8&1.!+FCA$"RK SF52FCO#8O ^LEYM+\Z*:Y<4PW&#KL]
MR]2H&TH*/\C;U!/W&*G!&C #P)BSI7D^NS*G)9Q>3D.%9V/BZSG&-0#3<E$5
M[X(RGB0D$V.("VV -EB-$M&>A$15<KZ>8ZR1"*\#?[BJ#%=974U6%T@$$/R(
M(P5QDBG['&)$&G.+DD@2.X-=8!9(1,V<O:',V=526&KF[+IESE9,^DE,^K:]
MS!\TD9$DB;BUV>V@&'* 14AK'P/36G MLQ^4;-*:.ON@Q?G64V>K.%^#."_Z
M*91EQFF/O-<1\9A;,FNJ$;$*>ZFP3HEM;%&Y@I]BG3)G[Y4'8R>EZ,<YQS)^
M]8<6R'8'2';L-#\W$9@@%D\;DI++>7V&O9]C,W-YKV$<C8==/\XG(_!YI2GK
MX@=IEG4_[;2+^@;6=+^? 2[_?^=L&=^<KF#^8+L?YG\Q<V6%O95@;[E,F" T
MRESPPQJO$0^:(T-X0EBE& R!5<7I"C6O*Y%9%X%?#R)317\-1'^QW+T./$I&
MD: ZAX\RAW2R!GDI .49]<SX+/JU5,@->ED:=M.MA.9^^UU^"LE>PYL/PG*W
MCS9Z;18S&QRMT+<2]"U7/3,F>IZ81$P!U^':661"9"CXR*4+BAFK<J>O\[J
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M24'YNH@U%VICBYSC5;GH#*QJW<>I=5<*6[P2,-3C\9M$AL6P11P=QB1XE)@
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MHKTO[PGQ#'MAD8B6YK8;$1G*#0J&!0KV4H@& '70/P=/I]ASNJ;-'@+M"Y\
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M\[[+%1!X=.;B[I?W25)AM& H!!P03XP@1X1&C#*))94X$7-!V8#AZ?3>>MT
MVAQA+A4/6*H8<%I,(&_B[(LN*B)[I=-D6"C(8#+N3?'^>_4%'E#G\)? #)M
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MB7'OYRXI+2-0#U&=GDS!35*2GY;DI^L2QUHILL 7 -1[XWDW+B7IG" HDB#
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M67PQ7$8</'YA%D]B0S<%G^^R][\GR.*)ERC,'KW[[16C!S*;6D\WV,=RKRS
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MP<2LB>+ :W),\DVE&WLGT>=3[=;YYC@*5\:C_<5J\0Q9@H$= ALJ&=B00=%
M/$Z!DT#%3T$WICDB>)[30C41E=7F>-.,H6Y]8FX3$)*_;*L?MYL]W^KT^K (
M*W(D1ZK-2W&HPCU^_:[1'790APU^].5L_T>M>0"B</#I.P6;B8- 7.S5M^BH
M.%0O=LE>?8?MUT,KIW/5MM\W]NF?K=JGVJ^#^C[83(<YG4M4MP\2B!NK'?[4
M"J?<]P<E2A3B2>7C.9/3L(Q/-#)"N!X]6#42C"C/E%:@K6#FK8Y48R=ML-0(
MHT8/\?*T5_[.\UXYCC;/>J$DQTV1FSM^\A'P@W>^/5*B)8M!@AJUG'/XE.9.
M)\5!R6LE$WOR(^"K'3=DT&F'STWKFJWF:3/VJH/)"'OMKS''S\#8@ _4.NWN
MY9_O;:_96R6.G65L4U[]\E/&I*-G!K'( ;=UP0'/+;*@2 $X$ACS8>W.C@<'
MMBZV.F>5$X"JPK)LM@?*O5 \KM,_'>':&:;99=73NMYJ\"%[6LEI%]UX"#9#
MMW5^*8NA^&RV=IOY]]-*NA;7_ Y,"/@7I\4U8J4506$5'#_PM/F%&Y]N-&/7
M=GWC/*O#_%Y^>3#2T^@;[>9_^G"5LUCIG\*P+N!NIQVP>$YC]QB>_\:57MA1
MM\ED/GJ>DVYP,SF?CSGFOLOJ3<)$>=4G8>N9CP/H)<W <JXZW;P^&1<,N>],
MZF&>B8?"X#-F[3TY"441QIPV+%Y.]",G>NJ\E'FW]^PE48N]^LM@7BG6HNC.
M^!C&FK6:C<^%.?<HXJ,UG(]',1JMX7RP93,\K=6<E@A4(E")0(]!H%=$EE9$
M<][.M1NF+M&?"YG+J]_.C9IF( MYFI=ZD77+?*UVVO&\<FR[O^)IS@,HJMEF
MY<]8_\RP"<^Y7AE>25F6$@T,)\X=PS90::R60@FO H_3YFY\L+W&5COD?W;^
MTV_^;5LYWC_AR')53O#G/0L:I(#!=?>/=^G^T:^+_1_[%_ =4ONQPZO;,*;C
MC\WJT3ZM%=D X\P3>_5&<__HH+E7KS4.\KVWOY/]^N%9]=/!\?Z/W?,:?#=G
M Q3,$^,I8)S0%"172!@1$">)("<\1<DPPR*W0J:< C8[U]<TF_])>@.76+(F
M6**,,L8Q'RT-7*>HF?!<*"DX3=@)6F+)DK'D?)3%!CN $@9;5"F)N(VY03E5
MB(O$DV+!1>%*+"FQ9!E8DH0-&E,F9.1<6T<TU_"?(!C5)CR%7;+:144O!6-&
MN4D-=XX%JY&W14(J-L@XQ<!RH<9B3X*4=G%%127,E# S"\P(!X9*4@3,9L,-
M)4YYV)9$*RXPZ$16PLR*P@P>@1F;?(R6$V05=XC38)$E)B)"&75:<^E(7%&8
MF2$L-R':M ; L\;X0DU4/&)-4@*7B%A-O Z,4&RLHE:Y::LG2I?HB7!DE(-8
MZA1HP!*)(#S@"'/(TA@1"PP['#$V F<J=7K-&C@=BBS6)BD1X*4@@.;1X^#!
M;4F<LRSWVE)F#.%6\B15B0!+1@ ZVO<E<>(E!F4?&;@ICA#D: A(>TRTU$2+
MP$H$*!%@>@2(F$7&,>@2RT'4G?"6!YN"L 8KB9\  4H?8Q'(,$KZ[9AVCBF#
MJ'<&; .BD?6:(\53=+D&&R<UIX]18L/KQ(:DI278:1,\YRI8*X,)W"6MB-2&
MF!(;5A0;^*C50(WBEHC<L80@+@ @K+)@.H#90,'YH\F()6+#NJ6OU)O'$02B
M($P?2UN9CJEMRACNR\<8V'[&80^[,PANH['4@1J3SE$B$C6R/)9=)I;4/HRS
M_"BOE, 8K OL$&=*(8--1-P8Z8,B.H(Z  \$;](5C626@E?PXF!,G3!4<^=Y
M(";G-]M$C, A6J?+,\Q5%<C1/ DEC%-&!82CDV#XTX"LXQQTO=;8\! TXZM^
MN%"*9!9)+ CF#M;,*LJY9(8)$AQ-Q(K,H%6F*"U;]$;3!Q)3S(5$$;-4YW,]
MC+05%!&M%/,<_C&TU(6K+WC*VB R(5PPD5-!<K<T85C2U$H>HRIUX8H*Y-A!
MN]69/TB@0',^#V6@!I-)R'L6P"YE3#FZZKIPAOH7.M%'7E,A#4)A0Q5U5@I.
MB'=86VE3I$+93#E7GE4M61A'3ZN=D8YQ;9$0H!.Y#PZ9)$VFF)+)*I-SL3?>
M43QS'\JG4X*O0(P\Z#H:@[22.&ZUMS(9%2/'AD6#@R^#NBLJ7J-'P0;6+CJ?
MD"7@[7%!//A]PJ+DO9%:,F<=6^Z!S^L4,)Q,S'RV0CK,-2Q2;KL;%=.,>0-O
MEGIJR8(T=G+*P=#7T2&0F8BXXQ(9^!5YG#AA& NK3:FGGEN,"',J@,?E$B:<
M>JFUB(F 11&"CI$\17)BJ:<6(5ZCAX_)^B0%#B@H)?(Q@466:X>L .\I8*FD
M\.7AX\)$;!N^]G?1TKG2;/=.N_TA(7!Y"OD,30*N)W_ +E)BQRS8,=ZB#BPI
M*RP-R"E%\MF&0KD_,6P: 1 BDR9<;+R3FVQ%8SFE= V/&KU@PE$M-4\X@<%%
MM&4JI1"I"F1^Z2HU]B*D;O1$43(CK#41"9<;^230V"!H(']$)*&TL92D58^B
MEI*7)<]PH@@3Q%M#N2*YKSNE@5(B<ZC NU*O/8^$C1X<"B-8# (CFK/RN+<>
M66,#B!D)VFJ-HY2E7EMUZ0*(E,9)YJ3*+2RD-MX8265T!OZK1*G7EBMUHZ>#
M)N<O*RD1X=(BSKA')H"&RR=)43.*15J#,MS7&2Y:5">P4A:?1A9'#P=]QDTC
M00,ZQQ"/!I2?\Q()P3"F7G/K9'EZL03.":$Y3H8('0G/R8.)"67 B+1@/"HQ
M=3U8*4=/(T>CIX"<)<JI<$BZS)(%YCW2'.96*IP8"U19CTLY6H(^B@$[G #<
M6. J$">QYEJ)B(64@4^=K5+*T=/(T>@AH'1&&$P4,E8ZQ+&DR+'H$$M$FQ2#
MQV;>+.I2CAYS#*BI<L$)EGVLI(S.RLG*0*2,6DU?@UC*T=/(T>AI'V7@2"EK
MP:EB($<D1*1QX$C%Q'!FW'1)OYC3OH%(L9=P[#>Q\\7C6=K7I$C[L3.P7IBZ
MJ-/. 9*6&4F/!-'FV+&G#,$KK&*NU]:(A^21\9HB&0VLBL324+'QCFBR*1<4
MIIJZK\=3T5664/0ZH6A!1\,E%"T(BD;/@HFTA*8H4=+*@%\D!-+<,\2%5)(Y
MPIGW"V7A+I&H1**7?%1>(M&"D&B,J]MJD<#Y1S8?%G#I,+)<&D1-B(EC'1*W
MN=A6;HH2BDHH6K5'7T)>P3U05 :_%@%1HPD&2AAJK4I(Y_@QCPK\-JP"BH$D
MX7/S&1(6G6#PY" U.P/XZX&MUXA.B\JT* VE!:'06&I%M,H%SY$G!"-N<N,D
M02.R+ 43"8O1QHUW;':.X&>SATK\6&/\6%2&28D?"\*/T902GZC"U)H<> 8K
MA@6*G$T"$5@D0Q,5TI"Y.,9+_"CQ8W4R:TK\6!!^C*;2Q.BY%C8B$:E''%8'
M&4HE,H2XY,!#HC'-54]?XD>)'ZN3451&5YX85T93BTS,I8<Z&R)@C< ^8,AY
MKG)TA221:SCDW$2G3XHLZT8Q\+EI7;/5/&W&WML[B078PR5B-V:=P=2&3M^U
MXNUIO[.XI;S\5)>?922+>9X7?)5UD],/\ D8<&R?9@W8:\)DV(R%CVJQN@96
MSRML);NHE+_W_1X,H]?[T#EVS7:QFZYWV8>;F^Q229R79L\,9L_>>,,%:IT2
MW'G$4LH9U4XCC7U"P6GE< 0/6,B-=WIA"3AE?^H25)XW>6\N4"E]K$6 S5BZ
M7U16&A<0IIFSEU.#G/$4L<B53ISAX.V*ELB7@+/V@+.H'+T2<)8&.*-9?3)(
M;Y5@*.),OAHH1UHZB:1VT7#MA#$+3YDI :<$G.?-Q"O=IB<'EC&R'VX2C10C
M+'+/@>1R]X&@D,24"9-RLVRW@F[3[-EV:P8S:XPFB\J<*]'DR=%D-*=.!!:B
M] 01%P!-B.3(J1012TZ%P*A6N<D>4[,V^BI;:[].*%A4$ESIR2P-(D;3Y@*3
M4A$I$0TY3NLRETR$N641>\^9=X3.RRY8HL3K1(E%I;J5*+$TE!CCF5(&>\ %
M!,9@0EP;CHPR8$A@JD/P!MQ,4J)$B1)+2&@KW8HG1X/1E#9/N*$YI0U64&:F
M?8P<=1X)1HD &Y&)1);E5JQ;-DS9&&<E&N/<2!XL;8Q%H,IXUYSHN:#"$V22
M#HA[%9'%AB#O/(8%Y4Z&E><Y+\7O:3KGE.*W</$;S:$0EDCG@D*!,Q _S20R
M."FDN4TDI62$+<7O18C?XMOGE.*W</$;S2@ G1>C!Z%3*F#$;63(&?A-1:&Q
MH2894W:O>A'BM_C^.J7X+5S\1L_=(Y5$^R@0D=0A;GQ #I0>RKVPL> :>^U6
M7?S*)CO/U63GED"6@C>+X(T>41O/>&0N][3"('A!&&13R'1Y*7&34B2#GG(S
M)KR4W0M6X)BWU&!/*$BC![F*$QJ2B@A<;P8&9'!(!^X0HU$2XP+XX:9L!?)R
M3T-+[;, H1D]UR0IKX2V" P!$!K%,7(N1,24#9PY[E0HM<\+/1@LM<\3"M+H
MD2 6GA(L'$K2YH(([9#37B K?%+@$0MXZ84UT.&;XB4<$#ZFA<Y@]&,T Z^'
M2>A)YV>]8'E19ZHWP+AD,7L<#L-S9 PN#E+WZCOG>]M??L; N-> P28%@;A,
M AF9 (TCCU@YRAQ;:-W](B3EZ;GH2Z K@>ZY3Z\? KK2$%T, #9O Z#VT@3P
MM)%7@8(EB@7*!R\(U!0.8(UZP\03L=F7(+@2LEZ"X.KD$)0@^#P@>'X;!(73
MB6MK$2P?1EP3@@SL=&3 3S>)">[$PI-Y2A!<)5DO07!U,CE*EW>A8%?[, )V
MUF)C+4$XVER<9 W22D;DK70RAFB28VOD\L[=V>C50U^)<$^5&E,BW&(1;B2H
M1W3T@&@.!<HTXAQ^,YXYQ!3CPL$BLA VWG&VR>8B$%^VR5;"4PE/3YJ(5'JA
MSP-;(Z$X08+@,E D I, 6S8BYTA"AM%HL=12R'D/A4OD*I%KE9%K45E?I6&U
M6(0:B9-%1R)5EB/I,H^GU1Q9#DZDXU:E2)3%FLV1_U6B4XE.JXQ.BTJQ*]%I
MH>BT-QK8(M%*F0R"M>* 3@Q,)\T,L@1 BECO@I'S\&PL$YZ*3+Q_GEJX'?P;
MFG^_NQQ[K7\,&]^_^__AQ<N1'MON8;-].5)S&X:.^KW39CJ?+'/$<"+B_3*W
M'8^;<\L<G:I73?& ,S[0X*5F.\!EWQ)=1/0F/"'U^;]/B"KW/F&E=2W[%=OK
M=7S3GL90.6N>-BINR,D#7[DBY8%/=6/E.-H,#:%B3RL)(*/R=\:,S4J]$7OQ
MUC6[\:0+K\%]X<D[#B9H<-].JIPV8N5#YQBFY+QRVJF<PD/W4NQ6\O;,G[&M
M/*)XVBO>A0_W8@N>[+#2:\ 8&IT6/ 0,IQTJG;-V_K69*JE_"N.JQ+\SO4JE
MXWV_6^ET\S,/KGDY_--)8WWL\^>_FFT?3XHGS .#%Z+UC4JO[WKQ/_T\#3 A
MG6Y>BTJ .Q7#J/B&A;6!!V@7SWGSBG"SDRX@=Q<V1B7 *\.YB+]/HL\CM<>=
M?C&[H7+:/,[7[5Q-0SN"X -V]]Y4SF ?-8K+-=LG_3RG#1A<P_X-G^K PL"^
M^CM+<P5N]2M/SQ:LRHUQW1@3N-G%$/PT>ZH;6\6$#H<]7._"653_ZL&S=4+?
MGPYFU;=@!9JI"1\?SL3PX__3 Z&!RV32G/QXG9/AK?*:P<U[Q:O#:PV>>+-R
M6WAO@=-M->HD"28*FA@W/)\018XY,Z!'L<'&DI_;Q?D0P01='Q3=UJ!7:O.&
M*JT.]\A>^VN$;=B%J7IO>\W>]_;U;._FM8"W.VT/WRH>J0[C>M_J^%\O4]NV
MXO]^/3_X$4X<Y;)ZL4M "[+]>FC!9T!SOF_LTS];M4^U7P=UT+CUPPO0J**Z
M?0":\Q>KG?VD1&@9?438:H]X8A8Y&A-BT3D=#=CY$>R7"";)"<S_:;<?-UXV
M,F?Y3YU6JW.69;?0J)4F[&N0G)O;XA(P783':^>/9HF/[:S)*\ZV+.!.(1K]
M[L.">?ZV,KUJ@\D9C.JVV0&3U+(GO?CV\I=_A6;OI&7/WS;;Q5,67_K7[<OE
M5/P1NZ)8B\';_SIKAM-&MH,W\< 6'N;Z#^\\?'NS>&O$&!J\I^0FX_3.M_$F
MF?,]IOA<W[QOL!1O:CW=91\H?!@_XQS:38_J!?D$UYC5"RTVYY2N6+UY#/JF
M%L\J7SO'MOTX+VS$\!X8N-.LQ+16]^H[XN^'H )FPC8 \K$#TXR1-Y7L4T[3
M>/7!F;C_F/O51#1>5\QB44?55Q;7T,S*IN$/,-K'K*O>;?.J=]L8NR(3+:ZU
M'J&.XZ^_JMN_8"P'#?@\K5U\;=0N=GCM^*"U3_?9_L6?C8/M_*V=\]%0Q\&G
M+S"VUO'!\0X8:_NL]FF'5>N'].#XKZ.#HW!4/?[XJYI-MOJ?J3K._:<(9TF:
M@'"R!G$</'*$)Z0\<XF&X#B=BU&T[) ]4^?=PFN[[;3-U2D[%?]YV  H":/F
M=B,70XF\U>WF)2\X90>KO]O>*N(">^DA%F52@MXLH-<<;Y$;B7'2,B1YRDG:
M(2!GC4:8IJ"3=LDRMO&.;.H5XIM:-\C[%D]/6_%^3N42Z>Z=PC^6"77S6G-W
M&',WMD.);K.@V_D8NDFGK N*(<( XC@8[4C#XB-IL=$RX1A4[CV%-\T8O/VC
M1+:%>N%_]MNQPG#A@=.G@+FR]J:LO5E1NHG2W5^V;K@LU[GI[E-*K& 8&8$I
MN/N99EPYA["+6+BH(G5K0U*Q^(2'ATZA[H3O9SV>VNKE4Z6L>@9K=JE_BN.G
MR[CP\*UA</C-X'08Q"Z?0!6GW=?G5P^?357.;*_R7TO F#E:$'T8/.3MU/-V
M_QB%SBD:WNNEH\PC3G1W2>W+3P:.0;0F(*Z"!90P"1F2B_M8C-A$PS#-%N2F
M'$.)"FSJUF4JQ2P[8HF];LL=<?^.H-7#GX*ZX+Q,R+(H$0AK0!8K@2A+U$M.
MI0H.=@3=5'<HCN&^>%/IQEY.@VG^'5OG;XIMDL&CV?:M?AADD0 .QNX5&-W,
M3.FT+P$)$+@70X%'66D4^2J71^J]1HRGO4&:#@P$S0]KS4D#FWM (T>3,$V#
M(?2+V]Y21D,\Y_GP_:33*_*@WA9Y.3!OUV?N_WT[D6*HN_#U5ZR#T?1/[_[*
M4,^B;,Z_9?)AK8>6G7Q!Q,@\WOC9Z%X_UV%$KAOM+V33:>R^M:TS>][;^.=M
MG0\*?WAQP>'N=\W2C3GQ, FQN\S,QYWJSM=/.[5ZY?WNWK>]S]_KNWNU;Y7=
MVH?-.Q-$5FK\-8">;Y7Z7N7#7FU[I_9M9SO_!D^RN[U5AS\^[M:V:A]VMSY7
MOM7AA2H\ZK>7\61_]-NV'YH@^F\R7 PAK_>F$G_G#,-!$F0!>2> (\._BIA_
M[Q^3-O4(0@P4#]&2Q2#!4K*<<QNLYDXGQ:WB6LG$-IXM<6ZKR/3<:H?[,^C@
M [5.NWO+J<O?'Z;.^4:[^9]^[-6SG?Z*,^EX]>RGBS(Z:B2*5!#$,ZF"DT:@
M)'$F&<=)2/_4F72KX<-DW7VU92J?(U@+%78SH_7X.JC0NTIOO<X]G4:Y#S3[
M('WW*INO!U/53.!3PC?[-R(5PQS<6;+P_C4)G%Y,7AX1FT+*A6?0E9=]VLNJ
MN]]>9';BA(CP8(O/$OH< LO3:64\4D=QR_^K7#F <P7F'Y\F.:,-\SRSE;5[
MY:]!(<,=<:0)*9;KOXNN+);*E<GR1-MF56?@9MR^4@3N7]D$?,U9.J_LF7\4
M?\10V8*AV9'''RJ1D:#%T*8<F9MNYVPAB=>3)^JX&4(K+O. [6NN7\MV:;,5
M>Z>=]L#/ZW;.;0ML36=[,=RW=29-SP-G*NLQ;S/%B!TFE%OX7R9R2$Q;2BUA
M)BAKM/3^"4\-7GK\=UA1_9T?U*OGU8M<$1V.J_!9^ Z\!W[HT?>S6KWQZ^#3
MQU_[/[Z/553#>RWP:"_@_[A&]W^#%PO>[,?FP7$>QQ;9^_05OO>U<5!O3$HS
MMAI62%N&:-'CV%J%3$P<W%MK'6/"&D\FGSM>AE%FE9XU$9+"&\Z5_3E,E /,
MMM>H)'!6%U+/\6(2.RYGH )R.94.7OBCSVZP+SFSH]W/Y[RC!Z\J>ID$BU9Y
MCCTUA J#@S<R)$(XG@RA; $(>B,+I# >KQ 5T1)2IX'4VXUS/QA\\'\-[(__
M:ML?IK]W_/UW;?L+VZ<PPN/=W_OUK[]JVP?-VM$7LG\4FM7ZGXW](P]C/3S[
MOXLO/Y7/IZW.(8!>ACAH3V2(BDA1 &IK1"*);[PS$V@-_WMZ]V]Q$+Q\ )I-
MS!Q34D688D(M]R(:'5AD5"DG-;?*EF*VLF(VVB;7&ZXMV.)(28<15\0ABTE$
MU KL+&66&_>0I-SM+%$^R5EZJ9FO_^YVW&5X/;,[V/.\#Z=0UZ];*4MF,56&
MD6 ,3]':@+TG1DF"O6%:3D8+6J+%LM&B^8!2/OK8K&WOTMJ%%WO%.+[0ZJ=:
MLW:Q=;ZWW8)GR?/A6:U^^#LK92R%]CQI9+Q.B!LKD5'>(*LUH(V/.E"S\8Z*
M<:2IH,IL6TXS+$P$-]J[Q$'=6\\4-Q$S@^$N_(Y62^666Z\M]^NGC($PH@W*
MY@KBG#'D=.:W]A*< I."]&'CG<"/, /7WMA3Q!A-7!*)$4Z=MXX*$"'#\W1:
M?4>SBM+86P%9&C7V@DHX<J.134P@+BQ%@(\.:<9PLMICY<3&.XXW[Q.(5V3M
M'0T(S<ZC[2[,X%M54"A2Z%$^ =5K^X!\?!.O#6/D=5?R2K/=.^WV;]<>S\,7
MN<R8,.B>V*V<=BX?8&D)N95:YS16])O*Y DNSL$:,1P6!&@Y\;M(%+QGV,^S
M'2I+G[B<M7;<*>@=!Y4'1=V$Z_1/"TJX,'$Z[T[R777YJW7:Z&_;;1;Y SF,
M#T_H3A_U.%.R CZ/0 [*KB;MJM5(J9RU(.P>^7B>";U-JWJ;??9_>C,ZO$D:
M;W(/ "\=5SX:RTPDTF"!M<743#;2=VL?1\WT;=BTNU?RN)M5>>R=?H7]_"WS
MG89_QVY6\/8POGAK_!'IS/L"K&DLA8A61R2#C(A++)$1-*+$"4M&@C%MS*S.
M5G#$^H 5T41Q36 =8R(X1<&3DR*YR75BY3H^:AV=E%0K@E@(#'&F'#(A4A1B
M3$S3X$74N1Q0J_'0U(18U;?8;H+J^][NY01O<!^R =&;N89T/HF>0*7?:1_6
M8_<X;XBKVH:R&'#R?O#GL!] >)77"B/M4T*Y_ 19&BS\Z115-'*I<WDH,1/<
MY%O5@#-7B<XG_>6:/V[-+ZI??EH*BXNST$N=ZX*50%9&@PRAN334IL!M;H1W
M=R>\X9H/ZC)O*/8L]R$"_!Z#!1! R8.E=-@8DII7>F *^]MLZ*VB&H1>LJ+G
M/12:W>A/6^<W6-$WEV_@%SSQMML]+UR?0:'7B!USQ:H^K"V%?8GR5%2N+.7F
M4#-=F\PP"=?<<15[<M+M_(8M>EJ4LL"T7L]MK_)'+\:!@V:R@^9._S%5&6JQ
MPWE,G I&,,['4D:;%!0-Q&-8:Q*H^"G$QI1LU,_@=*B)2Z W!YMO_.<35\E=
M.\/71D:NE?O?@2>\=>4(7W=M697BM]JW2X3Q<#U A>-=0)A]L5__P@Z.]CG\
M36H7^^<'GW;A&CM\GWXY'T68VH4_WS_^3O>/0JMVU&KD.&[MZ!#^_LYJ1W_^
MVC\ZA.LUC@ZV_TQ5&$OM[*=F*G(MLE8Q18DY*!0<"<*6:TVT\=K'C6%A5S^&
MK8S36$L3O(L\>L%-;D<<E+1"!*J,P%&.%LO-&*(8"7:-=B<8+\Y\>#RWQ\]3
M\L$2;IT-/!"K&952*"*,=V!8X8?*^VZ5;V<'>-I:[>=Q^;\V>[\ R-OV<-@'
MPAT-2O\S"N;CCL,;48['A>)6KD' 99N49B\W_NCT!@TU?.R>6KA5%V8F=]!H
M%I.0NIWC"CQ>H]*$W7C5P^1FSXS<.0#V3N=X@%7#UB@#97IYJY-NL^V;)[8%
MBG PZ[WB@L7] 6"*KBRV<M8,L= O<9"F<76_HB_+Y3UM:SC(:X5\O8ZIN*[/
MP:OK;U\)SNU178[D:OC%9=\,ZR_SX]]2<6\JK>9_^LV0<TCR@#QX",W3XDLW
MVJJXX76+!@R-RS+J-Y?FPL HZ'>O^C#DX0X[T^2W;K60R6U8X!+]7K$M;X3=
M4K-M84)A)FX&X"K?3L DS"6BK<Q@<;,E3@-,F2*X7_!%P&3?5MZ],WM2K,%@
M2FZN2^[LDG=#'.R%D48J X?ITET:SH@][,9B.> 3PX.7PKJXQW)X7/!PI41L
M-UTQA-RT=XH%S#6\!0''A.D?*/]N/+:%M9E[U,!X.G_'005Q&QYQ\)'3L]CZ
M>Q@P.X;A-'JWU_JLTV^%7*,\Z(!S/OCD+,Z,Y+F"/Q*'P<;@V7/EX,-PJKC'
MSJK9*3D_V%[C8ZMSEFV,^ D>\'.GUZMWWL>O\;I/3Z9@:[;KQ=-5B^=:&=?F
MN0T/<(W.?D9#M8A2(D*]1AQ6 ^E@.3(>EH:&)!TXD^_X!"[@*ZXCV'2Y;5/(
M)S)90 ]AZGN%( \VA?6^?]P?-%4:DMO )NK&1FSW,LZ ^3?<EP5HW,,H<U=+
MI3OW+RJV;N:;:';"9F6KU:ITP&DZM8,N-%?5!(7Y _(#;D2_.)&H[/G33NX?
M 5N/;8Z9/D]H.7_S,)9^*^ZEB3;T*[:2V1[XX8[Q8 Q#7K,TL)*MBQA%3)55
M3.G$\5HU6[J+S6Y4\X81(H>;VWQ4$UZ9G /%>P9OWE0;N4'9J&!D&^+65;)!
M\G8]6S()OLF$>9KF22^JTY-8%I?"K D_"RL&+B[[MGD*M_13I(S\,8GF:'!N
M,Y"8*]@>8Y9>W\+IP6GWU23L3D@V6;V>7BL[CYV!,SHINVZAA4>7NF_ETK)V
MQYV8N?;1XJO'ES\W=WI;U\@SXG0)9Q,8_,(X,/ %T4829P(30C*!1;@C67?"
M^?% P/?2S9/C:X.U][^Q%:X<*_PR;=5A-FYHUNH[HDJ_\YQ!NW_TY7>U?M"L
M'H%=^N-C8Z]^<%3=_MC*6;ICV;ATEU3KORX.ZH>DNOU7L[:]\QON=;[W"9[A
MQXZH'5?/JC^^YRS=247CGM D./8($Y;)JJ5#QA"'J*62*:NM%&SCW3CCZ-.*
MQV,ZC3R"<']%B>5G"7C,)WOC<8YK,;O4#H/.22\]D/'<\G8Q(F_<4*TMT<@:
MFGO!N82,T(6#&40$M][G$PE8JSO/]>>DAY^' /Y>$WG:].6E1C)VV]\NPSE[
MZ>-EK/G?0^[>J[2$5QSPX-6MGXXQ@[W2*'C%$'>1YDWI$1>2)^)@SUHV1\!C
M1:(;^:!D$!=P,4<;3L"4* +YI_=E/UYE#3QT6#$2U1C&,N"WL]AJY7\'&0.7
MT6$_/"\9L%K?IJ]>TU@'P9O,+#Y\\$27-9M,Z_4?[/.'>U9N"I8S6#-=>.[)
M>IN3^VSHX45NMY1Y2A_V>2(<!8WVC>*9IXT2O<89OJJ7O7.6GSN$NX+LK\5,
MC5CQDTN[Y=0[Z*F#3,\S*=,U\7MMLW)9-U2Y+!EZ4MAZ;;-;[KG9]]R36253
M7&.MIOFR@>FW[/A5/G<&;N%CY'NMIN>:(KV<DG+'/-^.*7&JW'4E3I4[YMEW
MS&0R(\;NY?FGCTO'F.0^+Y^M_BH7(Y_V5[Z5N1@WYF:OR&P>-E.M#)K#/<UY
MX"MH2/^Z6L[K%)/(]&I1**XP=SRJY(FGQ%C'PAVLY/<E!ER=GMX\>RWVY'HD
M"1S_=;1_]+%9I;56M?ZQL;?]]:BV76O"6/#^Q3X^J'^'\1Z2O1^UQE@'^1^U
M9O7'[L4^_?Z["M>M?:KB*H7Q'<$UX)EK]5]B;_N[V*<?4_4<GX]U<H@Z2&V0
M#S&3>C"#=.;XB#QB3IRG,?C)]1+/GB(P18_X5\!</@LNOQKX?8TH&[W$./C$
MC16<1F,,%5P+XS@/A@LV+7G&="A[DTLC-7_'@"YBMU.B[VSHBT?0%^=L)&,Y
M\M(KQ)E5R 7)D?+.6"J"-D'G8QQ-"?W7C B\!*!]5$AC_8WH&XV5*Z4I79K2
M4X \P58F9QFUWG*?J#:9BB)WK)!"6<479$K?:(Q6 OTB@)Z. +TR,KK(.1+$
M$<0]L0B@G2#0VU@&V-Z:XWF!OC2UGQN]2WO[%4*Q"0ZP%FL<.=C<BFAN(_%)
M$LX3BS0MR-Y>O1Z5+P1R^6AD \QGP:Q!NNCT9*)&1C"!O+ R4E@Z6,H<V1@G
MN5RB77U'HX&)L?F'\/_%(NY\P>9UP]BIGG.](-93[(S'TC,A.*'&)I^<9Y$E
M %XN71DX7A*\UCZ,!8ZYCE2E8)$2-H%%RQ4RVN5"'I,<,TI$23?>D9GA=4HT
M>X*HQ7KAY)K!X3JCGL)2IRC!OG2<$6*-H)Q2%JP'WQ_C,I"[>F@X&LA-Q)F(
MC4 ZB-SK3TFDO6;(I<@DH&'NO3:G?[_:X=H7"YY3N/.EI;F^F!NCX)C%Z$SB
M1'+CK#'>6Q?!E0]6EW'5U<3=T;@J3MAH+L'L#%$AKH)$EAB%@O#4)($E-G31
M<=72$IT#3-<,,]<8&C-UB[)$$.8C2);4SH!+QT0*7E$??1GG7"X$CL8Y(PM*
M<RN0Q-8!!$J>FYQJ!&HL&FDQ4\EF1UP^O]DY!67+Y(85M\.?/+-&G R)5-YV
M8ZO80-=D$?]]NP1W6.B,K[]B7:_3ZI_>_95;Q/M,/DRC>@\7__,PC1 Y4M9[
MXV>C>_U<AQ&Y;K2_D$V@/][:UID][VW\\S;C1[-]>7'!X>YWS=*4M<W/TXQ@
MI[KS]=-.K5YYO[OW;>_S]_KN7NU;9;?VX6Y6])4:?VVOOO.M4M^K?-BK;>_4
MONULY]_@27:WM^KPQ\?=VE;MP^[6Y\JW.KQ0A4?]]C*>[(]^V_9#\S2&W!5@
MG%"TU\AM?S)/_PF8#L._!NUT_C%I4T]LS?'85ALK3I/\;.UL>O_NM)K^_!6S
M4HGJEY]4*S!E. ,=*@GX$IXBDZ1#BC$FL2=>6#[*2I6YGC*;TU53BDRR-*E#
M1/-60ZQ!GY3<M*-U7K$^2P2\>GVAT^@;[>9_^O%63XW0[/DL(9E!_HK+VK9M
MZ[P'EQ\R/,7?)X,&WE<?*8BNH_6-"0/+;3V:O>N+=&-JP==[EX3UI]E,Z-M6
M)0^]=\\#WAQG_LB G7[0&..TWP43[TTA[?U>)MZ^ZN@U; F&G.T5O1UR]Z\[
MVXCD[A!_#[M[-(]/6LT\9YUL"+1N]"@9:1TQ:3%LP0T^LAIYU)<-RC+)N.V&
MRG$\;70"R/SA^; CP.GE1V\L1NH7!/N%0S^8]JO>'7]TNKF?1&R> *Y=M26Y
M\=VKY;IJ\5%<X/([Q04NK_:/P0/>_N1=M\IM7(I)+5KR#>]SM4V'0[XU.7")
MU.F>Y><>3/0_!EQD^0ES Y.Q59NX.IN5'_FZOM,]Z0Q>'K0VN=[<-F2P'0RZ
MV1YE13N.-O=/&;R=>]OD7F@G\,2G65:&^W/06"=W5.Z<M2N D;#=BMA*+@0L
MVLI<3C4,[V38GV@PY=T3VSV]9EN;\-UBEGL/#+S@EV]W8*^ ]BAHUMJGE]WK
M<A/HD:<"X]CG;A%%9X?+]P<RTKLDB(MAL[)[>9?+;7:;+VZDA_2E@%Y?,J:4
MIR?OU?$'>P.CKC3LX(L] )]N'$P2"),=?FNXP_/T90Y^F'W0#(/=-IB.V&[D
M"Q:S\*;2Z^<&?@.X $N[^"Y<IF"#@[FVK4SI#X_7Z+0"?/RX7X#)58^_P[X%
MK7D:+V7W%I1.DMQD6ZU!&Y[/5QT#1^>IT80;=WWC?//!;E_+(XJ\;.5R!V'D
M]<J]8J7,:X<_D^)&<&509)0C3@5&)H".UC8X(A/.N;!KU1OC7O;(:_$>:6:1
MC8@,;X7\M2O3=*=Y=-?YY^6#-&93$3H/'23%F^ 4+)ZQCVTRO/B.&D]U6;,I
M\'2]+U9AM'!9,AV7Y!V%[/K>0O9GHJ]:-RJY#P-0R0@R8.?.2)0UV3__R+KL
M'Y6OT7? '+HH;/G*WH?=#$;7^N\!$KHY5^@%D3%<LE-<SEL%S+;KJ;OJYS:P
MM[=N@/C>A\\#LV<7+.OCN\D_7N&FO',GSC&=U_MR,JP0/E,.[HO<J/@F5]WK
MZ?"#1\GHGDC&5O71OS5_5P:](RL[8 F'RL0M\,K%XE[FQK5]Y(70@+ZL1W[U
MJ_P4[;A>+/]369==UF4_1[/G(H_JP\U(S< ^S2;MQ$;0UU;NP*]X'U.G&^OV
M]WKDTQS!WT=;9&_[?6MO^SN!<5[L'^WRZM'N6?6B2JO;C4;U^&/SX,?.^6@^
M3;7>:%:WO_/JI]QRZ:_CG(=3/3H\KQYM750O]L_V/NV<[__XL[5?_S/7#8ZV
M*4N2"1]\0$1JBSC##EEN-%)&8B4DTS&G<LM-]E+*M,OJY)<*2'_,@$C)8J>,
M9TX2P:5R6G(CO714$\4IY@4BD4M$FIB_E\^SX+<2FE8%FD9K[K ,B7H;4:ZQ
M0UP0C*R5&M'DJ0TV,"M$AB8R!DUC_7J7R!*T0(Z(%3(A\RE[NS<6GBOMQ]=C
M/\X"U\XSSS*ECR"6*Q<-%I@JX@"6250T3F% EG"]8G ]6A2H#"<>EA0):S'
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MR7@J*#*4,<0#5\BJ8!&.UAAP'B+C0"<>KOU8K<[KJL[4IT14\#)YS&U0UN4
M'^,Q%6FOM7E>1W6>#=9C!RY?Q!Q%YC""EQ)9&SSRQ 0I9/2*Y]/><N4(7GT(
MY)ES8E7B C,2(B>Y.(I3'"NMJ""2"&)\78QA';5S-JG >\],-"ADB\L%<<@)
M'1"GE%AL!:-&;6QSOFH'@EH)GZH/"!91Y4UN!3P7Z*[!.DI/J3=48J%K)5Q#
M)9R-B8/_*I-V A&3FX$0+9#3SB%OH]',)NHDW]BFJSJPM0X^454BC(U407(I
M+0?TM)B0)!P&#U3+D'"M@VNH@_,G1<"]M$0P!,32(0Y+"9;0&N2YU='10*0#
MMY/+58/8=:AZV?F07BGF<T'J.V;CE(_QAL&<AN[0M6.Y-5 G_#W(_/Q@$.V3
MHC1IHL!7"5&8H).**GKL'%"E>_>?K4_HK8:[)W/1>ZP8BR9Z0%QGP0&Q,G?8
M=H@&'3ASQGB6#^BQAXL//(1ZO(RDYQHA:X2\<ZQ5"FMIY($&RIT3+E)/*&=9
M(T6HHCDU0CX%0LZ6P?()O M@HE$K@L#!H$ACK)"/RB0.Z FF+/=>8P_==KM&
MR!HA:X2<2$LEP41!$^.&)QYLY)@S(P/!!H/K6"/D4R'D[!:3TUP%[C'R.B>@
MT4B0(R0A%4E2WD87@MW8%@*O6E#X!2'DW9KL+A[PC6/^$5'OX2;CQX(XKW10
MFJ: M<HEPIR)SF.:G)?.6W;O2&8-<2M#W P)Y-93IW-;/D[@1X@1:5>DQU"P
M0RDYEI/<&!,KGWE[,%VH\:S&LS7#,TV8DUA23I3A+@:G')9*)Q,X5U+=.T6A
MQK-5\6QVR],!M1)28*1EY !JQB#C(T9<^,B5YC%JH&P<BY5KP]9X5N/9CXIG
M5EEMO374*L6]LE9S*X$71!8YDV3U\I\UGMTW2#>[?<P-$&43*9(\%QKT*2";
M%*":H9(1ST@T9&-;<?SR *W8??[/P,)-MXNQ9YEL=8:V&/PBQ:$^__-PBJ-F
M%8<6BN-Z_ZE^5%.W8"C$<"+BS4/9C>>M>^MP,93#V#MO=8H):733=('#1K_J
M+=^P)[T8BRJ(EZW!:>-WN&$_=AI_GMK>N?5Q6"Q!?[.QU_%;8VD(K2_;_P,_
M1L]U;GLGK<Y('LPTSI\-^X-6NBK_U.H$N-<;H@N#\P3+M'AN#CJ-WX?MJP;=
M;  HX<W&N_/8.\FS\&NK^[';'N99ZQ</O=D8G/:ZPY/31FO0;UR>=MOM*]2]
M[$30AJ'KMT++]JXF+K _-<_5P=!\L5]M>] Z[_;B9N.//]YN-N##L0=7:74&
MW89]B/79;'0[,:_UX#0N^63C;?<<)KT%5X;/_=X][?1!//X_>W[QR_BWG_+7
M-W9&-][X>3/7$FRT89$C*C"Y$7K#D^+Q![;CX\S8EUVXJ(FG?NG#$W^)(!,G
MQ<3 F#[N?/B(WG;_1K3QQ7H/J[79V E4;KT]^)NBCYN-7O3=<P?"#-/@;!\F
M#:Z=1[D3_K:^,8C^M /B<W)5CCW?B.)?_NQUP] /BM_(+S__:.(+2RT+\:6;
MQ5R4*WO5N.AUO[0"S!&(U4@(;*/3A?6/4_/3+/XTFIX2(T D6[ BKA>M/QV)
MTE@4"CGXJ?5S(]E6>]B+#7<UO@7<K;KSU&CRZU[\WV&KWQK$_/WH;7_0'UVZ
M>"MKP?\.87%;@ZO\1K5P^9(N-BZ&/7]:+/K$W8:P$+WIP?T"(X.AP9? %J16
M[WSTX0FY&^2'@$_ ;(RO.S-$P,S6^?!\:D#Y$Z-!P=?Z^:U\F9G[YS.N, 88
M1*O3'T0;-D%I.P$%@(N9B;2G\':^=!JV4ZO=SGH#G^A?W[^:F:+F\E;CC[PR
M6>J7KSO,;&Q]@6E*O>[YQ,K#@"^ZO0&\<=EK#6 &1K*0'VS"1DR*QNC;\R(R
M+P\6/EE<?D9Z8G_^\S<8Q4<GMH7FN*O).=N$A:KR%ANVW8XG>?:N17M*CD&\
M8R_75"WL0->U*_S*8@42=W[1;A586,"T'_9Z^7E/NMV9TL*@))EA96C_R;_?
M_Q,F%=85[@03>0'7\)G2 -9>ED>F>_%DV*[NDW^_?93](5SF6E&*X4S([]:U
M9%27&IS:0?&)&Q;G:6"M>HIG%Y(18#S[A%QKTB50A0*U0+(*"<G"D%>NP(!>
M3 6O&$Q3OFG=N^P.VR$#:DPI@@A^@8N4+" SH0I2MAJ'$^(46OV+X0!N7\G,
M?_<K;9^6QU(^)Y5IXO.NU<XH"I)9WG=JD+-@.HT[TX/)MQN]#P,KB-&(!YP#
M\1D #VO8\^X0 +,4:@MS%H9Q=/'QA6!4H%C]87LPBX$NW^:J<1[A/M-W=['=
M L>T7UQI=)<%%R_G -;"#<L!Y$5KM\Y;@\(B;Q90$3O]\GX9/\=4;V2X,]]I
MG3N8FFN0[=G+,;[V)TQBGA1PVY#/V-,N)*-PO6 U\ELIPG7S]Z/MP2)//.HU
M#ISF^9C$@@[04?#0*G)6/FNCM?!I1U(X]<?^:2%I%_8:A6RVV/T+\/I3*X^Z
MO.;D0DR3LWF/;H*N52K"!>C01;=?#/1-+V:8_!)_N6R%P>DHC#'QK8K=X>NO
M6-?/3'_Y5RI'%>5(U1LF;^>%Z+F)(3$S\SCQ\[1W_5Q Y#.T_(ML IEX8]N7
M]JJ_\9]I5@R4N+JXX'#W9;,T,2>^\&D63\#3.+WO]M]]>/^N>=CX=>_@X\$?
MGP[W#IH?&WO-M\O9_UJ-OWEP^.YCX_"@\?:@N?NN^?'=;GX%3[*WNW,(O_RV
MU]QIOMW;^:/Q\1#^L ^/^O%E/-E/PXX%XS#(^ ;7/<^DM[ :\:N/.49TFM$R
M PKPK-%O)<[^O$BH9Q"B#!%2:Z5W@@"YCEP$XK1@C-B 651*&E+&+N$[,>SD
MTO@.:T:4Q#9&!9-@G1*4<P>_<X&]\ALK^XG/J?V5R:]P^+_[<VQQ@L0N<*"F
M#5XV"]EV9=^[%PI3<U7-7A'G +I;F/8<2BC =\KC'-U\1%W[4Q9BTIA>%58R
MT]0N6,QS>/*R(4?AK(5^ON:7UDFWUQWVP8*%F&)A<R8?<X3H8*%ZE2,UHB[9
MO%3AG&Q?P<SV)VC*>0RM4GK@CO_)ODS/M09EP.8'"A?L7D_+X#2S)J!+@]-^
M V82%JWP*!E>[%)^ 2H!G_D_JQ1\Y]H;19.*#'/)A+&!)^6XD!@[-VZ,R6_(
M2>O#3,*KY3L#D[TM.L-S\+ 'J+K$2]\V:,?_^^'J\S_APE$NF^^/OC5WFZ>?
M=SU<^]-E\_W^M\__O!-'9W"=LW_QT9D7S</3T[P%T-S]%S>_G5SNG^WC?1CW
MP5_'PAE..<$H\9"3T%A E@>'C# <V'C2V.8Z!\NS="N4SC3Y H2A52IAAH23
M#@A@&)V7REI:R#_X)^?#DHF-WYOX^ +4&3G,XZ]YVS_-NY7M6(P$>/A.Y:9T
M8CFJQ<): E8#0*F= X0]N%GU&GR#AO6^Y.QEF*1@RA.P-0.$WZ$Q([3TP,=S
M[!=>APB3YUMCOVP5;3*"RR 2%9B07$38:E@X&A(UB<$+LW*&Y]MN?W"0WG>[
MH;_3"1\KY^-CMQUJM;J#6M'F7\>*6^*<-DB'?#::BH!,9#$7%^3.JV@-$2OM
MH1K)=*X9+;0T7*9H(Z.<&B9\D"0P?@?(K!?Y@1?9*IXH<QH%9DQ>9)GS0A)X
MVH"@+B8"4@#821><O;T%3&=@!R0!^$A_<<P&",!I@6PNQLXUNA0AQWX1OKA;
M1[/\C>IF0$FR28=7Q;9L,93^ /Y3A)KS);OC3:L?B 3-<MM50-@YYCUWC'C*
MN(G2%57<#!4,DZ(FX][=U'*O Q9QT.U=?;"7^Z-H3C."JGZ(.0Q44YLEZGGV
M232_[="#0\^;9W^)_<MC3I)0RGMD100,ED8C2Z-&'D<F'0M)F9354R[-KY_@
M-M/1M=9HE:;T+4?]EVB/L^TB]-\_C7$P#JK.LA6X&M  \(T&A>NQ()B7 W6+
M]'\R4E>Z9%5X,$R[;/&+;0]+:(&_9M;3BZ"0WPJRD]^K-H=;D\^X;+B;%3"%
MD@C9 4"0M\-^;'PLB5D#>".?AZQ1E&_:XVME[C1H#=I5%!0\^[Q37.Q[P( Z
M)_W9J.?<LBP-=8ZP+=/-XGOV&A0G@[MY>B_A0;)3DV>FW^ULWC#(', LXZ^3
M^VG5&L$T3(VN6(AQ&'YZAGOQW+:*>'D1/1^,@M;?)4W BL<QVO;5/!.V%^#N
M?FWE 0)C?PZPVZD8]Y_V*B_68<^&^+;<%P-.T@3A*G^I(>]VR/OT=7_GF#CK
M?+ 6 2M)B#LJD,[I]XE:J3FA*155Z_1=$&^Q(BV%KA$/^5+N9XS(2+G?/+DQ
MLPBB5N 04Q'WS!B^(^+^-&'-7W<^[.XTWA[\O;>+B($+7I.P/X>NW?+HSQZX
MFX/8^-/V!AV8Y=/6Q8_#JO8Z50+5]*Y0!S3?5W:HU<];?&6^@6T,;/_?4MRJ
M8$!WV&O$KZU^817?%F'J F3WX")?JM!N!\#NBRVNN#O#<J?3K7YZN[>SN__S
M;-94N4CYJN.%JA*-;F'-14[$K4O<6+#$/Y>F^5[?S88HFX16*!+$;*.=&PJ4
M4='^*))1\85R$G<^OFUH7NW>M@#;<QK&Q%2?VC!I%<=<8'B1#=TJU@$KEMLX
M<F- OR+0+L))4)9P[HQPU!?6 1/*R,W6X8_8[W=[TWT31BW&#[N_Q@\5NM36
M8;%U.!+'/+?/],$CR0@'"BS!'D1"$%>1\.0,29)L;$MZNT$HX^W%QG6HTJ&R
M.[(D=]3;"^OSGGZ1 # 1YXI?0?U'CFS.:OI/ EG,T;S1-PK!@R\-5I(YSZT"
M,B(2D8)KQBW7E&LG>6#!,TIJF7L2F?MVPHZQQ I+P7*[8XHX8Q09PBGR2@F/
MDU.4T(UMP1>%1>9E;J5MA63A#I0&0P@WP3IG223)2DZ(H3'60O T0O O/@Z2
M$,8]0U0J(**1&*2]=DA&>,,R38-F&]MZ^3FI2@:RRY?=Q1SV;U]M-3X.73_^
M[Q!68N313)BP2V"6!<!4J:T57N7_EEF28/$ 9UKYO_EF7\JMR9*Y%A\J?.Q\
MU=+\P346)7C-GZ]/Q?]^>5)>M8IF,!)<LI$KK"@78)>)D-J'I(T!?3&LT Q"
M<*T9CZD9!X=[Y#AYP;SS&"4E::[Z "99$(\B R<-S)>FQH))%GAI)[%*-;8:
M!SD+[DL\=R#[I'##R 3+?O;4Q"KYJ^2WY\/!,(<A2MX]$=D^OVC'$8E87V6;
MSB8H7(AKKER0'%",O'^7'VV,2%,)C_?V$V83+D-CI5Y!-I#$K18N\1BY820F
MCUV@&&MK;NNMOM?\;18#EC8RFT*#*02 6?<9!2YA5OJQ\\K4OKF[3_8OCV5P
M(%N,H\"] 9-H(](\8*2\CHH1EOVDU6J?):8H=<Q9CN$?Z;C&A&$'2)*X\NZ6
M+<%Z:1]L:2-F.##*D05%0]P1AS26$DFO4S(<1THCX&'W]FW P74J1.72C\K-
MCA,CLG_? X [*:,7$PE-SX[X92($P.'Z GFCW_IZ0ZK&@KR.C.YS7WKVJ9Z+
MP)*Y)),JH69&C%9,+@%;[16AQ%*M>*3$)&*)MUJ!9%//5'5VF]_Y[/8],*8F
MD/,1?[C>#ML_.3;@5BFA*!*8 O0H\+8=(00)!_;>)@^PKS>V%5[0":-Q7S\;
M2T-T,)P'0KDF7O/H B%!2A.2D'?O=%S+Q(/+!#_XZQ@33[070#*4BXAS#^:(
M"86P\L)[)C G2]N/-Q8ZWIO3&2G3)FB%#)"-U4S"T^S/O-W=/Q@EM #R%WC9
M_W'V7][&WL#F=/IA>]!"5]'V&L435X>*)E>R7V5:=L_/8\_G#0)?-6_HCX,I
MLQ/5N,R[VM4AP]''BTV^(DJ<!Y*%)K1ZQ<DN^%M.$,@;/8 Z75<,K3HFGK<D
MLH?8;H]R!L"*=;KG, TN=F)JE;E'5?J GST//VSE<VCE^,JCP!,6L72B)KRT
M4>IIJS]I+#,:PBKU;!XWRI.93Y/#9[I?JJS4G"XP&EXQ ^65RQW\@CD4'^C,
M)*#/3%OA^'8[Q9Q/[,/W1ZY=<YC3W/WLQHJ./ 438Z+<86:I#, OA2+)YJCG
MY+;[?-PFQFF8_3 :<?%;+@4Q3^R!7&:!>660NI^A=.?81^>+K&AC-4/<<XLL
MM@9IIPB.7# 5BOXV8Q"M%FV[D>>LO[7&X8S)@,)PT&K#5_O%[E]_@"[:PSZ0
MW1#;A=[&,C^F/ .?M30 UN4B$OU8GDF_Z(U.BH\TXEJXRZ3O=M?GD,8X7C+:
MN*P.5,;!94X6N/[Z*(UG5E.>D'0O+MVRM;XKVABWUVFDX6!X?3)J-I=TE(8Q
M46B@GX_" '07IT4=(-UFXQ*P%TQ9QJ31]681;.Q1E#485G(JL-$L1RIP()Q&
MI3GU0LBDK&&:X'37_*'JM,<8R?XL3R[E-("#\>G[FC;>ECQT</C7)=#&$*Q3
M%'N$I76(QQ"0CI&@1(&$.:$Q9W%C>Y$G,;UM5^7:E1:QR-](5;K@*C)"' A'
M8I8Q(GG0P9F *3/),)[ #M):1IY:1J[ )@IP_$04&DG/ N+6)^24<?GT$#;"
M66#L<F-;;)';9026CZTF$E%0P A)+,^[6 3XC_?&1*]=8%SZ.Z<=UB+Q4"*!
M]R^/J7)*66*1)A%$PH>42\AI))RFRH28N! 9-I8UPID6";Z:2/C !'% @3%/
MG!*F;6*1.\V,(%%@68O$4XL$V0>4X$I&%C3"*@)S)L$C9Y5"B1%!DM$""WT7
MD9@6#;%RH$JXP!TWE%H!5L-;FX],$:<X_(&+6$O'DTM'/C;%M3(XYX:P!"X5
MQX8 SZ :Q02^+0&F(;S+?M5MZ4$@%86C!>SSJ@N2D45D/A95DO7I@HLK!ZJ>
MMBHC7+%?"7?I7#V[XW-3,L'33$KE1!9NS'6LY>):$2?K;3UJ\&X]_+V['WBN
MW+?9S-ZBW Y,5[\HM[-D(HLXW;V/B5B-$S8* V/S/$0''H3UQ"H7@2I(%FKX
M??Q0UMD>;9X<$R*"M82A:(1 7.4H%CA3B$7':/0D8"UR3N8BXGZ]370=/"W"
MQ#E..Q4\GBI7NBC\.CZ%]C7O+/1+71YM=^?ZIF?=WD0]Q5K67IBL[?/]!Y*U
M?/#@#O"4Y; *-W1 %&Z,G@N?3^0+IK$WW/-\C#X* X/ACB00F.71\SO)Q+M"
MIF,X;)W#1P[2QV+PY7/!%UK=0!;&UXNT@E<G*7#OG6.M%?<F<124!B*8CRA8
MDA@R,8*@!,%4!$FA?"Z^7J9B5%LZ5:&X7/*GF/KB6.AT79'QV<Z[R)0'4^]/
M,ZJ5-ZCLYSC<.8+!9T\!&>'P71XJ?BUW[ZYSFPL-BU_S/E]1+?FBY)N%I([/
MRU: /2Z/.YK72=C?:ARD016_OUZ!Z;VYB6SK<FK[UT6:QWN&G1C#J*1IOSOL
MY;W)+[;5KNI#;L',?8F]3GG@%NA7<>%,3H D3ZQ="X9<[31>#^>B*LT;8KL%
M%X&!E(O;'_JBX--<7:RI0U_7HR]..5?'&J<^,QI0KJW:[54G@O,E/WU\7Z5N
M37Y\Q,;*(8,MZBX>]P)!WJKK(#Z$]E!<UT&LZR"NY9,]21W$[ZQK^)SS\W:<
M>)]K);P&;W_2>1KMGO<7%BS+4I$K(/9Z1=&(7$=_UF\;V923V!GMZ([-T69U
M&FI4EGA\Y#.7-QF7JP FE<UN[ VN-AL7;5OQKUR._OJ8]&0<(G1C?U2;NE<<
MWBHK!5P?.![:]G6R4"[*MEGM*_OIQ5Y>ZJVXZ2[,1#X/4[TU?RJF"(JL%D5^
M*-=R)+;_P"*\K4C/3GZH)OQ;U[JXV6/XML^;E\?$DZ1I9$A[$Q#'A"(KE$9!
MZFB-2^#323#M<D&UPGMGNRK*L+3&<&<<CQP[[D$4! O,>Q\XK\[.W7JJM%[^
M[UI^T=PY5E'SP U%8*P8XE)HY"*V".R5M"*E:%UV&,F"4Z7+\EHGRZ--FY/G
M*^D_KBE5A3<6X/QF4;MIA2I!_77.77H9^S)CVC%1U_C'21/^YS1VEH8/1G1@
MD+>F*G)1M*0:.^]5@?]<>;DHXM*+V0VN]FA:76"R1='6ZXI L\'D*EO-3F[T
M#$Z[_;AT4$7F;FH74;><Q.87K,]**C(JGS+F3S"B5KN\;G>4DWSS@&8F:#(G
M>NO&Z*23))@H:&+<\,0#T'#,F9&!8(.-)0O/:=[1P.QTPA_5E%P=%H6VX+:_
MPCS_^\K,2'-W'X,9"8[@:*1$BBJ)N$H<:>$CHE(GH9T508;9,O",!.JLLL1C
MRAVS&@#'4DE=$)0%8S<:$6SS178E>\-8,O;4!6&^+'+""VY>U?:K,N/AS6SK
M+VTOC,)/<Q)\-9+0_IO9(.AW(<_&$J?PUJ?<_I_R4::[/.92S/:B']^,7OR2
M:ZNW[=6;5J= FN)+OTR/+,>D9AHX%@,MW[Z.H6SA,HZ2VSE>]Y>LWMXJWIKI
M/5F^IX %<KKT;;Q%[OD>4_Q>W[QIL!1O:7VWRQ9]+0?C"%4%XA07YF-Q%]]Y
M,U]9S&7M?=?B&M6#WM::^ 'Z!C^ZA2TD>.2;-D9NZ6SKU-7[+_]@'91_X![(
MC^E%CHW[2_</RW[(YW^WX?-?F^='I'D(QGOWPVGSVX?3_?-FNWD&_WS[EQS1
MOUM'Y[__.]L/^?,_?P,1>$<_GWTBN0Y1\_T[!O^_.J*?Z#[=AWO]??;YG]_A
MNQ_2?M7;'?XK]@_W.! #Z85.7"2$C?*("^>1\S@AP8V1. I#I<D')Y>FP-]!
MKK^KG?&3H.'3Z,YN0;)M>V*7ZSOP</Q1>H.QB2+_<WO;^9>/-O?R)A;!3G3]
MFR%G5&+X!^G%_E38TYK#'FNMT-99%"*-B#LAD+-&(>TT#1@'GGP [%ET9OOF
M1NQW48,:E$H5^S#7CZ;&I!LG[*>U!*7=F),]:E1:%96NYE"):BV=T3)G9P$C
MHA8CG2A(K](A %G%T614 B=]#I5^_K$!Z6E\QJGB1-_O+RZ=^RJ04X5F&,Q^
MZ YSH"?CR.C=0??B35Z8(GY:OO.#.:"/.S\O ,_79%N\]FCO@]_-MW/XK;%G
M5G*,A'0$\!MS9+R.2)F@?.(6JQ!SBNW2]G[/H2C?!?[_*6+-B_(B'W./[FFZ
MSM\[]:5*+F@4>W)E>OW"W;)<0?G9][_7)3=G#$)OZ]2,F_;4=KXU3XY38EA$
M(A'\I(@;(/'.)H&X-M8[)X6FM.@\<TO![QND[VETK-"E%Z4#3Q):KG7@9AW(
ME1# L96<"XN(-CA7^+6@ U$@2:/(N6F),0TZ0&X[V?SL.C"=)/7LRK!9Z&2V
M39/IJ&5GN)%E6Y#S,97<\>QS>O\JB4^:Y+0SGVLV/?#'R6')(9V/_C2&83L>
MI-$@/HS'T(R#5Y^Y<K!S+*.AA+J E"<&<>\8TB%AI+@FSE-LJ JSF2AW8+QK
MDH*V0/8F"^B/FW4ORGN?2>+<+-/DR_ZW@\E<G#?W2YP9GPIY,?DO@FTI+5Y2
M_LN+2M:YV\S>$H]\,8DY"R)[I4:L$L*J<HL?V8*M&C*MYV]Z_FY.4[I-H.\:
MX%G_&/&OA;$I$NWO(D6W/O@]0_)UT+T.J]\GHE6*[\BGOV;2/\J6Z!'\OO_U
MZ"RTC\[V\>?#O[XUO_TKCK[MB?UO)_SH[-WEY\,=UCP_PG,A];/3TZ-OO[6:
M]._6_K</;>#6</WV&7#N;P>[IZW]PU]A#)Y^/BN2Q*YF0NI"$&6L9\@&K1!7
M-")KHT&162^EL4;E$IB$F ?+U'C<J/DJ>%99H-L@[=4@UVL$J(<*-]8 ]4
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MN$%71*4X2J)!Y1"IYT91CLX$^V&'SK(G9J'D<MH9%YSE3FL(VI6@K.+>))%
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M,BJA@'#K) $&@CC)-:$L*.\2+T?O+U["-;G:4W _'QEXZ*/V6P^F@EP%N=N
M7'9!&V\ELRX"C<ZF3 7S+&G- 12M(+=PD)L\*?>*62Z<(]9K2D!%1XQQ0+0"
M9ID4@MM40&Z:]:B"7 6Y"G(ONJ&<NTGIA),9@DH>_^\Y30A[4<0H*L@M'.0F
M3\(Y-3I8[4D&+D@I[2&>,4^H3XE[Y4&4SECZ&HZ:"G(5Y"K(O>A*X:+SU -D
M!HQKST+3_D$*ZYBANH+<PD$.)BDY<@I*.$Y<]A[=526)%2X39I5%@UM+I4LM
MH[JFEG')4.[N1$'+B3%;UZ1#=)L4FI9/N3](K4$*/3<<=C..NZS(#P\M9B_
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M:>*MLD0S82W^I4&6TA9Y+SK:.<+/4^,7^@$=[2^%0>C7^[#2WBM5_[9 O*1
M=3?"BN53E,]AK69*FK"*"2&%5 HTU39E;@6DZ$-VAHNF>()1-BJ>8)7:;BGT
MSI]33K<OI93,&4(- P(:./%,!9*#P[6D(3K."_OLO7/(JD0ONYGHE70N4"=3
MB&"XM4[C']P@T<2@$MQ"I&^P%ZML+T:V)Y.F6(PT@R&!<D= ,DN<3XY$X0V3
M)@N>&F;IIQ7.KV(]4?:LG7'!H5^A-03M7&G&QKU)(H%0C%6Q7G*QGG05HY2*
M2@Y$9(^N8@R!V&0"H4)%YF,&2UVI>KY/EE#U%!^/B?8Y UOU%E=GK1;K+59Z
MPZ501Q^N(9QE(MGB,H(PZ$&:1$P.AB2=2J<#KZ@/I>A^^M2V2OD*2'E%Y-59
MJZ7P"BHB+QJ1)QV$#%EZYA2!7/Q^+RWQ%A+QP0<-^*]G<=D0^>Y>PGF^]-))
MXTRLLN-3I@6Y!T^/]VFFB CWSC(G=  )0@C#%1<Q1%]*VC4?I2+/ GGU//R>
M&+8SE8KLM%?:LD12E(*@90G$\Z!)8HZ*8#)XEF92>-&8 #SER)@#]#\,,&9X
M"7@#@)3Q'F&P2OOUJ%LE6.4-ATBBTAYU7ABKNV!-Y-DK7&Q]?=;Z_0-DRU$L
M/$?3]^EIAD<]U*[0L%!HF(Q-Q*B53HF2E!(0P-4ESC-.N!;6ND+WJ.U<&%(J
M'*P*'"S)B7@%AL4"PZ3-$$W(W"=BK;<$$OK)1II$J!-22Q:!%3Z1N1R-5TQ8
M>DQ8;-RL(L%C(L%DL$P;KQRP3'1V%!U-RXF7F1/I C=1IXS07WH*W+L[TT+@
MH+(7S,(9S!Z<N> 9LRW--@,KH"5JB'&5D3_4$&/=*G?=*C7$^!/_H>K!J@>O
M@T3!@K?2Q>"I Q%0B))G1@D7;98:3-6#BP>WR2!IIEQ+Z@5QU&<"00EB(4O"
MM)0YH*/+P)7"]^DN2A7+*I8]'RR3W#HEC*<V4W#<&1]X"-13RD,$&2J6/0*6
M31AJTA@>2]?8+-$\ P&4N. 3D58E6SRP(!#+S#RJZ"N652Q;JD>?B8TQ>$$9
MIX$B= 6N$-0X*&^YD]X*2BN6+1[+)B/35-+ LI!$ W7H=#I'3$R19.65BEQ'
M1MF+EYPOOV%6Z:#K$%=TB/5 Y0<'*FTW"/M7N* ?_D3EN=@E3]GZ<. \S=0E
ME3($%IV(GH6DM<A*\'!N?8A*2+8HZ^/+5,@[&R64CH8P+TMSL91)(:PD*7"M
M#:@HI:M<T!5]EN,!9T$?;KP!0/"1-H+4RFL136)"L11MU**BS^+19ZJU(061
MA'5$<&D)*"V(D\D369(O1<J"*EK09SHKIZ+/T@EG19]+Z,-\EC%+T(Q&2 Z\
M3!%8D#HGR;2#BCZ/@#Z3?3!45,(;4;B?2Q\N8,1Z2TE.:/<D0#.HE V8-5/1
MIZ+/HS_@+.AC('O-3<JEH@$5J:<T"$%U]$);;F-%G\6CSV3<U^9H7(Z6).JA
M\'M1XI4&HJW%99)12%HRDF$><=\ESCFN5-!/C9ZD4LFLSEK-HE22BA;UB;0I
M"I!&.5JLVIR-$=E):L=YKU 9)I=1 WU>G\X(B\D8;Q)1.BD"GB;40%(2*9P0
MV3!C;5XBALDJU@]1Z689:)XSHRQ& "71+.% HP;.?=+!W$*JJS _AC!/.K,R
M4\6U(!%428E20!RH3*AV6GHP4?E4A%DN$1M4E>B'D.BHA=1,9I^4!.F9=<'@
M=F ,Y=?A+JD2O9P2/>D@,BK1%W2&1$$I >4C2K23A'% B+;>Z=A(]+1_N(K\
M;LOI)%86Z.HH5OTSF_YY.#^Q<HXN5B=M3KN,RH#3*9.8"J&*MI0XS1P)$A08
MQ0!\[2.TNE)>$7EUUFJQ'D%%Y"5!Y*GR 6:M,$*22%D@D (CWL=$A.4Y"9Z$
M"G;9$'D&+T$WF=+7B>4-&=/+)Z@S$43/X#(\D!.UW3U(PU8GG;3>]0_<X1*1
M8U?2LA_#/,B46-!"1)J QF!-]K:8W]I&)B7,'OBY+Q])[@\.W!$.[=O1[[G[
M+45RE@;]BODS87[[(FD;G^D;_I5[(6IJM!:$!<$(9,F)L:!)1M"GP5%.G;VP
MYE:"T:P2'*Z<DUZYBQX3$\X]\PM,\,EY"2(0EG@J),B..,$421PD$XZQ+',Q
M!.=U %3QX"GAP?R/@2L>+!8/IFR$Q)GRDA%JK2$ GA%CLB3!^.BHC#E3.<\#
MX8H'3PD/YG^(7/%@H7BP-6D?&*J9]P;M UPV HEEM ]2*JSH6EKGO>"Y,"#/
MJUU894!^M(+]QV- 'DWD%.="Y1^:R_RL@(JI[,FKK#;>3O$#>.-U%MD2D:Q%
M*Y(9XJ73A!LN*:!9(#R=$S_ /$1DR6OK*DI6E*S<NJN/DI-I,8)[X36E)%,(
M!'+VQ 8KB6ELZQ29RWF^W+H5)2M*5I2LK+U+C9)3? M,"?">^"95Q=A(7%"&
M*)"42[3_P9GYLO96E*PH65&R\@$O,TI.)O3ALA@9J"2%'X) I(D88Q-QUF:N
M W.R)/3-E0_X46"RB>#^HPGR7\0E1\_3.3Y 40BCW\O^[1X>NU&;G4OQV;$0
M0(G+?NT/N^4#OP]2#S_Y=_KG23<>[9\?>USZUOA1Z?>O.(\/=GQT\U>N!(*%
M^GD8F#!S4R"8A_+G 2&!E]%S,1'OO?3O_N#[<WU*Q ^2^T)</DJ#WUWOQ)T.
M7_SCRM,?= _/+RX![W[3+%V:DX"3D ;73P"SP&3Z\01LI(/N_29@L[WY[LUF
M9[OUQ]NM]UO__K#]=JOSOO6V\VKMZL0LZ_@[" ;O6]M;K5=;G8W-SOO-C?(3
M/LG;C?5M_.7UV\YZY]7;]7^WWF_C"VU\U/>K\62_'!^ZX]@]2O&W%EX7;],K
MA:2_M=*WD K([+M!:KG#6-)%SW\;%>']>MVFGD"(D<KAWJ<LJ>'>&,C<.[!2
MZV13R6X2)EZ<A(Z19K(=-(LV29X%6,@072HTA59%1BVU;M3[E9_W=^,C;3FA
M%L-^BL>]M)5O./'<;LXV\99_]%"!KJ:F[*7_>7>Z^S%^]6A#H%8[W3G;_;+S
M<9.U-_[JH=;K-6,L8]^(!YV#G3/\B\_0]&>%SOH>-PIB#(+X4(XA(W!BDH9R
M*AF<<0*TLR]:"<V)KV47#X[35<0Y<(-/"$YC1"^IW^-7BL*RYS ]QN3'AN3M
M_=3*_5ZO?X*JI-5HO19NC&$JU:5'^.:1^]9*.:?05)N.ZDJ/^JWDPGZ3+-T_
M+#G4_?SS_.G?;T2"Z1F[#AM&@[O0EXT-@'/5<U^'Z??S'_X9N\.O/7?Z>_>P
M>=CF2_^\>@,YG8W?W&_T]G=-LD9'VF1\G#N^\_CMM>:M"8-F])Z@:Y+:&]^F
M:^S&]WYT6;MFV-VN^N/WA(8ZUCK6YSY6KFYUU9\D>$R[-&/[Y0>9'R.$F\6#
M'[M)#V<3T9%N&*34:N/G]H>M3=17\<82&":?Y R4A)76.%>%WZ($ZJ?/?F/>
MWS.80'9E N\K1W?JPK*Z$_F?04)+[$&WX-.<N&VT7_](AREWCUJ_;'[[BI9I
MNKF4K\[CCRHFT<JOF[!*;Y7>E9O'&Z3W)TKXW)<^1"?_QW-5/[F:GZP;X)E_
M\F=F^&V/VI;_H'X#O_9W<PC7>GLX/!H<'Y08YYU('5(L?YYW(9:)3 O/A;'"
ME)8DGF6?K%8BV.BY=./3"+AR&G'70JP1S>?SJ,3J=<Z^X+W?X7MMNO,9Q_/Q
M+>R<;9[L\,V3]O:[;F<[T)VSG6_3!_P?Q-;VZR^=-SMG[3/\W,;K_9W/^Y_;
MVW]\WME>_]9Y\Y9USMY][GQ^G2^JM-]3V?F\SCKK>YYG:I/A)"0:"90.$,X
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M[5XB^*R==RJN/@%<K>5UCXVM<@I; ]4NQ4@DJ("FJ:+$Z$R)+PTHJ,@\4_\
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M$0#&II0#]:Z4^3P%F_6:GB_CA^H<'Z#LA-'O9<=W#X^;"L!15YAF:T'*P*5
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M-#2;?T8E .N'L>+9@^/9Z02>04*EQ'0DQD<@H+TD3AA)I'!6%FY*E9H:5O.
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M>R-,U$)J)K-/2H+TS+I@$'$80SQQ,M.[(DR-W<P(&S !&]D[Q35+1$;N";!
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M79:,'KJ![/JA)FN:886@3)M>Z+YZIZZ]!E P*\&LGE?CLM3 I:86ZH9KA$9
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M'^L2'V.N/D<S3,LT'=GV:(!33 .9N+HE!ZX'MZ:KGA_8.RL_7I2O;Q$*#(S
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M=G'=F.LU0 \@F/94M6T9!:V!4F<#E&HJ:Y=X(1G **?#BIN*?2I!<6-[_0,
MBD#BVJ+&@31$(C7$\(J1FP.I<QG'Q_F5S.>^^<U)>ETI$J7:@%/+=Y:WC5A.
MNB!$[BG7$KHD8WKDCQ27!-;2[<6DNETF] O2KU!Z5/B 4N;CC?4!N@6\C&T'
M) A#4<0@J?&5<KLS=-AGU\*:2MA!<>0;VBU*"C$K"FG\SFJ:\@-B&K?G9S'6
M87OU%$E4^M]^KR/];]1! LE^2E?T'C@D>U-M6HQ; 166,=Z,?_G23L& O,AC
M%C.Z8G+_-(T!'S)F5TCHD<S2F"W\!32@7H-U-PV/(?N%G_@SG#=+?X)4 MCE
MP]_FEDLIM:XK3CTDON"N;FN"PG&&;61:67_L#&? ;Q\0*1<1'U/<'TL*C3&I
M4))$'C&.F#&3_( EQ0?J98S]:DWVNQ8Y43IEI@B'T]9)BTD%I"A9<6U#OKS]
MQIT9[*!P[5'!5H*=1\D]Z-AXH00]33+Z2J1N;<:SHP UP249S7,,6&5E7G-:
MA,^B3+JL#>BSTH!F?+Q>M7JFOH>6]._T ?@MF(99+\9;9;HLV .EV0P_H4A@
MJE>6]^#%3%*46],JN_P:P_[LFTP_CX<MERYLF?V>*<8QAJX3&>02)3$;-/BC
M%_!H\9Q"XZ 8=^U=JIU+ W]3R9ZY_[74*E2GPH<E>?8WH'Q<Z#PN$&W/,9;T
M=SLJ.&G] ;911OO 8/L)K%@+W=,H\V&QANJ,$\?NP*B#I4[1PNP?+Z<]KXW]
M]2<POR>5Z)!$<>G2[2 UX(9JUN)S:0-?ZQ#F^&5F8"\O'T"ORI##\W<T:B?[
M/)-@8(*F2):<F8SP9&X'U1;\?93&/ ."N7?@+M?.M#<X'UN;"_VE#>Y@_GFK
MHU*IEETL;(R9<4A-I2 ;D3%#0H;3!HN)E^Y(QA8' J>\3408GZNT7/Z@=)*2
M'B/Z4UDU91 @IW_)<'[#M1JBP&V^K=+E*^_I'TRGOVGH](#T-Z4^_WE$ES^K
M%/7C(<;.IRGCZB+=9BWI-M;T=!N1.;,'^24B<V;>S)F)20BK)A7,FT+P/,*B
MXKC<K7R742YZF<]D5.>M7"115O2E(UUY+6&>,P9G0)+T@0F'+"+74+O'5?OQ
M>!CG]8OX5B8X@28(BDK E"%_[5E4[.=AP1?)UI6,(<N8.;6\]+[6 89#:FV"
M80B?1GA;S>!?E/RG%V5U2DK/ZZ8T07]ABG@':C#FU?H]KG(.*X;Y(*3"0FM?
M, $_YR8W[..4@)[;1Q2(0?/IE_Z5H:_\$74 M_I>+P.+H<.LDSIMXM]I+V?[
M[T3P#N;ZN,8P"P*@7 M5^CI2>4-C#+[<]#R_^0P'0@;&\7V4]0"5LXBE.=_
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MM);J-*!41'&%\/T7X5/X,LUC5S&$C3+JY_:%EH>:[J?DTIODG/TQ<Y9[YF9
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M,;$ER@+-]UB%(V9.]'%5IIY4.5LL2W]"5LZ+L&6Q?((1:#54AKFT&PK@/3U
MLW:14T\T4R<XXDO4+Y-.:EV=*?!14CO>2VRGC]3OX7LJ#WN97(?)=VQG=4+=
M$$MLHFF(CN;\N,SMP-8[/LL1+G7\P1S@02;:L133.W0=\0[;P+>95$-I6 [,
M;20#IUDWY3[(ZM.%LKSVEB0N$IR%)Q7D\9!0_FL]B)FE!T6-0[*Z)HX[I1>R
MEU=9$'YZEY3!G#:@2QN3)+A?F*6A<TPLJCXD54;[A'2CH;5&5V"= 6$O4I6!
M '_Y25G;E6:%D4?+WV/#2_;]C()029B.5*[_BU;93Q,'@K,!W9TNAKS&7QJ%
MI7^]_D4.!G*&K21^4I9W#9>'+3K1/4QY."TO9S+CJ3 V>SR25H:T5^;49U&1
M5Q55U2L.*!WODB0@.GE1((TC8%NEIL!TR#SO=;H#'H.^B X3\HULQM)!?1_5
MK26'T)2-GZU*%,JOE^6!Z(%7[;=YK=$BFZV#F)/XUKSE7/KL<BY[F^5<\\75
MKNA#0SSP(@"2!?/R-WOWL>_#A!GNR913@RG(!FB!)<@'S6O'TGNF6C+;!*P9
M,-=J1M5EA:/=,D$3M8$T1@653;> (WP&:TVZD"+LYZ0>UR/G_ZR3+[^,CYR?
M6Y+N 6Z=UN5' U!W 41U\4A-ZX>#;3P,C'&[81]IBMO+><YXB28H4B=(HN.Q
MRK,Z#HC2#4"9!:P"@5=#-4 [0,=!] _[('8+_FQ5<'Q<U0;DV-P ^&4'9.?@
M,HZE'[W@;N"M:')HQK;1N@,E$QT/W%> 6$R#.O,(Y2=+< &MLLP\9NX0?&G1
M/QZ4]E55*4DUU;MB^4BM,9]4R2FK2HC@Z_+TA\'2+2Q9APM/D[N4A4,9R8(=
M6CJ>:552,_F /)3-@KIE<P:4U,//()$"\:)''#&:U=*P ?9<,4[J8HHZ5V08
M9@^TDGU,6F7 9L *\.+2/&Y()W[[+(R/GPPL6[@E/%QC[U[:XU?@DRSKXX<L
MNV3:#=1^P*)?9Z#S.^.^FN%;V=UL"X8O+>G$+WJL*)*##K$RB+#(J"Z]R!M8
MW9+.!@7H>?2( 8ZBG4OH"0MXB;VN-!H>9+1!@4D*CX .&<+E8V 3U+T['GYA
MQ#TWGZMR"S@]LD&_O)IQ7!+\;ZTS]RG)RFV>49^BJXPW(=15ME_X$S,KHKCR
MJK#2T?/3B07U(C-X?CS3E:<A.*^F:+T2^<0BGQA L)Q)MPO@>(8$XQWJA#&?
M>OMEDD4Y_Q7#U@N6VU>S5*R[EEG IYO3-]4/;T?B#.RAM\/+36@^R$#%/WX[
MEKM=9/!O,)+:W6(?_5X$XY]I:DNUIW^LM-2IGSVUK--27'.I59_^3+<-L5>Q
M5[%7L=<-[%4S[+E6_9UQ6<YI@9FC7/B?5_JKZ;94*;9*L?=&D50F):H7U6MH
MZOR+:-U'7&9<GQAK5LM$Q61Y6AIY:Y.GTUPGV+G]DIMEYT-F62U51T$AP#D]
ME DV[FQ@;@Q)YUBCU'BP@;**NB.ZQ23L.+4XN#M1$,1TF^!&Q\$J:#H;& +4
M U"K M3/ NK?I%/FZQ+@?A9P_VL-X!9 %9Q9<.:#![7@S-OGS+.4YV4 @,[.
M18R)C3=H51K-@\J,Q(06;Y;".VKB/\MA!FO8O0AD5,]4O1F(L3ID>"AN'FBL
MA=@.!Z4$X 3@=A1P*TF_N7G<6H O%GF.168(^A%*D-A_M99F[@-5\%[4]7C(
ML7FQPV[NJ?C>A($B[0U/^&VE<ZZDGSS/ 55%;5F3.=\B1ZW0>H$C+\%@)]#3
M >#2_J&,U=*>1!F!&2\3,XZ,EO5Z9W!B$,&;*(DGXL?. G9#8-W:B?ZU@IXM
M=(T]U35<HV4+74-(E 50QE%:AM U!&:,8X;1TG<,,0Y(X7!6 ^UNHOZ_%HG.
M[+73YN3TY%*#]TQ5LK39'LI]15U6TJV]W1<]XX"8QCR0%P ^7 !/99Y[ -JK
MRW4$?@Z8K8*^];0B+GCJ"R3Y_0?P3+P6#'4=#/6@M>VD:&?DL9Z<_!*U;M?<
MGS#B 7$O4VV9N\J]]A^ZAM%2!70WYF-ZFF&\Q,C62Y 4JNO.2!\0HF)3:1M"
M5FQ. =)FQ#8%=%>1%1N%[8[(BD.VD:Y9W[NA:8POT4PRE)8B9-^S@UW3A>C;
MH&8A%(L-0M=^FF$<AN@39M(H?"Q+2(HM@%W7=BZW_9"@J[=6S"P2P9;-!%LT
MLV7OA2%QFQ:#R<K5!/:$%JM8$_,5L>X3H6FZO:R3;>Z*WNVPOL.[*]519]V5
MN))G#JO-5+YV^T;V%>[Z1L-M!V_K'!XA&O:L-'\AQW;EKG35G1$N%U?RW*J%
M:>ZW:K&O@#?<%R#(%C,S=]^T/(5O9#CA<6BP-QNOVIA#O%)KLR6\$.*KJ_19
MVOK.=O.KAQQJOJ'9?>2_S/CRK"04$3383&J5/B/[68!WE>XG.)K(%8UE-@%:
MUQ:=95Z6B#"-&=D:0D9L1$;8L[S\ KPKR0C5:FV*E[UPT%K.8<N(0S:&/N'
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MNO&$\;QG^'R(RMJ\#; -9XETUPD/[0T!7UU*LG25%E*'D@1V'O;B<<#]7A#
M5_AO$-V_^[_P1[75#LGNHJ1";1?>6 ) QM.^43F ^7)>]ON[>NG9"S'(14E
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M=I^(_^4UUA_RWYZF'=A\O\+//J["!"#@:9O G:9QG#X\X?_?J/OW>7GF+&?
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M^P;_=<I&U.=L:08(OE<X.Y^V#EC<9PTL*/';U=CTF.1XAD&_CS#* 7)L,MX
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MB_RHR^AX8),,C/9)%=1E633LZ3[RZ1#H2N]!'U[ 5*(!;DXL<ZX+H0<51^7
M\T6J@O:O@O>__H]K&5H=,=W2/D;(%0B?@84^1EQMGEJ[_59<SK8NY_^S]Z;-
M;5S;EN!?R;A=]9X4 ?):\JCG[HJ@*<G6?9:E$B4[JK]T)( #(JU$)FX.I.!?
MWWOMX0R)!$D--D0:]>J&11+(X0S[[&'MM?@ ;NJ9<_-VG$> _CKOC9[@]/'S
M%[91#].VOVF+^2%&"224-.)[_.XP3?N:)NR?,U<5-?XSHP.,=I T63^5:)PC
M=3WB),^-*[/CI-W8ERY;Y9O,M2@R%<8ITA4K/G?QW[OE[*+]GOY7]2O7U#T%
M!47[5L:HKV84JN5%):/6MO6L8#_CLNB69J;8=+%'4184V7%XD!@MOA1L7+R%
MA(=EM0(_"HW.'Q)BI :03BW:4G-DK)@O!;/2.O<VP\SC\^S5=*ZIF!+%_'#$
M0]+N'']PX373%R6=CYRUV1QG+^AVZNF8HY1X0Y?D0M.#PW5"<+5BSXBV?MW0
M*Y-'KZG;>].^RZH:S?:K0B*J^P<':&]6@$ESL-HFV*^!]Z?M--L9%F[R%S/L
M6TN5YKW'M$O&<<=QO"/!<J#"N9(*YYL#%<Z!"N= A?.^5#A_.?#C]IF6S_Z(
M@O-2<6;GDNZTA.>9S]CYR,A_E6(4U@T6"#EA[EQP[?6*WJ2 SS7M6SBO LZP
MJ!%Y9#=;5O2*Y\4A9MSS'/.$RO$-#Z-REU87M$C$_,YB!;=5_4[&@EQB+GTR
M)WSM,*5[G5)-MF<UA8?GRJ$5V+TPC%.R_-B7AXG:ZT2ULWKMV#*>-S0;C#?H
MRR[X_*U%G(F_[^LXA^G;:QY'H!5,6V<$K%KK$0P7B,&F=2.P)V 3*X>H_!Q\
M=A5/)?TOV%G J\+?R.#6S3F=HW_H#C9D9+P4>.7DJ\-"^.S\I*@L%25YV(-N
M1PM5P4";[+:XV]&%=+8/&=R]3[BWS=LIPF"=X_R;I71H=MXZ>$N3*+M#X5#7
M%-.^NULXA6>ZRGW:4@NOG,TMJH@!E#;.RCF!IUV1[&0V44YX5DY (4K,'?@A
M*ZY:&>/TNB</: 8G==T4%XA-<#4@1!J#H2P<,F8(5>CUL[+.*PY0(MNMN!2Z
MD*M:3M4U#4"J_$AW:[I@MW+0@>,<:X'D*-JVYW*]C%N+DH4N;HPYFZYE79+I
M:J4H\0X,WPYS,B]*6='92S\-/,@IXSGMDD667^1%"5#^A*]"D65=@DV<W"*+
M-T >*_L)V^_"53FOB+)X"V;9&LA'>D4ZA!7]'.HL;ZI6*RV_U "7 O'R\(N'
MW_F\_W7UF(F:]5G=EW/)H&>,BI'^S6S@"W0Y/1)PHP6M;[8'G%)I>[I$CCP+
M##POI' P8$SP[@D8.D5$T#$@<Y%$;.MUW71]I<\Y[3?X!%K]_%G3,!@GYSO2
M^BQHL<W;XVQ[NCUK_0W7OE19:/4U<^F\8)/7\0Q.0=9+>[W-FXV !FG!X;&7
MV45>]LRGRLU4'$EB ..4@.S888T%O^5:ICZ/M,YWKEGI\L"-4>.8 MIZ02^
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M$9L_/$\J<*9*XZ? T"U0(&[4,VD"%C080:(;J-6W^XRU$&SG,#7U^I>.FHQ
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MP%L+%SVLP;]@#:K<[((<0:[S"64\\@"*S%E!,K1E"\)G>UENR"W0E5MN1.3
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M,Q0CX#H0[2TGF@D7-,1ULSG8OCVU/"\&6Y5MG2_V-$I#AFT)\-1*.3:XO7D
MQ0]A(P/RE"9:$;7H<3,<"-/)!_0'E@AW12D=FM:8M(7#ZDSUE%M'8T"21;W<
M!](D6>^DTRZ&?-5@BJSP:>T7B?VQ.V^R2W>N60)R='NA.3U4A^[X%G]3+?*+
MNA&-G8"!E[7 !)P.7Y&92P!7T%ORL8JLC$"/<],U$B$TKR9E/RR(O["UE4TT
M3<[+GUY+*[UTI<ZUD#X#P'Y6M"M?-DJZ5A=]PX;>?VP2 /@K6DWY) 'LTXJI
MJ\J5X8AH?>#$J\JNAQ*EDOB;>9IDE3OGBE%*R=0N8=S8D9@DC;I\C[0#.^^$
MAT-6(I\C'2N9'?J\#OOD:N\VI.K@9<PV.$A;H6]'5F!6S#G\ ]F$K=UHX2G]
M=&(D0S-JR?S?)9[!?"IY(@>N6E4-J<$%?K"4^R($@AO%/4?B25IC_B9HFLRE
MCXU9 :KBW_33WZ8[(.(;/GB0=W@;O!@2FBB/3]0H[^=K3(:667=RZ9^)<9]S
MU@JD25M2M"=0<$T0+'J@O@]F[[.8;PV](ZB0T=MAQJ(8O<F+UED_-* %%3EO
M;NX.; F?QT3&92A1H[AP9)&]O@CVYYFKBKH1B9J@C/HT94N2- \+B.:FF7KW
MC[M1?$#;P<,#2B.?_;LOVB*@UV?0DIO6W@@>3L<[N\ET%7!N5*2(I8S4U)>\
MUT1,-UDA'N[>]C/HR"SZ#Y<T.<S@1\]@5*T/$\(1&LVK:*S.-&%M6U:,X3\Y
M?]TZ!GVDNKEF" 918<P:JEI 03,G7B-_$XLZ["84[M35JL:CUK.WD8TC;['O
MN#3 '81LA@]V;W^[QB<UE(HKRLKI44<F;BN!!Y Y3;OU!2IGNU<X7<AEEG4Y
M/P"C]IO]LCKM<$MRRIBEF22GBI"P3=I(WG4@-\XN:L#]8?GNEC%+!0^F#I$O
MZIL(E%8UJR[2OTMF'&]G3;'V:]L@0G1<S(4@"MMA2JZXY<3A&42Z3SZQ>'69
MI4ZD;X.'^''COD]M@A]?_/KDU2_/T2/ HK$GIZ^?_?(CRVG<+AT-ONQ_,4G8
M[ ;O_9?HTN]\IIV2W)$"-%V5N;>2)EX(C@4"WL91;-D[20<-F>]3%O6$3)]9
MO98%69E&V=+D;O./NYV1]Q]GSV0+TF=8=.G;[]M/+@I0M/&C,M:!J8@FGR+B
MRR[M7!W8B*TTRZ$MZWT-^U=?'-JR;DU;UO[M^G46\R9VTMH"N'5',5":_C:C
MUEYC1(^SD];,$OJV1BF5/0:*"18;)Y]<T@-3*,:"JA:02:)*45BN(C<>JS)&
MP\_RGMDJYV0T-@'C%X6X1F>N3\4=:1S;F;V,?9TAD:/3*G\U#)PUL^+4Z52=
M8!NF.^1@LKB5IB%LH?A0RS(*NDA&S@MT= =><3Y"UX[?+&,\CFJQ\T(+YYP
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MF\W'LU"L8SCM!WGN>NIX8D3OW>K*I.5\@WTR7-/^*OI1'&I0B:<HF1<;IPZ
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M)]DV]&&WO6G8S<A%SA=_'MM#3'G.Z9\2/D) &XQOK>/LI!K=3C>9I,C>MUF
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M)R-!U<<U Y5S5I9+A^[,B5?!D_5@8,%00EY0",*PDR!)%R^G0(DS?(P<$(.
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M,Y'T$P["/ZNZ<ZMVV7O6>5\J?0>CBRA*Q@;S$G2VQJ)"[S6EO'%I3ZL#FA+
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M8<Y:$V.DVSB'V:YS2QW\RZF3+I(%2R:(5P?=F4BDAX80\7]"-J4F/.*;2KG
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M-PF$!S/._"=ZM(*R1"-IC,[+GU[O4-^D!2-BY3OF-(U:M. :9!YRF8?XI-8
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M2V7R64[?JM*TKQ%(\QE+N*'J8G]NX3T!QB.MYXIN;R63X5=UO0*K)9^E"8V
M@R8"G5E;.*\5G9F 8FDD#%L#Q[,_AGBSZMF#!(,=AM@#%:#* 3![NL*T]-R
M0_%2&=R2S\A$;3X7Q>(;3I!<K'$OJ]Y3@R74]N\[7#6LP&4LA@O91%=JN=PP
MJWD 6Y/VJ[9GD@S*:M&-2J5/8*CU77U5@RI)7!J_!0&7#4S! [,37PC  "?:
M;O]I[5WM@96(SO30-(L:!:%U G8%N%Y:)9> O1!GC&C[5FM"K^MO2W4S0+6"
M,6P+=CX;U]-.-6':U&;#S;:*9Z"BV]9$J2*X:-+>O$C&8_L<M!V3&6(E];X.
MU9]"GYT==,6>Z)):":3!/';$0PD8G@*E9HB$;4S9^"<>VR&ANV$WF1R=,;D(
M#3GJW(I+-BE\34(.8O2-+Q"[%GRUR.CHQ^Y^]"9"U##Y_1>9N=0>@T89N[U!
M9^UF=#2TRKN=,P0K[,VF':62G .X)=K'[L<$<J:1Z6#?R('P3X9#Z>="0RBX
MP  ,O#%XO?74QB)E 7Z0J8F8N@+GHJE$<T7O^O$O[SYTT/J:2@%Q@*(1U#@!
MY?_8T<5@KT2Q5_\+1-Q#\!8'^QT3*HNF.>8L&?Z6,FWAE[ESKJS23\;,:$3]
M\W8<*:&)<(I.7A>--/:\Z@^)X3@<C, A4ABK; 0$]]Q:QK.NLF5T==XCE <3
M]&A([J"O![39%%&2D"<LJUF58:?*=>1<OH&XRE7:*@_'_/K&%K_-:_$]<!LL
M:C>0W#=ULMJ'@5.Q*,%6 ]Z80.F\<4-;:'^"#8.&Y)2M#?A$/I& J%.\@MVS
M4]BOXR!/N(85?"&LX-D:5K"&%=QJZ2S:RH[NF&JR18E%9^Q!2&KKM*!AMJ$Q
M%X *[ -U?[%7+8!1PX%#BR1-,#!G#NNHSNP;)577LJ#PQ)")T$^&49<[KQ"U
MQ(0^=F?CP_ -$_<YB!8PB")?DZ&NOJ/7^EA8.0DIYOEAH5[#ABWNO)(WIO*@
M0^0G\M+.M@Z\M;:B;["D#P]40Y7,U< 1YNF^&4<+RIO45DC)6?]YN,H(1'&D
ME2#L1T2Z 84X)>YN9@.GCY",._I:2+/ /0/@VZ:50=]<3A%N(L@N'$$Q%#D&
M5>21R9B8AOS#+GRW28;E2XJS):V9%1UIA*5,Y4,!(<9S3F[#CE"-$ /G_???
M!^X/E928NUG=80NK'/V-J^LL6BN3?>0U;?'=L$->)M29DYNF$65(R9KJG-6:
M4?5NYD?B^=ID_\6J>Y!/*</T>2>]LIZSNYFS;FSL9X3I:4+G \DD> K74W9'
M"M%MC>T"5*0.=]A .I8STT0&XD"-J->2<C9-850JPJA(P%GZE)/^W'KJ[V;J
MG827C7K.RNK,]?3;.9ID#4_UA2E:LZ:QOKMIRHH_6M4ZV_08G8EF1@O->"*<
MAY/H.N'XD7UJ+K>#RZT=;)'_N465" )%W N(S]%D+&U!S8G]0I&/2;MGFZL7
M$,H''H_RQR']*:1O34T=8J(L@])&!-<U+E2A$&4^G+D.$WL,L,Y<OL]^\MSD
MDRBWT0P\CVJB,T!/1I>,U?6\KA_++O5S[+W:>&I#[3F6:EUF6(+6L0W(5(<\
M%&J!0HI@W =<FA\J_FD/ 5*,U%Z<$K#+?:H/O<A#_03<,P44A1JJ]6H@E_8C
MG88\^"P$D,(, X'4N0JC"'_D$5#HIO?TCEX(Z@F01.]-$]#B02MI6 ;A @?-
M,?!A97F><%?DM"RRALW (CR&\;7KPV[I,Q#*"RM9B&6IX^NT_7':!$L6U  8
M\J_[[+RT%TJ?;8<=WJ0/R$2%\&]?D1&<()6&AM#;=1^.H-;7@CZ\-;3NJ\V<
MFX9'V:;9E.[^<C+9P'JNM/?3M%3TWP#K[96-/50%KNA@PWUL52)Y+4(K!WC-
MNH<!"])9O83CX\UHCQ?<W'$"A%R#2OV+UV'ZA<B8*^0U'>)N6+FY(_@(5A%A
M8(\$\X,U!JH*XRDNJL:>B\91R=4^;_?QY)?'6(:\Q);6>D!]S^F+BD @J>F>
MX85,<09D P%$8!F&""?L.J,5+\()]=VW ?$S1R)(R7?R"$.=3(U8\V96<:2'
M"D+X JZPJEI4Z+WM!173NF+*_\*3@=H"2&MJI759;MHA[ITN+J^CRYB)8S
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ME\A\E5R41%9KS0AV+%$^C!/!N"[\$TJ_3T&,.XT$QF23WW#\L5]653MK[,%
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ML!YKF(A" /C-H.)^'W?FAM57%<4\!%TYU-1:\CYG!M:/8:@ZF!*LJSZ@A0+
M'#NI[5C W*F9,E=9KPW<?PX,5TFD]'I&00A4?/3NEP<6& !^DXNRHEYHOY+<
M1REU -H "!"76[)EA(21Z=^+\/PMYO60+4V8'FI<*'9ZZ#,P_WGM22$2Q<3>
MUHN:SKY>N]AJ+:(;1GL X'R5D=,/\#J:&N?NHU"!6*3 X;>1B" A L'CU1JM
MI6,CXZ(A=\,)MECA'?"D9+WAI,8%Z)2Z.^,<2R<0.P'2CZX:;GW_C\'6$3L5
M?#4_ 4XB?!#XX&.MH%-A$Z9=9A"%QO&8X(MSR,A_=\\)['PDH&P*I-P#.]2Z
M3@%\Y3$5K>ISY@>8FH C&_>6E%=IPVT.K,"L"'W(; 8=R\8=-B0G&+OV,\JJ
M[NWOO=NQSCRF?1.]1C'VI#@:&7FI[:Y_7V0DE+Y9S/Q>5ZFX89T?)SU,8@O$
M8D,9,S>_W?NJKLBU!;NA!7N_=[R_]_YO?]U^_N1E]*A(\O(SS/"O^X>/H_<)
M<$2=S"KJLE$]F#XBP&8[^VP='W6YF J(:Z7,_SET@3!.6:GAO\9@JX&$4Z(>
M&@*$[NQL;3^+HU-SD40?@K15;?^*:!SP<=]RGQ(,YN!G/Y[L18\@'*#X#'I+
MX7./H8&)* 3V1B-H]4.HSGL;Y[P&=O$]W\,4/=I[_WKO,0:87=4:,;(N] +Q
M<WXA93;HU?&U0+,!V06<'+IJR8,G<VEQN.L:U?-MUR1UL8%.+:)UHGUK,0&2
M.LY2 @,ZWQ6F1LIOUAS 1W!V084'@E8D!&K(]&;5U!_$=$E[!;ND3))[ =DW
M+!&Y#TW'V4/2U#@JHM=F3!W .SO2NH+;$U,R2-'>H+QH6XR%3M^&9K)UG"4N
MT C78(0WHZ/"NP7@.L71B9V/\K\NE9 &U$U"9*'Z(9=<'DYIV-V8E)0&#,?0
M08'O 75B-SR%T,Q$9><'-'=LI9T7KPZNH<-*)? 9F!'4<>"O'ZQ+FYV5T<??
MHC>'[_>/G,W^8+]@KUB?9[/H$7_J<8SH*C+.M"B N@QM88:'PD^;?AYJTS2Y
MT![+?>Q3O3&CBOJF:/5M46'1Q:V)*#[XQ%W4SM@1PW6J[+-L]0<TR2?H:X)0
M;WA6U?ZPBK ]"(O0U@T4Z5IT*-E_<<0P(8ZI>_PQK[<0;6,8KR8>IX[VL4.)
MR%=ITN"4;J 3&C*H8%7)%).D,D!U7;8'2H'VH0AAX/UI<HX5DXP$89PST">P
MG-2!M*5 );"TK11,2&#;+JA82.61HES(\AR8.!DQ4F3B".FX46NLF!NHCY&(
MF#!#<CZO 4E8((H#H?38$)9179]P_#+:+LBTSKP3&N[,E##1]UT4@%!?)#;8
M&>6F@YNVKR!-B';SO8@=[P&(46-+!^2&(8U6(I\Z  CA4=&+@I2?]=& ,DIW
M@V+?(:0"$>6CR(+L' [99D[ZMTUI-] ?AM*(XHXY'\P-(CP=9HSLZVW87VP@
MO !8/N3:+@G_<+:TLMM8-$#C+0M@J/K]#9YTYUI/&GW#)[C>6 6;VR[_/6OH
M\FAW2S?9>L%XZ JTZ^9SDI;?[LFM\WPM?M5>!=LZX#]O[.*W.Z[YR.Y.N "2
MPS[Y:>>NR6'_\@_PLSLV25++Y"__FGV:]D*XV!JD\2:G:E.3(Q; 7@GR3-A-
M7)MAAW&]TD,UZ:/*?"ZCO5?4-@Z]J<<NV7_JTVPU57;P?-6)?T$)$P+3[HMA
M8ZVU2FIFG6+89HLM75$YR\HL1?.,DP?'<&6__X"L\5X_W:.]9A*6J50-E5QH
M.MV04$:&-NZ>>]RKBD Y.'UQY#]E3K4.SL2]Z>P\L4Y(-;R7_E[[F:,+L[?E
M\HF_)?G?_KJSN_NRM)\]^/W_.SQ:F[XO6A!A=M&/^N-H#Z;WD*=WM;; #;.M
M'UQS*/(28R9ZPD5AV!'4LT]-#DE6=4D?)<'&U=]^09# LAIF3=A5S>II/>F$
MF>*!X(G%E"0O'D"PN30N.D80QCPDA]&5+?P)C)5Y<I7#P$IBIPF !'HZFPCU
MQ8C%33!.$LVP*2ZRJBR8=.X4KRL?8PH202S3%Y)+>_U"R:&[0B+-A(TD3=(@
MUG@*BP-"$VH.+@P1D0(TVL9-M2,+Q#(P7,&@883$39Y $JHLJ"^*;L$9.\ T
MP%I" CDD4X>E@G4A^/,:=OB%L,,7:]CA&G9XJZ5#6Q]-@:FJTN[:*55=$9T'
MI6$B).0>;D* 6]LP-HZJ00P*;'W^P#DIY*$)(DIZKM\QM@2L%I@,=YTX!!OU
M3S5(XT##9BWR[NYH$] *Y$&$$W\$O3D]SEN$Z7CON]'\IM1I ^DYAOK-[*EE
M#9MQZGPAV-(IXM'3##,C"X+&<2E^5Y7CZX=1&J+(HA$XL78V<]7FXJ<D4)H@
M H^J!)$$^J+G'N ,ENIRW(R 5:<%[WZ$^=-&BX7@>:5[(LN*:5!JF'G#RA0H
M$>C(*6/W/%_'4TK-A,63<&MQ*E7ESWT*UCD4=N$QA;;?IW^O.SNU]2O1@V8!
MRD:?1Z'K!#S%LT*)<\C:5I_"G%@7&H&I5 /U'84V2\9P_X1SM7#G=_OOG!M1
MF=%<,4\O -$)J.QR#<FX39# #2/#K*UE-8.\-NI_F\\VVJV!\H?@? /80T:&
MLQFE)+ULBDN@5HL)%ZHOY<4NB)E<T?PBY]F[/=JFE!M$\^O:5P)DXXI-T]))
M^>AH]8YH!@@C <4?&1\::# @V(#ELPDU\O2HB;.#3X+I"?T;H,2":7+I(NC&
MQ;,^B2H(-ZQS0[VCE=\IF]$OPLY-!+W]-2"*K<$#R&-F91&6[IG<G&BB)EE5
M-P/D=*Y^SXH\6 5U:CSVS<X1$8"Y2G>?6%@J10D([&###!X)Z^QZ0X2%:+\H
M/444=?K6OLP1+D4ABPZ>.M=/Z0KH\BS!+S78KO-Z!*"&@X >UI%RBZP'OT-6
MHP9P$<U-4M6#L,('M#$."VJ3]Z ..RD # .AIX7F"@R:!Q+Z@P-KA<37B=1H
M7CNXLWJ\&)3<%S>+(_KR>X3U\7#OT%[P?1GE3"2E[7<FQA5Y=[:V8AM>= A0
MBI;I2@8F5-2F13%;<9,+J4KO:?R>0<4!\VGA<#GV>)3[0MP%-HLD5>KEMR[-
M=0Z)Q%>M%UI^!PF@;IU&O 6W8Y!I0V5SF1**A7"&FHA<(2G8;<J0!0XF;A\,
M>GNFLU;X4EEN<(\0@<2BELOWNI^4;*)/.=*O40K6_?DDJ3FU'@64B^A(- 25
MXXPG6U^? XR#25R'&J=(3^03A!_VOW^0G?=8'F2XHW4+5+>;<A#U9MD50.V-
M<@ ,A&\'Y[=3IZO]*X$W;&H:(GT^ +QKC<'[IC94$:9"+.%6 T^<[A" E>0)
M]Q.,L>V*0\8E6!K_:2$N:[HZ<DXJ$'Z'[6?N [2FE #38F]C90D)#M^?'KQ]
M>[!_^G'O;?3A^.C#P?'IOQ\^&<$'LMV"W&\7=7Y5\!UL=@>F4N172C#A4N;,
MBUTSE7$0O+GDLJ+Z2&T@7?;Q1M>+\N*5#O.N"NH2.5*E3U>.UJ63HI!9,)#,
MIOEWZ/:K3<@9P<!J^F*,Y"0&_.#P-\ '41G?C#.K,A(FLS,S(24-I'MTU$.Q
M0ZYAHH.ICS3?'I05@$,;IY(>F_@G*DC<<.^96XD%XJ40S\2$Z5E1V+CBH7'V
M'7G^;V$7E=Y-GS&Z>E,N[TKR/&>5@;N \S"NA('6+A;K9M,,-==ERAA:9@]H
M6DX H!C4U>PK0M*Z$1BMZN;EJ3-%0M*KO75_Q=QQ;R\S 66^^0' D^"-AQJ*
M_%<D4&3]HMASN\"\@I] SV$'.!.QWXDGFY=KA#M.,;U*V7(*?,05.=$VJ,]2
M%&3T;YBHBU^Q2.-.L;0>VS]3WR,W'U_K(MS;CC$@83&=EK$=(5.<D<I=;LXP
M_<IRDUTU'Y&)PH((;#/]4DN?X $M\B,T#K2\916J98Y\8W$D0IWX3S33;NV0
MG)%KY@KW 'V^MVU BYC"?I_1[^"(\8[T=7FL/P.8<D._"4G)<$VA7041M'L
MGSG\</R89%X,'!W+CH:95,_Q0Z12$?("#LZ@E"SXE*(]HVP*^GL=K^(!;1H%
M60MW3D>,'%EB/S=,;:+P.7QP^/.>>.?0""T]*+H388>-VS-2JFBQZ-[@15A
MID-P&I;%IM3>8U1>%V\=L+)?\V$SI9-)C;VL<VKJ)J8DQIQ\/Q/AR6;.,JVV
MG )\]8PKNI1&IB]WG(_56EDW-#&G;GKF0?V36&-@<*P'#E5Q$>3H!%0W+: ]
MX- JVO?CUZL'8\K3_O4, -<+!]:!$X+2Z#5]95^:1;9@/YM8M,A!V>NLQ##
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MN84)IA>(YP7N!Q6U,C<;Y/)CH=0N,&MO^!>H2Y99HP:\$_4YX'JH&"NH$OY
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M@6>Z$;8D6T<=04H71IKO/*J)*_FP$;2$ J2&9 JPGU7TX+VV@IMS" <+JH#
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MZ8+S?@JLD.#X[QZ=;@D-X1,1NP'L,9VT+-S[ ;EV1UT9H$]VB "+VT)&W@X
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MY;=*S _# R0L2R/[(?N4.2,SH#[O7/:"4:0L2^KI),7(4IC.HX*)-0GZ<(#
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MBAS\<AJ\KYC+%<1GLFNKR##6 R^'%)6 A_=+$8V$](Y@4=U-1U3:\&F ,\Z
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M;9WQ/N1HC\2CC'_S!+%!G<Y7YA-Q%9"+8 R>JM?MG>A-O33Y'MC\A?,'5(I
M!L*$^((Y(%8(;F[9O7706$Q@K&03X@B(K!!00_.3T1<&LS,6NA]QO[QB\)X#
M38!=?W$MKUP5C\'P#V+[3^P2WH(R!X1ZSY#CJ!D3.I[XQ<'MKY"]IVEPF.T\
MR7VL,,)6OD@4=93\LJ_D&:$"<H9K8P,&9"PG%AA?+%/:#4%<1[$'7?QK(*NB
M;,T);/\2>XZ:A2WVXAJ*5P*'>CX9$U["-4>SA_>C["<)7Z.;89_(W/_D,OM[
M80,K<GE%$/U82J6>I2I8HE=%Y790?\<_FRQD  V&JI_6ZUN108EH5E??K0H*
M[T&/&A!UCJ[D>C]:2=8O\0S;,(+9Y##*TN]!8Z.K?59.O+^3XU-2LK.59[ ?
M_2P_B5<G%0%JU";RT3*9KS@6*&;S0P<$Y08N80(H2SRH:FTY#LJR>R4=Q$3E
M8^4E1+LQXV"I$ 6#H4OM7PAD9Q,Y#8G]S9%S(_V/CJ,E)AZVGKG8)R=FV_"(
MR[7GZ_D,>T*YWANHV T,/L6DG-^NRF4?&@Z_'.)<JJ'6Q9@3LCGPZFGVH%'K
M<\VR5U5<15DAV8,FE?.83R]5XTTNAQ\::CY=#*XN]&"M%-D#<*K/:ETI!_@T
M(4\3RATYM;7#*;,\YOLP;5;. @?,=<-#(;;/(-9X_?#T(3.Y#6%A&DP!*HYG
MBR<9^\/F!%P0D<!ZC;DW8 LY_W/OW000/HF:9 NW5.DSZU<0]Z.3DW]!:"7>
MPP3S*;8)L+:AU3"LU7N-351[X$C6 ;N"@3K(L5/:CW!)O$)I],LQVP='H5W\
MNR)RU%]_\3!-OZ=SI.K3@CL&/ISPJ?1T-]A6==<;^$:R/;#P:&Q;;H:GH/ >
M-".3+KZPBOEE0K 'S9$&<\>P5\[.BDKO04/6?=XMA!3N*9G8W8D7K<!Q+URI
M^BR.>EJ7.$CN(RQ>GJ_*YP<OT\0S+=&FFL_$2[;%JVGCC7,T&LJ_+@%2^TB%
M/2%3_/'-_P!02P,$%     @ (9 !5;&Z3 O;'0  U!D! !0   !E8G,M,C R
M,C V,S!?8V%L+GAM;.5=6W-;1W)^WU^A**\9:^X7UWI3DBQO7.5=J20YSAMJ
M+CTB8A"'P0%I,;\^/0<DS0M(@D #.E*VO)1(@>=\/?U-7V9Z>O[Z[Y^/9\_.
M8-%/N_D/S\5W_/DSF.>N3.>??GC^Z\>?F'_^[W_[RU_^^B^,_=>K][\\^['+
MI\<P7SY[O8"XA/+LC^GRZ-EO!?K?G]5%=_SLMV[Q^_0L,O:WX9=>=R?GB^FG
MH^4SR:6\_:^+[YW-R9B@65#",PU&L""=8]IX";$JDVK\MT_?Y^1ET3XSH4)F
M6D=@GAO)HO2BA%)E #\\=#:=__Y]^Y)B#\]0N'D_?/O#\Z/E\N3[%R_^^../
M[SZGQ>R[;O'IA>1<O;C\]/.+CW^^\_D_U/!I$4)X,?SKU4?[Z;H/XF/%B__Z
MQR\?\A$<1S:=]\LXS^T%_?3[?OCA+UV.RV','\7U[-Y/M._8Y<=8^Q$3DBGQ
MW>>^//_;7YX]6PW'HIO!>ZC/VI^_OO_YZI5P#(M/J,LT[?IN=MK@]-_E[OA%
M^^"+U]V\P+R'@G_!?YZ6INY7<=8D^7 $L.Q1GN'YR_,3^.%Y/ST^F<'ESXX6
M4']X#JEG3>_<*MY _>L&#WWQ)_ <9_ET-HS3+_C]Q:,;NCW) )^7@+^Q&KQ+
M%+,NW_C0K*FN6US^YBPFF T_G9SV[%.,)Y-?IC%-9]/E%/K7IXL%PIL$"(VU
MG!7="!QS9BFIRDSRQD6 D*VY.79-P!XE'%1>8Y\&O5^\XD4;U1<P6_:7/QG&
M>1CC^U&LQG9[N5[FW)W.E_V[>![3#"YE2TY'G*V6\60YTSP'YKVUS,1L00CC
MBO'$LJU'<E.^:^QYN<C/ND6!!9JXY\_^@&:0+JS="E9<Y!NTNCO7+C[QHC\]
M/AZ>R:9+.+[\_6;Z2#FP[,B'?J5EE(. !HM3*&LDU+K(&'QDRO""<(1BWMG$
MJBTB1^6YRI6>">O!;$(&^=62@4 !9'QX@X:_.P?T,;-F7]? $C8&"RFP5 %]
MNT3/G8ROK$)P*N>@%#AB7CP*:A-^J*^3'[0*(>/)/[LEW#9@/LA2318(1""0
M&A*+T6D&13CNLC%: C$SUL#8A OZZ^3"KH-.IOVWRR-8K!%.)AF+0NX):RQF
M  )8-! QTO=!<663RYF8 ?= V80%YNMD <7@DS'A&HZ7\_)AV>7?C[H9#F__
MYG].I\OSB:@"DC:912<3TUXEEJ2T3>;H(-MB-+6[> S3KC*OD=)HQ1-(ST3,
MBNGL/*:S+C,CC%%0K(F5.B5X3*[1A,R[\^+V#-A1 ?L@_\2(J!5XP:R+'KUP
ME2QD%"^GY MW+E1N]\?SD0;(]*K?=LCI$J:^A^65S8VQ0$1[BS87 S"M1&5>
M( %=,C%I(:3PD3I)N@Y@5VE>Q_X(E=3^:,HYBS-\:/]R^3HN%N?3^:?_C+-3
MF/A<759*,U6-8=H&S7Q%EQ4Q4ZW.1P&!VKIM!&Q,!F][7MRF.+U.R,C_'OKE
M8IHQ#VGHK@*/$E03B06><#X;65@2N6((:AQ$#&LD4,?]:X&,R0C2T6'W,:=<
M+!H6KMY#!N0E9B'_A.4E(LC1AQ@#XS68MGR%B$Q53'AG,46)$F3:T\KA.CQC
M6A*@(P.9!L@X\?/\#-_=+<X1R"0*Q8M-BDEH^SX>OT2K,@.T5#EJ'RQP8@Y<
M?_^84G\ZG6\]PF0Z?K> DS@M;SZ?M T8]$U#"GI30AM]-A 2\Z5@,)9\9#X
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M."ZD4M0%7INC&Y7[_^KIN:OZ]TW/GZ;S.,\W\4DC' =161:M32?.).9+#,R
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M$IPI."_:U6F8:WD6#7AF2])1*0N9/+ _D&ACNI_J0'0>(VGV:%O?')_,NG.
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M6UV=O N?<?[S9Y('/7\\";,ORP.45I?J-<ITZ3*OM\,1F<[%&)U JU2S'^F
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MKO?4&T(;,2Z3$>05Y\ DJ.@U^.@*Z% 2V=B(Y![W=M#= /(UD^EPS6QM]W-
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M9)VE;QT.O(_B6#<9!^OU09[L+-\>#H+;B&XT&.F"JZ>KAFV8CG.K<*C.'J3
M@0(?DA"!2>=U*D#\Q]5=G*A3%]%%GK5RK+0N)AF6"(]< 0S%@UWDW'@LU5N<
MC*>SOT_F]2H6\^_3!<Y_NL 7%^\OY@O2CEL/J<^J-A]2P'(B&Z8X#9X+#O1M
MZZ6R,K,N[9@Z/N[8UN"^NIGV*]@>O,EJL2Y6%FN=1'UYIQ4RQHP.(N,*5)W'
M$9F2('1FUA@KA6G]WF_"<2HFP,$R[L$IN(MIS?8.J'HR 38C.HX!<+C&'J'
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M]- MS$S1 97D8'.H^7.<4$J+9&E[,H<<]T4-,>SJV 6;3R<XLI=F>DA"?+"
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MY@0<LQ*>*>94:U-E.YH34W\CL??0^N.726UM/YU]>1/^_"TLR%(*9W7:9A7
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M[VY&/:FAAU/R&B 9ZY,T/ALO<;U>?,#9B_Q?%_/%Y5R*R*-C!DD:N@Y8U49
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M" 3OB>^WY;>/*%M<4>_>QU8;%>YEN-]]FFW'/VOGK;%> >&X7A$\>L1EV&Q
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M']$O)JE$]= MYH2[F&4[;3H:]UG>\1^C%ON5;QQ.SZ G E7:B>@%9%;@6I+
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MDN 6*:P5,IF4:C<,.OL81 5B!\<;#F>E;8#UJ7MMG4+V7CK(@J/W*(($0ZP
MSH-Q*8<0;.U^[^<:;VBJ,K4X&+>&]+>U1?SS+,\7UROPI0'&+$RFD]6OYOD3
MFGRNC&S\=3'/DV5Y*XID-_^P6\[?XA?.IY.XC@H?&UMH!*1B;&$,43V(+3@F
M A6:!^8]'GO6)JVMYD0*;4A._*H1IJ$5Z:OO_IS^*)<(LZ^WD&9?BW/Y?K[8
M >K]':@OWV&Z\TFE])8QS2 RW'2%MN@>1)Z!<#39N,N2Q.HM:=LL97@5T;_2
M[":5!^'W+Q<N+/]OLOSV%G<=]*H6[_X,TYM8AGMW7<+_XA?WYQ6CT0;%%'!/
M<9M308/+0:!-9<H(5.)\]<X 1\ \P;RJ,]#6QU5%;?FM:(W@1GYU*Z"/R75I
M]6/MW[^9Q6.6$K72:-('R&5\@A B@I64@K;16>&5Y)X]<YPT@'79JGEJGAMX
M81O(W94O%J!%")PSCA:@#6"L2/CJN-(UKM2.U*XRVC[[LI5J$!,-0@OKYJ$?
MYO-XOZ7,;_-IO$([76JN,T3/>3'A WBI%!#! I54,T%J7\_L1_-#:RJRU:"H
M]L,"5[^6PY5+N)LY[X$HI4&P,KK'6PF:6AYSI"Y6#P?<>_P/31G"1X,BUY]N
M.EQ2U[V=7_O);.6DE?,2I8%K+RN?Q)5TOA]JN6Y!]//LS?7\9H9*O^>??)PX
MCY)>_D6ON*,IE#"*U,'B3LH)F$P(4*.8$Y&8$&KW>1MI:3]4^ESUZ/'K(H>X
M%>MKM!17;^\_W.+K9';E!0E*Y@R24-S8G> H,K0;%8E<R4B8$<_=-.WYZLM6
MJQKR?DR_&IQ[M,_C6'W<C/?MKABQ7+IL@*-NHN_K$E@2$;3,)A$D'_]?.\7H
M(&27K50-67RL:[I":YY[-Z>?=MV<WI-3][V@UED,(B>B-#HM.:#M*9QRX*A,
MX&P4(D5!2=35'<FAJ,?*03I'S1R9\[-+8-I:$=L%KL+MADA#@]%@0NE() Q:
MR#%P?"VYS<IP=,-K1PR?!'2J!*:QE6-?6M-@DIH,JUAAV810#P'3*)WI.R G
M3F,:3M2C3L1#I=R<>DY3Q)W6%KWV(*ASI5^5 "NLH5SQ3%3].23-*3\T7:DQ
MXWV$6Y'IX@QL6VMO &V+)&.,F24&U!-3SEH+-J:2)>PD%491XNP![M?.+S^9
MK7R,L.<U)54Y''=[$_H=(/3B@PJ:X]ECT9/3PH/5@8#UFD46)3>&'T#=SB]_
MJ=0-EU2;X1P/)E)$*CDI5S!6XWXB$90O\X4C441EDS/1!S7!>$$#?$YD>E6A
M8+QI/0> NJ1I/7TX.FQ:SQ$"'FU:CTK).H):S3Q%M]=J Y9'!5P+'C/AC+B#
M\GG.B_7>TWJJD]Y'KI5MKFWB1$'U8>%P8]L:$Y[@CL4C,%>:I"O+P">O$5BI
MF4&^:#[DUGO?]Y_+T)9>HI]7EEN##.WOYP1%'@T++ %3.H)(:!N:5(;3<,FM
M1GLPI-J7@V<Y>>D8EH=+M(DC?'].4.)<&Q$4!,_1X$^&ENF "83)6N"'TO.J
MNB-\AI.7AM![O$0K&UUWYB1*<'7-O#IMDI;&"Z[1B$P*/8,R =)9#][K'%.9
M(718.^IGSMS=3[] 6[P"#16S>W8CVO9T/ !316-\'X[Q;?$:'#U)^0 !5S;&
M]V*C0@8\@DK',(4[E4@$K/$4B$Q*49+QMP]JVGY6I#]ABH_%>1^Y-CC@_X$[
MV&+BI@\BE5OK,J=L4Z3H<<2R7"8%^)P]:$$\51Y]$5L[)?1I1..: '58FS<3
M^5Z#?J1"NNT0ZGE^&/F^]Y?\7]N;S(J5<\<]N6FI7 5A/*B-(\KP3(E603&A
MO?2$..F-]BIQ)7W:41MW'(BZQ7#WGO3Q-H6A=+6TP41PB5K<.*7$-R:@=>9D
M=M0;3GCMG>007$/WS[^E/Q8IK.W&-[Y;^>A7+'@CE,MEH@VNM;S,UL4,SO%,
MB*!1T]I5?+MPG#XS:[ F/-P[!XN[P17(?4REF5Y@S',HD;&"18+3(8 ,1LD4
MM;?5.]+=?_[XE ]GY F*>XFSQ?7'9C?]]-1N^M-V-]VT^2FN'HD.I-0$!*4!
MC$\!F* J6"XX);5'LQX!\U09<=5WA-84O8Q\-G0]'.>"H02]!\$)&HW$,:#<
MXONFK=!!7$(^6W-MZ)7 UH>5YEE,AX"YU 2V7D0]F<YTC)2;4Q^RIHHR/'^9
M$R"4UH#GLRF5@XGRP(6(U4<,GGD"6SW&^PAWE 0V(RF>FXD LU&!0(<1C#$)
MDL@Z&V.=U0],T)>3P-9+V,\FL/61U"@);-QKI2WS$)1!K?32@J?X*;I0]@R5
ME#DD]_ L$]B.I6ZXI)I?D:]38@5Z(U;0,@N-XXZB<'V2.%"69QXLS=D<Y/F]
MJ,#96/96);DW#Z%NT]@/P'1)D;)>'!T2-3E&P&-%RG36)J>4(9"BW]8H,"4[
M@ 0?>-2)9E(CE_7<(V75.>\CU_$C9<I'0351^'Z0DJB#9H17C@*UQAM'#%H7
MM8=:OXA(62_6^D7*^HB\=J3L$5\K0:44K__[70GB=!,\ZM[-;JYOVPUTRP,B
M7SUTHCRPNU.*\NA^\:T*2[B-5PUL\]IU"?VR;=BB[EORX,MK3 I9?^4OJ),W
MB]4PC;J(=S]C_($=.UG9.6ECGT#ZOG6;WRX_O.O2__S7_P-02P,$%     @
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M@1  IB3P?^__H^\/7#UPN5U;\T3PZO!QYIR.ID@RR39*I1O44K4S=" 7SWW
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M[2_ZW LLNICU9[0TI ]5:(7UMJI>6$)NG-.4=V<^_RT^R+9.<F&#I,/VP@G
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MQ$\S/:Q+;H_E,>64TJ(M@WY*ITK3(P?:J[ ')I_ F/4>MHI.OXN[^M"!M5)
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M7@ C%.X*CG4O3586V<=3=LC>>\V@=YMVR-4;!&'U5*!7_-5ZR=_)]78_063
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MSK4%=#2.LKS^12(!]QW]D*H(RQ-+4P\/5%(8*-_RS$(\Y@)IV;Y3]%0E(B6
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M)5E[BE<HRU>9!S^I*"DV0:ZP-G/D.2BJI;NW^O,IY_SMC0/CLK?&>!'T[.<
M[QU=2J$Q8>;#&O UM*?'&K6O5Q'Z8_*Q@1<G.@D :A/9M&D=US]^+.SMQ=W&
MD@171.WFLEM>MKF$-'-K_TARJ%X[>S[S8W4EHK9!R@;M[)SMNB>B8[:7I6UD
MP)/&Y51=U[QE8JE0^C7?;CB$^"3SM"B0,M$HLWI+D;(HT-WES$OIVY48)P#U
M?MU;YO&%EA5[^>>M#UN=]?!4ZV.Z>3$!,;JUBDFTT/Q\.AT6A9I9J&Z8+"
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M=,QQZZ@S*OR,]@TVT7</YH"IXUC;._*H,)'M;QUH[[BXK@1=:DFP"FD<"57
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MM%Y$^<Y38VAI OFSC;[JD'I530Y?1?4##DV7@V_P.D;TXI("T_S?MI!QU^G
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M.&N=@[D@BPJ3^^XMU+B1)^PC\42B%H>+ F\'&<R<LREBK^9DW: 4Q0IH;2]
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MD<A"T=D+^]_B1:*+9W^8?<B?M\X3$A04$A5>("SZ__M"2P$)D?GD>8&" NN
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MO-0HNDQ1BZ'$GAW:'R/[QP9VZW]J9/_OP/YC7)W 8D$!S'B"$@ >@*8Y.'X
M"ERP@%331]^QZ0SC<DK7V\K5(BAP1Z%2WH]7DL84.VB;%#2U/=XVT=9YA5?O
M]S#5$7'H3A<B^@ %3+Q0X+U_ 0K4O$"!V^:T_@W4'#J_"/P^?IV//!4OQ?VR
M8J YK2>%.AE+A%^X4>'K-/#%[ZJ_J_ZN^KOJ[ZJ_J_ZOJMHWC2Q:A +SWZ+
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M\L6D5$YQXHA*0G[7VX+AZHU;3*[@0? G:EIT> Y]Y=P5YH5JL&K&C=E?/5%
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M^J^_S&C3-P:O5,7FL[<4SU'!_#7)@O#JZ"\LU^!A# <E#^/J<;X,*AS=0JO
M\Y6H5"T,I&Q!\[\-?$[0U+;]%%CVEHB6KV4#!J=74A!9+JZQ%3-T/JZ*\<?N
MY4_ 1CC0]G>+'1+^)B1M3;D#;V#B5D(Q-66(5-/SDI:<%5&W/GZ>OZE);Z5
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M;VOG1VP7>A!4JCLYKU" 9^C=XWH?J<<D?RXM X]1(X8J3Y_:B3\^#J<K>Z&
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M*\TYY& K(_^A1M9WKT.T./DM9R]5;,@7&YY8'.9:)[3QFD\J<\Q[N*G>#%E
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M;\G4HV<3"-[K/SNDP#GF/W:_ZWPJ  DX\9QD]N_P7+GZ>_MT2OW1Y\]SSZ$
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M3N;3/>MN[MZX0+9AOGC,#3PX^*I!R%NO@K $7O&,A&>=B93QI\2[QLR0(T\
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MJ+Y3.]W&[%4$R_2)/ \ZI(.(RO4TM&_ GR&L'MJ&:+ <VP)QS-"8!V]W-7W
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M;.Q*8<I5O"V-P099!S5F=&EPMB<%V9?XJT.0\):$DL/_<?A281(%H#M%VU$
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MH> FUX']5FTH$-;6?ZSQ!V@^;I$QT/(_KMU8OYKQSJ"&:NET&VLI@]V+W+&
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M_+[79M#WYXA](=A[[N=U].\&2V9O2O]_V'L/J*:V;FTXBHJ*BB!%$(@**(J
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M$+=ZL!P&>GBY#%-<=TV$#R0 E6KBJU VDATC0@&HXF0>@[[--=1 )P.R/ZP
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MNK2BE&I+C;"1QC*/MGD]/95^?4D52O7.U+#-CZP31T>0GK";4:<[QDMZ%+V
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M6)8.?_#&!AN@E76Z\"HS?^*%9Z&W?K^&)#.WN*%J*%#0M)@I1('Q+P7QA!B
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M[UC.OFA]///&_J;$USFM^6O0U*N&&BA#Z@\7^FE.%SWP,R6U#K-BF$ZB?AR
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MVD17]RJIX3,B>O59X-MQ*/&M:1RA._6\I)QYI<6..D0-E_CW'I3C<@I3#[Q
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MK$F>DT:Y\XRRXA&O?GY?_],QSXA;G]U.Z#RL?W)#.>+P"]CJ@@V.)R*C!$B
M7M>V*<A@R89 0ZG8D4MGX[&N5  \)K"DDHT5'#Z^R+8**@HT!03YY:V-B=0G
MP=,U?K(!OQ1\E<HNVSQ,@LFS@HW8*RM3N^_=&..Q5:VK<F>>]9O:;Y!6&*5K
MG9U#=.&(.%=Z+I'\F-3Y>-$OS4FXFF&P6.XIRA5S=ME:(_'RKB=1^ULC6I0?
MSBB/]E F<UGGH:^2.T">'(^$D8G X?9T7,2V'UVU2ND+,QK8H0,'^ CWS[R\
MV4AF5M<0AE"43'0Y_BFD;'9Z$I6YWE;J;F/W6*2IEIYH[*%XT 5X]<8^!Y?R
MK69$7.9SCJ18?J#EU/!B+D.@-5-EF*U2%*C59CXV/RE/3_[RYO;72U]3!>W0
MY\6Q'^VT"ZZ'7HEKL_Z:E*RE)%FP_+7CKGE^P(=>0F9N+XX?%&;)XGH)%0)M
MJ)%9JF%K,'GWY-Q!Y:<NH.]4Y$]6VLI/XT9)$FT^U2KJ@MJDXQ_6Y=?MV[<\
MFM!\+L?/^(:+Q*) #GV8DM4"=QCZ%>#I)J(\.3X4DL$ZT:O>O<%J5$0[/'^?
M$YQ?8)CW_0'NU1%,>7F<>L;)3]*E#65/KX]DZQ)>5>X/./8M)+EZV(DPG'\M
MC#NY*" DN6)^@UTH/(<LP[!?H8AF<+-7AU+UG0"G1ZQCFXA/_>S3OZ?"<H!Y
M/]5&LT<;^RW!X7Q.U&_^)S/WCY.:7Z'I?BAV]C( 7VNXFDDP\%PK@';#E.&Y
M8\_O1RD7(<MA)Q[.:M8'395-Q++5V0-L"GP],Y?XI],'X'SZTU-K^&_<OK^%
ML?EA30!7=FR( IKO*:3-0<^$,)&<R7]LJ"I5^U=NJ.*:.1L \:)8ZN!C^X;A
M%6P 0_-84UTB[?9CF@3M2'GI36&]UIA,Q)P\GGT&R7391+S91-"R(/%@,@.?
MG_=:($G;!+ZMNYRT!CUJM[XNC%F.X<<*G:LG?*=8H[?$OA;;JL=^[U%(2.@P
MM/N%A@Z;<3* .;CZ?6L,VD1T7>+89U?G1.(C3"R3B^_13@3>L30MQ&#4",=P
M%D";'!P:&(X(BEV-1_UR-V2?RV+!-]@+$X^N!VN;B)3DC6HKU8F "_0O"3YX
M,.)JZ.?/0V?716U.<E\<'DCZ%9P4-<8R%&,OSD(?86J8Q$C]E96QB> E4$@K
M#U$[%-E6,A$X!:"MLZU)J/;KD0%42?&CLNJZV_;9'_SW&:6,&WO?M>'56GU@
M@]Q$[,F%N@D_KFTB5B=ATW][ARL*W;_]P'2 D(5MN(K66FE# :+/(2.(L(:2
M0]&$8-17#44C(?OA+'8%W@ ,@\'E$E8 3*/S-&=Q82T95L495,Y0]FE'CRF#
MNB"+CJ7L9]?BP1<\>PWEC8X4:,FGD3W>VP?,50IIXU0JQB<?VUIOE7O'SR;_
MRGJ>Q=@)+(YM(@SB-Q%*WWL@._._T"[/_0PSNCCC7>]/#6^[STM+&!&Y+6['
M'$1B.ZWNG'PI^>9YW(YC$Z@E<<Q:&5!V<A,QS7:&7+_)_-G"2\AR4?8>/J8[
M)U-;,]]-@('J$$621+M\ZHD/X'ZWOW4;,9?DLB86WYC0N7\%'=1K.]AQTU,_
MY5Z=:DXJA?Y3<[ZC9Q J_.4*20BP3@$P)V68;2)VGUT!>^$?$9PTPAP YFXB
M(B37V9X+'@HOEG1LX=_TH3_(/U!L2Y@1Q =#IP$B''4NF TD!(<$M;-Q$W%P
M(ST*\1=2AS,"<R%^F%B'W@PDM]ED*C$PH>Q;>1X/GLQXCHWAQ1TKDBX^*)<8
M3V<U1=58Y1M-[O/L'?GR3M[**E>(8]7S$* =Z &/BG($E84!JB><,^V_S?L%
M:)$ES*4%%L",SYX R3=!V94;DPH0SGC%!6W9"O34<#Z"/-#AE_"ZYD#O288-
M)%(-L*V0C%VS['W14&1J%(%>"9,(6L'*@NR_77GCI[8,FQ4_'O\_OFA\$8TP
M.]W$1/Y'K&D]2^P!U7,@WG9Z1IM^.X'?3T!L+OW%HS>B=4#<BE12UQUOA_"Y
MNRAY5E2411OM=I%<5:.M>2OUC4('+^H\MOQ/_G3[DR-5?ZH*/ZI=[?E3*<GY
MLR,'!J[P=*'H<\!H!@27X"@ ]%D!.FIZ(@ET70%0!M_A=6',!BS(#5QQJBM_
M2/34>3?5]>F@[*?QJ_O&=[T<'CMM=<XW][A;/>J(ZXZK\8J#PVET ;8^S!^Y
MLS<1V<XT/%O)>Q,!?D#]R1 VY %KLGT[T/,I9)&X$&CV:QU9BQ0E 2T\J!N-
M*.H?63R%VOJ,FP*\)O7=] J4B+]5?U; 9'=)ZF?-E>29T@9!.-N_PR!#K>D@
M&$?N0.WV0R/G#C86X[H^S&7M]><S?G'OQ'UCP8+C>E*/T7Z]QM\U,K"8%><0
M&WYV]+)AZ^3O$6]_F%!EH/<U&*)B<%)N3:CAG\&%(0560]"1!=& 4]>O>Z?8
MN-Q!(#[-R?EG@>H8B+>1=M;,;(BM_Q:K2VCL\SI4V5>\@I-:V-?ES,VUQT"P
M/.F@(7OGVVV+VT)Z#9!V;?@JB*G\X08P.XZ;QB)I:%!=$.)-F#KK >P+)+8V
M:0Q6BB7R=T/O&%LW@MX=NBX2<*^[,_\#ZJ]B2XZ#$2)\^QV55UM1OP)@6\&P
MJ.U4%OV2\L:QW].;K4,KL/_R*\B@6C7$>RO'0VVC*96^WE[B:/<ER=X,&5M,
M-#SR['/S,B5T"[Y)-N=[(!Q RD?72S;>[P6ZX##_'ZX>+^?^]ZK'D&@;"CQ,
M7C1AN!)S6]'[*I6?DB9?N-K&IKQA;%^]R&[_,M1R]H+9+/I&K^G)Y\Z!]2J7
M5%YZ'?7#<OU%OL:#X;X0K\$FXGQ7.QJTFX"7L5K_*4P88J#75M'!FE#NDTU$
ME@\KX7\B+LU_-MBPV:F3_S4L_]+4.7^N"B$< ^2_A;3._^UU5VW"")1H<ADR
M5%O+E:K,&YA%<\EZ[T[?<:>P"'?$2?%NQQGY&#HL]:\01Z&8U\0K7NG"^!2
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MH+ZO2-QP4G1]MCS!=B:)?2KH6OKSS=I7M_4%+H5S@, "MH@3*&M$( IG# V
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M>([YLM&HWL+U *O520@9!(-89"M+?Y,N>6 B>&%3[N+L65#)NHYP,3  MO]
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MEI;U._#W;Z^H%4X%'E*FN_Q*;> X_;VKH!/-*>R%Y5*="K*+45<.)PV")&Z
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M ,H@!/:X0U&S6>V(X5$ !^X"W=K6 8GAP11&4P!0Z?&J/U>V0"C*\3>5#4:
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MI!\A"4K!E&-,!P Q;IG(Q/'WE-UU"D3@JDS&#N0H+-#5$5)_.KEJMF=,J9^
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M$RI(R_Z;CG9YPIVGE[/?.G[C%,PB;B5:/P61V?Z1+/Z2X^Q+0<BD*OR@CL8
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M@(I?DQ4DFM_\7N&7Q& WF'@UC'(;$8CY&>7N5\!-AI>-?@/6FT6 ):('=0X
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M-,4YI&M81<:V??;L$-+EO!;?;,PMH?*Z*M].?KY7X*4!/F:9WO NYU$?Z(.
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M+^</QVF4<-)Q[5QP6[S?HA.35E:*\*X]S<@;]%6TMES(<U*#S!UF._9E175
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M/X,\A5>(O!QZS/1-VM$'WLW[W]"XGXBP@-N'/!<P3ZQ!NAB>R:--,\>Z=[,
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M(E<*K3=JB";MKWL(=S/-W9<>G<?E(3X]TPMY>:]C_V%_WL_W)^-[!_9TH7U
M7UB8?_'[TQC]MS=&Z.6+$QWK,IIX&I\M.-U'F#E+3.Z0 5LH;V  M9Z Y4\)
M%BF)%4'"*%G,2*]=')\(5((Q<\H"!A,NW.@?]N ,P:)=A/@-80^7[-O25_ "
MQ_?WKBZ%T85,F&:K8R"-[SI^XZ)J( 93\ VQI/R2N9EIN*0E"K::PA1%*(+7
M#S9KHM.I?RJ\?P.%)TKO\UUF&D8[,>OZ$1N:N1OG"5-%S?@E'5<D50P&@\X\
MC& 3GE/PYU,K-Z0S.0!Z-W(:I/D]UA=!U^+?_>'13AF2K*^^;M@/P^&\ZFMP
MQJ%D-1#[$O:%YG#D GTQS#I2-C/1!(/NG_<SI$=.@T'(.'IT(V;I_%7D'&R&
M5K+@J?DKW/V':I#,<:30M/W6S_ETU'B@I92T;I.PZM>O]0M&G^_ ['LV@WPD
MMP3.?U'7)NM/CT<1?-">-B>38U?/O4M=N_P^87Y.ID$W_8!8\VMV4F7AD%3S
MQ,NPZG+\Z..1T5BI<"_'.(?>@J&JH2C]KZ7QZW:YZSP3ZM#>_KO%>8[S54+D
MRG-]*IU41L6BF0UR'^AWOOWA1+=W]RRG?]G\#,T!NY>1+A\H?E)+TKZ,W\#X
M8.#Q_#6]WK2;GCNE-_;-HG?T3ZFZT;4HB47DM682,KH*>2!SZFF.OHZVH&JH
MQ,G9[8Y&/WA$U]ZEBK0[AGJF/;N6&+/P=7V%]@8GD0CA&PXN;^\0WWW4=$[F
MPAMB15^9G=K QO+/;4IA*Y?^/;8F8?XB_()2F7W$[707ES>X.CP,4"%W0, 9
M+[V;S#E</MXA\_SH8F,_]>'7P,+A+H[N_/B^7L?[K[\:RU96N8;W'5(_C@#-
M[%5I>YC]"70<(PDF=!=4%,A'P$D<2LCUC>QHP$GW>VP;#]SA(OGXZZ.%@W$"
MT8WI1J?=;1&/WM8BU>A>\ !:<7TLH-#?F044HQ9@G<#1V$M'T+2O;WS-B^Z/
M1<6ZY9<L;AG\>KJ -#+KKW,SX4:,'?N)/4[A[PQT+UL]85]1B[QQ0-]SVY!-
M&T$JQ^'VC5#NAWK2^MA&F@VS'UFZ5L\"8JA$=N(5CR\&S>.#)%]K5:?&BJER
MBHSZEH$9@X"(RR4EAO$DC^(SX\-^$FBN@T*)[^,TV%88, 7-6]!N,@?!':"K
MH#CN [($.7]RC!CJ-B;(;N6ZMI$?3#'3.1FAGI\5^JFW3_NPY:$X5?7=1VZU
M%>P:C+#(G?/_)S*CZ"2Q&+,01\ZE>L4=M+LY=#UYJ)-'KG-EJ;)3T.!Q:\,E
MZFQSCJV7S65R+\7"XNC^6PG3,3JXRT'M^SJ$(G-><O:R &OB[E=S%]"M3 %X
M$?)\^2SZS-N;6 !?B8#,QQ&/P3Q-T:JEYK6G.N\^'?/^H7NWOP>W@R(3,L[@
M[6Y@;N^]7-.]^'(;R6ZP9C).\(3@RJP@=_)TD^.[^6K"&[TF9G3@[/1XFV_8
MGHX+J5R%>+6Y"_VM&0O?7<6=TR+'CCW\22@;YW]A;T??OP=@XJVP]['C%<3&
MI%P8_7,^**^_H7RGQTIV,$+RD2NNZ)5LS$>G6.2D;Q\XK^H)<YIU#2):EQ=!
M76.2<)VC:Q3/FD=PQ2SOA<DL&'GS#W;*'1R-Q,#V@@]F#9L+,#6TNLYNK)]D
M;L[\N2!D(B.D!,502:PA$+XLQ:Z+?H93$Y1;EXHD3F8U@?T#L/([ R_L"NH?
MN>L77M=2Y/R,PH($^<VT_\'.DWDS/@C7SLDG8]+4AY\+YG?XS+=ED 7\>T5+
M$4)H/GO-5Y6GU:8G/NS;?J.#\SQ?./I^+W[UJWM51XN'!/80S+3U7QWIR D/
M[MFCCN.Z(WM^]";Y5#R[W/S27&_>=1"\BOS2T8P7HOME0<O--5+EW3K[LVPS
MNZ4@?K><PJWM(M>_[.9A]UII.GYD9D-"/]! (:K @OSIF5).:ZY6 *.-%#A/
M[U<C9ZO63NUOL,R?/:$VJ_/*K>Q 9<6B0_Y/GHW8>/OO ):B4"_M)NX]L62$
M+CPQP4RB78<[5*A1(/FNU8);=34)X:NH@7;;"LNWE125Q+5HS4\IMW>HZ'>Z
M7VB2U'@CY*61X:DPGX?#040FSSK,PJK0><<Q=5YF!UB2'42W>#% OUY%N5,=
M&ULCW:I2(VQ2KBDQV/8N^$*I:[M1*CFGS.& 8]*-*,GY<X+PC8.LF,,CFY&C
M&?C"K_U-Z@!=H8ILRHB-U)06'!>_NYKB*#Q-6A)-I YCXDY5/IC;=2ORX]3S
MV7QI0UC9<IJ2-7!?F8A"N!LTI*7%W;01^C@7:]>[$ZD0JJ/@"DH/'G@WIK9X
MK5BLM!/_]-Z[%"G5H7Y/FA*NKF($1L.#T,1[!!=SK_4L41@+CKNY-LGL@<+&
M SFDW$P:K>.^JJXDBBV],+GC^$"UT&A?7,BP51'^&5,(CM816!:6$#FJCKQQ
M9G+"=\_&JMN=;+ NWB"$8TU LM3"T<1L4(W=MD,EJ4%[[UY#2;>E\4C%\5-6
M$Q< 1%IB7Q_5NY-D?:*@<1M'S,'MO"\N <> K!'[@9G$\]>MHX=NV@PV=*%T
M/HG*Z4M<N^(+ ,8*6<I--3H_][@T/P"O(>'%9N"1-]Q,WN/V=W[O;%QK"%@4
ML)D3MWXFEJG;4UBOS3%R4R3QIJ_\@TMQ=H@%/S*Z$5,<-M\Q@;PK(TA9)Y=T
M/%A!=^;?F2S5:'5UO'D*?6VGA-'CO&2'Z.4E;66O,@[V-GB&299:^*TX82B;
MVD\1??/J%1VD/.^(FN>L$Y+7E;E@HLHEXR\X7VESL6V4;?=0<^XV7,IK>TGR
M5,CHXA87IA"Y)DD@YFGF17VG[(LV^5\61B,V&4K&M+U^P3:]=^'O$A+[<[N;
MU4]9B#7YZX.-1#U,\!U:ZV^;UYNWP[57AQAE7&3PC"G0PY7!_GZX5H[#\+4N
MMWJ<T.(1(:/1A]OE2[.BE(7O\:GJ6>5Q2O'[=JMY\[%-#Q2E[VXBVKLN=U _
M,![0_<@3S<E)L3J<8Y7/4?62S]N_*KV]VT+R.J+2:90;OW6;-_',)>%4HEW=
MX6>:_!9&%UQ.&U\D*G_%KM!BV["6[44[W&U.E,JHG<OZ]B&Q,M/%IK (/>/U
MW9^6Q.0QF5!ULB +1NH(!QRH3HW-L>EPK)HTI(8D^ OJ/3EYM;=U$2,):8V5
MQ3)WN2J-P7 ,(<UZ%J6IZX<2WPP&?IG8?,QD*[<7!H:!@F880^>_D]\X^W_H
M-,V;34*X]LG?_R9$O?OVU8^M/C\^--S4#ZBRB*PW5+WMT/TLN7#VS1JM>!TO
M/!9J\Z1G?/OXF-@K/9.G*SZ69LL^165Q<Q?,]''.H,'_XU>PO_(4,?,HTU4'
M=E-R3;#DNNP:RY#L)=-=R.=^6C%J-S66FQ@5O0)#8-E3^,98"=K=7]T*S>MW
MOJ -\4<'@6M^!+;DAT%RZXB6(0N8<PX=8-; )NWT95C-IOG^PYYR9!/F2*B0
M%1N"D&M9E(>3([N)YX%-WCD2.EN,5]CC;W)KCB?OHCP@EC2'TO7&VRMS_4H(
MW+,'\B.[$>JH$,?[)WG.>3\]$?]IB/[C_;;7)>M4!/]<DWEUO.G&@/U(W\B!
MM6?>5W>(S-0:/FTS0[4:YWRE#T?E5S_]L8)^A 4KXSTB1@2KU,=3^LO(N.Q
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M9[*K+PFN)H4AIP\E,?G#UE,#]/W%Z1HC3:@-;F<D9 UC1(+AKZ^I]C =ZRK
MV-!.#_Z[ *S(_?+<G +RX :1A3%/Q^P.F-9 <R\RJ!O8_6=2 Z3?Y+!)\ 6W
M+%@C_Y 0F$)#H_1UL?2SZ:[E_\D<NJ WN_K+0]*U9:84GFH(ZZ95>-8CWUG
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MY\:A'4F#W6<=FBYM=+FD7?)#N>G@AZQM *PL,ROC1P(A7]OP2+(>A2V-P1)
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MX:+8UJA<2E*D4Z2<801>P3"[],V!#U4AGO;)$X/N4LNC_P)02P,$%     @
M(9 !51M':)+09   ]YL  !,   !E8G,M,C R,C V,S!?9S4N:G!G[+P'6%/=
MMC8:1 1$1)H@+4H1E*8404!B^>@"(DU B(AT:2*]1%%ZB8" @!*E"@B1WHGT
M)B(=04@(39HDE!!(NTOW_L_=^]/GN6??<_YSSW_NMW@F#YF9:\TQQQSS?<>8
M<RQH$S0,Z)BNIHXFB.X '>@.\ .B?0<=O7+/XZX]R!X$7'2T*= UT &Z']>/
MWP=^7 ?I?_QF.'B0_N AAD.'?A9&9B:@,!XZQ,3"Q'SXQP7\=83E\)$?'WX\
MY&^W'F"@IV<XS'B(\?"_?-$^@-B9Z+X>B**G$P8=8*>C9Z>CM8/ @(P,/\6C
M _W]HCM ?Y#A$",@!@O0H.H8(#X]/2 T R Q\&T(\#WH(#L#QZGS5PYQ&MDR
M"GMQR3U.?,,D<K6LA?OF($Y4_NZ#,.;#QWEX3_")G1:7.'-60?&"DO)%E6M_
M:&AJ:>OH&IN8FIG?LK"TNV?OX.CD[.+]T,?7SS\@\,G3\(C(J.B8I.3G*:EI
M+](SLG-R\_(+WA86E5=45E77U-;5M[:U=W1V=??T#@V/C(Z-3WR9G,7.S2\L
M+GU;7L%O;FWO$':)>_L_QD4'HJ?[7]=OQ\4.C.O CSE@_#$NN@-^/QJP'V0X
M=?X0QQ4C1ELO3F&YQTQ<5Q/?E+4PB\C?Q''??3!X^+BHPJP8_L?0?H[LWS>P
ML/]7(_NW@?W?XYH$':&G R:/GAT$ 1%W"6!*) WD;DB41*[WX-&S6JWPJ89V
M(28:Z*E(.U\XJ;D$RVIP*R]ZY^*;6SFW[/E]YY83)-?8B$^GJ(?3:2 =7QJH
M-Z*.!NIZ2P,]T4<MG$%4H2F-L.7-0 KU-=L'\&\;1NFC,(6([30/\EM7!#D0
M!7O[5]._FO[5]*^F?S7]J^G_KJ;SNU06%AKH8 ,-%/:8!FH1HO+[JV*UVN%$
MB?RZ.5XUNU+#_"DKIT!J,?U4XXUHO;+4^\>N=#)P[S/30(R--%#/.S(;#53^
M&'C\,E/V(S4:B,IZ@09ZGA\Z#B/@::""GM7=?10(AAGVV--U7/>C@3S ^\%9
M0-^@[!B)_ZZ%'L](90N@@9(MB& :R)[>B 8:8M< XX(&R!D#'V@@D@0?G/H,
M:#=  _TRLF(<XV]T\.BP1/9_?9',PJ,Z8)$PUAU]>@T\*J:DDH3B<CV3YW1\
M*$(VR+][4TJ72R"XK.ZK9PZ(@_D$.N%6/L.;E-N'SNI6>UYI =]PHALQ\;:V
MG.KADO_:"5<+/VGN>22^LGJ4L7#RG:?JF4M%NB")MU(^^O+&6Z@*'UX9]0'Y
M:Y!$.52:\(YFRVQ$ &.B\6<Z#2T/'U??>+&\CP^*NKO[^2/HGJ?8*W]G.IG0
M;O(<9&3T==KR2\>2]=<NCGNLF\I&29Z'#)MT+C-P&?U2P%&07^8 <+%F8/-C
MH8PTT)?+([#MIT:7A6 TT*%,6*\QQ!5%\J>!AN=W2!3H(PC.N8:<)T\ ;+T&
M3E$WA*)&0$8:7/_YY;;A.@-),YB'DAK*WX^WF^M*N//YH7;I;$6,64TJ-JBA
M#G'O0O483J3?QTM$0/1<3O=2]DL^W, 7)/4PA70F]#.:<[V98085K79BKL2N
M8[(T>A;&Y#_0LE^:'E0L%J,OE<8>VZ=M<E="U%F$(>-0^X-C'U\_"C'6"$!W
M;4P68]+6AB8/(?!Z[6EVYGC[[50;3MRG\.QIEXSJ*C7G1>WJ:C.O'K5BON!-
M;<Z^:&WG$W3]LA_8)C,QB'7YHPT\K0C.VSV%_E9&UI .&\&QAT$E\J:#[A8'
MHP5'4[YZ#1S=/C68?D$;)2<OJT#W[:'Y&7SF7%HKVQ?TA^%@7>(LGE\7UQEY
M!#]% SFYC%]53 TX.O$Z.G1[6#6XD..0GSNW#K:RD6ZN!(PU#"]IM'OM/-E1
MDC=QFJEJ_<#&]?H/RGU6UET"@TOO'QHGC-!5:'C#>)IE@^6(C+@!2V(//JUS
M3$@0UQ7Y+F/#8LSGC.\UMV,G[^U(=<0498=]^ECTN@Q$1*S%TD ,SI2G$#<:
M*'J_ID7V$8+G>RX^"VY/F$(<]L]LXXN(?:OG^$Q]^ @/[NJPUI:,[@&3<U)<
M[,_8<B6R8T#_6,@GWA/C22*NJ!IX-.0>FB@):[$^C9[+*B$9];^U)'9A'9XG
M3;AF'4J5[-Z>4)C:ZYQ2U8Y\5GA P>63T6/GIV&0"<B$%L&\FA('<ZRE@IRS
MA!M&%=8A'<VG4(.ER)TS'C+'.TFW&IJK8RP6/R8U>GX5M9\H.ZV6>LEP:7>]
MCW0+UB(#P>2B&<G\.!CA&U[K$1E2Y 060&Y#>9VH,J.<?Z"&*U<=1J4S;U1D
MS0X9N<HFNLDB6"KMTT6\:[F0SL#*>$"6Q6>V0-XCHX)/S:'XB+'M60>&J-*N
M8S ZM2O8VER]=;T/>#6CY7&Q>X=7C\15-%YYU'Z_X3*\#T3_BO)6_11U:A>!
MNXV8H($^H'F"Y3%(MF#QS/89M5I<2EJDFI%WH8M*TWI-N(_$V#[%OJ(F8=RM
MZ=,$)JZOLO_",GBAJPK68D\]1[Y,]"-)^?O-*K4BCZ/]@]JA_.K21+O9+ 16
M6LY.\%/:<61HF?77JW,O%HY'/^"XLB5RSJLW9LN#*#'0/A"IS@M04T]HBYFZ
M*/Y[O*UB:0W^V+1&0&$'Y^73N(9KS)X?+P0DJ0@[\J<_.G&ZB9_*<A$'[VJ^
M1$DA*^&#9OV>;C1>09(YB'6SL.C44*$AC-S7%<]EGE6QK\=>+^JPODR3>JON
M:,\D=^LP:&MCTF\6V@HCGH:O7R+)D&]34JA@9QLF' T4KRYF%2R"WXULO.A4
M/3:YD)IG_W#?K:-7YN#X\9K4MSV>>VEN'WMO1;.&>)-T7&&5G>&XYL4Y@BXQ
M"(/F\.^U4"M6A0H2LY9TATN>=P)4>90PEB:G7]4.JV,1VG&@K!R3WU1:U\?K
MS1J2N3()"  XV$+[(,<J$?S?0H\14USQ05TVIW#3*]963AF^F?8/,QZ:RZ2S
MZ_L%/(P58(W6KDZ/><S/1T*9C#YL8C/,-!^KD@Q2U7N(OC0ZTB?@A2R6/P;:
M5:##0\C\*"P\BJH$:/2.D[H<L:-4JY!88TJ,GG-%<:Z<H_2]NFK(N6+H)8Q3
M-WM>)W"4"?,062N)01$OD#JIK'@_,B=8KQI7$[.]KFL%B6J64_*Z-9-; DIK
M#WPZR'-8QQJOHK)45"ORQ&8 SS_G]QCE/G T]#/D?==:,>D/&W\]K,?C[6\*
M;%S^X6H7'W:U^:FD5#3*M4-[K"+.B]8ZV3/P'CAAT'I97180;]ZU?GS=FB2^
M"A%4H%@N@B.@1ZE2_L:Z.%&SK7(M;(@KE<.*WXIB78V8L9PJUK>_S]8G4C4_
MX4.2>K+CB^*%8$K19;MD;GJ,!YDS7@V"9Z,>EL9<@GT(!,>0^?.=FX]^5@=-
M.:W>Y[%Z'];7EZHZ_D6 (T!V(;SMG94<_;W06O(A7%<GVZ%@X<_D\_A=[*NT
M^$9;Q_L]I<0" ]S^\@T7CG3>2#V-I"M,3*:^D?=3Q)LEZ$O_#W8DU(%NPCZ%
M]M! 58AU1ESQ;%<G9.(!2;N.B,!!L/8%\62E62A[]_&V=@=>\0@]<0=[D\0D
MN[(OSX[4;\2]3PP%P#;,&' ?M6#VX"G&.1-(1=JZ!69::U9V702#CL\2QB<D
MXE8[SNVYRY:6;)04A TM?V:)?V]S^U!<U+S;FQ3K&U4A;21G8AJA$Z<5T\Q#
MG"+H$2'B<+>'&US3-%!K*Z[(/PE]W;5?<'OO,V]NG4]X@5ZR.S[GV3O3YXVV
ML<@/@4IK_7ACZF$KTM5@9?PE^)H/%A)11A:@E"IZ"/G#L6GQI=LOD+:5-<VI
MOKCIE[Y*:7(#HN,'V"[V6/DWQA7WWCI MQVYSO+.&4H'P]2BCP#\A8#7YS4G
MX[;:T16$8@R<T3_3_+E6@7/H695VGG*K'GFLJG/IVC/1ZQW7\[_D6'?%+*+L
M$0F0(R@G#Z*R_!PT&N:PP0.P R\.N;8\2P.Q$6D@T\_N24'\"/;XN]^#/.WC
MGJ?>*A%-D@K3?9ZH+-':W$!Y&VR!-S;$7:>R$"$D>61[O*-%E7])B4^_YJ>!
M*U7W'R'?]JF>"'[FJ6O5XG6FBTD=AX5@7D'?^T2NZ6'8V%U"I?!B:='J8F3-
M<8,FO'Q'*I]3175#TX1(Q- G.D3%A&7KP>.XI87+5F%K$O3S$ ;_)X0J2@,*
M4PKC#54+5B?J8Y"<_F""[4CD8^KQR>#+>(W1^.="8B05O6+K-NZFO$X/JX_:
M#%-X#[K+B;U#=89UL+NRDZ16=#6JA1YO]0?NU6[$CIMD.Q\\4LUY5M#L7M)J
MV_XBPG-LMUI.#2:5*7J[N)2^\]O$S0ZM)^2C.)YU!B#P6"6NXE<-!V$.,.Y@
M0QRX Q7M!V-O/%5$/+ZEK^1K64*I:C3?-UU3&O>=N;%5DJKM>!-_/^5I/+\$
M8R5@<QZA'Q%\J'L#7XJ[FL6).:^=QQ&<ZN)D;;Q2.Y+=WUQWU&328B7P9?-]
M2Q/SZV]N:7&9X2HGIE!!K'UAE]6?XI?:( S!U_G4;)0'149L/U=U*\:R6,$S
MP-67P=V)G\FE=KX<^1C?/H$'1^3.@$]01R!,"AN3LE26$)(R,7DV_*EK$9D!
MAXC:V8A1%ZG4+W&S+;*DQ.H.V2>&;B?W$WK&CB_8QIB# E[7>..U"&6 O''^
M,"KS<@[9'E= YBREPN VI[2JTF;=$=@2]?VIM@?I#J:-=?7.&+TH,XFYM)[H
MFHK>9ZE7FDTV41-M<S7K?1AK\RM$^3Q8BPCU%/&!QW'_4LF-:"@/592X^T>M
M:_J]>TJ3>9.W>H<,ST= SO**F,2<?'\U3/FN"0C\NM)( \3U#^4!ZAB5*?@T
M$4EYI'Z*R-%E(G1\7&1,@>L5DY7>B);&<X:32GTBY)(4T; K)]E'@1ONN:#9
MR(Q(Z(6"4J*X=E.=)_U7Z^4R[370ASZY)$_EDD")UX<S;)Z\^09SHK8/EDA1
MQSW'>:#V-;?(RU8;VJ3+7[OHI0(497+RER>;GF>XE]BRCE;V55L%13W)@5]]
MQZ2HR$7WZHV_5FL6C[-5FSKO<.7<N0-V=O8"Z@[R\5.@3W)>"&/S[*KJ" OQ
MB&GVQ3O#*J\9ND$'#$-! @2N?8D#K%K7AWUBC>V+G3];7[6XU>9UN#[UYN&7
MYT1./M)ZPWV)ZP:=QJ^%$<M&%MJB@4Y7X"#4WD,Y-%"N< P$LXO84T0 X3#A
MAB*8<@IHA@"P+1^]^7Q@<H,Z ]G>NQ1* YECV,A\ /"=N4XII8'6YV@@P^3Q
MC9U_4O)_3H$J0H'^H3#,JPS[[4FWW776\J  RS/)5';IV^OVHNR)SD^ZUV^9
M=]B^'R,,&S6/.T,W5#T#W.U>U$F)G1A90*?*F#6/E_O6;9=P;\F2U66IS!TT
MD!8/#92: !AE]W-8&Q:@GY?0;2_8GM,JF!Q]FP::3'<DTT"15 ;PEBIJM%2$
M!GI]%D64@<V'*&H$]P%P!OC985ZP0>!)"SGO8)MB8!P1113GH0A J98J7320
ML!&E,!4V0(1A -([1P.9U<*ICXJ ?NIHH,3MT7^G)%J$? L:" +@YV,M<AO%
M$@O9/U ,]+Q$U1HV,?^(^J73WTGV#V-AVW&-HH&^'49261![8'TCJ!P-]$N?
MOQ/,Q1ZQ1043N6 ?(7_2Q@,8@[HR68:2'0JV))L0+V+AZ_&'"!9WJU$D+@)I
M4DEB[MZWA'.]6F?E$^2M[7U;/0L9)!H**JR$-"Q-G4Q35,J\GEMGN/0KUCNO
MO##2X-:TA0(2XBS1>]JR,9 USCS 710P)7G]KG:S$3 ,X5K /PV]3E%MA>V=
M<:2!;(#O\B[OJ<=((/L-O[W^LT>R#:.R I2:.(>%4\(>HBC\WM!"Q3W C@]]
M!P:*QVM16U2@U/@ZY$@&Q3P",J]G2)T!O)9T<AM6BYS*"]>&+;,#+D/3UNS5
M&(G7!_Y>V-K!Q$M+5'U'#(SRG%6+!M+6X(*U;$ V72'T--#::Q?(_E6@%>37
M Q'D!S!188IZ,YUD30--=5$1XDCT"NC/H=A_M$CNO<,OD>%\ Y3P4LBVJ_EV
M ;3?$0Z9]Q^#K4E[T4 YELW@>/7#8,(N=3)T$+.+]VI^#JS_K;. %I] //_L
M+T'<89@8Z"8<R4(#35B9 /KI<5W9W[M&90*4+[&/0U'"JPPI4JG-2.3$)GR/
M^S/ =#"1/?X8U'Q^)VS\"S![UP&QM@U!DG@PE<4*0!$&O-;/^1")0;G_IK+9
M'##K>7,P'MF#*/ WI('$I&B@U1'4]ENP^* &]UXAA>O/P!$*!U"C ;6I%@RL
MBO<&:< HW5UW3J.D49AI])Z0N@0@N[@>#318H[B?#"W"=9&C@9AQ"KUO#'D1
MK$T#);6Q+[-1A$]I<)DW!TO\PPX''?')[W;_X+]8 -T28+-_WG09)=+_9GOF
MM_L]_Z$"4\Q2^V'G 'Z\K^JBQKM0GZ_^R0K:\ 4MUWZ8]Y3AI)H0549I"$&=
ML0<6(<[Q^R]4L3Y 9M>C&NW,PD@L+HA]"^D0*%0"UL*%6@#; $#QOKH06'=)
MXZ,[)"% W\+U8 Q\'B;B94Y^/C&P3X)0SH1S&=E$8QA" ?1H<84MG&R6^/NT
MY'J9KW?\MKH7#R/'S%$5]^2W-YB!^<]#4 +3J"GT\_L2V2A%2';8/RS!G\MP
MD 8B*OE1M> Q$ +S$ VT[=8?FCN^4$/F!R9 I*L#3#JX#-N_L(BZZ;IC T36
MB=(04A -I.NXQ18-WKQU]](IH-\_ -/<'0C_)X,_!OLS*QK]M]L!1BY6="$V
MU5PAA., )@Z60(=>_6($Q% %H@1L"DUR)FD]07=T[@-AR]3'(HGLYB.4#Y(
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MG6+ E<.Y;Y#A8"[83[;\-I5!T4'V>?QF=:PTG@?6JR4,P/[G XM@#LC\^_;
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MP1WH2E@+# SXZ$=M^=2J"6-"I\<4:*"*@JGD?J?7K55M/)<'NT[5J 8CY5U
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M,(0OF NROD&II.2T;&#G0H!P:WW1E,L(>B@4\TL \A60ZM?=^LW(7[?URQ;
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M:526R+U_[T,VOQ<7.4\*I7F7N.PF3DU:?-B:OJT[<2M'0^JCX1V0. X93KT
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M+M-CW.0Q_RVJ5KPCM74<O*]8O&_\2_X-6R>"@>U'?I$;Q D71*Q%Z\)( 2D
M_K8@:G_!QQH(3D-V3VL\G 9:DRZ"+=^KV@D)?@-0[DT:Z'F(/_0GVJ7J0<W'
MUP*TR#'?8&&01')\!W33V ZRN@;82SY $H'BC[B) / PE  WA1%S?B8S)G9
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MDQ\09>><*J<?C+<EWW*MM\=,>Q3>"O<[ZZ]Z^\"$J'=XR^U[RZ$?H>#*@>C
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M$&),H5(_X/NL +&-M$2&9ZFTXC7@LZX H5$( RL2V8\Y]4NB_9)+_]1%'.^
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M"MPG[?LT,/-B<HG?-B$F^'"=]T>/SW)"8;/)8"8D9LR-X 56@+0@@-6-YS*
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M5LW&'3ENI_*2=V]_*"48_6]02P,$%     @ (9 !53"@51Q@9P  ,Y@  !,
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MZ%/V-(5+[KMOO_)-[F6@U([S<5Q^9Z6 !W*S5O"QEYA\7V*C\82$/4(, >Z
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ME2(34)" ]AL!^0"!C=">]# _)YC 2F<G$]C<5X5=;Y9G&-"A-U/8+"809-B
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M$WBN1ZNG6T_ MW9D0\N>9>AU7[=H(_Q*'TL+_R-]W/RG]/&?MP4;C'.B,8%
MQB[8*L\Z,@CRV+GP#&[<)NR*,4*)"?SMF;];V+_M!=Z;)\D$WLL2P..8*5\5
M'=37WSWS;PNC9\9@.B#>0BL\\7=J" :LYV4X[$US. X>/VQUTS?5U5R4G3VB
M=MFD'ST;U'VU[1=BRVWF4&9I6+$.>D >? UIL9:!:'?"PJ>\^S"+"@\AI+:N
M@85K<\&@T'\0W3FV07E8$\T$J*NR$$3[PQ_\#3]=,6,AB!4LGAL24IOK$$JW
M(.>W-B\P.*"@1F:+3* '%!O1Y6-J\/@?*]A-P>^0LXF1W!0/(4RE-V'Z!YC
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MIQ=N/'8C/57!BUY(NE*I\7&EY4AU$4&'HKI5R-I(V(UZ.(YC V=K!UVSDVU
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MZ-CI/'JF\U"\G._Y?:,Z=<^ECN<83]Y04I/+/M8L:AJRY<_@-/J5$ *=_W&
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M-)T%:*YU,"4#"C"]V+N(E?E:R/BJ,(2DJL#--;(B@S[, C:/X<^\**"I0[B
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M0A64)B*BB(F-)B*B0BA"!$2ZO(I(U)!1E%XBH*"H1 %%!8Q2%9!(%UND2X>
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MJ7J-,0F?<Y+CS3R/3*B*O)5(><,L5GZMP^QAM2$K""'L1EZ/$UO(4CP@D =
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MCK3=0:9C[J,O\.<>E;*V#7'2/.":C=5.AY,JJ^\<S!2Z.%-T<$#LQF/3IJJ
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MN6K6M_Y(LT?%&9NO'N77/9,2;@N$]_S5T^$^^I P(_@.<%(/<8_9+M2'IG"
M&4)9Z@T(\7H$D+@*[0R.'^/P,M^Q6EDD(6I\XAP2RI;=/F9O3I!G7_Y[9,P.
M^57D]@[U<XQ';+P!OGT6#:DOHM[V.B TNLT(KD*8\( '$BAFX?EP2+[!<!E8
MM#*(P_P978TI.;#/_&KO3"4.2:B0T#.1>)"[LP9<W.C# ]R1[Q[N7D0CK/S1
M[OO]O]OS'/@+3[X8]*NPGHN-PHS8V,']"'W?YM32+3EIZTA6X)@DPKVO9X?V
M_B5:$J]#_735#_Q[]GQ?'/-SX$9Y@_HYP@/^[JK^C!DQ4"L3Q7J!:%N>@X?K
MN$]@23>(QCK10?6[0XE51D'50TYP\^/O1;B"8;O<<=E%P2_R"\+KGDWK[TW4
M'Y+&Y9&?^\0B_@BS'O[DB),$/6E*8_VJ$$@O )V8*\F/_4ZNBNQX\+C7O:_Q
MZY1%9-HW^@G/4.R^F><""M  ?;J1VD-ZXZX$A3#8K +NE<I@^D(A]_[I$4;'
MJZ%=X+XV3^:&E$:LK&.Z1#^N6J^DN21-0T>M6#?92/X86?>2)4?R*$N<29U4
M9)OBA_<S%Z[-\0#A/HX51'T&?6L=ZD]^K-F7>U67<G!C0'9.,_SCZ.IMS"@\
M;/MA;YJ(_&4S+.O),KTP>  L.L:6)_@R@Z>,AJGRI+7^ Y(%Q=35^&MCS#&B
M8BFI5NY(3/Z#HI++(XL/7)PSG-T\$HSN955-<!\1=Y(N@VM2G9K-S$*G92;*
M$RZ:7#'335T,+IA8&[79]4?U#/UPBNW6EVJ*>*T;$>IJ5;[<2C,4DUJ'8QR=
M[C(:-KF,\<&MPZ?6X(1+,.N.XX=Q+:HE,P5KCWVV32Q+*_R4<F@_)5WR2??C
MBW?Y?V!*<9RULRPW;M4YDK@OM;CSFG'0$0-1G.V%!TW94)%]BV9IAA/GB>*'
M%YER)XXF&*IW7T;OQUT>'=3BR,:S<"WS2.J-! 7X,ASDQ91S84['98CKS1=X
M>CP4SA5-\8IT4(]85;A_&V./A(:%&#$%^S4L$8DF!@RZJ+4@ S'$B"I=R(UQ
MM*&%8-!JID,7)2GXSW*P'3X!ML[*'^?:9C=0343R'0-SP(KPE]>51+@ <P!)
MQVWV<I\2A!E%U;BBXQ<':FW#+-M^F 4P-T./5BG6IA]N+._H=7H^>YHP6G-Z
M7^3 2T:T"LH,H2$-RB,HE3G!^@ QZ7;] 65@R9KL(7XC[DC+G)Z17>F+:Q>U
MU]JIK#<R,G'4(#/VN8X5!R-IK0)1P)E0+EY#ZDYOK))B)/#_Z/$[,XX)B!+D
M :>,\-^!08$W;];E]2M"X<Q9EB#W"7$;-#"$G1R@B\?VKX!Z\EVA6HOG#.*#
MW.J0+.BQL[G/I8#S9642D645LAVMFBUIDB]OGW10=@X^@(C#%VZ"#;C7J:=6
M5:*86(?G5.9"O-G1?/Q[^BY6FE./S;/QSD+WXSD'W\@E&1BJ8%7DG/9)F)P
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MY4SJK#7L\^#:Q]G JCNYD76'[KI6V-_-HO0W%=C14-"9TD0>@"8BTZ!F#/"
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M](#W'>SGK8N><<()UU+5\AN^:>[8>41F3PVP P/MN#H\/57!Z(2%/S)M:E$
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M2*?UI,+"J4,QZ!4$+\1!39#7^IGFUJZ+NNU3X.+4T"EG&CZ?L-NUKU'#\"V
M;S(H-CRIG\"WY&H[ZRD5<S"^\MG@[5'EEW,4),B,"(([<ED3W&M5<L2.U+'K
M7>[XUIKK;N,=Y[MF[E/W?G;+N:"QZ$G?N'=DU%?^6R6EGOS<AQ1*@_27'R<<
M?,#L_U0EU8+QB9\6/;X)QS .GMK-M/#LNT<*#MW)V#9=>G0A9BO??,.39]\S
M4*G<DOSN+NXC#QEJ]S-9S+9]S7)G%&\MK?%O)W@S)^!5\6Q58B]Z(S.Z;J!G
MH38=\4L<>[IH3T7P&G?26IQK]9">DE635\"C6NE8):E5:3L>G;?<TMNTT;/Y
MYIY&1*@OT9NAH0)B-:*W"\STQJ7H^, J)<))IM95 A_]XY&CNMU55W+?2Q\^
M>%+CMLPI$\.-3=W7GZZ1 /@6,K.1Z>UGL<I+BP("-'LSW7+"Y$02C9@S]SU-
ME"WY.PJPM3Q@/680B4]>=$X][3> 8MGGQA1R$Q'L%XY/=N%+46L'D/QBU;W;
MR7"M]\.]A;J;+8/DTE.:46@/C92HV6TB5,9IRWH[$DJ6.IBFO+8=C89:INOE
M+IK$E!2(UU;I4I-S[KBTZ%)RRLI>^G@>O/6%J9-B[835N)O"M^#P+]'5J@^/
M'_9=!DZFX%<\SHTC&.K$##/77S52VE1 E[++=:G8NKFWAK4@D9_\]N')Q#89
M;W4!B8MQG$!$Q>W$6F4IY'\@L1.S!C-822XLFUS(PGV'A3O52Z&O@[LP%M?V
MA'C\41# I0BX[C7?;IVQ[3I?K&UESAFCS4*3D5^Y2??$NXU%O]PG;9_=<%V;
M]LCV&)+Y%M50YXS\> "D0![&2< ]* 6B J*'P[ "9, 2YJ8;%YC4E:+6F^D(
MQ9IYT^=*K.F,]"LY.[VK5NS>[Q+9/.#MGV"2$T6W %PW8Y8/_$!%O,,7=1:2
M1$><@O:Y<._P@)-V 'Z?0QE4,,15F2C'1 4-MVD5;5OPH&=,!-_;Q@/T1&^O
MCR_\&FOV66C*DJ.9*<,#'MRQ0W+>-AZ@D/;>[?.\?!4M=V);:E/"9-20TW G
MT$E'J&.].F*-G[B7T2O :GT#HC%!D'N]DF\P6/I[U;86SZ(.@N)07O@6Q[@+
M"AL]4R?'(TYN"BFI!BY;B(57#-,@U6".U/2P2?4=-R%S;@IG(X/MEGHP+DBK
M$;.Z^%:Q7H!UY<P5F\?Z!3+KRLL^EBRHG_-6R0#8IG<T7NSG2S,_[*2M>R;E
MHG@!$406#6 "D=AL&%MK%T]^P0.F0H;]S(XRM5A!$#EL\#6VOI4T$) F6?G$
M+\S0K#*GIW=C2-HYJZ[XG3M1RS\^U@179^[B5A'E.4H,4NU$UV!Z-:88$UEY
MM*!8#MZGGRK04GM![6O4:)+.U4W#WS[@#%R )=;24N/!HM3#;12ULK)(T8]F
M,P+[[=O2S/A^^+Z@OFC7'6[;VO/VF=ZWW0R:P)7FMCG5:(%+<8L+K%?+OS?'
MT>.^)JKYE>)**-T$6P:U=FDO.I5!UW,?;WG'=KGP<)9"Z>@;-E'3=NS3:[Z5
MM;5,]YWU7JHJLE"#*CXD8Q7@(*.T$LYR+X.G$D.PP9<-&.D'F?5EUZ;G=U""
M..J4X_TYPG[\'SZ\W7#-S2;"9DN.:_P%C\?\\VNR2RN*7UND?!K?X:#AVY?U
M1[6;M>/1I&L2>];'U%](G_)A*K+(T!E& Q+/=NFPSA9!R?2>&VD[UV..,;VK
MDKU]-M#Z/I[1H!HU5LA;-0PG>(>\)"!6O;(7&F@<6(L9O-$O#R4R78^R@^,0
M;Z(,O;=GKA]%4:GDNHO7RL0;E=Y^P@\C2JSZQ9/B_ZN??:(QPZ(F*[V';.UJ
M%%++>_S+S['"Q.07(VP4U26GHXP7EW_Z"R+@F4*3.+8:QQ81L#_A$.1 7W]I
MV&"2RY1=:B.8,3Y(@+X32Z<?G"WL'I=M&'?RD*7IMLB^3-D?MSWAT ^!Q^(3
M;OCT*1-$0^-<$B: )C>&D:K:1M#8 E7LN5:;!?747IQB13]SKCM+R&G;VG7_
MU<S,!T*1ZL$B M7PK= W,D=.%!;A#T(<,1\WU0.9PV&"-H0:QH@2/Y.ET5K?
M^U%M1&FHU39N)W?#.^'LMD/Y+=U-NRH[A)KBY0P/-!5]]")M9"X),DETRX1*
M^?N^*(:=W9<)U[AANA_CYL.' [%:EVV#!G?)>,H.N[X^/OBIQD0V[=J/5[>M
MMT=M'#FD6(=A["=U#=<H&[? :/@M2HK@P\@;EDV^H!O//#)<9T+<2&W7>Y1@
M:9R45=Z[@ HJ\1;9[WVCX3M%4?73CR!PL!<#;<"2C&UMZ)93E@P>4#<@#:M!
MI"/D(TR05$*+<?D:V9 7IILP$G])],N)".UJ27.I#>IQ6X^7]M7QCQMT80<7
MWHAW&0T]2V0K$23;/,P9YV/7US>0=\W0'K\MDWKW\;$[JK*E[[AHK((C_X?4
MCYO01X2>8&.(=4BV?0CUA8I0\0/\U5KJ"UKU.49D61SE0263+^C2X3;OUQD:
M&^7]@I]MN"[H&*A]XGZ%DG<L>F WG\KJ5)PJM&#9BAG,0Z,+&;:WY'!%Z5<(
M=C+3,26ZIZ_2W5]Y;<>?8Q-;QF33#?-3/[YS.[[W^B.ON%/@(Z(!09MAV8B+
M4IBNIL4Z8LO0**;^'7UR?O=8]\<.\E96BUBAA;Z>9IQOK?ZQ&Z$:4D81Y@1W
M*B,PG2,IKT>L(;\H&+QZBJ9!<&0Z?GS9T OZ>ZV;VHT*QKLVHL68U&A2/$&5
M'B]F9^,:?VM-MO>YPCW?7#\P#E54]\S82,?T,NRC_1=/+>QK_3.JD3';-:Q3
M-POZX*)@#9)SL[)]3)4&%-5,2\;?YW(5WAUVWX;1FWJG&W]+Q>(ER\V2I<Z]
M'6K0M0;SQ8Q@EOE^Z)B[PM7:L:%$]3J7R'CP5)VT:$A8L*F;1#60G%#Q:#5]
M+]U2;'8M6%V(8^SW*6&+P@UE46)WS%*9KO6NVX85SW"?)'B5 .&U0^+KH*.-
ML/+5^JI53)G,@H=]<K+E2633]ZO9ZY/C3$>V]^9O$192DM(Y\ (MSS%A6%;3
MHDV%:NRBB,K15HS1R+D -ZT]+05=MW4GI^A.'I$V4G6ZOGEI&G=/IEPH*/]7
M:]:9R1U"Y\EQUE; :VR@U[D$7VPK097M#.D<:D<KX:-\O]2'%?A=;U3J=CJQ
MV<?SM+.7_*E9O1LK6K4Q3]M'!XHID[EL4^(7LM@(9,VVY:@T(\S >ND:DU_B
M*QS@UZGJ$W%,1Z_ROI3 BRW;5^_>ON$RVH;[#!Q\21;'>!M$$HVJEG\1YQ0J
ME@<(EVPDK'T\CA$]Q?QVQ[,C<TN%U>6H!F%=_1_$C^=I&H%!I_<?R?>^?2,P
MU-T 7M4\]!$+"R/<*. )N0Y.)[E+MNLC>NJ'9P\C]E*[4X#?L;W$=J^S5DFK
M9^+;F1%7ASCK?MLG@7E&[]XF&XD?7WY:1T .(8:+B-_XD&$7L]4N)MVTX.$S
MFC">[ 15T]>[LVM"\O*O]_E%'WG],JG#=V2_]XGHG>>?>^OFRM6#C+V8R[@2
M@[C[?S[V8P:]H%.[%>O*'5-E;P[=F=IG_XI1_RS9-^G'MYUNLO0^!?JI,Z,'
M!PCF$JON7 #F$9]@,KB!S-XZH3#0$-QMV6BJ-]I 27)7B;"3QO7T!EUY&-4'
M-]X?BX.2IW0+4@Y7!E^/C[^]XO8ZK6:9F=S)/&3JRU&)Y[*]*N3S %]R5Q[+
MQU0\88ZM&+]3[/1L0WG_HP[&ISN:PNOG)YN?>&N&"?;R;Q98N6/IV661Q4Y6
M/O21R4\GQ?W@ 1[D+IVZ1)_A/JRM);,Q<>JZM7CM/>4_+'N4N!UMCW;3W[7-
MN'+5=JO&3"]MJMH 74'8?1*L5D%OPO, 5RB7*<YR:Y\/EH!2C]VQ[PP-H,2[
M;S)R[SM0GXE5/RJO0;Z_#@"6?V4543(EBEJ$.* ^QNP![G4TD(BNM8-"[SOO
MSE0N*Y<Z[NQZT'OFT4M876-:>D8>]2VY+NFLM?$LBJ.4R@.T+:$%'G!"#W$(
M=K+&T]07/LO/<NY=#@$@.2<HF*W,09%J%"RH^?>P3M<FL-T)96&G-.(_^$WG
M9AP72-R]F\W7NS?BPZ'<J0"V/$S#E)G4O"=%8(H7(HWM)/"'F#<&OF]S-VC?
MFG>IK[!QDW!]Y =EO+-:8IN5DX[^;OD=P(^JOV6I'>*U!E']<I#Y8")F:#2B
MYYBI>_KIY\[Z191^_Y <_Q5/[\0W>=]^ _"]^AC\E\>\!9;CR@$16)EC@\S=
MD./63C@SE!<P01'N=IH@*I;?\+1%PSN_J#G3/=Z]2/+S0N?I\'=4L2C:RS\E
MY&G7165-00%:U;3NU!H7:@Q!YX_O"QF"Y$3CH$T=C)QXM0MCN7V[M435U!^G
M_N%XV&+5_366L/#&H3[^6A3#AMS57UM[T?;U73F48*5QN-GYYDBIWMZQY\=[
M#WUA(]ZW2>?%UTP+3VN-SD94R>Q])#R@@"='=(UX@(A)W7$?^%X)C6&\),_>
M"K]',$ ]:1!Y,:S:X/)%-.41WM6JS"9<R[K=S/6)_WNO%3XG-U<].+.S7N'J
MY;CJW0#?9<.OH 1F,)G\/*P>U0T>Y!:;A3"&Z\.HTN<.YV5!]40]*%/Q'MIX
MUG#U"CWS(^O \,V&:C%O;U8?65_(-X/A2)\C0;$!+*GC":35^#)U>&BA9"Z7
M(Z?%JH2.LA'-5!M6Z4$DNE;LY%0H1@:/.L;HO%K\Y!2NV+_\X7Q^VN?ZU>!%
MVRB<,8N4MKTO"2B@) XP+'%?A%@)T$ NW();!ROA&QV9_<F^0>>"U^8VX&1<
M^OR>KU4U=#6NREU7MF_4YF:"-MKK8@9N!7(RQ>4'=8C\4,5#SD5<UPPHA:_=
MYQVTU@V*'0X/KC?RF\P]:\;O_+K<R<UII>-N>:<5JU04 (3E!'9S[W&"V9N0
M(;1@(8XDE)KS,7>B&[Q:_Z,@UTW5.7"TZF4&MV#DZ+M*T._+^ZX;2>WS#M*'
MA3Y12WP:@F-0T@2',/9JN,E=8QMQ5_NY$5 )W]^U_SIG1_.H0/@+6E_0@9/]
MN@5VFD5G5"3JPI:T)ML9G2R0>Z=*V0]7*/1&,O<+DAVM*1;57EO;L;#7)E['
M+Z'J6">J[N0]>N8^=4[+]N1/UANJ O_'3)QRCAN/&223"Q%7TOBFO+$6_+(P
MR"%*M!AS3XZ7UVFY5+5Y5U08:KA[V86;M0QJ^*\0^K*&+BWKN7L[K;N"KI5
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M*"TJL]IS02/YK<C],.-A:C&&(Q7"4N3F5TE_)_-3_<3Y\-0&]%K&;/V&]*P
MC!SA$%,W62?G[%N++(4+,B=#I0ZXO?$TBOMFM@]9YX[E[ 3?(;H+0\=4([+
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M2F4NYO55 ; *BAYKK'/?T)G1[J];83'N7%Z:SW7XF%'>FEOP)7V+:D+$S2]
MD+;"?!<W@/"%5N0#5B-3YHD*3:94.^/567'3@])I'P8.#^0$/:;*N[N.]$3<
M?=XC5]KSU>.Z5J^ZWD^/]Y9*?0L;=HDJ?.!Y0BX>[!S&['"M@T?]\1_Q66-7
M]I0^Z5=K3_X\-O#UC%-B-V:-5M@Z*Z.==4TZ-KYQL>&HE8$V56O$^ \H]+<T
M:8H7K?N0?8R,I ]%DK?[!1YD*3[.H?IEGLN1*(3KVOLEM*[FEZ<&O(O0+?P1
MY7RW.N"@^(B:O.,NT?_BAHI$_Q(P2#W7#PYU$L0%P-==[>#,;<==:T !(/88
M;#Z,]J%P P5 V] LEX\-0;.\BWF96S@(L183^188+*4=<+22_\\VH7DK;@"4
M TL@L2$:"3G1J5(\/S8J])69 X,69U(IQ4YIO]&728S$ZXOFG+_;_,&,4A'>
MU]^_.DQ/1;%YR$A$Q@NY]FMF#MS=/NB\55'E6]B/!SYGLB5K"2NAB@$9&3P*
MBLW)-^O78:4\B;?R)KS=L>Z<N^,5S2N?IG0.[DN[-RO30.J.X3CRGQF8F?BQ
M ^CKP[8^9SU_DQP79X@W]]&QD[<U*Y)1[I/=G&\,7GUSS"QZAH_&O&F]H-XZ
M4Z;CF^N;YIS+S!V44'5\49/V@G$$ (1#1 $\&C'G0'O!N&'O($<N? I62L7&
M+E 2$_;)4WBV!FTA-WB?8V;]U>J#/;F6< M*E'(&,>,&C2G*M806NFI@:=:0
MHUVN3U+>>W:OQ-FXI5-YNCL5$YV_B!ZRNV3DB+?D/Z2<I<14:MUJ0"L( "^R
M<"#)J?"HJYM3G85<?D7)[0W-88GGOMY?(J1D=KH4MQ+2K:[<PBJ'Q=D1MPL^
MN5J5WK;T3Q^[)DOU,3X9*IOFK].\5$G$X^;H+OFM8 PH=55FJ3=IA3]%N;MG
MQ+2L)S>\T.RQ+Y:Y-OA)0=90[!F]Z%??+<TB0W[ZBS,$0!1*JE(!_B@ 6,Z8
MD#7+^;=XLFF!F"/LUP\&=L#FD$T51]9EM(N@&M[H'Y>=?;PW+'I'V\%S \4E
MGBMM/1/U/SX2GGS,7&W381Q5CL[V/M:EN$J1B3._P]*MU=I?MO_";=^-1^C9
M2IK1P_ J_')H/<NT87P_I,L*JNF7*:J\;Q^$8^!D7+W9WVS%A$NKHM5"S \X
M /[&CE: _']Q(ZQ%A.0D>LH'+2P )IZ>1R_LT4G_#1X#R"<\%5\!L&$__[4
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M \ _^[@" \M[51LN:%8BL%%SH_>/X/GS)^3-F&0'DLT!U?OM0;IK7/ZRH\?
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M*[@!20^-$01KMR'#7$E]ZC0TQU-%^$";5H7FZ'P2 )D8[*NM\XC^%4>RKBF
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M[Q6/J2D-S?H'?NH>J*C\?'>P5T%\0CO[6Z 'O(S!O8A'M3D_CYY+!=B^%4_
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M (264]ZC.]U5D6GMP4*;43^"XP6 V"S8),Z>X\=^$0"C&YU&MN*1PDH$QW\
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M'LPP6[BFO0R@, ([MI$8FY.0A2AYPG;))G"8N[*<R[I4UE_HM/(CZ.+NL#7
M+^9S9/GNY]>-RP(FA*^&Q'DEA;IM-X(./\4D?:<#^X<GT(&R;/K1801QJ,/Z
M/7M,ZEP]\W8*I/JV#)<FW0_].)1*^+9WQ16!PZ:+%G(^ ::))L*#+9=:HG^4
M7T]<_=A6&*H0[)%W7?5A[QIYZT<K?6?5E;P';X:?^FJZG$>=L.P>)VF1V$W8
M%I3 /-H@%=EM8@R4=H?8R?XL_++ G,;[^>P\?SW8FY:_L#'A72Q_E@>M(&@
M./YOV!8X_1=TN7M+OG^1^(T);X4*#X[%U9W/>S97ZKU\&#/O;GU9[C-P]ZZ.
MV]'_ JWUDM,DQFZI)^#2&[I6=G,1<=PK(]EI!WBK4FKW7/2@C>[?UO06@ZXU
M+=EF]_W+]8TE0>MRI,\"JY,3M$HV/M"7!>'**, A+]#236#,)>FGE$/*SDLM
MMF15)]K-1:OW@!XD#C6'N&K<;VA4&LSIS3W+-$"H'GUR('JKYN.PAZN JW:=
M*$]B-Z4M<JE#X;#A'#RZPX;X"MH )O.0*T%T-_/+PW5/DB)W%%)U[XE'=/HH
M]O<?*=U>1#A?L>G:&F"[VHR&#^DGDZ*B6>(J8)Q/!J;,RG%/WT2(O/*I-2$O
M*[_YO#*])("L\Y[=>M-3GW8Y9.#4T0-7/M-!\U*IMJ0+U?(K[Z?7Q#U>,G_\
MOM1,5DE08-O:8CPXC5$&>OYO.)UM'<T4E2_.'7RG43IZ4KMZH*9I9JGQ2]FM
MX1XDN)XE>")R"PH;/T/1(-AS5FL3B<-'Z[[YN!O%5NRBC;=M*GI#NQ^U?&H1
M@1=.HCE4_D; E;B9L-<J03RL,7-.-Z<ZKS<+_Q>T,&\=Q;G4].<Q];__0'"W
M1<3E>L+(OKK#.HHDUZ&60N4%Y.#M[&PP:SF#4Z'?WX\X>)XL 3!UZ\<B:.3F
MF#OR)4<0%N.=."!!@7]#XA2+0]"PS,$ ,*44MRHQ/A=2HHUB7)QJ$[\,&"3-
MZ4<$5F[ZO5&8?RWLCM*L.V9\1J>WI>7C'I5GB=>4Y&LNZ4>L<F;\,$5UI6&Q
M3A8D!AQWV;=1BDZK8E$F1$L83M0ATRBB]ILM5DD%D7YC1'3*J:VTYD)SZ^:N
M8W^[9*)F6\]F=GC7=AR2-'/Z+_U<1.@3,&\(P5RJHB='X'=@I#'>WE:.R_98
M5YY@LV\^>'/:<MJ)7A7$,NN;RK^_0LHK%A%Z=&X]@_S!=_C7^^EMHDLB'/F(
M43J'C'1?\:/!U(C_>(RREW;DI.'VG.QM9AVW;\NU9XA39(\@0V@4YI4=:*D)
M&/^(3S 1V5>D-\;J_LJS<0B8GZA]-6+J,W_=0%IJL*W(Z.0!.#KFH-1A,XWM
M7"CM)IO,C$Y]6WA.+[H3[)QJW^QNXLQ<FSZZ^Q/R:7>AHQ9.D<30=E*4;I#=
MQ,:0)SW8% 9JY21XOHN)[ LQLS5WHQ4QMT>DKASU1[QXU6_W_>.504/$0C^/
M)5##\K^*-G<FFSCN):=+D[B*!&N[AK;8;V53KX5\\>5%A,[SL33FU[M>:^]\
M/G8:=7_\)04(P2^S9X$6D?TYHS.-WQ-Q\D[/ZD+V?#A_?LHQA2JH=9DHB4WY
M8-*CO.#"_IK_ #*3F@'4'N-=R[07A%G\) .N3QIYQ].].TUZ+]U6+_P?/(W\
M/W59\W"3+N(068>=]+0HF^? 9X@B&>?(V=)DH *M/B7=(/HK\\SHX8^3DRQR
M*Y/EO%ZRHUNE<E5.Y34+Q?(;BO*IUUP1A"2).A'.:_7;-TL\'*3:6N).D5Z6
M!4A&=QD[<(39&'OV/2M>TYO$;9%ZIVS>'D9MFI_WN*#B_LB^P"_LWO*R)P"Z
M<YS5C)7J7.$Y76OH' '/B[.!Z0(>2CF$MZH@<F^;X?'&8Y3?LV^,'6<"[EG=
M3-OMU397-B *N(!!\[Q@HS"Y8C3_;>'FN<(KIXL?3828'@L*2QC8Z%:\E='=
M;U/4%)'LN^SO;*E.M7B?K(J$IT\,>H%(0.XKXXP6.O]'R#G)05$6-5FY;\LD
M&.^KSVUMN4Z__N9NB4WY,HN5.YQ*@4^0V=,W@CA,<&U0X&S\*H?6LB3)E+/V
MK7?K4JJB]635AJBC 5&WD:8@2;(=I.R7-3NM(;ZK<'K/1Y-:,1NK05SG&?_:
MP9E#GFVWDLY$?+RM] #]X'#K5&=O=.R5RP="90\Q*$E BI!]<!&1C0VCYSN9
M &CR9WIS*K8G=/T;.@V_IBWX8NS%J+.#F#5C1D9:?:,NU#LC.U4O?ZQMUK]F
M<7T-TR#7>NOVFYK53OTF/^<I?"O)>N(8O5DH\(*9)L^KSYJ$<*^41HMNU5\Z
M<008ST$_L*-EQ(<;%W?.[<BWVA:18_0X@IFL=E_1?'9A_?)/BPC0IC2[W5G4
M+-X5_Z&Z4Q.FWTH._63-:$B]*6H/+[*^?>;T/=PV@;8A_OEDR4Q[#^6<J\)L
MJI[;6\+VZD,II#VT0!L^OKJ-EN[HIKG^H \?L1RXBV>355[R(L"\A)I^NQ;U
MZ\S41NE$9&O+65UWLSS,'HO$@IK)C#59MKT7?3+?_;>[Y/\^9VN?$[?*ZCOT
MH3Y4,PZ.GS&X_-)'+IQA^6^G9AW3TI;;,O0#&[GR:<=*_ LMY--"7>73AQ#G
M;'5^_Y(8IJ AY4B8+!N"J%IH DM#"5JXU/1S\62;OD9 P@GHPB&_U40M'*A.
MNLG,_-X0GFS_:;['U]]UOLA%5=[&1TM\ L[(LHAO6<V1@G$N"ES;+]5V\6D3
M#>?4 L?Z\SI4"/N!X>SB 5[_N0B-00OQYL!N2<U8]2JOS(L;MF5V'!PP0&"=
MHZBOO"8#X+ 5(KQ ;QY?.N=>U:$/3WP!/#5\&#A>D,!M#!>?S>8,Y4\;MXWB
MJV/S"C8FZ:Z;G8UBNSL<)F0%^)K/.^]R^B[+6T1$36*9O\3N8+S$)RCEG.<:
M3"K[^?;#J1O<ID]\>IQND>)R)%[Y\]6M*]G+.N%5P.M\P;4^>+*T[?+P:R].
MB_B:F<M,D7B"28TAX*;/]T=Y@^_,'MX07,KI-J?8^RD/#/RUZ?XF9 8T3-$F
ML2LI,%6[AI)O=ZF/81X;[D?E0#JCZHT\_.F=?N&<S\]HYU\F!3_;GF#XK/]$
MNNZRS]53@\I;>XYW*GR@!7SNS^^PAJ.H-_RV5W%MJ$ZJ*C2*;;TMJW)"$H@B
M 3U=2&HE*!VMFB4:CMM="HYF;W5!JFS\>##'N^C%,YW6%T2^K"F.'A/BU;D0
MV>TUH>#SEH;63:'Z2[0AS/L?&:1(CO&.L.*@GUHG]C6.+2+,7.15&8>"WE$V
M]IO>1@97T?_X0<_' 7Y(<)VE5#N#3><+) >)XWF2701S6672ZBDMC_=)V)5!
M40O]F3_OF 7IR;U:4:*DTN<4MA/W1Z:+_B:HXK\I]A%62R*A:1*MK1<-KK=;
MVDLN@O68#&:X \("O6X2<$6* ^_=^S;3X,9.U;\Z7]U*N_S[-,OSBPMMOVI,
MFX;F?8.R#=A6O>YXT(HEU9*PS]R3A$)#BX@V;"[D4)]NLSI0--Q%SR,:C6 :
MS^^_&/\L5J71KFOTO!7ODKO9FDWW\ Q_4VL$,<T'IV\IT)"XPBOLAXU<:D&\
M]-G'*4(T2DFZFD=5,2;U8K7CV]$K&^]$UP_%)E0%!;\FOAX/2WDPRCUN8QJ<
MR+P?N0>W30;GQM'8R3EQ$CR: I9"2@Z2L](3S2 #3P)>I4@XI-YMA#]7EJ:N
MO3"=6A*\_8-M?VF1:6GLJ>Z!E\<U[_8M6[!UU1$)<R%K:%*\B  .LY2DBB.8
M0SF [M_BLQTBW7LU6W/B=I>]<JR?",H<\=JV;T7O#44+I2;ZRYLMB-1,5X*/
M9(\4 3^\A?B>:"4*R"?*0=-%Q-<+NMD-4]&+""3!"@]PA_TIAV*##,T;8DKU
MSM\P>WS#J%M5\4#P%E^'ZWQO.'5F:-+CZ 6XME)^^MV4*^)2X'EAN<B:T]^S
M([C3R2EUPXZ2TJ<5MSZ5/LEQ-(VH^(-!Q&V,8.KL]5XF7J$#X*1Z.$CY-WN)
MW_-O\ I4.,,YZ,]@_YUO*\>[MAXZ7F#;.?+EB<FAF&3-Z\QI[8L;B_QW$5[J
M:,7*]:3VLB<G&SVZ#/VK4S<6QQ9L55IW.<UA\YZ:BAU#B.A_+H2%29V!DEH>
M26DJ)7:O2-S"R2N_V'.(E3W4QA20?UT1_#&DX32\&AF#8%;1K>GL<ER+4- (
MH"#E*9$UI$3^Q_F>AI]TO3F]A?V'Z)VV,4*7T1]3V)ZRL-\"J\G8V-6KJU<I
M')^_*T[>M[G%0Z8@"0>[Q<6R:IB3DQ2@/M9#!X$KURN[&/0?(CB+OO8ZKKQ2
MAW.IB=YLD7>T[B[KT.M[#:'N-[0PKO%Q\X^V)08@)(ZYTA+P*Q>V=&07''9L
M QA8<%T'#%\K_, V; 9QK=3Q'<'Y_EQ J#Z0/B9X8!LV%J*I%[)JM_FZUYBL
M O*K#^;YD="8X5>I=C4;)=7=+$Z5I?\@@]:6/8.+" 0A:L0^^)EDCK("]$PJ
MV!IL[=&PM_#8**8T(*IJ3GVGW9\6?R!D9ZOH?RXBXB1D< -U:1N:$R(4/ 3.
MB[O'L%&H9> Z^PZP"'C&+<W<<MYC)K'VB!W:QM[8;&"LWV*OQ]42AYUWA[,G
M/],_8IMQ_7  9[7@^# >L9@>G(.?KJ0D]T%&M/=;KCAF7C.K^ ,ZG*ND8J;I
M,VZI>G^[MT*\*^$\EYZ[B&B5T:5Z#ETDN2U>NE6$%>VRBOAVU[LS:E7!1>N:
MU1O$_D<3_5YKIB<<WZ4D=P(]'VD;A*/%=R)!ZP!!))>BD]+/1@MF]/C"RJAS
MM]Y3@%]=)2QUFY_1/^M:BJH<2QH2DI\46^<4O?JC,].UV=7\;&$O0H'Y(P 6
M%]A-G813(L%GB6E,A86L5HH.KY/N Q-$2'\ 2:;L(Q^K_5Y??W;M]["_+AE8
MYO^!*WT5M#735_L4G6;)_PVKJ4C68$?P%)'8>@))+*"KY@1]1V7AU*YPGI=4
M/;VH.[_))?E^R%1VD0E0?]VL<$<K\%(_HM@9AL^G=ZA7Z>P\5EMVCQ>XGLPW
MKB0D@4-L"5ZK;^',PSOPPITI4?2?^&EMD._KJ6@A" C)#["P+O7>Z^WUCO;/
M!6#<+1* R\.!5L).KXEF'UDSB7V+TE*:F]@+!)>S3 A.(<O=GF>E&BW[&L+<
MT9M?W <@0EV/)VV,3Z#U9R]8<O[!68^(QJ5:I_K%4 9/!P!3(&6\KZ3'84AE
M=NN#V_VVS351&E1?WE:NA4O'D;N5;:IIJ7JN1/P,:R6=W6 8R5?BT2>1O#:I
M-H5+SV@/5[@H=>;"R"+]LPGHO_C*"?6H</I\(W9_1S'>Q-W.SM<B)\XX9.7\
MM^I/?Z^^(+O(6ZJ]01]8@)NMI?AWQQ)4$7Q&,*1[H$/(N["'>8P*S7*W7&[?
M=['^U:[$].U[!F/*Z03UP,L)F;>1[PVMY[LAQ9EZ$L,%RZZA )Y41>)XQXY_
MS.(/?,W'>"3<Z\'_@'U@5\BF*4'2ZO+ \A>E;INV62LW6UV/N'*A.GT.!7C%
M@^LM!3ZUQ(^0/3S4 T8\MX#N!7*/4!5,P'BRT3DF^F^'"DH+M^B>S(ILL6A\
M/KK9^"7JQ?[3ZY>_9*U7F/X1<(/(?/JUSTN5V$_1(7A*ML=81_,$#ISW+<GL
MP9)F#S+Z0&Y?9*N9I6HAX=U^:VNK;0--+YR0$B?"4A>R+,+2L;D#!$V1^JU[
MT:58(Z(E&+#7L:V@96B9)SF[Y/N(<.V[.+Z@)T9H_$@^4*&$G&RS?E*C'($*
M&\&5FFP"J; UNL!3^! _DN3@5&0OQ,P07P)WB"3]K9#"<V@"6)N5UP#&'GZZ
M!E^?-J&*L>E/\%^[R\V,[S^Y1H8&TV$M*!!L@-!:$9*[\KEZ:=6,;A_/9\Q2
MU5>QWW^-L^6=;TJWU7*M.2APG5"J8PV9K(&?J"NKPF@ HW\?],I"J6'0G%B4
M,N/N-V'$KU_-'@W/O]28E]G?TCSL8JC0N7'2/--70'EVYW^L5BC]!3/A&H(2
M+]X$UJ869#T)FC'/9XT^2 SQ.]C:YGO(0]_>(_+&)6/_C3GE38$Y ERECENO
MB3[PM:#=_@ZXN<_0N*ZA9E:\:2*F#"]5L=$[,U_I;E:DO^K;BU>U7O*::H@4
M=#=]<EB\%O23&$G7@"]%:'$^X)".L>1YK9SQXJB0M<#B2:_<SX:O=35<OSI^
MZKM?";]4 +D<3\#!BX<:_X$MI  GZ_G&;.J%LMK6^OLIL;M%R#R,<T.TG\W#
MNHR$.%5-VIU]OWU5@J^YW'2H>"SA.3& 24CQIVA0[/ZV)3X+U204G.?@MW.R
M*G7XA@'=BXA\NN*57E[WF;;BLVU;S^C=(T4Z?&#B*/SFWR\?QX6]"BKOPQ[S
M BTH MABY,O!(IXL6.P$N*4[;8RE:+9;JM_@+"+R0FW?J>>=9EN-!*86T$:/
MNR<FE0[<,*4E7=N]:UV0W.[.Y7-(T&IE+9?,I#C38:L[(I5_QT2ODNX9Z4%I
M8]SBEKNQZ0H?=7._<_U>2$(^>=@WUBB41I:$7Q)\'!_%J4"K4]#L\6X<DK &
M3*ARJUO:_UC[H*AR9D33G_F:J9.ES\!<OI.[Z2R7[M2A!FO/ LNFTI=O:0P;
MY_R2ZIT;&!#V/!U;&,ZQMR9/Q.YYWCZ6I/2P(_I!'+K,/?=N392^H'!]=8&.
MN:NS6,BO!L)AJ$=TR']CJ778$DZ-06O!!U,/[# >O*%##/RZ]_&1M[X4^\05
MSN#UI\T+M<.*^@W-@*JT';KEVC[!/4W=AE5FF;M]TFXG(LYHS_[^!2F[22RA
M$7HKA?_;H1,](1%WXC)\YO168_P>.+,I@O+&/=UQA@.;Q9/QS379.?IQD?OK
M!^Y/IF'>H^0/D1C[2'A8]]#(+GL*&YZA@>7%CH4>IHSWV=4Q/7>ICP9&O[#(
MM2J5BVU8&V%KI#R:>FW+2'#/N)[FW3VY05.3RW9^*O9RQLF!.$BI )[H:,O;
M1&P6M E6 KN&CCQAT4Q[1S#G(">J=P/2TD.8_7GK;N'/QIZ)>-O=5;>V1..I
MJ;-W0H8 !?B1/_2+BV1/.Y0GI"J@EN18L-1D-(ZJ K[V WXFS21)O+UK,^*?
MMP4V7L_6ZO/WVJ&_IS?\;TUO=4L.*XVS=+X#FC+1E3U+4DEE*1&5 V?/H.1K
MDGB]Y][-WS?,ON1-TLD_V6?;J)_Q=6,9!UER]*S3 #43HP4;W1+>-_9SD6K?
M%A%PDL9N%5*EV-&?'E;V0GDP4IPX(G5<Z+@E?VFHWE90.U$R:J6!J=NH>C&L
M.@.7].9?CEA^SI9J02D=NK"5O,*VQG<+<RA/QJ5);*IZ2@:CU &'GDR\;MO(
MN[YKZ->%+0_7+'\.I_5N3"=+6(A,B $Y@!ZB@(- LL 9^-6G2U=OMVS @4)/
M8!&1*T#7/J1E*6&$CMMJPK39=0D76':G>X\2IRG ?EPVJ95<0$#!L--%T?@9
MGT71AXQ_-["I.1W&S5E? AMK59L#0YFO,8V[!G;.KVR[@IHS6NEC 9.=== T
M#G"F,]^*^<">4LO>8>8DY^#[A^Q4M?OM:VM2L.P>2*]E_ @27JECLVTG9]NT
M"IR<E2NS/IKU[7MQ=Q]BYU82>\+ZJJP,7KD,2!MLD.Q,R4*JIR2@X<"UJL E
MJ/1E[N ^R8G'U_)2Q\*-BM&_+N;N25:5K9!H2>5%R;U()GFIL>0!5F&%1OL;
MJ3./HL8$_3C)F4F!JLD=1D!(^]!I%//RWSI3/P=;/C55'/%3]<P.6I$2T,/Z
MX $I4R3QV#2^%C?@ BD")T>P;'U;WD52322I!H+S+.]WMB[WDT];OXP]88N_
MAA^JV9_ONWO35;?"=;AHV2WLT6'0"G71"0.2N#@!#/LK$MO!%@X6F5K%12-F
M2"MH+!7GL^> =A_/TPF1IX28A+,%INGI+F9],F]OA?&QM]I[?/XL\+A[+<#Z
MA8*!P8]MJ,OU/CM-W"1'H-%?E&96NFTB.=O) *<-,[+\T6B2*F%5L2 5Y_LA
M^-55\L^M_G.2N?*,^5[-B@<CU9]A<]F^B @W1HF1LM(MI/2BE/PYYH_QTG.L
M0H*WZ$1J<FC'M0=HZKY%A#+M_D&]NWU%#18-EE\H.O! &RR[ 0XN+>A\; Q]
M&8D11:.HSSE9Y0=.,-OX0W6SUE712FM2:(-N[6,U44=575XV1U>X:KH_N2!8
MV"XVEMW 1@LGQ-V]CBQ!LB1^%F4D#>;NV,7B+WSJ4&D%!!6E]8S5BHVF32TE
M>Z^UOXQ,OKEJ/M[UQ.]]>Q5@\V&\Q,Y?))%)8KFWI!^B<-PQ*781483<O8AH
M<FV#<@\!P^ &-[XKCP6NI_)3N?$?)%UTHT0Z8J9C8Y9BDN#X+T9QK(/<^CC!
M=^^=]U)C'FJ^T0F#CA\$E?=X-1/, !:98 Q\=0?:>NCZT>>@A_43KO%)]Z*8
MVF4G]+:OLA/%KQUBY-^,(-MG8\+2'/?]UX*P Y;]91$Q<667",<W)<4)5\S]
M,C$ &R5_SKZOL 04\A+'Y+@VT\']MO=,1 \W#FR^Z2Y'4MD67T5G7UY$J/V@
MJA$91 38?SXUX6Y*-P^5O641<8FDT>Y!HGV<,YQNC%PQ-O^GMUR_?F);EOVR
M\ N*EY&EY13@ .E#*9<LU781[Q-9\O/8%*;"7O!L#=BEB)>ZW@M-,?2,F;E=
MR+42[UPAN[L[L$?GQD6*M1%^F_D#628IDI*+?93,?\*F3U"Y\7T[S/LM.RL,
MFMYL23WO 1#*-@\>BY1C*-S2"IU:>7EWT879 27?,W]W*G216H32QF2))6E"
M3:0'78F]2@%\6+^#PL5P#O4PLI>^$/^<&@&R8+RKE-41T23& <PRV.1WOETJ
MX2C/Z,'O2[.B8>$XVJ'FF1!K1W&<JIE+P(I'M[\:/&]G<7!GK?F:;4?>T6-Q
MH,6X "?91V(X=RPU"W.6;I8D@]N[RL:[/#?,]S,J4%?8%W^);X>L[3G]\M37
MD((OIZZP\?-C9V-VR?AIYZE2';\^H@:@(-7:#B-O+B8I6?50!$Z!X*;:=6;9
M\;.T&4ZA1D6C1;%%S/;F].EV"J3V'J#GM,/T3MX?7%8#/E(*?UK>5>KPT*;S
M OY!TNI[Y>'#X?(/-?BNIQ<1-*Q4<SF<!'=0:4M-+AFN)':UGM,?8$A=S"H6
M3FH#'@/>$=8>>^"II>"<>I*9*>@968GX??2RG,,:-V7>]WA5,+9[6@68IK"%
M2E&MS+AK-1]Z(^NBWWM?XK2TY<BY:4>U;]BPX<[R-(3VLI.]&E?_"O>=K3TX
M,+^L;T^JNL(GZY>D$RAFZ-_B\P#,'X"OW=9<<D['QC)/-(=\03.$>F\V6.5L
M<1%4-S!%2CU]DAA8Y?>.N85TF#K\?W)D9.S_[LB5,TN.//FOCHQ8"(:46!)]
M.(0UD?A/JJ6J>3V1H>-U[<_>2T]SL_/"YY[^_-&8D'HN #Q8&W;GN?^6 O>U
M[IL@)IU&RG-"@H[C'%*GIQDK!.SG?:KHYE"SU\5/U7!VEAYL[W3RIQPW/EZQ
MZT_91ZNG0=P]M1)UZ!6%]HLO.<J]%2]^)FO[B2PDVHI,*N/%J:=P*R93S@Q[
MO&477/2_''AHT&+?=$3SL]>*9QVJ6@FUEE^BZ.RK=,#?TYPW7H"-HB\UT8ZC
MW;+N<7(HV])1"AF<W_]<=^M&W:T+^'NA,:?:=8OBCFM8'[TU'< R;[Z,O(\]
M0ODPQT UN?%OP:0BOO/I3>;54.-'9]XE#=)Z%CIJ,8T[/O-OWMS2IKE7<NI,
MPP'Y3!V^/1?W$,EG279#PZ'JXV1!D"1\%FN$B>6JQ0K\4AX)N\XLJ.J6N&NZ
MK2CHH.#-NY77:+X(^6O&Y(SM364Q\Y\J-+GB@6'?YO*_QO!FC]L>YU17*/'4
MB\U5-SVJ4#2][,S.P.50FM#\@QSJ!0J 0^;B@/TJ**.8-A:"H!2/A..<@G3+
M3>H'?-(O1X+_2U-36M/DZB_%6RRCBT='W51'(J#)_>NB0O!3_KOJPQWC$&(+
MN4T['CFU /1N-+A60; =@-G><RX,J9G#@FZ.A\RCCZCMI1H#*>$R-O=&E?FJ
M>-EMBX0FHS6/B+V?7,N0"^KKK%F!6$!#RAIPI$>*NJ&7"CFD'^].XXQ(#"3V
M\R'<"A@>-XNRH9M),1(_\6L0)7(37Y.5$XX""IS(WN?F# >GS8! G$/BJ@5T
M^<:N8[Z?5;C@GZ73WB+G7=@;=..JD6:V/K4"&X$#UR$%KA)3$L.^;JEQ".@B
M_@ 4UN/C:V*>XK*EQU*!F*3';P7QTU^"DCN?3K_\Y&X74GWJX$YE U0CXB0+
MB*%(;__B8&69&'<X=9J<93OM")D$%Q&0.A-$U8&&SJ=/LW$3@WZ4/NJ)T^)
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MBA)/<Y?J;4;$\!PI@F4;4=ZG?% CL+ QVK2:-9;;Y]PO,=,B,Y(L?<]@9&\
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M.P@782]H->-+!LN5V1Q.RR/@TD5B4E[YQSIS*;O.A."\Q0R*KCQ4&+*\_V,
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M%YO#P8)0$NJ;^39=DIR/)(^KP$"ELE\!O7Q9O$]]NJ;II.:/DK8"=O1G$\7
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MU;@89?;A *MF#O3#:$WD]WE*0B"ZH,DB>\M!5;/$6\-JRD:$?*(?!RN4W<W
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MS07X;;E"Z1G>7^U]^*RR_L%WK$!\WU6OBH@[![T7NHIX!QD&'3&:SLH9$NS
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M"P0L(&4F_;W(!2NR(A5NUWWG!,V-=1H]0:<H:#5U/&<[!ZGE>9H'H$*?FYW
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M!.%.28>&1<Z-"=Z,3ZYK@:\=)_A%+3!!'/GY73W-F!N ,.SQ">3Y=T+@BWH
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M,"UP)B,-:Q[Q4;[#Q[+F1@Q[)]>K-AVI_M8;?4$\TF/X!+YV:PE/J 4FAA[
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M@G&8HSS2&X6,0L9S!B,1I30N<!&IQ-9-YIR0N3'X$SW;:GLCO&3.0MK/IKZ
M"DR+HS!R\I$9 N$"%YFS34_F(3-DW*&#S."SXY:'NMFF+L(_RLW7UP_U9J6G
MI/9*IMJ=2#PV^7;V?MTQC34;) K&#$N(.$X@UC^#.$]S%?$HR]U.,D?H,#>R
M^+1:+M5JW93GU#/_UB*K,SAO_6*W0 N,=GC&:9']KM4'6_VO]H@WIEP=]X!>
MJ)G#YD^2R_);DS\J9!JI"T#VM-H:H\&DJZH+('J^>KJDJ?$Y96[DNER)MY5X
MHY=FBR(U/L.:!0LA,$1I3"!+.($\2XL8TT2HR"JYQ5D)<Z.\7:*55DN]G1'
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M)\*ITKB-T+G-N ,Y_4??^EEU@-VIH&]8 T\&'A!USWKG )&O-'<V(J?-:^<
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M/(8()1$D"C.(42HBF>:Q_A9<QG2OM+F-;Z-ELT,H#U1U&^C]Z-H->F^8!2:
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MV#Y#CR-C>Y\>>?8O;\WIW"=Y;ZX3JMOWE5JM[YJUQ0<M[/U&WM4+%,68JDQ
M1:4ITYUC2+E@D"49$3DFFB/<SOTMA,Z-%3J=P4YI<* U^,/H#1K%70_^;3K
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M>N3(8=N>I#7(<XUTR<@YKIT&&H^^UU2G3W\.#46_";L18(VU)KM$E6'7:A%
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M;N#K&7[BR@LCW]^]K'_\S\IPR$)\?_ELVV_5"P-&N1:,%J#$,+-];BA@*)6
M08@T8659T+#8]Y-BQT8!6P7"U\K6=<&_7/_?H.6;(_J.$1W1,>T[=N,".,.#
MXIW0B1T6?UKHVP3&.P%Q-#3>[>[H@6N_+^;+Y20O!,MA2@"4W*Q-S'($4%QP
M0%).D((<.18:=Q4X-B)Z/U_Z=N([!ZDCQT0$JF]V.1D9=I74^@X2^+6#3/_!
M78VXL01P[1CO$:2U>U]HDLW4_/7A=S4S!#6]GLEK^6@DVGB&E9'9K<,Q9YQ*
M" ')56;;%A2 EE(#S#DG.>)(Y'YY_TYBQ\8IK=97R4.C=_TE9CN:^Z;=.*'O
M&+P0'=.^ QHZ.'_?@G-7Z;.QP0%I-SXH1<N[<1(Z<.*-#Q#[F3=>=_<=-7&]
M6-A>$746XOOO]L>;V?6C+?MTJ\\=-V83I"4KF$Y!F4H,H.UCS"A1 !=49CS3
MFLF>0BPNTGML]-@88,-0M5VV_*B7+7-](B+#>Z=XJ#="(%5B5ICO'='6A48E
MX!(70!>"9EF!D$JSB='^_W_OP[HMP.H-WH9Q#G9>$EA*C$&*1&F<&RP +Z4
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MW'FWZ1(X>F8K#R2\W*1C)@>Y1WL/&\PM.F;&MCMT])H+-U8W5#!1!:1YBA7
M7.3&LR$2L-S\A A'%-D3M[SP*7]X0(;7%!V@\&'WR9S:3V9B1Z5KN3*?A6ZJ
M;B'JN:4:AM-@&ZH[_D4/^ZG[YL?>3=V2\#9[J?LF'MU)/7!IV%0W#UK87=D/
MJOG?F]G-[(?YK,\7E5I.*"^U*!0$9I+;\'>SIN&"ID"BLM149@QKU<71NDW[
MD_*<7NS=\-G>*6"MG-^$/XVKV]2_'*MA2*#3,_FET_17F_CI@ITW'SAA$HD9
M3LL:E".<S'[-%FXWA?9T^^M:")L::<- %_.9^5$TF9.'VTESJ+-"2P24R#"
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M1P_TN A'8MQ(2@W*P'&!?,W(D9\>QM#OYX^/MAV<6>+O"9X@I06&. ,BQQK
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MA3%KZ]7+5_,VK*YG\N,_GZLG&R;][N7>/-%VJI]HH:7"6@/(2_,?)"6@4$$
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M[E.R!CZX=C![_P3:Y:8P#GG75$7^]EVIE>T9;>6TAQY2V%*PVI;\LWG_*2*
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MH$C.OI/(09U\'Q!>._=>]_H[]7^KIN8[.)^I-C[\=J;:^"+",_,280B*G)<
M,BT!L:$8.<PD%3IE6&6NSOI1*6-CF;6BZWAYHZJ[CW8<S?,><A2,>N:/@_"<
MC]'RP,G=1XV"UT"^I]]KY>4DGH7AA/-W_-[!G+JSZF\[:^<O#G3"JB5[>%BH
MIC'HK6[[A]:!TA,M6(E$RH#*=08@424P#I<&F888"L&R#'I50CXE;&QTN*NK
M73FUVK91Y)ZA)"=Q=G2X(J'7MZ,5#)R_A^6 2"S/ZI2H83TJ!Z/W/"F7>\((
MY%J8S\ASO==:GQT=*/9@"W,T+[HJI<YRJ$!!BQ3 HJ2 I!D#(I<"$IQK#0L?
M0O$1/C:"V=*];39YHJQ)&.EXC8T;"?6%>,^D%!=L;Z(*02T2<7F)'I3(0D!Y
M36Q!SPAO*V,6G_9_/O[SN?K!IL8-6U[_K)83(4N2XSP%"@IF:(VF@+"<&3^)
M0K..Y+@L2]_>,H=%C8W$ZI)P=@NE_F%+V>1/JZXG7YV V(V=X@#7,Q<%8Q;4
M?^8T'!&;T!P1-'@GFM,&'VI'<^:.T#P?2S^+IWE=-FE6M[IZ;_?4%R_OY]*L
MK3*&,4X)*%#!;(H@ 42(#)10<Z@)1-B-,QSEC8TXVC26'9VOFCYM!N:DU3RQ
MJOMF )W&_321](!FSVP2 \B W" G>"Y($3K]_($SA9R,W4\8<KLMS!MI&MG?
MZH\_Q7=;U,3VL+^=61I[165W:KE:5,(X2"W5[?YBZ\H)T[DR')0"28O<!N%S
M0!$7(%6P5!H97A)>H7<]Z#@Z&JM-M)L<JC6R.6AO?E[: W5;C_BJJ4JLMK[U
MU@%8K,VL_^[G+/7Q!KAY66\\KGT3ZGI(._MLC3=EA_)]/92OW3;;+&(]CLTE
M=G!?_7+W#ML=O)H]-^6'5,,0$>,->QRA2!YC'QH.ZFKV"/%K'[5/4<'U[>K>
MZ;9BT<K(^=CU3?^B5A.-.2D)UL 6HC.K88X!R[0"N10*$2IXZG9ZZB)L;-^#
MKZ>:RM?U5+T+RAT'&I8<,\4+0#.< JA+#$BF#.Y2%QG+N*80^Y3/C@;T /6S
M[ZV,Y&E(N-T^CK% [/DKMWE1OZZ1^[A![LL)Y$+*X)V%)%X5N^.BABY"=];H
M S7DSM\3N%YHP^*WJLJU80>JI#E,2P(T%@3 O-" \ R!0N2D*!#.J2!>7O\Q
M26/CZEK!MOJC9][=<30=/>@8&/7,$&<K:+9U,^.7*3J+3BP?]*B<83W)<^;N
M^8-G;PCCB/M%W7?UI7YNW9QUH@M;\-%X%U(P!2#1"%!M/ ZEE4H%9U26V61F
MSY65=*.'?2%.[SQMWOEM43TZ%ZV.R=(J:99SJT3,E^:51[^5]9>R^(W8I+Q'
M\_HOVX*SYC]/RA8-5E//HL$'8'=CD4 HAZ&/-8;?&@QK_>)QQ'';(Y'# 0&#
MLL)Q U_3P8DK UN/S5=J:2C?'IK6IZKMSUWY/9%*2)#*09E#"* H.& Y12 K
M25GFJ<Y9X77<>4;>V/P&VU,R^3QGGJ'WYU!UF_,1L>J9 &I-DU:]JS;JHM.V
M!Z_!$9E8G<'.2!NV'9B;Z7L]P!QO"TWOV6Z\<*>D>JQ=E:;!PH>Y;=,Z226A
MJ500*,*P[<:3 TZ@ HR6J2*4TEP[-5SW$3HV/MGK-+)1^ZKM)I+\V:CN&W3J
M,@1NO!,;V)[))PJF 1D_[B!%R_AQ$#EPQH\["/L9/Q[W!O:=G\\>[!?<BIID
M@F NJ?5?4 9@2BA@A)N%#C?,PZA&A?:*1]U^^-AHIMDQM1F]G@WBMP$K"89Y
M6D @D"UCP&W':XHTR(L<ZXS3U/A^DQ]JP>=]0[8MI#_0K'9@91V^"X%S8]E0
M,'IFTQJ%VNW]< H%;[X\9&ZL9O?;CQZVI?T!H_8:UQ^ZYH(Z:E_FLWESC&R+
MWMNHUX\_;<4@-5&L+"0I!("4I  JF0%"* ,4ZA066A .O=9JI\6-C?-J;0/.
M@<Z ZC:9XT'5\_1NEF;;FJ[CX5ME?XU<=.TL*C&KKQT7-GP9MK.&'ZS'=OZN
M,.YXQZ:V3=&W[TJM/MN1L_G5-MI:*Z5((17@4IEE&><:,&C[ .F4%9(1E3,O
MUC@F:&Q\T>J9U(HFG:9!L>Q'L74CCQB(]4P;86!Y$\8Y)")1Q5$Q@Y+$.6-?
MT\/9ZX.;MC_:D-6Y^$?3P>SZ>?5]OJC^I>0$EZ7B!26 E$5I/ HB ,.$@ )R
M(B$O.4F]:M"?D#4V>GC?'ODT)QK-R4_"UNHFOU3=>=#Q#Z8WWFY\$0G%GBFC
M!; ]$FH433::1FW,?@Z.>(W9CTH:NC'[.9,/-&8_>TM@QT$;[5[7*="-PV)S
M;/9S\]:]$[@L1,E+"#*ES%H%L1(PS7*09BDM.<Y$SKTJ#7C*'QO1K-6W8<@'
M,U5#6UKX#HP;^_0(=\^,% 5I_V:!87C%:A+H*7W8YH!AT.PU!0Q\C!_=+1>K
MR=_8S^KQ^;$]Q<T49X1G*4 4&N\HIPRPPE :RB"#*N4YQTZ=__:>/#:*:I5S
M8Y]]G$[SRD76]\P8K5X13["/6GMJOIN;MN:Z^==FGN\_;Y 9?-2,;FX>OR#T
MA'E1_6"K>C)W9T9+,\__4\F':O9PW;1PK]16&YOEYVJF;@PS+"<I+&R+&0ER
MG9J9FG)IUC$( 8%EJ:&2&A&O/8Z+M!G;[-X8LW6*VB2MM?8D&X.VFC\MDS^M
M34EME/=I]27#Z>:H##9(/9-0S^,3</(= ==H1^*7Z#+P67D$V/8/T6,\M-=J
M4%^4\<ONV<\)*B5/B90 I;+>3,H!R[ $I3!>%%-,<.+5]\M3_MAH=[M,T;SI
M#;:S)#&CM0PXSO(=%3<N[1'KGMG3JQI4G0QE5X?&AL$K0KT&;]BB4&OI8ZP+
M]1J:P-)0>X_Q+R1\IY9J\:,MK?<W-GO69D7YO#!<^YZ9-[!:O;2+'I@7+)><
M@)PC#F")&:"I+  1D),48R)S)Y?31^C8*&Y+[^16)SN:)YWJ[N5TG;$_S6E]
M(=HSD3F!&5"DV!E5]YK%?: [4 GCRUY9KY+&OBB=J'#L_*C!"A[[&K==_]C[
MWJA%_E;OV6+Q8H0UZ5D,IA1A8H.J"L/C&&? T#<$6*1$J12GB'A5.'"2.C8B
M7Y>Q>UW:)DK-OU>(.QZ"QL:Q[^/08Y4 ZY3#3NO8J7->*/5;(/"5S#'4"CP,
M@V/9P",WQVJ;::L&V=.*OU>K[^^?EROCPJX;\[Y,4)93E)D5M%E&4P!SP@"Q
M6YLJ*V%9V&H@PFLM[2E_=/S4*AO>5MMW -Q(JD=8>Z:K(RTTUT#_9?1/.@.N
MUITT([A&%V+76RO-T]+?N)NF$S3G&VJZ/29PN[!N--RUJ\=I#FE6(,!2@@#4
M! .6"^M@"5((1DE-8.[UC':>[D5/@Q4P:ALL!S7_W@7/<<\N%)*^=^3:-M_O
M8_?X/FAPK%VTG6</NT=VR*R]';"#%X6>M2ZKAYG=3+M>M@<)F].%=C. "RV8
MRLW\%5@!F!4I($@1(%2J)18Y3+%G,N]9F6-S.C8JFRF]/HK;:.U[(GH>=-=S
MSZA0]GZZ>1K%'JH'>  4[9CRO,2!#R.=(=@_<G2_-61__<'NX\\7+^LN6%W1
M#)62E)08 <IMH@I&!'#,"$@Y1:GB!.<8N^^H'Q,S-I;9:)IL5/79W3V*I\LN
M>0R4>M\7/P!0T#[X4:1\=KYC(#;87K?/J^6YMWT.AY.[V4=O'G#_^IP!NSO6
M9Z\.S/CM4@$_VP7:7?7P?76K_UBJVMW;BGO]5,W83%1L^G6^K.Q;\_'GRIY^
M\JGZ7"U7$\H8X\(R9FK+.)4J U25#)08LMPP*27:*50ULEYC(]NU64EMUU52
M6P;F&AC;DMJXMM]"%T:^-C#I+$S^W-B86",]0^-B#;F;L_@& ]GS]R#Z&'Z<
M&3)NRK9'=$(C Q\KB3J25L-F6\>%<B\M._+C0WL,?7MDT^F[YV5E/B[+B8)(
M%!FS]=:1\891F0-6I@HHC5.>9THIR?QZ"NT\?VS,W+:^J75,.B5]NP7M(GB:
M("/@TC/1^4$2T/?GH.$7]/G9?=[ ?7T.&K/?Q^?P9:&)D7/QC^_SJ;EC:4\.
M5R^V"M\F$O=>_5R],UK^8Y)2F6HB[4D>+VQ*) 749ESGMLRFU@43U*L;C[/D
MT4WS6EG?-$=7F-U<HE[ ZYD+MG7^7TFC=6+5WLH'2/ZTFB>UZE'S&SWABI;9
MZ"IWX)Q&3SCVLQE]'Q#&3I]8M:A#%_Y6EQ2NG9A/"_7/9S43+VV]2)H**:40
M@ I+3DP30#$30&J$$<HIXH3Z\)*#S+$QTI:FR5K5P!J=+I"[<51D('MFIT ,
MO:G( Y5().0B<5#Z\8#@-?'XW-K#;M;UXWRQJO[%FI534WP-LD*F,L]!@7)I
M_*(,&O[)"2"IX"@5C"KEM,@)56!L9+2MHMVY6'1;&\]+%117X#TB$7:5+L1Y
M#-M'.^/0VC#0UM )](;8 SHD?CR;/2? \=K5.?6<,.J[4S_4[%DMU\56D.*"
M4 Q!EJ:Y#:#( 4^I %BE"IK?R3SUVI%_+6!LU-7I]^]^!+6'FQL!78)&[^>5
MC6J]%)LY9G<D:MA[_*!3_YAQKZ?VT>L"%TK5K%JIS]4/)6]F*S.4=D>WB;>R
MK0)IQF69&:>DS#,"H,WV(\(NF5(-BY0RR8E79\;3XKRF]0"AC:>:!X:@Z;C\
MB891SY.]4134FB8;59,N!C)J[T4W5&*M?$X+&W;1XV3XWGK'[:Z+OO=WRBZ;
MC)?Q52WT?/%H"WC>\FGUL'8M;,/>^^K17'*KOYG?+FVRV[H-0C:1TI"(X1(@
MF=T:)I@"ED$&RA)1*5DF$=4!?L+%BHW4O[#-V5K+DJ>-:<E\;=M5HEKKDE5M
MGEU(+;<,O+(W&A.#')7+!]S+P1ET&(=QC&S_EFX$MZQ*;K=&L#,LN5^/X+>=
M$?QZ>@1#_:IH<,?UQRY7ZRW\N&A@'O'_XCT_\/BO>IA5NA*VOZ\0\^>976U^
MG4\K4:GEYE"JH!(3EC% )2H-P:,,L#2W!X"E*GB)->=>?6G<Q(Z-OM^Q9;6T
M\_C)/+4+?:SS99\6U4Q43[:1G/FS><66QA99_]WSG-!M/!P/":.CW/<)X4;A
M9*-QTJG<U^&@%TRQ3@;=A Y[+.@%Q-Z9H-_=P87@GY[-7/\VUZN_V$*]<HK;
M6.@4"DYDE@,"D0909(:I$-&@T!BE$K%2,:<H?"^I8V.K3EGORN\. +OQ3W38
M>J:?3M^D4_AJ;SG<0Z:/%TKQBL0[R!RZ7+P[# <*QWO<'$8]7Q>VY\WJY>O4
M,MQ,VKB')WO^>"B*AV"&4P4UX"@W#A,G&/"BY* D65X0*)CFN5]?.A_Q/G-J
MF+YUG?9FW6KUKYTFU5D04$'0:S#<V*HO@'LFK0VR7]?(KE7O/[(J!+5().8E
M>E N"P'E-:4%/2,RL]V;Y[4A/R3E:9J3#$BHC$M5<F46?[ $A$C!,%4$2Z^C
M0 >98W.HZJZ3S2[Y_2NG("C2R@7V"ZDK#,R>&>L"'./1TSXR?;/2EL1QD-$^
M!,X<=.#66#6EVK7C\DX)5?VP[=\G,*>T%+0$2A@7"L*2 2(I PJ7'*NTS%,I
M)C/U8/.]W=C'1:S3C*'-C-D6WF-D5:MCLE@K>6D!J0-HNU%.- 3?M%34&M&[
M\XA&* YU'*+>*D(=$/G&9:".@W"^]M.)>_TSUKXI\;RH5B]9SN^KE7GS\]PL
MV001@,N"6!\' L)T"E!6JJ)0!:22N*:KO7[XV)R96BF[69WEO_!?DTY=]VRU
M/?1.\\:EF/3,#[YP>&6J';,[*$UM[V&#Y:@=,V,[0>WH-8'!V(L'-FMC'-]O
MGZH89^3KUB',5F+K.MEU>6@K $D%N: :%"DQKH1@#/"\@"#-8($+8?Z?]JI)
M&5O!L=&$7Q9K;\/FYI.\Y6#TS$_;IETE.\;5.S[;YNV6"]A8V/]F4%\#$"MH
M/+9ZPP:5]P3N7M!Y7W("(Q1L(]AWQONKVR6JV;+19;$PTZ.6^>YE<\E7]F)_
M=?T76\C;)WOA\G=SX6IYT\9+3/)"IECG$BADNT7+G)@/ "Q CAC-569+T'CM
M8\55;VST7^=Y)O-&U>3!ZGI)6^G(8^D8!?%F(]1WM(35&M1J)]NF)5NV)?PE
MV;ZNM2^I#;Q*6A.ODL9(NR1NS%PW&?HT7VA5K6Q/KH@1%[T,2:S(C+C*#1O!
MT0NP>Y$>_4@)+03+5YO:CI_7_1<Q(TP)H4!!; =OPB!@2%)0*$ESB')"J5<,
MR!$Y8V-LJ^9.9=+/X>TO#P/KQKH1X.J9/H.0"JCC>A*':+5;#TL9N%[K25/W
M:[2>OOR">C8WR^6SDA_J=CP-R=1\M#Q,7!-<*)V6(@=*<)L=51:V8)4$)>$P
MY9EQ#5.O.M$!.HR-1AJ?@=<^@]CV+5C3K?/E B<P8(0</;U^<1_"G5LFC?Y7
MC=>VO#KLO6T^M5<)TS9D;>.G1:Z:$X9GS/HYGAH,7TDG#**#-74"'Q6CU,6F
M;PR5%%-8$J YM.E<.@>,,\N,+*,EIY03YI,M>D2.%^<-U@%COJZM,*T/#(.[
M]1Q#UW$O\W+,^MZ2?%V$HH?^.F=0Z*68Q!OURSECZNG2$+'ZWWQ3#_:C<J>>
M;&V)V<.AO7A*,*-$*R"0#:['L@1$"@TH%H03JE-"E9>W=%[FZ+RC1F6S>JAS
MM@+2?!QP=O1YXJ+7MX_3 K=6=X#2?^X Q7):'"0.ZZ2X0[#GE'C<&DHY4_/7
MA]_5S!#:]'HFK^5C-:ML50RSTE!M99NNRX&&E-&,($ 4%L8AX1F@N<P!9"5&
MA$C)A%>Q+2_IXZ.A6OFKY*%1OSX)9#L&^-*2SUBX$E1/"/=.52VXOV^!NZM[
M5U7+H9-' &T%P!:-P'QD#TQE ;#LDUK(0\+H[;-:+N>+76^M7<8O[^?O5!/)
MIN2$89J3$D$@<U;8I18#G$ .,I0*I'--RM+K8-)5\-A(K='[ZO4Z["IY:I5/
M5O.$JS8&5GE6P' >#C=RZP/DGGFMPW=O^?9U%]^[<_AZ4YHO6)'8S%GLH$3F
M"\9K#O.^/Y"^-KL?AB?WRSZO2]Z518IS66@@59T?A!@@!4>@A"G+LI(2R+Q*
M +D*'AU]W5R_N_E\<W_S\5MR_>5#\NW^]OW_^Y^WGS]\O/OVOY*/_^>/F_O_
M\J0LUR%PI*P>@.V;LC8JK],;5R^]U";T12<61[F*'9:C/,'8XRC?^R\L$M_4
M13.BM@2W=:+E[>S.AB;;?75SP9?Y;-']LZ[J<E^GOFC(I,Y+"<HB8P!*L["D
M-G"@S"'2&<5IJKS*W$33;&PL9PU+:LML):Q6W7IN;NN?_%DK'UJ _N+A="/$
M-QFDGADSTOB$%[>/A67L$O@7Z_4VA?)CP7FTG'XT 6$4_G=E:ULK>?W#^+,/
MZLNS77G?ZN;L\_9YM5R9=]?*7[N;&8)9B4M (8$ IFD*F! 2()K!O"PXQIE7
MTP]?!<9&R&WPP+.-$JAF=<C&<[VXFZF5^87YMTI^F<Z7RU]MX4C[]\=Y&[_A
MQ\[>(^5&PGWBWS/7=JHGK>Y)HWQ=[[$9E2W]KY(/U?397MV']QJ*8B26]18_
M*)F&@O.:,X.?$YHA_\.LZ>>+%UMY6F"9259J4$HD *0* TJA D@)SCDI("N(
M7UFA[<?[3*IAR@9UVE4V$LJ[2- .=)!HGA=9!E3),@,=L?NK3 +%"HI*BF *
MO4J@AP(W7"1+%0\\-Q(/A:1G@EZK%;F4^2%SH^7Q;SUZX'S]?:/V\_(/7!/&
M;EU"_U?V8MW(]\:O-(^>E @1,UDU("A/;?"^,HZ>X  C+5 ).:0I\^.YPX+&
MQWCKBA1/C:)^D_8(G&[3]W*(>I[(:VQ:#:^25L=X<_HT!I%F]Q$A@\[STX:^
MGO%GK@Z;^_^IY(/QD^[4M(Z@6GZOGMJJ5YP0D2.5 I1GR*SNL 8TQPI@51!,
M5*'+W&MU=U32V)9QK:+)MJ:!U<6.H^O&!E$PZYD0PN#R)H6S4$3BA>-R!J6&
ML^:^9H?S-UQ$$!_4LGJ8-3F&/ZNE#4 M2%YR4&"<&W:0 G!&-%"(DE+E99D7
M(H =7HD9*S5LJ9G\:14-XX77H'J1P@50#<0('BB%TL$1$.)RP6LA;T$$1PP]
MP@+'KO:OS]4TN_]43=7B/5NI![/@F%"5,4XD!*DJ!8!Y40(J"VF6\@7*<I@5
MA7;*ZCWR_+%-^D;%I-8QZ91TK]%U",'3$ST"+CW/<#](O.ITG3 \J%37H><-
M5JWKA#';!;M.7=;O68X]/!(3P;7&MJD,+IF9T!(6@.<,VKTY1 26A!78;Z7O
M)7]\&P"U6N'9M7[H$YU#1"@#&:OW63 !#-GM45BBG*FTI,C+E>H-^R'(ME,>
ML/8@9[8^R&F&PN9##S<V<0_.O!$?UZE9K?[P!V4[J U\2M;('N41V0XLH>=C
MNP^YH-K#3DS9S4Q,GV7=>6A1^Z"KU:+BSRN[;74__V)PF,]6!A/ST(>;F:$5
MM5RMSZIE3E*D6 YD:DE02@XHM%W/<&G\2D4A3KWVG>*J-S:^W+;N?]7=/%8O
MGIVS(X^?&V6^W:CTS*F[ ]*89EL8M<8EK77)MGDVVG_7P*2SL)<0A7[ CUEN
M(IYRPU>BB [LP2(5\:7XL;_B2UL;?/ZH[ME/M?R\+DU%%"\D)0400N4 4IR;
M=42> U48AY88=S853OQ]3,#8&+C1,:F5#*CT=13'TSP: YV>F; O8.1<U-6J
MFJI$?0*T(VD8H"XG^7.&-S1MKJJI-RV+M*;?H[<-0J#GE.XH\.QU?B16'Z@N
M7B9_?)L4@N8%EQG '#, 2RH!QYD""$.NL,QP+G(7VMH\<FQ$]<=OWWY+?I^;
M%<'L\=1Y_3&$3A-2F-T]4] ?7V[N/]K\K^O[C]\NGUK[-I[8DFPO;ER>]A\;
M;V?K48-,L'W5NREUX"]AZ\ [U64'W^J_*5D]/]ZKQ>.7^4HM)XJ0$C(BS**N
MP,8IX 4@J5G4"5RFFM,,FZG6=0^Z=U_;G1#I]!;N=@ZZ'V 2?FV:5+/I)I7:
M+ ;,]'],IG,V2S03I\LW>4/OMAZ[%,EAYO-&2[M'U>@):O!J3>.MD!S@B+3<
M.25IT+6+@\FO%R(NMP2&)$[K,5+R<,V]MCK$),VA3G7* "_-IQI2A0!C0@!1
MBD(3RLJ2>R4\NXD=VX>]B31>'JL6JAJM/8,8W0; C5SBP]KW)LZY>I\?SV#J
M'_/H!5&L&$@WH</&1'H!L1<CZ7=W>+^RCS_%=_LZ?#%OT22399KF#(&"T0)
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M-Q[6HF1C4MWN*K&F)+]\KEL_OB[\]Y4MZG/!Z*Y;3-3C-=VY7*6A6_1$ _%
M0Y]XS[ZPL>'?YXM_W,R^+N9"+9=&X*V^4TNU^*&6$Y%S5)2VU0<G D"="D#J
M_6..8)JA#*?0*^G50>;86-=J"JH9>&IT#6SB=P)C-QZ-C%S/-+G5\L_J:UOB
MMAHWI#C72:=U#_T ST,4NTW@"8EOTSWP/ 1'FPHZW-I+,,0F[)"K G&."( E
M5@ 6TI;V(1@8)S$3&$N.H5,]/E_!8Z.>[IS8K%WG#[/*YN=%/8#W#?3L \>W
M/VI/_NPE M07K&$.U=\H,M07#,_C\TLC1FUIT=U=?WL@.&.U_V5W]&QZ_)VM
M9G$[4Y.,91PQD0.E$0:0(0983E* .&$$$D(H= K0\I(Z-FZJ#Z6JM>97B6AU
MKUL=)]-6_61A];]*'MG/ZO'YT;W\K_MPG.:NWD#NF;A>'?I=)>_7^%H'JM,\
MN6OP-<KW@:U[O>5>,!ZH"'-$K+U*-7MC=J)^L_NS!BOJ[&W>=J5G_YL#TXJ:
M=+([]637V+,'WUX61VX?$9-L$N9:'?OI*W$&B%C)+L?$#)OH<L;8O227<]?[
MNRLV,N3SG,T^M46#VTU9*7@AH5DZJ9P36Z5, )XI!526<5*46&#CFSC%+Q\7
MXO-N#Q.>7(?)6$633UXUE$\ >=ZKN!R<GB?^/BKG=YJ=WS-GQ^!RF ;R N[7
MA;AEN[TO:E63/,V*W^)\\4^#<>+S?N3&P;[EIQ7?_G"?N=*?Z;XJ,\!F]!_4
MK;Y=5 _5C$W7I=2;:D5WJJEU=C^ORU)_>#9__O^J^];>N'$MV^_S*P@,[IUN
MP.PK4=2#<X$!'"<YDYF<=F"[9S#H#P4^;9TI5_F4JI)X?OTE]:B2ZZ$B592L
M>] G<1))>^]%<8GD?CT^/,F'IWPE_DO2U0PQ2AB."<Q(; (P<0Q)PA5,$$,H
M82SE/+3=L_E0:&K;N9U-YFQV65L%7K8EZVEI%UC5AAGOU<J8!D1I&U@_2?U_
M;1UXU>;9\XN7T3U/UF./V<#4_G:X&H/ KL- 91*X:PU7:17XN!NNTC#P7^,/
ME_W'8^QA&^M3\U0>C)2#ES?=WM9/= U^T (P:4;HA>:B[ ^AK]W.1U&>NICJ
M5M7E>;&;B/EB;Q)Z^F;Y'(..+YP7,:-]#WV"TOYZ>GVNC_R%.RGD\XN9#M_*
M,KX//Y;U$I A%= T0!"%B$%,< JS@%'(4H4EHB0+W7S#EG*G]N7\XZ69I)R7
MY9%X.:TIJ N!ZVE9=^"[),?A]##8G5,, .[8!Z [I:] I3;0>@\0/..(U2 9
M$J>EOF/6Q%DHNC,ISM_N1EC%:CV[UVQ)]<,^+U>2TV)=3PHL1, 2D\&-3"J%
MB"5D)OV*L%A@I1"FQ,I%<UK$U&BHT<Z.9#J@Z^83/X ,3!V-8AZYX;S=732@
M[VY1@/[3;OIW/'B4F7[>L&926US9LTY/W4CJ3I;Q< _+!_K3>'=-FUN]M-&R
MCG=TF458$9R$,8PQ51 G7*] E-[>(YF0C,4L$'3;6<YN#=)7%:N7_VW'N:&/
M1,O6J^4FPD3IG^P01?DZ_^[<=*[WD-FM5@8=AI%VZ)4)5Z9H VCI?@7.-)CR
M6!CH0A1]E0OJJ\:X180N!.N@M-"ES^O'I5]SRLRQ:RZ+ZX4X[!8^2Y@07*0!
MC$UA(2R4YLPL-&&])%&*H$B:2HFFJYP=8YX3Z+1.VHH=D!?+AGGSG=9EC:ZB
MI?<_ 5EJ[L:(9X&W8SZ?< [,<%_W,/S4C9HS?=E"X8FFSHH;E8YLC=^G'>O[
M+LP9N*,_FFJOI:#-R\M<RWP;V8Y4Q'%*&518,HB#+(($F0Y:&0\%P5@BY13'
MZR1]:ALTK3-X;I2N2*=6NV=*@=40V+'.8, .3$&M- ,#[U_?P-LH/T;&@0MN
MOG,/K&2_3Q:""RPG\Q&<'M*/UCYM5DNQG,_IJCX$45A$<2 $Q-I^B!52,$NB
M"&I"XV&(982%4Z.J?0%3(R>C7WUZ[;CN.8#.CG$N 61@4MFI-L#9\BF[/9'"
MP>-'G?>GC-N?VB>OZYF WFHV>:L^YPNZX'J+=;,LUGH-@I(@P!3#%'.IIS,-
M(.,I@H++5/ 8Q7'@EEC>(6QJL[JMJ_D BJ9;DFK4!MSH[9@\W@6WW>SW!>+
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M>%:5I+M?T]7:;F_6*=/E_=Z7/-RK_D'J77-Y\K%4O6KP=>.L8AFS $>0Q#B
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MC$/&4,I#%#DU,CP4,36JW,N^=CI?[0#2TI=U$3Q#.[#<D''W6ITTWI>KZE#
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MFWR1K^77_+L47Q9K_7[D;%[U8B^T3/JWY>IF3HNBG 64$HH0U3L]S%*(DXS
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MJ\T6Z=8OS:K %\O+?SD+$6>;[TXR3B>;3WX65^ME2.N)4$YXA1&\+AJ4E(F
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M$W)=8TV3@R0Y^9J<TA%"D%Y;EI**3W7G.P1/#Y Q;M)G( 0=*^X.[-$F2?$
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MQ!;6JXD-B7NM$PFJMK%4@IPN55\A"5L\)I6T-CMXLSLNU]=ET(&*70PKY4Z
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M*$(+4"4P" HE<&4TVFP4NWN[TW'4>?T@KVZI^F[XZMV,M^1RFJPAY\V<[N#
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M ^9?CX%KL-G7RDFPP2"H+,BKM^35.^UL<4D7W3RX[]%$WB@?$%QK(S+176]
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MTN^4/OB.X7AH[1\D W_H47.TN/N RZ:_PP4'J\NM5&K?K6(!>=I,-<L0M&6
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M1>/:BB.T?Z_XH)W@?PS;<'"'B%O_?  [,6#7ASMX889EQ&1 D6D'A;K:>E^
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M9[=-_I25-5XK4&R]R*Y3=(.3F78V><4IZF"9/QT:'R)Q7$0.!I7=(7FTWCJ
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M*R2A07*'5H5"LFX=J35F8>JN/EWB>U0<]+\-?L'9_-UB]9P8\G(]5F >[PF
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M#%%!!W!ZYI:?[&Q$I144$>I =R$!?1%05-(HF1'D5/S='U<&:7J_QY4A8N\
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MS6J5KU8WTU,2]SQ8VES*"5"1&PA.&! N<$5L"=,\J>\Y6OH#T"&Z7HP@^%X
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M),0+;2LA==*,^^3:9P>]0-#$#ZE=N)?M--8!_![QL-V=:(H/WE<;7A.M+09
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M-BQ)HQ,33NV3?+#CTWN!TOX=0-E"]AW$-<^&=>L??\._-@5B@GFIL3B0M!-
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M97AE+FAT;5!+ 0(4 Q0    ( "&0 54,/&OND H  )\8   <
M  "  <X*  !A,C P+3(P,3=X.3(V,S1X;6]D,CEE>&4N:'1M4$L! A0#%
M  @ (9 !5=<C>EL(!P  &R$  !@              ( !F!4  &$S,3$M:W)A
M;65R8V5R=#8S,#(R+FAT;5!+ 0(4 Q0    ( "&0 547'?[,!@<  %PA   9
M              "  =8<  !A,S$R+6QI;F1H86QC97)T-C,P,C(N:'1M4$L!
M A0#%     @ (9 !51P1!8,;!   N T  !@              ( !$R0  &$S
M,C$M:W)A;65R8V5R=#8S,#(R+FAT;5!+ 0(4 Q0    ( "&0 56HTPTWT ,
M -4-   9              "  60H  !A,S(R+6QI;F1H86QC97)T-C,P,C(N
M:'1M4$L! A0#%     @ (9 !52#YB-^]$ , L;\@ !               ( !
M:RP  &5B<RTR,#(R,#8S,"YH=&U02P$"% ,4    "  AD %5,XJ.O><0  !I
MN   $               @ %6/0, 96)S+3(P,C(P-C,P+GAS9%!+ 0(4 Q0
M   ( "&0 56QNDP+VQT  -09 0 4              "  6M. P!E8G,M,C R
M,C V,S!?8V%L+GAM;%!+ 0(4 Q0    ( "&0 55!XF1536$  ))'!  4
M          "  7AL P!E8G,M,C R,C V,S!?9&5F+GAM;%!+ 0(4 Q0    (
M "&0 55/HRIG8HH  (@G 0 3              "  ??- P!E8G,M,C R,C V
M,S!?9S$N:G!G4$L! A0#%     @ (9 !517X6FACLP  ]R0! !,
M     ( !BE@$ &5B<RTR,#(R,#8S,%]G,BYJ<&=02P$"% ,4    "  AD %5
MFX25<O=D  "BG   $P              @ $># 4 96)S+3(P,C(P-C,P7V<S
M+FIP9U!+ 0(4 Q0    ( "&0 54:<M[*.58  %2(   3              "
M 49Q!0!E8G,M,C R,C V,S!?9S0N:G!G4$L! A0#%     @ (9 !51M':)+0
M9   ]YL  !,              ( !L,<% &5B<RTR,#(R,#8S,%]G-2YJ<&=0
M2P$"% ,4    "  AD %5,*!5'&!G   SF   $P              @ &Q+ 8
M96)S+3(P,C(P-C,P7V<V+FIP9U!+ 0(4 Q0    ( "&0 57NU'00@44  -!\
M   3              "  4*4!@!E8G,M,C R,C V,S!?9S<N:G!G4$L! A0#
M%     @ (9 !56Z(1 WE90  SY8  !,              ( !]-D& &5B<RTR
M,#(R,#8S,%]G."YJ<&=02P$"% ,4    "  AD %5&]Z$-P=?  !:D0  $P
M            @ $*0 < 96)S+3(P,C(P-C,P7V<Y+FIP9U!+ 0(4 Q0    (
M "&0 54^O!GX->,  &I""0 4              "  4*?!P!E8G,M,C R,C V
M,S!?;&%B+GAM;%!+ 0(4 Q0    ( "&0 57):WE^=94  (3!!@ 4
M      "  :F"" !E8G,M,C R,C V,S!?<')E+GAM;%!+!08     %0 5 'L%
(  !0& D    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
